Tokushima University / Educator and Researcher Directory --- Shimada, Mitsuo

Personal Web Page

https://researchmap.jp/read0067383 (researchmap)

Field of Study

○

Subject of Study

○	(肝臓移植, 消化器外科·内視鏡外科, コンピューター外科, 臨床腫瘍学, 外科代謝栄養学)

Book / Paper

Book:

1.	MATSUMOTO Rikizo, Susumu Nishio, Yukina Hirata, Sae Morita, Asami Yuasa, 山尾雅美, Takumi Kakimoto, Yu Saitou, Kenya Kusunose, Hirotsugu Yamada, Hisanori Uehara, Mitsuo Shimada and Masataka Sata : 術前の画像検査で肝細胞癌と診断された肝炎症性偽腫瘍の1例, (一社)日本超音波検査学会, Oct. 2023. (Summary) 症例は70代,男性.近医の定期的な血液検査で胆道系酵素の上昇を認めたため,腹部超音波検査を施行したところ,肝左葉内側区に腫瘤を認めた.当院消化器外科に紹介となり,肝内側区切除術が施行され,肝細胞癌と診断された.術後7ヵ月,当院で経過観察目的に施行した造影CT検査で肝左葉外側区に新たに腫瘤を認め,再度精査となった.血液検査では,γ-GTPの軽度上昇を認めるのみで,腫瘍マーカーの上昇は認めなかった.術前の精査目的に施行した腹部超音波検査では,肝左葉外側区(S2)に18×16mm大の腫瘤を認めた.境界明瞭,輪郭は後面が整,前面がやや不整,内部エコーは等輝度で不均質であった.辺縁に比較的厚い低エコー帯を伴っていた.心拍動の影響で血流シグナルの評価は困難であった.腹部造影CT検査では,肝左葉外側区(S2)に2cm大の腫瘤を認め,早期濃染および洗い出しが確認された.本症例は,術前の超音波検査で,肝細胞癌としては非典型的な像を呈していたが,他の画像所見および既往歴から肝細胞癌の再発が否定できず,肝部分切除術が施行され,肝炎症性偽腫瘍と診断された.本症例のように肝細胞癌のリスクが高い症例においても,新規に腫瘤を認めた際には,超音波検査でその特徴を注意深く観察し,典型像と異なる場合には肝炎症性偽腫瘍も鑑別疾患の一つとして考慮した方がよいと考える.(著者抄録) (Keyword) 肝炎(画像診断,外科的療法,病理学) 肝細胞癌肝切除 MRI 腫瘍再発鑑別診断術前評価超音波診断 X線CT 肉芽腫(画像診断,外科的療法,病理学) 肉芽腫-形質細胞(画像診断,外科的療法,病理学) Gadoxetic Acid(診断的利用) Azan染色肝肉芽腫(画像診断,外科的療法,病理学) 腹部CT ヒト高齢者(65∼79) 男 (Link to Publication Site) ● Publication site (DOI): 10.11272/jss.405 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11272/jss.405 (DOI: 10.11272/jss.405)
2.	Yuji Morine, Mitsuo Shimada and Toru Utsunomiya : IV胆道発癌 1.全国集計からみた発癌頻度と特徴., 医学図書出版, Nov. 2011. (Keyword) 和文論文
3.	Mitsuo Shimada, Toru Utsunomiya and Yuji Morine : V治療 2.全国集計からみた外科治療, 医学図書出版, Nov. 2011. (Keyword) 和文論文
4.	Yuji Morine, Mitsuo Shimada and Toru Utsunomiya : 臓器部位別の治療戦略肝がんー手術とインターベンション, PEIT, RFA, TAEなどー., 2010. (Keyword) 和文論文
5.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 岩橋衆一 and 斎藤裕 : 腹腔鏡下肝切除術 4．術中・術後のトラブルと回避法ガス塞栓, NANZANDO Co.,Ltd., 2010. (Keyword) 和文論文
6.	Toru Utsunomiya, Mitsuo Shimada and Satoru Imura : Ⅱ 基本手技 3.肝臓ハンギング法，肝脱転肝胆膵高難度外科手術, IGAKU-SHOIN Ltd.Tokyo,Japan, Tokyo, 2010. (Keyword) 和文論文
7.	Yutaka Nakaya, Masashi Kuwahata, Akira Tangoku, Toshio Doi, Yutaka Taketani, Yoshihiko Noma, Eiji Takeda, Hiroyuki Azuma, Mitsuo Shimada, Nobuhiro Kurita, Tetsuro Ohmori, Masaharu Nishi, Yoshinori Aono, Yasuhiko Nishioka, Katsuhiko Yoshimoto and ほか 65名 : NST用語ハンドブック, Medical Review Co.,Ltd, Tokyo, Feb. 2006.
8.	Shinji Tanaka, Mitsuo Shimada, Ken Shirabe, Shin-ichiro Maehara, Eiji Tsujita, Akinobu Taketomi and Yoshihiko Maehara : Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe, Sep. 2005. (Summary) Hepatocellular carcinoma (HCC) originating in the caudate lobe is rare, and the treatment for this type of carcinoma is difficult because of its unique anatomic location. This retrospective study assessed the surgical outcome of patients with caudate lobe HCC. There were 20 cases of HCC originating in the caudate lobe among 435 patients with primary HCC who underwent hepatic resection in our department from 1990 to 2002. The caudate tumors were located in the Spiegel lobe in 3 patients, the paracaval portion in 15 patients, and the caudate process in 2 patients. Surgical procedures consisted of limited resection of the caudate lobe in 6 patients and extended caudate lobectomy in 14 patients. Recurrence was recognized in 12 patients, including 8 patients with multiple intrahepatic recurrences, 1 with peritoneal dissemination, and 1 with lymph node metastasis. There was no significant difference in postoperative survival rate between patients who underwent limited resection of the caudate lobe and those who underwent extended caudate lobectomy. Compared with 415 patients with HCC originating in other locations, the 20 patients with caudate lobe HCC showed significantly more intraoperative blood loss (P<.05), longer operation time (P<.0001), and more postoperative complications (P<.005). Intrahepatic recurrence was more frequent in the caudate lobe HCC compared with HCC originating in other locations (40% vs 17.6%; P<.05). There was a significantly poor survival rate in the postoperative patients with caudate HCC (25.9% vs 54.1% for five-year survival; P=.01). Intrahepatic multiple recurrences were frequently recognized in the patients with caudate lobe HCC, indicating no significance for extended caudate lobectomy. Because of the relatively poor prognosis in patients with caudate lobe HCC, adjuvant therapy combined with surgical operation should be considered. (Keyword) Aged / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Japan / Liver Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Retrospective Studies / Survival Rate / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.amjsurg.2004.12.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16105535 ● Search Scopus @ Elsevier (PMID): 16105535 ● Search Scopus @ Elsevier (DOI): 10.1016/j.amjsurg.2004.12.005 (DOI: 10.1016/j.amjsurg.2004.12.005, PubMed: 16105535)
9.	K Nomoto, Takashi Nishizaki, Mitsuo Shimada, S Okano, Ryosuke Minagawa and Keizo Sugimachi : Extended lobectomy for procurement of the left lobe with caudate lobe for living-related liver transplantation, Jul. 2005. (Summary) Liver transplantation from living-related donors has been established for end-stage liver disease. In adult cases, the left lobe with a caudate lobe was transplanted in order to increase the graft volume. However, the procurement operation should be less invasive for the donor. In this article, we represent our technique by which the blood loss can be reduced during the harvesting operation. The technique was used to improve the extended left lobectomy for the procurement in 27 patients between May 1997 and December 1999 at Kyushu University Hospital. The groups included the following: 1) Procurement operation of the extended left lobe with caudate (n=9), 2) without caudate (n=18). The detailed record during the operation showed that the mean blood loss and the amount for the group with caudate was significantly smaller than that in the group without caudate. To reduce the blood loss during the procurement operation, we continue to use this technique in the living-related donors for adult recipients. (Keyword) Adult / Blood Loss, Surgical / Hepatectomy / Humans / Liver Failure / Liver Transplantation / Living Donors / Middle Aged / Retrospective Studies / Tissue and Organ Harvesting / Treatment Outcome (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16001664 ● Search Scopus @ Elsevier (PMID): 16001664 (PubMed: 16001664)
10.	Shinji Tanaka, Mitsuo Shimada, Ken Shirabe, Shin-ichiro Maehara, Norifumi Harimoto, Eiji Tsujita, Keizo Sugimachi and Yoshihiko Maehara : A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma, May 2005. (Summary) Advanced hepatocellular carcinoma (HCC) with portal vein invasion and/or intrahepatic metastasis has an unfavorable prognosis even after radical hepatic resection. The aim of this study was to evaluate the effectiveness of a novel postoperative adjuvant chemotherapy given through the hepatic artery and based on biochemical modulation using cisplatin (CDDP) and 5-fluorouracil (5-FU). Fifteen patients with advanced HCC with portal vein invasion into the main trunk and/or intrahepatic metastases of more than 3 segments were included in this study. After radical hepatic resection, the patients were divided to two groups: the adjuvant chemotherapy group (n=7) given the novel arterial infusion regimen with CDDP and 5-FU, and the control group (n=8) given no adjuvant chemotherapy. Three-year survival rate of the adjuvant chemotherapy group tended to be significantly longer compared to that for the control group (p < 0.05). Most of the tumor recurrence was in the remnant liver, 5 cases in both of the groups. Significant difference of the recurrence patterns was recognized, rather than difference of the disease-free survival rate between the two groups. All of the intrahepatic recurrences are multiple in the control group, but in the adjuvant chemotherapy group, 2 cases of the recurrences showed a localized tumor surgically resected. It is noteworthy that the occurrence of multiple recurrence was significantly later in the adjuvant chemotherapy group compared to the control group (18.9 months vs. 6.5 months; p<0.05). Our data suggest that this novel adjuvant chemotherapy can improve the postoperative prognosis of patients with the advanced HCC. (Keyword) Aged / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Hepatocellular / Catheters, Indwelling / Chemotherapy, Adjuvant / Cisplatin / Combined Modality Therapy / Disease Progression / Drug Administration Schedule / Female / Fluorouracil / Hepatectomy / Humans / Infusions, Intra-Arterial / Liver / Liver Neoplasms / Male / Middle Aged / Neoplasm Invasiveness / Neoplasm Staging / Portal Vein / Prognosis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15966221 ● Search Scopus @ Elsevier (PMID): 15966221 (PubMed: 15966221)
11.	Akihiro Nishie, Kengo Yoshimitsu, Yoshiki Asayama, Hiroyuki Irie, Hitoshi Aibe, Tsuyoshi Tajima, Kenji Shinozaki, Tomohiro Nakayama, Daisuke Kakihara, Mitsuo Shimada, Shin-ichi Aishima, Kisaku Yoshida and Hiroshi Honda : Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings, American Roentgen Ray Society, Apr. 2005.
12.	Norifumi Harimoto, Akinobu Taketomi, Dai Kitagawa, Yousuke Kuroda, Shinji Itoh, Tomonobu Gion, Shinji Tanaka, Ken Shirabe, Mitsuo Shimada and Yoshihiko Maehara : The newly established human hepatocyte cell line: application for the bioartificial liver, European Association for the Study of the Liver, Apr. 2005. (Summary) Human hepatocyte cell lines are reported to lose many of their biochemical functions in a hybrid artificial liver support system (HALSS). Differentiation therapy is useful to up-regulate liver function. The human hepatoblastoma cell line HepG2 was transfected with HSV/tk gene. Albumin synthesis and ammonia removal activity were evaluated when HepG2/tk was cultured with histone deacetylase inhibitor (FR228) and peroxisome proliferator activated receptor-gamma ligand (pioglitazone). To investigate the function of HepG2/tk in vivo, cell transplantation for 90% hepatectonized rats was conducted. We established stable cell lines which expressed HSV/tk and were sensitive to gancyclovir in vitro and in vivo. Both albumin synthesis rate and ammonia removal rate improved for HepG2/tk incubated with FR228 and pioglitazone for 3 days, which induced nuclear transport of p21. Rats with intrasplenic injection of HepG2/tk precultured for 3 days with FR228 and pioglitazone survived significantly longer than the control rats. The ammonia and total bilirubin concentrations were significantly lower in the test group than in the control group. The injection of gancyclovir inhibited the prolonged survival of the rats with precultured HepG2/tk. HepG2/tk is safe as well as enhancing high levels of liver function. It will be a potential cell source for HALLS in the future. (Keyword) HepG2 / Hepatoblastoma / Differentiation / Bioartificial liver / Histone deacetylase inhibitor / Peroxisome proliferator activated receptor-gamma ligand (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jhep.2004.11.038 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15763342 ● Search Scopus @ Elsevier (PMID): 15763342 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jhep.2004.11.038 (DOI: 10.1016/j.jhep.2004.11.038, PubMed: 15763342)
13.	Takashi Maeda, Mitsuo Shimada, Norifumi Harimoto, Eiji Tsujita, Shin-ichiro Maehara, Tatsuya Rikimaru, Shinji Tanaka, Ken Shirabe and Yoshihiko Maehara : Role of tissue trace elements in liver cancers and non-cancerous liver parenchyma, H.G.E. Update Medical Publishing, Jan. 2005. (Summary) The role of trace elements in liver fibrosis, carcinogenesis and progression of hepatocellular carcinoma (HCC) has not yet been clarified. The aim of this study is to analyze the characteristics of trace elements in liver cancers and non-cancerous liver and to discuss their role in hepatic fibrosis, hepatocarcinogenesis and progression of HCC. The amount of zinc (Zn), iron (Fe), and copper (Cu) in 20 HCCs, 2 cholangiocellular carcinomas (CCC), 7 metastatic liver cancers (Meta) and their non-tumorous liver parenchyma were measured using an atomic absorption spectrophotometer. The amounts of Zn and Fe in non-tumorous liver parenchyma were reduced by liver fibrosis, and the amounts were lower in HCC tissue compared to non-tumorous liver parenchyma. The amounts of Zn and Cu were higher in HCC than the amounts found in CCC and Meta. The amount of Zn in HCC tissue decreased, but the amount of Fe increased in tumors more than 4cm in diameter. These results suggest that the decrease in the amount of Zn and Fe found in non-tumorous liver parenchyma correlates with liver fibrosis leading to cirrhosis and hepatocarcinogenesis. Also that decreases in Zn and increases of Fe in HCC tissue correlates with HCC tumor progression. (Keyword) Carcinoma, Hepatocellular / Case-Control Studies / Cholangiocarcinoma / Humans / Liver / Liver Cirrhosis / Liver Neoplasms / Trace Elements (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15783026 ● Search Scopus @ Elsevier (PMID): 15783026 (PubMed: 15783026)
14.	Tsuyoshi Tajima, Kengo Yoshimitsu, Hiroyuki Irie, Hitoshi Aibe, Kenji Shinozaki, Akihiro Nishie, Hiroshi Honda and Mitsuo Shimada : Detecting postsurgical recurrent hepatocellular carcinoma with multiphasic helical computed tomography: intrahepatic metastasis or multicentric occurrence?, Lippincott Williams & Wilkins, Jan. 2005. (Summary) The aim of this study was to assess the computed tomography (CT) patterns of postoperative recurrent hepatocellular carcinoma (HCC). Of 84 patients with histologically proven HCC by hepatectomies, multiphasic helical CT demonstrated 54 HCC lesions of intrahepatic recurrence in 31 (37%) patients. The initial and final appearances of HCC on hepatic arterial phase images were retrospectively determined by the serial CT scans, which were compared with appearances of primary HCC. The initial appearances of 54 recurrent HCCs were identical to the appearances of primary HCC in 41 (76%) lesions. Serial changes from the initial appearance to the final appearance of recurrent HCC were observed in 10 (42%) of 24 lesions. The 13 discordant lesions and the 10 lesions with altered lesion vascularity in our series implied that at least 43% were of multicentric occurrence. More than 40% of postoperative recurrent HCCs show intranodular hemodynamic changes. The incompatibility between CT findings of primary and recurrent HCCs implies that these tumors contain nodules of multicentric occurrence. (Keyword) Adult / Aged / Aged, 80 and over / Carcinoma, Hepatocellular / Female / Follow-Up Studies / Hepatectomy / Hepatic Artery / Humans / Image Processing, Computer-Assisted / Liver Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Neoplasm, Residual / Retrospective Studies / Tomography, Spiral Computed (Link to Publication Site) ● Publication site (DOI): 10.1097/01.rct.0000146482.64324.6e (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15665682 ● Search Scopus @ Elsevier (PMID): 15665682 ● Search Scopus @ Elsevier (DOI): 10.1097/01.rct.0000146482.64324.6e (DOI: 10.1097/01.rct.0000146482.64324.6e, PubMed: 15665682)
15.	Shin-ichiro Maehara, Shinji Tanaka, Mitsuo Shimada, Ken Shirabe, Yoshiro Saito, Kazuhiko Takahashi and Yoshihiko Maehara : Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells, John Wiley & Sons, Inc., Nov. 2004. (Summary) Gemcitabine is a new standard chemotherapeutic agent used in the treatment of pancreatic cancer, but the mechanisms of gemcitabine sensitivity are still controversial. In our study to determine a mechanism that regulates gemcitabine sensitivity, we carried out molecular analysis on the susceptibility of the pancreatic cancer cells. Using a gemcitabine-sensitive pancreatic cancer cell line KLM1, we established a resistant cell line KLM1-R exhibiting a 20-fold IC50-value (the concentration of gemcitabine causing 50% growth inhibition). Microarray analysis of genes showed specific expression of selenoprotein P, one of the anti-oxidants, in the KLM1-R cell line but not in the KLM1 cell line. Administration of selenoprotein P inhibited the gemcitabine-induced cytotoxicity in the pancreatic cell lines. The levels of intracellular reactive oxygen species (ROS) were increased in the KLM1 cells by gemcitabine, but selenoprotein P suppressed the gemcitabine-induced ROS levels. Furthermore interferon-gamma suppressed the expression of selenoprotein P mRNA and increased intracellular ROS level, leading to the recovery of the gemcitabine sensitivity in KLM1-R. These results suggest a novel mechanism that selenoprotein P reduces the intracellular ROS levels, resulting in the insusceptibility to gemcitabine. (Keyword) microarray / sensitivity / free radical scavenger / reactive oxygen species (Link to Publication Site) ● Publication site (DOI): 10.1002/ijc.20304 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15352029 ● Search Scopus @ Elsevier (PMID): 15352029 ● Search Scopus @ Elsevier (DOI): 10.1002/ijc.20304 (DOI: 10.1002/ijc.20304, PubMed: 15352029)
16.	Taketoshi Suehiro, Takashi Matsumata, Yasunori Shikada, Mitsuo Shimada, Ken Shirabe and Keizo Sugimachi : Change in alpha glutathione s-transferase levels during liver resection, H.G.E. Update Medical Publishing, Nov. 2004. (Summary) Alpha-glutathione s-transferase (GST) is a 50,000-kDa cytosol protein of the hepatocytes. It comprises 5% of the soluble protein of hepatocytes and is readily released in response to injury. Its half-life time is 60 minutes (AST: 47 hrs, ALT: 22 hrs). The aim of this study is to clarify the usefulness of GST measurement during liver resection. We obtained data from 26 patients undergoing liver resection and compared GST levels with AST and ALT levels. Patients included 15 hepatocellular carcinoma, 5 cholangiocellular carcinoma and 6 metastatic cancers (4: colon, 2: stomach). We performed lobectomy for 11, segmentectomy for 5 and partial resection for 10 patients. From these patients, blood samples were collected before surgery, beginning of resection, end of resection, 15, 30, 60 min after resection, end of surgery, 1, 3, 6, 12, 24 hr after operation and 2, 3, 4, 5, 6, 7, 10, 14 postoperative days (POD). GST (Biotrin, Ireland) levels in the serum samples were determined by an ELISA. We also measured AST, ALT levels from the same set of samples. At the end of resection, GST showed highest level and quickly decreased at 1 hr after operation. On the other hand, AST and ALT showed peak levels at 12 hr after operation. Our findings suggest that perioperative GST measurement may be a sensitive and useful marker to evaluate liver function after liver resection. (Keyword) Adult / Aged / Biomarkers, Tumor / Carcinoma, Hepatocellular / Cholangiocarcinoma / Female / Glutathione Transferase / Hepatectomy / Humans / Liver Cirrhosis / Liver Function Tests / Liver Neoplasms / Male / Middle Aged / Monitoring, Intraoperative / Perioperative Care / Prognosis / Prospective Studies / Risk Assessment / Sensitivity and Specificity / Treatment Outcome (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15532818 ● Search Scopus @ Elsevier (PMID): 15532818 (PubMed: 15532818)
17.	Taketoshi Suehiro, Takashi Matsumata, Yasunori Shikada, Mitsuo Shimada, Ken Shirabe and Keizo Sugimachi : Preoperative hyaluronic acid measurement to assess the hepatic functional reserve, H.G.E. Update Medical Publishing, Nov. 2004. (Summary) With liver surgery, preoperative assessment of the hepatic functional reserve is important for estimating the extent of hepatectomy. Hyaluronic acid (HA) is specifically cleared and metabolized by endothelial cells in the liver. Its half-life time is 2-5 min and HA might be a sensitive liver function marker. We obtained data from 44 patients with liver tumor undergoing liver resection. We studied 44 liver resected patients. Blood samples were obtained before surgery and HA levels and other liver function markers [type IV collagen (IV), procollagen-III-peptide (PIIIP), lecithin-cholesterol acyltransferase (LCAT), cholinesterase (ChE), albumin (Alb), platelets (Plt), prothrombin time (PT%)] levels in the samples were measured. We also performed indocyanine green retention test and calculate R15% (ICG). HA showed strong positive correlation with ICG, IV and PIIIP, negative correlation with LCAT, ChE, Alb, Plt and PT%. ICG was not correlated with ChE, Plt and PT%. The HA levels and ICG of the patients who had more than 2 segments of the liver resected were below 100 ng/mL and 20%, respectively. In the patients with obstructive jaundice HA levels of the 3 patients with obstructive jaundice who underwent bisegmentectomy were below 100 ng/mL. Our findings suggest that HA is a useful preoperative liver function test as well as ICGR15%. Preoperative HA levels <100 ng/mL and ICGR15% <20% might be helpful indicators for major liver resection. We also recommend that HA measurement for evaluating liver function in the patients with obstructive jaundice ICG is not helpful. (Keyword) Adult / Aged / Aged, 80 and over / Biomarkers, Tumor / Cohort Studies / Female / Hepatectomy / Humans / Hyaluronic Acid / Liver Function Tests / Liver Neoplasms / Liver Regeneration / Male / Middle Aged / Neoplasm Staging / Postoperative Complications / Preoperative Care / Probability / Prognosis / Risk Assessment / Sensitivity and Specificity / Statistics, Nonparametric / Survival Analysis / Treatment Outcome (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15532824 ● Search Scopus @ Elsevier (PMID): 15532824 (PubMed: 15532824)
18.	Ryosuke Minagawa, Shinji Okano, Yukihiro Tomita, Kenji Kishihara, Hisakata Yamada, Kenichi Nomoto, Mitsuo Shimada, Yoshihiko Maehara, Keizo Sugimachi, Yasunobu Yoshikai and Kikuo Nomoto : The critical role of Fas-Fas ligand interaction in donor-specific transfusion-induced tolerance to H-Y antigen, Lippincott Williams & Wilkins, Sep. 2004. (Summary) Donor-specific transfusion (DST) has been clinically used to enhance the survival of transplanted organs, and it has been shown in mice to induce tolerance to male (H-Y) antigen (Ag). Although the biologic mechanisms that initiate and maintain DST-induced tolerance involve clonal deletion, induction of anergy, and generation of regulatory cells, the molecules essential to tolerance induction are still unclear. In this study, we investigated the role of Fas-FasL interaction in DST-induced tolerance to H-Y Ag. C57BL/6 (B6) or B6-Fas(lpr) (lpr) female mice were intravenously injected with B6, lpr, or B6-FasL(gld) (gld) male spleen cells (SC). B6 male skin grafts, mixed lymphocyte reaction (MLR) assay, and cytotoxicity assay (CTL) were performed 7 days after DST. In some experiments, purified B-cells were used as transfused cells. B6 female mice treated with B6 male SC permanently accepted B6 male skins, whereas untreated B6 or lpr female mice rejected B6 male skins. On the other hand, B6 female mice treated with gld male SC acceleratingly rejected male skin, as did lpr female mice treated with B6 or gld male SC. The recipient mice in the experimental groups, in which DST resulted in the accelerated rejection of the skin grafts, had strong allo-responses to H-Y Ag in MLR and CTL. Further, B6 female mice treated with gld male B-cells acceleratingly rejected male skins, whereas B6 female mice treated with B6 or lpr male B-cells from mice accepted male skins. These findings suggest that the interaction between FasL upon infused SC, especially upon B-cells and Fas in a recipient, is essential in DST-induced tolerance to H-Y Ag. (Keyword) Animals / Antigens, CD95 / Cell Transplantation / Cytotoxicity, Immunologic / Fas Ligand Protein / Female / H-Y Antigen / Lymphocyte Culture Test, Mixed / Male / Membrane Glycoproteins / Mice / Mice, Inbred C57BL / Skin Transplantation / Transplantation Chimera / Transplantation Tolerance (Link to Publication Site) ● Publication site (DOI): 10.1097/01.TP.0000129799.96439.6F (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15385797 ● Search Scopus @ Elsevier (PMID): 15385797 ● Search Scopus @ Elsevier (DOI): 10.1097/01.TP.0000129799.96439.6F (DOI: 10.1097/01.TP.0000129799.96439.6F, PubMed: 15385797)
19.	Takashi Maeda, Ken-ichi Taguchi, Shin-ichi Aishima, Mitsuo Shimada, Deborah Hintz, Nicholas Larusso, Gores Gores, Masazumi Tsuneyoshi, Keigo Sugimachi, Jack R. Wands and Suzanne M. de la Monte : Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma, International Society for Preventive Oncology (ISPO), Sep. 2004. (Summary) Aspartyl (asparaginyl) beta-hydroxylase (AAH) expression in surgically resected intrahepatic cholangiocarcinoma significantly correlated with tumor size, growth type, differentiation, vascular invasion, and prognosis after surgery. AAH may have a role in regulating invasive or metastatic tumor cell growth of human intrahepatic cholangiocarcinoma. Recent studies demonstrated increased expression of the AAH gene in the majority of cholangiocarcinomas. The present study was undertaken to determine the relationship between high or low levels of AAH expression and the clinical course of intrahepatic cholangiocarcinoma (ICC). AAH expression was examined in 50 surgically resected primary ICCs, 12 samples of normal liver, and 12 cases of primary sclerosing cholangitis (PSC). The sections were evaluated by immunohistochemical staining with the FB-50 monoclonal antibody to human AAH protein. The sections were examined under code and graded for relative levels of AAH immunoreactivity. The results were analyzed with respect to multiple clinical and histopathological variables to determine correlates of AAH expression in ICCs. Forty-six of the 50 (92%) ICCs had AAH immunoreactivity, whereas the 12 normal liver and 12 PSC specimens were AAH negative. In the ICC specimens, the highest levels of AAH immunoreactivity were detected at the infiltrating margins that interfaced with uninvolved liver tissue, and the lowest levels occurred in the central portions of the tumors. Multivariate analysis demonstrated that high levels of AAH expression were correlated with tumor size (P < 0.05), infiltrative growth pattern (P < 0.01), aggressive histological grade (P < 0.01), vascular invasion (P < 0.05), and poor prognosis (P < 0.05). These findings suggest that AAH has an important role in regulating invasive or metastatic tumor cell growth of human ICC, and that high levels of AAH expression correlate with poor prognosis. (Keyword) Invasion / Metastasis / Biomarkers of malignancy (Link to Publication Site) ● Publication site (DOI): 10.1016/j.cdp.2004.06.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15542253 ● Search Scopus @ Elsevier (PMID): 15542253 ● Search Scopus @ Elsevier (DOI): 10.1016/j.cdp.2004.06.001 (DOI: 10.1016/j.cdp.2004.06.001, PubMed: 15542253)
20.	Kenji Shinozaki, Kengo Yoshimitsu, Hiroyuki Irie, Hitoshi Aibe, Tsuyoshi Tajima, Akihiro Nishie, Tomohiro Nakayama, Daisuke Kakihara, Mitsuo Shimada and Hiroshi Honda : Comparison of test-injection method and fixed-time method for depiction of hepatocellular carcinoma using dynamic steady-state free precession magnetic resonance imaging, Lippincott Williams & Wilkins, Sep. 2004. (Summary) The purpose of this study was to clarify the usefulness of the test-injection method as compared with the fixed-time method in dynamic magnetic resonance (MR) imaging of hepatocellular carcinoma (HCC). Ninety-seven patients with a total of 118 hepatocellular carcinomas underwent 3-dimensional fast imaging with steady-state free precession (3D-FISP) for dynamic study of the liver as well as catheter-assisted computed tomography hepatic angiography (CTHA) for preoperative evaluation. In 42 cases, the fixed-time method (30-second scan time delay in the hepatic arterial phase [HAP]) was performed (group 1), and in 55 cases, the test-injection method was performed (group 2). The following parameters were evaluated: 1) the adequacy of the HAP, 2) tumor vascularity using CTHA findings as a gold standard, and 3) the contrast-to-noise ratio (CNR) of the HCC during the HAP of dynamic MR imaging. In group 1, 79% (33 of 42) of the cases were obtained at the optimal HAP; the percentage in group 2 was 98% (54 of 55) of the cases. This difference was statistically significant (P < 0.05). The vascularity of 82% of the tumors in group 1 and 89% of those in group 2 was diagnosed correctly. Regarding hypervascular tumors, correct evaluation of tumor vascularity was made in 87% of group 1 cases and 95% of group 2 cases. No significant difference was present between the 2 groups (total: P = 0.43, hypervascular HCC: P = 0.29). 3) The CNR calculated for all HCCs in group 2 (mean +/- SD: 8.66 +/- 11.0) was significantly higher than that for HCCs in group 1 (4.29 +/- 9.44; P < 0.05). As for the hypervascular tumors, the CNR calculated for group 2 (mean +/- SD: 9.89 +/- 10.6) was also significantly higher than that for group 1 (5.52 +/- 9.81; P < 0.05). The 3D-FISP dynamic MR imaging using the test-injection method resulted in better demonstration of HCC than the 3D-FISP using the fixed-time method. (Keyword) Adult / Aged / Carcinoma, Hepatocellular / Catheters, Indwelling / Contrast Media / Female / Hepatic Artery / Humans / Image Interpretation, Computer-Assisted / Image Processing, Computer-Assisted / Injections, Intravenous / Japan / Liver Neoplasms / Magnetic Resonance Imaging / Male / Middle Aged / Time Factors / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1097/01.rct.0000138009.62478.8f (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15480036 ● Search Scopus @ Elsevier (PMID): 15480036 ● Search Scopus @ Elsevier (DOI): 10.1097/01.rct.0000138009.62478.8f (DOI: 10.1097/01.rct.0000138009.62478.8f, PubMed: 15480036)
21.	Yo-ichi Yamashita, Mitsuo Shimada, Ryosuke Minagawa, Eiji Tsujita, Norifumi Harimoto, Shinji Tanaka, Ken Shirabe, Jun-ichi Miyazaki and Yoshihiko Maehara : Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation, American Association for Cancer Research, Sep. 2004. (Summary) We developed a new potent nonviral gene transfer method into mouse muscles in vivo named "electrosonoporation." We tried in this report to treat murine orthotopic hepatocellular carcinoma (HCC) by muscle-targeted mouse interleukin-12 (mIL-12) gene transfer using in vivo electrosonoporation. I.m. administration of the mIL-12 gene with electrosonoporation elevated serum IL-12 and IFN-gamma and significantly prolonged the survival periods with both growth inhibition of orthotopic HCC and inhibition of spontaneous lung metastasis. The IL-12 gene therapy reduced the number of microvessels and induced more Mac-1-positive cells into HCC. These results show that muscle-targeted mIL-12 gene therapy for orthotopic HCC using in vivo electrosonoporation is very efficient and is thus promising for further clinical trial. (Keyword) Animals / Electroporation / Gene Transfer Techniques / Genetic Therapy / Injections, Intramuscular / Interleukin-12 / Liver Neoplasms, Experimental / Macrophage-1 Antigen / Mice / T-Lymphocytes, Cytotoxic (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15367712 ● Search Scopus @ Elsevier (PMID): 15367712 (PubMed: 15367712)
22.	Shinichi Aishima, Shuji Matsuura, Takahiro Terashi, Kenichi Taguchi, Mitsuo Shimada, Yoshihiko Maehara and Masazumi Tsuneyoshi : Aberrant expression of laminin gamma 2 chain and its prognostic significance in intrahepatic cholangiocarcinoma according to growth morphology, United States and Canadian Academy of Pathology, Aug. 2004. (Summary) Laminin gamma 2 chain is an extracellular matrix protein that plays an important role in cell migration and tumor invasion. We report altered expression and characteristic localization of this chain in a series of 105 cases of intrahepatic cholangiocarcinomas examined immunohistochemically. All tumors were grossly classified into the following three types: intraductal growth type (n=9), periductal infiltrating type (n=8) and mass-forming type (n=88). The tumors exhibited three distinct staining types: basement membrane staining, cytoplasmic staining and stromal staining. The basement membranous staining of laminin gamma 2 chain was more frequent in biliary dysplasia, intraductal growth and periductal infiltrating type than in mass-forming type. The cytoplasmic staining of carcinoma cells was observed especially at the cancer-stromal interface or at the invasive front of tumors. Stromal staining of laminin gamma 2 chain was essentially localized in the stroma around cancer cells at the invasive area, and the expression was significantly correlated with tumor aggressive factors and a poor prognosis in patients with intrahepatic cholangiocarcinoma. We conclude that laminin gamma 2 chain exhibits aberrant expression in a stepwise manner through different aggressive stages of tumor progression. (Keyword) intrahepatic cholangiocarcinoma / laminin gamma 2 chain / growth morphology (Link to Publication Site) ● Publication site (DOI): 10.1038/modpathol.3800143 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15105812 ● Search Scopus @ Elsevier (PMID): 15105812 ● Search Scopus @ Elsevier (DOI): 10.1038/modpathol.3800143 (DOI: 10.1038/modpathol.3800143, PubMed: 15105812)
23.	Norifumi Harimoto, Mitsuo Shimada, Shin-ichi Aishima, Dai Kitagawa, Shinji Itoh, Eiji Tsujita, Shin-ichiro Maehara, Akinobu Taketomi, Shinji Tanaka, Ken Shirabe and Yoshihiko Maehara : The role of heat shock protein 27 expression in hepatocellular carcinoma in Japan: special reference to the difference between hepatitis B and C, International Association for the Study of the Liver, Aug. 2004. (Summary) A recent report showed that heat shock protein (HSP)-27 expression was related to histological grade and survival of patients with hepatocellular carcinoma (HCC). The aim of this study was to examine the effect of expression of HSP-27 on clinicopathological variables in Japanese patients with HCC. An immunohistochemical study for HSP-27 was performed on 60 HCC cases using a monoclonal anti-HSP-27 antibody. We divided 60 patients into two groups, patients with a low expression of HSP-27 (n = 34) and those with a high expression of HSP-27 (n = 26). Forty patients tested positive for the hepatitis C virus (HCV) antibody and 20 tested positive for the hepatitis B surface antigen. There appeared to be no relationship between HSP expression and clinicopathologic factors and no differences were observed between the high expression group and the low expression group. In the hepatitis B virus (HBV) group (n = 20), HSP-27 expression correlated significantly with prognosis, disease-free survival (DFS) and overall survival. High expression was significantly associated with poor prognosis in the HBV group. In contrast, patients with a high expression tended to have a good prognosis in the HCV group (n = 40): DFS and overall survival. This study showed the possibility that HSP-27 plays different roles in HBV- and HCV-associated HCCs. (Keyword) heat shock protein 27 / hepatitis virus / hepatocellular carcinoma (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1478-3231.2004.0927.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15287854 ● Search Scopus @ Elsevier (PMID): 15287854 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1478-3231.2004.0927.x (DOI: 10.1111/j.1478-3231.2004.0927.x, PubMed: 15287854)
24.	Akira Hirao, Masao Yamasaki, Hitomi Chujo, Nami Koyanagi, Hiroaki Kanouchi, Shin Yasuda, Aya Matsuo, Eri Nishida, Tatsuya Rikimaru, Eiji Tsujita, Mitsuo Shimada, Yoshihiko Maehara, Hirofumi Tachibana and Koji Yamada : Effect of dietary conjugated linoleic acid on liver regeneration after a partial hepatectomy in rats, The Vitamin Society of Japan, Feb. 2004. (Summary) We examined the effect of dietary conjugated linoleic acid (CLA) on liver regeneration after a partial hepatectomy (PH) in Sprague-Dawley rats. PH was performed on rats fed a 0 or 1 wt.% CLA diet for 3 wk. Average liver weight in the CLA fed rat population was heavier than the control rat population at the time of PH and 1-d after PH. Conversely. CLA fed rats' liver weight was significantly lower than control rats at 7-d after PH. This suggests that dietary CLA reduced liver weight gain after PH. Dietary CLA did not affect serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) activities. However. CLA significantly reduced serum albumin levels at 1-d but not at 7-d after PH. 5-Bromo- and 5-iododeoxyuridine incorporation into hepatocytes 1-d post PH was lower in the CLA group. In conclusion, the data suggests that dietary CLA inhibits DNA synthesis after PH, which results in hepatocyte proliferation inhibition. (Keyword) conjugated linoleic acid / liver regeneration / hepatectomy / Sprague-Dawley rats / DNA synthesis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15228211 ● Search Scopus @ Elsevier (PMID): 15228211 (PubMed: 15228211)
25.	Takahiro Terashi, Shinichi Aishima, Kenichi Taguchi, Yoshiki Asayama, Keishi Sugimachi, Shuji Matsuura, Mitsuo Shimada, Shinichiro Maehara, Yoshihiko Maehara and Masazumi Tsuneyoshi : Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma, International Association for the Study of the Liver, Feb. 2004. (Keyword) aggressiveness / clinical outcome / immunohistochemistry / intrahepatic cholangiocarcinoma / invasion / metastasis / osteopontin
26.	Mitsuo Shimada : コンセンサス2004 肝疾患治療, Arcmedium, Tokyo, Feb. 2004.
27.	Mitsuo Shimada, Yo-ichi Yamashita, Shinji Tanaka, Ken Shirabe, Kohji Nakazawa, Hiroyuki Ijima, Ryoichi Sakiyama, Junji Fukuda, Kazumori Funatsu and Keizo Sugimachi : Characteristic Gene Expression Induced by Polyurethane Foam/Spheroid Culture of Hepatoma Cell Line, Hep G2 as A Promising Cell Source for Bioartificial Liver, 2004.
28.	Yo-ichi Yamashita, Mitsuo Shimada, Norifumi Harimoto, Shinji Tanaka, Ken Shirabe, Hiroyuki Ijima, Kohji Nakazawa, Junji Fukuda, Kazumori Funatsu and Yoshihiko Maehara : cDNA microarray analysis in hepatocyte differentiation in Huh 7 cells, Cognizant Communication Corporation, 2004. (Summary) The risk of xenozoonosis infections poses the greatest obstacle against the clinical application of a hybrid artificial liver support system (HALSS). Primary human hepatocytes are an ideal source for HALSS, but the shortage of human livers available for hepatocyte isolation limits this modality. To resolve this issue, we previously demonstrated the upregulation of hepatocyte-specific function by spheroid formation in polyurethane foam and by culturing with the histone deacetylase inhibitor, trichostatin A (TSA), in a human hepatoma cell line (Huh 7). In this article we analyze the gene expression profile using cDNA microarray (1281 genes) in spheroid formation or culturing with TSA in Huh 7 to determine the target genes in hepatocyte differentiation. In both the spheroid formation and in the culture with TSA, the Oct-3/4 transcription factor was upregulated more thantwofold, while the early growth response-1 (EGR-1) transactivator was downregulated less than 0.5-fold. These results indicate that expressions of Oct-3/4 and EGR-1 may be key factors in the induction of hepatocyte differentiation in Huh 7. (Keyword) cDNA microarray / Hepatocyte differentiation / Hybrid artificial liver support system (HALSS) (Link to Publication Site) ● Publication site (DOI): 10.3727/000000004783983396 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15690981 ● Search Scopus @ Elsevier (PMID): 15690981 ● Search Scopus @ Elsevier (DOI): 10.3727/000000004783983396 (DOI: 10.3727/000000004783983396, PubMed: 15690981)
29.	Shunji Taniguchi, Yasushi Mochida, Takeshi Uchiumi, Tomoko Tahira, Kenshi Hayashi, Koichi Takagi, Mitsuo Shimada, Yoshihiko Maehara, Hiroyuki Kuwano, Suminori Kono, Hitoo Nakano, Michihiko Kuwano and Morimasa Wada : Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon, American Association for Cancer Research, Dec. 2003. (Summary) The multidrug resistance 1 (MDR1) is a key molecule in determining not only the resistance of cancer cells to anticancer agents but also the disposition of a variety of drugs in intestinal and other tissues. However, the mechanism underlying interindividual variations in levels of MDR1 activity and expression in various tissues remains unclear. We analyzed the nucleotide sequence polymorphisms in the 5' upstream regulatory region of the gene spanning 4 kb from the transcriptional start site of MDR1 and tried to identify any associations between polymorphisms and MDR1 expression. Within that region, we identified eight single nucleotide polymorphisms (SNPs) in the region in the Japanese population. Of the SNPs identified, -2410T>C, -1910T>C, and 692T>C were in perfect linkage disequilibrium. In normal colorectal mucosa, diplotypes at the region showed more significant association with the expression level of MDR1 mRNA than each SNP did. In an in vitro reporter assay, transcription activity of the minor-type construct carrying haplotypes 2 and 3 was significantly lower than that of the major-type construct carrying haplotype 1. We next identified two DNA binding proteins: one protein bound to the nucleotide sequence carrying -692T but not to that carrying -692C and another bound to the nucleotide sequence carrying -2352G but three times weaker than that carrying -2352A. This suggested the significance of SNP at -692 and -2352 of MDR1 in variable expression in the colon interindividually. This is the first report connecting SNPs and interindividual variety of MDR1 expression rationally. (Keyword) Alleles / Base Sequence / Colon / Colonic Neoplasms / DNA Primers / Electrophoretic Mobility Shift Assay / Genes, MDR / Haplotypes / Humans / Intestinal Mucosa / Japan / Liver / Polymorphism, Single Nucleotide / Rectum / Regulatory Sequences, Nucleic Acid (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14707276 ● Search Scopus @ Elsevier (PMID): 14707276 (PubMed: 14707276)
30.	Keizo Sugimachi, Shinji Tanaka, Kenichi Taguchi, Shinichi Aishima, Mitsuo Shimada and Masazumi Tsuneyoshi : Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma, BMJ Publishing Group Ltd & Association of Clinical Pathologists, Nov. 2003. (Summary) Aim: Angiopoietin 1 (Ang-1) and its antagonist, angiopoietin 2 (Ang-2), are novel ligands that regulate the Tie2 receptor. The Ang-2 gene is upregulated in the hypervascular type of human hepatocellular carcinoma (HCC). To gain a better understanding of the role of the Ang-Tie2 system in HCC the expression of these genes was investigated in a series of human HCCs. The expression of the angiopoietin and Tie2 proteins was investigated in nine normal liver tissues and 52 surgically resected HCCs. In addition, the effects of hypoxic stimuli on Ang-1, Ang-2, vascular endothelial growth factor (VEGF), and erythropoietin (EPO) expression was investigated in Hep3B cells. Ang-1, rather than Ang-2, was more frequently expressed in the normal liver. Ang-1 was expressed in 68% of HCCs, whereas Ang-2 was expressed in 81%, and was significantly higher in poorly differentiated HCCs characterised by high vascularity (p = 0.02), and in tumours with a peliotic change (p = 0.02). Strong expression of Tie2 was seen in tumour vessels in accordance with Ang-2 expression. In Hep3B cells, hypoxic stimuli upregulated VEGF and EPO, but not Ang-1 or Ang-2. These data support the evidence that the reversal of Ang-1 and Ang-2 expression plays an important role in the angiogenic and dedifferentiation processes in HCC. The hypoxic stimuli were not responsible for Ang-2 upregulation, unlike that of VEGF, in human HCC cells. (Keyword) angiopoietin / Tie2 / hypoxia / angiogenesis / hepatocellular carcinoma (Link to Publication Site) ● Publication site (DOI): 10.1136/jcp.56.11.854 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14600132 ● Search Scopus @ Elsevier (PMID): 14600132 ● Search Scopus @ Elsevier (DOI): 10.1136/jcp.56.11.854 (DOI: 10.1136/jcp.56.11.854, PubMed: 14600132)
31.	Mizuki Ninomiya, Noboru Harada, Satoko Shiotani, Shoji Hiroshige, Ryosuke Minagawa, Yuji Soejima, Taketoshi Suehiro, Takashi Nishizaki, Mitsuo Shimada and Keizo Sugimachi : Hepatocyte growth factor and transforming growth factor beta1 contribute to regeneration of small-for-size liver graft immediately after transplantation, Springer-Verlag, Berlin, Nov. 2003. (Summary) Although the ability of the liver to regenerate to a predetermined size after resection made adult-to-adult living donor liver transplantation (LDLT) possible, there is little information regarding the growth regulatory mechanism for a small-for-size graft. Forty-one cases of LDLT were divided into two groups by graft volume to standard liver volume ratio (GV/SLV); small graft group (Group S, GV/SLV<40%, n=16) and non-small graft group (Group NS, GV/SLV>40%, n=25). The regeneration rate (GV at 1 week/harvested GV) and serum levels of hepatocyte growth factor (HGF), transforming growth factor-alpha (TGF-alpha) and transforming growth factor-beta1 (TGF-beta1) were compared between two groups. The regeneration rates in Group S were significantly higher than that of Group NS (217+/-12% and 178+/-10%, respectively, P<0.01). The serum HGF levels of Group S were significantly higher than those of Group NS on POD 1. The TGF-beta1 levels of Group S were significantly higher than those of Group NS on POD 3 and 5. The TGF-alpha levels were not different at any time points studied. These results indicate that a small-for-size graft retains the capacity to regenerate faster by modulation of expression pattern of HGF and TGF-beta1 immediately after LDLT. After the acceleration of the regenerative response by HGF, subsequent elevation of TGF-beta1 synergistically controls graft size, regulating uncontrolled proliferation of hepatocytes. (Keyword) Liver regeneration / Small grafts / CT volumetry / Regeneration rates (Link to Publication Site) ● Publication site (DOI): 10.1007/s00147-003-0628-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12879228 ● Search Scopus @ Elsevier (PMID): 12879228 ● Search Scopus @ Elsevier (DOI): 10.1007/s00147-003-0628-9 (DOI: 10.1007/s00147-003-0628-9, PubMed: 12879228)
32.	Shin-ichi Aishima, Ken-ichi Taguchi, Takahiro Terashi, Shuji Matsuura, Mitsuo Shimada and Masazumi Tsuneyoshi : Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma, United States and Canadian Academy of Pathology, Oct. 2003. (Summary) Tenascin and decorin are components of the extracellular matrix (ECM) that are implicated in cell proliferation in tumors. Here, we propose that abnormal expression of stromal ECM may play an important role in the progression of intrahepatic cholangiocarcinoma, which is characterized by desmoplastic reaction. To explore this hypothesis, we performed immunohistochemical analysis in order to examine the expression and distribution of tenascin and decorin in 75 cases of intrahepatic cholangiocarcinoma. In the intratumoral stroma, positive staining for tenascin was observed in 51 (68%) cases, and positive staining for decorin was observed in 61 (81%) cases. However, at the invasive front, positive staining for tenascin was found in 23 (31%) cases, and positive staining for decorin was found in 6 (8%) cases. Decorin staining was not correlated with aggressive behavior of intrahepatic cholangiocarcinoma, whereas intratumoral tenascin staining was correlated with lymphatic permeation and proliferative activity measured by Ki67. Tenascin staining at the invasive front was associated with tumor size, lymphatic permeation, lymph node metastasis, and proliferative activity and appeared to be a useful prognostic factor by univariate analysis, although it was not an independent prognostic factor. These results indicate that tenascin plays a role in tumor progression in cases of intrahepatic cholangiocarcinoma and that tenascin expression, especially at the invasive front, may be a useful marker in evaluating an unfavorable prognosis in patients with intrahepatic cholangiocarcinoma. (Keyword) Decorin / Intrahepatic cholangiocarcinoma / Invasive front / Prognosis / Tenascin (Link to Publication Site) ● Publication site (DOI): 10.1097/01.MP.0000086860.65672.73 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14559985 ● Search Scopus @ Elsevier (PMID): 14559985 ● Search Scopus @ Elsevier (DOI): 10.1097/01.MP.0000086860.65672.73 (DOI: 10.1097/01.MP.0000086860.65672.73, PubMed: 14559985)
33.	Tohru Utsunomiya, Mitsuo Shimada, Tatsuya Rikimaru, Hirofumi Hasegawa, Yoichi Yamashita, Takayuki Hamatsu, Masao Yamasaki, Shihoko Kaku, Koji Yamada and Keizo Sugimachi : Antioxidant and anti-inflammatory effects of a diet supplemented with sesamin on hepatic ischemia-reperfusion injury in rats, Thieme, Stuttgart, ALLEMAGNE, Sep. 2003.
34.	Ken Shirabe, Mitsuo Shimada, Takashi Matsumata, Hidefumi Higashi, Yohichi Yakeishi, Shigeki Wakiyama, Yasuharu Ikeda, Takuhiro Ezaki, Shingo Fukuzawa, Kenji Takenaka, Keishi Kishikawa, Tetsuo Ikeda, Ken-ichi Taguchi, Yoshihiko Maehara and Keizo Sugimachi : Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection, Thieme, Stuttgart, ALLEMAGNE, Sep. 2003.
35.	Kosei Moriyama, Kazuhiro Hayashida, Mitsuo Shimada, Shuji Nakano, Yoshiyuki Nakashima and Yasuyuki Fukumaki : Antisense RNAs transcribed from the upstream region of the precore/core promoter of hepatitis B virus, Society for General Microbiology, Jul. 2003. (Summary) The bidirectional activity of the precore/core promoter of hepatitis B virus (HBV) has been demonstrated in cultured cell lines. However, HBV antisense transcripts (asRNAs) have not been demonstrated in vivo. In the present study using liver tissue from patients with chronic hepatitis, an anchored 5'RACE mapping the 5' ends at position 1680/1681, 1655 or 1609/1602 was carried out. In limited cases, RLM-3'RACE detected asRNAs to terminate at four or five consecutive dT residues in the 0.7 kb downstream region. PCR of oligo(dT)-primed cDNA did not amplify a typical polyadenylated asRNA. RT-PCR using various primers did not detect any spliced forms. Competitive RT-PCR estimated the copy numbers of the asRNAs to be 0.05-0.4 % of total sense RNAs. All sequenced asRNAs had ORF6 but, in one patient, the asRNA initiating at position 1680/1681 had additional initiation and termination codons in front of ORF6. Therefore, asRNAs are transcribed by RNA polymerase III at a low level, encompass a dispensable ORF6 gene and might be retained in the nucleus. The endogenous asRNAs complementary to the common ends of all sense RNAs suggest antisense-mediated self-regulation of hepadnavirus. (Keyword) Base Sequence / Gene Expression Regulation, Viral / Hepatitis B Core Antigens / Hepatitis B virus / Hepatitis B, Chronic / Humans / Liver / Molecular Sequence Data / Promoter Regions, Genetic / Protein Precursors / RNA, Antisense / Trans-Activators / Transcription, Genetic / Viral Regulatory and Accessory Proteins (Link to Publication Site) ● Publication site (DOI): 10.1099/vir.0.19170-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12810886 ● Search Scopus @ Elsevier (PMID): 12810886 ● Search Scopus @ Elsevier (DOI): 10.1099/vir.0.19170-0 (DOI: 10.1099/vir.0.19170-0, PubMed: 12810886)
36.	Takayuki Hamatsu, Tatsuya Rikimaru, Yo-ichi Yamashita, Shinichi Aishima, Shinji Tanaka, Ken Shirabe, Mitsuo Shimada, Yasushi Toh and Keizo Sugimachi : The role of MTA1 gene expression in human hepatocellular carcinoma, May 2003. (Summary) The MTA1 gene has been identified as metastasis-associated gene and has been seen to correlate with the degree of invasion and lymphatic metastasis in gastric, colorectal, and esophageal carcinomas. We investigated the possible role of MTA1 gene expression in hepatocellular carcinoma (HCC). The mRNA expression level of the MTA1 gene was examined using reverse transcription polymerase chain reaction (RT-PCR) in HCC and paired non-tumor liver tissues which were obtained from 33 patients who underwent curative hepatectomy. The expression level of each case was calculated as tumor/non-tumor (T/N) ratios. To clarify the clinical significance of MTA1 gene expression in HCC, patient disease-free survival rate after hepatectomy were univariately analyzed using 25 clinicopathological variables, including MTA1 expression level. High expression (T/N > or =1) of the MTA1 gene in HCC as compared to the paired non-tumor tissues was recognized in 14 of 33 (42%) samples. With regard to the differentiation of HCC, the high expression of MTA1 gene in well or moderately differentiated HCC and poorly differentiated HCC were observed in 9 of 27 (33%) and 5 of 6 (83%) samples, respectively. There was no relation between expression levels of the MTA1 gene and cancer invasion to the portal vein or intrahepatic metastasis. However, the disease-free survival rate of the MTA1-high expression group (T/N > or =1) was significantly lower than that of the MTA1-low expression group (T/N <1) (p<0.05). High expression of the MTA1 gene is suggested to be a new prognostic indicator after curative hepatectomy for HCC. (Keyword) MTA1 gene / RT-PCR / hepatocellular carcinoma / disease-free survival rate (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12684630 ● Search Scopus @ Elsevier (PMID): 12684630 (PubMed: 12684630)
37.	Yo-ichi Yamashita, Mitsuo Shimada, Norifumi Harimoto, Tatsuya Rikimaru, Ken Shirabe, Shinji Tanaka and Keizo Sugimachi : Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells, Wiley-Liss, Inc., Feb. 2003. (Summary) Remodeling of the chromatin template by inhibition of HDAC activities represents a potential transcriptional therapy for neoplastic disease. A number of HDAC inhibitors that modulate in vitro cell growth and differentiation have been developed. We analyzed the effects of TSA, a specific and potent HDAC inhibitor, on the human hepatoma cell lines HepG2 and Huh-7. TSA increased levels of acetylated histones H3 and H4 in both HepG2 and Huh-7. It inhibited cell proliferation in vitro and induced G(0)/G(1) arrest in HepG2 and apoptosis in Huh-7. Gene expression of liver-specific functions and liver-enriched transcription factors was upregulated by TSA. TSA upregulated the ammonia removal rate and the albumin synthesis rate of HepG2 and Huh-7. Our results indicate that TSA can induce cell-cycle arrest/apoptosis and hepatocyte differentiation in human liver cancer cell lines. (Keyword) histone deacetylase inhibitor / trichostatin A / hepatocyte differentiation / HepG2 / Huh-7 (Link to Publication Site) ● Publication site (DOI): 10.1002/ijc.10699 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12494463 ● Search Scopus @ Elsevier (PMID): 12494463 ● Search Scopus @ Elsevier (DOI): 10.1002/ijc.10699 (DOI: 10.1002/ijc.10699, PubMed: 12494463)
38.	Asaki Hattori, Naoki Suzuki, Makoto Hashizume, Tomohiko Akahoshi, Kozo Konishi, Shohei Yamaguchi, Mitsuo Shimada and Mitsuhiro Hayashibe : A robotic surgery system (da Vinci) with image guided function--system architecture and cholecystectomy application, IOS Press, Amsterdam, 2003.
39.	陳献, 久田俊明, 佐久間一郎, 土肥健純, Mitsuo Shimada and 橋爪誠 : 有限要素法による肝臓手術ナビゲーションに関する研究, 2003.
40.	Takashi Maeda, Hidetoshi Itasaka, Kenji Takenaka, Takashi Matsumata, Mitsuo Shimada, Toshihiko Ikeda and Keizo Sugimachi : Low-dose cisplatin plis oral tegafur and uracil for the treatment of lung metastases of hepatocellular carcinoma, 2003.
41.	Junji Fukuda, Ken Okamura, Kohji Nakazawa, Hiroyuki Ijima, Yo-ichi Yamashita, Mitsuo Shimada, Ken Shirabe, Eiji Tsujita, Keizo Sugimachi and Kazumori Funatsu : Efficacy of a polyurethane foam/spheroid artificial liver by using human hepatoblastoma cell line (Hep G2), Cognizant Communication Corporation, 2003. (Keyword) Hybrid artificial liver / Spheroids / Polyurethane foam / Hep G2 / Human primary hepatocytes / Porcine primary hepatocytes
42.	Mitsuo Shimada and 杉町圭蔵 : A.肝 17. 肝細胞眼ー外科手術と集学的治療, Nankodo, Tokyo, 2003.
43.	Masao Yamasaki, Hitomi Chujo, Yasuko Koga, Ayana Oishi, Tatsuya Rikimaru, Mitsuo Shimada, Keizo Sugimachi, Hirofumi Tachibana and Koji Yamada : Potent cytotoxic effect of the trans10, cis12 isomer of conjugated linoleic acid on rat hepatoma dRLh-84 cells, Elsevier Science, Ireland, Dec. 2002. (Keyword) Conjugated linoleic acid / caspase / apoptosis / Hepatoma (Link to Publication Site) ● Publication site (DOI): 10.1016/S0304-3835(02)00459-7 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/S0304-3835(02)00459-7 (DOI: 10.1016/S0304-3835(02)00459-7)
44.	Masao Yamasaki, Atsushi Ikeda, Akira Hirao, Yoko Tanaka, Tatsuya Rikimaru, Mitsuo Shimada, Keizo Sugimachi, Hirofumi Tachibana and Koji Yamada : Dose-dependent effect of dietary conjugated linoleic acid on the growth of rat hepatoma dRLh-84 cells in vivo, The Japanese Society of Food & Nutrition and the Vitamin Society of Japan, Dec. 2002. (Summary) In this study, the effect of varying doses of conjugated linoleic acid (CLA) on the growth of transplanted hepatoma dRLh-84 cells and the relationship between tumor growth and prostaglandin (PG) E2 production or cyclooxygenase (COX)-2 expression were examined. Donryu rats were fed an experimental diet containing 0, 0.1, 0.5, or 2 wt.% CLA for 3 wk, and then dRLh-84 cells were transplanted into the liver. Results show that dietary CLA (0.5 and 2 wt.%) significantly enhanced the growth of the transplanted hepatoma cells compared to the non-CLA diet group at 20 d after cell transplantation. Tumor weight at 10 d after transplantation was also significantly higher in the 2 wt.% CLA group than in non-CLA fed rats. Ten days after transplantation, the PGE2 level in the tumor tissue was shown to be depressed in a CLA dose-dependent manner. Cyclooxygenase-2 (COX-2) mRNA expression in the tumor also tended to be lower in the CLA group than in the non-CLA diet group 10 d after transplantation. Dietary CLA did not affect the tumor phospholipid arachidonic acid level, which is a substrate for PG synthesis. These results indicate that dietary CLA of at least 0.5 wt.% enhances the growth of transplanted dRLh-84 cells in vivo. It is believed that growth promotion of dRLh-84 cells in vivo by CLA cannot be clarified by the PG synthesis dependent mechanism. (Keyword) Animals / Blotting, Southern / Body Weight / Cell Division / Cyclooxygenase 2 / Dietary Fats, Unsaturated / Dinoprostone / Dose-Response Relationship, Drug / Isoenzymes / Linoleic Acid / Liver / Liver Neoplasms, Experimental / Male / Organ Size / Phospholipids / Prostaglandin-Endoperoxide Synthases / RNA, Messenger / Rats / Reverse Transcriptase Polymerase Chain Reaction (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12775118 ● Search Scopus @ Elsevier (PMID): 12775118 (PubMed: 12775118)
45.	Shin-ichi Aishima, Yoshiki Asayama, Ken-ichi Taguchi, Keishi Sugimachi, Ken Shirabe, Mitsuo Shimada, Keizo Sugimachi and Masazumi Tsuneyoshi : The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma, the United States and Canadian Academy of Pathology,Inc, Nov. 2002. (Keyword) Intrahepatic cholangiocarcinoma / Keratin 903 / Prognostic marker
46.	Ichiro Yoshino, Makoto Hashizume, Mitsuo Shimada, Morimasa Tomikawa and Keizo Sugimachi : Video-assisted thoracoscopic extirpation of a posterior mediastinal mass using the da Vinci computer enhanced surgical system, The Society of Thoracic Surgeons, Oct. 2002. (Summary) A 28-year-old woman presented a left posterior mediastinal mass surrounded by the intercostal vein, hemiazygos vein, sympathetic nerve, and descending aorta. We successfully resected the mass, that was revealed to be a bronchogenic cyst, by a totally thoracoscopic procedure using the da Vinci computer-enhanced system (Intutive Surgical, Mountain View, CA) without injuring the neighboring structures or the capsule of the mass. (Keyword) Adult / Bronchogenic Cyst / Female / Humans / robotics / Surgery, Computer-Assisted / Thoracic Surgery, Video-Assisted (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12400778 ● Search Scopus @ Elsevier (PMID): 12400778 (PubMed: 12400778)
47.	Mitsuo Shimada, 辻田英司 and 杉町圭蔵 : 最新消化器内視鏡治療第2部第14章, 先端医療技術研究所, Tokyo, Jul. 2002.
48.	Ken-ichi Taguchi, Yoshiki Asayama, Shin-ichi Aishima, Hidehiro Nishi, Keishi Sugimachi, Shuji Matsuura, Takahiro Terashi, Takeharu Yamanaka, Mitsuo Shimada, Keizo Sugimachi and Masazumi Tsuneyoshi : Morphologic approach to hepatocellular carcinoma development in man: de novo or the so-called 'dysplastic nodule-carcinoma' sequence?, D.A. Spandidos, Athens, Jul. 2002. (Summary) The so-called dysplastic nodule-carcinoma sequence in the liver is generally accepted because hepatocellular carcinoma is not an uncommon finding in precancerous lesions. In order to evaluate the existence and frequency of de novo hepatocarcinogenesis we studied 112 surgically resected early well-differentiated hepatocellular carcinomas showing replacing growth without less differentiated component in themselves. They were divided into two groups: carcinoma in dysplastic area (type A) and carcinoma without dysplastic area (type B) and were analyzed clinicopathologically. We encountered 77 cases of type A (68.8%) and 35 of type B (31.2%). The frequency of type A in cirrhotic group (74.7%) is statistically higher than that of non-cirrhotic group (54.5%) (p=0.0453). Using multivariate analysis, the occurrence of type A was related with higher age, the presence of cirrhosis and hepatitis B surface antigen positive. The tumor size and the presence of fatty change in the tumor tended to relate with type A. We propose two pathways morphologically in early hepatocarcinogenesis, one of which has a close relation to hepatitis B virus and/or cirrhosis. (Keyword) Carcinoma, Hepatocellular / cell differentiation / Cell Transformation, Neoplastic / Female / Hepatitis B Surface Antigens / Humans / Liver / Liver Cirrhosis / Liver Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Precancerous Conditions (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12066201 ● Search Scopus @ Elsevier (PMID): 12066201 (PubMed: 12066201)
49.	Kenji Shinozaki, Hiroshi Honda, Kengo Yoshimitsu, Ken-ichi Taguchi, Toshiro Kuroiwa, Hiroyuki Irie, Hitoshi Aibe, Akihiro Nishie, Tomohiro Nakayama, Mitsuo Shimada and Kouji Masuda : Optimal multi-phase three-dimensional fast imaging with steady-state free precession dynamic MRI and its clinical application to the diagnosis of hepatocellular carcinoma, Medical Tribune Inc., May 2002. (Summary) To determine the appropriate acquisition parameters for three-dimensional fast imaging with steady-state free precession (3D-FISP), to clarify the superiority of 3D-FISP to two-dimensional fast low-angle shot (2D-FLASH) on phantom study, and to clarify the clinical usefulness of 3D-FISP in diagnosing hepatocellular carcinoma (HCC). 3D-FISP images with varying flip angles were compared by using a phantom. Signal-to-noise ratios (SNRs) and contrast-enhancement ratios (CERs) were compared for the four two-dimensional fast low-angle shot (2D-FLASH) sequences and 3D-FISP sequences in a phantom. The optimal 3D-FISP dynamic study was compared with plain, postcontrast MR sequences used to study 78 HCC cases and analyzed according to histological grade. The 3D-FISP image obtained 30 sec after gadopentetate dimeglumine (Gd) administration was also compared with CT hepatic angiography (CTHA). A 25 degrees flip angle and double-dose Gd administration were appropriate for 3D-FISP dynamic study. CER was the highest with 3D-FISP, and SNR was higher in 3D-FISP than in 2D-FLASH images in a phantom with high Gd concentration. Among the 105 lesions, 103 (98%) were depicted on 3D-FISP images. The detection rate of HCC on 3D-FISP was higher than 95% for each histological grade. The vascularity of the tumors as determined by CTHA findings was correctly diagnosed on 3D-FISP in 80% of cases. In phantom study, 3D-FISP with double-dose Gd injection showed higher contrast than 2D-FLASH as a sequence for liver dynamic study. In clinical study, 3D-FISP is useful in the detection of HCC, regardless of tumor vascularity and histological grade. (Keyword) magnetic resonance imaging / three-dimensional image / phantom / liver / hepatocellular carcinoma (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12126083 ● CiNii @ National Institute of Informatics (CRID): 1574231875582103424 ● Search Scopus @ Elsevier (PMID): 12126083 (PubMed: 12126083, CiNii: 1574231875582103424)
50.	Tsuyoshi Tajima, Hiroshi Honda, Ken-ichi Taguchi, Yoshiki Asayama, Toshirou Kuroiwa, Kengo Yoshimitsu, Hiroyuki Irie, Hitoshi Aibe, Mitsuo Shimada and Kouji Masuda : Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation, American Roentgen Ray Society, Apr. 2002.
51.	Shinichi Aishima, Ken-ichi Taguchi, Keishi Sugimachi, Mitsuo Shimada, Keizo Sugimachi and Masazumi Tsuneyoshi : c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma, the British Division of the International Academy of Pathology, Mar. 2002. (Summary) The c-erbB-2 and c-Met proto-oncogenes are important for tumour invasiveness and metastasis in many types of malignant tumours. Previous studies have indicated that these proteins are associated with carcinogenesis in intrahepatic cholangiocarcinoma. In this study, we examined c-erbB-2 and c-Met expression by immunohistochemistry in hepatolithiasis, intrahepatic cholangiocarcinoma and metastatic lymph node, in order to clarify whether these proteins play a role in carcinogenesis and tumour metastasis in intrahepatic cholangiocarcinoma. In hepatolithiasis, the staining for c-erbB-2 was positive in 14 of the 23 (61%) cases, while staining for c-Met was positive in eight of the 23 (35%) cases. In intrahepatic cholangiocarcinoma, staining for c-erbB-2 was positive in 45 of the 81 (55%) cases, while staining for c-Met was positive in 28 (35%) cases. The positivity of c-Met staining in intrahepatic cholangiocarcinoma was significantly higher in the differentiated type of cholangiocarcinoma than in the undifferentiated type. In addition, c-Met-positive staining had an inverted correlation with tumour size, the presence of perineural invasion and the presence of lymph node metastasis. c-Met staining had a significantly higher positivity in cases at an early stage of intrahepatic cholangiocarcinoma. In contrast, the positivity of c-erbB-2 staining in intrahepatic cholangiocarcinoma was significantly higher in cases with lymph node metastasis than in cases without. In metastatic lymph nodes, the staining for c-erbB-2 was positive in 20 of the 25 (80%) cases, while staining for c-Met was positive in six of the 25 (24%) cases. There was no difference in survival between c-erbB-2-positive and negative patients. However, the patients with c-Met-positive tumours had a significantly longer survival than those with c-Met-negative tumours in the medium survival term. The multivariate analysis showed the presence of lymph node metastasis, lymphatic permeation and histological differentiation to be independent prognostic factors. These results indicate that increased c-Met expression participates in cholangiocarcinogenesis and in the early developmental stages of intrahepatic cholangiocarcinoma, while increased c-erbB-2 expression contributes to the development of cholangiocarcinogenesis into an advanced stage associated with tumour metastasis. (Keyword) hepatolithiasis / intrahepatic cholangiocarcinoma / c-erbB-2 / c-Met / immunohistochemistry (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1365-2559.2002.00353.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11895493 ● Search Scopus @ Elsevier (PMID): 11895493 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1365-2559.2002.00353.x (DOI: 10.1046/j.1365-2559.2002.00353.x, PubMed: 11895493)
52.	K Kanoh, Ken-ichi Nomoto, T Shimura, Mitsuo Shimada, Keizo Sugimachi and Hiroyuki Kuwano : A comparison of right-lobe and left-lobe graft for living-donor liver transplantation, Jan. 2002.
53.	Yuh Fujiwara, Mitsuo Shimada, Kenji Takenaka, Kiyoshi Kajiyama, Ken Shirabe and Keizo Sugimachi : The Sialyl Lewis X expression in hepatocarcinogenesis: Potential predictor for the emergence of hepatocellular carcinoma, Thieme, Stuttgart, ALLEMAGNE, Jan. 2002.
54.	Shinichi Aishima, Kenichi Taguchi, Keishi Sugimachi, Yoshiki Asayama, Hidehiro Nishi, Mitsuo Shimada, Keizo Sugimachi and Masazumi Tsuneyoshi : The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma, Westminster Publications, Jan. 2002.
55.	Kohji Nakazawa, Hiroyuki Ijima, Junji Fukuda, Ryo-ichi Sakiyama, Yo-ichi Yamashita, Mitsuo Shimada, Ken Shirabe, Eiji Tsujita, Keizo Sugimachi and Kazumori Funatsu : Development of a hybrid artificial liver using polyurethane foam/hepatocyte spheroid culture in a preclinical pig experiment, Wichtig Editore, Milano,Italy, Jan. 2002. (Summary) We describe a preclinical study of our original hybrid artificial liver support system (HALSS) for a clinical trial. We designed a HALSS comprising a multi-capillary polyurethane foam packed-bed module (MC-PUF module) containing a total 200 g (2 x 10(10) cells) porcine hepatocytes, and an extracorporeal circulation device. Almost all porcine hepatocytes in the MC-PUF module formed many spherical multicellular aggregates (spheroids). This extracorporeal circulation device was improved to promote solute exchange between a living body and a MC-PUF module by including a plasma bypass line in the circulation loop. The efficacy of the HALSS was evaluated using a 25-kg pig with warm ischemic liver failure by portocaval shunt and ligation of hepatic artery (HALSS group, n=3). As a control experiment, the same system without hepatocytes in the module was used with the same kind of liver failure pig (Control group, n=3). The blood ammonia in the control group was 143 N-microg/dl at the start of circulation, and rapidly increased to 351 N-microg/dl at 2 hours and to 704 N-microg/dl at 6 hours. But the blood ammonia in the HALSS group was completely suppressed, and remained less than the hepatic coma level (over 200 N-microg/dl) during the circulation time. The blood glucose in the control group gradually decreased, and became less than 40 mg/dl within 6 hours of circulation. But the blood glucose in the HALSS group was maintained well, and remained the normal glucose level (50 - 105 mg/dl) for more than 20 hours of circulation. Improvement in blood creatinine and lactate, and the stabilization of vital signs and urinary excretion, were observed in the HALSS group. The survival time of the pigs in the HALSS group was 19.3 hours compared with 8.9 hours in the control group. In conclusion, our HALSS was effective to stabilize the general conditions of the body in addition to supporting various liver functions. These results suggest that our HALSS has a strong possibility to be used in treating liver failure patients. We have applied for approval of the clinical trial of our HALSS to our institutional ethics committee. (Keyword) Animals / Cell Culture Techniques / Equipment Design / Extracorporeal Circulation / Hepatocytes / Liver, Artificial / Models, Animal / Polyurethanes / Swine (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11853072 ● Search Scopus @ Elsevier (PMID): 11853072 (PubMed: 11853072)
56.	Takashi Kanematsu, Junichiro Furui, Katsuhiko Yanaga, Sadayuki Okudaira, Mitsuo Shimada and Ken Shirabe : A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000, Mosby,Inc, Jan. 2002. (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2002.119497 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1067/msy.2002.119497 (DOI: 10.1067/msy.2002.119497)
57.	服部麻木, 鈴木直樹, 橋爪誠, Mitsuo Shimada, 赤星朋比古, 小西晃造, 山口将平 and 林部充宏 : ロボット手術システム(da Vinci)のための術中ナビゲーターの開発, 2002.
58.	Yo-ichi Yamashita, Mitsuo Shimada, Eiji Tsujita, Ken Shirabe, Hiroyuki Ijima, Kohji Nakazawa, Ryoichi Sakiyama, Junji Fukuda, Kazumori Funatsu and Keizo Sugimachi : High metabolic function of primary human and porcine hepatocytes in a polyurethane foam/spheroid culture system in plasma from patients with fulminant hepatic failure, Cognizant Communication Corporation, 2002. (Keyword) Fulminant hepatic failure / Human hepatocytes / Porcine hepatocytes / Polyurethane foam/spheroid culture system
59.	Junji Fukuda, Ryoichi Sakiyama, Kohji Nakazawa, Hiroyuki Ijima, Yo-ichi Yamashita, Mitsuo Shimada, Ken Shirabe, Eiji Tsujita, Keizo Sugimachi and Kazumori Funatsu : Mass preparation of primary porcine hepatocytes and the design of a hybrid artificial liver module using spheroid culture for a clinical trial, European Society for Artificial Organs, Milano, Nov. 2001. (Summary) To isolate a large number of porcine hepatocytes, we originally developed a mass preparation method that combined the usual collagenase perfusion method of a whole liver with a collagenase redigestion method of tissue fragments after liver perfusion. Using a pig of 10kg, collagenase perfusion only resulted in a yield of 63+/-78 x 10(8) total cells with a viability of 69.2+/-25.3 %, but our combined method had a yield of 167+/-31 x 10(8) total cells with a viability of 87.9+/-4.4% (mean +/- SD). Also, the combined method was applied to two pigs of 10kg body weight at the same time, and isolated 387+/-89 x 10(8) hepatocytes with a viability of 87.1+/-6.9% and a purity of 93.6+/-2.8 % in 11 experiments. We designed a large multi-capillary polyurethane foam (MC-PUF) packed-bed module containing 1 x 10(10) porcine hepatocytes on a clinical trial scale. The porcine hepatocytes in the module formed spherical multicellular aggregates (spheroids) of 200 - 500 microm diameter. Most hepatocytes forming spheroids were viable judged by fluorescein diacetate and ethidium bromide staining. The activities of ammonia removal, albumin secretion and oxygen consumption of the large MC-PUF module were the same as for a small MC-PUF module containing 2 x 10(8) porcine hepatocytes, and were maintained for at least 9 days of culture. These results show that a large MC-PUF module is successfully scaled up 50 times. In conclusion, we succeeded in developing a mass preparation method of porcine hepatocytes and a large hybrid artificial liver module on a clinical trial scale. (Keyword) Animals / Cell Culture Techniques / Clinical Trials as Topic / Hepatocytes / Liver, Artificial / Spheroids, Cellular / Swine (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11797850 ● Search Scopus @ Elsevier (PMID): 11797850 (PubMed: 11797850)
60.	Ichiro Yoshino, Makoto Hashizume, Mitsuo Shimada, Morimasa Tomikawa, Makiko Tomiyasu, Ryuichi Suemitsu and Keizo Sugimachi : Thoracoscopic thymomectomy with the da Vinci computer-enhanced surgical system, The American Association for Thoracic Surgery, Oct. 2001. (Link to Publication Site) ● Publication site (DOI): 10.1067/mtc.2001.115231 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1067/mtc.2001.115231 (DOI: 10.1067/mtc.2001.115231)
61.	Keishi Sugimachi, Ken-ichi Taguchi, Shin-ichi Aishima, Shinji Tanaka, Mitsuo Shimada, Kiyoshi Kajiyama, Keizo Sugimachi and Masazumi Tsuneyoshi : Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma, the United States and Canadian Academy of Pathology,Inc, Sep. 2001. (Keyword) Intrahepatic cholangiocarcinoma (ICC) / β-catenin / Cell-to-cell adhesion / Nuclear translocation / immunohistochemistry / PCR-SSCP / Direct sequence
62.	Ken-ichi Noguchi, Munechika Enjoji, Makoto Nakamuta, Makoto Nakashima, Hidehiro Nishi, IIlesung Choi, Ken-ichi Taguchi, Kazuhiro Kotoh, Mitsuo Shimada, Keizo Sugimachi, Masazumi Tsuneyoshi, Hajime Nawata and Takeshi Watanabe : Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma, Elsevier Science, Ireland, Jul. 2001. (Summary) RCAS1 has been reported as a tumor-associated antigen in uterine and ovarian carcinomas. In vitro studies on RCAS1 indicated that it might function as an apoptosis-inducing factor since binding between RCAS1 and its receptor induced apoptosis in receptor-expressing cells. In this study, 68 surgically resected samples of hepatocellular carcinoma (HCC) were prepared and RCAS1 expression was examined immunohistochemically, because RCAS1 was also positive in all HCC cell lines tested. Clinical and pathological parameters were then compared between RCAS1-positive and -negative HCC cases. As a result, RCAS1 is expressed in 26.5% of HCC cases and vascular invasion is observed at a much higher rate in the RCAS1-positive cases (72.2%) than in RCAS1-negative cases (24.0%). RCAS1 is not an antigen specific for gynecological cancers. In HCC cases, the RCAS1-positive percentage is not high, however, RCAS1-positive HCCs exhibited a trend towards invasive character. (Keyword) Hepatocellular carcinoma / Tumor-associated antigen / Vascular invasion / Monoclonal antibody (Link to Publication Site) ● Publication site (DOI): 10.1016/S0304-3835(01)00541-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11403925 ● Search Scopus @ Elsevier (PMID): 11403925 ● Search Scopus @ Elsevier (DOI): 10.1016/S0304-3835(01)00541-9 (DOI: 10.1016/S0304-3835(01)00541-9, PubMed: 11403925)
63.	Ken Shirabe, Mitsuo Shimada, Eiji Tsujita, Shin-ichiro Maehara, Yo-ichi Yamashita, Tatsuya Rikimaru, Shinji Tanaka and Keizo Sugimachi : Thrombectomy before hepatic resection for hepatocellular carcinoma with a tumor thrombus extending to the inferior vena cava, Minerva Medica, Turin,Italy, Jul. 2001.
64.	Kengo Yoshimitsu, Hiroshi Honda, Toshiro Kuroiwa, Hiroyuki Irie, Hitoshi Aibe, Tsuyoshi Tajima, Kazuo Chijiiwa, Mitsuo Shimada and Kouji Masuda : Liver metastasis from gallbladder carcinoma: anatomic correlation with cholecystic venous drainage demonstrated by helical computed tomography during injection of contrast medium in the cholecystic artery, American Cancer Society, Jul. 2001. (Keyword) gallbladder carcinoma / hepatic metastasis / venous drainage / helical computed tomography (CT) imaging
65.	Tohru Utsunomiya, Mitsuo Shimada, Ken Shirabe, Kiyoshi Kajiyama, Tomonobu Gion, Kenji Takenaka and Keizo Sugimachi : Clinicopathological characteristics of patients with extrahepatic recurrence following a hepatectomy for hepatocellular carcinoma, H.G.E. Update Medical Publishing, Jul. 2001. (Summary) None of the previous studies have compared the prognosis or clinicopathological factors between the patients with extrahepatic recurrence and those with intrahepatic recurrence of hepatocellular carcinoma after a hepatic resection. The clinicopathological features and prognoses of patients with extrahepatic recurrence after a curative hepatectomy for hepatocellular carcinoma were investigated. Twenty-three patients with extrahepatic recurrence had more advanced-stage hepatocellular carcinoma at the primary operation compared to 186 patients with intrahepatic recurrence. After adjusting for tumor size, the prognosis of the 2 groups were comparable. However, among the patients with hepatocellular carcinoma exceeding 5 cm in diameter, the number of patients whose plasma levels of des-gamma-carboxy prothrombin was higher than 2.0 AU/mL in the patients with extrahepatic recurrence (62.5%) was significantly more (P < 0.05) than that in the patients with intrahepatic recurrence (20.0%). On the other hand, the prognosis of the 13 patients with extrahepatic recurrence alone was significantly better than in the 10 patients with both intrahepatic and extrahepatic recurrences. The prognoses of the 3 patients who underwent a surgical resection for isolated extrahepatic recurrence were markedly better than that of the remaining 10 patients only treated palliatively. If patients have tumors exceeding 5 cm in diameter and their plasma levels of des-gamma-carboxy prothrombin are higher than 2.0 AU/mL, more careful follow-up examinations than usual may thus be necessary in order to detect extrahepatic recurrence as early as possible. Furthermore, a surgical resection for the isolated extrahepatic recurrence of hepatocellular carcinoma is also recommended to produce long-term survivors. (Keyword) Adult / Aged / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Prognosis / Survival Analysis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11490807 ● Search Scopus @ Elsevier (PMID): 11490807 (PubMed: 11490807)
66.	Mitsuo Shimada, Takayuki Hamatsu, Yo-ichi Yamashita, Tatsuya Rikimaru, Ken-ichi Taguchi, Tohru Utsunomiya, Ken Shirabe and Keizo Sugimachi : Characteristics of multicentric hepatocellular carcinomas: comparison with intrahepatic metastasis, Springer-Verlag, Tokyo, Jul. 2001. (Summary) Characteristics of multicentric hepatocellular carcinomas (HCCs) remain obscure. We therefore aimed to clarify them and compare them with HCC with intrahepatic metastases. A series of 118 patients who had definite hepatitis C viral status and multinodular HCC were divided into two groups: a multicentric occurrence (MO) group (n = 38), with multicentric HCCs; and an intrahepatic metastasis (IM) group (n = 80), with HCC having intrahepatic metastases. Clinicopathologic variables, including the patient's survival and disease-free survival rates, were compared between the MO and IM groups. Univariate analysis revealed the presence of esophageal varices, the presence of hepatitis C virus infection, a platelet count of less than 10 x 10(4)/microliter, hepaplastin test, gamma-globulin, the histologically active hepatitis, tumor size, des-gamma-carboxy prothrombin > 0.1 AU/ml, positive portal vein invasion, and histologic grade as discriminating factors. The MO score to differentiate multicentric HCCs from intrahepatic metastatic HCCs was determined using the following four independent factors selected by a stepwise regression analysis: the presence of hepatitis C virus infection, a platelet count of less than 10 x 10(4)/microliter, tumor size, and histologic grade. The sensitivity and specificity of the MO scores using those factors were 84% and 70%, respectively, when the cutoff value was 0.4. The disease-free survival rate in the MO group was similar to that in the IM group, whereas the survival rate in the MO group was significantly better than that in the IM group. The multivariate analysis revealed the multicentric occurrence of HCC as one of the independent prognostic factors. Clinicopathologic factors differentiating multicentric HCCs from intrahepatic metastatic HCCs were the presence of hepatitis C virus infection, a platelet count of less than 10 x 10(4)/microliter, small tumor size, and low histologic grade. (Keyword) Carcinoma, Hepatocellular / Female / Humans / Liver Neoplasms / Male / Middle Aged (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11571981 ● Search Scopus @ Elsevier (PMID): 11571981 (PubMed: 11571981)
67.	Tohru Utsunomiya, Yasunori Emi, Koji Ikejiri, Minoru Suzuki, Hideki Saitsu, Shigeru Yakabe, Michiyasu Nonaka, Motonori Saku, Koji Yoshida, Mitsuo Shimada and Keizo Sugimachi : Retrospective study on the effects of lipiodolization before a potentially curative hepatectomy for colorectal liver metastases: long-term results of a pilot study, Thieme, Stuttgart, ALLEMAGNE, May 2001.
68.	Takashi Nishizaki, Toru Ikegami, Shoji Hiroshige, Koji Hashimoto, Hideaki Uchiyama, Tomoharu Yoshizumi, Keishi Kishikawa, Mitsuo Shimada and Keizo Sugimachi : Small graft for living donor liver transplantation, Lippincott Williams & Wilkins, Apr. 2001. (Summary) To evaluate the impact of graft size on recipients in living donor liver transplantation (LDLT) to establish a clinical guideline for the minimum requirement. Although the minimum graft size required for LDLT has been reported to be 30% to 40% of graft volume (GV)/standard liver volume (SLV), the safety limit of the graft size was unknown. A total of 33 cases of LDLT, excluding auxiliary transplantation, were reviewed with a minimum observation period of 4 months. The 33 patients were divided into three groups according to GV/SLV: medium-size graft group, small-size graft group, and extra-small graft group. The effect of GV/SLV on graft function, graft regeneration, and survival was evaluated. The overall patient survival rate was 94% at a mean follow-up of 15 months with a minimum observation period of 4 months. There were no statistically significant differences in postoperative bilirubin clearance, alanine aminotransferase, prothrombin time, and frequency of postoperative complications among the three groups. One week after transplantation, the regeneration rate (GV at 1 week/harvested GV) in the extra-small and small groups was significantly higher than that of the medium group. The graft and patient survival rates were both 100% in the extra-small group, 75% and 88% in the small group, and 90% and 95% in the medium group. Small-for-size grafts less than 30% of SLV can be used with careful intraoperative and postoperative management until the grafts regenerate. (Keyword) Adult / Case-Control Studies / Female / Follow-Up Studies / Graft Survival / Humans / Liver / Liver Regeneration / Liver Transplantation / Living Donors / Male / Time Factors (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11303141 ● Search Scopus @ Elsevier (PMID): 11303141 (PubMed: 11303141)
69.	Makoto Nakamuta, Seiya Tada, Koutaro Uchimura, Munechika Enjoji, Naoko Kinukawa, Hiroaki Iwamoto, Rie Sugimoto, Mitsuo Shimada, Masao Ohashi, Keizo Sugimachi and Hajime Nawata : Serum leptin levels in patients with nonalcoholic chronic liver disease, Thieme, Stuttgart, ALLEMAGNE, Mar. 2001.
70.	Kazumori Funatsu, Hiroyuki Ijima, Kohji Nakazawa, Yo-ichi Yamashita, Mitsuo Shimada and Keizo Sugimachi : Hybrid artificial liver using hepatocyte organoid culture, The International Federation for Artificial Organs, Mar. 2001. (Summary) We developed 2 types of hybrid artificial liver modules using hepatocyte organoid culture. One was a polyurethane foam (PUF)/hepatocyte spheroid packed-bed module. Hepatocytes spontaneously formed spheroids in the PUF pores, and they maintained liver-specific functions well for at least 2 weeks in vitro. As a preclinical experiment, a hybrid artificial liver with 200 g porcine hepatocytes was applied to a pig (25 kg) with liver failure and showed that the hybrid artificial liver was effective in support of liver functions and stabilization of general conditions. We established a new technique of hepatocyte organoid formation using centrifugal force. A hepatocyte organoid formed by centrifugation in hollow fibers maintained functions for more than 4 months in vitro. We developed a new sinusoid-like structure module having hollow fibers arranged by spacers in a micro-regular arrangement. Inoculated hepatocytes in the extra-fiber space of the module formed the organoid by centrifugation, and they maintained the functions for at least 1 month in vitro. The results indicated that this module seems to be promising as a hybrid artificial liver. (Keyword) Hybrid artificial liver support system / Polyurethane foam / Spheroid / Hollow fiber / Hepatocyte organoid / Preclinical experiment (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1525-1594.2001.025003194.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11284886 ● Search Scopus @ Elsevier (PMID): 11284886 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1525-1594.2001.025003194.x (DOI: 10.1046/j.1525-1594.2001.025003194.x, PubMed: 11284886)
71.	Kengo Yoshimitsu, Hiroshi Honda, Makiko Jimi, Toshiro Kuroiwa, Hiroyuki Irie, Hitoshi Aibe, Kenji Shinozaki, Yoshiki Asayama, Mitsuo Shimada and Kouji Masuda : Correlation of three-dimensional gradient echo dynamic MR imaging with CT during hepatic arteriography in patients with hypervascular hepatocellular carcinomas: preliminary clinical experience, International Society for Magnetic Resonance in Medicine, Feb. 2001. (Summary) The purpose of this study is to elucidate the usefulness of dynamic MR study of the whole liver using 3DFISP with double dose gadolinium (Gd) enhancement in detecting enhancing lesions in 20 patients. Twenty patients with hepatocellular carcinoma (HCC) underwent 3DFISP dynamic study with double dose Gd. The demonstration of enhancing hypervascular lesions regardless of etiology was evaluated on a segment-by-segment basis with receiver operating characteristic (ROC) analysis, using findings on CT during hepatic arteriography as a gold standard. Diagnostic accuracy of 3DFISP in the detection of HCC was also evaluated. As to the demonstration of enhancing lesions, the Az value of the ROC curve was 88%. The detection rate of HCC with 3DFISP was 98%. 57% of enhancing pseudolesions were not detected on 3DFISP. We concluded that Dynamic MR study of the whole liver using 3DFISP with double dose Gd enhancement is a useful method to demonstrate hypervascular HCC. (Keyword) magnetic resonance / contrast enhancement / liver neoplasm / three-dimensional image / dynamic study (Link to Publication Site) ● Publication site (DOI): 10.1002/1522-2586(200102)13:2%3C258::AID-JMRI1037%3E3.0.CO;2-B (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11169832 ● Search Scopus @ Elsevier (PMID): 11169832 ● Search Scopus @ Elsevier (DOI): 10.1002/1522-2586(200102)13:2%3C258::AID-JMRI1037%3E3.0.CO;2-B (DOI: 10.1002/1522-2586(200102)13:2%3C258::AID-JMRI1037%3E3.0.CO;2-B, PubMed: 11169832)
72.	Hiroyuki Irie, Hiroshi Honda, Hitoshi Aibe, Toshiro Kuroiwa, Kenzo Yoshimitsu, Kenji Shinozaki, Koji Yamaguchi, Mitsuo Shimada and Kouji Masuda : Efficacy of three-dimensional fast imaging with steady precession dynamic MR imaging in evaluating pancreatic ductal adenocarcinoma, Elsevier Science, Jan. 2001. (Summary) To compare the diagnostic efficacy of three-dimensional fast imaging with steady precession (3D-FISP) dynamic MR imaging in assessing pancreatic ductal adenocarcinoma with conventional MR imaging and helical CT, 15 patients with surgically proven pancreatic ductal adenocarcinoma were studied. Contrast-to-noise ratio (CNR) of the tumor, tumor detectability, local tumor extension, and vascular involvement were evaluated for all techniques. The results indicate that 3D-FISP dynamic MR imaging may improve the imaging assessment of pancreatic ductal adenocarcinoma. (Keyword) Pancreas carcinoma / MR / 3D dynamic study (Link to Publication Site) ● Publication site (DOI): 10.1016/S0899-7071(00)00235-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11435041 ● Search Scopus @ Elsevier (PMID): 11435041 ● Search Scopus @ Elsevier (DOI): 10.1016/S0899-7071(00)00235-7 (DOI: 10.1016/S0899-7071(00)00235-7, PubMed: 11435041)
73.	Masao Yamasaki, Atsushi Ikeda, Akira Hirao, Yoko Tanaka, Yoshiyuki Miyazaki, Tatsuya Rikimaru, Mitsuo Shimada, Keizo Sugimachi, Hirofumi Tachibana and Koji Yamada : Effect of dietary conjugated linoleic acid on the in vivo growth of rat hepatoma dRLh-84, Lawrence Erlbaum Associates, 2001. (Summary) We examined the effect of dietary conjugated linoleic acid (CLA) on the growth of injected hepatoma dRLh-84 in Donryu rats. After experimental diets containing 0% or 2% CLA were given to male Donryu rats for 3 wk, dRLh-84 cells were injected into the left lobe of the hepatic capsule, and the experimental diet was continued. The cells formed a solid tumor > or = 1 wk after the injection, and thereafter the tumor grew with feeding duration. In a morphological study, this tumor appeared to be a low-differentiated hepatoma, and there was no remarkable difference in the morphology of the tumor between 0% and 2% CLA groups. Tumor weight was significantly higher in the 2% CLA group than in the 0% CLA group throughout the feeding period after the injection. Serum glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase activities were significantly higher in 2% CLA-injected rats than in 0% CLA-injected rats at 3 wk after the injection. CLA upregulated acyl-CoA oxidase activity, especially 1 wk after the injection. However, dietary CLA did not activate carnitine palmitoyl transferase II, which is a rate-limiting enzyme in the mitochondrial beta-oxidation pathway. Natural killer cell activity in the spleen tended to be higher in injected rats, but a significant effect of dietary CLA was not recognized. Serum interferon-gamma and tumor necrosis factor-alpha levels were higher in injected than in sham rats. Moreover, these levels were higher in 2% CLA groups than in the respective 0% CLA groups. (Keyword) Adipose Tissue / Alanine Transaminase / Animals / Aspartate Aminotransferases / cell division / Dietary Fats, Unsaturated / Interferon-gamma / Killer Cells, Natural / Linoleic Acid / Liver / Liver Neoplasms, Experimental / Male / Organ Size / oxidation and reduction / Rats / Safflower Oil / Tumor Necrosis Factor-alpha (Link to Publication Site) ● Publication site (DOI): 10.1207/S15327914NC402_10 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11962249 ● Search Scopus @ Elsevier (PMID): 11962249 ● Search Scopus @ Elsevier (DOI): 10.1207/S15327914NC402_10 (DOI: 10.1207/S15327914NC402_10, PubMed: 11962249)
74.	服部麻木, 鈴木直樹, 橋爪誠, 赤星朋比古, 小西晃造, 山口将平, Mitsuo Shimada and 林部充宏 : ナビゲーション機能を備えたロボット手術システム(da Vinci)の開発, 2001.
75.	田中真二, 杉町圭史, 山下洋市, Mitsuo Shimada and 杉町圭蔵 : 肝細胞癌の新規血管新生因子Angiopoietin-2の同定とそのシグナル抑制によるtumor dormancy therapyの開発, 2001.
76.	Mitsuo Shimada, 竹中賢治, 調憲, 福澤謙吾, 板坂英俊, 穴井秀明, 原口勝, 園田孝志, 江崎卓弘, 松股孝, 小柳信洋, 岡村健, 岡留健一郎, 朔元則 and 杉町圭蔵 : 肝細胞癌切除例に対するUFTの再発予防効果の検討, 2001.
77.	Hiroyuki Ijima, Kohji Nakazawa, Mitsuru Kaneko, Junji Fukuda, Mitsuo Shimada, Yo-ichi Yamashita, Tomonobu Gion, Ken Shirabe, Keizo Sugimachi and Kazumori Funatsu : Development of a Hybrid Artificial Liver Support System and Preclinical Animal Experiments, Springer, Sep. 2000. (Link to Publication Site) ● Publication site (DOI): 10.1007/BF02479976 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-0034537910 (DOI: 10.1007/BF02479976, Elsevier: Scopus)
78.	Shinji Tanaka, Keishi Sugimachi, Ken Shirabe, Mitsuo Shimada, Jack R. Wands and Keizo Sugimachi : Expression and antitumor effects of TRAIL in human cholangiocarcinoma, American Association for the Study of Liver Diseases, Sep. 2000.
79.	Hiroyuki Ijima, Kohji Nakazawa, Shingo Koyama, Mitsuru Kaneko, Taku Matsushita, Tomonobu Gion, Ken Shirabe, Mitsuo Shimada, Kenji Takenaka, Keizo Sugimachi and Kazumori Funatsu : Conditions required for a hybrid artificial liver support system using a PUF/hepatocyte-spheroid packed-bed module and it's use in dogs with liver failure, Wichtig Editore, Milano,Italy, Jul. 2000. (Summary) We studied the effects of a hybrid artificial liver support system we developed on dogs with hepatic failure. The system consisted of a multi-channel polyurethane foam packed-bed culture module, including primary dog hepatocyte spheroids. Blood ammonia was well metabolized by 20 g hepatocytes, but the other functions such as glucose concentration, total bile acid concentration, and survival time required 30 g hepatocytes to improve conditions. We found that we should use a culture substratum that easily forms spheroids, and that an artificial liver module should be used as soon as possible after spheroid formation by hepatocytes in the module. (Keyword) Animals / Cells, Cultured / Dogs / Female / Hepatocytes / Liver Failure / Liver, Artificial / Male / Polyurethanes (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10941638 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033898410 (PubMed: 10941638, Elsevier: Scopus)
80.	Takashi Maeda, Kenji Takenaka, Kenichi Taguchi, Kiyoshi Kajiyama, Ken Shirabe, Mitsuo Shimada, Hiroshi Honda and Keizo Sugimachi : Small hepatocellular carcinoma with minute satellite nodules, Thieme, Stuttgart, ALLEMAGNE, Jul. 2000.
81.	Mitsuo Shimada, Yo-ichi Yamashita, Takayuki Hamatsu, Tatsuya Rikimaru, Hirofumi Hasegawa, Tomonobu Gion, Ken Shirabe, Kenji Takenaka and Keizo Sugimachi : Surgical indications for advanced hepatocellular carcinoma, H.G.E. Update Medical Publishing, Jul. 2000.
82.	Mitsuo Shimada, Kenji Takenaka, Tatsuya Rikimaru, Takayuki Hamatsu, Yo-ichi Yamashita, Kiyoshi Kajiyama, Ken-ichi Taguchi, Ken Shirabe and Keizo Sugimachi : Characteristics of sarcomatous cholangiocarcinoma of the liver, H.G.E. Update Medical Publishing, Jul. 2000. (Summary) The aim of this study was to clarify the clinicopathological characteristics of intrahepatic cholangiocarcinoma with sarcomatous changes. Four cases of cholangiocarcinoma with sarcomatous change were identified and investigated. The clinicopathological findings, including the results of immunohistochemical staining, were investigated in comparison with those of ordinary cholangiocarcinoma. Two of them exhibited pyrexia as the initial symptom. The serum alkaline phosphatase level in sarcomatous cholangiocarcinoma was significantly lower than that in ordinary cholangiocarcinoma. Both the serum carcinoembryonic antigen and carbohydrate 19-9 level in sarcomatous cholangiocarcinoma also tended to be lower than those in ordinary cholangiocarcinoma. The carcinomatous component of all tumors was mostly poorly differentiated adenocarcinoma. The associated microscopic findings were as follows: lymphocyte infiltration in the tumor, accompanied by both necrosis and extensive lymph node metastases. Three of them predominantly exhibited spindle-shaped sarcomatous changes, whereas the other case predominantly demonstrated pleomorphic-type sarcomatous changes. The sarcomatous area was positive for both vimentin, a mesenchymal marker, and for epithelial markers, furthermore, in 3 of 4 cases, the carcinoma portions were also positive for vimentin. The overall survival curves were not significantly different between the 2 groups, however, no long-term survivor was found in sarcomatous cholangiocarcinoma. The main characteristics of cholangiocarcinoma with sarcomatous changes are considered to be as follows: 1) often demonstrating pyrexia as a symptom; 2) not always demonstrating remarkable abnormal findings in the laboratory data including tumor markers; 3) histologically showing poorly differentiated adenocarcinoma; and 4) showing a very poor prognosis (especially, in a pleomorphic-type). (Keyword) Aged / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Chi-Square Distribution / Cholangiocarcinoma / Female / Humans / Immunohistochemistry / Liver Function Tests / Male / Middle Aged / Sarcoma / Statistics, Nonparametric / Treatment Outcome (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11020857 ● Search Scopus @ Elsevier (PMID): 11020857 (PubMed: 11020857)
83.	Hiroshi Honda, Tsuyoshi Tajima, Ken-ichi Taguchi, Toshiro Kuroiwa, Kengo Yoshimitsu, Hiroyuki Irie, Hitoshi Aibe, Kenji Shinozaki, Yoshiki Asayama, Mitsuo Shimada and Kouji Masuda : Recent developments in imaging diagnostics for HCC: CT arteriography and CT arterioportography evaluation of vascular changes in premalignant and malignant hepatic nodules, Springer-Verlag, Tokyo, Jun. 2000.
84.	Hiroyuki Ijima, Kohji Nakazawa, Shingo Koyama, Mitsuru Kaneko, Taku Matsushita, Tomonobu Gion, Ken Shirabe, Mitsuo Shimada, Kenji Takenaka, Keizo Sugimachi and Kazumori Funatsu : Development of a hybrid artificial liver using a polyurethane foam/hepatocyte-spheroid packed-bed module, Wichtig Editore, milano, Jun. 2000. (Summary) Primary dog hepatocytes spontaneously formed spheroids in the pores of polyurethane foam (PUF) within 1-2 days of stationary culture. The spheroids, about 100-150 microm in diameter, partly attached to the surface and immobilized inside these pores. The lidocaine disappearance rate decreased to about 4 microg/10(5) viable cells/day for 10 days, while in the PUF/spheroid culture the rate was maintained at almost the initial level of 8 microg/10(5) viable cells/day for 10 days. Then, two scales of PUF packed-bed modules were designed. A small module (PUF volume; 14.5 cm3) was used for in vitro culture to investigate optimum culture conditions, and a large module (PUF volume; 300 cm3) was designed for dog experiments. Hepatocytes inoculated in these modules also formed spheroids and maintained almost the same activity of albumin secretion rate (111 microg/cm3 PUF/day in the small module and 87.7 microg/cm3 PUF/day in the large module). These results indicate that the PUF packed-bed module containing hepatocyte-spheroids is promising as a hybrid artificial liver. (Keyword) Albumins / Ammonia / Anesthetics, Local / Animals / Cell Adhesion / Cells, Cultured / Dogs / Equipment Design / Female / Hepatocytes / Lidocaine / Liver, Artificial / Male / Polyurethanes (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10919756 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033940088 (PubMed: 10919756, Elsevier: Scopus)
85.	Hiroyuki Irie, Hiroshi Honda, Hitoshi Aibe, Toshiro Kuroiwa, Kengo Yoshimitsu, Kenji Shinozaki, Koji Yamaguchi, Mitsuo Shimada and Kouji Masuda : MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas, American Roentgen Ray Society, May 2000.
86.	Takashi Maeda, Kenji Takenaka, Kenichi Taguchi, Kiyoshi Kajiyama, Ken Shirabe, Mitsuo Shimada, Masazumi Tsuneyoshi and Keizo Sugimachi : Clinicopathological characteristics of surgically resected minute hepatocellular carcinomas, H.G.E. Update Medical Publishing, Mar. 2000.
87.	佐久間一郎, 正宗賢, 小林英津子, 辻隆之, 土肥健純, Mitsuo Shimada, 北村薫, 後藤謙和, 橋爪誠 and 杉町圭蔵 : 肝臓手術ナビゲーションシステム開発を目的とした術中肝臓変形に関する基礎的検討, 2000.
88.	濱津隆之, Mitsuo Shimada, 橋爪誠, 力丸竜也, 山下洋市, 田中真二, 調憲 and 杉町圭蔵 : 肝切除における三次元エコーによる術中ナビゲーション, 2000.
89.	Mitsuo Shimada, Takayuki Hamatsu, Tatsuya Rikimaru, Yo-ichi Yamashita, Shinji Tanaka, Ken Shirabe, Hiroshi Honda, Makoto Hashizume and Keizo Sugimachi : Impact of combined preoperative three-dimensional computed tomography and intraoperative real-time three dimensional ultrasonography on liver surgery, Springer-Verlag, London, 2000.
90.	Hiroshi Honda, Tsuyoshi Tajima, Kiyoshi Kajiyama, Toshiro Kuroiwa, Kengo Yoshimitsu, Hiroyuki Irie, Hitoshi Aibe, Mitsuo Shimada and Kouji Masuda : Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings, American Roentgen Ray Society, Nov. 1999.
91.	Tsuyoshi Tajima, Hiroshi Honda, Toshirou Kuroiwa, Kengo Yoshimitsu, Hiroyuki Irie, Hitoshi Aibe, Ken-ichi Taguchi, Mitsuo Shimada and Kouji Masuda : Radiologic features of intrahepatic bile duct adenoma: a look at the surface of the liver, Lippincott Williams & Wilkins, Sep. 1999. (Summary) We report the radiological features of intrahepatic bile duct adenoma (BDA) in three patients. BDA was shown as a small mass located in the peripheral region of the liver with each imaging modality: a hypervascular mass on angiography and a mass appearing as early nodular enhancement found disproportionately evident compared with their small size and distinct delayed or prolonged enhancement on CT. BDA should be included in the diseases to be differentiated from hypervascular hepatic tumors. (Keyword) Adenoma / Aged / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Biopsy / Carcinoma, Hepatocellular / Diagnosis, Differential / Female / Hepatectomy / Humans / Liver / Liver Neoplasms / Male / Middle Aged / Neoplasms, Multiple Primary / Tomography, X-Ray Computed / Ultrasonography (Link to Publication Site) ● Publication site (DOI): 10.1097/00004728-199909000-00008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10524847 ● Summary page in Scopus @ Elsevier: 2-s2.0-0032876751 (DOI: 10.1097/00004728-199909000-00008, PubMed: 10524847, Elsevier: Scopus)
92.	Kohji Nakazawa, Hiroshi Mizumoto, Mitsuru Kaneko, Hiroyuki Ijima, Tomonobu Gion, Mitsuo Shimada, Ken Shirabe, Kenji Takenaka, Keizo Sugimachi and Kazumori Funatsu : Formation of porcine hepatocyte spheriacal multicellular aggregates (spheroid) and analysis of drug metabolic functions, Springer-Verlag, Netherlands, Sep. 1999.
93.	Mitsuo Shimada, Hirofumi Hasegawa, Tomonobu Gion, Ken Shirabe, Ken-ichi Taguchi, Kenji Takenaka, Shinji Tanaka and Keizo Sugimachi : Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy, H.G.E. Update Medical Publishing, Jul. 1999. (Summary) Little has been documented to differentiate between recurrence originating from microscopic residual tumor cells and recurrence due to metachronous multicentric origin of hepatocellular carcinoma (HCC). The aim of this study was to clarify the risk factors of HCC recurrence closely related to residual tumor cells. A retrospective review of hepatic resections for HCC during the period between April 1985 and April 1997 was undertaken at a University Hospital with a long history of hepatectomy for HCC. Three hundred and thirteen HCC patients without any definite multicentric recurrence, who underwent hepatectomy, were retrospectively investigated. Main outcome measures were: (Study 1) Risk factors for recurrence were univariately and multivariately investigated among various clinicopathological variables, including the vi factor as a new indicator of the potential malignancy of HCC (i.e., the presence of both microscopic portal vein invasion and intrahepatic metastasis). (Study 2). The risk factors for recurrence were then analyzed according to the period of recurrence. (Study 1) Independent risk factors were: (tumor factors) a positive vi factor, alpha-fetoprotein > 100 ng/ml, and poorly differentiated histology; (host factors) albumin < 3.8 g/dl, the presence of diabetes mellitus, platelet count < 14 x 10(4)/microliter, Y-globulin fraction > 20%. In those risk factors, the relative risk of the vi factor (2.6) was the largest. (Study 2) Within 1 year after hepatectomy, only tumor factors, including the vi factor and poorly differentiated histology, were significant risk factors, tumor factors were significant only up to 2 years after hepatectomy, and thereafter only host factors were significant. The risk factors for non-multicentric recurrence of HCC are considered to be a positive vi factor, alpha-fetoprotein, and poorly differentiated histology, and the vi factor is considered to be a new prognostic indicator expressing the potential malignancy of HCC such as invasion and metastasis. (Keyword) Carcinoma, Hepatocellular / Female / Humans / Liver Neoplasms / Male / Multivariate Analysis / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Neoplasm, Residual / Neoplasms, Second Primary / Portal Vein / Retrospective Studies / Risk Factors / alpha-Fetoproteins (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10522022 ● Search Scopus @ Elsevier (PMID): 10522022 (PubMed: 10522022)
94.	Kazuharu Yamamoto, Kenji Takenaka, Takashi Matsumata, Mitsuo Shimada and Keizo Sugimachi : The effect of octreotide on morphological hepatic regeneration and hepatic functional recovery after a two-thirds hepatectomy in rats, H.G.E. Update Medical Publishing, May 1999. (Summary) The aim of this study was to clarify the effect of octreotide on either morphological hepatic regeneration or hepatic function after a two-thirds hepatectomy in rats. The rats were separated into two groups as follows: group 1 received 100 microg of octreotide acetate subcutaneously every 6 hours from 24 hours before hepatic resection until sacrifice; group 2 received 0.9% saline solution instead of octreotide as a control. Morphological hepatic regeneration, protein synthesis and mitochondrial function were all studied. The regenerative rate in liver volume and the BrdU labeling index in group 1 were significantly lower than those in group 2. The levels of glutamic acid dehydrogenase were significantly lower in group 1 than those in group 2 at 24 (64.2+/-14.6 and 77.8+/-8.3 IU/l, respectively), 36 (46.1+/-14.4 and 60.6+/-5.9 IU/l, respectively) and 48 hours (39.7+/-13.7 and 51.0+/-11.8 IU/l, respectively) after hepatectomy. At 24 hours after hepatectomy, the levels of arterial ketone body ratio was higher in group 1 than in group 2 (0.67+/-0.05 and 0.51+/-0.07, respectively), and the energy charge of the liver was also higher in group 1 than in group 2 (0.662+/-0.031 and 0.605+/-0.053, respectively). Our results suggest that morphological hepatic regeneration is not necessarily synchronized with hepatic functional recovery. In addition, hepatic functional recovery was preserved by keeping the energy metabolism in hepatocytes, even when the use of octreotide suppressed morphological hepatic regeneration. (Keyword) Animals / Cell Division / Energy Metabolism / Female / Hepatectomy / Injections, Subcutaneous / Liver / Liver Function Tests / Liver Regeneration / Octreotide / Premedication / Rats / Rats, Sprague-Dawley (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10430363 ● Search Scopus @ Elsevier (PMID): 10430363 (PubMed: 10430363)
95.	Hidetoshi Itasaka, Taketoshi Suehiro, Shigeki Wakiyama, Katsuhiko Yanaga, Mitsuo Shimada and Keizo Sugimachi : The mechanism of hepatic graft protection against reperfusion injury by prostaglandin E1, Springer-Verlag, Tokyo, May 1999.
96.	Kazuharu Yamamoto, Kenji Takenaka, Kiyoshi Kajiyama, Mitsuo Shimada, Ken Shirabe, Akinobu Taketomi, Takashi Maeda and Keizo Sugimachi : Cell proliferation and cell loss in nodule-in-nodule hepatocellular carcinoma, H.G.E. Update Medical Publishing, Athens, Mar. 1999. (Summary) In order to clarify the significance of the balance between cell proliferation and cell loss during the progression of hepatocellular carcinoma, 16 operative specimens of nodule-in-nodule hepatocellular carcinoma were investigated. In 16 specimens, cell proliferation was evaluated by the expression of Ki-67 nuclear antigen, and cell loss was also examined by the method of terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL). The expressions of p53 protein, bcl-2 protein and Fas antigen were also investigated to clarify the relationship between their expression and cell kinetics. The Ki-67 labeling index of the inner nodules was higher than that for the outer nodules (18.9% vs. 7.2%; p < 0.05) and the TUNEL labeling index of the inner nodules was also higher than that for the outer nodules (12.8% vs. 6.6%; p < 0.05). The increasing rate of the Ki-67 labeling index from Edmondson's grade I to II was 3.9 +/- 3.0, that from grade II to III was 3.9 +/- 2.4, while the increasing rate of the TUNEL labeling index from grade I to II was 2.7 +/- 0.3 and that from grade II to III was 1.7 +/- 0.2 (p < 0.05). p53 Protein was observed in 5 cases, while bcl-2 protein was found in 4 cases in the border area of the inner nodule. However, Fas antigen was found in none of the examined cases. Regarding the Ki-67 positive rate in the inner nodule, the Ki-67 positive rate in the p53 protein positive cases was significantly higher than that in the negative cases (30.3 +/- 15.4 vs. 11.9 +/- 9.2; p < 0.05). However, the TUNEL labeling index was not affected by the expression of those proteins. This study suggested that tumor progression depends on a disturbance in the cell kinetic balance caused not by a decrease in the absolute amount of cell loss but in the chaotic balance between cell loss and cell proliferation. (Keyword) Apoptosis / Carcinoma, Hepatocellular / Cell Division / Humans / Immunoenzyme Techniques / In Situ Nick-End Labeling / Ki-67 Antigen / Liver / Liver Neoplasms / Mitotic Index / Prognosis / Proto-Oncogene Proteins c-bcl-2 / Tumor Suppressor Protein p53 / fas Receptor (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10370619 ● Search Scopus @ Elsevier (PMID): 10370619 (PubMed: 10370619)
97.	Mitsuo Shimada, Tomonobu Gion, Takayuki Hamatsu, Yo-ichi Yamashita, Hirofumi Hasegawa, Tohru Utsunomiya, Kenji Takenaka and Keizo Sugimachi : Evaluation of major hepatic resection for small hepatocellular carcinoma, H.G.E. Update Medical Publishing, Jan. 1999. (Summary) The aim of this study is to clarify the significance of a major hepatectomy for small hepatocellular carcinomas (HCCs). Seventy-eight patients with solitary HCC measuring less than 3 cm in diameter, whose liver function was considered sufficient to tolerate a right hepatic lobectomy, were classified into 2 groups consisting of: a major group (n = 18), who underwent a major hepatectomy (2 segments or more); and, a minor group (n = 60), who underwent a hepatectomy including one segment or less. The early post-operative outcome and the long-term outcomes, comprising patient survival as well as disease-free survival, were compared. In addition, the post-operative long-term changes in liver function tests and esophageal variceal occurrence were also compared. In the post-operative mortality and morbidity, no significant differences were found between the 2 groups. However, 1 patient in the major group unexpectedly died of liver failure 6 months after operation. No significant difference was observed in patient survival and disease-free survival. The platelet count in the major group tended to decline more rapidly than that in the minor group. Furthermore, 1 patient in the major group demonstrated risky esophageal varices 29 months after operation, which had to be treated by endoscopic injection sclerotherapy. Based on the above findings, a major hepatectomy is therefore not recommended for patients with solitary small HCC measuring 3 cm or less in diameter. (Keyword) Aged / Carcinoma, Hepatocellular / Evaluation Studies as Topic / Female / Hepatectomy / Humans / Liver Function Tests / Liver Neoplasms / Male / Middle Aged / Recurrence / Time Factors / Treatment Outcome (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10228830 ● Search Scopus @ Elsevier (PMID): 10228830 (PubMed: 10228830)
98.	Mitsuru Kaneko, T Ito, Kohji Nakazawa, Hiroyuki Ijima, Taku Matsushita, Tomonobu Gion, Mitsuo Shimada, Ken Shirabe, Hirofumi Hasegawa, Kenji Takenaka, Keizo Sugimachi and Kazumori Funatsu : Development of a Hybrid Artificial Liver Support System with Porcine Hepatocyte Spheroids for Preclinical Use, 1999.
99.	Kohji Nakazawa, Hiroyuki Ijima, Mitsuru Kaneko, Junji Fukuda, Tomonobu Gion, Mitsuo Shimada, Ken Shirabe, Kenji Takenaka, Keizo Sugimachi and Kazumori Funatsu : Development of a hybrid artificial liver support system and its application to hepatic failure animals, 1999.
100.	Hiroyuki Ijima, Kohji Nakazawa, Mitsuru Kaneko, Hiroshi Mizumoto, Taku Matsushita, Tomonobu Gion, Mitsuo Shimada, Ken Shirabe, Kenji Takenaka, Keizo Sugimachi and Kazumori Funatsu : The formation of a spheroid of primary hepatocytes and the expression of liver-specific functions depend on the characteristics of polyurethane foam, Springer Japan, Sep. 1998.
101.	Mitsuo Shimada, Tomonobu Gion, Yuh Fujiwara, Ken Shirabe, Kenji Takenaka, T Kano and Keizo Sugimachi : A branched chain amino acid-enriched solution does not induce any beneficial effect on the postoperative intestinal functions., May 1998.
102.	Mitsuo Shimada, Kenji Takenaka, Yuh Fujiwara, Tomonobu Gion, Hirofumi Hasegawa, Ken Shirabe and Keizo Sugimachi : Significance of the peroral phenolsulfonphthalein test in hepatic resection: a possible predictor of bacterial translocation, H.G.E. Update Medical Publishing, Mar. 1998. (Summary) The aim of this study was to evaluate the perioperative changes in intestinal permeability by using the phenolsulfonphthalein (PSP) test and to also to clarify the significance of the peroral PSP test in hepatic resection. Fifty patients, all of whom underwent hepatic resection, were prospectively studied. Postoperative complications occurred in 16 patients, and 10 of these complications were infectious. A peroral PSP test, which was scheduled before operation and on postoperative days 3, 7, and 14, was performed as follows: after the administration of 30 mg of PSP, a 24-hour urine was collected, and the urinary PSP was measured by colorimetric assay. The correlation between the preoperative PSP value and various clinical variables, such as perioperative changes in urinary PSP excretion, and the relationship between the postoperative PSP value and postoperative complications, were investigated. Preoperative urinary PSP excretion was found to increase in proportion to the degree of liver dysfunction. In contrast, urinary PSP excretion did not significantly change during the perioperative period. However, urinary PSP excretion on postoperative day 3 in patients with postoperative infectious complications (27.3%) was significantly greater than that in those without infectious complications (17.4%; p < 0.05). Furthermore, PSP excretion on postoperative day 3 in those with infectious complications was also significantly greater as compared to the preoperative level. The patients with a urinary PSP excretion level on postoperative day 3 of greater than 25%, exhibited infectious complications more frequently than patients with a level under 25% (60% versus 10.3%, respectively; p < 0.05). The peroral PSP test is thus suggested to be a possible predictor of bacterial translocation after hepatic resection. (Keyword) Bacterial Infections / Bacterial Translocation / Coloring Agents / Female / Hepatectomy / Humans / Male / Middle Aged / Phenolsulfonphthalein / Postoperative Complications / Predictive Value of Tests / Prospective Studies (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9638432 ● Search Scopus @ Elsevier (PMID): 9638432 (PubMed: 9638432)
103.	Mitsuo Shimada, T Kano, Y Matsuzaki, N Miyazaki and K Ninomiya : Gastroenterological surgery for patients with chronic respiratory insufficiency, Mar. 1998.
104.	Kenji Takenaka, Yuh Fujiwara, Tomonobu Gion, Takashi Maeda, Ken Shirabe, Mitsuo Shimada, Katsuhiko Yanaga and Keizo Sugimachi : A thoracoabdominal hepatectomy and a transdiaphragmatic hepatectomy for patients with cirrhosis and hepatocellular carcinoma, American Medical Association, Jan. 1998.
105.	Mitsuo Shimada, Takashi Matsumata, Kazuharu Yamamoto, Akinobu Taketomi, Ken Shirabe, Kenji Takenaka and Keizo Sugimachi : The role of growth hormone, somatostatin and glucagon in hepatic resection, Jan. 1998. (Summary) The aim of this study was to clarify the roles of growth hormone, somatostatin, and glucagon in vital reactions against surgical stress as well as in hepatic regeneration. Eleven consecutive patients, who underwent hepatic resection, were included in this study. Changes in intrinsic hormones, specifically growth hormone, somatostatin, and glucagon, were investigated. Furthermore, a comparison was made between major (more than 2 segments) and minor (less than 1 segment) hepatectomies. Growth hormone was observed to increase four-fold during hepatectomy and thereafter remained at relatively high levels. Somatostatin reached its lowest level on postoperative day 1 and then returned to near the preoperative level on postoperative day 7, while glucagon gradually increased and reached a peak around postoperative day 3. The concentrations of both somatostatin and glucagon in the portal vein were higher than those in the peripheral vein. No significant differences between major and minor hepatectomies were found throughout the perioperative course. Growth hormone is considered to be a sensitive parameter in terms of surgical stress and can also act as a trigger as well as a promoter of hepatic regeneration, while a dissociation between somatostatin and glucagon in the early postoperative period indicates the promotion of hepatic regeneration. Furthermore, portal blood, which contains higher concentrations of these substances, plays an important role in regulating hepatic regeneration. However, the absence of a correlation between the extent of the hepatectomy and these parameters suggests that some other, as yet unidentified mechanism, may also be related to the regulation of hepatic regeneration. (Keyword) Aged / Female / Glucagon / Growth Hormone / Hepatectomy / Humans / Male / Middle Aged / Somatostatin / Stress, Physiological (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9496509 ● Search Scopus @ Elsevier (PMID): 9496509 (PubMed: 9496509)
106.	中澤浩二, 井嶋博之, 金子充, 伊東俊純, 松下琢, 祇園智信, 調憲, Mitsuo Shimada, 竹中賢治, 杉町圭蔵 and 船津和守 : 初代ブタ肝細胞のポリウレタンフォーム(PUF)/スフェロイド培養法を用いたハイブリッド型人工肝臓開発のための培養条件の検討, 1998.
107.	Takashi Maeda, Kenji Takenaka, Ken-ichi Taguchi, Kiyoshi Kajiyama, Ken Shirabe, Mitsuo Shimada, Masazumi Tsuneyoshi and Keizo Sugimachi : Adenosquamous carcinoma of the liver: clinicopathologic characteristics and cytokeratin profile, American Cancer Society, Aug. 1997. (Keyword) adenosquamous carcinoma / immunohistochemistry / cytokeratin / histo-genesis
108.	Takashi Matsumata, Kazuharu Yamamoto, Ken Shirabe, Mitsuo Shimada, Keizo Sugimachi, F Takesue, Yoichi Muto and Tetsuo Ikeda : Urinary excretion of prostaglandins and renal function after hepatic resection, May 1997.
109.	Akinobu Taketomi, Kenji Takenaka, Takashi Matsumata, Mitsuo Shimada, Hidefumi Higashi, Ken Shirabe, Hidetoshi Itasaka, Eesuke Adachi, Takashi Maeda and Keizo Sugimachi : Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma before and after hepatic resection, Mar. 1997.
110.	Ken Shirabe, Kenji Takenaka, Tomonobu Gion, Mitsuo Shimada, Yuh Fujiwara and Keizo Sugimachi : Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection, John Wiley & Sons, Inc., Feb. 1997. (Keyword) hepatocellular carcinoma / prognostic factor / alpha-fetoprotein / recurrence
111.	Ken Shirabe, Takashi Matsumata, Mitsuo Shimada, Kenji Takenaka, Naoyuki Kawahara, Kazuharu Yamamoto, Takashi Nishizaki and Keizo Sugimachi : A comparison of parenteral hyperalimentation and early enteral feeding regarding systemic immunity after major hepatic resection--the results of a randomized prospective study, Jan. 1997. (Summary) To compare the nutritional efficacy, especially regarding the systemic immunity of early enteral (EEN) and total parenteral nutrition (TPN) in major hepatic resection. A randomized, prospective controlled study was performed in the Second Department of Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan. Twenty-six patients who underwent a major hepatic resection were divided into 2 groups: EEN (n = 13), and TPN (n = 13). There was no significant difference between the two groups in regard to either clinical backgrounds, nutritional parameters. There was no significant difference in the nutritional parameters after hepatectomy, such as the serum levels of retinol binding protein, transierrin, pre-albumin, and 3-methylhistidine between the two groups. Among the immunologic parameters, NK activity and changes in the lymphocyte number, the PHA response and the NK activity, which was expressed as a percentage of the preoperative values, was significantly higher in the EEN group than in the TPN group (p < 0.05). The incidence of infectious complications in the TPN group was 4 of 13 patients (31%), although the same incidence in the EEN group was only 1 of 13 (8%). In one case of TPN, a bacterial strain of gut origin was isolated from the intra-abdominal abscess, which suggested that bacterial translocation occurred. No significant difference was observed in the nutritional parameters between the EEN and TPN groups. Early enteral feeding maintained immunocompetence, and thus such feeding possibly reduced the rate of infectious complications after major hepatic resection. (Keyword) Aged / Amino Acids, Branched-Chain / Bacterial Translocation / Cytotoxicity, Immunologic / Enteral Nutrition / Hepatectomy / Humans / Immunocompetence / Immunoglobulins / Infection / Leukocytes, Mononuclear / Liver Neoplasms / Middle Aged / Parenteral Nutrition, Total / Postoperative Complications / Prospective Studies / Retinol-Binding Proteins / Time Factors (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9058145 ● Search Scopus @ Elsevier (PMID): 9058145 (PubMed: 9058145)
112.	松下琢, 小山信吾, 井嶋博之, 中澤浩二, 祇園智信, 調憲, Mitsuo Shimada, 竹中賢治, 杉町圭蔵 and 船津和守 : PUF/肝細胞スフェロイド充填層型人工肝臓のイヌ温虚血肝不全モデルへの適用, 1997.
113.	Mitsuo Shimada, Kenji Takenaka, Naoyuki Kawahara, Ken Shirabe, Takashi Nishizaki, Katsuhiko Yanaga, T Kano and Keizo Sugimachi : Hepatic resection for interic type hepatocellular carcinoma, 1997.
114.	Katsuhiko Yanaga, Kenji Takenaka, Kazuharu Yamamoto, Takashi Nishizaki, Ken Shirabe, Mitsuo Shimada, Naoyuki Kawahara, A Chishaki and Keizo Sugimachi : Cardiac complications after hepatic resection, British Journal of Surgery Society Ltd., Oct. 1996.
115.	Kenji Takenaka, Tomonobu Gion, Yuh Fujiwara, Ken Shirabe, Takashi Nisizaki, Mitsuo Shimada, Katsuhiko Yanaga and Keizo Sugimachi : Evaluation of indications for the surgical treatment of cavernous hemangioma of the liver, Springer Japan, Tokyo, Jun. 1996.
116.	Ken Shirabe, Kenji Takenaka, Kazuharu Yamamoto, M Kitamura, Hidetoshi Itasaka, Takashi Matsumata, Mitsuo Shimada and Keizo Sugimachi : The role of prostanoid in hepatic damage during hepatectomy, May 1996. (Summary) The aim of this study in hepatectomy is to investigate whether or not hepatic ischemia elevates the serum prostanoid levels, and whether or not thromboxane A2 (TXA2) synthetase inhibitor (OKY 046) improves hepatic damage. The prostanoid levels were measured in 22 hepatectomy cases. The beneficial effects of thromboxane A2 synthetase inhibitor were examined in cases who underwent hepatectomy under hemihepatic vascular control. The total prostanoid levels (6-keto PG Fla+ PGE2 + TXB2) were measured in 22 cases before and after hepatectomy. The hepatic ischemic time (HIT) was defined as the time required to perform a hepatic mobilization plus the right hemihepatic vascular control technique. The total prostanoid levels increased after hepatectomy (P < 0.01). The changes in the total prostanoid levels positively correlated with the HIT (P < 0.01). The 17 cases who underwent hepatectomy with the HIT were randomly divided into 2 groups; the OKY group (n = 9), OKY 046 (0.2 mg/kg/hr), the control group (n = 8); no drug was given. The OKY 046 administration reduced the TXB2 levels (P < 0.01), without any changes in the PGE2, or 6-keto PGF1a levels. The serum glutamic oxaloacetic transaminase levels after operation were lower, and the hepaplastin tests were higher in the OKY group than those of the control (P < 0.05). These results demonstrated that hepatectomy under ischemia elevated the prostanoid levels. OKY 046 significantly reduced the TXB2 levels and the degree of hepatic damage in hepatectomy under ischemia. (Keyword) Aspartate Aminotransferases / Enzyme Inhibitors / Female / Hepatectomy / Humans / Liver / Male / Methacrylates / Middle Aged / Prostaglandins / Reperfusion Injury / Thromboxane-A Synthase (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8799402 ● Search Scopus @ Elsevier (PMID): 8799402 (PubMed: 8799402)
117.	Takashi Nishizaki, Kenji Takenaka, Katsuhiko Yanaga, Mitsuo Shimada, Ken Shirabe, Takashi Matsumata and Keizo Sugimachi : Nutritional support after hepatic resection: a randomized prospective study, May 1996. (Summary) A consensus as to whether hypertonic dextrose should be given to patients with chronic liver diseases such as cirrhosis or chronic hepatitis after major hepatectomy has not been reached, mostly because metabolism in the remnant liver switches from utilization of blood glucose to utilization predominantly of fatty acid as an energy source. We investigated whether nutritional support would have beneficial effects for such patients. Among 19 patients, 10 were given peripheral dextrose (10 kcal/kg/day) for seven days following hepatectomy and the other 9 were given hypertonic glucose. Twenty and 30 kcal/kg/day was the average non-protein caloric intake, including free oral intake during the first one week following hepatectomy, respectively. The groups were comparable with regard to laboratory data and operative stress. There were no untoward effects related to this support. In patients given nutritional support, retinol binding protein and prealbumin improved (p < 0.05 and p < 0.05, respectively), urinary 3-methylhistidine excretion decreased (p < 0.01) and the nitrogen balance normalized earlier (p < 0.05), as compared to findings with the conventional method. The remnant liver can utilize dextrose and nutritional support improves the nutritional status and may even preserve muscle protein mass. (Keyword) Amino Acids, Branched-Chain / Catheterization, Central Venous / Female / Food, Formulated / Glucose / Glucose Solution, Hypertonic / Hepatectomy / Humans / Liver / Liver Neoplasms / Male / Middle Aged / Parenteral Nutrition / Postoperative Care / Prospective Studies (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8799404 ● Search Scopus @ Elsevier (PMID): 8799404 (PubMed: 8799404)
118.	Takashi Matsumata, Akinobu Taketomi, Yuh Fujiwara, Mitsuo Shimada, Kenji Takenaka and Keizo Sugimachi : Renal function after elective hepatic resection, May 1996. (Summary) Although morbidity and mortality associated with liver surgery has declined, in particular operative death from liver failure, accumulation of fluid in the peritoneal or pleural cavities after hepatic resection is still the most common post-operative complication and it often decreases the patient's quality of life. The purpose of this retrospective review is to discuss the effect of renal dysfunction following hepatic resection on ascites formation in patients who underwent hepatic resection. The patients who underwent hepatectomy were assigned to two groups; Group A patients (n = 119) had some form of ascites or pleural effusion, either intractable or easily controlled, while Group B patients (n = 178) had neither ascites nor pleural effusion. We compared the clinical and laboratory data, operative risk factors, and the post-operative renal as well as hepatic functions of the two groups. In addition to ordinary risk factors associated with ascites formation such as decreased plasma oncotic pressure due to hypoalbuminemia along with increased hydrostatic pressure in the portal circulation, renal dysfunction after hepatic resection might be the primary cause of fluid accumulation in the peritoneal cavity. As one of the mechanisms of ascites formation following hepatic resection, we must consider the presence of renal dysfunction and protect against ascites formation and treat refractory ascites after hepatic resection not only by such traditional methods such as water and salt restriction, the use of diuretics, and the infusion of albumin products, but also by preserving the renal function after hepatectomy. (Keyword) Ascites / Carcinoma, Hepatocellular / Case-Control Studies / Female / Hepatectomy / Humans / Kidney / Liver Neoplasms / Male / Middle Aged / Postoperative Complications / Retrospective Studies / Risk Factors (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8799403 ● Search Scopus @ Elsevier (PMID): 8799403 (PubMed: 8799403)
119.	Taketoshi Suehiro, Katsuhiko Yanaga, Hidetoshi Itasaka, Keiji Kishikawa, Ken Shirbe, Mitsuo Shimada and Keizo Sugimachi : Thromboxane A2 in preservation-reperfusion injury: the effect of thromboxane A2 synthetase inhibitor, Academic Press, May 1996. (Link to Publication Site) ● Publication site (DOI): 10.1006/jsre.1996.0198 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1006/jsre.1996.0198 (DOI: 10.1006/jsre.1996.0198)
120.	Katsuhiko Yanaga, Naoyuki Kawahara, Akinobu Taketomi, Ken Shirabe, Takashi Nishizaki, Mitsuo Shimada, Takashi Matsumata, Kenji Takenaka and Keizo Sugimachi : Retrograde right hepatic trisegmentectomy, May 1996. (Keyword) Adult / Female / Humans / Liver / Liver Neoplasms / Male / Medical Illustration / Middle Aged / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1016/S0039-6060(96)80272-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8619217 ● Search Scopus @ Elsevier (PMID): 8619217 ● Search Scopus @ Elsevier (DOI): 10.1016/S0039-6060(96)80272-8 (DOI: 10.1016/S0039-6060(96)80272-8, PubMed: 8619217)
121.	竹中賢治, 藤原雄, 祇園智信, 梶山潔, 前田貴司, 調憲, Mitsuo Shimada and 杉町圭蔵 : 組織学的分化度よりみた小肝細胞癌切除の意義, 科学評論社, 1996.
122.	Mitsuo Shimada, Kenji Takenaka, Naoyuki Kawahara, Kazuharu Yamamoto, Ken Shirabe, Yoshihiko Maehara and Keizo Sugimachi : Chemosensitivity in primary liver cancers: evaluation of the correlation between chemosensitivity and clinicopathological factors, 1996.
123.	Hidetoshi Itasaka, Taketoshi Suehiro, Shigeki Wakiyama, Katsuhiko Yanaga, Mitsuo Shimada and Keizo Sugimachi : Significance of hyaluronic acid for evaluation of hepatic endothelial cell damage after cold preservation/reperfusion, Academic Press, Nov. 1995. (Link to Publication Site) ● Publication site (DOI): 10.1006/jsre.1995.1209 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1006/jsre.1995.1209 (DOI: 10.1006/jsre.1995.1209)
124.	Ken Shirabe, Takashi Matsumata, Eisuke Adachi, Takashi Maeda, Mitsuo Shimada, Akinobu Taketomi and Keizo Sugimachi : Prognosis of well differentiated small hepatocellular carcinoma--is well differentiated hepatocellular carcinoma clinically early cancer?, Nov. 1995. (Summary) The purpose of this study is to examine whether or not well differentiated (w-d) hepatocellular carcinoma (HCC) is indeed clinically early cancer. Seventy six patients with solitary small HCCs up to 3 cm in diameter, who underwent hepatectomy, were observed for at least 2 years for possible recurrence. These patients were divided into two groups: 10 patients with w-d HCCs (Edmondson and Steiner's grade I) and 66 patients with less differentiated (l-d) HCCs (Edmondson and Steiner's grade I-II, II-III, and III). The histological analysis revealed that w-d HCCs had lower incidences of fibrous capsule formation (P<0.01), when compared to l-d HCCs. There were no significant differences in the incidence of intrahepatic metastasis, or portal vein invasion. In a resected specimen of w-d HCC, barium sulfate and gelatin were injected into portal vein and a transparent specimen was made. The transparent specimen showed that the portal vein in the tumor seemed to be intact. Microscopically, cancer cell infiltration into the fibrous frame of the portal tract was present. There were no significant differences in the disease free survival between the two groups. An analysis of tumor volume doubling time in recurrent foci suggested that minute cancerous foci had been present at the time of operation. W-d HCCs were clinically demonstrated not to be early cancer, because there was no significant difference in disease free survival between the patients with w-d and l-d HCCs. (Keyword) Carcinoma, Hepatocellular / Case-Control Studies / Disease-Free Survival / Female / Follow-Up Studies / Hepatectomy / Humans / Incidence / Liver / Liver Neoplasms / Male / Middle Aged / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Portal Vein / Prognosis / Time Factors (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8847047 ● Search Scopus @ Elsevier (PMID): 8847047 (PubMed: 8847047)
125.	Ysuharu Ikeda, Kiyoshi Kajiyama, Eisuke Adachi, M Yamagata, Mitsuo Shimada and Katsuhiko Yanaga : Early recurrence after surgery of hepatocellular carcinoma, Sep. 1995. (Summary) In 231 patients with hepatocellular carcinoma who underwent liver resection from 1986 to 1992 to determine the significance of alpha-fetoprotein (AFP) levels. There were 13 patients (5.6 per cent) with early recurrence within six months after hepatectomy. Preoperative serum alpha-fetoprotein (AFP) levels were significantly higher in patients with early recurrence (p < 0.01). Postoperative histological examination revealed that there were significant correlations between patients with early recurrence and intrahepatic metastasis (p < 0.01), and portal vein infiltration (p < 0.01). There were significant correlations between patients with early recurrence and preoperative diagnosis of intrahepatic metastasis (p < 0.01), however, preoperative diagnosis of portal vein infiltration could not be detected enough. Eight (73%) of 11 patients with over 1000 ng/ml of AFP and preoperative diagnosis of intrahepatic metastasis had early recurrence (p < 0.01). We found that patients of hepatocellular carcinoma with over 1000 ng/ml of AFP and preoperative diagnosis of intrahepatic metastasis are the most important factors in the preoperative clinical data linked to early recurrence type of HCC after hepatectomy. (Keyword) Aged / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Recurrence / Retrospective Studies / Tomography, X-Ray Computed / alpha-Fetoproteins (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8751199 ● Search Scopus @ Elsevier (PMID): 8751199 (PubMed: 8751199)
126.	Mitsuo Shimada, Naoyuki Kawahara, Kiyoshi Kajiyama, Ken Shirabe, Takashi Nishizaki and Katsuhiko Yanaga : A refined method of trans-thoracoabdominal hepatectomy for cirrhotic patients with hepatocellular carcinoma, Sep. 1995. (Summary) A hepatectomy in cirrhotic patients with hepatocellular carcinoma, located in either the posterior or superior part of the right lobe, inevitably requires a forced mobilization of the right lobe. Such a forced procedure causes a decreased hepatic blood flow resulting in postoperative morbidity and mortality, as well as an increased risk of the intrahepatic dissemination of cancer cells during the operation. We have thus refined the method of trans-thoracoabdominal hepatectomy to minimize those demerits of conventional transabdominal hepatectomies. The main characteristics of our refinements are as follows; (1) an optimal incision for the best short-cut to the hepatocellular carcinoma is determined by a three-dimensional imaging of either helical computed tomography and/or magnetic resonance imaging before operation; (2) a complete view of the operative field is obtained by the pertinent use of rotating the operation table, on which the patient is placed in a left semi-lateral position; (3) this method is suitable for resecting a tumor located in the posterior segment such as a posterior segmentectomy. This refined method is considered to decrease the postoperative morbidity including post-operative hepatic dysfunction and is also useful for cirrhotic patients with hepatocellular carcinoma. (Keyword) Carcinoma, Hepatocellular / Hepatectomy / Humans / Liver Cirrhosis / Liver Neoplasms / Tomography, X-Ray Computed (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8751194 ● Search Scopus @ Elsevier (PMID): 8751194 (PubMed: 8751194)
127.	Takashi Matsumata, Katsuhiko Yanaga, Mitsuo Shimada, Ken Shirabe, Akinobu Taketomi and Keizo Sugimachi : Occurrence of intraperitoneal septic complications after hepatic resections between 1985 and 1990, Springer-Verlag, Tokyo, Jan. 1995. (Keyword) intraperitoneal sepsis / hepatic resection / bile leakage / blood transfusion / gut-origin sepsis
128.	Mitsuo Shimada, 狩野律, 斉藤純 and 大町盛久 : 消化器外科手術後のmethicillin -resistant Staphylococcus aureus 腸炎予防における周術期バンコマイシン投与の意義, 1995.
129.	Hiroshi Hayashi, Takashi Maeda, Eisuke Adachi, Mitsuo Shimada, Takashi Matsumata and Kenji Takenaka : Argyrophilic nuclear organizer regions (AgNOR) of resected intrahepatic cholangio cellular carcinoma, 1995.
130.	Mitsuo Shimada, Takashi Matsumata, Akinobu Taketomi, Ken Shirabe, Kazuharu Yamamoto, Kenji Takenaka and Keizo Sugimachi : The role of interleukin-6, interleukin-1β, tumor necrosis factor-α, and endotoxin in hepatic resection, 1995.
131.	Mitsuo Shimada, A Saitoh and T Kano : Oral administration of vancomycin in preventing postoperative methicillin-resistant staphylococcus aureus enterocolitis, Adis International, 1995.
132.	Mitsuo Shimada, 脇山茂樹, 山本一治, 武富紹信, 前田貴司, 板阪英俊, 竹中賢治 and 杉町圭蔵 : 肝切除時のプロスタノイド動態に対する Thromboxane A2 synthetase inhibitor(OKY-046) の効果, 現代医療社, Tokyo, Nov. 1994.
133.	Hidefumi Higashi, Takashi Matsumata, J Hayashi, Katsuhiko Yanaga, Mitsuo Shimada, Ken Shirabe, Akinobu Taketomi, S Kashiwagi and Keizo Sugimachi : Detection of hepatitis C virus RNA in the ultrasonic dissector irrigating solution used in liver surgery, British Journal of Surgery Society Ltd., Sep. 1994.
134.	Mitsuo Shimada, Takashi Matsumata, Kazuharu Yamamoto, Hidetoshi Itasaka, Akinobu Taketomi and Keizo Sugimachi : Initiation of a fibrinolytic system in hepatic resection: the roles of tissue-type plasminogen activator and plasminogen activator inhibitor-1, Springer-Verlag, Tokyo, Sep. 1994. (Keyword) hepatectomy / fibrinolysis / tissue-type plasminogen activator / plasminogen activator inhibitor-1
135.	Hidetoshi Itasaka, Keiji Kishikawa, Taketoshi Suehiro, Katsuhiko Yanaga, Mitsuo Shimada, Hidefumi Higashi, Saburo Kakizoe, Tetsuo Ikeda, Shigeki Wakiyama and Keizo Sugimachi : Serum hyaluronic acid for the assessment of graft viability in porcine liver transplantation, Springer-Verlag, Tokyo, Aug. 1994. (Keyword) hyaluronic acid / endothelial cells / liver transplantation / graft viability
136.	Mitsuo Shimada, Kenji Takenaka and Keizo Sugimachi : A comprehensive multi-institutional study of empiric therapy with flomoxef in surgical infections of the digestive organs. The Kyushu Research Group for Surgical Infection, Aug. 1994. (Summary) The effect of flomoxef as empiric therapy for surgical infections of the digestive organs was analyzed in 103 patients, most of whom (94.2%) had intra-abdominal infections. Surgical procedures were performed on 73 patients contemporaneously with the flomoxef therapy. Flomoxef is an oxacephem and has a potent and broad bactericidal spectrum against aerobes and anaerobes. It provokes fewer adverse reactions than latamoxef such as vitamin K deficiency and platelet dysfunction. Flomoxef was administered intravenously at a dose 1-4g/day for more than 3 days without any other antimicrobial agent. The clinical response was classified into 3 groups; cured, improved and failed, and both the cured and improved responses were defined as satisfactory. A satisfactory response was obtained in 99 patients (96.1%). Regarding bacteriological response, the overall eradication rate was 81.3%. Adverse reactions including abnormal laboratory data occurred in only two patients. One had abdominal pain, and the other had a mild elevation of transaminases, and both were mild and easily reversible. Therefore, flomoxef is considered to have the potential of becoming one of the most effective agents in empiric therapy for surgical infections of the digestive organs. (Keyword) Adolescent / Adult / Aged / Aged, 80 and over / Bacterial Infections / Cephalosporins / Child / Digestive System Surgical Procedures / Female / Humans / Male / Middle Aged / Postoperative Complications (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7830103 ● Search Scopus @ Elsevier (PMID): 7830103 (PubMed: 7830103)
137.	Makoto Hashizume, Keizo Sugimachi, Seigo Kitano, Mitsuo Shimada, Hideo Baba, Kiichiro Ueno, Masayuki Ohta and Morimasa Tomikawa : Laparoscopic splenectomy, Elsevier Science, Jun. 1994. (Link to Publication Site) ● Publication site (DOI): 10.1016/0002-9610(94)90109-0 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/0002-9610(94)90109-0 (DOI: 10.1016/0002-9610(94)90109-0)
138.	Katsuhiko Yanaga, Takashi Matsumata, Hiroshi Hayashi, Mitsuo Shimada, Keiko Urata and Keizo Sugimachi : Isolated hepatic caudate lobectomy, Jun. 1994.
139.	Mitsuo Shimada, Takashi Matsumata, Takashi Nishizaki, Akinobu Taketomi, Hidetoshi Itasaka and Keizo Sugimachi : Major hepatic resection in patients with a prosthetic heart valve receiving anticoagulation treatment, Jun. 1994. (Summary) We experienced two patients with a prosthetic heart valve, who underwent hepatic resection for hepatoma while on anticoagulation therapy. Patients with a prosthetic heart valve have the following characteristics; an increased risk of thromboembolism due to diminished anticoagulation in the perioperative period, a greater risk of endocarditis due to the artificial material in the heart, and impaired cardiopulmonary function including possible arrhythmia and heart failure. Furthermore, when such patients also have liver cirrhosis with a hepatoma, there is an increased risk of perioperative bleeding while on anticoagulation due to coagulopathy and also a risk of infection due to decreased cellular immunity. Patients with a prosthetic heart valve therefore require special care and attention whenever they have to undergo hepatic resection. With respect to anticoagulation, a minimal level is required to prevent bleeding and thromboembolism. Warfarin being administered preoperatively may be switched to heparin while closely monitoring the activated clotting time (biomaterial valve: 130-150 sec, non-biomaterial valve: 150-180 sec); the heparin should then be changed back to warfarin immediately after starting oral intake following operation. For the prevention of infection, a broad spectrum antibiotic should be used prophylactically both intra-operatively and postoperatively. The cardiopulmonary function must also be carefully monitored. For the assessment of postoperative liver function, lecithin: cholesterol acyltransferase, serum bilirubin and albumin are useful because there is no relevance of coagulation parameters such as prothrombin time under anticoagulation. (Keyword) Carcinoma, Hepatocellular / Clinical Protocols / Combined Modality Therapy / Heart Valve Diseases / Heart Valve Prosthesis / Heparin / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Mitral Valve / Postoperative Complications / Preoperative Care / Treatment Outcome / Tricuspid Valve / Warfarin (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7959557 ● Search Scopus @ Elsevier (PMID): 7959557 (PubMed: 7959557)
140.	Takashi Matsumata, Hidefumi Higashi, Mitsuo Shimada, Eisuke Adachi, Ken Shirabe and Keizo Sugimachi : Indications for major hepatectomy in cirrhotic liver, Apr. 1994. (Summary) In an investigation of the indications for major hepatic resection of the cirrhotic liver, the records of 152 consecutive patients who had undergone a right hepatic resection between April 1985 and January 1991 were reviewed. A comparison of right hepatic lobectomy and right partial hepatectomy of the liver with no cirrhotic changes, revealed that postoperative values of serum glutamic pyruvic transaminase were significantly higher after right partial hepatectomy than after right lobectomy, despite the fact that there were no significant differences with respect to preoperative laboratory data, and there was a greater blood loss and total weight of the resected liver in patients receiving a right lobectomy as compared with those undergoing partial hepatectomy. These results suggest that in order to enable a more favorable recovery from hepatic resection, it is essential to avoid both mechanical damage and ischemic injury to the residual liver during hepatic surgery. A total of 77 patients underwent a partial hepatectomy of a cirrhotic liver, and among these patients, 16 patients had values of the indocyanine green test of less than 20%, as well as a portal pressure of less than 200 mm saline. Compared with these 16 cirrhotic patients and those patients who underwent right lobectomy, there were no significant differences with regard to the pre-operative laboratory data and portal pressure. These results therefore suggest that major hepatic lobectomy could be performed on selected patients with cirrhotic livers. (Keyword) Adult / Aged / Alanine Transaminase / Aspartate Aminotransferases / Blood Loss, Surgical / Female / Hepatectomy / Humans / Indocyanine Green / Liver / Liver Cirrhosis / Liver Function Tests / Male / Middle Aged (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8056407 ● Search Scopus @ Elsevier (PMID): 8056407 (PubMed: 8056407)
141.	Mitsuo Shimada, Takashi Matsumata, Eisuke Adachi, Hidetoshi Itasaka, Shigeki Wakiyama and Keizo Sugimachi : Estimation of degree of liver cirrhosis using a fibrosis score; a multivariate analysis of clinical parameters and resected specimens, Apr. 1994. (Summary) We designed this study to estimate the degree of liver cirrhosis using clinical parameters and surgically resected specimens. One hundred and twenty-nine cases who underwent hepatic resection in the Department of Surgery II, Kyushu University Hospital during the period between April 1985 and July 1991 for whom data for all 29 variables evaluated were available, were admitted to this study. On the basis of the histological findings of fibrosis of the liver, the non-neoplastic part of the resected specimens were classified into 3 groups; Z0, no cirrhosis (n = 63), Z1, mild cirrhosis (n = 38), and Z2, severe cirrhosis (n = 28). A univariate analysis revealed 14 significant variables. After multiple logistic regression analysis of these, five independent variables (low platelet count, female, low value of hepaplastin test, a high Pugh's score and a high value of ICG) were identified. We obtained a fibrosis score using the coefficient of each above-mentioned variable. This score increased the discriminative power. The fibrosis score is therefore considered useful for estimating the severity of liver cirrhosis. (Keyword) Adult / Aged / Female / Fibrosis / Hepatectomy / Humans / Indicators and Reagents / Indocyanine Green / Liver / Liver Cirrhosis / Liver Function Tests / Male / Middle Aged / Multivariate Analysis / Organic Chemicals / Platelet Count / Regression Analysis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8056410 ● Search Scopus @ Elsevier (PMID): 8056410 (PubMed: 8056410)
142.	Mitsuo Shimada, Takashi Matsumata, Hidetoshi Itasaka, Ken Shirabe, Akinobu Taketomi and Keizo Sugimachi : The prediction of portal pressure: a multivariate analysis of clinical data and intraoperative portal pressure, Springer-Verlag, Tokyo, Apr. 1994. (Summary) Portal pressures were estimated non-invasively in 100 patients who underwent hepatic resection and completely fulfilled the 21 variables evaluated. Ten variables were selected from among all those in the univariate analysis, and a stepwise discriminant analysis revealed four independent significant variables, namely: The indocyanine green dye retention test at 15 min (ICGR15); the prothrombin time index; the platelet count; and the globulin fraction. An equation to estimate the portal pressure was made using the coefficients in the analysis, the reliability of which was confirmed (r = 0.70484, P = 0.0001). The univariate analysis revealed ten significant variables to discriminate portal hypertension, defined as a portal pressure of over 200 mmH2O. A multiple logistic regression analysis of these variables revealed two independent variables, being ICGR15 and the platelet count. Thus, we consider that our equation for estimating portal pressure is potentially useful, and that the platelet count and ICGR15 are the most significant parameters in discriminating between the presence or absence of portal hypertension. Moreover, a platelet count of less than 120 x 10(3)/mm3 and an ICGR15 value of more than 15% correlated well with portal hypertension. (Keyword) Adult / Aged / Analysis of Variance / Discriminant Analysis / Female / Hepatectomy / Humans / Hypertension, Portal / Indocyanine Green / Male / Middle Aged / Monitoring, Intraoperative / Multivariate Analysis / Platelet Count / Portal Pressure / Predictive Value of Tests / Prothrombin Time / Regression Analysis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8038504 ● Search Scopus @ Elsevier (PMID): 8038504 (PubMed: 8038504)
143.	Mitsuo Shimada, Takashi Matsumata, Tatsuro Kamakura, Taketoshi Suehiro, Hidetoshi Itasaka and Keizo Sugimachi : Changes in regulating blood coagulation in hepatic resection with special references to soluble thrombomodulin and protein C, Jan. 1994. (Summary) The protein C anticoagulant pathway in hepatic resection was studied. The patients were divided into two groups--group 1 consisted of patients with a normal liver and group 2 consisted of patients with either hepatitic or a cirrhotic liver. Plasma protein C activity and soluble thrombomodulin were then sequentially measured during hepatectomy and in the early postoperative period. The protein C activity in group 1 decreased during hepatectomy and reached a low immediately after operation, and thereafter, recovered to near preoperative levels. However, the preoperative value in group 2 was lower than that in group 1 and the postoperative values were significantly lower than those in group 1 (p < 0.05). The level of soluble thrombomodulin in group 1 decreased during hepatectomy but later returned to preoperative levels. However, in group 2, the preoperative value was higher than that in group 1 and the postoperative values were greater than that of the preoperative values, while the values were significantly higher than those in group 1 (p < 0.05). During hepatectomy, hypercoagulability may contribute to the low levels of protein C and soluble thrombomodulin. The postoperative significant increase of soluble thrombomodulin may, thus, indicate the occurrence of endothelial injury in the remnant liver. The sequential measurements of both parameters can, therefore, be useful in detecting coagulopathy and endothelial injury in hepatic resection. (Keyword) Aged / Blood Coagulation / Female / Hepatectomy / Hepatitis / Humans / Liver Cirrhosis / Male / Middle Aged / Protein C / Thrombomodulin (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8156121 ● Search Scopus @ Elsevier (PMID): 8156121 (PubMed: 8156121)
144.	Takashi Matsumata, Hidetoshi Itasaka, Ken Shirabe, Mitsuo Shimada, Katsuhiko Yanaga and Keizo Sugimachi : Strategies for reducing blood transfusions in hepatic resection, 1994. (Summary) A comparison of 60 blood transfused and 71 nonblood transfused hepatic resection patients was done to evaluate strategies for reducing blood transfusions during hepatic surgery. There were no significant differences between the two groups with regard to preoperative laboratory data, except for prothrombin time and hematocrit value. The mean operative blood loss was 1990 ml and 760 ml in the blood transfused and nonblood transfused groups, respectively. A multivariate analysis suggested that the patient's body weight, preoperative prothrombin time, and operative blood loss independently predicted the need for intraoperative blood transfusion. Major postoperative complications developed more frequently in the blood transfused group than in the nonblood transfused group (31.7 vs. 11.3%, p < 0.005). These results suggest that the difference in operative blood loss between the two groups was related to the prolonged prothrombin time and a susceptibility for blood transfusion was found to exist particularly in patients with a lower hematocrit value as well as a lower body weight. Thus, the improvement of these preoperative laboratory data combined with avoiding the use of the hematocrit value as a determining factor for intraoperative transfusion could correspond to a reduction in operative blood loss, while curtailing the demands on blood bank facilities, and lowering the risk of postoperative complications. (Keyword) Adult / Aged / Blood Loss, Surgical / Blood Transfusion / Body Weight / Carcinoma, Hepatocellular / Combined Modality Therapy / Female / Hematocrit / Hepatectomy / Humans / Intraoperative Care / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Postoperative Complications / Predictive Value of Tests / Preoperative Care / Prothrombin Time / Risk Factors / Time Factors / Treatment Outcome (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7993858 ● Search Scopus @ Elsevier (PMID): 7993858 (PubMed: 7993858)
145.	Ken Shirabe, Takashi Matsumata, Mitsuo Shimada, Akinobu Taketomi, Takashi Nishizaki and Keizo Sugimachi : The effects of pirenzepine and famotidine on hepatic resection. a randomized prospective study, 1994.
146.	Takashi Nishizaki, Takashi Matsumata, Katsuhiko Yanaga, Mitsuo Shimada, Hideshi Higashi and Keizo Sugimachi : Open and closed suction drainage after hepatic resection, Springer-Verlag, Tokyo, Oct. 1993. (Keyword) hepatic resection / intraperitoneal septic complications
147.	Mitsuo Shimada, Tatsuro Kamakura, Hidetoshi Itasaka, Takashi Matsumata, Makoto Hashizume and Keizo Sugimachi : The significance of methicillin-resistant Staphylococcus aureus infection in general surgery: a multivariate analysis of risk factors and preventive approaches, Springer-Verlag, Tokyo, Oct. 1993. (Keyword) MRSA / Staphyloccus aureus / risk factors
148.	Katsuhiko Yanaga, Keiji Kishikawa, Mitsuo Shimada, Saburo Kakizoe, Hidefumi Higashi, Takashi Nishizaki, Takashi Matsumata, Takayuki Kanematsu and Keizo Sugimachi : Extracorporeal hepatic resection for previously unresectable neoplasms, Jun. 1993.
149.	Katsuhiko Yanaga, Takashi Matsumata, Hiroshi Hayashi, Mitsuo Shimada, Keiko Urata, Taketoshi Suehiro and Keizo Sugimachi : Effect of diabetes mellitus on hepatic resection, American Medical Association, Apr. 1993.
150.	Katsuhiko Yanaga, Takashi Matsumata, Takashi Nishizaki, Mitsuo Shimada and Keizo Sugimachi : Alternate hemihepatic vascular control technique for hepatic resection, Elsevier Science, Mar. 1993. (Summary) This report describes a simple and improved inflow control technique for resection of a hepatic tumor that lies across the right and left hepatic lobes. With alternate hemihepatic inflow control by en masse occlusion of Glisson's sheath of each hemipedicle at the bifurcation, hepatic resection across the two hepatic lobes is completed. Compared with Pringle's maneuver, this technique eliminates splanchnic congestion and reduces warm ischemia of the remnant liver, while maintaining a comparable hemostatic effect. (Keyword) Humans / Infant, Newborn / Liver / Liver Neoplasms / Methods (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8447545 ● Search Scopus @ Elsevier (PMID): 8447545 (PubMed: 8447545)
151.	Yasuharu Ikeda, Takayuki Kanematsu, Takashi Matsumata, Mitsuo Shimada, M Yamagata and Keizo Sugimachi : Liver resection and intractable postoperative ascites, Feb. 1993. (Summary) Among 211 patients who, between 1985 and 1990, underwent liver resection in Kyushu University Hospital, uncontrollable ascites occurred in 53 (25%). A univariate analysis revealed that postoperative death with liver failure occurred more frequently in patients with intractable ascites (p < 0.05). Alanine amino transferase levels were significantly higher in patients with intractable ascites (p < 0.05), but serum bilirubin, alkaline phosphatase and serum albumin levels did not differ significantly. Portal pressure (p < 0.05), the operation time (p < 0.01) and blood loss (p < 0.01) were significantly higher in patients with intractable postoperative ascites. A multiple analysis showed a correlation between the operation time, portal hypertension and postoperative intractable ascites. Postoperative histology revealed that a larger number of patients with cirrhosis had intractable ascites (p < 0.05). We conclude that cirrhosis, portal pressure and operating time are the most important factors related to intractable ascites in the case of hepatectomy. Areas of the liver to be resected should be limited in cirrhotic patients with portal hypertension. (Keyword) Adult / Aged / Alanine Transaminase / Ascites / Female / Hepatectomy / Humans / Hypertension, Portal / Liver Cirrhosis / Liver Diseases / Liver Neoplasms / Male / Middle Aged / Retrospective Studies (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8462921 ● Search Scopus @ Elsevier (PMID): 8462921 (PubMed: 8462921)
152.	Mitsuo Shimada, Takashi Matsumata, Shigeki Wakiyama, Takashi Maeda, Takayuki Kanematsu and Keizo Sugimachi : A safe and simple technique for exchanging central venous catheters, The Fellowship of Postgraduate Medicine, Feb. 1993.
153.	Mitsuo Shimada, 杉町圭蔵, 岩松正義, 上尾裕昭, 牛島賢一, 岡直剛, 奥平恭之, 甲斐秀信, 神代龍之介, 狩野律, 北村昌之, 木村専太郎, 白日高歩, 朔元則, 園田孝志, 竹中賢治, 友田博次, 中橋恒, 中山真一, 野田尚一, 藤永裕, 皆川清三, 嶺博之, 宮原正樹, 森琳, 守永和正, 森山正明, 矢毛石陽一 and 渡辺俊治 : 外科領域感染症に対するempiric therapyにおけるFMOXの有用性の検討, 1993.
154.	Mitsuo Shimada, Makoto Hashizume, M Ohta, Kouhei Akazawa, Tatsuro Kamakura, Keizo Sugimachi and Yoshiaki Nose : Prediction of survival of patients with esophageal varices treated by endoscopic injection sclerotherapy in Japan, 1993.
155.	Mitsuo Shimada, 松股孝, 林洋, 浦田啓子, 池田泰治, 西崎隆, 矢永勝彦 and 杉町圭蔵 : 肝切除術における血液凝固線容系の変動, 現代医療社, Tokyo, Apr. 1992.
156.	Mitsuo Shimada, Katsuhiko Yanaga, Hidefumi Higashi, Leonard Makowka, Saburo Kakizoe and Thomas E. Starzl : Pretransplant assessment of human liver grafts by plasma lecithin: cholesterol acyltransferase (LCAT) activity in multiple organ donors, Springer-Verlag, Berlin, Mar. 1992. (Summary) In spite of the improved outcome of orthotopic liver transplantation (OLTx), primary graft nonfunction remains one of the life-threatening problems following OLTx. The purpose of this study was to evaluate plasma lecithin: cholesterol acyltransferase (LCAT) activity in multiple organ donors as a predictor of liver allograft viability prior to OLTx. Thirty-nine donors were studied during a 5-month period between April and August 1988. Allograft hepatectomy was performed using a rapid technique or its minor modification with hilar dissections, and the allografts were stored cold (4 degrees C) in University of Wisconsin (UW) solution. Early post-transplant allograft function was classified as good, fair, or poor, according to the highest SGOT, SGPT, and prothrombin time within 5 days following OLTx. Procurement records were reviewed to identify donor data, which included conventional liver function tests, duration of hospital stay, history of cardiac arrest, and graft ischemic time. Blood samples from the donors were drawn immediately prior to aortic crossclamp, and from these plasma LCAT activity was determined. Plasma LCAT activity of all donors was significantly lower than that of healthy controls (12.4 +/- 8.0 vs 39.2 +/- 13.3 micrograms/ml per hour, P less than 0.01). LCAT activity (16.4 +/- 8.3 micrograms/ml per hour) in donors of grafts with good function was significantly higher than that in those with fair (8.6 +/- 4.5 micrograms/ml per hour, P less than 0.01) or poor (7.3 +/- 2.4 micrograms/ml per hour, P less than 0.01) function.(ABSTRACT TRUNCATED AT 250 WORDS) (Keyword) Viability test,human livers / Liver transplantation, plasma lecithin assessment / Lecithin, viability, liver donors / Cholesterol acyltransferase, in liver donors (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 1580983 ● Search Scopus @ Elsevier (PMID): 1580983 (PubMed: 1580983)
157.	西崎隆, 矢永勝彦, 末廣剛敏, 岸川圭嗣, Mitsuo Shimada and 杉町圭蔵 : イヌの肝移植実験と問題点, 1992.
158.	Mitsuo Shimada, 松股孝 and 杉町圭蔵 : 尾状葉原発肝細胞癌切除術の問題点, 1992.
159.	Kenji Takenaka, Mitsuo Shimada, Kengo Fukuzawa, Hidetoshi Itasaka, Tetsuo Ikeda, Kenichiro Okadome and Keizo Sugimachi : Flow-waveform controlled pulsatile perfusion for liver preservation, 1992.
160.	Kenji Takenaka, Mitsuo Shimada, Kengo Fukuzawa, Tetsuo Ikeda, Hidetoshi Itasaka, Hidefumi Higashi and Keizo Sugimachi : Viability of porcine transplanted liver graft determinable by serum lecithin:cholesterol acyltransferase (LCAT) activity, 1992.
161.	Katsuhiko Yanaga, Mitsuo Shimada, Robert D Gordon, Andreas G Tzakis, Leonard Makowka, J Wallis Marsh, Andrei C Stieber, Satoru Todo, Shunzaburo Iwatsuki and Thomas E Starzl : Pancreatic complications following orthotopic liver transplantation, 1992.
162.	Kouhei Akazawa, Mitsuo Shimada, Sunao Moriguchi, K Fujisawa, Tomohiro Odaka and Yoshiaki Nose : Interactive statistical analysis system for clinical investigators, Taylor & Francis, London, Oct. 1991. (Summary) We have developed an interactive statistical analysis system (ISAS-Q) with which clinical investigators with little experience in computers and programming can easily perform statistical analyses. ISAS-Q can perform most of the frequently used statistical methods, including multivariate analysis, in an interactive mode. Furthermore, ISAS-Q has self-consistent and extensive help functions. (Keyword) Data Interpretation, Statistical / Hospital Information Systems / Hospitals, University / Japan / Multivariate Analysis / Online Systems / Research / Software / User-Computer Interface (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 1762470 ● Search Scopus @ Elsevier (PMID): 1762470 (PubMed: 1762470)
163.	Kouhei Akazawa, Tomohiro Odaka, Maki Sakamoto, Shigeaki Ohtsuki, Mitsuo Shimada, Tatsuro Kamakura and Yoshiaki Nose : A random allocation system with the minimization method for multi-institutional clinical trials, Springer-Verlag, Netherlands, Aug. 1991. (Summary) This paper describes the random allocation system used to perform precise and rapid treatment assignments in multi-institutional clinical trials. This system is based on sophisticated randomization procedures, according to Pocock and Simon's minimization method and Zelen's method for institution balancing. The major advantage of randomized treatment assignments with this system is to balance treatment numbers for each level of various prognostic factors over the entire trial and at the same time balance the allocation of treatments within an institution. Therefore, the randomized treatment assignments by this system can prevent degrading of the statistical power of a particular treatment factor. This system is designed to run on a small-sized notebook computer and therefore can be set up beside a telephone for registration, without occupying a large space. At present, this system is conveniently being used in two clinical trials. (Keyword) Algorithms / Computer Simulation / Computers / Humans / Multicenter Studies as Topic / Prognosis / Random Allocation / software / Software Design (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 1800602 ● Summary page in Scopus @ Elsevier: 2-s2.0-0026329932 (PubMed: 1800602, Elsevier: Scopus)
164.	Kouhei Akazawa, Tsuyoshi Nakamura, Sunao Moriguchi, Mitsuo Shimada and Yoshiaki Nose : Simulation program for estimating statistical power of Cox's proportional hazards model assuming no specific distribution for the survival time, Elsevier Science, Ireland, Jul. 1991. (Keyword) simulation / Proportional hazards / Hazard / Survival analysis / Statistical power / Censored survival analysis (Link to Publication Site) ● Publication site (DOI): 10.1016/0169-2607(91)90122-A (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/0169-2607(91)90122-A (DOI: 10.1016/0169-2607(91)90122-A)
165.	K Fujisawa, Kouhei Akazawa, Y Hayashi, Mitsuo Shimada, Hidefumi Higashi, Yoshiaki Watanabe, Sunao Moriguchi and Yoshiaki Nose : A 24-hour ordering system for clinical examinations, Jul. 1991. (Summary) We have developed a 24-hour ordering system for clinical examinations, making use of the features of multi-function workstation (IBM5550) which performs two functions both in an on-line terminal and in a personal computer. It is used as an on-line terminal for the host computer (IBM4381) in day time. At night or on holiday, it is used as a stand-alone type personal computer to order clinical examinations. For this purpose, basic information of the inpatients (patient number, name, sex, date of birth, clinic, ward) are transferred from the host computer to the disket in the workstation in the evening when host computer finished on-line service. A physician can input the patient number followed by examination items using the touch panel according to the dialogue type guides written in Chinese character. Then, specimen label, list of ordered tests and an order form are printed out instantly. The date (patient number, examination items, identification number of the specimen, etc.) stored in the disket in the workstation at night are transferred from workstation to the host computer next morning. The host computer merges the information ordered in day time and at night and supplies working documents for examination (worksheets, master log, etc.) to technicians. Thus physicians can order examinations all day long using workstation, which make it possible to spare the time. (Keyword) Clinical Laboratory Information Systems / Computer Communication Networks / Hospital Information Systems / Japan / Laboratory Techniques and Procedures / Medical Records Systems, Computerized / Time Factors (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10170754 ● Search Scopus @ Elsevier (PMID): 10170754 (PubMed: 10170754)
166.	Mitsuo Shimada, Kouhei Akazawa, Sunao Moriguchi, Tomohiro Odaka and Yoshiaki Nose : A personal computer network system for equitable allocation of cadaver organs, Taylor & Francis, London, Jul. 1991. (Summary) We developed a personal computer network system for the equitable allocation of cadaveric organs. This network consists of a host computer (IBM PS55 model 5570 T) and various kinds of personal computers manufactured by many different computer makers in Japan. The merits of our personal computer network include lower cost and an easy access to the host computer from all the centres participating in this network while using their own favourite personal computers. Among the programs made for allocating cadaveric organs, we present in this paper the program for livers. This program was developed with a modified version of the logic developed by Starzl et al. The grade modification for the United Network for Organ Sharing (UNOS) in the United States was used as the basis for classification of medical urgency. Our program weighed the factors of medical urgency, compatibility of blood group and waiting time. Distance factors were omitted because of the smaller area of the network compared to that of UNOS. This computer network would be linked to other computer networks in creating a national organ procurement and transplant network in Japan, in order to help them to catch up with other advanced transplant countries. Such an equal and objective computer system should allow organ transplantation to become more widely accepted. (Keyword) Computer Communication Networks / Histocompatibility Testing / Humans / Japan / Microcomputers / Organ Transplantation / Regional Medical Programs / Software / Software Design / Tissue and Organ Procurement (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 1758219 ● Search Scopus @ Elsevier (PMID): 1758219 (PubMed: 1758219)
167.	Tomohiro Odaka, Yoshiaki Watanabe, Sunao Moriguchi, Kouhei Akazawa, Mitsuo Shimada, Maki Sakamoto, Taturo Kamakura and Yoshiaki Nose : Micro-mainframe-like personal clinical research system, Springer-Verlag, Netherlands, Jun. 1991.
168.	Kengo Fukuzawa, Mitsuo Shimada, Hidetoshi Itasaka, Kenji Takenaka and Keizo Sugimachi : Ammonia elimination as a rapid index of viability in liver grafts in dogs, Elsevier Science Inc. USA, USA, Jan. 1991. (Link to Publication Site) ● Publication site (DOI): 10.1016/0022-4804(91)90015-E (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/0022-4804(91)90015-E (DOI: 10.1016/0022-4804(91)90015-E)
169.	Katsuhiko Yanaga, Leonard Makowka, Mitsuo Shimada, G Lebeau, D Kahn, A L Mieles, L Sher, P Chapchap, G L Podesta and Thomas E Starzl : Improved method of porcine renal allografting for transplantation research, 1991. (Summary) This study presents a refined, reproducible, and clinically appropriate animal model of renal transplantation. A pair of kidneys are harvested from a donor pig and preserved in Euro-Collins' solution (4 degrees C). After a set period of preservation, the allografts are transplanted to two recipient pigs. The abdomen is entered through a midline incision. The right common iliac artery and vein are dissected and bilateral native nephrectomy is performed. Each allograft is then randomly assigned and transplanted to the recipients. Three minutes before unclamping, 100 mg of furosemide and 10 g of mannitol are given IV. Immediately after reperfusion, urine output is measured for 1 h. The allograft is biopsied and ureteroneocystostomy is created. Cystostomy is then placed using a 16F Foley catheter. The bladder neck is ligated to secure complete diversion of urine, and the abdomen is closed in layers. This kidney transplant model allows an absolutely paired study of the kidney allograft function from the same donor and also collection of pure urine at any time postoperatively, obviating the need for metabolic cages or sedation for urinary collection. This model and its unique modifications allow various transplant studies, including organ preservation, immunosuppressive protocol, and the prevention of reperfusion injury from oxygen free radicals. (Keyword) Animals / Female / Kidney Transplantation / Male / Models, Biological / research / Swine / Tissue Donors / Transplantation, Homologous (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2069932 ● Summary page in Scopus @ Elsevier: 2-s2.0-0025819508 (PubMed: 2069932, Elsevier: Scopus)
170.	Mitsuo Shimada, Kengo Fukuzawa, Hidetoshi Itasaka, Kenji Takenaka and Keizo Sugimachi : A simple and reliable assessment of liver allograft quality by analysis of effluent flushed from the grafts before liver transplantation in dogs, 1991.
171.	Kouhei Akazawa, Mitsuo Shimada, Y Hayashi, Yoshiaki Watanabe, Hidefumi Higashi, Sunao Moriguchi, K Fujisawa and Yoshiaki Nose : A disposable patient identification card made of a paper, Japan Hospital Association, Jul. 1990. (Summary) This paper describes a patient identification system with a disposable paper card. In general, total costs of cards themselves, equipments and personnel are remarkable, not negligible for the hospital management. Therefore, a disposable identification cards made of a paper were issued to out-patients in our hospital. Many order forms were integrated into only one sheet. Patient identification data were printed on this sheet by a computer system when a patient came to the reception desk, and quickly transmitted to physicians. We could save the hospital costs and printing works by physicians, and also shorten the waiting time of patients at reception desks. (Keyword) Ambulatory Care Information Systems / Disposable Equipment / Evaluation Studies as Topic / Japan / Medical Records Systems, Computerized / Outpatient Clinics, Hospital / Paper / Patient Identification Systems (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10108043 ● Search Scopus @ Elsevier (PMID): 10108043 (PubMed: 10108043)
172.	Mitsuo Shimada, Kouhei Akazawa, Hidefumi Higashi, Yoshiaki Watanabe, Y Hayashi, Sunao Moriguchi, K Fujisawa and Yoshiaki Nose : Development of an automatic medical summary report system, Japan Hospital Association, Jul. 1990. (Summary) We developed a medical summary report system. In this system, each department can specify the predetermined conditions for issuing the summary report. The summary is made through a hierarchical database in the integrated hospital information system according to the predetermined conditions. The summary automatically issued after reception of the outpatient, or also issued by on-line summary report program with the patient number if requested by doctors. The report is sent to the proper consulting room from the reception desk using an air-shooter. The report contains the patient information such as a patient name, age, sex, birthday, a clinic name, a chart number, a patient number, diagnoses and examinations. The doctors can refer to the points of the clinical history of the patient in his own and other departments, and make a correct diagnoses and avoid the overlaps of the examinations and medications. This system has contributed to the quality-up of the patient care by availability of patient information even in other departments without the medical chart. (Keyword) Hospital Information Systems / Japan / Medical Records / Medical Records Department, Hospital / Models, Theoretical / Outpatient Clinics, Hospital (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10108042 ● Search Scopus @ Elsevier (PMID): 10108042 (PubMed: 10108042)
173.	Hidefumi Higashi, Katsuhiko Yanaga, Mitsuo Shimada, Leonard Makowka, DH Thiel Van and Thomas E Starzl : Plasma lecithin/cholesterol acyltransferase (LCAT) activity in multiple-organ donors: a predictor of allograft viability in clinical liver transplantation, Apr. 1990. (Keyword) Adolescent / Adult / Biological Markers / Brain Death / children / Female / Humans / Liver Transplantation / Male / Phosphatidylcholine-Sterol O-Acyltransferase / Prognosis / Tissue Donors / Transplantation, Homologous (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2326946 ● Search Scopus @ Elsevier (PMID): 2326946 (PubMed: 2326946)
174.	Kengo Fukuzawa, Mitsuo Shimada, Kenji Takenaka and Keizo Sugimachi : Ex vivo perfusion for accurate assessment of liver graft viability in dogs, Taylor & Francis, 1990. (Summary) A new type of ex vivo liver perfusion model (EVPM) was developed. The system includes a physiological porto-portal connection, using a centrifugal pump and an aorto-aortal connection, through a heparin-coated tube. Ten pairs of mongrel dogs, weighing 13-20 kg, were used. Grafts of the liver procured from donors were perfused on the EVPM for 3 h. These grafts were divided into two groups: group A (n = 5), nonpreserved graft; group B (n = 5), 8-h graft preserved with lactated Ringer's solution (4 degrees C). The orthotopic liver transplantation (OLTx) series with the nonpreserved graft was reviewed, and dogs surviving for over 7 days following OLTx, group C (n = 5), were selected for liver grafts in the actual OLTx. In comparison with groups A and C, no difference was noted among enzyme levels (sGOT, sGPT, LDH) or in the recovery rate of ATP content in the graft liver tissue after revascularization. There were significant differences between group A and group B after revascularization. This simple and physiological EVPM accurately reflects graft function and hemodynamics in the actual OLTx. Graft viability, as a substitute for OLTx, in large animals can be reliably assessed. This EVPM is expected to contribute to research on events related to liver transplantation. (Keyword) Adenosine Triphosphate / Animals / Aorta, Abdominal / Dogs / Female / Graft Survival / Hepatic Artery / Liver / Liver Function Tests / Liver Transplantation / Male / Organ Preservation / Perfusion / Portal Vein (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2078548 ● Search Scopus @ Elsevier (PMID): 2078548 (PubMed: 2078548)
175.	Katsuhiko Yanaga, Leonard Makowka, G Lebeau, R R Hwang, Mitsuo Shimada, Saburo Kakizoe, J A Demetris and Thomas E Starzl : A new liver perfusion and preservation system for transplantation research in large animals, Taylor & Francis, 1990. (Summary) A kidney perfusion machine, model MOX-100 (Waters Instruments, Ltd, Rochester, MN) was modified to allow continuous perfusion of the portal vein and pulsatile perfusion of the hepatic artery of the liver. Additional apparatus consists of a cooling system, a membrane oxygenator, a filter for foreign bodies, and bubble traps. This system not only allows hypothermic perfusion preservation of the liver graft, but furthermore enables investigation of ex vivo simulation of various circulatory circumstances in which physiological perfusion of the liver is studied. We have used this system to evaluate the viability of liver allografts preserved by cold storage. The liver was placed on the perfusion system and perfused with blood with a hematocrit of approximately 20%, and maintained at 37 degrees C for 3 h. The flows of the hepatic artery and portal vein were adjusted to 0.33 mL and 0.67 mL/g of liver tissue, respectively. Parameters of viability consisted of hourly bile output, oxygen consumption, liver enzymes, electrolytes, vascular resistance, and liver histology. This method of liver assessment in large animals will allow the objective evaluation of organ viability for transplantation and thereby improve the outcome of organ transplantation. Furthermore, this pump enables investigation into the pathophysiology of liver ischemia and preservation. (Keyword) Animals / Cold Temperature / Liver / Liver Circulation / Liver Transplantation / Organ Preservation / Oxygen Consumption / Perfusion / Swine (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2282350 ● Search Scopus @ Elsevier (PMID): 2282350 (PubMed: 2282350)
176.	Katsuhiko Yanaga, Andreas G Tzakis, Mitsuo Shimada, William E Campbell, J Wallis Marsh, Andrei C Stieber, Leonard Makowka, Satoru Todo, Robert D Gordon, Shunzaburo Iwatsuki and Thomas E Starzl : Reversal of hypersplenism following orthotopic liver transplantation, Aug. 1989.
177.	Katsuhiko Yanaga, Mitsuo Shimada, Leonard Makowka, Hidefumi Higashi, Satoru Todo and Thomas E Starzl : The effect of preservation fluid on the blood flow of pediatric liver allografts, Aug. 1989. (Keyword) Child / Humans / Liver / Liver Transplantation / Organ Preservation (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2667214 ● Search Scopus @ Elsevier (PMID): 2667214 (PubMed: 2667214)
178.	Kenji Takenaka, Takashi Kanematsu, Mitsuo Shimada and Keizo Sugimachi : Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma, Elsevier Science, Aug. 1989. (Summary) The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system. Twenty-five HCC patients were administered 3.4 mg/kg HCFU once orally, after which the blood levels of HCFU and its derivatives (5-FU, CPEFU, CPRFU, HHCFU, OHCFU and F-beta-alanine) were serially measured using high performance liquid chromatography. The area under the concentration curve (AUC) of HCFU in the group of ICG R15 greater than or equal to 30% (group 2) was 5.35 +/- 1.73 h.micrograms/ml, a value which was significantly higher than the 2.60 +/- 1.19 h.micrograms/ml recorded for the group of ICG R15 less than 30% (group 1) (P less than 0.001). The AUC of HCFU had a significant positive correlation with the value of ICG R15 (P = 0.002) or the serum total bilirubin (P = 0.0005). The AUC of 5-FU showed no difference between the two groups. The AUC of CPRFU in group 2 was 0.16 +/- 0.25 h.micrograms/ml, a value significantly lower than the 0.48 +/- 0.39 h.micrograms/ml in group 1 (P = 0.023). There was no correlation between the AUC of other derivatives and the markers of liver function. These data suggest that, in patients with advanced cirrhosis, the accumulation of HCFU is related to the occurrence of side-effects from the administered drug, ingested over a long-term period. Therefore, when HCFU is given to cirrhotic patients with both HCC and 30% or more ICG R15, a careful monitoring for side-effects is required. (Keyword) Antineoplastic Agents / Carcinoma, Hepatocellular / Female / Fluorouracil / Humans / Liver Cirrhosis / Liver Neoplasms / Male / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1016/0277-5379(89)90414-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2548869 ● Search Scopus @ Elsevier (PMID): 2548869 ● Search Scopus @ Elsevier (DOI): 10.1016/0277-5379(89)90414-8 (DOI: 10.1016/0277-5379(89)90414-8, PubMed: 2548869)
179.	Katsuhiko Yanaga, Mitsuo Shimada, Leonard Makowka, O C Esquivel, Andreas G Tzakis and Thomas E Starzl : Significance of blood flow measurement in clinical liver transplantation, Feb. 1989. (Keyword) Adult / Emergencies / Female / Hepatic Artery / Humans / Liver Transplantation / Male / Portal Vein / Regional Blood Flow / Renal Circulation (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2652755 ● Search Scopus @ Elsevier (PMID): 2652755 (PubMed: 2652755)
180.	Kenichiro Okadome, Hiroshi Eguchi, Takashi Yukizane, Yoichi Muto, Mitsuo Shimada and Keizo Sugimachi : Long-term results of arterial reconstruction of lower extremities determined by flow waveform analysis, Torino(Italy), Jan. 1989. (Summary) Arterial reconstructions of the lower extremities were reviewed to assess the usefulness of flow waveform analysis. Six hundred and thirty-four arterial reconstructions were divided into two groups: a former (1965-1973) group of 218 reconstructions not assessed by flow waveform analysis and a recent (1974-1985) group of 416 reconstructions analyzed according to flow waveform. The cumulative patency rates of the former and the recent group at 5 years were as follows: aorto-femoral, 75.2% and 86.7% (P less than 0.05); femoral-distal, 34.6% and 61.5% (P less than 0.001); extra-anatomical, 63.6% and 80.2% (P = 0.06), respectively. Based on the various flow waveforms evidenced intraoperatively, the cumulative patency rate of cases in the recent group with type 0 and I flow waveform was compared to the rate of those with type II flow waveform. The cumulative patency rates at 5 years were as follows: aorto-femoral, 92% and 82.7% (P = 0.15); femoral-distal, 77.7% and 49.3% (P less than 0.001); extra-anatomical, 91.8% and 68.9% (P less than 0.05), respectively. These results indicate that intraoperative flow waveform analysis is a simple and useful indicator for predicting the long-term results of arterial reconstruction. (Keyword) Arterial Occlusive Diseases / Electromagnetic Phenomena / Follow-Up Studies / Humans / Leg / Regional Blood Flow / Rheology / Vascular Patency / Vascular Surgical Procedures (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2522453 ● Search Scopus @ Elsevier (PMID): 2522453 (PubMed: 2522453)
181.	Katsuhiko Yanaga, Leonard Makowka, Mitsuo Shimada, O C Esquivel, S J Bowman, Satoru Todo, Andreas G Tzakis and Thomas E Starzl : Hepatic artery thrombosis following pediatric liver transplantation:assessment of blood flow measurement in allografts, 1989.
182.	Mitsuo Shimada, 岡留健一郎, 江口博 and 武藤庸一 : 腹部大動脈瘤術後合併症の検討-特に術前腎機能と術後合併症との関連について, 1988.
183.	Mitsuo Shimada, 武藤庸一, 岡留健一郎, 江口博, 行実崇, 杉町圭蔵, 白神俊美 and 河合義雄 : 移植自家静脈片内膜肥厚防止のための血流改善補助ポンプの開発に関する研究, 1987.

Academic Paper (Judged Full Paper):

1.	Koichi Okamoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Kouzou Yoshikawa, Masahiro Sogabe, Yasushi Sato, Joji Shunto, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Gastric fundic gland polyposis and cancer development after eradication of Helicobacter pylori in patient with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)., Gastric Cancer, Vol.27, No.3, 635-640, 2024. (Summary) A 44-year-old woman with gastric cancer (GC) and fundic gland polyposis (FGPs) was referred to our hospital for further diagnosis and treatment. She successfully underwent eradication therapy for Helicobacter pylori (HP) 6 years ago, but did not exhibit FGPs at that time. When she underwent an esophagogastroduodenoscopy 2, 4, and 5 years after the eradication of HP, her imaging results revealed the existence of FGPs which gradually increased in her gastric fundus and body. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) was suspected and a mutational analysis was performed, revealing an APC promoter 1B variant c.-191T > C. A robotic total gastrectomy with lymphadenectomy was performed. Histopathological analysis of the surgical specimens revealed GC with no lymph node metastasis. GAPPS is characterized by GC and FGPs. However, our case shows different gastric phenotypes that are dependent on the status of HP infection. (Keyword) Female / Humans / Adult / Stomach Neoplasms / Helicobacter pylori / Adenocarcinoma / Helicobacter Infections / Polyps / Adenomatous Polyps (Link to Publication Site) ● Publication site (DOI): 10.1007/s10120-024-01473-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38407681 ● Search Scopus @ Elsevier (PMID): 38407681 ● Search Scopus @ Elsevier (DOI): 10.1007/s10120-024-01473-x (DOI: 10.1007/s10120-024-01473-x, PubMed: 38407681)
2.	Chie Takasu, Shuhai Chen, Luping Gao, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Role of Nrf2 signaling in development of hepatocyte-like cells, The Journal of Medical Investigation : JMI, Vol.70, No.3,4, 343-349, 2023. (Summary) Generation of hepatocytes from human adipose-derived mesenchymal stem cells (hADSCs) could be a promising alternative source of human hepatocytes. However, mechanisms to differentiate hepatocytes from hADSCs are not fully elucidated. We have previously demonstrated that our three-step differentiation protocol with glycogen synthase kinase (GSK) 3 inhibitor was effective to improve hepatocyte functions. In this study, we investigated the activation of the nuclear factor erythroid-2 related factor 2 (Nrf2) on hADSCs undergoing differentiation to HLC (hepatocyte-like cells). Our three-step differentiation protocol was applied for 21 days (Step 1:day 1-6, Step2:day 6-11, Step3:day 11-21). Our results show that significant nuclear translocation of Nrf2 occurred from day 11 until the end of HLC differentiation. Nuclear translocation of Nrf2 and CYP3A4 activity in the GSK3 inhibitor-treated group was obviously higher than that in Activin A-treated groups at day 11. The maturation of HLCs was delayed in Nrf2-siRNA group compared to control group. Furthermore, CYP3A4 activity in Nrf2-siRNA group was decreased at the almost same level in Activin A-treated group. Nrf2 translocation might enhance the function of HLC and be a target for developing highly functional HLC. J. Med. Invest. 70 : 343-349, August, 2023. (Keyword) Humans / NF-E2-Related Factor 2 / Glycogen Synthase Kinase 3 / Cytochrome P-450 CYP3A / Hepatocytes / Cell Differentiation / RNA, Small Interfering (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.343 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940517 ● Search Scopus @ Elsevier (PMID): 37940517 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.343 (DOI: 10.2152/jmi.70.343, PubMed: 37940517)
3.	Shoko Yamashita, Chie Takasu, Yuji Morine, Hiroki Ishibashi, Tetsuya Ikemoto, Hiroki Mori, Shin-ichiro Yamada, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : Characteristic submucosal alteration in biliary carcinogenesis of pancreaticobiliary maljunction with a focus on inflammasome activation., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.30, No.4, 462-472, 2023. (Summary) Activated fibroblasts and M2 macrophages in the GB lamina propria may be associated with biliary carcinogenesis of PBM, possibly through inflammasome activation. (Keyword) Humans / Inflammasomes / Bile Ducts / Caspase 1 / NLR Family, Pyrin Domain-Containing 3 Protein / Pancreaticobiliary Maljunction / Pancreatic Ducts / Biliary Tract Neoplasms / Gallbladder Neoplasms / Cholecystitis / Carcinogenesis (Tokushima University Institutional Repository) ● Metadata: 119056 (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.1253 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36259178 ● Search Scopus @ Elsevier (PMID): 36259178 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.1253 (Tokushima University Institutional Repository: 119056, DOI: 10.1002/jhbp.1253, PubMed: 36259178)
4.	Shohei Okikawa, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Effect of duodenal-jejunal bypass on diabetes in the early postoperative period, Scientific Reports, Vol.13, No.1, 1856-1856, 2023. (Summary) <jats:title>Abstract</jats:title><jats:p>Metabolic surgery is an effective treatment for patients with type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the effect of duodenal-jejunal bypass (DJB) in a rat model of T2DM during the early postoperative period. A rat model of non-obese T2DM was allocated to two groups: a sham group and a DJB group. On postoperative day 1 (1POD), oral glucose tolerance testing (OGTT) was performed and the changes of glucose transporter expressions in the small intestine was evaluated. [18F]-fluorodeoxyglucose ([18]-FDG) uptake was measured in sham- and DJB-operated rats using positron emission tomography-computed tomography (PET-CT). DJB improved the glucose tolerance of the rats on 1POD. The expression of sodium-glucose cotransporter 1 (SGLT1) and glucose transporter 1 (GLUT1) was high, and that of GLUT2 was low in the alimentary limb (AL) of rats in the DJB group. PET-CT showed that [18F]-FDG uptake was high in the proximal jejunum of DJB-operated rats. These results may show that DJB improve glucose tolerance in very early postoperative period as the result of glucose accumulation in the AL because of changes in glucose transporter expression.</jats:p> (Keyword) Multidisciplinary (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-28923-3 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1360580230617360512 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-28923-3 (DOI: 10.1038/s41598-023-28923-3, CiNii: 1360580230617360512)
5.	Shohei Okikawa, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Effect of duodenal-jejunal bypass on diabetes in the early postoperative period., Scientific Reports, Vol.13, No.1, 1856, 2023. (Summary) Metabolic surgery is an effective treatment for patients with type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the effect of duodenal-jejunal bypass (DJB) in a rat model of T2DM during the early postoperative period. A rat model of non-obese T2DM was allocated to two groups: a sham group and a DJB group. On postoperative day 1 (1POD), oral glucose tolerance testing (OGTT) was performed and the changes of glucose transporter expressions in the small intestine was evaluated. [18F]-fluorodeoxyglucose ([18]-FDG) uptake was measured in sham- and DJB-operated rats using positron emission tomography-computed tomography (PET-CT). DJB improved the glucose tolerance of the rats on 1POD. The expression of sodium-glucose cotransporter 1 (SGLT1) and glucose transporter 1 (GLUT1) was high, and that of GLUT2 was low in the alimentary limb (AL) of rats in the DJB group. PET-CT showed that [18F]-FDG uptake was high in the proximal jejunum of DJB-operated rats. These results may show that DJB improve glucose tolerance in very early postoperative period as the result of glucose accumulation in the AL because of changes in glucose transporter expression. (Keyword) Rats / Animals / Jejunum / Diabetes Mellitus, Type 2 / Positron Emission Tomography Computed Tomography / Fluorodeoxyglucose F18 / Duodenum / Glucose / Glucose Transport Proteins, Facilitative / Blood Glucose / Gastric Bypass (Tokushima University Institutional Repository) ● Metadata: 118744 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-28923-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36726038 ● Search Scopus @ Elsevier (PMID): 36726038 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-28923-3 (Tokushima University Institutional Repository: 118744, DOI: 10.1038/s41598-023-28923-3, PubMed: 36726038)
6.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Mayuko Shimizu, Koichi Tsuneyama, Mitsue Nishiyama, Shiori Ishizawa and Mitsuo Shimada : Effect of daikenchuto (TU-100) on carcinogenesis in non-alcoholic steatohepatitis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 66-73, 2023. (Summary) TU-100 regulates the intestinal microbiome and may suppress subsequent hepatocarcinogenesis in the NASH model. J. Med. Invest. 70 : 66-73, February, 2023. (Keyword) Mice / Animals / Non-alcoholic Fatty Liver Disease / Carcinoma, Hepatocellular / Liver Neoplasms / Liver / Carcinogenesis (Tokushima University Institutional Repository) ● Metadata: 118309 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.66 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164745 ● Search Scopus @ Elsevier (PMID): 37164745 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.66 (Tokushima University Institutional Repository: 118309, DOI: 10.2152/jmi.70.66, PubMed: 37164745)
7.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Mayuko Shimizu, Koichi Tsuneyama and Mitsuo Shimada : Inhibitory effect of non-alcoholic steatohepatitis on colon cancer liver metastasis., EJSO - European Journal of Surgical Oncology, Vol.49, No.2, 410-415, 2023. (Summary) The WD-fed NASH mouse model showed an inhibitory effect on CLM. Suppressed interleukin-6/signal transducer and activator of transcription 3 signaling and serum amyloid A/matrix metalloproteinase 9 expression may affect this phenomenon. (Keyword) Male / Mice / Animals / Non-alcoholic Fatty Liver Disease / Mice, Inbred C57BL / Liver / Liver Neoplasms / Disease Models, Animal / Colonic Neoplasms / RNA, Messenger (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejso.2022.11.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36371329 ● Search Scopus @ Elsevier (PMID): 36371329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejso.2022.11.002 (DOI: 10.1016/j.ejso.2022.11.002, PubMed: 36371329)
8.	Satoshi Sumida, Mayuko Shimizu, Yuko Miyakami, Takumi Kakimoto, Tomoko Kobayashi, Yasuyo Saijo, Minoru Matsumoto, Hirohisa Ogawa, Takeshi Oya, Yoshimi Bando, Hisanori Uehara, Shu Taira, Mitsuo Shimada and Koichi Tsuneyama : Histological and immunohistochemical analysis of epithelial cells in epidermoid cysts in intrapancreatic accessory spleen., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 251-259, 2023. (Summary) Novel histological features of epithelial cells of ECIPAS were indicated. Although more cases need to be evaluated, we propose that the cause of ECIPAS may be different from that of pancreatic ductal origin. J. Med. Invest. 70 : 251-259, February, 2023. (Keyword) Humans / Epidermal Cyst / Spleen / Pancreatic Diseases / Epithelial Cells / Immunohistochemistry (Tokushima University Institutional Repository) ● Metadata: 118205 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.251 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164730 ● Search Scopus @ Elsevier (PMID): 37164730 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.251 (Tokushima University Institutional Repository: 118205, DOI: 10.2152/jmi.70.251, PubMed: 37164730)
9.	Shinji Nagasaka, Yoshiro Abe, Yutaro Yamashita, Hiroyuki Yamasaki, Kazuhide Mineda, Mitsuo Shimada and Ichiro Hashimoto : Radiographic Study Evaluating Perforator Vessels in the Ischiorectal Fossa for Safe Elevation of Island Flaps, Plastic and Reconstructive Surgery. Global Open, Vol.10, No.10, e4561, 2022. (Summary) Perforator flaps based on the ischiorectal fossa (IRF) (ie, internal pudendal artery perforator flaps) are useful for perineal reconstruction. The three-dimensional characterization of perforator arteries in the IRF remains unclear, as the IRF contains thick adipose tissue as well as organs, such as the rectum, vagina, and urethra. This study aimed to evaluate perforators in the IRF to guide the safe elevation of skin flaps designed based on the IRF. IRF vessels were examined in 200 bilateral computed tomography angiography scans performed in 100 patients. We examined branching patterns arising from the internal iliac artery and the origins of the skin perforators in the IRF. The branching patterns of the internal iliac artery were divided into three groups: perforators derived exclusively from the internal pudendal artery (78%), perforators derived from the internal pudendal artery and the inferior gluteal artery (18%), and perforators derived exclusively from the inferior gluteal artery (4%). The average number of perforators in the IRF was 1.5 ± 0.7. The number of perforators was significantly higher in women than in men. The perforator arteries were found exclusively around the medial and dorsal sides of the ischial tuberosity. We found that perforators in the IRF were stable. All cases had more than one skin perforator, which was mainly derived from the internal pudendal artery. Although perforators cannot be identified during flap elevation because the fatty tissue in the IRF is very thick, physicians must focus on preserving the perforator-containing fatty tissue around the ischial tuberosity. (Link to Publication Site) ● Publication site (DOI): 10.1097/GOX.0000000000004561 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36246082 ● Search Scopus @ Elsevier (PMID): 36246082 ● Search Scopus @ Elsevier (DOI): 10.1097/GOX.0000000000004561 (DOI: 10.1097/GOX.0000000000004561, PubMed: 36246082)
10.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 【先天性胆道拡張症up-to-date】胆嚢外瘻と手術術式, Japanese Journal of Pediatric Surgery, Vol.54, No.9, 861-864, 2022. (Keyword) 和文論文 (Link to Publication Site) ● Publication site (DOI): 10.24479/ps.0000000224 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390014183340621440 ● Search Scopus @ Elsevier (DOI): 10.24479/ps.0000000224 (DOI: 10.24479/ps.0000000224, CiNii: 1390014183340621440)
11.	Beibei Ma, Hiroyuki Ueda, Koichi Okamoto, Masahiro Bando, Shota Fujimoto, Yasuyuki Okada, Tomoyuki Kawaguchi, Hironori Wada, Hiroshi Miyamoto, Mitsuo Shimada, Yasushi Sato and Tetsuji Takayama : TIMP1 promotes cell proliferation and invasion capability of right-sided colon cancers via the FAK/Akt signaling pathway., Cancer Science, Vol.113, No.12, 4244-4257, 2022. (Summary) Although right-sided colorectal cancer (CRC) shows a worse prognosis than left-sided CRC, the underlying mechanism remains unclear. We established patient-derived organoids (PDOs) from left- and right-sided CRCs and directly compared cell proliferation and invasion capability between them. We then analyzed the expression of numerous genes in signal transduction pathways to clarify the mechanism of the differential prognosis. Cell proliferation activity and invasion capability in right-sided cancer PDOs were significantly higher than in left-sided cancer PDOs and normal PDOs, as revealed by Cell Titer Glo and transwell assays, respectively. We then used quantitative RT-PCR to compare 184 genes in 30 pathways among right-sided and left-sided cancer and normal PDOs and found that the TIMP1 mRNA level was highest in right-sided PDOs. TIMP1 protein levels were upregulated in right-sided PDOs compared with normal PDOs but was downregulated in left-sided PDOs. TIMP1 knockdown with shRNA significantly decreased cell proliferation activity and invasion capability in right-sided PDOs but not in left-sided PDOs. Moreover, TIMP1 knockdown significantly decreased pFAK and pAkt expression levels in right-sided PDOs but not in left-sided PDOs. A database analysis of The Cancer Genome Atlas revealed that TIMP1 expression in right-sided CRCs was significantly higher than in left-sided CRCs. Kaplan-Meier survival analysis showed significantly shorter overall survival in high-TIMP1 patients versus low-TIMP1 patients with right-sided CRCs but not left-sided CRCs. Our data suggest that TIMP1 is overexpressed in right-sided CRCs and promotes cell proliferation and invasion capability through the TIMP1/FAK/Akt pathway, leading to a poor prognosis. The TIMP1/FAK/Akt pathway can be a target for therapeutic agents in right-sided CRCs. (Keyword) Humans / Prognosis / Signal Transduction / Colorectal Neoplasms / Colonic Neoplasms / Cell Proliferation / Tissue Inhibitor of Metalloproteinase-1 (Tokushima University Institutional Repository) ● Metadata: 117615 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.15567 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36073574 ● Search Scopus @ Elsevier (PMID): 36073574 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15567 (Tokushima University Institutional Repository: 117615, DOI: 10.1111/cas.15567, PubMed: 36073574)
12.	Nanami Nasu, Sonoko Yasui-Yamada, Natsumi Kagiya, Mami Takimoto, Yumiko Kurokawa, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : Muscle strength is a stronger prognostic factor than muscle mass in patients with gastrointestinal and hepatobiliary-pancreatic cancers., Nutrition, Vol.103-104, 111826, 2022. (Summary) Sarcopenia has been reported as a prognostic risk factor in patients with gastrointestinal (GI) and hepatobiliary pancreatic (HBP) cancers. This study aimed to investigate whether the loss of muscle mass or strength is a stronger prognostic factor, and explore the cutoff values of skeletal muscle mass index (SMI) and handgrip strength (HGS) based on the survival outcome in patients with GI and HBP cancers. A total of 480 elderly patients with primary GI and HBP cancers who underwent their first resection surgery were analyzed retrospectively. Patients were divided into four groups: Appropriate SMI and HGS, low SMI alone, low HGS alone, and low SMI and HGS. Low SMI was derived from a bioelectrical impedance analysis, and low HGS was defined according to the Asian Working Group for Sarcopenia 2019 criteria. The multivariate analysis showed that low SMI was a significant risk factor for mortality in men only, but low HGS was significant in both sexes. From the multivariate analysis of the four groups, low HGS alone and low SMI and HGS showed a significantly higher hazard ratio than appropriate SMI and HGS in both sexes. An SMI of 7.21 kg/m and HGS of 28 kg were obtained as cutoff values based on the 3-y survival outcomes in men. Low muscle strength was a stronger prognostic factor than low muscle mass. Therefore, measuring muscle strength in all patients is essential. (Keyword) Male / Female / Humans / Aged / Sarcopenia / Hand Strength / Prognosis / Retrospective Studies / Muscle Strength / Muscle, Skeletal / Pancreatic Neoplasms (Tokushima University Institutional Repository) ● Metadata: 118201 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.nut.2022.111826 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36122543 ● Search Scopus @ Elsevier (PMID): 36122543 ● Search Scopus @ Elsevier (DOI): 10.1016/j.nut.2022.111826 (Tokushima University Institutional Repository: 118201, DOI: 10.1016/j.nut.2022.111826, PubMed: 36122543)
13.	Yosuke Iwakawa, Kouzou Yoshikawa, Koichi Okamoto, Tetsuji Takayama, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : Four cases of gastric adenocarcinoma and proximal polyposis of the stomach treated by robotic total gastrectomy, Surgical Case Reports, Vol.8, No.1, 70, 2022. (Summary) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is a rare disease and characterized by a unique point mutation in the promoter 1B region of the adenomatous polyposis coli (APC) gene. There are two aims in surgery for GAPPS; the first is prophylactic gastrectomy, and the second is excising concurrent cancer. We performed robotic total gastrectomy (RTG) for four cases of GAPPS. Case 1 was a woman in her 40 s whose sister had died from gastric cancer. Mutational analysis revealed mutation of APC exon 1B. We performed prophylactic gastrectomy. Case 2 was a woman in her 30 s who had a mutation of APC exon 1B, and preoperative biopsy revealed suspected adenocarcinoma. Case 3 was a woman in her 40 s who was diagnosed with gastric cancer with multiple polyps in the stomach and a mutation of APC exon 1B. Case 4 was a woman in her 20 s in whom biopsy revealed low-grade dysplasia of a raised lesion. She had a mutation in APC exon 1B. We performed RTG with D1 + lymphadenectomy in all patients, and there were no intraoperative complications. Patients with GAPPS are mainly followed regularly with repeat biopsy, and tumors are detected in an early stage. As the safety of robotic surgery for the early gastric cancer is reported, RTG is an option for these patients. This is the first report of RTG for GAPPS patients. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-022-01425-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35435526 ● Search Scopus @ Elsevier (PMID): 35435526 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-022-01425-6 (DOI: 10.1186/s40792-022-01425-6, PubMed: 35435526)
14.	Shoko Yamashita, Masaaki Nishi, Kozo Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Yuma Wada, Toshiaki Yoshimoto, Yosuke Iwakawa, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : Gastric carcinoma with lymphoid stroma derived from hamartomatous inverted polyp with osteoclast-like giant cells: a case report., International Cancer Conference Journal, Vol.11, No.3, 196-200, 2022. (Summary) Gastric carcinomas with lymphoid stroma (GCLS) are characterized by prominent stromal infiltration of lymphocyte and account for 1-4% of gastric cancers. Although, osteoclast-like giant cells (OGC) have been reported in some GCLS, OGCs in gastric tumors is exceedingly rare. A 60-year-old woman presented to our hospital after the finding of a positive fecal blood test during a routine medical check. Esophagogastroduodenoscopy revealed a Type 0-III + IIc tumor in the middle part of the gastric body. Biopsy revealed a poorly differentiated tumor and she was referred to our department. Early phase computed tomography showed thickening of the wall in the middle of the gastric body and enlargement of nearby lymph nodes. Laparoscopic total gastrectomy was performed. Pathological examination revealed a hamartomatous inverted polyp (HIP) in the submucosal layer with tub2-por1 tumor in the HIP. Prominent lymphocytic infiltration and OGCs were found around the tumor. Immunohistochemical analysis showed that the tumor cells were negative for EBER, MLH-1, and MSH2, 6. These findings suggest that this tumor was a non-microsatellite instability (MSI)-high GCLS without Epstein-Barr virus (EBV) infection. The patient's postoperative course was uneventful and she was discharged 11 days after surgery. She remains well 3 years after surgery. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13691-022-00547-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35669900 ● Search Scopus @ Elsevier (PMID): 35669900 ● Search Scopus @ Elsevier (DOI): 10.1007/s13691-022-00547-w (DOI: 10.1007/s13691-022-00547-w, PubMed: 35669900)
15.	Hiroki Mori, Hiroki Ishibashi, Noriko Yokota and Mitsuo Shimada : Risk factors for metachronous contralateral inguinal hernia after laparoscopic percutaneous extraperitoneal closure for unilateral inguinal hernia in children., Surgery Today, Vol.52, No.10, 1491-1496, 2022. (Summary) We use the laparoscopic percutaneous extraperitoneal closure (LPEC) method as the standard procedure for pediatric inguinal hernia. Despite judging there to be no contralateral patent processus vaginalis (PPV) at the time of the first LPEC, we experienced five cases in which metachronous contralateral inguinal hernia (MCH) developed, so we report the characteristics, including the predictors. For pediatric inguinal hernia, the LPEC method was used in 1277 cases from 2005 to 2019 in our department. Of these, 374 patients underwent unilateral LPEC, and we compared the 5 patients with MCH onset and the 369 without MCH onset. The items to be examined were the gender, age, presence of a low birth weight, initial-onset side, and contralateral internal inguinal ring classification. There was no significant difference in the gender, age, initial-onset side, or contralateral internal inguinal ring classification between the two groups. Low-birth-weight infants were significantly more common among those with MCH than among those without MCH. The only predictor of a contralateral onset after LPEC for pediatric inguinal hernia was a low birth weight. Therefore, for the above-mentioned unilateral LPEC cases, the possibility of a contralateral onset after LPEC due to acquired factors rather than congenital factors should be considered. (Keyword) Child / Hernia, Inguinal / Herniorrhaphy / Humans / Infant / Laparoscopy / Male / Retrospective Studies / Risk Factors / Testicular Hydrocele / 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-022-02480-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35211805 ● Search Scopus @ Elsevier (PMID): 35211805 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-022-02480-0 (DOI: 10.1007/s00595-022-02480-0, PubMed: 35211805)
16.	Mami Takimoto, Sonoko Yasui-Yamada, Nanami Nasu, Natsumi Kagiya, Nozomi Aotani, Yumiko Kurokawa, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : Development and Validation of Cutoff Value for Reduced Muscle Mass for GLIM Criteria in Patients with Gastrointestinal and HepatobiliaryPancreatic Cancers, Nutrients, Vol.14, No.943, 1-10, 2022. (Summary) The Global Leadership Initiative on Malnutrition (GLIM) criteria recommends using race- and sex-adjusted cutoff values for reduced muscle mass (RMM), but the only cutoff values available for Asians are the skeletal muscle mass index (SMI) established by the Asian Working Group for Sarcopenia (AWGS). This retrospective study aimed to develop and validate cutoff values for the fat-free mass index (FFMI) and arm circumference (AC) of Asians, and to investigate the association between GLIM malnutrition and prognosis. A total of 660 patients with primary gastrointestinal (GI) and hepatobiliary-pancreatic (HBP) cancers who underwent their first resection surgery were recruited and randomly divided into development and validation groups. The FFMI and AC cutoff values were calculated by receiver operating characteristic curve analysis for the AWGS SMI as the gold standard. The cutoff values for each RMM were used to diagnose malnutrition on the basis of GLIM criteria, and the survival rates were compared. The optimal FFMI cutoff values for RMM were 17 kg/m for men and 15 kg/m for women, and for AC were 27 cm for men and 25 cm for women. In the validation group, the accuracy of the FFMI and AC cutoff values to discriminate RMM were 85.2% and 68.8%, respectively. Using any of the three measures of RMM, overall survival rates were significantly lower in the GLIM malnutrition group. In conclusion, the cutoff values for the FFMI and AC in this study could discriminate RMM, and GLIM malnutrition using these cutoff values was associated with decreased survival. (Keyword) Female / Humans / Leadership / Male / Malnutrition / Muscles / Pancreatic Neoplasms / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116863 (Link to Publication Site) ● Publication site (DOI): 10.3390/nu14050943 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35267918 ● Search Scopus @ Elsevier (PMID): 35267918 ● Search Scopus @ Elsevier (DOI): 10.3390/nu14050943 (Tokushima University Institutional Repository: 116863, DOI: 10.3390/nu14050943, PubMed: 35267918)
17.	Hiroki Ishibashi, Noriko Yokota, Hiroki Mori and Mitsuo Shimada : 【小児外科疾患の家族内発生】側頸瘻, Japanese Journal of Pediatric Surgery, Vol.53, No.12, 1243-1247, 2021. (Link to Publication Site) ● Publication site (DOI): 10.24479/j00645.2022081267 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390858608270543872 ● Search Scopus @ Elsevier (DOI): 10.24479/j00645.2022081267 (DOI: 10.24479/j00645.2022081267, CiNii: 1390858608270543872)
18.	Yu Saitou, Mitsuo Shimada, Yuji Morine, Shin-ichiro Yamada and Maki Sugimoto : Essential updates 2020/2021: Current topics of simulation and navigation in hepatectomy., Annals of Gastroenterological Surgery, Vol.6, No.2, 190-196, 2021. (Summary) With the development of three-dimensional (3D) simulation software, preoperative simulation technology is almost completely established. The remaining issue is how to recognize anatomy three-dimensionally. Extended reality is a newly developed technology with several merits for surgical application: no requirement for a sterilized display monitor, better spatial awareness, and the ability to share 3D images among all surgeons. Various technology or devices for intraoperative navigation have also been developed to support the safety and certainty of liver surgery. Consensus recommendations regarding indocyanine green fluorescence were determined in 2021. Extended reality has also been applied to intraoperative navigation, and artificial intelligence (AI) is one of the topics of real-time navigation. AI might overcome the problem of liver deformity with automatic registration. Including the issues described above, this article focuses on recent advances in simulation and navigation in liver surgery from 2020 to 2021. (Tokushima University Institutional Repository) ● Metadata: 117276 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12542 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35261944 ● Search Scopus @ Elsevier (PMID): 35261944 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12542 (Tokushima University Institutional Repository: 117276, DOI: 10.1002/ags3.12542, PubMed: 35261944)
19.	Masaki Kaibori, Kosuke Matsui, Mitsuo Shimada, Shoji Kubo and Kiyoshi Hasegawa : Update on perioperative management of patients undergoing surgery for liver cancer., Annals of Gastroenterological Surgery, Vol.6, No.3, 344-354, 2021. (Summary) Hepatocellular carcinoma is often accompanied by chronic hepatitis or cirrhosis. Preoperative evaluation of liver function and postoperative nutritional management are critical in patients with hepatocellular carcinoma who undergo liver surgery. Although the incidence of postoperative complications and death has declined in Japan over the last 10 years, postoperative complications have not been fully overcome. Therefore, surgical procedures and perioperative management must be improved. Accurate preoperative evaluations of liver function, nutrition, inflammation, and body skeletal muscle are required. Determination of the optimal surgical procedure should consider not only tumor characteristics but also the physical reserve of the patient. Nutritional management of chronic liver disorders, especially maintaining protein synthesis for postoperative protein/energy, is important. Prophylactic antibiotics are recommended for short-term use within 24 hours after surgery. Abdominal drainage is recommended for patients with cirrhosis who may develop large amounts of ascites, who are at risk of postoperative bleeding, or who may have bile leakage due to a large resection area. Postoperative exercise therapy may improve insulin resistance in patients with chronic liver damage. Implementation of an early/enhanced recovery after surgery program is recommended to reduce biological invasive responses and achieve early independence of physical activity and nutrition intake. We review the latest information on the perioperative management of patients undergoing liver resection for hepatocellular carcinoma. (Tokushima University Institutional Repository) ● Metadata: 117277 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12529 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35634181 ● Search Scopus @ Elsevier (PMID): 35634181 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12529 (Tokushima University Institutional Repository: 117277, DOI: 10.1002/ags3.12529, PubMed: 35634181)
20.	Jun Uemura, Keiichi Okano, Minoru Oshima, Hironobu Suto, Yasuhisa Ando, Kensuke Kumamoto, Kyuichi Kadota, Shuji Ichihara, Yasutaka Kokudo, Takashi Maeba, Yoshihide Nanno, Hirochika Toyama, Yasutsugu Takada, Mitsuo Shimada, Kazuhiro Hanazaki, Tsutomu Masaki and Yasuyuki Suzuki : Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors., Annals of Surgery, Vol.274, No.6, e949-e956, 2021. (Summary) The goal of this retrospective study was to clarify the clinical implications of immunohistochemically detected protein expression for genes that are frequently mutated in pancreatic neuroendocrine tumors (PNETs). The clinical management of PNETs is hindered by their heterogenous biological behavior. Whole-exome sequencing recently showed that 5 genes (DAXX/ATRX, MEN1, TSC2, and PTEN) are frequently mutated in PNETs. However, the clinical implications of the associated alterations in protein expression remain unclear. We collected Grade 1 and 2 (World Health Organization 2017 Classification) primary PNETs samples from 100 patients who underwent surgical resection. ATRX, DAXX, MEN1, TSC2, and PTEN expression were determined immunohistochemically to clarify their relationships with prognosis and clinicopathological findings. Kaplan-Meier analysis indicated that loss of TSC2 (n = 58) or PTEN (n = 37) was associated with significantly shorter overall survival, and that loss of TSC2 or ATRX (n = 41) was associated with significantly shorter recurrence-free survival. Additionally, loss of ATRX or TSC2 was significantly associated with nodal metastasis. In a multivariate analysis, combined loss of TSC2 and ATRX (n = 31) was an independent prognostic factor for shorter recurrence-free survival (hazard ratio 10.1, 95% confidence interval 2.1-66.9, P = 0.003) in G2 PNETs. Loss of ATRX, TSC2, and PTEN expression might be useful as a method of clarifying the behavior and clinical outcomes of Grade 1 and 2 PNETs in routine clinical practice. Combined loss of TSC2 and ATRX had an especially strong, independent association with shorter recurrence-free survival in patients with G2 PNETs. Loss of pairs in ATRX, TSC2, or PTEN would be useful for selecting the candidate for postoperative adjuvant therapy. (Link to Publication Site) ● Publication site (DOI): 10.1097/SLA.0000000000003624 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31599805 ● Search Scopus @ Elsevier (PMID): 31599805 ● Search Scopus @ Elsevier (DOI): 10.1097/SLA.0000000000003624 (DOI: 10.1097/SLA.0000000000003624, PubMed: 31599805)
21.	Katsuki Miyazaki, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Tetsuya Ikemoto, Satoru Imura, Haun Hu, Hisayoshi Morioka, Koichi Tsuneyama and Mitsuo Shimada : Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient., International Journal of Clinical Oncology, Vol.26, No.12, 2265-2274, 2021. (Summary) Tumor-infiltrating lymphocytes (TILs) are a prognostic factor or an indicator of chemotherapy response for various malignancies. The aim of this study was to investigate the prognostic impact of TILs in resected intrahepatic cholangiocarcinoma (IHCC). We also investigated the usefulness of the apparent diffusion coefficient (ADC) in diffusion-weighted magnetic resonance imaging (DW-MRI) to predict TILs. We enrolled 23 patients with IHCC who underwent initial hepatic resection in Tokushima University Hospital from 2006 to 2017. We evaluated stromal TILs in the tumor marginal area and central area in surgical specimens. Patients were divided into low vs high stromal TILs groups. We analyzed the patients' clinicopathological factors, including prognosis, according to the degree of stromal TILs. We also analyzed the correlation between stromal TILs and the minimum ADC value. Stromal TILs in the marginal area reflected overall survival more accurately than that in the central area. Additionally, marginal low TILs was significantly associated with lymph node metastasis and portal vein invasion. Both overall- and disease-free survival rates in the marginal low TILs group were significantly worse than those in the marginal high TILs group (P < 0.05). In the multivariate analysis, marginal low TILs were an independent prognostic factor for both overall- and disease-free survival (P < 0.05), and marginal low TILs were significantly associated with lower minimum ADC values (P < 0.02). Stromal TILs, especially in the marginal area, might demonstrate prognostic impact in patients with IHCC. Moreover, the ADC values from MRI may predict TILs in IHCC tumor tissue. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Diffusion Magnetic Resonance Imaging / Humans / Lymphocytes, Tumor-Infiltrating / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-021-02026-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34596803 ● Search Scopus @ Elsevier (PMID): 34596803 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-02026-3 (DOI: 10.1007/s10147-021-02026-3, PubMed: 34596803)
22.	Hiroki Ishibashi, Noriko Yokota, Hiroki Mori and Mitsuo Shimada : 【消化管重複症のすべて】腹部食道, Japanese Journal of Pediatric Surgery, Vol.53, No.9, 924-929, 2021. (Link to Publication Site) ● Publication site (DOI): 10.24479/j00645.2022002817 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390858608270600576 ● Search Scopus @ Elsevier (DOI): 10.24479/j00645.2022002817 (DOI: 10.24479/j00645.2022002817, CiNii: 1390858608270600576)
23.	Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Masato Miyake, Yuji Morine, Seiichi Oyadomari and Mitsuo Shimada : Effective three-dimensional culture of hepatocyte-like cells generated from human adipose-derived mesenchymal stem cells., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.28, No.9, 705-715, 2021. (Summary) The aim of this study was to clarify the effectiveness of a new three-dimensional (3D) culture system for hepatocyte-like cells (HLCs) generated from human adipose-derived mesenchymal stem cells (ADSCs). Human ADSCs (2 × 10 ) with or without 0.1 mg/mL human recombinant peptide μ-piece per well were seeded in a 96-well U-bottom plate and then our three-step differentiation protocol was applied for 21 days. At each step, cell morphology and gene expression were investigated. Mature hepatocyte functions were evaluated after HLC differentiation. These parameters were compared between 2D- and 3D-cultured HLCs, and, DNA microarray analysis was also performed. Finally, HLCs were transplanted in to CCl induced acute liver failure model mice. Two-dimensional-cultured HLCs at day 21 did not have a spindle shape and had formed spheroids after day 6, which gradually increased in size for 3D-cultured HLCs. Definitive endoderm, hepatoblast, and hepatocyte genes showed significantly higher expression in the 3D culture group. Three-dimensional-cultured HLCs also had higher albumin expression, CYP3A4 activity, urea synthesis, and ammonium metabolism, and much higher expression of ion transporter, blood coagulation, and cell communication genes. HLC transplantation improved serum liver function, especially in T-Bil levels, and engrafted into immunodeficient mice with HLA class I positive staining. Our new 3D culture protocol is effective to improve hepatocyte functions. Our HLCs might be promising for clinical cell transplantation to treat metabolic disease. (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.1024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34318615 ● Search Scopus @ Elsevier (PMID): 34318615 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.1024 (DOI: 10.1002/jhbp.1024, PubMed: 34318615)
24.	Masaaki Nishi, Ryosuke Miyamoto, Kasane Shima, Hirokazu Miki, Hideo Terasawa, Chie Takasu, Kouzou Yoshikawa, Takuro Oyama, Katsuya Tanaka, Yuishin Izumi and Mitsuo Shimada : Robot-assisted total gastrectomy for gastric cancer in a patient with amyotrophic lateral sclerosis receiving long-term tracheostomy invasive ventilation, International Cancer Conference Journal, Vol.10, No.4, 318-323, 2021. (Summary) Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Although affected patients may develop cancers, major surgical intervention has been hampered by its questionable overall benefit due to limited prognosis and risk of postoperative respiratory collapse. A recent study, however, showed that tracheostomy invasive ventilation (TIV) prolonged median survival to 11.3 years; thus, patients with ALS receiving TIV might benefit from major surgery. A 66-year-old man with ALS, who had received TIV and enteral tube feeding for 8 years, presented with bloody stool. The patient also had type 2 diabetes mellitus, stage 4 chronic kidney disease, abdominal aortic aneurysm, and anti-phospholipid syndrome, as well as multiple episodes of pneumonia and catheter-related urinary tract infection treated by antibiotics. Medical examination and esophagogastroduodenoscopy revealed a type 3 tumor in the middle part of the stomach. The patient's preoperative diagnosis was gastric cancer (GC), MU, type3, Less-Post, T3(SS), N1, H0, P0, M0, cStage III. The estimated mortality rate was 30.5%, according to the Japanese National Clinical Database. The patient and his family were fully informed of the risk of surgery; the patient clearly requested curative surgery by eye movement. Thus, robot-assisted total gastrectomy (RATG) was performed. The tissues were extremely fragile and hemorrhagic. The surgical time was 7 h 0 min; intraoperative blood loss was 324 ml. Pathological examination revealed GC, MU, type3, T4a(SE), N2, H0, CY0, P0, M0 fStage IIIB. The postoperative course was uneventful. He has remained in stable condition for 3 months. Our findings suggest that patients with ALS who achieve longer survival with TIV can undergo major cancer surgery, including robot-assisted surgery, which may facilitate a better mid-long-term prognosis. The online version contains supplementary material available at 10.1007/s13691-021-00499-7. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13691-021-00499-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34567945 ● Search Scopus @ Elsevier (PMID): 34567945 ● Search Scopus @ Elsevier (DOI): 10.1007/s13691-021-00499-7 (DOI: 10.1007/s13691-021-00499-7, PubMed: 34567945)
25.	Yuji Morine, Hiroki Ishibashi and Mitsuo Shimada : 【胆管損傷と(医原性)術後胆管狭窄:回避とリカバリー法】先天性胆道拡張症手術における胆道再建と術後胆管狭窄へのリカバリーショット, Journal of Biliary Tract & Pancreas, Vol.42, No.7, 631-637, 2021.
26.	Hiroki Ishibashi, Noriko Yokota, Hiroki Mori and Mitsuo Shimada : 【シミュレーションとナビゲーション】胸腔鏡下肺葉切除術, Japanese Journal of Pediatric Surgery, Vol.53, No.5, 520-524, 2021. (Link to Publication Site) ● Publication site (DOI): 10.24479/j00645.2021229968 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390577133293882240 ● Search Scopus @ Elsevier (DOI): 10.24479/j00645.2021229968 (DOI: 10.24479/j00645.2021229968, CiNii: 1390577133293882240)
27.	Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, Ryosuke Tateishi, Kazuya Kariyama, Shuichiro Shiina, Hidenori Toyoda, Yasuharu Imai, Atsushi Hiraoka, Masafumi Ikeda, Namiki Izumi, Michihisa Moriguchi, Sadahisa Ogasawara, Yasunori Minami, Kazuomi Ueshima, Takamichi Murakami, Shiro Miyayama, Osamu Nakashima, Hirohisa Yano, Michiie Sakamoto, Etsuro Hatano, Mitsuo Shimada, Norihiro Kokudo, Satoshi Mochida and Tetsuo Takehara : Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update., Liver Cancer, Vol.10, No.3, 181-223, 2021. (Summary) The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC. (Tokushima University Institutional Repository) ● Metadata: 117353 (Link to Publication Site) ● Publication site (DOI): 10.1159/000514174 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34239808 ● Search Scopus @ Elsevier (PMID): 34239808 ● Search Scopus @ Elsevier (DOI): 10.1159/000514174 (Tokushima University Institutional Repository: 117353, DOI: 10.1159/000514174, PubMed: 34239808)
28.	Shoko Yamashita, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shinichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2., World Journal of Surgical Oncology, Vol.19, No.1, 142, 2021. (Summary) This method could be used to classify IHCC into peripheral and perihilar type by embryological expression patterns of SSTR2 and Bcl2. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Humans / Prognosis / Proto-Oncogene Proteins c-bcl-2 / Receptors, Somatostatin (Tokushima University Institutional Repository) ● Metadata: 116986 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02216-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33962620 ● Search Scopus @ Elsevier (PMID): 33962620 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02216-3 (Tokushima University Institutional Repository: 116986, DOI: 10.1186/s12957-021-02216-3, PubMed: 33962620)
29.	Nozomi Aotani, Sonoko Yasui-Yamada, Natsumi Kagiya, TAKIMOTO Mami, Yu Ohiwa, Matsubara Atsumi, Sayaka Matsura, Mayu Tanimura, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : Malnutrition by European Society for Clinical Nutrition and Metabolism criteria predicts prognosis in patients with gastrointestinal and hepatobiliary-pancreatic cancer, Clinical Nutrition ESPEN, Vol.42, 265-271, 2021. (Summary) The European Society for Clinical Nutrition and Metabolism (ESPEN) proposed the ESPEN diagnostic criteria (EDC) for malnutrition in 2015. There is no report on the association between the EDC and prognosis in patients with gastrointestinal (GI) and hepatobiliary-pancreatic (HBP) cancer. This study aimed to (1) determine the prevalence of EDC malnutrition, (2) investigate the validity of the EDC as a nutritional and prognostic indicator, and (3) examine which components of the EDC are most related to long-term prognosis in patients with GI and HBP cancers. A total of 634 patients with primary GI and HBP cancers who underwent their first resection surgery between July 2014 and March 2018 were retrospectively recruited. According to the EDC, patients were divided into malnourished and non-malnourished groups. Clinical parameters and survival between these two groups were compared. The prognostic effects of the EDC and the EDC components were analyzed using Cox proportional hazard models. The prevalence of EDC malnutrition was 22%. Anthropometric data and biochemical data were associated with EDC malnutrition. The 5-year survival rate was lower in the malnourished group (72%) than in the non-malnourished group (73%; P = 0.007). The multivariate analysis demonstrated that the malnourished group was an independent risk factor for mortality (hazard ratio = 1.70 in the malnourished group; 95% confidence interval 1.08-2.63; P = 0.024). Among EDC components, body mass index (BMI) of <18.5 kg/m was an independent poor prognostic factor. EDC malnutrition is associated with poor postoperative long-term prognosis. Among the EDC components, BMI of <18.5 kg/m is most associated with prognosis in patients with preoperative GI and HBP cancers. (Tokushima University Institutional Repository) ● Metadata: 115904 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clnesp.2021.01.023 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33745591 ● Summary page in Scopus @ Elsevier: 2-s2.0-85100771924 (Tokushima University Institutional Repository: 115904, DOI: 10.1016/j.clnesp.2021.01.023, PubMed: 33745591, Elsevier: Scopus)
30.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 342-346, 2021. (Summary) Background : Several prognostic factors were reported in pancreatic cancer. The fibrinogen-platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. Cases of non-curative resection were excluded. The FPR was calculated using the preoperative plasma fibrinogen and the platelet counts and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. The patients were divided into high and low FPR groups according to this cut-off value. Results : The cut-off value of FPR was 25.2. Among age, sex, body mass index (BMI), and surgical factors including surgery type, volume of blood loss and surgery time, there was no significant difference between the two groups. Patients in the low FPR group had significantly better overall survival (OS) and relapse-free survival (RFS) compared with the high FPR group (P < 0.05). On multivariate analysis, a high FPR, CA19-9 > 300 U /l, and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 342-346, August, 2021. (Keyword) Biomarkers, Tumor / Fibrinogen / Humans / Neoplasm Recurrence, Local / Pancreatic Neoplasms / Prognosis / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116535 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.342 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759156 ● Search Scopus @ Elsevier (PMID): 34759156 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.342 (Tokushima University Institutional Repository: 116535, DOI: 10.2152/jmi.68.342, PubMed: 34759156)
31.	Sonoko Yasui-Yamada, Yu Oiwa, Yu Saitou, Aotani Nozomi, Matsubara Atsumi, Matsuura Sayaka, Tanimura Mayu, Yoshiko Suzuki, Hideya Kashihara, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : Impact of phase angle on postoperative prognosis in patients with gastrointestinal and hepatobiliary-pancreatic cancer, Nutrition, Vol.79-80, 110891, 2020. (Tokushima University Institutional Repository) ● Metadata: 115901 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.nut.2020.110891 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32731162 ● Summary page in Scopus @ Elsevier: 2-s2.0-85088663807 (Tokushima University Institutional Repository: 115901, DOI: 10.1016/j.nut.2020.110891, PubMed: 32731162, Elsevier: Scopus)
32.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Yu Saitou, Satoru Imura, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib Three case reports., Medicine, Vol.99, No.42, e22782, 2020. (Summary) Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion therapy with hepatectomy or ablation. However, the feasibility of conversion therapy after LEN treatment in unresectable HCC remains largely unknown. Here, we reported 3 cases of unresectable HCC: case 1, a 69-year-old man diagnosed with ruptured HCC; case 2, a 72-year-old woman with nonalcoholic steatohepatitis-based HCC; and case 3, a 73-year-old man with a history of alcoholic cirrhosis-based HCC. In all cases, cirrhosis was classified as Child-Pugh 5 and modified albumin-bilirubin grade 1 or 2a. HCC was diagnosed as Barcelona Clinic Liver Cancer (BCLC) stage B. In all cases, LEN was initiated after conventional-transcatheter arterial embolization enforcement, while maintaining liver function. In all cases, the main tumor size decreased after 6 months of LEN treatment and no satellite nodes were detected, indicating downstaging of HCC to BCLC stage A. Subsequently, conversion hepatectomy or ablation was performed. After successful conversion therapy, the general condition of the patients was good, without tumor recurrence during the observation period (median 10 months). This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve. (Keyword) Ablation Techniques / Aged / Biomarkers / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Phenylurea Compounds / Protein Kinase Inhibitors / Quinolines / alpha-Fetoproteins (Tokushima University Institutional Repository) ● Metadata: 116240 (Link to Publication Site) ● Publication site (DOI): 10.1097/MD.0000000000022782 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33080748 ● Search Scopus @ Elsevier (PMID): 33080748 ● Search Scopus @ Elsevier (DOI): 10.1097/MD.0000000000022782 (Tokushima University Institutional Repository: 116240, DOI: 10.1097/MD.0000000000022782, PubMed: 33080748)
33.	Masanori Takehara, Yasushi Sato, Tetsuo Kimura, Kazuyoshi Noda, Hiroshi Miyamoto, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, Hironori Wada, Yoshimi Bando, Tetsuya Ikemoto, Mitsuo Shimada, Naoki Muguruma and Tetsuji Takayama : Cancer-associated Adipocytes Promote Pancreatic Cancer Progression Through SAA1 Expression, Cancer Science, Vol.111, No.8, 2883-2894, 2020. (Summary) Although pancreatic cancer often invades into peripancreatic adipose tissue, little is known about the cancer-adipocyte interaction. We first investigated the ability of adipocytes to de-differentiate to cancer-associated adipocytes (CAAs) by co-culturing with pancreatic cancer cells. We then examined the effects of CAA-conditioned media (CAA-CM) on the malignant characteristics of cancer cells, the mechanism underlying those effects, and their clinical relevance in pancreatic cancer. When 3T3-L1 adipocytes were co-cultured with pancreatic cancer cells (PANC-1) using Transwell system, adipocytes lost their lipid droplets and morphologically changed to fibroblast-like cells (CAA). Adipocyte-specific marker mRNA levels significantly decreased but those of fibroblast-specific markers appeared, characteristic findings of CAA, as revealed by real-time PCR. When PANC-1 cells were cultured with CAA-CM, significantly higher migration/invasion capability, chemoresistance, and epithelial-mesenchymal transition (EMT) properties were observed compared with control cells. To investigate the mechanism underlying these effects, we performed microarray analysis of PANC-1 cells cultured with CAA-CM, and found 78.5-fold higher expression of SAA1 compared with control cells. When SAA1 gene in PANC-1 cells was knocked down with SAA1 siRNA, migration/invasion capability, chemoresistance, and EMT properties were significantly attenuated compared with control cells. Immunohistochemical analysis on human pancreatic cancer tissues revealed positive SAA1 expression in 46/61 (75.4%). Overall survival in the SAA1-positive group was significantly shorter than in the SAA1-negative group (p=0.013). In conclusion, we demonstrated that pancreatic cancer cells induced de-differentiation in adipocytes toward CAA, and CAA promoted malignant characteristics of pancreatic cancer via SAA1 expression, suggesting that SAA1 is a novel therapeutic target in pancreatic cancer. (Tokushima University Institutional Repository) ● Metadata: 115328 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.14527 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32535957 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087562532 (Tokushima University Institutional Repository: 115328, DOI: 10.1111/cas.14527, PubMed: 32535957, Elsevier: Scopus)
34.	Hiroki Ishibashi, Mitsuo Shimada and Yuji Morine : 【膵・胆管合流異常と先天性胆道拡張症】疫学, Clinical Gastroenterology, Vol.35, No.4, 355-362, 2020. (Link to Publication Site) ● Publication site (DOI): 10.19020/cg.0000001104 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390285300151312256 ● Search Scopus @ Elsevier (DOI): 10.19020/cg.0000001104 (DOI: 10.19020/cg.0000001104, CiNii: 1390285300151312256)
35.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara and Mitsuo Shimada : Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab., Annals of Gastroenterological Surgery, Vol.4, No.2, 151-155, 2020. (Summary) The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a washout period for bevacizumab. (a) We retrospectively investigated seven patients who underwent emergency surgery for bevacizumab-associated intestinal perforation. (b) We investigated 104 patients with advanced colorectal cancer treated with neoadjuvant therapy who underwent surgery from 2008 to 2018, retrospectively. (a) In the seven patients undergoing emergency surgery for gastrointestinal perforation, the median bevacizumab administration and washout periods were 16 weeks and 24 days, respectively. A stoma was created in all patients except in those who were not candidates. Two patients developed postoperative abdominal abscesses, and two patients died from perioperative sepsis and gastrointestinal bleeding, respectively; both of these patients had poor performance status. (b) In patients receiving bevacizumab (n = 45) and patients treated with bevacizumab-free regimens as neoadjuvant therapy (n = 59), 31 and 52 patients received chemoradiotherapy, respectively. We found no correlation with postoperative complications with or without bevacizumab. The surgical indications should be considered carefully in patients with gastrointestinal perforation secondary to bevacizumab administration. Meanwhile, after appropriate cessation time, scheduled surgery following bevacizumab administration is feasible. (Tokushima University Institutional Repository) ● Metadata: 116475 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12312 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32258980 ● Search Scopus @ Elsevier (PMID): 32258980 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12312 (Tokushima University Institutional Repository: 116475, DOI: 10.1002/ags3.12312, PubMed: 32258980)
36.	Daichi Ishikawa, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : Anastomotic recurrence after laparoscopic distal gastrectomy with delta-shaped anastomosis : report of a case., The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 211-213, 2020. (Summary) Delta-shaped anastomosis is nowadays an increasingly performed reconstruction method in laparoscopic distal gastrectomy for early gastric cancer. To date, anastomotic recurrence at the delta-shaped anastomotic site has not been reported. Surgery for this disease is more complicated than anastomotic recurrence at the site of conventional Billroth-I anastomosis. A 68-year-old female was referred to our institute with early gastric cancer on the posterior wall of the antrum. She underwent laparoscopic distal gastrectomy with delta-shaped Billroth-I anastomosis. Follow-up gastrofiberscopy 16 months after the operation revealed suspected anastomotic recurrence, and gastric biopsy revealed signet-ring cell carcinoma. Open total gastrectomy with reconstruction with the Roux-en-Y method was performed. At the distal part of the previous anastomosis, an adequate length of the duodenum was dissected from the pancreas. Then, the duodenum was transected 3 cm distal to the anastomosis using a linear stapler. The patient recovered well and was discharged on postoperative day 14. The patient is alive without re-recurrence 3 years postoperatively. We successfully treated a patient with anastomotic recurrence of gastric cancer after delta-shaped anastomosis. Adequate resection of the duodenal stump was performed without any residual tumor or injury to the pancreas. J. Med. Invest. 67 : 211-213, February, 2020. (Keyword) Aged / Anastomosis, Surgical / Female / Gastrectomy / Humans / Laparoscopy / Neoplasm Recurrence, Local / Recurrence / Stomach Neoplasms (Tokushima University Institutional Repository) ● Metadata: 114831 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.211 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378612 ● Search Scopus @ Elsevier (PMID): 32378612 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.211 (Tokushima University Institutional Repository: 114831, DOI: 10.2152/jmi.67.211, PubMed: 32378612)
37.	Shuichi Iwahashi, Feng Rui, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Hepatic Stellate Cells Contribute to the Tumor Malignancy of Hepatocellular Carcinoma Through the IL-6 Pathway., Anticancer Research, Vol.40, No.2, 743-749, 2020. (Summary) The hepatic stellate cells (HSCs) have relationship to cancer progression. The aim of this study is to investigate the effect of HSCs and the role of IL-6/Stat3 pathway on hepatocellular carcinoma (HCC) progression. HCCs were co-cultured with HSCs. The viability and migration ability of cancer cells were detected. Epithelial-mesenchymal transition (EMT) marker (E-cadherin), stem cell marker (CD44) and p-signal transducer and activator of transcription 3 (p-STAT3) of cancer cells were evaluated. Finally, interleukin-6 (IL-6) neutralization was performed. Co-culture of HCCs with HSCs increased cancer cell viability and migration ability. EMT and stemness of cancer cells increased with HSCs. Following IL-6 neutralization, phospho-STAT3 activation, cancer cell viability and migration, as well as EMT, and stemness of cancer cells decreased. HSCs promoted HCC progression through the IL-6/STAT3 pathway. (Keyword) Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Survival / Coculture Techniques / Hep G2 Cells / Hepatic Stellate Cells / Humans / Interleukin-6 / Liver Neoplasms / Neoplastic Stem Cells / STAT3 Transcription Factor / Signal Transduction (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.14005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32014916 ● Search Scopus @ Elsevier (PMID): 32014916 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.14005 (DOI: 10.21873/anticanres.14005, PubMed: 32014916)
38.	Daichi Ishikawa, Kouzou Yoshikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Jun Higashijima and Mitsuo Shimada : Expression Level of MicroRNA-449a Predicts the Prognosis of Patients With Gastric Cancer., Anticancer Research, Vol.40, No.1, 239-244, 2020. (Summary) In previous studies, we demonstrated the significant role of microRNA-449a (miR-449a) in colorectal cancer with in vivo and clinical samples. The importance of miR-449a in gastric cancer is still to be elucidated. This study examined the impact of miR-449a expression in tumor tissue and serum and investigated its potential as a prognostic marker in gastric cancer. Sixty-six patients with gastric cancer who underwent surgery were included in the study. miR-449a expression in tumor tissue and serum were investigated by real-time polymerase chain reaction analysis. The association of miR-449a expression with clinicopathological factors and patient prognosis were also investigated. miR-449a expression was lower in tumor tissue than non-tumor tissue. miR-449a in tumor tissue negatively correlated with the malignancy of tumor and clinical stage. Increased carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels were seen at significantly higher frequencies in patients with low miR-449a expression. Patients with low miR-449a expression had poorer cancer-specific survival compared to those with high miR-449a expression. The univariate analysis showed that lymphovascular invasion, increased CEA and CA19-9 and a low expression of miR-449a were associated with a poorer 5-year cancer-specific survival. miR-449a expression level in serum correlated to that in tumor tissue and was also associated with tumor malignancy. The miR-449a level in tumor tissue might be useful as a prognostic indicator for patients with gastric cancer and miR-449a in serum appears to reflect its expression in tumor tissue. (Keyword) Aged / Disease-Free Survival / Female / Gene Expression Regulation, Neoplastic / Humans / Male / MicroRNAs / Prognosis / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13945 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31892572 ● Search Scopus @ Elsevier (PMID): 31892572 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13945 (DOI: 10.21873/anticanres.13945, PubMed: 31892572)
39.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Toru Utsunomiya : Effect of epigenetic modulation on cancer sphere., The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 70-74, 2020. (Summary) Background : Cancer stem cell properties are highly relevant to the biology of treatment-resistant cancers. Epigenetic modification regulates gene expressions by chromatin remodeling during malignant transformation. The aim of this study was to elucidate the possible strategy for cancer stem cells focusing on epigenetic modification. Methods : We made cancer sphere from HepG2 cells, and we added Histone deacetylase (HDAC) inhibitor, valproic acid to cancer sphere. And we compared methylation status and the gene expression between normal HepG2 and cancer sphere groups, and between cancer sphere and sphere with HDAC inhibitor treatment groups. Results : Valproic acid (VPA) cancelled this spheroid formation. In comparison between normal HepG2 and cancer sphere, the number of methylation status changes more than 0.1 of beta level was 826 probes, and we could isolate some epithelial-mesenchymal transition (EMT) related genes. And VPA reduced the expressions of EMT related genes in sphere with RT-PCR. On the other hand, in comparison between cancer sphere and sphere with VPA treatment, we detected 29 probe of methylation status change, and VPA reduced the expressions of Bcl-6 in sphere. Conclusions : HDAC inhibitor affected the methylation status of cancer stem cells. Histone-acetylation might overcome treatmet-resistant cancer through the regulation of cancer stem cell. J. Med. Invest. 67 : 70-74, February, 2020. (Keyword) DNA Methylation / Epithelial-Mesenchymal Transition / Hep G2 Cells / Histone Deacetylase Inhibitors / Humans / Neoplasms / Neoplastic Stem Cells / Spheroids, Cellular / Valproic Acid (Tokushima University Institutional Repository) ● Metadata: 114755 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.70 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378621 ● Search Scopus @ Elsevier (PMID): 32378621 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.70 (Tokushima University Institutional Repository: 114755, DOI: 10.2152/jmi.67.70, PubMed: 32378621)
40.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Takashi Iwata : Establishment of an evaluation system for non-technical skills in surgery : Surgeon and paramedical staff assessments., The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 83-86, 2020. (Summary) Purposes : Non-technical skills contribute to safe and efficient team performance. The aim of this study was to clarify the importance of non-technical skills by a questionnaire and the usefulness of feedback to the operator. Method : A questionnaire was administered to the operator and paramedical staff for 404 operations. Total and individual scores were compared, and the effect of feedback was analyzed by comparison between pre-feedback and post-feedback. Results : The total score of the paramedical staff was 100 [full score] [n = 186], 90-99 [n = 133], and 80-89 [n = 47]. In all cases, the score of the paramedical staff was significantly better than that of the operator. After feedback, the rate of a score less than 80 was significantly decreased. In junior doctor cases with laparoscopy, feedback tended to have a positive effect. Conclusions : Questionnaires completed by both surgeons and paramedical staff are useful for identifying problems with non-technical skills. J. Med. Invest. 67 : 83-86, February, 2020. (Keyword) Allied Health Personnel / Clinical Competence / Communication / Decision Making / Evaluation Studies as Topic / General Surgery / Humans / Leadership / Patient Care Team / Surgeons / Surveys and Questionnaires (Tokushima University Institutional Repository) ● Metadata: 114757 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.83 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378623 ● Search Scopus @ Elsevier (PMID): 32378623 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.83 (Tokushima University Institutional Repository: 114757, DOI: 10.2152/jmi.67.83, PubMed: 32378623)
41.	Shogo Ohta, Tetsuya Ikemoto, Yuma Wada, Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : A change in the zinc ion concentration reflects the maturation of insulin-producing cells generated from adipose-derived mesenchymal stem cells., Scientific Reports, Vol.9, No.1, 18731, 2019. (Summary) The generation of insulin-producing cells (IPCs) from pluripotent stem cells could be a breakthrough treatment for type 1 diabetes. However, development of new techniques is needed to exclude immature cells for clinical application. Dithizone staining is used to evaluate IPCs by detecting zinc. We hypothesised that zinc ion (Zn) dynamics reflect the IPC maturation status. Human adipose-derived stem cells were differentiated into IPCs by our two-step protocol using two-dimensional (2D) or 3D culture. The stimulation indexes of 2D -and 3D-cultured IPCs on day 21 were 1.21 and 3.64 (P < 0.05), respectively. The 3D-cultured IPCs were stained with dithizone during culture, and its intensity calculated by ImageJ reached the peak on day 17 (P < 0.05). Blood glucose levels of streptozotocin-induced diabetic nude mice were normalised (4/4,100%) after transplantation of 96 3D-cultured IPCs. Zn concentration changes in the medium of 3D cultures had a negative value in the early period and a large positive value in the latter period. This study suggests that Zn dynamics based on our observations and staining of zinc transporters have critical roles in the differentiation of IPCs, and that their measurement might be useful to evaluate IPC maturation as a non-destructive method. (Tokushima University Institutional Repository) ● Metadata: 114940 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-55172-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31822724 ● Search Scopus @ Elsevier (PMID): 31822724 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-55172-0 (Tokushima University Institutional Repository: 114940, DOI: 10.1038/s41598-019-55172-0, PubMed: 31822724)
42.	Yuzo FUKUSHIMA, Mitsuo Shimada, Tomonori KAWAI, Ryosuke FUJITA, Rikitoshi UENO, Tae FUNAKOSHI, Junichiro MIAKE and Tokuo SUGIHARA : A Case of Stomachache Successfully Treated with Yokukansankachinpihange, Kampo Medicine, Vol.70, No.4, 361-365, 2019. (Summary) <p>We report the case of a 36-year-old male who presented with an abdominal complaint after straightening of irregular teeth. He was examined and treated, however, the cause of the abdominal complaint could not be determined and the treatment was ineffective. He was treated in our clinic with yokukansankachinpihange for obvious pulsation in the supraumbilical region following the oral tradition of Kampo medicine, and the symptom gradually disappeared. We discussed the mechanism of the stomachache in Kampo medicine. After treatment, this case was diagnosed as somatoform autonomic dysfunction in psychiatric medicine. Advanced treatment by a psychiatrist was necessary to treat this disease in psychiatric medicine. In this case it is suggested that treatment following the oral tradition of Kampo medicine was effective.</p> (Keyword) supraumbilical region pulsation / yokukansan / yokukansankachinpihange (Link to Publication Site) ● Publication site (DOI): 10.3937/kampomed.70.361 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390565134833748224 ● Search Scopus @ Elsevier (DOI): 10.3937/kampomed.70.361 (DOI: 10.3937/kampomed.70.361, CiNii: 1390565134833748224)
43.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 先天性胆道拡張症と膵・胆管合流異常, Japanese Journal of Pediatric Medicine, Vol.51, No.10, 1516-1520, 2019.
44.	Tetsuya Ikemoto, Rui Feng, Shuichi Iwahashi, Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Satoru Imura, Munehide Matsuhisa and Mitsuo Shimada : In vitro and in vivo effects of insulin-producing cells generated by xeno-antigen free 3D culture with RCP piece., Scientific Reports, Vol.9, No.1, 2019. (Summary) To establish widespread cell therapy for type 1 diabetes mellitus, we aimed to develop an effective protocol for generating insulin-producing cells (IPCs) from adipose-derived stem cells (ADSCs). We established a 3D culture using a human recombinant peptide (RCP) petaloid μ-piece with xeno-antigen free reagents. Briefly, we employed our two-step protocol to differentiate ADSCs in 96-well dishes and cultured cells in xeno-antigen free reagents with 0.1 mg/mL RCP μ-piece for 7 days (step 1), followed by addition of histone deacetylase inhibitor for 14 days (step 2). Generated IPCs were strongly stained with dithizone, anti-insulin antibody at day 21, and microstructures resembling insulin secretory granules were detected by electron microscopy. Glucose stimulation index (maximum value, 4.9) and MAFA mRNA expression were significantly higher in 3D cultured cells compared with conventionally cultured cells (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of streptozotocin-induced diabetic nude mice converted to normoglycaemic state around 14 days after transplantation of 96 IPCs under kidney capsule or intra-mesentery. Histological evaluation revealed that insulin and C-peptide positive structures existed at day 120. Our established xeno-antigen free and RCP petaloid μ-piece 3D culture method for generating IPCs may be suitable for clinical application, due to the proven effectiveness in vitro and in vivo. (Tokushima University Institutional Repository) ● Metadata: 114941 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-47257-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31341242 ● Search Scopus @ Elsevier (PMID): 31341242 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-47257-7 (Tokushima University Institutional Repository: 114941, DOI: 10.1038/s41598-019-47257-7, PubMed: 31341242)
45.	Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Koji Yasutomo and Mitsuo Shimada : The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer., Anticancer Research, Vol.39, No.6, 2855-2860, 2019. (Summary) miR-449a level might be a prognostic indicator for colorectal cancer and miR-449a might regulate HDAC1 expression. (Keyword) Aged / Antigens, Tumor-Associated, Carbohydrate / Colorectal Neoplasms / Female / Gene Expression Regulation, Neoplastic / Histone Deacetylase 1 / Humans / Liver Neoplasms / Male / MicroRNAs / Middle Aged / Neoplasm Invasiveness / Prognosis / Survival Analysis (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13414 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31177123 ● Search Scopus @ Elsevier (PMID): 31177123 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13414 (DOI: 10.21873/anticanres.13414, PubMed: 31177123)
46.	Akemi Hara, Yuko Nakagawa, Keiko Nakao, Motoyuki Tamaki, Tetsuya Ikemoto, Mitsuo Shimada, Munehide Matsuhisa, Hiroki Mizukami, Nobuhiro Maruyama, Hirotaka Watada and Yoshio Fujitani : Development of monoclonal mouse antibodies that specifically recognize pancreatic polypeptide., Endocrine Journal, Vol.66, No.5, 459-468, 2019. (Summary) Pancreatic polypeptide (PP) is a 36-amino acid peptide encoded by the Ppy gene, which is produced by a small population of cells located in the periphery of the islets of Langerhans. Owing to the high amino acid sequence similarity among neuropeptide Y family members, antibodies against PP that are currently available are not convincingly specific to PP. Here we report the development of mouse monoclonal antibodies that specifically bind to PP. We generated Ppy knockout (Ppy-KO) mice in which the Ppy-coding region was replaced by Cre recombinase. The Ppy-KO mice were immunized with mouse PP peptide, and stable hybridoma cell lines producing anti-PP antibodies were isolated. Firstly, positive clones were selected in an enzyme-linked immunosorbent assay for reactivity with PP coupled to bovine serum albumin. During the screening, hybridoma clones producing antibodies that cross-react to the peptide YY (PYY) were excluded. In the second screening, hybridoma clones in which their culture media produce no signal in Ppy-KO islets but detect specific cells in the peripheral region of wild-type islets, were selected. Further studies demonstrated that the selected monoclonal antibody (23-2D3) specifically recognizes PP-producing cells, not only in mouse, but also in human and rat islets. The monoclonal antibodies with high binding specificity for PP developed in this study will be fundamental for future studies towards elucidating the expression profiles and the physiological roles of PP. (Tokushima University Institutional Repository) ● Metadata: 118704 (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ18-0441 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30842364 ● Summary page in Scopus @ Elsevier: 2-s2.0-85067126364 (Tokushima University Institutional Repository: 118704, DOI: 10.1507/endocrj.EJ18-0441, PubMed: 30842364, Elsevier: Scopus)
47.	Yu Saitou, Satoru Imura and Mitsuo Shimada : Gastroenterological, Hepatobiliary and Pancreatic Surgery, Journal of Japan Society of Computer Aided Surgery, Vol.21, No.3, 150-152, 2019. (Link to Publication Site) ● Publication site (DOI): 10.5759/jscas.21.150 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390845702278940544 ● Search Scopus @ Elsevier (DOI): 10.5759/jscas.21.150 (DOI: 10.5759/jscas.21.150, CiNii: 1390845702278940544)
48.	川瀬和美, 前田耕太郎, 岩瀬弘敬, 野村幸世, 小川朋子, 柴崎郁子, Mitsuo Shimada, 田口智章, 竹下恵美子, 冨澤康子, 花崎和弘, 葉梨智子, 山下啓子, 中村清吾 and 富永隆治 : MENTALITIES OF SURGEONS AND WORK STYLE REFORM : HOW CAN WE PROMOTE GENDER EQUALITY IN SURGERY?, Journal of Japan Surgical Society, Vol.119, No.6, 705-708, 2018. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572358255446912 (CiNii: 1520572358255446912)
49.	Tumenjin Enkhbat, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Masahide Tominaga and Mitsuo Shimada : Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy., Anticancer Research, Vol.38, No.11, 6247-6252, 2018. (Summary) Epigallocatechin-3-gallate (EGCG) is a major polyphenolic component of green tea. EGCG plays a potential role in radio-sensitizing cancer cells. The combined effect of EGCG and radiation was investigated in a colorectal cancer cell line, focusing on nuclear factor (erythroid-derived 2)-like 2 (Nrf2) autophagy signalling. HCT-116 cells were treated with 12.5 μM EGCG for different periods of time, 2 Gy radiation, or both. Cell viability was determined with the WST-8 assay. The number of colonies was determined with the colony formation assay. mRNA expression of LC3 and caspase-9 was analyzed with quantitative real-time polymerase chain reaction. Combination treatment with EGCG and radiation significantly decreased the growth of HCT-116 cells. The number of colonies was reduced to 34.2% compared to the control group. Immunofluorescence microscopy images showed that nuclear translocation of Nrf2 was significantly increased when cells were treated with the combination of EGCG and radiation compared to the control and single-treatment groups. Combined treatment with EGCG and radiation significantly induced LC3 and caspase-9 mRNA expression. EGCG increased the sensitivity of colorectal cancer cells to radiation by inhibiting cell proliferation and inducing Nrf2 nuclear translocation and autophagy. (Keyword) Caspase 9 / Catechin / Cell Nucleus / Cell Proliferation / Cell Survival / Colorectal Neoplasms / Gene Expression Regulation, Neoplastic / HCT116 Cells / Humans / Microtubule-Associated Proteins / NF-E2-Related Factor 2 / Protein Transport / Radiation-Sensitizing Agents / Transcriptional Activation (Tokushima University Institutional Repository) ● Metadata: 113340 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12980 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30396944 ● Summary page in Scopus @ Elsevier: 2-s2.0-85056084372 (Tokushima University Institutional Repository: 113340, DOI: 10.21873/anticanres.12980, PubMed: 30396944, Elsevier: Scopus)
50.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Photobiomodulation with red light emitting diodes accelerates hepatocytes proliferation through reactive oxygen species / extracellular signal-regulated kinase pathway., Hepatology Research, Vol.48, No.11, 926-936, 2018. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13182 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85050405346 (DOI: 10.1111/hepr.13182, Elsevier: Scopus)
51.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction, Cell Communication & Signaling, Vol.16, No.1, 54, 2018. (Summary) The M2 phenotype of tumor-associated macrophages (TAM) inhibits the anti-tumor inflammation, increases angiogenesis and promotes tumor progression. The transcription factor Nuclear Factor (erythroid-derived 2)-Like 2 (Nrf2) not only modulates the angiogenesis but also plays the anti-inflammatory role through inhibiting pro-inflammatory cytokines expression; however, the role of Nrf2 in the cancer cell and macrophages interaction is not clear. Hepatocellular carcinoma cells (Hep G2 and Huh 7) and pancreatic cancer cells (SUIT2 and Panc-1) were co-cultured with monocytes cells (THP-1) or peripheral blood monocytes derived macrophages, then the phenotype changes of macrophages and epithelial-mesenchymal transition of cancer cells were detected. Also, the role of Nrf2 in cancer cells and macrophages interaction were investigated. In this study, we found that cancer cells could induce an M2-like macrophage characterized by up-regulation of CD163 and Arg1, and down-regulation of IL-1b and IL-6 through Nrf2 activation. Also, Nrf2 activation of macrophages promoted VEGF expression. The Nrf2 activation of macrophages correlated with the reactive oxygen species induced by cancer cells derived lactate. Cancer cells educated macrophages could activate Nrf2 of the cancer cells, in turn, to increase cancer cells epithelial-mesenchymal transition (EMT) through paracrine VEGF. These findings suggested that Nrf2 played the important role in the cancer cells and macrophages interaction. Macrophage Nrf2 activation by cancer cell-derived lactate skews macrophages polarization towards an M2-like phenotype and educated macrophages activate Nrf2 of the cancer cells to promote EMT of cancer cells. This study provides a new understanding of the role of Nrf2 in the cancer cell and TAM interaction and suggests a potential therapeutic target. (Keyword) Cell Communication / Cell Movement / Cell Transformation, Neoplastic / Epithelial-Mesenchymal Transition / Gene Expression Regulation, Neoplastic / Hep G2 Cells / Humans / Lactic Acid / Macrophages / NF-E2-Related Factor 2 / Phenotype / Reactive Oxygen Species / Vascular Endothelial Growth Factor A (Tokushima University Institutional Repository) ● Metadata: 114549 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12964-018-0262-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30180849 ● Summary page in Scopus @ Elsevier: 2-s2.0-85053152003 (Tokushima University Institutional Repository: 114549, DOI: 10.1186/s12964-018-0262-x, PubMed: 30180849, Elsevier: Scopus)
52.	Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Yuji Morine, 杉本真樹 and Mitsuo Shimada : 肝癌手術エキスパートへの道 (特集癌手術エキスパートになるための道), Journal of Clinical Surgery, Vol.73, No.9, 1108-1114, 2018. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390845702315677568 (CiNii: 1390845702315677568)
53.	Kouzou Yoshikawa and Mitsuo Shimada : 【手術で臓器が「どうなる?」から術後後ケアが見える!わかる!イラスト理解消化器外科の術式・術後ケア】実はこんな臓器も切られている!, Gastroenterological Surgery Nursing, Vol.23, No.8, 681-682, 2018. (Keyword) 和文論文
54.	Yu Saitou, Shin-ichiro Yamada, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 胆道再建を含む肝切除術 (ビギナーズ特集手術で臓器が「どうなる?」から術後ケアが見える! わかる! イラスト理解消化器外科の術式・術後ケア), Gastroenterological Surgery Nursing, Vol.23, No.8, 709-714, 2018. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521980703420258944 (CiNii: 1521980703420258944)
55.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period., Anticancer Research, Vol.38, No.8, 4901-4905, 2018. (Summary) The aim of this study was to investigate the effect of Roux-en-Y (RY) reconstruction on type 2 diabetes with gastric cancer in the early postoperative period. A total of 44 patients with gastric cancer with type 2 diabetes who underwent total gastrectomy (TG) or distal gastrectomy (DG) with Roux-en-Y reconstruction or DG with Bilroth I were enrolled. All three groups had their fasting glucose and daily insulin dose recorded preoperatively, on day 2 postoperatively (POD2) and at discharge. The TG group showed low fasting glucose and daily insulin dose on POD2 compared to their preoperative state. On discharge, the fasting glucose and daily insulin dose were significantly lower in both TG and DG Roux-en-Y groups than preoperatively. Roux-en-Y reconstruction showed early improvement of type 2 diabetes regardless of any body weight loss. The effect of Roux-en-Y reconstruction in TG on type 2 diabetes was more remarkable than that of DG. (Keyword) Aged / Aged, 80 and over / Anastomosis, Roux-en-Y / Blood Glucose / Diabetes Mellitus, Type 2 / Female / Gastrectomy / Gastroenterostomy / Humans / Insulin / Male / Middle Aged / Postoperative Period / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12805 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30061267 ● Search Scopus @ Elsevier (PMID): 30061267 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.12805 (DOI: 10.21873/anticanres.12805, PubMed: 30061267)
56.	Kazumi Kawase, Kyoko Nomura, Ryuji Tominaga, Hirotaka Iwase, Tomoko Ogawa, Ikuko Shibasaki, Mitsuo Shimada, Tomoaki Taguchi, Emiko Takeshita, Yasuko Tomizawa, Sachiyo Nomura, Kazuhiro Hanazaki, Tomoko Hanashi, Hiroko Yamashita, Norihiro Kokudo and Kotaro Maeda : Analysis of gender-based differences among surgeons in Japan: results of a survey conducted by the Japan Surgical Society. Part. 2: personal life., Surgery Today, Vol.48, No.3, 308-319, 2018. (Summary) To assess the true conditions and perceptions of the personal lives of men and women working as surgeons in Japan. In 2014, all e-mail subscribed members of the Japan Surgical Society (JSS, n = 29,861) were invited to complete a web-based survey. The questions covered demographic information, work environment, and personal life (including marital status, childcare, and nursing care for adult family members). In total, 6211 surgeons (5586 men and 625 women) returned the questionnaires, representing a response rate of 20.8%. Based on the questionnaire responses, surgeons generally prioritize work and spend most of their time at work, although women with children prioritize their family over work; men spend significantly fewer hours on domestic work/childcare than do their female counterparts (men 0.76 h/day vs. women 2.93 h/day, p < 0.01); and both men and women surgeons, regardless of their age or whether they have children, place more importance on the role of women in the family. The personal lives of Japanese surgeons differed significantly according to gender and whether they have children. The conservative idea that women should bear primary responsibility for the family still pertains for both men and women working as surgeons in Japan. (Keyword) Adult / Aged / Family / Female / Gender Identity / General Surgery / Humans / Japan / Life / Male / Middle Aged / Occupational Health / Physicians, Women / Societies, Medical / Surgeons / Surveys and Questionnaires / Work (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-017-1586-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28921482 ● Search Scopus @ Elsevier (PMID): 28921482 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-017-1586-7 (DOI: 10.1007/s00595-017-1586-7, PubMed: 28921482)
57.	Ken Shirabe, Susumu Eguchi, Hideaki Okajima, Kiyoshi Hasegawa, Shigeru Marubashi, Koji Umeshita, Seiji Kawasaki, Katsuhiko Yanaga, Mitsuo Shimada, Toshimi Kaido, Naoki Kawagishi, Akinobu Taketomi, Koichi Mizuta, Norihiro Kokudo, Shinji Uemoto and Yoshihiko Maehara : Current Status of Surgical Incisions Used in Donors During Living Related Liver Transplantation-A Nationwide Survey in Japan., Transplantation, Vol.102, No.8, 1293-1299, 2018. (Summary) Smaller surgical incisions have recently been introduced in living donor liver procurement. This study used national data from Japan to clarify the present status of surgical incisions in living donor liver procurement. A nationwide, questionnaire-based survey related to 3121 donors and recipients was used. Donors were divided into 2 groups: left lateral segment graft (LLSG) procurement (n = 690) and other types (n = 2431). Incisions were classified into 6 types: type I, upper midline and bilateral subcostal; type II, upper midline and right subcostal; type III, upper midline and right subcostal to the right lateral margin of the abdominal rectus muscle; type IV, upper midline without laparoscopy; type V, upper midline with laparoscopy; and type VI, lower abdominal using the full laparoscopic technique. Types I, II, and III were regarded as standard, and types IV, V, and VI as small incisions. In LLSGs, blood transfusion and postoperative complication rates were significantly less frequent in the small incision group than in the standard group. In other graft types, there were no significant differences in blood transfusion, postoperative complication, and recipients' graft loss rates. The rates of wound extension during surgery were 2.8% and 2.1% in the small incision group in LLSGs and in other graft types, respectively. A small incision was adapted more frequently and postoperative complications were less common in high-volume centers. Various incisions have been adopted in living donor liver procurement. Donor safety and graft integrity appear to have been retained for donors receiving small incisions. (Keyword) Blood Transfusion / End Stage Liver Disease / Hepatectomy / Humans / Japan / Laparoscopy / Liver / Liver Transplantation / Living Donors / Multivariate Analysis / Postoperative Complications / Postoperative Period / Surgical Wound / Surveys and Questionnaires / Wound Healing (Link to Publication Site) ● Publication site (DOI): 10.1097/TP.0000000000002126 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29424768 ● Search Scopus @ Elsevier (PMID): 29424768 ● Search Scopus @ Elsevier (DOI): 10.1097/TP.0000000000002126 (DOI: 10.1097/TP.0000000000002126, PubMed: 29424768)
58.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro., Cancer Science, Vol.109, No.8, 2509-2519, 2018. (Summary) Cancer-associated fibroblasts (CAF), derived from stroma of cancer tissues, interact with cancer cells and play an important role in cancer initiation, growth, and metastasis. Nab-paclitaxel (nab-PTX) is a 130 nm albumin-binding paclitaxel and recommended for many types of cancer chemotherapy. The nab-PTX stromal-disrupting effect during pancreatic cancer treatment has been reported. The aim of the present study was to determine the role of nab-PTX in cancer cells and CAF interaction. Cancer cells (MIA PaCa-2 and Panc-1) were cocultured with CAF or treated with CAF conditioned medium, after which their migration and invasion ability, epithelial-mesenchymal transition (EMT)-related marker expression and C-X-C motif chemokine 10 (CXCL10) expression and secretion were detected. Nab-PTX treatment was carried out during the coculture system or during preparation of CAF conditioned medium. Then cancer cell migration and invasion ability, EMT-related marker expression, CXCL10 expression and secretion, and interleukin-6 (IL-6) expression and secretion by CAF were checked After coculture with CAF, migration and invasion ability of cancer cells increased. CAF also downregulated E-cadherin and upregulated N-cadherin and vimentin expression in cancer cells. During coculture or stimulation with cancer cell-cultured medium, CAF significantly increased IL-6 expression and secretion. However, nab-PTX in the coculture system canceled CAF-induced migration and invasion promotion and EMT-related gene changes. Moreover, nab-PTX increased CXCL10 expression of cancer cells which blocked CAF IL-6 expression and secretion. Nab-PTX treatment could increase CXCL10 expression of cancer cells which blocks CAF cancer cell migration and invasion-promoting effect by inhibiting IL-6 expression. (Keyword) Albumins / Biomarkers, Tumor / Cadherins / Cell Line, Tumor / Cell Movement / Cell Proliferation / Chemokine CXCL10 / Coculture Techniques / Down-Regulation / Epithelial-Mesenchymal Transition / Fibroblasts / Humans / Interleukin-10 / Interleukin-6 / Neoplasm Invasiveness / Paclitaxel / Pancreatic Neoplasms / Up-Regulation / Vimentin (Tokushima University Institutional Repository) ● Metadata: 112899 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.13694 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29902349 ● Summary page in Scopus @ Elsevier: 2-s2.0-85050858344 (Tokushima University Institutional Repository: 112899, DOI: 10.1111/cas.13694, PubMed: 29902349, Elsevier: Scopus)
59.	Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi and Mitsuo Shimada : A learning curve for laparoscopic liver resection: an effective training system and standardization of technique., Translational Gastroenterology and Hepatology, Vol.3, 45, 2018. (Summary) The incidence of laparoscopic liver resection (LHx) has been increased in the past decade. There have been some reports about some advantages of LHx, in both short and long-term outcomes after operation. The use of a minor LHx was regarded as a standard surgical practice, and some peri-operative complications hindered worldwide increase of LHx in the Second International Consensus Conference on LHx at Morioka. However, no suggestions were described in terms with how to provide the best teaching and training necessary to shorten the learning curve for inexperienced surgeons using a new surgical technique while continuing to maintain a low rate of morbidity from the very beginning. This study includes a literature review of published research which looked at a learning curve for LHx. As well, it proposes a new step-wise training method for inexperienced surgeons and standardization of a technique for LHx focusing especially on laparoscopic left hepatectomy (LLHx). (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.21037/tgh.2018.07.03 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30148230 ● Summary page in Scopus @ Elsevier: 2-s2.0-85052017722 (DOI: 10.21037/tgh.2018.07.03, PubMed: 30148230, Elsevier: Scopus)
60.	Youichiro Kawashita, Yuji Morine, Yu Saitou, Chie Takasu, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Masato Yoshikawa, Satoru Imura, Toshiyuki Yagi and Mitsuo Shimada : Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas., Journal of Gastroenterology and Hepatology, Vol.33, No.7, 1407-1412, 2018. (Summary) Heat shock factor 1 (HSF1), a master regulator of heat shock response, has been shown to play a multifaceted role in cancer progression. However, the clinical significance and biological effect of HSF1 expression in intrahepatic cholangiocarcinoma (IHCC) remain unknown. Forty-nine patients with IHCC who underwent hepatic resection were enrolled in this study. HSF1 expression in tumor tissue was determined by immunohistochemistry, and patients were divided into two groups, those with high (n = 20) and low (n = 29) HSF1 expression. Clinicopathological factors including prognosis were compared in these two groups. HSF1 expression was significantly higher in tumors than in normal tissue. The overall survival rate was significantly lower in patients with high than low HSF1. Multivariate analysis showed that high HSF1 expression was a factor independently prognostic of patient survival. High HSF1 expression in tumor tissues may be a prognostic biomarker in patients with IHCC. (Keyword) Adult / Aged / Aged, 80 and over / Bile Duct Neoplasms / Cell Line, Tumor / Cholangiocarcinoma / Disease Progression / Female / Gene Expression / Heat Shock Transcription Factors / Humans / Immunohistochemistry / Male / Middle Aged / Multivariate Analysis / Prognosis / Survival Rate / Tumor Microenvironment (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.14078 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29278438 ● Summary page in Scopus @ Elsevier: 2-s2.0-85043330492 (DOI: 10.1111/jgh.14078, PubMed: 29278438, Elsevier: Scopus)
61.	Tumenjin Enkhbat, Masaaki Nishi, Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer., Anticancer Research, Vol.38, No.6, 3367-3373, 2018. (Summary) Programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1(PD-L1) axis is associated with immune tolerance via inhibition of T cell activation. The aim of this study was to clarify the significance of PD-1 and PD-L1 expressions and analyze the relationships between PD-1, PD-L1, transforming growth factor-β (TGF-β) and Forkhead box P3 (Foxp3) expressions in colorectal cancer (CRC). A total of 116 patients who underwent curative colectomy for stage II/III CRC were included in the study. PD-1, PD-L1, TGF-β, and Foxp3 expressions were examined by immunohistochemistry and related to prognostic factors by Kaplan-Meier. PD-1 expression was correlated with PD-L1, TGF-β, and Foxp3 expressions. Overall survival rates were significantly poorer in the PD-1 and PD-L1-positive groups. Multivariate analysis showed that PD-L1-positive is an independent risk factor. Disease-free survival (DFS) was tended in the PD-L1-positive group. The group with double-positive expression had significantly poorer prognosis. PD-1 and PD-L1 expressions were associated with a poor prognosis and correlated with TGF-β and Foxp3 expressions in patients with CRC. (Keyword) Adult / Aged / Aged, 80 and over / B7-H1 Antigen / Colectomy / Colorectal Neoplasms / Female / Forkhead Transcription Factors / Humans / Immunohistochemistry / Kaplan-Meier Estimate / Male / Middle Aged / Prognosis / Programmed Cell Death 1 Receptor / Transforming Growth Factor beta (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12603 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29848685 ● Summary page in Scopus @ Elsevier: 2-s2.0-85048247787 (DOI: 10.21873/anticanres.12603, PubMed: 29848685, Elsevier: Scopus)
62.	Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuma Wada and Mitsuo Shimada : The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer., Anticancer Research, Vol.38, No.6, 3387-3392, 2018. (Summary) Indoleamine 2,3-dioxygenase (IDO) down-regulates T cell activation, attenuates regulatory T cell (Treg) activation and is related to immune tolerance. The aim of the study was to clarify the significance of IDO expression and analyze the relationships between the expression of IDO, TGF-β, and Foxp3 in gastric cancer (GC). A total of 60 patients who underwent curative gastrectomy for stage III gastric cancer were included in the study. The expression of IDO, TGF-β, and Foxp3 was examined by immunohistochemistry and the relationship of each expression level to several prognostic factors was examined using univariate and multivariate analyses. IDO expression was not positively correlated with any of the factors examined. IDO expression was positively correlated with TGF-β expression (p<0.05), and TGF-β expression was positively correlated with FoxP3 expression (p<0.05). Overall survival (OS) rates were significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year OS, 78.5% vs. 90%, respectively; p<0.05). Multivariate analysis confirmed IDO expression as independent prognostic factors in OS. Disease-free survival (DFS) was significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year DFS, 59.3% vs. 69.3%, respectively; p<0.05). IDO is associated with poor prognosis and immuno-tolerance through attenuation of Treg activation in Stage III GC. (Keyword) Adult / Aged / Aged, 80 and over / Female / Forkhead Transcription Factors / Gastrectomy / Humans / Immunohistochemistry / Indoleamine-Pyrrole 2,3,-Dioxygenase / Kaplan-Meier Estimate / Male / Middle Aged / Multivariate Analysis / Neoplasm Staging / Prognosis / Stomach Neoplasms / T-Lymphocytes, Regulatory / Transforming Growth Factor beta1 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12605 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29848687 ● Summary page in Scopus @ Elsevier: 2-s2.0-85048212303 (DOI: 10.21873/anticanres.12605, PubMed: 29848687, Elsevier: Scopus)
63.	野村幸世, 冨澤康子, 大津洋, 小川朋子, 柴崎郁子, Mitsuo Shimada, 竹下恵美子, 花崎和弘, 葉梨智子, 山下啓子, 明石定子, 山内英子, 岩瀬弘敬, 田口智章, 前田耕太郎 and 中村清吾 : CURRENT STATUS OF SUPPORT FOR FEMALE DOCTORS IN THE SPECIALIST MEDICAL SOCIETIES OF THE JAPANESE ASSOCIATION OF MEDICAL SCIENCE IN 2015 : RESULTS OF A QUESTIONNAIRE SURVEY, Journal of Japan Surgical Society, Vol.119, No.1, 97-99, 2018. (Keyword) Global Gender Gap Index (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572357910337920 (CiNii: 1520572357910337920)
64.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Daichi Ishikawa : Usefulness of the Transoral Anvil Delivery System for Esophagojejunostomy After Laparoscopic Total Gastrectomy: A Single-institution Comparative Study of Transoral Anvil Delivery System and the Overlap Method., Surgical Laparoscopy, Endoscopy & Percutaneous Techniques, Vol.28, No.2, e40-e43, 2018. (Summary) Many reconstruction techniques have been reported after laparoscopic total gastrectomy (LTG), but it is not clear which anastomosis technique is most useful, and no standard methods have been established. This study examined whether LTG using the transoral anvil delivery system (TOADS) is a feasible and safe procedure for gastric cancer. A series of 47 patients underwent the overlap method and 36 underwent the hemi-double-stapling technique with TOADS. Intraoperative and postoperative outcomes were compared between the 2 groups. In the TOADS group, operation time for reconstruction was shorter (16 3 vs. 45 10in, P=0.003), and blood loss was reduced (45 15 vs. 126 13L, P=0.0002). There were no significant differences in intraoperative complications, conversion to open surgery, and intraoperative anastomosis-related complications between the 2 groups. Furthermore, there were no significant differences in the incidence of complications, reoperation, mortality, and postoperative hospital stay. LTG using TOADS for gastric cancer may be a technically feasible surgical procedure with acceptable morbidity. (Keyword) Adult / Aged / Aged, 80 and over / Esophagostomy / Female / Follow-Up Studies / Gastrectomy / Humans / Jejunostomy / Laparoscopy / Male / Middle Aged / Mouth / Natural Orifice Endoscopic Surgery / Operative Time / Postoperative Complications / Reoperation / Retrospective Studies / Stomach Neoplasms / Suture Techniques / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1097/SLE.0000000000000495 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29064880 ● Search Scopus @ Elsevier (PMID): 29064880 ● Search Scopus @ Elsevier (DOI): 10.1097/SLE.0000000000000495 (DOI: 10.1097/SLE.0000000000000495, PubMed: 29064880)
65.	Tetsuya Ikemoto, Rui Feng, Mitsuo Shimada, Yu Saitou, Shuichi Iwahashi, Yuji Morine and Satoru Imura : A new 2-step acceleration protocol using a histone deacetylase inhibitor to generate insulin-producing cells from adipose-derived mesenchymal stem cells, Pancreas, Vol.47, No.4, 477-481, 2018. (Summary) We aimed to develop a simple protocol for deriving insulin-producing cells (IPCs) from adipose-derived mesenchymal stem cells (ADSCs). We established a 2-step creation method and an acceleration strategy with a histone deacetylase inhibitor that promoted a pro-endocrine pancreatic lineage. We seeded ADSCs in 96-well dishes and cultured in Dulbecco's modified Eagle's medium/F12 medium containing 1% fetal bovine serum, 1% B27 supplement, 1% N2 supplement, 50-ng/mL human activin A, and 10-nM exendin-4 for step 1 of differentiation (7 days). Then 10-mM nicotinamide and 50-ng/mL human hepatocyte growth factor, with or without 1 mM histone deacetylase inhibitor, were added for step 2 of differentiation (14 days). After the 2-step differentiation was complete, cell morphology, immunohistochemistry, messenger RNA expression, and function were investigated. Our new differentiation protocol with the histone deacetylase inhibitor significantly accelerated IPC differentiation compared with the conventional protocol without the histone deacetylase inhibitor (median, 21.6 vs 38.8 days; P < 0.05). It also improved the islet morphology score (P < 0.05) and the glucose stimulation index (3.1). By applying our new and easy 2-step protocol using a histone deacetylase inhibitor, ADSCs may be an effective cell source for differentiation of IPCs. (Keyword) Adipose Tissue / Cell Culture Techniques / Cell Differentiation / Cells, Cultured / Culture Media / Histone Deacetylase Inhibitors / Humans / Insulin / Insulin-Secreting Cells / Mesenchymal Stem Cells / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1097/MPA.0000000000001017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29517636 ● Summary page in Scopus @ Elsevier: 2-s2.0-85044238547 (DOI: 10.1097/MPA.0000000000001017, PubMed: 29517636, Elsevier: Scopus)
66.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Syohei Eto and Yoshimi Bando : Ki-67 and Survivin as Predictive Factors for Rectal Cancer Treated with Preoperative Chemoradiotherapy., Anticancer Research, Vol.38, No.3, 1735-1739, 2018. (Summary) To evaluate the usefulness of Ki-67 index and survivin as predictive prognostic factors for rectal cancer treated with preoperative chemoradiotherapy. The Ki-67 index and survivin expression were examined in patients with stage II/III rectal cancer (n=46) by immunohistochemistry. Patients were divided into a high-group and a low-group for the Ki-67 index, and positive and negative groups for survivin expression. Overall and disease-free survival were compared between the groups, and the correlation between Ki-67 index and survivin expression was assessed. The 5-year disease-free survival rate of the group with high Ki-67 index was significantly lower than that of the group with low Ki-67 index (53% and 88%, p=0.03), as was the 5-year overall survival rate (68% and 100%, p=0.03). Findings for survivin were not significant. Ki-67 index and survivin may be useful biomarkers for rectal cancer with preoperative CRT. (Keyword) Aged / Biomarkers, Tumor / Chemoradiotherapy / Disease-Free Survival / Female / Humans / Immunohistochemistry / Inhibitor of Apoptosis Proteins / Ki-67 Antigen / Middle Aged / Neoplasm Staging / Predictive Value of Tests / Preoperative Period / Prognosis / Rectal Neoplasms / Survivin (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12409 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29491110 ● Search Scopus @ Elsevier (PMID): 29491110 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.12409 (DOI: 10.21873/anticanres.12409, PubMed: 29491110)
67.	Mureo Kasahara, Koji Umeshita, Seisuke Sakamoto, Akinari Fukuda, Hiroyuki Furukawa, Shotaro Sakisaka, Eiji Kobayashi, Eiji Tanaka, Yukihiro Inomata, Seiji Kawasaki, Mitsuo Shimada, Norihiro Kokudo, Hiroto Egawa, Hideki Ohdan and Shinji Uemoto : Living donor liver transplantation for biliary atresia: An analysis of 2085 cases in the registry of the Japanese Liver Transplantation Society., American Journal of Transplantation, Vol.18, No.3, 659-668, 2018. (Summary) Biliary atresia (BA) is the most common indication for liver transplantation (LT) in pediatric population. This study analyzed the comprehensive factors that might influence the outcomes of patients with BA who undergo living donor LT by evaluating the largest cohort with the longest follow-up in the world. Between November 1989 and December 2015, 2,085 BA patients underwent LDLT in Japan. There were 763 male and 1,322 female recipients with a mean age of 5.9 years and body weight of 18.6 kg. The 1-, 5-, 10-, 15-, and 20-year graft survival rates for the BA patients undergoing LDLT were 90.5%, 90.4%, 84.6%, 82.0%, and 79.9%, respectively. The donor body mass index, ABO incompatibility, graft type, recipient age, center experience, and transplant era were found to be significant predictors of the overall graft survival. Adolescent age (12 to <18 years) was associated with a significantly worse long-term graft survival rate than younger or older ages. We conclude that LDLT for BA is a safe and effective treatment modality that does not compromise living donors. The optimum timing for LT is crucial for a successful outcome, and early referral to transplantation center can improve the short-term outcomes of LT for BA. Further investigation of the major cause of death in liver transplanted recipients with BA in the long-term is essential, especially among adolescents. (Link to Publication Site) ● Publication site (DOI): 10.1111/ajt.14489 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28889651 ● Search Scopus @ Elsevier (PMID): 28889651 ● Search Scopus @ Elsevier (DOI): 10.1111/ajt.14489 (DOI: 10.1111/ajt.14489, PubMed: 28889651)
68.	Satoru Imura, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria., International Journal of Clinical Oncology, Vol.23, No.1, 98-103, 2018. (Summary) Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study. We investigated the risk factors of recurrence. In addition, we divided them into two groups: mvi-negative group and mvi-positive group, based on pathological findings after surgery. We compared the clinicopathological factors between the two groups and determined the risk factors for mvi. Overall survival rate at 1, 3, and 5 years were 91.6%, 80.5%, and 74.9%, and the recurrence-free survival rate at 1, 3, and 5-years were 72.3%, 51.6%, and 37.2%. Risk factor analysis for tumor recurrence revealed that total bilirubin, albumin, ICGR15, AFP-L3, tumor number, mvi, and tumor stage had a significant predictive value. Multivariate analysis revealed that tumor number and mvi were significant independent risk factors for tumor recurrence. Predictive analysis for risk factors of mvi revealed that multiple tumors and AFP-L3 > 10% were significant independent risk factors for mvi in HCC classified within the Milan criteria. The mvi was one of the independent risk factors for tumor recurrence in HCC classified within the Milan criteria. Multiple tumors and high AFP-L3 value were independent predictive factors for mvi. (Keyword) Aged / Bilirubin / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Retrospective Studies / Risk Factors / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-017-1189-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28875240 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028981662 (DOI: 10.1007/s10147-017-1189-8, PubMed: 28875240, Elsevier: Scopus)
69.	Toshiaki Yoshimoto, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Hiroki Teraoku, Yoshimi Bando and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy., Anticancer Research, Vol.38, No.1, 501-507, 2018. (Summary) We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department. Thirty-eight patients with unresectable HCC who were administrated sorafenib from 2009 to 2015 were investigated retrospectively. The 1-year overall survival rate was 59.3%. The macroscopic vascular invasion and response rate were independent prognostic factors of survival. Surgical resection after sorafenib achieved long-term survival in two cases. Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection. This tumor tested positive for FGF4. Case 2: A patient with a history of hepatectomy for HCC had multiple distant metastases. Most lesions were reduced in size after sorafenib therapy and new lesions in the remnant liver and residual lung metastases were resected. The sorafenib-resistant lesions were negative for FGF4. Sorafenib combined with surgical resection is a feasible option in advanced HCC patients, if sorafenib has been effective. (Keyword) Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Carcinoma, Hepatocellular / Combined Modality Therapy / Female / Fibroblast Growth Factor 4 / Hepatectomy / Hepatitis B / Humans / Liver Neoplasms / Male / Middle Aged / Niacinamide / Phenylurea Compounds / Retrospective Studies / Salvage Therapy / Sorafenib / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12250 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29277815 ● Summary page in Scopus @ Elsevier: 2-s2.0-85039796842 (DOI: 10.21873/anticanres.12250, PubMed: 29277815, Elsevier: Scopus)
70.	Hiroki Ishibashi, Mitsuo Shimada, Hiroki Mori, Yuji Morine and 安藤久實 : 【慢性炎症から肝胆膵癌にいたるランドスケープ】膵・胆管合流異常と胆道癌, KAN TAN SUI, Vol.77, No.3, 659-667, 2018. (Keyword) 和文論文
71.	Keigo Yada, Yuji Morine, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : Treatment strategy for successful hepatic resection of icteric liver., The Journal of Medical Investigation : JMI, Vol.65, No.1.2, 37-42, 2018. (Summary) The treatment strategy for jaundiced patients with hilar cholangiocarcinoma (HC) is not well established. In this study, we evaluate the feasibility of our perioperative protocol for jaundiced patients with HC. Twenty patients with HC who underwent hepatic resection at our institute were enrolled, and patients were divided into icteric(n=6) and normal(n=14) group. As a perioperative protocol, Oral administration of Inchinkoto(ICKT), steroid and nafamostat mesilate were introduced. The evaluation of functional future remnant liver(FRL) by asiaroscintigraphy, and postoperative outcomes were retrospectively compared. Indocyanine green dye retention rate at 15 minutes was higher, and LHL15 values was lower in icteric group. However, in the functional evaluation of FRL, which was the sum of GSA uptake of the future FRL, there was no significant difference of LHL15 values of the remnant liver functional reserve between the two groups. As results, according to the difference of liver function, serum AST level was not different between two groups. The number of patients with postoperative morbidity in the two groups was comparable. Even in HC patients with icteric liver, accurate assessment of liver functional reserve and effective perioperative treatment may attribute to successful hepatectomy and favorable post-operative outcomes. J. Med. Invest. 65:37-42, February, 2018. (Keyword) Aged / Aged, 80 and over / Bile Duct Neoplasms / Cholangiocarcinoma / Female / Hepatectomy / Humans / Jaundice, Obstructive / Male / Postoperative Complications / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 111389 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.65.37 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29593191 ● Search Scopus @ Elsevier (PMID): 29593191 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.65.37 (Tokushima University Institutional Repository: 111389, DOI: 10.2152/jmi.65.37, PubMed: 29593191)
72.	Shoko Wada, Hisami Okumura, Takafumi Katayama, Yuji Morine, Satoru Imura and Mitsuo Shimada : Major liver resection reduces nonprotein respiratory quotient and increases nonesterified fatty acid at postoperative day 14 in patients with hepatocellular carcinoma., Clinical Nutrition ESPEN, Vol.23, 194-199, 2017. (Tokushima University Institutional Repository) ● Metadata: 115066 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clnesp.2017.10.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29460798 ● Summary page in Scopus @ Elsevier: 2-s2.0-85031825628 (Tokushima University Institutional Repository: 115066, DOI: 10.1016/j.clnesp.2017.10.001, PubMed: 29460798, Elsevier: Scopus)
73.	Masanori Niki, Kohhei Nakajima, Daichi Ishikawa, Jun Nishida, Chieko Ishifune, Shin-ichi Tsukumo, Mitsuo Shimada, Shinji Nagahiro, Yoshinori Mitamura and Koji Yasutomo : MicroRNA-449a deficiency promotes colon carcinogenesis., Scientific Reports, Vol.7, No.1, 10696, 2017. (Summary) MicroRNAs have broad roles in tumorigenesis and cell differentiation through regulation of target genes. Notch signaling also controls cell differentiation and tumorigenesis. However, the mechanisms through which Notch mediates microRNA expression are still unclear. In this study, we aimed to identify microRNAs regulated by Notch signaling. Our analysis found that microRNA-449a (miR-449a) was indirectly regulated by Notch signaling. Although miR-449a-deficient mice did not show any Notch-dependent defects in immune cell development, treatment of miR-449a-deficient mice with azoxymethane (AOM) or dextran sodium sulfate (DSS) increased the numbers and sizes of colon tumors. These effects were associated with an increase in intestinal epithelial cell proliferation following AOM/DSS treatment. In patients with colon cancer, miR-449a expression was inversely correlated with disease-free survival and histological scores and was positively correlated with the expression of MLH1 for which loss-of function mutations have been shown to be involved in colon cancer. Colon tissues of miR-449a-deficient mice showed reduced Mlh1 expression compared with those of wild-type mice. Thus, these data suggested that miR-449a acted as a key regulator of colon tumorigenesis by controlling the proliferation of intestinal epithelial cells. Additionally, activation of miR-449a may represent an effective therapeutic strategy and prognostic marker in colon cancer. (Tokushima University Institutional Repository) ● Metadata: 112383 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-017-10500-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28878284 ● Summary page in Scopus @ Elsevier: 2-s2.0-85029002400 (Tokushima University Institutional Repository: 112383, DOI: 10.1038/s41598-017-10500-0, PubMed: 28878284, Elsevier: Scopus)
74.	Naoki Muguruma, Koichi Okamoto, Tadahiko Nakagawa, Katsutaka Sannomiya, Shota Fujimoto, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Jun Higashijima, Mitsuo Shimada, Yoko Horino, Shinya Matsumoto, Kenjiro Hanaoka, Tetsuo Nagano, Makoto Shibutani and Tetsuji Takayama : Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1., Scientific Reports, Vol.7, No.1, 6536, 2017. (Summary) Aberrant crypt foci (ACF), the earliest precursor lesion of colorectal cancers (CRCs), are a good surrogate marker for CRC risk stratification and chemoprevention. However, the conventional ACF detection method with dye-spraying by magnifying colonoscopy is labor- and skill-intensive. We sought to identify rat and human ACF using a fluorescent imaging technique that targets a molecule specific for ACF. We found that glutathione S-transferase (GST) P1-1 was overexpressed in ACF tissues in a screening experiment. We then synthesized the fluorogenic probe, DNAT-Me, which is fluorescently quenched but is activated by GSTP1-1. A CRC cell line incubated with DNAT-Me showed strong fluorescence in the cytosol. Fluorescence intensities correlated significantly with GST activities in cancer cell lines. When we sprayed DNAT-Me onto colorectal mucosa excised from azoxymethane-treated rats and surgically resected from CRC patients, ACF with strong fluorescent signals were clearly observed. The ACF number determined by postoperative DNAT-Me imaging was almost identical to that determined by preoperative methylene blue staining. The signal-to-noise ratio for ACF in DNAT-Me images was significantly higher than that in methylene blue staining. Thus, we sensitively visualized ACF on rat and human colorectal mucosa by using a GST-activated fluorogenic probe without dye-spraying and magnifying colonoscopy. (Tokushima University Institutional Repository) ● Metadata: 112373 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-017-06857-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28747791 ● Search Scopus @ Elsevier (PMID): 28747791 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-017-06857-x (Tokushima University Institutional Repository: 112373, DOI: 10.1038/s41598-017-06857-x, PubMed: 28747791)
75.	Yasushi Sato, Hiroyuki Ohnuma, Takayuki Nobuoka, Masahiro Hirakawa, Tamotsu Sagawa, Koshi Fujikawa, Yasuo Takahashi, Shinya Minami, Shinichi Katsuki, Minoru Takahashi, Masahiro Maeda, Yutaka Okagawa, Naoki Uemura, Syouhei Kikuch, Koichi Okamoto, Hiroshi Miyamoto, Mitsuo Shimada, Ichiro Takemasa, Junji Kato and Tetsuji Takayama : Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study., Gastric Cancer, Vol.20, No.3, 517-526, 2017. (Summary) Conversion therapy is an option for unresectable metastatic gastric cancer when distant metastases are controlled by chemotherapy; however, the feasibility and efficacy remain unclear. This study aimed to assess the feasibility and efficacy of conversion therapy in patients with initially unresectable gastric cancer treated with docetaxel, cisplatin, and S-1 (DCS) chemotherapy by evaluating clinical outcomes. One hundred unresectable metastatic gastric cancer patients, enrolled in three DCS chemotherapy clinical trials, were retrospectively evaluated. The patients received oral S-1 (40 mg/m2 b.i.d.) on days 1-14 and intravenous cisplatin (60 mg/m2) and docetaxel (50-60 mg/m2) on day 8 every 3 weeks. Conversion therapy was defined when the patients could undergo R0 resection post-DCS chemotherapy and were able to tolerate curative surgery. Conversion therapy was achieved in 33/100 patients, with no perioperative mortality. Twenty-eight of the 33 patients (84.8 %) achieved R0 resection, and 78.8 % were defined as histological chemotherapeutic responders. The median overall survival (OS) of patients who underwent conversion therapy was 47.8 months (95 % CI 28.0-88.5 months). Patients who underwent R0 resection had significantly longer OS than those who underwent R1 and R2 resections (P = 0.0002). Of the patients with primarily unresectable metastases, 10 % lived >5 years. Among patients who underwent conversion therapy, multivariate analysis showed that the pathological response was a significant independent predictor for OS. DCS safely induced a high conversion rate, with very high R0 and pathological response rates, and was associated with a good prognosis; these findings warrant further prospective investigations. (Keyword) Administration, Oral / Adult / Aged / Antineoplastic Combined Chemotherapy Protocols / Cisplatin / Drug Combinations / Female / Humans / Male / Middle Aged / Oxonic Acid / Postoperative Care / Prognosis / Retrospective Studies / Stomach Neoplasms / Survival Analysis / Taxoids / Tegafur / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1007/s10120-016-0633-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27553665 ● Summary page in Scopus @ Elsevier: 2-s2.0-84983383466 (DOI: 10.1007/s10120-016-0633-1, PubMed: 27553665, Elsevier: Scopus)
76.	Yuri Matsumoto, Hiroshi Miyamoto, Akira Fukuya, Fumika Nakamura, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Mitsuo Shimada, Yoshimi Bando and Tetsuji Takayama : Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas., Clinical Journal of Gastroenterology, Vol.10, No.2, 185-190, 2017. (Summary) Hemosuccus pancreaticus is a gastrointestinal hemorrhage through the main pancreatic duct. Here, we report a rare case of hemosuccus pancreaticus due to a mucinous cystic neoplasm of the pancreas. A 62-year-old woman who had been followed for a branch duct intraductal papillary mucinous neoplasm visited our emergency room due to severe abdominal pain and bloody discharge. Computed tomography revealed that the pancreatic cyst increased the tension of the wall and a high-density area indicative of bleeding into the cyst was observed. Endoscopy showed opening of and hemorrhaging from the papilla of Vater. The patient was diagnosed with hemosuccus pancreaticus caused by hemorrhaging into the cyst from the branch duct intraductal papillary mucinous neoplasm. Based on this diagnosis, elective distal pancreatectomy was performed. The histopathological diagnosis was a mucinous cystic neoplasm with intermediate-grade dysplasia based upon the pathological findings that fibrous ovarian-type stroma existed abundantly and the stroma cells were positive for progesterone receptor and inhibin. Hemosuccus pancreaticus caused by a mucinous cystic neoplasm is extremely rare and there has been only one case reported to date. In conclusion, it should be recognized that pancreatic cystic neoplasms including mucinous cystic neoplasms may cause hemosuccus pancreaticus. (Keyword) Ampulla of Vater / female / Gastrointestinal Hemorrhage / Humans / magnetic resonance imaging / Middle Aged / Neoplasms, Cystic, Mucinous, and Serous / Pancreatic Cyst / Pancreatic Ducts / Pancreatic Neoplasms / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0711-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28054178 ● Summary page in Scopus @ Elsevier: 2-s2.0-85008158342 (DOI: 10.1007/s12328-016-0711-2, PubMed: 28054178, Elsevier: Scopus)
77.	Naoji Mita, Shinji Kawahito, Tomohiro Soga, Kazumi Takaishi, Hiroshi Kitahata, Munehide Matsuhisa, Mitsuo Shimada, Kinoshita Hiroyuki, Yasuo Tsutsumi and Katsuya Tanaka : Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative acute kidney injury, Journal of Artificial Organs, Vol.20, No.1, 76-83, 2017. (Summary) The aim of the present study was to evaluate the usefulness of a closed-loop system (STG-55; Nikkiso, Tokyo, Japan), a type of artificial endocrine pancreas for the continuous monitoring and control of intraoperative blood glucose, for preventing postoperative acute kidney injury (AKI) in patients undergoing hepatectomy. Thirty-eight patients were enrolled in this study. Glucose concentrations were controlled with either a manual injection of insulin based on a commonly used sliding scale (manual insulin group, n = 19) or the programmed infusion of insulin determined by the control algorithm of the artificial endocrine pancreas (programmed insulin group, n = 19). After the induction of anesthesia, a 20-G intravenous catheter was inserted into the peripheral forearm vein of patients in the programmed insulin group and connected to an artificial endocrine pancreas (STG-55). The target range for glucose concentrations was set to 100-150 mg/dL. The mean serum creatinine concentrations of preoperative, postoperative 24 and 48 h were 0.72, 0.78, and 0.79 mg/dL in the programmed insulin group, and 0.81, 0.95, and 1.03 mg/dL in the manual insulin group, respectively. Elevations in serum creatinine concentrations postoperative 48 h were significantly suppressed in the programmed insulin group. The STG-55 closed-loop system was effective for maintaining strict blood glucose control during hepatectomy with minimal variability in blood glucose concentrations and for suppressing elevations in serum creatinine concentrations. Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative AKI. (Keyword) Acute Kidney Injury / Aged / Aged, 80 and over / Blood Glucose / Creatinine / Female / Hepatectomy / Humans / Insulin / Insulin Infusion Systems / Japan / Male / Middle Aged / Pancreas, Artificial / Postoperative Complications / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 110117 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10047-016-0925-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27557726 ● Search Scopus @ Elsevier (PMID): 27557726 ● Search Scopus @ Elsevier (DOI): 10.1007/s10047-016-0925-6 (Tokushima University Institutional Repository: 110117, DOI: 10.1007/s10047-016-0925-6, PubMed: 27557726)
78.	Satoshi Teramae, Koichi Okamoto, Kumiko Tanaka, Reika Matsumoto, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Duodenal cancer in a young patient with Peuts-Jeghers syndrome harboring an entire deletion of the STK11 gene., Clinical Journal of Gastroenterology, Vol.10, No.3, 232-239, 2017. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-017-0731-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28303455 ● Summary page in Scopus @ Elsevier: 2-s2.0-85015616972 (DOI: 10.1007/s12328-017-0731-6, PubMed: 28303455, Elsevier: Scopus)
79.	Yasuteru Fujino, Shunsaku Takeishi, Kensei Nishida, Koichi Okamoto, Naoki Muguruma, Tetsuo Kimura, Shinji Kitamura, Hiroshi Miyamoto, Akiko Fujimoto, Jun Higashijima, Mitsuo Shimada, Kazuhito Rokutan and Tetsuji Takayama : Downregulation of miR-100/miR-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion., Cancer Science, Vol.108, No.3, 390-397, 2017. (Summary) A majority of early colorectal cancers (CRCs) with submucosal invasion undergo surgical operation, despite a very low incidence of lymph node metastasis. Our study aimed to identify microRNAs (miRNAs) specifically responsible for lymph node metastasis in submucosal CRCs. MicroRNA microarray analysis revealed that miR-100 and miR-125b expression levels were significantly lower in CRC tissues with lymph node metastases than in those without metastases. These results were validated by quantitative real-time PCR in a larger set of clinical samples. The transfection of a miR-100 or miR-125b inhibitor into colon cancer HCT116 cells significantly increased cell invasion, migration, and MMP activity. Conversely, overexpression of miR-100 or miR-125b mimics significantly attenuated all these activities but did not affect cell growth. To identify target mRNAs, we undertook a gene expression array analysis of miR-100-silenced HCT116 cells as well as negative control cells. The Ingenuity Pathway Analysis, TargetScan software analyses, and subsequent verification of mRNA expression by real-time PCR identified mammalian target of rapamycin (mTOR) and insulin-like growth factor 1 receptor (IGF1R) as direct, and Fas and X-linked inhibitor-of-apoptosis protein (XIAP) as indirect candidate targets for miR-100 involved in lymph node metastasis. Knockdown of each gene by siRNA significantly reduced the invasiveness of HCT116 cells. These data clearly show that downregulation of miR-100 and miR-125b is closely associated with lymph node metastasis in submucosal CRC through enhancement of invasion, motility, and MMP activity. In particular, miR-100 may promote metastasis by upregulating mTOR, IGF1R, Fas, and XIAP as targets. Thus, miR-100 and miR-125b may be novel biomarkers for lymph node metastasis of early CRCs with submucosal invasion. (Keyword) Antigens, CD95 / Cell Line, Tumor / Cell Movement / Cell Proliferation / Colorectal Neoplasms / HCT116 Cells / HT29 Cells / Humans / Lymphatic Metastasis / Matrix Metalloproteinases / MicroRNAs / RNA Interference / RNA, Small Interfering / Receptors, Somatomedin / TOR Serine-Threonine Kinases / X-Linked Inhibitor of Apoptosis Protein (Tokushima University Institutional Repository) ● Metadata: 112375 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.13152 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28032929 ● Search Scopus @ Elsevier (PMID): 28032929 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.13152 (Tokushima University Institutional Repository: 112375, DOI: 10.1111/cas.13152, PubMed: 28032929)
80.	Hiroki Ishibashi, Mitsuo Shimada and Keigo Yada : Japanese clinical practice guidelines for congenital biliary dilatation, The Japanese Journal of Gastro-enterology, Vol.113, No.12, 2004-2015, 2016. (Summary) <p>先天性胆道拡張症(congenital biliary dilatation;CBD)は，総胆管を含む肝外胆管が限局性に拡張する先天性の形成異常で，膵・胆管合流異常を合併し，胆汁と膵液の流出障害や相互逆流，胆道癌など肝，胆道および膵にさまざまな病態を引きおこす疾患であるが，診療ガイドラインはいまだ策定されていない．今回，CBD診療ガイドラインの作成にあたり，膵・胆管合流異常診療ガイドラインから，抜粋，一部改変し，clinical question作成，引用文献のレベル分類，ステートメントの推奨度決定を行い，科学的根拠に基づいたCBD診療ガイドラインを作成したので，ダイジェスト版として紹介する．</p> (Keyword) 術後合併症 (Link to Publication Site) ● Publication site (DOI): 10.11405/nisshoshi.113.2004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27916767 ● CiNii @ National Institute of Informatics (CRID): 1390282681380115328 ● Summary page in Scopus @ Elsevier: 2-s2.0-85002497840 (DOI: 10.11405/nisshoshi.113.2004, PubMed: 27916767, CiNii: 1390282681380115328, Elsevier: Scopus)
81.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Ichio Suzuka, Takashi Nishizaki, Hiroshi Okitsu, Toshiyuki Yagi, Hidenori Miyake, Murato Miura, Mitsutoshi Fukuyama, Daisuke Wada and Yoshiaki Bando : Propensity score-matched study of laparoscopic and open surgery for colorectal cancer in rural hospitals., Journal of Gastroenterology and Hepatology, Vol.31, No.10, 1700-1704, 2016. (Summary) Various randomized clinical studies have suggested that short- and long-term outcomes of laparoscopic surgery (LAP) for colorectal cancer are comparable with those of open surgery (OP). However, these studies were performed in high-volume hospitals. The aim of the present study was to compare the outcomes of LAP versus OP for colorectal cancer in rural hospitals. This was a multicenter retrospective propensity score-matched case-control study of patients who underwent colorectal surgery from January 2004 to April 2009 in 10 hospitals in Japan. All patients underwent curative surgery for pathologically diagnosed stage II or III colorectal cancer. The primary end point was 5-year overall survival (OS). The secondary end points were disease-free survival (DFS) and postoperative complications. In total, 319 patients who underwent LAP and 1020 patients who underwent OP were balanced to 261 pairs. There was no significant difference in the OS and DFS between two groups. The operation time was significantly shorter for OP than for LAP. Blood loss was significantly lower in LAP than in OP. There was no difference in intraoperative morbidity between the two groups. The postoperative morbidity was significantly lower in LAP than in OP. The hospital stay was significantly shorter in LAP than in OP. There was no significant difference in 90-day postoperative mortality. Laparoscopic surgery may be a feasible option for colorectal cancer in rural hospitals. (Keyword) Adult / Aged / Aged, 80 and over / Colectomy / Colorectal Neoplasms / Feasibility Studies / Female / Hospitals, Rural / Humans / Laparoscopy / Length of Stay / Male / Middle Aged / Neoplasm Grading / Neoplasm Staging / Propensity Score / Retrospective Studies / Survival Analysis / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.13322 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26896303 ● Summary page in Scopus @ Elsevier: 2-s2.0-85002156898 (DOI: 10.1111/jgh.13322, PubMed: 26896303, Elsevier: Scopus)
82.	Tetsuo Kimura, Hiroshi Miyamoto, Akira Fukuya, Shinji Kitamura, Koichi Okamoto, Masako Kimura, Naoki Muguruma, Tetsuya Ikemoto, Mitsuo Shimada, Akiko Yoneda, Yoshimi Bando, Makoto Takishita and Tetsuji Takayama : Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma., Clinical Journal of Gastroenterology, Vol.9, No.4, 261-265, 2016. (Summary) Neuroendocrine carcinoma (NEC) of the pancreas is very rare, and its origin is not fully elucidated. Here, we present a case of a small-size NEC of the pancreas that is genetically similar to invasive ductal adenocarcinoma (IDA). A 65-year-old man was referred to our hospital due to obstructive jaundice and found to have a 12-mm solid tumor in the pancreas head. The tumor exhibited low vascularity on enhanced computed tomography, and endoscopic retrograde pancreatographic imaging revealed an irregular obstruction in a branch duct of the pancreas. The patient was thereby diagnosed with a pancreatic ductal cancer, and stomach-preserving pancreaticoduodenectomy with regional lymph node resection was performed. Histochemical analysis of the resected tumor showed that the neoplastic cells with scanty cytoplasm and hyperchromatic nuclei strongly expressed chromogranin A and synaptophysin. The Ki-67 index was 40 % in the most proliferative tumor regions, and the tumor was diagnosed as a NEC of the pancreas. However, in the analysis of genetic alterations of the tumor tissue, the neoplastic cells showed altered KRAS, TP53, and SMAD4/DPC4, suggesting that the NEC in our case is genetically related to IDA. Our data suggest that poorly differentiated IDAs may transform into NECs. (Keyword) Aged / Carcinoma, Neuroendocrine / Carcinoma, Pancreatic Ductal / Cholangiopancreatography, Endoscopic Retrograde / Disease Progression / Genes, p53 / Humans / Male / Mutation / Pancreatic Neoplasms / Proto-Oncogene Proteins p21(ras) / Smad4 Protein / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0655-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27262570 ● Search Scopus @ Elsevier (PMID): 27262570 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-016-0655-6 (DOI: 10.1007/s12328-016-0655-6, PubMed: 27262570)
83.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Syohei Eto : Combined liver mobilization and retraction: A novel technique to obtain the optimal surgical field during laparoscopic total gastrectomy., Asian Journal of Endoscopic Surgery, Vol.9, No.2, 111-115, 2016. (Summary) During laparoscopic gastrectomy, it is important to establish a good operative field and ensure an adequate working space. The combined liver mobilization and retraction method is used to get a safe and optimal view. We retrospectively analyzed 32 consecutive patients who underwent laparoscopic total gastrectomy for gastric cancer. The patients were divided into two groups: the mobilization (+) group (n = 12) and the mobilization (-) group (n = 20). Hepatic function tests were performed in all patients. Mobilization provided a satisfactory view of the working field, especially the gastroesophageal junction and the angle of His during laparoscopic total gastrectomy, and no complications were observed during liver retraction. On postoperative hepatic function testing, there was no significant difference between the two groups on any day. Combined liver mobilization and retraction may be helpful in laparoscopic total gastrectomy. (Keyword) Adult / Aged / Dissection / Female / Gastrectomy / Humans / Laparoscopy / Liver / Liver Function Tests / Male / Middle Aged / Retrospective Studies / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12271 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26679094 ● Summary page in Scopus @ Elsevier: 2-s2.0-85016924826 (DOI: 10.1111/ases.12271, PubMed: 26679094, Elsevier: Scopus)
84.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : Intrascrotal lipoblastoma: report of a case and the review of literature., Surgical Case Reports, Vol.2, No.1, 34, 2016. (Summary) Intrascrotal lipoblastoma is a rare pediatric benign soft tissue neoplasm, and only 11 cases have been reported. The accurate preoperative diagnosis is difficult because of its rarelity and the similarity with the other soft tissue tumors. Among them, accurate preoperative diagnosis had been made in only one case. Thus, almost all of the cases had required inguinal mass excision (and orchidectomy in one case). In this paper, we discuss the accurate preoperative diagnosis of intrascrotal lipoblastoma and subsequent simple tumorectomy via minimal invasive scrotal skin incision, in 1-year-old boy. On physical examination, intrascrotal extra-testicular lobulated mass was palpated on the right scrotum. An ultrasonography revealed the well-circumscribed, iso-echoic, scant blood-flow, and lobulated tumors with each lobules of 1 to 4 cm in diameter, and the tumor located outside of the tunica vaginalis testis. The serum values of alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (b-hCG) were within normal limit. The preoperative diagnosis of intrascrotal lipoblastoma was made, and the mass was excised via minimal scrotal incision. The right testicle and epididymis were normal. The lesion consisted of the distinct two lobulated tumors, and microscopic examination confirmed the diagnosis of intrascrotal lipoblastoma. The postoperative course was uneventful without evidence of recurrence. A rare intrascrotal lipoblastoma is seldom made accurate preoperative diagnosis; however, the accurate preoperative suspicion of this tumor leads to the minimal invasive tumorectomy via scrotal skin incision and favorable postoperative recovery without recurrence. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-016-0160-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27059472 ● Search Scopus @ Elsevier (PMID): 27059472 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-016-0160-7 (DOI: 10.1186/s40792-016-0160-7, PubMed: 27059472)
85.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Yuji Morine, Chengzhan Zhu, Rui Feng, Toru Kono and Mitsuo Shimada : The Kampo medicine "Daikenchuto (TU-100)" prevents bacterial translocation and hepatic fibrosis in a rat model of biliary atresia., Surgery, Vol.159, No.6, 1600-1611, 2016. (Summary) Biliary atresia is the most common cause of end-stage liver disease in children. It is known that bile duct ligation contributes to liver fibrosis via bacterial translocation (BT) and toll-like receptor 4 (TLR4) signaling of hepatic stellate cells (HSCs). We have reported previously that the traditional Japanese medicine, "Dai-kenchu-to (TU-100)," a form of "Kampo medicine" prevents BT in rats exposed to the stress of fasting. The aim of this study was to clarify the effect of TU-100 on a rat model of biliary atresia using bile duct ligation. Bile duct ligation and subsequent daily oral administration of TU-100 was performed in 6-week-old rats. The rats were killed at 3, 7, or 14 days after bile duct ligation to evaluate the liver injury, occurrence of BT, and hepatic fibrosis. As an in vitro experiment, we isolated fresh HSCs from the rats undergoing bile duct ligation. After cell attachment, TU-100 and its 3 component herbs (eg, processed ginger, ginseng radix, and Japanese pepper) were added, and the expressions of Alpha actin2 (acta2), Alpha-1 type I collagen (colIa1), and tissue inhibitor of metalloproteinase 1 (timp1) were analyzed. In vivo experiments demonstrated that oral administration of TU-100 decreased liver injury and atrophy of intestinal mucosa BT, hepatic fibrosis, and hepatic expression of alpha smooth muscle actin ( SMA) and TLR4, compared with rats that underwent bile duct ligation only. In vitro experiments showed that administration of TU-100 or the component herbs inhibited the expressions of acta2, colIa1, and timp1 in the HSCs. TU-100 prevented BT, activation of HSCs, and subsequent hepatic fibrosis. TU-100 may prevent progression of hepatic fibrosis in children with biliary atresia and improve prognosis. (Keyword) Actins / Animals / Bacterial Translocation / Biliary Atresia / Cell Culture Techniques / Disease Models, Animal / Hepatic Stellate Cells / Liver Cirrhosis / Male / Medicine, Kampo / Phytotherapy / Plant Extracts / Rats / Rats, Wistar / Toll-Like Receptor 4 (Tokushima University Institutional Repository) ● Metadata: 109712 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.surg.2016.02.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26994485 ● Search Scopus @ Elsevier (PMID): 26994485 ● Search Scopus @ Elsevier (DOI): 10.1016/j.surg.2016.02.002 (Tokushima University Institutional Repository: 109712, DOI: 10.1016/j.surg.2016.02.002, PubMed: 26994485)
86.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Yuji Morine and Mitsuo Shimada : 【イラストでみる最新の胆・膵消化管吻合術】肝管空腸吻合先天性胆道拡張症，戸谷分類IV-A型, Journal of Biliary Tract & Pancreas, Vol.37, No.3, 215-220, 2016. (Keyword) 空腸(外科的療法)
87.	Tomohiro Nishina, Toshikazu Moriwaki, Mitsuo Shimada, Jun Higashijima, Yoshinori Sakai, Toshiki Masuishi, Mitsuharu Ozeki, Kenji Amagai, Yuji Negoro, Shunju Indo, Tadamichi Denda, Mikio Sato, Yuji Yamamoto, Go Nakajima, Minoru Mizuta, Ikuo Takahashi, Yoshinori Hiroshima, Hiroyasu Ishida, Takashi Maeba and Ichinosuke Hyodo : Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged · 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study)., Clinical Colorectal Cancer, Vol.15, No.3, 236-242, 2015. (Summary) We previously reported that uracil-tegafur with oral leucovorin (UFT/LV) treatment for elderly patients (aged · 75 years) was well-tolerated in a phase II study. In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported. The present study was a single-arm, open-label, multicenter, cooperative group clinical trial. The key eligibility criteria included age · 75 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, first-line chemotherapy, measurable lesions, and preserved organ function. Patients received UFT 300 mg/m(2)/d and LV 75 mg/d on days 1 to 21 and intravenous bevacizumab 5 mg/kg on days 1 and 15. Treatment was repeated every 28 days. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were the objective response rate (ORR), overall survival (OS), and safety. Of the 55 patients enrolled from 15 Japanese institutions, 52 eligible patients were evaluated. Their median age was 80 years (range, 75-87 years), and 73% had an ECOG performance status of 0. The median PFS was 8.2 months (95% confidence interval [CI], 6.2-10 months). The ORR was 40% (95% CI, 27%-55%). The median OS was 23 months (95% CI, 12-33 months). The most common grade 3 and 4 treatment-related adverse events were hypertension (12%), fatigue (8%), anemia (8%), nausea (6%), and diarrhea (6%). Treatment-related death occurred in 2 patients. UFT/LV (3 weeks of therapy and 1 week without) combined with biweekly bevacizumab is a tolerable and effective treatment option for elderly patients (aged · 75 years) with metastatic colorectal cancer. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clcc.2015.12.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26778644 ● Summary page in Scopus @ Elsevier: 2-s2.0-84952923831 (DOI: 10.1016/j.clcc.2015.12.001, PubMed: 26778644, Elsevier: Scopus)
88.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi and Hideya Kashihara : 手術手技合併症から学ぶ腹腔鏡下胃全摘出術R-Y再建の工夫, Operation, Vol.69, No.13, 1821-1825, 2015. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521980705650664448 (CiNii: 1521980705650664448)
89.	Yuji Morine and Mitsuo Shimada : The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics., Journal of Gastroenterology, Vol.50, No.9, 913-927, 2015. (Summary) Lymph node (LN) metastasis from intrahepatic cholangiocarcinoma (IHCC) might be one of the most important indicators of aggressive surgical resection, yet the value of LN dissection is still controversial. To address this clinical problem, we need to better understand the multidirectional lymphatic outflow from the liver. Although most hepatic lymph flows into the hilar LNs along portal triads, there are also several lymphatic outflows directly communicating with distant areas or the general lymphatic system. Moreover, it has been revealed that LN metastasis spreads to more distal LNs through the hepatoduodenal ligament or other multidirectional lymphatic pathways connected to the general lymphatic system. Therefore, systematic LN dissection might merely be LN sampling in IHCC with LN metastasis. A multidisciplinary strategy focusing on adjuvant treatment after surgery is immediately necessary in these cases. In IHCC without LN metastasis, the accuracy of preoperative imaging assessment of LN metastasis is unsatisfactory and useless for detecting metastatic LNs in clinical settings. Therefore, prophylactic systematic LN dissection for IHCC without preoperative LN swelling is recommended for accurate LN status assessment and reduction of local recurrences. However, this procedure might not offer any clinical benefit according to the results of retrospective comparative studies. In this review, we summarize previous reports regarding lymphatic outflow of the liver and discuss LN dissection for IHCC. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-015-1071-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25833009 ● Search Scopus @ Elsevier (PMID): 25833009 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-015-1071-2 (DOI: 10.1007/s00535-015-1071-2, PubMed: 25833009)
90.	Toshihiro Nakao, Takashi Iwata, Masanori Hotchi, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Shohei Eto, Hiroki Teraoku and Mitsuo Shimada : Prediction of response to preoperative chemoradiotherapy and establishment of individualized therapy in advanced rectal cancer., Oncology Reports, Vol.34, No.4, 1961-1967, 2015. (Summary) Preoperative chemoradiotherapy (CRT) has become the standard treatment for patients with locally advanced rectal cancer. However, no specific biomarker has been identified to predict a response to preoperative CRT. The aim of the present study was to assess the gene expression patterns of patients with advanced rectal cancer to predict their responses to preoperative CRT. Fifty-nine rectal cancer patients were subjected to preoperative CRT. Patients were randomly assigned to receive CRT with tegafur/gimeracil/oteracil (S-1 group, n=30) or tegafur-uracil (UFT group, n=29). Gene expression changes were studied with cDNA and miRNA microarray. The association between gene expression and response to CRT was evaluated. cDNA microarray showed that 184 genes were significantly differentially expressed between the responders and the non-responders in the S-1 group. Comparatively, 193 genes were significantly differentially expressed in the responders in the UFT group. TBX18 upregulation was common to both groups whereas BTNL8, LOC375010, ADH1B, HRASLS2, LOC284232, GCNT3 and ALDH1A2 were significantly differentially lower in both groups when compared with the non-responders. Using miRNA microarray, we found that 7 and 16 genes were significantly differentially expressed between the responders and non-responders in the S-1 and UFT groups, respectively. miR-223 was significantly higher in the responders in the S-1 group and tended to be higher in the responders in the UFT group. The present study identified several genes likely to be useful for establishing individualized therapies for patients with rectal cancer. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2015.4196 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26260776 ● Search Scopus @ Elsevier (PMID): 26260776 ● Search Scopus @ Elsevier (DOI): 10.3892/or.2015.4196 (DOI: 10.3892/or.2015.4196, PubMed: 26260776)
91.	Nobuhiro Kurita, Hiroaki Miyata, Mitsukazu Gotoh, Mitsuo Shimada, Satoru Imura, Wataru Kimura, Naohiro Tomita, Hideo Baba, Yukou Kitagawa, Kenichi Sugihara and Masaki Mori : Risk Model for Distal Gastrectomy When Treating Gastric Cancer on the Basis of Data From 33,917 Japanese Patients Collected Using a Nationwide Web-based Data Entry System., Annals of Surgery, Vol.262, No.2, 295-303, 2015. (Summary) To establish a risk model for distal gastrectomy in Japanese patients with gastric cancer. Risk stratification for distal gastrectomy in Japanese patients with gastric cancer improves surgical outcomes. The National Clinical Database was constructed for risk determination in gastric cancer-related gastrectomy among Japanese individuals. Data from 33,917 gastric cancer cases (1737 hospitals) were used. The primary outcomes were 30-day and operative mortalities. Data were randomly assigned to risk model development (27,220 cases) and test validation (6697 cases) subsets. Stepwise selection was used for constructing 30-day and operative mortality logistic models. The 30-day, in-hospital, and operative mortality rates were 0.52%, 1.16%, and 1.2%, respectively. The morbidity was 18.3%. The 30-day and operative mortality models included 17 and 21 risk factors, respectively. Thirteen variables overlapped: age, need for total assistance in activities of daily living preoperatively or within 30 days after surgery, cerebrovascular disease history, more than 10% weight loss, uncontrolled ascites, American Society of Anesthesiologists score (≥ class 3), white blood cell count more than 12,000/μL or 11,000/μL, anemia (hemoglobin: males, <13.5 g/dL; females, <12.5 g/dL; or hematocrit: males, <37%; females <32%), serum albumin less than 3.5 or 3.8 g/dL, alkaline phosphatase more than 340 IU/L, serum creatinine more than 1.2 mg/dL, serum Na less than 135 mEq/L, and prothrombin time-international normalized ratio more than 1.25 or 1.1. The C-indices for the 30-day and operative mortalities were 0.785 (95% confidence interval, 0.705-0.865; P < 0.001) and 0.798 (95% confidence interval, 0.746-0.851; P < 0.001), respectively. The risk model developed using nationwide Japanese data on distal gastrectomy in gastric cancer can predict surgical outcomes. (Keyword) Aged / Aged, 80 and over / Female / Gastrectomy / Hospital Mortality / Humans / internet / Japan / Laparoscopy / Logistic Models / Male / Middle Aged / Odds Ratio / Quality Indicators, Health Care / Risk Factors / Sensitivity and Specificity / Stomach Neoplasms / Survival Rate / Treatment Outcome / 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1097/SLA.0000000000001127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25719804 ● Search Scopus @ Elsevier (PMID): 25719804 ● Search Scopus @ Elsevier (DOI): 10.1097/SLA.0000000000001127 (DOI: 10.1097/SLA.0000000000001127, PubMed: 25719804)
92.	Chie Takasu and Mitsuo Shimada : 外科の立場からのキャリアアップ支援と問題点, 第40回日本外科系連合学会学術集会, 2015.
93.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, Hiroki Ishibashi and Toru Utsunomiya : Detection of Lymph Nodes Metastasis in Biliary Carcinomas:Morphological Criteria by MDCT and the Clinical Impact of DEI-MRI, Hepato-Gastroenterology, Vol.62, No.140, 777-781, 2015. (Summary) This study was conducted to assess the usefulness of multi-slice CT (MDCT) and diffusion weighted MR images (DWI-MRI) for diagnosis of metastatic lymph nodes (LNs) in biliary carcinomas. Eighteen patients with biliary carcinomas (total 121 LNs) underwent surgical resection were included. In MDCT, the following criteria were measured: the maximum diameter, the enhanced value and the long and short axis (L/S) ratio. In DWI-MRI, the apparent diffusion coefficients (ADCs) were measured from ADC maps. In ROC analysis, the maximum diameter has the highest diagnostic power with area under curves of 0.903. And when the maximum diameter 8 mm and L/S ratio is less than 2, the accuracy was improved with a sensitivity of 81%, positive predictive value (PPV) of 45%. In DWI-MRI, ADCs values of metastatic LNs significantly lower than that of non-metastatic LNs (mean: 1.65 vs. 2.11 x10 3mm2/s). When the ADC value of 1.8 x10(-3) was used as a cut-off value, the best results were obtained with sensitivity of 75%, PPV of 82%. Using MDCT, diagnosis of LNs metastasis should be more than 8mm diameter and less than 2 of L/S ratio. In addition, DWI-MRI is more useful modality for diagnosis of LNs metastasis. (Keyword) 欧文論文 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26901999 ● Search Scopus @ Elsevier (PMID): 26901999 (PubMed: 26901999)
94.	Shohei Eto, Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Horohiko Sato and Nobuhiro Kurita : The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer., Anticancer Research, Vol.35, No.4, 2071-2076, 2015. (Summary) Gastric cancer is one of the most common types of cancer. Cancer stem cells (CSCs) have been reported to play important roles in multiple cancer types. This study investigated the correlation between cluster of differentiation 133 (CD133), histone deacetylase 1 (HDAC1) and thrombospondin-1 (THBS1) expression in advanced gastric cancer. The study included 65 patients with gastric cancer with recurrence after surgery. Expression of CD133, HDAC1 and THBS1 was examined by immunohistochemistry. Prognostic factors were investigated by multivariate analysis using Cox's proportional hazard model. Clinicopathological variables, including survival, of patients positive for CD133 expression (n=6, 23%), were compared with those without CD133 expression (n=20, 77%). Positive HDAC1 expression and THBS1 expression were observed in 34 (52%) and 17 (26%) patients, respectively. Using univariate analysis, positive expression of CD133 and negative expression of THBS1 predicted significantly worse prognosis. Multivariate analysis revealed CD133-positive and THBS1-negative expression were independent prognostic indicators. CD133 expression and THBS1 expression were prognostic factors, and a negative relationship between HDAC and THBS1 was observed in advanced gastric cancer. These biomarkers may help determine postoperative treatment in patients with gastric cancer. (Keyword) 欧文論文 / Aged / Aged, 80 and over / Antigens, CD / Biomarkers, Tumor / Female / Gene Expression Regulation, Neoplastic / Glycoproteins / Histone Deacetylase 1 / Humans / Kaplan-Meier Estimate / Male / Middle Aged / Neoplasm Recurrence, Local / Neoplastic Stem Cells / Peptides / Prognosis / Stomach Neoplasms / Thrombospondin 1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25862862 ● Search Scopus @ Elsevier (PMID): 25862862 (PubMed: 25862862)
95.	Mami Kanamoto, Satoru Imura, Yuji Morine, Tohru Utsunomiya, Hiroki Mori, Yusuke Arakawa, Chie Takasu and Mitsuo Shimada : Effective use of a vessel-sealing system for laparoscopic unroofing of liver cysts., Asian Journal of Endoscopic Surgery, Vol.8, No.1, 91-94, 2015. (Summary) Liver cysts that present with symptoms such as jaundice, abdominal pain, and intra-cystic infection require treatment. In laparoscopic unroofing of liver cysts, appropriate treatment is needed in cases where the cystic walls contain vessels or bile ducts. A vessel-sealing system can seal not only vessels, but also bile ducts. We experienced four cases in which laparoscopic unroofing of liver cysts was performed with a vessel-sealing system. Case 1 was a woman in her 70s who presented at our hospital with abdominal pressure. Abdominal CT showed liver cysts with a maximum diameter of 13 cm. Laparoscopic unroofing was performed with LigaSure Impact. Case 2 was a woman in her 50s with abdominal discomfort. CT showed a cyst 15 cm in diameter situated in the right lobe. We performed SILS using a LigaSure Blunt Tip to unroof the cyst. Case 3 was a man in his 80s with abdominal pain. CT showed a huge cyst 25 cm in diameter in the right lobe. We performed hybrid SILS with a LigaSure Blunt Tip to unroof the cysts. Case 4 was a woman in her 70s with upper abdominal pain. CT showed multiple cysts with a maximum diameter of 15 cm in the bilateral lobes. We performed hybrid SILS to successfully unroof her cysts. None of the cases experienced postoperative complications, such as bleeding or bile leakage, and none experienced recurrence of cysts. A laparoscopic unroofing using a vessel-sealing system can be a minimally invasive and safe treatment for liver cysts. (Keyword) Aged / Aged, 80 and over / Blood Loss, Surgical / Cysts / Equipment Design / Female / Follow-Up Studies / Hepatectomy / Hepatic Artery / Hepatic Veins / Humans / Laparoscopy / Liver Diseases / Male / Middle Aged / Postoperative Hemorrhage / Suture Techniques / 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12134 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25598064 ● Summary page in Scopus @ Elsevier: 2-s2.0-84944232248 (DOI: 10.1111/ases.12134, PubMed: 25598064, Elsevier: Scopus)
96.	Mitsuo Shimada : Highlights of topic "Intrahepatic cholangiocarcinoma: recent advancements in pathogenesis, diagnosis and treatment"., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.22, No.2, 91-93, 2015. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Combined Modality Therapy / Diagnostic Imaging / Hepatitis, Viral, Human / Humans (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.153 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25627459 ● Search Scopus @ Elsevier (PMID): 25627459 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.153 (DOI: 10.1002/jhbp.153, PubMed: 25627459)
97.	Mitsuo Shimada, Yuji Morine, Hiroaki Nagano, Etsuro Hatano, Takashi Kaiho, Masaru Miyazaki, Toru Kono, Toshiya Kamiyama, Satoshi Morita, Junichi Sakamoto, Mitsuo Kusano, Shigetoyo Saji, Takashi Kanematsu and Masaki Kitajima : Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001)., International Journal of Clinical Oncology, Vol.20, No.1, 95-104, 2015. (Summary) This multi-center, phase III trial assesses the efficacy of daikenchuto (TU-100) on gastrointestinal disorders after hepatic resection (UMIN Registration No. 000003103). A total of 231 patients, who underwent hepatic resection at 26 Japanese centers, were enrolled. Patients were randomly assigned to receive either oral doses (15 g/day, three times a day) of TU-100 or placebo control from preoperative day 3 to postoperative day 10, except on the day of surgery. Primary end points were the time from extubation until the first postoperative bowel movement (FBM-T), serum C-reactive protein (CRP) and ammonia levels. Finally, 209 patients (TU-100: n = 108, placebo: n = 101) were included in the statistical analysis. The median FBM-T was 88.2 h (95 % CI 74.0-94.1) in the TU-100 group and 93.1 h (95 % CI 83.3-99.4) in the placebo group, demonstrating that TU-100 accelerated the time to first bowel movement significantly more than placebo control. Serum CRP levels did not differ significantly during the study period, although serum CRP levels in the TU-100 group tended to be lower than those in the placebo group in patients with grade B liver damage. Meanwhile, the two groups had similar serum ammonia levels. TU-100-related serious adverse events did not occur during the study. TU-100 appears to improve gastrointestinal dysmotility and reduce serum CRP levels in patients with grade B liver damage after hepatectomy. TU-100 is an effective treatment option after hepatic resection in patients with liver cancer. (Keyword) Aged / Aged, 80 and over / Ammonia / Asian Continental Ancestry Group / C-Reactive Protein / Female / Gastrointestinal Diseases / Hepatectomy / Humans / Liver / Liver Neoplasms / Male / Medicine, East Asian Traditional / Middle Aged / Naphthoquinones / 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-014-0678-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24595550 ● Summary page in Scopus @ Elsevier: 2-s2.0-84894631671 (DOI: 10.1007/s10147-014-0678-2, PubMed: 24595550, Elsevier: Scopus)
98.	Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Hirohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi and Chie Takasu : Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids., Journal of Gastroenterology and Hepatology, Vol.30, No.2, 308-315, 2015. (Summary) Bariatric surgery not only elicits weight loss but also rapidly resolves diabetes. However, the mechanisms remain unclear. The present study investigates how diabetes and liver steatosis are improved after duodenal-jejunal bypass (DJB) compared with a glucagon-like peptide-1 (GLP-1) analog and correlations between bile acids and GLP-1 secretion. We initially determined the effects of bile acids on GLP-1 in vitro and then assigned 12 male 16-week-old Otsuka Long-Evans Tokushima Fatty rats to groups that underwent DJB, a sham operation, or were treated with the GLP-1 receptor agonist, liraglutide (n = 4 each). Blood glucose, insulin, GLP-1, serum bile acids, liver steatosis, and the number of GLP-1 positive cells (L cells) in the small intestine and colon were investigated in the three groups at eight weeks postoperatively. Levels of GLP-1mRNA were upregulated and GLP-1 secretion increased in cells incubated with bile acids in vitro. Weight gain was suppressed more in the DJB than in the sham group in vivo. Diabetes was more improved and GLP-1 levels were significantly higher in the DJB than in the sham group. Serum bile acids were significantly increased, the number of L cells in the ileum was upregulated compared with the sham group, and liver steatosis was significantly improved in the DJB compared with the other two groups. Duodenal-jejunal bypass might improve diabetes and liver steatosis by enhancing GLP-1 secretion through increasing serum bile acids and the proliferation of L cells in the ileum, compared with liraglutide. (Keyword) 欧文論文 (Tokushima University Institutional Repository) ● Metadata: 109345 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.12690 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25088988 ● Search Scopus @ Elsevier (PMID): 25088988 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12690 (Tokushima University Institutional Repository: 109345, DOI: 10.1111/jgh.12690, PubMed: 25088988)
99.	Noriko Kambe, Shinji Kawahito, Naoji Mita, Kazumi Takaishi, Tosiko Katayama, Yoko Sakai, Tomohiro Soga, Hiroaki Kawano, Munehide Matsuhisa, Mitsuo Shimada, Tetsuya Kitagawa and Hiroshi Kitahata : Impact of newly developed, next-generation artificial endocrine pancreas, The Journal of Medical Investigation : JMI, Vol.62, No.1-2, 41-44, 2015. (Summary) Recent studies have shown that strict perioperative blood glucose management may reduce mortality and morbidity in critically ill adult patients. The purpose of this study was to assess the accuracy and efficacy of the intraoperative application of a newly developed, next-generation artificial endocrine pancreas (STG-55, Nikkiso Co., Ltd., Tokyo, Japan). Twenty patients scheduled to undergo surgery were enrolled in this study. The STG-55 is designed to be more user-friendly than its conventional counterpart (STG-22) while maintaining the latter's fundamental functions, such as a closed-loop system using algorithms for insulin and glucose infusion. After anesthetic induction, a 20G intravenous catheter was inserted into a peripheral forearm vein and connected to a continuous blood glucose monitor. The resultant 105 scores for paired blood glucose values were compared by Bland-Altman analysis. Stable blood glucose values were maintained automatically, and there were no complications related to use of the STG-55. A close correlation (r=0.96) was observed between continuous glucose measurements using the STG-55 and conventional intermittent glucose measurements. The difficulty of manipulation using this system was decreased by improved preparation procedures. The glycemic control system using the STG-55 could provide an alternative way to achieve effective and safe perioperative glycemic control. (Keyword) artificial endocrine pancreas (Tokushima University Institutional Repository) ● Metadata: 111244 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.62.41 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25817282 ● Summary page in Scopus @ Elsevier: 2-s2.0-84925857956 (Tokushima University Institutional Repository: 111244, DOI: 10.2152/jmi.62.41, PubMed: 25817282, Elsevier: Scopus)
100.	Yusuke Arakawa and Mitsuo Shimada : 再発抑制のための抗ウイルス療法, Pharma Medica, Vol.33, No.1, 59-62, 2015. (Keyword) 和文論文
101.	Chinbold Enkhbold, Yuji Morine, Tohru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shinichiro Yamada, Daichi Ishikawa and Mitsuo Shimada : Dysfunction of liver regeneration in aged liver after partial hepatectomy., Journal of Gastroenterology and Hepatology, Vol.30, No.7, 1217-1224, 2015. (Summary) A remarkable feature of the liver is its regenerative capacity following partial hepatectomy. However, the regenerative capacity of many organs and tissues loses its natural ability to divide with aging. In this study, we investigated the association of aging with endoplasmic reticulum stress, the cell cycle, autophagy, and apoptosis-related genes during liver regeneration after hepatectomy. Balb/c 4-week and 40-week-old male mice were subjected to 70% hepatectomy. Animals were sacrificed at 24, 48, and 72 h after hepatectomy. Immunohistochemical stainings for proliferating cell nuclear antigen, LC3, Atg5, and caspase-3 were used to quantify protein expression. Real-time reverse transcription-polymerase chain reaction was used to detect p16, CHOP, LC3, Atg5, hepatocyte growth factor, cMet, cyclin D1, cyclin A2, and caspase-3 expression. After hepatectomy, old group showed a lower survival rate and significantly lower expression of hepatocyte growth factor, cMet, cyclin D1, cyclin A2, proliferating cell nuclear antigen labeling index, and SMP30 compared with young group. The liver weight/body weight ratio was significantly lower at 48 h and 72 h after hepatectomy and was accompanied by markedly elevated levels of the liver cell injury markers, LC3 and caspase-3. Immunohistochemical results showed that LC3, Atg5, and caspase-3 protein expression were higher in old group than in young group. These results revealed that impaired liver regeneration was due to aging, which was expressed by decreased cell cycle and increased autophagy and apoptosis. Therefore, understanding the molecular basis for aged liver regeneration might provide a new therapeutic option for old patients. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.12930 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25682855 ● Search Scopus @ Elsevier (PMID): 25682855 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12930 (DOI: 10.1111/jgh.12930, PubMed: 25682855)
102.	Tetsuya Ikemoto, Koji Sugimoto, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Shinichiro Yamada : Clinical role of Notch signaling pathway in intraductal papillary mucinous neoplasm of the pancreas., Journal of Gastroenterology and Hepatology, Vol.30, No.1, 217-222, 2015. (Summary) This study was performed to elucidate the expression of the Notch signaling pathway and its correlations to clinicopathological factors of intraductal papillary mucinous neoplasms (IPMNs). It is incontrovertible that regulatory T cells (Tregs) play an important role in tumor immunity. However, the whole mechanism of control of peripheral Tregs remains unclear. It is also known that the Notch signaling pathway is involved in Treg suppressor function. Moreover, IPMNs have a high malignant potential. Peripheral blood samples and resected specimens from 18 patients with IPMN were evaluated. All patients were pathologically diagnosed with IPMN. Resected specimens were immunohistochemically evaluated (anti-Notch1, anti-Notch2, and anti-Notch2-intracellular domain antibody staining) and compared in terms of clinicopathological factors. Peripheral Treg populations were analyzed with an automated flow cytometer. Disease-free survival was significantly worse in the Notch1 high-expression group (P = 0.023). Notch2 family expressions were higher in intraductal papillary mucinous carcinoma (IPMC) than in intraductal papillary mucinous adenoma (IPMA) (Notch2, P = 0.012; Notch2-intracellular domain, P = 0.036). Jagged1 expression was significantly higher in IPMC than in IPMA (P < 0.05) and was significantly related to recurrence. The Treg population in peripheral blood was higher in patients with IPMC than in those with IPMA (P < 0.01). Notch signaling, especially Jagged1 expression, reflects IPMN aggressiveness. Our data may suggest that the Notch signaling pathway is a key pathway that determines IPMN pathological aggressiveness and reflects the peripheral Treg population. (Keyword) Adenocarcinoma, Mucinous / Aged / Calcium-Binding Proteins / Carcinoma, Pancreatic Ductal / Carcinoma, Papillary / Female / Gene Expression Regulation, Neoplastic / Humans / Intercellular Signaling Peptides and Proteins / Male / Membrane Proteins / Middle Aged / Pancreatic Neoplasms / Receptor, Notch1 / Receptor, Notch2 / Signal Transduction / 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.12660 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25041344 ● Search Scopus @ Elsevier (PMID): 25041344 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12660 (DOI: 10.1111/jgh.12660, PubMed: 25041344)
103.	Satoru Imura, Mitsuo Shimada and Toru Utsunomiya : Recent advances in estimating hepatic functional reserve in patients with chronic liver damage., Hepatology Research, Vol.45, No.1, 10-19, 2015. (Summary) Preoperative estimation of liver functional reserve is important in liver surgery to prevent postoperative liver failure. Although the hepatic functional reserve of patients with chronic liver disease is generally evaluated by measuring indocyanine green dye retention at 15 min, no standard method of estimating regional liver function has been established to date. Several recently introduced imaging modalities, such as hepatobiliary scintigraphy and magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid, may be used to evaluate liver function. Here, we review recent advances in estimating hepatic functional reserve, mainly by radiological modalities, in patients with chronic liver damage. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.12325 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24606181 ● Summary page in Scopus @ Elsevier: 2-s2.0-84921064319 (DOI: 10.1111/hepr.12325, PubMed: 24606181, Elsevier: Scopus)
104.	Kohei Sugihara, Hisami Okumura, Arisa Teramoto, Eri Urano, Takafumi Katayama, Yuji Morine, Satoru Imura, Tohru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Recovery of nutritional metabolism after liver transplantation, Nutrition, Vol.31, No.1, 105-110, 2015. (Summary) Perioperative nutritional assessment is critically important to reflect nutritional management because liver transplantation (LTx) often is undertaken in patients with poor nutritional status. The aim of this study was to evaluate nutritional status, including the non-protein respiratory quotient (npRQ), resting energy expenditure (REE), nitrogen balance, and blood biochemical parameters in patients before and after LTx. Fourteen patients undergoing LTx and 10 healthy controls were enrolled in this study. The npRQ and REE were measured using indirect calorimetry before LTx and at 2, 3, and 4 wk after the procedure. Blood biochemistry and nitrogen balance calculated by 24-h urine collection were performed concurrently with indirect calorimetric measurement; the results were compared between the two groups. Before LTx, npRQ was significantly lower and serum non-esterified fatty acid levels were significantly higher in the patients than in the controls. Furthermore, a negative nitrogen balance was observed in the patients. These, however, improved significantly at 4 wk after LTx. REE did not significantly increase compared with the preoperative values in recipients. Blood biochemistry showed gradually increasing levels of serum cholinesterase and albumin. These failed to reach to normal levels by 4 wk post-transplant. The findings revealed that improvement of nutritional metabolism after LTx may require 4 wk. Additional nutritional strategies, therefore, may be needed to minimize catabolic state during the early post-transplant period. Adequate, individualized nutritional guidance before and after LTx should be performed in these patients. (Keyword) Body Mass Index / Body Weight / Calorimetry, Indirect / Case-Control Studies / Cholinesterases / energy metabolism / Fatty Acids, Nonesterified / Female / Humans / Liver Transplantation / Male / Middle Aged / Nitrogen / Nutrition Assessment / Nutritional Status / Perioperative Care / Serum Albumin (Link to Publication Site) ● Publication site (DOI): 10.1016/j.nut.2014.05.016 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25441593 ● Summary page in Scopus @ Elsevier: 2-s2.0-84922214411 (DOI: 10.1016/j.nut.2014.05.016, PubMed: 25441593, Elsevier: Scopus)
105.	Shin-ichiro Yamada, Mitsuo Shimada and Yuji Morine : 膵癌・胆道癌 ─基礎・臨床の最新研究動向─, Nihon Rinsho. Japanese Journal of Clinical Medicine, 618-621, 2015. (Keyword) 和文論文
106.	Chie Takasu, Mami Kanamoto, 松本規子, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, 江藤祥平 and Mitsuo Shimada : 外科の立場からのキャリアアップ支援, Journal of Japanese College of Surgeons, Vol.40, No.2, 170-173, 2015. (Keyword) 和文論文 (Link to Publication Site) ● Publication site (DOI): 10.4030/jjcs.40.170 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204344302080 ● Search Scopus @ Elsevier (DOI): 10.4030/jjcs.40.170 (DOI: 10.4030/jjcs.40.170, CiNii: 1390001204344302080)
107.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : New ports placement in laparoscopic central lymph nodes dissection with left colic artery preservation for sigmoid colon and rectal cancer., The Journal of Medical Investigation : JMI, Vol.62, No.3-4, 223-227, 2015. (Summary) Lymph nodes (LNs) dissection around inferior mesenteric artery (IMA) with left colic artery (LCA) preservation is difficult due to the anatomical feature of IMA. The aim of this study is to evaluate the usefulness of new ports placement inserted from a suprapubic region in laparoscopic LNs dissection around IMA with LCA preservation for sigmoid colon and ractal cancer. Twenty-two patients who underwent laparoscopic colectomy for sigmoid colon and recal cancer were included. The new ports placement group (n=15, new group) was compared with the basic ports placement group (n=7, basic group). Average number of harvested LNs, total operation time, central LNs dissection time, intraoperative blood loss were compared. There was no significant difference in the average number of harvested LNs. The mean of intraoperative blood loss of new group was significantly lower than that of the basic group (40.0±39.8 ml vs 95.7±81.0 ml, p<0.05). In addition, the mean of operation time of the new group was significantly shorter than that of the basic group (250.0±55.7 min vs 353.4±80.2 min, p<0.05). The new ports placement is useful in laparoscopic LNs dissection around IMA with LCA preservation for sigmoid colon and rectal cancer. (Keyword) 欧文論文 (Tokushima University Institutional Repository) ● Metadata: 111283 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.62.223 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26399352 ● Search Scopus @ Elsevier (PMID): 26399352 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.62.223 (Tokushima University Institutional Repository: 111283, DOI: 10.2152/jmi.62.223, PubMed: 26399352)
108.	Michihito Asanoma, Hiroki Mori, Tetsuya Ikemoto, Toru Utsunomiya, Satoru Imura, Yuji Morine, Jun Hanaoka, Mami Kanamoto, Yu Saitou, Shinichiro Yamada and Mitsuo Shimada : Clinical role of Foxp3+ regulatory T cell in Living donor related liver transplantation for prediction of life-threatening complications., The Journal of Medical Investigation : JMI, Vol.62, No.1-2, 37-40, 2015. (Summary) It is no doubt that regulatory T cells (Foxp3(+)CD4(+)CD25(+)T cells: Treg) play important roles in transplant immunity. We investigated the significance of Treg expression in acute stage of living donorrelated liver transplantation (LDLT) for the possibility of the sensitive marker for immunological state and homeostatic stress after liver transplantation. Peripheral blood was drawn from 5 recipients of LDLT preoperatively and on post operative 1, 4, 7, and 14 days. The peripheral blood mononuclear cells (PBMCs) were stained with CD4, CD25, Foxp3, and were analyzed with FACScan. This data was compared with clinical output of LDLT. The populations of Treg were significantly decreased in all patients on day 1 after LDLT and significantly increased in patients who had early postoperative complications compared with patients who had no complications. The population of Treg in peripheral blood may reflect the surgical stress such as life-threatening complications after LDLT. (Keyword) 欧文論文 (Tokushima University Institutional Repository) ● Metadata: 111243 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.62.37 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25817281 ● Summary page in Scopus @ Elsevier: 2-s2.0-84925882618 (Tokushima University Institutional Repository: 111243, DOI: 10.2152/jmi.62.37, PubMed: 25817281, Elsevier: Scopus)
109.	Kayo Hirose, Shinji Kawahito, Naoji Mita, Kazumi Takaishi, Tomiya Kawahara, Tomohiro Soga, Toshiko Katayama, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mitsuo Shimada, Munehide Matsuhisa and Hiroshi Kitahata : Usefulness of artificial endocrine pancreas during resection of insulinoma., The Journal of Medical Investigation : JMI, Vol.61, No.3-4, 421-425, 2014. (Summary) A 71-year-old woman had an episode of syncope due to hypoglycemia of 27 mg/dl. She was diagnosed with insulinoma and scheduled for laparoscopic enucleation along with the use of an artificial endocrine pancreas (STG-22, Nikkiso Co., Ltd., Tokyo, Japan). Anesthesia was maintained with sevoflurane and remifentanil. Her blood glucose level was controlled using the artificial endocrine pancreas, which enabled continuous blood glucose monitoring and computer-operated glucose and insulin infusion to maintain the blood glucose level at a steady state. The target concentration of blood glucose was set at 80-120 mg/dl during surgery. Until removal of the tumor, the blood glucose level was kept at around 80-100 mg/dl. After removal of the tumor, the blood glucose level gradually increased, but it was kept in the normal range by the artificial endocrine pancreas. The artificial endocrine pancreas was useful to monitor and maintain blood glucose levels during and after the removal of insulinoma, without any hyper- or hypoglycemia. J. Med. Invest. 61: 421-425, August, 2014. (Tokushima University Institutional Repository) ● Metadata: 109597 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.421 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25264066 ● Summary page in Scopus @ Elsevier: 2-s2.0-84907483198 (Tokushima University Institutional Repository: 109597, DOI: 10.2152/jmi.61.421, PubMed: 25264066, Elsevier: Scopus)
110.	Chengzhan Zhu, Tohru Utsunomiya, Tetsuya Ikemoto, Shinichiro Yamada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Chie Takasu, Daichi Ishikawa, Issei Imoto and Mitsuo Shimada : Hypomethylation of Long Interspersed Nuclear Element-1 (LINE-1) is Associated with Poor Prognosis via Activation of c-MET in Hepatocellular Carcinoma., Annals of Surgical Oncology, Vol.21, No.4, 729-735, 2014. (Summary) LINE-1 hypomethylation is significantly associated with poor prognosis in patients with HCC, possibly due to activation of c-MET expression. (Tokushima University Institutional Repository) ● Metadata: 109505 (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-014-3874-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24992910 ● Summary page in Scopus @ Elsevier: 2-s2.0-84940245895 (Tokushima University Institutional Repository: 109505, DOI: 10.1245/s10434-014-3874-4, PubMed: 24992910, Elsevier: Scopus)
111.	KKohei Sugihara, Hisami Okumura, Arisa Teramoto, Eri Urano, Takafumi Katayama, Hiroki Mori, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Recovery pattern of non-protein respiratory quotient and non-esterified fatty acid after liver resection, Nutrition, Vol.30, No.4, 443-448, 2014. (Summary) Perioperative nutritional care is important to maintain preoperative and postoperative nutritional status. However, few reports have investigated energy metabolism after hepatectomy. The aim of this study was to determine differences in energy metabolism, blood biochemistry, and nutritional status before and after liver resection in patients with hepatocellular carcinoma (HCC) and healthy living donors for liver transplantation. Eighteen hospitalized patients with HCC group and 13 living donors for liver transplantation (donor group) were enrolled in this study. The donor group was divided into two groups on the basis of age; Y-donor group (age < 40 y, n = 7), and O-donor group (age ≥ 40 y, n = 6). Energy metabolism was measured by indirect calorimetry at preoperative day and postoperative day (POD) 7 and 14, and blood biochemistry was also examined. Recovery of non-protein respiratory quotient (npRQ) and blood biochemical data such as total bilirubin, aspartate aminotransferase and alanine aminotransferase levels were observed in Y-donor group on POD 14. However, although biochemical data improved in the HCC and O-donor group, npRQ remained unchanged on POD 14. Improvement of npRQ took longer than blood biochemical data in patients with HCC and older donors. Because the recovery of npRQ is associated with donor age, careful nutritional management may be required for a longer time depending on the pathophysiological condition of each patient after hepatectomy. (Keyword) Adult / Age Factors / Aged / Alanine Transaminase / Aspartate Aminotransferases / Bilirubin / Calorimetry, Indirect / Carcinoma, Hepatocellular / energy metabolism / Fatty Acids, Nonesterified / Female / Hepatectomy / Hospitalization / Humans / Liver / Liver Neoplasms / Liver Transplantation / Living Donors / Male / Middle Aged / Nutritional Status / Postoperative Care / Postoperative Period / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1016/j.nut.2013.09.012 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24332605 ● Summary page in Scopus @ Elsevier: 2-s2.0-84895475137 (DOI: 10.1016/j.nut.2013.09.012, PubMed: 24332605, Elsevier: Scopus)
112.	Ahmed Zaied Bhuyan, Michihito Asanoma, Akiko Iwata, Chieko Ishifune, Yoichi Maekawa, Mitsuo Shimada and Koji Yasutomo : Abrogation of Rbpj attenuates experimental autoimmune uveoretinitis by inhibiting IL-22-producing CD4+ T cells., PLoS ONE, Vol.9, No.2, e89266, 2014. (Summary) Experimental autoimmune uveoretinitis (EAU) is an organ-specific T cell-mediated disease induced by immunizing mice with interphotoreceptor retinoid binding protein (IRBP). Autoaggressive CD4(+) T cells are the major pathogenic population for EAU. We investigated the contribution of Notch signaling in T cells to EAU pathogenesis because Notch signaling regulates various aspects of CD4(+) T cell functions. Rbpj is required for Notch signaling, and Rbpj deficiency in T cells inhibited EAU disease severity. The amelioration of EAU in T cell-specific Rbpj-deficient mice correlated with low levels of IL-22 production from CD4(+) T cells, although IRBP-specific CD4(+) T cell proliferation and Th17 differentiation were unaffected. Administration of recombinant IL-22 during the late phase, but not the early phase, of EAU increased EAU clinical scores in T cell-specific Rbpj-deficient mice. Notch inhibition in mice immunized with IRBP with a -secretase inhibitor (GSI) suppressed EAU progression, even when GSI was administered as late as 13 days after IRBP immunization. Our data demonstrate that Rbpj/Notch-mediated IL-22 production in T cells has a key pathological role in the late phase of EAU, and suggest that Notch blockade might be a useful therapeutic approach for treating EAU. (Tokushima University Institutional Repository) ● Metadata: 106133 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0089266 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24586644 ● Search Scopus @ Elsevier (PMID): 24586644 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0089266 (Tokushima University Institutional Repository: 106133, DOI: 10.1371/journal.pone.0089266, PubMed: 24586644)
113.	A Teramoto, Hisami Okumura, E Urano, T Nakamura-Kutsuzawa, K Sugihara, Takafumi Katayama, Hidenori Miyake, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Comparison of measured and predicted energy expenditure in patients with liver cirrhosis, Asia Pacific Journal of Clinical Nutrition, Vol.23, No.2, 197-204, 2014. (Summary) Obesity is a risk factor for the onset of liver cancer in patients with cirrhosis. To prevent overfeeding and obesity, estimation of energy requirement is important, but energy expenditure in patients with liver cirrhosis has not been fully elucidated. This study aimed to investigate resting energy expenditure (REE) and energy intake in patients with cirrhosis and determine adequate energy intake criteria. In this cross-sectional study, indirect calorimetry measurement was conducted in 488 Japanese inpatients with cirrhosis. We compared REE measured by indirect calorimetry (M-REE) with basal energy expenditure (BEE) predicted by the Harris-Benedict equation (H-BEE) and Dietary Reference Intakes (DRI) for Japanese (D-BEE). Mean M-REE (1256 kcal) was significantly lower than H-BEE (1279 kcal); however, it was not significantly different from D-BEE (1254 kcal). Mean M-REE expressed in relation to body weight (BW; REE/kg BW) was 21.7 kcal/kg BW. H-BEE was significantly higher than M-REE in patients in the first and second quartiles of BMI, and D-BEE was significantly different from MREE in patients in the highest and lowest quartiles of BMI. Average energy intake was 30.5 kcal/kg BW, which was 1.4 times greater than REE/kg BW. Although DRI is a useful tool for the estimation of REE in patients in the second and third quartiles of BMI, M-REE is recommended to ensure the provision of adequate nutritional care to patients with cirrhosis, including those in the highest and lowest quartiles of BMI. (Keyword) Basal Metabolism / Body Mass Index / Calorimetry, Indirect / Cross-Sectional Studies / Energy Metabolism / Female / Humans / Japan / Liver Cirrhosis / Male / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.6133/apjcn.2014.23.2.12 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24901087 ● Summary page in Scopus @ Elsevier: 2-s2.0-84905192746 (DOI: 10.6133/apjcn.2014.23.2.12, PubMed: 24901087, Elsevier: Scopus)
114.	Ahmed Shawky Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Satake Mitsuo, Moriyama Noriyuki, Toru Utsunomiya and Mitsuo Shimada : Blood vessel-based liver segmentation using the portal phase of an abdominal CT dataset, Medical Physics, Vol.40, No.11, 113501(17pp.), 2013. (Summary) Blood vessel (BV) information can be used to guide body organ segmentation on computed tomography (CT) imaging. The proposed method uses abdominal BVs (ABVs) to segment the liver through the portal phase of an abdominal CT dataset. This method aims to address the wide variability in liver shape and size, separate liver from other organs of similar intensity, and segment hepatic low-intensity tumors (LITs). Thin ABVs are enhanced using three-dimensional (3D) opening. ABVs are extracted and classified into hepatic BVs (HBVs) and nonhepatic BVs (non-HBVs) with a small number of interactions, and HBVs and non-HBVs are used for constraining automatic liver segmentation. HBVs are used to individually segment the core region of the liver. To separate the liver from other organs, this core region and non-HBVs are used to construct an initial 3D boundary surface. To segment LITs, the core region is classified into non-LIT- and LIT-parts by fitting the histogram of the core region using a variational Bayesian Gaussian mixture model. Each part of the core region is extended based on its corresponding component of the mixture, and extension is completed when it reaches a variation in intensity or the constructed boundary surface, which is reconfirmed to fit robustly between the liver and neighboring organs of similar intensity. A solid-angle technique is used to refine main BVs at the entrances to the inferior vena cava and the portal vein. The proposed method was applied to 80 datasets: 30 Medical Image Computing and Computer Assisted Intervention (MICCAI) and 50 non-MICCAI; 30 datasets of non-MICCAI data include tumors. Our results for MICCAI-test data were evaluated by sliver07 (http://www.sliver07.org/) organizers with an overall score of 85.7, which ranks best on the site as of July 2013. These results (average ± standard deviation) include the five error measures of the 2007 MICCAI workshop for liver segmentation as follows. Results for volume overlap error, relative volume difference, average symmetric surface distance, root mean square symmetric surface distance, and maximum symmetric surface distance were 4.33 ± 0.73, 0.28 ± 0.87, 0.63 ± 0.16, 1.19 ± 0.28, and 14.01 ± 2.88, respectively; and when applying our method to non-MICCAI data, results were 3.21 ± 0.75, 0.06 ± 1.29, 0.45 ± 0.17, 0.98 ± 0.26, and 12.69 ± 3.89, respectively. These results demonstrate high performance of the method when applied to different CT datasets. BVs can be used to address the wide variability in liver shape and size, as BVs provide unique details for the structure of each studied liver. Constructing a boundary surface using HBVs and non-HBVs can separate liver from its neighboring organs of similar intensity. By fitting the histogram of the core region using a variational Bayesian Gaussian mixture model, LITs are segmented and measuring the volumetry of non-LIT- and LIT-parts becomes possible. Further examination of the proposed method on a large number of datasets is required for clinical applications, and development of the method for full automation may be possible and useful in the clinic. (Link to Publication Site) ● Publication site (DOI): 10.1118/1.4823765 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24320472 ● Search Scopus @ Elsevier (PMID): 24320472 ● Search Scopus @ Elsevier (DOI): 10.1118/1.4823765 (DOI: 10.1118/1.4823765, PubMed: 24320472)
115.	Yu Saitou, Hiroki Mori, Chie Takasu, Masato Komatsu, Jun Hanaoka, Shin-ichiro Yamada, 淺野間理仁, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : Beneficial effects of green tea catechin on massive hepatectomy model in rats., Journal of Gastroenterology, 2013. (Summary) BACKGROUND: Green tea catechin, especially epigallocatechin gallate (EGCG), is a well-known scavenger of reactive oxygen species and it may also function as an antioxidant through modulation of transcriptional factors and enzyme activities. METHODS: Green tea extract (GTE(®)) which contained numerous EGCG was used. Wistar rats were performed 90 % hepatectomy and classified into 2 groups with (GTEHx, n = 25) or without GTE treatment (Hx, n = 25) and sacrificed at 1, 3, 7 and 14 days after operations. All rats had free access to drinking water supplemented with or without GTE from the 7th pre-operative day. Liver regeneration, hepatic inducible nitric oxide synthase (iNOS), anti-oxidative enzymes [superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px)] and inflammatory markers [cyclooxygenase-2 (COX-2), nuclear factor kappa B (NFκB), tumor necrosis factor-α (TNF-α)] were investigated. RESULTS: The liver weight to body weight ratio (p < 0.01), proliferating cell nuclear antigen labeling index (p < 0.05) and phosphorylated extracellular signal-regulated kinase 1/2 (p < 0.05) at day 1 in the GTEHx group significantly increased compared to the Hx group. Hepatic iNOS levels at day 1 significantly decreased (p < 0.01) in the GTEHx group. Hepatic SOD, CAT and GSH-Px levels at day 1 significantly increased (SOD: p < 0.01, CAT and GSH-Px: p < 0.05) in the GTEHx group. In contrast, COX-2, NFκB and TNF-α levels at day 1 significantly decreased (COX-2: p < 0.01, NFκB and TNF-α: p < 0.05) in the GTEHx group. CONCLUSIONS: GTE pretreatment stimulated liver regeneration and improved liver damage after massive hepatectomy through anti-oxidative and anti-inflammatory effects. Green tea catechin might have the potential to attenuate liver dysfunction in early stage after massive hepatectomy. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-013-0799-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23543313 ● Summary page in Scopus @ Elsevier: 2-s2.0-84899985774 (DOI: 10.1007/s00535-013-0799-9, PubMed: 23543313, Elsevier: Scopus)
116.	Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, Yasuo Miyoshi, Toshihito Tanahashi, Kazuhito Rokutan, Rui Yamaguchi, Ayumu Saito, Seiya Imoto, Satoru Miyano, Yusuke Nakamura, Mitsunori Sasa, Mitsuo Shimada and Toyomasa Katagiri : Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis., International Journal of Oncology, Vol.42, No.2, 478-506, 2013. (Summary) Triple negative breast cancer (TNBC) has a poor outcome due to the lack of beneficial therapeutic targets. To clarify the molecular mechanisms involved in the carcinogenesis of TNBC and to identify target molecules for novel anticancer drugs, we analyzed the gene expression profiles of 30 TNBCs as well as 13 normal epithelial ductal cells that were purified by laser-microbeam microdissection. We identified 301 and 321 transcripts that were significantly upregulated and downregulated in TNBC, respectively. In particular, gene expression profile analyses of normal human vital organs allowed us to identify 104 cancer-specific genes, including those involved in breast carcinogenesis such as NEK2, PBK and MELK. Moreover, gene annotation enrichment analysis revealed prominent gene subsets involved in the cell cycle, especially mitosis. Therefore, we focused on cell cycle regulators, asp (abnormal spindle) homolog, microcephaly-associated (Drosophila) (ASPM) and centromere protein K (CENPK) as novel therapeutic targets for TNBC. Small-interfering RNA-mediated knockdown of their expression significantly attenuated TNBC cell viability due to G1 and G2/M cell cycle arrest. Our data will provide a better understanding of the carcinogenesis of TNBC and could contribute to the development of molecular targets as a treatment for TNBC patients. (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2012.1744 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23254957 ● Search Scopus @ Elsevier (PMID): 23254957 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2012.1744 (DOI: 10.3892/ijo.2012.1744, PubMed: 23254957)
117.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Koji Sugimoto, Yu Saitou, Shinichiro Yamada and Michihito Asanoma : Beneficial effects of enteral nutrition containing with hydrolyzed whey peptide on warm ischemia/reperfusion injury in the rat liver., Hepatology Research, Vol.44, No.1, 114-121, 2013. (Summary) This study examined the efficacy of enteral nutrition containing hydrolyzed whey peptide (HWP) on warm ischemia/reperfusion (I/R) injury in the rat liver. Male Wistar rats were subjected to 30 min of warm hepatic ischemia followed by immediate p.o. intake of enteral nutrition with WHP (HWP group) or 20% glucose solution (control group) (0.025 mL/g). The animals were killed at 6 or 12 h after reperfusion. The serum aspartate aminotransferase (AST) and alanine aminotransferase alt (ALT) levels were measured. The necrotic areas were assessed histologically. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and caspase-3 activation were assessed to evaluate apoptosis. The expressions of hepatic tumor necrosis factor (TNF)-α, interleukin (IL)-6 and nuclear factor (NF)-κB in the liver tissue were assessed by real time reverse transcription polymerase chain reaction. Significant reductions in the serum AST and ALT levels were seen in the HWP group compared with the control group at both 6 and 12 h after reperfusion. The necrotic areas and numbers of TUNEL positive cells were significantly decreased in the HWP group at 6 and 12 h after reperfusion. The caspase-3/7 activities were significantly decreased in HWP group at 6 and 12 h after reperfusion. The mRNA expressions of TNF-α and IL-6 were significantly reduced in the HWP group at 12 h after reperfusion. NF-κB mRNA expression was significantly increased in the HWP group at 6 and 12 h after reperfusion. Enteral nutrition containing HWP ameliorated the hepatic warm I/R injury possibly through the suppression of pro-inflammatory cytokine expressions and the induction of NF-κB in the rat liver. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.12097 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23578099 ● Summary page in Scopus @ Elsevier: 2-s2.0-84891758377 (DOI: 10.1111/hepr.12097, PubMed: 23578099, Elsevier: Scopus)
118.	Tsuyoshi Okada, Shinji Kawahito, Naoji Mita, Munehide Matsuhisa, Hiroshi Kitahata, Mitsuo Shimada and Shuzo Oshita : Usefulness of continuous blood glucose monitoring and control for patients undergoing liver transplantation., The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 205-212, 2013. (Summary) The STG-22 closed-loop system is effective for maintaining strict blood glucose control during liver transplantation with minimal variability in blood glucose concentration. (Tokushima University Institutional Repository) ● Metadata: 106358 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.205 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190037 ● Summary page in Scopus @ Elsevier: 2-s2.0-84887004443 (Tokushima University Institutional Repository: 106358, DOI: 10.2152/jmi.60.205, PubMed: 24190037, Elsevier: Scopus)
119.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, Mami Kanamoto and Shuichi Iwahashi : 手術手技前区域枝門脈灌流領域が上右肝静脈を包含する症例に対する，下右肝静脈温存，上右肝静脈とドレナージ領域を含む, Operation, Vol.66, No.(12), 1741-1745, 2012. (Keyword) 拡大前区域切除 / 術後肝うっ血 / 上区域切除 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388080475074432 (CiNii: 1523388080475074432)
120.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 淺野間理仁 : 肝切除支援ソフトによる術前シミュレーション，術中ナビゲーション，部分肝臓機能解析, JJSCAS, Vol.14, No.(3), 148-149, 2012.
121.	Satoru Imura, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hidenori Miyake and Mitsuo Shimada : [達人こだわりの手術テクニック] II. 肝胆膵領域 3. 肝癌に対する区域切除, Operation, Vol.66, No.(10), 1399-1405, 2012. (Keyword) Glisson一括処理 / 肝ハンギング / エネルギーデバイス (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521417755569899520 (CiNii: 1521417755569899520)
122.	Kotaro Miyake, Masanori Nishioka, Satoru Imura, Erdenebulgan Batmunkh, Yoshihiro Uto, Hideko Nagasawa, Hitoshi Hori and Mitsuo Shimada : The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1 targeted gene expression, Experimental Cell Research, Vol.318, No.13, 1554-1563, 2012. (Summary) Tumor hypoxia has been considered to be a potential therapeutic target, because hypoxia is a common feature of solid tumors and is associated with their malignant phenotype. In the present study, we investigated the antitumor effect of a novel hypoxic cytotoxin, 3-[2-hydroxyethyl(methyl)amino]-2-quinoxalinecarbonitrile 1,4-dioxide (TX-2098) in inhibiting the expression of hypoxia inducible factor-1α (HIF-1α), and consequently vascular endothelial cell growth factor (VEGF) expression in pancreatic cancer. The antitumor effects of TX-2098 under hypoxia were tested against various human pancreatic cancer cell lines using WST-8 assay. VEGF protein induced pancreatic cancer was determined on cell-free supernatant by ELISA. Moreover, nude mice bearing subcutaneously (s.c.) or orthotopically implanted human SUIT-2 were treated with TX-2098. Tumor volume, survival and expression of HIF-1 and associated molecules were evaluated in treatment versus control groups. In vitro, TX-2098 inhibited the proliferation of various pancreatic cancer cell lines. In s.c model, tumors from nude mice injected with pancreatic cancer cells and treated with TX-2098 showed significant reductions in volume (P<0.01 versus control). Quantitative real-time reverse transcription-PCR analysis revealed that TX-2098 significantly inhibited mRNA expression of the HIF-1 associated molecules, VEGF, glucose transporter 1 and Aldolase A (P<0.01 versus control). These treatments also prolong the survival in orthotopic models. These results suggest that the effect of TX-2098 in pancreatic cancer might be correlated with the expression of VEGF and HIF-1 targeted molecules. (Keyword) TX-2098 / Bioreductive agent / Hypoxic cytotoxin / Pancreatic cancer / Hypoxia inducible factor-1 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.yexcr.2012.03.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22472348 ● Search Scopus @ Elsevier (PMID): 22472348 ● Search Scopus @ Elsevier (DOI): 10.1016/j.yexcr.2012.03.013 (DOI: 10.1016/j.yexcr.2012.03.013, PubMed: 22472348)
123.	矢田圭吾, Mitsuo Shimada, Hiroki Ishibashi, Horohiko Sato, Hiroki Mori and 淺野間理仁 : 縦隔腫瘍と鑑別を要した左肺葉外肺分画症の1例, Journal of the Japanese Society of Pediatric Surgeons, Vol.48, No.3, 592, 2012. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204831280128 (CiNii: 1390001204831280128)
124.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾, 淺野間理仁, Horohiko Sato and Mitsuo Shimada : 腹腔鏡補助下肝部分切除術を施行した肝芽腫の1例, Journal of the Japanese Society of Pediatric Surgeons, Vol.48, No.3, 450, 2012. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204831901184 (CiNii: 1390001204831901184)
125.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura and Tetsuya Ikemoto : 「内視鏡外科医のための微細局所解剖アトラス」肝胆膵肝外側区域切除-脈管処理のコツ, 手術.2012, Vol.66, No.(6), 753-759, 2012.
126.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 【必読イレウスの診断から治療まで】機械的イレウス複雑性または絞扼性イレウスヘルニア嵌頓, Surgery, Vol.74, No.3, 273-278, 2012.
127.	Hisami Okumura, Akihiko Kawaura, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Treatment of rapid weight loss in a donor with hepatic steatosis in a living donor liver transplantation: a case report, Hepato-Gastroenterology, Vol.59, No.115, 869-871, 2012. (Summary) The use of steatotic livers for transplantation is often associated with increased primary non-function. To reduce the risk of liver injury, steatosis of the donor liver in living donor liver transplantation (LDLT) was treated with restricted diet and exercise. A 21-year-old male donor, 167cm in height and 87kg in body weight, initially received a 1800kcal/day diet for 9 days which was then gradually reduced using a 1600kcal/day diet for 43 days, followed by a 1500kcal/day diet for one day and was finally maintained on a 1400kcal/day diet for 52 days. Daily exercise consumed 500kcal/day. The non-protein respiratory quotient (npRQ) gradually increased while the non-esterified fatty acids (NEFA) decreased during the course of the 105-day treatment. Consequently, the initial 80% steatosis was reduced to 10% and was accompanied by 13% weight loss for 81 days. The npRQ values and NEFA concentrations in the later period of dietary and exercise treatment were higher and lower, respectively, than in the early treatment period, indicating compensation through long-term treatment. Therefore, energy metabolism and NEFA levels represent important biomarkers for short-term intensive treatment by restricted diet and exercise in donors with hepatic steatosis. (Keyword) Biological Markers / Caloric Restriction / Donor Selection / energy metabolism / Exercise / Fatty Acids, Nonesterified / Fatty Liver / Hepatectomy / Humans / Liver Transplantation / Living Donors / Male / Severity of Illness Index / Time Factors / Treatment Outcome / Weight Loss / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.5754/hge10237 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22469734 ● Search Scopus @ Elsevier (PMID): 22469734 ● Search Scopus @ Elsevier (DOI): 10.5754/hge10237 (DOI: 10.5754/hge10237, PubMed: 22469734)
128.	Horohiko Sato, Mitsuo Shimada, 小笠原卓, 大塚敏弘, Tsutomu Ando and 長堀順二 : A case of small intestinal mesenteric liposarcoma, Shikoku Acta Medica, Vol.68, No.1-2, 41-44, 2012. (Summary) We report a case of small intestinal mesenteric liposarcoma. An 84-year-old woman wasadmitted to our hospital with a chief complaint of abdominal distension and pointing out a tumor inher abdomen. On physical examination an adult's head-sized tumor was palpated from the leftupper portion of the pelvis. Abdominal computed tomography(CT)revealed the mass24×18×13cm in size which had clear borderline and smooth surface. Multi-detector-CT scan revealed aheterogeneously enhanced mass fed by the Superior mesenteric artery. With a clinical diagnosisof liposarcoma arisen from the small intestinal mesentery, the patient was operated on. The tumorwas present in the mesentery of the small intestine and a removal of the tumor with associatedresection of the small intestine was perfomed. The histological diagnosis was well-differentiatedliposarcoma. The patient has been followed for nine months after the operation without evidenceof local recurrence. (Keyword) mesenteric liposarcoma / well-differentiated liposarcoma / small intestine (Tokushima University Institutional Repository) ● Metadata: 97916 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050865122808043904 (Tokushima University Institutional Repository: 97916, CiNii: 1050865122808043904)
129.	Hiroki Ishibashi, Horohiko Sato, Hiroki Mori and Mitsuo Shimada : 血流障害，遊走脾を伴った急性胃軸捻転症の1例, Journal of the Japanese Society of Pediatric Surgeons, Vol.48, No.2, 274, 2012. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282679808212992 (CiNii: 1390282679808212992)
130.	Toru Utsunomiya, Mitsuo Shimada, Jun Hanaoka, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Masafumi Harada : Possible utility of MRI using Gd-EOB-DTPA for estimating liver functional reserve, Journal of Gastroenterology, Vol.47, No.4, 470-476, 2012. (Summary) Preoperative estimation of the liver functional reserve is important in liver surgery. We evaluated the role of dynamic magnetic resonance (MR) imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), i.e., EOB-MRI, for determining liver functional reserve. Fifty patients who underwent EOB-MRI to examine their liver tumors were included in this study. We first performed a pixel-by-pixel comparison of registered MR images and activity images with Tc-99m galactosyl human serum albumin (GSA) on each slice, and the correlation coefficient was calculated for 8 patients. We also determined the correlation coefficient between the relative signal intensity (SI) values of EOB-MRI and preoperative liver function, such as the GSA, indocyanine green dye retention at 15 min (ICGR15), and prothrombin time. The mean of the correlation coefficients for 512 × 512 matrices between the EOB-MRI and the GSA was 0.83 ± 0.05 (ranging from 0.73 to 0.87). The correlation coefficient between the relative SI of the EOB-MRI and the receptor index (LHL15) of GSA was 0.56 (P < 0.01). Better correlation coefficients were observed between the relative SI and the liver function test, including ICGR15 (r = -0.67, P < 0.01) and prothrombin time (r = 0.59, P < 0.01). In a patient with hilar cholangiocarcinoma whose right hepatic duct was obstructed, the relative SI in the right lobe (2.4 ± 0.3) was significantly lower than that in the left lobe (3.1 ± 0.1). EOB-MRI represents a practical and reliable imaging technique that may be used to estimate regional liver functional reserve in the clinical setting. (Keyword) Adult / Aged / Aged, 80 and over / Contrast Media / Female / Gadolinium DTPA / Humans / Liver / Liver Function Tests / magnetic resonance imaging / Male / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-011-0513-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22170416 ● Summary page in Scopus @ Elsevier: 2-s2.0-84863084638 (DOI: 10.1007/s00535-011-0513-8, PubMed: 22170416, Elsevier: Scopus)
131.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 癌治療に求められる漢方の意義臨床現場にどのように活かすか"牛車腎気丸"によるFOLFOX関連末梢神経障害の軽減, 産婦人科漢方研究のあゆみ, Vol.29, 22-27, 2012.
132.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine and Hidenori Miyake : [達人が教える肝胆膵高度技能専門医手術-コツとピットフォール] 肝葉切除(右肝・左肝切除)非手割法, Operation, Vol.66, No.(3), 287-293, 2012. (Keyword) Hanging maneuver / Hepatic vascular exclusion / anchor suture (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520854803472703488 (CiNii: 1520854803472703488)
133.	Tetsuya Ikemoto and Mitsuo Shimada : II-4 抗癌剤「肝胆膵」, 消化器外科レビュー, Vol.2012, 216-221, 2012.
134.	Chie Takasu, Mitsuo Shimada, Kouzou Yoshikawa, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani and 柏原秀也 : Bevacizumab併用化学療法中に大腸穿孔・穿通をきたした症例の検討, 日本腹部救急医学会雑誌, Vol.32, No.2, 424, 2012.
135.	Shuichi Iwahashi, Yoichi Maekawa, Jun Nishida, Chieko Ishifune, Akiko Kitamura, Hideki Arimochi, Keiko Kataoka, Shigeru Chiba, Mitsuo Shimada and Koji Yasutomo : Notch2 regulates the development of marginal zone B cells through Fos., Biochemical and Biophysical Research Communications, Vol.418, No.4, 701-707, 2012. (Summary) B cells are classified into several subsets depending on their functions, marker expression pattern and localization. Marginal zone B (MZB) cells are a distinct lineage from follicular B cells, and regulate host defenses against blood-borne pathogens. Notch2/RBP-J signaling regulates the development of MZB cells by interacting with delta-like 1 ligand, although the target genes for Notch2 signaling remain unclear. We identified Fos as an upregulated gene in LPS-stimulated B cells that received Notch2 signaling. Fos is expressed in CD21(high)CD23(low) MZB cells at a higher level compared to CD21(Int)CD23(high) follicular B cells. Deleting the Notch2 gene in CD19(+) B cells decreased Fos expression in B cells. Overexpression of Fos in Notch2-deficient B cells or bone marrow cells partially restored MZB development. Fos promoter activity was upregulated by Notch2 signaling, indicating that Notch2 directly controls Fos transcription associated with MZB development. These data identify Fos as one of the target genes for Notch2 signaling that is crucial for MZB development. (Keyword) Animals / B-Lymphocytes / Gene Expression Regulation, Developmental / Genes, Reporter / Luciferases / Mice / Mice, Inbred C57BL / Oncogene Proteins v-fos / Promoter Regions, Genetic / Receptor, Notch2 / Spleen / Transcription, Genetic (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrc.2012.01.082 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22293205 ● Summary page in Scopus @ Elsevier: 2-s2.0-84857441564 (DOI: 10.1016/j.bbrc.2012.01.082, PubMed: 22293205, Elsevier: Scopus)
136.	Yuji Morine and Mitsuo Shimada : Hepatic and pancreatic regenerative medicine using Adipose tissue-derived mesenchymal stem cell, Journal of Clinical and Experimental Medicine, Vol.42, No.(4), 303-308, 2012. (Keyword) 肝・膵再生医療 / 間葉系幹細胞(MSC) / 脂肪 / 肝細胞 / 膵β細胞 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521136279934467840 (CiNii: 1521136279934467840)
137.	Hidenori Miyamoto, 淺野間理仁, 宮本英之 and Mitsuo Shimada : ALTA療法の効果判定としての経肛門超音波パワードップラー法の可能性, 臨床肛門病学 2012, Vol.4, No.(1), 23-26, 2012.
138.	Hiroki Ishibashi, Tomomi Kuwahara, H Nakayama-Imaohji, Y Ohnishi, Hiroki Mori and Mitsuo Shimada : Effects of indole-3-carbinol and phenethyl isothiocyanate on bile and pancreatic juice excretion in rats., The Journal of Medical Investigation : JMI, Vol.59, No.3-4, 246-252, 2012. (Summary) Bile and pancreatic juice contain a number of parameters for cancer chemoprevention. Indole-3-carbinol (I3C) and phenethyl isothiocyanate (PEITC), which are hydrolytic products of brassica plants, have been established to be anti-cancer agents. Here, we developed a method for the continuous and selective sampling of bile and pancreatic juice, and the effects of I3C and PEITC on bile and pancreatic excretion and γ-glutamyl transpeptidase (γ-GTP) activity in the samples were investigated. Male Fisher 344 rats (eight weeks of age) were challenged intragastrically with I3C (150 mg/kg) or PEITC (160 mg/kg) for five days. Twenty-four hours after the final administration, cannulation was undertaken into the rats' bile and pancreatic ducts, and the bile and pancreatic juice were separately collected for 48 h. In this rat model, bile was stably excreted, and the bile and pancreatic excretion of the control rats was 21.9 ± 1.4 ml/48 h and 12.8 ± 1.7 ml/48 h, respectively. Bile excretion for the first 24 h significantly increased in the I3C- or PEITC-treated rats compared with the control rats. In the case of pancreatic juice, excretion during the first 24 h significantly increased in the PEITC-treated rats. In bile, γ-GTP activity was significantly increased for the first 24 h in the I3C- and PEITC-treated rats, but no difference was observed in the pancreatic juice. Increases of bile excretion and γ-GTP activity in bile might be a factor involved in the anti-cancer effect of I3C and PEITC. Our rat model described here is a useful tool for the study of cancer chemoprevention. (Keyword) 欧文論文 (Tokushima University Institutional Repository) ● Metadata: 106028 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.59.246 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23037195 ● Search Scopus @ Elsevier (PMID): 23037195 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.59.246 (Tokushima University Institutional Repository: 106028, DOI: 10.2152/jmi.59.246, PubMed: 23037195)
139.	Hiroki Ishibashi, Takehito Oshio, Tomoko Sogami, Akira Nii, Hiroki Mori and Mitsuo Shimada : Torsion of an accessory spleen with situs inversus in a child., The Journal of Medical Investigation : JMI, Vol.59, No.1-2, 220-223, 2012. (Summary) We present an unusual case of acute abdomen caused by torsion of an accessory spleen with situs inversus in a child. A three-year-old girl was admitted to our hospital with an 11-day history of right flank pain with fever. Her medical history revealed an operation of coarctation of the aorta with situs inversus at one month of age. Physical examination revealed a right flank mass and tenderness. A contrast-enhanced CT scan showed a normally enhanced small spleen in the right upper quadrant and a 7.0×6.0×3.5 cm, hypodense, marginal enhancing mass in the right midabdomen adjacent to the intestine. An emergency laparotomy was decided upon with a preoperative diagnosis as an acute abdomen. During surgery, a mass was found under the greater omentum and two accessory spleens of 1.5 cm in diameter were found surrounding the main spleen. Several loops of bowel were adherent to the mass. The loops of bowel were dissected away. A pediculated congested mass was observed as an accessory spleen emerging from the greater omentum. The mass was twisted on its vascular pedicle and strangulated. The necrotic mass was removed and the postoperative recovery was uneventful. Though torsion of an accessory spleen is extremely rare, it should be considered in the differential diagnosis of acute abdomen in childhood. (Keyword) Abdomen, Acute / Child, Preschool / Female / Humans / Laparotomy / Situs Inversus / Spleen / Splenectomy / Torsion Abnormality (Tokushima University Institutional Repository) ● Metadata: 106024 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.59.220 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22450011 ● Search Scopus @ Elsevier (PMID): 22450011 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.59.220 (Tokushima University Institutional Repository: 106024, DOI: 10.2152/jmi.59.220, PubMed: 22450011)
140.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : Evaluation of the usefulness of Roux-en-Y reconstruction with jejunal pouch by radioisotope scintigraphy and 13C breath test, Japanese Journal of Cancer Clinics, Vol.56, No.5, 377-382, 2011. (Keyword) Total gastrectomy / Roux-en-Y reconstruction / Jejunal pouch / Radioscintigraphy (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388080215860608 (CiNii: 1523388080215860608)
141.	Hisami Okumura, 浦野恵利, 板東友美, 山内利香, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Nutritional Assessment of Pre- and Post- Liver Resection by Energy Metabolism and Laboratory Data, Journal of Japanese Society of Clinical Nutrition, Vol.32, No.3, 133-140, 2011. (Keyword) liver resection / indirect calorimetry / non-protein respiratory quotient (npRQ) / non-esterified fatty acids (NEFA) / 遊離脂肪酸 / NEFA / liver resection / indirect calorimetry / non-protein respiratory quotient / non-esterified fatty acids (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853832562768896 (CiNii: 1520853832562768896)
142.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Hidenori Miyake : 【内視鏡外科手術をめぐる最近のトピックス】新たな領域への手術適応保険収載後の腹腔鏡下肝切除術の展開, Gastroenterological Surgery, Vol.34, No.1, 69-77, 2011. (Keyword) 質問紙法; 医療保険; 肝細胞癌(外科的療法); 肝切除(有害作用); 空気塞栓症(病因); 術後合併症; 胆管癌(外科的療法); 胆管腫瘍(外科的療法); 腹腔鏡法(有害作用); 失血-外科; 近代医学史 / ヒト / 和文論文
143.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine and Tetsuya Ikemoto : 薬物治療学の進歩-この30年-，IX. 肝移植 1)ネオーラル(ノバルティス), KAN TAN SUI, Vol.61, No.6, 1170-1176, 2010. (Keyword) 和文論文
144.	Toru Utsunomiya, Mitsuo Shimada, Yuji Morine, Satoru Imura, Hidenori Miyake and Nobuhiro Kurita : 術後障害に対する漢方治療., Surgical Therapy, Vol.103, No.3, 576-583, 2010. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523951029955509888 (CiNii: 1523951029955509888)
145.	Kotaro Miyake, Satoru Imura, Masanori Nishioka, Erdenebulgan Batmunkh, Koji Sugimoto, Yasukazu Ohmoto and Mitsuo Shimada : Serum evaluation of soluble interferon-alpha/beta receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer., Cytokine, Vol.49, No.3, 251-255, 2010. (Summary) Serum soluble interferon-alpha/beta receptor (sIFN-alpha/betaR) and high-sensitivity C-reactive protein (hs-CRP) levels were evaluated in the patients with gastrointestinal and hepatobiliary-pancreatic cancer. We compared the sensitivity and specificity of serum sIFN-alpha/betaR with that of serum hs-CRP and evaluated the two diagnostic parameters in combination. Serum sIFN-alpha/betaR levels were measured in 92 patients and 25 healthy individuals by enzyme-linked immunosorbent assay. The diagnoses were 37 cases of hepatocellular carcinoma, 17 cases of pancreatic cancer, 15 cases of colon cancer, 13 cases of biliary tract cancer, and 10 cases of gastric cancer. Serum levels of sIFN-alpha/betaR and hs-CRP were significantly higher in the patients than in healthy individuals (p<0.05). The optimal cut-off values of sIFN-alpha/betaR and hs-CRP were 3600pg/ml and 0.5microg/ml, respectively. The sensitivity and specificity for these thresholds were 94.6% and 88.0%, whereas positive predictive and negative predictive values were 96.7% and 81.5%. These results suggest that a combination of serum sIFN-alpha/betaR and hs-CRP thresholds may be more reliable diagnostic parameter for gastrointestinal and hepatobiliary-pancreatic cancer. (Keyword) 欧文論文 / Aged / Aged, 80 and over / Biliary Tract Neoplasms / C-Reactive Protein / Female / Gastrointestinal Neoplasms / Humans / Liver Neoplasms / Male / Middle Aged / Pancreatic Neoplasms / Predictive Value of Tests / Receptor, Interferon alpha-beta / Sensitivity and Specificity / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1016/j.cyto.2009.09.010 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19879773 ● Search Scopus @ Elsevier (PMID): 19879773 ● Search Scopus @ Elsevier (DOI): 10.1016/j.cyto.2009.09.010 (DOI: 10.1016/j.cyto.2009.09.010, PubMed: 19879773)
146.	Tetsuya Ikemoto, Hirofumi Noguchi, Yasutaka Fujita, Morihito Takita, Masayuki Shimoda, Koji Sugimoto, Andrew Jackson, Bashoo Naziruddin, Mitsuo Shimada, Marlon F. Levy and Shinichi Matsumoto : New stepwise cooling system for short-term porcine islet preservation., Pancreas, Vol.39, No.7, 960-963, 2010. (Summary) Porcine islets are the most suitable for xeno-islet transplantation. However, it is necessary to establish an effective preservation method against its fragility. Recently, we developed a new cooling and preservation (Keep and Fresh [KFC]; FUJIYA Co, Tokushima, Japan) system, which can maintain viability of hepatocyte. In this study, we examined the KFC for porcine islet preservation. (Keyword) 欧文論文 / Cell Survival / Islets of Langerhans / Islets of Langerhans Transplantation / Organ Preservation / Swine (Link to Publication Site) ● Publication site (DOI): 10.1097/MPA.0b013e3181dab19a (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20467350 ● Search Scopus @ Elsevier (PMID): 20467350 ● Search Scopus @ Elsevier (DOI): 10.1097/MPA.0b013e3181dab19a (DOI: 10.1097/MPA.0b013e3181dab19a, PubMed: 20467350)
147.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 【特集】大腸がん鏡視下手術の標準化, Japanese Journal of Cancer Clinics, Vol.56, No.9, 641-648, 2010. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523669555415783296 (CiNii: 1523669555415783296)
148.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 岩橋衆一, 川田祐子 and 斎藤裕 : 問題を有するドナーからの生体肝移植 ∼胃癌術後ドナーおよび喘息罹患ドナー∼., The Japanese journal of clinical and experimental medicine, Vol.87, No.9, 1282-1283, 2010. (Keyword) 和文論文
149.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Jun Hanaoka : 急性肝不全に対する肝移植術施行のタイミングに難渋した症例, The Japanese journal of clinical and experimental medicine, Vol.87, No.9, 118-119, 2010. (Keyword) 和文論文
150.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi, Yu Saito, Hisami Okumura and Eiji Takeda : Impact of splenectomy in patients with liver cirrhosis: Results from 18 patients in a single center experience., Hepatology Research, Vol.40, No.9, 894-900, 2010. (Summary) Aim: With the recent advances in medical or surgical treatments in chronic hepatic disorders, the indications for splenectomy in hepatic disorders have greatly expanded. We performed splenectomy for cirrhotic patients and investigated the effects of splenectomy on hepatic functional reserve and nutrition metabolism. Methods: Eighteen patients (Child-Pugh B/C: 12/6; Child-Pugh A: excluded) who underwent splenectomy at our institute between 2005 and 2008 were enrolled. Twelve patients (67%) had hepatocellular carcinoma (HCC), eight of whom met the Milan criteria. Results: Overall survival rate was 83.3% at 1 year and 62.7% at 2 years. The survival rate of six patients with liver cirrhosis classified a Child-Pugh C was 80.0% at 1 year and 60.0% at 2 years. Three patients underwent hepatic resection and nine patients received ablation therapy against hepatocelluar carcinoma. Portal pressure decreased after splenectomy in most patients (mean decrease, 4.7 mmHg). Four weeks after the operation, the markers of hepatic functional reserve, indocyanine green retention rate at 15 min (ICGR15) and Technetium-99m-galactosyl human serum albumin value ((99m)Tc-GSA), improved from 38.5% to 35.1% and from 0.773 to 0.788 (LHL15), respectively. The non-protein respiratory quotient (npRQ) did not change in short period after the operation. Other outcomes, including liver function test in cirrhotic patients with long-term (1 year) follow-up after splenectomy (n = 7), did not improve significantly. Post-operative complications included portal thrombus (n = 2), ascites (n = 2) were observed in six patients (33%). Conclusion: Splenectomy improved hepatic functional reserve and nutritional metabolism in some cases. However, the long-term outcomes should still be evaluated. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1872-034X.2010.00688.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20887594 ● Search Scopus @ Elsevier (PMID): 20887594 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1872-034X.2010.00688.x (DOI: 10.1111/j.1872-034X.2010.00688.x, PubMed: 20887594)
151.	浅野間理仁, Hiroki Mori, Nobuhiro Kurita, Toru Utsunomiya and Mitsuo Shimada : ステロイド長期投与患者における周術期ステロイドカバー., Shikoku Acta Medica, Vol.66, No.3.4, 85-90, 2010. (Summary) In patients receiving chronic corticosteroid therapy, the adrenocortical function has decreased because of suppression of the hypothalamic-pituitary-adrenal axis. Under such a condition, it is easy to fall into a serious acute adrenocortical insufficiency during surgical stress. Corticosteroid supplementation is done as prevention of adrenocortical insufficiency. It is changing from corticosteroid supplementation of high dose into that of low dose that based on extrapolation from what constitutes a normal cortisol response to stress in recent years. On the other hand, some authors reported that patients receiving therapeutic doses of corticosteroids who undergo a surgical procedure do not routinely require corticosteroid supplementation so long as they continue to receive their usual daily dose of corticosteroid. Therefore, furthermore investigation should be necessary. (Keyword) 和文論文 (Tokushima University Institutional Repository) ● Metadata: 110320 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050583647830842752 (Tokushima University Institutional Repository: 110320, CiNii: 1050583647830842752)
152.	Takashi Iwata, Tetsuya Ikemoto, Nobuhiro Kurita, Masanori Nishioka, Toru Utsunomiya and Mitsuo Shimada : 手術機器の使い方-基本と応用- 鏡視下手術用機器 5.リトラクター, Operation, Vol.64, No.6, 839-844, 2010. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522825128351606400 (CiNii: 1522825128351606400)
153.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura and Tetsuya Ikemoto : 特集/必読最新の肝切除—その2 2.Liver hanging maneuver, Surgery, Vol.72, No.5, 461-465, 2010. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001288081381504 (CiNii: 1390001288081381504)
154.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 岩橋衆一 and 斎藤裕 : 性差による肝胆膵疾患の臨床，病態，治療効果のDiscrepancy I.性差と各種肝疾患 7)肝移植と性差, KAN TAN SUI, Vol.60, No.5, 793-799, 2010. (Keyword) 和文論文
155.	Hisami Okumura, Taki Nakamura, Hidenori Miyake, Harumi Takeuchi, Takafumi Katayama, Yuji Morine, Satoru Imura, Mitsuo Shimada and Eiji Takeda : Effect of long-term late-evening snack on health-related quality of life in cirrhotic patients., Hepatology Research, Vol.40, No.5, 470-476, 2010. (Summary) Aim: In patients with liver cirrhosis, abnormal energy metabolism induces low health-related quality of life (HRQOL) scores. However, late-evening snack (LES) prevents morning starvation in cirrhotic patients. Our aim is to assess the effect of long-term LES on HRQOL in cirrhotic patients, using the 36-item Short Form (SF-36) health survey. Methods: Thirty-nine cirrhotic patients classified as Child-Pugh grade A were recruited. The patients were randomly divided into two groups: 24 were assigned to the non-LES group and 15 to the LES group. SF-36 scores, anthropometric data and serum biochemical parameters were examined in the non-LES and LES groups at 0, 6 and 12 months. Results: Neither anthropometric data nor laboratory data showed significant differences between the non-LES and the LES groups at 0, 6 and 12 months. The role-emotional (RE) HRQOL scores at 6 months and mental health (MH) scores at 6 and 12 months were significantly reduced from the baseline level in the non-LES group. In contrast, these scores remained unchanged in the LES group. General health perception (GH) scores at 12 months, RE at 6 months and MH at 6 and 12 months in the LES group were significantly higher than those of the non-LES group. Conclusion: Long-term LES administration may be helpful in maintaining higher HRQOL in patients with cirrhosis. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1872-034X.2010.00637.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20412329 ● Search Scopus @ Elsevier (PMID): 20412329 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1872-034X.2010.00637.x (DOI: 10.1111/j.1872-034X.2010.00637.x, PubMed: 20412329)
156.	Mitsuo Shimada, Koji Sugimoto, Shuichi Iwahashi, Toru Utsunomiya, Yuji Morine, Satoru Imura and Tetsuya Ikemoto : CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma., Journal of Gastroenterology, Vol.45, No.8, 896-902, 2010. (Summary) CD133 is one of the most important cancer-initiating (stem) cell markers and was confirmed to be expressed in solid cancers such as colon cancer. However, no one has investigated the role of CD133 in intrahepatic cholangiocarcinoma (IHCC). The aim of this study was to clarify the clinical role of CD133 expression in IHCC. (Keyword) 欧文論文 / Aged / Aged, 80 and over / Antigens, CD / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Female / Gene Expression Regulation, Neoplastic / Glycoproteins / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Metastasis / Peptides / Prognosis / Proportional Hazards Models / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-010-0235-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20379837 ● Search Scopus @ Elsevier (PMID): 20379837 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-010-0235-3 (DOI: 10.1007/s00535-010-0235-3, PubMed: 20379837)
157.	荒川悠佑, Mitsuo Shimada, Hideaki Uchiyama, Satoru Imura, Yuji Morine, 金村普史, Jun Hanaoka, 金本真美, 杉本光司 and 西正暁 : Pseudostenosis of the Common Hepatic Duct caused by Compression of the Cystic Artery, The Japanese Journal of Gastroenterological Surgery, Vol.43, No.4, 405-410, 2010. (Summary) Bile duct way stenosis mimic malignant such as cholangiocellular carcinoma lesions and gall bladder carcinoma invasion. A 74-year-old woman a gallbladder (GB) polyp combined with common hepatic duct (CHD) stenosis was found in admitted for surgery to treat. Preoperative evaluation revealed to have a polypoid tumor 12mm in diameter and relatively smooth CHD stenosis. Because the possibility of malignancy could not be excluded, she underwent open abdominal surgery. We conducted the usual cholecystectomy. The CHD was compressed by the cystic artery, so we thoroughly confirmed the absence of any suspicious CHD lesion by directly inspecting the inner side of the stricture by choledochotomy. The definitive diagnosis of the GB tumor was early GB carcinoma. Although CHD compression by the cystic artery is considered uncommon, we suggest that it should be included in the differential diagnosis of extrahepatic biliary stenosis, especially when biliary stenosis is relatively smooth. (Keyword) 和文論文 (Link to Publication Site) ● Publication site (DOI): 10.5833/jjgs.43.405 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204916721408 ● Summary page in Scopus @ Elsevier: 2-s2.0-77953046874 (DOI: 10.5833/jjgs.43.405, CiNii: 1390001204916721408, Elsevier: Scopus)
158.	Lu Elaine Wang, Zhi-Rong Qian, Masahiko Nakasono, Toshihito Tanahashi, Katsuhiko Yoshimoto, Yoshimi Bando, Eiji Kudo, Mitsuo Shimada and Toshiaki Sano : High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer., British Journal of Cancer, Vol.102, No.5, 908-915, 2010. (Summary) BACKGROUND: The Toll-like receptor (TLR) 4 signalling pathway has been shown to have oncogenic effects in vitro and in vivo. To demonstrate the role of TLR4 signalling in colon tumourigenesis, we examined the expression of TLR4 and myeloid differentiation factor 88 (MyD88) in colorectal cancer (CRC). METHODS: The expression of TLR4 and MyD88 in 108 CRC samples, 15 adenomas, and 15 normal mucosae was evaluated by immunohistochemistry, and the correlations between their immunoscores and clinicopathological variables, including disease-free survival (DFS) and overall survival (OS), were analysed. RESULTS: Compared with normal mucosae and adenomas, 20% cancers displayed high expression of TLR4, and 23% cancers showed high expression of MyD88. The high expression of TLR4 and MyD88 was significantly correlated with liver metastasis (P=0.0001, P=0.0054). In univariate analysis, the high expression of TLR4 was significantly associated with shorter OS (hazard ratio (HR): 2.17; 95% confidence interval (95% CI): 1.15-4.07; P=0.015). The high expression of MyD88 expression was significantly associated with poor DFS and OS (HR: 2.33; 95% CI: 1.31-4.13; P=0.0038 and HR: 3.03; 95% CI: 1.67-5.48; P=0.0002). The high combined expression of TLR4 and MyD88 was also significantly associated with poor DFS and OS (HR: 2.25; 95% CI: 1.27-3.99; P=0.0053 and HR: 2.97; 95% CI: 1.64-5.38; P=0.0003). Multivariate analysis showed that high expressions of TLR4 (OS: adjusted HR: 1.88; 95% CI: 0.99-3.55; P=0.0298) and MyD88 (DFS: adjusted HR: 1.93; 95% CI: 1.01-3.67; P=0.0441; OS: adjusted HR: 2.25; 95% CI: 1.17-4.33; P=0.0112) were independent prognostic factors of OS. Furthermore, high co-expression of TLR4/MyD88 was strongly associated with both poor DFS and OS. CONCLUSION: Our findings suggest that high expression of TLR4 and MyD88 is associated with liver metastasis and is an independent predictor of poor prognosis in patients with CRC. (Keyword) Adenocarcinoma, Mucinous / Aged / Colon / Colorectal Neoplasms / female / Follow-Up Studies / Humans / Immunoenzyme Techniques / Liver Neoplasms / male / Myeloid Differentiation Factor 88 / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Peritoneal Neoplasms / Prognosis / Rectum / Survival Rate / Toll-Like Receptor 4 / Tumor Markers, Biological (Tokushima University Institutional Repository) ● Metadata: 114377 (Link to Publication Site) ● Publication site (DOI): 10.1038/sj.bjc.6605558 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20145615 ● Summary page in Scopus @ Elsevier: 2-s2.0-77649272127 (Tokushima University Institutional Repository: 114377, DOI: 10.1038/sj.bjc.6605558, PubMed: 20145615, Elsevier: Scopus)
159.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, Tomohiko Miyatani, Hidenori Miyamoto and Yoshiyasu Terashima : Two Cases of Emergency Operations in Patients Undergoing Bevacizumab Treatment, Journal of the Japan Society of Coloproctology, Vol.63, No.2, 56-60, 2010. (Summary) Bevacizumab has become a widely used intervention in patients with advanced colon cancer. In view that a negative effect of wound healing has been reported, surgery should be performed 4-6 weeks after the last treatment. This study examined the approaches to the management of emergency operations in patients undergoing bevacizumab treatment. In this report, four operations were performed for two patients undergoing bevacizumab treatment. Surgical complications and the postoperative course were examined. Case1: The patient was a male in his 50s with descending colon cancer, multiple liver metastasis and lung metastasis. This patient was suffering from ileus due to descending colon cancer. A transverse colostomy was performed. In addition, a descending colectomy and drainage were conducted for the retroperitoneal abscess formation. Case2: The patient was a male in his 70s with mucinous cystadenocarcinoma of the appendix and carcinomatous peritonitis. This patient was suffering from abdominal pain. As a CT showed free air, an emergency operation was performed. Drainage was also performed. The extent of the surgical procedures should be limited, and construction of a stomy should be preferred to primary anastomosis.<br> (Keyword) 和文論文 (Link to Publication Site) ● Publication site (DOI): 10.3862/jcoloproctology.63.56 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204855157376 ● Search Scopus @ Elsevier (DOI): 10.3862/jcoloproctology.63.56 (DOI: 10.3862/jcoloproctology.63.56, CiNii: 1390001204855157376)
160.	Erdenebulgan Batmunkh, Mitsuo Shimada, Yuji Morine, Satoru Imura, Hirofumi Kanemura, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, Koji Sugimoto and Masaaki Nishi : Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma., International Journal of Clinical Oncology, Vol.15, No.1, 59-64, 2010. (Summary) Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that plays a central role in biologic processes under hypoxic conditions, especially concerning tumor angiogenesis. Vascular endothelial growth factor (VEGF) is a potent proangiogenic agent and a multifunctional angiogenic cytokine in many malignant tumors. (Keyword) 欧文論文 / Aged, 80 and over / Female / Gallbladder Neoplasms / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Immunohistochemistry / Male / Middle Aged / Neovascularization, Pathologic / Prognosis / Transcription Factors / Vascular Endothelial Growth Factor A (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-009-0011-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20082206 ● Search Scopus @ Elsevier (PMID): 20082206 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-009-0011-7 (DOI: 10.1007/s10147-009-0011-7, PubMed: 20082206)
161.	Hideaki Uchiyama, Mitsuo Shimada, Satoru Imura, Yuji Morine, Hirofumi Kanemura, Yusuke Arakawa, Mami Kanamoto, Masaaki Nishi and Jun Hanaoka : Living donor liver transplantation using a left hepatic graft from a donor with a history of gastric cancer operation., Transplant International, Vol.23, No.2, 234-235, 2010. (Keyword) 欧文論文 / Gastrectomy / Hepatic Artery / Humans / Liver Failure / Liver Transplantation / Living Donors / Male / Middle Aged / Stomach Neoplasms / Tissue Adhesions (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1432-2277.2009.00920.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19659795 ● Search Scopus @ Elsevier (PMID): 19659795 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1432-2277.2009.00920.x (DOI: 10.1111/j.1432-2277.2009.00920.x, PubMed: 19659795)
162.	Tomohiko Miyatani, Masanori Nishioka and Mitsuo Shimada : Ⅰ.消化管 20. 肛門癌, Surgery, Vol.72, No.12, 1356-1359, 2010. (Keyword) 和文論文
163.	Shinya Morimoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori and Jun Hanaoka : 肝癌ステージングと予後推定., 臨床消化器内科, Vol.25, No.4, 399-494, 2010. (Keyword) 和文論文
164.	Takashi Iwata and Mitsuo Shimada : 人工臓器., 標準外科学第12版, 213-225, 2010. (Keyword) 和文論文
165.	Masanori Nishioka, Mitsuo Shimada, Jun Higashijima and Tomohiko Miyatani : S上結腸SM癌に対するS状結腸切除 D2郭清., 腹腔鏡下大腸手術の基本手術手技, 1-35, 2010. (Keyword) 和文論文
166.	Nobuhiro Kurita, Mitsuo Shimada, Toru Utsunomiya, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Jun Higashijima and Toshihiro Nakao : Predictive factors of peritoneal metastasis in gastric cancer., Hepato-Gastroenterology, Vol.57, No.101, 980-983, 2010. (Summary) Preoperative radiological diagnosis of gastric cancer with peritoneal metastasis is still incomplete. Staging laparoscopy is performed for patients who are diagnosed T3 or T4 preoperatively. The aim of this study is to establish a method for predicting peritoneal metastasis. (Keyword) 欧文論文 / Adult / Aged / Aged, 80 and over / Female / Gastrectomy / Humans / Laparoscopy / Male / Middle Aged / Multivariate Analysis / Peritoneal Neoplasms / Sensitivity and Specificity / Stomach Neoplasms / Young Adult (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21033263 ● Search Scopus @ Elsevier (PMID): 21033263 (PubMed: 21033263)
167.	Mitsuo Shimada : 脂肪肝グラフトを用いた肝移植における移植後グラフト機能不全の機序解明., 上原記念生命化学財団研究報告集, Vol.24, 1-7, 2010. (Keyword) 和文論文
168.	Toru Utsunomiya, Mitsuo Shimada, 三浦文彦, 山本雅一 and 高田忠敬 : 特集/消化器外科データベースの構築とその展開4. 高度技能医制度を包括するデータベース., Surgery Frontier, Vol.17, No.4, 32-38, 2010. (Keyword) 和文論文
169.	Yuji Morine, Mitsuo Shimada, 久山寿子, 高松英夫 and Seiki Tashiro : 全国集計からみた先天性胆道拡張症, 膵・胆管合流異常の胆道癌発生率とその特徴, 胆と膵, Vol.31, No.11, 1293-1299, 2010. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572824500996378752 (CiNii: 1572824500996378752)
170.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一 and 斎藤裕 : 肝移植の画像診断ー生体ドナーの安全とレシピエントの予後向上をめざしてー, 肝胆膵画像, Vol.2, No.1, 69-78, 2010. (Keyword) 和文論文
171.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shinya Morimoto and Hiroki Mori : メタボリックシンドロームと肝細胞癌, G.I.Research, Vol.18, No.3, 224-230, 2010. (Keyword) 和文論文
172.	Hiroki Mori, Mitsuo Shimada, Yuji Morine, Satoru Imura, Kouzou Yoshikawa and Toru Utsunomiya : 肝・胆・膵手術と漢方, G I Research, Vol.18, No.4, 313-320, 2010. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573950400903287936 (CiNii: 1573950400903287936)
173.	Satoru Imura, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya, Hidenori Miyake and Mitsuo Shimada : 腹腔鏡下肝切除:腹腔鏡下肝切除術における最近の話題 ∼気腹とガス塞栓∼., 消化器外科, Vol.33, No.9, 1439-1444, 2010. (Keyword) 和文論文
174.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine and Tetsuya Ikemoto : 肝・胆道系症候群(Ⅱ)— その他の肝・胆道系疾患を含めて - 肝臓編(下)第2版 XIV 肝細胞癌以外の肝腫瘍「原発性肝肉腫(Primary hepatic sarcoma)」, 日本臨床2010, 276-280, 2010. (Keyword) 和文論文
175.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, 川田祐子, Yu Saitou, Jun Hanaoka, Hiroki Mori, Satoru Imura, Yuji Morine and Toru Utsunomiya : 乳癌が併存するレシピエント，高度脂肪肝ドナーという組み合わせに施行した生体肝移植., The Japanese journal of clinical and experimental medicine, Vol.87, No.9, 1280-1281, 2010. (Keyword) 和文論文
176.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Hiroki Mori : 血液型不適合肝移植後interferon治療に難渋したC型肝炎の1例, The Japanese journal of clinical and experimental medicine, Vol.87, No.9, 1330-1331, 2010. (Keyword) 和文論文
177.	Kotaro Miyake, Mitsuo Shimada, Masanori Nishioka, Koji Sugimoto, Erdenebulgan Batmunkh, Yoshihiro Uto, Hideko Nagasawa and Hitoshi Hori : Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer, Cancer Chemotherapy and Pharmacology, Vol.64, No.5, 885-892, 2009. (Summary) Purpose It is well known that hypoxic milieu is the primary cancer environment. Therefore, tumor hypoxia is considered to be a potential therapeutic target. In the present study, we investigated the antitumor and antimetastatic effect of hypoxic cell radiosensitizer, TX-1877 on xenograft model of rectal cancer. Methods Nude mice bearing subcutaneously or orthotopically implanted human colon cancer cell lines HCT-116 and HT-29 were treated with TX-1877, irradiation or TX-1877 with irradiation. Tumor volume, survival, expression of matrix metalloproteinase (MMP)-2, MMP-7, MMP-9 and urokinase-type plasminogen activator (uPA) and incidence of lymph node metastasis were evaluated in treatment versus control group. Results In subcutaneous model, tumor treated with TX-1877 and irradiation showed significant reductions in volume (P < 0.05 vs. control, TX-1877 or irradiation group). Quantitative real-time reverse transcription-PCR and immunohistochemical analysis revealed that TX-1877 significantly inhibited expression of the MMP-9 and uPA. These treatments also inhibited the para-aortic lymph node metastasis, however, did not prolong the survival in orthotopic model. Conclusions These data show that the treatment of TX-1877 with irradiation decreased growth of human rectal cancer and, furthermore, suppressed lymph node metastasis. (Keyword) TX-1877 / Radiosensitizer / Hypoxic cell / Antimetastasis / Lymph node metastasis (Link to Publication Site) ● Publication site (DOI): 10.1007/s00280-009-0937-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19214512 ● Search Scopus @ Elsevier (PMID): 19214512 ● Search Scopus @ Elsevier (DOI): 10.1007/s00280-009-0937-5 (DOI: 10.1007/s00280-009-0937-5, PubMed: 19214512)
178.	Hideaki Uchiyama, Noboru Harada, Kensaku Sanefuji, Hiroto Kayashima, Akinobu Taketomi, Yuji Soejima, Toru Ikegami, Mitsuo Shimada and Yoshihiko Maehara : Dual hepatic artery reconstruction in living donor liver transplantation using a left hepatic graft with 2 hepatic arterial stumps., Surgery, Vol.147, No.6, 878-886, 2009. (Summary) A left hepatic graft in living donor liver transplantation (LDLT) often has 2 thin and short hepatic arterial stumps, which makes hepatic artery (HA) reconstructions much more difficult to perform. Consequently, some investigators regard using a left graft as a contraindication to LDLT, whereas others report that the reconstruction of only 1 HA is sufficient for most LDLTs. The aim of this retrospective study was to investigate whether 2 HAs on a left hepatic graft in an LDLT can be reconstructed safely and whether the outcomes of LDLTs are affected by reconstructing both HAs (dual reconstruction). (Keyword) 欧文論文 / Blood Group Incompatibility / Female / Hepatectomy / Hepatic Artery / Humans / Living Donors / Male / Middle Aged / Postoperative Complications / Reconstructive Surgical Procedures / Retrospective Studies / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1016/j.surg.2009.06.028 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19758670 ● Search Scopus @ Elsevier (PMID): 19758670 ● Search Scopus @ Elsevier (DOI): 10.1016/j.surg.2009.06.028 (DOI: 10.1016/j.surg.2009.06.028, PubMed: 19758670)
179.	Tetsuji Takayama, Kouzou Yoshikawa, Toshiya Okahisa, Masako Kaji, Nobuhiro Kurita, Masanori Nishioka, Toru Ikegami, Toshiaki Sano, J Inoi and Mitsuo Shimada : Idiopathic phlebosclerosis: an atypical presentation of ischemic colitis treated by laparoscopic colectomy., Surgery, Vol.145, No.6, 682-684, 2009. (Keyword) Aged / Colectomy / Colitis, Ischemic / Colon / Colonoscopy / Female / Humans / Intestinal Mucosa / Laparoscopy / Tomography, X-Ray Computed / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.surg.2008.04.015 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19486773 ● Search Scopus @ Elsevier (PMID): 19486773 ● Search Scopus @ Elsevier (DOI): 10.1016/j.surg.2008.04.015 (DOI: 10.1016/j.surg.2008.04.015, PubMed: 19486773)
180.	Shinji Kawahito, 中村智芳, 神邊紀子, Hiroshi Kitahata, Mitsuo Shimada, Masaji Nishimura and Shuzo Oshita : ② 意外に難しいスライディング・スケール法による血糖管理, 胆と膵, Vol.29, No.11, 1021-1028, 2008.
181.	Kotaro Miyake, Mitsuo Shimada, Masanori Nishioka, Koji Sugimoto, Erdenebulgan Batmunkh, Yoshihiro Uto, Hideko Nagasawa and Hitoshi Hori : The novel hypoxic cell radiosensitizer, TX-1877 has antitumor activity through suppression of angiogenesis and inhibits liver metastasis on xenograft model of pancreatic cancer., Cancer Letters, Vol.272, No.2, 325-335, 2008. (Summary) Tumor hypoxia has been considered to be a potential therapeutic target, because hypoxia is a common feature of solid tumors and is associated with their malignant phenotype. In the present study, we investigated the antitumor effect of hypoxic cell radiosensitizer, TX-1877 in inhibiting angiogenesis and liver metastasis on pancreatic cancer xenograft model. The antitumor effects of TX-1877 were tested against various human tumor cell lines using cell proliferation assay. Nude mice bearing s.c. or orthotopically implanted human SUIT-2 were treated with TX-1877 alone, irradiation alone or TX-1877 and irradiation. Tumor volume, survival, expression of angiogenic molecules and liver metastasis were evaluated in treatment versus control groups. In vitro, TX-1877 inhibited the proliferation and potentiated the radiosensitivity of various pancreatic cancer cell lines. In an orthotopic model, tumors from nude mice injected with pancreatic cancer cells and treated with TX-1877 and irradiation showed significant reductions in volume (p<0.05 versus control, TX-1877 alone or irradiation alone). Quantitative real-time reverse transcription-PCR and immunohistochemical analysis revealed that treatment with TX-1877 alone or with TX-1877 and irradiation inhibited expression of the angiogenic molecules, vascular endothelial growth factor; basic fibroblast growth factor, interleukin-8 and matrix metalloproteinase 9 more than control or did treatment with irradiation alone. These treatments also induced apoptosis in cancer cells. These data show that treatment of TX-1877 and irradiation decreased growth of human pancreatic cancer, suppressed angiogenesis and inhibited liver metastasis, leading to prolonged survival. (Keyword) Antineoplastic Agents / Cell Hypoxia / Cell Line, Tumor / Humans / Immunohistochemistry / In Situ Nick-End Labeling / Liver Neoplasms / Neovascularization, Pathologic / Nitroimidazoles / Pancreatic Neoplasms / Radiation-Sensitizing Agents / Reverse Transcriptase Polymerase Chain Reaction / Transplantation, Heterologous (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2008.07.020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18762366 ● Search Scopus @ Elsevier (PMID): 18762366 ● Search Scopus @ Elsevier (DOI): 10.1016/j.canlet.2008.07.020 (DOI: 10.1016/j.canlet.2008.07.020, PubMed: 18762366)
182.	Hirofumi Kanemura, Kenji Kusumoto, Hidenori Miyake, Seiki Tashiro, Kazuhito Rokutan and Mitsuo Shimada : Geranylgeranylacetone prevents acute liver damage after massive hepatectomy in rats through suppression of a CXC chemokine GRO1 and induction of heat shock proteins., Journal of Gastrointestinal Surgery, Vol.13, No.1, 66-73, 2008. (Summary) BACKGROUND AND METHODS: Acute liver failure after massive hepatectomy remains a challenging problem. In this study, using a microarray designed to monitor the side effects of drugs, we examined changes in gene expression in the remnant liver during the 24 h after hepatectomy and the effects of a nontoxic heat shock protein (HSP) 70 inducer, geranylgeranylacetone (GGA), after 90% hepatectomy in rats. RESULTS: A single oral administration of 100 mg/kg GGA significantly suppressed the release of aminotransferases and improved survival compared with vehicle administration. The hepatectomy upregulated 74 genes and downregulated 95. Interestingly, ten cytokine genes were upregulated, while no cytokine-related gene was downregulated. Among the ten cytokine genes, a potent chemoattractant for neutrophils, GRO1, was most rapidly and markedly upregulated after 90% hepatectomy. GGA effectively suppressed the up-regulation of GRO1 messenger ribonucleic acid, and this was validated by Northern hybridization. Microarray and immunoblot analyses showed that, in addition to HSP70 and HSP27, GGA preferentially induced an endoplasmic reticulum chaperone, BIP. CONCLUSION: Considering hemodynamic and metabolic overloading as a primary cause of acute lever failure, the ER stress response enhanced by GGA may also play an important role in the prevention of overload-induced liver damage. (Keyword) Animals / Anti-Ulcer Agents / Autoradiography / Blotting, Western / Chemokine CXCL1 / Disease Models, Animal / Diterpenes / Dose-Response Relationship, Drug / gene expression / HSP70 Heat-Shock Proteins / Hepatectomy / Liver Failure, Acute / male / Microarray Analysis / RNA / Rats / Rats, Wistar / Reverse Transcriptase Polymerase Chain Reaction (Link to Publication Site) ● Publication site (DOI): 10.1007/s11605-008-0604-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18683011 ● Summary page in Scopus @ Elsevier: 2-s2.0-57849122454 (DOI: 10.1007/s11605-008-0604-x, PubMed: 18683011, Elsevier: Scopus)
183.	Mika Kijima, Takeshi Yamaguchi, Chieko Ishifune, Yoichi Maekawa, Akemi Koyanagi, HIdeo Yagita, Shigeru Chiba, Kenji Kishihara, Mitsuo Shimada and Koji Yasutomo : Dendritic cell-mediated NK cell activation is controlled by Jagged2-Notch interaction., Proceedings of the National Academy of Sciences of the United States of America, Vol.105, No.19, 7010-7015, 2008. (Summary) Natural killer (NK) cells regulate various immune responses by exerting cytotoxic activity or secreting cytokines. The interaction of NK cells with dendritic cells (DC) contributes to NK cell-mediated antitumor or antimicrobial responses. However, the cellular and molecular mechanisms for controlling this interaction are largely unknown. Here, we show an involvement of Jagged2-Notch interaction in augmenting NK cell cytotoxicity mediated by DC. Enforced expression of Jagged2 on A20 cells (Jag2-A20 cells) suppressed their growth in vivo, which was abrogated by depleting NK cells. Moreover, Jag2-A20 cells exerted a suppression on the growth of nonmanipulated A20 cells in SCID mice in an NK-dependent manner. Consistently, coinoculation of A20 cells with DC overexpressing Jagged2 (Jag2-DC) suppressed the growth of A20 cells in mice. Stimulation of NK cells with Jagged2 directly enhanced their cytotoxicity, IFN-gamma production, and proliferation. Ligation of Notch2 on NK cells enhanced their cytotoxic activity, and Jag2-DC or CpG-treated DC-mediated NK cell cytotoxicity was suppressed by a gamma-secretase inhibitor. These results indicate that the Jagged2-Notch axis plays a crucial role in DC-mediated NK cell cytotoxicity. Furthermore, manipulation of this interaction may provide an approach to induce potent tumor immunity or to inhibit certain autoimmune diseases caused by NK cell activation. (Keyword) Animals / Cell Proliferation / Cell Transplantation / Cytotoxicity, Immunologic / Dendritic Cells / Immunotherapy, Adoptive / Killer Cells, Natural / Lymphocyte Activation / Membrane Proteins / Mice / Mice, Inbred BALB C / Mice, SCID / Neoplasms / Protein Binding / Receptors, Notch / signal transduction (Link to Publication Site) ● Publication site (DOI): 10.1073/pnas.0709919105 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18458347 ● Search Scopus @ Elsevier (PMID): 18458347 ● Search Scopus @ Elsevier (DOI): 10.1073/pnas.0709919105 (DOI: 10.1073/pnas.0709919105, PubMed: 18458347)
184.	山井礼道, Takahiro Yoshida, Jun-ichi Seike, 本田順子, Takanori Miyoshi, Hirokazu Takechi, 湯浅康弘, Atsushi Umemoto, Akira Tangoku and Mitsuo Shimada : A Case of Solitary Para-Aortic Lymph Node Metastasis of Hepatocellular Carcinoma Treated with Single Resection, The Japanese Journal of Gastroenterological Surgery, Vol.41, No.4, 412-417, 2008. (Summary) We report a case of the which was treated with TAE, RFA and surgery. In 2003, a 60-year-old man followed up for chronic hepatitis C and admitted for examination of intrahepatic lesions detected in urtrasonography was found in abdominal computed tomography (CT) to have two intrahepatic masses of about 4cm and 4.5cm and a solitary swollen 2.8cm lymph node to the right of the aorta. We diagnosed the intrahepatic lesions as hepatocellular carcinoma (HCC), but we could not diagnose the paraaortic lesion as a metastatic lymph node. We treated the hepatic lesion with TAE and RFA, and followed up the paraaortic mass, which became enlarged two months later. We resected the lymph node. The postoperative course was uneventful and the patient was discharged. Serum AFP decreased from a preoperative 2,685ng/ml to a postoperative 3ng/ml. Two years later, neither intrahepatic recurrence nor the presence of the metastatic lymph node was seen. (Keyword) solitary lymph node metastasis / hepatocellular carcinoma / paraaortic lymph node metastasis (Link to Publication Site) ● Publication site (DOI): 10.5833/jjgs.41.412 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282679895798016 ● Summary page in Scopus @ Elsevier: 2-s2.0-42149157678 (DOI: 10.5833/jjgs.41.412, CiNii: 1390282679895798016, Elsevier: Scopus)
185.	S Yamasaki, N Kurita, J Hata, Maki Moritani, Mitsuo Itakura and Mitsuo Shimada : The effect of transgenic expression of TGF-beta1 on transplanted islet graft survival., Hepato-Gastroenterology, Vol.54, No.78, 1617-1621, 2007. (Summary) Transgenic mice expressing the active form of porcine TGF-beta1 (NOD- TGF-beta1 Tg) were completely protected from autoimmune diabetes in the NOD genetic background in our previous study. Here, we attempted to determine whether transgenic expression of TGF-beta1 in transplanted islets prevents autoimmune destruction in NOD mice. We transplanted islets to the subcapsular region of the kidney using NOD-TGF-beta1 Tg and NOD mice as donor and recipient or vice versa. Cyclophosphamide was administered twice to streptozocin-induced diabetic females NOD-TGF-beta1 Tg or their female littermates after islet transplantation. All islets grafts of NOD-TGF-beta1 Tg in spontaneously diabetic NOD mice were rejected earlier than those of their littermates. Hyperglycemia was induced in all littermates, but three out of four NOD-TGF-beta1 Tg, which were STZ-induced diabetic female mice, remained normoglycemic in response to the administration of cyclophosphamide after islet transplantation. Our results lack direct evidence for the local paracrine TGF-beta1 to protect the transplanted islet grafts. We observed, however, prolonged survival of NOD islets grafts in diabetic NOD-TGF-beta1 Tg suggesting the protective role of transgenic TGF-beta1 to suppress the autoimmune process in our syngenic transplantation model. We are convinced that this data could help resolve many problems regarding islet transplantation for type 1 diabetes. (Keyword) Animals / Autoimmune Diseases / Cyclophosphamide / Diabetes Mellitus, Experimental / Diabetes Mellitus, Type 1 / Female / Graft Rejection / Graft Survival / Humans / Islets of Langerhans Transplantation / Kidney / Mice / Mice, Inbred NOD / Transforming Growth Factor beta1 / Transgenes (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18019678 ● Search Scopus @ Elsevier (PMID): 18019678 (PubMed: 18019678)
186.	Yoshitaka Imoto, Naoki Muguruma, Tetsuo Kimura, Eriko Aoyagi, Koichi Okamoto, Seisuke Okamura, Susumu Ito, Nobuya Sano and Mitsuo Shimada : Relationship between mucin expression and preoperatie bile juice cytology in biliary tract carcinoma, The Journal of Medical Investigation : JMI, Vol.54, No.1-2, 41-47, 2007. (Summary) The present study evaluated correlations between preoperative bile juice cytology and mucin expression of surgical specimens in biliary tract carcinoma. Twenty-five patients with biliary tract carcinoma surgically treated at our hospital, whose bile juice cytology had been evaluated before operation, were allocated to this study. Biliary cytology was classified into three categories based on the Papanicolaou classification. Immunohistochemical staining of tissues was performed using MUC1 and MUC2 monoclonal antibodies. Lesions showing MUC1 expression of ++ or higher and MUC2 expression of - were classified as Group A, and the remaining lesions as Group B. According to the epithelial site, preoperative cytology was highly correlated in Group A, while it was negative in Group B (p<0.05). In the advanced site of carcinomas, preoperative cytology tended to highly be positive in Group A, while it tended to be negative in Group B (p<0.05). These results suggest that the bile juice cytology results are affected by characteristics of mucin expression in the tissue. Based on the possibility that mucin expression correlates with the prognosis of each carcinoma, a positive cytological result suggests a poor prognosis for the carcinoma, which may be informative for predicting the post-operative courses and choosing treatments. (Keyword) Adult / Aged / Antigens, Neoplasm / Bile / Biliary Tract Neoplasms / Female / Humans / immunohistochemistry / Male / Middle Aged / Mucin-1 / Mucin-2 / Mucins (Tokushima University Institutional Repository) ● Metadata: 111493 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.54.41 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17380013 ● Search Scopus @ Elsevier (PMID): 17380013 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.54.41 (Tokushima University Institutional Repository: 111493, DOI: 10.2152/jmi.54.41, PubMed: 17380013)
187.	Hisami Okumura, Taki Nakamura, Harumi Takeuchi, Hidenori Miyake, Takafumi Katayama, Hidekazu Arai, Yutaka Taketani, Masahiko Fujii, Mitsuo Shimada and Eiji Takeda : Effect of late evening snack with rice ball on energy metabolism in liver cirrhosis., European Journal of Clinical Nutrition, Vol.60, No.9, 1067-1072, 2006. (Summary) This study investigates the effects of a late evening snack (LES), of 200 kcal of rice ball, on energy metabolism in cirrhotic patients. Impaired nutritional metabolism has been associated with cirrhosis, and frequent intake of small meals may prevent early-onset starvation, and maintain nourishment in these patients. Twenty-one cirrhotic patients and 26 control subjects (Control) were recruited for this study. Patients were subsequently treated by LES (LC-LES) and by a non-LES regimen (LC-NLES). Resting energy expenditure and respiratory quotient (RQ) were assessed by indirect calorimetry at 0830, 1130 and 1430. Blood glucose and non-esterified fatty acids (NEFA) were measured just before the energy metabolism measurements. The regular diet included three major meals and LES, at 0900, 1200, 1800 and 2100, respectively. The Control and LC-NLES groups received only the major meals, whereas the LC-LES group received three meals plus 200 kcal LES for 7 days. There was no difference in the total energy intake among Control, LC-NLES and LC-LES groups. Respiratory quotient in LC-NLES was significantly lower than that of Control at 0830. Respiratory quotient value in LC-LES significantly elevated from that in LC-NLES. The RQ values did not differ among Control, LC-NLES and LC-LES at 2 h after the meal (1130 and 1430). Non-esterified fatty acids in LC-LES were lower than that in LC-NLES after overnight fasting. The ingestion of a 200 kcal rice ball LES can improve the nutritional metabolism in cirrhotic patients. (Keyword) Basal Metabolism / Blood Glucose / Calorimetry, Indirect / Circadian Rhythm / Dietary Carbohydrates / Energy Metabolism / Fatty Acids, Nonesterified / Humans / Liver Cirrhosis / Male / Middle Aged / Oryza sativa / Oxygen Consumption (Link to Publication Site) ● Publication site (DOI): 10.1038/sj.ejcn.1602420 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16508643 ● Search Scopus @ Elsevier (PMID): 16508643 ● Search Scopus @ Elsevier (DOI): 10.1038/sj.ejcn.1602420 (DOI: 10.1038/sj.ejcn.1602420, PubMed: 16508643)
188.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro, Tomoharu Yoshizumi, Keiji Kishikawa and Yoshihiko Maehara : Reconstruction of the middle hepatic vein tributaries using the recipient's recanalized umbilical vein in right-lobe living-donor liver transplantation, Surgery, Vol.139, No.3, 442-445, 2006. (Summary) Right-lobe grafts without the middle hepatic vein (MHV) can cause severe congestion of the anterior segment in living-donor liver transplantation (LDLT). However, the indications and methods for reconstructing the MHV or its tributaries remain controversial. We herein describe two cases of the successful use of the recipient's recanalized umbilical vein as an interposition graft to drain the major MHV tributaries in right-lobe LDLTs. After surgery, both right-lobe grafts are currently functioning well and all of the reconstructed venous tributaries have been confirmed to be patent by doppler ultrasonography. The histopathological features of the recanalized umbilical vein showed an intact intima with thickened media. The use of the recipient's recanalized umbilical vein is a good option for reconstructing MHV tributaries in right-lobe LDLTs. (Keyword) Hepatic Veins / Humans / Kidney Failure, Chronic / Liver / Liver Transplantation / Living Donors / Male / Middle Aged / Reconstructive Surgical Procedures / Retrospective Studies / Umbilical Veins (Link to Publication Site) ● Publication site (DOI): 10.1016/j.surg.2005.08.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16546511 ● Summary page in Scopus @ Elsevier: 2-s2.0-33645011480 (DOI: 10.1016/j.surg.2005.08.005, PubMed: 16546511, Elsevier: Scopus)
189.	Otsuka Toshihiro, Keisuke Izumi, Itsuo Tokunaga, Takako Gotohda, Ipposhi Kaneshige, Yoshiharu Takiguchi, Kaneda Shinya, Nobuo Satake, Takamasa Ohnishi, Seiki Tashiro and Mitsuo Shimada : Prevention of lethal hepatic injury in Long-Evans Cinnamon(LEC) rats by D-galactosamine hydrochloride, The Journal of Medical Investigation : JMI, Vol.53, No.1-2, 81-86, 2006. (Summary) Repeated injections of D-galactosamine hydrochloride (GalN) increase the survival rate of Long-Evans Cinnamon (LEC) rats, an animal model of Wilson's disease. The aim of the present study was to investigate the mechanism of GalN for prevention of spontaneous lethal hepatic injury in LEC rats. Male LEC rats were given a single subcutaneous injection of 300 mg/kg of GalN or vehicle (0.9% NaCl) at 14 weeks, and killed at 28 weeks of age. Next, 6-week-old male LEC rats were given weekly subcutaneous injections of 300 mg/kg of GalN or vehicle for 3 or 12 weeks, and their hepatic 8-hydroxydeoxy-2'-guanosine (8-OHdG), glutathione peroxidase (GPX), and catalase activities were measured. None of GalN-treated rats died of hepatic injury (0/12), whereas the mortality rate of control rats given 0.9% NaCl was 17% (2/12). GalN administration for 12 weeks decreased the hepatic 8-OHdG, and GalN administration for either 3 or 12 weeks increased the glutathione peroxidase activity. GalN administration increased the serum level of alanine aminotransferase, and accelerated megalocytic degeneration of the hepatocytes. GalN treatment is effective in preventing lethal hepatitis in LEC rats and decrease of oxidative DNA damage by GalN plays an important role in increase of the survival rate. (Keyword) Animals / Disease Models, Animal / Free Radicals / Galactosamine / Hepatolenticular Degeneration / Humans / Liver / Male / Rats / Rats, Inbred LEC (Tokushima University Institutional Repository) ● Metadata: 110791 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.53.81 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16537999 ● Summary page in Scopus @ Elsevier: 2-s2.0-33645835974 (Tokushima University Institutional Repository: 110791, DOI: 10.2152/jmi.53.81, PubMed: 16537999, Elsevier: Scopus)
190.	Hisami Okumura, 竹内晴美, 中村多希, Masahiko Fujii, Hidenori Miyake, Mitsuo Shimada and Eiji Takeda : 肝硬変患者における就寝前夜食療法継続指導の健康関連QOLに対する効果, 日本病態栄養学会誌, Vol.9, No.2, 159-164, 2006. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1574231875812577408 (CiNii: 1574231875812577408)
191.	Makoto Nakamuta, Shusuke Morizono, Yuji Soejima, Tomoharu Yoshizumi, Shinji Aishima, Shin-ichiro Takasugi, Kengo Yoshimitsu, Munechika Enjoji, Kazuhiro Kotoh, Akinobu Taketomi, Hideaki Uchiyama, Mitsuo Shimada, Hajime Nawata and Yoshihiko Maehara : Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation, Transplantation, Vol.80, No.5, 608-612, 2005. (Summary) The use of steatotic livers is associated with increased primary nonfunction in liver transplantation. To reduce the risk of liver injury, we applied a short-term combination therapy of diet, exercise and drugs for 11 living-donor liver transplantation (LDLT) candidates with steatosis. Subjects were treated with a protein-rich (1000 kcal/day) diet, exercise (600 kcal/day), and bezafibrate (400 mg/day) for 2-8 weeks. The treatment significantly improved macrovesicular steatosis (30+/-4% vs. 12+/-2% [mean +/- SEM], P = 0.0028). Body weight and BMI were significantly reduced (73.7 +/- 3.2 kg vs. 66.9 +/- 2.9 kg, P = 0.0033, 26.4 +/- 0.7 kg/m vs. 24.1 +/- 0.8 kg/m, P = 0.0033). The treatment completely normalized liver function tests and lipid metabolism. Seven treated liver grafts (left lobe) were transplanted to the recipients. We compared transplanted graft function and resected liver function of donors using parameters such as peak total bilirubin, prothrombin time at postoperative day 3, and peak alanine aminotransferase between treated liver (n = 7) and donor liver without hepatic steotosis (n = 37). The transplanted grafts showed good liver functions, and there was no difference between them with respect to functional parameters. The treated donors also showed good liver functions, and no significant differences in functional parameters. The results of this study indicate that our short-term treatment effectively reduced steatosis and contributed to safer LDLT. Our findings also suggest that even severely steatotic livers can be used for LDLT grafting subsequent to our short-term treatment regimen. (Keyword) Adult / Bezafibrate / Biopsy / Dietary Proteins / Exercise / Fatty Liver / Female / Humans / Hypolipidemic Agents / Liver Transplantation / Living Donors / Male / Middle Aged / Preoperative Care / Severity of Illness Index / Tissue and Organ Procurement (Link to Publication Site) ● Publication site (DOI): 10.1097/01.tp.0000166009.77444.f3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16177634 ● Search Scopus @ Elsevier (PMID): 16177634 ● Search Scopus @ Elsevier (DOI): 10.1097/01.tp.0000166009.77444.f3 (DOI: 10.1097/01.tp.0000166009.77444.f3, PubMed: 16177634)
192.	Taketoshi Suehiro, Mitsuo Shimada, Keiji Kishikawa, Tatsuo Shimura, Yuji Soejima, Tomoharu Yoshizumi, Kohji Hashimoto, Yasushi Mochida, Shinji Hashimoto, Yoshihiko Maehara and Hiroyuki Kuwano : Effect of intraportal infusion to improve small for size graft injury in living donor adult liver transplantation, Transplant International, Vol.18, No.8, 923-928, 2005. (Summary) The most important problem in the living donor adult liver transplantation (LDALT) is a small for size graft. Although a right lobe graft is used in many cases in order to avoid small for size graft, for a donor, the risk has few in left lobe graft. We evaluate the effect of an intraportal infusion treatment to the small for size graft. One hundred and twelve patients who underwent LDALT were studied. The graft weight recipient standard liver volume ratio (GV/SLV) of these patients were 50% or less. We divided the patients into following two groups; infusion group (n = 53) and control group (n = 59). For the infusion group, 16 G double lumen catheter was inserted into portal vein and nafamostat mesilate (protease inhibitor which stabilize coagulofibrinolytic state; 200 mg/day), prostaglandin E(1) (vasodilator and hepatoprotective effect; 500 microg/day) and thromboxane A(2) synthetase inhibitor (vasodilator and anticoagulant effect; 160 mg/day) were administrated continuously for 7 days. Small-for-size graft syndrome was defined as bilirubin >10 mg/dl and ascites >1000 cc on postoperative day (POD) 14. Comparison examination of a background factors and postoperative bilirubin and amount of ascites was carried out. The mean GV/SLV did not have the difference at 39.1% of infusion group, and 38.3% of control group (P = 0.58). By the control group, 15 patients (25.4%) were small-for-size graft syndrome, however, there was only two (3.8%) small-for-size graft syndrome in infusion group (P = 0.04). The bilirubin levels of infusion and control group on 7 and 14 POD were 9.9 and 7.8 vs. 9.5 and 10.5 mg/dl, respectively. The amount of ascites of infusion group on 7 and 14 POD were 870 and 430 cc, respectively. On the contrary, in control group, the amount of ascites on 7 and 14 POD were 1290 and 1070 cc, respectively. Bilirubin levels and the amount of ascites on 7 and 14 POD were lower in the patients with infusion group then those with control group. There were no differences between infusion group and control group in age, sex and Child's classification. The intraportal infusion had an effect in prevention of hyperbilirubinemia and loss in quality of excessive ascites in the patients with small for size graft. This was suggested to be what is depended on the improvement of the microcirculation insufficiency considered one of the causes of small-for-size graft syndrome. (Keyword) intra-portal infusion / living donor adult liver transplantation / small for size graft injury (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1432-2277.2005.00159.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16008741 ● Search Scopus @ Elsevier (PMID): 16008741 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1432-2277.2005.00159.x (DOI: 10.1111/j.1432-2277.2005.00159.x, PubMed: 16008741)
193.	Mitsutoshi Fukuyama, Kazuhito Rokutan, Toshiaki Sano, Hidenori Miyake, Mitsuo Shimada and Seiki Tashiro : Overexpression of a novel superoxide-producing enzyme,NADPH oxidase 1,in adenoma and well differentiated adenocarcinoma of the human colon, Cancer Letters, Vol.221, No.1, 97-104, 2005. (Summary) A superoxide-producing enzyme, NADPH oxidase 1 (Nox1), dominantly expressed in the colon, is implicated in the pathogenesis of colon cancer. Immunohistochemistry showed that Nox1 was constitutively expressed in surface mucous cells. Adenomas and well differentiated adenocarcinomas up-regulated Nox1 expression. Ki-67-negative, well differentiated tumor cells contained abundant Nox1, whereas Ki-67-positive, proliferating cells did not express it. This differentiation-dependent expression in normal as well as tumor tissues suggests distinct roles of Nox1 besides mitogenic function. Nuclear factor (NF)-kappaB was predominantly activated in adenoma and adenocarcinoma cells expressing abundant Nox1, suggesting that Nox1 may stimulate NF-kappaB-dependent antiapoptotic pathways in colon tumors. (Keyword) NADPH oxidase 1 / reactive oxygen species / Colon cancer (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2004.08.031 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15797632 ● Summary page in Scopus @ Elsevier: 2-s2.0-15244339921 (DOI: 10.1016/j.canlet.2004.08.031, PubMed: 15797632, Elsevier: Scopus)
194.	Mitsuo Shimada, Yusuke Yonemura, Hideki Ijichi, Noboru Harada, Satoko Shiotani, Mizuki Ninomiya, Takahiro Terashi, Tomoharu Yoshizumi, Yuji Soejima and Yoshihiko Maehara : Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value, Transplantation Proceedings, Vol.37, No.2, 1177-1179, 2005. (Summary) Des-gamma-carboxy prothrombin (DCP) is a sensitive marker related to vascular invasion of hepatocellular carcinoma (HCC). The aim of this study was to clarify the risk factors of HCC recurrence in living donor liver transplantation (LDLT) with special reference to preoperative DCP values. Forty consecutive adult HCC patients who underwent LDLT were examined for a correlation between the DCP value and vascular invasion. Risk factors for recurrence were also investigated using clinicopathological variables including preoperative DCP levels. The incidence of positive histological vascular invasion in patients with DCP values above 300 mAU/mL was higher than that with those with DCP value below 300 mAU/mL. Other significant risk factors for recurrence were over 5 cm tumor diameter, not meeting the Milan criteria, AFP value >400 ng/mL, histological vascular invasion, poorly differentiated histology, and male gender. Among the patients who did not meet the Milan criteria, those with both no more than 5 cm of tumor diameter and no more than 300 mAU/mL DCP exhibited a good prognosis. A high DCP value, namely >300 mAU/mL correlated with histological vascular invasion and was one of the strongest prognostic variables. Therefore, special attention should be paid to HCC patients with high DCP values. No correlation between the number of tumor nodules and recurrence was found; therefore, the Milan criteria may require revision regarding the number of tumor nodules. (Keyword) Adult / Carcinoma, Hepatocellular / Cytidine Diphosphate / Disease-Free Survival / Female / Follow-Up Studies / Humans / Liver Neoplasms / Liver Transplantation / Living Donors / Male / Middle Aged / Neoplasm Invasiveness / Prothrombin Time / Recurrence / Retrospective Studies / Survival Analysis / Time Factors / Tumor Markers, Biological (Link to Publication Site) ● Publication site (DOI): 10.1016/j.transproceed.2004.12.030 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15848661 ● Search Scopus @ Elsevier (PMID): 15848661 ● Search Scopus @ Elsevier (DOI): 10.1016/j.transproceed.2004.12.030 (DOI: 10.1016/j.transproceed.2004.12.030, PubMed: 15848661)
195.	Shinya Morimoto, Noriyuki Nishimura, Tomoya Terai, Shinji Manabe, Yasuyo Yamamoto, Wakako Shinahara, Hidenori Miyake, Seiki Tashiro, Mitsuo Shimada and Takuya Sasaki : Rab13 Mediates the Continuous Endocytic Recycling of Occludin to the Cell Surface, The Journal of Biological Chemistry, Vol.280, No.3, 2220-2228, 2005. (Summary) During epithelial morphogenesis, adherens junctions (AJs) and tight junctions (TJs) undergo dynamic reorganization, whereas epithelial polarity is transiently lost and reestablished. Although ARF6-mediated endocytic recycling of E-cadherin has been characterized and implicated in the rapid remodeling of AJs, the molecular basis for the dynamic rearrangement of TJs remains elusive. Occludin and claudins are integral membrane proteins comprising TJ strands and are thought to be responsible for establishing and maintaining epithelial polarity. Here we investigated the intracellular transport of occludin and claudins to and from the cell surface. Using cell surface biotinylation and immunofluorescence, we found that a pool of occludin was continuously endocytosed and recycled back to the cell surface in both fibroblastic baby hamster kidney cells and epithelial MTD-1A cells. Biochemical endocytosis and recycling assays revealed that a Rab13 dominant active mutant (Rab13 Q67L) inhibited the postendocytic recycling of occludin, but not that of transferrin receptor and polymeric immunoglobulin receptor in MTD-1A cells. Double immunolabelings showed that a fraction of endocytosed occludin was colocalized with Rab13 in MTD-1A cells. These results suggest that Rab13 specifically mediates the continuous endocytic recycling of occludin to the cell surface in both fibroblastic and epithelial cells. (Keyword) Adherens Junctions / Animals / Biotin / Cadherins / Cell Line / Endocytosis / Humans / Membrane Proteins / Microscopy, Fluorescence / Tight Junctions / rab GTP-Binding Proteins (Link to Publication Site) ● Publication site (DOI): 10.1074/jbc.M406906200 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15528189 ● Search Scopus @ Elsevier (PMID): 15528189 ● Search Scopus @ Elsevier (DOI): 10.1074/jbc.M406906200 (DOI: 10.1074/jbc.M406906200, PubMed: 15528189)
196.	森園周祐, 中牟田誠, 国府島庸之, 宮城譲, 吉本剛志, 有村英一郎, 古藤和浩, 遠城寺宗近, Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, Mitsuo Shimada, 前原喜彦 and 名和田新 : Evaluation of Acute Hepatic Failure Treated at the Department of Medicine III, Kyushu University Hospital : Indications for Living-donor Liver Transplantation, Fukuoka Acta Medica, Vol.95, No.12, 321-331, 2004. (Summary) To evaluate indications for living-donor liver transplantation (LDLT), we examined 25 consecutive patients with acute hepatic failure admitted to the Department of Medicine III, Kyushu University Hospital between November 2001 and July 2004. These cases were diagnosed as fluminant hepatitis (n=13), severe-type acute hepatitis (n=11), or late-onset hepatic failure (n=1). Nine patients (36 %) improved with conservative treatment (conservative treatment group), and the other 16 patients (64 %) needed LDLT (LDLT indicated group). In the LDLT indicated group, 11 patients received LDLT, and 4 died because of lack of LDLT donors (n=3), or renal failure (n=1). The LDLT survival rate was 82 % (9/11) ; two patients died due to hepatic infarction and brain edema, respectively. It is very important to predict whether a patient with acute hepatic failure belongs to the conservative treatment group or the LDLT indicated group on admission. Therefore, we analyzed variables that could influence prognosis, including, parameters of hepatic function and platelet counts on admission, and relative hepatic volume (%), which represents the ratio of hepatic volume measured by CT relative to standard hepatic volume calculated with body surface area. Univariate logistic analysis showed that relative hepatic volume, gammaglutamyl transpeptidase (γ-GTP), alkaline phosphatase (ALP), and the ratio of direct bilirubin to total bilirubin (DB/TB) were significant predictors of survival (p < 0.05). Using these factors plus prothrombin time (PT) and total cholesterol, both of which were relatively significant predictors of survival (p < 0.2), we proposed a model for predicting the probability of survival by the stepwise method. Consequently, we proposed a model using four parameters : ALP, GGTP, PT, and relative hepatic volume (Volume) as shown below : P(%) = 1/1+exp { ?(-36 .2375+ALP x 0.0251+ γ-GTP x 0.0102+PT x 0.2558+Volume x 21.2158)} ×100 This model showed a significant correlation between prediction and consequence of survival (r2 = 0.7388, p = 0.0003). In conclusion, LDLT is an effective treatment for acute hepatic failure. The results of this study suggested that our model can adequately predict prognosis in the early phase of acute hepatic failure. (Keyword) Adult / Alkaline Phosphatase / Female / Humans / Liver / Liver Failure, Acute / Liver Transplantation / Living Donors / Male / Prothrombin Time / Survival Rate / gamma-Glutamyltransferase (Link to Publication Site) ● Publication site (DOI): 10.15017/19252 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15732374 ● CiNii @ National Institute of Informatics (CRID): 1390009224763706112 ● Search Scopus @ Elsevier (PMID): 15732374 ● Search Scopus @ Elsevier (DOI): 10.15017/19252 (DOI: 10.15017/19252, PubMed: 15732374, CiNii: 1390009224763706112)
197.	Noboru Harada, Mitsuo Shimada, Shinji Okano, Taketoshi Suehiro, Yuji Soejima, Yukihiro Tomita and Yoshihiko Maehara : IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice, The Journal of Immunology, Vol.173, No.11, 6635-6644, 2004. (Summary) Immunosuppressive therapy for organ transplantation is essential for controlling rejection. When liver transplantation is performed as a therapy for hepatocellular carcinoma (HCC), recurrent HCC is one of the most fatal complications. In this study, we show that intratumoral murine IL-12 (mIL-12) gene therapy has the potential to be an effective treatment for malignancies under immunosuppression. C3H mice (H-2(k)), injected with FK506 (3 mg/kg) i.p., were s.c. implanted with 2.5 x 10(6) MH134 cells (H-2(k)) and we treated the established HCC with electroporation-mediated gene therapy using mIL-12 plasmid DNA. Intratumoral gene transfer of mIL-12 elevated intratumoral mIL-12, IFN-gamma, and IFN-gamma-inducible protein-10, significantly reduced the number of microvessels and inhibited the growth of HCC, compared with HCC-transferred control pCAGGS plasmid. The inhibition of tumor growth in immunosuppressed mice was comparable with that of mIL-12 gene therapy in immunocompetent mice. Intratumoral mIL-12 gene therapy enhanced lymphocytic infiltration into the tumor and elicited the MH134-specific CTL response even under FK506. The dose of FK506 was sufficient to prevent the rejection of distant allogenic skin grafts (BALB/c mice, H-2(d)) and tumors, B7-p815 (H-2(d)) used as transplants, during mIL-12 gene therapy against MH134. Ab-mediated depletion studies suggested that the inhibition of tumor growth, neovascularization, and spontaneous lung metastasis by mIL-12 was dependent almost entirely on NK cells and partially on T cells. These results suggest that intratumoral mIL-12 gene therapy is a potent effective strategy not only to treat recurrences of HCC in liver transplantation, but also to treat solid malignant tumors in immunosuppressed patients with transplanted organ. (Keyword) Angiogenesis Inhibitors / Animals / Antineoplastic Agents / Carcinoma, Hepatocellular / Cell Line, Tumor / Dose-Response Relationship, Immunologic / Electroporation / Female / Gene Transfer Techniques / Genetic Therapy / Genetic Vectors / Graft Rejection / Growth Inhibitors / Immunosuppressive Agents / Interleukin-12 / Killer Cells, Natural / Liver Neoplasms, Experimental / Mice / Mice, Inbred BALB C / Mice, Inbred C3H / Neoplasm Metastasis / Neoplasm Transplantation / Skin Transplantation / T-Lymphocyte Subsets / T-Lymphocytes, Cytotoxic / Tacrolimus (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15557154 ● Search Scopus @ Elsevier (PMID): 15557154 (PubMed: 15557154)
198.	Satoko Shiotani, Mitsuo Shimada, Yuji Soejima, Tomoharu Yoshizumi, Shinji Uemoto, Tetsuya Kiuchi, Koichi Tanaka and Yoshihiko Maehara : S100beta protein: The preoperative new clinical indicator of brain damage in patients with fulminant hepatic failure, Transplantation Proceedings, Vol.36, No.9, 2713-2716, 2004. (Summary) The aim of this study was to clarify the role of serum S100 beta on the accurate assessment of reversibility of brain damage after fulminant hepatic failure (FHF). Among the 13 patients with FHF enrolled in this study, 12 underwent living donor liver transplantation; one patient could not the procedure because of volvulus of the sigmoid colon. Serum S100 beta was serially measured using a chemiluminescent immunoassay. Preoperative serum S100 beta in patients with diffuse brain edema was significantly higher than that in patients with localized brain edema (P < 0.05). Patients with preoperative brain death showed serum S100 beta levels over 7.0 microg/L. Serum S100 beta levels correlated with the degree of brain edema of FHF. It has the potential to be a new clinical, noninvasive indicator of brain damage due to FHF. (Keyword) Adult / Atrophy / Biological Markers / brain / Brain Death / Brain Edema / Electroencephalography / Female / Humans / infant / Liver Failure, Acute / Liver Transplantation / Male / Middle Aged / S100 Proteins (Link to Publication Site) ● Publication site (DOI): 10.1016/j.transproceed.2004.09.030 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15621131 ● Search Scopus @ Elsevier (PMID): 15621131 ● Search Scopus @ Elsevier (DOI): 10.1016/j.transproceed.2004.09.030 (DOI: 10.1016/j.transproceed.2004.09.030, PubMed: 15621131)
199.	Satoko Shiotani, Mitsuo Shimada, Taketoshi Suehiro, Yuji Soejima, Tomoharu Yosizumi, Hiroaki Shimokawa and Yoshihiko Maehara : Involvement of Rho-kinase in cold ischemia-reperfusion injury after liver transplantation in rats, Transplantation, Vol.78, No.3, 375-382, 2004. (Summary) Reperfusion of ischemic tissues is known to cause the generation of reactive oxygen species (ROS) with resultant tissue damage. However, the sources of ROS in reperfused tissues are not fully characterized. We hypothesized that the small GTPase Rho and its target effector Rho-kinase/ROK/ROCK are involved in the oxidative burst in reperfused tissue with resultant reperfusion injury. In an in vivo rat model of liver transplantation using cold ischemia for 12 hr followed by reperfusion, a specific Rho-kinase inhibitor, fasudil (30 mg/kg), was administered orally 1 hr before the transplantation. Fasudil suppressed the ischemia-reperfusion (I/R)-induced generation of ROS after reperfusion (P<0.01) and also suppressed the release of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta) 3 hr after reperfusion, resulting in a significant reduction of I/R-induced hepatocellular injury (P<0.05), necrosis, apoptosis (P<0.01), and neutrophil infiltration (P<0.0001) 12 hr after reperfusion. All animals receiving a graft without fasudil died within 3 days, whereas 40% of those receiving fasudil survived (P<0.001). The present study demonstrates that Rho-kinase-mediated production of ROS and inflammatory cytokines are substantially involved in the pathogenesis of hepatocellular necrosis and apoptosis induced by cold I/R in vivo and that Rho-kinase may be regarded as a novel therapeutic target for the disorder. (Keyword) Alanine Transaminase / Animals / Aspartate Aminotransferases / cytokinesis / Graft Survival / Intracellular Signaling Peptides and Proteins / ischemia / Liver / Liver Circulation / Liver Transplantation / Male / Models, Animal / Protein-Serine-Threonine Kinases / Rats / Rats, Inbred BN / reactive oxygen species / Reperfusion Injury / Time Factors / Transplantation, Isogeneic / rho-Associated Kinases (Link to Publication Site) ● Publication site (DOI): 10.1097/01.TP.0000128618.41619.E7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15316365 ● Search Scopus @ Elsevier (PMID): 15316365 ● Search Scopus @ Elsevier (DOI): 10.1097/01.TP.0000128618.41619.E7 (DOI: 10.1097/01.TP.0000128618.41619.E7, PubMed: 15316365)
200.	Mitsuo Shimada, Hideki Ijichi, Yusuke Yonemura, Noboru Harada, Satoko Shiotani, Mizuki Ninomiya, Tomoharu Yoshizumi, Yuji Soejima, Taketoshi Suehiro and Yoshihiko Maehara : Is graft size a major risk factor in living-donor adult liver transplantation?, Transplant International, Vol.17, No.6, 310-316, 2004. (Summary) Graft size is known to be a major risk factor in living donor adult liver transplantation (LDALT). The aim of this study is to reassess whether graft size is a critical factor in LDALT or not. A series of 75 LDALTs excluding auxiliary transplantation and ABO blood-type incompatible transplantation were analyzed. The patients were divided into two groups, according to graft volume (GV) and standard liver volume (SLV): group 1 (small-size group) (GV/SLV: <40%), and group 2 (non-small-size group) (> or =40%). Perioperative clinical data were compared between the two groups, including graft survival and postoperative complications. These parameters were also compared under the conditions of cirrhotic recipients. No difference in graft survival was found between the two groups. No difference was found in incidence of postoperative complications, such as intractable ascites and persistent hyperbilirubinemia. Even in cirrhotic patients with Child-Pugh's class C, there was no difference in graft survival between the two groups. Risk factors related to graft loss were a preoperative urgent status due to chronic liver disease, pre-operative hyperbilirubinemia of over 10 mg/dl, and ABO blood type of not identical but compatible combination between donor and recipient. Graft size is not always considered to be a major risk factor in LDALT, although the number of patients was small in this study. Therefore, a left-lobe graft, even a "small-for-size" graft for adult recipients, remains a feasible option in LDALT. (Keyword) Small-for-size graft / Left-lobe graft / Graft survival / Cholestasis / Intractable ascites (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1432-2277.2004.tb00448.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15221124 ● Search Scopus @ Elsevier (PMID): 15221124 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1432-2277.2004.tb00448.x (DOI: 10.1111/j.1432-2277.2004.tb00448.x, PubMed: 15221124)
201.	Noboru Harada, Mitsuo Shimada, Tomoharu Yoshizumi, Taketoshi Suehiro, Yuji Soejima and Yoshihiko Maehara : A simple and accurate formula to estimate left hepatic graft volume in living-donor adult liver transplantation, Transplantation, Vol.77, No.10, 1571-1575, 2004. (Summary) In the field of living-donor adult liver transplantation, a small-for-size graft often occurs, particularly when using left-lobe grafts. This is because of the limited volumes associated with left-lobe grafts. The accurate preoperative evaluation of graft volumes is crucial to avoid this complication. The aim of this study is to clarify the usefulness of a new formula to estimate the left-lobe graft volume. In 61 left-lobe grafts, a new formula was created with stepwise regression analysis using the following variables: height, weight, the thoracic and abdominal distance from anterior to posterior side (A-P), and distance from left to right side (L-R) of the initial 20 donors. With another 41 donors, the difference between the actual and estimated graft volume using the formula and two- and three-dimensional computed tomography was prospectively evaluated. On the basis of the results of the stepwise regression analysis, a new formula was created as follows: graft volume (ml) = 313.4 + 7.7 x weight (kg)-12.6 x thoracic L-R (cm). The difference between the actual and estimated graft volumes using the formula was significantly better (10.8 +/- 9.5%) than that of the volumetry using two-dimensional computed tomography (16.3 +/- 10.1%) (P < 0.05). In conclusion, the new formula can estimate the actual graft volume more accurately than conventional volumetry with two-dimensional computed tomography. The formula is useful to estimate the volume of left-lobe graft in living-donor adult liver transplantation. (Keyword) Adult / Female / Humans / Imaging, Three-Dimensional / Liver / Liver Transplantation / Living Donors / Male / Middle Aged / Models, Anatomic / Organ Size / Predictive Value of Tests / Preoperative Care / Regression Analysis / Tissue and Organ Harvesting / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1097/01.TP.0000131991.10802.AA (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15239624 ● Search Scopus @ Elsevier (PMID): 15239624 ● Search Scopus @ Elsevier (DOI): 10.1097/01.TP.0000131991.10802.AA (DOI: 10.1097/01.TP.0000131991.10802.AA, PubMed: 15239624)
202.	Mitsuo Shimada, Hideki Ijichi, Yusuke Yonemura, Noboru Harada, Satoko Shiotani, Mizuki Ninomiya, Takahiro Terashi, Tomoharu Yoshizumi, Yuji Soejima, Taketoshi Suehiro and Yoshihiko Maehara : The impact of splenectomy or splenic artery ligation on the outcome of a living donor adult liver transplantation using a left lobe graft, Hepato-Gastroenterology, Vol.51, No.57, 625-629, 2004. (Summary) The aim of this study was to clarify the impact of splenectomy or splenic artery ligation on the outcome in living donor adult liver transplantation (LDALT) using a left lobe graft. Forty-eight LDALT cases using a left lobe graft were enrolled in this study. The patients were classified into two groups: Group A (n=40), in which neither a splenectomy nor a splenic artery ligation was performed, and Group B (n=8), in which a splenectomy (n=6) or a splenic artery ligation (n=2) was performed. Indications for splenectomy were as follows: 1) demonstrating a hypersplenism and/or 2) having splenic aneurysms. None of the patients receiving a splenectomy or a splenic artery ligation experienced any septic complication in this series. The graft-recipient weight ratio in group B tended to be smaller than in group A. In group B, all patients were classified into Child's class C or B. The incidence of esophageal varices in group B was significantly higher than in group A. Moreover, the platelet count and the white blood cell count in group B were significantly lower than in group A. No statistical difference was found in postoperative functional cholestasis and intractable ascites. None of the participants in group B experienced both postoperative hyperbilirubinemia and intractable ascites, which were characterized as a small-for-size graft after LDALT. The patient survival rate in group B seems to be better than in group A. In a majority of the cases the portal pressure as well as the portal vein flow after a splenectomy decreased in comparison to that before the splenectomy. Splenectomy or splenic artery ligation is considered to be beneficial for improving the outcome in LDALT using a left lobe graft. (Keyword) Adult / Female / Humans / Ligation / Liver Transplantation / Living Donors / Male / Middle Aged / Splenectomy / Splenic Artery / Treatment Outcome (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15143878 ● Search Scopus @ Elsevier (PMID): 15143878 (PubMed: 15143878)
203.	Shinji Itoh, Takashi Maeda, Mitsuo Shimada, Shin-ichi Aishima, Ken Shirabe, Shinji Tanaka and Yoshihiko Maehara : Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma, Clinical Cancer Research, Vol.10, No.8, 2812-2817, 2004. (Summary) Although hepatocellular carcinoma (HCC) is the most common cancer of the human liver, the mechanisms that regulate HCC development and progression remain unclear. The aim of this study was to investigate whether focal adhesion kinase (FAK) is involved in the progression of human HCC. Western blot analysis for FAK was performed on three HCC cell lines. We reviewed 64 consecutive patients who had undergone initial liver resection for HCC without preoperative treatment. Immunohistochemistry analysis for FAK was performed on paraffin-embedded tissues. FAK expression was confirmed by Western blot analysis in several clinical samples. We investigated the correlation between FAK expression and clinical outcome. FAK proteins were detected in all HCC cell lines. Hepatocytes in the normal liver and chronic hepatitis with or without cirrhosis were negative for immunohistochemical staining for FAK expression. Cytoplasmic FAK expression was observed in 18 of 64 patients (28.1%), and this positive staining was correlated with gender (P < 0.05), a lower level of serum albumin (P < 0.05), and portal venous invasion (P < 0.01). Positive staining for FAK was associated with significantly poorer survival (P < 0.05). In multivariate analysis, FAK overexpression was an independent factor in determining the prognosis of patients. These data suggest that FAK plays an important role in promoting tumor progression, especially vascular invasion, in HCC. FAK could play an important role in HCC progression and would be a novel target for HCC therapeutics as well as a prognostic marker. (Keyword) Aged / Blotting, Western / Carcinoma, Hepatocellular / Cell Line, Tumor / Disease Progression / Female / Focal Adhesion Kinase 1 / Focal Adhesion Protein-Tyrosine Kinases / Humans / Immunohistochemistry / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Invasiveness / Prognosis / Proportional Hazards Models / Protein-Tyrosine Kinases / Time Factors / Treatment Outcome / Tumor Markers, Biological (Link to Publication Site) ● Publication site (DOI): 10.1158/1078-0432.CCR-1046-03 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15102689 ● Search Scopus @ Elsevier (PMID): 15102689 ● Search Scopus @ Elsevier (DOI): 10.1158/1078-0432.CCR-1046-03 (DOI: 10.1158/1078-0432.CCR-1046-03, PubMed: 15102689)
204.	Ken Shirabe, Mitsuo Shimada, Eiji Tsujita, Shin-ichi Aishima, Shin-ichiro Maehara, Shinji Tanaka, Kenji Takenaka and Yoshihiko Maehara : Prognosis factors in node-negative intrahepatic cholangiocaecinoma eith special reference to angiogenesis, The American Journal of Surgery, Vol.187, No.4, 538-542, 2004. (Summary) The aim of this study was to clarify prognostic factors and recurrence patterns in patients with node-negative intrahepatic cholangiocarcinoma (IHCC). A retrospective study was performed to review prognostic factors and recurrence patterns (1) in 22 patients with node-negative IHCC after curative hepatic resection and (2) in 49 patients who underwent resection and lymph node dissection for IHCC. In addition to determining the clinicopathologic factors, the investigators also performed immunohistochemical examination of microvessel counts using antihuman CD-31 and antibody. The significant poor prognostic factors in node-negative IHCC were the presence of intrahepatic metastasis, portal vein invasion of cancer cells, and high microvessel counts. After multivariate analysis was conducted, the independent poor prognostic factors were the presence of intrahepatic metastases and high microvessel counts. Of 9 patients who had postoperative recurrence of their disease, intrahepatic recurrence was observed in 7 (78 %). The factors linked to poor prognosis in IHCC were tumor angiogenesis and the presence of intrahepatic metastasis. Because intrahepatic recurrence was common, regional and adjuvant chemotherapy to the liver may improve the outcome of patients with these risk factors and node-negative IHCC. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Female / Humans / Male / Microcirculation / Middle Aged / Prognosis / Recurrence / Retrospective Studies / Survival Rate / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.amjsurg.2003.12.044 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15041507 ● Search Scopus @ Elsevier (PMID): 15041507 ● Search Scopus @ Elsevier (DOI): 10.1016/j.amjsurg.2003.12.044 (DOI: 10.1016/j.amjsurg.2003.12.044, PubMed: 15041507)
205.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro, Shoji Hiroshige, Hisashi Gondo, Akiyoshi Takami, Shizuka Yasue and Yoshihiko Maehara : Graft-versus-host disease following living donor liver transplantation, Liver Transplantation, Vol.10, No.3, 460-464, 2004. (Summary) Graft-versus-host disease (GVHD) is the most common and well-known cause of morbidity and mortality following allogeneic bone marrow transplantation. Sporadic cases have been reported after cadaveric donor liver transplantation with usually fatal outcomes, however, the actual incidence and the characteristics of GVHD after living donor liver transplantation (LDLT) remain unknown. We herein report a person who developed fatal GVHD following LDLT and discuss the applicability of an HLA-homozygous donor to an HLA-haploidentical recipient. A 48-year-old male underwent LDLT for unresectable hepatocellular carcinoma with alcoholic liver cirrhosis. The donor was his 20-year-old son whose pretransplant HLA typing was homozygous at all loci. GVHD occurred 35 days after LDLT and was characterized by fever, diarrhea, maculopapular rash, and leukopenia, which led to the development of fatal pneumonia. We identified 4 cases of GVHD after LDLT in Japan and 1 in the United States, all associated with the use of an HLA-homozygous donor. The use of an HLA homozygous donor which results in a complete 1-way donor-recipient HLA match carries an extremely high risk of developing GVHD after LDLT. Therefore, it is possible that LDLT should be ruled out for such donors. A pretransplant work-up of the HLA type in both the donors and recipients is therefore imperative before determining the indications for LDLT. (Keyword) Fatal Outcome / Graft vs Host Disease / HLA Antigens / Humans / Liver Transplantation / Living Donors / Male / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1002/lt.20101 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15004778 ● Search Scopus @ Elsevier (PMID): 15004778 ● Search Scopus @ Elsevier (DOI): 10.1002/lt.20101 (DOI: 10.1002/lt.20101, PubMed: 15004778)
206.	Mizuki Ninomiya, Mitsuo Shimada, Takahiro Terashi, Hideki Ijichi, Yusuke Yonemura, Noboru Harada, Yuji Soejima, Taketoshi Suehiro and Yoshihiko Maehara : Sustained spatial disturbance of bile canalicular networks during regeneration of the steatotic rat liver, Transplantation, Vol.77, No.3, 373-379, 2004. (Summary) Although it is generally considered that livers with moderate steatosis can be safely used in the setting of living-donor liver transplantation, the effect of the regenerative process of such a graft on postoperative liver function is incompletely understood. We assessed the morphologic and functional alterations during the regeneration of fatty liver, with special reference to the biliary system. Wistar rats with normal or fatty livers induced by a choline-deficient diet were subjected to 70% partial hepatectomy (PH). The regenerated liver weight and serum parameters were compared. Furthermore, to assess the spatial alterations of bile canalicular networks, the distribution of AGp110, a fibronectin receptor that localizes on the apical (bile canalicular) membrane of the hepatocytes, was analyzed immunohistochemically. The serum albumin levels of the fatty-liver rats decreased significantly after 24 hours, and this continued until day 7. The increase in the total bile acid levels of the fatty-liver group was higher and more prolonged compared with that of the normal-liver group. At 24 hours after PH, discontinuity of the AGp110-positive canalicular network was evident in both groups. At 7 days after PH, the typical AGp110-positive canalicular network was almost restored in the normal-liver group. In contrast, the fatty-liver group showed sustained discontinuity of canalicular networks at the same time point. The livers with moderate steatosis are associated with prolonged cholestasis after 70% PH, and this was caused, in part, by sustained spatial disturbance of bile canalicular networks during the regenerative process. (Keyword) Animal Nutritional Physiological Phenomena / Animals / Bile Acids and Salts / Bile Canaliculi / Biliary Tract / Fatty Liver / Hepatectomy / Immunohistochemistry / Liver / Liver Regeneration / Male / Organ Size / Rats / Rats, Wistar / Receptors, Fibronectin / Serum Albumin / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1097/01.TP.0000109777.51902.09 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14966410 ● Search Scopus @ Elsevier (PMID): 14966410 ● Search Scopus @ Elsevier (DOI): 10.1097/01.TP.0000109777.51902.09 (DOI: 10.1097/01.TP.0000109777.51902.09, PubMed: 14966410)
207.	Mizuki Ninomiya, Mitsuo Shimada, Noboru Harada, Yuji Soejima, Taketoshi Suehiro and Yoshihiko Maehara : The hydroxyl radical scavenger MCI-186 protects the liver from exprimental cold ischaemia-reperfusion injury, The British Journal of Surgery, Vol.91, No.2, 184-190, 2004. (Summary) Oxidative stress contributes to hepatic ischaemia-reperfusion (IR) injury in a biphasic pattern. In addition to direct cytotoxic effects, oxidative stress also initiates the signal transduction processes that promote second-phase liver injury. The present study investigated the effects of the hydroxyl radical scavenger MCI-186 on the biphasic process of hepatic cold IR injury. After cold preservation for 16 h, rat livers were reperfused on an isolated liver perfusion system for 120 min with oxygenated Krebs-Henseleit bicarbonate buffer. Perfusate samples were obtained serially, and portal flow rates were also recorded. To determine whether MCI-186 affected cytokine levels that control the second-phase injury, levels of interleukin (IL) 10 and tumour necrosis factor (TNF) alpha were measured in the perfusate. Addition of MCI-186 1 mg/l into the perfusate significantly improved portal flow (P<0.050), hepatic enzyme release into the perfusate (P=0.038), total bile production (P=0.029) and malondialdehyde concentration (P=0.038). Furthermore, treatment with MCI-186 led to a substantial increase in IL-10 release (P=0.032). TNF-alpha levels were not affected. MCI-186, an agent ready for clinical use, appears to have direct and indirect protective effects against hepatic cold IR injury. (Keyword) Animals / Antipyrine / Cold Temperature / Free Radical Scavengers / Hydroxyl Radical / Interleukin-10 / Liver / Liver Diseases / Male / Organ Size / RNA, Messenger / Rats / Rats, Wistar / Reperfusion Injury / Weight Gain (Link to Publication Site) ● Publication site (DOI): 10.1002/bjs.4401 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14760666 ● Search Scopus @ Elsevier (PMID): 14760666 ● Search Scopus @ Elsevier (DOI): 10.1002/bjs.4401 (DOI: 10.1002/bjs.4401, PubMed: 14760666)
208.	調憲, Mitsuo Shimada, 武冨紹信, Yuji Soejima, 吉住朋晴, 祇園智信, 北川大, 伊藤心二, 播本憲史 and 前原喜彦 : 進行肝癌に対するGFP療法を基本とした集学的治療, 消化器科, Vol.39, 224-228, 2004.
209.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, 祇園智信, Mitsuo Shimada and 前原喜彦 : 進行肝細胞癌に対する根治的治療法としての生体肝移植, Japanese Journal of Cancer Clinics, Vol.50, 913-919, 2004.
210.	末廣剛敏, Mitsuo Shimada, Yuji Soejima, 吉住朋晴 and 前原喜彦 : 急性肝不全生体肝移植症例の再検討, 消化器科, Vol.38, 122-130, 2004.
211.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro, Keiji Kishikawa, Tomoharu Yoshizumi, Koji Hashimoto, Ryosuke Minagawa, Shoji Hiroshige, Takahiro Terashi, Mizuki Ninomiya, Satoko Shiotani, Noboru Harada and Keizo Sugimachi : Use of steatotic graft in living-donor liver transplantation, Transplantation, Vol.76, No.2, 344-348, 2003. (Summary) The degree of fatty infiltration in hepatic grafts is known to be an important risk factor for primary graft nonfunction in cadaveric liver transplantation. However, the effect of hepatic steatosis in living-donor liver transplantation (LDLT) has not yet been well defined. In this study, we evaluated the impact that the degree of hepatic graft steatosis has on the outcome of LDLT. Sixty consecutive donors and recipients who underwent LDLT between October 1996 and August 2001 at Kyushu University Hospital were the subjects of this study. The pathologic findings of the prereperfusion biopsy of the graft were classified into the following three groups according to the degree of macrovesicular steatosis: None (n=23), 0% steatosis; Mild (n=23), 0% to 20% steatosis; and Moderate (n=6), 20% to 50% steatosis. Liver function tests including total bilirubin (at postoperative day [POD] 7), the peak alanine aminotransferase (ALT) and prothrombin time (at POD 3), and both patient and graft survival were compared among the groups. Furthermore, we also compared the donor parameters including the peak ALT and total bilirubin (at POD 3) and the operative time, blood loss, and length of hospital stay after surgery. The 1-year patient and graft survival were comparable among the groups. The peak ALT was significantly higher in the Moderate group (606+/-641 IU/L) than in the None (290+/-190 IU/L) and Mild (376+/-296 IU/L) groups. Total bilirubin (POD 7) and prothrombin time (POD 3) were comparable among the groups. The donor parameters were comparable among the groups except for the fact that the donor body weight of the Mild and Moderate groups were significantly heavier (P<0.0001) than that of the None group. In conclusion, the use of a fatty liver graft up to the moderate level can be justified in LDLT, even though ischemia-reperfusion injury tends to be severe in such grafts. (Keyword) Adult / Alanine Transaminase / Bilirubin / Biopsy / Body Weight / Child / Fatty Liver / Female / Graft Survival / Humans / Liver Transplantation / Living Donors / Male / Middle Aged / Prothrombin Time / Severity of Illness Index (Link to Publication Site) ● Publication site (DOI): 10.1097/01.TP.0000071205.52835.A4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12883190 ● CiNii @ National Institute of Informatics (CRID): 1361137045548000768 ● Search Scopus @ Elsevier (PMID): 12883190 ● Search Scopus @ Elsevier (DOI): 10.1097/01.TP.0000071205.52835.A4 (DOI: 10.1097/01.TP.0000071205.52835.A4, PubMed: 12883190, CiNii: 1361137045548000768)
212.	Koji Hashimoto, Mitsuo Shimada, Taketoshi Suehiro, Yuji Soejima, Ryosuke Minagawa, Shoji Hiroshige, Satoko Shiotani, Mizuki Ninomiya, Noboru Harada, Kimihiro Komori and Keizo Sugimachi : Gore-Tex jump graft for portal vein thrombosis following living donor liver transplantation, Hepato-Gastroenterology, Vol.50, No.52, 1146-1148, 2003. (Summary) Portal vein thrombosis is a rare surgical complication following liver transplantation, which remains a cause of graft loss and death. We describe here the treatment of portal vein thrombosis following living donor liver transplantation using an extended left lobe graft. The patient was treated with a Gore-Tex vascular jump graft extra-anatomically interposed between the recipient superior mesenteric vein and the donor umbilical vein. This technique allowed the hepatic hilum to be left untouched and supplied suitable blood flow to the hepatic allograft. Our experience suggests that this innovative technical solution can be helpful in the effort to rescue cases of hepatic allograft with vascular complications. (Keyword) Adult / Blood Vessel Prosthesis Implantation / Humans / Liver Circulation / Liver Cirrhosis / Liver Transplantation / Living Donors / Male / Portal System / Portal Vein / Regional Blood Flow / Venous Thrombosis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12846001 ● Search Scopus @ Elsevier (PMID): 12846001 (PubMed: 12846001)
213.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro, Shoji Hiroshige, Mizuki Ninomiya, Satoko Shiotani, Noboru Harada, Ijichi Hideki, Yusuke Yonemura and Yoshihiko Maehara : Outcome analysis in adult-to-adult living donor liver transplantation using the left lobe, Liver Transplantation, Vol.9, No.6, 581-586, 2003. (Summary) Graft size problems remain the greatest limiting factor for expansion of living donor liver transplantation (LDLT) to the adult population. The result of adult-to-adult LDLT using the left lobe with special reference to graft size has not been fully evaluated to date. In this study, we evaluated the outcome of adult-to-adult LDLT using the left lobe and also analyze the impact of using small-for-size grafts on outcome. Thirty-six recipients who underwent adult-to-adult LDLT using the left lobe (n = 14) or left lobe plus caudate lobe (n = 22) were included in the study. Variables including preoperative and operative data, patient and graft survival, complications, and causes of graft loss were studied. Furthermore, the incidence of small-for-size syndrome and its impact on graft survival were studied. Mean graft volume (GV) was 420 +/- 85 g (range, 260 to 620 g), which resulted in 38.2% +/- 8.1% (range, 22.8% to 53.8%) of the recipient standard liver volume (SLV). Overall 1-year patient and graft survival rates were 85.7% and 82.9%, respectively. Seven grafts were lost. Small-for-size syndrome occurred in 7 of 16 patients (43.8%) with cirrhosis and only 1 of 20 patients (5.0%) without cirrhosis (P =.005). Recipients who developed small-for-size syndrome had inferior graft survival to those who did not (P =.07). In conclusion, adult-to-adult LDLTs were found to be feasible without affecting patient or graft survival. Small-for-size syndrome developed more frequently in patients with cirrhosis. Minimum GV in adult-to-adult LDLT should be 30% less than the recipient's SLV in patients without cirrhosis, whereas 45% less was required in patients with cirrhosis. (Keyword) Adult / Aged / Female / Graft Survival / Humans / Incidence / Liver Cirrhosis / Liver Transplantation / Living Donors / Male / Middle Aged / Organ Size / Postoperative Complications / Risk Factors / Survival Rate / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1053/jlts.2003.50114 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12783399 ● Search Scopus @ Elsevier (PMID): 12783399 ● Search Scopus @ Elsevier (DOI): 10.1053/jlts.2003.50114 (DOI: 10.1053/jlts.2003.50114, PubMed: 12783399)
214.	Keishi Sugimachi, Shinji Tanaka, Toshifumi Kameyama, Ken-ichi Taguchi, Shin-ichi Aishima, Mitsuo Shimada, Keizo Sugimachi and Masazumi Tsuneyoshi : Transcriptional repressor snail and progression of human hepatocellular carcinoma., Clinical Cancer Research, Vol.9, No.7, 2657-2664, 2003. (Summary) Snail protein is a suppressive transcriptional factor of E-cadherin that mediates cell-to-cell adhesion, tumor progression, and metastases. We explored the expression and function of Snail and its family member Slug in human hepatocellular carcinoma (HCC) to identify its role in tumor progression. Transfection of Snail cDNA in Li-7, endogenous E-cadherin-positive human HCC cells, selectively induced the loss of E-cadherin protein expression. We then investigated the expression of Snail and Slug mRNA in 43 human tissue samples of HCC. Using in situ hybridization, Snail mRNA was determined to dominantly express in HCC cells, but not in bile duct cells, blood vessels or infiltrating leukocytes. The mRNA of Snail and Slug were quantified using real-time reverse transcriptase-PCR, and correlations with E-cadherin expression and clinicopathological factors were investigated. Snail mRNA was overexpressed in 7 cases (16%) of HCC compared with adjacent noncancerous liver tissue. E-Cadherin protein expression determined in the same 43 cases by immunohistochemistry was significantly down-regulated in those cases with Snail mRNA overexpression (P = 0.04). The tumor and nontumor ratio of Snail mRNA independently correlated with tumor invasiveness (P = 0.04). However, Slug mRNA correlated with neither E-cadherin expression nor tumor invasiveness. The data indicate that Snail both down-regulates E-cadherin expression and promotes the invasion in human HCC. (Keyword) Aged / Bile Ducts / Cadherins / Carcinoma, Hepatocellular / Cloning, Molecular / DNA, Complementary / DNA-Binding Proteins / Disease Progression / Down-Regulation / Female / Green Fluorescent Proteins / Humans / Immunohistochemistry / In Situ Hybridization / Leukocytes / Liver Neoplasms / Luminescent Proteins / Male / Microscopy, Fluorescence / Middle Aged / Neoplasm Invasiveness / Neoplasm Metastasis / Protein Structure, Tertiary / RNA, Messenger / Retrospective Studies / Reverse Transcriptase Polymerase Chain Reaction / Tissue Distribution / Transcription Factors / Transcription, Genetic / Transfection (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12855644 ● Search Scopus @ Elsevier (PMID): 12855644 (PubMed: 12855644)
215.	Shoji Hiroshige, Mitsuo Shimada, Noboru Harada, Satoko Shiotani, Mizuki Ninomiya, Ryousuke Minagawa, Yuji Soejima, Taketoshi Suehiro, Hiroshi Honda, Makoto Hashizume and Keizo Sugimachi : Accurate preoperative estimatin of liver-graft volumetry using three-dimensional computed tomography, Transplantation, Vol.75, No.9, 1561-1564, 2003. (Summary) The aim of this study was to clarify the value of three-dimensional computed-tomography (3D-CT) volumetry for size matching in living-donor liver transplantation (LDLT). 3D-CT volumetry was applied to 25 donors who underwent hepatectomy for a living relative needing an orthotopic liver transplantation. Fifteen patients underwent extended left lobectomy, one patient an extended left lateral lobectomy, and nine patients right lobectomy. 3D-CT imaging was performed with the workstation ZIO M900 (Zio Software Inc., Tokyo, Japan). The estimated volume of the grafts in two-dimensional (2D) and 3D images were compared, and an error ratio was calculated. 3D-CT imaging revealed the anatomy of the hepatic vein bifurcation and the shape of the graft. The error ratio was 12.8+/-2.3% in 3D, compared with 19.4+/-2.5% in 2D. As such, 3D-CT volumetry appears to be more exact than conventional 2D-CT volumetry, but volumetry by 3D-CT still produces an error ratio of approximately 13%. The weight transition of the rats' livers under preservation in University of Wisconsin (UW) solution indicated that the graft volume seems to decrease during perfusion with UW solution. Mismatch of the cutting line and volume reduction by dehydration (approximately 5% reduction 1 hour after perfusion) seems to cause the error in 3D-CT volumetry. Three-dimensional CT volumetry is useful for size matching in cases of living-related orthotopic liver transplantation. (Keyword) Adult / Aged / Animals / Female / Humans / Imaging, Three-Dimensional / Liver / Liver Transplantation / Male / Middle Aged / Rats / Rats, Sprague-Dawley / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1097/01.TP.0000053755.08825.12 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12792515 ● Search Scopus @ Elsevier (PMID): 12792515 ● Search Scopus @ Elsevier (DOI): 10.1097/01.TP.0000053755.08825.12 (DOI: 10.1097/01.TP.0000053755.08825.12, PubMed: 12792515)
216.	Shinji Tanaka, Keishi Sugimachi, Toshifumi Kameyama, Shin-ichiro Maehara, Ken Shirabe, Mitsuo Shimada, Jack R. Wands and Yoshihiko Maehara : Human WISP1v, a menber of CCN family, is associated with invasive cholangiocarcinoma, Hepatology, Vol.37, No.5, 1122-1129, 2003. (Summary) Family members of the connective tissue growth factor, cysteine-rich 61, nephroblastoma over-expressed gene (CCN) encode cysteine-rich secreted proteins with roles in human fibrotic disorders and tumor progression. In this study, we identified a CCN family member, WISP1v, as over-expressed in human cholangiocarcinomas. Genetic analysis of WISP1v was performed on surgically resected specimens of cholangiocarcinoma. The WISP1v biological effects were analyzed using the HuCCT1 human cholangiocarcinoma cell line. The WISP1v gene was expressed in 19 of 39 cholangiocarcinoma tissues (49%) but not in normal livers. Expression of WISP1v was significantly associated with lymphatic and perineural invasion of tumor cells (P <.05), as well as a poor clinical prognosis (P <.01). In the intraductal papillary cholangiocarcinomas, WISP1v was detected only in the cases with duct wall invasion but not in the cases without duct wall invasion (P <.05). No mutation of WISP1v gene was detected in the examined samples. In vitro analysis revealed that WISP1v stimulated the invasive phenotype of cholangiocarcinoma cells with activation of both p38 and p42/p44 mitogen-activated protein kinases (MAPKs). Furthermore, WISP1v-induced cholangiocarcinoma invasion was significantly suppressed by the p38 MAPK inhibitor SB203580 but not by the p42/p44 MAPK kinase (MEK) inhibitor PD98059. Our findings suggest that WISP1v-mediated signaling is involved in the generation of invasive cellular properties and leads to progression of cholangiocarcinoma. (Keyword) 3T3 Cells / Aged / Animals / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / CCN Intercellular Signaling Proteins / Cholangiocarcinoma / Female / Gene Expression Regulation, Neoplastic / Growth Substances / Humans / Intracellular Signaling Peptides and Proteins / MAP Kinase Signaling System / Male / Mice / Middle Aged / Mitogen-Activated Protein Kinases / Neoplasm Invasiveness / Oncogene Proteins / Proto-Oncogene Proteins / RNA Splice Sites / p38 Mitogen-Activated Protein Kinases (Link to Publication Site) ● Publication site (DOI): 10.1053/jhep.2003.50187 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12717393 ● Search Scopus @ Elsevier (PMID): 12717393 ● Search Scopus @ Elsevier (DOI): 10.1053/jhep.2003.50187 (DOI: 10.1053/jhep.2003.50187, PubMed: 12717393)
217.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro, Keiji Kishikawa, Ryosuke Minagawa, Shoji Hiroshige, Mizuki Ninomiya, Satoko Shiotani, Noboru Harada and Keizo Sugimachi : Feasibility of duct-to-duct biliary reconstruction in left-lobe adult-living-donor liver transplantation, Transplantation, Vol.75, No.4, 557-559, 2003. (Summary) A Roux-en-Y choledochojejunostomy (CDJ) has been the sole method of choice for the reconstruction of the bile duct in living-donor liver transplantation (LDLT) using left-lobe grafts. In this study, we evaluated the feasibility of duct-to-duct (DD) biliary reconstruction in adult-to-adult LDLT using left-lobe grafts. Between October 1996 and October 2001, 46 adult-to-adult LDLTs using the left lobe were performed at our institution. The DD biliary reconstruction (hepaticocholedochostomy) over a T-tube was performed for seven of the last nine recipients (DD group, n=7), whereas the conventional Roux-en-Y CDJ was used for the remaining cases (CDJ group, n=39). The technical problems and the incidence of biliary complications were compared between the groups. Bile leakage developed in only 1 of 7 (14%) in the DD group (leakage from a T-tube exit site), whereas it occurred in 8 of 39 (20%) in the CDJ group. Up to now, no patients from the DD group developed anastomotic stricture, whereas twelve (30.7%) patients from the CDJ group did. Other complications included bleeding from the Roux-en-Y jejunojejunostomy (n=1) and anastomotic occlusion caused by an internal stent (n=1), and both complications were associated with CDJ. In conclusion, DD anastomosis is a simple and viable option for biliary reconstruction in left-lobe LDLTs. A long-term follow-up, especially regarding the incidence of biliary stricture, is thus warranted in such patients. (Keyword) Adult / Anastomosis, Roux-en-Y / Bile Ducts / Feasibility Studies / Female / Humans / Liver Transplantation / Living Donors / Male / Middle Aged / Reconstructive Surgical Procedures (Link to Publication Site) ● Publication site (DOI): 10.1097/01.TP.0000048220.90971.5A (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12605127 ● Search Scopus @ Elsevier (PMID): 12605127 ● Search Scopus @ Elsevier (DOI): 10.1097/01.TP.0000048220.90971.5A (DOI: 10.1097/01.TP.0000048220.90971.5A, PubMed: 12605127)
218.	Yo-ichi Yamashita, Mitsuo Shimada, Eiji Tsujita, Ken Shirabe, Hiroyuki Ijima, Kohji Nakazawa, Ryoichi Sakiyama, Junji Fukuda, Kazumori Funatsu and Keizo Sugimachi : Effecacy of a larger version of the hybrid artificial liver support system using a polyurethane foam/spheroid packed-bed module in a warm ischemic liver failure pig model for preclinical experiments, Cell Transplantation, Vol.12, No.2, 101-107, 2003. (Summary) We have reported the usefulness of a polyurethane foam packed-bed culture system of hepatocyte spheroids as a hybrid artificial liver support system (PUF-HALSS). The aim of this study was to evaluate in detail the efficacy in serum parameters regarding the liver function of a larger version of the PUF-HALSS containing 2 x 10(10) porcine hepatocytes for clinical use in warm ischemic liver failure pigs. Warm ischemic liver failure pigs weighing 25 kg were divided into two groups: (1) a control group (n = 3), in which each pig was attached to a PUF-HALSS without hepatocytes, and (2) a HALSS group (n = 3), in which each pig was attached to a PUF-HALSS. In the HALSS group, the increase of blood ammonia was completely suppressed and blood lactate levels were significantly suppressed. The Fisher's ratio was better maintained, and the increase of total bile acid, glycochenodeoxycholic acid, and taurochenodeoxycholic acid was significantly suppressed in the HALSS group. Serum creatinine levels were significantly lower, and blood glucose levels were significantly higher in the HALSS group. Serum levels of tumor necrosis factor- a were not elevated in either group. In conclusion, the larger version of the PUF-HALSS demonstrated many advantages as a liver support system in warm ischemic liver failure pigs. (Keyword) Amino Acids / Ammonia / Animals / Bile Acids and Salts / Culture Techniques / Extracorporeal Circulation / Female / Hepatocytes / Humans / Ischemia / Lactic Acid / Liver Failure / Liver, Artificial / Polyurethanes / Spheroids, Cellular / Swine / Temperature (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12797371 ● Search Scopus @ Elsevier (PMID): 12797371 (PubMed: 12797371)
219.	Mizuki Ninomiya, Mitsuo Shimada, Noboru Harada, Satoko Shiotani, Shoji Hiroshige, Yuji Soejima, Taketoshi Suehiro and Keizo Sugimachi : Beneficial effect of MCI-186 on hepatic warm ischemia-reperfusion in the rat, Transplantation, Vol.74, No.10, 1470-1472, 2002. (Summary) Despite growing evidence that reactive oxygen species are responsible for deleterious effects of ischemia-reperfusion (I/R) injury of the liver, there exists, until now, no reliable antioxidant therapeutics applicable in the clinical setting. We investigated the effects of free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), using an isolated liver perfusion model to elucidate its possible therapeutic effects on hepatic warm I/R injury. Isolated livers from Wistar rats were reperfused for 120 min with an oxygenated Krebs-Henseleit bicarbonate buffer after 1 hr of warm ischemia. Addition of MCI-186 (1 mg/L) into the perfusate significantly improved portal flow, hepatic enzyme release into the perfusate, total bile production, histologic alteration, and malondialdehyde concentration but not sinusoidal endothelial cell function as assessed by the clearance of hyaluronic acid. MCI-186 seems to have protective effects against hepatic warm I/R injury by attenuating the damage of the hepatocyte, which is the major target of oxidative damage in this model. (Keyword) Animals / Antipyrine / Apoptosis / Free Radical Scavengers / In Situ Nick-End Labeling / Ischemia / Liver / Male / Rats / Rats, Wistar / Reactive Oxygen Species / Reperfusion Injury (Link to Publication Site) ● Publication site (DOI): 10.1097/00007890-200211270-00021 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12451250 ● Search Scopus @ Elsevier (PMID): 12451250 ● Search Scopus @ Elsevier (DOI): 10.1097/00007890-200211270-00021 (DOI: 10.1097/00007890-200211270-00021, PubMed: 12451250)
220.	Yo-ichi Yamashita, Mitsuo Shimada, Katsuro Tachibana, Norifumi Harimoto, Eiji Tsujita, Ken Shirabe, Jun-ichi Miyazaki and Keizo Sugimachi : In Vivo Gene Transfer into Muscle via Electro-Sonoporation, Human Gene Therapy, Vol.13, No.17, 2079-2084, 2002. (Summary) Among the nonviral techniques for gene transfer in vivo, electroporation is simple, potent, inexpensive, and safe. To upregulate the expression levels of the transferred gene, we investigated the applicability of in vivo electro-sonoporation, which consists of a combination of electric pulse and ultrasound, for gene transfer using plasmid DNA encoding luciferase and mouse interleukin-12 (mIL-12). The quadriceps muscles of mice were injected with plasmid DNA, then sonoporated for 5 min, and electroporated by a pair of electrode plates at the middle of the duration of sonoporation. Three days later, mice that had undergone electro-sonoporation demonstrated twofold higher luciferase activity and low tissue damage in quadriceps muscle compared to mice having undergone electroporation alone. Serum mIL-12 levels in mice that had undergone electro-sonoporation (peaking at 25.5 ng/ml) were twofold higher after gene transfer than were those in mice having undergone electroporation alone (peaking at 14.3 ng/ml), and maintained high serum level of 13.9 ng/ml at 28 days after gene transfer. The efficacy of gene transfer via electro-sonoporation was superior when the plasmid DNA solution was 0.85% NaCl compared to albumin microbubble echo-contrast material. These results demonstrated that gene transfer into muscle via electro-sonoporation could provide a new potent nonviral technique for gene transfer in vivo. (Keyword) Animals / DNA / Electroporation / Female / Gene Expression / Gene Transfer Techniques / Genetic Markers / Injections, Intramuscular / Interleukin-12 / Luciferases / Mice / Mice, Inbred C3H / Mice, Inbred Strains / Muscle, Skeletal / Plasmids / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1089/10430340260395929 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12490002 ● Search Scopus @ Elsevier (PMID): 12490002 ● Search Scopus @ Elsevier (DOI): 10.1089/10430340260395929 (DOI: 10.1089/10430340260395929, PubMed: 12490002)
221.	Mitsuo Shimada, Satoko Shiotani, Mizuki Ninomiya, Takahiro Terashi, Shoji Hiroshige, Ryosuke Minagawa, Yuji Soejima, Taketoshi Suehiro and Keizo Sugimachi : Characteristics of liver graft in living-donor adult liver transplantation: comparison between right-and left-lobe graft, Archives of Surgery, Vol.137, No.10, 1174-1179, 2002. (Summary) Few studies have investigated the results of research focused on living-donor adult liver transplantation. Different characteristics between right- and left-lobe grafts have not yet been clarified in living-donor adult liver transplantation. Left-lobe graft remains an important option, even in adult recipients. A single liver transplantation center with a long history of hepatic resection. Forty-five donors received left-lobe (n = 39) and right-lobe (n = 6) grafts. The clinicopathological data for the donor, graft, and recipient were compared. All left-lobe grafts were extended grafts that included the middle hepatic vein, and 24 of the 39 left-lobe grafts included the left caudate lobe. No right-lobe graft included a middle hepatic vein. The postoperative aspartate aminotransferase and total bilirubin values of the donor in the right-lobe graft group were higher, and the postoperative hospital stay was longer than in the left-lobe graft group. Graft weight in the left-lobe graft group was lighter than in the right-lobe graft group (median weight, 450 vs 675 g). The median graft weight divided by the standard liver volume in the left-lobe graft group was 41% (range, 21%-66%), compared with 52% (range, 47%-75%) in the right-lobe graft group. We found no difference in terms of the incidence of postoperative complications between groups. No difference in induced complications of small-for-size grafts such as intractable ascites and persistent hyperbilirubinemia was evident between groups. The survival rate for grafts at 18 months was 75.0% in the right-lobe graft group compared with 85.6% in the left-lobe group. In the right-lobe graft group, we found a few cases in which a marked poor-perfusion area in the anterior segment caused liver dysfunction. Left-lobe grafts are a feasible option for living-donor adult liver transplantation, and in the case of right-lobe grafts, hepatic venous drainage is one of the most critical problems. (Keyword) Adult / Aspartate Aminotransferases / Bilirubin / Hepatic Veins / Humans / Liver Failure / Liver Function Tests / Liver Transplantation / Living Donors / Organ Size / Postoperative Complications / Tissue and Organ Harvesting / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1001/archsurg.137.10.1174 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12361430 ● Search Scopus @ Elsevier (PMID): 12361430 ● Search Scopus @ Elsevier (DOI): 10.1001/archsurg.137.10.1174 (DOI: 10.1001/archsurg.137.10.1174, PubMed: 12361430)
222.	三嶋一登, 牧野和隆, Mitsuo Shimada, 末廣剛敏, Yuji Soejima, 千堂年昭, 手嶋大輔, 伊藤義規 and 大石了三 : 薬剤師の生体肝移植チームにおける役割, Japanese Journal of Pharmaceutical Health Care and Sciences, Vol.28, No.4, 393-400, 2002. (Summary) This study aimed to evaluate the role of the pharmacist as a member of the liver transplant team in controlling tacrolimus concentrations and the incidence of convulsions as a side effect. Interventions of the pharmacist in the liver transplant team include the indications of dose setting, the checking of drug interactions, the monitoring of adverse effects and the instruction for patient compliance. Fifty-two patients who underwent a living-related liver transplantation were enrolled. The total number of 691 whole blood samples were collected during 2 weeks after liver transplantation and then were analyzed by microparticle enzyme immunoassay (MEIA) for tacrolimus trough concentrations. The standard deviation of tacrolimus trough level was 5.9 before pharmacist participation, while it decreased markedly to 3.7 after pharmacist participation. In addition, the variance significantly decreased. Five of 25 patients treated with tacrolimus before pharmacist participation encountered convulsions, however, none of the 27 patients showed any signs of convulsion after pharmacist participation. There was no significant difference in the rejection before (32%) or after (26%) pharmacist participation. We conclude that pharmacotherapy in the liver transplant team improved after pharmacist participation. (Keyword) liver transplantation / tacrolimus / pharmacist participation / therapeutic drug monitoring / convulsion (Link to Publication Site) ● Publication site (DOI): 10.5649/jjphcs.28.393 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204775502208 ● Search Scopus @ Elsevier (DOI): 10.5649/jjphcs.28.393 (DOI: 10.5649/jjphcs.28.393, CiNii: 1390001204775502208)
223.	Makoto Hashizume, Mitsuo Shimada, Morimasa Tomikawa, Yasuharu Ikeda, I Takahashi, R Abe, F Koga, N Gotoh, Kozo Konishi, Shin-ichiro Maehara and Keizo Sugimachi : Early experiences of endoscopic procedures in general surgery assisted by a computer enhanced surgical system, Surgical Endoscopy, Vol.16, No.8, 1187-1191, 2002. (Summary) We performed a variety of complete total endoscopic general surgical procedures, including colon resection, distal gastrectomy, and splenectomy, successfully with the assistance of the da Vinci computer-enhanced surgical system. The robotic system allowed us to manipulate the endoscopic instruments as effectively as during open surgery. It enhanced visualization of both the operative field and precision of the necessary techniques, as well as being less stressful for the endoscopic operating team. This technological innovation can therefore help surgeons overcome many of the difficulties associated with the endoscopic approach and thus has the potential to enable more precise, safer, and more minimally invasive surgery in the future. (Keyword) Adult / Aged / Aged, 80 and over / Anastomosis, Surgical / Cholecystectomy / Endoscopy / Esophageal Neoplasms / Female / Gastrectomy / Gastrointestinal Diseases / Hernia / Humans / Length of Stay / Male / Mediastinal Neoplasms / Middle Aged / Patient Care Team / Robotics / Splenectomy / Surgery, Computer-Assisted / Suture Techniques / Thoracoscopy (Link to Publication Site) ● Publication site (DOI): 10.1007/s004640080154 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11984681 ● Search Scopus @ Elsevier (PMID): 11984681 ● Search Scopus @ Elsevier (DOI): 10.1007/s004640080154 (DOI: 10.1007/s004640080154, PubMed: 11984681)
224.	Shinji Tanaka, Keishi Sugimachi, Mitsuo Shimada, Yoshihiko Maehara and Keizo Sugimachi : Variant WISPs as targets for gastrointestinal carcinomas., Gastroenterology, Vol.123, No.1, 392-393, 2002. (Keyword) Carcinoma / Gastrointestinal Neoplasms / Growth Substances / Humans / Intracellular Signaling Peptides and Proteins / Oncogene Proteins / Protein Isoforms / Proto-Oncogene Proteins (Link to Publication Site) ● Publication site (DOI): 10.1053/gast.2002.34589 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12105881 ● Search Scopus @ Elsevier (PMID): 12105881 ● Search Scopus @ Elsevier (DOI): 10.1053/gast.2002.34589 (DOI: 10.1053/gast.2002.34589, PubMed: 12105881)
225.	Taketoshi Suehiro, Mizuki Ninomiya, Satoko Shiotani, Syoji Hiroshige, Noboru Harada, Minagawa Ryosuke, Yuji Soejima, Mitsuo Shimada and Keizo Sugimachi : Hepatic artery reconstruction and biliary stricture formation after living donor adult liver transplantation using the left lobe, Liver Transplantation, Vol.8, No.5, 495-499, 2002. (Summary) Biliary complications, including bile leak, biliary stricture, and cholangitis, are seen in 15% to 29% of all cases after living related liver transplantation. We investigate risk factors and discuss the management of biliary complications after living related liver transplantation in adults using left-lobe grafts. We studied 37 adult patients who underwent living related liver transplantation using left-lobe grafts. Perioperative variables were evaluated as risk factors for biliary strictures. The overall incidence of biliary complications was 43.2% (16 of 37 patients). Anastomotic strictures occurred in 8 patients, whereas bile leaks and cholangitis occurred in 9 and 8 patients, respectively. Anastomotic stricture was strongly related to a partial artery reconstruction (P <.02) and cholangitis (P <.01). Anastomotic biliary stricture was not associated with bile leak, acute cellular rejection, or infection. Our results suggest that an important risk factor for biliary anastomotic biliary strictures is a partial artery reconstruction. To minimize the risk for biliary anastomotic strictures, we will reconstruct both the middle and left hepatic artery. (Keyword) Adult / Cholestasis / Female / Hepatic Artery / Humans / Incidence / Liver Transplantation / Living Donors / Male / Middle Aged / Risk Factors / Vascular Surgical Procedures (Link to Publication Site) ● Publication site (DOI): 10.1053/jlts.2002.32986 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12004352 ● Search Scopus @ Elsevier (PMID): 12004352 ● Search Scopus @ Elsevier (DOI): 10.1053/jlts.2002.32986 (DOI: 10.1053/jlts.2002.32986, PubMed: 12004352)
226.	Shinji Tanaka, Keishi Sugimachi, Yo-ichi Yamashita, Takefumi Ohga, Ken Shirabe, Mitsuo Shimada, Jack R Wands and Keizo Sugimachi : Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma, Hepatology, Vol.35, No.4, 861-867, 2002. (Summary) Hepatocellular carcinoma (HCC) is generally characterized as a hypervascular tumor of rapid growth. We have previously reported that angiopoietin (Ang), a ligand for Tie2 vascular endothelial-specific receptor tyrosine kinase, may play a role in the progression of human HCC (J Clin Invest 1999;103:341-345) and matrix proteinase expression (Cancer Res 2001;61:2145-2153). However, the role of Tie2 receptor in hepatic oncogenesis is unknown. The Tie2 receptor protein was overexpressed in the neovascular endothelium of 31 of 39 (80%) human HCC tumors by immunohistochemical analysis with significant correlation to cell dedifferentiation and tumor size (P <.05). In vitro expression of a dominant-negative construct, containing a soluble Tie2 ectodomain (sTie2), led to Ang protein interaction, inhibition of endogenous Tie2 phosphorylation in vascular endothelial cells and matrix metalloproteinase 9 (MMP-9) suppression. In conclusion, tumorigenicity with neovascularization was suppressed by in vivo gene transfer and sTie2 expression in a murine HCC model, suggesting a possible role for Tie2 expression in the induction of HCC neovascularization and disease progression. Inhibition of the Ang/Tie2 signal transduction cascade is a promising approach for tumor treatment. (Keyword) Angiopoietin-1 / Angiopoietin-2 / Carcinoma, Hepatocellular / Cell Differentiation / Cells, Cultured / Electroporation / Endothelium, Vascular / Enzyme Activation / Female / Gene Expression / Humans / Immunohistochemistry / Liver Neoplasms / Male / Membrane Glycoproteins / Middle Aged / Neoplasm Proteins / Proteins / Proto-Oncogene Proteins / Receptor, TIE-2 (Link to Publication Site) ● Publication site (DOI): 10.1053/jhep.2002.32535 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11915032 ● CiNii @ National Institute of Informatics (CRID): 1361981469134703488 ● Search Scopus @ Elsevier (PMID): 11915032 ● Search Scopus @ Elsevier (DOI): 10.1053/jhep.2002.32535 (DOI: 10.1053/jhep.2002.32535, PubMed: 11915032, CiNii: 1361981469134703488)
227.	Tohru Utsunomiya, Hiroshi Inoue, Ken-ichi Taguchi, Mitsuo Shimada, Keizo Sugimachi and Masaki Mori : G protein gamma 7 expression as a new clinicopathological maeker in patients with intrahepatic cholangiocarcinoma, Archives of Surgery, Vol.137, No.2, 181-185, 2002. (Summary) The signal alterations mediated by small G proteins such as Ras, Rho, and Rac have been reported in several cancers. The human G protein gamma 7 (G-gamma 7) gene, which is down-regulated in various digestive organ cancers, was recently identified and cloned. Thus, the G-gamma 7-coupled heterotrimeric G proteins may also contribute to carcinogenesis in human cancers. University hospital and medical institute of bioregulation. The clinicopathological significance of G-gamma 7 expression in 18 patients with intrahepatic cholangiocarcinoma (IHCC) was examined. The tumor-nontumor ratio of G-gamma 7 expression was determined using reverse transcription polymerase chain reaction analysis. To visualize the localization of G-gamma 7, an immunohistochemical study was performed. Clinicopathological significance of G-gamma 7 expression in human IHCC. Expression of G-gamma 7 messenger RNA was lower in tumor tissue than in the corresponding nontumor tissue in 17 (94%) of 18 patients with IHCC. The mean tumor-nontumor ratio was 0.54. Eleven patients with tumor-nontumor ratios less than 0.5 showed significantly poorer differentiated IHCC than 7 with tumor-nontumor ratios of 0.5 and greater (P<.01). Decreased expression of G-gamma 7 protein in the carcinoma tissue, especially in the poorly differentiated IHCC tissue, was confirmed using immunohistochemical staining. Reduced expression of G-gamma 7 is associated with the histological grade of IHCC and may therefore prove to be a useful marker for predicting the biological aggressiveness of human IHCC. (Keyword) Adult / Aged / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Chi-Square Distribution / Cholangiocarcinoma / Down-Regulation / Female / Heterotrimeric GTP-Binding Proteins / Humans / Immunohistochemistry / Male / Middle Aged / RNA, Messenger / Reverse Transcriptase Polymerase Chain Reaction (Link to Publication Site) ● Publication site (DOI): 10.1001/archsurg.137.2.181 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11822957 ● Search Scopus @ Elsevier (PMID): 11822957 ● Search Scopus @ Elsevier (DOI): 10.1001/archsurg.137.2.181 (DOI: 10.1001/archsurg.137.2.181, PubMed: 11822957)
228.	Yo-ichi Yamashita, Mitsuo Shimada, Shinji Tanaka, Masahiro Okamoto, Jun-ichi Miyazaki and Keizo Sugimachi : Electroporation-mediated tumor necrosis factor related apotosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma, Human Gene Therapy, Vol.13, No.2, 275-286, 2002. (Summary) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2 ligand (Apo2L) has been identified as important in promoting programmed cell death in breast and colon cancer xenografts. More importantly, normal liver tissue appears not to be susceptible to the cytotoxic effects of TRAIL/Apo2L, although activation of the related Fas ligand receptor system is known to promote massive liver apoptosis terminating in fulminant hepatitis. In the present study, we investigated the therapeutic potential of TRAIL/Apo2L gene therapy in hepatocellular carcinoma (HCC) and evaluated its side effects in an immune-competent mouse model. Intratumoral administration of the TRAIL/Apo2L vector by electroporation elevated serum TRAIL/Apo2L through at least day 28 after gene therapy and significantly inhibited the growth not only of the HCC directly administered TRAIL/Apo2L vector, but also of distant subcutaneous HCC. In addition, intratumoral administration of the TRAIL/Apo2L vector inhibited spontaneous lung metastasis. Serum alanine aminotransferase was mildly elevated by TRAIL/Apo2L gene therapy, but without showing such histological signs as TUNEL staining. These results demonstrate that TRAIL/Apo2L gene therapy for HCC by electroporation in vivo is efficient without significant side effects, and is thus promising for use in future clinical trials. (Keyword) Animals / Apoptosis Regulatory Proteins / Carcinoma, Hepatocellular / Electroporation / Female / Genetic Therapy / Lung Neoplasms / Membrane Glycoproteins / Mice / Mice, Inbred C3H / Neoplasm Metastasis / Precipitin Tests / TNF-Related Apoptosis-Inducing Ligand / Tumor Necrosis Factor-alpha (Link to Publication Site) ● Publication site (DOI): 10.1089/10430340252769798 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11812283 ● Search Scopus @ Elsevier (PMID): 11812283 ● Search Scopus @ Elsevier (DOI): 10.1089/10430340252769798 (DOI: 10.1089/10430340252769798, PubMed: 11812283)
229.	Takashi Nishizaki, Shoji Hiroshige, Toru Ikegami, Hideaki Uchiyama, Koji Hashimoto, Yuji Soejima and Mitsuo Shimada : Living-donor liver transplantation for fulminant hepatic failure in adult patients with a left-lobe graft, Surgery, Vol.131, No.Supplement 1, S182-S189, 2002. (Summary) Living donors are practically the only source of organs in countries where the availability of cadaveric donors is severely restricted, such as Japan. A left-lobe graft, in which one third of the liver is donated, is therefore used for adult-to-adult living-donor liver transplantation (LDLT) in patients with fulminant hepatic failure (FHF). Fifteen adult patients with FHF, ranging from 22 to 59 years of age, were treated with LDLT with a left-lobe graft. Preoperative encephalopathy was grade II in 2 patients, grade III in 4 patients, and grade IV in 9 patients. The graft volume (GV) ranged from 260 to 570 mL, thus corresponding to 23% to 54% of the recipients' standard liver volume (SLV). The patients were divided into 2 groups according to their GV/SLV: a medium-size graft group (GV/SLV > or =30%; group M, n = 11) and a small-size graft group (GV/SLV <30%; group S, n = 4). The effects of GV/SLV on graft function and survival were compared. Postoperative neurologic complications were also evaluated. The donors are all doing well. Twelve (80%) of the 15 recipients are still alive, with a follow-up period of from 3 to 43 months. No statistically significant differences were observed in the postoperative serum levels of bilirubin and alanine aminotransferase, prothrombin time, or frequency of postoperative complications between the 2 groups. The graft and patient survival rates were 75% (3/4) and 75% (3/4) in group S and 73% (8/11) and 82% (9/11) in group M, respectively. All patients who survived the perioperative period recovered without any neurologic sequelae. The high success rate and low donor risk of LDLT may therefore justify its use for adult patients with FHF using a left-lobe graft. (Keyword) Adult / Alanine Transaminase / Bilirubin / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Failure / Liver Transplantation / Living Donors / Male / Middle Aged / Postoperative Care / Postoperative Complications / Prothrombin Time / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2002.119574 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11821808 ● Search Scopus @ Elsevier (PMID): 11821808 ● Search Scopus @ Elsevier (DOI): 10.1067/msy.2002.119574 (DOI: 10.1067/msy.2002.119574, PubMed: 11821808)
230.	Toru Ikegami, Satoko Shiotani, Mizuki Ninomiya, Ryosuke Minagawa, Takashi Nishizaki, Mitsuo Shimada and Keizo Sugimachi : Auxiliary partial orthotopic liver transplantation from living donors, Surgery, Vol.131, No.Supplement 1, S205-210, 2002. (Summary) Auxiliary liver transplantation was originally started in Western countries in the form of heterotopic auxiliary liver transplantation for end-stage liver disease. It thereafter developed into the form of auxiliary partial orthotopic liver transplantation for acute liver failure. In Japan, where living-donor liver transplantation is the main mode of liver transplantation, auxiliary partial orthotopic liver transplantation was initially used for patients with metabolic liver diseases and has since developed into an effective solution for small-for-size living donor grafts. Although there has been a reported case of successful auxiliary partial orthotopic liver transplantation from a living donor for the treatment of acute liver failure, wide application of this technique is made difficult at present by such unsolved problems as functional competition, small graft size, severe clinical status, and toxic liver syndrome. Auxiliary partial orthotopic liver transplantation from a living donor is an established procedure for small-for-size living-donor grafts and metabolic liver diseases, and the future establishment of its successful application to cases of acute liver failure is anticipated. (Keyword) Adolescent / Adult / Body Constitution / Cholangitis, Sclerosing / Female / Humans / Liver / Liver Failure, Acute / Liver Transplantation / Living Donors / Male / Metabolic Diseases (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2002.119578 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11821812 ● Summary page in Scopus @ Elsevier: 2-s2.0-0036165715 (DOI: 10.1067/msy.2002.119578, PubMed: 11821812, Elsevier: Scopus)
231.	Hideaki Uchiyama, Koji Hashimoto, Shoji Hiroshige, Noboru Harada, Yuji Soejima, Takashi Nishizaki, Mitsuo Shimada and Taketoshi Suehiro : Hepatic artery reconstruction in living donor liver transplantation: review of its techniques and complications, Surgery, Vol.131, No.1 Supplement 1, S200-S204, 2002. (Summary) Hepatic arterial reconstruction is one of the most difficult procedures in living-donor liver transplantation (LDLT) because the artery used is generally small in diameter and has a short stalk. If hepatic artery thrombosis (HAT) occurs, the recipient clinical course will be unstable. The introduction of microvascular hepatic arterial reconstruction has significantly decreased the incidence of HAT. Fifty-two cases of LDLT were performed from October 1995 to May 2001 in our institution. Hepatic arterial reconstruction was performed under microscopic guidance. HATs were recognized in 2 cases (3.8%), both of which needed reoperation. Surgeons who perform hepatic arterial reconstruction in LDLT should be highly trained in microvascular techniques to decrease the incidence of HAT. This commentary reviews the surgical techniques of hepatic arterial reconstruction and possible complications that may arise in a reconstructed hepatic artery. (Keyword) Hepatic Artery / Humans / Liver Transplantation / Living Donors / Postoperative Complications / Vascular Surgical Procedures (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2002.119577 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11821811 ● Search Scopus @ Elsevier (PMID): 11821811 ● Search Scopus @ Elsevier (DOI): 10.1067/msy.2002.119577 (DOI: 10.1067/msy.2002.119577, PubMed: 11821811)
232.	Yuji Soejima, Mitsuo Shimada, Noburu Harada, Taketoshi Suehiro, Ryosuke Minagawa, Shoji Hiroshige, Mizuki Ninomiya, Satoko Shiotani and Takashi Nishizaki : Perioperative management and complications of donor in living donor liver transplantation, Surgery, Vol.131, No.Supplement 1, S195-199, 2002. (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2002.119576 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1067/msy.2002.119576 (DOI: 10.1067/msy.2002.119576)
233.	Ken Shirabe, Mitsuo Shimada, Norifumi Harimoto, Keishi Sugimachi, Yo-ichi Yamashita, Eiji Tsujita and Shin-ichi Aishima : Intrahepatic cholangiocarcinoma: its mode o spreading and therapeutic modalities, Surgery, Vol.131, No.Supplement 1, S159-164, 2002. (Summary) Intrahepatic cholangiocarcinoma (IHCC) is a primary adenocarcinoma of the liver, arising from the intrahepatic bile ducts. The prognosis is generally poor because locoregional extension is usually advanced at the time of diagnosis. Even after a resection, the outcome for patients with advanced IHCC is extremely poor, and the presence of lymph node metastasis has been reported in most previous studies to be the worst prognostic factor after a resection. There are no clear guidelines on lymph node dissection with IHCC. In this article, we review the mode of invasion and the therapeutic modalities: hepatic resection, lymph node dissection, liver transplantation, radiation, and chemotherapy for IHCC. (Keyword) Adenocarcinoma / Bile Duct Neoplasms / Cholangiocarcinoma / Humans / Liver Neoplasms / Lymphatic Metastasis (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2002.119498 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11821804 ● Summary page in Scopus @ Elsevier: 2-s2.0-0036160991 (DOI: 10.1067/msy.2002.119498, PubMed: 11821804, Elsevier: Scopus)
234.	Yuji Soejima, 末廣剛敏 and Mitsuo Shimada : 生体肝移植後の遷延性門脈圧亢進症, 今日の移植, Vol.15, 362-365, 2002.
235.	広重彰二, Mitsuo Shimada, 原田昇, 塩谷聡子, 二宮瑞樹, 皆川亮介, Yuji Soejima, 末廣剛敏, 本田浩, 橋爪誠 and 前原喜彦 : 生体肝右葉移植における3D-CT肝静脈画像構成の有用性, Journal of Japan Society of Computer Aided Surgery, Vol.3, No.3, 155-156, 2001. (Keyword) Preoperative planning / visualization (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1574231875587515520 (CiNii: 1574231875587515520)
236.	Shoji Hiroshige, Takashi Nishizaki, Yuji Soejima, Koji Hashimoto, Ryuji Ohta, Ryousuke Minagawa, Mitsuo Shimada, Hiroshi Honda, Makoto Hashizume and Keizo Sugimachi : Beneficial effects of 3-dimensional visualization on hepatic vein reconstruction in living donor liver transplantation using rught lobe graft, Transplantation, Vol.72, No.12, 1993-1996, 2001. (Summary) Recently, virtual operation planning and navigation systems have been introduced in the field of neurosurgery and orthopedic surgery. We report here the beneficial effects of 3-dimensional (3D) visualization on hepatic venous reconstruction in living donor liver transplantation (LDLT) using right lobe graft. 3D-image reconstruction of the liver was rendered with 3-mm slices of helical computed tomography (CT) data using zioM900 (Zio Software Inc., Tokyo, Japan). To understand the anatomy of the donor's vessels and design an operation plan, a picture of the vessels in and around the liver was reconstructed. The 3D image demonstrated two short hepatic veins next to the inferior right hepatic vein (IRHV) as well as a large IRHV. The 3D image showed a more precise diameter of the right hepatic vein (RHV) and the IRHV and a more accurate distance between the two hepatic veins than did images measured by 2-dimensional CT. This preoperative information allowed the donor surgeon to dissect the inferior vena cava (IVC) and hepatic veins with reduced blood loss because of reduced risk of injury to the blood vessels. The 3D image revealed that both the RHV and the IRHV branched off at the same angle from the cylindrical IVC. Preoperative planning based on this information secured smooth anastomosis. 3D visualization is useful for hepatic venous reconstruction of the recipient as well as for donor surgery in LDLT using right lobe graft. (Keyword) Female / Hepatic Veins / Humans / Imaging, Three-Dimensional / Liver Transplantation / Living Donors / Middle Aged / Tissue and Organ Harvesting / Tomography, X-Ray Computed / Video-Assisted Surgery (Link to Publication Site) ● Publication site (DOI): 10.1097/00007890-200112270-00022 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11773902 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035664208 (DOI: 10.1097/00007890-200112270-00022, PubMed: 11773902, Elsevier: Scopus)
237.	Toru Ikegami, Takashi Nishizaki, Katsuhiko Yanaga, Mitsuo Shimada, Keishi Kishikawa, Kenichi Nomoto, Hideaki Uchiyama and Keizo Sugimachi : The impact of donor age on living donor liver transplantation, Transplantation, Vol.70, No.12, 1703-1707, 2001. (Summary) The impact of the age of the donor on the outcome of living related liver transplantation is yet to be clarified. During October 14, 1996 and December 20, 1999, 34 living related liver transplantations were performed. Of these, 26 cases were performed using the extended left lobe graft, which were classified into three groups; younger donor group (group Y, donor age < 30, n = 7), middle-aged donor group (group M, 30 < or = donor age <50, n=13), and older donor group (group O, donor age < 50, n = 6). Early allograft function and regeneration were compared between these groups. There was no difference in standard liver volume, and predicted or harvested graft size between the three groups. Although serum transaminase and total bilirubin levels within postoperative day 7 were not different between the groups, the prothrombin time on postoperative day 3 was significantly longer in group O than in group Y. One week after transplantation, group Y had significantly greater graft/standard liver volume ratio than group O, and greater graft volume than group M and O. One month after transplantation, however, there was no significant difference in such graft size parameters between the groups. Graft and patient survival were comparable between the three groups. Although function and regeneration of the allografts from older donors in living donor liver transplantation is worse than those of their younger counterparts, the outcome is not affected by the age of the liver. (Keyword) Adult / Age Factors / Aging / Alanine Transaminase / Aspartate Aminotransferases / Bilirubin / Female / Graft Survival / Humans / Liver Regeneration / Liver Transplantation / Living Donors / Male / Middle Aged / Organ Size / Prothrombin Time (Link to Publication Site) ● Publication site (DOI): 10.1097/00007890-200012270-00007 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11152100 ● Summary page in Scopus @ Elsevier: 2-s2.0-0034722934 (DOI: 10.1097/00007890-200012270-00007, PubMed: 11152100, Elsevier: Scopus)
238.	Eiji Hiroshita, Ken-ichi Taguchi, Akihiko Inokuchi, Takeshi Uchiumi, Naoko Kinukawa, Mitsuo Shimada, Masazumi Tsuneyoshi, Keizo Sugimachi and Michihiko Kuwano : Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection, Journal of Hepatology, Vol.35, No.6, 765-773, 2001. (Summary) To understand hepatic injury during the process of hepatitis viral infection, determination of liver-specific functions at molecular levels is critical. Because the transport of endogenous/exogenous toxic substances is an intrinsically important hepatic function, we examined whether expression of the ATP-binding cassette (ABC) transporter gene was affected in patients with hepatitis viral infection. To determine which ABC transporter was expressed differently in patients with hepatic viral infection, we assayed the expression of MDR1, MDR3, MRP1, MRP2, and MRP3 in non-cancerous regions in the liver of 42 patients with hepatic tumors using both quantitative RT-PCR and immunological staining analysis, and compared the hepatic expression levels between patients with hepatitis viral infection and non-infected controls. Of the five ABC transporter genes studied, the mRNAs of MRP2 and MRP3 were highly expressed in the human liver. There was a significant reduction in MRP2 expression to 29% in the virus-infected liver. Treatment of hepatic cells with inflammatory cytokines resulted in decreased mRNA levels of MRP2 and decreased MRP2 promoter activity. The down-regulation of MRP2 might induce a failure in the transport of various genotoxic substances in the liver with hepatitis virus infection. (Keyword) Adult / Aged / Down-Regulation / Female / Hepatitis C / Humans / Interleukin-1 / Interleukin-6 / Liver / Liver Neoplasms / Male / Membrane Transport Proteins / Middle Aged / Multidrug Resistance-Associated Proteins / Promoter Regions, Genetic / RNA, Messenger / Time Factors / Tumor Necrosis Factor-alpha (Link to Publication Site) ● Publication site (DOI): 10.1016/S0168-8278(01)00216-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11738104 ● Search Scopus @ Elsevier (PMID): 11738104 ● Search Scopus @ Elsevier (DOI): 10.1016/S0168-8278(01)00216-1 (DOI: 10.1016/S0168-8278(01)00216-1, PubMed: 11738104)
239.	Mitsuo Shimada, Yo-ichi Yamashita, Shinichi Aishima, Ken Shirabe, Kenji Takenaka and Keizo Sugimachi : Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma, The British Journal of Surgery, Vol.88, No.11, 1463-1466, 2001. (Summary) Hepatectomy with extensive lymph node dissection is the standard operation for intrahepatic cholangiocarcinoma (IHCC). However, lymph node dissection may not always be effective at reducing tumour recurrence. Forty-nine patients with IHCC who underwent hepatectomy were investigated to determine patterns of tumour recurrence and to estimate the value of lymph node dissection during resection. At hepatectomy most metastatic lymph nodes were identified at least to the level of group 2 lymph nodes. Among 23 patients who developed recurrence, 17 had liver metastases and the other six had recurrence at other sites, mainly in the peritoneum. Poorly differentiated histology was related to the development of liver metastases. No patient with the intraductal growth type of IHCC had tumour recurrence. Lymph node dissection did not appear to improve patient survival. Histological findings of lymph node metastases and intrahepatic metastases were independent indicators of poor prognosis. Lymph node metastases were seldom limited to the regional lymph nodes; most tumour recurrence occurred in the liver. Lymph node dissection did not appear to improve patient survival. Lymph node dissection alone is not likely to improve the prognosis without further control of liver metastases. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / CA-19-9 Antigen / Cholangiocarcinoma / Hepatectomy / Humans / Lymph Node Excision / Lymphatic Metastasis / Neoplasm Recurrence, Local / Survival Analysis (Link to Publication Site) ● Publication site (DOI): 10.1046/j.0007-1323.2001.01879.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11683741 ● Search Scopus @ Elsevier (PMID): 11683741 ● Search Scopus @ Elsevier (DOI): 10.1046/j.0007-1323.2001.01879.x (DOI: 10.1046/j.0007-1323.2001.01879.x, PubMed: 11683741)
240.	Shinji Tanaka, Keishi Sugimachi, Hiroshi Saeki, Junko Kinoshita, Takefumi Oga, Mitsuo Shimada, Yoshihiko Maehara and Keizo Sugimachi : A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhosu gastric carcinoma, Oncogene, Vol.20, No.39, 5525-5532, 2001. (Summary) Scirrhous carcinoma of the stomach is characterized by rapid growth with a vast fibrous stroma, high invasiveness, and substantially a poor prognosis. Little is known of the molecular pathogenesis of this disease. Members of the emerging family of the CCN gene (for connective tissue growth factor, cysteine-rich 61, nephroblastoma overexpressed) encode cysteine-rich secreted proteins with roles in human fibrotic disorders and cancer progression. Using targeted differential displays, we identified a novel variant of the CCN family member WISP1 (Wnt-induced secreted protein 1), named WISP1v, as overexpressed in scirrhous gastric carcinomas. Predicted protein of the WISP1v completely lacks a module of Von Willebrand type C that is thought to participate in protein complex formation. Ectopic expression revealed WISP1v to be a secreted oncoprotein inducing a striking cellular transformation and rapid piling-up growth. It is noteworthy that WISP1v transfectants enhanced the invasive phenotype of co-cultured gastric carcinoma cells, while wild-type WISP1 had no such potential. These findings suggest that CCN protein WISP1v is involved in the aggressive progression of scirrhous gastric carcinoma. (Keyword) 3T3 Cells / Adenocarcinoma, Scirrhous / Alternative Splicing / Amino Acid Sequence / Animals / Base Sequence / Cell Transformation, Neoplastic / Cloning, Molecular / Growth Substances / Humans / Intracellular Signaling Peptides and Proteins / Mice / Molecular Sequence Data / Neoplasm Invasiveness / Oncogene Proteins / Proto-Oncogene Proteins / RNA, Neoplasm / Sequence Homology, Amino Acid / Stomach Neoplasms / Tumor Cells, Cultured / Up-Regulation / von Willebrand Factor (Link to Publication Site) ● Publication site (DOI): 10.1038/sj.onc.1204723 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11571650 ● Search Scopus @ Elsevier (PMID): 11571650 ● Search Scopus @ Elsevier (DOI): 10.1038/sj.onc.1204723 (DOI: 10.1038/sj.onc.1204723, PubMed: 11571650)
241.	Mitsuo Shimada, Tatsuya Rikimaru, Takayuki Hamatsu, Yo-ichi Yamashita, Takahiro Terashi, Ken-ichi Taguchi, Shinji Tanaka, Ken Shirabe and Keizo Sugimachi : The role of macroscopic classification in nodular-type hepatocellular carcinoma, The American Journal of Surgery, Vol.182, No.2, 177-182, 2001. (Summary) Little has been reported on the role of macroscopic classification of hepatocellular carcinoma (HCC). We hypothesized that macroscopic classification of HCC might have a strong correlation with long-term prognosis after hepatectomy. Four hundred and four patients with a macroscopically nodular type of HCC who underwent a hepatectomy were studied. The patients were divided into three groups: single nodular (SN) group (n = 312); single nodular with extranodular growth (SNEG) group (n = 52); and confluent multinodular (CMN) group (n = 40). Clinicopathological variables were compared among the three groups. The patient survival rate was also compared among the three groups. Finally, a multivariate analysis was performed to clarify the independent significant variables of the long-term prognosis. To confirm the consistency of the results in small-size HCC, the same analyses were made using patients whose tumor size was equal to or less than 3 cm in diameter. The alpha-fetoprotein value, tumor size, and rate of absolute noncurative operation in the SNEG group were higher than in other groups. The positive rate of both portal vein invasion of cancer cells and intrahepatic metastasis in the SN group was lower than those in other groups. The rate of poorly differentiated histology in the SN group was lower than in the other groups. Patient survival in the SNEG group was worst among the three groups. However, patient survival showed no significant difference between the SN and CMN groups. The multivariate analysis showed that the presence of intrahepatic metastasis, the macroscopic classification of SNEG type, and absolute noncurative operation were independent poor prognostic indicators. The results for patients with small HCCs measuring equal to or less than 3 cm in diameter were quite similar to the results for the other patients. Among the three subtypes of macroscopically nodular type of HCCs, the SNEG type showed higher rates of portal vein invasion of cancer cells, intrahepatic metastasis, and poorly differentiated histology. The patient survival rate in the SNEG type was worst, and the SNEG type was an independent poor prognostic indicator. The macroscopic classification of HCC, especially the SNEG type, helps predict the long-term outcome after hepatectomy. (Keyword) Carcinoma, Hepatocellular / Female / Humans / Liver Neoplasms / Male / Middle Aged / Prognosis / Survival Rate / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/S0002-9610(01)00682-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11574092 ● Search Scopus @ Elsevier (PMID): 11574092 ● Search Scopus @ Elsevier (DOI): 10.1016/S0002-9610(01)00682-1 (DOI: 10.1016/S0002-9610(01)00682-1, PubMed: 11574092)
242.	Keishi Sugimachi, Shin-ichi Aishima, Ken-ichi Taguchi, Shinji Tanaka, Mitsuo Shimada, Kiyoshi Kajiyama, Keizo Sugimachi and Masazumi Tsuneyoshi : The role of overeexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma, Journal of Hepatology, Vol.35, No.1, 74-79, 2001. (Summary) Intrahepatic cholangiocarcinoma (ICC) is a primary liver malignant tumor with an extremely poor prognosis, but less attention has been directed to factors related to molecular carcinogenesis, including cell cycle proteins. We examined the expression and gene amplification of cyclin D1, the cell cycle regulating protein. Our objective was to evaluate correlations with clinicopathological factors in ICC. Cyclin D1 overexpression and cellular proliferative activity (Ki-67 labeling index) were investigated immunohistochemically, and 20 cases were further investigated for cyclin D1 gene amplification, using differential PCR. We examined the correlation between the expression and gene amplification of cyclin D1 and clinicopathological factors, including overall survival in patients with ICC. Immunohistochemical analysis revealed an overexpression of cyclin D1 protein in 28 of 66 subjects with ICCs (42%). The cyclin D1 overexpression was associated with poor histological differentiation (P = 0.04), high cellular proliferative activity (P < 0.01), and a poor prognosis (P = 0.02) by univariate analysis, although it is not an independent prognostic factor by multivariate analysis. Cyclin D1 gene amplification was confirmed in five of the 20 patients. Of those five cases of ICC, all had poor histological differentiation, and four of the five ICCs (80%) showed evidence of cyclin D1 immunoreactivity. Overexpression and gene amplification of cyclin D1 are frequent and contribute to dedifferentiation and cellular proliferative activity of ICCs, and overexpression also indicates a poor prognosis for patients with ICC. (Keyword) Adult / Aged / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cell Division / Cholangiocarcinoma / Cyclin D1 / Female / Gene Amplification / Humans / Immunohistochemistry / Ki-67 Antigen / Liver Neoplasms / Male / Middle Aged / Polymerase Chain Reaction / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1016/S0168-8278(01)00079-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11495045 ● Search Scopus @ Elsevier (PMID): 11495045 ● Search Scopus @ Elsevier (DOI): 10.1016/S0168-8278(01)00079-4 (DOI: 10.1016/S0168-8278(01)00079-4, PubMed: 11495045)
243.	Mitsuo Shimada, Makoto Hashizume, Shin-ichiro Maehara, Eiji Tsujita, Tatsuya Rikimaru, Yo-ichi Yamashita, Shinji Tanaka, Eisuke Adachi and Keizo Sugimachi : Laparoscopic hepatectomy for hepatocellular carcinoma, Surgical Endoscopy, Vol.15, No.6, 541-544, 2001. (Link to Publication Site) ● Publication site (DOI): 10.1007/s004640080099 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-0034990733 (DOI: 10.1007/s004640080099, Elsevier: Scopus)
244.	Ken-Ichi Taguchi, Shin-Ichi Aishima, Yoshiki Asayama, Kiyoshi Kajiyama, Naoko Kinukawa, Mitsuo Shimada, Keizo Sugimachi and Masazumi Tsuneyoshi : The role of p27kip1 protein ezpression on the biological behavior of intrahepatic cholangiocarcinoma, Hepatology, Vol.33, No.5, 1118-1123, 2001. (Summary) Recent studies have reported that a decreased p27kip1 protein (p27) expression is associated with aggressive tumor behavior in several human malignancies. In this study, we examined the role of p27 expression in intrahepatic cholangiocarcinoma (ICC) and the noncancerous intrahepatic bile duct epithelium and assessed its association with clinicopathologic features, especially the influence of decreased p27 expression by the tumor on its prognosis as determined by immunohistochemistry. Almost all noncancerous bile duct epithelia show positive nuclear staining and reveal a faintly positive reaction in the cytoplasm. In 62 surgically resected ICCs, a variable degree of positive p27 nuclear staining is recognized. A subset (13 of 62 cases; 21.0%) of the carcinomas displayed cytoplasmic staining. We classified 62 cases into 2 groups, a low expression group (< 50% of p27 nuclear positive cells) and a high expression group (> or = 50% of p27 nuclear positive cells), and tested for the association between positive expression and clinicopathologic features. We found that a low expression of nuclear p27 was correlated with positive vascular invasion (P < .05). The survival curve of the group with low p27 nuclear expression was significantly lower than that of the group with high p27 nuclear expression (P < .005). According to the multivariate analyses, low p27 expression can be considered an independent prognostic factor whose occurrence indicates a worse prognosis. We conclude that a decreased p27 expression adds an independent parameter that can be used when determining the prognosis of patients with ICC. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cell Cycle Proteins / Cholangiocarcinoma / Cyclin-Dependent Kinase Inhibitor p27 / Female / Humans / Male / Microtubule-Associated Proteins / Middle Aged / Multivariate Analysis / Prognosis / Proportional Hazards Models / Survival Analysis / Tumor Suppressor Proteins (Link to Publication Site) ● Publication site (DOI): 10.1053/jhep.2001.24028 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11343239 ● Search Scopus @ Elsevier (PMID): 11343239 ● Search Scopus @ Elsevier (DOI): 10.1053/jhep.2001.24028 (DOI: 10.1053/jhep.2001.24028, PubMed: 11343239)
245.	Hirofumi Hasegawa, Mitsuo Shimada, Yoshikazu Yonemitsu, Tohru Utsunomiya, Tomonobu Gion, Yasufumi Kaneda and Keizo Sugimachi : Preclinical and therapeutic utility of HVJ liposomes as a gene transfer vecotr for hepatocellular carcinoma using herpes simplex virus thymidine kinase, Cancer Gene Therapy, Vol.8, No.4, 252-258, 2001. (Summary) Although gene therapy has been suggested to be a novel strategy to treat hepatocellular carcinoma (HCC), no study showing the clinical feasibility of vectors to treat HCC has been reported. In this preclinical study, we show evidence indicating that hemagglutinating virus of Japan (HVJ) liposomes are a feasible vector to treat HCC in a clinical setting using ganciclovir (GCV) and herpes simplex virus thymidine kinase (HSV-tk), which is driven by the cytomegalovirus immediate early enhancer/promoter (plasmid pcDNA3/HSV-tk). In in vitro experiments, almost complete tumor cell regression was achieved with the optimal GCV concentration (100 microg/mL) and more than 1/3 regression was seen even with a 20% transduction ratio using HuH7 HCC cells stably transformed by HSV-tk. HVJ liposomes showed a 19.7% (mean) transduction rate of the lacZ gene in a relatively large mass of more than 300 mm3 in vivo, which is a clinically detectable size, implanted into SCID mice. Moreover, a single HSV-tk injection of HVJ liposomes followed by GCV treatment inhibited tumor growth at least within a week, and repeat administration was more effective. Furthermore, subcutaneous injection of an HVJ liposomes vehicle induced no apparent inflammatory response in C3H/HeN mice, whereas lacZ gene transfection resulted in inflammatory pathology, suggesting a lower immunogenicity of the HVJ envelope protein than those of bacteria-derived plasmid DNA or the beta-galactosidase gene product. From these findings, we conclude that HVJ liposomes are a clinically safe and effective gene transfer vector to treat HCC. (Keyword) Animals / Antiviral Agents / Body Weight / Carcinoma, Hepatocellular / Drug Evaluation, Preclinical / Ganciclovir / Gene Therapy / Gene Transfer Techniques / Genetic Vectors / Humans / Lac Operon / Liposomes / Liver Neoplasms, Experimental / Male / Mice / Mice, Inbred C3H / Mice, SCID / Respirovirus / Simplexvirus / Thymidine Kinase / Tumor Cells, Cultured (Link to Publication Site) ● Publication site (DOI): 10.1038/sj.cgt.7700307 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11393277 ● Search Scopus @ Elsevier (PMID): 11393277 ● Search Scopus @ Elsevier (DOI): 10.1038/sj.cgt.7700307 (DOI: 10.1038/sj.cgt.7700307, PubMed: 11393277)
246.	Yo-ichi Yamashita, Mitsuo Shimada, Takayuki Hamatsu, Tatsuya Rikimaru, Shinji Tanaka, Ken Shirabe and Keizo Sugimachi : Effects of preoperative steroid administration on surgical stress in hepatic resection, Archives of Surgery, Vol.136, No.3, 328-333, 2001. (Summary) Preoperative administration of methylprednisolone sodium succinate can control surgical stress in patients undergoing hepatic resection. A prospective randomized trial. A university hospital department of surgery. Thirty-three patients who underwent hepatic resection were classified into 2 groups: a control group (n = 16) and a steroid group (n = 17) in which patients were intravenously administered 500 mg of methylprednisolone 2 hours before surgery. Perioperative levels of interleukin (IL)-6 and IL-10 (serum and peritoneal), immunosuppressive acidic protein, Candida antigen, and other laboratory and clinical variables were measured. Postoperative levels of serum and peritoneal IL-6 and levels of C-reactive protein were significantly lower in the steroid group than in controls. Furthermore, serum and peritoneal IL-10 levels were significantly higher in the steroid group. The total bilirubin value on postoperative day 1 was significantly lower in the steroid group than in controls. Postoperative immunosuppressive acidic protein levels were also significantly lower in the steroid group, as was the positive rate of serum Candida antigen. No differences were found in the incidence of postoperative complications. Preoperative steroid administration significantly elevated anti-inflammatory cytokine IL-10 levels, suppressed the levels of inflammatory cytokines IL-6 and C-reactive protein, and prevented postoperative elevation of total bilirubin values. Furthermore, postoperative elevation of immunosuppressive acidic protein levels and the positive rate of Candida antigen were suppressed, indicating that the immune response was maintained by preoperative steroid administration. (Keyword) Acute-Phase Proteins / Acute-Phase Reaction / Adult / Aged / Bile Duct Neoplasms / Bilirubin / C-Reactive Protein / Carcinoma, Hepatocellular / Cholangiocarcinoma / Female / Hepatectomy / Humans / Interleukin-10 / Interleukin-6 / Liver Neoplasms / Male / Methylprednisolone Hemisuccinate / Middle Aged / Postoperative Complications / Premedication / Prospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1001/archsurg.136.3.328 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11231856 ● Search Scopus @ Elsevier (PMID): 11231856 ● Search Scopus @ Elsevier (DOI): 10.1001/archsurg.136.3.328 (DOI: 10.1001/archsurg.136.3.328, PubMed: 11231856)
247.	Yuh Fujiwara, Mitsuo Shimada, Yo-ichi Yamashita, Eisuke Adachi, Ken Shirabe, Kenji Takenaka and Keizo Sugimachi : Cytokine characteristics of jaundice in mouse liver, Cytokine, Vol.13, No.3, 188-191, 2001. (Summary) The aim of this study is to clarify the perioperative cytokine changes and their mechanism in jaundiced liver. Obstructive jaundice was induced using a common bile duct ligation (CBDL) and a two-thirds hepatectomy (HEP) was performed in six- to seven-week-old male C3H/HeN mice. When hepatectomy was added to CBDL, it was carried out 2 to 5 days after CBDL. The serum interleukin 6 (IL-6) levels and heat shock protein (HSP)-70 expression were evaluated. One mg per mouse of methylprednisolone (MPL) was intraperitonealy administered in some mice of CBDL+HEP group. The post-hepatectomy IL-6 values at 2 and 3 days after CBDL were significantly lower than those in the HEP group, while those at 5 days after CBDL were significantly higher than those in HEP group. The serum IL-6 value of the steroid group was significantly lower than that of non-steroid group in HEP group. However, no steroid effects were recognized on post-hepatectomy IL-6 values at 3 days after CBDL, steroid inhibited post-hepatectomy IL-6 production at 5 days after CBDL. No expression of HSP70 protein was observed in the control group, but HSP70 protein was expressed in both the hepatocytes and Kupffer cells 3 days after CBDL, then at 5 days after CBDL, no HSP70 protein was expressed in the Kupffer cells. In the early period of obstructive jaundice, the IL-6 level after hepatectomy did not increase in comparison to HEP group, and steroid had no effect on IL-6 level. According to the progression of obstructive jaundice, the IL-6 level after hepatectomy increased to a higher level than before, and the effect of MPL was restored. HSP70 is thus suggested to have an important role in cytokine production. (Keyword) Animals / Cholestasis, Extrahepatic / HSP70 Heat-Shock Proteins / Hepatectomy / Interleukin-6 / Ligation / Liver / Male / Mice / Mice, Inbred C3H / Postoperative Complications (Link to Publication Site) ● Publication site (DOI): 10.1006/cyto.2000.0781 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11161464 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035819494 (DOI: 10.1006/cyto.2000.0781, PubMed: 11161464, Elsevier: Scopus)
248.	Yo-ichi Yamashita, Mitsuo Shimada, Hirofumi Hasegawa, Ryosuke Minagawa, Tatsuya Rikimaru, Takayuki Hamatsu, Shinji Tanaka, Ken Shirabe, Jun-ichi Miyazaki and Keizo Sugimachi : Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model, Cancer Research, Vol.61, No.3, 1005-1012, 2001. (Summary) Applications of nonviral vectors for gene transfer into tumors in vivo have been limited by the relatively low expression levels of the transferred gene. The aim of this study is to evaluate the efficacy of electroporation-mediated interleukin-12 (IL-12) gene therapy for hepatocellular carcinoma (HCC). First, we investigated the optimal conditions of electric pulses (voltage, pulsing duration, numbers of shocks) of in vivo electroporation for gene transfer into HCC established by s.c. implantation of MH134 cells to C3H mice. This process made use of plasmid DNA that express the luciferase gene. We concluded that the optimal conditions for the electric pulses are as follows: voltage at 150 V; pulsing duration at 50 ms; nonpulsing duration at 950 ms; and the number of shocks at 10. Second, we tried to treat s.c. HCC by electroporation using plasmid DNA that expresses the murine interleukin-12 (mlL-12) gene. Intratumoral administration of the mIL-12 vector elevated serum IL-12 and IFN-gamma and significantly inhibited the growth not only of HCC into which the mIL-12 vector had been directly transferred, but also of the distant HCC. In addition, intratumoral administration of the mIL-12 vector inhibited spontaneous lung metastasis and delayed establishment of HCC injected 3 days after mIL-12 gene therapy. The IL-12 gene therapy induced more lymphocyte infiltration by NK cells, CD3+ cells, and Mac-1 positive cells into the tumor and reduced the number of microvessels. Therefore, more terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive tumor cells were found. These results demonstrate that gene therapy for HCC by electroporation in vivo using IL-12 is very efficient and is thus promising for further clinical trial. (Keyword) Animals / Cell Division / Disease Models, Animal / Electroporation / Female / Flow Cytometry / Genetic Therapy / Interferon-gamma / Interleukin-12 / Liver Neoplasms, Experimental / Luciferases / Lung Neoplasms / Lymphocyte Activation / Lymphocytes, Tumor-Infiltrating / Mice / Mice, Inbred C3H / T-Lymphocytes, Cytotoxic / Tumor Cells, Cultured (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11221826 ● Search Scopus @ Elsevier (PMID): 11221826 (PubMed: 11221826)
249.	Yo-ichi Yamashita, Mitsuo Shimada, Eiji Tsujita, Tatsuya Rikimaru, Hiroyuki Ijima, Kohji Nakazawa, Ryo-ichi Sakiyama, Junji Fukuda, Kazumori Funatsu and Keizo Sugimachi : The efficacy of nafamostat mesilate on the performance of a hybrid-artificial liver using a polyurethane foam/ porcine hepatocyte spheroid culture system in human plasma, The International Journal of Artificial Organs, Vol.24, No.1, 34-40, 2001. (Summary) Nafamostat mesilate (FUT) is a protease inhibitor of complement activation. The present study investigates whether FUT protects porcine hepatocytes from being injured by human plasma in a multi-capillary polyurethane foam packed-bed culture system (MC-PUF) such as the hybrid-artificial liver (PUF-HAL). Human plasmas with 1 mM of added ammonia were perfused using a small-scale PUF-HAL with porcine hepatocytes. FUT was continuously infused (10 microg/ml, 50 microg/ml). The ammonia detoxification was maintained in human plasma for 24 hours and for 48 hours with FUT which suppressed the rapid increase of asparaginic acid aminotransferase (AST) and alanine aminotransferase (ALT). After 60 hours of perfusion, hepatocyte spheroids completely collapsed in the human plasma, but a small amount of hepatocyte spheroid was maintained by FUT. The effect of FUT was slightly greater at 50 microg/ml than at 10 microg/ml. Our results suggest that FUT has protective effects against porcine hepatocytes in human plasma, and our PUF-HAL using porcine hepatocytes can function in human plasma for about 48 hours with FUT. (Keyword) Alanine Transaminase / Ammonia / Animals / Cell Survival / Female / Guanidines / Humans / Liver / Liver Failure / Liver, Artificial / Plasma / Polyurethanes / Protease Inhibitors / Swine / Transaminases (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11266040 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035119349 (PubMed: 11266040, Elsevier: Scopus)
250.	Toru Ikegami, Takashi Nishizaki, Katsuhiko Yanaga, Mitsuo Shimada, Saburo Kakizoe, Kenichi Nomoto, Shoji Hiroshige, Hideaki Uchiyama and Keizo Sugimachi : Changes in the caudate lobe that is trabsplanted with extended left lobe liver grft from living donor, Surgery, Vol.129, No.1, 86-90, 2001. (Summary) Caudate lobe transplantation with an extended left lobe graft is an innovative and promising method for increasing the graft volume in living donor liver transplantation. However, little is known about the fate of the caudate lobe after transplantation. Eight extended left lobe grafts with the caudate lobe were included in this study. No attempt was made to reconstruct the short hepatic veins. On the basis of the computed tomography scans that were obtained before the operation and 1 month after the transplantation, the increase in the graft volume by the addition of the caudate lobe and the changes in the transplanted caudate lobe were evaluated. The addition of the caudate lobe increased the graft volume by 25 +/- 2 g, corresponding to a 2% increase in graft volume/standard liver volume ratio. One month after the transplantation, the caudate lobe volume increased in all patients but 1. The regeneration rate of the caudate lobe and other segments (segments II-IV) 1 month after transplantation was 62% +/- 24% (24 +/- 4 mL- 37 +/- 4 mL) and 152% +/- 35% (374 +/- 45 mL-930 +/- 65 mL), respectively (P <.01). This technique affords a modest increase in liver volume with living donor left liver procurement. (Keyword) Humans / Liver Regeneration / Liver Transplantation / Living Donors / Organ Size / Time Factors / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2001.109499 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11150037 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035139656 (DOI: 10.1067/msy.2001.109499, PubMed: 11150037, Elsevier: Scopus)
251.	Yo-ichi Yamashita, Takayuki Hamatsu, Tatsuya Rikimaru, Shinji Tanaka, Ken Shirabe, Mitsuo Shimada and Keizo Sugimachi : Bile leakage after hepatic resection, Annals of Surgery, Vol.233, No.1, 45-50, 2001. (Summary) To identify the perioperative risk factors for postoperative bile leakage after hepatic resection, to evaluate the intraoperative bile leakage test as a preventive measure, and to propose a treatment strategy for postoperative bile leakage according to the outcome of these patients. Bile leakage remains a common cause of major complications after hepatic resection. Between January 1985 and June 1999, 781 hepatic resections without bilioenteric anastomosis were performed at the authors' institution. Perioperative risk factors related to postoperative bile leakage were identified using univariate and multivariate analysis. The characteristics of patients with intractable bile leakage and the effect of intraoperative bile leakage test were also examined. Management was evaluated in relation to the outcomes and the clinical characteristics of the patients with bile leakage. Bile leakage developed in 31 (4.0%) of 781 hepatic resections. This complication carried high risks for surgical death (two patients [6.5%] died). The stepwise logistic regression analysis identified high-risk surgical procedure, in which the cut surface exposed the major Glisson's sheath and included the hepatic hilum (i.e., anterior segmentectomy, central bisegmentectomy, or total caudate lobectomy), as the independent predictor of the development of postoperative bile leakage. None of the 102 cases in which an intraoperative bile leakage test was performed were subsequently complicated by postoperative bile leakage, and the preventive effect of the test was statistically significant. Patients with fisterographically demonstrable leakage from the hepatic hilum and with postoperative uncontrollable ascites had poor outcomes. Patients with bile leakage from the hepatic hilum and postoperative uncontrollable ascites tend to have a poor prognosis. Therefore, especially when a high-risk surgical procedure is performed in patients with liver cirrhosis, more careful surgical procedures and use of an intraoperative bile leakage test are recommended. (Keyword) Bile / Female / Hepatectomy / Humans / Incidence / Intraoperative Care / Logistic Models / Male / Postoperative Complications / Retrospective Studies / Risk Factors / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1097/00000658-200101000-00008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11141224 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035159787 (DOI: 10.1097/00000658-200101000-00008, PubMed: 11141224, Elsevier: Scopus)
252.	Yo-ichi Yamashita, Mitsuo Shimada, Eiji Tsujita, Shinji Tanaka, Hiroyuki Ijima, Kohji Nakazawa, Ryoichi Sakiyama, Junji Fukuda, T Ueda, Kazumori Funatsu and Keizo Sugimachi : Polyurethane foam/spheroid culture system using human hepatoblastoma cell line (Hep G2) as a possible new hybrid artificil liver, Cell Transplantation, Vol.10, No.8, 717-722, 2001. (Summary) The risk of xenozoonosis infections poses the greatest obstacle against the clinical application of hybrid artificial liver support system (HALSS). Primary human hepatocytes are an ideal source for HALSS, but the shortage of human livers available for hepatocyte isolation limits this modality. To resolve this issue, we used human hepatocytes with replication capacity (fetal hepatocytes, Hep G2, and Huh 7) in a polyurethane foam (PUF)/spheroid culture system in vitro, and analyzed liver functions such as ammonia removal and albumin synthesis capacity; results were compared to those of porcine hepatocytes. Human fetal hepatocytes, Hep G2, and Huh 7 formed spheroids spontaneously within 24 h in a PUF/spheroid culture system; ammonia removal activity (micromol/10(6) nuclei/h) was upregulated, as was albumin synthesis activity (microg/10(6) nuclei/day). In particular, Hep G2 spheroids demonstrated high ammonia removal and albumin synthesis activities: 85% of the ammonia removal activity and 171.7% of the albumin synthesis activity of porcine hepatocytes in the monolayer culture. These results indicate the possibility of the development of a multicapillary PUF (MC-PUF) packed-bed culture system of hepatocyte spheroids as a HALSS using Hep G2. (Keyword) Albumins / Ammonia / Animals / Cell Culture Techniques / Cell Division / Cells, Cultured / Culture Media / Hepatoblastoma / Hepatocytes / Humans / Liver / Liver Neoplasms / Liver, Artificial / Polyurethanes / Spheroids, Cellular / Swine / Time Factors / Tumor Cells, Cultured / Up-Regulation (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11814114 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035696340 (PubMed: 11814114, Elsevier: Scopus)
253.	Mitsuo Shimada, Tatsuya Rikimaru, Keishi Sugimachi, Takayuki Hamatsu, Yo-ichi Yamashita, Shin-ichi Aishima, Ken-ichi Taguchi, Shinji Tanaka, Ken Shirabe and Keizo Sugimachi : The Importance of Hepatic Resection for Hepatocellular Carcinoma Originating from Nonfibrotic Liver, Journal of the American College of Surgeons, Vol.191, No.5, 531-537, 2000. (Summary) Our study aimed to clarify the characteristics of hepatocellular carcinoma (HCC) in patients with a nonfibrotic liver and the role of surgical resection for HCC in nonfibrotic liver compared with patients with HCC in fibrotic or cirrhotic livers. A total of 516 patients who underwent hepatectomy between April 1985 and June 1999 were classified into two groups: a nonfibrotic liver group (n=65) and a fibrotic liver group (n=451), which included fibrotic or cirrhotic livers. Clinicopathologic variables were then compared between the groups, including disease-free survival rate and patient survival rate. Only 8 of 65 patients (12.3%) with a nonfibrotic liver showed a histologically completely normal liver. The numbers of men and patients with alcohol abuse in the nonfibrotic liver group were higher than in the fibrotic liver group. The numbers of patients with positive hepatitis B antigen and positive hepatitis C antibody in the nonfibrotic liver group were lower than in the fibrotic liver group. Results of liver function tests in the nonfibrotic liver group were better than those in the fibrotic liver group. The rates of both portal vein and hepatic vein invasion of cancer cells in the nonfibrotic liver group were higher than in the fibrotic liver group. The tumor size in the nonfibrotic liver group was larger than in the fibrotic liver group. The patient survival and disease-free survival rates in the nonfibrotic liver group were better than in the fibrotic liver group. Hepatic resection can be beneficial for patients with HCC originating from a nonfibrotic liver when compared with fibrotic or cirrhotic patients with HCC. (Keyword) Carcinoma, Hepatocellular / Disease-Free Survival / Female / Hepatectomy / Hepatitis B / Hepatitis C / Humans / Liver / Liver Cirrhosis / Liver Function Tests / Liver Neoplasms / Male / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1016/S1072-7515(00)00705-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11085733 ● Search Scopus @ Elsevier (PMID): 11085733 ● Search Scopus @ Elsevier (DOI): 10.1016/S1072-7515(00)00705-5 (DOI: 10.1016/S1072-7515(00)00705-5, PubMed: 11085733)
254.	Takashi Nishizaki, Keishi Kishikawa, Tomoharu Yoshizumi, Hideaki Uchiyama, Shinji Okano, Toru Ikegami, Koji Hashimoto, Kenichi Nomoto, Mitsuo Shimada, Katsuhiko Yanaga, Kenji Takenaka, Keizo Sugimachi, Yukio Ando and Masayuki Ando : Domino liver transplantation from a living related donor, Transplantation, Vol.70, No.8, 1236-1239, 2000. (Summary) Although domino liver transplantations (OLT) from cadaveric donors have been performed in about 50 cases since 1995, only one case in the Japanese literature has been reported on a domino OLT from a living related donor. The difficulties of the later surgery lie in the small size of the graft volume and the short length of the vascular cuffs in the graft. The left lobe graft was procured from a 43-year-old younger brother of a familial amyloidotic polyneuropathy (FAP) patient. Next, the left lobe graft (510 g, 44% of the estimated standard liver volume of the FAP patient) was implanted into the 48-year-old female FAP patient. At surgery for the FAP patient, a sufficient length of the vascular cuffs was secured by an extended left lobe resection, although the right lobe graft was able to maintain sufficient vascular cuffs. The right lobe graft (720 g, 54% of the recipient's estimated standard liver volume) was then implanted in the 43-year-old male patient with liver cirrhosis and hepatocellular carcinoma (stage IV-A). The two recipients were discharged from the hospital 1 month after OLT. At 7 months after OLT, they are both doing well and the domino recipient is free of any tumor recurrence. A domino OLT from the living related donor can therefore be done safely when careful attention is paid to the graft volume and the length of the vascular cuffs for anastomosis. (Keyword) Amyloid Neuropathies / Anastomosis, Surgical / Hepatectomy / Hepatic Veins / Humans / Liver Transplantation / Living Donors (Link to Publication Site) ● Publication site (DOI): 10.1097/00007890-200010270-00019 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11063347 ● Summary page in Scopus @ Elsevier: 2-s2.0-0034721897 (DOI: 10.1097/00007890-200010270-00019, PubMed: 11063347, Elsevier: Scopus)
255.	Mitsuo Shimada, Yo-ichi Yamashita, Takayuki Hamatsu, Hirofumi Hasegawa, Tohru Utsunomiya, Shin-ichi Aishima and Keizo Sugimachi : The role of des-g-caboxy prothrombin levels in hepatocellular carcinoma and liver tissues, Cancer Letters, Vol.159, No.1, 87-94, 2000.
256.	Shinji Tanaka, Keishi Sugimachi, Ken Shirabe, Mitsuo Shimada, Jack R. Wands and Keizo Sugimachi : Expression and antitumor efects of TAIL in Human Cholangiocarcinoma, Hepatology, Vol.32, No.3, 523-527, 2000.
257.	Mitsuo Shimada, Hirofumi Hasegawa, Tomonobu Gion, Tohru Utsunomiya, Ken Shirabe, Kenji Takenaka, Teruhisa Okutsu, Yoshihiko Maehara and Keizo Sugimachi : The role of telomerase activety in hepatocellular carcinoma, The American Journal of Gastroenterology, Vol.95, No.3, 748-752, 2000. (Summary) The aim of this study was to clarify the role of telomerase activity in hepatocellular carcinoma (HCC). Specimens from both HCC and noncancerous liver were obtained from 39 patients with HCC using a 14-gauge biopsy needle immediately after laparotomy. Telomerase activity was determined using a telomeric repeat amplification protocol assay. The 3+ of telomerase activity in HCC was defined as a high telomerase group, and 2+ or less of HCC telomerase activity was defined as a low telomerase group. In noncancerous liver, 2+ or more of telomerase activity was defined as an increased telomerase group, and 1+ or less of telomerase activity was defined as a nonincreased telomerase group. The correlation between telomerase activity in HCC or noncancerous liver and clinicopathological factors, including prognosis, was investigated. Telomerase activities in HCCs were 0 in one patient, 1+ in two, 2+ in seven, and 3+ in 29 patients. The disease-free survival rate in the high telomerase group was significantly worse than that in the low telomerase group. The des-gamma-carboxy prothrombin level in a high telomerase group (median, 330 mAU/ml) was significantly higher than that in the low telomerase group (median, 150 mAU/ml). A multivariate analysis revealed that higher TNM stage, high telomerase activity in HCC, female gender, and high alpha-fetoprotein value were independent significant factors related to be early recurrence. The incidence of multicentric HCC occurrence in the increased telomerase group (53.3%) tended to be higher than that in the nonincreased telomerase group (27.3%). A high telomerase activity in HCC correlated with the potential of HCC to be more malignant, which was expressed as both a high level of des-gamma-carboxy prothrombin and an earlier recurrence after hepatectomy than that of HCC with a low telomerase activity. (Keyword) Adult / Aged / Biological Markers / Biopsy, Needle / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Humans / Liver / Liver Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Neoplasm Staging / Prognosis / Protein Precursors / Prothrombin / Telomerase (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1572-0241.2000.01855.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10710069 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033994742 (DOI: 10.1111/j.1572-0241.2000.01855.x, PubMed: 10710069, Elsevier: Scopus)
258.	Tohru Utsunomiya, Mitsuo Shimada, Ken-ichi Taguchi, Hirofumi Hasegawa, Yo-ichi Yamashita, Takayuki Hamatsu, Shinichi Aishima and Keizo Sugimachi : Clinicopathologic features and postoperative prognosis of multicentric small hepatocellular carcinoma, Journal of American College of Surgeons, Vol.190, No.3, 331-335, 2000.
259.	Mitsuo Shimada, Hirofumi Hasegawa, Katsuya Rikimaru, Tomonobu Gion, Takayuki Hamatsu, Yo-ichi Yamashita, Ken Shirabe and Ken Sugimachi : The Significance of Thymidine Phosphorylase Activity in Hepatocellular Carsinoma and Chronic disease Livers: A Special Reference to Liver Fibrosis and Multicentric Tumor Occurrence, Cancer Letters, Vol.148, No.2, 165-172, 2000.
260.	Mitsuo Shimada, Makoto Hashizume, Ken Shirabe, Kenji Takenaka and Keizo Sugimachi : A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism : Performing a hepatectomy after a laparoscopic splenectomy, Surgical Endoscopy, Vol.14, No.2, 127-130, 2000. (Summary) Hepatectomy for cirrhotic patients with hypersplenism is a high-risk operative procedure. We report herein a new strategy for high-risk patients with hepatocellular carcinoma (HCC). Six cirrhotic patients with HCC and hypersplenism received a partial hepatectomy after first undergoing a laparoscopic splenectomy. We then compared the variables for these patients before splenectomy and before hepatectomy. The platelet count and the white blood cell count were found to be significantly elevated before hepatectomy. The ammonia value decreased significantly before hepatectomy. The albumin value tended to be elevated before hepatectomy. Furthermore, the Child's classification of all patients improved significantly before hepatectomy. However, other variables-such as the indocyanine green dye excretion test at 15 min and the bilirubin value-did not change after splenectomy. For hepatectomy patients who first underwent a laparoscopic splenectomy, operation time ranged from 265 to 440 min (average time, 361 min), and blood loss ranged from 500 to 2,200 ml (median volume, 1,300 ml). Four of six patients did not require any blood transfusion; furthermore, no patient needed a platelet-rich plasma transfusion. All but one patient, who suffered postoperatively from an intractable duodenal ulcer, had an uneventful postoperative course. Partial hepatectomy after an initial laparoscopic splenectomy is a new and effective choice of treatment for cirrhotic patients with HCC and hypersplenism. (Keyword) Aged / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Hypersplenism / Liver Cirrhosis / Liver Neoplasms / Male / Middle Aged / Splenectomy (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10656943 ● Search Scopus @ Elsevier (PMID): 10656943 (PubMed: 10656943)
261.	Ken Shirabe, Mitsuo Shimada, Kiyoshi Kajiyama, Hirofumi Hasegawa, Tomonobu Gion, Yasuharu Ikeda, Kenji Takenaka and Keizo Sugimachi : Expression of matrix metalloproteinase-9(MMP-9) in surgically resected intrahepatic cholangiocarcinoma(IHCC), Surgery, Vol.126, No.5, 842-846, 1999. (Summary) Matrix metalloproteinase-9 (MMP-9) has recently been reported to be related to cancer cell invasion. This study was performed to clarify the expression of MMP-9 in surgically resected intrahepatic cholangiocarcinoma (IHCC). In 37 patients with IHCC who underwent a surgical resection, the expression of MMP-9 and the clinicopathologic characteristics of MMP-9-positive IHCC were investigated. The expression of MMP-9 was immunohistochemically detected in 16 (43%) of 37 IHCC. The patients were divided into MMP-9 (-) IHCC (n = 21), MMP-9 (+) IHCC (n = 12), and MMP-9 (++) IHCC (n = 4). The survival rate after surgical resection in patients with MMP-9 (-), (+), and (++) IHCC, was 66%, 39%, and 0% at one year, 50%, 32% and 0% at 3 years, respectively (P = .001). The incidence rate of lymph node metastasis was 6 (28%) of 21 in MMP-9 (-) patients, 7 (58%) of 12 in MMP-9 (+) patients and 4 (100%) of 4 in MMP-9 (++) patients. The incidence rate of lymph node metastasis increased in proportion to an increase in the expression of MMP-9 in IHCC (P = .02). Recurrence in the lymph node was more common in patients with MMP-9 (+) and (++) cancers than in those with MMP-9 (-) cancers. The expression of MMP-9 in IHCC was a prognostic factor related to lymph node metastasis. (Keyword) Adult / Aged / Cholangiocarcinoma / Female / Humans / Immunohistochemistry / Liver Neoplasms / Lymphatic Metastasis / Male / Matrix Metalloproteinase 9 / Middle Aged / Neoplasm Recurrence, Local (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10568183 ● Search Scopus @ Elsevier (PMID): 10568183 (PubMed: 10568183)
262.	Hirofumi Hasegawa, Mitsuo Shimada, Tomonobu Gion, Hiroyuki Ijima, Kohji Nakazawa and Keizo Sugimachi : Modulation of immunologic reaction between cultured porcine hepatocytes and human sera, ASAIO Journal, Vol.45, No.5, 392-396, 1999.
263.	Tomonobu Gion, Mitsuo Shimada, Ken Shirabe, Kohji Nakazawa, Hiroyuki Ijima, Kazumori Funatsu and Keizo Sugimachi : Evaluation of a hybrid artificial liver using a polyurethane foam paced-bed culture system in dogs, Journal of Surgical Research, Vol.82, No.2, 131-136, 1999.
264.	Tohru Utsunomiya, Hideki Saitsu, Motonori Saku, Kohji Yoshida, Takashi Matsumata, Mitsuo Shimada and Keizo Sugimachi : Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus, The American Journal of Surgery, Vol.177, No.4, 279-281, 1999. (Summary) The rarity of the occurrence of metastatic malignancy in injured liver has been noted by many observers. However, since the clinicopathological features of primary carcinoma and the etiology of liver disease of these patients vary greatly, this phenomenon may not be universal. We evaluated the relationship between either hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and the incidence of colorectal liver metastasis in 438 patients undergoing surgical treatment for advanced colorectal carcinoma. The liver function of the patients in the infection group (n = 37) was significantly worse than that of those in the noninfection group (n = 401). The incidences of tumor recurrence in the lung or peritoneum were comparable between the two groups. However, the percentage of patients with liver metastases in the infection group (3 of 37, 8.1%) was significantly lower (P <0.05) than that of those in the noninfection group (85 of 401, 21.2%). The patients in the infection group tended to survive longer than the patients in the noninfection group. We herein report an initial finding that colorectal carcinoma rarely metastasizes to livers infected with HBV or HCV. (Keyword) Aged / Carcinoma / Colorectal Neoplasms / Female / Hepacivirus / Hepatitis B / Hepatitis B virus / Hepatitis C / Humans / Incidence / Liver Neoplasms / Male / Middle Aged / Prognosis / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1016/S0002-9610(99)00045-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10326842 ● Search Scopus @ Elsevier (PMID): 10326842 ● Search Scopus @ Elsevier (DOI): 10.1016/S0002-9610(99)00045-8 (DOI: 10.1016/S0002-9610(99)00045-8, PubMed: 10326842)
265.	Ken Shirabe, Mitsuo Shimada, Tomonobu Gion, Hirofumi Hasegawa, Kenji Takenaka, Tohru Utsunomiya and Keizo Sugimachi : Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remant liver volume, Journal of American College of Surgeons, Vol.188, No.3, 304-309, 1999.
266.	Tomonobu Gion, Akinobu Taketomi, Mitsuo Shimada, Ken Shirabe, Hirofumi Hasegawa, Kenji Takenaka and Keizo Sugimachi : Preoperative change in albumin messenger RNA levels in patients with hepatocellular carcinoma, Hepatology, Vol.28, No.6, 1663-1668, 1998.
267.	Naoyuki Kawahara, Mayumi Ono, Ken-ichi Taguchi, Masahiro Okamoto, Mitsuo Shimada, Kenji Takenaka, Kenshi Hayashi, Dean F. Moshe, Keizo Sugimachi, Masazumi Tsuneyoshi and Michihiko Kuwano : Enhanced Expression of Thrombospondin-1 and Hypovascularity in Human Cholangiocarcinoma, Hepatology, Vol.28, No.6, 1512-1517, 1998.
268.	Mitsuo Shimada, Kenichi Taguchi, Hirofumi Hasegawa, Tomonobu Gion, Ken Shirabe, Masazumi Tuneyoshi and Keizo Sugimachi : Nm23-H1 expression in intrahepatic or extrahepatic metastases of hepatocellular carcinoma, Liver, Vol.18, No.5, 337-342, 1998. (Summary) Decreased expression of nm23, a putative metastasis suppressor gene, has been reported to be related to either intrahepatic metastasis or a poor prognosis in hepatocellular carcinoma (HCC). The aim of this study was to elucidate the true role of nm23-H1 expression in both intrahepatic and distant metastases of HCC. Thirteen patients with single-nodule HCC, seven patients with HCC having satellite nodules and seven patients with HCCs having extrahepatic metastases were included in this study. The expression of nm23-H1 protein was immunohistochemically examined in both primary and metastatic nodules. Ten of 13 single-nodule HCCs were found to overexpress nm23-H1 protein. All main tumors, having satellite nodules, were found to overexpress nm23-H protein, except for two HCCs, which only partially expressed nm23-H1 protein. Regarding the nm23-H1 expression in intrahepatic metastases, most nodules overexpressed the protein. The expression of nm23-H1 was found to be low in only one intrahepatic metastasis specimen, while its primary tumor was also found to show a low expression of nm23-H1 protein. Microscopic portal vein invasion was found in three of the five patients studied, and all cancer cells in portal invasion overexpressed nm23-H1 protein. Nm23-H1 protein was expressed in all distant metastatic tumors and the staining intensity of most metastatic nodules was similar to that of the primary tumors. Our study demonstrated that nm23-H1 expression did not always decrease but instead tended to increase at both intrahepatic and extrahepatic metastatic sites. Based on these findings, nm23-H1 expression is not considered to be a reliable indicator of either intrahepatic or distant metastasis in HCC. (Keyword) Adrenal Gland Neoplasms / Aged / Carcinoma, Hepatocellular / Humans / Immunoenzyme Techniques / Kidney Neoplasms / Liver Neoplasms / Lung Neoplasms / Middle Aged / Monomeric GTP-Binding Proteins / NM23 Nucleoside Diphosphate Kinases / Nucleoside-Diphosphate Kinase / Peritoneal Neoplasms / Transcription Factors / Tumor Markers, Biological (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9831363 ● Search Scopus @ Elsevier (PMID): 9831363 (PubMed: 9831363)
269.	Yasuharu Ikeda, Mitsuo Shimada, Hirofumi Hasegawa, Tomonobu Gion, Kiyoshi Kajiyama, Ken Shirabe, Katsuhiko Yanaga, Kenji Takenaka and Keizo Sugimachi : Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection, Hepatology, Vol.27, No.6, 1567-1571, 1998.
270.	Mitsuo Shimada, Kenji Takenaka, Tomonobu Gion, Yuh Fujiwara, Kenichi Taguchi, Kiyoshi Kajiyama, Ken Shirabe and Keizo Sugimachi : Treatment Strategy for Patients With Cystic Lesions Mimicking a Liver Tumor, --- A Recent 10-Year Surgical Experience in Japan ---, Archives of Surgery, Vol.133, No.6, 643-646, 1998.
271.	Mitsuo Shimada, Kiyoshi Kajiyama, Hirofumi Hasegawa, Tomonobu Gion, Yasuharu Ikeda, Kenji Takenaka and Keizo Sugimachi : Role of adhesion molecule expression and theie soluble fractions in hepatic resection, Journal of the American College of Surgeons, Vol.186, No.5, 534-541, 1998. (Summary) Little has so far been documented about the relationship between liver injury and adhesion molecules. The aim of this study is to clarify the role of adhesion molecules in hepatic resection by studying both the expression of such adhesion molecules and the measurement of their soluble fractions in the blood. To study adhesion molecule expression in the liver, liver biopsies were obtained before and after hepatectomy in 14 patients. Using frozen sections, immunochemical staining for intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) was then performed. To study the soluble fractions of adhesion molecules in the hepatic venous blood, the serum soluble fractions of ICAM-1 and VCAM-1 from another 17 patients were measured using an enzyme-linked immunosorbent assay. The plasma levels of polymorphonuclear leukocyte (PMN) elastase were also measured using an enzyme immunoassay. Both the preoperative and postoperative values of the serum soluble fractions of ICAM-1, VCAM-1, and PMN elastase were then compared. The correlation between their values and the perioperative variables was also investigated. Either ICAM-1 or VCAM-1 was stained on the sinusoidal endothelial cells and Kupffer cells or circulating PMNs in the sinusoid. The positive rate of either ICAM-1 or VCAM-1 staining in livers with more than 40 minutes of total ischemic time (80%) was significantly higher than that in livers with less than 40 minutes of total ischemic time (0%; p < 0.05). The incidence of postoperative complications in the ICAM-1 positive staining group tended to be higher than that in the ICAM-1 negative group. Both soluble fractions of ICAM-1 and VCAM-1 in patients with cirrhotic liver disease were also significantly higher than those in patients with a normal liver. The soluble VCAM-1 level in patients with a chronic active hepatitic liver tended to be higher than that in those with a nonactive hepatitic liver. The preoperative level of soluble ICAM-1 correlated with that ofVCAM- 1, PMN elastase, albumin, aspartate aminotransferease (AST), and the indocyanine green dye retention test at 15 minutes (ICG R15), while the preoperative level of VCAM-1 correlated with albumin, the hepaplastin test, AST, and ICG R15. Both the serum soluble ICAM-1 and VCAM-1 levels after hepatectomy were significantly lower than those before hepatectomy. By contrast, the posthepatectomy level of PMN elastase was significantly higher than its prehepatectomy level. The difference between the postoperative and preoperative values of soluble ICAM-1 correlated with the postoperative AST level, postoperative alanine aminotransferase level, and total ischemic time. Adhesion molecules were expressed in the liver after hepatic resection, and such expression correlated with a total ischemic time during hepatectomy. In addition, judging from the soluble forms of such molecules, these adhesion molecules play an important role in hepatic resection. (Keyword) Aged / Aspartate Aminotransferases / Carcinoma, Hepatocellular / Coloring Agents / Endothelium / Enzyme-Linked Immunosorbent Assay / Female / Frozen Sections / Gene Expression Regulation / Hepatectomy / Hepatic Veins / Hepatitis / Hepatitis, Chronic / Humans / Immunoenzyme Techniques / Immunohistochemistry / Incidence / Indicators and Reagents / Indocyanine Green / Intercellular Adhesion Molecule-1 / Ischemia / Kupffer Cells / Leukocyte Elastase / Liver / Liver Cirrhosis / Liver Neoplasms / Male / Middle Aged / Neutrophils / Organic Chemicals / Postoperative Complications / Serum Albumin / Solubility / Vascular Cell Adhesion Molecule-1 (Link to Publication Site) ● Publication site (DOI): 10.1016/S1072-7515(98)00081-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9583693 ● Search Scopus @ Elsevier (PMID): 9583693 ● Search Scopus @ Elsevier (DOI): 10.1016/S1072-7515(98)00081-7 (DOI: 10.1016/S1072-7515(98)00081-7, PubMed: 9583693)
272.	Mitsuo Shimada, Kenji Takenaka, Yuh Fujiwara, Tomonobu Gion, Ken Shirabe, Katsuhiko Yanaga and Keizo Sugimachi : Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma, The British Journal of Surgery, Vol.85, No.2, 195-198, 1998. (Summary) The aim of this study was to clarify the risk factors for morbidity as well as to establish an optimum surgical strategy for hepatocellular carcinoma (HCC). The risk factors linked to postoperative complications were analysed in 388 patients over a 10-year period, according to the kind of operative procedure. Stepwise regression analysis revealed that the most important factors related to postoperative morbidity were: age, creatinine level and the histological grade of fibrosis for the bisegmentectomy; the presence of diabetes mellitus, blood urea nitrogen level, the indocyanine green dye retention rate at 15 min and blood loss for the segmentectomy; the presence of diabetes mellitus and blood loss for subsegmentectomy; the presence of diabetes mellitus, the aspartate aminotransferase level, and the total operating time for resection less than subsegmentectomy. The most important risk factors were not always related to liver function tests, but instead to other coexisting conditions such as diabetes mellitus and operation stress including operating time and blood loss. Therefore, any future treatment strategy of hepatic resection for HCC should make every effort both to evaluate coexisting conditions carefully and to reduce operative stress as far as possible. (Keyword) Age Factors / Blood Loss, Surgical / Carcinoma, Hepatocellular / Hepatectomy / Humans / Intraoperative Period / Liver Cirrhosis / Liver Neoplasms / Multivariate Analysis / Postoperative Complications / Risk Factors / Survival Analysis / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1365-2168.1998.00567.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9501814 ● Search Scopus @ Elsevier (PMID): 9501814 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1365-2168.1998.00567.x (DOI: 10.1046/j.1365-2168.1998.00567.x, PubMed: 9501814)
273.	Mitsuo Shimada, kenji Takenaka, Kenichi Taguchi, Yuh Fujiwara, Tomonobu Gion, Kiyoshi Kajiyama, Takashi Maeda, Ken Shirabe, Katsuhiko Yanaga and Keizo Sugimachi : Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma, Annals of Surgery, Vol.227, No.1, 80-85, 1998.
274.	Akinobu Taketomi, Mitsuo Shimada, Ken Shirabe, Kiyoshi Kajiyama, Tomonobu Gion and Keizo Sugimachi : Natural killer cell activity in patients with hepatocellular carcinoma, Cancer, Vol.83, No.1, 58-63, 1998.
275.	Ken Shirabe, Mitsuo Shimada, Kiyoshi Kajiyama, Tomonobu Gion, Yasuharu Ikeda, Hirofumi Hasegawa, Kenichi Taguchi, Kenji Takenaka and Keizo Sugimachi : Clinipothological features of patients with hepatocellular carcinoma surving more than 10 year after hepatectomy, Cancer, Vol.83, No.11, 2312-2316, 1998.
276.	Ken Shirabe, Kenji Takenaka, Tomonobu Gion, Yuh Fujiwara, Mitsuo Shimada, Katsuhiko Yanaga, Takashi Maeda, Kiyoshi Kajiyama and Keizo Sugimachi : Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin, The British Journal of Surgery, Vol.84, No.8, 1077-1080, 1997. (Summary) Liver resection for metastatic colorectal cancer has been established. Nevertheless, it is still controversial whether the surgical margin from the tumour edge to the cut surface of the liver is a significant prognostic factor in hepatic resection for colorectal metastatic liver cancer. To clarify the prognostic risk factors in hepatic resection for colorectal metastasis, univariate and multivariate analyses were performed. Between April 1985 and April 1995, 31 patients underwent curative hepatic resection for metastatic colorectal cancer. The clinical and pathological factors were examined retrospectively. Overall 1-, 3- and 5-year survival rates of the patients were 92, 42 and 39 per cent respectively. Pathological study of 16 resected specimens with a solitary liver tumour revealed hepatic vein invasion by cancer cells in two of 16 cases, portal vein invasion in three, microsatellite lesions in two and biliary tract invasion in six cases. In resected specimens with a solitary tumour measuring less than 4 cm in diameter, one of these factors was observed in only two of nine cases, whereas in specimens with a solitary tumour measuring more than 4 cm in diameter, these factors were observed in six of seven patients (P < 0.05). The distance from the tumour edge to the intrahepatic invasion was less than 10 mm. With univariate analysis, tumour size of 4 cm or more in diameter, an interval of 6 months or less between colorectal and hepatic resection, four or more gross tumours, bilobar involvement and a resection margin from the tumour of less than 10 mm were found to be significant factors indicating a poor prognosis. Cox's proportional hazards model identified a tumour of 4 cm or more in diameter and a resection margin from the tumour of less than 10 mm as poor prognostic factors (P < 0.05). In treating metastatic colorectal cancer to the liver, the surgical margin should be more than 10 mm because occult intrahepatic invasion was always found to be located within 10 mm from the edge of the tumour. (Keyword) Adult / Aged / Colorectal Neoplasms / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Invasiveness / Neoplasm, Residual / Retrospective Studies / Risk Factors / Survival Analysis / Survival Rate / Treatment Outcome (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9278644 ● Search Scopus @ Elsevier (PMID): 9278644 (PubMed: 9278644)
277.	Kazuharu Yamamoto, Kenji Takenaka, Naoyuki Kawahara, Mitsuo Shimada, Ken Shirabe, Hidetoshi Itasaka, Takashi Nishizaki, Katsuhiko Yanaga and Keizo Sugimachi : Indications for palliative reduction surgery in advanced hepatocellular carcinoma. The use of a remnant tumor index, Archives of Surgery, Vol.132, No.2, 120-123, 1997. (Summary) To clarify the indications for and the significance of palliative reduction surgery in the multidisciplinary treatment of advanced hepatocellular carcinoma (HCC) and to propose the use of a remnant tumor index (RTI) as a simplified criterion for palliative reduction surgery in cases of advanced HCC. A comparison of survival based on the RTI. A large university hospital in Japan. Twenty-five patients with advanced HCC who underwent palliative reduction surgery were divided into 3 groups as follows: group 1 (n = 9), the remnant tumor after operation existed only in the liver and the RTI was less than 5.0; group 2 (n = 11), the remnant tumor after operation existed only in the liver and the RTI was greater than 5.0; and group 3 (n = 5), extrahepatic metastatic tumor existed after operation. Pathological findings and survival rate after surgery. There was no significant difference in the degree of macroscopic intrahepatic metastases among the 3 groups; however, both the portal vein invasion and the histological grade tended to be more severe in groups 2 and 3. The respective 1-year and 3-year survival rates for group 1 were 67% and 33%, and those for group 2 were 21% and 0%. There were no survivors in group 3 at 1 year after surgery. Significant differences were found in the survival rates between groups 1 and 2 (P < .05), and between groups 1 and 3 (P < .05). Palliative reduction surgery for advanced HCC is only considered effective for patients with both an RTI of less than 5.0 and no extrahepatic metastasis. (Keyword) Aged / Carcinoma, Hepatocellular / Female / Humans / Liver Neoplasms / Male / Middle Aged / Neoplasm Staging / Palliative Care / Survival Rate (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9041912 ● Search Scopus @ Elsevier (PMID): 9041912 (PubMed: 9041912)
278.	Mitsuo Shimada, Kenji Takenaka, Yuh Fujiwata, Tomonobu Gion, Ken Shirabe, Takashi Nishizaki, Katsuhiko Yanaga and Keizo Sugimachi : Characteristics of hepatocellular carcinoma associated with extrahepatic primary malignancies in southern Japan, The American Journal of Gastroenterology, Vol.91, No.4, 754-758, 1996. (Summary) This study was conducted to clarify the characteristics of patients with extrahepatic primary cancers (EHPC) associated with hepatocellular carcinoma (HCC), as well as to investigate the influence of EHPC on both patient survival and disease-free survival after hepatic resection. Forty-one of 463 patients who underwent hepatic resection were included. The clinicopathological factors, including survival, were compared between patients with and without EHPC. We also compared the same factors among the prehepatectomy, synchronous, and posthepatectomy groups. Different types of extrahepatic cancers were also investigated in detail. Gastric and colorectal cancers were the most common EHPC. No definite relationship was observed between HCC and other specific cancers such as B-cell lymphoproliferative disorders. There also were no differences in either the liver function tests, alpha-fetoprotein, or prognostic pathological indicators such as portal vein invasion and intrahepatic metastases. In addition, we found no difference in patient survival between the patients with and without EHPC. However, disease-free survival rates in patients with EHPC were significantly higher than in those without EHPC. Patients in the prehepatectomy group were older than those in the synchronous and posthepatectomy groups, and no positive hepatitis B surface antigen was found in the prehepatectomy group. Patient survival was significantly higher in the posthepatectomy group than in the prehepatectomy group; however, no significant difference in disease-free survival was found among the three groups. Only one patient died of EHPC. No specific clinicopathological factors were observed in patients with HCC associated with EHPC. Furthermore, EHPC had no adverse effect on either patient survival or disease-free survival after hepatic resection. The predominant cancer was gastric cancer, whereas the most frequent cause of death was HCC itself. Therefore, a strict follow-up of HCC--as well as screening for the most common cancers, such as gastric cancers in southern Japan--should be required for patients with HCC associated with EHPC. (Keyword) Carcinoma, Hepatocellular / Case-Control Studies / Cause of Death / Colorectal Neoplasms / Disease-Free Survival / Female / Hepatectomy / Humans / Incidence / Japan / Liver Neoplasms / Male / Middle Aged / Neoplasms, Multiple Primary / Stomach Neoplasms / Survival Rate / Time Factors (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8677943 ● Search Scopus @ Elsevier (PMID): 8677943 (PubMed: 8677943)
279.	Ken Shirabe, Kenji Takehara, Akinobu Taketomi, Naoyuki Kawahara, Kazuharu Yamamoto, Mitsuo Shimada and Keizo Sugimachi : Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma, Cancer, Vol.77, No.6, 1050-1055, 1996.
280.	Mitsuo Shimada, Kenji Takenaka, Yuh Fujiwara, Tomonobu Gion, Kiyoshi Kajiyama, Takashi Maeda, Ken Shirabe and Keizo Sugimachi : Des-r-carboxy prothrombin and α-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma, Cancer, Vol.78, No.10, 2094-2100, 1996.
281.	Mitsuo Shimada, Kenji Takenaka, Naoyuki Kawahara, Kiyoshi Kajiyama, Kazuharu Yamamoto, Ken Shirabe, Takashi Nishizaki, Katsuhiko Yanaga and Keizo Sugimachi : Surgical treatment strategy for patients with Stage IV hepatocellular carcinoma, Surgery, Vol.119, No.5, 517-522, 1996.
282.	Mitsuo Shimada, A Saitoh, T Kano, Kenji Takenaka and Keizo Sugimachi : The effect of a perioperative steroid pulse on surgical stress in hepatic resection, Int Surg, Vol.81, No.1, 49-51, 1996.
283.	Mitsuo Shimada, Kenji Takenaka, Tomonobu Gion, Yuh Fujiwara, Kiyoshi Kajiyama, Takashi Maeda, Ken Shirabe, Takashi Nishizaki, Katsuhiko Yanaga and Keizo Sugimachi : Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan, Gastroenterology, Vol.111, No.9, 720-726, 1996.
284.	Kengo Fukuzawa, Katsuhiko Yanaga, Kenji Takenaka, Mitsuo Shimada, Hidetoshi Itasaka and Keizo Sugimachi : Ammonia clearance as a rapid index of viability in liver transplantation, The American Journal of Gastroenterology, Vol.90, No.12, 2264, 1995. (Keyword) Ammonia / Graft Survival / Humans / Liver Transplantation / Postoperative Period (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8540539 ● Search Scopus @ Elsevier (PMID): 8540539 (PubMed: 8540539)
285.	Taketoshi Suehiro, Mitsuo Shimada, Takashi Matsumata, Akinobu Taketomi, Kazuharu Yamamoto and Keizo Sugimachi : Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma, Hepatology, Vol.21, No.5, 1285-1290, 1995. (Summary) Thrombomodulin (TM) converts thrombin from procoagulant into anticoagulant protein to activate protein C. Thrombin also plays an important role in the metastatic process of cancer cells. We performed an immunohistochemical and clinicopathological study of TM in 141 cases with resected hepatocellular carcinoma (HCC) measuring less than 6 cm in diameter. Twenty-five specimens (17.73%) stained positive for TM. TM was found in the cytoplasm and surface of cancer cells. The clinicopathological findings according to the positive of TM are examined in HCC. The preoperative plasma TM level of the patients with tissue that stained positive for TM was significantly higher than that of the patients with negative results; for the postoperative TM level, there were no differences between them. In addition, the frequencies of intrahepatic metastasis, tumor thrombus in the portal vein, and capsular infiltration were significantly lower in patients whose tissue stained positive for TM than in patients whose tissue stained negative for TM. The recurrence freedom rate was significantly higher in patients whose tissue stained positive for TM than patients whose tissue stained negative for TM. Thus, TM-producing HCC shows a slow intrahepatic spread. Therefore, these findings suggest that TM may inhibit the adhesion of tumor cells to the portal vein because of anticoagulant activity and thus prevent the spread of intrahepatic metastasis. (Keyword) Adult / Aged / Blood / Carcinoma, Hepatocellular / Female / Humans / Immunohistochemistry / Liver / Liver Neoplasms / Male / Middle Aged / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Prognosis / Staining and Labeling / Thrombomodulin (Link to Publication Site) ● Publication site (DOI): 10.1002/hep.1840210511 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7537712 ● Search Scopus @ Elsevier (PMID): 7537712 ● Search Scopus @ Elsevier (DOI): 10.1002/hep.1840210511 (DOI: 10.1002/hep.1840210511, PubMed: 7537712)
286.	Mitsuo Shimada, Takashi Matsumata, Akinobu Taketomi, Ken Shirabe, Hidetoshi Itasaka and Keizo Sugimachi : A new approach for liver surgery: transdiaphragmatic hepatectomy for cirrhotic patients with hepatocellular carcinoma, Arch Surg, Vol.130, No.2, 157-160, 1995.
287.	Katsuhiko Yanaga, Keishi Kishikawa, Taketoshi Suehiro, Takashi Nishizaki, Mitsuo Shimada, Hidetoshi Itasaka, Kenichi Nomoto, Saburo Kakizoe and Keizo Sugimachi : Patial hepatic grafting: porvine stdy on criticl volume reduction, Surgery, Vol.118, No.3, 486-492, 1995.
288.	Kenji Takenaka, Mitsuo Shimada, Hidefumi Higashi, Eisuke Adachi, Takashi Nishizaki, Katsuhiko Yanaga, Takashi Matsumata and Keizo Sugimachi : Liver resection for hepatocellular carcinoma in the elderly, Archives of Surgery, Vol.129, No.8, 846-850, 1994. (Summary) To estimate the effectiveness of hepatic resection on hepatocellular carcinoma (HCC) in the elderly. Comparison with younger patients. A municipal hospital and a large university hospital in Japan. The study included 39 patients (age > or = 70 years [the elderly group]) and 229 patients (age < 70 years [the younger group]) who underwent hepatic resection from April 1985 to March 1993. The preoperative clinical features (Child's classification, association of cirrhosis and liver functions) were comparable between two groups. The positive rate for hepatitis C virus antibody was higher in the elderly group (88% vs 59%; P = .016). Morbidity and survival following operation and the pathological features of HCC. The incidence of postoperative hepatic failure was higher in the elderly group (10% vs 2%; P = .018). However, the incidence of operative death in the elderly group (5% vs 1%) as well as the incidence of other postoperative complications and rates of long-term survival (75.9% vs 51.6% at 5 years) and disease-free survival (30.4% vs 31.0% at 5 years) were similar to those in the younger group. The pathological features of HCC were identical between the two groups. The outcome of surgical treatment of HCC in the elderly group was satisfactory when compared with that in the younger group. (Keyword) Age Factors / Aged / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Postoperative Complications / Survival Rate (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8048856 ● Search Scopus @ Elsevier (PMID): 8048856 (PubMed: 8048856)
289.	Mitsuo Shimada, Hidetoshi Itasaka, Taketoshi Suehiro, Shigeki Wakiyama, Yuji Soejima, Katsuhiko Yanaga and Keizo Sugimachi : The significance of tissue-type plasminogen activator for pretransplant assessment of liver graft viability: analysis of effluent from the graft in rats, Transplant International, Vol.7, No.4, 233-236, 1994. (Summary) We studied the significance of tissue-type plasminogen activator (tPA) on the pretransplant assessment of liver graft viability in rats. The liver grafts were excised from the rats and then divided into two groups. Group 1 consisted of grafts preserved for 4 h in chilled, lactated Ringer's solution (4 degrees C) and group 2 consisted of grafts preserved for 6 h in the same solution. After preservation, the liver grafts were flushed out through the portal vein using 5 ml of chilled, lactated Ringer's solution (4 degrees C). The entire effluent from the hepatic veins was then collected and analyzed for tPA, ammonia, lactate, pyruvate, glutamic oxaloacetic transaminase, and lactate dehydrogenase. The tPA concentration of effluent in group 2 was significantly higher than that in group 1 (0.80 +/- 0.23 ng/ml vs 0.42 +/- 0.08 ng/ml, P < 0.05). The lactate, pyruvate, and ammonia levels in group 2 were also higher than those in group 1 (134 +/- 13 mg/dl vs 120 +/- 2 mg/dl, 0.34 +/- 0.40 mg/dl vs 0.09 +/- 0.01 mg/dl, and 183 +/- 79 micrograms/dl vs 102 +/- 40 micrograms/dl, respectively). However, the discriminative power of tPA was stronger than that of the other parameters. Histological findings revealed a higher number of trypan blue-stained sinusoidal lining cells that were detached and swollen in group 2. We conclude that the amount of tPA in the effluent flushed from the graft can serve as a sensitive and reliable indicator of cold-preserved liver grafts in rats. (Keyword) Animals / Cell Survival / Graft Survival / Liver / Liver Transplantation / Male / Organ Preservation / Perfusion / Rats / Rats, Inbred Lew / Tissue Plasminogen Activator (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7916920 ● Search Scopus @ Elsevier (PMID): 7916920 (PubMed: 7916920)
290.	Mitsuo Shimada, Takashi Matsumata, Akinobu Taketomi, Hidetoshi Itasaka, Kazuharu Yamamoto and Keizo Sugimachi : Repeat hepatectomy for recurrent hepatocellular carcinoma, Surgery, Vol.115, No.6, 703-706, 1994. (Summary) The significance of repeat hepatectomy for recurrent hepatocellular carcinoma remains controversial. Therefore the aim of this study was to reevaluate both the survival and the surgical risks of repeat hepatectomy. The significance of repeat hepatectomy including the survival and the surgical risks for recurrent hepatocellular carcinoma were investigated with 21 patients who underwent a curative repeat hepatectomy during the period between May 1975 and July 1993. For a comparison of survival, 253 patients who underwent a curative primary hepatectomy during the period between April 1985 and July 1993 were used. Moreover, the preoperative liver function tests were also compared between the first and second hepatectomies. Regarding the preoperative liver function tests, the indocyanine green dye excretion rate at 15 minutes in the second hepatectomy (18.7% +/- 8.7%) was significantly higher than that in the first hepatectomy (14.7% +/- 5.9%). With regard to the surgical risks, there was no difference in the clinical parameters for blood loss, operation time, and the incidence of postoperative complications between the first and second hepatectomies. The postoperative hospital stay for the second hepatectomies was relatively shorter than that for the first hepatectomies. In addition, the patient's survival and disease-free survival after a curative repeat hepatectomy were almost identical to that after a curative primary hepatectomy. A curative repeat hepatectomy is thus considered to be the most effective therapeutic modality for recurrent hepatocellular carcinoma. (Keyword) Adult / Aged / Carcinoma, Hepatocellular / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Function Tests / Liver Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Reoperation / Risk Factors / Survival Analysis / Survival Rate (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8197562 ● Search Scopus @ Elsevier (PMID): 8197562 (PubMed: 8197562)
291.	Mitsuo Shimada, Takashi Matsumata, Ken Shirabe, Tatsuro Kamakura, Akinobu Taketomi and Keizo Sugimachi : Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection, Journal of the American College of Surgeons, Vol.178, No.5, 498-502, 1994. (Summary) The effect of nafamostat mesilate on coagulation and fibrinolysis was investigated in a study of 22 patients with hepatocellular carcinoma who underwent a hepatic resection. The patients were divided into two groups: group 1, control (n = 11) and group 2, those with the intraoperative and postoperative use of nafamostat mesilate (0.2 to 0.4 milligram per kilogram per hour, n = 11). Nafamostat mesilate tended to suppress the coagulation expressed by thrombin-antithrombin III complex and fibrinopeptide A both during and immediately after operation. Moreover, nafamostat mesilate significantly suppressed the fibrinolysis expressed by euglobulin lysis activity both during and after operation. With regard to the initial stage of the fibrinolytic system, such as tissue-type plasminogen activator and plasminogen activator inhibitor-1, there was no difference between the groups. Therefore, the suppression of the euglobulin lysis activity may be caused by the inhibition of plasmin activity. There was no difference between the groups regarding operative blood loss. However, the rate of blood transfusion in group 2 was lower than that in group 1, and no fresh frozen plasma was required for the patients who lost over 2,000 milliliters of blood. Nafamostat mesilate can suppress euglobulin lysis activity both intraoperatively and postoperatively, and thus decrease the amount of blood transfusion needed. Therefore, at present, nafamostat mesilate seems to be one of the most useful agents for stabilizing the coagulant and fibrinolytic systems in hepatic resection. (Keyword) Aged / Antifibrinolytic Agents / Blood Coagulation / Blood Loss, Surgical / Carcinoma, Hepatocellular / Female / Fibrinolysin / Fibrinolysis / Guanidines / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8167888 ● Search Scopus @ Elsevier (PMID): 8167888 (PubMed: 8167888)
292.	Mitsuo Shimada, Takashi Matsumata, Tatsuro Kamakura, Hiroshi Hayashi, Keiko Urata and Keizo Sugimachi : Modulation of congulation and fibrinolysis in hepatic resection; a randomized prospective control study using antithrombin concentrates, Thrombosis Research, Vol.74, No.2, 105-114, 1994. (Summary) A randomized prospective control trial for determining the efficacy of antithrombin III concentrates in hepatic resection was performed using 24 patients with hepatocellular carcinoma. Thirteen patients were given antithrombin III concentrates (1,500 IU) immediately before operation, during hepatectomy and immediately after operation. Coagulant and fibrinolytic profiles were determined by molecular markers such as thrombin-antithrombin III complex and plasmin-alpha 2plasmin inhibitor complex. During hepatic resection, both hypercoagulability and mainly primary hyperfibrinolysis occurred. Regarding the effectiveness of antithrombin III concentrates, in the antithrombin III treatment group, only a significant lower incidence of positive soluble fibrin monomer complex at postoperative days 1 and 5 was found among all the parameters studied. Therefore, no definite evidence of clinical usefulness of the perioperative administration of antithrombin III concentrates in hepatic resection was proved. (Keyword) Aged / Antithrombin III / Blood Coagulation / Carcinoma, Hepatocellular / Female / Fibrinolysis / Humans / Intraoperative Care / Liver Neoplasms / Male / Middle Aged / Prospective Studies (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8029811 ● Search Scopus @ Elsevier (PMID): 8029811 (PubMed: 8029811)
293.	Mitsuo Shimada, Takashi Matsumata, Kouhei Akazawa, Tatsuro Kamakura, Hidetoshi Itasaka, Keizo Sugimachi and Yoshiaki Nose : Estimation of risk of major complications after hepatic resection: a study of multivariate analysis of 209 cases, The American Journal of Surgery, Vol.167, No.4, 399-403, 1994. (Summary) To identify the risk factors predicting major postoperative complications from among preoperative and intraoperative variables, an extensive retrospective analysis of 209 patients who underwent hepatic resections was performed using multivariate logistic regression. The major complications were defined as liver failure, intractable ascites and pleural effusion, intraperitoneal infection, intra-abdominal hemorrhage requiring reoperation, major bile leakage, and gastrointestinal tract bleeding. First, detailed pre- and intraoperative data including medical history, laboratory data, portion and extent of hepatectomy, operative time, and amount of blood loss were univariately analyzed. Next, any significant variables were multivariately analyzed using the logistic regression method. Diabetes, increased intraoperative blood loss, resection of segment 8, and an increased serum blood urea nitrogen level were independent and significant variables predicting major postoperative complications. A higher level of serum cholesterol and a procedure involving a portion of left lateral segment were found to decrease the risk. Both more careful operative procedures and intensive management of DM and renal dysfunction in the perioperative period could result in a better quality of life after hepatic resection. (Keyword) Blood Loss, Surgical / Blood Urea Nitrogen / Carcinoma, Hepatocellular / cholesterol / diabetes mellitus / Female / Hemangioma / Hepatectomy / Humans / Liver Neoplasms / Logistic Models / Male / Middle Aged / Postoperative Complications / Retrospective Studies / Risk Factors / Sensitivity and Specificity (Link to Publication Site) ● Publication site (DOI): 10.1016/0002-9610(94)90124-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8179084 ● Search Scopus @ Elsevier (PMID): 8179084 ● Search Scopus @ Elsevier (DOI): 10.1016/0002-9610(94)90124-4 (DOI: 10.1016/0002-9610(94)90124-4, PubMed: 8179084)
294.	Mitsuo Shimada, Takashi Matsumata, Takashi Maeda, Katsuhiko Yanaga, Akinobu Taketomi and Keizo Sugimachi : Characteristics of hepatocellular carcinoma originating in the caudate lobe, Hepatology, Vol.19, No.4, 911-915, 1994. (Summary) Nine patients with hepatocellular carcinoma originating in the caudate lobe who underwent hepatic resection were studied. The caudate lobe was divided into three parts, according to the criteria of Kumon, including the Spiegel lobe, the paracaval portion and the caudate process. The tumors were located in the Spiegel lobe in four, the paracaval portion in four and the caudate process in one. Surgical procedures consisted of right hepatic lobectomy in one, central bisegmentectomy in one and caudate lobectomy in seven. The mean surgical time was 379 +/- 129 min; the mean estimated blood loss was 2,994 +/- 2,303 ml. The above-mentioned surgical risks were more clearly recognized in the paracaval portion than in the Spiegel lobe. In addition, most patients experienced significant post-operative complications. Six of eight patients with 6 mo or longer follow-up had recurrences, and two of six patients died. The characteristics of hepatocellular carcinoma in the caudate lobe were as follows: (a) a higher surgical risk, and more definite risk in the paracaval portion; and (b) a higher rate of early recurrence. A left lobectomy for the Spiegel lobe, a right or left trisegmentectomy for the paracaval portion and a right lobectomy for the caudate process would be ideal from the point of view of the portal supply of the caudate lobe. However, in cirrhotic patients either a caudate lobectomy or partial resection might be preferable because longer survival can be expected. (Keyword) Aged / Blood Loss, Surgical / Carcinoma, Hepatocellular / Female / Humans / Liver Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Postoperative Complications / Risk Factors / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1002/hep.1840190417 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8138265 ● Search Scopus @ Elsevier (PMID): 8138265 ● Search Scopus @ Elsevier (DOI): 10.1002/hep.1840190417 (DOI: 10.1002/hep.1840190417, PubMed: 8138265)
295.	Mitsuo Shimada, Takashi Matsumata, Akinobu Taketomi, Ken Shirabe, Kazuharu Yamamoto and Keizo Sugimachi : The role of prostaglandins in hepatic resection, Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol.50, No.2, 65-68, 1994. (Summary) The role of prostaglandins (PGs) and the efficacy of PGE1 were investigated in hepatic resection. Patients who underwent hepatic resection were randomly assigned to two groups consisting of a control (n = 5) and a PGE1 treatment group (n = 6). Then the amount of 6-keto PF1 alpha, thromboxane B2 and (TXB2) and PGE2 were serially measured both before and after hepatic resection. Regarding changes in the PGs, a remarkable increase in TXB2 during hepatectomy was demonstrated in both groups. In the control group, both 6-keto PF1 alpha and PGE2 showed only a slight increase both during and after the operation. Regarding the efficacy of PGE1 on liver damage, no significant difference in postoperative liver function was found, however the lipoperoxide level at postoperative day 3 in the PGE1 treatment group (1.9 +/- 0.4 nmol/ml) was significantly lower than that in the control (2.6 +/- 0.5 nmol/ml: P < 0.05). Judging from the remarkable increase of TXB2, a stable metabolite of TXA2 during hepatectomy, it may be suggested that TXA2 plays an important role in the development of liver damage during hepatic resection. (Keyword) 6-Ketoprostaglandin F1 alpha / Aged / Alprostadil / Dinoprostone / Female / Hepatectomy / Humans / Lipid Peroxides / Liver / Liver Function Tests / Male / Middle Aged / Thromboxane A2 / Thromboxane B2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8171069 ● Search Scopus @ Elsevier (PMID): 8171069 (PubMed: 8171069)
296.	Mitsuo Shimada, Takashi Matsunaga, Takashi Maeda, Hidetoshi Itasaka, Taketoshi Suehiro and Keizo Sugimachi : Hapatic regeneration following right lobectomy: estimation of regenerative capacity, Surgery Today, Vol.24, No.1, 44-48, 1994. (Keyword) major hepatectomy / multiple regression analysis / portal pressure / aging / liver cirrhosis / chronic hepatitis
297.	Mitsuo Shimada, Takashi Matsumata, Ken Shirabe and Keizo Sugimachi : A thromboxane A2 synthetase inhibitor, OKY-046, reduces liver damage in hepatectomy, Surgery, Vol.114, No.5, 993-995, 1993. (Keyword) Carcinoma, Hepatocellular / Hepatectomy / Humans / Liver Diseases / Liver Neoplasms / Methacrylates / Thromboxane-A Synthase (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8236027 ● Search Scopus @ Elsevier (PMID): 8236027 (PubMed: 8236027)
298.	Mitsuo Shimada, Katsuhiko Yanaga, Keiji Kishikawa, Saburo Kakizoe, Hidetoshi Itasaka, Tetsuo Ikeda, Taketoshi Suehiro and Keizo Sugimachi : Prediction of hepatic graft viability before reperfusion: an analysis of effluent from porcine allografts, Transplant International, Vol.6, No.1, 4-7, 1993. (Summary) Rapid and reliable assessment of hepatic graft viability is important for successful orthotopic liver transplantation (OLTx). OLTx was performed in 11 pairs of pigs via a venovenous bypass. Six of these grafts were transplanted immediately (group A), while the other five were preserved in University of Wisconsin (UW) solution for 24 h and then transplanted (group B). All grafts were flushed with 300 ml of chilled (4 degrees C) Ringer's lactate solution before reperfusion of the graft, when 20 ml of effluent from the graft was collected and the concentrations of ammonia, lactic acid, GOT, and LDH were measured. Four of the six pigs in group A survived longer than 3 days, while the other two pigs died of causes other than graft dysfunction. All five pigs in group B died either of hemoperitoneum or hemodynamic instability due to liver failure. The histology of postperfusion biopsies in group A showed minimal pathological changes, while the grafts in group B revealed moderate to severe ischemic injuries. Ammonia and lactic acid in the effluent of group B were significantly higher than those of group A (1511 +/- 216 vs 417 +/- 333 micrograms/dl and 114.1 +/- 12.2 vs 91.4 +/- 12.2 mg/dl, respectively; P < 0.05 in both cases). Before reperfusion, the rate of total adenine nucleotides in all of the substances in the graft, which were measured using high performance liquid chromatography (HPLC), inversely correlated with the ammonia levels in the effluent. We conclude that an analysis of the effluent, (i.e. the levels of ammonia and lactic acid), flushed from a hepatic graft before reperfusion could serve as a predictor of hepatic graft viability. (Keyword) Adenine Nucleotides / Ammonia / Animals / Graft Survival / Liver / Liver Transplantation / Perfusion / Swine / Tissue Preservation / Transplantation, Homologous (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8452631 ● Search Scopus @ Elsevier (PMID): 8452631 (PubMed: 8452631)
299.	Tetsuo Ikeda, Katsuhiko Yanaga, Keiji Kishikawa, Saburo Kakizoe, Mitsuo Shimada and Keizo Sugimachi : Ischemic injury in liver transplantation : difference in injury sites between warm and cold ischemia in rats, Hepatology, Vol.16, No.2, 454-461, 1992. (Summary) Using liver allografts with warm or cold ischemia, we evaluated functional and morphological alterations in hepatocytes, sinusoidal endothelial cells and Kupffer cells in a rat transplantation model. All recipients of allografts with either 4 hr of cold or 30 min of warm ischemia lived more than 22 days and were judged viable. On the other hand, all recipients of grafts with 6 hr of cold or 60 min of warm ischemia died within 2 days and were therefore judged to be nonviable. With these viable and nonviable allograft models, hepatocyte function was evaluated by the bile output and serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase and serum lactate dehydrogenase levels; endothelial cell function was judged by the serum hyaluronic acid level, and Kupffer cell function was measured by an intravenous colloidal carbon clearance test. Hepatocyte injury was the prominent feature in warm ischemic grafts, especially in the nonviable ones. On the other hand, serum hyaluronic acid values were significantly higher in the nonviable cold ischemic group, compared with the viable counterpart, suggesting that the functional depression of endothelial cells was predominant in cold, nonviable livers. Histological examinations coincided with the above findings. The phagocytic activity of Kupffer cells was depressed by warm or cold ischemia, whereas the number of Kupffer cells was reduced in the warm ischemia group. We conclude that in liver allografts the main site of injury in warm ischemia is the hepatocytes and suggest that cold ischemia is associated with endothelial cell damage. (Keyword) Animals / Hyaluronic Acid / Ischemia / Kupffer Cells / L-Lactate Dehydrogenase / Liver / Liver Transplantation / Male / Phagocytosis / Rats / Rats, Inbred Lew / Temperature / Transplantation, Homologous / Vascular Resistance (Link to Publication Site) ● Publication site (DOI): 10.1002/hep.1840160226 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 1639355 ● Search Scopus @ Elsevier (PMID): 1639355 ● Search Scopus @ Elsevier (DOI): 10.1002/hep.1840160226 (DOI: 10.1002/hep.1840160226, PubMed: 1639355)
300.	Mitsuo Shimada, Katsuhiko Yanaga, Leonard Makowka, Saburo Kakizoe, DH Thiel Van and Thomas E Starzl : Significance of lecithin:cholesterol acyltransferase activity as a prognostic indicator of early allograft function in clinical liver transplantation, Transplantation, Vol.48, No.4, 600-603, 1989. (Summary) Rapid and accurate assessment of allograft function in the early postoperative period is critical for successful liver transplantation. This study evaluated the efficacy of lecithin:cholesterol acyltransferase (LCAT) activity as an indicator of early allograft function in human orthotopic liver transplantation (OLTx). During a three-month period between September and November 1987, 9 of 11 adult OLTx recipients whose graft exhibited poor function were studied. Poor graft function was defined as primary nonfunction, need for retransplantation within a week after OLTx, or elevation of the prothrombin time over 20 sec early after OLTx. Plasma LCAT activities (measured pretransplant and at 0, 6, 12, 18, and 24 hr, as well as 3 days, after OLTx) and pretransplant clinical variables were compared with those of 15 control patients whose graft exhibited good function. A significant correlation was found between mean LCAT activities during the first 24-hr after OLTx and early allograft function (P less than 0.05, chi 2 = 5.23). When pretransplant histological findings of the 6 grafts with poor function and the 15 controls together were correlated with the mean LCAT activity within 24 hr following OLTx, a significant association was demonstrated (P less than 0.05). This study suggests that plasma LCAT activity is an effective and practical method for assessing early allograft function following OLTx. (Keyword) Humans / Liver / Liver Transplantation / Phosphatidylcholine-Sterol O-Acyltransferase / Prognosis / Time Factors (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2799912 ● Search Scopus @ Elsevier (PMID): 2799912 (PubMed: 2799912)

Academic Paper (Unrefereed Paper):

1.	Shuhai Chen, Yu Saitou, Yuhei Waki, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : Generation of Highly Functional Hepatocyte-like Organoids from Human Adipose-Derived Mesenchymal Stem Cells Cultured with Endothelial Cells., Cells, Vol.13, No.6, 2024. (Summary) Previously, we successfully established a highly functional, three-dimensional hepatocyte-like cell (3D-HLC) model from adipose-derived mesenchymal stem cells (ADSCs) via a three-step differentiation protocol. The aim of the present study was to investigate whether generating hepatocyte-like organoids (H-organoids) by adding endothelial cells further improved the liver-like functionality of 3D-HLCs and to assess H-organoids' immunogenicity properties. Genes representing liver maturation and function were detected by quantitative reverse transcription-PCR analysis. The expression of hepatic maturation proteins was measured using immunofluorescence staining. Cytochrome P (CYP)450 metabolism activity and ammonia metabolism tests were used to assess liver function. H-organoids were successfully established by adding human umbilical vein endothelial cells at the beginning of the definitive endoderm stage in our 3D differentiation protocol. The gene expression of alpha-1 antitrypsin, carbamoyl-phosphate synthase 1, and apolipoprotein E, which represent liver maturation state and function, was higher in H-organoids than non-organoid 3D-HLCs. H-organoids possessed higher CYP3A4 metabolism activity and comparable ammonia metabolism capacity than 3D-HLCs. Moreover, although H-organoids expressed human leukocyte antigen class I, they expressed little human leukocyte antigen class II, cluster of differentiation (CD)40, CD80, CD86, and programmed cell death ligand 1, suggesting their immunogenicity properties were not significantly upregulated during differentiation from ADSCs. In conclusion, we successfully established an H-organoid model with higher liver-like functionality than previously established 3D-HLCs and comparable immunogenicity to ADSCs. (Keyword) Humans / Ammonia / Hepatocytes / Human Umbilical Vein Endothelial Cells / Mesenchymal Stem Cells / Organoids / HLA Antigens (Link to Publication Site) ● Publication site (DOI): 10.3390/cells13060547 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38534391 ● Search Scopus @ Elsevier (PMID): 38534391 ● Search Scopus @ Elsevier (DOI): 10.3390/cells13060547 (DOI: 10.3390/cells13060547, PubMed: 38534391)
2.	Chie Takasu, Masaaki Nishi, Kozo Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative evaluation to determine the difficulty of No. 6 lymphadenectomy in laparoscopic gastrectomy., BMC Surgery, Vol.24, No.1, 69, 2024. (Summary) Laparoscopic gastrectomy (LG) requires a long learning curve because of the complicated surgical procedures. Infrapyloric (No. 6) lymph node dissection (LND) is one of the difficult procedures in LG, especially for trainees. This study investigated the impact of the prediction of the difficulty of No. 6 LND. We retrospectively reviewed the preoperative computed tomography (CT) images and individual operative video records of 57 patients who underwent LG with No. 6 LND to define and predict the No. 6 LND difficulty. To evaluate whether prediction of the difficulty of No. 6 LND could improve surgical outcomes, 48 patients who underwent laparoscopic distal gastrectomy were assessed (30 patients without prediction by a qualified surgeon and 18 patients with prediction by a trainee). The anatomical characteristic that LND required > 2 cm of dissection along the right gastroepiploic vein was defined as difficulty of No. 6 LND. Of the 57 LG patients, difficulty was identified intraoperatively in 21 patients (36.8%). Among the several evaluated anatomical parameters, the length between the right gastroepiploic vein and the right gastroepiploic artery in the maximum intensity projection in contrast-enhanced CT images was significantly correlated with the intraoperative difficulty of No. 6 LND (p < 0.0001). Surgical outcomes, namely intraoperative minor bleeding, postoperative pancreatic fistula, and drain amylase concentration were not significantly different between LG performed by a trainee with prediction compared with that by a specialist without prediction. Preoperative evaluation of the difficulty of No. 6 LND is useful for trainees, to improve surgical outcomes. (Keyword) Humans / Retrospective Studies / Stomach Neoplasms / Lymph Node Excision / Laparoscopy / Gastrectomy / Postoperative Complications (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-024-02349-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38389108 ● Search Scopus @ Elsevier (PMID): 38389108 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-024-02349-8 (DOI: 10.1186/s12893-024-02349-8, PubMed: 38389108)
3.	Chie Takasu, Yuji Morine, Kozo Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Role of stromal PD-L1 expression in colorectal liver metastasis., BMC Cancer, Vol.24, No.1, 97, 2024. (Summary) The outcomes of immune checkpoint blockade for colorectal cancer (CRC) treatment are unsatisfactory. Furthermore, the efficacy of immune checkpoint blockade for liver metastasis of various cancer is poor. Here, we investigated the relationship between stromal programmed death-ligand 1 (PD-L1) expression and the prognosis of patients with colorectal cancer liver metastasis (CRLM). The present study enrolled 84 CRLM patients who underwent surgery (R0) for CRC. Immunohistochemistry was performed to analyze stromal PD-L1 expression in CRLM. Stromal PD-L1 was expressed in 52.3% of CRLM samples, which was associated with fewer not optimally resectable metastases (p = 0.04). Stromal PD-L1 also tended to associate with a lower tumor grade (p = 0.08). Stromal PD-L1-positive patients had longer overall survival (p = 0.003). Multivariate analysis identified stromal PD-L1 expression (p = 0.008) and poorer differentiation (p < 0.001) as independent prognostic indicators. Furthermore, stromal PD-L1 expression was correlated to a high number of tumor-infiltrating lymphocytes (TILs). Stromal PD-L1- and low TIL groups had shorter OS than stromal PD-L1 + and high TIL groups (46.6% vs. 81.8%, p = 0.05) Stromal PD-L1-positive patients had longer disease-free survival (DFS) (p = 0.03) and time to surgical failure (p = 0.001). Interestingly, stromal PD-L1 expression was positively related to the desmoplastic subtype (p = 0.0002) and inversely related to the replacement subtype of the histological growth pattern (p = 0.008). Stromal PD-L1 expression may be a significant prognostic marker for CRLM. (Keyword) Humans / B7-H1 Antigen / Colorectal Neoplasms / Immune Checkpoint Inhibitors / Liver Neoplasms / Lymphocytes, Tumor-Infiltrating / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1186/s12885-024-11869-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38233811 ● Search Scopus @ Elsevier (PMID): 38233811 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-024-11869-8 (DOI: 10.1186/s12885-024-11869-8, PubMed: 38233811)
4.	Yuhei Waki, Yuji Morine, Takayuki Noma, Chie Takasu, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : Association between high expression of intratumoral fibroblast activation protein and survival in patients with intrahepatic cholangiocarcinoma., BMC Gastroenterology, Vol.23, No.1, 415, 2023. (Summary) Cancer-associated fibroblasts (CAFs) have been reported to exhibit protumorigenic effects. Among the well-known CAF markers such as smooth muscle actin (SMA) and fibroblast activation protein (FAP), high expression of SMA in the peritumoral stroma has been reported to be a prognostic factor in various cancers. However, the effect of high FAP expression in intrahepatic cholangiocarcinoma (IHCC) has not been fully clarified. We evaluated the expression of CAF markers, focusing on FAP expression in the peripheral and intratumoral regions, to clarify the association with survival in patients with IHCC. The study cohort comprised 37 patients who underwent curative resection for IHCC. The FAP expressions were evaluated in the peripheral and intratumoral regions of the resected tissues. Clinicopathological factors and survival outcomes were investigated between patients with high versus low FAP expression. Uni- and multivariate analyses were performed to identify the prognostic factors for overall survival and relapse-free survival. The median area percentages of FAP expression in the peripheral and intratumoral regions were 15.5% and 17.8%, respectively. High FAP expression in the intratumoral region was significantly associated with worse overall survival and disease-free survival than low FAP expression in the intratumoral region. Multivariate analysis identified high intratumoral FAP expression as a risk factor for worse overall survival (hazard ratio, 2.450; p = 0.049) and relapse-free survival (hazard ratio, 2.743; p = 0.034). High intratumoral FAP expression was associated with worse survival, suggesting that intratumoral FAP expression represents malignant progression in patients with IHCC. (Keyword) Humans / Neoplasm Recurrence, Local / Cholangiocarcinoma / Cancer-Associated Fibroblasts / Bile Ducts, Intrahepatic / Bile Duct Neoplasms / Prognosis (Tokushima University Institutional Repository) ● Metadata: 119225 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-023-03012-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38017374 ● Search Scopus @ Elsevier (PMID): 38017374 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-023-03012-x (Tokushima University Institutional Repository: 119225, DOI: 10.1186/s12876-023-03012-x, PubMed: 38017374)
5.	Yuhei Waki, Yu Saitou, Shuhai Chen, Tetsuya Ikemoto, Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : Effects of green light-emitting diode irradiation on hepatic differentiation of hepatocyte-like cells generated from human adipose-derived mesenchymal cells., Scientific Reports, Vol.13, No.1, 19954, 2023. (Summary) Light-emitting diode (LED) irradiation has been used in the differentiation of mesenchymal stem cells into a variety of cell types. This study investigated the effect of green LED (GLED) irradiation on the differentiation of adipocyte-derived mesenchymal cells into hepatocyte-like cells (HLCs) and the mechanism of its action. HLCs in the hepatocyte maturation phase were irradiated with GLED (520 nm, 21 W/m, 5 min/day for 10 days). The cells were then assessed for expression of hepatocyte maturity genes and opsin 3 (OPN3), hepatocyte function, viability, apoptosis, and levels of reactive oxygen species (ROS), intracellular adenosine triphosphate (ATP) and calcium ions (Ca). GLED irradiation increased Alpha-1 antitrypsin and Ornithine transcarbamylase gene expression, promoted Cytochrome P450 3A4 activity and urea synthesis, and elevated intracellular ROS, ATP and Ca levels. OPN3 expression was significantly more upregulated in GLED-irradiated HLCs than in the non-irradiated HLCs. No significant difference in cell viability or apoptosis was observed between GLED-irradiated and non-irradiated HLCs. GLED irradiation can promote hepatocyte maturation and functions through OPN3. GLED irradiation also stimulated mitochondrial function via Ca/ATP/ROS activation. GLED irradiation has potential to support cell-based transplantation in patients. (Keyword) Humans / Reactive Oxygen Species / Hepatocytes / Cell Differentiation / Adipocytes / Adenosine Triphosphate / Rod Opsins (Tokushima University Institutional Repository) ● Metadata: 119238 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-45967-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37968291 ● Search Scopus @ Elsevier (PMID): 37968291 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-45967-7 (Tokushima University Institutional Repository: 119238, DOI: 10.1038/s41598-023-45967-7, PubMed: 37968291)
6.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, Maki Nishi, Hiroshi Sakaue, Motomu Kamada, Tetsuya Matsuura and Mitsuo Shimada : Preoperative Weight Loss Program for Hepatocellular Carcinoma Patients with High Body Mass Index in Hepatectomy., World Journal of Surgery, Vol.47, No.12, 3348-3355, 2023. (Summary) This study aimed to investigate the usefulness of a weight-loss program (WLP) in patients with a high body mass index (BMI) prior to liver resection (Hx) for hepatocellular carcinoma (HCC). Among 445 patients with HCC who underwent initial Hx between 2000 and 2020, 19 with a high BMI (≥25.0) were enrolled in our WLP since 2014. For calorie restriction, the amount of energy consumed was calculated as the standard body weight (SBW) kg × 20-25 kcal/day. Protein mass was calculated as SBW kg × 1.0-1.2 g/day to maintain skeletal muscle mass. Patients also performed both aerobic and resistance exercises. The before-and-after changes were compared, and the effect of WLP on the short- and long-term results was investigated. The average length of WLP was 21 days, and weight loss was successfully achieved in all patients. Body fat mass was reduced during the program, while skeletal muscle mass was maintained. WLP led to improvements in liver function and fibrotic markers, without tumor progression. There were no postoperative complications (≥Clavien-Dindo [CD] III). A retrospective comparison between with and without WLP using propensity score-matching analysis revealed that WLP group showed better NLR value, however, there were no significant differences in both short and long-term outcomes after Hx based on participation in the WLP. WLP with multidisciplinary intervention improved immune-nutrition status and liver function of obese patients. WLP had not affected both short and long-term outcomes after Hx. (Keyword) Humans / Carcinoma, Hepatocellular / Hepatectomy / Liver Neoplasms / Body Mass Index / Weight Reduction Programs / Retrospective Studies / Propensity Score / Treatment Outcome / Laparoscopy (Link to Publication Site) ● Publication site (DOI): 10.1007/s00268-023-07220-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37840060 ● Search Scopus @ Elsevier (PMID): 37840060 ● Search Scopus @ Elsevier (DOI): 10.1007/s00268-023-07220-0 (DOI: 10.1007/s00268-023-07220-0, PubMed: 37840060)
7.	仲須千春, Shin-ichiro Yamada, Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 原因が不明であった肝palisading granulomaの1例, Acta Hepatologica Japonica, Vol.64, No.10, 504-509, 2023. (Summary) 患者は50代女性.検診の腹部超音波検査で肝S3に16×14mm大の腫瘤を指摘され精査加療目的に当科紹介となった.既往歴・生肉食歴なし.術前の血液検査で異常なく,末梢好酸球も正常.造影CTの動脈・門脈相では辺縁に造影効果を認めるが,平衡相では造影されず,MRI T1強調像で低信号,T2強調像で低∼等信号,拡散強調像でやや高信号であった.PET-CTで肝臓への集積は認めなった.悪性腫瘍の可能性を完全に否定できず,腹腔鏡下肝部分切除を施行した.病理組織学的には腫瘤全体に凝固壊死像が見られ,辺縁に線維増生を伴い,組織球が柵状に配列したpalisading granulomaであった.原因特定のために複数の染色を行ったが,病原体は同定できなかった.palisading granulomaは術前診断が困難であり,診断的治療として腹腔鏡下肝切除術は有用であると考えられた.(著者抄録) (Keyword) 肝切除肝臓疾患(病理学,画像診断,外科的療法) 超音波診断肉芽腫-好酸球性(病理学,画像診断,外科的療法) 腹腔鏡法幼虫移行症-内臓拡散MRI PET-CT検査ヒト中年(45∼64) 女 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.504 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.504 (DOI: 10.2957/kanzo.64.504)
8.	Kouzou Yoshikawa, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Shoichiro Takao : Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy., BMC Surgery, Vol.23, No.1, 281, 2023. (Summary) A variety of factors have been reported to affect long-term outcomes after radical resection of hepatocellular carcinoma (HCC). However, the indicators remain controversial. The purpose of this study was to evaluate the relationship between myosteatosis of the multifidus muscle and long-term outcomes after radical surgery for HCC. We retrospectively analyzed clinicopathological data for 187 patients with HCC who underwent radical surgery at Tokushima University between January 2009 and December 2020 and measured the density of fat in the multifidus muscle at L3 on their preoperative magnetic resonance images (MRI). Associations of myosteatosis and clinicopathological factors with long-term outcomes were evaluated. The patients were divided into a myosteatosis-negative group (n = 122) and a myosteatosis-positive group (n = 65). The cancer-specific survival rate after hepatectomy was significantly worse in the myosteatosis-positive group than in the myosteatosis-negative group (p = 0.03). Univariate analysis identified multiple tumors, stage III/IV disease, an alfa-fetoprotein level ≥ 10 ng/ml, PIVKA-II ≥ 400 AU/ml, vp(+) status, and myosteatosis to be prognostic factors for cancer-specific survival. Multivariate analysis revealed multiple tumors, an alfa-fetoprotein level ≥ 10 ng/ml, and myosteatosis to be independent prognostic factors. Myosteatosis measured by MRI is a simple and useful predictor of the long-term outcome after radical surgery for HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Hepatectomy / Retrospective Studies / Liver Neoplasms / Magnetic Resonance Imaging / Fetal Proteins (Tokushima University Institutional Repository) ● Metadata: 119226 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-02188-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37715229 ● Search Scopus @ Elsevier (PMID): 37715229 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-02188-z (Tokushima University Institutional Repository: 119226, DOI: 10.1186/s12893-023-02188-z, PubMed: 37715229)
9.	Takayuki Noma, Masaaki Nishi, Chie Takasu, Yuuma Wada, Kozo Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Yuko Miyakami, Kengo Atsumi, Hisanori Uehara and Mitsuo Shimada : Conversion surgery after successful response to chemotherapy (S-1 + oxaliplatin + nivolumab) in a patient with stage IV gastric cancer with peritoneal metastasis (P1, CY1): a case report., International Cancer Conference Journal, Vol.13, No.1, 11-16, 2023. (Summary) We here present a case report of a patient with Stage IV gastric cancer with peritoneal metastasis (P1, CY1) who underwent conversion surgery after a successful response to chemotherapy (S-1 + oxaliplatin + nivolumab). The patient was a woman in her 60 s. Her chief complaint was epigastric pain. Upper gastrointestinal endoscopy showed Type 4 advanced carcinoma on the lesser curvature of the gastric body. Biopsy showed Group 5 (poorly differentiated adenocarcinoma) and HER2 was negative. Staging laparoscopy revealed seeding in the round ligament of the liver (P1) and adenocarcinoma cells in ascites (CY1). Ten courses of chemotherapy (S-1 + oxaliplatin + nivolumab) were administered, after which contrast-enhanced computed tomography showed that the primary tumor had shrunk and seeding was no longer detectable. Upper gastrointestinal endoscopy revealed scar-like changes. A second staging laparoscopy revealed that ascites cytology was negative and a biopsy of the round ligament of the liver showed no malignant cells (P0, CY0). Conversion surgery comprising laparoscopic total gastrectomy with D2 lymph node dissection and resection of the round ligament of the liver was performed. The postoperative course was uneventful. Histopathological examination of the resected specimen revealed no tumor cells in the gastric mesentery or the round ligament of the liver. The pathological diagnosis was gastric cancer [M, U, L, Less, Ant, Post, type4, T3(SS), N0, M0 (H0, P0, CY0), ypStage IIA]. Adjuvant chemotherapy (S-1) was commenced. The patient is still alive 7 months later with no evidence of recurrence. (Link to Publication Site) ● Publication site (DOI): 10.1007/s13691-023-00628-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38187176 ● Search Scopus @ Elsevier (PMID): 38187176 ● Search Scopus @ Elsevier (DOI): 10.1007/s13691-023-00628-4 (DOI: 10.1007/s13691-023-00628-4, PubMed: 38187176)
10.	Hideya Kashihara and Mitsuo Shimada : Metabolic surgeryのインパクト肥満・糖尿病の治療が変わる, 徳島県医師会報, No.627, 4-7, 2023. (Keyword) 糖尿病(合併症,治療) 腹腔鏡法胃形成術肥満症(合併症,外科的療法) *肥満手術血糖管理十二指腸空腸吻合術ヒト
11.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Visualization of the pelvic nerves using magnetic resonance imaging for rectal cancer surgery., Surgical Endoscopy, Vol.37, No.6, 4315-4320, 2023. (Summary) This study evaluated the visualization of the pelvic nerves using magnetic resonance imaging (MRI) combined with computed tomography (CT) to synthesize three-dimensional (3D) reconstruction images of the pelvic organs. The CT and MRI scans were performed for patients with rectal cancer who underwent surgery. The out-of-phase image of LAVA-Flex was used to identify the pelvic nerves. The images of the pelvic nerves were extracted from the MRI scans, and those of the arteries and rectum and pelvis were extracted from the CT scans. Each extracted organ image was used to synthesize 3D reconstruction images. The MRI scan allowed adequate visualization of the pelvic splanchnic nerves, inferior hypogastric plexus, and obturator nerves. The comparison of 3D reconstruction images and intraoperative findings showed matched images. We visualized the pelvic nerves using MRI and synthesized 3D reconstruction images of the pelvic organs. Preoperative confirmation of the location of the pelvic organs is important to prevent unanticipated injury during rectal cancer surgery. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-022-09771-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36418640 ● Search Scopus @ Elsevier (PMID): 36418640 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-022-09771-0 (DOI: 10.1007/s00464-022-09771-0, PubMed: 36418640)
12.	Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Utility of robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: transhiatal robotic versus laparoscopic approach., BMC Surgery, Vol.23, No.1, 128, 2023. (Summary) Robotic surgery (RS) has been rapidly adopted for gastric cancer and adenocarcinoma of the esophagogastric junction (AEG). However, the utility of RS for Siewert type II/III AEG remains unclear. Forty-one patients who underwent either transhiatal RS (n = 15) or laparoscopic surgery (LS) (n = 26) for Siewert type II/III AEG were enrolled in this study. The surgical outcomes of the two groups were compared. In the entire cohort, there were no significant intergroup differences in the operative time, blood loss volume, or number of retrieved lymph nodes. The length of the postoperative hospital stay was shorter in the RS group than in the LS group (14.20 ± 7.10 days vs. 18.73 ± 17.82 days, respectively; p = 0.0388). The morbidity rate (Clavien-Dindo grade ≥ 2) was similar between the groups. In the Siewert II cohort, there were no significant intergroup differences in short-term outcomes. In the entire cohort, there was no significant difference between the RS and LS groups in the 3-year overall survival rate (91.67% vs. 91.48%, N.S.) or 3-year disease-free survival rate (91.67% vs. 91.78%, N.S.), respectively. Likewise, in the Siewert type II cohort, there was no significant difference between the RS and LS groups in the 3-year overall survival rate (80.00% vs. 93.33%, N.S.) or 3-year disease-free survival rate (80.00% vs. 94.12%, N.S.), respectively. Transhiatal RS for Siewert II/III AEG was safe and contributed to similar short-term and long-term outcomes compared with LS. (Keyword) Humans / Robotic Surgical Procedures / Retrospective Studies / Gastrectomy / Adenocarcinoma / Stomach Neoplasms / Laparoscopy / Esophagogastric Junction / Esophageal Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-02045-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37194030 ● Search Scopus @ Elsevier (PMID): 37194030 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-02045-z (DOI: 10.1186/s12893-023-02045-z, PubMed: 37194030)
13.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : The application of enhanced recovery after surgery in total gastrectomy: a propensity score-matched analysis., World Journal of Surgical Oncology, Vol.21, No.1, 148, 2023. (Summary) This study aimed to investigate the feasibility and safety of our enhanced recovery after surgery protocol including early oral intake and omitting nasogastric tube (NGT) placement after total gastrectomy. We analyzed 182 consecutive patients who underwent total gastrectomy. The clinical pathway was changed in 2015, and patients were divided into 2 groups (conventional group and modified group). Postoperative complications, bowel movement, and postoperative hospital stays were compared in the two groups in all cases and propensity score matching (PSM). Flatus and defecation were significantly earlier in the modified group compared with those in the conventional group (flatus: 2 (1-5) days vs 3 (2-12) days, p = 0.03; defecation: 4 (1-14) days vs 6 (2-12) days p = 0.04). The postoperative hospital stay was 18 (6-90) days in the conventional group and 14 (7-74) days in the modified group (p = 0.009). Days until discharge criteria were met were earlier in the modified group compared with that in the conventional group (10 (7-69) days vs 14 (6-84) days p = 0.01). Overall and severe complications occurred in nine patients (12.6%) and three patients (4.2%) in the conventional group and twelve patients (10.8%) and four patients (3.6%) in the modified group, respectively (p = 0.70 and p = 0.83) in all cases. In PSM, there is no significant difference between the two groups concerning the postoperative complications (overall complication 6 (12.5%) vs 8 (16.7%) p = 0.56, severe complications 1 (2%) vs 2 (4.2%) p = 0.83). Modified ERAS for total gastrectomy may be feasible and safe. (Keyword) Humans / Enhanced Recovery After Surgery / Propensity Score / Flatulence / Stomach Neoplasms / Retrospective Studies / Gastrectomy / Length of Stay / Postoperative Complications / Treatment Outcome / Laparoscopy (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-023-03034-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37194033 ● Search Scopus @ Elsevier (PMID): 37194033 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-023-03034-5 (DOI: 10.1186/s12957-023-03034-5, PubMed: 37194033)
14.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Takayuki Noma and Mitsuo Shimada : Surgical Outcomes of Gastrectomy in Hemodialysis Patients with Gastric Cancer., The American Surgeon, Vol.89, No.12, 6328-6330, 2023. (Keyword) Humans / Stomach Neoplasms / Retrospective Studies / Laparoscopy / Gastrectomy / Treatment Outcome / Renal Dialysis (Link to Publication Site) ● Publication site (DOI): 10.1177/00031348231173970 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37132264 ● Search Scopus @ Elsevier (PMID): 37132264 ● Search Scopus @ Elsevier (DOI): 10.1177/00031348231173970 (DOI: 10.1177/00031348231173970, PubMed: 37132264)
15.	Shuhai Chen, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : TU-100 Antagonizes the M2 Polarization Phenotype of Macrophages in the Tumor Microenvironment by Suppressing the TLR4/NF-B/STAT3 Axis., Anticancer Research, Vol.43, No.5, 1985-1992, 2023. (Summary) Macrophages are the most abundant immune cells in the tumor stroma, and their polarization states within the tumor microenvironment (TME) exert critical roles in tumorigenesis. TU-100 (Daikenchuto) is a commonly prescribed Japanese herbal medicine that has shown anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. However, its effects on tumor-associated macrophages (TAMs) remain unclear. TAMs were generated by macrophage exposure to tumor-conditioned medium (CM), and their polarization states were evaluated after TU-100 treatment. The underlying mechanism was further studied. TU-100 exhibited little cytotoxicity over a range of doses in M0 macrophages and TAMs. However, it could antagonize the M2-like polarization of macrophages evoked by tumor-CM exposure. These effects might be caused by the inhibition of TLR4/NF-B/STAT3 signaling in the M2-like phenotype of macrophages. Interestingly, TU-100 antagonized the malignancy promoting effects of M2 macrophages on hepatocellular carcinoma cell lines in vitro. Mechanistically, the administration of TU-100 restrained the high expression of MMP-2, COX-2, and VEGF in TAMs. TU-100 may alleviate the progression of cancer by regulating the M2 polarization of macrophages within the TME, suggesting a viable therapeutic approach. (Keyword) Humans / Cell Line, Tumor / Cell Polarity / Macrophages / Naphthoquinones / NF-kappa B / Signal Transduction / Tumor Microenvironment / Antineoplastic Agents, Phytogenic / Carcinoma, Hepatocellular (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.16359 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37097685 ● Search Scopus @ Elsevier (PMID): 37097685 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.16359 (DOI: 10.21873/anticanres.16359, PubMed: 37097685)
16.	Takuya Tokunaga, Maki Sugimoto, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Yuhei Waki, Toshiaki Yoshimoto, Takayuki Noma and Mitsuo Shimada : Transanal lateral lymph node dissection with intraoperative hologram support in low rectal cancer., Surgical Endoscopy, Vol.37, No.7, 5414-5420, 2023. (Summary) In Japan, the standard treatment for stage II/III advanced low rectal cancer is total mesorectal excision plus lateral lymph node dissection (LLND). There are also recent reports on the use of transanal LLND. However, the transanal anatomy is difficult to understand, and additional support tools are required to improve the surgical safety. The present study examined the utility of holograms with mixed reality as an intraoperative support tool for assessing the complex pelvic anatomy. Polygon (stereolithography) files of patients' pelvic organs were created and exported from the SYNAPSE VINCENT imaging system and uploaded into the Holoeyes MD virtual reality software. Three-dimensional images were automatically converted into patient-specific holograms. Each hologram was then installed into a head mount display (HoloLens2), and the surgeons and assistants wore the HoloLens2 when they performed transanal LLND. Twelve digestive surgeons with prior practice in hologram manipulation evaluated the utility of the intraoperative hologram support by means of a questionnaire. Intraoperative hologram support improved the surgical understanding of the lateral lymph node region anatomy. In the questionnaire, 75% of the surgeons answered that the hologram accurately reflected the anatomy, and 92% of the surgeons answered that the anatomy was better understood by simulating the hologram intraoperatively than preoperatively. Moreover, 92% of the surgeons agreed that intraoperative holograms were a useful support tool for improving the surgical safety. Intraoperative hologram support improved the surgical understanding of the pelvic anatomy for transanal LLND. Intraoperative holograms may represent a next-generation surgical tool for transanal LLND. (Keyword) Humans / Treatment Outcome / Lymph Node Excision / Lymph Nodes / Rectal Neoplasms / Dissection (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-023-09977-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37017769 ● Search Scopus @ Elsevier (PMID): 37017769 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-023-09977-w (DOI: 10.1007/s00464-023-09977-w, PubMed: 37017769)
17.	Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 術前に肝細胞癌との鑑別が困難であった筋腫型肝血管筋脂肪腫の1例, Acta Hepatologica Japonica, Vol.64, No.4, 201-208, 2023. (Summary) 患者は40代女性.検診で肝から突出する15cmの巨大腫瘤を指摘され,精査加療目的に当科紹介となった.既往歴や背景肝に特記事項なく,腫瘍マーカーは正常であったが,造影CTの動脈・門脈相で肝右葉に15cm大の早期濃染と遅延相でwashoutを認めた.EOB-MRI肝細胞相ではdefectとして描出され肝細胞癌が疑われた.破裂の危険性を考慮し,まずTACEを行い,その後拡大肝右葉切除を施行した.病理組織学的には腫瘍の大半が平滑筋様細胞で構成されており,脂肪細胞は認めず,免疫組織化学染色にてVimentin,αSMA,HMB-45,melan Aが陽性であり,Perivascular epithelioid cell tumor(PEComa)として包括される腫瘍群の中の筋腫型の肝血管筋脂肪腫(Angiomyolipoma;AML)と診断した.今回我々は,術前に肝細胞癌との鑑別が困難であった,若年女性に発生した肝原発筋腫型AMLを経験したため報告する.(著者抄録) (Keyword) 肝細胞癌肝切除肝臓腫瘍(画像診断,病理学,外科的療法) 筋腫(画像診断,病理学,外科的療法) 鑑別診断術前評価超音波診断 X線CT 免疫組織化学 *血管筋脂肪腫(画像診断,病理学,外科的療法) 拡散MRI 腹部CT ヒト女 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.201 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.201 (DOI: 10.2957/kanzo.64.201)
18.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Shohei Eto and Toshiaki Yoshimoto : Usefulness of Diagnostic Staging Laparoscopy for Advanced Gastric Cancer., The American Surgeon, Vol.89, No.4, 685-690, 2023. (Summary) For advanced gastric cancer (AGC), peritoneal metastasis is the most common determinant of unresectability, but accurate preoperative diagnosis for peritoneal metastasis is challenging. Staging laparoscopy (SL) can detect unsuspected peritoneal metastasis. This study retrospectively evaluated the utility of SL and its indication in patients with AGC. In this study, we enrolled 114 patients with pathologically diagnosed gastric adenocarcinoma who underwent SL. Of the 114 patients, 43 (37.7%) had peritoneal metastasis (P1 or CY1). Higher age, larger tumor size, type 4 GC, deeper tumor depth, elevated CA125, and ascites findings in preoperative CT were found to be significant predictors of peritoneal metastasis. In multivariate analysis, peritoneal metastasis was associated with type 4 GC (odds ratio [OR]: 6.11; 95% confidence interval [CI]: 1.87-19.8; P < .01) and ascites in CT (OR: 4.25; 95% CI: 1.48-12.1; P < .01). Staging laparoscopy is an effective tool to detect peritoneal metastasis from AGC. It can increase the curative resection rate and decrease unnecessary laparotomies. (Link to Publication Site) ● Publication site (DOI): 10.1177/00031348211038554 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34382447 ● Search Scopus @ Elsevier (PMID): 34382447 ● Search Scopus @ Elsevier (DOI): 10.1177/00031348211038554 (DOI: 10.1177/00031348211038554, PubMed: 34382447)
19.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Shohei Eto and Toshiaki Yoshimoto : Transoral Anvil Delivery System With Tension-Free Method for Esophagojejunostomy After Laparoscopic Total Gastrectomy Prevents The Postoperative Stenosis., The American Surgeon, Vol.89, No.4, 1066-1068, 2023. (Link to Publication Site) ● Publication site (DOI): 10.1177/0003134820973393 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33307725 ● Search Scopus @ Elsevier (PMID): 33307725 ● Search Scopus @ Elsevier (DOI): 10.1177/0003134820973393 (DOI: 10.1177/0003134820973393, PubMed: 33307725)
20.	Yoshihiko Maehara, Eiji Oki, Mitsuhiko Ota, Norifumi Harimoto, Koji Ando, Ryota Nakanishi, Tetsuro Kawazoe, Yoshiaki Fujimoto, Kentaro Nonaka, Hiroyuki Kitao, Makoto Iimori, Kunio Makino, Teiji Takechi, Takeshi Sagara, Kazutaka Miyadera, Kazuaki Matsuoka, Hiroshi Tsukihara, Yuki Kataoka, Takeshi Wakasa, Hiroaki Ochiiwa, Yoshihiro Kamahori, Eriko Tokunaga, Hiroshi Saeki, Tomoharu Yoshizumi, Yoshihiro Kakeji, Ken Shirabe, Hideo Baba and Mitsuo Shimada : Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii., International Journal of Clinical Oncology, Vol.28, No.5, 613-624, 2023. (Summary) Prof. Setsuro Fujii achieved significant results in the field of drug discovery research in Japan. He developed nine well-known drugs: FT, UFT, S-1 and FTD/TPI are anticancer drugs, while cetraxate hydrochloride, camostat mesilate, nafamostat mesilate, gabexate mesilate and pravastatin sodium are therapeutic drugs for various other diseases. He delivered hope to patients with various diseases across the world to improve their condition. Even now, drug discovery research based on Dr. Fujii's ideas is continuing. (Keyword) Male / Humans / Pyrimidines / Gabexate / Antineoplastic Agents / Tegafur / Japan / Uracil (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-023-02326-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36961615 ● Search Scopus @ Elsevier (PMID): 36961615 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-023-02326-w (DOI: 10.1007/s10147-023-02326-w, PubMed: 36961615)
21.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : Stapler insertion angle toward the esophagus reduces the incidence of early postoperative Roux stasis syndrome after distal gastrectomy in minimally invasive surgery., BMC Surgery, Vol.23, No.1, 54, 2023. (Summary) Roux stasis syndrome (RSS) after Roux-en-Y (RY) reconstruction significantly prolongs the hospital stay and decreases the quality of life. The purpose of the present study was to evaluate the incidence of RSS in patients who underwent distal gastrectomy for gastric cancer and to identify the factors related to the development of RSS after mechanical RY reconstruction in minimally invasive surgery (MIS). This study included 134 patients who underwent distal gastrectomy in MIS with mechanical RY anastomosis. RSS was defined as the presence of symptoms such as nausea, vomiting, or abdominal fullness, and the confirmation of delayed gastric emptying on imaging or gastrointestinal fiber testing. Clinical data were checked, including body mass index, operative procedure, age, sex, operative time, blood loss volume, extent of lymph node dissection, final stage, stapler insertion angle, method of entry hole closure. The relationship between the incidence of RSS and these factors was analyzed. RSS occurred in 24 of 134 patients (17.9%). RSS occurred significantly more frequently in patients with D2 lymphadenectomy than in patients with D1 + lymphadenectomy (p = 0.04). All patients underwent side-to-side anastomosis via the antecolic route. The incidence of RSS was significantly greater in patients with a stapler insertion angle toward the greater curvature (n = 20, 22.5%) versus the esophagus (n = 4, 8.9%) (p = 0.04). The multivariate logistic regression model revealed that the stapler insertion angle to the greater curvature is identified as independent risk factor for RSS (OR 3.23, 95%Cl 1.01-10.3, p = 0.04). Stapler insertion angle toward the esophagus may reduce the incidence of early postoperative RSS rather than toward the greater curvature. (Keyword) Humans / Incidence / Quality of Life / Gastrectomy / Anastomosis, Roux-en-Y / Esophagus / Stomach Neoplasms / Minimally Invasive Surgical Procedures / Postoperative Complications (Tokushima University Institutional Repository) ● Metadata: 118879 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-01954-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36906525 ● Search Scopus @ Elsevier (PMID): 36906525 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-01954-3 (Tokushima University Institutional Repository: 118879, DOI: 10.1186/s12893-023-01954-3, PubMed: 36906525)
22.	Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita, Takeyuki Watadani, Masaki Kaibori, Shoji Kubo, Mitsuo Shimada, Hiroaki Nagano, Etsuro Hatano, Hiroshi Aikata, Hiroko Iijima, Kazuomi Ueshima, Kazuyoshi Ohkawa, Takuya Genda, Kaoru Tsuchiya, Takuji Torimura, Masafumi Ikeda, Junji Furuse, Masaaki Akahane, Satoshi Kobayashi, Hideyuki Sakurai, Atsuya Takeda, Takamichi Murakami, Utaroh Motosugi, Yutaka Matsuyama, Masatoshi Kudo and Ryosuke Tateishi : Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)., Hepatology Research, Vol.53, No.5, 383-390, 2023. (Summary) The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance-diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described. (Tokushima University Institutional Repository) ● Metadata: 119233 (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13892 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36826411 ● Search Scopus @ Elsevier (PMID): 36826411 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13892 (Tokushima University Institutional Repository: 119233, DOI: 10.1111/hepr.13892, PubMed: 36826411)
23.	Katsuki Miyazaki, Caiming Xu, Mitsuo Shimada and Ajay Goel : Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1., Pharmaceuticals, Vol.16, No.3, 383, 2023. (Summary) Colorectal cancer (CRC) is the leading cause of cancer-related deaths worldwide. The limitations of current chemotherapeutic drugs in CRC include their toxicity, side effects, and exorbitant costs. To assess these unmet needs in CRC treatment, several naturally occurring compounds, including curcumin and andrographis, have gained increasing attention due to their multi-targeted functionality and safety vs. conventional drugs. In the current study, we revealed that a combination of curcumin and andrographis exhibited superior anti-tumor effects by inhibiting cell proliferation, invasion, colony formation, and inducing apoptosis. Genome-wide transcriptomic expression profiling analysis revealed that curcumin and andrographis activated the ferroptosis pathway. Moreover, we confirmed the gene and protein expression of glutathione peroxidase 4 (GPX-4) and ferroptosis suppressor protein 1 (FSP-1), the two major negative regulators of ferroptosis, were downregulated by this combined treatment. With this regimen, we also observed that intracellular accumulation of reactive oxygen species and lipid peroxides were induced in CRC cells. These cell line findings were validated in patient-derived organoids. In conclusion, our study revealed that combined treatment with curcumin and andrographis exhibited anti-tumorigenic effects in CRC cells through activation of ferroptosis and by dual suppression of GPX-4 and FSP-1, which have significant potential implications for the adjunctive treatment of CRC patients. (Tokushima University Institutional Repository) ● Metadata: 119401 (Link to Publication Site) ● Publication site (DOI): 10.3390/ph16030383 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36986483 ● Search Scopus @ Elsevier (PMID): 36986483 ● Search Scopus @ Elsevier (DOI): 10.3390/ph16030383 (Tokushima University Institutional Repository: 119401, DOI: 10.3390/ph16030383, PubMed: 36986483)
24.	Hiroki Mori, Takayuki Noma, Yuji Morine, Hiroki Ishibashi and Mitsuo Shimada : Carcinogenic risk in the biliary epithelium of children with congenital biliary dilatation via the DNA damage repair pathway., Surgery Today, Vol.53, No.10, 1126-1131, 2023. (Summary) Congenital biliary dilatation (CBD) is a high-risk factor for biliary tract cancer (BTC). We previously reported the potential for carcinogenesis in the biliary epithelium of patients with CBD. In this study, we investigated potential carcinogenetic pathways, focusing on the DNA damage repair response, in children with CBD and compared the findings with those in adults. We enrolled 6 children with CBD and 10 adults with CBD without BTC who underwent extrahepatic bile duct resections, plus 4 control patients who underwent pancreaticoduodenectomy for non-biliary cancer. Levels of phosphorylated histone H2AX (γH2AX), MRE11, and Ku-70 in the biliary tract epithelium were evaluated by immunohistochemistry. The levels of γH2AX, MRE11, and Ku-70 were significantly higher in the gallbladder epithelium and bile duct epithelium of both children and adults than in controls. Children and adults with CBD might develop BTC via the DNA damage repair pathway, as evidenced by increased γH2AX, MRE11, and Ku-70 expression. (Keyword) Adult / Humans / Child / Choledochal Cyst / Carcinogens / Biliary Tract / Epithelium / Biliary Tract Neoplasms / Carcinogenesis / DNA Damage / Dilatation, Pathologic (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-023-02664-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36828910 ● Search Scopus @ Elsevier (PMID): 36828910 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-023-02664-2 (DOI: 10.1007/s00595-023-02664-2, PubMed: 36828910)
25.	Katsuki Miyazaki, Yuji Morine, Caiming Xu, Chiharu Nakasu, Yuuma Wada, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Mitsuo Shimada and Ajay Goel : Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma., Cells, Vol.12, No.4, 612, 2023. (Summary) Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Curcumin / Liver Neoplasms / Proto-Oncogene Proteins c-akt / Phosphatidylinositol 3-Kinases / Cell Line, Tumor / Signal Transduction / Protein Kinase Inhibitors / ErbB Receptors (Tokushima University Institutional Repository) ● Metadata: 118580 (Link to Publication Site) ● Publication site (DOI): 10.3390/cells12040612 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36831279 ● Search Scopus @ Elsevier (PMID): 36831279 ● Search Scopus @ Elsevier (DOI): 10.3390/cells12040612 (Tokushima University Institutional Repository: 118580, DOI: 10.3390/cells12040612, PubMed: 36831279)
26.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki, Takayuki Noma, Tetsuya Ikemoto and Mitsuo Shimada : Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage hepatocellular carcinoma., Hepatology Research, Vol.53, No.6, 531-539, 2023. (Summary) Recent advances in treatment modalities have been made, limiting the indication of hepatic resection in the treatment strategy for hepatocellular carcinoma (HCC) patients. This retrospective study investigated the significance of multiplication of tumor maximum diameter and number (MDN) as a surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC. A total of 49 patients with Barcelona Clinic Liver Cancer intermediate-stage HCC who underwent curative hepatic resection between 2000 and 2020 were enrolled in this study. Prognostic factors of overall survival and disease-free survival, including the product of MDN, were analyzed. Patients with MDN >12 experienced significantly worse prognosis compared with those with MDN ≤12 (p = 0.0395), and 5-year overall survival rates after hepatic resection were 60.0% and 23.4%, respectively. Furthermore, the disease-free survival rate of patients with MDN >12 was significantly worse compared with those with MDN ≤12 (p = 0.0049), and all patients with MDN >12 experienced recurrence within 3 years after hepatic resection. In the multivariate analysis, MDN >12 was identified as the only independent prognostic factor of both overall survival and disease-free survival. In addition, patients with MDN >12 suffered from uncontrollable recurrence by locoregional treatment, such as more than four intrahepatic and extrahepatic recurrences, after hepatic resection. MDN index might be a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC, and influence clinical decision-making for individual treatment strategies. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13887 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36755370 ● Search Scopus @ Elsevier (PMID): 36755370 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13887 (DOI: 10.1111/hepr.13887, PubMed: 36755370)
27.	Susumu Kunisawa, Haku Ishida, Hiroshi Ikai, Hiroaki Nagano, Toshiyoshi Fujiwara, Hideki Ohdan, Yoshiyuki Fujiwara, Yoshitsugu Tajima, Tomio Ueno, Yoshinori Fujiwara, Mitsuo Shimada, Yasuyuki Suzuki, Yuji Watanabe, Kazuhiro Hanazaki, Yoshihiro Kakeji, Hiraku Kumamaru, Arata Takahashi, Hiroaki Miyata and Yuichi Imanaka : Impact of the hospital volume and setting on postoperative complications of surgery for gastroenterological cancers in a regional area of Western Japan., Surgery Today, Vol.53, No.2, 214-222, 2023. (Summary) A research subgroup was established by the Japanese Society of Gastroenterological Surgery to improve the health care quality in the Chushikoku area of Western Japan. The records of four surgical procedures were extracted from the Japanese National Clinical Database and analyzed retrospectively to establish the association between hospital characteristics, defined using a combination of hospital case-volume and patients' hospital travel distance, and the incidences of perioperative complications of ≥ Grade 3 of the Clavien-Dindo classification after gastroenterological surgery. This study analyzed 11,515 cases of distal gastrectomy for gastric cancer, 4,705 cases of total gastrectomy for gastric cancer, 4,996 cases of right hemicolectomy for colon cancer, and 5,243 cases of lower anterior resection for rectal cancer, with composite outcome incidences of 5.6%, 10.2%, 5.5%, and 10.7%, respectively. After adjusting for patient characteristics and surgical procedures, no association was identified between the hospital category and surgical outcomes. The findings of our study of the Chushikoku region did not provide positive support for the consolidation and centralization of hospitals, based solely on hospital case volume. Our grouping was unique in that we included patient travel distance in the analysis, but further investigations from other perspectives are needed. (Keyword) Humans / Stomach Neoplasms / Retrospective Studies / Japan / Hospitals / Postoperative Complications / Gastrectomy (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-022-02569-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35947194 ● Search Scopus @ Elsevier (PMID): 35947194 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-022-02569-6 (DOI: 10.1007/s00595-022-02569-6, PubMed: 35947194)
28.	Yosuke Iwakawa, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Mitsuo Shimada, Yasuyo Saijo, Minoru Matsumoto, Takeshi Oya and Hisanori Uehara : Pleomorphic type undifferentiated gastric sarcoma, report of a case., Clinical Journal of Gastroenterology, Vol.16, No.1, 20-25, 2023. (Summary) Reports on pleomorphic type of undifferentiated sarcoma (PUS) originating from the gastrointestinal tract, especially the stomach, are extremely rare. We herein report a case of pleomorphic type undifferentiated gastric sarcoma. The patient was a 67-year-old woman. The chief complaint was upper abdominal pain. Upper gastrointestinal endoscopy, ultrasonography, and contrast-enhanced computed tomography showed two submucosal tumors at the greater curvature of the fundus and the lesser curvature of the gastric angle. Endoscopic ultrasound-guided fine-needle aspiration revealed a c-kit-negative spindle cell tumor at the greater curvature of the fundus. Total gastrectomy, splenectomy, and partial resection of the diaphragm and liver were performed. One lesion had invaded the lateral segment of the liver, left diaphragm and spleen. The postoperative course was uneventful. Histopathological and immunohistochemical examinations of the resected specimen revealed PUS. Peritoneal dissemination was detected at 8 months after surgery. However, no effective therapeutic agents were adopted for chemotherapy. The patient had poor performance status due to disease progression and underwent best supportive care. The patient died 10 months after surgery. This case highlights the imaging, histological diagnosis, and treatment strategy for PUS originating from the stomach. Surgeons should be aware of PUS as a differential diagnosis in cases with submucosal tumor of the stomach. (Keyword) Female / Humans / Aged / Stomach Neoplasms / Gastrectomy / Sarcoma / Endoscopy, Digestive System / Liver Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-022-01729-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36289170 ● Search Scopus @ Elsevier (PMID): 36289170 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-022-01729-y (DOI: 10.1007/s12328-022-01729-y, PubMed: 36289170)
29.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki, Chiharu Nakasu and Mitsuo Shimada : Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study., BMC Surgery, Vol.23, No.1, 6, 2023. (Summary) We investigated the usefulness of apparent diffusion coefficients (ADC) from diffusion-weighted images (DWI) obtained using magnetic resonance imaging (MRI) for prognosis of early hepatocellular carcinoma (HCC): Barcelona Clinic Liver Cancer (BCLC) stage 0 and A. We enrolled 102 patients who had undergone surgical resection for early HCC: BCLC stage 0 and A, and calculated their minimum ADC using DWI-MRI. We divided patients into ADC (n = 72) and ADC (n = 30) groups, and compared clinicopathological factors between the two groups. The ADC group showed higher protein induced by vitamin K absence-II (PIVKA-II) levels (p = 0.02) compared with the ADC group. In overall survival, the ADC group showed significantly worse prognosis than the ADC group (p < 0.01). Univariate analysis identified multiple tumors, infiltrative growth, high PIVKA-II, and low ADC value as prognostic factors. Multivariate analysis identified infiltrative growth and low ADC value as an independent prognostic factor. ADC values can be used to estimate the prognosis of early HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Liver Neoplasms / Case-Control Studies / Retrospective Studies / Prognosis (Tokushima University Institutional Repository) ● Metadata: 118558 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01892-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36631851 ● Search Scopus @ Elsevier (PMID): 36631851 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01892-6 (Tokushima University Institutional Repository: 118558, DOI: 10.1186/s12893-022-01892-6, PubMed: 36631851)
30.	Katsuki Miyazaki, Yuuma Wada, Keisuke Okuno, Tatsuro Murano, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroaki Ikematsu, Yusuke Kinugasa, Mitsuo Shimada and Ajay Goel : An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer., Molecular Cancer, Vol.22, No.1, 2, 2023. (Summary) According to current guidelines, more than 70% of patients with invasive submucosal colorectal cancer (T1 CRC) undergo a radical operation with lymph node dissection, even though only ~ 10% have lymph node metastasis (LNM). Hence, there is imperative to develop biomarkers that can help robustly identify LNM-positive patients to prevent such overtreatments. Given the emerging interest in exosomal cargo as a source for biomarker development in cancer, we examined the potential of exosomal miRNAs as LNM prediction biomarkers in T1 CRC. We analyzed 200 patients with high-risk T1 CRC from two independent cohorts, including a training (n = 58) and a validation cohort (n = 142). Cell-free and exosomal RNAs from pre-operative serum were extracted, followed by quantitative reverse-transcription polymerase chain reactions for a panel of miRNAs. A panel of four miRNAs (miR-181b, miR-193b, miR-195, and miR-411) exhibited robust ability for detecting LNM in the exosomal vs. cell-free component. We subsequently established a cell-free and exosomal combination signature, successfully validated in two independent clinical cohorts (AUC, 0.84; 95% CI 0.70-0.98). Finally, we developed a risk-stratification model by including key pathological features, which reduced the false positive rates for LNM by 76% without missing any true LNM-positive patients. Our novel exosomal miRNA-based liquid biopsy signature robustly identifies T1 CRC patients at risk of LNM in a preoperative setting. This could be clinically transformative in reducing the significant overtreatment burden of this malignancy. (Keyword) Humans / Lymphatic Metastasis / Exosomes / Colorectal Neoplasms / Biomarkers, Tumor / MicroRNAs / Liquid Biopsy (Tokushima University Institutional Repository) ● Metadata: 118926 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12943-022-01685-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36609320 ● Search Scopus @ Elsevier (PMID): 36609320 ● Search Scopus @ Elsevier (DOI): 10.1186/s12943-022-01685-8 (Tokushima University Institutional Repository: 118926, DOI: 10.1186/s12943-022-01685-8, PubMed: 36609320)
31.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Fontan associated liver disease(FALD)関連肝癌に対しての腹腔鏡肝切除の1例 Fontan循環における肝離断対策, Acta Hepatologica Japonica, Vol.64, No.1, 18-25, 2023. (Summary) 30代男性,3歳時に単心房・単心室症を背景にFontan手術を受けた.Fontan associated liver disease(FALD)として肝臓内科にフォローを開始されて以来3年後にFALD関連肝癌を疑われ,腹腔鏡肝切除を施行した.肝離断中は,Central venous pressure(CVP)圧を下げるため,positive end expiratory pressureをオフし,最小限の輸液量,利尿剤併用しながらの麻酔管理を行うも,Fontan循環の影響でCVPコントロールは不良で,静脈性出血が継続したままの肝離断となった.本症例は,術後合併症なく経過したものの,FALD関連肝癌症例は,Fontan循環による高CVP下での肝離断を余儀なくされるため,そのジレンマを解決する必要があり,その対策に関して考察を加え報告する.(著者抄録) (Keyword) 肝細胞癌(画像診断,病理学,外科的療法) 肝切除肝内胆管(画像診断,病理学,外科的療法) 超音波診断胆管癌(画像診断,病理学,外科的療法) 胆管腫瘍(画像診断,病理学,外科的療法) X線CT 中心静脈圧 *腹腔鏡法免疫組織化学複合腫瘍と混合腫瘍(画像診断,病理学,外科的療法) 超音波外科拡散MRI 腹部CT ヒト成人(19∼44) 男 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.18 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.18 (DOI: 10.2957/kanzo.64.18)
32.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The Impact of the Pre-operative Neutrophil-lymphocyte Ratio as the Predictive Marker of Post-operative Weight Loss and Improving Diabetes in Sleeve Gastrectomy., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 140-144, 2023. (Summary) The aim was to investigate the impact of the neutrophil-lymphocyte ratio (NLR) in sleeve gastrectomy (SG). 15 obese patients were enrolled in this study ; mean body weight (BW) 127.5kg ; mean body mass index (BMI) 46.7kg/m. 10 of these were diabetics who underwent a SG. The impact of the pre-operative NLR on the percentage of excess weight loss (%EWL) and remission of diabetes 1 year post-operative were examined. The %EWL at 1 year post-operative were 46.3%. Improvements were also evident in the diabetes at 1 year post-operative : complete remission (CR) 40%, partial remission (PR) 20% and Improve 40%. Comparing pre-operative NLR in %EWL<50% and ≧50% in 1 year post-operative, <50% was 2.64 and ≧50% was 2.03. The NLR in CR and PR was significantly lower than that in Improve. The pre-operative NLR may be a predictive marker of weight loss and improving diabetes after SG. J. Med. Invest. 70 : 140-144, February, 2023. (Keyword) Humans / Obesity, Morbid / Treatment Outcome / Neutrophils / Retrospective Studies / Laparoscopy / Diabetes Mellitus / Weight Loss / Body Mass Index / Gastrectomy (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.140 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164710 ● Search Scopus @ Elsevier (PMID): 37164710 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.140 (DOI: 10.2152/jmi.70.140, PubMed: 37164710)
33.	Kunitsugu Kubota, Toru Kono, Mitsuo Shimada, Atsushi Takata, Jun Higashijima, Kouzou Yoshikawa, Takuya Tokunaga, Naoki Fujitsuka and Alessandro Fichera : Intestinal hypomotility due to longitudinal enterotomy can be alleviated by transverse closure., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 180-188, 2023. (Summary) Heineke-Mikulicz (HM) strictureplasty is commonly used to treat short stenoses in Crohn's disease. However, the degree to which intestinal motility is maintained remains unclear. We compared the peristalsis and transport capacity of the sutured intestines with HM configuration and transverse (TS) and longitudinal (LS) incisions. The intestinal diameter, intraluminal pressure, and bead transit time of each sutured group were compared with that of the non-treatment (NT) group in the isolated proximal colon of rats. Propulsive contractions were induced using hydroxy-?-sanshool (HAS), a constituent of Japanese pepper. There was no change in the intestinal diameter between HM, TS, and NT groups ; however, it was significantly narrowed at the suture site and its distal side in the LS group. After HAS administration, the intestinal diameter at the suture site in the HM group was higher than that in the LS group. The intraluminal pressure was higher and the transit time was shorter in the HM group compared to those in the LS group. The HM configuration, which widens the incision site and distal diameter and shortens the cut surface of the circular muscle in the longitudinal direction, may help maintain basal and HAS-induced intestinal peristalsis and motility. J. Med. Invest. 70 : 180-188, February, 2023. (Keyword) Rats / Animals / Intestines / Crohn Disease / Constriction, Pathologic / Colon / Anastomosis, Surgical (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.180 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164718 ● Search Scopus @ Elsevier (PMID): 37164718 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.180 (DOI: 10.2152/jmi.70.180, PubMed: 37164718)
34.	Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Shin-ichiro Yamada, Toshiaki Yoshimoto and Mitsuo Shimada : Prognostic impact of frailty after gastrectomy in elderly gastric cancer patients., The Journal of Medical Investigation : JMI, Vol.70, No.3.4, 423-429, 2023. (Summary) Frailty plays a crucial role in cancer patients who have received surgery in this recent aging society. We aimed to investigate frailty as a prognostic factor in elderly gastric cancer (GC) patients who underwent curative gastrectomy. We analyzed 86 elderly (over 75 years old) GC patients who underwent curative gastrectomy. Patients were assigned to two groups;frailty group (n=29) and no-frailty group (n=57). Clinicopathological values were compared between the two groups. The OS rate of the frailty group was significantly poorer than that of the no-frailty group (5-yr OS rate;frailty group 52.49% vs. no-frailty group 74.87%, p<0.05). Multivariate analysis of the OS showed that frailty tended to be significant prognostic factor (p=0.09). The DFS rate of the frailty group was significantly poorer than that of the no-frailty group (5-yr DFS rate;frailty group 42.30% vs. no-frailty group 71.55%, p<0.05). Multivariate analysis of the DFS showed that frailty tended to be significant prognostic factor (p=0.14). We identified the clinical impact of frailty prognostic factor for elderly GC patients who underwent gastrectomy. J. Med. Invest. 70 : 423-429, August, 2023. (Keyword) Humans / Aged / Prognosis / Stomach Neoplasms / Frailty / Aging / Gastrectomy / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.423 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940527 ● Search Scopus @ Elsevier (PMID): 37940527 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.423 (DOI: 10.2152/jmi.70.423, PubMed: 37940527)
35.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Shohei Okikawa, Katsuki Miyazaki, Chiharu Nakasu, Takayuki Noma, Akira Takahashi and Mitsuo Shimada : Impact of pancreatic resection in patients with liver cirrhosis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 189-194, 2023. (Summary) Several reports have shown a high mortality rate in patients with liver cirrhosis (LC) who undergo pancreaticoduodenectomy, however, there are few reports on its long-term prognosis. Twelve patients with LC who had undergone pancreatic resection were enrolled. To compare clinicopathological variables, 159 non-LC patients who had undergone resection for pancreatic cancer were enrolled. Pancreaticoduodenectomy (PD) was performed in 5 LC patients and distal pancreatectomy (DP) was performed in 7 LC patients. Patients in the LC group had more co-morbidities, lower platelet counts and higher Fib4 index than the non-LC group. The postoperative complication rate was higher in the LC group (83.3% vs 47.8%). While the postoperative hospital stay and 30-day mortality rate were not different, the 90-day mortality rate was higher in the LC group (25.0% vs 2.5% ; p<0.01). Comparison by operative procedure showed no significant differences of postoperative outcomes in DP cases. However, in PD cases, postoperative complications were more frequent (100% vs 42.3%) and 90-day mortality was higher (40.0% vs 2.9% ; p<0.01) in the LC group. PD resulted in higher postoperative morbidity and mortality rates in patients with LC compared with non-LC patients. DP could be tolerated in the LC patients. J. Med. Invest. 70 : 189-194, February, 2023. (Keyword) Humans / Pancreatectomy / Treatment Outcome / Retrospective Studies / Pancreaticoduodenectomy / Pancreatic Neoplasms / Postoperative Complications / Liver Cirrhosis (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.189 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164719 ● Search Scopus @ Elsevier (PMID): 37164719 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.189 (DOI: 10.2152/jmi.70.189, PubMed: 37164719)
36.	Baasansuren Selenge, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Hiroki Teraoku, Shohei Okikawa and Mitsuo Shimada : Impact of L-type amino acid transporter 1 on intrahepatic cholangiocarcinoma., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 160-165, 2023. (Summary) Amino acid transporters, such as L-type amino acid transporter 1 (LAT1), have an effect on tumor growth, metastasis, and survival of various solid tumors. However, the role of LAT1 in patients with intrahepatic cholangiocarcinoma (IHCC) remains unknown. Forty-six patients who had undergone initial hepatic resection for IHCC at Tokushima University Hospital were enrolled in this study. Immunohistochemical analysis of LAT1 and phosphorylated Akt (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were analyzed between LAT1-high and LAT1-low groups. The LAT1-high group showed a higher proportion of periductal infiltrating type and higher carcinoembryonic antigen/carbohydrate antigen 19-9 levels compared with the LAT1-low group. Multivariate analysis revealed that LAT1-high expression was an independent prognostic factor for disease-free survival. Furthermore, the proportion of p-AKT positivity was higher in the LAT1-high group than in the LAT1-low group. LAT1 expression was associated with poor prognosis of IHCC and higher p-Akt expression. J. Med. Invest. 70 : 160-165, February, 2023. (Keyword) Humans / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Biomarkers, Tumor / Cholangiocarcinoma / Prognosis / Proto-Oncogene Proteins c-akt (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.160 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164714 ● Search Scopus @ Elsevier (PMID): 37164714 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.160 (DOI: 10.2152/jmi.70.160, PubMed: 37164714)
37.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : Short- and long-term outcomes of pancreatectomy in patients with hemodialysis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 105-109, 2023. (Summary) Several reports have shown the high mortality rate of pancreatic resection in patients with hemodialysis (HD), however, its long-term outcome remains unclear. In this study, we examined cases of pancreatic resection in patients with HD and conducted a literature review. Four patients with HD who underwent pancreatic resection from 2004 to 2019 were enrolled. To compare the clinicopathological variables of HD and non-HD patients, 161 non-HD patients who had undergone surgical resection for pancreatic cancer were enrolled. Among four cases of pancreatic resection with HD, three cases were malignant diseases. All patients with HD had some co-morbidities (100% in HD group, 45.3% in the non-HD group) and postoperative complications (100% in the HD group, vs 46.6% in the non-HD group). Although one patient had severe postoperative complications and length of postoperative hospital stay was longer, the 30- and 90-day mortality rates were both 0% in patients with HD. However, three cases in the HD group (75%) died approximately 6 months after surgery, including one cancer-related death. Pancreatic surgery in patients with HD should be carefully indicated, especially pancreaticoduodenectomy or total pancreatectomy, because of the poor prognosis induced by non-cancer-related causes of death. J. Med. Invest. 70 : 105-109, February, 2023. (Keyword) Humans / Pancreatectomy / Pancreatic Neoplasms / Pancreaticoduodenectomy / Postoperative Complications / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.105 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164704 ● Search Scopus @ Elsevier (PMID): 37164704 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.105 (DOI: 10.2152/jmi.70.105, PubMed: 37164704)
38.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shohei Okikawa, Shoko Yamashita and Mitsuo Shimada : Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy., BMC Cancer, Vol.22, No.1, 1263, 2022. (Summary) The role of the immune system in locally advanced rectal cancer (LARC) following preoperative chemoradiotherapy (CRT) has been widely investigated in recent years. This study examined the prognostic significance of indoleamine-pyrrole 2,3-dioxygenase (IDO) expression in patients with LARC who received preoperative CRT. Ninety patients with LARC who underwent preoperative CRT and curative resection were enrolled. IDO and programmed death-ligand 1 (PD-L1) expression was evaluated by immunohistochemistry. Clinicopathological factors did not significantly differ between patients with positive or negative IDO expression, excluding the correlation of positive IDO expression with better tumor differentiation (p = 0.02). IDO expression was not associated with pathological response (p = 0.44), but it was associated with PD-L1 expression. The 5-year overall survival (OS) rate was significantly worse in the IDO-positive group than in the IDO-negative group (64.8% vs. 85.4%, p = 0.02). Univariate analysis identified IDO and PD-L1 expression (p = 0.02), surgical procedure (p = 0.01), final pathological stage (p = 0.003), lymph node metastasis (p < 0.001), and lymphatic invasion (p = 0.002) as significant prognostic factors for OS. Multivariate analysis revealed that IDO expression (HR: 7.10, p = 0.0006), surgical procedure (HR: 5.03, p = 0.01), lymph node metastasis (HR: 2.37, p = 0.04) and lymphatic invasion (HR: 4.97, p = 0.01) were independent prognostic indicators. Disease-free survival was not correlated with IDO or PD-L1 expression. IDO expression in patients with LARC who received preoperative CRT could be a potential prognostic indicator. IDO expression could be a useful marker for specifying individual treatment strategies in LARC. (Keyword) Humans / B7-H1 Antigen / Chemoradiotherapy / Lymphatic Metastasis / Neoadjuvant Therapy / Prognosis / Rectal Neoplasms / Indoleamine-Pyrrole 2,3,-Dioxygenase (Tokushima University Institutional Repository) ● Metadata: 118002 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12885-022-10357-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36471264 ● Search Scopus @ Elsevier (PMID): 36471264 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-022-10357-1 (Tokushima University Institutional Repository: 118002, DOI: 10.1186/s12885-022-10357-1, PubMed: 36471264)
39.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 【胆膵疾患と最新テクノロジーの融合】胆膵疾患における最新の術前術中手術支援システム, Journal of Biliary Tract & Pancreas, Vol.43, No.12, 1631-1636, 2022. (Summary) 胆膵手術における術前シミュレーションは,腫瘍進展範囲あるいは主要脈管解剖をいかに正確にイメージできるかが,ポイントとなる．空間認識力という意味で,extended realityは有用である．また,術中ナビゲーションに関しては,ICG蛍光法がゴールドスタンダードとなるが,人工知能を駆使した最新の知見,ならびに自験例も踏まえて,本稿で紹介する．(著者抄録) (Keyword) Indocyanine Green(診断的利用) 術中モニタリング人工知能膵臓疾患(X線診断,外科的療法) 膵頭十二指腸切除ソフトウェア X線CT 胆道疾患(X線診断,外科的療法) DICOM 蛍光血管撮影シミュレーション訓練手術ナビゲーションシステム胆管切除術ヒト
40.	Yuji Morine, Tohru Utsunomiya, Hisami Yamanaka-Okumura, Yu Saitou, Shin-ichiro Yamada, Tetsuya Ikemoto, Satoru Imura, Shohei Kinoshita, Akiyoshi Hirayama, Yasuhito Tanaka and Mitsuo Shimada : Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis., Oncotarget, Vol.13, 1286-1298, 2022. (Summary) Metabolomics, defined as the comprehensive identification of all small metabolites in a biological sample, has the power to shed light on phenotypic changes associated with various diseases, including cancer. To discover potential metabolomic biomarkers of hepatocellular carcinoma (HCC), we investigated the metabolomes of tumor and non-tumor tissue in 20 patients with primary HCC using capillary electrophoresis-time-of-flight mass spectrometry. We also analyzed blood samples taken immediately before and 14 days after hepatectomy to identify associated changes in the serum metabolome. Marked changes were detected in the different quantity of 61 metabolites that could discriminate between HCC tumor and paired non-tumor tissue and additionally between HCC primary tumors and colorectal liver metastases. Among the 30 metabolites significantly upregulated in HCC tumors compared with non-tumor tissues, 10 were amino acids, and 7 were essential amino acids (leucine, valine, tryptophan, isoleucine, methionine, lysine, and phenylalanine). Similarly, the serum metabolomes of HCC patients before hepatectomy revealed a significant increase in 16 metabolites, including leucine, valine, and tryptophan. Our results reveal striking differences in the metabolomes of HCC tumor tissue compared with non-tumor tissue, and identify the essential amino acids leucine, valine, and tryptophan as potential metabolic biomarkers for HCC. (Keyword) Humans / Amino Acids, Essential / Carcinoma, Hepatocellular / Tryptophan / Leucine / Liver Neoplasms / Valine (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.28306 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36441784 ● Search Scopus @ Elsevier (PMID): 36441784 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.28306 (DOI: 10.18632/oncotarget.28306, PubMed: 36441784)
41.	Chie Takasu, 調憲, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : オンライン時代は女性医師キャリア形成の追い風となる, The Japanese Journal of Gastroenterological Surgery, Vol.55, No.11, 729-732, 2022. (Summary) 新型コロナウイルス感染症の拡大が,これまで停滞していた医師の働き方改革の推進へとつながっている.その中でも,学会のオンライン化は医師の働き方に大きな変化をもたらした.学会のリモート参加は,自宅に居ながら参加でき,地方からも参加しやすく,移動時間と費用の大きな削減となる.オンデマンド配信は,時間・場所にかかわらず学ぶ機会を得られる非常に有効なツールとなる.また,学会の委員活動など,習慣的に行われていた対面での会議が,現在はほぼ遠隔で行われている.これまで時間的制約により,積極的に学会活動に手を挙げることができなかった女性医師の同分野での活躍推進が期待される.特に子育て中の女性医師にとって,オンライン化はワーク・ライフ・バランスを維持しながらキャリアを形成していく有効なツールとなりうる.この変化を逃さず女性活躍推進へとつなげるための,オンライン学会(ハイブリット形式)の継続を強く要望したい.(著者抄録) (Keyword) 育児労働衛生女性医師抄録作成と索引作成職歴の移動テレビ会議テレワーキングヒト女 (Link to Publication Site) ● Publication site (DOI): 10.5833/jjgs.2022.sr005 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390857226420483072 ● Search Scopus @ Elsevier (DOI): 10.5833/jjgs.2022.sr005 (DOI: 10.5833/jjgs.2022.sr005, CiNii: 1390857226420483072)
42.	Yuji Morine and Mitsuo Shimada : 【膵・胆管合流異常-先天性胆道拡張症の最新トピックス-】膵・胆管合流異常先天性胆道拡張症の分類と臨床的意義, Journal of Biliary Tract & Pancreas, Vol.43, No.11, 1507-1513, 2022. (Summary) 本邦で先天性胆道拡張症は,膵・胆管合流異常を合併するものと定義されていることから,戸谷分類のI型(Ibは除く)とIV-A型が対象となり,このため拡張胆管形態の分類に加えて,膵管胆管合流形態の分類も診断する必要がある．膵管胆管合流形態については,これまで合流形態のみの分類にとどまっていたが,臨床症状をより反映する分類が日本膵・胆管合流異常研究会診断基準検討委員会によって2015年に提案され,分類に応じて術中対処法も異なってくる．また拡張胆管に関しては,戸谷分類が広く引用されており,戸谷分類に応じて術中対処法だけでなく術後合併症も異なる．しかしながら,これまでの分類は一定の臨床的意義を示すものの,発生や病態,臨床症状,治療法すべてに対応する分類は依然確立されておらず,今後の検討課題と思われる．(著者抄録) (Keyword) 内視鏡的逆行性胆道膵管造影胆管造影胆汁うっ滞(病因) X線CT 分類超音波内視鏡検査三次元イメージング磁気共鳴胆道膵管造影膵胆管合流異常(画像診断) 胆道拡張症(画像診断,外科的療法) 吻合部狭窄(病因) MPR (Multiplanar Reconstruction) 胆管切除術胆道再建術(有害作用) ヒト
43.	Yuji Morine and Mitsuo Shimada : 【術前画像の読み解きガイド-的確な術式選択と解剖把握のために】胆道先天性胆道拡張症に対する胆管切除+胆道再建解剖把握と術中所見, Journal of Clinical Surgery, Vol.77, No.11, 274-281, 2022. (Summary) <文献概要>先天性胆道拡張症は,戸谷分類で5型に分類され,戸谷I型(Ibは除く)とIV-A型では,膵・胆管合流異常を合併する.膵液の胆道内への逆流(膵液胆道逆流現象)の防止および胆道癌発生予防の目的のため,(肝外)胆管切除+胆道再建術が標準術式として確立されているが,拡張胆管の切除が不十分であったり,肝門部胆管形成が不適切であれば,難治性胆管炎や肝内結石,遺残胆管癌などの術後合併症が危惧される.本稿では,先天性胆道拡張症における(肝外)胆管切除+胆道再建の術中・術後合併症を回避するための基本手技とともに,理解すべき術前・術中画像による解剖把握のポイントについて概説する. (Keyword) 局所解剖学術中期術前評価内視鏡的逆行性胆道膵管造影胆道外科磁気共鳴胆道膵管造影胆道拡張症(外科的療法,画像診断) 胆管切除術胆道再建術ヒト (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1407213920 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1407213920 (DOI: 10.11477/mf.1407213920)
44.	Baasansvren Selenge, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Hiroki Teraoku and Mitsuo Shimada : Impact of L-type amino acid transporter 3 on the prognosis of hepatocellular carcinoma., Oncology Letters, Vol.24, No.5, 418, 2022. (Summary) The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P<0.05). Multivariate analysis revealed that high LAT3 expression and multiple tumors were independent prognostic factors for cancer-specific survival. Furthermore, the rate of p-AKT-positive cases was higher in the LAT3-high group than in the LAT3-low group. Overall, these findings suggested that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression. (Tokushima University Institutional Repository) ● Metadata: 118271 (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13538 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245821 ● Search Scopus @ Elsevier (PMID): 36245821 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13538 (Tokushima University Institutional Repository: 118271, DOI: 10.3892/ol.2022.13538, PubMed: 36245821)
45.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in gastric cancer., Oncology Letters, Vol.24, No.5, 415, 2022. (Summary) Previous studies have revealed the usefulness of neoadjuvant chemotherapy (NAC) followed by surgery for clinical stage III gastric cancer (GC). The tumor volume at the primary tumor site (PT) is sometimes difficult to measure because of the luminal structure; therefore, evaluation of the lymph node (LN) response to NAC may help to more accurately predict survival outcomes. The present study therefore evaluated the LN response to NAC for prediction of survival outcomes in patients with GC. The study involved 160 patients with clinical stage III GC who underwent NAC (n=14) and upfront surgery (n=146). PT and LN responses to NAC were evaluated, various clinicopathological factors were evaluated and Cox proportional hazard regression analyses were performed to determine survival outcomes. Overall survival (OS) and disease-free survival (DFS) were not significantly different between patients who underwent NAC and those who underwent upfront surgery (OS, P=0.71; DFS, P=0.50). However, although there were no significant differences in PT responses, patients classified as LN non-responders to NAC had a significantly worse prognosis compared with patients classified as LN responders in terms of DFS (PT, P=0.93; LN, P<0.01) and OS (PT, P=0.84; LN, P<0.01). Moreover, a higher neutrophil-lymphocyte ratio tended to be associated with poor DFS [univariate: hazard ratio (HR)=4.23, P=0.06; multivariate: HR=6.45, P=0.04]. Finally, an LN response to NAC was significantly better for prediction of recurrence (univariate, HR=7.79, 95% confidence interval=1.16-63.51, P=0.02; multivariate, HR=7.44, P=0.01). Overall, the current study revealed the clinical importance of the LN response to NAC for predicting survival outcomes in patients with GC. These findings highlight the potential clinical impact of optimizing treatment strategies to improve the selection and management of patients. (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13535 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245824 ● Search Scopus @ Elsevier (PMID): 36245824 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13535 (DOI: 10.3892/ol.2022.13535, PubMed: 36245824)
46.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Computed tomography texture analysis for the prediction of lateral pelvic lymph node metastasis of rectal cancer., World Journal of Surgical Oncology, Vol.20, No.1, 281, 2022. (Summary) This study aimed to investigate the usefulness of computed tomography (CT) texture analysis in the diagnosis of lateral pelvic lymph node (LPLN) metastasis of rectal cancer. This was a retrospective cohort study of 45 patients with rectal cancer who underwent surgery with LPLN dissection at Tokushima University Hospital from January 2017 to December 2021. The texture analysis of the LPLNs was performed on preoperative CT images, and 18 parameters were calculated. The correlation between each parameter and pathological LPLN metastasis was evaluated. The texture parameters were compared between pathologically metastasis-positive LPLNs and metastasis-negative LPLNs. A total of 40 LPLNs were extracted from 25 patients by preoperative CT scans. No LPLNs could be identified in the remaining 19 patients. Eight of the 25 patients had pathologically positive LPLN metastasis. Extracted LPLNs were analyzed by the texture analysis. Pathologically metastasis-positive LPLNs had significantly lower mean Hounsfield unit, gray-level co-occurrence matrix (GLCM) energy, and GLCM Entropy_log2 values, and a significantly larger volume than pathologically metastasis-negative LPLNs. Multivariate analysis revealed that the independent predictive factors for LPLN metastasis were volume (a conventional parameter) (odds ratio 7.81, 95% confidence interval 1.42-43.1, p value 0.018) and GLCM Entropy_log2 (a texture parameter) (odds ratio 12.7, 95% confidence interval 1.28-126.0, p value 0.030). The combination of both parameters improved the diagnostic specificity while maintaining the sensitivity compared with each parameter alone. Combining the CT texture analysis with conventional diagnostic imaging may increase the accuracy of the diagnosis of LPLN metastasis of rectal cancer. (Keyword) Humans / Lymph Node Excision / Lymph Nodes / Lymphatic Metastasis / Rectal Neoplasms / Retrospective Studies / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 118078 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-022-02750-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36057660 ● Search Scopus @ Elsevier (PMID): 36057660 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-022-02750-8 (Tokushima University Institutional Repository: 118078, DOI: 10.1186/s12957-022-02750-8, PubMed: 36057660)
47.	淺野間理仁, Kouzou Yoshikawa, 田上誉史, 正宗克浩, 吉田禎宏 and Mitsuo Shimada : 腹腔鏡下切除を行った限局性盲腸壊死の1例, Journal of Japan Surgical Association, Vol.83, No.9, 1615-1619, 2022. (Summary) 症例は82歳,男性.来院前日から腹痛が出現し,血便も認めたため当院紹介となった.腹部は平坦・硬で腹部全体に圧痛を認め,反跳痛,筋性防御も伴っていた.腹部単純CTで回盲部から上行結腸に著明な壁肥厚,周囲の炎症所見,腸管外ガスを認め,また血液生化学所見では白血球数とCRPの上昇を認めた.結腸穿孔と診断し同日腹腔鏡下に緊急手術を行い,術中所見で盲腸に虚血壊死所見を認めたため腹腔鏡下回盲部切除術を行った.術後経過は問題なく術後11日目に退院となった.稀な疾患である限局性盲腸壊死に対し腹腔鏡下に切除を行った1例を経験したので,若干の文献的考察を加えて報告する.(著者抄録) (Keyword) 壊死(X線診断,外科的療法,病理学) X線CT 腹腔鏡法 *盲腸疾患(X線診断,外科的療法,病理学) 小腸切除大腸切除回盲部(外科的療法) 腹部CT ヒト高齢者(80∼) 男 (Link to Publication Site) ● Publication site (DOI): 10.3919/jjsa.83.1615 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3919/jjsa.83.1615 (DOI: 10.3919/jjsa.83.1615)
48.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Syoko Yamashita : Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study., International Journal of Clinical Oncology, Vol.27, No.9, 1439-1449, 2022. (Summary) This study was performed to assess the impact of osteopenia on chemotherapy-induced neutropenia and the prognosis for patients treated with FOLFOXIRI for colorectal cancer. In total, 77 patients who underwent FOLFOXIRI for un-resectable metastatic and advanced colorectal cancer were retrospectively evaluated. Osteopenia was evaluated by the bone mineral density, which was measured using the average pixel density of the trabecular bone in the 11th thoracic vertebra by computed tomography before the introduction of chemotherapy. The relationship between osteopenia and neutropenia was evaluated. Progression-free survival and overall survival of patients with osteopenia and patients with neutropenia were evaluated. Grade ≥ 3 neutropenia was significantly more common in patients with than without osteopenia (p = 0.002). The multivariate analysis showed that osteopenia was a significant independent predictive factor for grade ≥ 3 neutropenia (p = 0.016). There was no significant difference in progression-free survival or overall survival between patients with and without osteopenia. Patients with grade ≥ 3 neutropenia tended to have a higher progression-free survival rate than others (p = 0.059). The overall survival rate was significantly higher in patients with grade ≥ 3 neutropenia than in others (p = 0.011). Osteopenia might be a predictor of chemotherapy-induced neutropenia, and neutropenia might be a prognostic factor for progression-free survival and overall survival in patients with colorectal cancer treated with FOLFOXIRI. (Keyword) Antineoplastic Agents / Antineoplastic Combined Chemotherapy Protocols / Bevacizumab / Bone Diseases, Metabolic / Camptothecin / Colorectal Neoplasms / Fluorouracil / Humans / Leucovorin / Neutropenia / Organoplatinum Compounds / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02199-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35908137 ● Search Scopus @ Elsevier (PMID): 35908137 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-022-02199-5 (DOI: 10.1007/s10147-022-02199-5, PubMed: 35908137)
49.	Takuya Tokunaga, Maki Sugimoto, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, Yosuke Iwakawa, Noriko Yokota and Mitsuo Shimada : Intraoperative holographic image-guided surgery in a transanal approach for rectal cancer., Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie, Vol.407, No.6, 2579-2584, 2022. (Summary) Urethral injury is one of the most important complications in transanal total mesorectal excision (TaTME) in male patients with rectal cancer. The purpose of this study was to investigate holographic image-guided surgery in TaTME. Polygon (stereolithography) files were created and exported from SYNAPSE VINCENT, and then uploaded into the Holoeyes MD system (Holoeyes Inc., Tokyo, Japan). After uploading the data, the three-dimensional image was automatically converted into a case-specific hologram. The hologram was then installed into the head mount display, HoloLens (Microsoft Corporation, Redmond, WA). The surgeons and assistants wore the HoloLens when they performed TaTME. In a Wi-Fi-enabled operating room, each surgeon, wearing a HoloLens, shared the same hologram and succeeded in adjusting the hologram by making simple hand gestures from their respective angles. The hologram contributed to better comprehension of the positional relationships between the urethra and the surrounding pelvic organs during surgery. All surgeons were able to properly determine the dissection line. This first experience suggests that intraoperative holograms contributed to reducing the risk of urethral injury and understanding transanal anatomy. Intraoperative holograms have the potential to become a new next-generation surgical support tool for use in spatial awareness and the sharing of information between surgeons. (Keyword) Dissection / Humans / Laparoscopy / Male / Postoperative Complications / Proctectomy / Rectal Neoplasms / Rectum / Surgery, Computer-Assisted / Transanal Endoscopic Surgery (Link to Publication Site) ● Publication site (DOI): 10.1007/s00423-022-02607-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35840706 ● Search Scopus @ Elsevier (PMID): 35840706 ● Search Scopus @ Elsevier (DOI): 10.1007/s00423-022-02607-4 (DOI: 10.1007/s00423-022-02607-4, PubMed: 35840706)
50.	Yuuma Wada, Masaaki Nishi, Kozo Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative nutrition and exercise intervention in frailty patients with gastric cancer undergoing gastrectomy., International Journal of Clinical Oncology, Vol.27, No.9, 1421-1427, 2022. (Summary) The frailty was associated with the worse surgical outcomes and poor prognosis in several cancers. Therefore, we aimed to identify the usefulness of nutrition and exercise intervention (NEI) in frailty patients with GC. We analyzed 58 frailty patients with GC who underwent radical surgery. Among these, 15 patients were performed NEI by nutritional and rehabilitation support team. We compared the surgical outcomes between NEI and non-NEI groups with frailty patients and evaluated the nutrition and rehabilitation markers in pre- and post-NEI groups. The postoperative complication of NEI groups was 6.7% and less than that of non-NEI groups (p = 0.08). The mean postoperative hospital stay of NEI groups was 13.0 ± 1.0 days for NEI groups and significantly shorter than that of non-NEI groups (p = 0.03). The NLR was 4.3 ± 0.6 for pre-NEI and significantly improved by NEI between pre- and post-NEI (p = 0.03). We identified the clinical importance of NEI for improving the surgical outcomes in frailty patients with GC. Our findings highlight the potential clinical impact of optimizing treatment strategies to select and manage the frailty patients. (Keyword) Exercise Therapy / Frailty / Gastrectomy / Humans / Postoperative Complications / Preoperative Care / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02202-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35771395 ● Search Scopus @ Elsevier (PMID): 35771395 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-022-02202-z (DOI: 10.1007/s10147-022-02202-z, PubMed: 35771395)
51.	Yixiu Wang, Yuwei Xie, Bingzi Dong, Weijie Xue, Shuhai Chen, Mitsuo Shimada, Hao Zou, Yujie Feng, Kai Ma, Qian Dong, Jingyu Cao and Chengzhan Zhu : The TTYH3/MK5 Positive Feedback Loop regulates Tumor Progression via GSK3-β/β-catenin signaling in HCC., International Journal of Biological Sciences, Vol.18, No.10, 4053-4070, 2022. (Summary) Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, and identification of novel targets is necessary for its diagnosis and treatment. This study aimed to investigate the biological function and clinical significance of tweety homolog 3 (TTYH3) in HCC. TTYH3 overexpression promoted cell proliferation, migration, and invasion and inhibited HCCM3 and Hep3B cell apoptosis. TTYH3 promoted tumor formation and metastasis . TTYH3 upregulated calcium influx and intracellular chloride concentration, thereby promoting cellular migration and regulating epithelial-mesenchymal transition-related protein expression. The interaction between TTYH3 and MK5 was identified through co-immunoprecipitation assays and protein docking. TTYH3 promoted the expression of MK5, which then activated the GSK3β/β-catenin signaling pathway. knockdown attenuated the activation of GSK3β/β-catenin signaling by TTYH3. TTYH3 expression was regulated in a positive feedback manner. In clinical HCC samples, TTYH3 was upregulated in the HCC tissues compared to nontumor tissues. Furthermore, high TTYH3 expression was significantly correlated with poor patient survival. The CpG islands were hypomethylated in the promoter region of in HCC tissues. In conclusion, we identified TTYH3 regulates tumor development and progression via MK5/GSK3-β/β-catenin signaling in HCC and promotes itself expression in a positive feedback loop. (Keyword) Carcinoma, Hepatocellular / Catenins / Cell Line, Tumor / Cell Movement / Cell Proliferation / Chloride Channels / Epithelial-Mesenchymal Transition / Feedback / Gene Expression Regulation, Neoplastic / Glycogen Synthase Kinase 3 / Glycogen Synthase Kinase 3 beta / Humans / Intracellular Signaling Peptides and Proteins / Liver Neoplasms / Protein Serine-Threonine Kinases / Wnt Signaling Pathway / beta Catenin (Tokushima University Institutional Repository) ● Metadata: 118833 (Link to Publication Site) ● Publication site (DOI): 10.7150/ijbs.73009 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35844789 ● Search Scopus @ Elsevier (PMID): 35844789 ● Search Scopus @ Elsevier (DOI): 10.7150/ijbs.73009 (Tokushima University Institutional Repository: 118833, DOI: 10.7150/ijbs.73009, PubMed: 35844789)
52.	Hideya Kashihara, Kouzou Yoshikawa, Mitsuo Shimada, Munehide Matsuhisa and Sumiko Yoshida : クリニカルカンファレンスから(第23回) 徳島大学病院の症例高度肥満による続発性無月経に対し腹腔鏡下スリーブ状胃切除術を施行し妊娠・出産に至った一例, 肥満症治療学展望, Vol.9, No.3, 34-35, 2022. (Keyword) Dydrogesterone(治療的利用) 術後期経口投与腹腔鏡法無月経(病因,診断,薬物療法) 胃形成術出産 *肥満症(合併症,診断,外科的療法) ヒト妊娠成人(19∼44) 女
53.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : A Hepatectomy Based on a Hybrid Concept of Portal Perfusion of Anterior Segment and Venous Drainage Area of Superior Right Hepatic Vein., The American Surgeon, 3134820984872, 2022. (Summary) Right hepatic vein sometimes could not be a reliable landmark between the anterior and posterior segment. The aim of this study was to clarify the portal perfusion area of the anterior segment and to propose a less invasive hepatectomy based on both the portal perfusion and the hepatic venous drainage. Three-dimensional computerized tomography images of 66 patients were constructed. A case, in which the perfusion area of the anterior segment crossed over superior right hepatic vein (SRHV), was called as SRHV-inclusion. It was defined as inclusion of more than 1 cm of the proximal site of SRHV surrounded by the portal perfusion area of the anterior segment. SRHV-inclusion was observed in 26%. The cases with large inferior right hepatic vein (IRHV) had more frequent SRHV-inclusion (47%). The elderly patient with hepatic disorder, who had hepatocellular carcinoma near the root of the SRHV, underwent a less invasive hepatectomy (anterior segment + SRHV drainage area) resulting in the preservation of the IRHV. The perfusion area of the anterior segment crossed over SRHV in one fourth of patients in the study. Our proposed less invasive hepatectomy based on a hybrid concept might be an alternative operative procedure other than right hepatectomy. (Link to Publication Site) ● Publication site (DOI): 10.1177/0003134820984872 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33382339 ● Search Scopus @ Elsevier (PMID): 33382339 ● Search Scopus @ Elsevier (DOI): 10.1177/0003134820984872 (DOI: 10.1177/0003134820984872, PubMed: 33382339)
54.	Shuhai Chen, Masaaki Nishi, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Akiko Nakamoto, Tohru Sakai and Mitsuo Shimada : Polymethoxylated flavone sudachitin is a safe anticancer adjuvant that targets glycolysis in cancer-associated fibroblasts., Oncology Letters, Vol.24, No.1, 236, 2022. (Summary) Sudachitin is a polymethoxylated flavone found in the peel of , a unique specialty citrus fruit in Tokushima Prefecture, Japan. Previous reports have demonstrated that sudachitin has anti-inflammatory and metabolic regulatory activities. However, to the best of our knowledge, no studies have explored whether sudachitin can act as an antitumor therapeutic agent by regulating metabolic functions in the tumor microenvironment. In the present study, cell proliferation and cytotoxicity assays were used to determine whether sudachitin inhibited the growth of liver cancer and pancreatic carcinoma, cholangiocarcinoma and colorectal cancer cells and to compare its toxicity against normal fibroblasts and induced cancer-associated fibroblasts (CAFs). Using lactate assays and reverse transcription-quantitative PCR, the effects of sudachitin on glycolysis in CAFs were investigated. The effects of CAFs on malignant tumor cells were evaluated using cell proliferation, wound healing and invasion assays. As result, sudachitin inhibited various types of tumor cells with different half-maximal inhibitory concentrations. Treatment with 50 µM sudachitin for 48 h suppressed tumor and CAFs proliferation but was not cytotoxic against normal fibroblasts. This dose also inhibited glycolysis in CAFs and, thus, diminished their pro-tumorigenic activities. Overall, the present study revealed that sudachitin has promise as a safe and widely available natural antitumor adjuvant. (Tokushima University Institutional Repository) ● Metadata: 118072 (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13356 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35720469 ● Search Scopus @ Elsevier (PMID): 35720469 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13356 (Tokushima University Institutional Repository: 118072, DOI: 10.3892/ol.2022.13356, PubMed: 35720469)
55.	Yu Saitou, Maki Sugimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Intraoperative support with three-dimensional holographic cholangiography in hepatobiliary surgery., Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie, Vol.407, No.3, 1285-1289, 2022. (Summary) This study was performed to investigate the potential of intraoperative three-dimensional (3D) holographic cholangiography, which provides a computer graphics model of the biliary tract, with mixed reality techniques. Two patients with intraductal papillary neoplasm of the bile duct were enrolled in the study. Intraoperative 3D cholangiography was performed in a hybrid operating room. Three-dimensional polygon data using the acquired cholangiography data were installed into a head mount display (HoloLens; Microsoft Corporation, Redmond, WA, USA). Upon completion of intraoperative 3D cholangiography, a hologram was immediately and successfully made in the operating room using the acquired cholangiography data, and several surgeons wearing the HoloLens succeeded in sharing the same hologram. Compared with usual two-dimensional cholangiography, this 3D holographic cholangiography technique contributed to more accurate reappearance of the bile ducts, especially the B1 origination site, and moving the hologram from the respective operators' angles by means of easy gesture-handling without any monitors. Intraoperative 3D holographic cholangiography might be a new next-generation operation-support tool in terms of immediacy, accurate anatomical reappearance, and ease of handling. (Keyword) Bile Duct Neoplasms / Bile Ducts / Biliary Tract / Cholangiography / Humans (Link to Publication Site) ● Publication site (DOI): 10.1007/s00423-021-02336-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34557939 ● Search Scopus @ Elsevier (PMID): 34557939 ● Search Scopus @ Elsevier (DOI): 10.1007/s00423-021-02336-0 (DOI: 10.1007/s00423-021-02336-0, PubMed: 34557939)
56.	Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Chiharu Nakasu and Mitsuo Shimada : Pincer Approach to Gastrosplenic Ligament in Robotic Total Gastrectomy for Gastric Cancer., Journal of Gastrointestinal Surgery, Vol.26, No.7, 1552-1555, 2022. (Keyword) Gastrectomy / Humans / Laparoscopy / Ligaments / Retrospective Studies / Robotic Surgical Procedures / Robotics / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1007/s11605-022-05356-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35578006 ● Search Scopus @ Elsevier (PMID): 35578006 ● Search Scopus @ Elsevier (DOI): 10.1007/s11605-022-05356-3 (DOI: 10.1007/s11605-022-05356-3, PubMed: 35578006)
57.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Syoko Yamashita and Yosuke Iwakawa : Vascular variations encountered during laparoscopic surgery for transverse colon, splenic flexure, and descending colon cancer: a retrospective cohort study., BMC Surgery, Vol.22, No.1, 170, 2022. (Summary) Laparoscopic surgery for cancer located in the transverse colon or splenic flexure is difficult because of vascular variability in this region and adjacent vital organs such as the pancreas, spleen, and duodenum. This retrospective cohort study involved 51 patients who underwent laparoscopic surgery for colon cancer at Tokushima University Hospital from July 2015 to December 2020. Variations of the middle colic artery (MCA), left colic artery (LCA), middle colic vein (MCV), and first jejunal vein (FJV) and short-term outcomes of laparoscopic surgery in patients with each vascular variation were evaluated. Variations of the MCA, LCA, MCV, and FJV were classified into four, three, five, and three patterns, respectively. The short-term outcomes of laparoscopic surgery for transverse colon cancer in patients with MCA variations and those with FJV variations were evaluated, and no significant difference was found in the operation time, blood loss, postoperative complication rate, time from surgery to start of dietary intake, or time from surgery to discharge among the different variations. Additionally, no significant differences were found in the short-term outcomes of laparoscopic surgery for descending colon cancer in patients with LCA variations. Preoperative assessment of vascular variations may contribute to the stability of short-term outcomes of laparoscopic surgery for transverse colon, splenic flexure, and descending colon cancer. (Keyword) Colectomy / Colon, Descending / Colon, Transverse / Colonic Neoplasms / Humans / Laparoscopy / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 118005 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01603-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35538458 ● Search Scopus @ Elsevier (PMID): 35538458 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01603-1 (Tokushima University Institutional Repository: 118005, DOI: 10.1186/s12893-022-01603-1, PubMed: 35538458)
58.	Tetsuya Ikemoto and Mitsuo Shimada : 【1型糖尿病-診療と研究の最前線】治療研究膵β細胞再生医療の可能性脂肪由来幹細胞の有用性, Journal of Clinical and Experimental Medicine, Vol.281, No.6, 729-734, 2022. (Summary) 1型糖尿病治療としての再生医療はいまだ研究段階の域をでていないが，本領域は急速に発展しており，さまざまなコンセプトのもとで臨床応用も目前に迫っている．本稿では，再生医療における幹細胞の役割，分類(分化能力，その起源)を明らかにし，現在，最も臨床応用が近いと考えられる体性幹細胞(なかでも脂肪由来幹細胞)における筆者らの研究成果と，医師主導治験確立に向けた取り組みを示すとともに，すでに行われている1型糖尿病に対する幹細胞を用いた臨床研究など(幹細胞を直接投与するもの，幹細胞からβ細胞様細胞へ分化誘導させるもの)をレビューし，将来，再生医療がどのように1型糖尿病治療にコミットメントしていくかの展望を示す．(著者抄録) (Keyword) 脂肪組織糖尿病-1型(治療) 臨床試験インスリン分泌細胞再生医学間葉系幹細胞移植 *間葉系幹細胞ヒトマウス動物
59.	Toshiaki Yoshimoto, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Shohei Okikawa and Kouzou Yoshikawa : Blue light irradiation inhibits the growth of colon cancer and activation of cancer-associated fibroblasts., Oncology Reports, Vol.47, No.5, 2022. (Summary) Irradiation with a specific wavelength of light using light-emitting diodes (LEDs) has various effects on cells and organisms. Recently, the antitumor effects of visible blue light on tumor cells were reported; however, the mechanism and effects on the tumor microenvironment remain unclear. Human colon cancer cells (HCT-116) were injected into the rectal wall of nude mice. Tumors were irradiated with a 465-nm LED light at 30 mW/cm for 30 min. Tumor volumes and the expression levels of opsin 3 (Opn3), autophagy-related factors, cancer-associated fibroblast (CAF) markers, and programmed cell death 1-ligand (PD-L1) were measured. Additionally, human intestinal fibroblasts were cultured in HCT116-conditioned medium (CM) to prepare CAFs. CAFs were divided into an LED group and a control group, and the effect of the LED light on CAF activation in colon cancer cells was examined. Irradiation with blue LED light suppressed tumor growth; Opn3 expression was localized to the cell membrane in the LED group. Irradiated tumors exhibited increased autophagy-related gene expression. Furthermore, in the LED group, TGF-β and α-SMA expression levels in the fibroblasts were decreased. Regarding CAFs, α-SMA and IL-6 expression levels were decreased in the LED group. HCT-116 cells cultured in CAF-CM with LED irradiation showed no enhanced migration or invasion. In the HCT-116 cells cultured in CM of CAFs irradiated with LED, the relative increase in PD-L1 expression was lower than that noted in the CAF-CM without LED irradiation. Blue LED light may have a direct antitumor effect on colon cancer and also an inhibitory effect on CAFs. (Keyword) Animals / B7-H1 Antigen / Cancer-Associated Fibroblasts / Cell Movement / Cell Proliferation / Colonic Neoplasms / HCT116 Cells / Humans / Light / Mice / Mice, Nude / Rod Opsins / Tumor Microenvironment (Tokushima University Institutional Repository) ● Metadata: 118073 (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2022.8315 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35417035 ● Search Scopus @ Elsevier (PMID): 35417035 ● Search Scopus @ Elsevier (DOI): 10.3892/or.2022.8315 (Tokushima University Institutional Repository: 118073, DOI: 10.3892/or.2022.8315, PubMed: 35417035)
60.	Kazunori Tokuda, Tetsuya Ikemoto, Shoko Yamashita, Katsuki Miyazaki, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice., Scientific Reports, Vol.12, No.1, 5852, 2022. (Summary) Insulin-producing cells (IPCs) generated by our established protocol have reached the non-clinical 'proof of concept' stage. Our strategy for their clinical application is the autotransplantation of IPCs into patients with type 1 diabetes mellitus (T1DM). In this context, the autoimmunity that characterized T1DM is important, rather than allorejection. We aimed to determine how these IPCs respond to T1DM autoimmunity. IPCs were generated from the subcutaneous fat tissue of non-obese diabetic (NOD) mice using our protocol. IPCs derived from NOD mice were transplanted under the kidney capsules of NOD mice at the onset of diabetes and the subsequent changes in blood glucose concentration were characterized. Blood glucose decreased within 30 days of transplantation, but increased again after 40-60 days in three of four recipient NOD mice. In tissue samples, the numbers of CD4 and CD8 T cells were significantly higher 60 days after transplantation than 30 days after transplantation. In conclusion, IPCs significantly ameliorate the diabetes of mice in the short term, but are damaged by autoimmunity in the longer term, as evidenced by local T cells accumulation. This study provides new insights into potential stem cell therapies for T1DM. (Keyword) Animals / Autoimmunity / Blood Glucose / CD8-Positive T-Lymphocytes / Diabetes Mellitus, Experimental / Diabetes Mellitus, Type 1 / Humans / Insulin / Insulin-Secreting Cells / Mice / Mice, Inbred NOD / Stem Cells (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-022-09838-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35393479 ● Search Scopus @ Elsevier (PMID): 35393479 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-09838-x (DOI: 10.1038/s41598-022-09838-x, PubMed: 35393479)
61.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Syoko Yamashita and Yosuke Iwakawa : Risk factors for postoperative ileus after diverting loop ileostomy closure., BMC Surgery, Vol.22, No.1, 131, 2022. (Summary) Postoperative ileus is one of the most common complications after diverting loop ileostomy closure. Some reports have investigated the risk factors for postoperative complications or ileus after ileostomy closure; however, these studies did not evaluate the index surgery sufficiently. In this study, we evaluated the risk factors, including the details of the index surgery, for ileus after diverting ileostomy closure. This was a retrospective study of patients who underwent ileostomy closure following index surgery for rectal cancer. Patients who developed postoperative ileus [POI (+)] and patients who did not [POI (-)] after ileostomy closure were compared. Sixty-eight patients were evaluated and were divided into two groups: POI (+) (n = 11) and POI (-) (n = 57), and the groups were compared. There were no significant differences in the details of the index surgery, operative procedure, transanal total mesorectal excision, lateral lymph node dissection, operating time, or blood loss. The incidence of Clavien-Dindo grade ≥ III complications and adjuvant chemotherapy after index surgery were significantly higher in the POI (+) group. The incidence of Clavien-Dindo grade ≥ III complications and adjuvant chemotherapy after index surgery may increase the risk of postoperative ileus after ileostomy closure. (Keyword) Humans / Ileostomy / Ileus / Postoperative Complications / Rectal Neoplasms / Retrospective Studies / Risk Factors (Tokushima University Institutional Repository) ● Metadata: 118004 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01583-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35392877 ● Search Scopus @ Elsevier (PMID): 35392877 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01583-2 (Tokushima University Institutional Repository: 118004, DOI: 10.1186/s12893-022-01583-2, PubMed: 35392877)
62.	Takuya Tokunaga, Hideya Kashihara and Mitsuo Shimada : 【大腸外科医のための骨盤解剖学】直腸癌手術に必要な画像シミュレーション, Operation, Vol.76, No.5, 709-714, 2022. (Keyword) Fluorouracil(治療的利用) ホログラフィー Leucovorin(治療的利用) 腫瘍多剤併用療法腫瘍侵入性前立腺腫瘍(X線診断,外科的療法,薬物療法) 前立腺切除 X線CT *直腸腫瘍(X線診断,外科的療法,薬物療法) 腹腔鏡法リンパ節切除コンピュータシミュレーション三次元イメージングネオアジュバント療法 Irinotecan(治療的利用) Oxaliplatin(治療的利用) コンピュータ支援手術直腸切断術ロボット手術低位前方切除 FOLFOXIRI Protocol ヒト男 (Link to Publication Site) ● Publication site (DOI): 10.18888/op.0000002751 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.18888/op.0000002751 (DOI: 10.18888/op.0000002751)
63.	Masaaki Nishi, Mitsuo Shimada, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yuuma Wada : 【外科代謝栄養と東洋医学:漢方による周術期管理へのサポート】大建中湯による周術期管理のサポート, The Japanese Journal of Surgical Metabolism and Nutrition, Vol.56, No.2, 59-61, 2022. (Summary) 近年では漢方の分子生物学的な作用機序の解明が進み，臨床においても質の高いランダム化比較試験により漢方の有用性が明らかになってきた．現在では大建中湯を含む多くの漢方製剤が広く臨床の現場で用いられている．大建中湯は乾姜，人参，山椒の3つの生薬に膠飴を加えた漢方で，外科領域においては癒着性イレウスや麻痺性イレウス，過敏性腸症候群，クローン病などを適応とし，消化管運動促進作用，腸管血流増加作用，抗炎症作用などが報告されている．近年では，食道・胃・大腸・肝臓・膵臓・肝移植外科それぞれの領域でランダム化試験が実施され，大建中湯の周術期管理における有効性が証明されている．また分子生物学的なメカニズムについても解明がすすみ，現在，大建中湯は消化管外科・肝胆膵外科の分野を問わず消化器外科全般における周術期管理のkey drugとして位置付けられている．本稿では消化器外科領域における大建中湯による周術期管理のサポートについて概説する．(著者抄録) (Keyword) 消化管運動消化器外科バクテリアルトランスロケーション周術期管理 *大建中湯(薬理学,治療的利用) 伊東細胞腫瘍微小環境ヒト (Link to Publication Site) ● Publication site (DOI): 10.11638/jssmn.56.2_59 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11638/jssmn.56.2_59 (DOI: 10.11638/jssmn.56.2_59)
64.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Yosuke Iwakawa : The correlation of immunoscore and frailty in colorectal cancer., International Journal of Clinical Oncology, Vol.27, No.3, 528-537, 2022. (Summary) The Immunoscore is a useful prognostic and predictive factor for colorectal cancer. Frailty predicts overall and recurrence-free survival following resection of colorectal cancer, and the immunosuppressive state of frailty might affect tumor progression. This study investigated the relationship between the Immunoscore and frailty in colorectal cancer. This retrospective study included patients who underwent radical surgery for stage II and III colorectal cancer (n = 108). Patients were divided into frail (n = 11) and non-frail (n = 97) groups, and low (IS0-2) (n = 70) and high (IS3-4) Immunoscore groups (n = 38), for comparison. American Society of Anesthesiologists physical status was higher, tumor diameter was larger, number of well-differentiated tumors was higher, albumin was lower, 5-year overall survival (OS) was lower (frail group: 50.0%, non-frail group: 90.5%, p < 0.001) and 5-year disease-free survival (DFS) was lower (frail group: 36.4%, non-frail group: 75.2%, p = 0.024) in the frail than in the non-frail group. Left colon cancer was more, 5-year OS was lower (IS0-2 group: 82.0%, IS3-4 group: 96.7%, p = 0.040) and 5-year DFS was lower (IS0-2 group: 66.3%, IS3-4 group: 83.3%, p = 0.043) in the IS0-2 than in the IS3-4 group. The Immunoscore was lower in the frail than in the non-frail group. Immunoscore and frailty are prognostic and predictive factors in colorectal cancer, and they are correlated with each other. The immunosuppressive state from frailty might affect this correlation. (Keyword) Colonic Neoplasms / Colorectal Neoplasms / Disease-Free Survival / Frailty / Humans / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-021-02096-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34846645 ● Search Scopus @ Elsevier (PMID): 34846645 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-02096-3 (DOI: 10.1007/s10147-021-02096-3, PubMed: 34846645)
65.	Shohei Okikawa, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Hiroki Teraoku, Katsuki Miyazaki, Shoko Yamashita, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer., Oncology Reports, Vol.47, No.4, 2022. (Summary) Tumor-associated macrophage (TAMs) are paramount for tumor progression and immune tolerance in the tumor microenvironment of various types of cancer, including liver cancer. The aim of the present study was to investigate the effect of vascular endothelial growth factor (VEGF) inhibition on TAM polarization and function during their interactions with macrophages and liver cancer cells. TAMs were induced by culturing M0 macrophages with cancer cell-conditioned medium. TAMs cultured with cancer cell-conditioned medium and vascular endothelial growth factor (VEGF) inhibitor were defined as modified TAMs, and the expression levels of TAM-associated markers and VEGF receptor 2 were evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of TAMs and modified TAMs on cancer cell proliferation and migration were investigated using conditioned medium. Programmed death-ligand 1 (PD-L1) mRNA expression in modified TAMs and cancer cells cultured in modified TAM-conditioned medium (TAM-CM) for 48 h was examined using RT-qPCR. In order to investigate signaling pathways in macrophages, western blot analysis was performed. CD163 and CD206 and M2 macrophage marker expression was upregulated in TAMs and modified TAMs. Modified TAM-CM exhibited a decreased ability to promote cancer cell proliferation and migration in comparison with the use of TAM-CM. The VEGF concentration was significantly higher in the TAMs than in M0 macrophages; however, the modified TAMs displayed a significantly lower VEGF secretion than TAMs. PD-L1 expression was decreased in modified TAMs as compared with TAMs. Western blot analysis revealed that the Akt/mTOR signaling pathway was significantly suppressed in the modified TAMs compared with TAMs. It was observed that TAMs cultured in a VEGF-depleted environment displayed lower secretion levels of cytokines involved in tumor progression and a decreased immune tolerance-inducing ability. On the whole, the results of the present study suggested that VEGF inhibition in TAMs may be a potential therapeutic target for liver cancer. (Keyword) Cell Line, Tumor / Humans / Liver Neoplasms / Signal Transduction / Tumor Microenvironment / Tumor-Associated Macrophages / Vascular Endothelial Growth Factor A (Tokushima University Institutional Repository) ● Metadata: 118964 (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2022.8282 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35169858 ● Search Scopus @ Elsevier (PMID): 35169858 ● Search Scopus @ Elsevier (DOI): 10.3892/or.2022.8282 (Tokushima University Institutional Repository: 118964, DOI: 10.3892/or.2022.8282, PubMed: 35169858)
66.	Hiroki Mori, Kazunori Masahata, Satoshi Umeda, Yuji Morine, Hiroki Ishibashi, Noriaki Usui and Mitsuo Shimada : Risk of carcinogenesis in the biliary epithelium of children with congenital biliary dilatation through epigenetic and genetic regulation., Surgery Today, Vol.52, No.2, 215-223, 2022. (Summary) Congenital biliary dilatation (CBD), defined as pancreaticobiliary maljunction (PBM) with biliary dilatation, is a high risk factor for biliary tract cancer (BTC). KRAS and p53 mutations reportedly affect this process, but the mechanisms are unclear, as is the likelihood of BTC later in life in children with CBD. We investigated potential carcinogenetic pathways in children with CBD compared with adults. The subjects of this study were nine children with CBD and 13 adults with PBM (10 dilated, 3 non-dilated) without BTC who underwent extrahepatic bile duct resections, as well as four control patients who underwent pancreaticoduodenectomy for non-biliary cancer. We evaluated expressions of Ki-67, KRAS, p53, histone deacetylase (HDAC) and activation-induced cytidine deaminase (AID) in the biliary tract epithelium immunohistochemically. The Ki-67 labeling index (LI) and expressions of KRAS, p53, HDAC, and AID in the gallbladder epithelium were significantly higher or tended to be higher in both the children with CBD and the adults with PBM than in the controls. BTC may develop later in children with CBD and in adults with PBM, via HDAC and AID expression and through epigenetic and genetic regulation. (Keyword) Adult / Aged / Biliary Tract Neoplasms / Child / Child, Preschool / Choledochal Cyst / Epithelium / Female / Gallbladder / Gene Expression Regulation, Neoplastic / Histone Deacetylases / Humans / Infant / Ki-67 Antigen / Male / Middle Aged / Pancreaticobiliary Maljunction / Proto-Oncogene Proteins p21(ras) / Risk / Tumor Suppressor Protein p53 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-021-02325-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34132887 ● Search Scopus @ Elsevier (PMID): 34132887 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-021-02325-2 (DOI: 10.1007/s00595-021-02325-2, PubMed: 34132887)
67.	Sanae Hayashi, Masanori Isogawa, Keigo Kawashima, Kyoko Ito, Natthaya Chuaypen, Yuji Morine, Mitsuo Shimada, Nobuyo Higashi-Kuwata, Takehisa Watanabe, Pisit Tangkijvanich, Hiroaki Mitsuya and Yasuhito Tanaka : Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application., Scientific Reports, Vol.12, No.1, 2133, 2022. (Summary) The persistence of covalently closed circular DNA (cccDNA) poses a major obstacle to curing chronic hepatitis B (CHB). Here, we used droplet digital PCR (ddPCR) for cccDNA quantitation. The cccDNA-specific ddPCR showed high accuracy with the dynamic range of cccDNA detection from 10 to 10 copies/assay. The ddPCR had higher sensitivity, specificity and precisely than qPCR. The results of ddPCR correlated closely with serum HB core-related antigen and HB surface antigen (HBsAg) in 24 HBV-infected human-liver-chimeric mice (PXB-mice). We demonstrated that in 2 PXB-mice after entecavir treatment, the total cccDNA content did not change during liver repopulation, although the cccDNA content per hepatocyte was reduced after the treatment. In the 6 patients with HBV-related hepatocellular carcinoma, ddPCR detected cccDNA in both tumor and non-tumor tissues. In 13 HBeAg-negative CHB patients with pegylated interferon alpha-2a, cccDNA contents from paired biopsies were more significantly reduced in virological response (VR) than in non-VR at week 48 (p = 0.0051). Interestingly, cccDNA levels were the lowest in VR with HBsAg clearance but remained detectable after the treatment. Collectively, ddPCR revealed that cccDNA content is stable during hepatocyte proliferation and persists at quantifiable levels, even after serum HBsAg clearance. (Keyword) Animals / Carcinoma, Hepatocellular / DNA, Circular / DNA, Viral / Hepatitis B / Hepatitis B virus / Humans / Interferon-alpha / Liver / Mice, Transgenic / Polyethylene Glycols / Polymerase Chain Reaction / Recombinant Proteins (Tokushima University Institutional Repository) ● Metadata: 117386 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-022-05882-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35136096 ● Search Scopus @ Elsevier (PMID): 35136096 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-05882-9 (Tokushima University Institutional Repository: 117386, DOI: 10.1038/s41598-022-05882-9, PubMed: 35136096)
68.	Noriko Yokota, Hiroki Ishibashi, Kenichi Suga, Hiroki Mori, Akiko Kitamura, Ryuji Nakagawa and Mitsuo Shimada : A case of Gross E esophageal atresia discovered following a unique clinical course., The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 141-144, 2022. (Summary) The patient was a 15 months-old boy who had been diagnosed CHARGE syndrome, which is a multiple congenital anomaly syndrome caused by mutations in the CHD7 gene. Mechanical ventilation management was initiated 2 hours after birth for dysphagia and respiratory failure, and tracheotomy was performed 3 months after birth for dysphagia and failed extubation. He was repeatedly hospitalized due to pneuomoniae. Approximately 1 year after birth, the boy had two consecutive episodes of sudden ventilatory insufficiency while replacing the tracheotomy cannula. A bronchoscopic examination under general anesthesia revealed a tracheoesophageal fistula directly below the tracheostomy. The patient was diagnosed with Gross E esophageal atresia, and we speculated that the cannula migrated to the esophagus via the fistula during tracheostomy cannula replacement. Gross E esophageal atresia is a rare disease. Its diagnosis is often delayed, and it is discovered by recurrent pneumonia in many cases. A tracheoesophageal fistula may also be found in children with deformities of the respiratory system. Furthermore, tracheoesophageal fistulae are often found in the neck. Therefore, when sudden ventilatory insufficiency occurs in a child with a tracheostomy after replacing the tracheostomy cannula, caution must be exercised since the cannula may have migrated to the esophagus via a fistula. J. Med. Invest. 69 : 141-144, February, 2022. (Keyword) Abnormalities, Multiple / Child / Deglutition Disorders / Esophageal Atresia / Humans / Infant / Male / Tracheoesophageal Fistula (Tokushima University Institutional Repository) ● Metadata: 117025 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.141 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466136 ● Search Scopus @ Elsevier (PMID): 35466136 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.141 (Tokushima University Institutional Repository: 117025, DOI: 10.2152/jmi.69.141, PubMed: 35466136)
69.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Mori and Ajay Goel : A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma., British Journal of Cancer, Vol.126, No.8, 1196-1204, 2022. (Summary) The prognosis in patients with intrahepatic cholangiocarcinoma (ICC) is generally poor. To improve treatment selection, we sought to identify microRNA (miRNA) signature associated with survival outcomes in ICC. We first analysed the miRNA expression profiles of primary ICC from two public datasets to identify a miRNA panel to detect patients for short-term survival. We then analysed 309 specimens, including 241 FFPE samples from two clinical cohorts (training: n = 177; validation: n = 64) and matched plasma samples (n = 68), and developed a risk-stratification model incorporating the panel and CA 19-9 levels to predict survival outcomes in ICC. We identified a 7-miRNA panel that robustly classified patients with poor outcomes in the discovery cohorts (AUC = 0.80 and 0.88, respectively). We subsequently trained this miRNA panel in a clinical cohort (AUC = 0.83) and evaluated its performance in an independent validation cohort (AUC = 0.82) and plasma samples from the additional validation cohort (AUC = 0.78). Patients in both clinical cohorts who were classified as high-risk had significantly worse prognosis (p < 0.01). The risk-stratification model demonstrated superior performance compared to models (AUC = 0.85). We established a novel miRNA signature that could robustly predict survival outcomes in resected tissues and liquid biopsies to improve the clinical management of patients with ICC. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Humans / MicroRNAs / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1038/s41416-022-01710-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35079106 ● Search Scopus @ Elsevier (PMID): 35079106 ● Search Scopus @ Elsevier (DOI): 10.1038/s41416-022-01710-z (DOI: 10.1038/s41416-022-01710-z, PubMed: 35079106)
70.	Shuhai Chen, Masaaki Nishi, Yuji Morine, Mitsuo Shimada, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Shinichiro Yamada and Yuma Wada : Epigallocatechin 3allate hinders metabolic coupling to suppress colorectal cancer malignancy through targeting aerobic glycolysis in cancerssociated fibroblasts., International Journal of Oncology, Vol.60, No.2, 2022. (Summary) In recent times, researchers working on tumor metabolism have paid increasing attention to the tumor microenvironment. Emerging evidence has confirmed that epigenetic modifications of cancerssociated fibroblasts (CAFs) alters the characteristics of glucose metabolism to achieve a symbiotic relationship with the cancer cells. Epigallocatechin 3allate (EGCG) exerts antiumor effects via a variety of mechanisms, although the underlying mechanism that accounts for the effects of EGCG on glucose metabolic alterations of CAFs have yet to be elucidated. In the present study, through coulture with colorectal cancer (CRC) cells, human intestinal fibroblasts were transformed into CAFs, and exhibited enhanced aerobic glycolysis. Induced CAFs were able to enhance the proliferation, migration and invasion of CRC cells . EGCG treatment led to direct inhibition of the proliferation and migration of CRC cells; furthermore, EGCG treatment of CAFs suppressed their tumorromoting capabilities by inhibiting their glycolytic activity. Blocking the lactic acid efflux of CAFs with a monocarboxylate transporter 4 (MCT4) inhibitor or through silencing MCT4 could also suppress their tumorromoting capabilities, indicating that lactate fulfills an important role in the metabolic coupling that occurs between CAFs and cancer cells. Taken together, the results of the present study showed that EGCG targeting of the metabolism of tumor stromal cells provided a safe and effective strategy of antiancer therapy. (Keyword) Cancer-Associated Fibroblasts / Catechin / Colorectal Neoplasms / Humans / Neoplasms / Oxidative Coupling / Warburg Effect, Oncologic (Tokushima University Institutional Repository) ● Metadata: 117318 (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2022.5309 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35029285 ● Search Scopus @ Elsevier (PMID): 35029285 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2022.5309 (Tokushima University Institutional Repository: 117318, DOI: 10.3892/ijo.2022.5309, PubMed: 35029285)
71.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Mori and Ajay Goel : A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases., European Journal of Cancer, Vol.163, 66-76, 2022. (Summary) Cancer recurrence is an important predictor of survival outcomes in patients with colorectal cancer-associated liver metastasis (CRLM), who undergo radical hepatectomy. Therefore, identification of patients with the greatest risk of recurrence is critical for developing a precision oncology strategy that might include frequent surveillance (in low-risk patients) or a more aggressive treatment approach (in high-risk patients). We performed genome-wide expression profiling, to identify and develop a transcriptomic signature for predicting recurrence in patients with CRLM. We analysed a total of 383 patients with CRLM, including 63 patients from a publicly available data set (the NCBI's Gene Expression Omnibus with accession number GSE81423). and 320 patients from whom surgical specimens were collected for independent training (n = 169) and validation (n = 151) of identified biomarkers. Using Cox's proportional hazard regression analysis, we evaluated the clinical significance of the identified gene signature by comparing its performance with several key clinical factors. We identified a six-gene panel that robustly categorised patients with recurrence in the discovery (area under the curve (AUC) = 0.90). We showed that the panel was a significant predictor of recurrence in the clinical training (AUC = 0.83) and validation cohorts (AUC = 0.81). By combining our panel with key clinical factors, we established a risk-stratification model that emerged as an independent predictor of recurrence (AUC = 0.85; univariate: hazard ratio (HR) = 4.34, 95% confidence interval (CI) = 2.71-6.93, P < 0.001; multivariate: HR = 3.40, 95% CI = 1.76-6.56, P < 0.001). The stratification model revealed recurrence prediction in 89% of high-risk group and non-recurrence in 62% of low-risk group. We established a novel transcriptomic signature that robustly predicts recurrence, which has significant implications for the management of patients with CRLM. (Keyword) Biomarkers, Tumor / Colorectal Neoplasms / Gene Expression Regulation, Neoplastic / Hepatectomy / Humans / Liver Neoplasms / Neoplasm Recurrence, Local / Precision Medicine / Prognosis / Transcriptome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejca.2021.12.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35042069 ● Search Scopus @ Elsevier (PMID): 35042069 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejca.2021.12.013 (DOI: 10.1016/j.ejca.2021.12.013, PubMed: 35042069)
72.	Takeshi Matsui, Susumu Hamada-Tsutsumi, Yutaka Naito, Masanori Nojima, Etsuko Iio, Akihiro Tamori, Shoji Kubo, Tatsuya Ide, Yasuteru Kondo, Yuichiro Eguchi, Atsumasa Komori, Yuji Morine, Mitsuo Shimada, Tohru Utsunomiya, Ken Shirabe, Koichi Kimura, Yoichi Hiasa, Natthaya Chuaypen, Pisit Tangkijvanich, Aya Naiki-Ito, Satoru Takahashi, Takahiro Ochiya and Yasuhito Tanaka : Identification of microRNA-96-5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma., Hepatology Research, Vol.52, No.1, 93-104, 2022. (Summary) The microRNA (miR) clusters miR-183/96/182 and miR-217/216a/216b are significantly upregulated in nonviral hepatocellular carcinoma (NBNC-HCC). Here, we investigate the impact of each member of these clusters on the clinical outcome of NBNC-HCC and analyze the antitumor effects of miR-96-5p. The association between recurrence-free survival of 111 NBNC-HCC patients and the levels of miR-183-5p, miR-96-5p, miR-182-5p, miR-217-5p, miR-216a-5p, and miR-216b-5p in tumor and adjacent tissues was investigated. The impact of miR-96-5p on apoptosis and invasion of a hepatoma cell line, HepG2, was investigated by cell counting, Transwell assay, and flow cytometry, respectively. MicroRNA-183-5p, miR-96-5p, miR-182-5p, miR-217-5p, and miR-216b-5p were significantly upregulated in tumor tissues compared to the adjacent tissues (p = 0.0005, p = 0.0030, p = 0.0002, p = 0.0011, and p = 0.0288, respectively). By multivariate Cox regression analysis, high tumor/adjacent ratios of miR-182-5p (p = 0.007) and miR-217-5p (p = 0.008) were associated with poor recurrence-free survival. In contrast, a low tumor/adjacent ratio of miR-96-5p (p < 0.001) was associated with poor recurrence-free survival. It suggested that further upregulation of miR-96-5p in tumors might have an inhibitory effect on recurrence. Transfection of miR-96-5p mimic significantly induced apoptosis of HepG2 cells, in association with downregulation of Nucleophosmin 1 (NPM1) and a decrease of phosphorylated AKT protein. Interestingly, simultaneous knockdown of the NPM1 and AKT genes induced apoptosis. MicroRNA-96-5p also suppressed proliferation and invasion, which inhibited epithelial-to-mesenchymal transition of HCC cells. MicroRNA-96-5p as a tumor suppressor would be valuable to stratify NBNC-HCC patients at high risk of recurrence. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13674 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34038612 ● Search Scopus @ Elsevier (PMID): 34038612 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13674 (DOI: 10.1111/hepr.13674, PubMed: 34038612)
73.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Shoko Iwahashi : Usefulness of a stepwise training program for laparoscopic gastrectomy., Asian Journal of Endoscopic Surgery, Vol.15, No.1, 121-127, 2022. (Summary) Laparoscopic gastrectomy (LG) is a complicated procedure with a long learning curve. This study was performed to investigate the usefulness of our stepwise training program for LG for improving the quality of the surgery. The stepwise training method comprised the following four steps: (1) basic training using a dry box and checking by mentors; (2) advanced training, including the use of animals and cadavers; (3) clinical experience, including standardization and preoperative three-dimensional simulation; and (4) self-assessment and feedback. In total, 153 patients who underwent curative gastrectomy for gastric cancer were included in this study. The operative time gradually decreased for both laparoscopic distal gastrectomy (LDG) (2013, 395inutes; 2017, 278inutes; P < .001; = -0.68) and laparoscopic total gastrectomy (LTG) (2013, 476inutes; 2017, 319inutes; P < .001; = -0.56). The blood loss volume gradually decreased for both LDG (2013, 43.0 mL; 2017, 18.6 mL; P < .005; = -0.30) and LTG (2013, 143.8 mL; 2017, 13.5 mL; P < .005; = -0.41). Our stepwise training program contributes to reduce operation time and blood loss in LG. (Keyword) Gastrectomy / Humans / Laparoscopy / Retrospective Studies / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12979 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34514719 ● Search Scopus @ Elsevier (PMID): 34514719 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.12979 (DOI: 10.1111/ases.12979, PubMed: 34514719)
74.	Shohei Eto, Kouzou Yoshikawa, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Jun Higashijima, Takashi Iwata and Mitsuo Shimada : Strategy for laparoscopic repair of inguinal hernia after robot-assisted radical prostatectomy., Asian Journal of Endoscopic Surgery, Vol.15, No.1, 155-161, 2022. (Summary) Robot-assisted radical prostatectomy (RARP) is nowadays being performed worldwide, and inguinal hernia (IH) continues to be a common complication of radical prostatectomy. Laparoscopic repair of IH is often difficult via internal dissection because of adhesion of the preperitoneal cavity. This study aimed to categorize the intraoperative condition of, and devise a strategy for, IH after RARP. Of 577 patients who underwent RARP, 18 developed IH. These 18 patients then underwent laparoscopic IH repair using the transabdominal preperitoneal approach (TAPP) or modified intraperitoneal onlay mesh repair (mIPOM). Internal dissection was categorized into two groups according to the appearance of Cooper's ligament (exposed or not exposed). After RARP, four patients had exposure of Cooper's ligament while 14 patients showed no exposure. Both patients in the exposed group underwent TAPP and all patients in the not-exposed group underwent mIPOM. There was no significant difference between normal TAPP and RARP regarding operative factors, and IH recurrence was not observed. Laparoscopic repair of IH after RARP is rendered safe and efficient by using our categorization based on the exposure of Cooper's ligament and extension of preperitoneal space. (Keyword) Hernia, Inguinal / Herniorrhaphy / Humans / Laparoscopy / Male / Prostatectomy / Robotics (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12985 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34514724 ● Search Scopus @ Elsevier (PMID): 34514724 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.12985 (DOI: 10.1111/ases.12985, PubMed: 34514724)
75.	Chie Takasu, Emiko Kono, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : A "diversity and inclusion" lecture for promoting self-awareness among medical students., Surgery Today, Vol.52, No.6, 964-970, 2022. (Summary) The concept of 'diversity and inclusion' is being adopted worldwide, but it is not yet understood well in Japan. We conducted this study to evaluate the impact of a lecture aimed at increasing awareness of academic careers and the benefits of having diversity and inclusion. Two female surgeons delivered a 120-min lecture on "diversity and inclusion" to third-year medical students at Tokushima University. To assess the impact of the lecture, a questionnaire was distributed, for participants to complete anonymously before and after the lecture. Eighty-two students participated in the study (39 men, 38 women, and 5 unknown). Based on the questionnaire responses, 57.1% of the students had already perceived inequality in conduct because of gender. A comparison of pre- and post-lecture responses revealed a significant increase in confidence to succeed in their medical career (56.5% vs. 77.5%, p < 0.01). Learners were more likely to believe that gender would not become a barrier to career development (42.4% vs. 66.7%, p < 0.01). Moreover, 90.4% of the students felt positively about a career in surgery following the lecture. The lecture promoted awareness about diversity, self-awareness, and career development and motivated students to consider specializing in surgery later in their career. (Keyword) Career Choice / Female / Gender Identity / Humans / Japan / Male / Students, Medical / Surveys and Questionnaires (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-021-02424-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35001195 ● Search Scopus @ Elsevier (PMID): 35001195 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-021-02424-0 (DOI: 10.1007/s00595-021-02424-0, PubMed: 35001195)
76.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : Propensity Score-Matched Analysis of the Short- and Long-Term Outcomes of Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer., Annals of Surgical Oncology, Vol.29, No.6, 3887-3895, 2022. (Summary) Robotic gastrectomy (RG) has been rapidly adopted for gastric cancer (GC) treatment. However, the benefits of RG over laparoscopic gastrectomy (LG) for GC remain unclear. A total of 451 patients who underwent either RG (n = 83) or LG (n = 368) for GC were enrolled in this study. A 1:1 matched, propensity score-matched analysis was performed using the following factors: age, sex, body mass index, pT, pN, pStage, tumor location, vessel invasion, tumor markers, surgical procedure, reconstruction method, extent of lymphadenectomy, and Endoscopic Surgical Skill Qualification System qualified surgeon as an operator. The surgical outcomes of the two groups were compared. A well-balanced cohort of 158 patients was analyzed (n = 79 in the RG group, n = 79 in the LG group). Regarding the short-term outcomes, the respective blood loss volume, drain amylase content, and number of retrieved lymph nodes in the RG and LG groups were 38.62 ± 73.06 ml and 67.53 ± 108.20 ml (p < 0.05), 450 ± 371 IU/l and 1590 ± 6392 IU/l (p < 0.01), and 35.02 ± 15.51 and 25.28 ± 11.70 (p < 0.01). The morbidity rate was similar between the RG and LG groups (not significant [NS]). Regarding the long-term survival outcomes, there were no intergroup differences in 3-year overall survival (91.72% in the RG group vs. 83.39% in the LG group: NS) and 3-year, disease-free survival (93.31% in the vs. 90.44%: NS). RG was safe and contributed to better short-term outcomes and similar long-term survival outcomes compared with LG. (Keyword) Gastrectomy / Humans / Laparoscopy / Postoperative Complications / Propensity Score / Retrospective Studies / Robotic Surgical Procedures / Stomach Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-021-11203-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35006502 ● Search Scopus @ Elsevier (PMID): 35006502 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-021-11203-7 (DOI: 10.1245/s10434-021-11203-7, PubMed: 35006502)
77.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu and Yuuma Wada : ASO Author Reflections: The Role of Robotic Gastrectomy for Gastric Cancer., Annals of Surgical Oncology, Vol.29, No.6, 3896-3897, 2022. (Keyword) Gastrectomy / Humans / Robotic Surgical Procedures / Robotics / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-021-11226-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34988837 ● Search Scopus @ Elsevier (PMID): 34988837 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-021-11226-0 (DOI: 10.1245/s10434-021-11226-0, PubMed: 34988837)
78.	川瀬和美, 長谷川潔, 江口晋, 北川雄光, Mitsuo Shimada, 高折恭一, 吉田和彦, 矢永勝彦 and 國土典宏 : リーダーを担う女性外科医の育成わが国の女性外科医がリーダーシップを発揮するためのヒントアメリカ外科学会での女性外科医のリーダーシップ教育の例, Journal of Japan Surgical Society, Vol.123, No.1, 133-135, 2022. (Keyword) リーダーシップ医学生涯教育女性医師就労女性 *女性の権利アメリカ日本外科医ヒト女 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853882469186304 (CiNii: 1520853882469186304)
79.	久保正二, Mitsuo Shimada, 永野浩昭, 波多野悦朗, 海堀昌樹, 玄田拓哉, 田中肖吾, 居村暁, 松井康輔, 徳光幸生, 中村育夫, 新川寛二, 木下正彦 and 長谷川潔 : 【改訂:肝癌診療ガイドライン】肝癌診療ガイドライン手術, 消化器・肝臓内科, Vol.11, No.1, 91-98, 2022. (Keyword) *肝細胞癌(外科的療法) 肝切除肝臓移植肝機能検査術前評価診療ガイドライン周術期管理ヒト
80.	Shuhai Chen, Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Newly Generated 3D Schwann-Like Cell Spheroids From Human Adipose-Derived Stem Cells Using a Modified Protocol., Cell Transplantation, Vol.31, 9636897221093312, 2022. (Summary) Peripheral nerve injury (PNI) is a relatively frequent type of trauma that results in the suffering of many patients worldwide every year. Schwann cells (SCs) are expected to be applied in cell therapy because of their ability to promote peripheral nerve regeneration. However, the lack of clinically renewable sources of SCs hinders the application of SC-based therapies. Adipose-derived stem cells (ADSCs) have generated great interest in recent years because of their multipotency and ease of harvest, and they have already been verified to differentiate into Schwann-like cells (SLCs) in vitro. However, the efficiency of differentiation and the functions of SLCs remain unsatisfactory. We newly generated three-dimensional (3D) SLC spheroids from ADSCs using a modified protocol with human recombinant peptide (RCP) petaloid -piece. Morphological analysis, gene expression analysis by qRT-PCR, ELISA measurement of the secretion capabilities of neurotrophic factors, and neurite formation assay were performed to evaluate the functions of these 3D SLCs in vitro. Motor function recovery was measured in a sciatic nerve injury mouse model to analyze the nerve regeneration-promoting effect of 3D SLCs in vivo. The differentiation efficiency and the secretion of neurotrophic factors were enhanced in 3D SLCs compared with conventional SLCs. 3D SLCs could more effectively promote neurite growth and longer neurite extension in a neuron-like SH-SY5Y model. Additionally, 3D SLCs had a better therapeutic effect on nerve regeneration after transplantation into the sciatic nerve injury mouse model. These findings demonstrated that the potential of ADSC-derived SLCs to promote nerve regeneration could be significantly increased using our modified differentiation protocol and by assembling cells into a 3D sphere conformation. Therefore, these cells have great potential and can be used in the clinical treatment of PNI. (Keyword) Adipocytes / Adipose Tissue / Animals / Humans / Mice / Nerve Growth Factors / Peripheral Nerve Injuries / Schwann Cells / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 117435 (Link to Publication Site) ● Publication site (DOI): 10.1177/09636897221093312 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35469470 ● Search Scopus @ Elsevier (PMID): 35469470 ● Search Scopus @ Elsevier (DOI): 10.1177/09636897221093312 (Tokushima University Institutional Repository: 117435, DOI: 10.1177/09636897221093312, PubMed: 35469470)
81.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : Short-term outcomes of laparoscopic / robotic gastrectomy compared with open gastrectomy for advanced gastric cancer following chemotherapy., The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 261-265, 2022. (Summary) Purpose : This study aimed to investigate the short-term outcomes of laparoscopic gastrectomy / robotic gastrectomy after chemotherapy in patients with advanced gastric cancer and compare these outcomes with those of open gastrectomy. Methods : Fifty patients who underwent radical gastrectomy for advanced gastric cancer after chemotherapy between 2007 and 2021 were retrospectively analyzed. The patients were divided into two groups : the laparoscopic gastrectomy / robotic gastrectomy (n = 11) and open gastrectomy (n = 39) groups. The short-term outcomes of these procedures were subsequently examined. Results : The laparoscopic gastrectomy / robotic gastrectomy group had significantly shorter hospital stays and lower intraoperative blood loss than the open gastrectomy group. The overall complication rates were 12.8% (5 of 39 patients) and 0% (0 of 11 patients) in the open gastrectomy and laparoscopic gastrectomy / robotic gastrectomy groups, respectively (P = 0.1). Conclusions : Laparoscopic gastrectomy / robotic gastrectomy may be a surgical option after chemotherapy for patients with advanced gastric cancer. J. Med. Invest. 69 : 261-265, August, 2022. (Keyword) Gastrectomy / Humans / Laparoscopy / Retrospective Studies / Robotic Surgical Procedures / Stomach Neoplasms / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 117728 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.261 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244778 ● Search Scopus @ Elsevier (PMID): 36244778 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.261 (Tokushima University Institutional Repository: 117728, DOI: 10.2152/jmi.69.261, PubMed: 36244778)
82.	Jun Higashijima, Toru Kono, Mitsuo Shimada, Ayumu Sugitani, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga and Kouzou Yoshikawa : High Ligation of the Inferior Mesenteric Artery Induces Hypoperfusion of the Sigmoid Colon Stump During Anterior Resection., Frontiers in Surgery, Vol.8, 756873, 2021. (Summary) Anastomotic leakage (AL) after colorectal surgery is associated with insufficient vascular perfusion of the anastomotic ends. This study aimed to evaluate the effect of high vs. low ligation of the ileocolic artery and inferior mesenteric artery, respectively, on the vascular perfusion of the bowel stumps during ileocecal resection (ICR) and anterior rectal resection (AR). We retrospectively evaluated patients who underwent ICR or AR between 2016 and 2020. Real-time indocyanine green fluorescence angiography was performed to measure the fluorescence time (FT) as a marker of the blood flow in the proximal and distal stumps before anastomosis. Thirty-four patients with lower right-sided colon cancer underwent laparoscopic ICR. Forty-one patients with rectosigmoid colon or rectal cancer underwent robotic high AR (HAR) ( = 8), robotic low AR (LAR) ( = 6), laparoscopic HAR ( = 8), or laparoscopic LAR ( = 19). The FT was similar in the ileal and ascending colon stumps ( = 1.000) and did not differ significantly between high vs. low ligation of the ileocolic artery ( = 0.934). The FT was similar in the sigmoid colon and rectal stumps ( = 0.642), but high inferior mesenteric artery ligation significantly prolonged FT in the sigmoid colon during AR compared with low ligation ( = 0.004), indicating that the high ligation approach caused significant hypoperfusion compared with low ligation. The AL rate was similar after low vs. high ligation. Low vascular perfusion of the bowel stumps may not be an absolute risk factor for AL. High inferior mesenteric artery ligation could induce sigmoid colon stump hypoperfusion during anterior rectal resection. (Tokushima University Institutional Repository) ● Metadata: 117310 (Link to Publication Site) ● Publication site (DOI): 10.3389/fsurg.2021.756873 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34966775 ● Search Scopus @ Elsevier (PMID): 34966775 ● Search Scopus @ Elsevier (DOI): 10.3389/fsurg.2021.756873 (Tokushima University Institutional Repository: 117310, DOI: 10.3389/fsurg.2021.756873, PubMed: 34966775)
83.	Yuuma Wada, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Zhongxu Zhu, Xin Wang, Ane Etxart, Yangsoon Park, Luis Bujanda, In Ja Park and Ajay Goel : Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer., JCO Precision Oncology, Vol.5, 2021. (Summary) Patients with locally advanced rectal cancer (LARC) are recommended to receive preoperative chemoradiotherapy (PCRT) followed by surgery. Response to PCRT varies widely: 60%-70% of patients with LARC do not derive therapeutic benefit from PCRT, whereas 15%-20% of patients achieve pathologic complete response (pCR). We sought to develop a liquid biopsy assay for identifying response to PCRT in patients with LARC. We analyzed two genome-wide microRNA (miRNA) expression profiling data sets from tumor tissue samples for discovery (GSE68204) and validation (GSE29298). We prioritized biomarkers in pretreatment plasma specimens from clinical training (n = 41; 15 responders and 26 nonresponders) and validation (n = 65; 29 responders and 36 nonresponders) cohorts of patients with LARC. We developed an integrated miRNA panel and established a risk assessment model, which was combined with the miRNA panel and carcinoembryonic antigen levels. Our comprehensive discovery effort identified an 8-miRNA panel that robustly predicted response to PCRT, with an excellent accuracy in the discovery (area under the curve [AUC] = 0.95) and validation (AUC = 0.92) cohorts. We successfully established a circulating miRNA panel with remarkable diagnostic accuracy in the clinical training (AUC = 0.82) and validation (AUC = 0.81) cohorts. Moreover, the predictive accuracy of the panel was significantly superior to conventional clinical factors in both cohorts ( < .01) and the risk assessment model was superior (AUC = 0.83). Finally, we applied our model to detect patients with pathologic complete response and showed that it was dramatically superior to currently used pathologic features (AUC = 0.92). Our novel risk assessment signature for predicting response to PCRT has a potential for clinical translation as a liquid biopsy assay in patients with LARC. (Keyword) Chemoradiotherapy / Circulating MicroRNA / Humans / Liquid Biopsy / MicroRNAs / Rectal Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1200/PO.21.00015 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34913022 ● Search Scopus @ Elsevier (PMID): 34913022 ● Search Scopus @ Elsevier (DOI): 10.1200/PO.21.00015 (DOI: 10.1200/PO.21.00015, PubMed: 34913022)
84.	Chie Takasu, Shoko Yamashita, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : The role of the immunoescape in colorectal cancer liver metastasis., PLoS ONE, Vol.16, No.11, e0259940, 2021. (Summary) The expression of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) indicate the efficacy of anti-PD-1/PD-L1 therapy in colorectal cancer (CRC), but are less useful for monitoring the efficacy of therapy of CRC liver metastasis (CRLM). This study investigated the effects of immune molecules on the prognosis of CRLM. We enrolled 71 patients with CRLM who underwent curative resection for CRC. We used immunohistochemistry to analyze the expression of PD-1, PD-L1, indoleamine-pyrrole 2,3-dioxygenase (IDO), and CD163 (a marker of tumor-associated macrophages [TAMs]) in metastatic tumors. The immune molecules PD-1, PD-L1, IDO, and TAMs were expressed in 32.3%, 47.8%, 45.0%, and 47.9% of metastatic CRC samples, respectively. The 5-year overall survival rates associated with immune molecule-positive groups were significantly better than in the negative groups (PD-1: 87.7% vs 53.2%, p = 0.023; PD-L1: 82.4% vs 42.3%, p = 0.007; IDO: 80.7% vs 43.5%, p = 0.007; TAMs: 82.6% vs 48.0%, p = 0.005). Multivariate analysis revealed PD-1 expression (p = 0.032, hazard ratio: 0.19), IDO expression (p = 0.049, hazard ratio: 0.37), and tumor differentiation (p<0.001, hazard ratio: 0.02) as independent prognostic indicators. PD-1 and TAMs in metastases were associated with less aggressive features such as smaller tumors. Furthermore, TAMs positively and significantly correlated with PD-1 expression (p = 0.011), PD-L1 expression (p = 0.024), and tended to correlate with IDO expression (p = 0.078). PD-1, PD-L1, IDO, and TAMs in CRLM were associated with less aggressive features and better prognosis of patients with CRC, indicating adaptive antitumor immunity vs immune tolerance. These molecules may therefore serve as prognostic markers for CRLM. (Keyword) Adaptive Immunity / Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, Differentiation, Myelomonocytic / B7-H1 Antigen / Biomarkers, Tumor / Colonic Neoplasms / Colorectal Neoplasms / Diagnostic Tests, Routine / Female / Gene Expression / Humans / Immune Tolerance / Indoleamine-Pyrrole 2,3,-Dioxygenase / Japan / Liver / Liver Neoplasms / Male / Middle Aged / Neoplasm Metastasis / Prognosis / Programmed Cell Death 1 Receptor / Receptors, Cell Surface / Rectal Neoplasms / Transcriptome / Tumor-Associated Macrophages (Tokushima University Institutional Repository) ● Metadata: 117381 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0259940 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34797860 ● Search Scopus @ Elsevier (PMID): 34797860 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0259940 (Tokushima University Institutional Repository: 117381, DOI: 10.1371/journal.pone.0259940, PubMed: 34797860)
85.	Luping Gao, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Chie Takasu, Katsuki Miyazaki and Mitsuo Shimada : Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells., PLoS ONE, Vol.16, No.9, e0256755, 2021. (Summary) As a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems. Because the mechanism controlling sorafenib-resistance is not well understood, this study focused on the connection between tumor characteristics and the Nrf2 signaling pathway in a sorafenib-resistant HCC cell line. A sorafenib-resistant HCC cell line (Huh7) was developed by increasing the dose of sorafenib in the culture medium until the target concentration was reached. Cell morphology, migration/invasion rates, and expression of stemness-related and ATP-binding cassette (ABC) transporter genes were compared between sorafenib-resistant Huh7 cells and parental Huh7 cells. Next, a small interfering RNA was used to knock down Nrf2 expression in sorafenib-resistant Huh7 cells, after which cell viability, stemness, migration, and ABC transporter gene expression were examined again. Proliferation, migration, and invasion rates of sorafenib-resistant Huh7 cells were significantly increased relative to the parental cells with or without sorafenib added to the medium. The expression levels of stemness markers and ABC transporter genes were up-regulated in sorafenib-resistant cells. After Nrf2 was knocked down in sorafenib-resistant cells, cell migration and invasion rates were reduced, and expression levels of stemness markers and ABC transporter genes were reduced. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant HCC cells. (Keyword) ATP-Binding Cassette Transporters / Antineoplastic Agents / Carcinoma, Hepatocellular / Cell Line, Tumor / Cell Movement / Cell Proliferation / Cell Survival / Drug Resistance, Neoplasm / Gene Expression / Gene Expression Regulation, Neoplastic / Gene Knockdown Techniques / Humans / Liver Neoplasms / NF-E2-Related Factor 2 / Protein Kinase Inhibitors / Signal Transduction / Sorafenib / Transfection (Tokushima University Institutional Repository) ● Metadata: 117382 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0256755 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34473785 ● Search Scopus @ Elsevier (PMID): 34473785 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0256755 (Tokushima University Institutional Repository: 117382, DOI: 10.1371/journal.pone.0256755, PubMed: 34473785)
86.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 【肝内胆管癌診療の最前線∼ガイドラインReview∼】肝内胆管癌の外科治療:リンパ節郭清しない立場から, Journal of Biliary Tract & Pancreas, Vol.42, No.9, 835-842, 2021. (Summary) 肝内胆管癌に対する治療は根治的外科切除が基本であるが，リンパ節郭清の意義については一定の見解が得られていない．われわれは末梢型肝内胆管癌において，リンパ節転移陰性例では予防的郭清を行わず，陽性例でもサンプリングにとどめている．その理由として，肝のリンパ流にはさまざまな経路があり遠隔・全身のリンパ流とつながっているため，領域リンパ節郭清は単にサンプリングの意義しかないことがあげられる．実際にリンパ節転移陽性例は，リンパ節郭清を行っても予後は極めて不良であり，肝内胆管癌の予後向上のためには手術のみならず化学療法を含めた集学的治療が必要であると考えられる．(著者抄録) (Keyword) 肝内胆管(外科的療法) リンパ行性転移胆管癌(外科的療法,予後,薬物療法) 胆管腫瘍(外科的療法,予後,薬物療法) リンパ節切除アジュバント化学療法ネオアジュバント療法予防的手術生存期間ヒト
87.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Tetsuya Ikemoto and Mitsuo Shimada : Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis., Anticancer Research, Vol.41, No.9, 4637-4644, 2021. (Summary) The aim of this study was to investigate frailty as a prognostic factor in patients with colorectal liver metastasis undergoing hepatectomy. Eighty-seven patients who underwent hepatectomy at our institution were enrolled. Frailty was defined as a score of ·4 on a clinical frailty scale. Patients were divided into frailty (n=29) and non-frailty (n=58) groups. Overall and cancer-specific survival rates were significantly worse in the frailty group compared with the non-frailty group, and multivariate analysis revealed frailty as an independent prognostic factor. Disease-free survival tended to be worse in the frailty group. Fifty-eight patients relapsed after the first hepatectomy. Twenty-one of 58 recurrent patients were allocated to the frailty group. After recurrence, chemotherapy was significantly more frequently performed in the non-frailty group compared with the frailty group. Frailty can predict the prognosis of patients with colorectal liver metastasis undergoing hepatectomy. (Keyword) Adult / Aged / Aged, 80 and over / Colorectal Neoplasms / Drug Therapy / Female / Frailty / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Prognosis / Retrospective Studies / Survival Analysis / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.15277 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34475092 ● Search Scopus @ Elsevier (PMID): 34475092 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.15277 (DOI: 10.21873/anticanres.15277, PubMed: 34475092)
88.	Luping Gao, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shouhei Okikawa, Chie Takasu and Mitsuo Shimada : The BAFF/NF B axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts., Cancer Science, Vol.112, No.9, 3545-3554, 2021. (Summary) The tumor microenvironment affects malignancy in hepatocellular carcinoma (HCC) cells, and cancer-associated fibroblasts (CAFs) play an important role in the microenvironment. As recent studies indicated a difference between CAFs isolated from chemoresistant and non-resistant cancer tissues, therefore we investigated the intracellular mechanism in resistant HCC co-cultured CAFs and interactions between these CAFs with cancer cells. We established a sorafenib-resistant (SR) Huh7 (human HCC) cell line, and characterized it with cytokine assays, then developed CAFs by co-culturing human hepatic stellate cells with resistant or parental Huh7 cells. The 2 types of CAFs were co-cultured with parental Huh7 cells, thereafter the cell viability of these Huh7 cells was checked under sorafenib treatment. The SR Huh7 (Huh7 ) cells expressed increased B-cell activating factor (BAFF), which promoted high expression of CAF-specific markers in Huh7 -co-cultured CAFs, showed activated BAFF, BAFF-R, and downstream of the NF B-Nrf2 pathway, and aggravated invasion, migration, and drug resistance in co-cultured Huh7 cells. When we knocked down BAFF expression in Huh7 cells, the previously increased malignancy and BAFF/NF B axis in Huh7 -co-cultured CAFs reversed, and enhanced chemoresistance in co-cultured Huh7 cells returned as well. In conclusion, the BAFF/NF B pathway was activated in CAFs co-cultured with cell-culture medium from resistant Huh7, which promoted chemoresistance, and increased the malignancy in co-cultured non-resistant Huh7 cells. This suggests that the BAFF/NF B axis in CAFs might be a potential therapeutic target in chemoresistance of HCC. (Keyword) Antineoplastic Agents / B-Cell Activating Factor / Cancer-Associated Fibroblasts / Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Survival / Coculture Techniques / Drug Resistance, Neoplasm / Gene Knockdown Techniques / Humans / Liver Neoplasms / NF-kappa B / Signal Transduction / Sorafenib / Transfection (Tokushima University Institutional Repository) ● Metadata: 116388 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.15041 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34159680 ● Search Scopus @ Elsevier (PMID): 34159680 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15041 (Tokushima University Institutional Repository: 116388, DOI: 10.1111/cas.15041, PubMed: 34159680)
89.	Takuya Tokunaga, Hideya Kashihara, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and Mitsuo Shimada : A Transabdominal Robotic Purse-String Suture Technique for Transanal Total Mesorectal Excision., Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A, Vol.31, No.8, 937-941, 2021. (Summary) Transanal total mesorectal excision (TaTME) is a novel technique that overcomes the problem of access to the deep pelvis during radical surgery for mid-rectal and lower rectal cancer. Although TaTME has several important steps, the creation of the distal purse-string suture following TaTME plays an important role in ensuring the integrity of the colorectal anastomosis. However, this procedure represents a major technical challenge for the surgeon. Robot-assisted surgery may make this suturing procedure easier than laparoscopic surgery because it permits intuitive wrist movements and a three-dimensional view. The aim of the present study was to investigate the usefulness of transabdominal robotic purse-string suture during anastomosis in TaTME. Twenty-seven patients, who underwent anastomosis using a single stapling technique (SST) during the TaTME of mid-rectal or lower rectal cancer, were enrolled in the study. The patients were allocated to two groups: 11 patients underwent transabdominal robotic purse-string suturing (the Robot group) and 16 patients underwent transanal purse-string suturing (the Transanal group). The characteristics and short-term surgical outcomes of the participants were compared between the two groups. The Robot group tended to have a shorter purse-string suturing time (541 206 seconds versus 729 310 seconds; = .07). Regarding the shape of the "donut" after SST anastomosis, in the Transanal group, 5 of the 16 participants had incomplete donuts with muscular defects and required additional suturing, whereas in the Robot group, all the participants had complete donuts ( = .04). Transabdominal robotic purse-string suturing may facilitate the suturing procedure and contribute to reliable anastomosis. (Keyword) Humans / Laparoscopy / Rectal Neoplasms / Rectum / Robotic Surgical Procedures / Robotics / Suture Techniques / Transanal Endoscopic Surgery (Link to Publication Site) ● Publication site (DOI): 10.1089/lap.2021.0286 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34242512 ● Search Scopus @ Elsevier (PMID): 34242512 ● Search Scopus @ Elsevier (DOI): 10.1089/lap.2021.0286 (DOI: 10.1089/lap.2021.0286, PubMed: 34242512)
90.	Masaaki Nishi, Mitsuo Shimada, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada, Shohei Eto and Toshiaki Yoshimoto : Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer., World Journal of Surgical Oncology, Vol.19, No.1, 201, 2021. (Summary) The lymphocyte to C-reactive protein (CRP) ratio (LCR) is an indicator of systemic inflammation and host-tumor cell interactions. The aim of this study was to investigate the prognostic significance of LCR in lower rectal cancer patients who received preoperative chemo-radiotherapy (CRT). Forty-eight patients with lower rectal cancer who underwent CRT followed by curative surgery were enrolled in this study. Routine blood examinations were performed before and after CRT were used to calculate pre-CRT LCR and post-CRT LCR. The median LCR was used to stratify patients into low and high LCR groups for analysis. The correlation between pre- and post-CRT LCR and clinical outcomes was retrospectively investigated. The pre-CRT LCR was significantly higher than the post-CRT LCR (11,765 and 6780, respectively, P < 0.05). The 5-year overall survival rate was significantly higher for patients with high post-CRT LCR compared with low post-CRT LCR (90.6% and 65.5%, respectively, P < 0.05). In univariate analysis, post-CRT LCR, post-CRT neutrophil to lymphocyte ratio, and fStage were significant prognostic factors for overall survival. In multivariate analysis, post-CRT LCR, but not other clinicopathological factors or prognostic indexes, was a significant prognostic factor for overall survival (P < 0.05). Post-CRT LCR could be a prognostic biomarker for patients with lower rectal cancer. (Keyword) C-Reactive Protein / Chemoradiotherapy / Humans / Lymphocytes / Neoplasm Staging / Prognosis / Rectal Neoplasms / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117394 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02319-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34229704 ● Search Scopus @ Elsevier (PMID): 34229704 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02319-x (Tokushima University Institutional Repository: 117394, DOI: 10.1186/s12957-021-02319-x, PubMed: 34229704)
91.	Shuhai Chen, Yuji Morine, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Tetsuya Ikemoto and Mitsuo Shimada : Cancerssociated fibroblastnduced M2olarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor 1 pathway., International Journal of Oncology, Vol.59, No.2, 59, 2021. (Summary) Targeting the tumor stroma is an important strategy in cancer treatment. Cancerssociated fibroblasts (CAFs) and tumorssociated macrophages (TAMs) are two main components in the tumor microenvironment (TME) in hepatocellular carcinoma (HCC), which can promote tumor progression. Plasminogen activator inhibitor 1 (PAI 1) upregulation in HCC is predictive of unfavorable tumor behavior and prognosis. However, the crosstalk between cancer cells, TAMs and CAFs, and the functions of PAI 1 in HCC remain to be fully investigated. In the present study, macrophage polarization and key paracrine factors were assessed during their interactions with CAFs and cancer cells. Cell proliferation, wound healing and Transwell and Matrigel assays were used to investigate the malignant behavior of HCC cells . It was found that cancer cells and CAFs induced the M2 polarization of TAMs by upregulating the mRNA expression levels of CD163 and CD206, and downregulating IL 6 mRNA expression and secretion in the macrophages. Both TAMs derived from cancer cells and CAFs promoted HCC cell proliferation and invasion. Furthermore, PAI 1 expression was upregulated in TAMs after being stimulated with CAFonditioned medium and promoted the malignant behavior of the HCC cells by mediating epithelialesenchymal transition. CAFs were the main producer of C motif chemokine ligand 12 (CXCL12) in the TME and CXCL12 contributed to the induction of PAI 1 secretion in TAMs. In conclusion, the results of the present study suggested that CAFs promoted the M2 polarization of macrophages and induced PAI 1 secretion via CXCL12. Furthermore, it was found that PAI 1 produced by the TAMs enhanced the malignant behavior of the HCC cells. Therefore, these factors may be targets for inhibiting the crosstalk between tumor cells, CAFs and TAMs. (Keyword) Cancer-Associated Fibroblasts / Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Polarity / Cell Proliferation / Coculture Techniques / Disease Progression / Gene Expression Regulation, Neoplastic / Humans / Liver Neoplasms / Macrophage Activation / Plasminogen Activator Inhibitor 1 / Prognosis / Signal Transduction / THP-1 Cells / Tumor Microenvironment / Tumor-Associated Macrophages / Up-Regulation (Tokushima University Institutional Repository) ● Metadata: 117319 (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2021.5239 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34195849 ● Search Scopus @ Elsevier (PMID): 34195849 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2021.5239 (Tokushima University Institutional Repository: 117319, DOI: 10.3892/ijo.2021.5239, PubMed: 34195849)
92.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Utility of cone unit liver resection for small hepatocellular carcinoma: a propensity score matched analysis., HPB, Vol.23, No.5, 739-745, 2021. (Summary) Anatomical resection (AR) is performed widely for hepatocellular carcinoma (HCC). However, it is controversial whether typical AR, which removes the whole feeding territory of the tumor-bearing portal branch bordered by the landmark veins, is necessary. The aim of this study was to investigate the utility of small AR, so-called cone unit resection, for small HCC. Between 2007 and 2019, 372 hepatectomies were performed for HCC. Among them, 91 initial resections for small (<5 cm) solitary HCC were performed by typical AR (n = 44) or cone unit AR (n = 47). Propensity score matching was performed and clinicopathological features including prognosis were compared. At baseline, platelet count was higher, and liver function (serum albumin level) and indocyanine green retention at 15 min were better in the typical AR than cone unit AR group. There was no significant difference between the typical AR and cone unit AR group for tumor characteristics, short- and long-term outcomes. Even after propensity score matching (n = 29), the short- and long-term outcomes were also equivalent in between the two groups. There was no difference in prognosis of typical and cone unit AR. Therefore, cone unit AR is a feasible procedure for small HCC. (Keyword) Carcinoma, Hepatocellular / Hepatectomy / Humans / Liver Neoplasms / Propensity Score / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1016/j.hpb.2020.09.010 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32988753 ● Search Scopus @ Elsevier (PMID): 32988753 ● Search Scopus @ Elsevier (DOI): 10.1016/j.hpb.2020.09.010 (DOI: 10.1016/j.hpb.2020.09.010, PubMed: 32988753)
93.	Jun Higashijima, Toru Kono, Mitsuo Shimada, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Ayumu Sugitani and Kouzou Yoshikawa : Intestinal hypoperfusion in patients with Crohn's disease revealed by intraoperative indocyanine green fluorescence imaging., Annals of Medicine and Surgery, Vol.66, 102402, 2021. (Summary) Anastomotic leakage has been reported as an independent risk factor for surgical recurrence at the anastomotic site in patients with Crohn's disease. An inadequate blood supply may contribute to this leakage. Real-time indocyanine green angiography has been useful for confirming vascular perfusion of the intestines. The aim of this study was to evaluate the use of intraoperative indocyanine green angiography to detect vascular perfusion of the intestines during ileocaecal resection in patients with Crohn's disease and colon cancer. We retrospectively evaluated the medical records of 26 consecutive patients with colon cancer arising in the caecum or ascending colon and 3 consecutive patients with Crohn's disease without a history of disease-related surgery. The patients in the 2 cohorts had undergone ileocaecal resection at Tokushima University Hospital between January 2018 and January 2021. After ileocaecal resection, blood flow was evaluated in ileal (oral) and colon (anal) stapled stumps by indocyanine green fluorescence angiography. The fluorescence time was defined as the time from indocyanine green injection and flush of the injection route to the point when the stump showed the strongest fluorescent signal in the monitor. The fluorescence time for the ileal and colon stumps in patients with Crohn's disease was 43.3 8.8 s each and was significantly longer than the fluorescence time in the patients with colon cancer (29.4 6.5 s and 29.6 6.8 s, respectively) (P < 0.05). Intraoperative indocyanine green fluorescence imaging is safe and reproducible for assessing intestinal perfusion prior to anastomosis in patients with colon cancer and Crohn's disease. (Tokushima University Institutional Repository) ● Metadata: 117278 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.amsu.2021.102402 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34136203 ● Search Scopus @ Elsevier (PMID): 34136203 ● Search Scopus @ Elsevier (DOI): 10.1016/j.amsu.2021.102402 (Tokushima University Institutional Repository: 117278, DOI: 10.1016/j.amsu.2021.102402, PubMed: 34136203)
94.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma., Surgery Today, Vol.51, No.12, 1985-1995, 2021. (Summary) To clarify whether the preoperative lymphocyte/C-reactive protein (CRP) ratio (LCR) is a prognostic factor for patients with intrahepatic cholangiocarcinoma (IHCC), and investigate its mechanism via tumor-infiltrating lymphocytes. The subjects of this retrospective study were 42 patients who had undergone hepatectomy for IHCC. We divided the patients into low LCR and high LCR groups (cutoff value: 8780) and analyzed their overall survival (OS) and disease-free survival (DFS) with respect to LCR and other clinicopathological factors. We also investigated the levels of stromal tumor-infiltrating lymphocytes (TILs) and CD8 TILs in surgical specimens, and the relationship between LCR and TILs. A low LCR was identified in 21 patients and was significantly correlated with older age, a high CRP-albumin ratio, and advanced disease stage, and was a prognostic factor for OS and DFS. Multivariate analysis revealed that a low LCR was an independent prognostic factor for worse OS (HR 10.40, P = 0.0077). Although the LCR and levels of stromal TILs were not significantly related, LCR and levels of CD8 TILs were significantly related (P = 0.0297). The preoperative LCR may predict the postsurgical prognosis of patients with IHCC and reflect the CD8 TILs. (Keyword) Bile Duct Neoplasms / Biomarkers, Tumor / C-Reactive Protein / CD8-Positive T-Lymphocytes / Cholangiocarcinoma / Female / Humans / Lymphocyte Count / Lymphocytes, Tumor-Infiltrating / Male / Predictive Value of Tests / Preoperative Period / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-021-02295-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34009433 ● Search Scopus @ Elsevier (PMID): 34009433 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-021-02295-5 (DOI: 10.1007/s00595-021-02295-5, PubMed: 34009433)
95.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : The influence and countermeasure of obesity in laparoscopic colorectal resection., Annals of Gastroenterological Surgery, Vol.5, No.5, 677-682, 2021. (Summary) The aim of this study was to investigate the influence of obesity and the usefulness of a preoperative weight loss program (PWLP) for obese patients undergoing laparoscopic colorectal resection (LCR). Study 1: 392 patients who underwent LCR for colorectal cancer were divided into two groups: those with a body mass index (BMI) ·25 kg/m (n = 113) and those with a BMI <25 kg/m (n = 279). The influence of BMI on LCR was investigated. Study 2: Patients with a BMI ·28 kg/m who were scheduled to undergo LCR (n = 7, mean body weight 87.0 kg, mean BMI 33.9 kg/m) undertook a PWLP including caloric restriction and exercise for 29.6 (15-70) days. The effects of this program were evaluated. Study 1: The BMI ·25 kg/m group had a prolongation of operation time and hospital stay than the BMI <25 kg/m group. Study 2: The patients achieved a mean weight loss of 6.9% (-6.0 kg). The mean visceral fat area was significantly decreased by 18.0%, whereas the skeletal muscle mass was unaffected. The PWLP group had a significantly lower prevalence of postoperative complications compared with the BMI ·25 kg/m group. Obesity affected the surgical outcomes in LCR. A PWLP may be useful for obese patients undergoing LCR. (Tokushima University Institutional Repository) ● Metadata: 117274 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12455 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34585052 ● Search Scopus @ Elsevier (PMID): 34585052 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12455 (Tokushima University Institutional Repository: 117274, DOI: 10.1002/ags3.12455, PubMed: 34585052)
96.	Chie Takasu, Katsuki Miyazaki, Kouzou Yoshikawa, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Toshiaki Yoshimoto, Hirohisa Ogawa, Yuji Morine and Mitsuo Shimada : Effect of TU-100 on Peyer's patches in a bacterial translocation rat model., Annals of Gastroenterological Surgery, Vol.5, No.5, 683-691, 2021. (Summary) Daikenchuto (TU-100), a Japanese herbal medicine, is widely used for various gastrointestinal diseases. We have previously reported that TU-100 suppresses CPT-11-induced bacterial translocation (BT) by maintaining the diversity of the microbiome. In this study we show that TU-100 modulates the immune response during BT by inducing PD-1 expression in Peyer's patches. Eighteen male Wistar rats were divided into four groups: a control group; a control + TU-100 group, given TU-100 1000 mg/kg orally for 5 d; a BT group, given CPT-11 250 mg/kg intra-peritoneal for 2 d; and a TU-100 group, given TU-100 1000 mg/kg orally for 5 d with CPT-11 250 mg/kg intra-peritoneal on days 4 and 5. The size of Peyer's patch was significantly bigger in the BT group compared to the control group (9.0 104 m vs 29.4 104 m, < .05), but improved in the TU-100 group (15.4 104 m, < .005). TU-100 significantly induced PD-1 expression in Peyer's patch compared to the control group and the BT group (control vs BT vs TU-100 = 4.3 4.9 vs 5.1 10.3 vs 17.9 17.8). The CD4 cells were increased in the BT group ( < .05) compared to the control group but decreased in the TU-100 group. The Foxp3 cells were increased in the BT group compared to the control group ( < .05), and further increased in the TU-100 group compared to the BT group. CPT-11 significantly increased TLR4, NF- , TNF- mRNA expressions in the BT group. TU-100 cotreatment significantly reversed these mRNA expressions. TU-100 may have a protective effect against BT through PD-1 expression in Peyer's patch. (Tokushima University Institutional Repository) ● Metadata: 117275 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12460 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34585053 ● Search Scopus @ Elsevier (PMID): 34585053 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12460 (Tokushima University Institutional Repository: 117275, DOI: 10.1002/ags3.12460, PubMed: 34585053)
97.	Yuuma Wada, Mitsuo Shimada, Tatsuro Murano, Hiroyuki Takamaru, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Francesc Balaguer, Luis Bujanda, Maria Pellise, Ken Kato, Yutaka Saito, Hiroaki Ikematsu and Ajay Goel : A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer., Gastroenterology, Vol.161, No.1, 151-162.e1, 2021. (Summary) We recently reported use of tissue-based transcriptomic biomarkers (microRNA [miRNA] or messenger RNA [mRNA]) for identification of lymph node metastasis (LNM) in patients with invasive submucosal colorectal cancers (T1 CRC). In this study, we translated our tissue-based biomarkers into a blood-based liquid biopsy assay for noninvasive detection of LNM in patients with high-risk T1 CRC. We analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from 2 clinical cohorts-a training cohort (N = 46) and a validation cohort (N = 142)-and matched formalin-fixed paraffin-embedded samples (N = 142). We performed quantitative reverse-transcription polymerase chain reaction, followed by logistic regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model combined with clinical risk factors. We used comprehensive expression profiling of a training cohort of LNM-positive and LMN-negative serum specimens to identify an optimized transcriptomic panel of 4 miRNAs (miR-181b, miR-193b, miR-195, and miR-411) and 5 mRNAs (AMT, forkhead box A1 [FOXA1], polymeric immunoglobulin receptor [PIGR], matrix metalloproteinase 1 [MMP1], and matrix metalloproteinase 9 [MMP9]), which robustly identified patients with LNM (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.72-0.94). We validated panel performance in an independent validation cohort (AUC, 0.82; 95% CI, 0.74-0.88). Our risk-stratification model was more accurate than the panel and an independent predictor for identification of LNM (AUC, 0.90; univariate: odds ratio [OR], 37.17; 95% CI, 4.48-308.35; P < .001; multivariate: OR, 17.28; 95% CI, 1.82-164.07; P = .013). The model limited potential overtreatment to only 18% of all patients, which is dramatically superior to pathologic features that are currently used (92%). A novel risk-stratification model for noninvasive identification of T1 CRC has the potential to avoid unnecessary operations for patients classified as high-risk by conventional risk-classification criteria. (Keyword) Adult / Aged / Aged, 80 and over / Biomarkers, Tumor / Colorectal Neoplasms / Decision Support Techniques / Feasibility Studies / Female / Gene Expression Profiling / Hepatocyte Nuclear Factor 3-alpha / Humans / Liquid Biopsy / Lymph Nodes / Lymphatic Metastasis / Male / Matrix Metalloproteinase 1 / Matrix Metalloproteinase 9 / MicroRNAs / Middle Aged / Neoplasm Staging / Nomograms / Predictive Value of Tests / RNA, Messenger / Receptors, Polymeric Immunoglobulin / Reproducibility of Results / Retrospective Studies / Risk Assessment / Risk Factors / Transcriptome / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1053/j.gastro.2021.03.062 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33819484 ● Search Scopus @ Elsevier (PMID): 33819484 ● Search Scopus @ Elsevier (DOI): 10.1053/j.gastro.2021.03.062 (DOI: 10.1053/j.gastro.2021.03.062, PubMed: 33819484)
98.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Chiharu Nakasu and Mitsuo Shimada : Robotic-assisted total gastrectomy in a patient with gastric cancer associated with situs inversus totalis: With video., Asian Journal of Endoscopic Surgery, Vol.14, No.2, 297-300, 2021. (Summary) Situs inversus totalis (SIT) refers to an inverted position of the major visceral organ as a "mirror image" of the regular location. We present a video of a robotic-assisted total gastrectomy in a 84-year-old man with SIT. The patient was diagnosed with advanced gastric cancer in the U region. The port placement was done as mirror images of our usual settings. Lymph node dissection was performed with a completely reverse approach to the usual procedure. After total gastrectomy, an intracorporal esophagojejunostomy was performed by circular method. All procedures were performed safely with no intraoperative complications and the patient was discharged uneventfully. Pathological diagnosis confirmed moderately differentiated adenocarcinoma and the depth of invasion was to the subserosa; there were five metastatic lymph nodes. In patients who have gastric cancer with SIT, a robotic-assisted total gastrectomy can be performed safely without surgical complication. Robots are useful for performing a total gastrectomy in SIT. (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12860 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32875706 ● Search Scopus @ Elsevier (PMID): 32875706 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.12860 (DOI: 10.1111/ases.12860, PubMed: 32875706)
99.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Takuya Tokunaga and Masaaki Nishi : Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma., World Journal of Surgical Oncology, Vol.19, No.1, 94, 2021. (Summary) Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be a prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection. One hundred and twenty patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma were enrolled. Frailty was defined as a clinical frailty scale score ·4. Patients were divided into frailty (n = 29) and non-frailty (n=91) groups, and clinicopathological factors were compared between the two groups. The frailty group showed an older age, lower serum albumin concentration, lower prognostic nutritional index, larger tumor diameter, and higher rate of lymph node metastasis than the non-frailty group (p < 0.05). Neutrophil-lymphocyte ratio and modified Glasgow prognostic score tended to be higher in the frailty group. Cancer-specific and disease-free survival rates were significantly poor in the frailty group (p < 0.05). With a multivariate analysis, frailty was an independent prognostic factor of cancer-specific survival. Frailty can predict the prognosis of patients with pancreatic ductal adenocarcinoma who undergo pancreatic resection. (Keyword) Aged / Carcinoma, Pancreatic Ductal / Frailty / Humans / Pancreatectomy / Pancreatic Neoplasms / Prognosis (Tokushima University Institutional Repository) ● Metadata: 116675 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02205-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33781262 ● Search Scopus @ Elsevier (PMID): 33781262 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02205-6 (Tokushima University Institutional Repository: 116675, DOI: 10.1186/s12957-021-02205-6, PubMed: 33781262)
100.	Yuuma Wada, Mitsuo Shimada, Kensuke Yamamura, Takeo Toshima, Jasjit K. Banwait, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hideo Baba, Masaki Morishima and Ajay Goel : A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma., Hepatology, Vol.74, No.3, 1371-1383, 2021. (Summary) Tumor recurrence is frequent even in intrahepatic cholangiocarcinoma (ICC), and improved strategies are needed to identify patients at highest risk for such recurrence. We performed genome-wide expression profile analyses to discover and validate a gene signature associated with recurrence in patients with ICC. For biomarker discovery, we analyzed genome-wide transcriptomic profiling in ICC tumors from two public data sets: The Cancer Genome Atlas (n = 27) and GSE107943 (n = 28). We identified an eight-gene panel (BIRC5 [baculoviral IAP repeat containing 5], CDC20 [cell division cycle 20], CDH2 [cadherin 2], CENPW [centromere protein W], JPH1 [junctophilin 1], MAD2L1 [mitotic arrest deficient 2 like 1], NEIL3 [Nei like DNA glycosylase 3], and POC1A [POC1 centriolar protein A]) that robustly identified patients with recurrence in the discovery (AUC = 0.92) and in silico validation cohorts (AUC = 0.91). We next analyzed 241 specimens from patients with ICC (training cohort, n = 64; validation cohort, n = 177), followed by Cox proportional hazard regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model for recurrence in ICC. We subsequently trained this transcriptomic panel in a clinical cohort (AUC = 0.89; 95% confidence interval [CI] = 0.79-0.95), followed by evaluating its performance in an independent validation cohort (AUC = 0.86; 95% CI = 0.80-0.90). By combining our transcriptomic panel with various clinicopathologic features, we established a risk-stratification model that was significantly superior for the identification of recurrence (AUC = 0.89; univariate HR = 6.08, 95% CI = 3.55-10.41, P < 0.01; and multivariate HR = 3.49, 95% CI = 1.81-6.71, P < 0.01). The risk-stratification model identified potential recurrence in 85% of high-risk patients and nonrecurrence in 76% of low-risk patients, which is dramatically superior to currently used pathological features. We report a transcriptomic signature for risk-stratification and recurrence prediction that is superior to currently used clinicopathological features in patients with ICC. (Link to Publication Site) ● Publication site (DOI): 10.1002/hep.31803 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33725402 ● Search Scopus @ Elsevier (PMID): 33725402 ● Search Scopus @ Elsevier (DOI): 10.1002/hep.31803 (DOI: 10.1002/hep.31803, PubMed: 33725402)
101.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : 【肝胆膵外科における再切除と再手術-最新の治療戦略】肝細胞癌切除後再発に対する再肝切除適応と治療成績, Operation, Vol.75, No.3, 249-256, 2021. (Keyword) 肝細胞癌(外科的療法,予後) 肝切除再手術術後合併症(外科的療法) 腫瘍再発腹腔鏡法癒着(病因,外科的療法) 診療ガイドライン治療成績ヒト (Link to Publication Site) ● Publication site (DOI): 10.18888/op.0000002091 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.18888/op.0000002091 (DOI: 10.18888/op.0000002091)
102.	Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Current status of hepatocyte-like cell therapy from stem cells., Surgery Today, Vol.51, No.3, 340-349, 2021. (Summary) Organ liver transplantation and hepatocyte transplantation are not performed to their full potential because of donor shortage, which could be resolved by identifying new donor sources for the development of hepatocyte-like cells (HLCs). HLCs have been differentiated from some stem cell sources as alternative primary hepatocytes throughout the world; however, the currently available techniques cannot differentiate HLCs to the level of normal adult primary hepatocytes. The outstanding questions are as follows: which stem cells are the best cell sources? which protocol is the best way to differentiate them into HLCs? what is the definition of differentiated HLCs? how can we enforce the function of HLCs? what is the difference between HLCs and primary hepatocytes? what are the problems with HLC transplantation? This review summarizes the current status of HLCs, focusing on stem cell sources, the differentiation protocol for HLCs, the general characterization of HLCs, the generation of more functional HLCs, comparison with primary hepatocytes, and HLCs in cell-transplantation-based liver regeneration. (Keyword) Bone Morphogenetic Proteins / Cell Differentiation / Cell- and Tissue-Based Therapy / Cells, Cultured / Coculture Techniques / Cytological Techniques / Fibroblast Growth Factors / Hepatocyte Nuclear Factor 4 / Hepatocytes / Homeodomain Proteins / Humans / Liver Diseases / Liver Regeneration / SOXF Transcription Factors / Stem Cells / Transcription Factors (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-020-02092-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32754843 ● Search Scopus @ Elsevier (PMID): 32754843 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-020-02092-6 (DOI: 10.1007/s00595-020-02092-6, PubMed: 32754843)
103.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Preoperative prognostic nutritional index predicts short- and long-term outcomes after liver resection in patients with hepatocellular carcinoma., Oncology Letters, Vol.21, No.2, 153, 2021. (Summary) The prognostic nutritional index (PNI) is one of the immune parameters calculated on the basis of the serum albumin and the total lymphocyte count. The aim of the present study was to investigate the prognostic significance of the PNI for short- and long-term outcomes after liver resection for patients with hepatocellular carcinoma (HCC). Data from 162 surgically treated patients with HCC (without any previous treatment) were retrospectively analyzed. The cutoff value of preoperative PNI was 45.0, which was calculated by a receiver operating characteristic curve for predicting the recurrence of HCC after liver resection. Patients were divided into low (n=86) and high (n=76) PNI groups. In short-term outcomes, patients in the low PNI group were more likely to experience postoperative complications compared with those in the high PNI group. The 5-year disease-free survival (DFS) rate in the low PNI group was significantly lower compared with that in the high PNI group (20.5% vs. 48.7%). In the multivariate analysis, a low PNI was an independent prognostic factor for DFS (HR, 1.65; 95% CI, 1.00-2.71). In conclusion, the preoperative PNI may be a prognostic factor for evaluating short- and long-term outcomes after liver resection in patients with HCC. (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2020.12414 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33552271 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099380892 (DOI: 10.3892/ol.2020.12414, PubMed: 33552271, Elsevier: Scopus)
104.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Takuya Tokunaga, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : The interaction between cancer associated fibroblasts and tumor associated macrophages via the osteopontin pathway in the tumor microenvironment of hepatocellular carcinoma., Oncotarget, Vol.12, No.4, 333-343, 2021. (Summary) Cancer-tumor associated macrophage (TAM)-cancer associated fibroblast (CAF) interactions are an important factor in the tumor microenvironment of hepatocellular carcinoma. Hepatic stellate cells (HSCs) were cultured with cancer cell-conditioned medium (Ca.-CM), TAM-CM and CAF-CM, and the expression of CAF markers were evaluated by RT-PCR. Whether HSCs cultured with Ca.-CM, TAM-CM and CAF-CM contributed to the enhanced malignancy of cancer cells was examined using proliferation, invasion and migration assays. Furthermore, the differences between these three types of CM were evaluated using cytokine arrays. HSCs cultured with Ca.-CM, TAM-CM and CAF-CM showed significantly increased mRNA expression of SMA, FAP and IL-6. All HSCs cultured with each CM exhibited significantly increased proliferation, invasion and migration of cancer cells. The osteopontin concentration was significantly higher in HSCs cultured with TAM-CM than the other CAF-CMs. Osteopontin inhibition significantly reduced osteopontin secretion from HSCs cultured with TAM-CM and suppressed the proliferation and invasion of cancer cells enhanced by HSCs cultured with TAM-CM. We observed enhanced osteopontin secretion from TAMs, and this increased osteopontin further promoted osteopontin secretion from HSCs cultured with TAM-CM, leading to increased malignancy. For the first time, we demonstrated the importance of cancer-TAM-CAF interactions via osteopontin in hepatocellular carcinoma. (Tokushima University Institutional Repository) ● Metadata: 116612 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27881 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33659044 ● Search Scopus @ Elsevier (PMID): 33659044 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27881 (Tokushima University Institutional Repository: 116612, DOI: 10.18632/oncotarget.27881, PubMed: 33659044)
105.	Kazumi Kawase, Kyoko Nomura, Sachiyo Nomura, Sadako Akashi-Tanaka, Tomoko Ogawa, Ikuko Shibasaki, Mitsuo Shimada, Tomoaki Taguchi, Emiko Takeshita, Yasuko Tomizawa, Kazuhiro Hanazaki, Tomoko Hanashi, Hideko Yamauchi, Hiroko Yamashita and Seigo Nakamura : How pregnancy and childbirth affect the working conditions and careers of women surgeons in Japan: findings of a nationwide survey conducted by the Japan Surgical Society., Surgery Today, Vol.51, No.2, 309-321, 2021. (Summary) To identify the conflicts between a career as a surgeon and pregnancy and childbirth for women in Japan. The Japan Surgical Society conducted a nationwide survey on pregnancy and childbirth among its members who are women. The questionnaire included items regarding demography, working styles, and pregnancy and childbirth, including adverse events and harassment. The response rate was 29.9% (1068 responses, median age, 37 years). Among the responders, 61% were married and 47% had children (average number of children, 1.7). Half of the respondents reported having experienced sexual harassment and 62% reported having received unwelcome comments about pregnancy. About 20% had undergone fertility treatment. In total, 51% had pregnancies, with miscarriages in 33% of these. The top answer for the best timing for pregnancy and childbirth was after becoming board-certified. Nearly one-third of first-time mothers experienced adverse events during pregnancy and delivery, and 28% quit or changed their job because of their pregnancy and the birth of their first child. Japanese women who choose a career as a surgeon face obstacles during pregnancy and childbirth. It is vital to share the findings of this study and understand the issues associated with pregnancy and childbirth regardless of gender. Interventions are essential to ensure that every pregnant surgeon has a safe working environment to allow unobstructed development of her career. (Keyword) Adult / Career Choice / Female / General Surgery / Humans / Japan / Occupational Health / Occupational Stress / Parturition / Physicians, Women / Pregnancy / Sexual Harassment / Societies, Medical / Surgeons / Surveys and Questionnaires / Workplace (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-020-02129-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32901376 ● Search Scopus @ Elsevier (PMID): 32901376 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-020-02129-w (DOI: 10.1007/s00595-020-02129-w, PubMed: 32901376)
106.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : Pre-operative Weight Loss Program for Obese Patients Undergoing Laparoscopic Gastrectomy., The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 165-169, 2021. (Summary) Background : The aim of this study was to investigate the influence of obesity and the usefulness of a pre-operative weight loss program (PWLP) for obese patients undergoing laparoscopic gastrectomy (LG) for gastric cancer (GC). Materials and Methods : Study1 : 219 patients who underwent laparoscopic distal gastrectomy (LDG) for GC were divided into 2 groups : body mass index (BMI) 28 and BMI < 28kg /2. The influence of BMI in LG surgery was investigated. Study2 : The BMI 28 kg /2 patients with a planned LG (n = 8) undertook a PWLP including calorie restriction and exercise. The effects of this program were evaluated. Results : Study1 : The BMI 28kg /2 group showed significantly longer operation times, more blood loss and a higher frequency of post-operative complications than that of the BMI < 28kg /2 group. Study 2 : The patients achieved a weight loss of 4.2%. The visceral fat area (VFA) was significantly decreased by 10.6%, whereas skeletal muscle mass was unaffected. The PWLP group showed shorter operation times, less blood loss and a lower frequency of post-operative complications compared with that of the BMI 28kg /2 group. Conclusion : Obesity is an important risk factor and a pre-operative weight loss program is useful for obese patients undergoing a LG. J. Med. Invest. 68 : 165-169, February, 2021. (Tokushima University Institutional Repository) ● Metadata: 116007 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.165 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994464 ● Search Scopus @ Elsevier (PMID): 33994464 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.165 (Tokushima University Institutional Repository: 116007, DOI: 10.2152/jmi.68.165, PubMed: 33994464)
107.	Jun Higashijima, Takuya Tokunaga, Toshiaki Yoshimoto, Shohei Eto, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Hiroshi Okitsu, Masashi Ishikawa, Hidenori Miyake, Toshiyuki Yagi, Toru Kono and Mitsuo Shimada : A multicenter phase II trial of preoperative chemoradiotherapy with S-1 plus oxaliplatin and bevacizumab for locally advanced rectal cancer., International Journal of Clinical Oncology, Vol.26, No.5, 875-882, 2021. (Summary) We clarified the safety and efficacy of preoperative chemoradiotherapy for locally advanced rectal cancer using a multidrug regimen (S-1 +xaliplatin +evacizumab). This multicenter phase II trial involved 47 patients with locally advanced rectal cancer. All patients received S-1 orally (80 mg/m/day on days 1-5, 8-12, 15-19, and 22-26) and infusions of oxaliplatin (50 mg/m on days 1, 8, 15, and 22) and bevacizumab (5 mg/kg on days 1 and 15). The total radiation dose was 40 Gy delivered in daily fractions of 2 Gy via the four-field technique. The primary endpoint was the pathological complete response rate. The secondary endpoints were safety (incidence of adverse events) and clinical response, relapse-free survival, overall survival, local recurrence, R0 resection, downstaging, and treatment completion rates. All 47 patients received chemoradiotherapy, and 44 patients underwent curative resection. Two patients refused surgery and selected a watch-and-wait strategy. The pathological complete response rate was 18.2% in patients who underwent curative resection. The clinical response rate was 91.3% in 46 patients. Concerning hematotoxicity, there was one grade 4 adverse event (2.1%) and seven grade 3 events (14.9%). Diarrhea was the most frequent non-hematotoxic event, and the grade 3 event rate was 25.5%. Although preoperative chemoradiotherapy for patients with locally advanced rectal cancer using the S-1 +xaliplatin +evacizumab regimen did not achieve the expected pathological complete response rate, this regimen led to an improved clinical response rate. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-021-01868-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33486623 ● Search Scopus @ Elsevier (PMID): 33486623 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-01868-1 (DOI: 10.1007/s10147-021-01868-1, PubMed: 33486623)
108.	Shoko Yamashita, Masaaki Nishi, Tetsuya Ikemoto, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto and Mitsuo Shimada : Clinical analysis of postoperative venous thromboembolism in Japanese patients after colorectal cancer surgery., Surgery Today, Vol.51, No.6, 1022-1027, 2021. (Summary) Venous thromboembolism (VTE) is a major complication after abdominal surgery; however, the best strategy for preventing VTE after surgery is not yet established. We performed this study to investigate the incidence of perioperative VTE and evaluate the efficacy of a VTE preventive strategy for patients undergoing surgery for colorectal cancer (CRC). The subjects of this retrospective analysis were 228 patients who underwent curative surgical resection for CRC between 2012 and 2016. The patients were treated with thromboprophylaxis including enoxaparin. We assessed the perioperative VTE occurrence rate and investigated the risk factors for postoperative VTE. Among the 228 patients, 77 had a preoperative D-dimer level of > 1.0 g/mL and 12 had deep vein thrombosis (DVT) diagnosed by ultrasonography preoperatively. Of the remaining 216 patients, short-term VTE (< 30 days) developed in two patients (0.9%) and long-term VTE (30 days-3 years) developed in seven (3.2%). The mortality rate of patients with VTE was 0%. The univariate analysis indicated that pulmonary disease was the risk factor for short-term VTE, whereas obesity, hyperlipidemia, and a preoperative history of pulmonary embolism were the risk factors for long-term VTE (p < 0.05). The findings of this analysis show that our preventive protocol including enoxaparin is an effective strategy for preventing postoperative VTE. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-020-02201-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33387025 ● Search Scopus @ Elsevier (PMID): 33387025 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-020-02201-5 (DOI: 10.1007/s00595-020-02201-5, PubMed: 33387025)
109.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of Frailty in Prognosis After Hepatectomy for Elderly Patients with Hepatocellular Carcinoma., Annals of Surgical Oncology, Vol.28, No.1, 439-446, 2021. (Summary) The concept of frailty becomes important for patients who undergo surgery in this recent aging society. The aim of this study is to investigate the frailty as a prognostic factor in elderly patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. A total of 92 patients over 75 years old who underwent hepatectomy were enrolled in this study. Frailty was defined as clinical frailty scale (CFS) 4. Patients were divided into two groups, i.e., frailty group (n = 21) and no-frailty group (n = 71), and clinicopathological features were compared between them. The frailty group showed significant higher PIVKA-II level and larger tumor diameter (p < 0.05). CRP level and modified Glasgow prognostic score were significantly higher in the frailty group (p < 0.05). The frailty group showed higher rate of postoperative complications of Clavien-Dindo III (p = 0.06) and longer postoperative stay (p = 0.08). Cancer-specific, overall, and disease-free survival rates were significantly worse in the frailty group (p < 0.05). Frailty was detected as an independent prognostic factor on multivariate analysis of cancer-specific survival. Frailty can estimate the prognosis of HCC patients who underwent hepatectomy. (Keyword) Aged / Carcinoma, Hepatocellular / Frail Elderly / Frailty / Hepatectomy / Humans / Liver Neoplasms / Neoplasm Recurrence, Local / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-020-08742-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
110.	Hiroki Mori, Yuji Morine, Kazuaki Mawatari, Ayumi Chiba, Shin-ichiro Yamada, Yu Saitou, Hiroki Ishibashi, Akira Takahashi and Mitsuo Shimada : Bile Metabolites and Risk of Carcinogenesis in Patients With Pancreaticobiliary Maljunction: A Pilot Study., Anticancer Research, Vol.41, No.1, 327-334, 2021. (Summary) Pancreaticobiliary maljunction (PBM), a disease with reflux of pancreatic and bile juice in the pancreaticobiliary tract, is a high-risk factor for biliary tract cancer. The aim of this study was to investigate the mechanism of carcinogenesis in PBM using a metabolomics analysis of bile sampled during surgery. Three patients with PBM without biliary tract cancer, four patients with extrahepatic bile duct cancer (EHBC), and three controls with benign disease were enrolled. Metabolomics analysis of bile samples was performed using capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry to discriminate the amino acid and lipidomic profiles. The principal component analysis in the capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry revealed similar metabolites in patients with PBM and those with EHBC; furthermore, there was a clear difference between patients with PBM or EHBC compared to controls. The amino acid profiles revealed the following 20 potential carcinogenic candidates for PBM: isoleucine, phenylalanine, tyrosine, leucine, tryptophan, arginine, lysine, valine, asparagine, methionine, aspartic acid, serine, threonine, histidine, glutamine, alanine, proline, glutamic acid, and pyruvic acid. The lipidomic profiles revealed the following 11 carcinogenic candidates: lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidyl glycerol, lysophosphatidyl glycerol, triacylglycerol, diacylglycerol, ceramide, sphyngomyeline, fatty acid, hyperforin, and vitamin D. Among these characteristic metabolites, the branched-chain amino acids, methionine and lysophosphatidylcholine are known to be related to carcinogenesis. The bile metabolites were extremely similar in patients with PBM and those with EHBC. Furthermore, amino acid and lipid metabolism was markedly different in patients with PBM or EHBC compared to healthy controls. (Keyword) Bile / Bile Duct Neoplasms / Cell Transformation, Neoplastic / Chromatography, Liquid / Disease Susceptibility / Electrophoresis, Capillary / Female / Humans / Male / Mass Spectrometry / Metabolomics / Pancreaticobiliary Maljunction / Pilot Projects / Risk Assessment / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.14779 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33419827 ● Search Scopus @ Elsevier (PMID): 33419827 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.14779 (DOI: 10.21873/anticanres.14779, PubMed: 33419827)
111.	Shohei Okikawa, Jun Higashijima, Masaaki Nishi, Toshiaki Yoshimoto, Shohei Eto, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Kouzou Yoshikawa and Mitsuo Shimada : SDF-1 expression after preoperative chemoradiotherapy is associated with prognosis in patients with advanced lower rectal cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 309-314, 2021. (Summary) Stromal cell-derived factor-1 (SDF-1) expression is associated with cancer progression, as a biomarker of prognosis. We clarified the significance of SDF-1 expression on chemoradiotherapy (CRT) resistance and prognosis in advanced lower rectal cancer patients. We evaluated 98 patients with advanced lower rectal cancer who underwent preoperative CRT. All patients received 40 Gy of radiation therapy, with concurrent chemotherapy containing fluorinated pyrimidines, followed by surgical resection. SDF-1 expression in surgical specimens was examined by immunohistochemistry. We divided the patients into SDF-1-positive- (n = 52) and SDF-1-negative groups (n = 46) and compared the clinicopathological factors and survival rates. The SDF-1-positive group was more resistant to CRT than the SDF-1-negative group (non-responder rate, 63.5% vs. 47.8%, respectively ; p = 0.12). Overall survival (OS) in the SDF-1 positive group was significantly poorer vs. the SDF-1-negative group (5-year OS, 73.4% vs. 88.0%, respectively ; p = 0.02), and disease-free survival (DFS) was worse (5-year DFS, 61.0% vs. 74.1%, respectively ; p = 0.07). Multivariate analysis confirmed that SDF-1 expression was a significant independent prognostic predictor of OS (p = 0.04). SDF-1 expression after preoperative CRT is significantly associated with a poor prognosis in advanced lower rectal cancer patients and is a promising biomarker. J. Med. Invest. 68 : 309-314, August, 2021. (Keyword) Chemoradiotherapy / Disease-Free Survival / Humans / Neoplasm Staging / Prognosis / Rectal Neoplasms / Rectum (Tokushima University Institutional Repository) ● Metadata: 116500 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.309 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759150 ● Search Scopus @ Elsevier (PMID): 34759150 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.309 (Tokushima University Institutional Repository: 116500, DOI: 10.2152/jmi.68.309, PubMed: 34759150)
112.	Shohei Eto, Kouzou Yoshikawa, Yukako Takehara, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Jun Higashijima, Takashi Iwata and Mitsuo Shimada : Usefulness of a multidisciplinary surgical site infection team in colorectal surgery., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 256-259, 2021. (Summary) Background : Surgical site infection (SSI) is an adverse event that places a major burden on patients and staff. In this study, we examined the occurrence of SSI and the characteristics of patients referred to the SSI team after colorectal surgery. Methods : In total, 955 patients underwent colorectal surgery at our hospital from 2014 to 2019. Of these 955 patients, 516 received therapeutic support by the SSI team from 2017 to 2019. All patients were evaluated using an SSI surveillance sheet, and we checked for reports of SSI once a month. Each attending physician performed SSI prophylaxis (use of new instruments before wound irrigation and closure). Results : SSI occurred in 80 (8.4%) patients. The incidence of SSI and the incidence of surface SSI were higher in the patients who did not receive intervention by the SSI team than in the patients who did. Organ /pace SSI occurred in 18 patients. Among patients with surface SSI, Enterococcus was the most commonly detected bacteria. Among the 18 patients with organ /pace SSI, 5 developed anastomotic leakage and 4 developed intra-abdominal abscesses. Conclusions : An SSI team for prevention and treatment of infection may contribute to reduction of SSI. J. Med. Invest. 68 : 256-259, August, 2021. (Keyword) Colorectal Surgery / Humans / Incidence / Risk Factors / Surgical Wound Infection / Therapeutic Irrigation (Tokushima University Institutional Repository) ● Metadata: 116491 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.256 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759140 ● Search Scopus @ Elsevier (PMID): 34759140 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.256 (Tokushima University Institutional Repository: 116491, DOI: 10.2152/jmi.68.256, PubMed: 34759140)
113.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 362-367, 2021. (Summary) Background : CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) is the master regulator of programmed cell death-ligand 1 (PD-L1). We aimed to clarify the significance of CMTM6 expression in gastric cancer (GC). Methods : A total of 105 patients who had undergone curative surgical resection for stage II /II GC at Tokushima University Hospital were included in this study. The expression of CMTM6 was examined by immunohistochemistry. Additionally, the relationship of each expression level to several prognostic factors was examined using univariate and multivariate analyses. Results : CMTM6 was not positively correlated with any of the factors examined. The overall survival (OS) rates were significantly poorer in the CMTM6 high-expression group than in the CMTM low-expression group (5-year OS : 57.2% vs. 79.2%, respectively ; p < 0.05). Disease-free survival (DFS) was significantly poorer in the CMTM high-expression group than in the CMTM6 low-expression group (5-year DFS : 52.8% vs. 72.4%, respectively ; p < 0.05). Multivariate analysis confirmed CMTM6 expression as an independent prognostic factor in DFS (p < 0.05). CMTM6 expression tended to be correlated with PD-L1 expression (p = 0.07). Conclusions : CMTM6 is associated with a poor prognosis and immunotolerance through PD-L1 in GC. J. Med. Invest. 68 : 362-367, August, 2021. (Keyword) B7-H1 Antigen / Chemokines / Humans / MARVEL Domain-Containing Proteins / Myelin Proteins / Prognosis / Stomach Neoplasms / Survival Rate (Tokushima University Institutional Repository) ● Metadata: 116552 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.362 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759159 ● Search Scopus @ Elsevier (PMID): 34759159 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.362 (Tokushima University Institutional Repository: 116552, DOI: 10.2152/jmi.68.362, PubMed: 34759159)
114.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Regeneration of caudate lobe after living donor liver transplantation : Comparison with a surrogate model of left lobe graft., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 330-333, 2021. (Summary) Background : The aim of this study is to clarify the regeneration of the CL (caudate lobe) without any reconstructions of short hepatic veins (SHVr) after LDLT (living donor liver transplantation) and compare the regeneration of the CL after right hepatectomy (Rt. Hx), as the surrogate model of extended left lobe graft (Ex LLG) with complete SHVr. Methods : Eleven Ex LLGs with CL were included in this study. SHVr was not performed in all cases. The volumetry was performed before, one month and six months after LDLT. Seven patients who underwent Rt. Hx were also included in this study as the surrogate model. Results : In Ex LLGs with CL, the regeneration rate of the large CL (> 30 ml) was worse than that of small CL (< 30 ml). In the surrogate model, the regeneration rate of the CL was not worse than other segments. However, the regeneration rate of the large CL was also worse than that of small CL even in the presence of complete SHVr. Conclusions : The regeneration of the large CL was worse than that of the small CL regardless of the presence or absence of SHVr, indicating that SHVr in Ex LLG with CL might not be necessary. J. Med. Invest. 68 : 330-333, August, 2021. (Keyword) Hepatectomy / Hepatic Veins / Humans / Liver / Liver Transplantation / Living Donors (Tokushima University Institutional Repository) ● Metadata: 116533 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.330 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759154 ● Search Scopus @ Elsevier (PMID): 34759154 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.330 (Tokushima University Institutional Repository: 116533, DOI: 10.2152/jmi.68.330, PubMed: 34759154)
115.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the CRP-albumin ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 244-255, 2021. (Summary) Background : The C-reactive protein (CRP)-albumin ratio (CAR) was reported as a prognostic factor of resectable hepatocellular carcinoma. The aim of this study was to analyse the significance of CAR in resectable pancreatic cancer. Patients and Methods : 163 patients with curative resection for pancreatic cancer were enrolled in this retrospective study. Cases of non-curative resection were excluded. The CAR was calculated with the preoperative plasma CRP and albumin values, with a cut-off value of 0.06, as calculated in a previous report. Results : Patients in the low CAR group had significantly better overall survival (OS) and disease-free survival (DFS) compared with the high CAR group (P < 0.05). On multivariate analysis, for high CAR, CA19-9 > 300 U /l and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. High CAR was significantly associated with advanced T stage. Conclusion : The CAR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 244-248, August, 2021. (Keyword) Albumins / C-Reactive Protein / Humans / Pancreatic Neoplasms / Prognosis / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116489 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.244 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759138 ● Search Scopus @ Elsevier (PMID): 34759138 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.244 (Tokushima University Institutional Repository: 116489, DOI: 10.2152/jmi.68.244, PubMed: 34759138)
116.	Shuhai Chen, Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective in vitro differentiation of adipose-derived stem cells into Schwann-like cells with folic acid supplementation., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 347-353, 2021. (Summary) Peripheral nerve injury (PNI) after pelvic surgery is a common issue with a significant impact on patients. Autologous nerve grafting is the gold standard treatment for PNI, but this technique cannot be applied to fine nerve fibers in the pelvis. Schwann-like cell (SLC) differentiation is a novel therapeutic strategy for this clinical condition. However, the efficiency of SLC differentiation remains unsatisfactory. We modified an SLC differentiation protocol using adipose-derived stem cells (ADSCs) and folic acid. Morphology, gene expression and secretion of neurotrophic factors were examined to assess the differentiation quality and phenotypic characteristics. Our new modified protocol effectively induced a Schwann cell (SC) phenotype in ADSCs as assessed by morphology and expression of SC markers [S100 calcium-binding protein B (S100B), P < 0.01 ; p75 neurotrophic receptor (p75NTR), P < 0.05]. SLCs produced by the new protocol displayed a repair phenotype with decreased expression of ERBB2 and early growth response protein 2 (EGR2) /ROX20 (P < 0.01). Furthermore, our new protocol enhanced both mRNA expression and secretion of nerve growth factors by SLCs (P < 0.01). This protocol enhanced the SC characteristics and functions of ADSC-derived SLCs. This promising protocol requires further research and may contribute to SC-based nerve regeneration. J. Med. Invest. 68 : 347-353, August, 2021. (Keyword) Adipose Tissue / Cell Differentiation / Cells, Cultured / Dietary Supplements / Folic Acid / Humans / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 116542 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.347 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759157 ● Search Scopus @ Elsevier (PMID): 34759157 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.347 (Tokushima University Institutional Repository: 116542, DOI: 10.2152/jmi.68.347, PubMed: 34759157)
117.	Yuji Morine, Toru Utsunomiya, Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Akihiro Kitagawa, Yuta Kobayashi, Seiichiro Takao, Keisuke Kosai, Koshi Mimori, Yasuhito Tanaka and Mitsuo Shimada : Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma., Oncotarget, Vol.11, No.52, 4803-4812, 2020. (Summary) Genome-wide analysis is widely applied to detect molecular alterations during oncogenesis and tumor progression. We analyzed DNA methylation profiles of hepatocellular carcinoma (HCC), and investigated the clinical role of most heypermethylated of tumor, encodes T-box 15 (TBX15), which was originally involved in mesodermal differentiation. We conducted a genome-wide analysis of DNA methylation of tumor and non-tumor tissue of 15 patients with HCC, and revealed was the most hypermethylated gene of tumor (Beta-value in tumor tissue = 0.52 compared with non-tumor tissue). Another validation set, which comprised 58 HCC with radical resection, was analyzed to investigate the relationships between tumor phenotype and mRNA expression. mRNA levels in tumor tissues were significantly lower compared with those of nontumor tissues ( < 0.0001). When we assigned a cutoff value = 0.5-fold, the overall survival 5-year survival rates of the low-expression group ( = 17) were significantly shorter compared with those of the high-expression group ( = 41) (43.3% vs. 86.2%, = 0.001). Multivariate analysis identified low expression as an independent prognostic factor for overall and disease-free survival. Therefore, genome-wide DNA methylation profiling indicates that hypermethylation and reduced expression of in tumor tissue represents a potential biomarker for predicting poor survival of patients with HCC. (Tokushima University Institutional Repository) ● Metadata: 116613 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27852 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33447348 ● Search Scopus @ Elsevier (PMID): 33447348 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27852 (Tokushima University Institutional Repository: 116613, DOI: 10.18632/oncotarget.27852, PubMed: 33447348)
118.	Yuuma Wada, Kazunori Tokuda, Yuji Morine, Shohei Okikawa, Shoko Yamashita, Tetsuya Ikemoto, Satoru Imura, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The inhibitory effect of TU-100 on hepatic stellate cell activation in the tumor microenvironment., Oncotarget, Vol.11, No.49, 4593-4604, 2020. (Summary) The tumor microenvironment is involved in acquiring tumor malignancies of colorectal liver metastasis (CRLM). We have reported that TU-100 (Daikenchuto) suppresses hepatic stellate cell (HSC) activation in obstructive jaundice. In this study, we report new findings as the direct and indirect inhibitory effects of TU-100 on cancer cell growth through the suppression of HSC activation. The HSCs (LX2) were cultured in colon cancer cells (HCT116 and HT29)-conditioned medium (CM) with or without TU-100 treatment (90, 270, 900 g/ml). Activated HSCs (aHSCs) were detected by -SMA and IL-6 mRNA expressions and cytokine arrays of HSC's culture supernatants. Cancer cell growth was analyzed for proliferation and migration ability, compared with TU-100 treatment. To investigate the direct anti-tumor effect of TU-100, cancer cells were cultured in the presence of aHSC-CM and TU-100 (90, 270, 900) or aHSC-CM alone, and assessed autophagosomes, conversion to LC3-II protein, and Beclin-1 mRNA expression. Colon cancer-CM significantly increased -SMA and IL-6 mRNA expressions of aHSC. -SMA and IL-6 mRNA expressions of aHSC, and IL-6 secretions from aHSCs were significantly decreased with TU-100 (270, 900) treatment, compared to colon cancer-CM alone. Compared with normal culture medium, aHSC-CM led to a significantly increased cell number and modified HSC-CM (TU-100; 270, 900) significantly suppressed cancer cell growth and migration. TU-100 (900) treatment induced autophagy and significantly promoted the autophagic cell death. TU-100 inhibited colon cancer cell malignant potential by both suppressing HSC activation and inducing directly autophagy of cancer cells. (Tokushima University Institutional Repository) ● Metadata: 116616 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27835 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33346211 ● Search Scopus @ Elsevier (PMID): 33346211 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27835 (Tokushima University Institutional Repository: 116616, DOI: 10.18632/oncotarget.27835, PubMed: 33346211)
119.	Hitoshi Ozawa, Akiyoshi Hirayama, Futaba Shoji, Midori Maruyama, Kumi Suzuki, Hisami Yamanaka-Okumura, Hiroshi Tatano, Yuji Morine, Tomoyoshi Soga, Mitsuo Shimada and Masaru Tomita : Comprehensive Dipeptide Analysis Revealed Cancer-Specific Profile in the Liver of Patients with Hepatocellular Carcinoma and Hepatitis., Metabolites, Vol.10, No.11, 2020. (Summary) As the physical properties and functionality of dipeptides differ from those of amino acids, they have attracted attention in metabolomics; however, their functions in vivo have not been clarified in detail. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and its major cause is chronic hepatitis. This study was conducted to explore tumor-specific dipeptide characteristics by performing comprehensive dipeptide analysis in the tumor and surrounding nontumor tissue of patients with HCC. Dipeptides were analyzed by liquid chromatography tandem mass spectrometry and capillary electrophoresis tandem mass spectrometry. Principal component analysis using 236 detected dipeptides showed differences in the dipeptide profiles between nontumor and tumor tissues; however, no clear difference was observed in etiological comparison. In addition, the N- and C-terminal amino acid compositions of the detected dipeptides significantly differed, suggesting the substrate specificity of enzyme proteins, such as peptidase. Furthermore, hepatitis-derived HCC may show a characteristic dipeptide profile even before tumor formation. These results provide insight into HCC pathogenesis and may help identify novel biomarkers for diagnosis. (Tokushima University Institutional Repository) ● Metadata: 116600 (Link to Publication Site) ● Publication site (DOI): 10.3390/metabo10110442 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33139606 ● Search Scopus @ Elsevier (PMID): 33139606 ● Search Scopus @ Elsevier (DOI): 10.3390/metabo10110442 (Tokushima University Institutional Repository: 116600, DOI: 10.3390/metabo10110442, PubMed: 33139606)
120.	Chie Takasu, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara and Yukako Takehara : 夢を実現し，輝く女性外科医たち-求められるサポート体制と働き方改革- 地方外科から発信するダイバーシティ・インクルージョンを目指した取り組み, Journal of Japan Surgical Society, Vol.121, No.6, 692-693, 2020. (Keyword) 労働衛生女性医師病院人事管理文化の多様性ワークライフバランス外科医ヒト女
121.	Shin-ichiro Yamada, Yuji Morine, Hiroki Ishibashi and Mitsuo Shimada : 【臨床に役立つ胆と膵の解剖学】膵・胆管合流異常の解剖と病型分類, Journal of Biliary Tract & Pancreas, Vol.41, No.11, 1085-1092, 2020. (Summary) 膵・胆管合流異常(pancreaticobiliary maljunction:PBM)は，解剖学的に膵管と胆管が十二指腸壁外で合流する先天性の形成異常であり，膵液と胆汁の相互逆流により高率な胆道発癌や膵炎をはじめとしたさまざまな病態を引き起こす．PBMの発生には，腹側膵原基と背側膵原基が癒合する以前の，下部胆管と腹側膵の異常が影響し，背側膵の関与はないと考えられている．PBMの分類においては胆管拡張の有無がとくに重要であり，拡張があるもの(先天性胆道拡張症)とないもの(胆道非拡張型)に分けられ，さらに胆管と膵管の合流形式などによってこれまでいくつかの分類が報告されている．また，共通管が6mm以上で合流部に括約筋作用が及ぶ例は膵胆管高位合流と定義され，PBMとは異なる病態として扱われる．今後の課題として，胆管拡張の定義や型分類の統一，高位合流との鑑別があげられる．(著者抄録) (Keyword) 局所解剖学分類 *膵胆管合流異常胆道拡張症病態生理ヒト
122.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Impact of sidedness of colorectal cancer on tumor immunity., PLoS ONE, Vol.15, No.10, e0240408, 2020. (Summary) Clinical and molecular characteristics differ between right-sided and left-sided colorectal cancer (CRC). This study aimed to clarify the correlation between CRC sidedness and tumor immunity. A total of 102 patients who underwent curative colectomy for stage II/III CRC were included in this study. The expression of programmed cell death (PD)-1, PD1-ligand 1 (PD-L1), forkhead box P3 (Foxp3), transforming growth factor (TGF)-β, and indoleamine-pyrrole 2,3-dioxygenase (IDO) were examined using immunohistochemistry and the relationships between sidedness and several prognostic factors were examined. Clinicopathological factors were not significantly different between right- and left-sided CRC. The tumor immunity-related molecule PD-L1 was more highly expressed in right-sided than in left-sided CRC (62.9% vs. 30.6%, p<0.01). No significant difference was found in overall survival (OS) and disease-free survival (DFS) by sidedness. PD-1 and Foxp3 expression were significant prognostic factors for OS. Lymph node metastasis (N), lymphatic invasion (ly), and PD-L1 expression were significant prognostic factors for DFS. In right-sided CRC, IDO-positive patients had a poor OS (p<0.05), and IDO was the only independent prognostic indicator for OS. N and venous invasion were identified as independent prognostic indicators for DFS. In left-sided CRC, univariate analysis identified PD-1, PD-L1, and Foxp3 expression as significant predictors of poor OS. Multivariate analysis confirmed PD-L1 expression as an independent prognostic indicator. N, ly, and PD-L1 expression levels were identified as significant predictors of poor DFS. The prognostic factors were IDO in right-sided CRC and PD-L1 and Foxp3 in left-sided CRC. These findings indicated that tumor immunity might play different roles depending upon sidedness. Tumor location may be an important factor to consider when assessing immune response and therapeutic decisions in CRC patients. (Keyword) Adult / Aged / Aged, 80 and over / B7-H1 Antigen / Biomarkers, Tumor / Colorectal Neoplasms / Disease-Free Survival / Female / Forkhead Transcription Factors / Gene Expression Regulation, Neoplastic / Humans / Indoleamine-Pyrrole 2,3,-Dioxygenase / Male / Middle Aged / Neoplasm Staging / Prognosis / Programmed Cell Death 1 Receptor / Transforming Growth Factor beta / Up-Regulation (Tokushima University Institutional Repository) ● Metadata: 115400 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0240408 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33045001 ● Search Scopus @ Elsevier (PMID): 33045001 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0240408 (Tokushima University Institutional Repository: 115400, DOI: 10.1371/journal.pone.0240408, PubMed: 33045001)
123.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori, Mitsuo Shimada, 遠藤秀子 and Yoshimi Bando : 同時性・異時性に多発した小児脂肪芽腫の1例, Journal of the Japanese Society of Pediatric Surgeons, Vol.56, No.6, 988-991, 2020. (Summary) 症例は3歳，男児．両側鼠径部外側と右背部の紡錘状の皮下腫瘤を認めたため，当科紹介受診となった．外来で経過観察を行っていたが，その後，左腋窩部及び右季肋部にも同様の皮下腫瘤が出現した．非典型的に多発し，悪性の可能性も否定できなかったため，背部皮下腫瘤を摘出し，脂肪芽腫と診断した．残りの4ヶ所を追加で切除したところ，最初の病変と同様に，脂肪芽細胞や小型の脂肪細胞を認め，同時・異時性に多発した脂肪芽腫と診断した．術後，約1年半が経過しているが，新たな腫瘤の発生や再発は認めていない．脂肪芽腫では，発見後の早期摘出が一般的であるが，稀に本症例のような多発例が存在することも念頭におき，早期摘出後も慎重な経過観察が必要であると思われた．(著者抄録) (Keyword) 腋窩(超音波診断,外科的療法) 腫瘍-多発性原発超音波診断鼠径部(超音波診断,外科的療法) 軟部組織腫瘍(超音波診断,外科的療法) 背部(超音波診断,外科的療法) 腫瘍-第二原発 *脂肪芽細胞腫(超音波診断,外科的療法) 季肋部(超音波診断,外科的療法) ヒト幼児(2∼5) 男 (Link to Publication Site) ● Publication site (DOI): 10.11164/jjsps.56.6_988 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1391130851445583872 ● Search Scopus @ Elsevier (DOI): 10.11164/jjsps.56.6_988 (DOI: 10.11164/jjsps.56.6_988, CiNii: 1391130851445583872)
124.	Hiroki Ishibashi, Noriko Yokota, Hiroki Mori and Mitsuo Shimada : 【そこが知りたいシリーズ:手術で必要な局所解剖(腹壁・後腹膜・泌尿器・腫瘍編)】大腿ヘルニア, Japanese Journal of Pediatric Surgery, Vol.52, No.10, 1049-1053, 2020. (Keyword) 局所解剖学鼠径部大腿ヘルニア(外科的療法) 腹腔鏡法ヘルニア縫合術ヒト小児(6∼12)
125.	Tetsuya Ikemoto, Kazunori Tokuda, Yuuma Wada, Luping Gao, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells., Pancreas, Vol.49, No.9, 1225-1231, 2020. (Summary) We aimed to determine whether responsive insulin-producing cells (IPCs) could be generated from adipose-derived stem cells (ADSCs) isolated from patients with type 1 diabetes mellitus (T1DM). We isolated ADSCs from adipose tissue of 4 patients (one patient with T1DM and 3 nondiabetic patients), who underwent surgery and differentiated them into IPCs with using a 2-step xeno-antigen free, 3-dimensional culture method. Characteristics of isolated ADSCs, in vitro cell quality, programmed cell death ligand-1 (PDL-1) expression, and transplantation into streptozotocin induced diabetic nude mice were investigated. Adipose-derived stem cells from T1DM patients and commercially obtained ADSCs showed the same surface markers; CD31CD34CD45CD90CD105CD146. Moreover, the generated IPCs at day 21 demonstrated appropriate autonomous insulin secretion (stimulation index, 3.5; standard deviation, 0.8). Nonfasting blood glucose concentrations of IPC-transplanted mice were normal at 30 days. The normalized rate of IPC-transplanted mice was significantly higher than that of the sham-operated group (P < 0.05). Insulin-producing cells generated from T1DM adipose tissue expressed high levels of PDL-1. Insulin-producing cells obtained from adipose tissue of T1DM patients are capable of secreting insulin long-term and achieve normoglycemia after transplantation. Expression of PDL-1 suggests the potential for immune circumvention. (Link to Publication Site) ● Publication site (DOI): 10.1097/MPA.0000000000001663 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32898009 ● Search Scopus @ Elsevier (PMID): 32898009 ● Search Scopus @ Elsevier (DOI): 10.1097/MPA.0000000000001663 (DOI: 10.1097/MPA.0000000000001663, PubMed: 32898009)
126.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shin-ichiro Yamada and Mitsuo Shimada : HIF-1 expression in liver metastasis but not primary colorectal cancer is associated with prognosis of patients with colorectal liver metastasis., World Journal of Surgical Oncology, Vol.18, No.1, 241, 2020. (Summary) The role of hypoxia-inducible factor-1 (HIF-1 ) in primary colorectal cancer (CRC) and colorectal liver metastasis (CRLM) has remained unclear. The aim of this study was to investigate HIF-1 expression and its association with prognosis in patients with CRLM with a focus on hepatic stellate cells (HSCs). Colon cancer cells were cultured in HSC-conditioned medium (CM), and HIF-1 expression and cell migration were analyzed. Seventy-five patients with CRLM who underwent an initial curative hepatectomy were enrolled. We examined HIF-1 expressions and patient prognosis between primary CRCs and the matched liver metastatic specimens. Activated HSCs induced HIF-1 mRNA and protein expression in colon cancer cells (p < 0.01) and promoted cell migration (p < 0.01). The positive rates of HIF-1 expression in primary CRCs and liver metastases were 68.0 and 72.0%, respectively. There were no differences in overall (OS) and disease-free survival (DFS) of HIF-1 expression in primary CRC. However, HIF-1 expression in liver metastasis correlated to poor prognosis in both OS and DFS. Furthermore, patients with HIF-1 positive expression in liver metastasis had poor prognosis. HIF-1 expression in liver metastasis determines poor prognosis of CRLM patients. HSCs might play a key role in aggressive phenotypes of tumor cells. (Keyword) Colonic Neoplasms / Colorectal Neoplasms / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / Prognosis (Tokushima University Institutional Repository) ● Metadata: 116676 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-020-02012-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32895059 ● Search Scopus @ Elsevier (PMID): 32895059 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-020-02012-5 (Tokushima University Institutional Repository: 116676, DOI: 10.1186/s12957-020-02012-5, PubMed: 32895059)
127.	Kazunori Tokuda, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma., International Journal of Clinical Oncology, Vol.25, No.12, 2083-2089, 2020. (Summary) Intrahepatic cholangiocarcinoma (IHCC) has a poor prognosis, and surgery remains the only effective treatment. However, tumor recurrence after primary hepatectomy is common. We examined the significance of repeat surgery for IHCC. We collected data for all patients with IHCC between 1992 and 2018 (n = 67) in our database. Fifty-three (79.1%) of all 67 patients experienced recurrence after primary hepatectomy and we analyzed data for those 53 recurrent patients. We divided recurrent patients into a repeat surgery group (n = 9), chemotherapy group (n = 19), and best supportive care group (n = 25). We analyzed differences in patients' clinicopathological factors, including prognosis, between the three groups. The IHCC recurrence rate after hepatectomy in our institution was 79.1%. Of the 53 patients with recurrence, nine underwent repeat surgery (17.0%). The characteristics of the patients undergoing repeat surgery was lower stage at primary hepatectomy. Recurrence sites in the repeat surgery group were liver (n = 6), lung (n = 2), and adrenal gland (n = 1), as a single nodule. The period between primary hepatectomy and recurrence was comparatively longer in the repeat surgery group, at 1.8 years. The prognosis in patients undergoing repeat surgery was significantly better compared with the other groups. Not undergoing repeat surgery (hazard ratio: 5.506; p = 0.0077) and positive lymph node metastasis (hazard ratio: 2.207; p = 0.0242) were independent poor prognostic factors. Repeat surgery should be considered in patients with IHCC with a single recurrence site and negative lymph node metastasis at primary surgery and at least more than 6 months of disease-free period after primary surgery. (Keyword) Adrenal Gland Neoplasms / Adrenalectomy / Adult / Aged / Aged, 80 and over / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Female / Hepatectomy / Humans / Liver Neoplasms / Lung Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Neoplasm Recurrence, Local / Prognosis / Proportional Hazards Models / Reoperation / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-020-01775-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32869120 ● Search Scopus @ Elsevier (PMID): 32869120 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-020-01775-x (DOI: 10.1007/s10147-020-01775-x, PubMed: 32869120)
128.	Shuichi Iwahashi, AHMAD AMMAR GHAIBEH, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Jun Hirose : Predictability of postoperative recurrence on hepatocellular carcinoma through data mining method., Molecular and Clinical Oncology, Vol.13, No.5, 46, 2020. (Summary) Hepatocellular carcinoma (HCC) is a highly lethal tumor and the majority of postoperative patients experience recurrence. In the present study, we focus on the predictability of postoperative recurrence on HCC through the data mining method. In total, 323 patients with HCC who underwent hepatic resection were included in the present study, 156 of whom suffered from cancer recurrence. Clinicopathological data including prognosis were analyzed using the data mining method for the predictability of postoperative recurrence on HCC. The resulting alternating decision tree (ADT) was described using data mining method. This tree was validated using a 10-fold cross validation process. The average and standard deviation of the accuracy, sensitivity, and specificity were 69.0 8.2, 59.7 14.5 and 77.7 10.2%, respectively. The identified postoperative recurrence factors were age, viral hepatitis, stage, GOT and T-cholesterol. Data mining method could identify the factors associated at different levels of significance with postoperative recurrence of HCC. These factors could help to predict the postoperative recurrence of HCC. (Link to Publication Site) ● Publication site (DOI): 10.3892/mco.2020.2116 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32874576 ● Search Scopus @ Elsevier (PMID): 32874576 ● Search Scopus @ Elsevier (DOI): 10.3892/mco.2020.2116 (DOI: 10.3892/mco.2020.2116, PubMed: 32874576)
129.	Shogo Oota, Masaaki Nishi, Takuya Tokunaga, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Mitsuo Shimada : Usefulness of an ICG fluorescence catheter system in TaTME for avoiding intraoperative urethral injury., The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 285-288, 2020. (Summary) Sometimes intraoperative urethral injury occurs in Transanal total mesorectal excision (TaTME). The aim of this study is to investigate the usefulness of indocyanine green (ICG) fluorescent catheter system for avoiding intraoperative urethral injury in TaTME in experimental model. A urethral catheter was filled with the mixture of albumin and ICG and raw hams were applied in layers as the surrogate model of rectourethral muscle. The detectability of ICG fluorescence in this catheter was investigated by using laparoscope-type fluorescence camera system. Fluorescence was detected when ICG was mixed with albumin or peripheral blood. ICG fluorescence could be detected within 4 mm depth of layered raw hams as the surrogate model. Quantitative analysis of the picture detected that ICG fluorescence plateaued in lower concentration than that of serum. ICG fluorescent catheter system may be useful for avoiding intraoperative urethral injury in TaTME. J. Med. Invest. 67 : 285-288, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115426 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.285 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148903 ● Search Scopus @ Elsevier (PMID): 33148903 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.285 (Tokushima University Institutional Repository: 115426, DOI: 10.2152/jmi.67.285, PubMed: 33148903)
130.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : Trans-abdominal Pre-peritoneal (TAPP) Inguinal Hernia Repair with Liquid-injection and Gauze Dissection., The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 271-273, 2020. (Summary) Purpose : This report describes a novel technique for trans-abdominal pre-peritoneal (TAPP) inguinal hernia repair using liquid injection and gauze dissection. Methods : Twenty-five cases underwent TAPP inguinal hernia repair with liquid-injection and gauze dissection. Before the initial peritoneal incision, liquid injection was performed percutaneously into the pre-peritoneal space at the outside of the internal inguinal ring and the inside of the seminal duct. Especially, at the inside of the seminal duct, the liquid was injected into the space between the superficial and deep lobe of pre-peritoneal fascia. Gauze was effectively used to dissect this liquid-injected space. Results : In comparison with the cases of inguinal hernia repair without liquid-injection and gauze dissection, the cases who underwent TAPP inguinal hernia repair with liquid-injection and gauze dissection experienced shorter operation times and no complications or recurrence. Conclusions : TAPP inguinal hernia repair with liquid-injection and gauze dissection appears to be a safe and feasible procedure. J. Med. Invest. 67 : 271-273, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115423 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.271 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148900 ● Search Scopus @ Elsevier (PMID): 33148900 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.271 (Tokushima University Institutional Repository: 115423, DOI: 10.2152/jmi.67.271, PubMed: 33148900)
131.	Yukako Takehara, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Desmoid-type fibromatosis difficult to distinguish from GIST : A case report., The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 375-377, 2020. (Summary) Background : Desmoid-type fibromatosis is a very rare disease that has no characteristic image findings, so it is often difficult to differentiate from gastrointestinal stromal tumor (GIST). A case of desmoid-type fibromatosis that was difficult to differentiate from GIST is reported. The decisive factor in the diagnosis was positive nuclear immunostaining for β-catenin nucleus. Case presentation : A man is his 30s had no significant past medical history, including no abdominal surgery. A medical check-up found a large tumor in the right lateral abdomen. After some examinations, a preoperative diagnosis of GIST was made, and open ileocecal resection was performed. However, the final diagnosis based on the pathological findings was desmoid-type fibromatosis. Conclusions : We should consider desmoid-type fibromatosis when we find a large abdominal mass, but it may be difficult to diagnose based only on imaging findings. Immunohistochemical examination of the specimen may make the diagnosis. J. Med. Invest. 67 : 375-377, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115460 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.375 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148921 ● Search Scopus @ Elsevier (PMID): 33148921 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.375 (Tokushima University Institutional Repository: 115460, DOI: 10.2152/jmi.67.375, PubMed: 33148921)
132.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : Impact of using a perioperative artificial endocrine pancreas in pancreatic resection., Annals of Gastroenterological Surgery, Vol.4, No.5, 591-596, 2020. (Summary) Pancreatectomy causes both hyperglycemia, secondary to surgical stress, and pancreatic diabetes, which leads to difficult-to-control postoperative blood glucose levels. We investigated whether using an artificial pancreas perioperatively to provide appropriate blood glucose control could reduce postoperative complications following pancreatectomy. We retrospectively enrolled 52 patients who underwent pancreatectomy at Tokushima University Hospital from 2015 to 2019. The most recent 26/52 patients received perioperative blood glucose control using an artificial pancreas. Postoperative blood glucose control with manual insulin injections based on a sliding scale was performed in the earlier 26 patients (controls). We compared surgical outcomes between the artificial pancreas group and the control group. There was no significant difference in patients' white blood cell or neutrophil counts, prognostic nutritional index, neutrophil-lymphocyte ratio, and C-reactive protein-to-albumin ratio on postoperative day 1; however, lymphocyte counts were higher in the artificial pancreas group. The number of serious complications of Clavien-Dindo grade >IIIa was significantly lower in the artificial pancreas group ( < .05). Using an artificial pancreas for perioperative blood glucose control in patients undergoing pancreatectomy decreased the number of serious complications through proper management of blood glucose levels without hypoglycemia, and may influence peripheral lymphocytes. (Tokushima University Institutional Repository) ● Metadata: 116476 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12374 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33005854 ● Search Scopus @ Elsevier (PMID): 33005854 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12374 (Tokushima University Institutional Repository: 116476, DOI: 10.1002/ags3.12374, PubMed: 33005854)
133.	Hiroki Teraoku, Yuji Morine, Naoto Uyama, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Satoru Imura, Masafumi Harada and Mitsuo Shimada : Role of Central Hypo-enhancement in the Hepatic Arterial Phase of Dynamic Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma., World Journal of Surgery, Vol.44, No.7, 2350-2358, 2020. (Summary) The enhancement pattern in the hepatic arterial phase (HAP) of dynamic computed tomography (CT) is reportedly a prognostic marker in patients with intrahepatic cholangiocarcinoma (IHCC). This study was performed to clarify the significance of central hypo-enhancement in the HAP in patients with mass-forming IHCC. Forty patients who had undergone initial surgical resection for mass-forming IHCC were enrolled. The dynamic CT was scanned 40 s after contrast agent injection as the HAP. A radiologist classified the patients into three groups based on the vascular pattern: the hyper-enhancement group (Hyper group), rim-enhancement group (Rim group), and hypo-enhancement group (Hypo group). The surgical specimens were immunohistochemically stained for hypoxia-inducible factor 1 (HIF-1). The correlation with clinicopathological findings and HIF-1 expression was investigated. The Hyper, Rim, and Hypo groups comprised 8, 7, and 25 patients, respectively. There were no significant correlations between the groups and clinicopathological factors. Overall survival (OS) was significantly worse in the Hypo than in the Hyper group (p = 0.03). OS was also significantly worse in the Rim +ypo group (i.e., hypo-enhancement in the central tumor) than in the Hyper group (p = 0.04). Furthermore, inclusion in the Rim +ypo group was a prognostic factor for OS (hazard ratio 6.68). High HIF-1 expression in the central part of the tumor was correlated with central hypo-enhancement (Hyper group: 25% and Rim +ypo group: 72%). Central hypo-enhancement was a prognostic factor in patients with IHCC. The high malignant potential of tumors with central hypo-enhancement might be associated with HIF-1 upregulation. (Keyword) Adult / Aged / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Biomarkers, Tumor / Cholangiocarcinoma / Contrast Media / Female / Follow-Up Studies / Hepatectomy / Hepatic Artery / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Male / Middle Aged / Multidetector Computed Tomography / Prognosis / Proportional Hazards Models / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1007/s00268-020-05456-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32152739 ● Search Scopus @ Elsevier (PMID): 32152739 ● Search Scopus @ Elsevier (DOI): 10.1007/s00268-020-05456-8 (DOI: 10.1007/s00268-020-05456-8, PubMed: 32152739)
134.	Katsuki Miyazaki, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Pancreatoduodenectomy co-morbid with celiac axis compression syndrome: a report of three cases., Surgical Case Reports, Vol.6, No.1, 113, 2020. (Summary) Celiac axis compression syndrome (CACS) is a relatively rare disease. Because of the nature of the blood flow in the celiac region when a pancreatoduodenectomy (PD) is performed for CACS, the celiac region can become ischemic. The aim of this study is to report on the importance of pre-operative diagnosis of CACS in terms of the outcomes for patients post-operatively. In this study, three 3 cases of PD co-morbid with CACS are reported: one intra-operative diagnosis case and two pre-operative diagnosis cases. The one case, not diagnosed with CACS prior to the operation, had a hard post-operative course because of complication caused by ischemia of the celiac region compared with the two cases diagnosed prior to the operation, who had a good post-operative course because of pre-operative or intra-operative intervention. Post-operative complications due to CACS are preventable by pre-operative diagnosis and appropriate interventions. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-020-00878-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32449014 ● Search Scopus @ Elsevier (PMID): 32449014 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-020-00878-x (DOI: 10.1186/s40792-020-00878-x, PubMed: 32449014)
135.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Toshiaki Yoshimoto and Mitsuo Shimada : Usefulness of virtual three-dimensional image analysis in inguinal hernia as an educational tool., Surgical Endoscopy, Vol.34, No.2, 1923-1928, 2020. (Summary) The pre-operative three-dimensional (3D) imaging technique has resulted in a better surgical outcome for patients and has been used as an education and diagnostic tool. However, there are no reports concerning the usefulness of the 3D imaging technique in laparoscopic transabdominal pre-peritoneal repair (TAPP) so the aim of this study was to investigate the usefulness of the 3D imaging technique in laparoscopic TAPP as an educational tool for medical students. Six (6) patients who underwent laparoscopic TAPP for inguinal hernia were enrolled in this study. 3D reconstruction was performed from pre-operative computed tomography (CT) and the usefulness of pre-operative 3D simulation compared with intra-operative laparoscopic imaging was validated. Moreover, thirty (30) medical students at the university completed a multiple-choice questionnaire (MCQ) to determine the level of their satisfaction and understanding of anatomy resulting from the study. The local anatomy of the patients was identified as the same during the operation as the pre-operative 3D simulation. The results of the MCQ showed that most of the medical students were extremely (23%) or very (67%) satisfied with the effect of pre-operative 3D simulation on the quality of the surgery. Moreover, most students could understand the surgery anatomy by the 3D simulation extremely well (40%) or very well (47%) and agreed on the usefulness of this procedure for learning anatomy. Pre-operative 3D simulation increases the understanding of detailed anatomy and virtual three-dimensional image analysis in laparoscopic TAPP is useful as an educational tool for medical students. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-019-06964-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31312962 ● Search Scopus @ Elsevier (PMID): 31312962 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-019-06964-y (DOI: 10.1007/s00464-019-06964-y, PubMed: 31312962)
136.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 【最先端医療を支える病理学】消化管最新外科手術における病理の役割, Shikoku Acta Medica, Vol.76, No.1-2, 3-8, 2020. (Summary) Recently, the surgical procedure of gastrointestinal tract has been developing. Compared with open surgery, laparoscopic surgery showed less invasiveness, intraoperative blood loss, postoperative pain and hospital stay. Since2018, robotic surgery in gastric and rectal cancer could be covered by insurance. Robotic surgery enables to perform minimally invasive surgery with an advanced set of instruments and a 3D high-definition view of the surgical area. So, robotic surgery enables to perform more accurate and less invasive surgery. In order to secure the curability and provide less invasive surgery, the role of pathology is very important. The aim of this study is to introduce a new surgical procedure and the role of pathology in gastrointestinal tract cancer. (Keyword) robotic surgery / gastric cancer / rectal cancer / pathology (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050865122805932544 (CiNii: 1050865122805932544)
137.	Yu Saitou and Mitsuo Shimada : 【最先端医療を支える病理学】肝胆膵外科の最先端手術画像支援と病理診断のコラボ, Shikoku Acta Medica, Vol.76, No.1-2, 9-12, 2020. (Summary) We introduced the pre and intra-operative3D hologram support system, which was a computer graphics model, with extended reality(XR)techniques. It contributed to a more extensive view of 3D anatomy from various angles and the sharing of the same hologram from several respective operators' angles. The colabolation between such an operative supporrt and pathological diagnosis enables more safe and higher quality operations. (Keyword) ホログラフィー肝臓疾患(画像診断,外科的療法,病理学) コンピュータグラフィックス細胞診術中期消化器外科コンピュータ支援診断膵臓疾患(画像診断,外科的療法,病理学) 胆道疾患(画像診断,外科的療法,病理学) ヒト (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050302172852511104 (CiNii: 1050302172852511104)
138.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.27, No.7, 388-395, 2020. (Summary) We evaluated apparent diffusion coefficient (ADC) of diffusion-weighted image MRI as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma (IHCC). We enrolled 26 patients who had undergone hepatic resections for mass-forming-type IHCC in this study, and calculated their mean ADC, using diffusion-weighted image MRI (b: 0, 20, 800 seconds/mm ; 1.5 T MRI). Patients were divided into the ADC and the ADC groups at the median ADC value (n = 13 for both). We also immunohistochemically evaluated hypoxia-inducible factor (HIF)-1 in tumor tissue. Median age in the ADC was older (P = .03), and showed significant higher rate of scirrhous tumor (P = .02). The 5-year overall survival rate in the ADC group was significantly worse than in the ADC group (P = .04). In multivariate analysis, hilar tumor, portal vein invasion and low ADC were independent prognostic factors (P < .05). The ADC group also had a higher rate of high HIF-1 expression than the ADC group (P < .05). Representative case of ADC group showed rich stroma and high HIF-1 expression. The ADC values in MRIs can predict IHCC prognosis, and correlated with stromal density and HIF-1 expression. (Keyword) Aged / Algorithms / Bile Duct Neoplasms / Biomarkers, Tumor / Cholangiocarcinoma / Contrast Media / Diffusion Magnetic Resonance Imaging / Female / Hepatectomy / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Male / Neoplasm Invasiveness / Prognosis / Survival Rate / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.732 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32162483 ● Search Scopus @ Elsevier (PMID): 32162483 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.732 (DOI: 10.1002/jhbp.732, PubMed: 32162483)
139.	Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : The usefulness of intraoperative X-ray fluoroscopy in avoiding urethral injury during transanal total mesorectal excision., Asian Journal of Endoscopic Surgery, Vol.13, No.2, 242-245, 2020. (Summary) Urethral injury is one of the most important complications that can occur during transanal total mesorectal excision in male patients with rectal cancer. This report shows the usefulness of intraoperative X-ray fluoroscopy to avoid urethral injury associated with transanal total mesorectal excision. Real-time navigation using fluoroscopy was performed to check the distance between the urethra and the dissection line at the level of the exposed rectourethral muscle, the middle level of the divided rectourethral muscle, and the level at which the prostate was identified. The dissection was completed transanally up to the level of peritoneal reflection on the anterior side without urethral injury. Pathological examination confirmed that the circumferential resection margin was tumor free. This novel technique using intraoperative X-ray fluoroscopy is an easy-to-use approach that helps prevent urethral injury in male patient who undergo transanal total mesorectal excision for rectal cancer. (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12717 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31215751 ● Summary page in Scopus @ Elsevier: 2-s2.0-85083042497 (DOI: 10.1111/ases.12717, PubMed: 31215751, Elsevier: Scopus)
140.	Satoru Imura and Mitsuo Shimada : 各分野のガイドラインを紐解く肝癌診療ガイドライン, Journal of Japan Surgical Society, Vol.121, No.2, 277-278, 2020. (Keyword) 肝切除 *肝臓腫瘍(外科的療法,薬物療法) 診療ガイドライン分子標的治療ヒト
141.	Daichi Ishikawa, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : The Role of Neutrophil-to-lymphocyte Ratio on the Effect of CRT for Patients With Rectal Cancer., In Vivo, Vol.34, No.2, 863-868, 2020. (Summary) Neutrophil-to-lymphocyte ratio (NLR) is an indicator of systemic inflammation and could be a predictive factor in malignant tumors. The aim of this study was to investigate the impact of NLR in patients with lower rectal cancer who received preoperative chemo-radiotherapy (CRT). Forty-eight patients with lower rectal cancer who underwent preoperative CRT and curative resection were enrolled. Blood samples were obtained before and after CRT. The relationship of NLR with clinical outcome was investigated. Post-CRT NLR was higher compared to pre-CRT NLR. The patients with higher post-CRT NLR tended to have worse pathological response to CRT compared to those with low post-CRT NLR. The patients with high post-CRT NLR showed poorer 5-year overall survival and 3-year disease free survival while there was no correlation according to pre-CRT NLR. The univariate analysis showed that post-CRT stage and post-CRT NLR were associated with a poorer 5-year overall survival. NLR after preoperative CRT could be a potential prognostic indicator for patients with lower rectal cancer. (Keyword) Aged / Aged, 80 and over / Biomarkers, Tumor / Chemoradiotherapy / Combined Modality Therapy / Female / Humans / Leukocyte Count / Lymphocytes / Male / Middle Aged / Neoplasm Staging / Neutrophils / Preoperative Care / Prognosis / Rectal Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11850 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32111796 ● Search Scopus @ Elsevier (PMID): 32111796 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11850 (DOI: 10.21873/invivo.11850, PubMed: 32111796)
142.	Hiroki Ishibashi, Noriko Yokota, Hiroki Mori and Mitsuo Shimada : 【そこが知りたいシリーズ:手術で必要な局所解剖(腹部編)】PSARP(中間位直腸肛門奇形), Japanese Journal of Pediatric Surgery, Vol.52, No.2, 158-162, 2020.
143.	Yu Saitou, Maki Sugimoto, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : Intraoperative 3D Hologram Support With Mixed Reality Techniques in Liver Surgery., Annals of Surgery, Vol.271, No.1, e4-e7, 2020. (Summary) The aim of this study was to investigate the potential of an intraoperative 3D hologram, which was a computer graphics model liver, with mixed reality techniques in liver surgery. The merits for the application of a hologram for surgical support are: 1) no sterilized display monitor; 2) better spatial awareness; and 3) 3D images shared by all the surgeons. 3D polygon data using preoperative computed tomography data was installed into head mount displays, HoloLens (Microsoft Corporation, Redmond, WA). In a Wi-Fi-enabled operative room, several surgeons wearing HoloLens succeeded in sharing the same hologram and moving that hologram from respective operators' angles by means of easy gesture-handling without any monitors. The intraoperative hologram contributed to better imagination of tumor locations, and for determining the parenchymal dissection line in the hepatectomy for the patients with more than 20 multiple colo-rectal liver metastases. In another case, the hologram enabled a safe Gliisonean pedicle approach for hepato-cellular carcinoma with a hilar anatomical anomaly. Surgeons could easily compare the real patient's anatomy and that of the hologram just before the hepatic hilar procedure. This initial experience suggested that an intraoperative hologram with mixed reality techniques contributed to "last-minute simulation," not for "navigation." The intraoperative hologram might be a new next-generation operation-supportive tool in terms of spatial awareness, sharing, and simplicity. (Tokushima University Institutional Repository) ● Metadata: 114184 (Link to Publication Site) ● Publication site (DOI): 10.1097/SLA.0000000000003552 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31425293 ● Search Scopus @ Elsevier (PMID): 31425293 ● Search Scopus @ Elsevier (DOI): 10.1097/SLA.0000000000003552 (Tokushima University Institutional Repository: 114184, DOI: 10.1097/SLA.0000000000003552, PubMed: 31425293)
144.	Kazunori Tokuda, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Shoko Yamashita, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : The Fragility of Cryopreserved Insulin-producing Cells Differentiated from Adipose-tissue-derived Stem Cells., Cell Transplantation, Vol.29, 963689720954798, 2020. (Summary) The aim of our study is to determine whether insulin-producing cells (IPCs) differentiated from adipose-tissue-derived stem cells (ADSCs) can be cryopreserved. Human ADSCs were differentiated into IPCs using our two-step protocol encompassing a three-dimensional culture and xenoantigen-free method. Thereafter, IPCs were frozen using three different methods. First, IPCs were immediately frozen at -80 C (-80 C group). Second, IPCs were initially placed into a Bicell freezing container before freezing at -80 C (BICELL group). Third, a vitrification method for oocytes and embryos was used (CRYOTOP group). Cell counting kit-8 (CCK-8) assay showed that cell viability was decreased in all groups after cryopreservation ( < 0.01). Corroboratively, the amount of adenosine triphosphate was markedly decreased after cryopreservation in all groups ( < 0.01). Immunofluorescence staining showed a reduced positive staining area for insulin in all cryopreservation groups. Furthermore, 4',6-diamidino-2-phenylindole and merged immunofluorescence images showed that cryopreserved cells appeared to be randomly reduced in the -80 C group and CRYOTOP group, while only the central region was visibly reduced in the BICELL group. Using immunohistochemical staining, IPCs after cryopreservation were shown to be positive for cleaved caspase-3 antibody in all groups. Finally, insulin secretion following glucose stimulation was significantly reduced in IPCs from all groups after cryopreservation ( < 0.01). In conclusion, IPCs may be too fragile for cryopreservation with accomplished methods and further investigations for a suitable preservation method are required. (Keyword) Adenosine Triphosphate / Adipose Tissue / Caspase 3 / Cell Differentiation / Cell Shape / Cell Survival / Cryopreservation / Dithizone / Glucose / Humans / Insulin / Insulin Secretion / Insulin-Secreting Cells / Staining and Labeling / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 116513 (Link to Publication Site) ● Publication site (DOI): 10.1177/0963689720954798 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32878465 ● Search Scopus @ Elsevier (PMID): 32878465 ● Search Scopus @ Elsevier (DOI): 10.1177/0963689720954798 (Tokushima University Institutional Repository: 116513, DOI: 10.1177/0963689720954798, PubMed: 32878465)
145.	Shogo Oota, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Shoko Iwahashi, Yoshimi Bando and Mitsuo Shimada : Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1 for Intrahepatic Cholangiocarcinoma., Anticancer Research, Vol.39, No.11, 6025-6033, 2019. (Summary) Carbohydrate antigen 19-9 (CA19-9) is a poor prognostic marker in intrahepatic cholangiocarcinoma (IHCC). Previous studies have shown a link between hypoxia and CA19-9 in cancer, and we have previously demonstrated a correlation between HDAC1 and HIF-1 in IHCC. Here, we evaluated the expression and correlation of CA19-9 with HIF-1 and HDAC in IHCC. This study included 62 patients with IHCC who underwent primary hepatectomy at our department. Clinicopathological characteristics were examined. Immunohistochemical expression of HIF-1 and HDAC1 in specimens was quantitatively evaluated. Patients with high preoperative serum CA19-9 levels showed clinicopathological characteristics associated with tumour progression. High CA19-9 levels were associated with worse overall and recurrence-free survival. Univariate and multivariate analysis detected high CA19-9 levels as an independent poor prognostic factor for IHCC. Serum CA19-9 was significantly correlated with both HIF-1 and HDAC1 expression. High serum CA19-9 level is a poor prognostic factor for overall survival in IHCC and correlates with HIF-1 and HDAC1 expression. (Keyword) Aged / Bile Duct Neoplasms / Biomarkers, Tumor / CA-19-9 Antigen / Cholangiocarcinoma / female / Follow-Up Studies / Gene Expression Regulation, Neoplastic / Histone Deacetylase 1 / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / male / Neoplasm Recurrence, Local / Prognosis / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13808 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31704828 ● Search Scopus @ Elsevier (PMID): 31704828 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13808 (DOI: 10.21873/anticanres.13808, PubMed: 31704828)
146.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The Differences in the Characteristics of Insulin-producing Cells Using Human Adipose-tissue Derived Mesenchymal Stem Cells from Subcutaneous and Visceral Tissues., Scientific Reports, Vol.9, No.1, 13204, 2019. (Summary) The aim of this study was to investigate the characteristics of insulin producing cells (IPCs) differentiated from adipose-tissue derived stem cells (ADSCs) isolated from human subcutaneous and visceral adipose tissues and identify ADSCs suitable for differentiation into efficient and functional IPCs. Subcutaneous and visceral adipose tissues collected from four (4) patients who underwent digestive surgeries at The Tokushima University (000035546) were included in this study. The insulin secretion of the generated IPCs was investigated using surface markers by: fluorescence activated cell sorting (FACS) analysis; cytokine release; proliferation ability of ADSCs; in vitro (glucose-stimulated insulin secretion: (GSIS) test/in vivo (transplantation into streptozotocin-induced diabetic nude mice). The less fat-related inflammatory cytokines secretions were observed (P < 0.05), and the proliferation ability was higher in the subcutaneous ADSCs (P < 0.05). Insulin expression and GISI were higher in the subcutaneous IPCs (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of all mice that received IPCs from subcutaneous fat tissue converted into normo-glycaemia in thirty (30) days post-transplantation (4/4,100%). Transplanted IPCs were stained using anti-insulin and anti-human leukocyte antigen antibodies. The IPCs generated from the ADSCs freshly isolated from the human fat tissue had sufficient insulin secreting ability in vitro and in vivo. (Tokushima University Institutional Repository) ● Metadata: 114942 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-49701-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31519950 ● Search Scopus @ Elsevier (PMID): 31519950 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-49701-0 (Tokushima University Institutional Repository: 114942, DOI: 10.1038/s41598-019-49701-0, PubMed: 31519950)
147.	Hiroki Mori, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Impact of Bevacizumab on Liver Damage After Massive Hepatectomy in Rats., In Vivo, Vol.33, No.5, 1469-1476, 2019. (Summary) The aim of this study was to evaluate the impact of pretreatment with bevacizumab on liver damage in a rat model of massive hepatectomy (Hx) model, as a surrogate model of massive Hx for liver metastasis from colorectal cancer. Male Wister rats (n=24) were separated into the following two groups: 90% Hx and 90% Hx plus bevacizumab group. Bevacizumab (5 mg/kg) was injected intraperitoneally 7 days before Hx. Samples of blood and remnant liver tissue were obtained 24 hours after hepatectomy and the following parameters were evaluated: Biochemical analysis; liver regeneration rate; survival rate; and real-time polymerase chain reaction for interleukin-1 beta (Il1b), tumor necrosis factor alpha (Tnfa), matrix metalloproteinase (Mmp) 2 and Mmp9 mRNA. In addition, samples of whole liver tissue were obtained immediately before Hx and real-time polymerase chain reaction was performed for X-box binding protein 1 (Xbp1), activating transcription factor 6 (Atf6), C/EBP homologous protein (Chop), glucose-regulated protein 78 (Grp78) and heat-shock protein 70 (Hsp70), as markers of endoplasmic reticulum stress response. The levels of transaminases 24 hours after Hx were significantly reduced in the group pretreated with bevacizumab compared to that not pretreated (p<0.05). The liver regeneration rate at 24 hours after Hx was significantly increased in the group pretreated with bevacizumab compared with the group which underwent Hx alone (p<0.05). The survival rate for the group pretreated with bevacizumab tended to be higher than that of the Hx-only group, 72 hours after Hx (p=0.09). The expressions of Il1b, Mmp2 and Mmp9 mRNA 24 hours after Hx in the group pretreated with bevacizumab tended to be lower than that of rats which underwent Hx alone (p=0.11, 0.09 and 0.15, respectively). The expression of Xbp1, Chop, Grp78 and Hsp70 mRNA immediately before Hx in the group pretreated with bevacizumab were significantly higher than the 90% Hx group (p<0.05). Bevacizumab pretreatment had protective effects on liver injury after massive hepatectomy in rats, apparently via the induction of the endoplasmic reticulum stress response, i.e. the so-called unfolded protein response. (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11626 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31471394 ● Search Scopus @ Elsevier (PMID): 31471394 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11626 (DOI: 10.21873/invivo.11626, PubMed: 31471394)
148.	Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Chie Takasu, Jun Higashijima, Satoru Imura and Mitsuo Shimada : Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis., Anticancer Research, Vol.39, No.9, 5089-5096, 2019. (Summary) We evaluated the clinical impact of FOLFOXIRI regimen aiming for conversion surgery in patients with unresectable multiple colorectal liver metastasis (CRLM). A total of 42 patients with unresectable multiple CRLM who received chemotherapy with molecular agents were included in the analysis. The clinical results of FOLFOXIRI with other regimens were compared. The total conversion rate of 42 unresectable CRLM was 48.1%, and conversion cases had a better prognosis. Clinicopathological characteristics of conversion cases were more frequent in FOLFOXIRI induction, liver limited disease and maximum diameter number (MDN) over 70. FOLFOXIRI achieved a higher conversion rate compared to other regimens (72.2% vs. 37.5%, p=0.0334), and significantly reduced the medication period until conversion surgery (median 5.8 courses) with a higher tumour necrotic rate. Consequently, the overall survival of conversion cases with FOLFOXIRI was better than that with other regimens (p=0.0055). FOLFOXIRI plus molecular agents might provide a higher probability of conversion surgery with a prognostic benefit. (Keyword) Antineoplastic Combined Chemotherapy Protocols / Camptothecin / Colorectal Neoplasms / Combined Modality Therapy / Conversion to Open Surgery / female / Fluorouracil / Hepatectomy / Humans / Kaplan-Meier Estimate / Leucovorin / Liver Neoplasms / male / Neoplasm Grading / Neoplasm Staging / Organoplatinum Compounds / Prognosis / Treatment Outcome / Tumor Burden (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13703 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31519620 ● Search Scopus @ Elsevier (PMID): 31519620 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13703 (DOI: 10.21873/anticanres.13703, PubMed: 31519620)
149.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : Duodenal-Jejunal Bypass Maintains Gut Permeability by Suppressing Gut Inflammation., Obesity Surgery, Vol.29, No.9, 2745-2749, 2019. (Summary) The aim of this study was to investigate gut inflammation and permeability in rats after duodenal-jejunal bypass (DJB) and in rats injected with a glucagon-like peptide-1 (GLP-1) receptor analog. Twelve male 16-week-old obese diabetic rats were divided into three groups: the DJB group, the sham group, and the group injected daily with a GLP-1 receptor agonist (liraglutide). Gut inflammation and the expression of tight junction protein (claudin-1) were analyzed in the three groups at 8 weeks after surgery. The DJB group showed significantly lower levels of gut inflammatory cytokines than the liraglutide group. Claudin-1 showed stronger intensity on immunofluorescent staining in the DJB group than that in the liraglutide group. In summary, DJB surgery might maintain gut permeability via suppression of gut inflammation. (Link to Publication Site) ● Publication site (DOI): 10.1007/s11695-019-03922-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31209833 ● Search Scopus @ Elsevier (PMID): 31209833 ● Search Scopus @ Elsevier (DOI): 10.1007/s11695-019-03922-4 (DOI: 10.1007/s11695-019-03922-4, PubMed: 31209833)
150.	Shoko Iwahashi, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 骨髄異形成症候群・発作性夜間血色素尿症合併胃癌に対する腹腔鏡手術の1例, Journal of Japanese College of Surgeons, Vol.44, No.4, 706-712, 2019. (Keyword) Haptoglobins(治療的利用) (Link to Publication Site) ● Publication site (DOI): 10.4030/jjcs.44.706 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390848250139518080 ● Search Scopus @ Elsevier (DOI): 10.4030/jjcs.44.706 (DOI: 10.4030/jjcs.44.706, CiNii: 1390848250139518080)
151.	Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Toshiaki Yoshimoto, Koichi Tsuneyama and Mitsuo Shimada : Two cases of non-mucinous cystadenomas of the pancreas with pancreatobiliary phenotype and ovarian-like stroma., Surgical Case Reports, Vol.5, No.1, 117, 2019. (Summary) Diagnosis of cystic tumor of the pancreas is based on the World Health Organization criteria that classify pancreatic cystadenomas into four types: intra-ductal papillary mucinous neoplasms, mucinous cystic neoplasms (MCNs), serous cystic neoplasms, and solid pseudo-papillary neoplasms depending on their secretion and presence of ovarian-like stroma. Recently, Albores-Saavedra identified non-mucinous cystadenomas of the pancreas with pancreato-biliary phenotype and ovarian-like stroma. This precipitated examination of the proportions of these rare tumors in patients treated at Tokushima University Hospital. Case 1 was a 40-year-old woman with a cystic tumor in the tail of the pancreas. Computed tomography (CT) revealed a diffuse and non-enhanced cystic tumor in the tail of the pancreas. This tumor was diagnosed as a simple cyst at this point. However, 2ears later, the tumor had increased in size by 3m. Thus, laparoscopic distal pancreatectomy was performed. The content of the cyst was serous. The epithelial cells were lined with a single layer of cuboidal cells and the tumor had ovarian-like stroma pathologically. The final pathological diagnosis was non-mucinous cystadenoma of the pancreas with ovarian-like stroma. In Case 2, a cystic tumor in the pancreas was found by medical examination in a woman in her sixties who presented without symptoms. CT showed a 1.5-cm cystic tumor in the tail and body of the pancreas and a septum in the cyst. Nine years later, the tumor had grown to 2.4m in diameter and had a clear septum in the cyst. This tumor was diagnosed preoperatively as MCN. Thus, laparoscopic distal pancreatectomy was performed. The cyst contained serous fluid. Microscopic examination showed no ovarian-like stroma and the epithelial cells were lined by a single layer of cuboidal cells. The final pathological diagnosis was non-mucinous cystadenoma of the pancreas with ovarian-like stroma. Accurate preoperative diagnosis of this type of pancreatic cystic tumor may be difficult, although it occurs more often than expected. Non-mucinous cystadenomas of the pancreas with ovarian-like stroma need to be considered as a differential diagnosis. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-019-0673-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31338648 ● Search Scopus @ Elsevier (PMID): 31338648 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-019-0673-y (DOI: 10.1186/s40792-019-0673-y, PubMed: 31338648)
152.	Shoko Iwahashi, Masaaki Nishi, Toshiaki Yoshimoto, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Yuuma Wada, Yoshimi Bando and Mitsuo Shimada : A case of gastric heterotopic pancreas with gastroduodenal invagination., Surgical Case Reports, Vol.5, No.1, 110, 2019. (Summary) Heterotopic pancreas (HP) is a rare disease commonly found incidentally on imaging studies, at endoscopy or at autopsy and can be associated with abdominal pain, vomiting, heart burn, gastric outlet obstruction, and even dysphagia in very rare cases. Heinrich's classified HP into three groups, types1-3, with Heinrich's type 3 HP the rarest and difficult to diagnose properly because it has only pancreatic ducts but has no islet and acini. The aim of this study is to report a case of gastric outlet obstruction caused by type 3 HP with gastroduodenal invagination with reference to the literature and diagnosed finally by immuno-histochemical analysis. The case presented is a 40-year-old male presenting with vomiting and abdominal pain. Computed tomography (CT) revealed a cystic mass in the upper abdomen and he was referred to the Tokushima University. Gastric fiber showed that the pedunculated mass originated from the stomach. An open distal gastrectomy was performed. Pathologically, there was small glands proliferation in the sub-mucosal (SM) layer which was membrane and cytoplasm (MUC)1 positive and muscle proliferation. This finding revealed the tumor as HP. Postoperative course was uneventful and the patient was discharged 12 days after surgery. The patient has remained well 12 months after surgery. HP should be considered in the differential diagnosis of SM tumors with gastroduodenal invagination even if this is a rare symptom. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-019-0669-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31292813 ● Search Scopus @ Elsevier (PMID): 31292813 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-019-0669-7 (DOI: 10.1186/s40792-019-0669-7, PubMed: 31292813)
153.	Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Kouzou Yoshikawa and Chie Takasu : 免疫チェックポイント時代における漢方とがん免疫, Kampo Medicine, Vol.70, No.2, 162-166, 2019. (Keyword) *漢方薬(薬理学,治療的利用) (Link to Publication Site) ● Publication site (DOI): 10.3937/kampomed.70.162 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390002184855144320 ● Search Scopus @ Elsevier (DOI): 10.3937/kampomed.70.162 (DOI: 10.3937/kampomed.70.162, CiNii: 1390002184855144320)
154.	Tooru Kouno, Mitsuo Shimada, Masaaki Nishi, Yuji Morine, Kouzou Yoshikawa, Hidetoshi Katsuno, Koutarou Maeda, Keisuke Koeda, Satoshi Morita, Masahiko Watanabe, Mitsuo Kusano, Junichi Sakamoto, Shigetoyo Saji, Hiroki Sokuoka, Yasuto Sato, Yoshihiko Maehara, Takashi Kanematsu and Masaki Kitajima : Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials., Surgery Today, Vol.49, No.8, 704-711, 2019. (Summary) Prolonged postoperative ileus (POI) is a common complication after open abdominal surgery (OAS). Daikenchuto (DKT), a traditional Japanese medicine that peripherally stimulates the neurogenic pathway, is used to treat prolonged POI in Japan. To analyze whether DKT accelerates the recovery from prolonged POI after OAS, we conducted a secondary analysis of three multicenter randomized controlled trials (RCTs). A secondary analysis of the three RCTs supported by the Japanese Foundation for Multidisciplinary Treatment of Cancer (project numbers 39-0902, 40-1001, 42-1002) assessing the effect of DKT on prolonged POI in patients who had undergone OAS for colon, liver, or gastric cancer was performed. The subgroup included 410 patients with no bowel movement (BM) before the first diet, a DKT group (n = 214), and a placebo group (n = 196). Patients received either 5 g DKT or a placebo orally, three times a day. The primary endpoint was defined as the time from the end of surgery to the first bowel movement (FBM). A sensitivity analysis was also performed on the age, body mass index and dosage as subgroup analyses. The primary endpoint was significantly accelerated in the DKT group compared with the placebo group (p = 0.004; hazard ratio 1.337). The median time to the FBM was 113.8 h in the placebo group and 99.1 h in the DKT treatment group. The subgroup analysis showed that DKT significantly accelerated the recovery from prolonged POI following OAS. UMIN000026292. (Keyword) Abdomen / adult / Aged / Aged, 80 and over / Body Mass Index / female / Humans / Ileus / male / Middle Aged / Plant Extracts / Postoperative Complications / Randomized Controlled Trials as Topic / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 115809 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-019-01787-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30805720 ● Search Scopus @ Elsevier (PMID): 30805720 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-019-01787-9 (Tokushima University Institutional Repository: 115809, DOI: 10.1007/s00595-019-01787-9, PubMed: 30805720)
155.	Yuuma Wada, Atsushi Takata, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : The protective effect of epigallocatechin 3-gallate on mouse pancreatic islets via the Nrf2 pathway., Surgery Today, Vol.49, No.6, 536-545, 2019. (Summary) Epigallocatechin 3-gallate (EGCG), a green tea polyphenol, has been shown to have anti-oxidant and anti-inflammatory effects in vitro and in vivo. The aim of this study was to investigate the effects and mechanism of EGCG on isolated pancreatic islets as pre-conditioning for pancreatic islet transplantation. The pancreatic islets were divided into two groups: an islet culture medium group (control) and an islet culture medium with EGCG (100 M) group. We investigated the islet viability, Nrf2 expression, reactive oxygen species (ROS) production, and heme oxygenase-1 (HO-1) mRNA. Five hundred islet equivalents after 12 h of culture for the EGCG 100 M and control group were transplanted under the kidney capsule of streptozotocin-induced diabetic ICR mice. The cell viability and insulin secretion ability in the EGCG group were preserved, and the nuclear translocation of Nrf2 was increased in the EGCG group (p < 0.01). While the HO-1 mRNA levels were also higher in the EGCG group than in the control group (p < 0.05), the ROS production was lower (p < 0.01). An in vivo functional assessment showed that the blood glucose level had decreased in the EGCG group after transplantation (p < 0.01). EGCG protects the viability and function of islets by suppressing ROS production via the Nrf2 pathway. (Keyword) Animals / Blood Glucose / catechin / Cell Survival / gene expression / Heme Oxygenase-1 / In Vitro Techniques / Insulin Secretion / Islets of Langerhans / Islets of Langerhans Transplantation / male / Mice, Inbred C57BL / Mice, Inbred ICR / NF-E2-Related Factor 2 / RNA, Messenger / reactive oxygen species / Tissue Culture Techniques / Transplantation Conditioning (Tokushima University Institutional Repository) ● Metadata: 114154 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-019-1761-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30730004 ● Search Scopus @ Elsevier (PMID): 30730004 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-019-1761-0 (Tokushima University Institutional Repository: 114154, DOI: 10.1007/s00595-019-1761-0, PubMed: 30730004)
156.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging., PLoS ONE, Vol.14, No.1, e0210579, 2019. (Summary) Dynamic magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) can be used not only to detect liver tumors but also to estimate liver function. The aim of this study was to establish a new EOB-MRI-based formula to determine the resection limit in patients undergoing hepatectomy. Twenty-eight patients with a normal liver (NL group) and five with an unresectable cirrhotic liver (UL group) who underwent EOB-MRI were included. Standardized liver function (SLF) was calculated based on the signal intensity (SI), the volume of each subsegment (S1-S8), and body surface area. A formula defining the resection limit was devised based on the difference in the SLF values of patients in the NL and UL groups. The formula was validated in 50 patients who underwent EOB-MRI and hepatectomy. The average SLF value in the NL and UL groups was 2038 and 962 FV/m2, respectively. The difference (1076 FV/m2) was consistent with a 70% in resection volume. Thus, the resection limit for hepatectomy was calculated as a proportion of 70%: 70 (SLF-962)/1076 (%). The one patient who underwent hepatectomy over the resection limit died due to liver failure. In other 49 patients, in whom the resection volume was less than the resection limit, procedures were safely performed. Our formula for resection limit based on EOB-MRI can improve the safety of hepatectomy. (Tokushima University Institutional Repository) ● Metadata: 113041 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0210579 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30682046 ● Search Scopus @ Elsevier (PMID): 30682046 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0210579 (Tokushima University Institutional Repository: 113041, DOI: 10.1371/journal.pone.0210579, PubMed: 30682046)
157.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Usefulness of blood flow evaluation by indocyanine green fluorescence system in laparoscopic anterior resection., The Journal of Medical Investigation : JMI, Vol.66, No.1.2, 65-69, 2019. (Summary) One of the major cause of anastomotic leakage (AL) in anterior resection of the rectum is insufficient blood flow of the remnant colon. The indocyanine green fluorescence system (ICG-FS) can visualize the blood flow of organs intra-operatively. The aim of this study is to investigate the usefulness of ICG-FS for evaluating the blood flow of the remnant colon in laparoscopic anterior resection. Rectal cancer patients (n=24) who underwent laparoscopic anterior resection were included in this study. After resection of the rectum, 7.5mg of ICG was administered intravenously, and the blood flow of the oral stump was evaluated by the ICG-FS. The relationship between the fluorescence time (FT) of the oral stump and AL was investigated retrospectively. Two of twenty-four patients (8.3%) suffered AL. The FT of these two cases were over 60 seconds. In the case with the FT was over 80 seconds, we performed additional resection of the late fluorescence portion of the remnant colon and could avoid AL. In patients whose FT was under 60 seconds, no patients suffered AL. ICG-FS may be useful for evaluating the blood flow of the remnant colon to avoid AL in laparoscopic anterior resection. J. Med. Invest. 66 : 65-69, February, 2019. (Tokushima University Institutional Repository) ● Metadata: 113323 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.65 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064957 ● Search Scopus @ Elsevier (PMID): 31064957 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.65 (Tokushima University Institutional Repository: 113323, DOI: 10.2152/jmi.66.65, PubMed: 31064957)
158.	Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Utility of virtual three-dimensional image analysis for laparoscopic gastrectomy conducted by trainee surgeons., The Journal of Medical Investigation : JMI, Vol.66, No.3.4, 280-284, 2019. (Summary) Purpose The aim of this study was to investigate the utility the three-dimensional (3D) imaging for laparoscopic gastrectomy performed by trainee surgeons. Methods 3D-reconstruction was performed using multi-detector computed tomography (MDCT) and SYNAPSE VINCENT software. Trainee surgeons made 3D-imaging and checked the anatomical structure. Thirty-three patients who underwent laparoscopic gastrectomy (LG) for gastric cancer were examined. Trainees performed 19 LG, while specialists performed 14 LG. The vascular pattern and the surgical outcomes were evaluated. Result 3D imaging depicted the correct positional relationship between the gastric vasculatures and the organs. Regarding vascular pattern detected by 3D imaging, the origins of the infrapyloric artery were the right gastroepiploic artery in 12 cases (36%), the gastroduodenal artery in eight cases (24%), the bifurcation of the right gastroepiploic artery and gastroduodenal artery in seven cases (21%), and not detected in one case (3%). The types of confluence of the infrapyloric vein were the right gastroepiploic vein in 16 cases (48%), the anterior superior pancreatoduodenal vein in 10 cases (30%), and not detected in seven cases (21%). Surgical outcomes were not different between trainee group using intraoperative 3D image with the specialist in instruction group without the intraoperative 3D image. Conclusions Preoperative 3D imaging might contribute to successful and safe LG by trainee surgeons. J. Med. Invest. 66 : 280-284, August, 2019. (Tokushima University Institutional Repository) ● Metadata: 114074 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.280 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656289 ● Search Scopus @ Elsevier (PMID): 31656289 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.280 (Tokushima University Institutional Repository: 114074, DOI: 10.2152/jmi.66.280, PubMed: 31656289)
159.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Yasuhiro Hamada : The Effect of Laparoscopic Sleeve Gastrectomy on Obesity and Obesity-related Disease : the Results of 10 Initial Cases., The Journal of Medical Investigation : JMI, Vol.66, No.3.4, 289-292, 2019. (Summary) Introduction : The number of patients who undergo laparoscopic sleeve gastrectomy (LSG) has been increasing. Department of Surgery, Tokushima University performed the first LSG in 2013. The aim of this study was to report the results of the initial ten cases who underwent a LSG. Patients and methods : Ten obese patients : five males and five females ; age range from thirty-three years to fifty-six years (mean age 42.2 years) ; mean body mass index (BMI) 50.3 ; five with diabetes ; nine with hypertension (HT) ; four with hyperlipidemia (HL) ; eight with sleep apnea syndrome (SAS) who underwent LSG were enrolled in this study. The data was analyzed retrospectively and included short- and long-term outcomes. Results : There were no post-operative complications in this study. The %EWL at three and six months and one year post-operative were 44.2%, 50.2% and 48.6% respectively. In three months post-operative the non-alcoholic fatty liver (NAFLD) and non-alcoholic steatohepatitis (NASH) had improved transaminase (AST/ALT), liver to spleen ratio in plain CT value. Improvements were also evident in the obesity-related diseases : diabetes 80% (4/5) ; HT 67% (6/9) ; HL 75% (3/4) ; and SAS 88% (7/8). Conclusion : LSG is a promising option for the treatment of morbid obesity and obesity-related diseases. J. Med. Invest. 66 : 289-292, August, 2019. (Tokushima University Institutional Repository) ● Metadata: 114081 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.289 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656291 ● Search Scopus @ Elsevier (PMID): 31656291 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.289 (Tokushima University Institutional Repository: 114081, DOI: 10.2152/jmi.66.289, PubMed: 31656291)
160.	Yu Saitou, Yuji Morine, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Hisami Yamanaka-Okumura, Akiyoshi Hirayama, Tomoyoshi Soga, Masaru Tomita and Mitsuo Shimada : Changes of liver metabolites following hepatectomy with ischemia reperfusion towards liver regeneration., Annals of Gastroenterological Surgery, Vol.2, No.3, 204-211, 2018. (Summary) Metabolome analysis is one of the omics which investigates the final product of a central dogma. Changes of liver metabolites during liver regeneration following hepatectomy (Hx) continue to remain unclear. The aim of the present study was to investigate the changes of liver metabolites following Hx with ischemia reperfusion (I/R) towards liver regeneration. Twenty-three patients who underwent Hx were enrolled in this study. Non-tumor tissues were sampled immediately before and after Hx and a comparison was made between the liver samples taken before and after Hx using capillary electrophoresis (CE)-time-of-flight mass spectrometry (TOFMS) as metabolome analysis. The metabolic pathway showed that there was a significant increase in "lactate" following Hx. There was a significant decrease in metabolites only in the first half of the tricarboxylic acid cycle (TCA) cycle, and adenosine triphosphate (ATP) by anaerobiotic glycolysis did not occur in time for energy consumption of the Hx. Principal component analysis revealed remarkably different component profiles between the samples taken before and after Hx. One hundred and three metabolites were selected as critical metabolites for separating components. Valine and tryptophan increased significantly after Hx and they were regulated by resected liver volume, ischemic time and liver function. The liver metabolites changed remarkably between before and after Hx. Especially, liver valine and tryptophan were increased. (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12058 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29863192 ● Search Scopus @ Elsevier (PMID): 29863192 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12058 (DOI: 10.1002/ags3.12058, PubMed: 29863192)
161.	Toshiaki Yoshimoto, Yuji Morine, Chie Takasu, Rui Feng, Tetsuya Ikemoto, Kouzou Yoshikawa, Shuichi Iwahashi, Yu Saitou, Hideya Kashihara, Masatake Akutagawa, Takahiro Emoto, Yosuke Kinouchi and Mitsuo Shimada : Blue light-emitting diodes induce autophagy in colon cancer cells by Opsin 3., Annals of Gastroenterological Surgery, Vol.2, No.2, 154-161, 2018. (Summary) Light emitting-diodes (LED) have various effects on living organisms and recent studies have shown the efficacy of visible light irradiation from LED for anticancer therapies. However, the mechanism of LED's effects on cancer cells remains unclear. The aim of the present study was to investigate the effects of LED on colon cancer cell lines and the role of photoreceptor Opsin 3 (Opn3) on LED irradiation in vitro. Human colon cancer cells (HT-29 or HCT-116) were seeded onto laboratory dishes and irradiated with 465-nm LED at 30 mW/cm for 30 minutes. Cell Counting Kit-8 was used to measure cell viability, and apoptosis and caspase 3/8 expression were evaluated by AnnexinV/PI and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Autophagy and expression of LC-3 and beclin-1 were also evaluated by autophagy assays, RT-PCR and Western blotting. We further tested Opn3 knockdown by Opn3 siRNA and the G G-protein inhibitor NF023 in these assays. Viability of HT-29 and HCT-116 cells was lower in 465-nm LED-irradiated cultures than in control cultures. LC-3 and beclin-1 expressions were significantly higher in LED-irradiated cultures, and autophagosomes were detected in irradiated cells. The reductive effect of cancer cell viability following blue LED irradiation was reversed by Opn3 knockdown or NF023 treatment. Furthermore, increased LC-3 and beclin-1 expression that resulted from blue LED irradiation was suppressed by Opn3 knockdown or NF023 treatment. Blue LED irradiation suppressed the growth of colon cancer cells and Opn3 may play an important role as a photoreceptor. (Tokushima University Institutional Repository) ● Metadata: 113689 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12055 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29863164 ● Search Scopus @ Elsevier (PMID): 29863164 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12055 (Tokushima University Institutional Repository: 113689, DOI: 10.1002/ags3.12055, PubMed: 29863164)
162.	Masaaki Nishi, Bat-Erdene Batsaikhan, Kozo Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : High STAT4 Expression Indicates Better Disease-free Survival in Patients with Gastric Cancer., Anticancer Research, Vol.37, No.12, 6723-6729, 2017. (Summary) The aim of this study was to investigate the significance of signal transducer and activator of transcription 4 (STAT4) expression and the correlation between STAT4 and interferon gamma (IFN- ) in patients with gastric cancer. Sixty-two patients who underwent gastrectomy for gastric cancer were enrolled in the study. STAT4 and IFNG mRNA expression was evaluated by quantitative real-time polymerase chain reaction (PCR). Immunohistochemistry was performed to examine CD8 T-cells, and STAT4 and IFN- expression. STAT4 mRNA expression was significantly correlated with IFNG mRNA expression (p<0.05). Regarding disease-free survival, there was a significant difference between the groups with high and low STAT4 expression (5-year disease-free survival: 77.8% and 56.4%, p<0.05). Univariate analysis revealed that tumor differentiation and STAT4 expression were significant factors for tumor recurrence. High expression of STAT4 in gastric cancer predicted a better clinical outcome. STAT4 might be a useful biomarker to identify patients at high risk of recurrence after gastrectomy. (Keyword) Aged / Disease-Free Survival / Female / Gastrectomy / Gene Expression Regulation, Neoplastic / Humans / Interferon-gamma / Kaplan-Meier Estimate / Male / Neoplasm Recurrence, Local / Outcome Assessment (Health Care) / Prognosis / STAT4 Transcription Factor / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12131 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29187449 ● Search Scopus @ Elsevier (PMID): 29187449 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.12131 (DOI: 10.21873/anticanres.12131, PubMed: 29187449)
163.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases., In Vivo, Vol.31, No.3, 419-423, 2017. (Summary) Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM. (Keyword) Adult / Aged / Aged, 80 and over / Cell Differentiation / Colorectal Neoplasms / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Multivariate Analysis / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28438872 ● Search Scopus @ Elsevier (PMID): 28438872 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11076 (DOI: 10.21873/invivo.11076, PubMed: 28438872)
164.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition., Anticancer Research, Vol.37, No.3, 1169-1175, 2017. (Summary) Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis. (Keyword) Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, CD34 / Cadherins / Carcinoembryonic Antigen / Carcinoma, Hepatocellular / Cell Adhesion Molecules / Disease-Free Survival / Epithelial-Mesenchymal Transition / Female / Follow-Up Studies / Humans / Immunohistochemistry / Liver Neoplasms / Male / Microcirculation / Middle Aged / Neovascularization, Pathologic / Predictive Value of Tests / Preoperative Period / Prognosis / Recurrence / Vimentin (Tokushima University Institutional Repository) ● Metadata: 112034 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.11430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28314278 ● Search Scopus @ Elsevier (PMID): 28314278 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.11430 (Tokushima University Institutional Repository: 112034, DOI: 10.21873/anticanres.11430, PubMed: 28314278)
165.	Yoshihiko Maehara, Ken Shirabe, Shunji Kohnoe, Yasunori Emi, Eiji Oki, Yoshihiro Kakeji, Hideo Baba, Masataka Ikeda, Michiya Kobayashi, Tadatoshi Takayama, Shoji Natsugoe, Masashi Haraguchi, Kazuhiro Yoshida, Masanori Terashima, Mitsuru Sasako, Hiroki Yamaue, Norihiro Kokudo, Katsuhiko Uesaka, Shinji Uemoto, Tomoo Kosuge, Yoshiki Sawa, Mitsuo Shimada, Yuichiro Doki, Masakazu Yamamoto, Akinobu Taketomi, Masahiro Takeuchi, Kouhei Akazawa, Takeharu Yamanaka and Mototsugu Shimokawa : Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial., Surgery Today, Vol.47, No.9, 1060-1071, 2017. (Summary) The use of absorbable sutures in wound closure has been shown to reduce the incidence of surgical site infection (SSI); however, there is no evidence that the intra-abdominal use of absorbable rather than silk sutures reduces the incidence of SSI after gastrointestinal surgery. We report the findings of a phase II trial, designed to evaluate the impact of the intra-abdominal use of absorbable sutures on the incidence of SSI. At 19 Japanese hospitals, 1147 patients undergoing elective gastrectomy, colorectal surgery, hepatectomy, or pancreaticoduodenectomy (PD) were randomly assigned to absorbable or silk intra-abdominal suture groups. The primary efficacy endpoint was the incidence of SSI. The secondary efficacy endpoints were the locations of SSI, time to resolution of SSI, length of hospital stay, and the incidence of bile leakage in hepatectomy and pancreatic fistula. The incidence of SSI was 11.3%, 15.5%, 11.3%, and 36.9% after gastrectomy, colorectal surgery, hepatectomy, and PD, respectively. The incidence of SSI was higher in the absorbable suture group than in the silk suture group for all the surgical procedures, but the difference was not significant. The intra-abdominal use of absorbable sutures did not have enough of an effect on the reduction of SSI in this phase II trial to justify the planning of a large-scale phase III trial. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-017-1480-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28233105 ● Search Scopus @ Elsevier (PMID): 28233105 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-017-1480-3 (DOI: 10.1007/s00595-017-1480-3, PubMed: 28233105)
166.	M Davaadorj, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Mitsuo Shimada : Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma., EJSO - European Journal of Surgical Oncology, Vol.43, No.2, 344-350, 2017. (Summary) Secreted Frizzled-Related Protein-1 (SFRP1) is a well-known negative regulator of the wingless type (Wnt)- -catenin pathway and its inactivation plays an important role in the development and progression of many cancers. In this study, we aimed to determine the clinical significance of SFRP1 expression in intrahepatic cholangiocarcinoma (IHCC) and to define the relationship to Wnt- -catenin pathway. Fifty IHCC patients who had liver resection were enrolled in this study. SFRP1 protein expression was examined by immunohistochemistry in tumor tissues. The patients were divided into two groups: SFRP1 positive (n = 30) and negative (n = 20). Clinicopathological characteristics were analyzed. SFRP1 significantly correlated with curability (Cur A, B vs. C, p = 0.029); and recurrent pattern (intrahepatic vs. extrahepatic, p = 0.010). The negative SFRP1 group had significantly poorer prognosis, and 5-year survival rates were 8.1% of the negative SFRP1 group and 44.6% of the positive SFRP1 group, respectively. Moreover, the disease-free survival rate in the negative SFRP1 group was significantly poorer (p < 0.001). Multivariate analysis revealed that loss of SFRP1served as an independent prognostic factor in IHCC for both overall (HR, 2.923; 95% CI, 1.30-6.56; p = 0.009) and disease-free (HR, 2.631; 95% CI, 1.31-5.27; p = 0.006) survival. In addition, SFRP1 expression negatively correlated to -catenin expression (p = 0.005). Those results suggested that the loss of SFRP1 could be a poor prognostic factor for IHCC, through the Wnt- -catenin pathway. (Keyword) Aged / Biomarkers, Tumor / Cholangiocarcinoma / Female / Hepatectomy / Humans / Immunohistochemistry / Japan / Liver Neoplasms / Male / Prognosis / Proteins / Survival Rate (Tokushima University Institutional Repository) ● Metadata: 110034 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejso.2016.11.017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28062160 ● Search Scopus @ Elsevier (PMID): 28062160 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejso.2016.11.017 (Tokushima University Institutional Repository: 110034, DOI: 10.1016/j.ejso.2016.11.017, PubMed: 28062160)
167.	Chie Takasu and Mitsuo Shimada : 【100字de看護・説明を深める!きわめる!消化器外科の病棟で行う治療・処置】, Gastroenterological Surgery Nursing, Vol.21, No.10, 909-924, 2016. (Keyword) *尿路カテーテル法(看護) / 和文論文
168.	Shohei Eto, Kouzou Yoshikawa, Masaaki Nishi, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Takashi Iwata and Mitsuo Shimada : Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection., Gastric Cancer, Vol.19, No.2, 466-471, 2016. (Summary) Programmed cell death protein 1 (PD-1) and its ligand PD-L1 downregulate T cell activation and are related to immune tolerance. The aim of this study was to clarify the significance of PD-1 and PD-L1 expression and to analyze the relationships among PD-1, PD-L1, and Foxp3 expression in gastric cancer. A total of 105 patients who underwent curative gastrectomy for stage II/III gastric cancer were included in this study. PD-1, PD-L1, and Foxp3 expression were examined by immunohistochemistry and related to prognostic factors by univariate and multivariate analyses. PD-1 expression was correlated with both PD-L1 and Foxp3 expression. Disease-free survival (DFS) was significantly poorer in PD-1-positive patients than in PD-1-negative patients (3-year DFS, 36.1 % vs. 64.7 %, respectively; p < 0.05). Overall survival also tended to be poorer in PD-L1-positive patients than in PD-L1-negative patients. Univariate analysis identified sex, T factor, lymphatic invasion, and PD-1 positivity as significant predictors of poor DFS. Multivariate analysis confirmed male sex, lymphatic invasion, and positive PD-1 expression as independent prognostic indicators. PD-1 expression is associated with a poor prognosis and is correlated with PD-L1 and Foxp3 expression in patients with gastric cancer. (Keyword) Adult / Aged / Aged, 80 and over / Antigens, CD274 / Biomarkers, Tumor / Female / Forkhead Transcription Factors / Gastrectomy / Humans / Kaplan-Meier Estimate / Male / Middle Aged / Prognosis / Programmed Cell Death 1 Receptor / Stomach Neoplasms (Tokushima University Institutional Repository) ● Metadata: 109661 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10120-015-0519-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26210691 ● Summary page in Scopus @ Elsevier: 2-s2.0-84937959229 (Tokushima University Institutional Repository: 109661, DOI: 10.1007/s10120-015-0519-7, PubMed: 26210691, Elsevier: Scopus)
169.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Limited lymph node dissection in elderly patients with gastric cancer., The Journal of Medical Investigation : JMI, Vol.63, No.1-2, 91-95, 2016. (Summary) The number of elderly patients with gastric cancer is continuing to increase along with the life expectancy of the general population. The purpose of this study was to investigate both the impact of age on postoperative outcome and the effect of limited lymph node dissection for elderly patients. Patients were classified into the following three groups: Group A, ·80 years old (n=44); Group B, 70-80 years old (n=139); Group C, <70 years old (n=219). Postoperative complication and survival rates were compared between the three groups Results: Limited lymph node dissection was performed significantly more frequently in Group A. In terms of surgery-related complications, no significant difference was seen between groups. In terms of general related complications, the complication rate increased with age, from 4% in Group C to 13% in Group B and 14% in Group A (p<0.05 each). Although limited lymph node dissection was frequently performed in Group A, cancer-specific survival showed no significant difference in R0 patients. Limited lymph node dissection for gastric cancer did not affect the cancer-specific survival in elderly patients. (Keyword) Adult / Age Factors / Aged / Aged, 80 and over / Female / Humans / Japan / Lymph Node Excision / Male / Middle Aged / Postoperative Complications / Stomach Neoplasms / Survival Analysis (Tokushima University Institutional Repository) ● Metadata: 111160 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.63.91 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27040060 ● Search Scopus @ Elsevier (PMID): 27040060 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.63.91 (Tokushima University Institutional Repository: 111160, DOI: 10.2152/jmi.63.91, PubMed: 27040060)
170.	Daichi Ishikawa, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shinichiro Yamada and Hidenori Miyake : Effect of Twist and Bmi1 on intraductal papillary mucinous neoplasm of the pancreas., Journal of Gastroenterology and Hepatology, Vol.29, No.12, 2032-2037, 2014. (Summary) Intraductal papillary mucinous neoplasm (IPMN) is a well-established entity among pancreatic neoplasms that ranges from low-grade dysplasia to invasive carcinoma. Epithelial-mesenchymal transition (EMT) contributes to tumor progression in various cancers. Moreover, Notch signaling is one of the important upstream effectors of EMT promotion. Currently, it is unclear whether EMT causes pathological progression of IPMN. We evaluated the expression of EMT-promoting transcription factors Twist and B cell-specific Moloney murine leukemia virus insertion site 1 (Bmi1) in IPMN. Patients who underwent resections at our institute and its affiliated hospital were enrolled in this study (n = 35). Protein expression of EMT markers Twist, Bmi1, Jagged1, and E-cadherin in resected specimens was investigated by immunohistochemistry. Expression of these proteins was compared with the clinicopathological factors and patient survival. Positive expression of Twist and Bmi1 was observed in 40.0% and 42.9% of IPMNs, respectively. Twist and Bmi1 expression was significantly higher in IPMNs with high-grade dysplasia (P < 0.05) and invasive carcinoma (P < 0.05) than that in IPMNs with low-grade dysplasia. High expression of Twist was correlated with Jagged1 expression and inversely correlated with expression of E-cadherin (P = 0.06 and P < 0.05, respectively). In survival analyses, the recurrence rate was significantly higher in the group that showed simultaneous high expression of Twist and Bmi1 (P < 0.05). Expression of Twist and Bmi1 is associated with aggressiveness and poor prognoses of IPMN through EMT promotion that might be induced by Notch signaling. (Tokushima University Institutional Repository) ● Metadata: 106298 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.12652 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24909638 ● Search Scopus @ Elsevier (PMID): 24909638 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12652 (Tokushima University Institutional Repository: 106298, DOI: 10.1111/jgh.12652, PubMed: 24909638)
171.	Bat-Erdene Batsaikhan, Kozo Yoshikawa, Nobuhiro Kurita, Takashi Iwata, Chie Takasu, Hideya Kashihara and Mitsuo Shimada : Cyclopamine decreased the expression of Sonic Hedgehog and its downstream genes in colon cancer stem cells., Anticancer Research, Vol.34, No.11, 6339-6344, 2014. (Summary) Backround: Most solid cancers including colon cancer are believed to be initiated from and maintained by cancer stem cells (CSCs), that are responsible for treatment resistance, resulting in tumor relapse. The aim of this study was to clarify the possible role of the Sonic Hedgehog (Shh) signaling pathway in the regulation of cancer stem cells. The HCT-116 cell line was cultured with fetal bovine serum in RPMI-1640 medium and its sphere was grown in serum-free non-adherent culture. Gene expressions were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) from cells treated with and without cyclopamine. HCT-116 sphere-derived cells grown in serum-free, non-adherent culture, showed significantly increased expression of stem cell markers, Shh downstream genes and epithelial-mesenchymal transition (EMT) markers compared to parental cells grown in conventional culture. The expression of stemness markers, Shh downstream genes and EMT markers were higher in cancer spheres than the parental cell line and down-regulated by cyclopamine treatment in a dose-dependent manner. Overall, these findings show that cyclopamine treatment could down-regulate the expression of stemness markers, shh downstream genes and EMT markers on HCT-116 spheres. (Keyword) Colonic Neoplasms / Epithelial-Mesenchymal Transition / Hedgehog Proteins / Humans / Neoplastic Stem Cells / RNA, Messenger / Real-Time Polymerase Chain Reaction / Reverse Transcriptase Polymerase Chain Reaction / Tight Junction Proteins / Tight Junctions / Tumor Cells, Cultured / Tumor Markers, Biological / Veratrum Alkaloids (Tokushima University Institutional Repository) ● Metadata: 109370 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25368233 ● Search Scopus @ Elsevier (PMID): 25368233 (Tokushima University Institutional Repository: 109370, PubMed: 25368233)
172.	Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Hirohiko Sato, Yoshikawa Kozo, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi and Noriko Matsumoto : CD133 expression is correlated with poor prognosis in colorectal cancer., Hepato-Gastroenterology, Vol.61, No.134, 1563-1567, 2014. (Summary) Cancer stem cells (CSC) was reported to play an important role in various kinds of cancer. CD133 is one of the cancer stem cell markers in solid cancers. However, the correlation between CD133 expression and the clinicopathological factors in colorectal cancer (CRC) remains unclear. Forty patients with CRC who underwent operations were enrolled. Expression of CD133 was investigated by immunohistochemistry (IHC). The staining was observed in the cytoplasm of cancer cells and the patients who have the staining were defined as CD133-positive cases. The patients were divided into two groups: the CD133-positive group (n = 22) and negative group (n = 18). Clinicopathological factors were compared between the two groups. The prognostic factors were investigated by multivariate analysis. In the CD133-positive group, the incidence of lymph node and liver metastasis, lymphatic and venous invasion, as well as the progression of stage of cancer were higher than that in the CD133-negative group. The 5-year survival rate and the disease-free survival rate in the CD133-positive group were lower than that in the CD133-negative group. The multivariate analysis revealed that CD133 expression tended to be an independent prognostic factor. CD133 expression is correlated with poor prognosis in CRC. (Keyword) Aged / Antigens, CD / Chi-Square Distribution / Colectomy / Colorectal Neoplasms / Disease-Free Survival / Female / Glycoproteins / Humans / Immunohistochemistry / Kaplan-Meier Estimate / Male / Multivariate Analysis / Neoplasm Staging / Peptides / Proportional Hazards Models / Risk Factors / Time Factors / Treatment Outcome / Tumor Markers, Biological (Link to Publication Site) ● Publication site (DOI): 10.5754/hge13657 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25436343 ● Search Scopus @ Elsevier (PMID): 25436343 ● Search Scopus @ Elsevier (DOI): 10.5754/hge13657 (DOI: 10.5754/hge13657, PubMed: 25436343)
173.	Noriko Matsumoto, Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto, Akira Takahashi, Masatake Akutagawa and Takahiro Emoto : Effect of light irradiation by light emitting diode on colon cancer cells., Anticancer Research, Vol.34, No.9, 4709-4716, 2014. (Summary) Recent studies have demonstrated the efficacy of irradiation from light emitting diodes (LED) for wound healing, anti-inflammation and anticancer therapies. However, little is known about the effects of visible light in colon cancer cells. The purpose of this study was to evaluate the biological response (including gene expression changes) of human colon cancer cells to different wavelengths of LED irradiation. Human colon cancer cells (HT29 or HCT116) were seeded onto laboratory dishes that were then put on LED irradiation equipment with a 465 nm-, 525 nm-, or 635 nm-LED. Irradiation at 15 or 30 mW was performed 10 min/day, each day for 5 days. The cell counting kit8 was then used to measure cell viability. Apoptosis and expression of several mRNAs (caspase, MAPK and autophagy pathway) in HT29 cultures irradiated with 465 nm LED were evaluated via AnnexinV/PI and RT-PCR, respectively. Viability of HT29 and HCT116 cells was lower in 465 nm-LED irradiated cultures than in control cultures, but viability of HT29 cells did not differ between control cultures and 525 nm-LED or 635 nm-LED irradiated cultures. Moreover, the expression of FAS, caspase-3, capase-8, and JUK were significantly higher in 465 nm-LED irradiated cultures than in control cultures, and expression of ERK1/2 and LC3 was lower in blue-irradiated cells. LED irradiation at 465 nm inhibited the proliferation of HT29 cells and of HCT116 cells. Notably, LED irradiation at 465 nm promoted apoptosis inHT29 cultures via the extrinsic apoptosis pathway and the MAPK pathway. (Keyword) apoptosis / Cell Cycle Checkpoints / Cell Line, Tumor / Cell Proliferation / Cell Survival / Colonic Neoplasms / Dose-Response Relationship, Radiation / Gene Expression Regulation, Neoplastic / HCT116 Cells / HT29 Cells / Humans / Lasers, Semiconductor / Light / Mitogen-Activated Protein Kinases / signal transduction (Tokushima University Institutional Repository) ● Metadata: 109346 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25202048 ● Summary page in Scopus @ Elsevier: 2-s2.0-84908691381 (Tokushima University Institutional Repository: 109346, PubMed: 25202048, Elsevier: Scopus)
174.	Gizachew Yismaw Wubetu, Tohru Utsunomiya, Daichi Ishikawa, Tetsuya Ikemoto, Shinichiro Yamada, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yusuke Arakawa, Satoru Imura, Hideki Arimochi and Mitsuo Shimada : Branched chain amino acid suppressed insulin-initiated proliferation of human cancer cells through induction of autophagy., Anticancer Research, Vol.34, No.9, 4789-4796, 2014. (Summary) Branched chain amino acid (BCAA) dietary supplementation inhibits activation of the insulin-like growth factor (IGF)/IGF-I receptor (IGF-IR) axis in diabetic animal models. However, the in vitro effect of BCAA on human cancer cell lines under hyper-insulinemic conditions remains unclear. Colon (HCT-116) and hepatic (HepG2) tumor cells were treated with varying concentrations of BCAA with or without fluorouracil (5-FU). The effect of BCAA on insulin-initiated proliferation was determined. Gene and protein expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting, respectively. BCAA supplementation had no significant effect on cell proliferation and did not show significant synergistic or antagonistic effects with 5-FU. However, BCAA significantly decreased insulin-initiated proliferation of human colon and hepatic cancer cell lines in vitro. BCAA supplementation caused a marked decrease in activated IGF-IR expression and significantly enhanced both mRNA and protein expression of LC3-II and BECN1 (BECLIN-1). BCAA could be a useful chemopreventive modality for cancer in hyperinsulinemic conditions. (Keyword) Amino Acids, Branched-Chain / Apoptosis / Autophagy / Cell Line, Tumor / Cell Proliferation / Dietary Supplements / HCT116 Cells / Hep G2 Cells / Humans / Insulin / Phosphorylation / Receptor, IGF Type 1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25202059 ● Search Scopus @ Elsevier (PMID): 25202059 (PubMed: 25202059)
175.	Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Hirohiko Sato, Kozo Yoshikawa, Tomohiko Miyatani, Chie Takasu and Noriko Matsumoto : Protein kinase Cι is a new prognostic factor in gastric cancer., Surgery Today, Vol.45, No.6, 759-764, 2014. (Summary) Protein kinase Cι (PKCι) is an important oncogenic K-ras effector, and its expression is correlated with tumor angiogenesis. The role of PKCι in gastric cancer remains unclear. The aim of this study was to clarify the role of PKCι in gastric cancer. Twenty-eight patients with gastric cancer who underwent gastrectomy were enrolled in this study. The expression of PKCι mRNA was determined, as were the clinicopathological factors. The patients were divided into PKCι high and low expression groups. The 5-year survival rate, ERK mRNA level and VEGF mRNA level were compared between the two groups. The prognostic factors were investigated by a multivariate analysis. High expression of PKCι was observed to be associated with a lack of differentiation, tumor invasion ≥muscularis propria≤, stage III and IV disease and peritoneal dissemination. The 5-year survival rate in the PKCι high group was lower than that in the PKCι low group. The multivariate analysis revealed that a high expression level of PKCι was an independent prognostic factor. The expression levels of ERK and VEGF in the PKCι high group were higher than those in the PKCι low group. Our results indicate that PKCι is correlated with tumor progression and angiogenesis. PKCι may be a new prognostic factor for gastric cancer. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-014-1010-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25108825 ● Search Scopus @ Elsevier (PMID): 25108825 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-014-1010-5 (DOI: 10.1007/s00595-014-1010-5, PubMed: 25108825)
176.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : Laparoscopic resection of hepatoblastoma: report of a case., Asian Journal of Endoscopic Surgery, Vol.7, No.3, 267-270, 2014. (Summary) Despite the increasing number of recent reports on laparoscopic resection of malignant liver tumors in adults, there have been few reports involving children. In this paper we discuss the laparoscopic resection of a hepatoblastoma in a 1-year-old boy. The CT scan revealed an exophytic hepatic tumor on S5 measuring 6 × 5 × 4 cm after preoperative chemotherapy. The operation time was 225 min with an estimated blood loss of about 38 mL; intraoperative transfusion was not required. Radiofrequency-assisted precoagulation was performed. The patient had an uncomplicated recovery and started postoperative chemotherapy on postoperative day 12. Our literature search revealed only five reported cases of laparoscopic resection of hepatoblastoma in which there was no postoperative complication or recurrence. Laparoscopic resection of a hepatoblastoma in a selected subgroup of patients can be safe and feasible. (Keyword) Age Factors / Hepatectomy / Hepatoblastoma / Humans / Infant / Laparoscopy / Liver Neoplasms / Male (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12106 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25131326 ● Summary page in Scopus @ Elsevier: 2-s2.0-84929262777 (DOI: 10.1111/ases.12106, PubMed: 25131326, Elsevier: Scopus)
177.	Bat-Erdene Batsaikhan, Kozo Yoshikawa, Nobuhiro Kurita, Takashi Iwata, Chie Takasu, Hideya Kashihara and Mitsuo Shimada : Expression of Stathmin1 in gastric adenocarcinoma., Anticancer Research, Vol.34, No.8, 4217-4221, 2014. (Summary) Over expression of Stathmin1 (STMN1), activation-induced cytidine deaminase (AID) and protein kinase C iota (PKCi) proteins participate in the regulation of carcinogenesis. In the present study, we investigated the expression of STMN1 in patients with gastric adenocarcinoma and also determined the correlation of STMN1 with AID and PKCi proteins. This study was conducted in the Tokushima University Hospital between September 2009 and September 2010 on a total of 59 patients with gastric adenocarcinoma. Stathmin1, AID and PKCi protein expressions were evaluated by immuno-histochemistry in gastric adenocarcinoma. A strong expression of STMN1 was significantly associated with gender- and poorly differentiated gastric adenocarcinoma (p<0.05). A high mRNA level of STMN1 was found in the tumor tissue of gastric adenocarcinoma compared to non-tumor tissue (p<0.05). In addition, STMN1 expression was significantly correlated with AID and PKCi protein expressions in gastric adenocarcinoma (p<0.05). High mRNA level of the Stathmin1 gene was significantly expressed in gastric tumor tissue than non-tumor and strong expression of STMN1 protein is correlated with poorly-differentiated gastric adenocarcinoma. (Keyword) Adenocarcinoma / Adult / Aged / Aged, 80 and over / Cytidine Deaminase / Female / Humans / Isoenzymes / Male / Middle Aged / Protein Kinase C / RNA, Messenger / Stathmin / Stomach Neoplasms (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25075050 ● Search Scopus @ Elsevier (PMID): 25075050 (PubMed: 25075050)
178.	Kozo Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Hirohiko Sato, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Noriko Matsumoto and Syohei Eto : Hybrid technique for laparoscopic incisional ventral hernia repair combining laparoscopic primary closure and mesh repair., Asian Journal of Endoscopic Surgery, Vol.7, No.3, 282-285, 2014. (Summary) Incisional ventral hernia is one of the most common surgical complications after laparotomy. Laparoscopic repair of incisional ventral hernia has been conducted recently, and the advantages of this procedure have been reported. However, in large orifice cases, the recurrence rate is increased. To improve recurrence rates in large cases, a hybrid method combining laparoscopic primary closure and mesh repair can be applied. Monofilament thread was inserted into the abdominal cavity for hernia closure and pulled from the other side of the orifice. The same procedure was performed from the upper side to the lower side without closure, and all thread was placed in line. Both sides of the thread were then introduced to the midline of the incision through a subcutaneous route. This procedure was conducted with an introducer. All threads were tied, and then a mesh was placed. Hybrid techniques already combine mini-laparotomy for hernia closure and subsequent laparoscopic intraoperative onlay mesh for reinforcement, but such techniques require laparotomy. In our technique, closure of the linea alba does not require laparotomy. All procedures were performed laparoscopically. This procedure is very easy and safe, and does not require the abdominal cavity to be opened. Thus, hybrid methods are effective for treating cases of incisional hernia involving a large orifice. (Keyword) Hernia, Ventral / Herniorrhaphy / Humans / Laparoscopy / Surgical Mesh / Suture Techniques (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12113 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25131330 ● Summary page in Scopus @ Elsevier: 2-s2.0-84929284022 (DOI: 10.1111/ases.12113, PubMed: 25131330, Elsevier: Scopus)
179.	Gizachew Yismaw Wubetu, Tohru Utsunomiya, Daichi Ishikawa, Shinichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yusuke Arakawa, Satoru Imura, Mami Kanamoto, Chengzhan Zhu, Yoshimi Bando and Mitsuo Shimada : High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma after hepatectomy., Annals of Surgical Oncology, Vol.21 Suppl 4, S721-8, 2014. (Summary) Signal transducer and activator of transcription 4 (STAT4) mediates the intracellular effects of interleukin-12, leading to the production of interferon gamma (IFN-γ) and natural killer cells cytotoxicity. However, the clinical significance of STAT4 expression in patients with hepatocellular carcinoma (HCC) remains virtually unknown. A total of 66 HCC patients who underwent hepatectomy were enrolled in this study. Quantitative real-time polymerase chain reaction was performed to determine STAT4 and IFNG mRNA expression levels. Tissue microarray-based immunohistochemistry was performed to examine CD8(+) T cells, STAT4, and INF-γ proteins. STAT4 was differentially expressed in tumor and nontumor tissues (P = 0.001) and positively correlated with IFNG expression (R (2) = 0.506, P < 0.05) and CD8(+) T cell infiltration (R (2) = 0.53, P < 0.001). Significant correlations were observed between STAT4 expression and tumor TNM stage (P = 0.043), hepatic venous invasion (P = 0.003), des-gamma-carboxy prothrombin (P = 0.011), tumor size (P = 0.036), and tumor differentiation (P = 0.034). Patients with high STAT4 expression had significantly better recurrence-free survival (P = 0.009). Low STAT4 expression (P = 0.030) and presence of portal venous invasion or hepatic venous invasion (P = 0.006) were independent risk factors for HCC recurrence. Downregulation of STAT4 in HCC indicated aggressive tumor behavior and predicted a worse clinical outcome. STAT4 might be a useful biomarker to identify patients at high risk of recurrence after hepatectomy. (Tokushima University Institutional Repository) ● Metadata: 109697 (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-014-3861-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24965572 ● Search Scopus @ Elsevier (PMID): 24965572 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-014-3861-9 (Tokushima University Institutional Repository: 109697, DOI: 10.1245/s10434-014-3861-9, PubMed: 24965572)
180.	Noriko Matsumoto, Yuji Morine, Tohru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shiniciro Yamada, Daichi Ishikawa, Chie Takasu, Hidenori Miyake and Mitsuo Shimada : Role of CD151 expression in gallbladder carcinoma., Surgery, Vol.156, No.5, 1212-1217, 2014. (Summary) CD151 is a member of the tetraspanin family, which interacts with laminin-binding integrins and other tetraspanins. CD151 is involved in several pathologic activities associated with tumor progression, including metastasis and angiogenesis. The aim of this study was to clarify the clinical use of CD151 expression in gallbladder cancer (GBC). Forty-five patients with GBC who had undergone operative treatment were enrolled in this study. Expressions of CD151 in the resected GBC specimens were evaluated with anti-CD151 antibody. The patients were divided into positive and negative groups according to CD151 expression: CD151-positive group (n = 26) and CD151-negative group (n = 19). Clinicopathologic factors, including Ki-67 and matrix metallopeptidase 9, also were compared between the two groups. CD151-positive expression was 58% and correlated with poorer prognosis; 5-year survival of CD151-positive and CD151-negative groups was 29% and 78%, respectively (P = .006). CD151 expression also correlated with lymphatic invasion and curability. Multivariate analysis revealed that CD151-positive expression was an independent prognostic factor (hazard ratio 2.97, P = .02). In addition, CD151 expression correlated with matrix metallopeptidase 9 expression (P < .05) but not with Ki67 expression. Those findings suggested that CD151-positive expression might be a potential prognostic indicator and one of the target molecules for the regulation of tumor metastasis for patients with GBC. (Keyword) Adult / Aged / Aged, 80 and over / Antigens, CD151 / Carcinoma / Female / Gallbladder / Gallbladder Neoplasms / Humans / Immunohistochemistry / Ki-67 Antigen / Male / Matrix Metalloproteinase 9 / Middle Aged / Multivariate Analysis / Prognosis / Tumor Markers, Biological (Link to Publication Site) ● Publication site (DOI): 10.1016/j.surg.2014.04.053 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24890568 ● Search Scopus @ Elsevier (PMID): 24890568 ● Search Scopus @ Elsevier (DOI): 10.1016/j.surg.2014.04.053 (DOI: 10.1016/j.surg.2014.04.053, PubMed: 24890568)
181.	Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Hirohiko Sato, Kozo Yoshikawa, Tomohiko Miyatani, Chie Takasu, Noriko Matsumoto and Hiroki Ishibashi : Duodenal-Jejunal Bypass Improves Insulin Resistance by Enhanced Glucagon-Like Peptide-1 Secretion Through Increase of Bile Acids., Hepato-Gastroenterology, Vol.61, No.132, 1049-1054, 2014. (Summary) The aim of this study is to investigate the mechanisms of improvement in insulin resistance after duodenal-jejunal bypass (DIB), especially regarding the correlation between bile acids and glucagon-like peptide-1 (GLP-1). SD rats were divided into two groups: DIB or Sham group. Blood glucose, insulin, GLP-1, bile acids, and the number of L cells in the small intestine were investigated three weeks after the operations. Next, to assess the effect of the bile acids on GLP-1 secretion in ileum, bile diversion model (=inhibition of rapid bile exposure to the ileum; BD group) were performed and postoperative glycemic parameters were measured. DJB improved insulin resistance and increased GLP-1 compared with sham. Higher bile acids in DJB were found than that in sham. The number of L cells in the common limb of DJB was increased compared with that in the distal segment of sham. In BD group, insulin resistance had not improved. GLP-1, bile acids, and the number of L cells revealed no significant changes compared with sham. DJB has a potential to improve insulin resistance, which may be related to enhanced GLP-1 secretion through the increase of bile acids in the common limb of the small intestine. (Link to Publication Site) ● Publication site (DOI): 10.5754/hge13029 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26158164 ● Search Scopus @ Elsevier (PMID): 26158164 ● Search Scopus @ Elsevier (DOI): 10.5754/hge13029 (DOI: 10.5754/hge13029, PubMed: 26158164)
182.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Hirohiko Sato and Mitsuo Shimada : The Role Of Surgical Treatment In The Multidisciplinary Therapy For Hepatoblastoma., Hepato-Gastroenterology, Vol.61, No.131, 553-556, 2014. (Summary) The aim of this study was to evaluate the clinico-patholigical features and effects of multi-disciplinary therapy for pediatric patients with hepatoblastoma (HB). Ten cases who underwent hepatectomy from 1996 to 2013 were studied. Our therapeutic protocol included neoadjuvant chemotherapy (NAC) + hepatectomy + adjuvant chemotherapy (AC). The regimens were CDDP+THP-ADR (n = 2), CITA (n = 1), PLADO (n = 5), and CDDP(n = 1). One case with 18-trisomy underwent only hepatectomy. Medical records were reviewed to evaluate characteristics, the effects of chemotherapy and prognosis. The median age at operation was 1.2 years (male: 7 and female: 3). PRETEXT classification was assigned to groups I (n = 2), II (n = 4), and III (n = 4). 15 years overall survival and disease-free survival rates were 100% and 80%, respectively. Two cases, who had post-operative lung metastasis, underwent chemotherapy with or without complete resection of lung tumors. No further recurrence was observed in these two cases. One case with 18 trisomy underwent right hepatectomy for PRETEXT II HB and is still doing well 67 months after hepatectomy. It was found that multidisciplinary therapy based on surgery, including complete resections of recurrent lesions, offers long-term survival, even for cases which develop recurrent metastatic tumors or cases complicated with 18 trisomy. (Link to Publication Site) ● Publication site (DOI): 10.5754/hge14068 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26176034 ● Search Scopus @ Elsevier (PMID): 26176034 ● Search Scopus @ Elsevier (DOI): 10.5754/hge14068 (DOI: 10.5754/hge14068, PubMed: 26176034)
183.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi and Hideya Kashihara : P1胃癌に対しS-1+PTXi.p.を行い5年生存が得られた1例, Journal of Japanese College of Surgeons, Vol.39, No.2, 199-203, 2014.
184.	Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa and Jun Higashijima : 腹腔鏡下切除を施行した骨形成性直腸癌同時肝転移の1例, Journal of Japan Surgical Association, Vol.75, No.7, 185-190, 2014. (Keyword) 和文論文 (Link to Publication Site) ● Publication site (DOI): 10.3919/jjsa.75.1949 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3919/jjsa.75.1949 (DOI: 10.3919/jjsa.75.1949)
185.	Chinbold Enkhbold, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa and Mitsuo Shimada : Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma., Hepatology Research, Vol.44, No.14, E346-52, 2014. (Summary) FBXW7 acts as a tumor suppressor gene by targeting several oncogenic regulators of proliferation, growth and apoptosis for proteasomal degradation. However, the significance of this protein is not yet well understood in intrahepatic cholangiocarcinoma (IHCC). In this study, we aimed to investigate the correlation between FBXW7 expression and clinicopathological variables in IHCC patients. Thirty-one patients with IHCC who underwent hepatic resection were enrolled. FBXW7 expression in tumor tissue was determined by immunohistochemistry and patients were divided into two groups, the FBXW7 high expression group (n = 11) and the FBXW7 low expression group (n = 20). We then compared clinicopathological variables including prognosis between the high and low expression groups in tumor tissue. FBXW7 expression was significantly correlated with staging (P = 0.006), and tended to correlate with lymph node metastasis. The FBXW7 low expression group had significantly poorer prognosis compared with the FBXW7 high expression group (P = 0.020); 3-year survival rates were 29.4% and 72.7%, respectively. Furthermore, the disease-free survival rate in the FBXW7 low expression group was significantly worse than in the FBXW7 high expression group (P = 0.022). On multivariate analysis, intrahepatic metastasis (P = 0.006) was a significant independent prognostic factor for disease-free survival, and FBXW7 low expression tended to be an independent prognostic factor for both overall (P = 0.067) and disease-free survival (P = 0.083). Our results confirmed that low expression of FBXW7 in IHCC correlates with tumor progression and poor prognosis in IHCC. (Tokushima University Institutional Repository) ● Metadata: 109369 (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.12314 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24552289 ● Search Scopus @ Elsevier (PMID): 24552289 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.12314 (Tokushima University Institutional Repository: 109369, DOI: 10.1111/hepr.12314, PubMed: 24552289)
186.	Nobuhiro Kurita and Mitsuo Shimada : 肝切除後のVTE予防策は?, エキスパートによる消化器外科静脈血栓塞栓症診療指針, 103-105, 2014. (Keyword) 和文論文
187.	Shinichiro Yamada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusue Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa and Mitsuo Shimada : Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy., Annals of Surgical Oncology, Vol.21 Suppl 3, S436-42, 2014. (Summary) Radiofrequency ablation (RFA) is a widely used therapy for hepatocellular carcinoma (HCC). Several reports have demonstrated the aggressive local recurrence of HCC after RFA, suggesting that induction of further malignant transformation of HCC has occurred. Eighty-eight (88) patients with HCC who underwent hepatic resection were included in this study. Hepatectomy was indicated for local recurrence of HCC after RFA (n = 10, RFA group) and for HCC without prior RFA (n = 78, non-RFA group). Clinicopathological data and the patient's prognosis after hepatectomy were compared between the two groups. Expression levels of hypoxia-inducible factor-1 (HIF-1), epithelial cell adhesion molecule (EpCAM), CD44, and vascular endothelial growth factor messenger RNA (mRNA) in the tumor tissues were also examined. The RFA group showed higher frequency of portal vein invasion and less tumor differentiation compared with the non-RFA group (p < 0.05). Overall and disease-free survival rates in the RFA group were significantly worse than those in the non-RFA group (p < 0.05). HIF-1 and EpCAM mRNA expression levels in the RFA group were significantly higher than those in the non-RFA group (p < 0.05). These results suggest that local HCC recurrence after RFA shows an aggressive tumor phenotype and poor prognosis through the enhanced expressions of HIF-1 and EpCAM in the residual HCC tumors after insufficient or sub-lethal treatment by RFA. (Keyword) Aged / Antigens, CD44 / Antigens, Neoplasm / Carcinoma, Hepatocellular / Case-Control Studies / Catheter Ablation / Cell Adhesion Molecules / Combined Modality Therapy / Female / Follow-Up Studies / Hepatectomy / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / Male / Neoplasm Recurrence, Local / Neoplasm Staging / Neoplasm, Residual / Prognosis / RNA, Messenger / Real-Time Polymerase Chain Reaction / Reverse Transcriptase Polymerase Chain Reaction / Survival Rate / Tumor Markers, Biological (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-014-3575-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24566861 ● Search Scopus @ Elsevier (PMID): 24566861 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-014-3575-z (DOI: 10.1245/s10434-014-3575-z, PubMed: 24566861)
188.	Akira Nii, Tohru Utsunomiya, Mitsuo Shimada, Toru Ikegami, Hiroki Ishibashi, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hajime Sasaki and Akihiro Kawashima : A hydrolyzed whey peptide-based diet ameliorates hepatic ischemia-reperfusion injury in the rat nonalcoholic fatty liver., Surgery Today, Vol.44, No.12, 2354-2360, 2014. (Summary) The number of patients with nonalcoholic fatty liver disease (NAFLD) is increasing. Hepatic steatosis is a major risk factor for hepatic failure after ischemia-reperfusion (I/R) injury. Hydrolyzed whey peptide (HWP) is a functional liquid-type nutritional diet containing whey peptide, which has previously been shown to exert anti-inflammatory effects. In the present study, we examined the effects of HWP on the hepatic I/R injury in a rat NAFLD model. Rats fed a methionine/choline-deficient diet for 4 weeks were divided into two groups after 30 min of whole liver ischemia. In Group-M, HWP was given immediately after reperfusion and every 6 h thereafter. In Group-C, the vehicle was given in the same manner. The liver function tests and microscopic findings of the liver after reperfusion were compared between the two groups. The serum transaminase levels in Group-M were significantly lower than those in Group-C after reperfusion. The gene expression levels of IL-6 and inducible nitric oxide synthase (iNOS) were significantly lower in Group-M compared to Group-C. The TNF-α and uncoupling protein-2 (UCP-2) expression levels were also markedly lower in Group-M. The hepatic necrotic areas in Group-M were significantly smaller than those in Group-C. The administration of a HWP diet ameliorated the hepatic I/R injury in rats with NAFLD. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-014-0853-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24492979 ● Search Scopus @ Elsevier (PMID): 24492979 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-014-0853-0 (DOI: 10.1007/s00595-014-0853-0, PubMed: 24492979)
189.	Bat-Erdene Batsaikhan, Nobuhiro Kurita, Takashi Iwata, Hirohiko Sato, Kozo Yoshikawa, Chie Takasu, Hideya Kashihara, Noriko Matsumoto, Hiroki Ishibashi and Mitsuo Shimada : The role of activation-induced cytidine deaminase expression in gastric adenocarcinoma., Anticancer Research, Vol.34, No.2, 995-1000, 2014. (Summary) Gastric adenocarcinoma is one of the most common malignant tumors and the leading cause of malignancy-related death worldwide. Studies have reported overexpression of activation-induced cytidine deaminase (AID) and protein kinase c iota (PKCi) proteins showing involvement in the regulation of carcinogenesis. In the present study, we investigated the expression of AID and PKCi in patients with gastric adenocarcinoma and determined the correlation between these proteins. This study was conducted between September 2009 and September 2010 on a total of 59 patients with gastric adenocarcinoma at the Tokushima University Hospital. AID, PKCi and mutated p53 protein expressions were evaluated by immunohistochemistry in gastric adenocarcinoma. High AID and PKCi expression was significantly (p<0.05) associated with poorly-differentiated gastric adenocarcinoma. In addition, PKCi expression was significantly correlated with clinicopathological findings such as a lymph node metastasis, and venous and lymphatic invasion (p<0.05). Furthermore, AID expression was significantly correlated with PKCi and mutated p53 protein expression in gastric adenocarcinoma (p<0.05). High AID and PKCi expressions were significantly correlated with poorly-differentiated gastric adenocarcinoma. (Keyword) Adenocarcinoma / adult education administration / Aged / Aged, 80 and over / Cytidine Deaminase / Enzyme Activation / Female / Humans / immunohistochemistry / Isoenzymes / Male / Middle Aged / Protein Kinase C / Stomach Neoplasms / Survival Rate / Tumor Suppressor Protein p53 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24511045 ● Search Scopus @ Elsevier (PMID): 24511045 (PubMed: 24511045)
190.	Kozo Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Hirohiko Sato, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Noriko Matsumoto and Syohei Eto : Characteristics of internal hernia after gastrectomy with Roux-en-Y reconstruction for gastric cancer., Surgical Endoscopy, Vol.28, No.6, 1774-1778, 2014. (Summary) Although the internal hernias have been a huge topic in the field of bariatric surgery, there were a few reports in gastric cancer. The purpose of this study was to analyze the incidence, clinical features, and prevention of internal hernia after gastrectomy for gastric cancer. Twelve patients who underwent surgical treatment for internal hernia in our hospital after gastrectomy were analyzed. Features, including incidence, symptoms, and signs, were investigated in detail. The operative procedures for preceding gastrectomies were open distal gastrectomy in three patients, open total gastrectomy in three patients, laparoscopic-assisted distal gastrectomy in two patients, and laparoscopic total gastrectomy in four patients. The most frequent sites of internal hernias were jejunojejunostomy mesenteric defects (five patients) and Petersen's defect (five patients), mesenterium of transverse colon (one patient), and esophagus hiatus (one patient). There was no significant difference between open and laparoscopic preceding gastrectomies. After closure of the mesenteric defect was introduced, no further internal hernias occurred. On CT examination, the whirl sign was present in ten patients on 3D images. The present data suggest the importance of early recognition and treatment of internal hernia, as well as its prevention by closure of mesenteric defects. (Keyword) Adult / Aged / Aged, 80 and over / Anastomosis, Roux-en-Y / Female / Gastrectomy / Gastric Bypass / Hernia / Herniorrhaphy / Humans / Imaging, Three-Dimensional / Intestinal Diseases / Laparoscopy / Male / Mesentery / Middle Aged / Stomach Neoplasms / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-013-3384-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24399525 ● Search Scopus @ Elsevier (PMID): 24399525 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-013-3384-7 (DOI: 10.1007/s00464-013-3384-7, PubMed: 24399525)
191.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada, Mitsuo Shimada, Tomoko Sogami and Akira Nii : Indigo carmine dye-assisted lymphatic-sparing laparoscopic Palomo varicocelectomy in children., The Journal of Medical Investigation : JMI, Vol.61, No.1-2, 151-155, 2014. (Summary) The ideal method for varicocelectomy in children remains controversial. We present our experience with dye-assisted lymphatic-sparing laparoscopic varicocelectomy (LSLV) in children, which overcomes the limitations of previously described techniques. Five consecutive LSLVs were performed over a period of three years on children with a mean age of twelve years. The varicocele grade was three in one case and grade 2 in four cases, respectively. A left subdartos injection of 2 ml of Indigo carmine dye was done using a 25-gauge needle at ten minutes before an operation. A scrotal injection of lymphatic dye was utilized to spare at least one lymphatic and the remaining spermatic vessels were divided. Lymphatic-sparing was accomplished in all cases. No peri-operative complication was noted. We spared one lymphatic channel in one patient (20%) and two channels in four patients (80%). There were no cases of hydrocele or residual varicocele. Dye-assisted LSLV is easily accomplished with an excellent surgical outcome and sparing one or two lymphatics appears to be sufficient to avoid secondary hydrocele. (Keyword) Adolescent / Child / Coloring Agents / Humans / Incidence / Indigo Carmine / Injections / Laparoscopy / Lymphatic System / Male / Organ Sparing Treatments / Postoperative Complications / Retrospective Studies / Severity of Illness Index / Treatment Outcome / Varicocele (Tokushima University Institutional Repository) ● Metadata: 109543 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.151 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705760 ● Search Scopus @ Elsevier (PMID): 24705760 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.61.151 (Tokushima University Institutional Repository: 109543, DOI: 10.2152/jmi.61.151, PubMed: 24705760)
192.	Hiroki Ishibashi, Takehito Oshio, Tomoko Sogami, Akira Nii, Hiroki Mori, Keigo Yada and Mitsuo Shimada : Iliopsoas abscess in an infant., The Journal of Medical Investigation : JMI, Vol.61, No.1-2, 213-216, 2014. (Summary) Iliopsoas abscess (IPA) is uncommon in childhood and very rare in the neonate and infant. We present a case of IPA after an umbilical granuloma in an infant. A baby girl with a birth weight of 2,970 g was born at thirty-seven weeks and two days gestation by Caesarean Section. On the fourteenth day after birth, her umbilicus was wet and developed the granulomatous formation. At two months of age, she presented with right leg and groin swelling with mild bluish discoloration and without fever. She had poor movement of her right leg and showed apparent discomfort. Her umbilicus was dry and there was no granulomatous material. Ultrasonography and computed tomography demonstrated an iliopsoas abscess in the right position. Therefore, an extraperitoneal surgical drainage was performed, aspirating yellowish pus. Culture of the purulent material revealed Staphylococcus aureus. Systemic antibiotic therapy was continued for ten days. After three days of drainage, full-range motion of the right leg was gained, and then after eleven days, CT findings comfirmed the disappearance of the iliopsoas abscess. IPA is extremely rare and it is difficult to diagnose. However, it should be included in the differential diagnosis of an infant with poor leg movement and swelling of the groin to the femur. (Keyword) Anti-Bacterial Agents / Diagnosis, Differential / Drainage / Female / Granuloma / Humans / Infant / Infant, Newborn / Infant, Newborn, Diseases / Psoas Abscess / Staphylococcal Infections / Staphylococcus aureus / Treatment Outcome / Umbilicus (Tokushima University Institutional Repository) ● Metadata: 109542 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.213 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705769 ● Search Scopus @ Elsevier (PMID): 24705769 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.61.213 (Tokushima University Institutional Repository: 109542, DOI: 10.2152/jmi.61.213, PubMed: 24705769)
193.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : 3.肝疾患ウイルス性肝炎, 日本臨床外科学会誌, Vol.69, No.11, 2014.
194.	Shuichi Iwahashi, Satoru Imura, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Yu Saitou, Chie Takasu and Mitsuo Shimada : 肝移植, 日本臨床外科学会誌, Vol.69, No.4, 2014.
195.	K Taguchi, Hisami Okumura, A Mizuno, T Nakamura, Mitsuo Shimada, Toshio Doi and E Takeda : Insulin resistance as early sign of hepatic dysfunction in liver cirrhosis, The Journal of Medical Investigation : JMI, Vol.61, No.1.2, 180-189, 2014. (Summary) Glucose intolerance characterized by postprandial hyperglycemia and hyperinsulinemia is commonly seen in patients with liver cirrhosis (LC). The aim of this study is to clarify the relation between glucose intolerance and disorder of liver function in patients with LC. The 75 g oral glucose tolerance test (75 g OGTT) and the hyperinsulinemic euglycemic clamp combined with 0.2 g/kg oral glucose load (HECGL) were conducted in 61 patients with LC. Based on the results of 75 g OGTT, the 61 patients with LC were divided into groups, 21 (34.4%) patients with normal glucose tolerance (LC-NGT), 12 (19.7%) patients with impaired glucose tolerance (LC-IGT) and 28 (45.9%) patients with diabetes mellitus (LC-DM). Fasting plasma glucose (FPG) level was normal in 50 (82.0%) patients with LC. All patients with LC showed insulin resistance in both peripheral (skeletal and adipose) and hepatic tissues evaluated by HECGL, although significant correlation between the degree of glucose intolerance and the severity of hepatic dysfunction was not observed. Insulin resistance in both liver and peripheral tissues is the early sign in the patients with LC. This fact indicates that nutritional care from early stages of LC would be necessary in the patients. (Tokushima University Institutional Repository) ● Metadata: 109552 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.180 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705764 ● Summary page in Scopus @ Elsevier: 2-s2.0-84897951186 (Tokushima University Institutional Repository: 109552, DOI: 10.2152/jmi.61.180, PubMed: 24705764, Elsevier: Scopus)
196.	Shinichiro Yamada, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : CXC receptor 4 and stromal cell-derived factor 1 in primary tumors and liver metastases of colorectal cancer., The Journal of Surgical Research, Vol.187, No.1, 107-112, 2013. (Summary) It has been determined that the chemokine receptor CXC receptor 4 (CXCR4) and its ligand, stromal cell-derived factor 1 (SDF-1), regulate several key processes in a wide variety of cancers. In this study, we investigate the possible role of SDF-1 (noncancerous liver tissue) and CXCR4 in liver metastases of colorectal cancer (CRC). Reverse transcription-polymerase chain reaction was performed to examine the expression of SDF-1 in noncancerous liver tissues of 16 CRC patients with liver metastasis and in normal liver tissues of six patients with benign liver disease. We also examined the expression of CXCR4 in cancerous tissues from primary and metastatic tumors. Using reverse transcription-polymerase chain reaction, CXCR4 expression in metastatic tumors tended to be higher than that in primary tumors (P = 0.16). High CXCR4 expression in a primary tumor was found to be related to an increased lymphatic invasion (P = 0.01), an advanced depth of tumor invasion (P = 0.07), and a decrease in the overall survival rate. The SDF-1 expression observed in noncancerous liver tissues of CRC with liver metastasis was significantly higher than that observed in normal liver tissues of benign liver disease (P < 0.05). In CRC with liver metastasis, CXCR4 expression demonstrated associations with local progression, liver metastasis, and poor overall survival. (Keyword) Aged / Chemokine CXCL12 / Colorectal Neoplasms / Female / Humans / Liver Neoplasms / Male / Middle Aged / Neoplasm Staging / Prognosis / Receptors, CXCR4 / Retrospective Studies / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jss.2013.10.030 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24238971 ● Search Scopus @ Elsevier (PMID): 24238971 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jss.2013.10.030 (DOI: 10.1016/j.jss.2013.10.030, PubMed: 24238971)
197.	Chie Takasu, Mitsuo Shimada, Hirohiko Sato, Tomohiko Miyatani, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mami Kanamoto, Nobuhiro Kurita, Shohei Eto and Tohru Utsunomiya : Benefits of simultaneous laparoscopic resection of primary colorectal cancer and liver metastases., Asian Journal of Endoscopic Surgery, Vol.7, No.1, 31-37, 2013. (Summary) Recently, consensus on the optimal strategy for resectable synchronous colorectal liver metastases (LM) seems to have shifted toward simultaneous resection. However, there are still relatively few reports about simultaneous laparoscopic resection. The aim of this study is to evaluate the outcomes of patients who underwent simultaneous laparoscopic resection. We evaluated 14 patients who underwent simultaneous resection of primary colorectal cancer and LM in our hospital from 2004 to 2012. Patients were selected by matched pair analysis based on the number of LM (≤4) and tumor size (≤5 cm). We divided them into two groups: the simultaneous laparoscopic resection of primary colorectal cancer and LM (Lap-S) group (n = 7) and the simultaneous open resection of primary colorectal cancer and LM (Open-S) group (n = 7). Clinical and oncologic outcomes were compared between the groups. The Lap-S patients were significantly older than the Open-S patients. The mean operative times of Lap-S and Open-S were 472 min and 466 min, respectively. The mean blood loss was significantly smaller in the Lap-S group (153 mL) than in the Open-S group (496 mL). There was no surgical mortality in either group. The incidence of postoperative complications in the Lap-S and Open-S groups was 12.3% and 33.0%, respectively. The mean postoperative hospital stay was significantly shorter in the Lap-S group (16 days) than in the Open-S group (36 days). There was no significant difference in long-term survival between the two groups. Lap-S patients had equivalent long-term outcomes to Open-S patients. Therefore, given its technical feasibility and safety, Lap-S may be one of the most promising options in selected patients. (Keyword) Aged / Aged, 80 and over / Colectomy / Colorectal Neoplasms / Feasibility Studies / Female / Follow-Up Studies / Hepatectomy / Humans / Kaplan-Meier Estimate / Laparoscopy / Length of Stay / Liver Neoplasms / Male / Middle Aged / Operative Time / Postoperative Complications / Retrospective Studies / Survival Rate / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.12066 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24127772 ● Search Scopus @ Elsevier (PMID): 24127772 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.12066 (DOI: 10.1111/ases.12066, PubMed: 24127772)
198.	Lkhagva-Ochir Tovuu, Tohru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, Koji Sugimoto, Yu Saitou, Shinichiro Yamada, Michihito Asanoma and Mitsuo Shimada : The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma., International Journal of Clinical Oncology, Vol.19, No.4, 622-628, 2013. (Summary) Aurora B is a serine-threonine kinase and chromosomal passenger protein involved in the control of chromosome assembly and segregation during mitosis. Aberrant expression of Aurora B has been reported in some tumors, including lung and hepatocellular carcinoma (HCC). We investigated the role of Aurora B expression in both HCC and matched adjacent non-tumor tissue. Sixty-three patients with HCC who underwent hepatic resection were enrolled in this study. Aurora B expression in tumor and non-tumor tissue was examined by use of quantitative reverse transcription-polymerase chain reaction. The patients were divided into high and low gene expression groups by median value, and clinicopathological data were compared between the two groups. Aurora B expression was significantly higher in tumor tissue than in non-cancerous tissue (P < 0.001). Disease-free survival was not significantly different between groups with high and low expression in the tumor tissues. For non-tumor tissues, disease-free survival of the low-expression group was significantly better than that of the high-expression group (P < 0.05). The gene expression level of Aurora B correlated with results from liver function tests, for example prothrombin time. Aurora B expression in non-cancerous tissues may be a prognostic factor for HCC. (Keyword) Adult / Aged / Aurora Kinase B / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Gene Expression Regulation, Neoplastic / Humans / Liver / Liver Neoplasms / Male / Middle Aged / Prognosis / Prothrombin Time / Tumor Markers, Biological (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-013-0593-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23893130 ● Search Scopus @ Elsevier (PMID): 23893130 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-013-0593-y (DOI: 10.1007/s10147-013-0593-y, PubMed: 23893130)
199.	Hisami Okumura, 山内利香, 浦野恵理, 寺本有沙, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : 肝硬変患者に対するテーラーメイド栄養管理の血液生化学指標についての検討, 栄養アセスメント, Vol.28, No.1, 18-20, 2011.
200.	Keiko Ogita, Tomoaki Taguchi, Yuji Soejima, Satoshi Ieiri, Shunsaku Katsura, Narito Takada, Toshiharu Matsuura, Tomoharu Yoshizumi, Mitsuo Shimada, Yoshihiko Maehara and Sachiyo Suita : Fatty liver caused by portal vein thrombosis after living donor liver transplantation: a case report, Journal of Pediatric Surgery, Vol.40, No.8, E7-E9, 2005. (Summary) Portal vein thrombosis (PVT) is a rare complication that occurs after liver transplantation: however, it cannot be ignored as a cause of graft loss and death. We herein report a pediatric case of PVT that caused a fatty change in the graft after living donor liver transplantation. The portal vein was successfully reconstructed using the left great saphenous vein of the same donor. Moreover, the fatty liver recovered after the operation. Our case suggests that the finding of fatty liver is an important marker of PVT and immediate portal reconstruction is performed. (Keyword) Fatty Liver / Female / Humans / Infant / Liver Transplantation / Living Donors / Portal Vein / Vascular Surgical Procedures / Venous Thrombosis (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jpedsurg.2005.05.029 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16080920 ● Search Scopus @ Elsevier (PMID): 16080920 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jpedsurg.2005.05.029 (DOI: 10.1016/j.jpedsurg.2005.05.029, PubMed: 16080920)
201.	Noboru Harada, Mitsuo Shimada, Taketoshi Suehiro, Yuji Soejima, Mizuki Ninomiya, Satoko Shiotani and Keizo Sugimachi : Unusual endoscopic findings of CMV esophagitis after liver transplantation, Hepato-Gastroenterology, Vol.52, No.64, 1236-1239, 2005. (Summary) Cytomegalovirus infections are associated with a high mortality rate after liver transplantation, but they are treated successfully by administration of the combination of ganciclovir plus intravenous immunoglobulin. We herein describe cytomegalovirus esophagitis in a patient having gastrointestinal symptoms such as dysphagia, retrosternal pain and epigastralgia after liver transplantation was detected by performing the surveillance of endoscopy. At first, the findings of endoscopy that were segmental erosive areas but no ulcerative areas on the esophageal lumen were unusual in this case of cytomegalovirus infections, but cytomegalovirus esophagitis was confirmed by cytomegalovirus immunohistochemical stain using biopsies. The patient was treated by ganciclovir at an oral dosage of 5mg/kg twice a day for 2 weeks. Our experience suggests that cytomegalovirus esophagitis should be taken into consideration when a patient has gastrointestinal symptoms such as dysphagia, retrosternal pain and epigastralgia and has endoscopic findings such as segmental erosions on the esophageal lumen despite having no cytomegalovirus-specific endoscopic findings such as ulcerative lesions. (Keyword) Antiviral Agents / Carcinoma, Hepatocellular / Cytomegalovirus Infections / Esophagitis / Esophagoscopy / Ganciclovir / Humans / Liver Neoplasms / Liver Transplantation / Male / Middle Aged (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16001670 ● Search Scopus @ Elsevier (PMID): 16001670 (PubMed: 16001670)
202.	Shunsaku Katsura, Keiko Ogita, Tomoaki Taguchi, Sachiyo Suita, Tomoharu Yoshizumi, Yuji Soejima, Mitsuo Shimada and Yoshihiko Maehara : Effect of liver transplantation on multiple bone fractures in an infant with end-stage biliary atresia: a case report, Pediatric Surgery International, Vol.21, No.1, 47-49, 2005. (Summary) Osteodystrophy is frequently found in children with chronic cholestatic liver disease. We herein report an end-stage case of biliary atresia that was associated with multiple bone fractures and severe growth retardation. The patient, an 8-month-old female, underwent a living-related liver transplantation and thereafter showed a dramatic improvement in growth and decrease in bone fractures. A correction of the liver function is therefore considered to be a key factor in treating osteodystrophy that is related to chronic cholestatic liver disease. It is also essential to perform liver transplantation at the most appropriate time to enhance and support the growth of these patients. (Keyword) Biliary atresia (BA) / Bone fractures / Living-related liver transplantation (LRLT) (Link to Publication Site) ● Publication site (DOI): 10.1007/s00383-004-1262-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15372289 ● Search Scopus @ Elsevier (PMID): 15372289 ● Search Scopus @ Elsevier (DOI): 10.1007/s00383-004-1262-z (DOI: 10.1007/s00383-004-1262-z, PubMed: 15372289)
203.	Keiko Ogita, Narito Takada, Tomoaki Taguchi, Sachiyo Suita, Yuji Soejima, Taketoshi Suehiro, Mitsuo Shimada and Yoshihiko Maehara : Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report, Asian Journal of Surgery, Vol.26, No.4, 218-220, 2003. (Summary) FK506 is an immunosuppressant that is thought to be less nephrotoxic than cyclosporine A. However, complications due to renal tubular acidosis (RTA) have recently been reported. We report a case of RTA secondary to FK506 administration in liver transplantation. A 6-month-old girl was treated with FK506 after undergoing living donor liver transplantation for fulminant hepatitis. On postoperative day 17, she demonstrated hyperkalaemia and metabolic acidosis; she was diagnosed to have hyperkalaemic distal RTA with aldosterone deficiency (type IV). Intravenous sodium bicarbonate and furosemide, and intrarectal calcium polystyrenesulfonate were administered to correct the acidosis and promote potassium secretion. Thereafter, the FK506 concentration in whole blood gradually decreased, and the hyperkalaemia and metabolic acidosis following RTA improved. RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated. The mechanism of RTA induced by FK506 has not yet been clearly elucidated. Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation. The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible. (Keyword) renal tubular acidosis / FK506 / liver transplant / hyperkalaemia (Link to Publication Site) ● Publication site (DOI): 10.1016/S1015-9584(09)60307-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14530108 ● Search Scopus @ Elsevier (PMID): 14530108 ● Search Scopus @ Elsevier (DOI): 10.1016/S1015-9584(09)60307-9 (DOI: 10.1016/S1015-9584(09)60307-9, PubMed: 14530108)
204.	伊地知秀樹, Mitsuo Shimada, 末廣剛敏, Yuji Soejima, 前原喜彦, 中牟田誠 and 名和田新 : 術前急性腎不全合併症例に対する生体肝移植の一例, Fukuoka Acta Medica, Vol.93, 266-271, 2002.
205.	寺師貴啓, 田口健一, 恒吉正澄, Mitsuo Shimada, 末廣剛敏, Yuji Soejima, 杉町圭蔵 and 柿添三郎 : 肝移植後液性拒絶反応が疑われた1症例, 今日の移植, Vol.14, 667-668, 2001.

Review, Commentary:

1.	Kouzou Yoshikawa and Mitsuo Shimada : 悪性疾患:腹腔鏡下胃全摘術食道空腸吻合関連合併症回避手技のABC, メディカルビュー, 196-209, 2022.
2.	Yu Saitou, Yasuhiro Hamada, Sonoko Yasui-Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 周術期の体組成評価:―サルコペニアの観点より―, The Japanese Journal of Surgical Metabolism and Nutrition, Vol.53, No.4, 147-156, Aug. 2019. (Link to Publication Site) ● Publication site (DOI): 10.11638/jssmn.53.4_147 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11638/jssmn.53.4_147 (DOI: 10.11638/jssmn.53.4_147)
3.	Hiroki Ishibashi, Mitsuo Shimada, Hiroki Mori, Yuji Morine and 安藤久實 : 膵・胆管合流異常と胆道癌(特集慢性炎症から肝胆膵癌にいたるランドスケープ), KAN TAN SUI, Vol.77, No.8, 659-667, Apr. 2019.
4.	Masaaki Nishi and Mitsuo Shimada : 【ドクターTの心の声を聞け!留置&抜去の理由がわかる! 術式別術後ドレーンの観察とケア】肝切除術, Gastroenterological Surgery Nursing, Vol.22, No.12, 1075-1078, Dec. 2017.
5.	野村幸世, 冨澤康子, 大津洋, 小川朋子, 柴崎郁子, Mitsuo Shimada, 竹下恵美子, 花崎和弘, 葉梨智子, 山下啓子, 明石定子, 山内英子, 岩瀬弘敬, 田口智章, 前田耕太郎 and 中村清吾 : 日本医学会分科会における女性医師支援2015年第3回アンケート調査, Journal of Japan Surgical Society, Vol.118, No.6, 668-672, Nov. 2017. (Keyword) 医学会分科会 / 男女共同参画 / ポジティブアクション (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290882554018304 (CiNii: 1520290882554018304)
6.	Yoichiro Kawashita, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shuichi Iwahashi, Shin-ichiro Yamada, Jun Higashijima, Satoru Imura, Hirohisa Ogawa, Toshiyuki Yagi and Mitsuo Shimada : Loss of Fbxw7 expression is a predictor of recurrence in colorectal liver metastasis., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.24, No.10, 576-583, Oct. 2017. (Summary) Fbxw7 is a tumor suppressor through ubiquitination and degradation of multiple oncoproteins. Loss of Fbxw7 is frequently observed in various human cancers. In this study, we examined the role of Fbxw7 expression in colorectal liver metastasis (CRLM) and its mechanism. Fifty-six patients with CRLM who undergo curative resection were enrolled. Fbxw7 in tumor tissue was determined by immunohistochemistry. Patients were divided into two groups, the Fbxw7 high and low groups. Clinicopathological factors including miR-223 expression were compared between the high (n = 32) and low Fbxw7 groups (n = 24). Fbxw7 expression in tumor tissues was significantly lower than that in normal tissues. The disease-free survival in the low Fbxw7 group was significantly worse than that in the high Fbxw7 group, and 3 years disease-free survival of the low and high Fbxw7 groups were 12.5% and 47.0%, respectively (P = 0.023). On multivariate analysis, loss of Fbxw7 was detected as one of the independent risk factors for recurrence of CRLM (hazard ratio: 2.390, P = 0.017). Likewise, Fbxw7 expression inversely correlated to miR-223 expression (P = 0.017). Loss of Fbxw7 in tumor tissues could be a reliable predictor of recurrence after hepatectomy in patients with CRLM, and miR-223 might be a possible regulator of Fbxw7. (Tokushima University Institutional Repository) ● Metadata: 110995 (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.500 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28846828 ● Search Scopus @ Elsevier (PMID): 28846828 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.500 (Tokushima University Institutional Repository: 110995, DOI: 10.1002/jhbp.500, PubMed: 28846828)
7.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima and Mitsuo Shimada : Treatment strategy of conversion hepatectomy for colorectal liver metastasis, Journal of Clinical Surgery, Vol.72, No.10, 1211-1216, Oct. 2017. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390283684865555456 (CiNii: 1390283684865555456)
8.	Shuichi Iwahashi, Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 【どこをどう切る?どうつなぐ?なぞって覚える!消化器外科術式理解イラストノート】肝臓・胆道の手術肝切除術, Gastroenterological Surgery Nursing, Vol.22, No.8, 704-708, Oct. 2017.
9.	Yuji Morine and Mitsuo Shimada : 胆・膵嚢胞切除先天性胆道拡張症に対する手術, 臨床外科, Vol.72, No.11, 235-240, Oct. 2017.
10.	Yu Saitou, Satoru Imura and Mitsuo Shimada : Evidence and topics of surgical treatment for hepatocellular carcinoma, The Japanese Journal of Gastro-enterology, Vol.114, No.9, 1611-1620, Sep. 2017. (Summary) <p>肝細胞癌に対する外科的治療のエビデンスとして，ガイドライン(2013年版)における，手術(外科的治療)に関係するClinical Questionの中で，CQ21 腫瘍条件からみた肝切除の適応は?，CQ22 肝切除後の予後因子は何か?，CQ24 系統的切除は予後に寄与するか?，CQ31 肝細胞癌に対する肝移植の適応基準は何か?，について概説する．また，今後エビデンス構築が期待されるトピックスとして，腹腔鏡下肝切除の治療適応，BCLC Stage Bに対する外科的治療選択，Conversion Hepatectomyに関しても言及する．</p> (Keyword) 肝細胞癌 / 外科治療 / 腹腔鏡下肝切除 / BCLC / Conversion (Link to Publication Site) ● Publication site (DOI): 10.11405/nisshoshi.114.1611 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28883290 ● CiNii @ National Institute of Informatics (CRID): 1390001206403613312 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028969066 (DOI: 10.11405/nisshoshi.114.1611, PubMed: 28883290, CiNii: 1390001206403613312, Elsevier: Scopus)
11.	Hideya Kashihara, Yuji Morine, Jun Higashijima, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : 【胆膵進行癌に対する外科治療戦略】閉塞性黄疸に対する最新の術前減黄戦略, Surgery, Vol.79, No.8, 708-713, Aug. 2017. (Keyword) 術前減黄処置 / 分肝機能 / 胆汁返還 / 大建中湯 (Link to Publication Site) ● Publication site (DOI): 10.15106/j00393.2017324283 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390846634830490368 ● Search Scopus @ Elsevier (DOI): 10.15106/j00393.2017324283 (DOI: 10.15106/j00393.2017324283, CiNii: 1390846634830490368)
12.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Yuji Morine, Jun Higashijima, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 【がん治療医のための漢方ハンドブック】漢方と癌診療, 臨床外科, Vol.72, No.8, 917-921, Aug. 2017.
13.	Tetsuya Ikemoto, Mitsuo Shimada and Shinichiro Yamada : Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation., Hepatology Research, Vol.47, No.1, 23-30, Jun. 2017. (Summary) Radiofrequency ablation (RFA) is effective for the local control of hepatocellular carcinoma (HCC), particularly when a patient's liver functional reserve does not allow radical resection. There is controversy regarding the superiority of surgical resection compared with RFA for such patients, particularly those with three or fewer tumors with diameters 3 cm. Moreover, HCC often recurs after RFA, and the tumor cells show distinct phenotypic changes. Incomplete ablation accounts for tumor recurrence, and recent studies provide new insights into the biological mechanisms responsible for the pathological changes of HCC after RFA. This review focuses on the roles of epithelial-mesenchymal transition and cancer stemness that are driven by a mechanism that involves microRNA-mediated upregulation of hypoxia-inducible factor-1. The studies reviewed here provide compelling evidence that complete ablation of HCC is required to prevent recurrence and indicate that further research is urgently required to develop a new systematic strategy to prevent tumor recurrence by targeting hypoxia-inducible factor-1. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.12705 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26990590 ● Search Scopus @ Elsevier (PMID): 26990590 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.12705 (DOI: 10.1111/hepr.12705, PubMed: 26990590)
14.	窪田正幸, 新井田達雄, 遠藤格, 小野滋, Mitsuo Shimada, 土岐彰, 野田卓男, 松村敏信 and 安藤久實 : 【先天性胆道拡張症の最前線】先天性胆道拡張症に胆道癌を合併した20歳以下症例の検討日本膵・胆管合流異常研究会登録委員会報告, Journal of Biliary Tract & Pancreas, Vol.38, No.4, 357-362, Apr. 2017.
15.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada and Mitsuo Shimada : 【先天性胆道拡張症の最前線】先天性胆道拡張症における胆道癌の発癌機序, Journal of Biliary Tract & Pancreas, Vol.38, No.4, 351-355, Apr. 2017.
16.	Hiroki Ishibashi, Mitsuo Shimada, Yuji Morine, Keigo Yada and Hiroki Mori : 【先天性胆道拡張症の最前線】先天性胆道拡張症の診療ガイドライン, Journal of Biliary Tract & Pancreas, Vol.38, No.4, 329-337, Apr. 2017.
17.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 【小児外科ディベート対決(日常よくみる疾患)】鼠径ヘルニアの手術 LPEC, Japanese Journal of Pediatric Surgery, Vol.49, No.2, 184-188, Apr. 2017.
18.	Satoru Imura and Mitsuo Shimada : Development of new molecular targeted therapy for advanced hepatocellular carcinoma, Surgery, Vol.79, No.2, 130-134, Feb. 2017. (Keyword) sorafenib (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522543655215967232 (CiNii: 1522543655215967232)
19.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : Effective stepwise training and procedure standardization for young surgeons to perform laparoscopic left hepatectomy., Surgical Endoscopy, Vol.31, No.6, 2623-2629, Dec. 2016. (Summary) Laparoscopic hepatectomy remains one of the most difficult procedures for young surgeons to perform. We recently developed a new training method and standardization procedure for teaching young surgeons to perform laparoscopic left hepatectomy (Lap-LHx). The aim of this study was to assess the effectiveness of our method. In 2004, we standardized a laparoscopic procedure for Lap-LHx, using a laparoscopy-assisted method as a stepping stone. The laparoscopic training method comprised the following three steps: (1) training in fundamental procedures using a dry box and checking by mentors; (2) detailed preoperative simulation using Vincent three-dimensional software for each patient; and (3) self-assessment including understanding of relevant anatomy and completion grade for each procedure using a check sheet and feedback by both mentors and a professor. Twenty-three Lap-LHx procedures performed during the study period were divided into two groups: those performed by young non-board-certified surgeons (n = 9) and those performed by senior board-certified surgeons (n = 14). The blood loss and operative time were similar in the young surgeon (194 g and 336 min, respectively) and senior surgeon groups (208 g and 322 min, respectively). Our standardized Lap-LHx procedure and stepwise training to perform it enable young surgeons to perform Lap-LHx as confidently and safely as more experienced surgeons. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-016-5273-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27928671 ● Search Scopus @ Elsevier (PMID): 27928671 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-016-5273-3 (DOI: 10.1007/s00464-016-5273-3, PubMed: 27928671)
20.	Shinichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku and Mitsuo Shimada : Liver regeneration after splenectomy in patients with liver cirrhosis., Hepatology Research, Vol.46, No.5, 443-449, Oct. 2016. (Summary) Splenectomy is a well-known procedure to improve thrombocytopenia and liver function in patients with liver cirrhosis (LC). However, the effect of splenectomy on liver regeneration remains unclear. The aim of this study is to investigate the effect of splenectomy on liver regeneration. Twenty patients with LC who underwent splenectomy were included in this study. Liver and splenic volumes were measured by a 3-D simulation imaging system. Liver volume (LV) and clinicopathological data were compared before and 6 months after splenectomy. Thereafter, patients were divided into two groups: the elevated LV group and the reduced LV group. Patient characteristics were compared between the two groups. Postoperative LV was increased in 14 patients compared with the preoperative state. Thrombocytopenia, leukopenia, total bilirubin and prothrombin time were improved after splenectomy. In the elevated LV group, four patients exhibited improved Child-Pugh grades after splenectomy, whereas no patients demonstrated improvement in the reduced LV group. The elevated LV group exhibited high albumin level, good indocyanine green retention rate at 15 min and large splenic volume compared with the same measurements in the decreased group. Patients with larger spleen volumes and higher albumin values before splenectomy showed increased rates of LV after splenectomy. Splenectomy for patients with LC improved pancytopenia and liver function. Especially, in patients with large spleen and high albumin levels, considerable increases in LV and improved liver function were observed. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.12573 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26428414 ● Search Scopus @ Elsevier (PMID): 26428414 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.12573 (DOI: 10.1111/hepr.12573, PubMed: 26428414)
21.	Shuichi Iwahashi, Mitsuo Shimada, Tohru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Chie Takasu, Yu Saitou and Shinichiro Yamada : Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation., Cancer Letters, Vol.375, No.1, 47-50, Mar. 2016. (Summary) We reported that poor prognoses of hepatocellular carcinoma (HCC) patients after radiofrequency ablation (RFA) are owing to up-regulation of expression of hypoxia-inducible factor-1 and epithelial cell adhesion molecule. We investigated aggressive progression in residual liver tumors (RLTs) after RFA to focus on expression of epithelial-mesenchymal transition (EMT)-related genes and miRNAs. Ten patients with recurrent HCC post-RFA who underwent hepatectomy (RFA group) and 78 patients with HCC without prior RFA (non-RFA group) were enrolled. We examined expression of transforming growth factor (TGF)-β, Twist, vimentin, and Snail-1 mRNAs in tumor tissues, and expression of miR-34a and miR-200c. Expression of TGF-β, Twist and Snail-1 in the RFA group was significantly higher than that in the non-RFA group (P < 0.05); vimentin expression in the RFA group was higher than that in the non-RFA group (P = 0.07). Expression of miR-200c and miR-34a in the RFA group was significantly lower than that in the non-RFA group (miR-200c: P = 0.04; miR-34a: P < 0.01). Increased expression of EMT markers through down-regulation of miRNA expression in RLTs after RFA may be related to poor prognoses of HCC patients with aggressive local recurrence after RFA. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2016.02.041 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26940140 ● Search Scopus @ Elsevier (PMID): 26940140 ● Search Scopus @ Elsevier (DOI): 10.1016/j.canlet.2016.02.041 (DOI: 10.1016/j.canlet.2016.02.041, PubMed: 26940140)
22.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou and Shin-ichiro Yamada : 【最新肝胆膵高難度外科手術アトラス】高難度外科手術手技肝臓肝下部下大静脈再建を伴う肝切除, Operation, Vol.70, No.4, 431-438, Mar. 2016. (Keyword) *下大静脈(外科的療法)
23.	Yu Saitou, Yasuhiro Hamada, Sonoko Yasui, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 【外科領域におけるサルコペニア】周術期サルコペニア発生の予防法, The Japanese Journal of Surgical Metabolism and Nutrition, Vol.50, No.1, 21-28, Feb. 2016. (Keyword) 周術期 / サルコペニア / 予防 (Link to Publication Site) ● Publication site (DOI): 10.11638/jssmn.50.1_21 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282679740177664 ● Search Scopus @ Elsevier (DOI): 10.11638/jssmn.50.1_21 (DOI: 10.11638/jssmn.50.1_21, CiNii: 1390282679740177664)
24.	Gizachew Yismaw Wubetu, Yuji Morine, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shinichiro Yamada, Tetsuya Ikemoto, Yu Saitou, Satoru Imura and Mitsuo Shimada : High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy., Anticancer Research, Vol.36, No.2, 757-762, Feb. 2016. (Summary) Better prognosis of cancer including hepatocellular carcinoma (HCC) remains unsatisfactory due to recurrence and chemoresistance. In this respect it is important to identify molecular targets specific to the disease in order to design effective therapeutic strategies. In the present study, we investigated the prognostic role of Never-in-mitosis-A-related kinase 2 (NEK2) in HCC. Fifty HCC patients who underwent hepatectomy were enrolled in the study. NEK2 gene and protein expression was examined by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, respectively. Higher expression of NEK2 was detected in HCC tumoral compared to adjacent non-tumor tissues (p<0.001), and protein expression was also relatively high in tumor than corresponding non-tumor tissues. Furthermore, high NEK2 expression was positively correlated with hepatic venous invasion (p=0.047), des-gammacarboxy prothrombin (p=0.003), and alpha-fetoprotein (AFP) (p=0.024). Patients with high NEK2 expression had significantly poor recurrence-free survival (p=0.042) and early recurrence. Overall, these results suggest that NEK2 could be a promising biomarker for HCC recurrence. (Keyword) Aged / Biomarkers, Tumor / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Gene Expression Regulation, Enzymologic / Gene Expression Regulation, Neoplastic / Hepatectomy / Humans / Kaplan-Meier Estimate / Liver Neoplasms / Male / Middle Aged / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Proportional Hazards Models / Protein-Serine-Threonine Kinases / Risk Factors / Time Factors / Treatment Outcome / Up-Regulation / 欧文論文 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26851035 ● Summary page in Scopus @ Elsevier: 2-s2.0-84979824116 (PubMed: 26851035, Elsevier: Scopus)
25.	Mandakhnaran Davaadorj, Satoru Imura, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shinichiro Yamada, Chie Takasu, Teraoku Hiroki, Masato Yoshikawa and Mitsuo Shimada : Loss of SFRP1 Expression Is Associated with Poor Prognosis in Hepatocellular Carcinoma., Anticancer Research, Vol.36, No.2, 659-664, Feb. 2016. (Summary) Secreted frizzled-related protein-1 (SFRP1) is a well-known inhibitor of the wingless type (WNT)-β-catenin signaling pathway and its inactivation plays an important role in the development and progression of various types of cancer. However, the clinical significance of SFRP1 expression in patients with hepatocellular carcinoma (HCC) remains unknown. A total of 63 patients with HCC who underwent hepatectomy at our Institution were enrolled in this study. A quantitative real-time polymerase chain reaction (RT-PCR) was performed to determine the SFRP1 mRNA expression level in both the tumorous and non-tumorous tissues of HCC. The patients were divided into low and high gene-expression groups based on the SFRP1 gene expression level in their tumor tissues. We analyzed the differences in clinicopathological characteristics between these two groups of patients. The expression level of SFRP1 was significantly lower in tumor tissue than in non-tumor tissue (p<0.0001). Significant correlations were observed between a high expression of SFRP1 in tumor tissue and older than 65 years (p=0.030), tumor size less than 5 cm (p=0.011); and no vascular invasion (p=0.004). Patients with high SFRP1 expression in tumor tissue had a significantly better overall survival rate (p=0.040). However, the SFRP1 expression level was not defined as an independent risk factor for patient survival based on results of multivariate analysis. SFRP1 may play a role in the development and progression of HCC. Therefore, more studies are required to investigate a potential role of SFRP1 in HCC prognosis. (Keyword) Adult / Aged / Aged, 80 and over / Biomarkers, Tumor / Carcinoma, Hepatocellular / Disease Progression / Disease-Free Survival / Down-Regulation / Female / Gene Expression Regulation, Neoplastic / Hepatectomy / Humans / Intercellular Signaling Peptides and Proteins / Kaplan-Meier Estimate / Liver Neoplasms / Male / Membrane Proteins / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Proportional Hazards Models / Prospective Studies / RNA, Messenger / Real-Time Polymerase Chain Reaction / Risk Factors / Time Factors / Treatment Outcome / 欧文論文 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26851021 ● Summary page in Scopus @ Elsevier: 2-s2.0-84979837519 (PubMed: 26851021, Elsevier: Scopus)
26.	Gizachew Y. Wubetu, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Daichi Ishikawa, Shuichi Iwahashi, Shinichiro Yamada, Yu Saitou, Yusuke Arakawa and Satoru Imura : Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation., Journal of Gastroenterology and Hepatology, Vol.31, No.1, 256-264, Jan. 2016. (Summary) The long-term survival of patients with hepatocellular carcinoma remains unsatisfactory because of the presence of cancer stem cells (CSCs), which are responsible for tumor recurrence and chemoresistance after hepatectomy. Drugs that selectively target CSCs thus offer great promise for cancer treatment. Although the antitumor effects of epigallocatechin gallate (EGCG) have been reported in some cancer cells, its effects on CSCs remain poorly studied. In this study, we investigated the effects of EGCG on human hepatoma and colon CSCs. HepG2 and HCT-116 cell lines were enriched by sphere formation, and their gene-expression profiles were analyzed by quantitative real-time polymerase chain reaction. EGCG-induced growth inhibition in the parental cells was determined by WST-8 assay, and protein expression was assessed by western blotting. Cell cycle profile and apoptosis analysis was performed using flow cytometer. Sphere-derived cells grown in serum-free, nonadherent cultures showed increased expression of stem cell markers, Nek2, and ATP-binding cassette transporter genes, compared with parental cells grown in conventional culture. EGCG induced growth inhibition in the parental cells in a dose-dependent manner. EGCG also inhibited self-renewal in hepatoma and colon CSCs, attenuated the expression of stem cell markers and ATP-binding cassette transporter genes, which are putative molecules associated with treatment resistance in CSCs, and decreased the transcription of Nek2 and p-Akt, resulting in the inhibition of Akt signaling. EGCG also altered cell cycle profile and apoptosis, which may in part play an important role in EGCG-induced cancer cell death. Overall, these results suggest that EGCG could be a useful chemopreventive agent for targeting hepatocellular carcinoma and colon CSCs, in combination with standard chemotherapies. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.13069 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26241688 ● Search Scopus @ Elsevier (PMID): 26241688 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.13069 (DOI: 10.1111/jgh.13069, PubMed: 26241688)
27.	Hiroki Teraoku, Yusuke Arakawa, Masato Yoshikawa, Shinichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Complication of portal vein thrombosis after right hemihepatectomy in a patient lacking the portal vein bifurcation., The Journal of Medical Investigation : JMI, Vol.63, No.3-4, 315-318, 2016. (Summary) Absence of portal vein bifurcation is a rare anomaly. We report a patient with this anomaly who underwent right hemihepatectomy for treatment of hepatocellular carcinoma. Although the procedure was carefully performed with a preoperative three-dimensional simulation and intraoperative cholangiography, postoperative portal vein thrombosis occurred. J. Med. Invest. 63: 315-318, August, 2016. (Keyword) Hepatectomy / Humans / Male / Middle Aged / Portal Vein / Postoperative Complications / Venous Thrombosis (Tokushima University Institutional Repository) ● Metadata: 111201 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.63.315 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644579 ● Search Scopus @ Elsevier (PMID): 27644579 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.63.315 (Tokushima University Institutional Repository: 111201, DOI: 10.2152/jmi.63.315, PubMed: 27644579)
28.	Yu Saitou, Sonoko Yasui, Yasuhiro Hamada, Chie Takasu, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝胆膵手術例の術前栄養管理, Surgery, Vol.76, No.11, 1201-1209, Nov. 2014.
29.	Yuji Morine, Mitsuo Shimada, Hiroki Ishibashi, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : 【膵・胆管合流異常の診断基準の改訂をめぐって】膵・胆管合流異常の診断の最前線胆汁中アミラーゼ値, Journal of Biliary Tract & Pancreas, Vol.35, No.10, 921-925, Oct. 2014. (Keyword) 和文論文
30.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi and Hideya Kashihara : Esophagus Hiatus Hernia after Laparoscopic Total Gastrectomy, The Japanese Journal of Gastroenterological Surgery, Vol.47, No.8, 460-465, Aug. 2014. (Summary) We report on a rare case of esophageal hitus hernia after laparoscopic total gastrectomy (LTG). A 73-year-old man underwent LTG with D2 lymph node dissection and Roux-en-Y (overlap) reconstruction for early gastric cancer. After one year, he was admitted to our hospital with acute abdominal pain. Abdominal CT scan revealed a dilated small intestine prolapsing into the thoracic cavity through the left side of the esophageal hiatus and ischemia of the prolapsed small intestine. He underwent emergency operation based on a diagnosis of strangulation ileus caused by esophageal hiatal hernia. We successfully reduced the prolapsed small intestine back to the abdominal cavity. There was no necrosis in the area. The hernia orifice was occluded by suturing posterior walls of the diaphragm crus and the esophagus was securely fixed by 4 sutures to the diaphragm crus. (Keyword) 和文論文 (Link to Publication Site) ● Publication site (DOI): 10.5833/jjgs.2013.0158 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282679894596736 ● Summary page in Scopus @ Elsevier: 2-s2.0-84923803079 (DOI: 10.5833/jjgs.2013.0158, CiNii: 1390282679894596736, Elsevier: Scopus)
31.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Horohiko Sato and Mitsuo Shimada : 嵌頓にて発症し術後縦隔膿瘍を来したcentral tendon defectの1例, Journal of the Japanese Society of Pediatric Surgeons, Vol.50, No.5, 906-909, Aug. 2014. (Keyword) 和文論文
32.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, 江藤祥平, 吉川雅登 and 寺奥大貴 : 【食道癌・胃癌におけるロボット支援手術の有用性】地方での胃癌に対するロボット支援手術導入の現状と問題点, Japanese Journal of Cancer Clinics, Vol.60, No.3, 319-323, Jul. 2014. (Keyword) 和文論文
33.	Yu Saitou, Mitsuo Shimada, Hiroki Ishibashi, Yuji Morine, Satoru Imura, Hiroki Mori, Yusuke Arakawa, Shuichi Iwahashi and Chie Takasu : 【肝胆膵・術後病態を學ぶ】膵胆管合流異常・先天性胆道閉鎖症術後膵胆管合流異常術後発癌の特徴, KAN TAN SUI, Vol.69, No.1, 37-49, Jul. 2014. (Keyword) 和文論文
34.	Tohru Utsunomiya, Mitsuo Shimada, Yuji Morine, Atsushi Tajima and Issei Imoto : Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis., Cancer Science, Vol.105, No.7, 749-754, Jul. 2014. (Summary) Hepatocellular carcinoma (HCC) is one of the most common human cancers and a major cause of cancer-related death worldwide. The bleak outcomes of HCC patients even after curative treatment have been, at least partially, attributed to its multicentric origin. Therefore, it is necessary to examine not only tumor tissue but also non-tumor liver tissue to investigate the molecular mechanisms operating during hepatocarcinogenesis based on the concept of "field cancerization". Several studies previously investigated the association of molecular alterations in non-tumor liver tissue with clinical features and prognosis in HCC patients on a genome-wide scale. In particular, specific alterations of DNA methylation profiles have been confirmed in non-tumor liver tissue. This review focuses on the possible clinical value of array-based comprehensive analyses of molecular alterations, especially aberrant DNA methylation, in non-tumor liver tissue to clarify the risk of hepatocarcinogenesis. Carcinogenetic risk estimation based on specific methylation signatures may be advantageous for close follow-up of patients who are at high risk of HCC development. Furthermore, epigenetic therapies for patients with chronic liver diseases may be helpful to reduce the risk of HCC development because epigenetic alterations are potentially reversible, and thus provide promising molecular targets for therapeutic intervention. (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.12431 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24766251 ● Summary page in Scopus @ Elsevier: 2-s2.0-84904333634 (DOI: 10.1111/cas.12431, PubMed: 24766251, Elsevier: Scopus)
35.	Yuji Morine, Mitsuo Shimada and Hiroki Ishibashi : 【膵・胆管合流異常の最前線】全国集計からみた膵・胆管合流異常, 日本消化器病学会雑誌, Vol.111, No.4, 699-705, Apr. 2014. (Keyword) 和文論文
36.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Chie Takasu, 柏原秀也 and 松本規子 : 【漢方を上手に使う―エビデンスに基づいた外科診療】周術期管理・合併症と漢方高アンモニア血症大建中湯効果のメカニズム, 臨床外科, Vol.68, No.12, 1302-1306, Nov. 2013.
37.	河野透, 上園保仁, 武田宏司, 笠井章次, Horohiko Sato and Mitsuo Shimada : Kampo for the treatment of adverse effects caused by anticancer drugs. Oxaliplatin-induced neurotoxicity : Goshajinkigan, Journal of Clinical Surgery, Vol.68, No.12, 1319-1323, Nov. 2013. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390002209886645248 (CiNii: 1390002209886645248)
38.	C Enkhbold, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, S Yamada, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : One-stop shop for 3-dimensional anatomy of hepatic vasculature and bile duct with special reference to biliary image reconstruction., Hepato-Gastroenterology, Vol.60, No.128, 1861-1864, Nov. 2013. (Summary) Three-dimensional CT has become an essential tool for successful hepatic surgery. Up to now, efforts have been made to simultaneously visualize hepatic vasculature and bile ducts. Herein, we introduce a new one-stop shop approach to hepatic 3D-anatomy, using a standard enhanced MDCT alone. A 3D-reconstruction of hepatic vasculature was made using data from contrast enhanced MDCT and SYNAPSE VINCENT software. We identified bile ducts from axial 2D image, and then reconstructed the 3D image. Both hepatic vasculature and bile duct images were integrated into a single image and it was compared with the 3D image, utilized with MRCP or DIC-CT. The first branches of both the right and left hepatic ducts were hand-traced and visualized for all 100 cases. The second branches of these ducts were visualized in 69 cases, and only the right second branch was recognized in 52 cases. Anomalous variations of bile ducts, such as posterior branch joining into common hepatic duct, were recognized in 12 cases. These biliary tract variations were all confirmed by MRCP or DIC-CT. Our new one-stop shop approach using the 3D imaging technique might contribute to successful hepatectomy as well as reduce medical costs and radiation exposure by omission of MRCP and DIC-CT. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge13536 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24088317 ● Search Scopus @ Elsevier (PMID): 24088317 ● Search Scopus @ Elsevier (DOI): 10.5754/hge13536 (DOI: 10.5754/hge13536, PubMed: 24088317)
39.	Hidenori Miyamoto, 浅野間理仁, 宮本英之, Chie Takasu and Mitsuo Shimada : Visualization and hypervascularization of the haemorrhoidal plexus in vivo using power Doppler imaging transanal ultrasonography and three-dimensional power Doppler angiography., Colorectal Disease, Vol.15, No.11, 686-691, Nov. 2013. (Summary) The purpose of this study was to demonstrate the distribution of haemorrhoidal arteries and the relationship between vascularity and growth of haemorrhoids. One-hundred and three patients with haemorrhoids were studied. Using power Doppler imaging (PDI) transanal ultrasound and three-dimensional power Doppler angiography (3D-PDA), the course of the arteries supplying the haemorrhoids was identified. Measurement of the PDI area was made using the cursor to outline the power Doppler signal of the haemorrhoid, approximately 1 cm above the dentate line. The haemorrhoidal arteries were seen as branches of the superior rectal artery and were detected in 75.7, 71.8, 68.0 and 62.1% of the 11, 7, 3 and 1 o'clock positions in the lithotomy position. The median number of haemorrhoidal arteries significantly increased from three to six with progression of the Goligher classification from Grade 1 to Grade 4 (P < 0.0001). The PDI areas in Grades 1, 2, 3 and 4 were 0.04 ± 0.03, 0.18 ± 0.07, 0.38 ± 0.18 and 0.96 ± 0.32 cm(2) (P < 0.05). The distribution of haemorrhoidal arteries varies widely in both number and position. Using PDI transanal ultrasonography and 3D-PDA it was possible to visualize the haemorrhoid plexus and the course of the haemorrhoidal artery in vivo. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/codi.12406 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24034699 ● Summary page in Scopus @ Elsevier: 2-s2.0-84887172265 (DOI: 10.1111/codi.12406, PubMed: 24034699, Elsevier: Scopus)
40.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Chie Takasu : Effects of splenectomy on hepatic gene expression profiles after massive hepatectomy in rats., Journal of Gastroenterology and Hepatology, Vol.28, No.10, 1669-1677, Oct. 2013. (Summary) Possible spleno-hepatic relationships affected by hepatectomy still remained unclear. We have previously reported that splenectomy may ameliorate liver injuries and promote appropriate liver regeneration after massive hepatectomy. Therefore, we investigated the effects of splenectomy on the DNA expression profile in the liver after massive hepatectomy in rats. Rats were divided into the following two groups: 90% hepatectomy (Hx group) and 90% hepatectomy with splenectomy (Hx + Sp group). Rats were sacrificed 3 and 6 h after surgery, and mRNA from liver tissue was isolated and hybridized to Affymetrix GeneChip Rat Genome 230 2.0 Array (Affymetrix, Santa Clara, CA, USA) and a pathway analysis was done with Ingenuity Pathway Analysis (Ingenuity Systems, Mountain View, CA, USA). We determined the Hx + Sp/Hx ratio to assess the influence of splenectomy, and cut-off values were set at more than 2.0-fold or less than 1/2 (0.5)-fold. Immediate early response gene including early growth response-1 and FBJ murine osteosarcoma-related pathways were markedly downregulated by splenectomy. In contrast, heme oxygenase-1 gene-related pathway was upregulated by splenectomy. Splenectomy provided the protective effects for liver failure and promoted liver regeneration, possibly owing to the downregulation of immediate early response genes and upregulation of the heat shock protein, heme oxygenase-1. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.12316 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23808869 ● Summary page in Scopus @ Elsevier: 2-s2.0-84897611157 (DOI: 10.1111/jgh.12316, PubMed: 23808869, Elsevier: Scopus)
41.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Hirohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, Masato Komatsu, Kashihara hideya and Chie Takasu : The effect of polysaccharide k with S-1 based chemotherapy in advanced gastric cancer., Hepato-Gastroenterology, Vol.60, No.126, 1387-1390, Sep. 2013. (Summary) Polysaccharide K (PSK) is widely used in Japan as a biological response modifier for cancer patients. We investigated the effects of PSK with S-1 based chemotherapy for advanced gastric cancer patients in immune response. Nine advanced gastric cancer patients who underwent chemotherapy at the University of Tokushima were included in this study. In all patients, 3g PSK was received orally and S-1 based chemotherapy for 2 weeks alternately for 8 weeks. Serial changes in immunological parameters (Foxp3, Natural killer (NK), CD4/CD8) were monitored. The levels of Foxp3 at 8 weeks was significantly decreased compared with 2 weeks (4.26% vs. 3.11%). In NK activity at 8 weeks was significantly increased compared with 2 weeks (27% vs. 47%). These results of this study suggested that chemotherapy with PSK improved the immune response in advanced gastric cancer patients. Especially Foxp3 was concerned in this mechanism. (Keyword) Aged / Antineoplastic Combined Chemotherapy Protocols / Drug Combinations / Female / Forkhead Transcription Factors / Humans / Killer Cells, Natural / Male / Middle Aged / Oxonic Acid / Proteoglycans / Stomach Neoplasms / Tegafur / 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge11355 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23933930 ● Search Scopus @ Elsevier (PMID): 23933930 ● Search Scopus @ Elsevier (DOI): 10.5754/hge11355 (DOI: 10.5754/hge11355, PubMed: 23933930)
42.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, Chie Takasu and Hidenori Miyake : 【各種デバイスを応用した私の手術―使用法と工夫】各種デバイスを応用した肝・胆手術, Surgery, Vol.75, No.9, 954-959, Sep. 2013. (Keyword) 和文論文
43.	Motoya Chikakiyo, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子, 江藤祥平 and Mitsuo Shimada : Evaluation of ICG fluorescence method for confirmation of blood folw in intraoperative pre-anastomosis for laparoscopic anterior resection., Journal of Japan Society of Computer Aided Surgery, Vol.15, No.2, 206-207, Aug. 2013. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573105975984398464 (CiNii: 1573105975984398464)
44.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : A challenge to ECFMG certification : An experience and difficulties of Japanese examinee, Shikoku Acta Medica, Vol.69, No.3,4, 187-192, Aug. 2013. (Summary) Recently, many Japanese pediatric surgeons undertake clinical training abroad, especially in the United States of America (USA) which is one of the most attractive country for advanced clinical training. Since the Japanese government introduced a 2-year mandatory residency program in 2004, it has become more and more important for busy Japanese residents to spent time efficiently in order to achieve ECFMG (Educational Commission For Foreign Medical Graduates) certification. ECFMG certification requires residents to pass both Step 1 and 2 of the United States Medical License Examination (USMLE). It is especially difficult to pass step2 CS (Clinical Skills) for many Japanese who are unfamiliar with the English language. For example, one of authors started to study for the USMLE in the 6th grade of the Japanese Medical School (MS4), passed step1 and step2 CK (Clinical Knowledge) during the 2-year mandatory intensive rotating residency program, and passed Step2 CS on the 3rd attempt during the general surgery residency program. This shows that a Japanese examinee can pass the ECFMG certificate even during a busy rotating residency program. (Keyword) 和文論文 (Tokushima University Institutional Repository) ● Metadata: 109637 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050865122807792768 (Tokushima University Institutional Repository: 109637, CiNii: 1050865122807792768)
45.	Motoya Chikakiyo, Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Masaaki Nishi, Chie Takasu, 柏原秀也 and 松本規子 : A case of rectal metastasis from gastric cancer, Shikoku Acta Medica, Vol.69, No.3.4, 175-178, Aug. 2013. (Summary) We report a case of rectal metastasis from gastric cancer. The patient was a 69-year-old man with diarrhea as his major symptoms, who underwent a distal gastrostomy for gastric cancer 2 years previously. We suspected primary or metastatic rectal cancer from colonoscopic examination and barium enema. A lower anterior resection was performed. Postoperative historical examination identified poorly differentiated adenocarcinoma and signet cell carcinoma identical to the gastric cancer. Finally the lesion was diagnosed as metastatic rectal cancer from gastric cancer that showed same pattern in PAS stain. There were only 40 cases in reports in the literature from 2002 to 2012, to our knowledge. We report a rare case. (Keyword) 和文論文 (Tokushima University Institutional Repository) ● Metadata: 109633 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050020697877662592 (Tokushima University Institutional Repository: 109633, CiNii: 1050020697877662592)
46.	Hiroki Mori, Mitsuo Shimada, Hiroki Ishibashi, Yuji Morine and 矢田圭吾 : 【膵・胆管合流異常アップデート】膵・胆管合流異常の全国集計成人の特徴, Japanese Journal of Pediatric Surgery, Vol.45, No.6, 614-616, Aug. 2013. (Keyword) 和文論文
47.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾 and Mitsuo Shimada : 【プロが見せる手術シリーズ(2):難易度の高い消化管手術】胃食道分離術, Japanese Journal of Pediatric Surgery, Vol.45, No.8, 813-817, Aug. 2013. (Keyword) 和文論文
48.	Tomohiko Miyatani, Nobuhiro Kurita, Masato Komatsu, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Chie Takasu, 柏原秀也 and Mitsuo Shimada : 抗リン脂質抗体症候群の臨床的特徴に関する検討, Journal of Japanese College of Surgeons, Vol.38, No.4, 759-764, Aug. 2013. (Keyword) 和文論文
49.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Toru Utsunomiya, Yuji Morine, Yusuke Arakawa and Mami Kanamoto : 【いつ何が大事かがわかる消化器外科術後の看護ポイント】腹腔鏡下胆嚢摘出術後の看護・観察ポイント 0∼12時間，12∼24時間，24∼72時間, Gastroenterological Surgery Nursing, Vol.18, No.8, 696-704, Aug. 2013. (Keyword) 和文論文
50.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mami Kanamoto and Shuichi Iwahashi : 【大腸癌肝転移up to date】大腸癌肝転移化学療法後の肝障害, Surgery, Vol.75, No.8, 828-833, Aug. 2013. (Keyword) 和文論文
51.	T Toshima, Mitsuo Shimada, Toru Ikegami, Toru Utsunomiya, Tetsuya Ikemoto, Yuji Morine, Tomoharu Yoshizumi, Yuji Soejima, K Shirabe and Y Maehara : Fairly rare spontaneous disappearance of a hepatic artery aneurysm following living donor liver transplantation., Liver Transplantation, Vol.19, No.8, 929-930, Aug. 2013. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1002/lt.23676 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23696536 ● Summary page in Scopus @ Elsevier: 2-s2.0-84881102318 (DOI: 10.1002/lt.23676, PubMed: 23696536, Elsevier: Scopus)
52.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto and Hiroki Mori : Significance of sonic hedgehog signaling after massive hepatectomy in a rat., Surgery Today, Vol.43, No.3, 300-307, Jun. 2013. (Summary) To clarify the functional involvement of hedgehog signaling, especially sonic hedgehog (Shh) and glioma-associated oncogene (Gli)-1 which are known to play an important role in embryonic development and cancer, in the regeneration of a hepatectomized rat liver. Six-week-old male Wistar rats were subjected to 70 or 90 % hepatectomy (Hx). Animals were killed at 24, 48 and 72 h after Hx. The liver/body weight ratio was measured as an index of regeneration. Formalin-fixed liver samples were embedded in paraffin, stained for immunohistochemistry with proliferating cell nuclear antigen (PCNA) antibody, and the labeling index was calculated. Immunohistochemistry was also performed with Shh and Gli-1 antibodies. The liver/body weight ratio gradually increased in both the 70 and 90 % Hx, groups. The hepatocytes were strongly stained for PCNA at 24 h after Hx. Non-parenchymal cells were gradually stained by PCNA from 24 to 72 h after Hx. Shh and Gli-1 expression in hepatocytes was higher after 24 h than at other times and then gradually decreased. Shh and Gli-1 expression in non-parenchymal cells increased gradually, and was found mainly in liver zone I at 72 h after 70 and 90 % Hx. The expression of both markers suggested that Shh signaling contributes to tissue reconstruction after Hx. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-012-0248-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22790641 ● Search Scopus @ Elsevier (PMID): 22790641 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-012-0248-z (DOI: 10.1007/s00595-012-0248-z, PubMed: 22790641)
53.	Yuji Morine, Mitsuo Shimada, H Takamatsu, T Araida, I Endo, M Kubota, A Toki, T Noda, T Matsumura, S Miyakawa, Hiroki Ishibashi, T Kamisawa and H Shimada : Clinical features of pancreaticobiliary maljunction: update analysis of 2nd Japan-nationwide survey., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.20, No.5, 472-480, Jun. 2013. (Summary) Pancreaticobiliary maljunction (PBM) is a congenital anomaly, which can be defined as a union of the pancreatic and biliary ducts located outside off the duodenal wall. We herein investigate clinical features of PBM including as the 2nd report of a Japanese nationwide survey. During a period of 18 years (from 1990 to 2007), 2,561 patients with PBM were registered at 141 medical institutions in Japan. Among them, eligible patients (n = 2,529) were divided into two groups: adult (n = 1,511) and pediatric patients (n = 1,018). Comparisons of clinical features including associated biliary cancers were performed according to the biliary dilatation (BD), age factor, and time era. Only one case in pediatric patients with BD combined with a bile duct cancer (0.1 %). In adult patients, the bile duct cancer and the gallbladder cancer was seen in 6.9 and 13.4 % patients with BD and in 3.1 and 37.4 % patients without BD, respectively. In adult patients with BD, the occurrence rates of biliary cancers were increased in latter period (00'-07') compared with former period (90'-99'). The ratio of biliary cancer localization was changed between former and latter period, and the bile duct cancer was increased in latter period (from 5.5 to 9.3 %). The largest series of PBM were evaluated to clarify the clinical features including the associated biliary cancer in this Japan-nationwide survey. This report could be widely used in the future as a reference data for diagnosis and treatment of PBM. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00534-013-0606-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23579999 ● CiNii @ National Institute of Informatics (CRID): 1523951030185921920 ● Summary page in Scopus @ Elsevier: 2-s2.0-84878981958 (DOI: 10.1007/s00534-013-0606-2, PubMed: 23579999, CiNii: 1523951030185921920, Elsevier: Scopus)
54.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾 and Mitsuo Shimada : 【膵・胆管合流異常アップデート】膵・胆管合流異常と胆道癌, Japanese Journal of Pediatric Surgery, Vol.45, No.6, 661-664, Jun. 2013. (Keyword) 和文論文
55.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司 and Yoshimi Bando : Oxaliplatin-related sinusoidal obstruction syndrome mimicking metastatic liver tumors., Hepatology Research, Vol.43, No.6, 685-689, Jun. 2013. (Summary) A 40-year-old woman who had undergone a curative low anterior resection for advanced rectal cancer was admitted to our hospital. She had been administrated oxaliplatin-based chemotherapy as postoperative adjuvant chemotherapy. The contrast-enhanced computed tomography revealed three hypovascular tumors, 3.0, 1.5 and 1.0 cm in diameter, located in the right hepatic lobe. The hepatocyte phase of the gadoxetic acid-enhanced magnetic resonance imaging demonstrated these lesions as hypointense tumors relative to the surrounding hepatic parenchyma. All these findings of the preoperative imaging modalities were compatible to metastatic liver tumors from the rectal cancer, and right hepatic lobectomy was successfully performed. Histopathologically, the tumors revealed sinusoidal dilation and severe congestion outlined by atrophic hepatocyte trabeculae, which was known as peliosis hepatis. The perisinusoidal space of Disse was extensively dilated and contained many erythrocytes. Taking these findings into account, the hepatic tumors were considered to be the space-occupying lesions resulting from the sinusoidal obstruction syndrome. We herein report the first case of focal sinusoidal obstruction syndrome mimicking metastatic liver tumors. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1872-034X.2012.01114.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23730707 ● Summary page in Scopus @ Elsevier: 2-s2.0-84878770639 (DOI: 10.1111/j.1872-034X.2012.01114.x, PubMed: 23730707, Elsevier: Scopus)
56.	Shuichi Iwahashi, Toru Utsunomiya, Mitsuo Shimada, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Yoshimi Bando : High expressions of cancer stem cell markers in cholangiolocellular carcinoma., Surgery Today, Vol.43, No.6, 654-660, Jun. 2013. (Summary) Cholangiolocellular carcinoma (CLC) is an extremely rare malignant liver tumor. It is thought to originate from the ductules and/or canals of Hering, where hepatic stem cells (HpSC) are located, but there are few reports on cancer stem cell markers in CLC. Thus, we evaluated the significance of cancer stem cell markers, including CD133, CD44, and EpCAM, in CLC. The subjects of this study were three patients with CLC and one patient with an intermediate type of combined hepatocellular cholangiocarcinoma (CHC). The cancer cell markers, CK7, CK19, and EMA, were evaluated immunohistochemically. Histological examination of the CLC revealed morphologically cholangiolar features and immunohistochemical examination revealed positivity for CD133, CD44, and EpCAM. On the other hand, in the intermediate type of CHC, only CD44 was positive, whereas CD133 and EpCAM were negative. CLC may have stronger features derived from HpSCs than an intermediate type of CHC. (Keyword) 英文論文 (Tokushima University Institutional Repository) ● Metadata: 115811 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-012-0437-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23192764 ● Summary page in Scopus @ Elsevier: 2-s2.0-84878013011 (Tokushima University Institutional Repository: 115811, DOI: 10.1007/s00595-012-0437-9, PubMed: 23192764, Elsevier: Scopus)
57.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Hideya Kashihara and Toru Utsunomiya : Impact of C-reactive protein on prognosis of patients with colorectal carcinoma., Hepato-Gastroenterology, Vol.60, No.123, 507-511, May 2013. (Summary) The aim of this study was to investigate the impact of preoperative serum C-reactive protein (CRP) level as a prognostic indicator in patients with colorectal carcinoma (CRC). We investigated the correlation between preoperative CRP level and clinicopathological factors including prognosis of 167 patients who underwent resection for CRC retrospectively. Clinicopathological variables were compared between patients with serum CRP levels >1mg/dL (29 patients; high-CRP group) and patients with serum CRP levels <1mg/dL (138 patients; low-CRP group). In high-CRP group, 9 patients were stage I+II and 20 patients ware stage III+IV. In low-CRP group, 93 patients were stage I+II and 45 patients were stage III+IV. There were significant differences in the clinical stage, tumor diameter, curativity, final stage between the two groups (p<0.01). The overall survival and recurrence-free survival rates in high-CRP group were lower compared with the rates in low-CRP group (p<0.05 and p=0.14). In addition, the overall survival rate in stage I+II patients with high-CRP was significantly lower than that in patients with low-CRP (p<0.05). Using multivariate analysis, the preoperative elevation of serum CRP level was an independent prognostic factor in patients with CRC (p<0.05). We found that the preoperative elevation of serum CRP to be an independent prognostic indicator of CRC. (Keyword) Adult / Aged / Aged, 80 and over / C-Reactive Protein / Carcinoma / Colectomy / Colorectal Neoplasms / Disease-Free Survival / Female / Humans / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Neoplasm Staging / Retrospective Studies / Risk Factors / Survival Analysis / Time Factors / Treatment Outcome / Tumor Markers, Biological / Up-Regulation / 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge11425 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23635436 ● Search Scopus @ Elsevier (PMID): 23635436 ● Search Scopus @ Elsevier (DOI): 10.5754/hge11425 (DOI: 10.5754/hge11425, PubMed: 23635436)
58.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine and Tetsuya Ikemoto : 【最新肝胆膵脾手術アトラス】肝臓右下肝静脈存在下での肝切除術, Operation, Vol.67, No.6, 715-720, May 2013. (Keyword) 和文論文
59.	Mitsuo Shimada : 総論18. 人工臓器, 標準外科第13版., Vol.13, No.1, 228-241, May 2013. (Keyword) 和文論文
60.	Tetsuya Ikemoto, M Takita, MF Levy, Mitsuo Shimada and B Naziruddin : CD11b(+) cells in donor-specific transfusion prolonged allogenic skin graft survival through indoleamine 2,3-dioxygenase., Cellular Immunology, Vol.283, No.1-2, 81-90, May 2013. (Summary) The aim of this study is to show the effect of donor-specific transfusion (DST) in inducing immunological tolerance mediated by regulatory T cells (Treg) and indoleamine 2,3-dioxygenase (IDO). Skin grafts from H2(d) Balb/c were transplanted into H2(k) C3H/He 7days after the infusion of donor splenocytes, isolated each immune cell populations. Graft survival prolonged in recipients who received splenocytes, MHC class II(+) CD90(-) cells and CD3(-)CD19(-) cells (p<0.001, p<0.05 and p<0.01, respectively). CD11b(+) cell infusion resulted in prolongation of graft survival when compared to CD11c(+) cell infusion (p<0.01). Foxp3(+)CD4(+)CD25(+) T cells were increased after the transplant in recipients infused with CD11b(+) cells (p<0.05). The mixed lymphocyte reaction showed donor-specificity (p<0.001). High IDO expression was observed in CD11b(+) cell infusion group. Graft survival with DST using IDO antagonist (1MT) were not prolonged. In conclusion, DST allows induction of donor-specific tolerance which involves Foxp3(+)CD4(+)CD25(+) T cells and IDO expression. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.cellimm.2013.06.004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23933136 ● Summary page in Scopus @ Elsevier: 2-s2.0-84884331152 (DOI: 10.1016/j.cellimm.2013.06.004, PubMed: 23933136, Elsevier: Scopus)
61.	Nobuhiro Kurita, Jun Higashijima and Mitsuo Shimada : 肥満症に対する外科療法腹腔鏡下スリーブ状胃切除術の1施行例, 徳島県医師会報, Vol.503, 32-35, Apr. 2013. (Keyword) 和文論文
62.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa and Mami Kanamoto : 【エキスパートが教える内視鏡外科手術・ポイントとなる解剖の理解】肝・胆・膵・脾の鏡視下手術肝癌に対する鏡視下手術腹腔鏡下肝部分切除術, Gastroenterological Surgery, Vol.36, No.5, 779-785, Apr. 2013. (Keyword) 和文論文
63.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, 山田眞一郎, Yuji Morine, Satoru Imura, Hiroki Mori, 杉本光司, Shuichi Iwahashi and 浅野間理仁 : The protective effect of adipose-derived stem cells against liver injury by trophic molecules., The Journal of Surgical Research, Vol.180, No.1, 162-168, Mar. 2013. (Summary) In this study we investigated whether adipose-derived stem cells (ADSCs) had any beneficial protective effects on liver injury and regeneration in vivo. Moreover, we examined whether ADSCs protect hepatocytes via trophic molecules. We transplanted ADSCs into mice after 70% hepatectomy and ischemia-reperfusion, and observed liver injury and regeneration after reperfusion. We co-cultured hepatocytes with ADSCs using a Transwell system for 7 d and evaluated the viabilities of hepatocytes and the cytokine levels in the culture medium. Bevacizumab was used to confirm the effect of vascular endothelial growth factor (VEGF) on hepatocytes. ADSCs improved serum liver function at 6 h after reperfusion in a nonlethal model and stimulated liver regeneration at 24 h after reperfusion in a lethal model. VEGF levels in the culture medium were increased by co-culture ADSCs with hepatocytes. ADSCs improved the viabilities of hepatocytes. The inhibited production of VEGF by bevacizumab did not affect the viability of hepatocytes. ADSCs were able to ameliorate liver injury and stimulate liver regeneration in subsequent hepatectomy and ischemia-reperfusion-injured model mice. Furthermore, hepatocytes were protected by the trophic molecules of the ADSCs. However, such protective effects might be provided by mechanisms other than VEGF signaling. (Keyword) 英文論文 (Tokushima University Institutional Repository) ● Metadata: 105888 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jss.2012.10.009 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23117122 ● Summary page in Scopus @ Elsevier: 2-s2.0-84873706630 (Tokushima University Institutional Repository: 105888, DOI: 10.1016/j.jss.2012.10.009, PubMed: 23117122, Elsevier: Scopus)
64.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 淺野間理仁, 山田眞一郎, 石川大地 and Hidenori Miyake : 【膵・胆管合流異常診療ガイドラインを巡る残された問題点】非拡張型膵・胆管合流異常の胆管癌発生頻度を巡る問題点, Journal of Biliary Tract & Pancreas, Vol.34, No.3, 241-244, Mar. 2013. (Keyword) 和文論文
65.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Yu Saitou, Mami Kanamoto, Hiroki Mori, Yuji Morine, Satoru Imura and Toru Utsunomiya : Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer., International Journal of Clinical Oncology, Vol.19, No.1, 81-86, Mar. 2013. (Summary) The prognosis of pancreatic cancer is extremely poor regardless of various combination therapies. Immunoaugumentation against tumor cells was recently A focus. We reported that the population of Foxp3(+)CD25(+)CD4(+) regulatory T cells (Foxp3(+)Treg) was the new parameter for the estimation of host immunity and had correlation with tumor aggressiveness. Here we show the immunoaugumentation effects of Japanese Kampo medicine, Juzen-Taihoto/TJ-48, empirically considered as an immunoaugumentation drug, with investigation of Treg and other immunological parameters. Peripheral Foxp3(+) Treg populations, CD4/CD8 ratio, and CD57(+) cells (NK cells) populations in advanced pancreatic cancer patients (n = 30, stage VI A and B according to TNM classification) were estimated after TJ-48 administration for 14 days before the anti-cancer therapy. Treg populations were significantly increased compared to healthy donors (Mann-Whitney U test, P < 0.001). Administration of Juzen-Taihoto/TJ-48 significantly decreased Treg populations (Mann-Whitney U test, P < 0.001) and increased the CD4/CD8 ratio (Mann-Whitney U test, P < 0.01), even though CD57(+) cell populations did not change significantly. Juzen-Taihoto/TJ-48 increased regulatory activities in T cells through decreasing Foxp3(+) Treg populations in advanced pancreatic cancer patients. This effect can lead to immunoaugumentation for various combination therapies. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-013-0529-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23443635 ● Summary page in Scopus @ Elsevier: 2-s2.0-84894563665 (DOI: 10.1007/s10147-013-0529-6, PubMed: 23443635, Elsevier: Scopus)
66.	Hidenori Miyamoto, 浅野間理仁, 宮本英之, Chie Takasu and Mitsuo Shimada : Three-dimensional power Doppler transanal ultrasonography, to monitor haemorrhoidal blood flow after Doppler-guided ALTA sclerosing therapy., Colorectal Disease, Vol.15, No.2, 84-88, Feb. 2013. (Summary) The study aimed to use power Doppler imaging (PDI) transanal ultrasonography to produce three-dimensional power Doppler angiography images of haemorrhoidal tissue and to monitor the effects of Doppler-guided aluminium potassium sulfate and tannic acid (DGALTA) sclerotherapy. Ninety-six haemorrhoids in 43 patients were examined using PDI transanal ultrasonography, and DGALTA sclerotherapy was performed from April 2011 to April 2012. DGALTA sclerotherapy was conducted using a four-step injection process with pulse wave Doppler ultrasound under perianal local anaesthesia. A three-dimensional power Doppler angiography image of the blood flow in haemorrhoidal tissue was produced using PDI transanal ultrasonography. The cross-sectional area of blood flow in the haemorrhoidal tissue (PDI area) significantly decreased after DGALTA sclerotherapy. The PDI areas in the preoperative state and 1 and 3 months after treatment were 0.35±0.27, 0.03±0.05 and 0.04±0.05 cm(2) (P<0.0001). A three-dimensional power Doppler angiography image of the haemorrhoidal tissue was technically possible and showed blood flow in the haemorrhoidal tissue to be significantly decreased after DGALTA sclerotherapy. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/codi.12024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22966905 ● Summary page in Scopus @ Elsevier: 2-s2.0-84873045526 (DOI: 10.1111/codi.12024, PubMed: 22966905, Elsevier: Scopus)
67.	Satoru Imura and Mitsuo Shimada : 抗癌剤【肝胆膵】, 消化器外科レビュー., Vol.2013-14, 215-220, Jan. 2013. (Keyword) 和文論文
68.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi, 山田眞一郎 and 浅野間理仁 : Regulatory T cells in the blood: a new marker of surgical stress., Surgery Today, Vol.43, No.6, 608-612, Jan. 2013. (Keyword) 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-013-0517-5 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573105975985904384 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-013-0517-5 (DOI: 10.1007/s00595-013-0517-5, CiNii: 1573105975985904384)
69.	Tetsuya Ikemoto, Mitsuo Shimada, Masato Komatsu, Shinichiro Yamada, Yu Saito, Hiroki Mori, Yuji Morine, Satoru Imura, Yoshimi Bando and Toru Utsunomiya : Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood., Pancreas, Vol.42, No.1, 130-134, Jan. 2013. (Summary) Intraductal papillary mucinous neoplasms (IPMNs) have a high malignant potential. We previously reported that peripheral Foxp3(+)CD4(+)CD25(+) T-cell (Foxp3(+) Treg) populations significantly increase with IPMN pathological aggressiveness. Dendritic cell-mediated induction of active Tregs from naive CD4(+) T cells requires indoleamine 2,3-dioxygenase (IDO). Here, we evaluated whether an IDO-Foxp3(+) Treg interaction plays a role in IPMN pathological aggressiveness. We evaluated peripheral blood samples and resected specimens from 12 patients with IPMN. We analyzed Foxp3(+)CD4(+)CD25(+) T cells in peripheral blood by fluorescence-activated cell sorting, evaluated the resected specimens by anti-IDO antibody staining, and compared them with the patients' clinicopathological factors. The pathological aggressiveness of IPMN was significantly associated with the number of peripheral Foxp3(+) Tregs (P < 0.05) and IDO-positive cells per high-power field (HPF) (P < 0.01). There was a significant correlation between the numbers of peripheral Foxp3(+) Tregs and IDO-positive cells/HPF (r = 0.625, P < 0.01). Patients with 7 or more IDO-positive cells/HPF had a significantly higher recurrence rate than those with less than 7 IDO-positive cells/HPF (P < 0.01, log-rank test). Peripheral Foxp3(+) Tregs accurately reflect the aggressiveness of IPMNs. An increase in Foxp3(+) Tregs can be induced by local IDO-positive cells in IPMN. (Keyword) Adenocarcinoma, Mucinous / Adenocarcinoma, Papillary / Aged / Aged, 80 and over / analysis of variance / Carcinoma, Pancreatic Ductal / cell separation / Disease-Free Survival / Female / Flow Cytometry / Forkhead Transcription Factors / Humans / immunohistochemistry / Indoleamine-Pyrrole 2,3,-Dioxygenase / Interleukin-2 Receptor alpha Subunit / Lymphatic Metastasis / Male / Middle Aged / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Pancreatic Neoplasms / T-Lymphocytes, Regulatory / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1097/MPA.0b013e3182575e4a (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22722263 ● Summary page in Scopus @ Elsevier: 2-s2.0-84872079174 (DOI: 10.1097/MPA.0b013e3182575e4a, PubMed: 22722263, Elsevier: Scopus)
70.	Kouzou Yoshikawa, Mitsuo Shimada, Tomomi Kuwahara, Hideki Hirakawa, Nobuhiro Kurita, Horohiko Sato, Toru Utsunomiya, Takashi Iwata, Tomohiko Miyatani, Jun Higashijima, Hideya Kashihara, Chie Takasu, Noriko Matsumoto and Haruyuki Nakayama-Imaohji : Effect of Kampo medicine "Dai-kenchu-to" on microbiome in the intestine of the rats with fast stress., The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 221-227, 2013. (Summary) Diversity of gut microbiome has been recently reported to be lost in inflammatory bowel disease. We have previously reported that the Dai-kenchu-to (DKT) prevented the bacterial translocation through suppression of cytokine and apoptosis in rat's fast stress model. The aim of this study was to evaluate the effect of DKT on maintenance of microbial diversity in rat's intestine with inflammation. Wister rats were received the fast stress for 5 days. In DKT group, rats were administered with DKT (300 mg/kg/day) during the fast stress (DKT-group). The gut microbiomes were analyzed at before- and after- fast stress, and the effect of DKT for on microbial diversities of the gut were evaluated by the PCR-clone library method targeting the 16 S ribosomal RNA gene. In Control-group, Erysipelotrichaceae increased to 86% in after fast stress, OTU of before-fast stress was 111 and after fast stress was only 9 (changing rate: 58%). The diversity of microbiome was severely decreased. On the other hand, in DKT-group, diversity of microbiome was kept after fast stress (Lachnospiraceae: Ruminococcaceae: Coriobacteriales 54%, 22%, 5%), Operational taxonomic units of before fast stress was 52 and after fast stress was 55 (changing rate: 6%). Family Lachnospiraceae which includes butyrate-producing Clostridia (Clostridium IV and XIVa). DKT prevented the reduction of diversity of microbiome in rat's fast stress model. Our data suggested the new anti-inflammatory mechanism of DKT through gut microbiome. (Keyword) 英文論文 (Tokushima University Institutional Repository) ● Metadata: 106360 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.221 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190039 ● Summary page in Scopus @ Elsevier: 2-s2.0-84887006293 (Tokushima University Institutional Repository: 106360, DOI: 10.2152/jmi.60.221, PubMed: 24190039, Elsevier: Scopus)
71.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 浅野間理仁 : Atypically large well-differentiated hepatocellular carcinoma with extensive fatty metamorphosis: report of a case., The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 267-271, 2013. (Summary) A large well-differentiated hepatocellular carcinoma (HCC) with fatty change is rare, and to date only a few cases have been reported. Herein, we present a 68-year-old man who developed a well-differentiated HCC with extensive fatty metamorphosis. The patient was referred to our institute because of a rapidly growing tumor in the left lobe of the liver. Ultrasonography showed a hyperechoic lesion with a peripheral hypoechoic area. Dynamic contrast-enhanced computed tomography (CT) scan in all three phases revealed the tumor which showed diffuse low attenuation with internal irregular enhancement. He underwent left lateral segmentectomy at the liver. Histological diagnosis confirmed well-differentiated HCC and the surrounding non-cancerous area was diagnosed as non-alcoholic steatohepatitis. The patient is still alive without recurrence after 17 months of follow-up. (Keyword) 英文論文 (Tokushima University Institutional Repository) ● Metadata: 106367 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.267 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190046 ● Summary page in Scopus @ Elsevier: 2-s2.0-84886996013 (Tokushima University Institutional Repository: 106367, DOI: 10.2152/jmi.60.267, PubMed: 24190046, Elsevier: Scopus)
72.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司, Shuichi Iwahashi, 山田眞一郎, 浅野間理仁 and Hiroki Ishibashi : Hepatic epithelioid angiomyolipoma with arterioportal venous shunting mimicking hepatocellular carcinoma : report of a case., The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 262-266, 2013. (Summary) A patient with hepatic epithelioid angiomyolipoma (Epi-AML) with arterioportal venous shunting, who was successfully treated by a laparoscopic left lateral sectionectomy, is presented herein. AML is an uncommon benign neoplasm of the liver. Tumors composed predominantly of epithelioid cells have been subcategorized into Epi-AML, and the treatment strategy for Epi-AML is currently undetermined. There are no reports describing Epi-AML with arterioportal venous shunting to date. An arterioportal venous shunting of the liver tumor was suggested to be one of the malignant signs of the liver tumor. It would be important to differentiate Epi-AML with arterioportal venous shunting from hepatocellular carcinoma and hypervascular metastatic tumors. Minimally invasive resection, such as laparoscopic hepatectomy, for patients having Epi-AML with arterioportal venous shunting may be recommended. (Keyword) Angiomyolipoma / Carcinoma, Hepatocellular / Diagnosis, Differential / Hepatic Artery / Humans / Liver Neoplasms / Magnetic Resonance Imaging / Male / Middle Aged / Portal Vein / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 106366 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.262 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190045 ● Search Scopus @ Elsevier (PMID): 24190045 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.262 (Tokushima University Institutional Repository: 106366, DOI: 10.2152/jmi.60.262, PubMed: 24190045)
73.	杉本光司, Toru Utsunomiya, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Chie Takasu and Mitsuo Shimada : Hand-assisted laparoscopic splenectomy for a huge splenic vascular lesion with aneurysms in a patient with impending Kasabach-Merritt syndrome-like phenomenon., The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 276-279, 2013. (Summary) Splenic vascular lesions are relatively rare and are usually found incidentally. However, the vascular lesions associated with Kasabach-Merritt syndrome, such as hemangioma, can be life-threatening. We herein describe the case of a young adult female patient with a huge splenic vascular lesion, aneurysms of the splenic artery, and increased plasma levels of fibrin/fibrinogen degradation products and D-dimers. Hand-assisted laparoscopic splenectomy was performed, after which the coagulopathy was drastically improved. Minimally invasive surgical intervention such as hand-assisted laparoscopic splenectomy should be considered as the first treatment choice in such a case. (Keyword) 英文論文 (Tokushima University Institutional Repository) ● Metadata: 106369 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.276 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190048 ● Summary page in Scopus @ Elsevier: 2-s2.0-84887005653 (Tokushima University Institutional Repository: 106369, DOI: 10.2152/jmi.60.276, PubMed: 24190048, Elsevier: Scopus)
74.	Shinichiro Yamada, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, Shuichi Iwahashi, Yu Saitou and Hiroki Ishibashi : Hilar cholangiocarcinoma accompanied by pancreaticobiliary maljunction without bile duct dilatation 20 years after cholecystectomy: report of a case, The Journal of Medical Investigation : JMI, Vol.60, No.1-2, 169-173, 2013. (Summary) Pancreaticobiliary maljunction (PBM) is associated with the occurrence of biliary cancer due to pancreatobiliary reflux. From the perspective of carcinogenesis, the treatment for PBM is controversial. We herein report a case of hilar cholangiocarcinoma 20 years after the occurrence of gallbladder cancer. A 75-year-old man was referred to our hospital regarding an obstructive jaundice and bile duct tumor. A cholecystectomy was performed for cholelithiasis on this patient 20 years ago, and cancer in situ was detected. Computed tomography (CT) and endoscopic retrograde cholangiopancreatography (ERCP) revealed a tumor of the portal hepatic region and PBM without dilatation of the bile duct. Adenocarcinoma was detected from bile cytology, and we diagnosed hilar cholangiocarcinoma. Despite the biliary decompression, jaundice was prolonged and the patient passed away. Our case suggests that not only cholecystectomy but also biliary diversion is needed for PBM regardless of the existence of bile duct dilatation. (Keyword) 欧文論文 (Tokushima University Institutional Repository) ● Metadata: 106060 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.169 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614928 ● Search Scopus @ Elsevier (PMID): 23614928 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.169 (Tokushima University Institutional Repository: 106060, DOI: 10.2152/jmi.60.169, PubMed: 23614928)
75.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Jun Hanaoka : Effects of a whey peptide-based enteral formula diet on liver dysfunction following living donor liver transplantation., Surgery Today, Dec. 2012. (Summary) BACKGROUND AND AIMS: Whey protein, a protein complex derived from milk is well known as a functional food with a number of health benefits. MEIN(®) (Meiji Dairies Co., Tokyo Japan) is a functional liquid-type nutritional diet containing whey-hydrolyzed peptide. In this study, we examined the effects of MEIN(®) on postoperative liver dysfunction in patients who underwent living donor-related liver transplantation (LDLT). METHODS: Sixteen adult patients transplanted between 2005 and 2011 at our institute were evaluated retrospectively. In MEIN group (n = 8), administration of MEIN(®) was started around 14 days after liver transplantation when serum liver enzymes were re-elevated, while MEIN(®) was not administered in the control group (n = 8) who did not have postoperative liver dysfunction. RESULTS: In the preoperative clinical characteristics, the model for end-stage liver disease score in the MEIN group was significantly lower than that in the control group. The graft-to-recipient body weight ratio in the MEIN group was lower than that in the control group. Elevation of enzymes in the liver function tests such as alanine aminotransferase and total bilirubin, and C-reactive protein in the MEIN group had significantly improved, and became almost normal values which were the same as those in the control group. CONCLUSION: These findings suggest that administration of whey-hydrolyzed peptide attenuates the post-transplant liver dysfunction and may avoid an unnecessary liver biopsy. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-012-0466-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23266751 ● Search Scopus @ Elsevier (PMID): 23266751 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-012-0466-4 (DOI: 10.1007/s00595-012-0466-4, PubMed: 23266751)
76.	Kouzou Yoshikawa, Mitsuo Shimada and Nobuhiro Kurita : Personalized medicine for laparoscopic gastrectomy used to treat gastric cancer., Surgical Endoscopy, Vol.26, No.12, 3703, Dec. 2012. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-012-2282-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22538689 ● Search Scopus @ Elsevier (PMID): 22538689 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-012-2282-8 (DOI: 10.1007/s00464-012-2282-8, PubMed: 22538689)
77.	Mitsuo Shimada, 神澤輝実, 安藤久實, 須山正文, Yuji Morine and Hiroki Mori : 膵・胆管合流異常診療ガイドライン(日本膵・胆管合流異常研究会・日本胆道学会編), Journal of Japan Biliary Association, Vol.26, No.5, 678-690, Dec. 2012. (Keyword) 和文論文
78.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu and Noriko Matsumoto : Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors., Surgery Today, Vol.43, No.10, 1162-1167, Nov. 2012. (Summary) Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. The risk category is usually determined by tumor size and mitotic count, but accurate preoperative diagnosis of GIST is very difficult. The purpose of this study is to evaluate the efficacy of positron emission tomography (PET)-CT for predicting the malignant potential of gastrointestinal stromal tumors. Ten patients with GIST who underwent a preoperative PET-CT examination were divided into two groups by risk category, and various factors were compared between the two groups. The relationships between the maximum standardized uptake value (SUVmax) and GIST parameters were examined. Patients were classified into two groups by their risk category: (low/intermediate-risk or high-risk). The SUVmax was significantly higher in the high-risk group (11.0 ± 3.04) than in the low/intermediate-risk group (2.1 ± 1.5). The Ki67 labeling index was also significantly higher in the high-risk group (8.63 ± 6.2) than in the low/intermediate-risk group (1.75 ± 0.52). There was a significant correlation between the Ki67 labeling index and the SUVmax (p = 0.028) and between the mitotic index and the SUVmax (p = 0.029). PET-CT can predict malignant potential. Cases with a SUVmax of over 5 may have malignant potential. (Keyword) Adult / Aged / Female / Fluorine Radioisotopes / Fluorodeoxyglucose F18 / Gastrointestinal Neoplasms / Gastrointestinal Stromal Tumors / Humans / Male / Middle Aged / Neoplasm Staging / Positron-Emission Tomography / Radiopharmaceuticals / Risk / Tomography, X-Ray Computed / 英文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-012-0411-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23143169 ● Search Scopus @ Elsevier (PMID): 23143169 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-012-0411-6 (DOI: 10.1007/s00595-012-0411-6, PubMed: 23143169)
79.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Chie Takasu and H Kashihara : Short-term results of laparoscopic surgery after preoperative chemoradiation for clinically staged T3 and T4 rectal cancer., Asian Journal of Endoscopic Surgery, Vol.5, No.4, 157-163, Nov. 2012. (Summary) The feasibility of laparoscopic surgery for clinically staged T3 and T4 rectal cancer has not been clearly defined specifically in cases following preoperative chemoradiation therapy (CRT). Our aim was to investigate the feasibility of laparoscopic surgery after preoperative CRT for clinically staged T3 and T4 rectal cancer. Between May 2003 and June 2009, 57 patients (T3: n = 50, T4: n = 7) who underwent preoperative CRT for rectal cancer were identified. Forty-three patients with laparoscopic surgery (Lap group) were compared with 14 patients who underwent open surgery (Open group). Perioperative data including postoperative morbidity were assessed between the two groups. All patients underwent complete laparoscopic operations, and none was converted to laparotomy. Operating time was longer in the Open group (331 vs 375 min, P < 0.01). Blood loss was lower in the Lap group (160 vs 316 mL, P < 0.01). Lymph node harvest and morbidity rate were similar in both groups. The distal tumor margin was negative in all patients. No patients had perioperative mortality associated with surgery after CRT. Laparoscopic surgery after preoperative CRT is a feasible and a safe option for T3 and T4 rectal cancer compared to conventional open surgery. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1758-5910.2012.00148.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22883429 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876741246 (DOI: 10.1111/j.1758-5910.2012.00148.x, PubMed: 22883429, Elsevier: Scopus)
80.	Masaaki Nishi, Mitsuo Shimada, Hideaki Uchiyama, Toru Ikegami, Yusuke Arakawa, Jun Hanaoka, 金村普史, Yuji Morine, Satoru Imura and Hidenori Miyake : The beneficial effects of Kampo medicine Dai-Ken-Chu-To after hepatic resection: a prospective randomized control study., Hepato-Gastroenterology, Vol.59, No.119, 2290-2294, Oct. 2012. (Summary) After hepatic resection, delayed flatus and impaired bowel movement often cause problematic postoperative ileus. Kampo medicine, Dai-kenchu-to (DKT), is reported to have a various beneficial effects on bowel systems. The aim of this study was to prospectively evaluate effects of DKT after hepatic resection. Thirty-two patients who underwent hepatic resection between July 2007 and August 2008 in Tokushima University Hospital were prospectively divided into DKT group (n=16) and control group (n=16). In DKT group, 2.5 g of DKT was administered orally three times a day from postoperative day (POD) 1. Blood was examined on POD 1, 3, 5 and 7. Postoperative first flatus, bowel movement and full recovery of oral intake, hospital stays and complications were checked. In DKT group, levels of c-reactive protein and beta-(1-3)-D-glucan on POD 3 were significantly decreased (p<0.05). Moreover, postoperative periods for the first flatus, bowel movement and the full recovery of oral intake were significantly shortened in DKT group (p<0.05). DKT suppressed inflammatory reaction, stimulated bowel movement and improved oral intake after hepatic resection, which may decrease serious morbidity after hepatic resection. (Keyword) Administration, Oral / Aged / Biological Markers / C-Reactive Protein / Chi-Square Distribution / Defecation / Drug Administration Schedule / Eating / Female / Flatulence / Gastrointestinal Transit / Hepatectomy / Humans / Ileus / Inflammation / Japan / Length of Stay / Male / Medicine, Kampo / Middle Aged / Plant Extracts / Prospective Studies / Recovery of Function / Time Factors / Treatment Outcome / beta-Glucans (Link to Publication Site) ● Publication site (DOI): 10.5754/hge10115 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23435143 ● Search Scopus @ Elsevier (PMID): 23435143 ● Search Scopus @ Elsevier (DOI): 10.5754/hge10115 (DOI: 10.5754/hge10115, PubMed: 23435143)
81.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima and Tomohiko Miyatani : Clinicopathological analysis of distal margin for rectal cancer after preoperative chemoradiation therapy., Hepato-Gastroenterology, Vol.59, No.119, 2142-2146, Oct. 2012. (Summary) Preoperative chemoradiation therapy (CRT) for advanced rectal cancer allows anal sphincter preservation in some patients who would require an abdominoperineal resection. But adequate distal margin in patients with locally advanced rectal cancer requiring preoperative CRT is unclear. The objective was to evaluate necessary distal margin from reduced tumor by preoperative CRT for anal sphincter preservation. This study included 11 consecutive patients who performed low anterior resection and abdominoperineal resection for rectal cancer after preoperative CRT. Distal margin length from reduced tumor by preoperative CRT to residual viable cancer, tumor grade, lymph-node-metastasis stage and pathological changes of tumors were examined. Length from anal side edge of reduced tumor by preoperative CRT to pathological residual tumor ranged from +6 mm to -9 mm. Tumor stages were as follows: T0-2, N0, M0=3, T3, N0, M0=5, T4, N0, M0=1 and T3, N0, M+1=2. Median follow-up was 19 months. Recurrence occurred in one patient and was distant and not local. Pathological examinations showed that no patient had lymph-node-metastasis and residual tumors by preoperative CRT. This study suggests that for patients with locally advanced rectal cancer undergoing resection and preoperative CRT, distal margins ≥1 cm from reduced tumor by preoperative CRT seem to compromise pathological outcome. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge11840 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22366527 ● Search Scopus @ Elsevier (PMID): 22366527 ● Search Scopus @ Elsevier (DOI): 10.5754/hge11840 (DOI: 10.5754/hge11840, PubMed: 22366527)
82.	Hiroki Mori, Mitsuo Shimada, Toru Ikegami, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Shuichi Iwahashi, 齋藤裕, 淺野間理仁, 山田眞一郎 and Hidenori Miyake : The Impact of Pegylated-Interferon alpha-2b on Partial and Massive Hepatectomy Model in Rats., Hepato-Gastroenterology, Vol.59, No.119, 2300-2304, Oct. 2012. (Summary) The impact of pegylated-interferon (PEG-IFN) α-2b on liver regeneration has not yet been elucidated. Rats were divided into the following four groups: 70% hepatectomy (Hx); 70% Hx+PEG-IFN; 90% Hx and 90% Hx+PEG-IFN group (n=6 each). Rats were pretreated with subcutaneous of PEGIFN α-2b (1.5 μg/kg) administration 24 hours before Hx. Samples were taken 24, 48 and 72 hours after Hx and the following parameters were investigated: blood analysis (AST, WBC, PLT); liver weight to body weight ratio (Lw/Bw ratio); survival and PCNA labeling index (LI). In the 90% Hx model, there was no significant difference between the Hx+PEG-IFN group and the Hx alone group in blood analysis; AST after postoperative 24 hours (2511 vs. 2466 IU/L), WBC (1200 vs. 1290) and PLT (107 vs. 111 x 104/mm³), in Lw/Bw ratio at postoperative 0, 24, 48, 72 hours, respectively (0.38, 0.60, 1.14, 1.69 vs. 0.37, 0.64, 1.12, 1.63), in postoperative survival (40% vs. 45%), and in PCNA LI at postoperative 0, 24, 48, 72 hours, respectively (10.4%, 16.8%, 14.6%, 12.8% vs. 10.0%, 17.1%, 15.6%, 13.7%). In the 70% Hx model, there was no significant difference between the Hx+PEG-IFN group and the Hx alone group for all parameters. Our data demonstrated that PEG-IFN α-2b did not affect liver regeneration and the early use of PEG-IFN α-2b would cause no problems after liver transplantation using partial grafts including living donor liver transplantation. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge10401 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23435145 ● Search Scopus @ Elsevier (PMID): 23435145 ● Search Scopus @ Elsevier (DOI): 10.5754/hge10401 (DOI: 10.5754/hge10401, PubMed: 23435145)
83.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 山田眞一郎 and 淺野間理仁 : Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein., Hepatology Research, Vol.42, No.9, 887-894, Sep. 2012. (Summary) Aim: Lens culinaris agglutinin A-reactive fraction of α-fetoprotein (AFP-L3) status has been reported to be an independent prognostic factor in patients with hepatocellular carcinoma (HCC). In this study, we evaluated the clinical usefulness of measuring preoperative AFP-L3 to predict the recurrence and prognosis of HCC after curative hepatectomy. Methods: One hundred and forty-two HCC patients who underwent curative hepatectomy were examined for the correlation between preoperative tumor marker, including AFP, des-γ-carboxy prothrombin (DCP) and AFP-L3, and clinicopathological variables. The prognostic factors of disease-free survival rates and overall survival rates were also determined using clinicopathological variables including these three tumor markers. Results: There were similar tendencies in the relationship between these three markers and malignant behaviors including lower grade tumor differentiation or vascular invasion. In multivariate analysis, increased AFP-L3 value (P = 0.019) was found to be an independent prognostic factor of disease-free survival after curative hepatectomy. In addition, elevated DCP (P = 0.013) and AFP-L3 values (P = 0.012) were found to be independent prognostic factors. Furthermore, the preoperative AFP-L3 value in the patients with early recurrence (within 1 year after hepatectomy) was significantly higher than that in those without early recurrence (26.9 ± 19.5 % vs 14.2 ± 19.8 %, P = 0.047). Conclusion: Preoperative AFP-L3 value was strongly correlated to disease-free and overall survival rate and the timing of recurrence, so it appears that it would be useful to predict the recurrence and prognosis of HCC after curative hepatectomy. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1872-034X.2012.01004.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22524419 ● Search Scopus @ Elsevier (PMID): 22524419 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1872-034X.2012.01004.x (DOI: 10.1111/j.1872-034X.2012.01004.x, PubMed: 22524419)
84.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, Shuichi Iwahashi and 齋藤裕 : Surgical results of pancreatoduodenectomy in elderly patients., Surgery Today, Vol.42, No.9, 857-862, Sep. 2012. (Summary) To assess the safety and feasibility of pancreatoduodenectomy (PD) in elderly patients, we investigated the clinical characteristics of patients aged ≥75 years, who underwent this procedure at our hospital. Between November 2005 and December 2010, 84 patients underwent PD at Tokushima University Hospital. We analyzed the clinicopathological data and outcomes after PD in patients aged ≥75 years compared with those in patients <75 years. The preoperative characteristics of the elderly group (n = 28) were similar to those of the younger group (n = 56). The hemoglobin and albumin levels were significantly lower in the elderly patients (P < 0.05), who also had a higher rate of preoperative pulmonary dysfunction (P < 0.05). The operation time and intraoperative blood loss did not differ significantly between the groups, but the incidence of pneumonia was higher in the elderly group (P < 0.05). The overall survival rate did not differ significantly between the groups. Advanced age alone does not have an adverse effect on surgical outcomes, including postoperative complications and long-term prognosis. Therefore, PD may be justified for selected elderly patients. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-012-0169-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22447454 ● Search Scopus @ Elsevier (PMID): 22447454 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-012-0169-x (DOI: 10.1007/s00595-012-0169-x, PubMed: 22447454)
85.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, H Kashihara, Toru Utsunomiya and H Uehara : Survivin expression can predict the effect of chemoradiotherapy for advanced lower rectal cancer., International Journal of Clinical Oncology, Vol.18, No.5, 869-876, Aug. 2012. (Summary) BACKGROUND: Chemoradiotherapy (CRT) has been used to improve local control and survival in patients with advanced rectal carcinoma. However, a significant proportion of patients show poor response to adjuvant CRT. We thus investigated the usefulness of survivin expression as a predictive marker of the CRT response and its characteristics. METHODS: Forty-three patients with lower rectal cancer who underwent CRT were investigated. All patients received preoperative CRT consisting of TS-1 concurrent with 40 Gy of pelvic irradiation followed by curative resection. The relationship between clinical response, or pathological response, and the expression of survivin of pre-CRT biopsy specimens was evaluated by immunohistochemistry and compared with post-CRT expression. RESULTS: Positive expression of survivin was observed in 26 of 43 patients (60 %) in pre-CRT specimens. Survivin was positively expressed in 77 % of stable disease cases, and 43 % of partial response (p < 0.05). Regarding the correlation between pathological response and survivin expression, positive expression of survivin was recognized in 75 % (18 of 24) of Grade 0 + 1 cases, 50 % (7 of 14) of Grade 2 cases, and 20 % (1 of 5) of Grade 3 cases. A reverse correlation was recognized between pathological responses and survivin expression (p < 0.05). There were differences in the tumor differentiation between the survivin-positive group and the negative group (p < 0.05). The expression concordance rate was 66 % between pre- and post-CRT tissues. In post-CRT tissues, nuclear survivin expression disappeared completely and cytoplasmic expression increased, especially in responder cases. CONCLUSION: Survivin expression in biopsy could be an important predictive factor of preoperative CRT response. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-012-0470-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22936565 ● Search Scopus @ Elsevier (PMID): 22936565 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-012-0470-0 (DOI: 10.1007/s10147-012-0470-0, PubMed: 22936565)
86.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, H Kashihara and Chie Takasu : Comparison of long-term prognosis of laparoscopy-assisted gastrectomy and conventional open gastrectomy with special reference to D2 lymph node dissection., Surgical Endoscopy, Vol.26, No.8, 2240-2246, Aug. 2012. (Summary) Laparoscopy-assisted gastrectomy (LAG) is becoming widely used for early gastric cancer. However, how the curability and long-term prognosis of LAG and open gastrectomy (OG) for early and advanced gastric cancer compare remains unclear. This study assessed short- and long-term outcomes after LAG with lymph node dissection in early and advanced gastric cancer. A total of 332 patients who underwent LAG or OG for early and advanced gastric cancer from January 2001 through December 2010 were reviewed retrospectively. The mean operating time, estimated mean blood loss, number of dissected lymph nodes, and survival rates were compared between LAG and OG for early and advanced gastric cancer. Overall, 47.6% (158/332) of patients underwent LAG; D1, D1+ lymph node dissection was carried out in 77.2%, with D2 dissection in 22.8%. Only one patient required conversion to OG. Comparing LAG and OG with D1, D1+ lymph node dissection for early gastric cancer (EGC), mean operating time was significantly longer, estimated mean blood loss was significantly smaller, and the average number of retrieved lymph nodes was significantly greater with LAG. The rate of specific postoperative morbidity was 17.2% for LAG patients and 25.0% for OG patients, with no postoperative mortality. Survival and recurrence rates were not significantly different. Comparing LAG and OG with D2 lymph node dissection for advanced gastric cancer (AGC), mean operating time was significantly longer and estimated mean blood loss was significantly smaller with LAG, while the average number of retrieved lymph nodes, specific postoperative morbidity and mortality, and survival and recurrence rates were not significantly different. LAG with D1, D1+ lymph node dissection for EGC is safe and equivalent to open gastrectomy in curability. Moreover, LAG with D2 lymph node dissection for AGC is comparable to OG with D2 lymph node dissection with regard to short- and long-term results. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-012-2167-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22311300 ● Search Scopus @ Elsevier (PMID): 22311300 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-012-2167-x (DOI: 10.1007/s00464-012-2167-x, PubMed: 22311300)
87.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, 齋藤裕, Shuichi Iwahashi, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto and Yuji Morine : Impact of a new refrigerator on the preservation of hepatic grafts., Hepatology Research, Vol.42, No.8, 798-805, Aug. 2012. (Summary) Aim: Current medical transplantation methods focus on solutions for major problems such as the shortage of donors. To overcome these issues, expanding organ preservation time has become a major concern. A new refrigerating chamber has been recently developed, which can cool the inside of a material to the required temperature by frequently sensing the temperature of both inside and surface of the materials. The purpose of this study is to evaluate the usefulness of a new refrigerating system in hepatic preservation. Methods: The liver grafts were harvested from rats and divided into two groups. Group A consisted of grafts preserved in chilled University of Wisconsin solution (UW) solution (on ice) for 24, 72 and 168 h. Group B consisted of grafts preserved in the UW solution in a new refrigerator at 4°C. Results: In group B, aspartate aminotransferase released into effluent after cold storage for 72 h showed a marked decrease compared to group A (P < 0.05). The levels of ammonia and lactate decreased significantly in group B (P < 0.05). In group B, the levels of adenosine triphosphate were significantly preserved after cold storage for 24 h and 72 h compared to group A (P < 0.05). Immunohistochemistry showed positive cells for heme oxygenase-1 were significantly increased in group B after cold storage. Conclusion: This new refrigerator can improve preservation injury of hepatic grafts and may provide an innovative technique for liver transplantation. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1872-034X.2012.00987.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22469252 ● Search Scopus @ Elsevier (PMID): 22469252 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1872-034X.2012.00987.x (DOI: 10.1111/j.1872-034X.2012.00987.x, PubMed: 22469252)
88.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi, 齋藤裕 and Hidenori Miyake : A Modified liver-hanging maneuver focusing on the ligamentum venosum in left hepatic lobectomy, Surgery Today, Vol.42, No.8, 720-723, Aug. 2012. (Summary) The liver-hanging maneuver (LHM) is a useful technique in major hepatectomy. We made modifications to this technique with special reference to the ligamentum venosum for performing a left hepatectomy (LH). The aim of this study was to clarify the usefulness of our new technique. Between August 2007 and May 2009, five patients underwent LH using our modified LHM and 12 patients underwent LH using a conventional procedure. The two groups were compared in terms of the patient characteristics, preoperative hepatic functions, surgical records, and outcomes. The characteristics and preoperative hepatic function tests were similar between the modified LHM and non-LHM groups. Intraoperative blood loss was significantly reduced in the modified LHM group compared with the non-LHM group (193 ± 133 vs. 375 ± 167 ml, P < 0.05). The lengths of the operations and time required to perform a parenchymal transection did not differ significantly between the two groups (duration of operations 273 ± 37 vs. 337 ± 70 min; transection times 29 ± 10 vs. 28 ± 13 min). The postoperative complications and hospital stays did not differ significantly between the two groups. Our modified LHM can reduce the intraoperative blood loss during LH, and our results have shown the usefulness of this modified technique for LH. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-011-0051-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22094437 ● Search Scopus @ Elsevier (PMID): 22094437 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-011-0051-2 (DOI: 10.1007/s00595-011-0051-2, PubMed: 22094437)
89.	T Kamisawa, H Ando, M Suyama, Mitsuo Shimada, Yuji Morine, H Shimada and Working Committee of Clinical Practice Guidelines for Pancreaticobiliary Maljunction; Japanese Study Group on Pancreaticobiliary Maljunction. : Japanese clinical practice guidelines for pancreaticobiliary maljunction., Journal of Gastroenterology, Vol.47, No.7, 731-759, Jul. 2012. (Summary) There have been no clinical guidelines for the management of pancreaticobiliary maljunction (PBM). The Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM) has proposed to establish clinical practice guidelines on how to deal with PBM, with the support of the Japan Biliary Association (JBA). Because the body of evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 46 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs covered distinct aspects of PBM: (1) Concepts and Pathophysiology (10 CQs); (2) Diagnosis (10 CQs); (3) Pancreatobiliary complications (9 CQs); and (4) Treatments and prognosis (17 CQs). Statements and comments for each CQ were prepared by the guidelines committee members and collaborating partners. The CQs were completed after review by members of the editorial committee, meetings of this committee, public comments on the homepages of the JSPBM and the JBA, public hearings, and assessment and approval by the guidelines evaluation board. PBM includes cases where the bile duct is dilated (PBM with biliary dilatation) and those in which it is not (PBM without biliary dilatation). In these guidelines, PBM with biliary dilatation is defined as being identical to congenital biliary dilatation of Todani type I (except for type Ib) and type IV-A, both of which are accompanied by PBM in almost all cases. These guidelines are created to provide assistance in the clinical practice of PBM management; their contents focus on clinical utility, and they include general information on PBM to make this disease more widely recognized. (Keyword) Bile Duct Diseases / Bile Ducts / Evidence-Based Medicine / Humans / Japan / Pancreatic Diseases / Pancreatic Ducts / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-012-0611-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22722902 ● Search Scopus @ Elsevier (PMID): 22722902 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-012-0611-2 (DOI: 10.1007/s00535-012-0611-2, PubMed: 22722902)
90.	Kouzou Yoshikawa, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, Masato Komatsu, H Kashihara and Chie Takasu : The effects of the Kampo medicine (Japanese herbal medicine) ``Daikenchuto'' on the surgical inflammatory response following laparoscopic colorectal resection., Surgery Today, Vol.42, No.7, 646-651, Jul. 2012. (Summary) The inflammatory response after surgery is associated with various postoperative complications. The aim of the present prospective study was to evaluate the effects of Daikenchuto (DKT) (a Japanese herbal medicine) on the inflammatory response in patients following laparoscopic colorectal resection. Thirty patients who underwent laparoscopic colectomy for colorectal carcinoma were divided into two groups: a DKT intake group (D group, n = 15) and a control group (C group, n = 15). The D group took 7.5 g/day of DKT from the day after surgery until the 7th postoperative day. The body temperature, heart rate, WBC count, lymphocyte count, C-reactive protein (CRP) level, β-D: -glucan level and Candida index were compared between the two groups. The patients' mean age in the D group was significantly younger than that in the C group. D3 lymph node dissection was performed more often in the D group. The time until first flatus was significantly shorter in the D group (1.8 ± 0.5 days) than in the C group (2.7 ± 0.5 days). The CRP level was significantly lower in the D group (4.6 ± 0.6 mg/dl) than in the C group (8.3 ± 1.1 mg/dl) on the 3rd postoperative day. Postoperative DKT administration significantly suppressed the CRP level and shortened the time until first flatus. DKT administration also significantly suppressed postoperative inflammation following surgery for colorectal cancer. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-011-0094-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22202972 ● Summary page in Scopus @ Elsevier: 2-s2.0-84863987987 (DOI: 10.1007/s00595-011-0094-4, PubMed: 22202972, Elsevier: Scopus)
91.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, H Kashihara, Chie Takasu and Hitoshi Ikushima : Preoperative radiotherapy combined with S-1 for advanced lower rectal cancer: phase I trial., Hepato-Gastroenterology, Vol.59, No.117, 1428-1432, Jul. 2012. (Summary) S-1 based chemoradiation is the recommended treatment for rectal cancer; however, the optimal scheduling and dosing are not yet established. A Phase I study was conducted to determine the maximum tolerated dose (MTD) of S-1 with radiotherapy (RT). Endpoints were the toxicity profile of this regimen and to determine the recommended dose (RD). Conformal RT was given using 4 fields at daily fractions of 2Gy on 5 days per week to a total dose of 40Gy. Concurrently S-1 was given twice daily throughout RT. Eligible patients had a newly diagnosed clinical stage T3-4 N0-2 M0 rectal adenocarcinoma located within 12cm of the anal verge suitable for curative resection. Surgery was performed 6 weeks from completion of preoperative chemoradiotherapy. The dose escalating from S-1 80mg/m2/day (Level 1) to 100mg/m2/day (Level 2). Nine patients were valid for safety. In all patients, S-1 was administered. There was no dose-limiting toxicity (DLT) in patients treated at dose Level 1. Six patients were enrolled in the dose-escalation phase. At dose Level 2, two patients developed DLT and this was considered the MTD. Objective response according to RECIST were observed in 5 of 9 patients who had measurable disease (56%). The RD of S-1 with concurrent RT was determined to be 80mg/m2/day. Preoperative RT combined with S-1 was feasible and well tolerated. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge11699 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22155856 ● Search Scopus @ Elsevier (PMID): 22155856 ● Search Scopus @ Elsevier (DOI): 10.5754/hge11699 (DOI: 10.5754/hge11699, PubMed: 22155856)
92.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Hiroki Mori : Huge focal nodular hyperplasia difficult to distinguish from well-differentiated hepatocellular carcinoma, Hepatology Research, Vol.42, No.7, 727-731, Jul. 2012. (Summary) We present a 43-year-old man with huge focal nodular hyperplasia (FNH) that was difficult to distinguish from well-differentiated hepatocellular carcinoma (HCC). He previously had abnormal portal vein circulation due to hypoplasia of the intrahepatic portal vein, which was treated with a superior mesenteric vein-inferior vena cava shunt. Laboratory findings included predominantly indirect hyperbilirubinemia with concomitant elevation in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and ammonia. Serum α-fetoprotein and des-γ-carboxy prothrombin were slightly elevated. Multidetector-row computed tomography detected the primary tumor in the left liver lobe, which partially showed a central stellate scar. Gd ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging showed some low-intensity areas in the tumor in the hepatocyte phase. 99mTc-galactosyl human serum albumin scintigraphy showed normal intake of agent in the tumor. We could not rule out well-differentiated HCC. Extended left hepatectomy was performed. Final histopathological findings showed that most of the tumor was FNH against a background of portal vein hypoplasia with moderate atypia and hemorrhage. And immunohistochemical analysis revealed high expression of organic anion transporter (OATP) 1B3 and low expression of multidrug resistance-associated protein (MRP) 2 in a part of the tumor. The patient has remained alive with no hepatic lesion for 1 year after surgery. We describe a case of huge FNH that was difficult to distinguish from well-differentiated HCC even by current fully preoperative imaging technology and demonstrate the effectiveness of curative surgical resection. (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1872-034X.2012.00974.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22686861 ● Search Scopus @ Elsevier (PMID): 22686861 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1872-034X.2012.00974.x (DOI: 10.1111/j.1872-034X.2012.00974.x, PubMed: 22686861)
93.	LO Tovuu, Satoru Imura, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 淺野間理仁, Hidenori Miyake and Mitsuo Shimada : Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma., International Journal of Clinical Oncology, Vol.18, No.4, 651-656, Jun. 2012. (Summary) CD44 is well known to be one of the cancer stem cell markers and is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion, and cell migration. We investigated the role of CD44 expression in both tumor and non-tumor tissues on recurrence of hepatocellular carcinoma (HCC). Forty-eight patients with HCC who underwent hepatic resection at our institution were enrolled in this study. CD44 expressions in both tumor and non-tumor tissues were examined using real time reverse transcription-polymerase chain reaction. The patients were divided into two groups: high and low gene-expression group, based on the CD44 expression level. We compared the clinicopathological factors between the high expression and low expression groups in both tumor and non-tumor tissues. In the tumor tissues, the gene-expression levels of CD44 did not correlate with any clinicopathological parameters. The disease-free survival rate showed no significant difference between the two groups. In non-tumor tissues, although there was no significant relationship between the CD44 expression levels and clinicopathological factors, disease-free survival rate in the CD44 low expression group was significantly better than that in the CD44 high expression group (P < 0.05). In multivariate analysis, the risk factors in tumor recurrence were presence of microscopic portal invasion and high expression level of CD44. The CD44 expressions in the non-tumor tissues may predict HCC recurrence. (Tokushima University Institutional Repository) ● Metadata: 106069 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-012-0432-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22706704 ● Search Scopus @ Elsevier (PMID): 22706704 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-012-0432-6 (Tokushima University Institutional Repository: 106069, DOI: 10.1007/s10147-012-0432-6, PubMed: 22706704)
94.	T Nakagawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka and H Miyamoto : Thymidylate synthase (TS) protein expression as a prognostic factor in advanced colorectal cancer: a comparison with TS mRNA expression., Hepato-Gastroenterology, Vol.59, No.116, 1059-1062, Jun. 2012. (Summary) The role of intratumoral thymidylate synthase (TS) mRNA or protein expression is still controversial and little has been reported regarding relation of them in colorectal cancer. Forty-six patients with advanced colorectal cancer who underwent surgical resection were included. TS mRNA expression was determined by the Danenberg tumor profile method based on laser-captured micro-dissection of the tumor cells. TS protein expression was evaluated using immunohistochemical staining. TS mRNA expression tended to relate TS protein expression. Statistical significance was not found in overall survival between the TS mRNA high group and low group regardless of performing adjuvant chemotherapy. The overall survival in the TS protein negative group was significantly higher than that in positive group in all and the patients without adjuvant chemotherapy. Multivariate analysis showed TS protein expression was as an independent prognostic factor. TS protein expression tends to be related TS mRNA expression and is an independent prognostic factor in advanced colorectal cancer. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge09243 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22580655 ● Search Scopus @ Elsevier (PMID): 22580655 ● Search Scopus @ Elsevier (DOI): 10.5754/hge09243 (DOI: 10.5754/hge09243, PubMed: 22580655)
95.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Takayuki Nakao and Masato Komatsu : Evaluation of relation of RAD51 and the effect of chemo-radiation therapy for advanced rectal cancer., Hepato-Gastroenterology, Vol.59, No.116, 990-993, Jun. 2012. (Summary) Chemo-radiation therapy (CRT) has been used to improve local control and survival in patients with advanced rectal carcinoma. However, a significant proportion of patients shows poor response to adjuvant CRT. We thus investigated the usefulness of RAD51 expressions as a predictive maker of the CRT response. Forty two patients who suffered from lower rectal cancer were investigated. All patients received preoperative CRT consisting of TS-1, concurrent with 40Gy of pelvic irradiation before having curative radical resection. The relationship between pathological responses of the tumors after therapy and expression of RAD51 was evaluated by immunostaining of resected specimen. Positive expression of RAD51 was observed in 24 of 42 patients (57.1%). RAD51 positively expressed in 68.2% (15 of 22 cases) of SD and 42.2% (9 of 20 cases) of PR and CR. There is a tendency of reverse correlation between clinical response and expression of RAD51. Regarding the correlation between pathological response and RAD51 expression, positive expression of RAD51 was recognized in 75.0% (15 of 20 cases) of Grade 1, 47.1% (8 of 17 cases) of Grade 2 and 20.0% (1 of 5 cases) of Grade 3. A significant reverse correlation was recognized between RAD51 expression and pathological responses. RAD51 expression could be one of the most important predictive factors of preoperative CRT for advanced lower rectal cancer. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge10068 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22580645 ● Search Scopus @ Elsevier (PMID): 22580645 ● Search Scopus @ Elsevier (DOI): 10.5754/hge10068 (DOI: 10.5754/hge10068, PubMed: 22580645)
96.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori and Jun Hanaoka : Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma, Surgery Today, Vol.42, No.6, 565-569, Jun. 2012. (Summary) Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are important enzymes in the metabolism of 5-fluorouracil, which have been examined as possible predictive markers. We conducted this study to clarify the role of TS and DPD expressions in gallbladder carcinoma (GBC). The subjects were 28 patients who underwent surgical resection of GBC. We examined intratumoral TS and DPD mRNA expressions, using the Danenberg tumor profile method. The expression levels were classified into two groups, based on median values. Clinicopathological variables, including prognosis, were then compared between the high and low expression groups. There was a significant difference in the incidence of lymph node metastasis between the high and low TS expression groups. The incidence of advanced clinical stage was higher in the low TS expression group than in the high TS expression group. However, no clear correlation was observed between the DPD mRNA expression and any clinicopathological variable. There was no significant difference in the postoperative survival rates between the groups, in accordance with the expression of TS or DPD genes. Low TS mRNA was correlated with a high incidence of lymph node metastasis and advanced clinical stage. Therefore, TS gene expression may help identify patients at increased risk of the progression of GBC. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-012-0118-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22270332 ● Search Scopus @ Elsevier (PMID): 22270332 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-012-0118-8 (DOI: 10.1007/s00595-012-0118-8, PubMed: 22270332)
97.	Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, 後藤正和 and Mitsuo Shimada : 単孔式腹腔鏡下に修復し得たSpiegelヘルニアの1例, Journal of Japan Society for Endoscopic Surgery, Vol.17, No.3, 347-351, Jun. 2012. (Keyword) 和文論文
98.	Satoru Imura, Mitsuo Shimada, 齋藤裕, Shuichi Iwahashi, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Toru Utsunomiya : Successful case with hemophagocytic syndrome after living donor liver transplantation., Hepato-Gastroenterology, Vol.59, No.115, 863-865, May 2012. (Summary) Hemophagocytic syndrome (HPS) is a rare but serious complication that is associated with hypercytokinemia caused by activated T lymphocytes and macrophages in immunologically compromised patients. Living donor liver transplantation (LDLT) between adults has been performed to compensate for the shortage of available organs. There have been some reports of HPS after LDLT but its prognosis is disappointingly poor. Herein, we report a case of HPS in a 53-year-old woman who underwent LDLT using a left lobe graft. HPS was diagnosed on postoperative day 6 and successfully treated with a steroid pulse. HPS is a fatal complication in immunologically compromised patients but its early diagnosis and appropriate treatment can lead to an improved outcome. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.5754/hge10081 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22469732 ● Search Scopus @ Elsevier (PMID): 22469732 ● Search Scopus @ Elsevier (DOI): 10.5754/hge10081 (DOI: 10.5754/hge10081, PubMed: 22469732)
99.	Tomohiko Miyatani, Nobuhiro Kurita, Toru Utsunomiya, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Jun Higashijima, H Kashihara, Chie Takasu, M Fukushima and Mitsuo Shimada : Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer., Cancer Letters, Vol.318, No.2, 199-205, May 2012. (Summary) A lot of radiosensitizers have been developed. However, there are few to be available in the clinical setting. Thymidine phosphorylase inhibitor (TPI) regulates the phosphorolysis of thymidine to thymine and 2-deoxy-d-ribose-1-phosphate which is essential for tumor angiogenesis. The aim of this study is to evaluate whether TPI augments the radiotherapy for colorectal cancer in vitro and in vivo studies. The cytotoxicity of TPI with irradiation on HT29 and HCT116 cells was examined using MTT- and colony formation assay. At 10days post-inoculation, HT29 bearing orthotopic model mice (n=28) were divided into four groups and orally treated with TPI- (50mg/kg/day for 2weeks), radiation (RT, 2Gy×4: Total 8Gy), their combination or the vehicle. The mechanisms underlying the efficacy were assessed genomically and immunohistochemically. Compared to each single treatment, the combination of TPI and RT synergistically inhibited the cell viability in a time- and dose-dependent manner. In the HT-29 bearing mice, the combination of TPI and RT reduced the tumor growth compared with RT alone. Notably, the mRNA levels of VEGF, TGF-β and, Rad51 and the protein expressions of VEGF and CD34 were significantly lower in the combination than the others. Furthermore, the combination markedly increased the TUNEL-positive cells, suggesting that TPI augments the cancer cell death through inhibition of angiogenesis and DNA repair system in the radiotherapy. Our study first demonstrated that the combination of TPI and irradiation was effective in colon cancer. TPI would provide a promising therapeutic strategy as a radiosensitizer. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2011.12.010 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22178656 ● Search Scopus @ Elsevier (PMID): 22178656 ● Search Scopus @ Elsevier (DOI): 10.1016/j.canlet.2011.12.010 (DOI: 10.1016/j.canlet.2011.12.010, PubMed: 22178656)
100.	山田眞一郎, Mitsuo Shimada, Hidenori Miyake, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi and 齋藤裕 : Outcome of hepatectomy in super-elderly patients with hepatocellular carcinoma., Hepatology Research, Vol.42, No.5, 454-458, May 2012. (Summary) Aim: The aim of this study was to investigate the characteristics of super-elderly hepatocellular carcinoma (HCC) patients aged 80 years or more who underwent hepatectomy and to clarify whether elderly patients with HCC benefit from hepatectomy. Methods: Between March 1992 and December 2008, 278 patients who underwent curative hepatectomy for HCC were investigated. Super-elderly patients were defined as those aged 80 years or more. Clinicopathological data and outcomes after hepatectomy were compared between super-elderly and non-super-elderly groups. Results: Preoperative parameters, such as biochemical examinations, and liver function tests in the non-super-elderly group were comparable with those of the super-elderly group (n = 11). Exceptionally, albumin level in the super-elderly group was lower than that in the non-super-elderly group (P = 0.03). Surgical data and the prevalence of postoperative complications did not differ significantly between the two groups. No mortality was observed in the super-elderly and non-super-elderly group. Conclusions: Hepatectomy for HCC was a feasible option even in super elderly patients aged 80 years or older with accurate selection. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1872-034X.2011.00952.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22295877 ● Search Scopus @ Elsevier (PMID): 22295877 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1872-034X.2011.00952.x (DOI: 10.1111/j.1872-034X.2011.00952.x, PubMed: 22295877)
101.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Yuji Morine, Kouzou Yoshikawa, 稲葉一樹 and 宇山一朗 : Robot-assisted distal gastrectomy using the da Vinci Surgical System, Shikoku Acta Medica, Vol.68, No.1-2, 53-58, Apr. 2012. (Summary) The da Vinci Surgical System is a telerobotic system consisting of4components, including theInsite vision system with a true3‐dimensional endoscope providing a high-resolution binocular view ofthe surgical field, and the Endo Wrist instrument system, which is capable of7degrees of freedomand2degrees of axial rotation to replicate human wrist-like movements. Distal gastrectomy andD1+lymphnode dissection was performed in a73-year-old man with cT1bN0N0StageIA gastriccancer. Preoperative abdominal CT findings were showed that celiac artery branching patternswas Adachi VI type26groups. The operating time was433minutes, and the blood loss was284g.The da Vinci Surgical System has useful advantages over conventional Laproscopic Assisted gastrectomy(LAG)surgery concerning the precise lymphnodes dissection. With further innovationsin the future, the da Vinci Surgical System has the potential to facilitate technically difficult surgeryemploying conventional LAG techniques. (Keyword) 和文論文 (Tokushima University Institutional Repository) ● Metadata: 97918 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050583647831332224 (Tokushima University Institutional Repository: 97918, CiNii: 1050583647831332224)
102.	Toshihiro Nakao, Nobuhiro Kurita, Masato Komatsu, Kouzou Yoshikawa, Takashi Iwata, Toru Utsunomiya and Mitsuo Shimada : Irinotecan injures tight junction and causes bacterial translocation in rat., The Journal of Surgical Research, Vol.173, No.2, 341-347, Apr. 2012. (Summary) Tight junctions are an essential component of intestinal epithelial barriers. Claudin-1, occludin, and ZO-1 are the components of tight junction. The purpose of this study was to investigate whether irinotecan induces bacterial translocation in rats, and thus elucidate the relationship between tight junction and bacterial translocation. Ten rats were divided into two groups: Five were treated with irinotecan and five were not treated with irinotecan, the control group. Irinotecan treated rats were administrated irinotecan 250 mg/kg intraperitoneally on days designated 0 and 1, were then killed at 48 h after treatment, and tissues were collected for analysis. Controls were treated with a saline solution. In eighty percent of irinotecan treated rats, bacteria were detected in the mesenteric lymph node or spleen. Large intestinal resistance of the rats was decreased. On the contrary, small intestinal resistance increased. Claudin-1 protein expression of both the small and large intestine decreased (P < 0.05), occludin protein expression of the small intestine decreased (P < 0.05), and occludin protein expression of the large intestine had decreasing tendency (P = 0.07) in irinotecan treated rats. In irinotecan treated rats, claudin-1 mRNA of the small intestine decreased (P < 0.05), claudin-1 mRNA of large intestine had a tendency to decrease (P = 0.05), occludin mRNA of both small and large intestine decreased (P < 0.05). Irinotecan injures claudin-1 and occludin. It causes disorders in the intestinal epithelial barrier and induces bacterial translocation. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jss.2010.10.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21176921 ● Search Scopus @ Elsevier (PMID): 21176921 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jss.2010.10.003 (DOI: 10.1016/j.jss.2010.10.003, PubMed: 21176921)
103.	Jun Higashijima, Masanori Nishioka, Horohiko Sato, Takashi Iwata, Mitsuo Shimada and Nobuhiro Kurita : 腹腔鏡下に切除した大腸平滑筋肉腫の1例, Journal of Japan Society for Endoscopic Surgery, Vol.17, No.1, 125-130, Feb. 2012. (Keyword) 和文論文
104.	Toru Utsunomiya and Mitsuo Shimada : Modified hanging method for liver resection., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.19, No.1, 19-24, Jan. 2012. (Summary) The liver hanging maneuver (LHM) is a useful technique to transect the liver parenchyma while lifting it with a tape passed between the anterior surface of the inferior vena cava (IVC) and the liver parenchyma. The original method was employed mostly for right hepatectomy with an "anterior approach" for huge liver tumors. The tape serves as a guide to the transection plane and facilitates the control of bleeding in the deeper parenchyma of the liver while protecting the anterior surface of the IVC. On the other hand, several recent studies have shown the feasibility and usefulness of modified LHM techniques. These methods can be applied to left hepatectomy with or without caudate lobectomy (segmentectomy 1), even for patients undergoing orthotopic liver transplantation. This report explains the methods and pitfalls of the original and modified LHM. In addition, important anatomical and technical aspects of the mobilization of hepatic lobes are also included. (Keyword) Dissection / Hepatectomy / Humans / Liver / Liver Neoplasms / Liver Transplantation / Vena Cava, Inferior / 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00534-011-0442-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21938412 ● Summary page in Scopus @ Elsevier: 2-s2.0-84857041120 (DOI: 10.1007/s00534-011-0442-1, PubMed: 21938412, Elsevier: Scopus)
105.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, H Kashihara and Chie Takasu : The safety and usefulness of the single incision, transabdominal pre-peritoneal (TAPP) laparoscopic technique for inguinal hernia., The Journal of Medical Investigation : JMI, Vol.59, No.3-4, 235-240, 2012. (Summary) The safety and usefulness of the SILS-TAPP (transabdominal pre-peritoneal) procedure remain unclear. The aim of this study was to clarify the safety and usefulness of the SILS-TAPP procedure compared with standard laparoscopic TAPP and TEPP (totally extra-peritoneal pre-peritoneal) procedures. 85 patients underwent laparoscopic inguinal hernia repairs (TEPP, 30 patients; TAPP, 20 patients; SILS-TAPP, 35 patients) from 2007 to 2011. The operative outcomes of the three groups were compared. There was no difference in the patients' characteristics among the three groups. The TEPP Group had a longer operation time. One patient in the SILS-TAPP group had an intraoperative complication. One patient in the TAPP group had a postoperative complication, and one patient had ileus and one had an umbilical hernia in the SILS-TAPP group. The postoperative hospital stay was not significantly different among the three groups. There were no recurrences in the TEPP group, 1 case of recurrence (5.0%) in the TAPP group, and 1 case (2.9%) in the SILS-TAPP group. The present findings show that the SILS-TAPP repair is safe and feasible for the repair of adult inguinal hernia. (Keyword) 欧文論文 (Tokushima University Institutional Repository) ● Metadata: 106026 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.59.235 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23037193 ● Search Scopus @ Elsevier (PMID): 23037193 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.59.235 (Tokushima University Institutional Repository: 106026, DOI: 10.2152/jmi.59.235, PubMed: 23037193)
106.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi, 齋藤裕 and 淺野間理仁 : Hepatic screlosed hemangioma which was misdiagnosed as metastasis of gastric cancer: report of a case, The Journal of Medical Investigation : JMI, Vol.59, No.3-4, 270-274, 2012. (Summary) A screlosed hemangioma of the liver is rare among hepatic tumors. A 75 years old male was referred to our hospital for gastric cancer and a hepatic tumor. The histological finding of gastric cancer was revealed to be well differentiated adenocarcinoma. The liver tumor was 1.1×1.0 cm in size and located in segment 8 of the liver. Computed tomography (CT) showed it to be a tumor with ring enhancement. Magnetic resonance imaging (MRI) showed the tumor to have a low signal on T1-weighted and slightly high signal on T2-weighted images. Level of hemoglobin was 7.8 g/dl. It was thought to be persistent bleeding from gastric cancer. With diagnosis of liver metastasis from gastric cancer, chemotherapy is recommended. However, to control the bleeding from gastric cancer, we performed distal gastrectomy and wedge resection of liver (S8). The histological examination of the liver tumor revealed to be a hepatic sclerosed hemangioma with hyalinized tissue and collagen fibers. We report herein a case of the rare tumor which was misdiagnosed as a liver metastasis of gastric cancer. (Keyword) 欧文論文 (Tokushima University Institutional Repository) ● Metadata: 106032 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.59.270 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23037199 ● Search Scopus @ Elsevier (PMID): 23037199 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.59.270 (Tokushima University Institutional Repository: 106032, DOI: 10.2152/jmi.59.270, PubMed: 23037199)
107.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, 原田昇, 米村祐輔, 伊地知秀樹, 中牟田誠, 森園周祐, Mitsuo Shimada and 前原喜彦 : 劇症肝不全に対する肝移植, KAN TAN SUI, Vol.51, No.1, 101-106, Jul. 2005.
108.	池本哲也, Yuji Morine, Satoru Imura, Masahiko Fujii, 石橋広樹 and Mitsuo Shimada : 特集. 術後感染症を防ぐーDPC時代に向けてー術後感染症を防ぐためのわれわれの工夫肝臓手術, Surgical Therapy, Vol.92, No.4, 420-428, Apr. 2005. (Keyword) DPC / クリニカルパス / 感染防御 / 周術期管理 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520573330987132160 (CiNii: 1520573330987132160)
109.	Mitsuo Shimada, Masahiko Fujii, Yuji Morine, Satoru Imura, Tetsuya Ikemoto and Hiroki Ishibashi : Living-donor liver transplantation: present status and future perspective, The Journal of Medical Investigation : JMI, Vol.52, No.1 2, 22-32, Feb. 2005. (Summary) About 15 years have passed since the first liver transplant from a living donor (living donor liver transplantation: LDLT), and the status of the procedure has since been established as a standard cure for end-stage liver disease in Japan where liver transplantation (LTx) from deceased donors has not yet been accepted. However, the following problems are surfacing with the increase in the number of LDLTs between adults: graft size mismatching, an ABO blood-type incompatible transplantation, the expansion of LDLT indication to hepatocellular carcinoma (HCC), the relapse of hepatitis C after LDLT, marginal donors, and the freedom from immunosuppressive treatment. In this article we outline the present conditions of these problems and the future view of the LDLT. (Keyword) ABO Blood-Group System / Blood Grouping and Crossmatching / Carcinoma, Hepatocellular / Hepatitis C / History, 20th Century / History, 21st Century / Humans / Japan / Liver Neoplasms / Liver Transplantation / Living Donors / Tissue and Organ Procurement (Tokushima University Institutional Repository) ● Metadata: 110753 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.52.22 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15751270 ● Search Scopus @ Elsevier (PMID): 15751270 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.52.22 (Tokushima University Institutional Repository: 110753, DOI: 10.2152/jmi.52.22, PubMed: 15751270)
110.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, Mitsuo Shimada and 前原喜彦 : 特集肝移植の最新の進歩と問題点選択，適応基準とIC取得，実践時期の設定 HCV肝硬変(外科から), KAN TAN SUI, Vol.50, No.1, 61-67, Jan. 2005.
111.	Yuji Morine, Masahiko Fujii, Satoru Imura, Tetsuya Ikemoto and Mitsuo Shimada : 特集肝移植の最新の進歩と問題点選択，適応基準とIC取得，実践時期の設定肝細胞癌に対する肝移植, KAN TAN SUI, Vol.50, No.1, 75-84, Jan. 2005.
112.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, Mitsuo Shimada and 前原喜彦 : HCV肝硬変(外科から), KAN TAN SUI, Vol.50, No.1, 61-67, Jan. 2005.
113.	Satoru Imura, 池本哲也, Yuji Morine, Masahiko Fujii, 石橋広樹 and Mitsuo Shimada : 特集. 肝切除術:成功の秘訣肝予備能検査:最新の知見, 消化器外科, Vol.28, 401-408, 2005.
114.	Mitsuo Shimada, Masahiko Fujii, Satoru Imura, Yuji Morine, 石橋広樹, 伊地知秀樹 and 八木博司 : 生体肝移植における過小グラフトに対する高圧酸素療法の有用性, 日本臨床高気圧酸素・潜水医学会雑誌, Vol.1, 46-50, 2005.
115.	Masahiko Fujii, Satoru Imura, Yuji Morine, 池本哲也, Yuji Soejima and Mitsuo Shimada : 剥離と切離実質臓器(肝胆膵), 消化器外科, Vol.28, 1369-1378, 2005.
116.	池本哲也, Yuji Morine, Satoru Imura, Yuji Soejima, Masahiko Fujii and Mitsuo Shimada : Present condition of liver transplantation and future problem. 3. Measure for rejection and infection., Acta Hepatologica Japonica, Vol.46, No.6, 310-316, 2005. (Keyword) 肝移植 / 拒絶反応 / 感染防御 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.46.310 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282679766043776 ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.46.310 (DOI: 10.2957/kanzo.46.310, CiNii: 1390282679766043776)
117.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, 原田昇, 米村祐輔, 伊地知秀樹, Mitsuo Shimada and 前原喜彦 : ウイルス肝炎と肝移植九州大学病院において, 今日の移植, Vol.18, 190-198, 2005.
118.	Mitsuo Shimada : 肝癌患者の移植適応の厳格化により5年生存率は向上したが，科学的根拠に基づいた肝癌の生物学的悪性度を基準に反映させる必要がある, Crtical Eyes on clinical oncology, No.12, 3-4, Oct. 2004.
119.	Shinji Tanaka, Mitsuo Shimada, Ken Shirabe and Yoshihiko Maehara : [Novel molecularly targeted peptides interfering the specific signal transduction of cancer metastasis], Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.62, No.7, 1251-1256, Jul. 2004.
120.	吉住朋晴, Mitsuo Shimada, Yuji Soejima and 前原喜彦 : 特集:肝臓外科∼課題とその対応∼, KAN TAN SUI, Vol.48, No.2, 231-239, Feb. 2004.
121.	辻田英司, Mitsuo Shimada, 播本憲史, 船津和守 and 前原喜彦 : 今日の問題ハイブリッド型人工肝臓の現状と将来展望, Surgical Therapy, Vol.90, No.1, 781-787, Jan. 2004.
122.	Masahiko Fujii, Satoru Imura, Yuji Morine, 池本哲也 and Mitsuo Shimada : 特集肝切除・部分肝移植後の肝再生と肝不全部分肝移植後の肝再生と肝不全—基礎と臨床—, 日本外科学会雑誌, Vol.105, 680-686, 2004.
123.	Yuji Morine, Masahiko Fujii, Satoru Imura, 池本哲也 and Mitsuo Shimada : 今日の問題生体肝移植の現状と将来展望, Surgical Therapy, Vol.91, 315-324, 2004.
124.	林純, 古庄憲法浩, 中牟田誠 and Mitsuo Shimada : ウイルス性肝炎(下)—基礎・臨床研究の進歩—, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.62, 106-107, 2004.
125.	吉住朋晴, Mitsuo Shimada, Yuji Soejima, 武冨紹信 and 前原喜彦 : ドミノ肝移植の現況と将来展望, Japanese Journal of Pediatric Surgery, Vol.36, 725-730, 2004.
126.	吉住朋晴, Mitsuo Shimada, Yuji Soejima, 内山秀昭, 武冨紹信 and 前原喜彦 : 肝炎から肝がんまで肝がんの治療肝移植, The Japanese journal of clinical and experimental medicine, Vol.81, 1306-1311, 2004.
127.	Yuji Soejima, 中牟田誠, 吉住朋晴, 内山秀昭, 武冨紹信, Mitsuo Shimada and 前原喜彦 : 生体肝移植とその短期及び長期成績脂肪肝グラフト, Surgery, Vol.66, 1012-1017, 2004.
128.	武冨紹信, Mitsuo Shimada, 調憲, 田中真二 and 前原喜彦 : 特集:肝細胞癌とどう戦うべきか再発治療とその予防再発肝細胞癌に対する治療, Surgery, Vol.65, No.8, 919-924, Aug. 2003.
129.	調憲, Mitsuo Shimada, 田中真二, 前田貴司 and 前原喜彦 : 特集:鏡視下手術の適応と限界肝癌に対する鏡視下肝切除と鏡視下ラジオ波腫瘍焼灼術, Surgical Therapy, Vol.88, No.4, 761-768, Apr. 2003.
130.	Shinji Tanaka, Keishi Sugimachi, Yo-ichi Yamashita, Ken Shirabe, Mitsuo Shimada, Jack R Wands and Keizo Sugimachi : Angiogenic switch as a molecular target of malignant tumors, Journal of Gastroenterology, Vol.38, No.Suppl 15, 93-97, Mar. 2003. (Summary) In vivo progression to malignancy is characterized by the switch to an angiogenic phenotype. The angiogenic switch is a critical control point for tumor expansion. The ability of a tumor to become neovascularized permits rapid expansion of tumor growth and increases the likelihood of metastases. The genetic alterations that accompany the switch to the angiogenic phenotype are unknown. Discoveries of such genes lead to comprehension of molecular mechanisms of the tumor progression, as well as development of novel therapeutic tools. We have isolated a novel "angiogenic switch molecule," angiopoietin-2, upregulated specifically in hypervascular hepatocellular carcinoma (HCC). Angiopoietin family proteins have been originally identified as ligands of the vascular endothelial receptor of tyrosine kinase Tie2. Ectopic expression of angiopoietin-2 promotes the rapid development of human HCCs and produces hemorrhage within tumors in nude mice. These results suggest a role for angiopoietin-2 in the neovascularization of HCC. In vitro expression of a dominant-negative construct, containing a soluble Tie2 ectodomain (sTie2), led to Angiopoietin protein interaction, inhibition of endogenous Tie2 phosphorylation in vascular endothelial cells. Tumorigenicity with angiogenesis was suppressed by in vivo gene transfer and sTie2 expression in a murine HCC model, suggesting a possible role for angiopoietin/Tie2 signaling in the induction of HCC neovascularization and disease progression. More important, inhibition of the angiopoietin/Tie2 signal transduction cascade is a promising approach for HCC treatment. (Keyword) Angiogenesis Inducing Agents / Angiopoietin-2 / Animals / Carcinoma, Hepatocellular / Disease Models, Animal / Enzyme Inhibitors / Gene Targeting / Humans / Liver Neoplasms / Mice / Neovascularization, Pathologic (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12698880 ● Search Scopus @ Elsevier (PMID): 12698880 (PubMed: 12698880)
131.	Mitsuo Shimada : 患者に優しいロボと手術, がん治療最前線, Vol.1, 68-72, Jan. 2003.
132.	相島慎一, 田口健一, 寺師貴啓, 松浦秀司, Mitsuo Shimada, 前原喜彦 and 恒吉正澄 : 肝内胆管癌および混合型肝癌におけるc-kit蛋白発現, Liver Cancer, Vol.9, 209-213, 2003.
133.	調憲, Mitsuo Shimada, 田中真二, 武冨紹信 and 前原喜彦 : 特集:癌転移—基礎と臨床アップデート—, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.61, 443-447, 2003.
134.	前原伸一郎, Mitsuo Shimada and 前原喜彦 : 肝切除におけるクリテイカルパスの有用性と抗菌役flomoxef (FMOX)の効果, The Japanese journal of clinical and experimental medicine, Vol.80, 1748-1752, 2003.
135.	辻田英司, Mitsuo Shimada, 調憲, 田中真二, 武冨紹信 and 前原喜彦 : 特集:ここまで進んだ内視鏡外科肝癌治療:腹腔鏡下手術の意義, 消化器内視鏡, Vol.15, 859-866, 2003.
136.	Yuji Soejima, Mitsuo Shimada, 吉住朋晴 and 前原喜彦 : 長期経過例における合併症, 今日の移植, Vol.16, 486-491, 2003.
137.	Mitsuo Shimada, 末廣剛敏, Yuji Soejima, 吉住朋晴 and 前原喜彦 : 肝細胞癌に対する生体肝移植術前術後化学療法, 日本移植学会雑誌, Vol.38, 173-182, 2003.
138.	Mitsuo Shimada, 末廣剛敏, Yuji Soejima, 吉住朋晴 and 前原喜彦 : 特集:肝細胞癌の治療方針:最近の進歩肝細胞癌に対する生体肝移植, 消化器外科, Vol.26, 603-611, 2003.
139.	Toru Ikegami, Takashi Nishizaki and Mitsuo Shimada : Temporary auxiliary liver transplantation from living donor to an adult recipient with familial amyloid polyneuropathy, Transplantation, Vol.74, No.9, 1356, Sep. 2002. (Keyword) Amyloid Neuropathies, Familial / Humans / Liver Transplantation / Living Donors (Link to Publication Site) ● Publication site (DOI): 10.1097/00007890-200211150-00028 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12451280 ● Search Scopus @ Elsevier (PMID): 12451280 ● Search Scopus @ Elsevier (DOI): 10.1097/00007890-200211150-00028 (DOI: 10.1097/00007890-200211150-00028, PubMed: 12451280)
140.	播本憲史 and Mitsuo Shimada : 特集:鏡視下手術の成績と評価 V. 肝臓, Surgery, Vol.64, No.9, 1029-1034, Sep. 2002.
141.	杉町圭蔵, Mitsuo Shimada and 杉町圭史 : 臨床外科学と基礎医学:人工肝臓の現状と問題点, 日本外科学会雑誌, Vol.103, No.3, 294-299, Mar. 2002.
142.	Mitsuo Shimada, Norifumi Harimoto, Shin-ichiro Maehara, Eiji Tsujita, Tatsuya Rikimaru, Yo-ichi Yamashita, Shinji Tanaka and Ken Shirabe : Minimally invasive hepatectomy: modulation of systemic reactions to operation or laparoscopic approach?, Surgery, Vol.131, No.Supplement 1, S312-S317, Jan. 2002. (Summary) A new concept of surgical stress has been proposed that consists of both aggressiveness of operation and systemic reactions to an operation. We have investigated a possible modulation of such systemic reactions to operation and have demonstrated the following 3 points: (1) coagulation and fibrinolytic systems are independently activated during hepatectomy and such activation can be modulated by protease inhibitors such as nafamostat mesilate and antithrombin III; (2) elevated thromboxane A2 during hepatectomy is characterized in the prostanoid system, the elevation of thromboxane A2 is inhibited by thromboxane A2 synthetase inhibitor, and postoperative liver injury is reduced; (3) cytokine response induced by hepatectomy is modulated by preoperative administration of methylprednisolone, leading to possible prevention of bacterial translocation. Therefore, modulating systemic reactions to hepatectomy may be important for successful minimally invasive hepatectomy. Another important option for minimally invasive hepatectomy is the use of operative procedures such as laparoscope or thoracoscope. We have investigated the usefulness of a laparoscopic hepatectomy from the standpoints of early and long-term outcome after hepatectomy. Laparoscopic hepatectomy, which is a difficult and dangerous procedure, can be a feasible option and can result in better short-term outcome and a similar long-term outcome after hepatectomy when compared with conventional open hepatectomy. Therefore, the laparoscopic approach is also a viable option for minimally invasive hepatectomy. Modulation of systemic reactions to the operation itself and laparoscopic hepatectomy may be new strategies for performing minimally invasive hepatectomy. (Keyword) Blood Coagulation / Fibrinolysis / Hepatectomy / Humans / Laparoscopy / Liver Diseases / Steroids / Stress, Physiological / Surgical Procedures, Minimally Invasive (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2002.120116 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11821830 ● Search Scopus @ Elsevier (PMID): 11821830 ● Search Scopus @ Elsevier (DOI): 10.1067/msy.2002.120116 (DOI: 10.1067/msy.2002.120116, PubMed: 11821830)
143.	Yo-ichi Yamashita, Mitsuo Shimada, Hiroyuki Ijima, Kohji Nakazawa, Kazumori Funatsu and Keizo Sugimachi : Hybrid-artificial liver support system, Surgery, Vol.131, No.Supplement 1, S334-S340, Jan. 2002. (Summary) We originally developed a multi-capillary polyurethane foam packed-bed module as a hybrid-artificial liver support system (HALSS) and have applied for the permission of the clinical application to our institutional ethical committee. We summarized here the history, recent obstacles in clinical applications, and future prospects of HALSS, including our own. (Keyword) Animals / Humans / Liver Diseases / Liver, Artificial (Link to Publication Site) ● Publication site (DOI): 10.1067/msy.2002.120118 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11821834 ● Search Scopus @ Elsevier (PMID): 11821834 ● Search Scopus @ Elsevier (DOI): 10.1067/msy.2002.120118 (DOI: 10.1067/msy.2002.120118, PubMed: 11821834)
144.	調憲, Mitsuo Shimada, 田中真二, 前田貴司 and 前原喜彦 : 高度門脈侵襲肝癌に対する治療, Fukuoka Acta Medica, Vol.93, 197-203, 2002.
145.	掛地吉弘, Mitsuo Shimada, 前原喜彦 and 杉町圭蔵 : da Vinciを用いた幽門側胃切除術, Surgical Therapy, Vol.86, 113-118, 2002.
146.	前原伸一郎, Mitsuo Shimada and 杉町圭蔵 : 外科手術とロボット, 成人病と生活習慣病, Vol.32, 676-677, 2002.
147.	Yuji Soejima, Mitsuo Shimada, 末広剛敏, 皆川亮介, 寺師貴啓, 二宮瑞樹, 塩谷聡子, 原田昇 and 杉町圭蔵 : 特集:わが国における肝移植の現況と展望ウイルス性肝硬変，肝細胞癌に対する肝移植, 消化器外科, Vol.25, 2305-2310, 2002.
148.	橋爪誠, Mitsuo Shimada, 吉野一郎, 北村薫, 富川盛雅, 赤星朋比古, 小西晃造 and 山口将平 : ダビンチ, Fukuoka Acta Medica, Vol.93, 47-48, 2002.
149.	Mitsuo Shimada, 調憲, 田中真二, 前田貴司, 山下洋市, 力丸竜也, 辻田英司, 前原伸一郎, 播本憲史, 池田泰治, 足立英輔, 宇都宮徹, 江崎卓弘, 古田斗志也, 薗田孝志, 松股孝, 竹中賢治 and 兼松隆之 : 肝臓, Fukuoka Acta Medica, Vol.93, 16-19, 2002.
150.	橋爪誠, 富川盛雅, Mitsuo Shimada and 杉町圭蔵 : da Vinciを用いたロボット手術, 臨床外科, Vol.57, 39-45, 2002.
151.	末廣剛敏, Mitsuo Shimada, 岸川圭嗣, Yuji Soejima, 吉住朋晴, 中尾理恵, 林田一洋, 中牟田誠, 本田浩, 入田和男, 児玉謙次, 稲葉 and 谷山卓郎 : 劇症肝不全に対する生体肝移植, Fukuoka Acta Medica, Vol.93, 141-152, 2002.
152.	Mitsuo Shimada, 末廣剛敏, Yuji Soejima, 皆川亮介, 廣重彰二, 二宮瑞樹, 塩谷聡子, 永田茂行, 寺師貴啓, 原田昇, 板阪英俊, 西崎隆, 矢永勝彦 and 杉町圭蔵 : 肝移植, Fukuoka Acta Medica, Vol.93, 23-27, 2002.
153.	Yuji Soejima, Mitsuo Shimada, 末廣剛敏, 皆川亮介, 廣重彰二, 二宮瑞樹, 塩谷聡子, 原田昇 and 杉町圭蔵 : ウイルス性肝硬変，肝癌症例への移植, 消化器外科, Vol.25, 305-310, 2002.
154.	Mitsuo Shimada and 前田貴司 : 腹腔内実質臓器に対する腹腔鏡下手術ーとくに腹腔鏡下肝切除の現状と将来展望, Journal of Clinical and Experimental Medicine, Vol.202, 449-452, 2002.
155.	調憲, Mitsuo Shimada, 田中真二, 前田貴司 and 前原喜彦 : 肝切除の最新の周術期管理, The Japanese journal of clinical and experimental medicine, Vol.79, 1191-1198, 2002.
156.	Mitsuo Shimada and 杉町圭蔵 : Robotic Surgeryの現状と将来展望, 福岡医学会雑誌, Vol.93, 57-63, 2002.
157.	Yuji Soejima, 寺師貴啓, 末廣剛敏, Mitsuo Shimada and 杉町圭蔵 : 肝移植手術のコツと術後管理急性拒絶反応, Surgery, Vol.63, No.11, 1336-1340, Nov. 2001. (Link to Publication Site) ● Publication site (DOI): 10.15106/J00393.2002076236 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.15106/J00393.2002076236 (DOI: 10.15106/J00393.2002076236)
158.	Keizo Sugimachi, Shinichiro Maehara, Shinji Tanaka, Mitsuo Shimada and Keishi Sugimachi : Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma, Journal of Hepato-Biliary-Pancreatic Surgery, Vol.8, No.5, 410-416, Oct. 2001. (Summary) Hepatic resection has been regarded as a curative treatment for primary hepatocellular carcinoma (HCC), but a high incidence of postoperative recurrence is general. Thus it is important to predict the patterns of recurrence and select the appropriate treatment for recurrence for a better long-term prognosis of patients with HCC. Clinicopathological studies on 80 patients with intrahepatic recurrence after curative hepatectomy suggested that nodular-type recurrence with up to three nodules is mainly due to metachronous multicentric hepatocarcinogenesis rather than intrahepatic metastases. We reviewed 300 patients with recurrent HCC, and repeat hepatectomy was done in 78 cases (26.0%). The 3- and 5-year survival rates after repeat hepatectomy were 82.8% and 47.5%, respectively, showing better prognosis than those for other treatments. Repeat hepatectomy is the preferred treatment offering a hope of long-term survival for patients with recurrent HCC as long as liver function is sufficient; thus early detection of recurrence should be ensured. (Keyword) Adult / Aged / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Neoplasms, Second Primary / Reoperation / Risk Factors / Survival Rate / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1007/s005340100002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11702249 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035238320 (DOI: 10.1007/s005340100002, PubMed: 11702249, Elsevier: Scopus)
159.	G Esumi, Morimasa Tomikawa, Makoto Hashizume, Kozo Konishi, Mitsuo Shimada and Keizo Sugimachi : Current status and future of surgical robotic systems, Fukuoka Acta Medica, Vol.92, No.9, 315-318, Sep. 2001.
160.	祇園智信, Mitsuo Shimada, 井嶋博之, 中澤浩二, 船津和守 and 杉町圭蔵 : ハイブリッド型人工肝臓の臨床応用の現状と問題点, Surgery, Vol.63, No.5, 533-538, May 2001.
161.	Mitsuo Shimada, Makoto Hashizume and Keizo Sugimachi : Reply to "Re: a new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism (14:2,127-130)", Surgical Endoscopy, Vol.15, No.1, 105, Jan. 2001.
162.	前原伸一郎, Mitsuo Shimada, 播本憲史, 辻田英司, 力丸竜也, 山下洋市, 田中真二, 調憲 and 杉町圭蔵 : 腹腔鏡下リアルタイム三次元エコーによる肝臓手術のナビゲーション, 第11回コンピュータ支援画像診断学会，第10回日本コンピュータ外科学会大会合同論文集, 91-92, 2001.
163.	山口将平, 富川盛雅, 小西晃造, 堤敬文, 起田桂志, 後藤謙和, 赤星朋比古, Mitsuo Shimada, 橋爪誠 and 杉町圭蔵 : 内視鏡下手術支援装置da VinciTMを使用した胃静脈瘤に対する胃上部血行遮断術, 第11回コンピュータ支援画像診断学会，第10回日本コンピュータ外科学会大会合同論文集, 81-82, 2001.
164.	福山誠一, 吉野一郎, Mitsuo Shimada, 富川盛雅, 鹿田康紀, 亀山敏文, 馬場博充, 富安真紀子, 末満隆一, 橋爪誠 and 杉町圭蔵 : 縦隔外科領域への内視鏡下手術支援装置(da VinciTM)の応用, 第11回コンピュータ支援画像診断学会，第10回日本コンピュータ外科学会大会合同論文集, 79-80, 2001.
165.	木村和恵, 大賀丈史, 佐伯浩司, 伊藤修平, 二木元典, 富川盛雅, Mitsuo Shimada, 橋爪誠 and 杉町圭蔵 : 内視鏡下手術支援装置da VinciTMを用いた食道癌に対する食道切除再建術, 第11回コンピュータ支援画像診断学会，第10回日本コンピュータ外科学会大会合同論文集, 75-76, 2001.
166.	広重彰二, Mitsuo Shimada, 原田昇, 塩谷聡子, 二宮瑞樹, 皆川亮介, Yuji Soejima, 末広剛敏, 本田浩, 橋爪誠 and 杉町圭蔵 : 生体肝移植における3D-CT肝静脈画像構成の有用性, 第11回コンピュータ支援画像診断学会，第10回日本コンピュータ外科学会大会合同論文集, 13-14, 2001.
167.	大浦剛, 中村亮一, 小林英津子, 正宗賢, 佐久間一郎, 土肥健純, 辻隆之, 矢作直樹, 橋本大定, Mitsuo Shimada and 橋爪誠 : 腹腔鏡下手術支援多自由度長鉗子の屈曲制御に関する研究, 第11回コンピュータ支援画像診断学会，第10回日本コンピュータ外科学会大会合同論文集, 13-14, 2001.
168.	濱津隆之, Mitsuo Shimada and 杉町圭蔵 : 肝癌の診断と治療—最新の研究動向—, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.59, 277-280, 2001.
169.	崎山亮一, 福田淳二, 中澤浩二, 井嶋博之, 山下洋市, Mitsuo Shimada, 辻田英司, 田中真二, 杉町圭蔵 and 船津和守 : 臨床用ハイブリッド型人工肝臓の開発, 日本バイオレオロジー学会誌(B&B), Vol.15, 14-25, 2001.
170.	力丸竜也, Mitsuo Shimada, 辻田英司, 前原伸一郎, 山下洋市, 足立英輔, 田中真二, 橋爪誠 and 杉町圭蔵 : 内視鏡下手術と癌治療—肝癌—, 癌治療と宿主, Vol.13, 163-169, 2001.
171.	中澤浩二, 井嶋博之, 山下洋市, Mitsuo Shimada, 杉町圭蔵 and 船津和守 : PUF/スフェロイド人工肝の倫理委員会申請と問題点, 組織培養工学, Vol.27, 16-19, 2001.
172.	Mitsuo Shimada, 富川盛雄, 橋爪誠 and 杉町圭蔵 : 外科手術におけるロボット技術への期待と課題, ロボット, Vol.141, 22-27, 2001.
173.	山下洋市, Mitsuo Shimada, 井嶋博之, 中澤浩二, 船津和守 and 杉町圭蔵 : ハイブリッド型人工肝臓の開発, 日本醫事新報, Vol.4012, 33-36, 2001.
174.	Tohru Utsunomiya, Mitsuo Shimada, Tatsuya Rikimaru, Keizo Sugimachi, Ken-Ichi Ohkura, Shihoko Kaku, Koji Yamada and Ken-Ichi Taguchi : Correspondence re: M. Kondo et al., Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma, Clinical Cancer Research, Vol.6, No.12, 4965-4966, Dec. 2000. (Keyword) Arachidonic Acid / Carcinoma, Hepatocellular / Chromatography, Gas / Cyclooxygenase 2 / Disease-Free Survival / Fatty Acids / Hepatitis, Viral, Human / Humans / Isoenzymes / Liver / Liver Cirrhosis / Liver Neoplasms / Membrane Proteins / Prostaglandin-Endoperoxide Synthases / alpha-Linolenic Acid (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11156258 ● Summary page in Scopus @ Elsevier: 2-s2.0-0034485835 (PubMed: 11156258, Elsevier: Scopus)
175.	Yo-ichi Yamashita, Mitsuo Shimada, Tomonobu Gion, Hirifumi Hasegawa, Hiroyuki Ijima, Kohji Nakazawa, Ryoichi Sakiyama, Junji Fukuda, Kazumori Funatsu and Keizo Sugimachi : Hybrid Artificial Liver Using a Polyurethane Foam Packed-Bed Culture System, New Aspects of High Technology in Medicine, 313-316, Oct. 2000.
176.	Makoto Hashizume, Mitsuo Shimada and Keizo Sugimachi : Laparoscopic hepatectomy: new approach for hepatocellular carcinoma, Journal of Hepato-Biliary-Pancreatic Surgery, Vol.7, No.3, 270-275, Jun. 2000. (Summary) This article presents the rationale for the laparoscopic approach to liver surgery, showing the technique of fully endoscopic and endoscopic-assisted formal and wedge hepatic resections. The early results are comparable to those of conventional surgery, with the benefits derived from minimal access surgery. Laparoscopic liver resections are technically feasible, with an acceptable morbidity and mortality rate, but extensive experience in conventional liver surgery, advanced laparoscopic surgery, and the availability of all requested technologies are indispensable prerequisites. (Keyword) liver resection / hepatocellular carcinoma / laparoscopic surgery (Link to Publication Site) ● Publication site (DOI): 10.1007/s005340070048 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10982626 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033657305 (DOI: 10.1007/s005340070048, PubMed: 10982626, Elsevier: Scopus)
177.	迫口太朗, 西崎隆, 末広剛敏, 野本健一, 橋元宏治, 大田隆二, 皆川亮介, 広重彰二, 寺師貴啓, 二宮瑞樹, 永田茂行, 塩谷聡子, Mitsuo Shimada and 杉町圭蔵 : 九州大医学における生体肝移植の現状, Fukuoka Acta Medica, Vol.91, 198-202, 2000.
178.	調憲, Mitsuo Shimada, 力丸竜也, 濱津隆之, 山下洋市, 田中真二, 橋爪誠 and 杉町圭蔵 : 超音波外科吸引装置(CUSA), 消化器外科, Vol.23, 761-765, 2000.
179.	Mitsuo Shimada and Keizo Sugimachi : New Generation in Hepato-Biliary Surgery, New Aspects of High Technology in Medicine Bruch HP. Kockerling F, Bouchard R, Schug-Pab (Eds.), 135-140, 2000.
180.	Mitsuo Shimada, 橋爪誠, 前原伸一郎, 足立英輔, 田中真二, 山下洋市, 力丸竜也, 辻田英司 and 杉町圭蔵 : 内視鏡下手術の再評価ー通常手術とした手術成績ー, Fukuoka Acta Medica, Vol.91, 198-202, 2000.
181.	Mitsuo Shimada, 橋爪誠 and 杉町圭蔵 : ロボティックサージャリーの進歩 ∼外科におけるロボテイクス∼, 組織培養工学, Vol.26, 253-257, 2000.
182.	山下洋市, 調憲, Mitsuo Shimada, 井島博之, 中澤浩二, 船津和守 and 杉町圭蔵 : 臨床応用可能な人工肝臓の開発, The Journal of Therapy, Vol.81, No.9, 2418-2419, Sep. 1999.
183.	橋爪誠, 田上和夫, 赤星朋比古, 森田真, Mitsuo Shimada, 大野真司 and 杉町圭蔵 : 外科における遠隔手術の役割, Surgery, Vol.61, No.3, 238-242, Mar. 1999.
184.	調憲, Mitsuo Shimada, 濱津隆之, 山下洋市, 力丸竜也, 田中真二 and 杉町圭蔵 : Stage IV-A 進行肝癌の病態と外科治療, 消化器外科, Vol.22, 1721-1726, 1999.
185.	杉町圭蔵 and Mitsuo Shimada : マルチメディア時代における外科学の展開, Surgery, Vol.61, No.3, 231-233, 1999.
186.	Mitsuo Shimada : 肝切除により惹起される生体反応と肝癌, 第99回日本外科学会記念誌, 1999.
187.	橋爪誠, Mitsuo Shimada and 杉町圭蔵 : 腹腔鏡下肝部分切除術, 消化器外科, Vol.22, 799-806, 1999.
188.	橋爪誠, Mitsuo Shimada, 田上和夫, 宇都宮徹, 調憲, 長谷川博文, 祇園智信, 田口健一, 山下洋市, 赤星朋比古 and 杉町圭蔵 : 腹腔鏡下手術:肝切除術, Surgical Therapy, Vol.80, No.4, 429-434, 1999.
189.	橋爪誠, Mitsuo Shimada, 竹中賢治, 矢永勝彦, 祇園智信, 長谷川博文 and 杉町圭蔵 : 腹腔鏡下肝部分，肝外側区域切除術, 臨床外科, Vol.53, No.5, 521-526, 1998.
190.	調憲, Mitsuo Shimada, 祇園智信, 長谷川博文, 梶山潔, 池田泰治 and 杉町圭蔵 : 肝癌領域における新しい腫瘍マーカー, MEDICO, Vol.28, No.10, 17-18, 1997.
191.	川原尚行, Mitsuo Shimada, 和田守正 and 杉町圭蔵 : 遺伝子の発現を解析:ディファレンシャル・ディスプレイ, KAN TAN SUI, Vol.35, No.6, 771-775, 1997.
192.	調憲, Mitsuo Shimada, 長谷川博文, 祇園智信, 梶山潔, 池田泰治 and 杉町圭蔵 : 高度進行肝癌に対する外科治療の適応と限界, Surgical Therapy, Vol.77, No.2, 147-151, 1997.
193.	竹中賢治, 祇園智信, 武冨紹信, Mitsuo Shimada and 杉町圭蔵 : 肝癌の遺伝子診断:定量的RT-PCR法による末梢血中肝細胞癌の検出, Surgery, Vol.59, No.8, 954-957, 1997.
194.	Mitsuo Shimada, Kenji Takenaka, Ken Shirabe and Keizo Sugimachi : Characteristics and treatment of recurrent hepatocellular carcinoma, Gastroenterol Int, Vol.10, No.1, 26-31, 1997.
195.	Mitsuo Shimada, 竹中賢治, 調憲, 藤原雄, 祇園智信 and 杉町圭蔵 : 肝切除により惹起される生体反応と組織障害について;とくにサイトカインを中心として, 臨床外科, Vol.52, No.5, 599-604, 1997.
196.	橋爪誠, 竹中賢治, Mitsuo Shimada, 調憲, 矢永勝彦, 御江慎一郎, 御江慎一郎 and 杉町圭蔵 : 最新の胸腹腔鏡下手術-適応と問題点-肝癌外科手術, 外科診療, Vol.38, 1051-1057, 1996.
197.	Mitsuo Shimada, 竹中賢治, 山田輝城, 調憲 and 杉町圭蔵 : 肝細胞癌に対する手術適応, The Japanese journal of clinical and experimental medicine, Vol.73, 866-870, 1996.
198.	Mitsuo Shimada : 一次線溶が大量出血に深く関与している-肝切除手術後の凝固・線溶系の亢進-, 日経メディカル 1月号, 22-23, 1995.
199.	Mitsuo Shimada, Yuji Soejima, 杉町圭蔵 and 岡留健一郎 : 免疫不全症例における外科手術の問題点とストラテジー, 日常診療と血液, Vol.4, 41-46, 1994.
200.	Mitsuo Shimada and 杉町圭蔵 : 外科領域感染症に対するempiric therapyの実際, PTM 6, Vol.5, No.3, 1993.
201.	Mitsuo Shimada, 松股孝 and 杉町圭蔵 : 消化器外科領域におけるソマトスタチンと(オクトレオチド), The Japanese journal of clinical and experimental medicine, Vol.70, 283-288, 1993.
202.	板阪英俊, Mitsuo Shimada and 杉町圭蔵 : 肝臓移植と感染症, 感染症, Vol.22, 201-207, 1992.
203.	Yoshiaki Nose, Kouhei Akazawa, Y Hayashi, Mitsuo Shimada, Yoshiaki Watanabe, Hidefumi Higashi, Sunao Moriguchi and K Fujisawa : Problems of protocol practice in Japan, Japan Hospitals, Vol.10, 19-24, Jul. 1991.
204.	Mitsuo Shimada, 矢永勝彦, 柿添三郎, 池田哲夫, 岸川圭嗣 and 杉町圭蔵 : 肝移植の現況, 癌・免疫・栄養, Vol.5, 24-27, 1991.
205.	矢永勝彦, 板阪英俊, 池田哲夫, Mitsuo Shimada, 東秀史 and 杉町圭蔵 : 部分肝移植, Surgical Therapy, Vol.63, 53-58, 1990.
206.	杉町圭蔵, 板阪英俊, 矢永勝彦, Mitsuo Shimada and 東秀史 : 肝臓移植再開をとりまく諸問題, 日本医師会雑誌, Vol.103, 556-560, 1990.
207.	杉町圭蔵, 矢永勝彦, Mitsuo Shimada, 東秀史, 柿添三郎, 池田哲夫, 岸川圭嗣 and 野瀬善明 : 肝移植の問題点と展望:とくに体外肝切除術の経験, Journal of Japan Surgical Society, Vol.91, 1406-1408, 1990.
208.	Mitsuo Shimada, 杉町圭蔵, 矢永勝彦, 板阪英俊 and 野瀬善明 : 臓器移植ネットワークシステム-その問題点-, The Journal of Clinical Science, Vol.26, 683-688, 1990.
209.	Mitsuo Shimada, 岸川圭嗣, 池田哲夫, 柿添三郎, 矢永勝彦 and 杉町圭蔵 : 肝移植のドナーシステム, Surgery, Vol.52, 1131-1138, 1990.
210.	吉田康洋, 竹中賢治, Mitsuo Shimada, 福沢謙吾 and 杉町圭蔵 : イヌ肝臓移植における迅速肝冷却摘出法の試み, 今日の移植, Vol.2, 399-403, 1989.

Proceeding of International Conference:

1.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : Preoperative weight loss program for HCC patients with high body mass index in hepatectomy., APASL 2024 Kyoto(アジア太平洋肝臓学会), Kyoto, Mar. 2024.
2.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki and Mitsuo Shimada : New onlocogical resectability of CRLM and multidisciplinary treatment strategy, APASL 2024 Kyoto(アジア太平洋肝臓学会), Kyoto, Mar. 2024.
3.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : Circulating exosomal microRNA signature to predict peritoneal metastasis in patients with advanced gastric cancer., ASCO-GI, San Francisco, Jan. 2024.
4.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Preoperative weight loss program for hepatocellular carcinoma patients with high body mass index in hepatectomy., ASCO-GI 2024, San Francisco, Jan. 2024.
5.	Mitsuo Shimada, Yuuma Wada, Takayuki Noma, Yu Saitou and Yuji Morine : The combination of CD8 and TIM3 expression to predict survival outcomes in hepatocellular carcinoma., ASCO-GI 2024, San Francisco, Jan. 2024.
6.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Immunoscore and Frailty in Colorectal Cancer, IASGO-CME Advanced Post-Graduate Course in Kobe 2023, Kobe, Nov. 2023.
7.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma, IHPBA2020, Melbourne, Nov. 2020.
8.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Shin-ichiro Yamada : Treatment Strategy for Synchronous Liver Metastases from Colorectal Cancer, IHPBA2020, Melbourne, Nov. 2020.
9.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : The impact of preoperative neutrophil-lymphocyte ratio as the predictive marker of postoperative weight loss and improving diabetes in sleeve gastrectomy., SAGES 2020, クリーブランド, Aug. 2020.
10.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefuluness of the OrVil method in LATG, SAGES 2020, クリーブランド, Aug. 2020.
11.	Kazunori Tokuda, Mitsuo Shimada, Tetsuya Ikemoto, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura and Yuji Morine : The investigation of optimal transplantation site of insulin producing cell differentiated from human adipose derived stem cell., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.194 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.194 (DOI: 10.1016/j.jcyt.2020.03.194)
12.	Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective 3D culture of hepatocyte like cells from human adipose derived mesenchymal stem cells., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.178 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.178 (DOI: 10.1016/j.jcyt.2020.03.178)
13.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura and Yuji Morine : The generation of effective insulin-producing cells from ADSC derived from type 1 diabetes mellitus patients., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.147 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.147 (DOI: 10.1016/j.jcyt.2020.03.147)
14.	Mitsuo Shimada, Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Yusuke Arakawa, Satoru Imura and Yuji Morine : Long-term results of transplanted insulin producing cells differented from human adipose stem cells in mice., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.186 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.186 (DOI: 10.1016/j.jcyt.2020.03.186)
15.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty in prognosis after hepatectomy in older patients with hepatocellular carcinoma., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-020-08742-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
16.	Yusuke Arakawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Evaluation of the ratio of plasma fibrinogen to platelet in resectable pancreatic cancer., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.756 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.756 (DOI: 10.1200/JCO.2020.38.4_suppl.756)
17.	Mitsuo Shimada, Hiroki Ishibashi, Yuji Morine, Kubota Masayuki and Fujii Hideki : Nationwide survey of pancreaticobiliary maljunction focusing on biliary cancer incidence in Japan., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.587 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.587 (DOI: 10.1200/JCO.2020.38.4_suppl.587)
18.	Takuya Tokunaga, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Mitsuo Shimada : The Usefulness of Intraoperative X-ray Fluoroscopy for Avoiding Urethral Injury in Transperineal total Mesorectal Excision, IASGO2019, Bangkok, Oct. 2019.
19.	Masato Yoshikawa, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, IASGO2019, Bangkok, Oct. 2019.
20.	Katsuki Miyazaki, Tetsuya Ikemoto, Mitsuo Shimada, Feng Rui, Yu Saitou, Shuichi Iwahashi, Yuji Morine and Satoru Imura : THE IMPACT OF RED LED IRRADIATION ON DIFFERENTIATION FOR INSULIN-PRODUCING CELLS FROM MESENCHYMAL STEM CELL, ESOT2019, Copenhagen, Sep. 2019.
21.	Yu Saitou, Shogo Oota, Tetsuya Ikemoto, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Shin-ichiro Yamada and Mitsuo Shimada : THE NEW ROLE OF ZINC ION IN INSULIN-PRODUCING CELLS DIFFERENTIATION FROM ADIPOSE DERIVED MESENCHYMAL STEM CELLS., ESOT2019, Copenhagen, Sep. 2019.
22.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Feng Rui, Shin-ichiro Yamada, Shuichi Iwahashi, Yuji Morine and Satoru Imura : THE POTNETIALLY CLINICAL APPLICATION OF XENO-ANTIGEN FREE DIFFERENTIATION PROTOCOL FOR INSULINPRODUCING CELLS USING HUMAN RECOMBINANT PEPTIDE PETALOID Μ-PIECE FROM ADIPOSE-TISSUE DERIVED MESENCHYMAL STEM CELL, ESOT2019, Copenhagen, Sep. 2019.
23.	Mitsuo Shimada, Tetsuya Ikemoto, Yuuma Wada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Shogo Oota : Characteristic difference of adiposederived mesenchymal stem cells from subcutaneous and visceral fat tissue for generating insulin-producing cell, ESOT2019, Copenhagen, Sep. 2019.
24.	Toshiaki Yoshimoto, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa, Yuji Morine and Mitsuo Shimada : The tumor suppressive effects of blue LED via Opn3 in colon cancer, 第10回日本・モンゴル国際消化器癌シンポジウム, ウランバートル, Aug. 2019.
25.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefulness of the orVil method in LATG, 第10回日本・モンゴル国際消化器癌シンポジウム, ウランバートル, Aug. 2019.
26.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : Standardization of surgical technique in laparoscopic distal pancreatectomy, SAGES 2019, Baltimore, Apr. 2019.
27.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefulness of our step-wise training system for robotic assisted gastrectomy, SAGES 2019, Baltimore, Apr. 2019.
28.	Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : Examination of the VR+AR training for understanding of regional anatomy in the laparoscopic training of the students., SAGES 2019, Baltimore, Apr. 2019.
29.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Preoperative Chemoradiotherapy for Lower-Advanced Rectal Cancer Patients Using SOX+Bev Regimen, SSO's 72nd Annual Cancer Symposium, San Diego, Mar. 2019.
30.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto, Masaaki Nishi and Chie Takasu : Prognostic Prediction of Mass-Forming Intrahepatic Cholangiocarcinoma from Diffusion Weighted Image of Magnetic Resonance Image, SSO's 72nd Annual Cancer Symposium, San Diego, Mar. 2019.
31.	Shoko Iwahashi, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Hideya Kashihara and Mitsuo Shimada : The strategy of zero-mortality due to postoperative VTE in patients with colorectal cancer., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.511 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.511 (DOI: 10.1200/JCO.2019.37.4_suppl.511)
32.	Masaaki Nishi, Mitsuo Shimada, Hideya Kashihara, Jun Higashijima, Kouzou Yoshikawa, Takuya Tokunaga, Tomohiko Miyatani, Chie Takasu and Shoko Iwahashi : The impact of sidedness of colorectal cancer in tumor immunity., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.584 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.584 (DOI: 10.1200/JCO.2019.37.4_suppl.584)
33.	Shogo Oota, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The feasibility of hepatectomy for the super-elderly patients with HCC., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.274 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.274 (DOI: 10.1200/JCO.2019.37.4_suppl.274)
34.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and 馮睿 : The effect of hepatic stellate cells on hepatocellular carcinoma progression., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.265 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.265 (DOI: 10.1200/JCO.2019.37.4_suppl.265)
35.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Validity of hepatic cone-unit resection for hepatocellular carcinoma., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.228 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.228 (DOI: 10.1200/JCO.2019.37.4_suppl.228)
36.	Mitsuo Shimada, Hiroki Teraoku, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu and Shin-ichiro Yamada : Role of central hypovascularity in the hepatic arterial phase of dynamic CT on mass-forming intrahepatic cholangiocarcinoma., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.205 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.205 (DOI: 10.1200/JCO.2019.37.4_suppl.205)
37.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : The approach for establishing safe, reliable and rapid pancreatoduodenectomy, 第9回日本・モンゴル国際消化器癌シンポジウム, Aug. 2018.
38.	Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : Transanal total mesorectal excision for rectal cancer, 第9回日本・モンゴル国際消化器癌シンポジウム, Aug. 2018.
39.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Outcome of left lobe living-donor liver transplantation in Tokushima, 27th International Congress of The Transplantation Society(TTS), Jun. 2018.
40.	Yu Saitou, Rui Feng, Chie Takasu, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Yuji Morine, Satoru Imura and Mitsuo Shimada : Establishment of effective differentiation protocols for insulin-producing cells using a new 3D culture system from adipose-tissue derived mesenchymal stem cell, 27th International Congress of The Transplantation Society(TTS), Jun. 2018.
41.	Mitsuo Shimada, Rui Feng, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Chie Takasu : Establishment of insulin producing cells differentiated from human adipose-derived mesenchymal stem cells using a 3D-culture system with xenoantigen free reagents, 27th International Congress of The Transplantation Society(TTS), Jun. 2018.
42.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto and Mitsuo Shimada : Significance of hypoxia inducible factor-1αexpression in colorectal liver metastasis., APASL STC2018, Yokohama, May 2018.
43.	Toshiaki Yoshimoto, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Sorafenib therapy combined with surgical resection or TACE, APASL STC2018, Yokohama, May 2018.
44.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : Usefulness of indocyanine green (ICG) fluorescence system and thermography for evaluating bloodflow of intestine in laparoscopic anterior resection., SAGES, Seattle, Apr. 2018.
45.	Takashi Iwata, Masashi Akaike, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Mitsuo Shimada : Usefulness of the rubric evaluation as the qualitative evaluation of the laparoscopic training., SAGES, Seattle, Apr. 2018.
46.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Reduced-port laparoscopic cholecystectomy for young surgeons, SAGES, Seattle, Apr. 2018.
47.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Laparoscopic hemi-hepatectomy for liver tumor, SAGES, Seattle, Apr. 2018.
48.	Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Jun Higashijima : Usefulness of one-stop shop simulation for liver surgery using EOB-MRI., SAGES, Seattle, Apr. 2018.
49.	Shogo Oota, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : Transabdominal preperitoneal (TAPP) inguinal hernia repair with liquid-injection and gauze dissection., SAGES, Apr. 2018.
50.	Takuya Tokunaga, Mitsuo Shimada, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Chie Takasu, Hideya Kashihara and Daichi Ishikawa : The Impact of Indoleamine Two to Three-Dioxygenase (IDO) Expression in Colorectal Cancer., SSO's 71st Annual Cancer Symposium, Chicago, Mar. 2018.
51.	Masaaki Nishi, Mitsuo Shimada, Kono Toru, Yuji Morine, Kouzou Yoshikawa, Katsuno Hidetoshi, Maeda Koutarou, Koeda Keisuke, Morita Satoshi, Masahiko Watanabe, Kusano Mitsuo, Sakamoto Junichi, Saji Shigetoyo, Sokuoka HIroki, Ohtake Yuaya, Sato Yasuto, Kanematsu Takashi and Kitajima Masaki : Daikenchuto for Postoperative Bowel Dysfunction After Open Abdominal Surgery: A Pooled Analysis of Three Randomized Controlled Trials., SSO's 71st Annual Cancer Symposium, Chicago, Mar. 2018.
52.	Noboru Niki, Yoshiki Kawata, Hidenobu Suzuki, Mitsuo Shimada, Masafumi Harada, Issei Imoto, Masahiro Abe, Keiji Umetani, Masahiko Kusumoto, Keiju Aokage, Genichirou Ishii, Gen Iinuma, Yuuji Matsumoto, Yasutaka Nakano and Hiroaki Sakai : Cancer diagnosis and prognosis assistance based on multidisciplinary computational anatomy - progress overview FY2017 -, The 4nd International Symposium on Multidisciplinary Computational Anatomy, 107-114, Mar. 2018.
53.	A.S. Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and Gen Iinuma : Automatic blood vessel based-liver segmentation using the portal phase abdominal CT, Proceedings of SPIE, Vol.10575, 1057527-1-7, Houston, Feb. 2018. (Link to Publication Site) ● Publication site (DOI): 10.1117/12.2293581 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85046270262 (DOI: 10.1117/12.2293581, Elsevier: Scopus)
54.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : The impact of indoleamine 2,3-dioxygenase(IDO)expression on stage III gastric cancer., ASCO-GI, San Francisco, Jan. 2018.
55.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota, Jun Higashijima and Mitsuo Shimada : Significance of hypoxia inducible factor-1 expression in liver metastasis of colorectal cancer., ASCO-GI, San Francisco, Jan. 2018.
56.	Yuji Morine, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Reduction of T-Box 15gene expression in tumor tissue as a prognostic biomarker for patients with heparocellular carcinoma., ASCO-GI, San Francisco, Jan. 2018.
57.	Hideya Kashihara, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu and Mitsuo Shimada : The Effect of Roux-en-Y Reconstruction on DM and Nonalcoholic Fatty Liver Disease(NAFLD)/Nonalcoholic Steatohepatitis, AMERICAN COLLEGE OF SURGEONS 2017(ACS), San Diego, Oct. 2017.
58.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : Preoperative Prognostic Nutritional Index Predicts Both Short-and Long-Term Outcomes after Liver Resection For Hepatocellular Carcinoma, AMERICAN COLLEGE OF SURGEONS 2017(ACS), San Diego, Oct. 2017.
59.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Rui Feng, Yu Saitou, Satoru Imura and Yuji Morine : The establishmenmt of effective differentiation protocols for insulin-producing cells using 3D culture system from rat adipose-tissue derived mesenchymal stem cell, 18th Congress of the European Society for Organ Transplantation(ESOT), Barcelona, Sep. 2017.
60.	Daichi Ishikawa, Jun Higashijima, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Kouzou Yoshikawa and Mitsuo Shimada : Preoperative chemoradiotherapy for advanced lower rectal cancer using SOX+Bev regimen and role of microRNA-223 as a predictive indicator for the responder., 第9回日本・モンゴル国際消化器癌シンポジウム, ウランバートル, Aug. 2017.
61.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : The usefulness of the OrVil method and liver mobilization for optimal surgical field in LTG., 第9回日本・モンゴル国際消化器癌シンポジウム, ウランバートル, Aug. 2017.
62.	Masaaki Nishi, Mitsuo Shimada, Tetsuya Ikemoto, Jun Higashijima, Kouzou Yoshikawa, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : Prognostic impact of neutrophil-to-lymphocyte ratio in patients with rectal cancer after preoperative chemoradiotherapy, 47th World Congress of Surgery(WCS), バーゼル, Aug. 2017.
63.	Rui Feng, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Kouzou Yoshikawa, Toshiaki Yoshimoto and Jun Higashijima : The impact of red LED irradiation on hepatocytes preservation, 18th Congress of the European Society for Organ Transplantation(ESOT)2017, Barcelona, Aug. 2017.
64.	Mitsuo Shimada, Rui Feng, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto and Jun Higashijima : A new 2-step protocol for human adipose derived mesenchymal stem cell differentiation to insulin-producing cells using xeno-antigen free reagents, 18th Congress of the European Society for Organ Transplantation(ESOT), Barcelona, Aug. 2017.
65.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Shuichi Iwahashi, Masaaki Nishi, Jun Higashijima, Satoru Imura and Yuji Morine : Clinical impact of Tr1 and FOXP3+regulatory Tcell as precise immunological biomarkers for reflecting cancer status, 47th World Congress of Surgery(WCS), バーゼル, Aug. 2017.
66.	Naoki Muguruma, Koichi Okamoto, Shota Fujimoto, Tadahiko Nakagawa, Katsutaka Sannomiya, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Mitsuo Shimada, Yoko Horino, Shinya Matsumoto, Kenjiro Hanaoka and Tetsuji Takayama : Optical Molecular Imaging of Aberrant Crypt Foci in the Human Colon by Glutathione S-Transferase-Activated Fluorogenic Probe., Digestive Disease Week2017, Chicago, May 2017.
67.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Development of the simulator for laparoscopic eye hand coordination training for teaching oneself training, American Gastrointestinal Endoscopic Surgeons, Apr. 2017.
68.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Masato Yoshikawa : Reduced-port laparoscopic cholecystectomy with 3mm minute-diameter forceps., SAGES, Houston, Mar. 2017.
69.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Comparative analysis of the outcome between open and laparoscopic partial liver resection for hepatocellular carcinoma., SAGES, Houston, Mar. 2017.
70.	Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Jun Higashijima : New technology of `One-stop shop' liver surgery simulation equipped with assessment of total and regional liver functional reserve., SAGES, Houston, Mar. 2017.
71.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Toshiaki Yoshimoto and Atsushi Takata : Feasibility of laparoscopic gastrectomy for elderly patients., SAGES, Houston, Mar. 2017.
72.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Development of the simulator for laparoscopic eye hand coordination training for teaching oneself training., SAGES, Houston, Mar. 2017.
73.	Noboru Niki, Yoshiki Kawata, Hidenobu Suzuki, Mitsuo Shimada, Masafumi Harada, Issei Imoto, Masahiro Abe, Keiji Umetani, Masahiko Kusumoto, Keiju Aokage, Genichirou Ishii, Gen Iinuma, Yuuji Matsumoto, Yasutaka Nakano and Hiroaki Sakai : Cancer diagnosis and prognosis assistance based on multidisciplinary computational anatomy - Progress Overview FY2016 -, The 3nd International Symposium on Multidisciplinary Computational Anatomy, 87-94, Mar. 2017.
74.	A.S. Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and Gen Iinuma : A hybrid 3D region growing and 4D curvature analysis-based automatic abdominal blood vessel segmentation through contrast-enhanced CT, Proceedings of SPIE, Vol.10134, 101344C-1-7, Orlando, Feb. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1117/12.2254327 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85020243437 (DOI: 10.1117/12.2254327, Elsevier: Scopus)
75.	Yu Saitou, Yuji Morine, Chie Takasu, Shuichi Iwahashi, Jun Higashijima, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Role of HSF1 expression for tumor microenvironment in intrahepatic cholangiocarcinoma., ASCO-GI, San Francisco, Jan. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.249 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.249 (DOI: 10.1200/JCO.2017.35.4_suppl.249)
76.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : Treatment strategy for colorectal liver metastases:Clinical impact of FOLFOXIRI regimen for unresectable cases., ASCO-GI, San Francisco, Jan. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.780 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.780 (DOI: 10.1200/JCO.2017.35.4_suppl.780)
77.	Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku and Jun Higashijima : Characteristics of intrahepatic cholangiocarcinoma according to tumor location., ASCO-GI, San Francisco, Jan. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.406 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.406 (DOI: 10.1200/JCO.2017.35.4_suppl.406)
78.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi and Chie Takasu : Thrombospondin-1 expressions in non-cancer tissue correlated with gastric carcinogenesis., ASCO-GI, San Francisco, Jan. 2017.
79.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Preoperative chemoradiotherapy for advanced lower rectal cancer using SOX+Bev regimen., ASCO-GI, San Francisco, Jan. 2017.
80.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Current status and effect of laparoscopic training for young surgeon, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
81.	Daichi Ishikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Yuji Morine, Satoru Imura and Mitsuo Shimada : Signigficance of CD4+CD49b+regulatory T cells and Foxp3+regulatory T cells in the peripheral blood of cancer patients, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
82.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Atsushi Takata and Mitsuo Shimada : Ki-67 and Survivin Expressions as Predictive Factors in the Rectal Cancer Treated with Preoperative CRT, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
83.	Atsushi Takata, Jun Higashijima, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : The influence of circular muscle incision on intestinal peristalsis and anastomosis, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
84.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : The usefulness of the OrVil method and liver mobilization for optimal surgical field in laparoscopic total gastrectomy(LTG), 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
85.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : Recurrent feature after radiofrequency ablation therapy for hepatocellular carcinoma, 4th International Conference of FACO, 廈門, Sep. 2016.
86.	Hisami Okumura, Shoko Wada, Takafumi Katayama, Satoru Imura, Yuji Morine, Mitsuo Shimada and Eiji Takeda : Effect of hepatectomy on energy metabolism in patients with liver cancer and cholangiocalcinoma by the difference of resection volume, 38th European Congress for Nutrition and Metabolism, Copenhagen, Sep. 2016.
87.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
88.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Atsushi Takata and Mitsuo Shimada : The usefulness of Ki-67 and survivin expressions as predictive factors for the rectal cancer with preoperative CRT, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
89.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : The Usefulness of the OrVil Method and Liver Mobilization for Optimal Surgical Field in LATG, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
90.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
91.	Satoru Imura, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Our strategy for antibody mediated rejection in living donor liver transplantation, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
92.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Mitsuo Shimada, T Oshio and M Ishikawa : Kampo medicine ``Daikenchuto (TU-100)'' prevents bacterial translocation and hepatic fibrosis in biliary atresia rat model., PAPS2016 (49th Annual Meeting of the pacific Association of Pediatric Surgeons), Hawaii, Apr. 2016.
93.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori, Mitsuo Shimada, T Oshio and M Ishikawa : Prevention of Bacterial Dermatitis during Adhesive Strapping of Infantile Umbilical Herni., PAPS2016 (49th Annual Meeting of the pacific Association of Pediatric Surgeons), Hawaii, Apr. 2016.
94.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : Laparoscopic percutaneous extraperitoneal closure (LPEC) for inguinal hernia repair in premature infants weighing 3kg or less: is it safe?, PAPS2016 (49th Annual Meeting of the pacific Association of Pediatric Surgeons), Hawaii, Apr. 2016.
95.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Kouzou Yoshikawa and Toshiaki Yoshimoto : The correlation between serum CA19-9 level and the epigenetic alteration in intrahepatic cholangiocarcinoma., IASGO Advanced Post-Graduate Course in Sendai 2016, Sendai, Apr. 2016.
96.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The effect od HDACi in ADSC differentiation in to insulin producing cells., Transplantation Science Symposium (TSS) Asian Regional Meeting 2016, Tokyo, Apr. 2016.
97.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi and Chie Takasu : Risk factoes of the resurrence after laparoscopic gastrectomy for gastric cancer., Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
98.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Hideya Kashihara : Novel prognostic factor in the colorectal cancer patients who underwent laparoscopic surgery., Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
99.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Usefulness of blood flow Evaluation by indocyanine green fluorescent system in laparoscopic colectomy., Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
100.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Mitsuo Shimada : Trial of the filipped classroom for open suturing and simulated laparoscopic cholecystectomy for medical., Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
101.	Satoru Imura, Takuya Tokunaga, Masayuki Sumitomo, Shin-ichiro Yamada, Chie Takasu, Yu Saitou, Jun Higashijima, Kouzou Yoshikawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Usefulness of telementoring system to develop laparoscopic surgery in rural hospital, Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
102.	Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yamada Shinichiro, Teraoku Hiroki, Yoshikawa Masato and Chie Takasu : Effective stepwise training and procedure-standardization for young surgeons to perform laparoscopic left hepatectomy., Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
103.	Yoshikawa Masato, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Yamada Shinichiro, Yoshimoto Toshiaki and Takata Atsushi : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT., The Asian Pacific Association for the Study of the Liver, Tokyo, Feb. 2016.
104.	Shinichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Teraoku Hiroki, Yoshikawa Masato, Yoshimoto Toshiaki and Takata Atsushi : High NEK2 expression in hepatocellular carcinoma patients after hepatectomy, The Asian Pacific Association for the Study of the Liver, Tokyo, Feb. 2016.
105.	Noboru Niki, Yoshiki Kawata, Hidenobu Suzuki, Mitsuo Shimada, Masafumi Harada, Issei Imoto, Masahiro Abe, Keiji Umetani, Hironobu Ohmatsu, Genichirou Ishii, Gen Iinuma, Keiji Aokage, Yuuji Matsumoto, Yasutaka Nakano, Michiaki Mishima and Hiroaki Sakai : Cancer diagnosis and prognosis assistance based on multidisciplinary computational anatomy - Progress Overview FY2015 -, The 2nd International Symposium on Multidisciplinary Computational Anatomy, 83-89, Feb. 2016.
106.	Ahmed S.Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya and Mitsuo Shimada : Automatic bone of torso segmentation using contrast enhanced CT, 1st Asia Oceania Workshop of Pulmonary Functional Imaging combined with 8th Japanese Society of Pulmonary Functional Imaging, P7-2-4, Jan. 2016.
107.	Shin-ichiro Yamada and Mitsuo Shimada : Recurrent feature after radiofrequency ablation herapy for hepatocelluar carcinoma : Risk of increasing malignant behavior., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.
108.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for intrahepatic cholangiocarcinoma: From optimal surgical management to adjuvant therapy., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.
109.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Hideya Kashihara and Chie Takasu : Sarcopenia with modified glasgow prognostic score is a predictor of long term survival in patients with gastric cancer., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.
110.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Impact of blue 465nm LED on suppression of cancer growth., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.
111.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Efeect of preoperative chemoradiotherapy on the long-term outcome for lower rectal cancer, Mongolia Japanese joint Symposium UPPER GI CANCER MANAGEMWNT, Mongol, Sep. 2015.
112.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Significance of blood flow evaluation by indocyanine green fluorescent system in laparoscopic anterior resection, Mongolia Japanese joint Symposium UPPER GI CANCER MANAGEMWNT, Mongol, Sep. 2015.
113.	Takata Atsushi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi and Hideya Kashihara : The effets of bariatric surgery on obesity and obesity-related disease from benchi to bedsaide, Mongolia Japanese joint Symposium UPPER GI CANCER MANAGEMWNT, Mongol, Sep. 2015.
114.	Mitsuo Shimada : A new strategy toward early ``conversion'' and better long-term outcome in patients with initially unresectable colorectal liver metastases, 25th World Congress of the International Asociation of Surgeons,Gastroenterologists,and Oncologists(IASGO), China, Sep. 2015.
115.	Takata Atsushi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Utility of virtual three-dimensional image analysis for laparoscopic gastrectomy conducted by trainee surgeons., 46th World Congress of Surgery (WCS)2015, Bangkok, Aug. 2015.
116.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : The usefulness of KI-67 index as predictive factor for the rectal cancer with preoperative chemo-radiotherapy., 46th World Congress of Surgery (WCS)2015, Bangkok, Aug. 2015.
117.	Teraoku Hiroki, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou and Chie Takasu : The expression of KI-67 is a useful prognostic factor in patients with colorectal liver metastasis., 46th World Congress of Surgery (WCS)2015, Aug. 2015.
118.	Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Jun Higashijima and Chie Takasu : Folfoxiri regimen brings early ``conversion'' and better long-term outcome in patients with initially unresectable colorectal liver metastases, 46th World Congress of Surgery (WCS)2015, Aug. 2015.
119.	Teraoku Hiroki, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa and Yoshikawa Masato : The expression of Ki-67 is a useful prognostic factor in patients with colorectal liver metastasis, IASGO 2015 post graduate course, Tokyo, Jun. 2015.
120.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and 江藤祥平 : Significance of blood flow evaluation by indocyanine green fluorescent system in laparoscopic anterior resection, IASGO 2015 post graduate course, Tokyo, Jun. 2015.
121.	S Wada, Hisami Okumura, B Zhou, Yutaka Taketani, Takafumi Katayama, Yusuke Arakawa, Satoru Imura, Mitsuo Shimada and Eiji Takeda : Effect of hepatectomy on energy metabolism in patients with liver cancer and cholangiocarcinoma by the difference of resection volume, 12th Asian Congress of Nutrition (ACN), May 2015.
122.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, 江藤祥平 and Mitsuo Shimada : Investigation of training for students who is weak in maneuver of laparoscopic surgery Laborer of the off-the-job training, Surgical Education Week, Seattle, Apr. 2015.
123.	Noboru Niki, Yoshiki Kawata, Hidenobu Suzuki, Mitsuo Shimada, Masafumi Harada, Issei Imoto, Masahiro Abe, Keiji Umetani, Hironobu Ohmatsu, Genichirou Ishii, Gen Iinuma, Keiju Aokage, Yuji Matsumoto, Yasutaka Nakano, Michiaki Mishima and Hiroaki Sakai : Cancer diagnosis and prognosis assistance based on multidisciplinary computational anatomy -Plan of five years and progress overview FY2014-, he First International Symposium on the Project ``Multidisciplinary Computational Anatomy'', 40-44, Fukuoka, Feb. 2015.
124.	良元俊昭, GY Wubetu, Shin-ichiro Yamada, 石川大地, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Impact of STAT4 expression on cellular immunity and prognosis in hepatocellular carcinoma., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
125.	Shuichi Iwahashi, Yismaw Gizachew, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 吉川雅登, 寺奥大貴 and Mitsuo Shimada : The antitumor effect of epigallocatechin-3-gallate on gastroenterological cancer., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
126.	Satoru Imura, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Hiroshi Shibata and Hidenori Miyake : Long-term survivors after sorafenib therapy in unresectable hepatocellular carcinoma., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
127.	Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登, Jun Higashijima and Chie Takasu : Impact of FOLFOXIRI regimen on early ``Conversion'' and long-term outcome in patients with initially unresectable colorectal liver metastases, ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
128.	Eto Shohei, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Mitsuo Shimada : Relationship of programmed death 1(PD-1)expression to the recurrence in gastric cancer., ASCO-GI 2015 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2015.
129.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Eto Shohei : Significance of platinum concentration in blood and red blood cell in patients with oxaliplatin-based chemotherapy., ASCO-GI 2015 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2015.
130.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Chie Takasu, 寺奥大貴 and 江藤祥平 : Effect of light irradiation by light emitting diode on colon cancer cells and cancer stem cells., ASCO-GI 2015 Gastrointestinal Cancers Symposium, 271, San Francisco, Jan. 2015. (Keyword) 国際学会 (Link to Publication Site) ● Publication site (DOI): 10.1200/jco.2015.33.3_suppl.271 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/jco.2015.33.3_suppl.271 (DOI: 10.1200/jco.2015.33.3_suppl.271)
131.	Hisami Okumura, K Sugihara, M Yamamoto, Yutaka Taketani, Tetsuya Ikemoto, Yusuke Arakawa, Satoru Imura, Yuji Morine, Satoru Imura, Mitsuo Shimada and Eiji Takeda : Recovery of non-protein respiratory quotient and health related quality of life after living-donor liver transplantation, 36th European Congress for Nutrition and Metabolism, Sep. 2014.
132.	Hisami Okumura, Akiyoshi Hirayama, Syoko Wada, Daisuke Kajiura, Masashi Masuda, Eiji Takeda, Yutaka Taketani, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada, Masaru Tomita and Tomoyoshi Soga : Perioperative serum and urine metabolome analysis in patients with hepatocellular carcinoma, 37th European Congress for Nutrition and Metabolism, Lisbon, Portugal, 2015, September 5-8, Sep. 2014.
133.	Kohei Sugihara, Hisami Okumura, Arisa Teramoto, Momo Yamamoto, Yutaka Taketani, Yu Saitou, Yusuke Arakawa, Mitsuo Shimada and Eiji Takeda : The non-protein respiratory quotient as biomarker for the recover from hepatectomy in patients with hepatocellular carcinoma., 36th European Congress for Nutrition and Metabolism, Geneva, Switzerland 2014, September 6-9, Sep. 2014.
134.	Hisami Okumura, Kohei Sugihara, Momo Yamamoto, Yutaka Taketani, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Mitsuo Shimada and Eiji Takeda : Recovery of non-protein respiratory quotient and health related quality of life after living-donor liver transplantation., 36th European Congress for Nutrition and Metabolism, Geneva, Switzerland 2014, September 6-9, Sep. 2014.
135.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : How many lymphatic vessels need to be preserved in dye assisted lymphatic sparing laparoscopic palomo varicocelectomy in children?, IPEG's 23rd Annual Congress for Endosurgery in Children, スコットランド, Jul. 2014. (Keyword) 国際学会
136.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Shuichi Iwahashi : Useless of 3D-virtual hepatectomy and intraoperative navigation system in liver resection, 第28回国際コンピュータ支援放射線医学・外科学会議(CARS), Fukuoka, Jun. 2014. (Keyword) 国際学会
137.	Ahmed Shawky Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Satake, Noriyuki Moriyama, Toru Utsunomiya and Mitsuo Shimada : Automatic extraction of abdominal blood vessel through the portal phase of a CT dataset, CARS International Journal of Computer Assisted Radiology and Surgery, S38-S39, Jun. 2014.
138.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : Usefulness of ultrasonography-guided hydrostatic reduction for intussusception in children, Pacific Association of Pediatric Surgeons 47th Annual Meeting(PAPS 2014), カナダ, May 2014. (Keyword) 国際学会
139.	Noboru Niki, Yoshiki Kawata, Hidenobu Suzuki, Masafumi Harada, Hideki Otsuka, Junji Ueno, Mitsuo Shimada, Tetsuji Takayama, Masahiro Abe, Haruimi Itoh, Kenji Eguchi, Masahiko Kusumoto, Takaaki Tsuchida, Hironobu Ohmatsu, Masashi Takahashi, Yasutaka Nakano, Hiroaki Sakai and Yuichi Takiguchi : Computer-aided diagnosis based on computational anatomical models:Progress overview FY2009-2013, The 5th International Symposium on the Project ``Computational Anatomy'', 39-43, Mar. 2014.
140.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Yu Saitou : Effects of valporic acid as a histone deacetylase inhibitor in combination with S-1 on advanced pancreatobiliary tract cancers:Clinical study phases and ., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
141.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : Clinical impact of reflection to expression of EMT marker in intraductal papillary mucinous neoplasm., Gastrointestial Cancers Symposium(ASCO-GI), Jan. 2014. (Keyword) 国際学会
142.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, D Ishikawa, Chie Mikami, Z Chengzhan, A Tajima and I Imoto : Identification of aberrant DNA methylation profiles in non-tumor liver tissues of patients with non-B, non-C hepatocellular carcinoma., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014. (Keyword) 国際学会
143.	Motoya Chikakiyo, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, 柏原秀也, Chie Takasu, 松本規子, 江藤祥平, Mitsuo Shimada, Masanori Hotsuchi, Hiroshi Okitsu, 惣中康秀 and 吉田禎宏 : A multicenter exploratory study of irinotecan-based chemotherapy on UGT1A1 polymorphisms for patients with colorectal cancer., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
144.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Yu Saitou : Effects of valproic acid as a histone deacetylase inhibitor in combination with S-1 on advanced pancreatobiliary tract cancers: Clinical study phases I and II., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
145.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : Clinical impact of reflection to expression of EMT marker in intraductal papillary mucinous neoplasm., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
146.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Chie Takasu, Chengzhan Zhu, Tajima A and Imoto I : Identification of aberrant DNA methylation profiles in non-tumor liver tissues of patients with non-B, non-C hepatocellular carcinoma., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
147.	Mitsuo Shimada, T Nishina, Jun Higashijima, T Moriwaki, T Masuishi, Y Sakai, M Ozeki, Y Negoro, S Indou, T Denda, M Sato, M Morimoto, G Nakajima, M Mizuta, I Takahashi, Y Hiroshima, H Ishida, T Maeba and I Hyodo : Bevacizumab (Bmab) in combination with uracil-tegafur (UFT) and oral leucovorin (LV) in elderly patients (≥ 75 years old) with metastatic colorectal cancer (mCRC): A multicenter phase II trial (J-BLUE study)., Gastrointestinal Cancers Symposium(ASCO-GI), San Francisco, Jan. 2014.
148.	江藤祥平, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Mitsuo Shimada : Relationship of programmed death 1(PD-1)expression to the recurrence in gastric cancer., ASCO-GI 2015 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2014. (Keyword) 国際学会
149.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and 江藤祥平 : Significance of platinum concentration in blood and red blood cell in patients with oxaliplatin-based chemotherapy., ASCO-GI 2015 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2014. (Keyword) 国際学会
150.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : Anti-Thrombotic Prophylaxis to Prevent Postoperative Venous Thromboembolism for High-Risk Patients after Abdomino-Pelvic Major Surgery., American College of Surgeons 2013(ACS), Washington, D.C., Oct. 2013.
151.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Chie Takasu : Potential Predictive Factors for Microscopic Portal Invasion in Hepatocellular Carcinoma wwithout Macroscopic Vascular Invasion., American College of Surgeons 2013(ACS), Washington, D.C., Oct. 2013.
152.	Zhu Chengzhan, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地, A Tajima, I Imoto and Mitsuo Shimada : Hypomethylation of LINE-1 is associated with a poor prognosis after hepatectomy for patients with hepatocellular carcinoma., 1st International Conference of Federation of Asian Clinical Oncology(FACO), 中国, Sep. 2013.
153.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地, Zhu Chengzhan, A Tajima and I. Imoto : Genome-wide analysis of aberrant DNA methylation profiling in non-tumor liver tissues of patients with non-B non-C hepatocellular carcinoma, 1st International Conference of Federation of Asian Clinical Oncology(FACO), 中国, Sep. 2013.
154.	Bat-Erdene Batsaikhan, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa and Jun Higashijima : The Role of Sonic Hedgehog Signaling in Regulation of Cancer Stem Cells., 第5回日本・モンゴル消化器がんシンポジウム, モンゴル, Sep. 2013.
155.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 石川大地 and Bat-Erdene Batsaikhan : Prediction of Recurrence of Hepatocellular Carcinoma after Curative Hepatectomy Using Preoperative lens Culinaris Agglutinin-Reactive Fraction of Alpha-Fetoprotein(AFP-L3)., 第5回日本・モンゴル消化器がんシンポジウム, モンゴル, Sep. 2013.
156.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地 and Bat-Erdene Batsaikhan : Recent Advancements in Liver Surgery : Assessment of Functional Reserve, Simulation, and Navigation., 第5回日本・モンゴル消化器がんシンポジウム, モンゴル, Sep. 2013.
157.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : Feasibility of Laparoscopic Surgery for Lower Rectal Cancer after CRT., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ブカレスト, Sep. 2013.
158.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也 and 松本規子 : Predictive Factors in Chemoradiotherapy for Rectal Cancer., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ブカレスト, Sep. 2013.
159.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 松本規子 : The Utility of PET-CT and MRI in Predicting Malignant Poteential of GIST., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ブカレスト, Sep. 2013.
160.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : Strategy for Major Complications after LAG for Gastric Cancer., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), Bucharest, Sep. 2013.
161.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi and 山田眞一郎 : Ompact of Expression of Twist1 and Bmi1 in Intraductal Papillary Mucinous Neoplasm., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ルーマニア, Sep. 2013.
162.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Chie Takasu : Significance of Stem Cell Markers Expression in Cholangiolocellular Carcinoma., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ルーマニア, Sep. 2013.
163.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : Impact of Bioelectrical Impedance Analysis in Pancreato-Duodenectomy., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ルーマニア, Sep. 2013.
164.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : Impact of Bioelectrical Impedance Analysis in Pancreato-Duodenectomy., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ルーマニア, Sep. 2013.
165.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎 and 石川大地 : Strategy for Intrahepatic Cholangiocarcinoma: From Cancer Stem Cell to Multidisciplinary., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ルーマニア, Sep. 2013.
166.	Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu and 山田眞一郎 : Recent Advancements in Liver Surgery: Assessment of Funcional Reserve, Simulation and Navigation., International Association of Surgeons, Gastroenterologists and Oncologists 2013(IASGO), ルーマニア, Sep. 2013.
167.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, 山田眞一郎 and Chie Takasu : The homing effect of adipose-derived stem cells to the injured liver: The shift of stromal cellderived factor 1 expressions., The 13th Congress of the Asian Society Of Transplantation 2013(CAST), Kyoto, Sep. 2013.
168.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya, Horohiko Sato and Hidenori Miyake : The gene profile in the spleen under rat small-for-size graft model using cDNA microarray and pathway analaysis., The 13th Congress of the Asian Society Of Transplantation 2013(CAST), Kyoto, Sep. 2013.
169.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : Successfully treated case of liver transplant recipient with donor-specific antibody against human leukocyte antigen., The 13th Congress of the Asian Society Of Transplantation 2013(CAST), Kyoto, Sep. 2013.
170.	Hiroki Mori, Hiroki Ishibashi, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, 矢田圭吾 and Mitsuo Shimada : Risk of carcinogenesis in the biliary epithelium in patients with pancreaticobiliary maljunction through both epigenetic and genetic regulation, International Surgical Week 2013(ISW), ヘルシンキ, Aug. 2013.
171.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa and Mami Kanamoto : ABO incompatible living donor liver transplantation for HCV positive recipients., International Surgical Week 2013(ISW), ヘルシンキ, Aug. 2013.
172.	Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Shuichi Iwahashi : Successful management of liver transplant recipient with strongly positive donor-specific antibody against human leukocyte antigen., International Surgical Week 2013(ISW), ヘルシンキ, Aug. 2013.
173.	Kohei Sugihara, Hisami Okumura, Arisa Teramoto, Eri Urano, Takafumi Katayama, Hiroki Mori, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Recovery Pattern of Energy Metabolism and Blood Biochemical Data after Liver Resection in Hepatocellular Carcinoma Patients and Liver Transplantation Donors., 8th Asia Pacific Conference on Clinical Nutrition, Chiba, Japan, Jun. 2013.
174.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : The usefulness of the volume rendering simulation in laparoscopic colectomy for transverse colon cancer., Society of American Gastrointestinal and Endoscopic Surgeons 2013(SAGES), Baltimore, Apr. 2013.
175.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : Profile and measures of postoperative complications after lapararoscopy assisted gastrectomy for gastric cancer., Society of American Gastrointestinal and Endoscopic Surgeons 2013(SAGES), Baltimore, Apr. 2013.
176.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, 山田眞一郎 and Hidenori Miyake : Laparoscopic hepatic resection for metastatic liver tumor of colorectal cancer: comparative analysis of short and long term results., Society of American Gastrointestinal and Endoscopic Surgeons 2013(SAGES), Baltimore, Apr. 2013.
177.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Shuichi Iwahashi, 山田眞一郎, 浅野間理仁 and 石川大地 : Laparoscopic surgery using vessel sealing systmen for giant liver cysts., Society of American Gastrointestinal and Endoscopic Surgeons 2013(SAGES), Baltimore, Apr. 2013.
178.	Mitsuo Shimada, Shuichi Iwahashi, 山田眞一郎, Yu Saitou, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : Laparoscopic hepatectomy could be the first choice of treatment in selected patients with hepatocellular., Society of American Gastrointestinal and Endoscopic Surgeons 2013(SAGES), Baltimore, Apr. 2013.
179.	Mitsuo Shimada, Yuji Morine, Hiroki Ishibashi, H Takamatsu and H Shimada : Characteristics of Biliary Tract Cancer in Patients with Pancreaticobiliary Maljunction : The Report of Japan-Nationwide Survey., The 2nd JSGE International Topic Conference, Mar. 2013. (Keyword) 国内学会
180.	Noboru Niki, Yoshiki Kawata, Hidenobu Suzuki, Masafumi Harada, Hideki Otsuka, Junji Ueno, Mitsuo Shimada, Tetsuji Takayama, Masahiro Abe, Harumi Itoh, Masahiro Kaneko, Kenji Eguchi, Masahiko Kusumoto, Takaaki Tsuchida, Hironobu Ohmatsu, Masashi Takahashi, Yasutaka Nakano, Hiroaki Sakai and Yuichi Takiguchi : Computer-Aided Diagnosis Based on Computational Anatomical Models: Progress Overview FY2012, he 4th International Symposium on the Project ``Computational Anatomy'', 45-51, Feb. 2013.
181.	Ahmed Shawky Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya and Mitsuo Shimada : Blood vessel-based liver segmentation through the portal phase of a CT dataset, Proceedings of SPIE, Vol.8670, 86700X-1-86700X-7, Orlando, Feb. 2013. (Link to Publication Site) ● Publication site (DOI): 10.1117/12.2007546 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84878420565 (DOI: 10.1117/12.2007546, Elsevier: Scopus)
182.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 松本規子 : The effect of duodenal-jejunal bypass on type2 diabetes., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Dec. 2012. (Keyword) 国際学会
183.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : Simultaneous laparoscopic resection of primary colorectal cancer and metastatic liver tumor., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Dec. 2012. (Keyword) 国際学会
184.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Kouzou Yoshikawa, 柏原秀也, Chie Takasu and 松本規子 : Prognosis after CONVERSION in patients with unresectable liver metastases from colorectal cancer., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Dec. 2012. (Keyword) 国際学会
185.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : Comparison of long-term prognosis of laparoscopy-assisted gastrectomy and conventional open gstrectomy with special reference to D2 lymph node dissection., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Dec. 2012. (Keyword) 国際学会
186.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mami Kanamoto, Yusuke Arakawa, Shuichi Iwahashi, 山田眞一郎 and Hidenori Miyake : Treatment Strategy for Advanced Biliary Circinomas:Repeat Resection of Biliary Cancers., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Paris, Dec. 2012. (Keyword) 国際学会
187.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁, 石川大地, Horohiko Sato and Hidenori Miyake : Treatment strategy based on the characteristics of non-tumor liver tissues in patients., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Paris, Dec. 2012. (Keyword) 国際学会
188.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Horohiko Sato and Hidenori Miyake : Impact of dendritic cell-induced regulatory T cell as a possible novel biomarker for surgical indication of IPMN., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Paris, Dec. 2012. (Keyword) 国際学会
189.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁 and 石川大地 : Recent Advancement of Surgical Treatment Of Liver Cancer., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Paris, Dec. 2012. (Keyword) 国際学会
190.	Mitsuo Shimada, Toru Utsunomiya, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Hidenori Miyake : A New Anatomical Resection of the Liver Based on hybrid Concept of Portal Perfusion of Anterior Segment and Venous Drainage of Superior Right Hepatic Vein., 22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists(IASGO2012), Paris, Dec. 2012. (Keyword) 国際学会
191.	A Teramoto, Hisami Okumura, Takafumi Katayama, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Comparison of measured REE with predicted BEE in Japanese cirrhosis, 34th ESPEN Congress, Barcelona, Sep. 2012.
192.	Hisami Okumura, A Teramoto, Takafumi Katayama, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Blood index for estimating non-protein respiratory quotient without using indirect calorimetry in cirrhotic patients, 34th ESPEN Congress, Barcelona, Sep. 2012.
193.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : Laparoscopic surgery for Stage IV colorectal cancer is safe and feasible., The13th KOREA-JAPAN-CHINA COLORECTAL CANCER SYMPOSIUM, Sep. 2012. (Keyword) 国際学会
194.	Tomohiko Miyatani, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也, Chie Takasu and Mitsuo Shimada : Randomized clinical trial of preoperative chemoradiotherapy by S- vs UFT to rectal cancer for personalized therapy., The13th KOREA-JAPAN-CHINA COLORECTAL CANCER SYMPOSIUM, Seoul, Sep. 2012. (Keyword) 国際学会
195.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : Laparoscopic Surgery after Preoperative Chemoradiation Therapy is a Safe and Feasible Option for T3 and T4 Rectal Cancer., 4th Japanese-Mongolian International Cancer Joint Symposium, Sep. 2012. (Keyword) 国際学会
196.	Takashi Iwata, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu, 松本規子 and Mitsuo Shimada : What is the Best Training for Laparoscopy Assisted Gastrectomy?, 4th Japanese-Mongolian International Cancer Joint Symposium, Sep. 2012. (Keyword) 国際学会
197.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 杉本光司, 齋藤裕 and 山田眞一郎 : Molecular Characteristics of Non-Tumor Liver Tissues May Help to Determine Therapeutic Strategy in Patients with Hepatocellular Carcinoma., American College Of Surgeons Annual Crinical Congress(ACS2012), Sep. 2012. (Keyword) 国際学会
198.	Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Tomohiko Miyatani, 齋藤裕, 山田眞一郎 and Enkhbold Chinbold : One-Stop Shopping for 3-Dimensional Anatomy of Hepatic Vasculature and Bile Duct with a Special Reference to Biliary Image Reconstruction., American College Of Surgeons Annual Crinical Congress(ACS2012), Chicago, Sep. 2012. (Keyword) 国際学会
199.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Horohiko Sato, Yuji Morine, Tetsuya Ikemoto, Tomohiko Miyatani, 柏原秀也 and 淺野間理仁 : Simultaneous laparoscopic resection of primary colorectal cancer and metastatic liver tumor., 4th Japanese-Mongolian International Cancer Joint Symposium, ウランバートル, Sep. 2012. (Keyword) 国際学会
200.	松本規子, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka and Hidenori Miyake : Role of CD151 expression in gallbladder carcinoma., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
201.	Tomohiko Miyatani, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori and Jun Hanaoka : Chemotherapeutic regimen to reduce the liver damage by oxaliplatin-based chemotherapy and to enhance conversion in patients with initially unresectable colorectal liver metastases., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
202.	寺奥大貴, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mami Kanamoto and Hidenori Miyake : Active resection for heterochronial triple cholangiocellar carcinomas., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
203.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Hidenori Miyake : Impact of TJ-137 administration for the prevention of asverse events during chemotherapy in patients with advanced pancreatic cancer patients., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
204.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori and Hidenori Miyake : Usefulness of evaluating functional of the liver using EOB-MRI and indocyanin green fluorescence navigation during operation for safe and curative hepatectomy., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
205.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Jun Hanaoka, Tomohiko Miyatani and Mami Kanamoto : Impact of human adipose tissue derived regenerative cell for cryopreserved porcine islets., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
206.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕 and Hidenori Miyake : Treatment strategy for advanced biliary carcinomas: Aspecial reference to adjuvant chemotherapy and repeated hepatectomy for intrahepatic recurrence., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
207.	Mitsuo Shimada, Toru Utsunomiya, Mami Kanamoto, Tomohiko Miyatani, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Hidenori Miyake : A new hepatectomy based on a hybrid concept of portal perfusion of anterior segment and venous drainage area of suoerior right hepatic vein., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
208.	Hiroki Mori, Hiroki Ishibashi, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hidenori Miyake and Mitsuo Shimada : Risk of carcinogenesis in the biliary epithelium in patients with pancreaticobiliary maliunction through both epigenetic and genetic pathway., 10th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2012), Paris, Jul. 2012. (Keyword) 国際学会
209.	Chie Takasu, Mitsuo Shimada, Kouzou Yoshikawa, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani and 柏原秀也 : The effect of Dai-kenchu-to in maintenance of microbiomal diversity on intestinal inflammation., Digestive Disease Week (DDW2012), May 2012. (Keyword) 国際学会
210.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, Tomohiko Miyatani, 齋藤裕, 山田眞一郎 and 淺野間理仁 : Indoleamine 2, 3-dioxygenase (IDO) and jagged 1 expression on dendrtic cells reflect peripheral regulatory T cells in pancreatic neoplasms., Digestive Disease Week (DDW2012), San Diego, May 2012. (Keyword) 国際学会
211.	Hiroki Mori, Hiroki Ishibashi, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 齋藤裕, 淺野間理仁, 山田眞一郎, Hidenori Miyake and Mitsuo Shimada : Risk of carcinogenesis in the biliary epithelium in patients with pancreaticobiliary maljunction., Digestive Disease Week (DDW2012), San Diego, May 2012. (Keyword) 国際学会
212.	Toru Utsunomiya, Mitsuo Shimada, Jun Hanaoka, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : Possible utility of MRI using Gd-EOB-DTPA for estimating liver functional reserve., Journal of Gastroenterology, Vol.47, No.4, 470-476, Apr. 2012. (Summary) Preoperative estimation of the liver functional reserve is important in liver surgery. We evaluated the role of dynamic magnetic resonance (MR) imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), i.e., EOB-MRI, for determining liver functional reserve. Fifty patients who underwent EOB-MRI to examine their liver tumors were included in this study. We first performed a pixel-by-pixel comparison of registered MR images and activity images with Tc-99m galactosyl human serum albumin (GSA) on each slice, and the correlation coefficient was calculated for 8 patients. We also determined the correlation coefficient between the relative signal intensity (SI) values of EOB-MRI and preoperative liver function, such as the GSA, indocyanine green dye retention at 15 min (ICGR15), and prothrombin time. The mean of the correlation coefficients for 512 × 512 matrices between the EOB-MRI and the GSA was 0.83 ± 0.05 (ranging from 0.73 to 0.87). The correlation coefficient between the relative SI of the EOB-MRI and the receptor index (LHL15) of GSA was 0.56 (P < 0.01). Better correlation coefficients were observed between the relative SI and the liver function test, including ICGR15 (r = -0.67, P < 0.01) and prothrombin time (r = 0.59, P < 0.01). In a patient with hilar cholangiocarcinoma whose right hepatic duct was obstructed, the relative SI in the right lobe (2.4 ± 0.3) was significantly lower than that in the left lobe (3.1 ± 0.1). EOB-MRI represents a practical and reliable imaging technique that may be used to estimate regional liver functional reserve in the clinical setting. (Keyword) Adult / Aged / Aged, 80 and over / Contrast Media / Female / Gadolinium DTPA / Humans / Liver / Liver Function Tests / Magnetic Resonance Imaging / Male / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-011-0513-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22170416 ● Summary page in Scopus @ Elsevier: 2-s2.0-84863084638 (DOI: 10.1007/s00535-011-0513-8, PubMed: 22170416, Elsevier: Scopus)
213.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司, 齋藤裕, 浅野間理仁 and 山田眞一郎 : Specific miRNA expression profiles of non-tumor liver tissues predict the risk for multicentric occurrence of hepatocellular carcinoma., American Association for Cancer Research (AACR2012), Chicago, Mar. 2012.
214.	吉川雅登, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto and Hidenori Miyake : Laparoscope-assisted hepatic resection for gallbladder cancer., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2012), San Diego, Mar. 2012.
215.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司 and Hidenori Miyake : Laparoscopic hepatic resection for hepatocellular carcinoma: comparative analysis of short and long term results., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2012), San Diego, Mar. 2012.
216.	Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka and Hidenori Miyake : Feasibility of laparoscopic hepatectomy for intrahepatic cholangiocarcinoma., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2012), San Diego, Mar. 2012.
217.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Toru Utsunomiya : Simultaneous laparoscopic resection of primary colorectal cancer and metastatic liver tumor., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2012), San Diego, Mar. 2012.
218.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Tomohiko Miyatani, Kouzou Yoshikawa, Masakazu Goto, 柏原秀也 and Chie Mikami : Laparoscopic surgery after preoperative chemoradiation for advanced lower rectal cancer., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2012), San Diego, Mar. 2012.
219.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Mikami : The utility of standardization of laparoscopy assisted gastrectomy and introduction of telesurgery mentoring system., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2012), San Diego, Mar. 2012.
220.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Chie Takasu and Tomohiko Miyatani : Protein Kinase Ciota is a new prognostic factor in gastric cancer., American Association for Cancer Research (AACR2012), Chicago, Mar. 2012.
221.	Noboru Niki, Yoshiki Kawata, Hidenobu Suzuki, Masafumi Harada, Hideki Otsuka, Junji Ueno, Mitsuo Shimada, Tetsuji Takayama, Masahiro Abe, Harumi Itoh, Masahiro Kaneko, Kenji Eguchi, Masahiko Kusumoto, Takaaki Tsuchida, Hironobu Ohmatsu, Masashi Takahashi, Yasutaka Nakano, Hiroaki Sakai and Yuichi Takiguchi : Computer-aided diagnosis based on computational anatomical models: progress overview FY2011, The 3rd International Symposium on the Project ``Computational Anatomy'', 35-42, Mar. 2012.
222.	Ahmed Shawky Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya and Mitsuo Shimada : Extraction of liver volumetry based on blood vessel from the portal phase CT dataset, Proceedings of SPIE, 83142O-1-83142O-8, San Diego, Feb. 2012. (Link to Publication Site) ● Publication site (DOI): 10.1117/12.911175 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84860739737 (DOI: 10.1117/12.911175, Elsevier: Scopus)
223.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 浅野間理仁 : Action of SDF-1/CXCR4 axis in liver metastasis of colorectal cancer., Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2012), San Francisco, Jan. 2012.
224.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎 and 浅野間理仁 : Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) for patients with advanced biliary carcinoma as a postoperative adjuvant chemotherapy., Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2012), San Francisco, Jan. 2012.
225.	Mitsuo Shimada, Toru Utsunomiya, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Tomohiko Miyatani, Horohiko Sato and Nobuhiro Kurita : Effect of bevacizmab on sinusoidal injury in patients receiving oxaliplatin-based chemotherapy and liver damage after massive hepatectomy in rats., Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2012), San Francisco, Jan. 2012.
226.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : Feasibility study of irinotecan based on UGT1A1 polynorphisms for metastatic colorectal cancer: Interin report., Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2012), San Francisco, Jan. 2012.
227.	Tomohiko Miyatani, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也, Chie Takasu and Mitsuo Shimada : Randomized clinical trial of preoperative chemoradiotherapy by S-1 versus UFT to rectal cancer for personalized therapy., Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2012), San Francisco, Jan. 2012.
228.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : The utility of PET-CT in predicting malignant potential of GIST., Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2012), San Francisco, Jan. 2012.
229.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : Assessment of gastric cancer malignancy based on CD133 and thrombospondin1(THBS1) expression and the role of histone acetylation., Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2012), San Francisco, Jan. 2012.
230.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司, 山田眞一郎 and 浅野間理仁 : Beneficial effects of adiose-derived stem cells on severe hepatic damage due to hepatectomy and ischemia reperfusion injury in mice., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
231.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 齋藤裕, 山田眞一郎 and 浅野間理仁 : Bevacizumab ameliorates sinusoidal injury after oxaliplatin-based chemotherapy and enhances liver regeneration after hepatectomy., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
232.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : Application of EOB-MRI as the preoperative simulation for liver surgery: simultaneous evaluation of liver function and volume., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
233.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司, 齋藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-009-0164-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19997856 ● Summary page in Scopus @ Elsevier: 2-s2.0-77949265477 (DOI: 10.1007/s00535-009-0164-1, PubMed: 19997856, Elsevier: Scopus)
234.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司, 齋藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : Effects of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) for patients with unresectable biliary carcinoma and its possible usefulness for postoperative adjuvant chemotherapy., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
235.	Mitsuo Shimada, Jun Hanaoka, Tomohiko Miyatani, Mami Kanamoto, Hiroki Mori, Satoru Imura, Yuji Morine and Toru Utsunomiya : Impact of FOLFOXIRI plus bevacizumab on conversion'' in patients with initially unresectable from colorectal cancer''., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
236.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也 and Chie Takasu : Impact of laparoscopic Surgery for lower rectal cancer with preoperative chemoradiation on postopretive anorectal function., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
237.	Masanori Nishioka, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : A phase II trial of preoperative chemoradiotherapy with oral DPD-inhibitory fluoropyrimidines in patients with advanced rectal cancer., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
238.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : Role of thrombospondin1(THBS1) expression in peritoneal metastasis of gastric cancer treated with taxanes., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
239.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : The mechanism of improvement on glucose tolerance after Duodenal-jejunal bypass., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
240.	Hidenori Miyamoto, 浅野間理仁, 宮本英之 and Mitsuo Shimada : Aluminum potassium sulfate and tannic acid (ALTA) sclerosing therapy is new nonexcisional and less invasive treatment of internal hemorrhoids., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
241.	Takashi Iwata, Mitsuo Shimada, 小松正人, 柏原秀也, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato and Nobuhiro Kurita : The growth inhibitoryeffect of human adipose tissue derived stem cell on pancreas and colon cancer cells., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
242.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : Long-term results of laparoscopy assisted gastrectomy for gastric cancer according to Japanese classification of gastric carcinoma (JCGC) stage-comparison with the results of open surgery-., 21st World Congress of the International Association of surgeons, Gastroenterologists and Oncologigts(IASGO2011), Tokyo, Nov. 2011.
243.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕, 山田眞一郎 and 浅野間理仁 : CD44 Expression Can Predict Prognosis of Intrahepatic Cholangiocarcinoma., 97th Clinical Congress of American college of Srgeons (ACS), San Francisco, Oct. 2011.
244.	Mitsuo Shimada, Yuji Morine, Hiroki Mori, Takamatsu Hideo and Shimada Hiroshi : Characteristics of Biliary Tract Cancer in Patients with Pancreaticobiliary Maljunction: Second Report of Japan-Nationwide Survey., 97th Clinical Congress of American college of Srgeons (ACS), San Francisco, Oct. 2011.
245.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕 and 浅野間理仁 : Cytoprotective effect of human adipose tissue derived stem cell on porcine islet cells., 12th Congress of the Asian Society of Transplantation (CAST2011), Seoul, Sep. 2011.
246.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, 山田眞一郎, Yuji Morine, Satoru Imura, Hiroki Mori, Jun Hanaoka, 杉本光司 and 浅野間理仁 : The possibility of adipose-derived stem cells for an alternative therapy for liver failure., 12th Congress of the Asian Society of Transplantation (CAST2011), Seoul, Sep. 2011.
247.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, 岩橋衆一 and 松本慎一 : The role of donor specific regulatory T cells expanded by interferon-gamma inducible indoleamine 2,3-dioxygenase(IDO)+ plasmacytoid dendritic cell., 12th Congress of the Asian Society of Transplantation (CAST2011), Seoul, Sep. 2011.
248.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎 and 浅野間理仁 : Impact of left lobe graft on adult living donor liver transplantation : small-for-size graft is not a risk factor for short and long outcome., 12th Congress of the Asian Society of Transplantation (CAST2011), Seoul, Sep. 2011.
249.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司, 山田眞一郎 and 浅野間理仁 : Ischemia reperfusion injury enhances SDF1 expressions and hhoming of adipose derived regenerative cells in the liver., 8th International Smposium on Minimal Residual Cancer (ISMRC2011), Osaka, Sep. 2011.
250.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎 and 浅野間理仁 : Peripheral regulatory Tcell induced by Indoleamine 2,3-dioxygenase as a precise biomarker of pancreatic neoplasms., 8th International Smposium on Minimal Residual Cancer (ISMRC2011), Osaka, Sep. 2011.
251.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 齋藤裕, 山田眞一郎 and 浅野間理仁 : Role of histone deacetylase expression in IHCC: A possible epigenetic regulation of cancer stem cell., 8th International Smposium on Minimal Residual Cancer (ISMRC2011), Osaka, Sep. 2011.
252.	Masakazu Goto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : Taylor-made therapy for rectal cancer Role of microRNA-223 expression-., 8th International Simposium on Minimal Residual Cancer (ISMRC2011), Osaka, Sep. 2011.
253.	柏原秀也, Mitsuo Shimada, 小松正人, Nobuhiro Kurita, Takashi Iwata and Horohiko Sato : A possible effect of HDAC inhibitor on differentiating colon cancer sphere., 8th International Simposium on Minimal Residual Cancer (ISMRC2011), Osaka, Sep. 2011.
254.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto and 柏原秀也 : Role of thrombospondin 1 (THBS1) expression in peritoneal metastasis of gastric cancer treated with Taxanes., 8th International Simposium on Minimal Residual Cancer (ISMRC2011), Osaka, Sep. 2011.
255.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 浅野間理仁, Kume Hisae and Sasaki Hajime : Whey protein isolate,MEIN®, can reduce liver damege early after living donor liver transplantation., European Society for Organ Transplantation, glasgow, Sep. 2011.
256.	浅野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕 and 山田眞一郎 : Cytoprotective effect of human adipose tissue derived regenerative cell on porcine islet cells., European Society for Organ Transplantation, Sep. 2011.
257.	Hiroki Mori, Mitsuo Shimada, 齋藤裕, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 浅野間理仁 and 山田眞一郎 : The possibility of adipose-derived regenerative cells for an alternative therapy for liver failure., European Society for Organ Transplantation, glasgow, Sep. 2011.
258.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 浅野間理仁 and 山田眞一郎 : Chance of salvage transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to up-to-7 criteria., European Society for Organ Transplantation, glasgow, Sep. 2011.
259.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 浅野間理仁 and 山田眞一郎 : Impact of left lobe graft on adult living donor liver transplantation: small-for-size graft is not a risk factor for short and long outcome., European Society for Organ Transplantation, glasgow, Sep. 2011.
260.	杉本光司, 松本慎一, Tetsuya Ikemoto, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 浅野間理仁, 山田眞一郎 and Mitsuo Shimada : The immunological tolerance effects of donor specific regulatory T cells through interferon-gamma inducible indoleamine 2,3-dioxygenase(IDO)+plasmacytoid dendritic cell., European Society for Organ Transplantation, Glasgow, Sep. 2011.
261.	Mitsuo Shimada, Satoru Imura, Hiroki Mori, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 浅野間理仁, 山田眞一郎 and Toru Utsunomiya : Regeneration of caudate lobe in extended left lobe graft including caudate lobe after living donor liver transplantation., European Society for Organ Transplantation, glasgow, Sep. 2011.
262.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, 柏原秀也 and Chie Mikami : Laparoscopic surgery after preoperative chemoradiation therapy for advanced rectal cancer is a safe and feasible option., International Surgical Week ISW 2011, Yokohama, Aug. 2011.
263.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, Chie Mikami and Masanori Nishioka : Role of thrombospondin 1 (THBS1) expression in peritoneal metastasis of gastric cancer treated with taxanes., International Surgical Week ISW 2011, Yokohama, Aug. 2011.
264.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa and Tomohiko Miyatani : A randomized phase II study of modified OPTIMOX1 or FOLFOX., nternational Surgical Week ISW 2011, Yokohama, Aug. 2011.
265.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Hidenori Miyake : Comparison of short-term outcome and surgical stress response to laparoscopic and open hemihepatectomy., International Surgical Week, Yokohama, Aug. 2011.
266.	Mitsuo Shimada : Over Milan criteria for living donor liver transplantation., International Surgical Week, Yokohama, Aug. 2011.
267.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa and Toru Utsunomiya : The Mechanism of Improvement Effect on Glucose Tolerance After Rubino's Procedure., Digestive Disease Week (DDW2011), Chicago, May 2011.
268.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Mami Kanamoto : Green Tea Catechins Improve Liver Dysfunction Following Massive Hepatectomy Through Anti-Oxidative and Anti-Inflammatory Activities in Rat., Digestive Disease Week, Chicago, May 2011.
269.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Chie Mikami and 柏原秀也 : Investigation of expression of RAD51 in biopsied apecimen as a predictive factor of chemo-radiation therapy for advancer rectal cancer., 102nd American Association for Cancer Research (AACR2011), Orlando, Apr. 2011.
270.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, Mami Kanamoto, 岩橋衆一, 齋藤裕 and 浅野間理仁 : Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell line., 102nd American Association for Cancer Research (AACR2011), Orlando, Apr. 2011.
271.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 山田眞一郎, 浅野間理仁 and Mami Kanamoto : Role of histone deacetylase expression in intrahepatic cholangiocarcinoma., 102nd American Association for Cancer Research, Orlando, Apr. 2011.
272.	Masanori Arita, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Chie Mikami and Hideya Kashihara : The significance of laparoscopic surgery for stage colorectal cancer, Society of American Gastrointestinal Endoscopic Surgeons (SAGES2011), テキサス, Mar. 2011.
273.	Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Toru Utsunomiya : The safety and usefulness of single incision laparoscopic TAPP, Society of American Gastrointestinal Endoscopic Surgeons (SAGES2011), テキサス, Mar. 2011.
274.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima and Hideya Kashihara : Laparoscopic surgery after preoprateive chemoradiation therapy is a safe and feasible option for T3 and T4 rectal cancer, Society of American Gastrointestinal Endoscopic Surgeons (SAGES2011), テキサス, Mar. 2011.
275.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, Chie Mikami and Hideya Kashihara : Technical feasibility and safety of esophagojejunostomy using overlap technique after laparoscopic, Society of American Gastrointestinal Endoscopic Surgeons (SAGES2011), テキサス, Mar. 2011.
276.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Shuichi Iwahashi and Yu Saito : Utility of hybrid sils with minute diameter forceps in cholecystectomy, Society of American Gastrointestinal Endoscopic Surgeons (SAGES2011), テキサス, Mar. 2011.
277.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Shuichi Iwahashi, Yu Saito, Nobuhiro Kurita and Hidenori Miyake : Minimal Invasiveness of laparoscopic left hepatic lobectomy : A special referece to systemic inflammatory response syndrome, Society of American Gastrointestinal Endoscopic Surgeons (SAGES2011), テキサス, Mar. 2011.
278.	Noboru Niki, Yoshiki Kawata, Hidenobu Suzuki, Masafumi Harada, Hideki Otsuka, Junji Ueno, Mitsuo Shimada, Tetsuji Takayama, Masahiro Abe, Harumi Itoh, Masahiro Kaneko, kenji Eguchi, Masahiko Kusumoto, Takaaki Tsuchida, Hironobu Ohmatsu, Masashi Takahashi, Yasutaka Nakano and Hiroaki Sakai : Computer-aided diagnosis based on computational anatomical models: progress overview FY2010, The 2nd International Symposium on the Project ``Computational Anatomy'', 95-100, Mar. 2011.
279.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Hideya Kashihara : A randomized phase study of modified OPTIMOX1 or FOLFOX in advanced colorectal cancer, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
280.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Hideya Kashihara : The role of UGT1A1 polymorphisms (28 and 26) in Japanese cancerpatients, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
281.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Hideya Kashihara : Effect of Kampo medicine Juzen-taiho-to on adverse events induced by cetuximab, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
282.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Hideya Kashihara and Chie Mikami : A randomized phase trial of chemoradiotherapy with oral fluoropyrimidine inhibitory for dihydropyrimidine dehydrogenase for low rectal cancer: An interim report, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
283.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Yuji Morine, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Hideya Kashihara : Role of thrombospondin 1(THBS1) expression in peritoneal metastasis of gastric cancer treated with taxanes, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
284.	Yu Saito, Mitsuo Shimada, Yuji Morine, Shuichi Iwahashi, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori and Jun Hanaoka : Role of histone deacetylase expression on regulating cancer stem cells in intrahepatic cholangiocarcinoma, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
285.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Yu Saito : Effect of a histone deacetylase inhibitor on antitumor effect of gemcitabine to focus the gene network of ingenuity pathways analysis, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
286.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Shuichi Iwahashi, Yu Saito and Shinichiro Yamada : The impact of bevacizumab on liver regeneration following hepatectomy in rats, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
287.	Mitsuo Shimada, Masanori Nishioka, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : Impact of FOLFOXIRI plus bevacizumab on resectability and survival in patients with initially unresectable liver metastases from colorectal cancer, Gastrointestinal Cancers Symposium:Science and Multidiscriplinary Management of GI Malignancies (ASCO-GI 2011), San Francisco, Jan. 2011.
288.	Ahmed Shawky Maklad, Mikio Matsuhiro, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya, Mitsuo Shimada and Hiromu Nishitani : Extraction of liver region from CT dataset based on blood vessel information, International Forum on Medical Imaging in Asia 2011, 283-286, Jan. 2011.
289.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Hideya Kashihara, Chie Mikami and Toru Utsunomiya : Step-by-step education by board-certified endoscopic surgeons on young surgeons' learning oflaparoscopic surgery, 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO2010), エジプト, Oct. 2010.
290.	Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Chie Mikami and Toru Utsunomiya : The growth inhibitory effect of human adipose tissue derived stem cell on pancreas and colon cancer cells, 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO2010), エジプト, Oct. 2010.
291.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, Hideya Kashihara and Chie Mikami : Effect of kampo medicine, dai-kenchu-to, on bacterial translocation, 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO2010), エジプト, Oct. 2010.
292.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Hideya Kashihara and Chie Mikami : Promising strategy of lower rectal cancer: Chemo-radiation followed by laparoscopic surgery, 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO2010), エジプト, Oct. 2010.
293.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Hideya Kashihara, Chie Mikami and Toru Utsunomiya : New strategy for peritoneal dissemination of gastric cancer: An intraperitoneal infusion therapy of paclitaxel with S-1., 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO2010), エジプト, Oct. 2010.
294.	Michihito Asanoma, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi, Yu Saito and Shinichiro Yamada : Role of regulatory T cell and IDO as a biomarker for pancreatic IPMN, 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), エジプト, Oct. 2010.
295.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Yu Saito and Michihito Asanoma : Histone deacetylase inhibitor enhances anti-tumor effect of gemcitabine on pancreatic cancer and cholangiocarcinoma cell line, 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), エジプト, Oct. 2010.
296.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi, Yu Saito, Michihito Asanoma and Shinichiro Yamada : Role of human adipose tissue-derived stem cells in gastroenterological disorders, 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), エジプト, Oct. 2010.
297.	Mitsuo Shimada : ABO-incompatible living donor liver transplantation for HCV-positive recipients, 20th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), エジプト, Oct. 2010.
298.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Yu Saito : Systematic anatomical hepatic repatic resection under preceding US-guided glissonean control by thermal ablation, アジアハイパーサーミア腫瘍学会第5回大会・日本ハイパーサーミア学会第27回大会合同大会, Fukuoka, Sep. 2010.
299.	Hisami Okumura, Rika Yamauchi, Eri Urano, Takafumi Katayama, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : Identification of laboratory biomarker reflecting non protein respiratory quotient (npRQ) in hepatic cirrhosis, 32th ESPEN congress, Nice, France, Sep. 2010.
300.	Kashihara Hideya, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima and Tomohiko Miyatani : A randomized phase study of modified OPTIMX1 or FOLFOX in advaced colorectal cancer : an interim report., The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
301.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Nakao Toshihiro, Oura Ryoko, Komatsu Masato and Kashihara Hideya : Laparoscopic surgery sfter preoperative chemoradiation for T3 and T4 rectal cancer., The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
302.	Kouzou Yoshikawa, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, Tomohiko Miyatani, Nakao Toshihiro, Komatsu Masato and Kashihara Hideya : Positron emission tomography can predicts the malignant potential and indication of Imatinib mesylate therapy in gastrointestinal stromal tumors., The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
303.	Yu Saito, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Shuichi Iwahashi : The correlation between cancer stem like cells and epigenetic alteration in intrahepatic cholangiocarcinoma, The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
304.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi, Yu Saito and Shinichiro Yamada : Indolamine 2,3-deoxygenase (IDO) has influences for the aggressiveness of IPMN through Foxp3+CD4+CD25+Tcell (Treg) in peripheral blood, The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
305.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi and Yu Saito : Laparoscopic left liver resection: Technical refinement for standardization of laparoscopic left hepatic lobectomy, The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
306.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shuichi Iwahashi and Yu Saito : Timing of salvage transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Up-to-7 criteria, The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
307.	Mitsuo Shimada : Role of Kampo medicine in cancer treatment, The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
308.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Nakao Toshihiro, Oura Ryoko, Komatsu Masato and Kashihara Hideya : Significance of preoperative chemoradiation therapy for low rectal and anal cancer ., The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
309.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Nakao Toshihiro, Komatsu Masato and Kashihara Hideya : Surgical risk factors and the measures for laparoscopy assisyed gastrectomy (LAG)., The 9th International Conference of The Asian Clinical Oncology Society(ACOS2010), Gifu, Aug. 2010.
310.	Kuyama Hisako, Hiroo Takehara, Akira Nii, Yuji Morine and Mitsuo Shimada : A case of infantile hemangioendothelioma with thrombocytopenia treated hepatectomy in emergency, 43th Annual Meeting of Pacific Association of Pediatric Surgeons.(PAPS), Kobe, May 2010.
311.	Shinichiro Yamada, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, Shuichi Iwahashi, Yu Saito, Yuko Kawata and Hidenori Miyake : Effect Rikkunshito, a kampo medicine, for gastro-intestinal sympotoms after pylorus-preserving pancreto-duodenectomy (PpPD), 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2010), ブエノスアイレス, Apr. 2010.
312.	Tetsuya Ikemoto, Mitsuo Shimada, Masato Komatu, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Yu Saito and Yuko Kawata : Effect of humen adipose-tissue derived-mesenchymas stem cell on streptozotocin-induced diabetic nude mice, 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2010), ブエノスアイレス, Apr. 2010.
313.	Mitsuo Shimada : Small for size syndrome in liver transplantation, 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA2010), ブエノスアイレス, Apr. 2010.
314.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Shuichi Iwahashi, Yu Saitou, Nobuhiro Kurita and Hidenori Miyake : Laparoscopic resection of the left liver Technical refinements for standardization-, Society of American Gastrointestinal Endoscopic Surgeons (SAGES2010), Washington, D.C., Apr. 2010.
315.	Motsumoto Noriko, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Nakao Toshihiro, Oura Ryoko, Komatsu Masato and Kashihara Hideya : The role of body mass index and visceral fat area in colorectal cancer patients treated with laparoscopic-assisted surgery., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2010), Washington, D.C., Apr. 2010.
316.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Nakao Toshihiro, Oura Ryoko, Komatsu Masato and Kashihara Hideya : Preoperative chemoradiation followed by laparoscopic intersphincteric resection for low rectal cancer., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2010), Washington, D.C., Apr. 2010.
317.	Takashi Iwata, Mitsuo Shimada, Kashihara HIdeya, Komatsu Masato, Nakao Toshihiro, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka and Nobuhiro Kurita : Investingation of the relationship risk factor of laproscopic assisted gastrectomy and the skill of the assistant of operation team., Society of American Gastrointestinal Endoscopic Surgeons (SAGES2010), Washington, D.C., Apr. 2010.
318.	Noboru Niki, Yoshiki Kawata, Hiromu Nishitani, Mitsuo Shimada, Junji Ueno, Masafumi Harada, Masahiro Abe, Hideki Otsuka, Harumi Itoh, Masahiro Kaneko, Takaaki Tuchida, Kenji Eguchi, Hironobu Ohmatsu, Masashi Takahashi and Yasutaka Nakano : Computer-aided diagnosis based on computational anatomical models, The First International Symposium on the Project ``Computational Anatomy'', 65-71, Tokyo, Feb. 2010.
319.	Mitsuru Kubo, Yoshihumi Kishi, Ahmed Shawky Maklad, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Mitsuo Shimada and Hiromu Nishitani : Computer aided treatment system for living donor liver transplantation using multi-slice CT images, International Forum on Medical Imaging in Asia 2009, Vol.108, No.385, 371-374, Taiwan, Jan. 2009.
320.	Fumiaki Masakiyo, Mitsuru Kubo, Yoshiki Kawata, Noboru Niki, M. Nishikawa, H. Miyamoto, K. Yoshikawa, Mitsuo Shimada and Hiromu Nishitani : Detection algorithm of abdominal lymph nodes based on multi-modality iamge, Proc. International Symposium on Biomedical and Physiological Engineering, 56-57, Harbin, Jan. 2008.
321.	Masahiko Fujii, Satoru Imura, Yuji Morine, H Shinohara and Mitsuo Shimada : Central Bisegmentectomy of the Liver with Pylorus-preserving Pancreatoduodenectomy for Advanced Cancer of the Gallbladder, 19th World Congress of International Society Digestive Surgery, Yokohama, Dec. 2004.
322.	Yuji Soejima, Mitsuo Shimada, Tomoharu Yoshizumi, Hideaki Uchiyama, Noboru Harada, Hideki Ijichi, Yusuke Yonemura, Akinobu Taketomi and Yoshihiko Maehara : Biliary strictures after living donor liver transplantation, The 5th Korea-Japan Transplantation Forum,Symposium, Korea, Oct. 2004.
323.	Yuji Soejima, Mitsuo Shimada, Tomoharu Yoshizumi, Hideaki Uchiyama, Noboru Harada, Hideki Ijichi, Yusuke Yonemura, Akinobu Taketomi and Yoshihiko Maehara : Biliary strictures after living donor liver transplantation, 10th Annual Congress of the International Liver Transplantatiion Society, Kyoto, Jun. 2004.
324.	Yuji Soejima, Mitsuo Shimada, Tomoharu Yoshizumi, Hideaki Uchiyama, Noboru Harada, Hideki Ijichi, Yusuke Yonemura, Akinobu Taketomi and Yoshihiko Maehara : Feasibility of left-lobe living-donor liver transplantation between adults:a single center experience of 94 cases, American Transplant Congress 2004, Boston, May 2004.
325.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro, Ryosuke Minagawa, Shoji Hiroshige, Mizuki Ninomiya, Satoko Shiotani, Noboru Harada and Yoshihiko Maehara : Impact of both graft veno-plasty and caval anastomosis on living donor liver transplantation using the left lobe, The 3rd Korea-Japan Transplantation Forum, Seoul, Sep. 2002.
326.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro and Keizo Sugimachi : Feasibility of duct-to-duct biliary reconstruction in adult-to-adult living donor liver transplantation using the left lobe, Transplant 2002 The Joint American Transplant Meeting, Washington, D.C., Apr. 2002.
327.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro, Ryosuke Minagawa, Shoji Hiroshige, Mizuki Ninomiya, Satoko Shiotani, Noboru Harada and Keizo Sugimachi : Small-for-size syndrome in adult-to-adult living donor liver transplantation using the lift lobe, 5th World Congress of the International Hepato-pancreato-biliary Association, Tokyo, Apr. 2002.
328.	Mitsuo Shimada, Taketoshi Suehiro, Yuji Soejima, Ryosuke Minagawa, Shoji Hiroshige, Satoko Shiotani, Mizuki Ninomiya, Noboru Harada, Takahiro Terashi, Takashi Nishizaki and Keizo Sugimachi : SMALL FOR SIZE GRAFT IN LIVING DONOR LIVER TRANSPLANTATION, Invited Speaker, GREECE, Nov. 2001.
329.	Yuji Soejima, Mitsuo Shimada, Taketoshi Suehiro, Ryosuke Minagawa, Shoji Hiroshige, Mizuki Ninomiya, Satoko Shiotani, Noboru Harada and Keizo Sugimachi : Outcome Analysis in Adult-to-adult Living Donor Liver Transplantation Using Left Lobe, Transplant 2001 The Joint American Transplant Meeting, Chicago, May 2001.
330.	Mitsuo Shimada, Takayuki Hamatsu, Tatsuya Rikimaru, Yo-ichi Yamashita, Shinji Tanaka, Ken Shirabe, Hiroshi Honda, Makoto Hashizume and Keizo Sugimachi : Impact of Combined Preoperative Three-Dimensional Computed Tomography and Intraoperative Real-Time Three-Dimensional Ultrasonography on Liver Surgery, MICCAI 2000(Medical Image Computing and Computer Assisted Intervention), Pittsburgh, U.S.A., Oct. 2000.
331.	Mitsuo Shimada and Keizo Sugimachi : New Generation in Hepato-Biliary Surgery., Symposium: Invited Speaker, Hannover, Germany, Oct. 2000.
332.	Mitsuo Shimada, Katsuhiko Yanaga, Leonard Makowka, DH Thiel Van and Thomas E Starzl : Lecithin: cholesterol acyltransferase activity as a prognostic indicator of early liver, The International Association for the Study of the Liver, Nov. 1989.

Proceeding of Domestic Conference:

1.	Yu Saitou, Tetsuya Ikemoto, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導した肝細胞様細胞の免疫原性獲得に関する研究, 第23回日本再生医療学会総会, Mar. 2024.
2.	Koichi Tomita, Teruyoshi Hirayama, Hiroki Umeshima, Koichi Tsuneyama, Akiyoshi Nishimura, Hideyuki Nushida, Masashi Akaike, Hiromitsu Takizawa, Mitsuo Shimada, Yasushi Takagi, Ichiro Hashimoto and Takashi Iwata : 徳島大学医学部の系統解剖実習における画像診断技術・病理診断技術・外科的手術手技を取り入れた垂直連携教育の実践, 第129回日本解剖学会全国学術集会, Mar. 2024.
3.	Takuya Tokunaga, Yuhei Waki, Hiroki Ishibashi, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ADSCから分化したSchwann cell-like cellが神経修復へ与える影響に関する基礎的検討, 第23回日本再生医療学会総会, Mar. 2024.
4.	Yuhei Waki, Yu Saitou, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導した肝細胞様細胞の尿素サイクル異常症モデルマウスへの移植効果, 第23回日本再生医療学会総会, Mar. 2024.
5.	Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療を用いた新たな膵β細胞(insulin producing cell:IPC)移植戦略の樹立に関する研究, 第23回日本再生医療学会総会, Mar. 2024.
6.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌腹膜播種予測におけるエクソソームmiRNAの有用性, 第96回日本胃癌学会総会, Feb. 2024.
7.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 局所進行胃癌に対するロボット支援手術の工夫と成績, 第96回日本胃癌学会総会, Feb. 2024.
8.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対する経裂孔ロボット支援手術, 第96回日本胃癌学会総会, Feb. 2024.
9.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The ingenuity of robotic surgery for advanced gastric cancer, 第96回日本胃癌学会総会, Feb. 2024.
10.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : エクソソームmiRNAを用いての胃癌腹膜播種の予測, 第56回制癌剤適応研究会, Feb. 2024.
11.	Hiroki Teraoku, Yuhei Waki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 腫瘍関連マクロファージ(TAM)とのcrosstalkを介したLenvatinib耐性肝細胞癌における悪性度獲得機序, 第56回制癌剤適応研究会, Feb. 2024.
12.	Sonoko Yasui-Yamada, Miyu Kubo, Yuna Izumi, Kazuhiro Nomura, Seiichiro Kamimura, Hideya Kashihara, Yu Saitou, Yoshiaki Kitamura, Mitsuo Shimada, Yasuhiro Hamada and Hiroshi Sakaue : 簡便に得られるデータから作成した四肢骨格筋量を予測する回帰式の妥当性検証, 第27回日本病態栄養学会年次学術集会, Jan. 2024.
13.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : Atezolizmab+Bevacizumab療法ならびにTremelimumab+Durvalumab療法により縮小が得られ肝切除を施行し得たVp4を伴う進行肝細胞癌の一例, 第29回日本肝がん分子標的治療研究会, Jan. 2024.
14.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第120回日本消化器病学会四国支部例会, Dec. 2023.
15.	Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 地方大学における小児内視鏡外科手術の教育-技術認定医取得を目指す取り組み-, 第36回日本内視鏡外科学会総会, Dec. 2023.
16.	Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 鼠径ヘルニアに対するLPEC法の限界およびピットフォール, 第36回日本内視鏡外科学会総会, Dec. 2023.
17.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : ロボット支援前立腺全摘後の鼠径ヘルニアに対する腹腔鏡下ヘルニア修復術についての検討, 第36回日本内視鏡外科学会総会, Dec. 2023.
18.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃癌手術におけるトレーニングプログラムの確立, 第36回日本内視鏡外科学会総会, Dec. 2023.
19.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対する経肛門的側方リンパ節郭清の手術手技と短期成績の検討, 第36回日本内視鏡外科学会総会, Dec. 2023.
20.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 局所進行胃癌に対するロボット支援手術の工夫と成績, 第36回日本内視鏡外科学会総会, Dec. 2023.
21.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 非アルコール性脂肪肝炎に対する減量・代謝改善手術の意義, 第36回日本内視鏡外科学会総会, Dec. 2023.
22.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット手術(経裂孔アプローチ)の有用性, 第36回日本内視鏡外科学会総会, Dec. 2023.
23.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第36回日本内視鏡外科学会総会, Dec. 2023.
24.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第36回日本内視鏡外科学会総会, Dec. 2023.
25.	Toshiaki Yoshimoto, Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 再発直腸癌に対する経肛門アプローチにおけるホログラムの有用性, 第32回日本コンピュータ外科学会大会, Dec. 2023.
26.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : 切除可能境界膵癌における集学的治療の意義, 第120回日本消化器病学会四国支部例会, Dec. 2023.
27.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 腹腔鏡下肝切除におけるPitfall -心房細動アブレーション後医原性心房中隔欠損を介した奇異性塞栓症-, 第36回日本内視鏡外科学会総会, Dec. 2023.
28.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 最大腫瘍径×個数を用いた新たなresectabilityと治療戦略の提唱, 第45回日本肝臓学会西部会, Dec. 2023.
29.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝内胆管癌における新たな予後予測 - MRI拡散強調画像と腫瘍浸潤リンパ球 –, 第45回日本肝臓学会西部会, Dec. 2023.
30.	Yuji Morine, Yu Saitou and Mitsuo Shimada : 進行肝細胞癌における至適肝切除適応の再考とconversion surgeryの意義, 第45回日本肝臓学会西部会, Dec. 2023.
31.	Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 当科におけるICG蛍光法の経験, 第85回日本臨床外科学会総会, Nov. 2023.
32.	Yuuma Wada, Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Hiroki Teraoku, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌におけるエクソソームmiRNAを介したLenvatinib耐性機序の検討, 第34回日本消化器癌発生学会総会, Nov. 2023.
33.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 青色LEDはmetabolic couplingを抑制することで抗腫瘍効果をもたらす, 第34回日本消化器癌発生学会総会, Nov. 2023.
34.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 大腸癌におけるImmunoscoreとフレイルの予後に与える影響, 第34回日本消化器癌発生学会総会, Nov. 2023.
35.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LED光による大腸癌の光受容体をターゲットとした治療法の開発, 第85回日本臨床外科学会総会, Nov. 2023.
36.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃癌手術のトレーニングプログラム, 第85回日本臨床外科学会総会, Nov. 2023.
37.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット手術(経裂孔)の有用性, 第85回日本臨床外科学会総会, Nov. 2023.
38.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 右側結腸癌に対するロボット支援下手術の可能性∼腹腔鏡手術との比較から∼, 第85回日本臨床外科学会総会, Nov. 2023.
39.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 経肛門アプローチを併用したロボット支援下直腸切除術の有用性, 第85回日本臨床外科学会総会, Nov. 2023.
40.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 上部胃癌に対するロボット支援手術の工夫と成績, 第85回日本臨床外科学会総会, Nov. 2023.
41.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌手術におけるMRIを用いた骨盤神経描出, 第85回日本臨床外科学会総会, Nov. 2023.
42.	Yuhei Waki, Yuji Morine, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : 肝細胞癌微小環境におけるNrf2シグナルを介した癌細胞とTAMの相互作用, 第34回日本消化器癌発生学会総会, Nov. 2023.
43.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第34回日本消化器癌発生学会総会, Nov. 2023.
44.	Mitsuo Shimada : New normal 時代における日本消化器癌発生学会の「創始と継志」, 第34回日本消化器癌発生学会総会, Nov. 2023.
45.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 80歳以上の高齢者膵癌に対する膵頭十二指腸切除の治療成績, 第85回日本臨床外科学会総会, Nov. 2023.
46.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 大腸癌多発肝転移における最大腫瘍径×個数を用いた肝切除基準と集学的治療方針の提唱, 第85回日本臨床外科学会総会, Nov. 2023.
47.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : EOB予備能評価に基づいた至適肝切除, JDDW 2023, Nov. 2023.
48.	Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, JDDW 2023, Nov. 2023.
49.	Yuji Morine, Yu Saitou and Mitsuo Shimada : 脈管侵襲陽性肝細胞癌の至適治療法は肝切除です, JDDW 2023, Nov. 2023.
50.	Hideya Kashihara, Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第61回日本癌治療学会学術集会, Oct. 2023.
51.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第61回日本癌治療学会学術集会, Oct. 2023.
52.	Yuhei Waki, Yuji Morine, Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : 微小環境におけるエクソソームを介した薬剤肝細胞癌の悪性度増強と耐性機序の解明, 第61回日本癌治療学会学術集会, Oct. 2023.
53.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 再発肝細胞癌に対する肝切除成績, 第61回日本癌治療学会学術集会, Oct. 2023.
54.	Hiroki Mori, Hiroki Ishibashi and Mitsuo Shimada : 先天性胆道拡張症根治術後8年経過して発症した膵管内蛋白栓の1例, 第46回日本膵・胆管合流異常研究会, Sep. 2023.
55.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌腹膜播種特異的なエクソソーム中miRNAの同定, 第82回日本癌学会学術総会, Sep. 2023.
56.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 上部胃癌に対するロボット支援胃癌手術の定型化-Left-handed LCS and pincer approach-, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
57.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腸内細菌叢の変化からみた減量・代謝改善手術の効果, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
58.	Kouzou Yoshikawa, Mitsuo Shimada, Yuji Morine, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 大建中湯の消化器疾患における役割, 第98回中国四国外科学会総会第28回中国四国内視鏡外科研究会, Sep. 2023.
59.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 膵・胆管合流異常における胆道上皮PD-L1発現, 第46回日本膵・胆管合流異常研究会, Sep. 2023.
60.	Hiroki Teraoku, Yu Saitou, 杉本真樹, Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto and Mitsuo Shimada : 胆道手術における3D胆道造影Extended realityによる手術支援, 第17回肝癌治療ナビゲーション研究会, Aug. 2023.
61.	Yu Saitou, 杉本真樹, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝胆膵手術支援の新展開-Extended reality・ホログラム・メタバース-, 第50回日本膵切研究会, Aug. 2023.
62.	Toshiaki Yoshimoto, Masaaki Nishi, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LEDによる大腸癌由来CAF制御および抗腫瘍効果, 第78回日本消化器外科学会総会, Jul. 2023.
63.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : エクソソームmiRNAを用いた胃癌腹膜播種の予測, 第78回日本消化器外科学会総会, Jul. 2023.
64.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌手術におけるMRIを用いた骨盤神経描出, 第78回日本消化器外科学会総会, Jul. 2023.
65.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除術後長期効果に影響を及ぼす因子に関する検討, 第78回日本消化器外科学会総会, Jul. 2023.
66.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動介入の意義:短期成績を改善するが長期成績には寄与しない, 第78回日本消化器外科学会総会, Jul. 2023.
67.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第78回日本消化器外科学会総会, Jul. 2023.
68.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 進行胃癌に対するロボット支援手術の有用性, 第78回日本消化器外科学会総会, Jul. 2023.
69.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 経肛門アプローチを用いた拡大骨盤手術手技, 第78回日本消化器外科学会総会, Jul. 2023.
70.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 大腸癌におけるFrailの意義と免疫栄養指標との関連, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
71.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌術前における栄養，リハビリ介入の検討, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
72.	Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 症例, 第59回日本肝癌研究会, Jul. 2023.
73.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌における微小環境クロストークによるLenvatinib耐性機序の検討, 第59回日本肝癌研究会, Jul. 2023.
74.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第59回日本肝癌研究会, Jul. 2023.
75.	Yuhei Waki, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Takayuki Noma, Tetsuya Ikemoto and Mitsuo Shimada : 内科的治療後再発・遺残肝細胞に対するRescue肝切除の意義, 第78回日本消化器外科学会総会, Jul. 2023.
76.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Hiroki Teraoku : 徳島大学病院全体と消化器・移植外科のFRT回避に係る連携とOODAループ, 第78回日本消化器外科学会総会, Jul. 2023.
77.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Takayuki Noma and Mitsuo Shimada : EOBによる肝予備能評価と最大腫瘍径×個数を用いた肝切除限界の提唱, 第78回日本消化器外科学会総会, Jul. 2023.
78.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 高齢者膵癌に対する膵頭十二指腸切除術の適応と限界, 第78回日本消化器外科学会総会, Jul. 2023.
79.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性 - ERAS導入による手術成績の向上 –, 第78回日本消化器外科学会総会, Jul. 2023.
80.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第78回日本消化器外科学会総会, Jul. 2023.
81.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto, Sonoko Yasui-Yamada, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性-ERAS導入による手術成績の向上 –, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
82.	Mitsuo Shimada : New Normal Kampo in Surgery/外科漢方のNew Normal, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
83.	MATSUMOTO Rikizo, Susumu Nishio, Kei Daizumoto, Sae Morita, Asami Yuasa, Yukina Hirata, 山尾雅美, Yu Saitou, Kenya Kusunose, Hirotsugu Yamada, Mitsuo Shimada and Masataka Sata : 後腹膜リンパ節転移を生じたBurned-out testicular tumorの1例, 第48回日本超音波検査学会学術集会, Jun. 2023.
84.	Sae Morita, Susumu Nishio, MATSUMOTO Rikizo, YAMAGUCHI Natsumi, Asami Yuasa, Yukina Hirata, 山尾雅美, Yu Saitou, Kenya Kusunose, Hirotsugu Yamada, Mitsuo Shimada and Masataka Sata : 分枝膵管型IPMNに由来した膵管内乳頭粘液性腺癌の一例, 第48回日本超音波検査学会学術集会, Jun. 2023.
85.	Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 小児abdominoscrotal hydrocele(ASH)に対する腹腔鏡下手術の有用性, 第60回日本小児外科学会学術集会, Jun. 2023.
86.	Takayuki Noma, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 切除不能進行胃癌に対してSOX-NIVO後Conversion手術を施行した2症例, 第44回癌免疫外科研究会, Jun. 2023.
87.	Chie Takasu, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 女性消化器外科医の技術向上とキャリア育成を目指した取り組み, 日本消化器病学会四国支部第119回例会, Jun. 2023.
88.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : The Correlation of Immunoscore and Frailty in Colorectal Cancer, 第48回日本外科系連合学会学術集会, Jun. 2023.
89.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入周術期管理の有用性, 第48回日本外科系連合学会学術集会, Jun. 2023.
90.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 食道胃接合部腺癌に対するロボット支援下手術(経裂孔)の有用性, 第32回日本癌病態治療研究会, Jun. 2023.
91.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, 仲須千春 and Mitsuo Shimada : PD-L1 expression of biliary epithelium in pancreaticobiliary maljunction, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
92.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : New strategy for CRLM using Maximum Diameter x Number: MDN, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
93.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto, Shin-ichiro Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : Preoperative weight loss program for high body mass index patients undergoing liver resection for hepatocellular carcinoma - Surgical outcomes of ERAS protocol, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
94.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Hiroki Teraoku : Establishment of investigator initiated clinical trial as a future cell transplantation for to complement existing transplantations, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
95.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : Reconsideration of indication of hepatic for advanced hepatocellular carcinoma and significance of conversion surgery, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
96.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 肝細胞癌におけるNrf2/VEGFシグナルを介したTumor-associated macrophage (TAM)との相互作用, 第44回癌免疫外科研究会, Jun. 2023.
97.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 術前の心構え「AWA spirits」に基づいたtraining systemによる肝胆膵外科の若手教育, 日本消化器病学会四国支部第119回例会, Jun. 2023.
98.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : StageIII/IVa肝細胞癌におけるMRI拡散強調画像ADC値とTumor infiltrative lymphocyte (TIL), 第59回日本肝臓学会総会, Jun. 2023.
99.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, 第59回日本肝臓学会総会, Jun. 2023.
100.	Yu Saitou, Yuji Morine and Mitsuo Shimada : 進行肝細胞癌に対する外科治療の新展開-肝癌微小環境におけるNrf2に着目した新たなアプローチ-, 第59回日本肝臓学会総会, Jun. 2023.
101.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第48回日本外科系連合学会学術集会, Jun. 2023.
102.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌における至適肝切除適応の再考とConversion surgeryの意義, 第48回日本外科系連合学会学術集会, Jun. 2023.
103.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 徳島大学病院における医療安全管理上の患者アドボカシーの実情と展望, 第48回日本外科系連合学会学術集会, Jun. 2023.
104.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌・食道胃接合部癌に対するロボット支援胃癌手術の手術手技, 第77回手術手技研究会, May 2023.
105.	Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 再生医療を用いたβ細胞補填治療法に関するFIH試験樹立に向けて, 第109回日本消化器病学会総会, Apr. 2023.
106.	仲須千春, Masaaki Nishi, Yuji Morine, Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Mitsuo Shimada : 青色LEDを用いたCAFの糖代謝に着目した腫瘍免疫制御のメカニズムの解明, 第123回日本外科学会定期学術集会, Apr. 2023.
107.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動リハビリの意義: 短期成績を改善するが長期成績には寄与しない, 第123回日本外科学会定期学術集会, Apr. 2023.
108.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 胃癌フレイル患者における術前栄養リハビリ介入の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
109.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腸脳相関からみたMetabolic surgeryの術後早期血糖抑制効果, 第123回日本外科学会定期学術集会, Apr. 2023.
110.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : Utility of robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: transhiatal robotic versus laparoscopic approach, 第123回日本外科学会定期学術集会, Apr. 2023.
111.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : 下部直腸癌に対する経肛門アプローチにおける術中ホログラム手術支援の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
112.	Toshiaki Yoshimoto, Shohei Okikawa, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : 青色LED光の腫瘍微小環境に対する効果, 第123回日本外科学会定期学術集会, Apr. 2023.
113.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するMRIを用いた骨盤神経描出, 第123回日本外科学会定期学術集会, Apr. 2023.
114.	Kouzou Yoshikawa, Mitsuo Shimada and Chie Takasu : 進行胃癌に対するロボット支援胃切除術の有用性, 第109回日本消化器病学会総会, Apr. 2023.
115.	Takayuki Noma, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 再発肝細胞癌に対する肝切除の意義, 第123回日本外科学会定期学術集会, Apr. 2023.
116.	Hiroki Teraoku, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Sonoko Yasui-Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肝細胞癌における肥満患者への術前栄養運動介入の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
117.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療によるインスリン産生細胞自家移植戦略は1型糖尿病治療を変える, 第123回日本外科学会定期学術集会, Apr. 2023.
118.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku, Takashi Iwata and Mitsuo Shimada : 消化器外科ナビゲーションの新展開 -Extended reality・ホログラム・メタバース –, 第123回日本外科学会定期学術集会, Apr. 2023.
119.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌における至適肝切除適応の再考とConversion surgeryの意義, 第123回日本外科学会定期学術集会, Apr. 2023.
120.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 大腸癌肝転移における切除不能の定義とコンバージョンを目指した治療戦略, 第109回日本消化器病学会総会, Apr. 2023.
121.	Takuya Tokunaga, Yu Saitou, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子, 岩川陽介 and Mitsuo Shimada : 経肛門アプローチを用いた腹腔鏡下側方郭清の手術手技と短期成績 ∼Hologramによるシミュレーションの有用性∼, 第122回日本外科学会定期学術集会, Apr. 2023.
122.	Yuhei Waki, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ADSCから分化したinsulin producing cell移植時の自己免疫による影響に関する検討, 第22回日本再生医療学会総会, Mar. 2023.
123.	Yu Saitou, 陳述海, Yuhei Waki, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, 第22回日本再生医療学会総会, Mar. 2023.
124.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 間葉系幹細胞を用いた新たなβ細胞補填治療法樹立に向けて, 第22回日本再生医療学会総会, Mar. 2023.
125.	Yuhei Waki, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療によって作成されたinsulin producing cell移植後の自己免疫による影響に関する基礎的検討, 第50回日本膵・膵島移植学会学術集会, Mar. 2023.
126.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Yuuma Wada, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いたβ細胞補填治療法に関する膵島移植とのクロストーク, 第50回日本膵・膵島移植学会学術集会, Mar. 2023.
127.	Hiroki Teraoku, Yuhei Waki, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : Lenvatinib耐性肝細胞癌におけるNrf2を介した悪性度上昇と薬剤耐性獲得機序の検討, 第55回制癌剤適応研究会, Feb. 2023.
128.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Mitsuo Shimada : 胃癌手術における術前栄養リハビリ介入の有用性, 第95回日本胃癌学会総会, Feb. 2023.
129.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌・食道胃接合部癌に対するロボット手術の有用性, 第95回日本胃癌学会総会, Feb. 2023.
130.	Chie Takasu, Masaaki Nishi, Yuuma Wada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 高齢者フレイル胃癌患者における術前栄養・運動介入の意義:短期成績を改善するが長期成績には寄与しない, 第95回日本胃癌学会総会, Feb. 2023.
131.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : MISによる胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第95回日本胃癌学会総会, Feb. 2023.
132.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するホログラムを駆使した新たな経肛門手術, 第266回徳島医学会学術集会, Feb. 2023.
133.	NASU Nanami, Sonoko Yasui-Yamada, TAKIMOTO Mami, Daisuke Sekimoto, Hideya Kashihara, Yu Saitou, Mitsuo Shimada and Yasuhiro Hamada : 膵液瘻高リスク患者における膵頭十二指腸切除術後の早期経口摂取と膵液瘻との関連, 第26回日本病態栄養学会年次学術集会, Jan. 2023.
134.	Yuhei Waki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : Lenvatinib耐性肝細胞癌における癌微小環境を介した悪性度獲得と薬剤耐性獲得機序の解明, 第27回日本肝がん分子標的治療研究会, Jan. 2023.
135.	Shin-ichiro Yamada, Yuji Morine, Yu Saitou, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝細胞癌BCLC intermediate stageにおけるMaximum tumor diameter × number の意義, 第27回日本肝がん分子標的治療研究会, Jan. 2023.
136.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 小児重症心身障害児のGERDに対する腹腔鏡下Nissen-Rossetti噴門形成術の有用性, 第35回日本内視鏡外科学会総会, Dec. 2022.
137.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Mitsuo Shimada : ロボット支援前立腺全摘後に発症した鼠径ヘルニアに対する腹腔鏡手術症例の検討, 第35回日本内視鏡外科学会総会, Dec. 2022.
138.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第35回日本内視鏡外科学会総会, Dec. 2022.
139.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 経肛門側方リンパ節郭清の手技と短期成績 ∼ホログラムシミュレーションの有用性∼, 第35回日本内視鏡外科学会総会, Dec. 2022.
140.	Chie Takasu, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 腹腔鏡下胃切除における6番リンパ節郭清困難性の術前予測, 第35回日本内視鏡外科学会総会, Dec. 2022.
141.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 食道胃接合部癌に対するロボット支援下手術(経裂孔)の工夫, 第35回日本内視鏡外科学会総会, Dec. 2022.
142.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 低侵襲胃全摘術後再建における肝臓脱転による視野確保とOrVil法の有用性, 第35回日本内視鏡外科学会総会, Dec. 2022.
143.	Hiroki Mori, Yuji Morine, Hiroki Ishibashi, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 慢性炎症状態の膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第33回日本消化器癌発生学会総会, Nov. 2022.
144.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義と集学的治療戦略, 第84回日本臨床外科学会総会, Nov. 2022.
145.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第84回日本臨床外科学会総会, Nov. 2022.
146.	Tetsuya Ikemoto, Mitsuo Shimada, Shin-ichiro Yamada, Hiroki Teraoku, Yu Saitou and Yuji Morine : de novo B型肝炎管理体制構築に向けた取り組み, 第84回日本臨床外科学会総会, Nov. 2022.
147.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第118回日本消化器病学会四国支部例会, Nov. 2022.
148.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 仲須千春, 髙橋叡, Takayuki Noma and Mitsuo Shimada : StageIII/IV肝細胞癌における拡散強調画像ADC値の意義, 第33回日本消化器癌発生学会総会, Nov. 2022.
149.	Mitsuo Shimada : New Normal時代の日本消化器癌発生学会:Diversity&Inclusion, 第33回日本消化器癌発生学会総会, Nov. 2022.
150.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : DST吻合における吻合部血流不全のリスク因子および追加切除例の検討, 第84回日本臨床外科学会総会, Nov. 2022.
151.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 局所進行直腸癌に対する術前化学放射線療法におけるADC値の有用性, 第84回日本臨床外科学会総会, Nov. 2022.
152.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第84回日本臨床外科学会総会, Nov. 2022.
153.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移における発育形式と予後に関する検討, 第84回日本臨床外科学会総会, Nov. 2022.
154.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第84回日本臨床外科学会総会, Nov. 2022.
155.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Yuuma Wada, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌に対するロボット支援胃癌手術の定型化- Left-handed LCS and pincer app roach –, 第84回日本臨床外科学会総会, Nov. 2022.
156.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 他臓器浸潤を伴う直腸癌に対する経肛門アプローチの有用性, 第84回日本臨床外科学会総会, Nov. 2022.
157.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第118回日本消化器病学会四国支部例会, Nov. 2022.
158.	Kouzou Yoshikawa, Mitsuo Shimada, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第52回胃外科・術後障害研究会, Nov. 2022.
159.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki and Mitsuo Shimada : Nrf2を基軸とした癌微小環境クロストークによる肝細胞癌Lenvatinib耐性機序解明に関する研究, 第33回日本消化器癌発生学会総会, Nov. 2022.
160.	Masaaki Nishi, 陳術海, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : CAFの糖代謝を標的とした治療法の開発 -フラボノイド(EGCGとSudachitin)の可能性-, 第33回日本消化器癌発生学会総会, Nov. 2022.
161.	Takuya Tokunaga, Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : 腫瘍関連マクロファージおよび大腸癌に対する青色LEDの効果, 第33回日本消化器癌発生学会総会, Nov. 2022.
162.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 大腸癌におけるImmunoscoreとFrailの相関についての検討, 第33回日本消化器癌発生学会総会, Nov. 2022.
163.	Masaaki Nishi, Chie Takasu, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Yuuma Wada, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 漢方とBacterial translocation-大建中湯の消化管疾患に対する多面的効果の検討-, 第35回日本外科感染症学会総会学術集会, Nov. 2022.
164.	Hiroki Mori, Hiroki Ishibashi and Mitsuo Shimada : 小児LPEC法症例における対側腹膜鞘状突起開存に対するBurning methodの有用性, 第38回日本小児外科学会秋季シンポジウム(PSJM2022), Oct. 2022.
165.	Hiroki Mori, Hiroki Ishibashi and Mitsuo Shimada : 小児abdominoscrotal hydrocele(ASH)に対するLPEC法の有用性, 第38回日本小児外科学会秋季シンポジウム(PSJM2022), Oct. 2022.
166.	Hiroki Mori, Hiroki Ishibashi, Noriko Yokota and Mitsuo Shimada : 鎖肛術後の高度便秘に対するサルベージ手術, 第38回日本小児外科学会秋季シンポジウム(PSJM2022), Oct. 2022.
167.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 再発鼠径ヘルニア症例に対するLPEC法によるサルベージ, 第38回日本小児外科学会秋季シンポジウム(PSJM2022), Oct. 2022.
168.	Hiroki Mori, Hiroki Ishibashi and Mitsuo Shimada : 緊急気管切開術により救命できた巨大頚部リンパ管腫の1例, 第32回小児外科QOL研究会, Oct. 2022.
169.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌におけるlymphocyte/C-reactive protein ratio(LCR)の有用性, JDDW 2022, Oct. 2022.
170.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者膵癌切除例におけるフレイルの影響に関する検討, JDDW 2022, Oct. 2022.
171.	仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌におけるNrf2に着目したレンバチニブ耐性獲得機序についての検討, 第60回日本癌治療学会学術集会, Oct. 2022.
172.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 仲須千春 and Mitsuo Shimada : 肝癌微小環境におけるNrf2/VEGFシグナルを介した肝癌細胞とTAMの相互作用, 第60回日本癌治療学会学術集会, Oct. 2022.
173.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Toshiaki Yoshimoto, 西麻希, Hiroshi Sakaue and Mitsuo Shimada : 肥満肝細胞癌患者に対する術前栄養運動介入の有用性 -ERAS導入による手術成績の向上-, 第60回日本癌治療学会学術集会, Oct. 2022.
174.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者膵癌切除例の予後におけるフレイルの影響に関する検討, 第60回日本癌治療学会学術集会, Oct. 2022.
175.	Tetsuya Ikemoto, Takuya Tokunaga, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Schwann-like cell分化誘導による末梢神経損傷修復に関する基礎的検討, 第60回日本癌治療学会学術集会, Oct. 2022.
176.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第60回日本癌治療学会学術集会, Oct. 2022.
177.	Yuhei Waki, Yu Saitou, Tetsuya Ikemoto, 陳術海, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出-肝不全・代謝性肝疾患に対する肝移植から細胞治療へ, 第58回日本移植学会総会, Oct. 2022.
178.	Yu Saitou, Mitsuo Shimada, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植ドナー不足解消にむけての普及啓発活動 - 医療系学生に対するドナーアクション(命の授業)の必要性 –, 第58回日本移植学会総会, Oct. 2022.
179.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いた移植治療確立へ向けた戦略∼新たなβ細胞補充治療法, 第58回日本移植学会総会, Oct. 2022.
180.	Hideya Kashihara, Takuya Tokunaga and Mitsuo Shimada : 低位直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, JDDW 2022, Oct. 2022.
181.	Kouzou Yoshikawa, Mitsuo Shimada and Masaaki Nishi : The usefulness of robotic surgery for advanced gastric cancer, JDDW 2022, Oct. 2022.
182.	Chie Takasu and Mitsuo Shimada : 癌治療におけるDiversity and inclusionを考える, 第60回日本癌治療学会学術集会, Oct. 2022.
183.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 髙橋叡 and Mitsuo Shimada : 大腸癌手術における予後因子としてのFrailの意義, 第60回日本癌治療学会学術集会, Oct. 2022.
184.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第60回日本癌治療学会学術集会, Oct. 2022.
185.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 上部胃癌に対するロボット手術の工夫 Pincer approach to gastrosplenic ligament, 第60回日本癌治療学会学術集会, Oct. 2022.
186.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : ハイブリッド側方リンパ節郭清手技と短期成績∼ホログラムシミュレーションの有用性∼, 第60回日本癌治療学会学術集会, Oct. 2022.
187.	Yuuma Wada, Mitsuo Shimada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 局所進行直腸癌における術前化学放射線療法においてADC値の有用性, 第60回日本癌治療学会学術集会, Oct. 2022.
188.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 大腸癌におけるImmunosoreとFrailの相関, 第60回日本癌治療学会学術集会, Oct. 2022.
189.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 胃全摘出術における術後パスの有用性―PSMによる解析―, 第60回日本癌治療学会学術集会, Oct. 2022.
190.	Hideya Kashihara, Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第77回日本大腸肛門病学会学術集会, Oct. 2022.
191.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 髙橋叡 : 他臓器浸潤直腸癌に対するTpAPR手術手技, 第77回日本大腸肛門病学会学術集会, Oct. 2022.
192.	Beibei Ma, Hiroyuki Ueda, Koichi Okamoto, Masahiro Bando, Yasuyuki Okada, Mitsuo Shimada, Yasushi Sato and Tetsuji Takayama : TIMP1 Promotes Cell Proliferation and Invasion Capability of Right-sided Colon Cancers., 第81回日本癌学会学術総会, Sep. 2022.
193.	Hiroki Mori, Yuji Morine, Hiroki Ishibashi, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 慢性炎症化下の膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第45回日本膵・胆管合流異常研究会, Sep. 2022.
194.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌腫瘍微小環境におけるNrf2/VEGFシグナルを介した癌細胞とTAMの相互作用, 第81回日本癌学会学術総会, Sep. 2022.
195.	Takayuki Noma, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 再発膵癌に対する残膵切除の治療成績, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
196.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Takayuki Noma and Mitsuo Shimada : 大腸癌肝転移におけるresectabilityの定義と集学的治療戦略, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
197.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
198.	Yu Saitou, 杉本真樹, Yuji Morine, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第16回肝癌治療ナビゲーション研究会, Sep. 2022.
199.	Yuuma Wada, Masaaki Nishi, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 癌関連線維芽細胞における糖代謝に着目した治療法の可能性, 第81回日本癌学会学術総会, Sep. 2022.
200.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 下部直腸癌に対するTaTME併用ロボット支援下直腸切除術(Hybrid robotic surgery)の有用性, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
201.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Yuuma Wada, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : 上部胃癌におけるロボット支援胃癌手術の工夫, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
202.	Chie Takasu, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, 髙橋叡 and Mitsuo Shimada : 腹腔鏡下胃切除における幽門下リンパ郭清困難性の術前評価, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
203.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下結腸癌手術における体腔内吻合の短期成績, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
204.	Masaaki Nishi, Shuhai Chen, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : CAFの糖代謝を標的とした治療法の開発-フラボノイド(EGCGとSudachitin)の可能性-, 第265回徳島医学会学術集会, Jul. 2022.
205.	仲須千春, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and 沖川昌平 : MRI拡散強調画像から見たミラノ基準内肝細胞癌の予後予測に関する検討, 第77回日本消化器外科学会総会, Jul. 2022.
206.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 膵癌残膵再発に対する残膵切除の治療成績, 第77回日本消化器外科学会総会, Jul. 2022.
207.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Toshiaki Yoshimoto, 西麻希, Hiroshi Sakaue and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第77回日本消化器外科学会総会, Jul. 2022.
208.	Tetsuya Ikemoto, Yu Saitou, Mitsuo Shimada, 沖川昌平, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いた細胞移植治療確立へ向けた戦略∼移植外科医・レシピエント双方の負担軽減という視点から, 第77回日本消化器外科学会総会, Jul. 2022.
209.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義とBRに対する集学的治療戦略, 第77回日本消化器外科学会総会, Jul. 2022.
210.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第77回日本消化器外科学会総会, Jul. 2022.
211.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yasuhiro Hamada, 沖川昌平 and Mitsuo Shimada : 肝細胞癌におけるmiRNA-132, 142-5pを介したLenvatinib耐性機序の検討, 第77回日本消化器外科学会総会, Jul. 2022.
212.	岩川陽介, Masaaki Nishi, Yuuma Wada, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 胃GISTに対するLECSの検討 -腫瘍径5㎝以上に対するLECS-, 第77回日本消化器外科学会総会, Jul. 2022.
213.	Takuya Tokunaga, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : Hologramによるシミュレーションを用いた経肛門的側方リンパ節郭清, 第77回日本消化器外科学会総会, Jul. 2022.
214.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 沖川昌平 and Mitsuo Shimada : 大腸癌腫瘍関連マクロファージに対する青色LEDの効果, 第77回日本消化器外科学会総会, Jul. 2022.
215.	Yuuma Wada, Mitsuo Shimada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and 岩川陽介 : 腹腔鏡下胃癌手術における術前栄養リハビリ介入の有用性, 第77回日本消化器外科学会総会, Jul. 2022.
216.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 腹腔鏡下スリーブ状胃切除術後長期効果に影響を及ぼす因子に関する検討, 第77回日本消化器外科学会総会, Jul. 2022.
217.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Yuuma Wada and 山下祥子 : 上部胃癌に対するロボット支援胃癌手術の工夫, 第77回日本消化器外科学会総会, Jul. 2022.
218.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 胃癌播種診断におけるCTスコアリングシステムを用いた診断率改善の試み, 第77回日本消化器外科学会総会, Jul. 2022.
219.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌におけるSorafenib/Lenvatinib耐性機序の検討, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
220.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
221.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除を中心とした治療戦略, 第31回日本癌病態治療研究会, Jun. 2022.
222.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第117回日本消化器病学会四国支部例会, Jun. 2022.
223.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 消化器・移植外科から発信する手術室医療安全, 第47回日本外科系連合学会学術集会, Jun. 2022.
224.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Associations between the ADC values based on MRI diffusion-weighted images and tumor-infiltrative lymphocytes in Stage III / IV hepatocellular carcinoma, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
225.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Masaaki Nishi, Hiroshi Sakaue and Mitsuo Shimada : Weight loss program for high body mass index patients undergoing liver resection for hepatocellular carcinoma, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
226.	Tetsuya Ikemoto, Yu Saitou, Mitsuo Shimada, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : Establishment of investigator initiated clinical trial for insulin producing cells from ADSC with Tokushima protocol to complement pancreas/islet transplantation., 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
227.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Role of surgical resection for advanced hepatocellular carcinoma focused on conversion surgery in MTA era, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
228.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第31回日本コンピュータ外科学会大会, Jun. 2022.
229.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Significance of the ADC values based on MRI DWI in Stage / HCC, 第67回国際外科学会日本部会総会, Jun. 2022.
230.	Yuji Morine, Yu Saitou and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療におけるConversion surgeryの意義, 第58回日本肝臓学会総会, Jun. 2022.
231.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 肝細胞癌におけるmiRNA-X,Yを介したLenvatinib耐性機序の検討, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
232.	Takuya Tokunaga, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性, 第31回日本癌病態治療研究会, Jun. 2022.
233.	Yuuma Wada, Kouzou Yoshikawa, Masaaki Nishi, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 進行胃癌に対するロボット支援下胃切除術の有用性, 第117回例会日本消化器病学会四国支部, Jun. 2022.
234.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 山下祥子 : 進行胃癌に対するロボット支援胃切除術の有用性とピットフォール, 第47回日本外科系連合学会学術集会, Jun. 2022.
235.	Toshiaki Yoshimoto, Takuya Tokunaga, Yu Saitou, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, 山下祥子, 岩川陽介 and Mitsuo Shimada : Intraoperative holographic image-guided lateral pelvic lymph node dissection in a transanal approach for rectal cancer, CARS 2022, Jun. 2022.
236.	Takuya Tokunaga, 杉本真樹, Yu Saitou, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 経肛門アプローチ併用ハイブリッド側方リンパ節郭清に対するホログラムの有用性, 第31回日本コンピュータ外科学会大会, Jun. 2022.
237.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : Apparent diffusion coefficient measurements predict survival outcomes after neoadjuvant chemoradiotherapy in locally advanced rectal cancer, 第67回国際外科学会日本部会総会, Jun. 2022.
238.	Toshiaki Yoshimoto, Hideya Kashihara, Kouzou Yoshikawa, Hiroki Ishibashi and Mitsuo Shimada : ロボット支援下前立腺全摘後の鼠径ヘルニアに対する腹腔鏡手術症例の検討, 第20回日本ヘルニア学会学術集会, Jun. 2022.
239.	Maki Hirata, Tetsuya Ikemoto, Kazunori Tokuda, Shohei Okikawa, 竹島雅之, Fumiki Morimatsu and Mitsuo Shimada : 糖尿病モデルマイクロミニブタの確立, 第69回日本実験動物学会総会, May 2022.
240.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori, 住田智志, Hisanori Uehara and Mitsuo Shimada : ロタワクチン接種を契機に発症した神経鞘腫を伴う回腸腸重積の1例, 第59回日本小児外科学会学術集会, May 2022.
241.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 早期治癒を目指した乳児臍ヘルニア圧迫療法の検討, 第59回日本小児外科学会学術集会, May 2022.
242.	Hiroki Mori, Shoko Yamashita, Yuji Morine, Hiroki Ishibashi, Koichi Tsuneyama and Mitsuo Shimada : 膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第59回日本小児外科学会学術集会, May 2022.
243.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 極低出生体重児発症の鼠径ヘルニアに対するLPEC法の妥当性, 第59回日本小児外科学会学術集会, May 2022.
244.	Hiroki Ishibashi, Yuji Morine, Yu Saitou, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 小児膵SPNに対する腹腔鏡下脾温存膵体尾部切除術, 第59回日本小児外科学会学術集会, May 2022.
245.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 症例, 第58回日本肝癌研究会, May 2022.
246.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義とBRに対する集学的治療戦略, 第58回日本肝癌研究会, May 2022.
247.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第58回日本肝癌研究会, May 2022.
248.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した肝胆道手術支援, 第58回日本肝癌研究会, May 2022.
249.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 再発肝細胞癌に対する肝切除の意義, 第58回日本肝癌研究会, May 2022.
250.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : ロボット胃癌手術における工夫 -Left handed LCS techniqueとPincer approach for gastro-splenic ligament-, 第76回手術手技研究会, May 2022.
251.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 術前抗がん剤治療を行った進行胃癌に対する低侵襲手術の有用性, 第122回日本外科学会定期学術集会, Apr. 2022.
252.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 小児鼠径ヘルニアに対するLPEC法の治療成績および適応拡大, 第122回日本外科学会定期学術集会, Apr. 2022.
253.	Takuya Tokunaga, Yu Saitou, 杉本真樹, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, 岩川陽介 and Mitsuo Shimada : 経肛門アプローチを用いた腹腔鏡下側方郭清の手術手技と短期成績∼Hologramによるシミュレーションの有用性∼, 第122回日本外科学会定期学術集会, Apr. 2022.
254.	Yuji Morine, Yu Saitou and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療におけるConversion Surgeryの意義, 第108回日本消化器病学会総会, Apr. 2022.
255.	髙橋叡, Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Stage III/IV 肝細胞癌におけるMRI拡散強調画像をもとにしたADC値の有用性に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
256.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Borderline resectableに着目した切除可能分類に基づく膵癌治療成績に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
257.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 膵癌切除例における早期再発の危険因子に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
258.	荒川悠佑, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 切除可能膵癌における術後予後予測因子としてのCRP・アルブミン比(CAR)の有用性, 第122回日本外科学会定期学術集会, Apr. 2022.
259.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己 and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第122回日本外科学会定期学術集会, Apr. 2022.
260.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, 沖川昌平, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 自己脂肪から作成したインスリン産生細胞自家移植が拓く再生医療の未来, 第122回日本外科学会定期学術集会, Apr. 2022.
261.	Hideya Kashihara, 沖川昌平 and Mitsuo Shimada : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する基礎的研究, 第108回日本消化器病学会総会, Apr. 2022.
262.	Yoshihito Matsuzaki, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara and Toshiaki Yoshimoto : ALS患者の胃癌2切除例, 第122回日本外科学会定期学術集会, Apr. 2022.
263.	Yuuma Wada, Masaaki Nishi, 陳術海, Yuji Morine, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, 山下祥子, 岩川陽介 and Mitsuo Shimada : 癌関連線維芽細胞の糖代謝を標的とした治療法の開発, 第122回日本外科学会定期学術集会, Apr. 2022.
264.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 間葉系幹細胞から肝細胞様細胞の誘導におけるNrf2の働きに関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
265.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子 and 岩川陽介 : 大腸癌におけるImmunoscoreとフレイルの検討, 第122回日本外科学会定期学術集会, Apr. 2022.
266.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 直腸癌に対するTaTME併用ロボット支援下直腸切除術の有用性 - TaTME併用腹腔鏡下直腸切除術との比較から –, 第122回日本外科学会定期学術集会, Apr. 2022.
267.	武原悠花子, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入術前減量プログラムの有用, 第122回日本外科学会定期学術集会, Apr. 2022.
268.	山下祥子, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and 岩川陽介 : 直腸癌の放射線化学療法における肥満細胞の役割, 第122回日本外科学会定期学術集会, Apr. 2022.
269.	沖川昌平, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, 山下祥子 and Yuji Morine : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
270.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, 沖川昌平, 山下祥子, 岩川陽介 and Mitsuo Shimada : 青色LEDの腫瘍関連マクロファージ(TAM)および大腸癌細胞に対する効果, 第122回日本外科学会定期学術集会, Apr. 2022.
271.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and 山下祥子 : ロボット支援胃癌手術の短期・長期成績-ロボットvs腹腔鏡:プロペンシティスコアマッチ解析-, 第122回日本外科学会定期学術集会, Apr. 2022.
272.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 高齢者におけるFrailtyの臨床的意義, 第94回日本胃癌学会総会, Mar. 2022.
273.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : Propensity score-matched analysis of the short-and long-term outcomes of RG vs. LG, 第94回日本胃癌学会総会, Mar. 2022.
274.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : The usefulness of the minimal invasive surgery for advanced gastric cancer with preoperative chemotherapy, 第94回日本胃癌学会総会, Mar. 2022.
275.	Tetsuya Ikemoto, Takuya Tokunaga, Yu Saitou, Shohei Okikawa, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導したSchwann-like cellに関する研究, 第21回日本再生医療学会総会, Mar. 2022.
276.	Chie Takasu, Yuji Morine, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Mitsuo Shimada : 腸管Microbiome解析からみた大建中湯の消化管疾患に対する多面的効果の検討, 第18回日本消化管学会総会学術集会(GI Week 2022), Feb. 2022.
277.	takimoto mami, Sonoko Yasui-Yamada, nasu nanami, kagiya natsumi, aotani nozomi, Yumiko Kurokawa, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Mitsuo Shimada and Yasuhiro Hamada : GLIM(Global Leadership Initiative on Malnutrition)基準の筋肉量減少を判定する指標の検討, 第24回・第25回日本病態栄養学会年次学術集会, Jan. 2022.
278.	Sonoko Yasui-Yamada, nasu nanami, kagiya natsumi, takimoto mami, Yumiko Kurokawa, Hideya Kashihara, Yu Saitou, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者において低筋量と低筋力のいずれが予後予測に有用か, 第24回・第25回日本病態栄養学会年次学術集会, Jan. 2022.
279.	Shohei Okikawa, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, NAKASU Chiharu and Mitsuo Shimada : VEGF阻害はTAMの機能を減弱させる, 第25回日本肝がん分子標的治療研究会, Jan. 2022.
280.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : ロボット支援下前立腺全摘術後に発症した鼠径ヘルニアの検討, 第34回日本内視鏡外科学会総会, Dec. 2021.
281.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 腹腔鏡・ロボット支援下胃癌手術のトレーニングプログラムの構築, 第34回日本内視鏡外科学会総会, Dec. 2021.
282.	Chie Takasu, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and Mitsuo Shimada : 腹腔鏡下胃切除における幽門下リンパ郭清困難性の術前評価, 第34回日本内視鏡外科学会総会, Dec. 2021.
283.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : NASHに対する新たな治療アプローチとしての腹腔鏡下スリーブ状胃切除術, 第34回日本内視鏡外科学会総会, Dec. 2021.
284.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃癌手術の有用性, 第34回日本内視鏡外科学会総会, Dec. 2021.
285.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 横行結腸・脾弯曲部・下行結腸癌における血管走行と腹腔鏡下手術手技に関する検討, 第34回日本内視鏡外科学会総会, Dec. 2021.
286.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 他臓器合併切除を要する直腸癌に対するTrasaperineal abdominoperineal resection, 第34回日本内視鏡外科学会総会, Dec. 2021.
287.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下スリーブ状胃切除における多職種介入周術期管理の有用性(WS5-2), 第34回日本内視鏡外科学会総会, Dec. 2021.
288.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : ロボット支援胃癌手術におけるLeft hand LCS techniqueを用いた定型化への取り組み(WS6-7), 第34回日本内視鏡外科学会総会, Dec. 2021.
289.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 肝癌微小環境においてTAMを介したNrf2/VEGFシグナルが悪性度増強に関与する, 第44回日本肝臓学会西部会, Dec. 2021.
290.	Yu Saitou, Yuji Morine and Mitsuo Shimada : 肝内胆管癌におけるMRI拡散強調画像を用いた新たな予後予測, 第44回日本肝臓学会西部会, Dec. 2021.
291.	Yuji Morine, Yu Saitou and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療におけるConversion surgeryの意義, 第44回日本肝臓学会西部会, Dec. 2021.
292.	Hiroki Teraoku, Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto, Yu Saitou and Mitsuo Shimada : 腹腔鏡下膵体尾部切除の手術手技と定型化, 第34回日本内視鏡外科学会総会, Dec. 2021.
293.	Toshiaki Yoshimoto, Shohei Okikawa, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 青色LEDの癌関連線維芽細胞および大腸癌に対する効果, 第32回日本消化器癌発生学会総会, Nov. 2021.
294.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Shoko Yamashita, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and IWAKAWA Yosuke : 直腸癌の放射線化学療法における肥満細胞の役割, 第32回日本消化器癌発生学会総会, Nov. 2021.
295.	Masaaki Nishi, Mitsuo Shimada, 陳述海, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : EGCGがCAFの糖代謝を標的とし，腫瘍悪性度を抑制する, 第32回日本消化器癌発生学会総会, Nov. 2021.
296.	Chie Takasu, Gao Luping, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : Nrf2を介した微小環境クロストークによる肝細胞癌薬剤耐性機序解明に関する研究, 第32回日本消化器癌発生学会総会, Nov. 2021.
297.	Takuya Tokunaga, 杉本真樹, Yu Saitou, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 直腸癌に対する経肛門的アプローチにおけるホログラムと尿道造影を併用した術中ナビゲーション, 第30回日本コンピュータ外科学会大会, Nov. 2021.
298.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Yuuma Wada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃切除の有用性-Robotic Versus Laparoscopic Gastrectomy: Propensi ty-Matched Analysis.-, 第116回日本消化器病学会四国支部例会, Nov. 2021.
299.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : taTMEの手術手技と治療成績, 第116回日本消化器病学会四国支部例会, Nov. 2021.
300.	IWAKAWA Yosuke, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 胃原発の未分化型多形肉腫の1例, 第83回日本臨床外科学会総会, Nov. 2021.
301.	Shoko Yamashita, Masaaki Nishi, Toshiaki Yoshimoto, Yuuma Wada, Hideya Kashihara, Chie Takasu, Toshihiro Nakao, Takuya Tokunaga, Kouzou Yoshikawa, Koichi Tsuneyama and Mitsuo Shimada : Osteoclast-like giant cellを伴うhamartomatous inverted polypから発生したリンパ球浸潤胃癌の一例, 第83回日本臨床外科学会総会, Nov. 2021.
302.	Shohei Okikawa, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Yuji Morine : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する検討, 第83回日本臨床外科学会総会, Nov. 2021.
303.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shoko Yamashita, IWAKAWA Yosuke and Mitsuo Shimada : 大腸癌予後因子としてのFrailの意義, 第83回日本臨床外科学会総会, Nov. 2021.
304.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移における免疫逃避機構の働き, 第83回日本臨床外科学会総会, Nov. 2021.
305.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : ロボット支援胃癌手術の標準化, 第83回日本臨床外科学会総会, Nov. 2021.
306.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 直腸切断術に対するTransperineal approachの有用性, 第83回日本臨床外科学会総会, Nov. 2021.
307.	Yuuma Wada, Mitsuo Shimada, Hideya Kashihara, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 腹腔鏡下胃癌手術における術前減量プログラムの有用性, 第83回日本臨床外科学会総会, Nov. 2021.
308.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : 経肛門的内視鏡下直腸間膜切除術TaTME併用による安全なロボット支援下直腸切除術の導入, 第83回日本臨床外科学会総会, Nov. 2021.
309.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 横行結腸癌における中結腸動脈の分岐からみた腹腔鏡下手術手技，治療成績, 第83回日本臨床外科学会総会, Nov. 2021.
310.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 腹腔鏡下胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第83回日本臨床外科学会総会, Nov. 2021.
311.	Chie Takasu, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and NAKASU Chiharu : 地方だからこそ発信できるインクルージョンを目指した働き方改革, 第83回日本臨床外科学会総会, Nov. 2021.
312.	Chie Takasu, Shoko Yamashita and Mitsuo Shimada : オンライン時代は女性医師キャリア形成の追い風となる, JDDW 2021, Nov. 2021.
313.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shohei Eto and Toshiaki Yoshimoto : ロボット時代の正確な腹膜播種診断に向けての胃癌Staging laparoscopyの有用性, JDDW 2021, Nov. 2021.
314.	Masaaki Nishi, Mitsuo Shimada and Kouzou Yoshikawa : Comparison of robotic and laoaroscopic gastrectomy for gastric cancer-Propensity score-matched analysis-, JDDW 2021, Nov. 2021.
315.	Yuuma Wada, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Shoko Yamashita : 外科手術におけるFrailtyの重要性, 第51回胃外科・術後障害研究会, Nov. 2021.
316.	Shohei Okikawa, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, NAKASU Chiharu and Mitsuo Shimada : VEGF阻害はTAMの悪性度を減じる, 第32回日本消化器癌発生学会総会, Nov. 2021.
317.	Hiroki Teraoku, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌におけるNrf2-PINK-1axisを介したLenvatinib耐性機序の検討, 第32回日本消化器癌発生学会総会, Nov. 2021.
318.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第32回日本消化器癌発生学会総会, Nov. 2021.
319.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa and Mitsuo Shimada : 肝細胞癌におけるソラフェニブ耐性獲得機序に関する検討, 第32回日本消化器癌発生学会総会, Nov. 2021.
320.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku, Takashi Iwata and Mitsuo Shimada : 消化器外科におけるホログラム次世代手術支援, 第30回日本コンピュータ外科学会大会, Nov. 2021.
321.	Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : One stop shop を目指したEOB-MRIによる部分肝機能評価，切除限界予測と腫瘍悪性度の評価に関する検討, 第116回日本消化器病学会四国支部例会, Nov. 2021.
322.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 再発膵癌に対する残膵切除の治療成績, 第83回日本臨床外科学会総会, Nov. 2021.
323.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション, 第83回日本臨床外科学会総会, Nov. 2021.
324.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 徳島大学の肝胆膵外科における若手教育, 第83回日本臨床外科学会総会, Nov. 2021.
325.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : 地方から世界に通用する一流の外科医を目指した取り組み, 第83回日本臨床外科学会総会, Nov. 2021.
326.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第83回日本臨床外科学会総会, Nov. 2021.
327.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 外科医をも守る消化器・移植外科から発信する手術室医療安全, 第83回日本臨床外科学会総会, Nov. 2021.
328.	Yu Saitou, 杉本真樹 and Mitsuo Shimada : 消化器外科手術におけるホログラム手術ナビゲーション, JDDW 2021, Nov. 2021.
329.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, IWAKAWA Yosuke and Mitsuo Shimada : DST吻合における吻合部血流不全のリスク因子:追加切除例の検討, 第59回日本癌治療学会学術集会, Oct. 2021.
330.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shoko Yamashita : 高齢者胃癌患者における外科手術の意義-Frailtyの重要性-, 第59回日本癌治療学会学術集会, Oct. 2021.
331.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 当科におけるTaTME手術手技と治療成績, 第59回日本癌治療学会学術集会, Oct. 2021.
332.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 腹腔鏡下胃・大腸癌手術における多職種介入術前減量プログラムの有用性, 第59回日本癌治療学会学術集会, Oct. 2021.
333.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : 進行胃癌に対するロボット手術の有用性, 第59回日本癌治療学会学術集会, Oct. 2021.
334.	Yuuma Wada, Mitsuo Shimada, Hideya Kashihara, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Shoko Yamashita, IWAKAWA Yosuke and Yasuhiro Hamada : 肥満外科手術における術前NLRの有用性, 第27回外科侵襲とサイトカイン研究会, Oct. 2021.
335.	Shoko Yamashita, Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 膵・胆管合流異常におけるNLRP3を介した腫瘍微小環境と発癌に関する検討, 第57回日本胆道学会学術集会, Oct. 2021.
336.	Shohei Okikawa, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第57回日本胆道学会学術集会, Oct. 2021.
337.	Shin-ichiro Yamada, Katsuki Miyazaki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita and Mitsuo Shimada : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第57回日本胆道学会学術集会, Oct. 2021.
338.	Masaaki Nishi, Ryosuke Miyamoto, Kouzou Yoshikawa, Chie Takasu, Yuishin Izumi and Mitsuo Shimada : Robot-assisted total gastrectomy for gastric cancer in a patient with amyotrophic lateral sclerosis receiving long-term tracheostomy invasive ventilation, PACTALS 2021 NAGOYA, Sep. 2021.
339.	Shohei Okikawa, Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto and Mitsuo Shimada : VEGF inhibition reduce TAM's malignant potential, 第80回日本癌学会学術総会, Sep. 2021.
340.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : The role of BAFF/BAFF receptor in microenvironment of sorafenib resistant he patocellular carcinoma, 第80回日本癌学会学術総会, Sep. 2021.
341.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : 生体肝移植術後短期長期成績に関する検討, 第57回日本移植学会総会, Sep. 2021.
342.	Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を基にした機能的肝細胞様細胞の分化誘導, 第57回日本移植学会総会, Sep. 2021.
343.	Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Shohei Okikawa, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療を用いたインスリン産生細胞自家移植による1型糖尿病根治治療確立へ向けた戦略, 第57回日本移植学会総会, Sep. 2021.
344.	Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション-マイクロ波手術デバイスAcrosurg®使用経験も含めて-, 第15回肝がんナビゲーション研究会, Sep. 2021.
345.	Mayu Ohhra, Hisami Okumura, 平山明由, Hana Kawakami, 多々納浩, Yuji Morine, Hirokazu Ohminami, Masashi Masuda, Mitsuo Shimada, 曽我朋義, 冨田勝 and Yutaka Taketani : メタボローム解析を用いた肝切除術による肝臓のアミノ酸代謝物の変化, 第 13 回日本臨床栄養代謝学会中国四国支部学術集会, Aug. 2021.
346.	Masaaki Nishi, Mitsuo Shimada, 陳述海, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto, Shoko Yamashita and IWAKAWA Yosuke : 癌関連線維芽細胞の糖代謝を標的とした治療法の開発, 第263回徳島医学会学術集会(令和3年度夏期), Aug. 2021.
347.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出-肝不全・代謝性肝疾患に対する肝移植から細胞治療へ-, 第263回徳島医学会学術集会(令和3年度夏期), Aug. 2021.
348.	Mayu Ohhra, Hisami Okumura, 平山明由, Hana Kawakami, 多々納浩, Yuji Morine, Hirokazu Ohminami, Masashi Masuda, Mitsuo Shimada, 曽我朋義, 冨田勝 and Yutaka Taketani : メタボローム解析を用いた肝切除術による肝臓の代謝物変化の検討, 第75回日本栄養・食糧学会大会, Jul. 2021.
349.	IWAKAWA Yosuke, Kouzou Yoshikawa and Mitsuo Shimada : 右胃大網動脈を用いた冠動脈バイパス術後の進行胃癌に対しロボット支援幽門側胃切除を施行した1例, 第76回日本消化器外科学会総会, Jul. 2021.
350.	Shohei Okikawa, Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yuji Morine : Duodenal-jejunal bypassの術後早期血糖抑制効果に関する検討, 第76回日本消化器外科学会総会, Jul. 2021.
351.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto, Shohei Okikawa and Mitsuo Shimada : 青色LEDの癌関連線維芽細胞および大腸癌細胞に対する効果, 第76回日本消化器外科学会総会, Jul. 2021.
352.	Toshihiro Nakao, 岩永将輝, 吉田金広, Yukikiyo Kawakami, Satoru Imura and Mitsuo Shimada : 穿孔性虫垂炎術後に十二指腸潰瘍が肝嚢胞へ穿通した1例, 第76回日本消化器外科学会総会, Jul. 2021.
353.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 進行胃癌に対するロボット支援胃切除術の有用性, 第76回日本消化器外科学会総会, Jul. 2021.
354.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : Feasibility of hybrid robotic rectal surgery with TaTME for lower rectal cancer, 第76回日本消化器外科学会総会, Jul. 2021.
355.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada, Toshiaki Yoshimoto and Shohei Eto : 高齢者胃癌に対するFrailityの意義, 第76回日本消化器外科学会総会, Jul. 2021.
356.	Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto and Mitsuo Shimada : 地方外科の実情と今後のリーダー育成に向けて, 第76回日本消化器外科学会総会, Jul. 2021.
357.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 直腸癌に対するTaTMEの手術手技と治療成績, 第76回日本消化器外科学会総会, Jul. 2021.
358.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Katsuki Miyazaki, Kazunori Tokuda, Shohei Okikawa, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第57回日本肝癌研究会, Jul. 2021.
359.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第57回日本肝癌研究会, Jul. 2021.
360.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第57回日本肝癌研究会, Jul. 2021.
361.	TAKAHASHI Akira, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第76回日本消化器外科学会総, Jul. 2021.
362.	NAKASU Chiharu, Tetsuya Ikemoto, Takuya Tokunaga, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞からSchwann-like cellの効果的分化誘導方法の研究, 第76回日本消化器外科学会総会, Jul. 2021.
363.	Shoko Yamashita, Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 膵・胆管合流異常におけるNLRP3活性化と発癌に関する検討, 第76回日本消化器外科学会総会, Jul. 2021.
364.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第76回日本消化器外科学会総会, Jul. 2021.
365.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝細胞癌の腫瘍微小環境におけるOsteopontinを介したCAF-TAM interactionについての検討, 第76回日本消化器外科学会総会, Jul. 2021.
366.	Yuuma Wada, Yuji Morine, Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Masaaki Nishi, Shin-ichiro Yamada, Kazunori Tokuda, Hiroki Teraoku and Mitsuo Shimada : 癌微小環境における大建中湯の癌細胞増殖抑制効果, 第76回日本消化器外科学会総会, Jul. 2021.
367.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第76回日本消化器外科学会総会, Jul. 2021.
368.	Yu Saitou, Maki Sugimoto, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Hiroki Teraoku, Katsuki Miyazaki, Takashi Iwata and Mitsuo Shimada : Navigation of rectal and hepatobiliary pancreatic surgery with intraoperative hologram, 第76回日本消化器外科学会総会, Jul. 2021.
369.	Hiroki Teraoku, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 両葉多発大腸癌肝転移に対する肝切除適応基準とConversion Surgery, 第76回日本消化器外科学会総会, Jul. 2021.
370.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第76回日本消化器外科学会総会, Jul. 2021.
371.	Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shohei Okikawa, Shoko Yamashita, IWAKAWA Yosuke and NAKASU Chiharu : 青色LEDの癌関連線維芽細胞および大腸癌細胞に対する効果, 第115回日本消化器病学会四国支部例会, Jun. 2021.
372.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第115回日本消化器病学会四国支部例会, Jun. 2021.
373.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 切除不能肝細胞癌に対するConversion・Salvage surgeryを目指した治療戦略, 第57回日本肝臓学会総会, Jun. 2021.
374.	Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出- 肝不全・代謝性肝疾患に対する肝移植から細胞移植へ –, 第57回日本肝臓学会総会, Jun. 2021.
375.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 小胞体ストレス応答に着目した非アルコール性脂肪肝炎の肝切除後肝再生/肝不全に関する研究, 第47回日本急性肝不全研究会, Jun. 2021.
376.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Kazunori Tokuda, Koichi Tsuneyama and Mitsuo Shimada : Endoplasmic reticulum stress response deficiency is a major cause of poor liver regeneration after hepatectomy in nonalcoholic steatohepatitis, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
377.	Hiroki Teraoku, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Katsuki Miyazaki : Significance of frailty for eldery patients in HPB surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
378.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : Treatment strategy of multiple colorectal liver metastasis-Criteria for upfront surgery and Conversion Surgery-, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
379.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography in biliary surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
380.	Yuji Morine, Hiroki Ishibashi, Hiroki Mori, T Araida, Mitsuo Shimada and H Fujii : Short-and long-term outcomes after surgical treatment of pancreaticobiliary maljunction:JSPBM nationwide survey data, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
381.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Katsuki Miyazaki : Clinical application of auto-transplantation of generated insulin-producing cells from ADSC with Tokushima protocol, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
382.	Mitsuo Shimada : 肝癌治療New Normal時代の外科医の役割, 第75回手術手技研究会, May 2021.
383.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃・大腸癌手術における術前減量プログラムは短期成績改善に寄与する, 第12回日本臨床栄養代謝学会首都圏支部会学術集会, May 2021.
384.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 進行胃癌に対するロボット支援下胃切除術の有用性と安全性, 第75回手術手技研究会, May 2021.
385.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 非アルコール性脂肪性肝疾患(NAFLD)における肝切除後肝再生機能不全に関する研究- 小胞体ストレス応答不全の観点より -, 第 121 回日本外科学会定期学術集会, Apr. 2021.
386.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝門部領域胆管癌の切除成績と術後補助療法の意義, 第121回日本外科学会定期学術集会, Apr. 2021.
387.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 異時性に磁石3個を誤飲し小腸イレウスを起こした1例, 第58回日本小児外科学会学術集会, Apr. 2021.
388.	Hiroki Mori, Yuji Morine, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常の胆道癌発癌機構にNrf2依存的インフラマソーム活性化が関与する, 第58回日本小児外科学会学術集会, Apr. 2021.
389.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 巨大胸骨後ヘルニアに対して腹壁筋Flapを併用した横隔膜修復術, 第58回日本小児外科学会学術集会, Apr. 2021.
390.	Hiroki Mori, Yuji Morine, Noriko Yokota, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常におけるNrf2依存的インフラマソーム活性化を介した胆道癌発癌機構に関する検討, 第121回日本外科学会定期学術集会, Apr. 2021.
391.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : リンパ管温存腹腔鏡下精巣動静脈切離術(Palomo法)における色素を用いた術中イメージングの有用性, 第121回日本外科学会定期学術集会, Apr. 2021.
392.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Mitsuo Shimada : 大腸癌予後因子としてのFrailの意義とメカニズムの検討, 第107回日本消化器病学会総会, Apr. 2021.
393.	Chie Takasu, Hideya Kashihara and Mitsuo Shimada : Metabolic surgeryによる NASH治療, 第107回日本消化器病学会総会, Apr. 2021.
394.	Kouzou Yoshikawa, Mitsuo Shimada and Masaaki Nishi : ロボット支援胃癌手術におけるLeft hand LCS techniqueの有用性, 第107回日本消化器病学会総会, Apr. 2021.
395.	Chiharu Nakasu, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Takuya Tokunaga, Hideya Kashihara, Yuishin Izumi and Ryosuke Miyamoto : 胃癌を発症したロックドイン状態のALS患者に対してロボット支援下胃全摘, 第121回日本外科学会定期学術集会, Apr. 2021.
396.	Jun Higashijima, Mitsuo Shimada, Shohei Okikawa, Toshiaki Yoshimoto, Shohei Eto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga and Kouzou Yoshikawa : 骨髄由来免疫抑制細胞を標的とした放射線治療抵抗性の制御メカニズムの解明, 第121回日本外科学会定期学術集会, Apr. 2021.
397.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Shohei Okikawa : 大腸癌および腫瘍微小環境に対する青色LEDの効果, 第121回日本外科学会定期学術集会, Apr. 2021.
398.	Shohei Eto, Kouzou Yoshikawa, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Toshihiro Nakao, Takuya Tokunaga, Jun Higashijima, Takashi Iwata and Mitsuo Shimada : ロボット支援腹腔鏡下前立腺切除術後の鼠径ヘルニア症例に対する治療戦略, 第121回日本外科学会定期学術集会, Apr. 2021.
399.	Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto and Mitsuo Shimada : 転移性肝癌におけるstromal PD-L1発現の意義, 第121回日本外科学会定期学術集会, Apr. 2021.
400.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : NASHに対する新たな治療アプローチとしてのmetabolic surgeryの可能性, 第121回日本外科学会定期学術集会, Apr. 2021.
401.	Takuya Tokunaga, Mitsuo Shimada, Yu Saitou, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and 杉本真樹 : ホログラムと術中尿道造影を駆使した経会陰的直腸切断術(TpAPR), 第121回日本外科学会定期学術集会, Apr. 2021.
402.	Tetsuya Ikemoto, Kazunori Tokuda and Mitsuo Shimada : 脂肪由来幹細胞から作製する消化器疾患に対する再生医療研究の展開, 第107回日本消化器病学会総会, Apr. 2021.
403.	Kanto Yamasaki, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : 術中Real-time 3D胆管造影を併用した胆道手術, 第121回日本外科学会定期学術集会, Apr. 2021.
404.	TAKAHASHI Akira, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞ADSCからのSuper HLC (肝細胞様細胞)の創出, 第121回日本外科学会定期学術集会, Apr. 2021.
405.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Adipose derived stem cellから作製したInsulin producing cellの臨床応用に向けた保存方法に関する研究, 第121回日本外科学会定期学術集会, Apr. 2021.
406.	Yu Saitou, Tetsu Tomonari, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Tetsuji Takayama and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療 - 分子標的治療薬使用によるConversion Surgery –, 第121回日本外科学会定期学術集会, Apr. 2021.
407.	Shoko Yamashita, Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 膵・胆管合流異常における腫瘍微小環境と発癌に関する検討, 第121回日本外科学会定期学術集会, Apr. 2021.
408.	Hiroki Teraoku, Gao Luping, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌におけるSorafenib耐性獲得機序に関する検討, 第121回日本外科学会定期学術集会, Apr. 2021.
409.	Shohei Okikawa, Yuji Morine, Kazunori Tokuda, Yu Saitou, Shin-ichiro Yamada, Shoko Yamashita, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 腫瘍微小環境におけるOsteopontinの意義, 第121回日本外科学会定期学術集会, Apr. 2021.
410.	Shin-ichiro Yamada, 陳術海, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌微小環境におけるPAI-1発現の意義に関する検討, Apr. 2021.
411.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Satoru Imura and Yuji Morine : 再生医療を用いたインスリン枯渇状態の患者に対する自律的インスリン分泌細胞自己移植に関するAMED橋渡し研究, 第121回日本外科学会定期学術集会, Apr. 2021.
412.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から作製したインスリン産生細胞の至適保存方法に関する研究, 第20回日本再生医療学会総会, Mar. 2021.
413.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出, 第20回日本再生医療学会総会, Mar. 2021.
414.	Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導したSchwann-like cellの基礎的検討, 第20回日本再生医療学会総会, Mar. 2021.
415.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 徳島大学の肝胆膵外科における若手教育-特に内視鏡手術に焦点をあてて-, 第33回日本内視鏡外科学会, Mar. 2021.
416.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, K Yamaguchi, M Takahashi, Hiro-omi Kanayama and Mitsuo Shimada : Surgical approach for inguinal hernia following robot-assisted radical prostatectomy, 第33回日本内視鏡外科学会, Mar. 2021.
417.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : The Usefulness of Intraoperative Urethrography for Avoiding Urethral Injury in TpTME, 第33回日本内視鏡外科学会, Mar. 2021.
418.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Usefulness of a left handed LCS technique for robotic gastrectomy, 第33回日本内視鏡外科学会, Mar. 2021.
419.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefulness of the OrVil method in LATG, 第33回日本内視鏡外科学会, Mar. 2021.
420.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : Usefulness of preoperative NLR as a predictive marker of DM remission in sleeve gastrectomy, 第33回日本内視鏡外科学会, Mar. 2021.
421.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるOrVil法の有用性, 第33回日本内視鏡外科学会, Mar. 2021.
422.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出- 肝不全・代謝性肝疾患に対する肝移植から細胞治療へ -, 第262回徳島医学会学術集会, Mar. 2021.
423.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and Yuuma Wada : Robotic Versus Laparoscopic Gastrectomy: Propensity-Matched Analysis, 第93回日本胃癌学会総会, Mar. 2021.
424.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 地方におけるロボット手術の定型化への試み, 第93回日本胃癌学会総会, Mar. 2021.
425.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty for elderly patients in HPB surgery, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
426.	Yu Saitou, Tetsuya Ikemoto, Yusuke Arakawa, Luping Gao, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective 3D culture of hepatocyte like cells human adipose derived mesenchymal stem cells, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
427.	Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography and indocyanine green navigation, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
428.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : The impact of frailty as a prognostic factor of colorectal liver metastasis, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
429.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : The value of CRP albumin ratio in patient with resectable pancreas cancer, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
430.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Basic research for aiming non-clinical PoC acquisition of insulin producing cells from ADSC with Tokushima protocol, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
431.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Optimal surgical treatment including lymph nodes dissection and adjuvant chemotherapy for intrahepatic cholangiocarcinoma, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
432.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Standardization and stepwise training for safe laparoscopic hepatectomy, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
433.	Yu Saitou, Tetsu Tomonari, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Yuji Morine, Tetsuji Takayama and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療-分子標的治療薬使用によるConversion Surgery-, 第23回日本肝がん分子標的治療研究会, Jan. 2021.
434.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Kazunori Tokuda and Katsuki Miyazaki : 肝胆膵領域悪性腫瘍におけるNrf2・VEGFに着目した腫瘍関連マクロファージ活性化についての検討, 第29回日本癌病態治療研究, Jan. 2021.
435.	Yu Saitou, 高露萍, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第38回日本肝移植学会学術集, Dec. 2020.
436.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : 肥満外科における術後体重減少・糖尿病寛解予測因子としてのNLRの有用性, 第57回日本外科代謝栄養学会学術集会, Dec. 2020.
437.	Toshiaki Yoshimoto, Takuya Tokunaga, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yukako Takehara and Mitsuo Shimada : TaTMEを安全に行うために∼術中尿道造影の有用性∼, 第45回日本外科系連合学会学術集会, Dec. 2020.
438.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : 鏡視下胃癌手術のトレーニングプログラムの構築Stepwise training programの有用性, 第45回日本外科系連合学会学術集会, Dec. 2020.
439.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, 杉本真樹 and Mitsuo Shimada : Hologramを用いた術中手術支援-術中Real-time3D胆管造影を併用した胆道手術-, 第45回日本外科系連合学会学術集会, Dec. 2020.
440.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第56回日本肝癌研究会, Dec. 2020.
441.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第56回日本肝癌研究会, Dec. 2020.
442.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第56回日本肝癌研究会, Dec. 2020.
443.	Yukako Takehara, Takuya Tokunaga, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : DST吻合における吻合部血流不全域のリスク因子:追加切除例の検討から, 第75回日本消化器外科学会総会, Dec. 2020.
444.	Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Toshiaki Yoshimoto, Yukako Takehara and Mitsuo Shimada : 直腸癌CRTにおける腫瘍のIDO発現の意義, 第75回日本消化器外科学会総会, Dec. 2020.
445.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 進行胃癌に対するロボット支援下胃切除術の有用性, 第75回日本消化器外科学会総会, Dec. 2020.
446.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 肥満外科における術後体重減少・糖尿病寛解予測因子としてのNLRの有用性, 第75回日本消化器外科学会総会, Dec. 2020.
447.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Yukako Takehara : ロボット支援下胃癌手術におけるLeft handed LCS techniqueの有用性, 第75回日本消化器外科学会総会, Dec. 2020.
448.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Yukako Takehara : TpTMEにおける前壁側剥離の工夫 ∼術中尿道造影の有用性∼, 第75回日本消化器外科学会総会, Dec. 2020.
449.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : 膵切除周術期における栄養指標からみた人工膵臓の有用性, 第75回日本消化器外科学会総会, Dec. 2020.
450.	Masato Yoshikawa, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : DWI-MRIのADC値を用いた転移性肝癌の切除後予後予測，抗癌剤効果予測に関する検討, 第75回日本消化器外科学会総会, Dec. 2020.
451.	Kazunori Tokuda, Yuji Morine, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 転移性肝癌切除症例におけるFrailの重要性についての検討, 第75回日本消化器外科学会総会, Dec. 2020.
452.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 胆嚢癌の悪性度評価におけるADCの有用性に関する検討, 第75回日本消化器外科学会総会, Dec. 2020.
453.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第75回日本消化器外科学会総会, Dec. 2020.
454.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 当院の肝胆膵手術症例におけるSSIサーベイランスによる検討, 第75回日本消化器外科学会総会, Dec. 2020.
455.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 長期予後と患者QoLに着目した膵全摘症例の検討, 第75回日本消化器外科学会総会, Dec. 2020.
456.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第75回日本消化器外科学会総会, Dec. 2020.
457.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 腹腔鏡下肝左葉切除の標準化への取り組み ∼手技定型化とstepwise training∼, 第75回日本消化器外科学会総会, Dec. 2020.
458.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Shohei Okikawa : 青色LEDによる大腸癌の光受容体をターゲットとする治療法の開発, 第31回日本消化器癌発生学会総会, Nov. 2020.
459.	Shohei Eto, Masaaki Nishi, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Toshihiro Nakao, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 下部進行直腸癌におけるCRT後のリンパ球CRP比(LCR)は予後不良因子となる, 第31回日本消化器癌発生学会総会, Nov. 2020.
460.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのリンパ球CRP比の意義と腫瘍浸潤リンパ球との関係, 第31回日本消化器癌発生学会総会, Nov. 2020.
461.	Shin-ichiro Yamada, 高露萍, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki and Mitsuo Shimada : ソラフェニブ耐性肝癌において，Nrf2は幹細胞性・遊走能・ABCトランスポーター発現を促進する, 第31回日本消化器癌発生学会総会, Nov. 2020.
462.	Yu Saitou and Mitsuo Shimada : VR・AR・MRを駆使した手術ナビゲーション, 第29回日本コンピュータ外科学会大会, Nov. 2020.
463.	Yuji Morine, Hiroki Mori, Yu Saitou, Shin-ichiro Yamada, Tetsuya Ikemoto, Satoru Imura, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常の発癌メカニズムに関する基礎研究:徳島大学の場合, 第43回日本膵・胆管合流異常研究会, Nov. 2020.
464.	Chie Takasu, Shoko Iwahashi and Mitsuo Shimada : 憧れの消化器外科専門医・スペシャリストを目指して, JDDW2020, Nov. 2020.
465.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : The Usefulness of Intraoperative Urethrography in Transperineal total Mesorectal Excision, JDDW2020, Nov. 2020.
466.	Yu Saitou, 杉本真樹 and Mitsuo Shimada : Hologramを用いた術中手術支援 -術中Real-time 3D胆管造影を併用した胆道手術-, JDDW2020, Nov. 2020.
467.	Tetsuya Ikemoto, Kazunori Tokuda and Mitsuo Shimada : 自己皮下脂肪組織の脂肪由来幹細胞から製造されるインスリン産生細胞の臨床応用へ向けた研究, JDDW2020, Nov. 2020.
468.	Katsuki Miyazaki, Yu Saitou, 高露萍, Tetsuya Ikemoto, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から分化誘導した肝細胞様細胞の遺伝子発現解析, 第56回日本移植学会総会, Nov. 2020.
469.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導したインスリン産生細胞の凍結保存方法についての検討, 第56回日本移植学会総会, Nov. 2020.
470.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 移植医から提案する再生医療技術を用いたインスリン産生細胞自家移植による1型糖尿病根治へ向けた戦略, 第56回日本移植学会総会, Nov. 2020.
471.	Mitsuo Shimada : New normal時代の外科漢方フォーラムの役割, 第82回日本臨床外科学会総会, Oct. 2020.
472.	Jun Higashijima, Toshiaki Yoshimoto, Shohei Eto, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Kouzou Yoshikawa and Mitsuo Shimada : ICG蛍光法を用いた大腸癌手術成績向上のための戦略, 第82回日本臨床外科学会総会, Oct. 2020.
473.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : ロボット支援胃癌手術の定型化-Left Handed LCS techniqueの有用性-, 第82回日本臨床外科学会総会, Oct. 2020.
474.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 肥満患者に対する術後合併症の回避を目指した術前減量プログラムの有用性, 第82回日本臨床外科学会総会, Oct. 2020.
475.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 術中尿道造影を併用したTpAPR手術手技, 第82回日本臨床外科学会総会, Oct. 2020.
476.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるOrVil法―Tension free methodの有用性―, 第82回日本臨床外科学会総会, Oct. 2020.
477.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 医療系学生に対するDonor Action(命の授業)の必要性, 第56回日本移植学会総会, Oct. 2020.
478.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki and Mitsuo Shimada : 膵癌切除症例における，Frailtyの意義に関する検討, 第82回日本臨床外科学会総会, Oct. 2020.
479.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 再生医療技術による1型糖尿病根治へ向けたシーズの臨床応用に関する検討, 第82回日本臨床外科学会総会, Oct. 2020.
480.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : Microbiome, HSCに着目した大建中湯の消化器癌に対する多面的効果の検討, 第82回日本臨床外科学会総会, Oct. 2020.
481.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : Hologramを用いた次世代術中手術支援 -術中Real-time 3D胆管造影を併用した胆道手術-, 第82回日本臨床外科学会総会, Oct. 2020.
482.	Yuji Morine, Mitsuo Shimada, Hiroki Ishibashi, 新井田達雄 and 藤井秀樹 : 膵・胆管合流異常における術式と短期・長期合併症:全国追跡調査から, 第82回日本臨床外科学会総会, Oct. 2020.
483.	湯浅麻美, Susumu Nishio, Sae Morita, 松本力三, Yukina Hirata, 山尾雅美, Takahiro Tanaka, Yu Saitou, Mitsuo Shimada and Masataka Sata : 神経内分泌癌との鑑別が困難であった膵腺房細胞癌の1例, 日本超音波医学会第30回四国地方会学術集会, Oct. 2020.
484.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Bevacizumab使用中の消化器外科手術に関する検討, 第56回日本腹部救急医学会総会, Oct. 2020.
485.	Katsuki Miyazaki, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 膵頭十二指腸切除術(PD)術後合併症回避に向けた腹腔動脈起始部圧迫症候群の周術期管理, 第56回日本腹部救急医学会総会, Oct. 2020.
486.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Mitsuo Shimada and 高露泙 : ソラフェニブ耐性肝細胞癌において，Nrf2は肝細胞性，遊走能，ABC transporterの発現を上昇させる, --- Nrf2 signaling promotes cancer stemness, migration and expression of ABC transporters in sorafenib-resistant HCC ---, 第79回日本癌学会学術集会, Oct. 2020.
487.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 小児慢性便秘症の特徴と治療効果に関する検討, 第57回日本小児外科学会学術集会, Sep. 2020.
488.	Hiroki Ishibashi, Noriko Yokota, Hiroki Mori and Mitsuo Shimada : 幽門腫瘤の固定に血管鉗子を用いた腹腔鏡下ラムステッド幽門筋切開術, 第57回日本小児外科学会学術集会, Sep. 2020.
489.	Hiroki Mori, Noriko Yokota, Hiroki Ishibashi and Mitsuo Shimada : 小児片側鼠径ヘルニアにおけるLPEC施行後対側発症例の特徴, 第57回日本小児外科学会学術集会, Sep. 2020.
490.	Hiroki Ishibashi, Noriko Yokota, Hiroki Mori and Mitsuo Shimada : 余剰皮膚を有する臍ヘルニア(臍突出症)に対する臍形成術(梶川法), 第57回日本小児外科学会学術集会, Sep. 2020.
491.	立木佐知子, 冨永誠記, Takahiro Tanaka, Shin-ichiro Yamada and Mitsuo Shimada : 徳島県における肝炎医療コーディネーターの活動―肝疾患診療連携拠点病院との連携から地域の肝炎医療コーディネーターの活動拡充へ―, 第56回日本肝臓学会総会, Aug. 2020.
492.	Yu Saitou, Tetsuya Ikemoto, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 3次元培養によるヒト脂肪由来間葉系幹細胞から肝細胞様細胞への効率的分化誘導, 第56回日本肝臓学会総会, Aug. 2020.
493.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第120回日本外科学会定期学術集会, Aug. 2020.
494.	Masato Yoshikawa, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : DWI-MRIのADC値を用いた転移性肝癌の予後予測に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
495.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵癌術後予後予測因子としての術前fibrinogen:血小板比の有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
496.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 切除可能大腸癌限局性肝転移の治療指針, 第120回日本外科学会定期学術集会, Aug. 2020.
497.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda and Masato Yoshikawa : 外科医の視点から開発された皮下脂肪から分離した脂肪由来幹細胞のインスリン産生細胞移植に関する研究, 第120回日本外科学会定期学術集会, Aug. 2020.
498.	Kazunori Tokuda, Tetsuya Ikemoto, 高露萍, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 肪由来幹細胞(ADSC)から肝細胞様細胞(HLC)への分化誘導における3D培養の有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
499.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 膵癌切除症例におけるFrailの意義に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
500.	Yu Saitou, Mitsuo Shimada, 杉本真樹, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Holographyを用いた次世代術中手術支援とICG蛍光法による肝離断navigation, 第120回日本外科学会定期学術集会, Aug. 2020.
501.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 小型肝癌に対する肝実質温存肝区画切除は妥当である, 第120回日本外科学会定期学術集会, Aug. 2020.
502.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 便秘で紹介になった小児の特徴と治療に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
503.	Hiroki Mori, Noriko Yokota, Hiroki Ishibashi and Mitsuo Shimada : 小児片側鼠径ヘルニアにおけるLPEC施行後対側発症を認めた5例の特徴, 第120回日本外科学会定期学術集会, Aug. 2020.
504.	Hiroki Ishibashi, Hiroki Mori, Yuji Morine, Mitsuo Shimada and 藤井秀樹 : 小児先天性胆道拡張症における晩期合併症と長期予後について-重症度分類と全国登録症例の追跡調査による検討-, 第120回日本外科学会定期学術集会, Aug. 2020.
505.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : ロボット支援下胃切除術の安全な導入と定型化, 第106回日本消化器病学会総会, Aug. 2020.
506.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : 血液透析患者に対する胃癌手術症例における予後因子の検討, 第92回日本胃癌学会総会, Jul. 2020.
507.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃全摘OrVil法におけるピットフォールとトラブルシューティング, 第92回日本胃癌学会総会, Jul. 2020.
508.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara and Chie Takasu : Left handed approach によるロボット支援下胃癌手術の有用性, 第92回日本胃癌学会総会, Jul. 2020.
509.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte/CRP ratio(LCR)の意義, 第113回日本消化器病学会四国支部例会, Jun. 2020.
510.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第113回日本消化器病学会四国支部例会, Jun. 2020.
511.	Kazunori Tokuda, Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Masato Yoshikawa, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura and Yuji Morine : 亜鉛イオンに着目したADSCから製造したInsulin-producing cell 成熟度に関する検討, 第19回日本再生医療学会総会, May 2020.
512.	Yu Saitou, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第19回日本再生医療学会総会, May 2020.
513.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura and Yuji Morine : T1DM患者から採取された脂肪組織から分離したADSCから製造したInsulin-producing cellに関する検討, 第19回日本再生医療学会総会, May 2020.
514.	Nozomi Aotani, Sonoko Yasui-Yamada, Natsumi Kagiya, Mayu Tanimura, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者における術前栄養評価としてのESPEN提唱栄養不良診断法の臨床的有用性, 第35回日本臨床栄養代謝学会学術集会, Feb. 2020.
515.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第53回制癌剤適応研究会, Feb. 2020.
516.	Masato Yoshikawa, Shin-ichiro Yamada, Yuji Morine, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 転移性肝癌におけるDWI-MRIのADC値を用いた予後予測に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
517.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 腫瘍関連マクロファージを介した肝胆膵癌の悪性度獲得に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
518.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : NBNC肝細胞癌の発癌と進展の分子標的からみた治療戦略, 第53回制癌剤適応研究会, Feb. 2020.
519.	Yukako Takehara, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : 大腸癌におけるFrailの意義とメカニズムの検討, 第53回制癌剤適応研究会, Feb. 2020.
520.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara and Mitsuo Shimada : Bevacizumab使用中の消化器外科手術に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
521.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 大腸癌のsidednessからみた腫瘍免疫, 第53回制癌剤適応研究会, Feb. 2020.
522.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 局所進行直腸癌に対する分子標的薬を加えた術前化学放射線療法の効果と感受性予測, 第53回制癌剤適応研究会, Feb. 2020.
523.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 経肛門的内視鏡下直腸間膜切除術TaTME併用ロボット支援下直腸切除術の有用性, 第34回四国内視鏡外科研究会, Feb. 2020.
524.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : ロボット支援下胃切除術の安全な導入と定型化, 第34回四国内視鏡外科研究会, Feb. 2020.
525.	Masato Yoshikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第260回徳島医学学会学術集会, Feb. 2020.
526.	Toshiaki Yoshimoto, Yukako Takehara, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa, Yuji Morine and Mitsuo Shimada : LED光による新たな癌制御法の開発, 第260回徳島医学会学術集会, Feb. 2020.
527.	Toshihiro Nakao, Satoru Imura, Yukikiyo Kawakami, 住友正幸, 吉田金広 and Mitsuo Shimada : Von Recklinghausen病に合併した腫瘍破裂による腹腔内出血を来した小腸多発GISTの1例, 第260回徳島医学会学術集会, Feb. 2020.
528.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Yasuhiro Hamada : 非アルコール性脂肪肝炎(NASH)に対する新たな外科治療の開発, 第260回徳島医学会学術集会, Feb. 2020.
529.	青井優, Kozo Kagawa, Nobuhito Naito, Seidai Satou, Hiroshi Kawano, Jinsei Miyoshi, Tomomi Matsuura, Hideya Kashihara, Kouzou Yoshikawa, Yuko Toyoda, Yoshimi Bando, Hiroshi Nokihara, Tetsuji Takayama, Mitsuo Shimada and Yasuhiko Nishioka : 好酸球性多発血管炎性肉芽腫症の治療中に回腸出血をきたし，血管炎との鑑別が困難であったCMV腸炎の1例, 第260回徳島医学会学術集会, Feb. 2020.
530.	Nozomi Aotani, Sonoko Yasui-Yamada, Natsumi Kagiya, Mami Takimoto, Mayu Tanimura, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者の術前評価におけるESPEN 提唱栄養不良診断基準の各診断項目と予後との関連, 第23回日本病態栄養学会年次学術集会, Jan. 2020.
531.	Yu Saitou, Tetsu Tomonari, Shin-ichiro Yamada, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Tetsuji Takayama and Mitsuo Shimada : 分子標的治療薬によりConversion Hepatectomyを施行し得た進行肝細胞癌の3例, 第21回日本肝がん分子標的治療研究会, Jan. 2020.
532.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yu Saitou, Satoru Imura, Mitsuo Shimada and Tetsuji Takayama : 進行肝癌におけるLenvatinibを用いたConversion Therapyの可能性―肝切除, Microwave ablation, 肝動脈塞栓術による追加治療の検討―., 第21回日本肝がん分子標的治療研究会, Jan. 2020.
533.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto and Yu Saitou : MRIを利用した肝切除限界予測と，腫瘍悪性度評価に関する検討, 第43回日本肝臓学会西部会, Dec. 2019.
534.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 小児鼠径ヘルニアに対する片側LPEC施行後に対側発症を来した5例, 第32回日本内視鏡外科学会総会, Dec. 2019.
535.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 小児鼠径ヘルニアに対するLPEC法のTips and Pitfalls, 第32回日本内視鏡外科学会総会, Dec. 2019.
536.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : Stepwise trainingとTaTME併用による安全なロボット支援下直腸切除術の導入, 第32回日本内視鏡外科学会総会, Dec. 2019.
537.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : ロボット支援胃癌手術におけるLeft handed approach の有用性, 第32回日本内視鏡外科学会総会, Dec. 2019.
538.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : TpTMEを安全に行うために ∼前壁剥離時の術中尿道造影の有用性∼, 第32回日本内視鏡外科学会総会, Dec. 2019.
539.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : スリーブ状胃切除における多職種介入術前減量入院の効果, 第32回日本内視鏡外科学会総会, Dec. 2019.
540.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 胆道閉鎖症lcystの4例, 第46回日本胆道閉鎖症研究会, Nov. 2019.
541.	Yu Saitou, 杉本真樹 and Mitsuo Shimada : Hologramを用いた次世代術前術中手術支援, 第28回日本コンピュータ外科学会大会, Nov. 2019.
542.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : The significance of metabolic surgery in the treatment for NASH, JDDW2019, Nov. 2019.
543.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Mitsuo Shimada : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, JDDW2019, Nov. 2019.
544.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 小児先天性胆道拡張症の根治術を考える(開腹アプローチの立場から), 第81回日本臨床外科学会総会, Nov. 2019.
545.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 小児鼠径ヘルニアに対するLPEC法の適応拡大と限界, 第81回日本臨床外科学会総会, Nov. 2019.
546.	Yukako Takehara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 大腸切除術における他職種介入SSI対策チームの有用性, 第81回日本臨床外科学会総会, Nov. 2019.
547.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 直腸癌手術におけるICG蛍光法・サーモグラフィによる血流評価を用いた縫合不全回避対策, 第81回日本臨床外科学会総会, Nov. 2019.
548.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : ロボット支援下胃癌手術におけるLeft handed approach の有用性, 第81回日本臨床外科学会総会, Nov. 2019.
549.	Masaaki Nishi, Mitsuo Shimada, 河野透, Yuji Morine, 勝野秀稔, 前田耕太郎, 肥田圭介, 森田智視, 渡邊昌彦, 草野満夫, 坂本純一, 佐野重豊, 前原喜彦, 兼松隆之 and 北島政樹 : 大建中湯の効果と投与条件の探索的研究-3つの臨床試験の統合解析-, 第81回日本臨床外科学会総会, Nov. 2019.
550.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, Yuji Morine and Mitsuo Shimada : 光受容体Opsin3をターゲットとした青色LEDの大腸癌抑制効果, 第81回日本臨床外科学会総会, Nov. 2019.
551.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 地方から発信する腹腔鏡技術認定医取得への教育プログラム, 第81回日本臨床外科学会総会, Nov. 2019.
552.	Masato Yoshikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第81回日本臨床外科学会総会, Nov. 2019.
553.	Tetsuya Ikemoto, Kazunori Tokuda, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : insulin-producing cell移植の細胞移植治療への臨床応用に向けた研究, 第81回日本臨床外科学会総会, Nov. 2019.
554.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第81回日本臨床外科学会総会, Nov. 2019.
555.	Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto, Yu Saitou, Yusuke Arakawa, Masato Yoshikawa, Satoru Imura and Mitsuo Shimada : 腸管Microbiome解析を加えた大建中湯の消化器疾患に対する多面的効果の検討, 第81回日本臨床外科学会総会, Nov. 2019.
556.	Mitsuo Shimada : 外科医の矜恃-Orthodox&Serendipity-, 第81回日本臨床外科学会総会, Nov. 2019.
557.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 便秘を主訴に当科紹介された小児例の検討, 第30回日本小児外科QOL研究会, Nov. 2019.
558.	Hiroki Mori, Yuji Morine, Noriko Yokota, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常におけるDNA切断修復応答を介した胆道癌発癌機構に関する検討, 第30回日本消化器癌発生学会総会, Nov. 2019.
559.	Toshiaki Yoshimoto, Masaaki Nishi, Yukako Takehara, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa and Mitsuo Shimada : 大腸癌のsidednessからみた腫瘍免疫, 第30回日本消化器癌発生学会総会, Nov. 2019.
560.	Mitsuo Shimada : 日本消化器癌発生学会の「創始と継志」―次の10年へ, 第30回日本消化器癌発生学会総会, Nov. 2019.
561.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Katsuki Miyazaki : 下部直腸癌に対する経肛門的アプローチ(TaTME)∼術中尿道造影の有用性∼, 第112回日本消化器病学会四国支部例会, Nov. 2019.
562.	Kouzou Yoshikawa, Mitsuo Shimada, Hideya Kashihara, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Toshiaki Yoshimoto, Yasuhiro Hamada and Sumiko Yoshida : スリーブ状胃切除における術前減量入院の効果とNLRによる術後減量効果予測, 第40回日本肥満学会第37回日本肥満症治療学会学術集会, Nov. 2019.
563.	Yukako Takehara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃切除術における術前減量プログラムの有用性, 第40回日本肥満学会第37回日本肥満症治療学会学術集会, Nov. 2019.
564.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : NASH治療におけるMetabolic surgeryの意義, 第40回日本肥満学会第37回日本肥満症治療学会学術集会, Nov. 2019.
565.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 胃癌に対するロボット手術の有用性, 第57回日本癌治療学会学術集会, Oct. 2019.
566.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, Yuji Morine and Mitsuo Shimada : 光受容体Opn3を介した青色LEDの大腸癌抑制効果, 第57回日本癌治療学会学術集会, Oct. 2019.
567.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Katsuki Miyazaki and Mitsuo Shimada : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第57回日本癌治療学会学術集会, Oct. 2019.
568.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Mitsuo Shimada : 臨床病理学的特徴と腫瘍悪性度解析からみたNBNC肝細胞癌の治療戦略, 第57回日本癌治療学会学術集会, Oct. 2019.
569.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 腹腔鏡下手術を行った，大網嚢胞が脱出した鼠径ヘルニアの1例, PSJM2019, Oct. 2019.
570.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 管理に難渋している前腸の多発奇形を合併した喉頭気管食道裂の1例, PSJM2019, Oct. 2019.
571.	Masato Yoshikawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への分化誘導, 第55回日本移植学会総会, Oct. 2019.
572.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脳死肝移植ドナー不足解消にむけての取り組み- 医療系学生に対するDonor Action(命の授業)の必要性 –, 第55回日本移植学会総会, Oct. 2019.
573.	Yusuke Arakawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞からインスリン産生細胞への分化誘導における赤色LEDの有用性に関する研究, 第55回日本移植学会総会, Oct. 2019.
574.	Tetsuya Ikemoto, Yu Saitou, Satoru Imura, Yuji Morine, Kazunori Tokuda, Shin-ichiro Yamada, Masato Yoshikawa and Mitsuo Shimada : 再生医療技術を用いたinsulin-producing cell移植の臨床応用に向けた研究, 第55回日本移植学会総会, Oct. 2019.
575.	Yukako Takehara, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Shoko Iwahashi, Koichi Tsuneyama and Mitsuo Shimada : SSTR2, Bcl2発現からみた肝内胆管癌の組織発生学的分類, 第55回日本胆道学会学術集会, Oct. 2019.
576.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第55回日本胆道学会学術集会, Oct. 2019.
577.	Yuji Morine, Mitsuo Shimada and 藤井秀樹 : 膵・胆管合流異常における術式と短期・長期合併症と胆道発癌ポテンシャルに関する検討, 第55回日本胆道学会学術集会, Oct. 2019.
578.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, JSH International Liver Conference, Oct. 2019.
579.	Toshiaki Yoshimoto, Mitsuo Shimada, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Tomohiko Miyatani and Kouzou Yoshikawa : 光受容体Opn3を介した青色LED光の大腸癌抑制効果, 第78回日本癌学会学術総会, Sep. 2019.
580.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第78回日本癌学会学術総会, Sep. 2019.
581.	Hiroki Mori, Yuji Morine, Noriko Yokota, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常の胆道癌発癌機構にDNA損傷修復経路が関与する, 第42回日本膵・胆管合流異常研究会, Sep. 2019.
582.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, 杉本真樹 and Mitsuo Shimada : Hologramを用いた次世代術前術中手術支援とICG蛍光法による肝離断navigation, 第14回肝癌治療ナビゲーション研究会, Sep. 2019.
583.	Yukako Takehara, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Toshiaki Yoshimoto : GISTとの鑑別を要したデスモイド型線維腺腫症の一例, 第71回日本消化器画像診断研究会, Sep. 2019.
584.	Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Yukako Takehara : 術前診断が困難であった成人小腸重複腸管の1例, 第71回日本消化器画像診断研究会, Sep. 2019.
585.	Masato Yoshikawa, Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Koichi Tsuneyama and Mitsuo Shimada : 卵巣様間質を伴う非粘液性嚢胞腺腫の二例, 第71回日本消化器画像診断研究会, Sep. 2019.
586.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第71回日本消化器画像診断研究会, Sep. 2019.
587.	Mitsuteru Yoshida, 山上真樹子, Akira Tangoku, Takashi Kitaichi, Masaaki Nishi, Hiromitsu Takizawa, Hiroki Ishibashi and Mitsuo Shimada : 徳島大学外科専門医研修プログラムの現状と今後の課題, 第94回中国四国外科学会総会・第24回中国四国内視鏡外科研究会, Sep. 2019.
588.	Hiroki Mori, Hiroki Ishibashi, Noriko Yokota and Mitsuo Shimada : 小腸端側吻合術後に大量下血を伴ったblind loop syndrome(盲管症候群)の1例, 第58回日本小児外科学会中国四国地方会, Sep. 2019.
589.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : LPEC法のTips and Pitfalls, 第58回日本小児外科学会中国四国地方会, Sep. 2019.
590.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 腹腔鏡高位鎖肛根治術におけるFinger-assist併用の有用性, 第58回日本小児外科学会中国四国地方会, Sep. 2019.
591.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 早期治療を目指した臍ヘルニアテープ固定法の有用性, 第58回日本小児外科学会中国四国地方会, Sep. 2019.
592.	Takashi Iwata, Mitsuo Shimada, Masahiko Azuma, Masami Nagamune and Masashi Akaike : VR+AR実習は学生の腹腔鏡模擬手術実習における局所解剖理解に有用である, 第51回日本医学教育学会大会, Jul. 2019.
593.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脳死肝移植ドナー不足解消にむけての取り組み- 医療系学生に対するDonor Action(命の授業)の必要性-, 第37回日本肝移植学会, Jul. 2019.
594.	Yusuke Arakawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Katsuki Miyazaki, Masato Yoshikawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への分化誘導, 第37回日本肝移植学会, Jul. 2019.
595.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Mitsuo Shimada : Bevacizumab使用中の消化器外科手術に関する検討, 第74回日本消化器外科学会総会, Jul. 2019.
596.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Yuuma Wada and Toshiaki Yoshimoto : Left handed approach によるロボット支援下胃癌手術, 第74回日本消化器外科学会総会, Jul. 2019.
597.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : VR+AR実習は学生の腹腔鏡模擬手術実習における局所解剖理解に有用である, 第74回日本消化器外科学会総会, Jul. 2019.
598.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Yasuhiro Hamada : スリーブ状胃切除における術前NLRと糖尿病改善についての検討, 第74回日本消化器外科学会総会, Jul. 2019.
599.	Chie Takasu, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Toshiaki Yoshimoto : 女性消化器外科医の技術向上とキャリア育成を目指した取り組み, 第74回日本消化器外科学会総会, Jul. 2019.
600.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Urethrography navigationを用いたTpTME手術手技, 第74回日本消化器外科学会総会, Jul. 2019.
601.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるOrVil法の有用性―合併症ゼロを目指した工夫―, 第74回日本消化器外科学会総会, Jul. 2019.
602.	Shoko Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : SSTR2・Bcl2発現による肝内胆管癌組織発生学的特徴に関する検討, 第74回日本消化器外科学会総会, Jul. 2019.
603.	Shuichi Iwahashi, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou and Shin-ichiro Yamada : 長期成績に着目した膵全摘症例の検討 -術後QOL評価に着目して-, 第74回日本消化器外科学会総会, Jul. 2019.
604.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝細胞癌に対する系統的肝区画切除は妥当である, 第74回日本消化器外科学会総会, Jul. 2019.
605.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : 肝細胞癌の肝切除術におけるFrailtyの意義に関する検討, 第74回日本消化器外科学会総会, Jul. 2019.
606.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : ホログラム術中胆道造影とウェアラブル近赤外蛍光法による肝切除手術支援, 第74回日本消化器外科学会総会, Jul. 2019.
607.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝内胆管癌の治療戦略:至適切除範囲と補助療法の効果, 第74回日本消化器外科学会総会, Jul. 2019.
608.	Tetsuya Ikemoto, Mitsuo Shimada, Masao Fuketa, Shinsuke Katoh, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : The utilization of `Big Data' in gastroenterological surgery, 第74回日本消化器外科学会総会, Jul. 2019.
609.	Sonoko Yasui-Yamada, Yu Ohiwa, Yu Saitou, Nozomi Aotani, Natsumi Kagiya, Mayu Tanimura, 菊井聡子, Yoshiko Suzuki, Akiko Matsumura, Hideya Kashihara, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者における術前栄養・予後指標としてのPhase Angle の臨床的実用性の検討, 日本外科代謝栄養学会, Jul. 2019.
610.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Yasuhiro Hamada : スリーブ状胃切除における多職種介入術前減量入院の効果とNLRによる術後減量効果, 日本外科代謝栄養学会第56回学術集会, Jul. 2019.
611.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第55回日本肝癌研究会, Jul. 2019.
612.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : EOB-MRIを用いた新たな肝切除基準の有用性, 第55回日本肝癌研究会, Jul. 2019.
613.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝内胆管癌の治療戦略:至適切除範囲と補助療法の効果, 第55回日本肝癌研究会, Jul. 2019.
614.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝癌に対する腹腔鏡肝切除の現状と今後の適応拡大, 第55回日本肝癌研究会, Jul. 2019.
615.	Masato Yoshikawa, Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Shoko Iwahashi and Mitsuo Shimada : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第26回外科侵襲とサイトカイン研究会, Jul. 2019.
616.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Left handed approachによるロボット支援下胃癌手術, 第111回日本消化器病学会四国支部例会, Jun. 2019.
617.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : DWI-MRIのADC値を用いたSorafenibの効果予測に関する検討, 第20回日本肝がん分子標的治療研究会, Jun. 2019.
618.	Chie Takasu, Mitsuo Shimada and Kouzou Yoshikawa : 大健中湯は小腸パイエル版のPD-1発現を介してバクテリアルトランスロケーション発症を予防する可能性がある, 第70回日本東洋医学会学術総会, Jun. 2019.
619.	Kouzou Yoshikawa, Mitsuo Shimada and Chie Takasu : 腹腔鏡下胃切除後ERAS(enhanced recovery after surgery)における大建中湯の有用性, 第70回日本東洋医学会学術総会, Jun. 2019.
620.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota, Hideya Kashihara, Kouzou Yoshikawa and Mitsuo Shimada : AYA世代の外鼠径ヘルニアに対するLPEC法の適応および妥当性, 第44回日本外科系連合学会学術集会, Jun. 2019.
621.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Shoko Iwahashi : 大腸癌手術における周術期VTE予防マネジメント, 第44回日本外科系連合学会学術集会, Jun. 2019.
622.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 学生の腹腔鏡模擬手術実習における局所解剖理解に対するVR+ARの有用性について, 第44回日本外科系連合学会学術集会, Jun. 2019.
623.	Tetsuya Ikemoto, Mitsuo Shimada, Masao Fuketa, Shinsuke Katoh, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 医療安全に関するAI活用と新たなアラートシステム構築, 第44回日本外科系連合学会学術集会, Jun. 2019.
624.	Katsuki Miyazaki, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : A case of preoperative nutritional and exercise intervention in HCC patient with alcoholic liver cirrhosis, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
625.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : Intraoperative support using holographic cholangiography and near-infrared fluorescence imaging, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
626.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : The effect of hepatic stellate cells on hepatocellular carcinoma progression, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
627.	Yuji Morine, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Standardization of surgical technique in laparoscopic distal pancreatectomy, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
628.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
629.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : Goal for board certified HBP surgeon, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
630.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : Our scientific approaches and investigation for Japanese Kampo Medicine in hepato-biliary-pancreatic diseases; especially TU-100 and TJ-48, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
631.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Evaluation of liver function using signal intensity of EOB-MRI for safe hepatectomy, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
632.	Hiroki Ishibashi and Mitsuo Shimada : 小児先天性胆道拡張症における成人移行への現状と問題点-全国登録症例の追跡調査と重症度分類による検討-, 第55回日本肝臓学会総会, May 2019.
633.	Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝癌に対する腹腔鏡肝切除の現状と今後の適応拡大, 第55回日本肝臓学会総会, May 2019.
634.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : ガーゼ剥離と膨潤TAPPを用いた腹腔鏡手術教育システムの有効性, 第17回日本ヘルニア学会学術集会, May 2019.
635.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : TpTMEにおける前壁剥離時の術中尿道造影の有用性, 第73回手術手技研究会, May 2019.
636.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第73回手術手技研究会, May 2019.
637.	Noriko Yokota, Hiroki Mori, Hiroki Ishibashi and Mitsuo Shimada : Finger-assistを併用し腹腔鏡下高位鎖肛根治術を施行した3例, 第56回日本小児外科学会学術集会, May 2019.
638.	Hiroki Mori, Yuji Morine, Noriko Yokota, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常におけるDNA損傷修復応答を介した胆道癌発癌機構に関する検討, 第56回日本小児外科学会学術集会, May 2019.
639.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 新生児先天性横隔膜ヘルニアに対する胸腔鏡下横隔膜修復術, 第56回日本小児外科学会学術集会, May 2019.
640.	Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : NASH治療におけるMetabolic surgeryの意義, 第105回日本消化器病学会総会, May 2019.
641.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto, 西山光恵 and 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第105回日本消化器病学会総会, May 2019.
642.	Tetsuya Ikemoto, Shuichi Iwahashi and Mitsuo Shimada : 脂肪幹細胞から創生されるインスリン産生細胞による糖尿病治療の臨床応用へむけた研究, 第105回日本消化器病学会総会, May 2019.
643.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : Usefulness of "one-stop shop" liver surgery simulation using EOB-MRI., ILLS2019, May 2019.
644.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : Standardization of surgical technique in laparoscopic left hemihepatectomy., ILLS2019, May 2019.
645.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 重症心身障害児における腹腔鏡下噴門形成術後のwrap herniation(再発)に関する検討, 第119回日本外科学会定期学術集会, Apr. 2019.
646.	Hiroki Mori, Yuji Morine, Noriko Yokota, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常におけるDNA損傷修復経路を介した胆道癌発癌機構に関する検討, 第119回日本外科学会定期学術集会, Apr. 2019.
647.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 小児LPEC法症例における対側腹膜鞘状突起開存率と予防的閉鎖の適応および手技について, 第119回日本外科学会定期学術集会, Apr. 2019.
648.	仲須千春, Masaaki Nishi, Mitsuo Shimada, Shoko Iwahashi, Tetsuya Ikemoto, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 大腸癌手術における周術期VTE予防マネジメント, 第119回日本外科学会定期学術集会, Apr. 2019.
649.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 直腸切断術におけるTaTMEの工夫 ∼尿道損傷回避のための術中尿道造影の有用性∼, 第119回日本外科学会定期学術集会, Apr. 2019.
650.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 側方転移を有する進行下部直腸癌に対する術前CRT+側方郭清の功罪, 第119回日本外科学会定期学術集会, Apr. 2019.
651.	Tomohiko Miyatani, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuuma Wada, Shogo Oota and Shoko Iwahashi : 直腸癌手術におけるICG蛍光法による血流評価の有用性と定量化, 第119回日本外科学会定期学術集会, Apr. 2019.
652.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : Step-wise trainingシステムによる安全なロボット支援胃切除導入の取り組み, 第119回日本外科学会定期学術集会, Apr. 2019.
653.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 大腸癌肝転移における免疫逃避機構は原発巣と異なる可能性がある, 第119回日本外科学会定期学術集会, Apr. 2019.
654.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Yasuhiro Hamada : スリーブ状胃切除における多職種介入術前減量入院の効果とNLRによる術後減量効果予測, 第119回日本外科学会定期学術集会, Apr. 2019.
655.	Masaaki Nishi, Mitsuo Shimada, Chie Takasu, Jun Higashijima, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga and Hideya Kashihara : 大腸癌におけるsidednessからみた腫瘍免疫機構, 第119回日本外科学会定期学術集会, Apr. 2019.
656.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 学生の腹腔鏡実習における局所解剖理解のためのVR実習の検討, 第119回日本外科学会定期学術集会, Apr. 2019.
657.	Katsuki Miyazaki, Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 卵巣様間質を伴う非粘液性嚢胞腺腫の2例, 第119回日本外科学会定期学術集会, Apr. 2019.
658.	Shoko Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : SSTR2発現からみた肝内胆管癌の組織発生学的分類, 第119回日本外科学会定期学術集会, Apr. 2019.
659.	Shogo Oota, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto and Shoko Iwahashi : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第119回日本外科学会定期学術集会, Apr. 2019.
660.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Yuuma Wada, Shogo Oota, Shoko Iwahashi and Mitsuo Shimada : 青色LED光のOpn3を介した大腸癌抑制効果 (第2報), 第119回日本外科学会定期学術集会, Apr. 2019.
661.	Yuuma Wada, Yuji Morine, Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 癌微小環境における大建中湯の肝星細胞活性化制御・癌細胞オートファジーを介した癌細胞増殖抑制効果, 第119回日本外科学会定期学術集会, Apr. 2019.
662.	Tetsuya Ikemoto, Mitsuo Shimada, Masao Fuketa, Shinsuke Katoh, Masaaki Nishi, Satoru Imura and Yuji Morine : 患者に信頼される病院を目指す戦略~AIを用いたインシデントレポート管理の未来, 第119回日本外科学会定期学術集会, Apr. 2019.
663.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : ホログラム術中胆道造影とウェアラブル近赤外蛍光法による肝切除手術支援, 第119回日本外科学会定期学術集会, Apr. 2019.
664.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto, Shoko Iwahashi, 西山光恵 and 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第119回日本外科学会定期学術集会, Apr. 2019.
665.	Shuichi Iwahashi, Tetsuya Ikemoto, Yuuma Wada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 臨床応用に向けたインスリン産生細胞分化誘導に関する研究, 第119回日本外科学会定期学術集会, Apr. 2019.
666.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Jun Higashijima : 大腸癌肝転移に対する肝切除を中心とした治療戦略 - Upfront肝切除適応基準と切除不能例に対するConversion surgery-, 第119回日本外科学会定期学術集会, Apr. 2019.
667.	Shogo Oota, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto and Shoko Iwahashi : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第18回日本再生医療学会総会, Mar. 2019.
668.	Yuuma Wada, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Shogo Oota, Shoko Iwahashi and Mitsuo Shimada : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第18回日本再生医療学会総会, Mar. 2019.
669.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yuji Morine and Mitsuo Shimada : 大腸癌に対する青色LED光の光受容体を介した抗腫瘍効果, 第52回制癌剤適応研究会, Mar. 2019.
670.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Toshiaki Yoshimoto : 肝胆膵領域癌におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第52回制癌剤適応研究会, Mar. 2019.
671.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Yasuhiro Hamada : 腹腔鏡下胃切除術における多職種介入術前減量プログラムの有用性, 第91回日本胃癌学会総会, Feb. 2019.
672.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : The usefulness of our step-wise training system for robotic assisted gastrectomy., 第91回日本胃癌学会総会, Feb. 2019.
673.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Toshiaki Yoshimoto and Yuuma Wada : 腹腔鏡下胃癌手術のトレーニングプログラムの構築, 第91回日本胃癌学会総会, Feb. 2019.
674.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : TaTMEにおける尿道損傷回避のための工夫 ∼術中尿道造影の有用性∼, 第33回四国内視鏡外科研究会, Feb. 2019.
675.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Step-wise trainingシステムによる安全なロボット支援下胃切除導入の取り組み, 第33回四国内視鏡外科研究会, Feb. 2019.
676.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第33回四国内視鏡外科研究会, Feb. 2019.
677.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Yuuma Wada and Toshiaki Yoshimoto : 安全なロボット支援下胃癌手術の再導入, 第2回徳島外科医会, Feb. 2019.
678.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : Lenvatinib投与中に呼吸不全を併発し急激な悪化の転機をたどった肝細胞癌多発肺転移の1例, 第2回徳島外科医会, Feb. 2019.
679.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第2回徳島外科医会, Feb. 2019.
680.	Yuuma Wada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 馮睿 and Mitsuo Shimada : 腫瘍関連マクロファージに着目した肝癌細胞悪性度上昇の検討, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
681.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Yuuma Wada : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
682.	Hiroki Mori, Hiroki Ishibashi, Noriko Yokota and Mitsuo Shimada : 重症心身障害児のGERDに対する腹腔鏡下Nissen-Rossetti噴門形成術の治療成績に関する検討, 第31回日本内視鏡外科学会総会, Dec. 2018.
683.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 小児胸腔鏡補助下肺切除術における定型化および3D simulation・navigationの有用性, 第31回日本内視鏡外科学会総会, Dec. 2018.
684.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 腹腔鏡下胃切除術における肥満症例に対する取り組み∼術前減量プログラムの効果∼, 第31回日本内視鏡外科学会総会, Dec. 2018.
685.	Chie Takasu, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga and Hideya Kashihara : 内視鏡外科技術向上を目指した総合的トレーニング法の効果, 第31回日本内視鏡外科学会総会, Dec. 2018.
686.	Jun Higashijima, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa and Mitsuo Shimada : 腹腔鏡下前方切除術における縫合不全回避のためのICG蛍光法とサーモグラフィーによる血流評価の有用性, 第31回日本内視鏡外科学会総会, Dec. 2018.
687.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 腹腔鏡下の局所解剖理解のためのVR実習と質的評価としてのルーブリック評価の検討, 第31回日本内視鏡外科学会総会, Dec. 2018.
688.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Takuya Tokunaga, Chie Takasu and Tomohiko Miyatani : 腹腔鏡下胃癌手術のトレーニングプログラムの構築, 第31回日本内視鏡外科学会総会, Dec. 2018.
689.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡手術におけるノンテクニカルスキル評価法の開発, 第31回日本内視鏡外科学会総会, Dec. 2018.
690.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : TaTMEにおける尿道損傷回避のための術中尿道造影の有用性, 第31回日本内視鏡外科学会総会, Dec. 2018.
691.	Yuuma Wada, Tetsuya Ikemoto, Shuichi Iwahashi, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masaaki Nishi, Satoru Imura and Mitsuo Shimada : 膵島保護におけるNrf2を介した Epigallocatechin-3-gallate (EGCG)の効果, 第48回創傷治癒学会, Nov. 2018.
692.	Hiroki Mori, Yuji Morine, Noriko Yokota, Hiroki Ishibashi, Kazuaki Mawatari, Akira Takahashi and Mitsuo Shimada : 膵・胆管合流異常における発がんメカニズムに関する検討, 第80回日本臨床外科学会総会, Nov. 2018.
693.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : 肝切除における術中手術支援のブレイクスル- -Virtual Reality & 肝離断Navigation –, 第80回日本臨床外科学会総会, Nov. 2018.
694.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : ガーゼ剥離と膨潤TAPPを用いた腹腔鏡手術教育システムの有効性, 第80回日本臨床外科学会総会, Nov. 2018.
695.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Evaluation of liver function for safe and radical hepatectomy in elderly patients (高齢者肝切除の安全性・根治性向上のための肝機能評価), 第80回日本臨床外科学会総会, Nov. 2018.
696.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Tomohiko Miyatani : 腹腔鏡下胃癌手術のトレーニングプログラムの構築-Road to white surgery-, 第80回日本臨床外科学会総会, Nov. 2018.
697.	Mitsuo Shimada : DKT-フォーラム・pooled解析(術後イレウス)について, 第80回日本臨床外科学会総会, Nov. 2018.
698.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 胃癌に対するConversion surgeryの有用性, 第80回日本臨床外科学会総会, Nov. 2018.
699.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 安全な中心静脈カテーテル(CVC)留置を目指したトレーニングシステムの構築・取組み・評価について, 第80回日本臨床外科学会総会, Nov. 2018.
700.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Toshiaki Yoshimoto : 大腸癌切除不能両葉多発肝転移におけるConversion後予後に関する検討-FOLFOXIRI療法の有用性-, 第80回日本臨床外科学会総会, Nov. 2018.
701.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Toshiaki Yoshimoto : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第10回膵臓内視鏡外科研究会・第12回肝臓内視鏡外科研究会, Nov. 2018.
702.	Jun Higashijima, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa and Mitsuo Shimada : Crohn's disease の外科治療成績について -Kono-S吻合の有用性-, 第110回日本消化器病学会四国支部例会, Nov. 2018.
703.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Rui Feng, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Toshiaki Yoshimoto : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第29回日本消化器癌発生学会総会, Nov. 2018.
704.	Mitsuo Shimada : 日本消化器癌発生学会の「創始と継志」, 第29回日本消化器癌発生学会総会, Nov. 2018.
705.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 大腸癌におけるmicroRNA-449a発現の意義, 第29回日本消化器癌発生学会総会, Nov. 2018.
706.	Hideya Kashihara, Toshiaki Yoshimoto, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Yuji Morine and Mitsuo Shimada : 大腸癌に対する青色LED光の効果と光受容体の関与についての研究, 第29回日本消化器癌発生学会総会, Nov. 2018.
707.	Shoko Iwahashi, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Koichi Tsuneyama and Mitsuo Shimada : Osteoclast-like giant cellを伴うhamartomatous inverted polypから発生したリンパ球浸潤胃癌の一例, 第29回日本消化器癌発生学会総会, Nov. 2018.
708.	Yu Saitou, 杉本真樹 and Mitsuo Shimada : Virtual Realityを用いた肝切除における術中手術支援, 第27回日本コンピュータ外科学会大会, Nov. 2018.
709.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, JDDW2018, Nov. 2018.
710.	Yu Saitou, 杉本真樹 and Mitsuo Shimada : 肝胆膵手術における解剖把握のためのVirtual Reality(VR)によるSimulationと術中手術支援, JDDW2018, Nov. 2018.
711.	Yuji Morine, Satoru Imura and Mitsuo Shimada : Treatment strategy for unresectable colorectal liver metastases: Clinical impact of FOLFOXIRI regimen, JDDW2018, Nov. 2018.
712.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : CKLF like MARVEL transmembrane domain containing 6(CMTM6)を介した胃癌再発機構, JDDW2018, Nov. 2018.
713.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 腹腔鏡下胃切除術における術前減量プログラムの効果, JDDW2018, Nov. 2018.
714.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Tomohiko Miyatani : 直腸縫合不全回避のためのICG蛍光法・サーモグラフィーを用いた血流評価の有用性, JDDW2018, Nov. 2018.
715.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 腹腔鏡下で肝静脈穿刺によりBroviacカテーテル留置を行った短腸症候群の1例, PSJM2018, Oct. 2018.
716.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 腹腔鏡下修復術を行った稀な小腸内ヘルニアの1例, PSJM2018, Oct. 2018.
717.	Hiroki Mori, Hiroki Ishibashi, Noriko Yokota and Mitsuo Shimada : 内臓逆位，無脾症候群を伴ったGERD症例に対して腹腔鏡下Nissen-Rossetti噴門形成術を施行した1例, PSJM2018, Oct. 2018.
718.	Hiroki Ishibashi, Noriko Yokota, Hiroki Mori and Mitsuo Shimada : 鎖肛術後の高度便秘，限局性直腸拡張症に対する腹腔鏡下直腸切除術の有用性, PSJM2018, Oct. 2018.
719.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第56回日本癌治療学会学術集会, Oct. 2018.
720.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : StageIV胃癌に対するConversion surgeryにおける問題点と治療戦略, 第56回日本癌治療学会学術集会, Oct. 2018.
721.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto and Shogo Oota : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第56回日本癌治療学会学術集会, Oct. 2018.
722.	Masaaki Nishi, Mitsuo Shimada, Chie Takasu, Hideya Kashihara, Kouzou Yoshikawa, Jun Higashijima, Daichi Ishikawa, Takuya Tokunaga, Yuuma Wada and Tomohiko Miyatani : 胃癌におけるCMTM6発現の意義, 第56回日本癌治療学会学術集会, Oct. 2018.
723.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下前方切除術におけるICG蛍光法・サーモグラフィーによる血流評価の有用性, 第56回日本癌治療学会学術集会, Oct. 2018.
724.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Shin-ichiro Yamada, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植ドナー不足解消にむけての取り組み-医療系学生に対するDonor Action(命の授業)の必要性-, 第54回日本移植学会総会, Oct. 2018.
725.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Satoru Imura and Mitsuo Shimada : Nrf2経路によるEGCGの膵島保護効果, 第54回日本移植学会総会, Oct. 2018.
726.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 臨床応用を目指した間葉系幹細胞から創生されるインスリン産生細胞による糖尿病の治療法確立に関する研究, 第54回日本移植学会総会, Oct. 2018.
727.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : Virtual Realityを用いた肝切除における術中手術支援, 第13回肝癌治療シミュレーション研究会, Sep. 2018.
728.	Yu Saitou, Hiroki Mori, Yuji Morine, Keigo Yada, Hiroki Ishibashi, 馬渡一論, Akira Takahashi and Mitsuo Shimada : メタボローム解析を用いた膵・胆管合流異常の胆汁中発癌物質の同定, 第54回日本胆道学会学術集会, Sep. 2018.
729.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Nrf2ActivationDriveMacrophagesPolarizationAndCancerCellEpithelial-Mesenchymal Transition During Interaction, 第77回日本癌学会学術集会, Sep. 2018.
730.	Tetsuya Ikemoto, Mitsuo Shimada, Shogo Oota, Yuuma Wada, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 膵癌患者における末梢血Tr1細胞が反映するPDL-1発現の意義に関する検討, 第77回日本癌学会学術集会, Sep. 2018.
731.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 新生児期に腎盂穿孔を来した先天性水腎症の1例, 第57回日本小児外科学会中国四国地方会, Sep. 2018.
732.	Hiroki Mori, Hiroki Ishibashi, Noriko Yokota and Mitsuo Shimada : Icyst型胆道閉鎖症を合併したCurrarino症候群の1例, 第57回日本小児外科学会中国四国地方会, Sep. 2018.
733.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 内視鏡下膜切開術が有効であった球部尿道弁の1例, 第57回日本小児外科学会中国四国地方会, Sep. 2018.
734.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Metabolic surgeryのNASH改善メカニズムに関する研究, 第27回消化器疾患病態治療研究会, Sep. 2018.
735.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Toshiaki Yoshimoto, Yuuma Wada and Shogo Oota : 長期予後に着目した膵全摘症例の検討-近年の化学療法の発展に伴う治療選択肢として-, 第27回消化器疾患病態治療研究会, Sep. 2018.
736.	Hiroki Ishibashi, Hiroki Mori, Noriko Yokota and Mitsuo Shimada : 出生前の肝門部嚢胞で先天性胆道拡張症が疑われた胆道閉鎖症Ⅰcystの3例, 第41回日本膵・胆管合流異常研究会, Sep. 2018.
737.	Yuji Morine, Mitsuo Shimada, Hiroki Ishibashi, 窪田正幸 and 安藤久實 : 膵・胆管合流異常症全国集計追跡調査2015・2017-特に非癌合併症例における短期・長期合併症について-, 第41回日本膵・胆管合流異常研究会, Sep. 2018.
738.	Takashi Iwata, Masami Nagamune, Masahiko Azuma, Mitsuo Shimada and Masashi Akaike : クリニカル・クラークシップでの手技実習の質的評価としてのルーブリック評価の有用性の検討, 第50回日本医学教育学会大会, Aug. 2018.
739.	Toshiaki Yoshimoto, Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : Nrf2に着目した肝癌細胞における腫瘍関連マクロファージ活性化の検討, 第18回日本肝がん分子標的治療研究会, Jul. 2018.
740.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : EOB-MRIは肝予備能を加味した術前simulationとして有用である, 第73回日本消化器外科学会総会, Jul. 2018.
741.	Shogo Oota, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : NLRを用いた胃癌における再建術式別栄養・免疫機能評価, 第73回日本消化器外科学会総会, Jul. 2018.
742.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : 肝切除における解剖把握のためのVirtual Reality(VR)によるSimulationと術中手術支援, 第73回日本消化器外科学会総会, Jul. 2018.
743.	Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 再発及び前立腺摘出術後の鼠径ヘルニア症例に対するTAPP法の有用性, 第73回日本消化器外科学会総会, Jul. 2018.
744.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Hiroki Teraoku and Shogo Oota : NCDデータからみた地方における消化器外科手術の特色と安全性評価に関する検討, 第73回日本消化器外科学会総会, Jul. 2018.
745.	Chie Takasu, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : 大健中湯は小腸パイエル版のPD-1発現を介してバクテリアルトランスロケーション発症を予防する可能性がある, 第73回日本消化器外科学会総会, Jul. 2018.
746.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : 肝内胆管癌に対する総合的治療戦略, 第73回日本消化器外科学会総会, Jul. 2018.
747.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : Metabolic surgeryのNASH改善メカニズムに関する研究, 第73回日本消化器外科学会総会, Jul. 2018.
748.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 手技定型化とstepwise training による安全な腹腔鏡下肝左葉切除, 第73回日本消化器外科学会総会, Jul. 2018.
749.	Masaaki Nishi, Mitsuo Shimada, Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Daichi Ishikawa and Yuuma Wada : CMTM6による胃癌再発機構の解明, 第73回日本消化器外科学会総会, Jul. 2018.
750.	Mitsuo Shimada : 地方にある日本で一番厳しい大学医局，それでも入りたくなる訳, 第73回日本消化器外科学会総会, Jul. 2018.
751.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada and Shogo Oota : TaTMEにおける尿道損傷回避のための工夫, 第73回日本消化器外科学会総会, Jul. 2018.
752.	Jun Higashijima, Mitsuo Shimada, Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Kouzou Yoshikawa and Hideya Kashihara : 局所進行下部直腸癌に対する術前化学放射線療法を用いた新たな治療戦略 ~Watch and wait導入へ向けて~, 第73回日本消化器外科学会総会, Jul. 2018.
753.	Kouzou Yoshikawa, Mitsuo Shimada, Hiroshi Okitsu, 江藤祥平, 富林敦司, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : StageIV胃癌に対するConversion surgeryにおける問題点と治療戦略, 第73回日本消化器外科学会総会, Jul. 2018.
754.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : ルーブリック評価を用いた腹腔鏡トレーニングの質的評価と局所解剖理解のためのVR実習の検討, 第73回日本消化器外科学会総会, Jul. 2018.
755.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : CT動脈相の造影効果から見た肝内胆管癌の腫瘍悪性度に関する検討, 第73回日本消化器外科学会総会, Jul. 2018.
756.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 胃癌におけるCMTM6発現の意義, 第25回外科侵襲とサイトカイン研究会, Jul. 2018.
757.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : 長期予後に着目した膵全摘症例の検討-近年の化学療法の発展に伴う治療選択肢として-, 第49回日本膵臓学会大会, Jun. 2018.
758.	Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Koichi Tsuneyama and Mitsuo Shimada : 症例, 第54回日本肝癌研究会, Jun. 2018.
759.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 肝星細胞はIL-6を介して肝癌細胞の悪性度増強・転移促進に寄与する, 第54回日本肝癌研究会, Jun. 2018.
760.	Yu Saitou, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Jun Higashijima : 同時性大腸癌肝転移に対する治療戦略, 第54回日本肝癌研究会, Jun. 2018.
761.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌に対する総合的治療戦略, 第54回日本肝癌研究会, Jun. 2018.
762.	Satoru Imura, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝癌に対する腹腔鏡肝切除の現状と今後の適応拡大, 第54回日本肝癌研究会, Jun. 2018.
763.	Shoko Iwahashi, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Mitsuo Shimada and Koichi Tsuneyama : 自然退縮を認めたInflammatory hepatocellular adenomaの一例, 第109回日本消化器病学会四国支部例会, Jun. 2018.
764.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 集学的治療としての膵全摘症例の検討, 第109回日本消化器病学会四国支部例会, Jun. 2018.
765.	Tetsuya Ikemoto, Mitsuo Shimada, Shinsuke Katoh, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 消化器・移植外科から発信する手術室の医療安全と効率化の両立, 第43回日本外科系連合学会学術集会, Jun. 2018.
766.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 肥満患者に対する腹腔鏡下胃切除術における術前減量プログラムの効果, 第43回日本外科系連合学会学術集会, Jun. 2018.
767.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : TaTMEにおける尿道損傷回避のための工夫, 第43回日本外科系連合学会学術集会, Jun. 2018.
768.	Yu Saitou, Satoru Imura and Mitsuo Shimada : 脳死肝移植ドナー不足解消にむけての取り組み―医療系学生に対するDonor Actionの必要性―, 第54回日本肝臓学会総会, Jun. 2018.
769.	Shuichi Iwahashi, Yuji Morine and Mitsuo Shimada : 大腸癌切除不能両葉多発肝転移に対する治療戦略―FOLFOXIRI療法のよるConversionの可能性―, 第54回日本肝臓学会総会, Jun. 2018.
770.	Yuji Morine, Mitsuo Shimada and Satoru Imura : 肝内胆管癌に対する総合的治療戦略, 第54回日本肝臓学会総会, Jun. 2018.
771.	Yu Saitou, Satoru Imura, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, 杉本真樹 and Mitsuo Shimada : Simulation and intraoperative support with virtual reality (VR)for anatomical grasp in hepatectomy., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
772.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Usefulness of 'one-stop shop' liver surgery simulation including estimation of total and regional liver functional reserve using EOB-MRI, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
773.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : Investigations for total pancreatectomy-focused on short-and long-term outcome-, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
774.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Treatment guidance in resectable colorectal liver metastasis., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
775.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Our educational system for safe and reliable hepatectomy., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
776.	Hiroki Teraoku, Tetsuya Ikemoto, Shogo Oota, Yuuma Wada, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine and Mitsuo Shimada : Preoperative care and surgical management for elderly and/or high-risk patients, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
777.	Yuuma Wada, Yuji Morine, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, shogo ohta and Mitsuo Shimada : Significance of hypoxia inducible factor-1 expression in liver metastasis of colorectal cancer., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
778.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 大腸癌におけるmicroRNA-449a発現の意義, 第27回日本癌病態治療研究会, May 2018.
779.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 末梢血Tr1比率はIPMNの悪性度評価に有用である, 第27回日本癌病態治療研究会, May 2018.
780.	Naoki Muguruma, Koichi Okamoto, 藤本将太, 宮本佳彦, Shinji Kitamura, Hiroshi Miyamoto, Mitsuo Shimada and Tetsuji Takayama : 分子解析に基づく大腸前癌病変 Aberrant crypt foci の新規イメージング技術開発., 第 13 回日本分子イメージング学会総会・学術集会, May 2018.
781.	Noriko Yokota, Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 先天性梨状窩嚢胞に対して新生児期に手術を行った2例, 第55回日本小児外科学会学術集会, May 2018.
782.	Hiroki Mori, Yuji Morine, Keigo Yada, Hiroki Ishibashi, Kazuaki Mawatari, Akira Takahashi and Mitsuo Shimada : メタボローム解析を用いた膵・胆管合流異常における胆汁発癌物質の検討, 第55回日本小児外科学会学術集会, May 2018.
783.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada, Noriko Yokota and Mitsuo Shimada : 女児卵巣脱出，卵管滑脱ヘルニアに対するLPEC法の有用性, 第55回日本小児外科学会学術集会, May 2018.
784.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada, Noriko Yokota, Yuji Morine, Mitsuo Shimada and 安藤久實 : 先天性胆道拡張症の全国集計からみた小児から成人移行への問題点―追跡調査と重症度分類での検討―, 第55回日本小児外科学会学術集会, May 2018.
785.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada, Noriko Yokota and Mitsuo Shimada : 小児鼠径ヘルニアに対するLPEC法の短期・長期成績, 第55回日本小児外科学会学術集会, May 2018.
786.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 発光ダイオード(LED)の波長強度可変装置による肝細胞保護に関する研究, 第36回日本肝移植研究会, May 2018.
787.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 医療系学生に対するDonor Actionの必要性- 移植医療理解・意思表示率向上にむけての取り組み –, 第36回日本肝移植研究会, May 2018.
788.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada and Mitsuo Shimada : Identification of bile carcinogens in patient with pancreaticobiliary maljunction using metabolome analysis., PAPS, May 2018.
789.	Jun Higashijima, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Kouzou Yoshikawa, Hiroki Mori, Takuya Tokunaga, Masaaki Nishi, Shuichi Iwahashi, Yu Saitou, Hideya Kashihara, Chie Takasu and Keigo Yada : Academic surgeon 育成のための新たな研修への取り組み―大学病院と市中病院の新たな連携―, 第36回臨床研修研究会, Apr. 2018.
790.	Tetsuya Ikemoto, Mitsuo Shimada, Chie Takasu and 和田佑馬 : IPMN悪性度診断に関する免疫学的パラメーターとIL-10発現に関する研究, 第104回日本消化器病学会総会, Apr. 2018.
791.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Daichi Ishikawa and Yuuma Wada : 肥満手術のインスリン抵抗性・NASH改善効果におけるマイクロバイオームの重要性, 第104回日本消化器病学会総会, Apr. 2018.
792.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 大建中湯 (TU-100) の肝星細胞抑制を介したNASH発癌抑制効果に関する検討, 第118回日本外科学会定期学術集会, Apr. 2018.
793.	Hiroki Mori, Yuji Morine, Keigo Yada, Hiroki Ishibashi, Kazuaki Mawatari, Akira Takahashi and Mitsuo Shimada : メタボローム解析を用いた膵・胆管合流異常の胆汁中発癌物質の同定, 第118回日本外科学会定期学術集会, Apr. 2018.
794.	Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Chie Takasu and Mitsuo Shimada : 胃癌組織中に発現するmicroRNA-449aの意義解明についての研究, 第118回日本外科学会定期学術集会, Apr. 2018.
795.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 肥満患者に対する腹腔鏡下胃・大腸切除術における術前減量プログラムの効果, 第118回日本外科学会定期学術集会, Apr. 2018.
796.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるOrVil法の有用性, 第118回日本外科学会定期学術集会, Apr. 2018.
797.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masashi Akaike : 腹腔鏡トレーニングの質的評価としてのルーブリック評価の有用性の検討, 第118回日本外科学会定期学術集会, Apr. 2018.
798.	宮崎克己, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Koichi Tsuneyama and Mitsuo Shimada : 自然退縮を認めたInflammatory hepatocellular adenomaの一例, 第118回日本外科学会定期学術集会, Apr. 2018.
799.	Chie Takasu, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Daichi Ishikawa : 大腸癌におけるPD-1/PDL-1発現の意義, 第118回日本外科学会定期学術集会, Apr. 2018.
800.	Yu Saitou, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Satoru Imura, Yuji Morine and Mitsuo Shimada : Epigallocatechin gallate(EGCG)による脂肪由来間葉系幹細胞(ADSC)からInsulin producing cell(IPC)への効率的な分化誘導に関する研究, 第118回日本外科学会定期学術集会, Apr. 2018.
801.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : 肝予備能を加味したOne Stop Shop SimulationとMixed realityによる新たなNavigation, 第118回日本外科学会定期学術集会, Apr. 2018.
802.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku and Jun Higashijima : 同時性大腸癌肝転移に対する治療戦略, 第118回日本外科学会定期学術集会, Apr. 2018.
803.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Lifting methodを駆使した安全・確実な開腹肝切除, 第118回日本外科学会定期学術集会, Apr. 2018.
804.	Shoko Iwahashi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Hirokazu Miki and Masahiro Oura : MDS・発作性夜間血色素尿症を合併する胃癌に対する手術が安全に施行可能であった1例, 第118回日本外科学会定期学術集会, Apr. 2018.
805.	Shogo Oota, Mitsuo Shimada, Masaaki Nishi, Takuya Tokunaga, Jun Higashijima, Daichi Ishikawa, Kouzou Yoshikawa, Chie Takasu, Hideya Kashihara and Yuji Morine : ICG蛍光システムを用いたTaTMEにおける尿道損傷回避に向けた取り組み, 第118回日本外科学会定期学術集会, Apr. 2018.
806.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota and Mitsuo Shimada : 大腸癌肝転移におけるHypoxia Inducible Factor-1発現の意義 -肝転移巣・原発巣における腫瘍悪性度評価-, 第118回日本外科学会定期学術集会, Apr. 2018.
807.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 肝内胆管癌の造影効果による腫瘍悪性度評価の検討, 第118回日本外科学会定期学術集会, Apr. 2018.
808.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Yuuma Wada and Hiroki Teraoku : Epigallocatechin-3-gallateはNrf2を介して膵島保護作用を有する, 第118回日本外科学会定期学術集会, Apr. 2018.
809.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Hiroki Teraoku and Shogo Oota : 臨床応用を目指した間葉系幹細胞から創生されるインスリン産生細胞による糖尿病の治療法確立に関する研, 第118回日本外科学会定期学術集会, Apr. 2018.
810.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Yuuma Wada : 腫瘍免疫からみた大腸癌再発機構の解明, 第118回日本外科学会定期学術集会, Apr. 2018.
811.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada and Shogo Oota : 腹腔鏡下前方切除術におけるICG蛍光法・サーモグラフィーによる血流評価の有用性, 第118回日本外科学会定期学術集会, Apr. 2018.
812.	Jun Higashijima, Mitsuo Shimada, Shogo Oota, Daichi Ishikawa, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga and Kouzou Yoshikawa : 局所進行直腸癌に対する分子標的薬を加えた術前化学放射線療法の効果と感受性予測:基礎的検討と臨床成績, 第118回日本外科学会定期学術集会, Apr. 2018.
813.	Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Masaaki Nishi, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 大腸癌の発癌・癌進展におけるmicroRNA-449aの役割解明, 第51回制癌剤適応研究会, Mar. 2018.
814.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Hiroshi Okitsu, 江藤祥平, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : StageIV胃癌に対するConversion surgeryにおける問題点と治療戦略, 第51回制癌剤適応研究会, Mar. 2018.
815.	Hiroki Teraoku, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : Sorafenib投与症例におけるHCC長期生存例の検討, 第51回制癌剤適応研究会, Mar. 2018.
816.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 肝星細胞はIL-9を介して肝癌細胞増強・転移促進に寄与する, 第51回制癌剤適応研究会, Mar. 2018.
817.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 肥満患者に対する腹腔鏡下胃切除術における術前減量プログラム, 第90回日本胃癌学会総会, Mar. 2018.
818.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Takuya Tokunaga, Chie Takasu and Daichi Ishikawa : LECS for GIST -single center experience-, 第90回日本胃癌学会総会, Mar. 2018.
819.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : The usefulness of the OrVil method and liver mobilization for optimal surgical field in LATG., 第90回日本胃癌学会総会, Mar. 2018.
820.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 鼠径ヘルニア再発症例に対するTAPP法の有用性, 第32回四国内視鏡研究会, Feb. 2018.
821.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuma Wada and Shogo Ohta : 当科におけるTaTMEの導入について, 第32回四国内視鏡研究会, Feb. 2018.
822.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 肥満に対する腹腔鏡下Sleeve状胃切除の経験, 第32回四国内視鏡研究会, Feb. 2018.
823.	Hiroki Mori, Noriko Yokota, Hiroki Ishibashi and Mitsuo Shimada : 腹腔鏡下修復術を行った稀な内ヘルニアの1例, 第2回徳島外科医会, Feb. 2018.
824.	Akiyo Kanazawa, Masato Tagi, Takahiro Yoshida, Mitsuo Shimada, Akemi Nakano and Tomoko Takagai : クリニカルパス支援体制の構築, 平成29年度大学病院情報マネジメント部門連絡会議, 116-117, Jan. 2018.
825.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 肝星細胞はIL-6を介して肝癌細胞増強・転移促進に寄与する, 第17回日本肝がん分子標的治療研究会, Jan. 2018.
826.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 小児再発鼠径ヘルニア症例に対するLPEC法の有用性, 第30回日本内視鏡外科学会総会, Dec. 2017.
827.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : ガーゼ剥離を用いた膨潤TAPP―再発症例より学至適剥離・メッシュ展開―, 第30回日本内視鏡外科学会総会, Dec. 2017.
828.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡下腹壁瘢痕ヘルニア根治術に対するHybrid法の有用性, 第30回日本内視鏡外科学会総会, Dec. 2017.
829.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下大腸手術における縫合不全回避のための血流評価の重要性, 第30回日本内視鏡外科学会総会, Dec. 2017.
830.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 当科における腹腔鏡(補助)下膵体尾部切除術の検討, 第9回膵臓内視鏡外科研究会, Dec. 2017.
831.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : 若手医師による術前術中3Dsimulation画像を用いた腹腔鏡下手術の定型化, 第11回肝臓内視鏡外科研究会, Dec. 2017.
832.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 手技定型化による安全な腹腔鏡下肝左葉切除, 第11回肝臓内視鏡外科研究会, Dec. 2017.
833.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota, Satoru Imura and Mitsuo Shimada : Nef2-Keap1経路の膵島保護作用におけるEpigallocatechin-3-gallate(EGCG)の役割, 第47回日本創傷治癒学会, Nov. 2017.
834.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori, Mitsuo Shimada and 安藤久實 : 先天性胆道拡張症の診療ガイドライン, 第79回日本臨床外科学会総会, Nov. 2017.
835.	Takuya Tokunaga, Chie Takasu, Daichi Ishikawa, Hideya Kashihara, Masaaki Nishi, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : Hybrid法を用いた腹腔鏡下腹壁瘢痕ヘルニア根治術の安全性と有用性, 第79回日本臨床外科学会総会, Nov. 2017.
836.	Daichi Ishikawa, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 鼠径ヘルニア再発症例に対するTAPP法の有用性, 第79回日本臨床外科学会総会, Nov. 2017.
837.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : ガーゼ剥離を用いた膨潤TAPP, 第79回日本臨床外科学会総会, Nov. 2017.
838.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡実習におけるルーブリック評価を用いた質的評価の検討, 第79回日本臨床外科学会総会, Nov. 2017.
839.	Shoko Iwahashi, Tetsuya Ikemoto, Yu Saitou, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Hiroki Teraoku and Mitsuo Shimada : 併存疾患多数のStageⅣa膵体部癌に対し集学的補助で化学療法jを導入し長期生存を得た一例, 第79回日本臨床外科学会総会, Nov. 2017.
840.	Shogo Oota, Yuuma Wada, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 初回切除後再発膵癌に対する再切除の有用性, 第79回日本臨床外科学会総会, Nov. 2017.
841.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku and Shogo Oota : 超高齢者に対する肝切除の妥当性に関する検討 -85歳以上の超高齢者にも肝切除は安全に施行可能である, 第79回日本臨床外科学会総会, Nov. 2017.
842.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Modified de-rotation法による完全動脈先行処理を用いた膵頭十二指腸切除術, 第79回日本臨床外科学会総会, Nov. 2017.
843.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Chie Takasu and Jun Higashijima : 大腸癌切除不能両葉多発肝転移に対するFOLFOXIRI療法の有用性, 第79回日本臨床外科学会総会, Nov. 2017.
844.	Mitsuo Shimada : Treatment strategy of chemotherapy and surgical treatment for HCC, 第79回日本臨床外科学会総会, Nov. 2017.
845.	Hiroki Mori, Yuji Morine, Keigo Yada, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常における胆汁発癌物質のメタボローム解析, 第28回日本消化器癌発生学会総会, Nov. 2017.
846.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 下部直腸癌に対するCRT効果予測因子としてのmiR223の意義, 第28回日本消化器癌発生学会総会, Nov. 2017.
847.	Masaaki Nishi, Mitsuo Shimada, Daichi Ishikawa, Chie Takasu, Takuya Tokunaga, Hideya Kashihara, Jun Higashijima and Kouzou Yoshikawa : IDOによる免疫能と胃癌転移機構の解明, 第28回日本消化器癌発生学会総会, Nov. 2017.
848.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Takuya Tokunaga : 胃GISTに対する腹腔鏡・内視鏡合同手術(LECS)の検討, 第108回日本消化器病学会四国支部例会, Nov. 2017.
849.	Hiroki Teraoku, Yu Saitou and Mitsuo Shimada : 肝胆膵外科手術における免疫指標を加味した新たな周術期栄養評価, 第108回日本消化器病学会四国支部例会, Nov. 2017.
850.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 2カ所のapple peel型閉鎖を伴った先天性小腸閉鎖症に対する手術におけるpitfall, 第33回日本小児外科学会秋季シンポジウム, Oct. 2017.
851.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : One stop shopを目指したEOB-MRIによる部分切除術肝機能評価, 第26回日本コンピュータ外科学会大会, Oct. 2017.
852.	Jun Higashijima, Mitsuo Shimada, Hiroshi Okitsu, Hidenori Miyake, 八木淑之, 三浦連人, 坂東儀昭, Tsutomu Ando, Masanori Hotsuchi, 石川正志, 福山充俊 and 和田大助 : 大腸癌患者において化学療法がQOL，夜間睡眠へ及ぼす影響についての検討(第2報), 第55回日本癌治療学会学術集会, Oct. 2017.
853.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : The impact of Indoleaine 2,3-dioxygenase (IDO) expression in stagelll gastric cancer, 第55回日本癌治療学会学術集会, Oct. 2017.
854.	Yuuma Wada, Yuji Morine, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Shuichi Iwahashi, Hideya Kashihara, Chie Takasu, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 青色LED光は光受容体(opsin3)を介し癌細胞増殖を抑制する, 第55回日本癌治療学会学術集会, Oct. 2017.
855.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌における局在・浸潤形式別悪性度, 第55回日本癌治療学会学術集会, Oct. 2017.
856.	Shuichi Iwahashi, AHMAD AMMAR GHAIBEH, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 人工知能を用いた肝細胞癌再発予測因子の検討, 第55回日本癌治療学会学術集会, Oct. 2017.
857.	Yuji Morine, Mitsuo Shimada and Satoru Imura : NBNC肝細胞癌における臨床病理学的・分子生物学的特徴の解析, JDDW 2017, Oct. 2017.
858.	坂東佳祐, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 多時相造影CTにおける大腸がんの転移性リンパ節解析, 第40回日本生体医工学会中国四国支部大会, III-3, Oct. 2017.
859.	Yu Saitou, Satoru Imura, Yuji Morine, Shogo Oota, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto and Mitsuo Shimada : 肝切除におけるVirtual Reality(VR) 画像を駆使した胆管解剖把握のための術中Navigation System, 第12回肝癌治療シミュレーション研究会, Sep. 2017.
860.	Daichi Ishikawa, Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 青色LED光は光受容体(opsin)を介し癌細胞増殖を抑制する, 第76回日本癌学会学術総会, Sep. 2017.
861.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : IL driven IL-10 Tr1細胞による細胞レベルのRO/R1手術達成評価に関する検討, 第76回日本癌学会学術総会, Sep. 2017.
862.	Hiroki Teraoku, Tetsuya Ikemoto, Yuuma Wada, Shogo Oota, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine, Mitsuo Shimada and Koichi Tsuneyama : 単純性嚢胞との鑑別に苦慮したnonmucinous cyctadenoma の1例, 第67回日本消化器画像診断研究会, Sep. 2017. (Keyword) 第67回日本消化器画像診断研究会
863.	Hiroki Mori, Yuji Morine, Keigo Yada, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常の胆汁中発癌物質におけるメタボローム解析の検討, 第40回日本膵・胆管合流異常研究会, Sep. 2017.
864.	Hiroki Ishibashi, Yuji Morine, Mitsuo Shimada and 安藤久實 : 先天性胆道拡張症の重症度分類(案)-指定難病取得に向けた取り組み-, 第40回日本膵・胆管合流異常研究会, Sep. 2017.
865.	Mitsuo Shimada : 外科漢方のOrthodox&Serendipity, 第40回日本膵・胆管合流異常研究会, Sep. 2017.
866.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 地方におけるロボット手術の現状について, 第92回中国四国外科学会総会, Sep. 2017.
867.	Hiroki Teraoku, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Shogo Oota, Satoru Imura and Mitsuo Shimada : Nrf2-Keap1制御系を介したEpigallocatechin-3-gallate(EGCG)による膵島保護作用に関する検討, 第53回日本移植学会総会, Sep. 2017.
868.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : 膵島移植に対するブレイクスルーとしてのAdipose tissue derived stem cellsからの効果的Insulin-producing cells創生, 第53回日本移植学会総会, Sep. 2017.
869.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第53回日本移植学会総会, Sep. 2017.
870.	Shoko Iwahashi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Shogo Oota : 術前診断が困難であった胃粘膜下異所性胃腺の1例, 第255回徳島医学会学術集会, Aug. 2017.
871.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 赤色発光ダイオード(LED)は肝細胞保護作用を有する, 第255回徳島医学会学術集会, Aug. 2017.
872.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, 市井啓仁 and Mitsuo Shimada : 転写因子制御による肝虚血再灌流障害の新たな治療法の開発, 第255回徳島医学会学術集会, Aug. 2017.
873.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Masami Nagamune and Masashi Akaike : 腹腔鏡下ペグタッチトレーニングの自学実習を目指したシミュレータの開発, 第49回日本医学教育学会大会, Aug. 2017.
874.	Keigo Yada, Hiroki Mori, Hiroki Ishibashi, Yuji Morine and Mitsuo Shimada : 大建中湯は胆道閉鎖症ラットモデルにおけるバクテリアルトランスロケーションと肝線維化を抑制する, 第72回日本消化器外科学会総会, Jul. 2017.
875.	Daichi Ishikawa, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 大腸癌の発癌・癌進展におけるmicroRNA-449aの役割解明, 第72回日本消化器外科学会総会, Jul. 2017.
876.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 肥満手術は町内最近叢変化を介して腸管炎症を抑制しインスリン抵抗性やNASH改善に寄与する, 第72回日本消化器外科学会総会, Jul. 2017.
877.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Toshiaki Yoshimoto and Atsushi Takata : 下部直腸癌のCRT後NLRは予後不良因子になる, 第72回日本消化器外科学会総会, Jul. 2017.
878.	Jun Higashijima, Daichi Ishikawa, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 局所進行下部直腸癌に対する術前化学放射線療法の長期成績と新たな治療戦略, 第72回日本消化器外科学会総会, Jul. 2017.
879.	Atsushi Takata, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuji Morine, Satoru Imura and Mitsuo Shimada : Epigallocatechin-3-gallate(EGCG)によるNrf2-Keap1制御系を介した膵島保護作用に関する検討, 第72回日本消化器外科学会総, Jul. 2017.
880.	Yu Saitou, Mitsuo Shimada, 瓜生原葉子, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第72回日本消化器外科学会総会, Jul. 2017.
881.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : One stop shopを目指したEOB-MRIによる部分肝機能評価, 第72回日本消化器外科学会総会, Jul. 2017.
882.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Jun Higashijima : 大腸癌肝転移に切除基準と腫瘍悪性度評価, 第72回日本消化器外科学会総会, Jul. 2017.
883.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Masato Yoshikawa : 肝胆膵手術における人工膵臓血糖管理の有用性に関する検討, 第72回日本消化器外科学会総会, Jul. 2017.
884.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : 肝内胆管癌における局在・浸潤形式別悪性度, 第72回日本消化器外科学会総会, Jul. 2017.
885.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 高度門脈侵襲陽性肝癌に対する集学的治療戦略, 第72回日本消化器外科学会総会, Jul. 2017.
886.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 下部直腸癌に対するCRT効果予測因子としてのmiR223の意義, 第87回大腸癌研究会, Jul. 2017.
887.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 腹腔鏡下胃切除術における肥満の影響と治療成績改善への取り組み, 日本外科代謝栄養学会第54回学術集会, Jul. 2017.
888.	Yu Saitou, Hisami Okumura, Yuji Morine, 平山明由, Toshiaki Yoshimoto, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : メタボローム解析を用いた肝切除後代謝物解析と肝再生因子の解明, 日本外科代謝栄養学会第54回学術集会, Jul. 2017.
889.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Koichi Tsuneyama : 症例, 第53回日本肝癌研究会, Jul. 2017.
890.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : 術前Prognostic nutritional index(PNI)は肝癌術後短期・長期予後予測因子になる, 第53回日本肝癌研究会, Jul. 2017.
891.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 超高齢者に対する肝切除の妥当性に関する検討, 第53回日本肝癌研究会, Jul. 2017.
892.	Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ntermediate stage肝癌に対する肝切除の有用性, 第53回日本肝癌研究会, Jul. 2017.
893.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Masato Yoshikawa : NBNC肝細胞癌における臨床病理学的・分子生物学的特徴の解析, 第53回日本肝癌研究会, Jul. 2017.
894.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 当科の小児鼠径ヘルニアに対するLPEC法の現況, 第14回中国四国ヘルニア手術研究会, Jul. 2017.
895.	Yu Ohiwa, Sonoko Yasui, Mayu Tanimura, Yoshiko Suzuki, Sayaka Matsura, Yu Saitou, 山田静恵, Akiko Matsumura, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者における主観的包括的栄養評価(SGA)による術前栄養評価の妥当性の検討, 日本外科系連合学会雑誌, Vol.42, Jun. 2017.
896.	Daichi Ishikawa, Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 青色LED光の光受容体(opsin)を介した癌細胞増殖抑制効果の検討, 第42回日本外科系連合学会学術集会, Jun. 2017.
897.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 外科診療における外来インフォームドコンセント導入の試み, 第42回日本外科系連合学会学術集会, Jun. 2017.
898.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡下胃癌手術における吻合法の工夫, 第42回日本外科系連合学会学術集会, Jun. 2017.
899.	Shoko Iwahashi, Tetsuya Ikemoto, Mitsuo Shimada, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine and Koichi Tsuneyama : 単純性嚢胞との鑑別に苦慮した極めて稀な膵嚢胞の1例, 第42回日本外科系連合学会学術集会, Jun. 2017.
900.	Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Mitsuo Shimada : 女性外科医が働き続けるために, 第42回日本外科系連合学会学術集会, Jun. 2017.
901.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : ICG蛍光システムを用いた腹腔鏡下前方切除術における縫合不全回避のための新たな戦略, 第42回日本外科系連合学会学術集会, Jun. 2017.
902.	Tetsuya Ikemoto, Mitsuo Shimada, Shinsuke Katoh, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 徳島大学病院GRMからみた手術室安全管理の取り組み, 第42回日本外科系連合学会学術集会, Jun. 2017.
903.	Yu Saitou, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝内胆管癌におけるSFRP1発現低下は予後不良因子となる, 第16回日本肝がん分子標的治療研究会, Jun. 2017.
904.	Daichi Ishikawa, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 大腸癌の発癌・腫瘍進展におけるmicroRNA-449aの意義, 第107回日本消化器病学会四国支部例会, Jun. 2017.
905.	Shogo Oota, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : 超高齢者に対する肝切除の妥当性に関する検討-85歳以上の超高齢者にも安全に施行可能である-, 第107回日本消化器病学会四国支部例, Jun. 2017.
906.	Yu Ohiwa, Mayu Tanimura, Sonoko Yasui-Yamada, Yu Saitou, Masaaki Nishi, Matsubara Atsumi, Shizuru Usui, Yoshiko Suzuki, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者の術前栄養評価における主観的包括的栄養評価(SGA)の妥当性の検討, Trend of Nutrition, Vol.2, No.2, 110, Jun. 2017.
907.	Satoru Imura, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Intermediate stageの肝癌に対する切除の有効性の検討, 第53回日本肝臓学会総会, Jun. 2017.
908.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Mitsuo Shimada : Treatment outcome for recurrent pancreatic cancer, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
909.	Shuichi Iwahashi, AHMAD AMMAR GHAIBEH, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : Predictability of postoperative recurrence on hepatocellular carcinoma through the alternating decision tree, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
910.	Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Photobiomodulation with red light emitting diodes accelerates hepatocytes proliferation through ROS/ERK pathway, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
911.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Masato Yoshikawa : EOB-MRI is useful for `one stop shop` modality based on functional liver volume, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
912.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Stylization of laparoscopic surgery using 3D simulation for young surgeo, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
913.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : Tr1 cells and Foxp3+regulatory T cell as a diagnostic biomarker for reflecting pathological agressiveness of cystic neoplasm of pancreas, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
914.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for colorectal liver matastasis-Surgical criteria for initially resectable and assessment toward conversion for unresectable cases-, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会, Jun. 2017.
915.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Liver resection for hepatocellular carcinoma of BCLC intermediate stage, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
916.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Mitsuo Shimada : Preoperative prognostic nutritional index (PNI) predicts both short and long-term outcomes after liver resection for hepatocellular carcinoma., IASGO Advanced Postgraduate Course in Yokohama, Jun. 2017.
917.	Satoru Imura and Mitsuo Shimada : Treatment strategy for advanced hepatocellular carcinoma with macroscopic portal invasion., IASGO Advanced Postgraduate Course in Yokohama, Jun. 2017.
918.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 小児鼠径ヘルニアに対するLPEC法の術後成績, 第15回日本ヘルニア学会学術集会, Jun. 2017.
919.	Daichi Ishikawa, Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 局所進行下部直腸癌に対するSOX+Bevレジメンによる術前化学放射線療法と効果予測因子としてのmiR-223の役割, 第26回日本癌病態治療研究会, Jun. 2017.
920.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第35回日本肝移植研究会, Jun. 2017.
921.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1細胞とFoxp3調節性T細胞は消化器担癌状態におけるバイオマーカーとして有用である, 第26回日本癌病態治療研究会, Jun. 2017.
922.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga, Chie Takasu and Daichi Ishikawa : ガーゼ剥離を用いた膨潤TAPPの有用性, 第71回手術手技研究会, May 2017.
923.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara and Daichi Ishikawa : 腹腔鏡下胃癌手術における吻合術・視野展開の工夫, 第71回手術手技研究会, May 2017.
924.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 肝葉切除術後に施行した膵切除術2例の経験, 第71回手術手技研究会, May 2017.
925.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 小児内視鏡外科手術における術前3D CTシミュレーション・術中ナビゲーションの有用性, 第54回日本小児外科学会学術集会, May 2017.
926.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada and Mitsuo Shimada : 重症心身障害児のGERDに対する腹腔鏡下Nissen-Rossetti噴門形成術の検討, 第54回日本小児外科学会学術集会, May 2017.
927.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 胸部腎を伴った左遅発性Bochdale孔ヘルニアに対する人工シートを用いた完全腹腔鏡下横隔膜修復術, 第54回日本小児外科学会学術集会, May 2017.
928.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 手術時体重3㎏未満の鼠径ヘルニア症例に対するLPEC法の妥当, 第54回日本小児外科学会学術集会, May 2017.
929.	壱岐豊, Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 術前3DCT simulationを行った小児先天性胆道拡張症の1例, 第117回日本外科学会定期学術集会, Apr. 2017.
930.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 大建中湯(TU-100)の肝星細胞活性化抑制効果に関する検討, 第117回日本外科学会定期学術集会, Apr. 2017.
931.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : 慢性炎症下の小児先天性胆道拡張症の胆道上皮における発癌関連遺伝子発現の検討, 第117回日本外科学会定期学術集会, Apr. 2017.
932.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori, Hideya Kashihara, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : AYA世代の外鼠径ヘルニアに対するLPEC法の適応について, 第117回日本外科学会定期学術集会, Apr. 2017.
933.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 胃切除術における肥満の影響と治療成績改善への取り組み, 第117回日本外科学会定期学術集会, Apr. 2017.
934.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 局所進行下部直腸癌に対するSOX+Bev regimenによる多剤併用術前化学放射線療法, 第117回日本外科学会定期学術集会, Apr. 2017.
935.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi and Chie Takasu : Metabolic surgery におけるmicrobiotaの変化は耐糖能異常・NAFLD/NASH改善に関与する, 第117回日本外科学会定期学術集会, Apr. 2017.
936.	Masaaki Nishi, Mitsuo Shimada, Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga and Hideya Kashihara : IDOによる免疫能と胃癌転移機構, 第117回日本外科学会定期学術集会, Apr. 2017.
937.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masashi Akaike : 腹腔鏡下eye hand coordinationトレーニングの自学実習を目指したシミュレータの開発, 第117回日本外科学会定期学術集会, Apr. 2017.
938.	宮崎克己, Yu Saitou, Yuji Morine, Koichi Tsuneyama, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Mitsuo Shimada : 限局性結節性過形成(FNH)術後に再発増殖し肝不全で死亡した一例, 第117回日本外科学会定期学術集会, Apr. 2017.
939.	Shogo Oota, Yuji Morine, Masato Yoshikawa, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto, Chie Takasu, Jun Higashijima and Mitsuo Shimada : 膵癌術後残膵再発に対する再切除導入効果の検証, 第117回日本外科学会定期学術集会, Apr. 2017.
940.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Yuji Morine, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 青色LED光は光受容体(opsin)を介し癌細胞増殖を抑制する, 第117回日本外科学会定期学術集会, Apr. 2017.
941.	Atsushi Takata, Jun Higashijima, Daichi Ishikawa, Masato Yoshikawa, Hideya Kashihara, Yu Saitou, Shuichi Iwahashi, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 腸管吻合におけるKono-S吻合の有用性に関する検討, 第117回日本外科学会定期学術集会, Apr. 2017.
942.	Hiroki Teraoku, Mitsuo Shimada, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 当科における膵全摘症例の検討-術後短期成績・長期予後の両面に着目して-, 第117回日本外科学会定期学術集会, Apr. 2017.
943.	Masato Yoshikawa, Rui Feng, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto, Chie Takasu, Jun Higashijima and Mitsuo Shimada : 肝細胞に対するROS/ ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第117回日本外科学会定期学術集会, Apr. 2017.
944.	Daichi Ishikawa, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 大腸癌の発癌・腫瘍進展におけるmicroRNA-449aの意義, 第117回日本外科学会定期学術集会, Apr. 2017.
945.	川下陽一郎, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌におけるHSF1発現の意義, 第117回日本外科学会定期学術集会, Apr. 2017.
946.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : Cancer-associated fibroblastsを介した膵癌細胞におけるnab-paclitaxelの効果, 第117回日本外科学会定期学術集会, Apr. 2017.
947.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1細胞とFoxp3調節性T細胞による腫瘍免疫状態を反映する免疫学的バイオマーカー探索, 第117回日本外科学会定期学術集会, Apr. 2017.
948.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Jun Higashijima, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝切除シミュレーション・ナビゲーションを駆使した若手教育法の確立, 第117回日本外科学会定期学術集会, Apr. 2017.
949.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 発光ダイオード(LED)の波長強度可変装置による肝細胞保護に関する研究, 第117回日本外科学会定期学術集会, Apr. 2017.
950.	Yu Saitou, Hisami Okumura, Yuji Morine, 平山明由, 梶浦大資, 多々納浩, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Mitsuo Shimada : メタボローム解析を用いた肝切除後代謝物解析と肝再生因子の解明, 第117回日本外科学会定期学術集会, Apr. 2017.
951.	Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Mitsuo Shimada : 「胆道拡張症，膵・胆管合流異常症の標準術式は?-小児外科および成人外科の立場から-」, 第117回日本外科学会定期学術集会, Apr. 2017.
952.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Takuya Tokunaga, Chie Takasu and Daichi Ishikawa : 超高齢者に対する腹腔鏡下胃切除は安全に施行可能か?, 第103回日本消化器病学会総会, Apr. 2017.
953.	Tetsuya Ikemoto, Jun Higashijima and Mitsuo Shimada : Tr1細胞を用いた免疫学的側面から見たIPMNの生物学的悪性度評価に関する研究, 第103回日本消化器病学会総会, Apr. 2017.
954.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 急性陰嚢症を契機に診断された再発性急性リンパ性白血病の1例, 第58回中国四国小児がん研究会, Apr. 2017.
955.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada and Mitsuo Shimada : 脂肪芽腫が疑われた先天性舌腫瘍の1例, 第58回中国四国小児がん研究会, Apr. 2017.
956.	Daichi Ishikawa, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下前方切除術におけるICG蛍光システムを利用した予防的回腸ストーマ造設の適応, 第31回中国四国ストーマリハビリテーション研究会, Mar. 2017.
957.	Jun Higashijima, Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 肛門温存を可能とする早期下部直腸癌に対する術前化学放射線療法併用局所切除術の成績について, 第31回中国四国ストーマリハビリテーション研究会, Mar. 2017.
958.	Yu Saitou, Yuji Morine, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝内胆管癌におけるHeat shock factor 1(HSF1)発現の意義, 第50回制癌剤適応研究会, Mar. 2017.
959.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 末梢血Tr1細胞とFoxp3陽性調節性T細胞は消化器担癌状態におけるバイオマーカーとして有用である, 第50回制癌剤適応研究会, Mar. 2017.
960.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi and Chie Takasu : 局所進行下部直腸癌に対するSOX+Bev regimenによる多剤併用術前化学放射療法, 第50回制癌剤適応研究会, Mar. 2017.
961.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Hideya Kashihara, Takuya Tokunaga, Chie Takasu, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : Indoleamine 2,3-dioxygenase(IDO)による胃癌再発機構, 第50回制癌剤適応研究会, Mar. 2017.
962.	Atsushi Takata, Tetsuya Ikemoto, Shuichi Iwahashi, Yuji Morine, Yu Saitou, Satoru Imura and Mitsuo Shimada : Epigallocatechin-3-gallate(EGCG)によるNrf2-Keap1制御系を介した膵島保護作用に関する検討, 第44回日本膵・膵島移植研究会, Mar. 2017.
963.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Toshiaki Yoshimoto, Masato Yoshikawa, Yu Saitou, Yuji Morine and Satoru Imura : 8 ADSCによるInsulin-producing cell(IPCs)作成における効果的新規分化誘導方法に関する検討, 第44回日本膵・膵島移植研究会, Mar. 2017.
964.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi and Chie Takasu : 耐糖能異常・NAFLD/NASHに対するRoux en Y再建の効果, 第89回日本胃癌学会総会, Mar. 2017.
965.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masato Yoshikawa : 肥満の胃切除術への影響と肥満患者における治療成績改善への取り組み, 第89回日本胃癌学会総会, Mar. 2017.
966.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara and Daichi Ishikawa : IDOによる胃癌再発機構の解明, 第89回日本胃癌学会総会, Mar. 2017.
967.	Shuichi Iwahashi, Mitsuo Shimada, Tetsuya Ikemoto, Yu Saitou and Toshiaki Yoshimoto : 465nm-LED光照射による癌幹細胞制御に関する研究, 第16回日本再生医療学会総会, Mar. 2017.
968.	Tetsuya Ikemoto, Mitsuo Shimada, Shuichi Iwahashi, Yu Saitou and Toshiaki Yoshimoto : ADSCによるInsulin-producing cell(IPCs)作成における効果的新規分化誘導方法に関する検討, 第16回日本再生医療学会総会, Mar. 2017.
969.	Sonoko Yasui, Yu Saitou, Yoshiko Tani, 山田静恵, 粟田由佳, 西麻希, 菊井聡子, 橋本脩平, 足立知咲, Akiko Matsumura, Mitsuo Shimada and Yasuhiro Hamada : NST介入により短期間で体脂肪減量に成功した腹壁瘢痕ヘルニア術前の高度肥満の1症例, 第36回日本食事療法学会, Mar. 2017.
970.	Toshiaki Yoshimoto, Yu Saitou, Yuji Morine, Koichi Tsuneyama, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Masato Yoshikawa, Atsushi Takata and Mitsuo Shimada : 限局性結節性過形成(FNH)術後に再発増殖し肝不全で死亡した一例-切除肝・病理解剖をふまえて-, 第66回日本消化器画像診断研究会, Feb. 2017.
971.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 術前診断が困難であった胃粘膜下異所性胃腺の1例, 第66回日本消化器画像診断研究会, Feb. 2017.
972.	atsumi Matsubara, Sonoko Yasui, Yu Saitou, Mayu Tanimura, Sayaka Matsura, Yu Ohiwa, 西麻希, 山田静恵, Yoshiko Tani, Akiko Matsumura, Mitsuo Shimada and Yasuhiro Hamada : 胃癌・膵癌患者における術前栄養評価と予後との関連, 第32回日本静脈経腸栄養学会学術集会, Feb. 2017.
973.	Hisami Okumura, 和田宵湖, Takafumi Katayama, Satoru Imura and Mitsuo Shimada : 肝切除後退院時のエネルギー代謝状態は回復しているのか?-重症度と切除量の違いによる検討―, 日本静脈経腸栄養学会, Feb. 2017.
974.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 膵腫瘍性病変におけるType1 regulatory T細胞の臨床的有用性の検討-Type1 regulatory T細胞は診断・再発予測バイオマーカーとして有用である-, 第254回徳島医学会学術集会, Feb. 2017.
975.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 術中膵管損傷を来した巨大嚢腫を伴う小児先天性胆道拡張症の1例, 第25回徳島外科術後管理研究会, Feb. 2017.
976.	Yu Saitou, Yuji Morine, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝門部胆管癌超ハイリスク症例に対して根治術施行し術後管理, 第25回徳島外科術後管理研究会, Feb. 2017.
977.	Daichi Ishikawa, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下前方切除術における縫合不全回避のためのICG蛍光システムの有用性, 第25回徳島外科術後管理研究会, Feb. 2017.
978.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 結腸切除術におけるDVTリスク評価とVTE予防, 第25回徳島外科術後管理研究会, Feb. 2017.
979.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masato Yoshikawa : 胃切除術における肥満の影響と治療成績改善への取り組み, 第25回徳島外科術後管理研究会, Feb. 2017.
980.	井村涼太, 掛田貴章, 平島孝樹, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 多時相造影CTにおける大腸癌の転移性リンパ節の解析, 第24回日本CT検診学会学術集会, 4-6, Feb. 2017.
981.	Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Atsushi Takata, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Long-term survivors of HCC using sorafenib, 2nd Eastern &Western Association Liver Tumors(EWALT), Jan. 2017.
982.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第15回日本肝がん分子標的治療研究会, Jan. 2017.
983.	Yu Saitou, Yuji Morine, 川下陽一郎, Masato Yoshikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝内胆管癌におけるHeat shock factor1(HSF1)発現の意義, 第15回日本肝がん分子標的治療研究会, Jan. 2017.
984.	Matsubara Atsumi, Sonoko Yasui, Yu Saitou, Mayu Tanimura, Sayaka Matsura, Yu Ohiwa, 西麻希, 山田静恵, Yoshiko Tani, Akiko Matsumura, Mitsuo Shimada and Yasuhiro Hamada : 胃癌・膵癌患者の予後予測に有用な栄養評価法の検討, 第20回日本病態栄養学会年次学術集会, Jan. 2017.
985.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Keigo Yada, Hiroki Mori and Hiroki Ishibashi : 小児先天性胆道拡張症の胆道上皮における発癌関連遺伝子発現の検討, 第106回日本消化器病学会四国支部例会, Dec. 2016.
986.	Masato Yoshikawa, Rui Feng, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, Masaaki Nishi, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞に対するROS/ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第46回日本創傷治癒学会, Dec. 2016.
987.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 鼠径ヘルニアを合併した小児精索静脈瘤に対する腹腔鏡下手術, 第29回日本内視鏡外科学会総会, Dec. 2016.
988.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 定型化と教育システムがもたらす安全な腹腔鏡下左葉切除, 第29回日本内視鏡外科学会総会, Dec. 2016.
989.	Jun Higashijima, Daichi Ishikawa, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 腹腔鏡下前方切除術における縫合不全回避のための戦略, 第29回日本内視鏡外科学会総会, Dec. 2016.
990.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下胃全摘におけるOrVil法の有用性, 第29回日本内視鏡外科学会総会, Dec. 2016.
991.	木下翔平, 多々納浩, 梶浦大資, Hisami Okumura, Mitsuo Shimada, Yuji Morine, 平山明由, 曽我朋義 and 冨田勝 : 患者組織と腫瘍切除前後の血清を用いたメタボローム解析による新規バイオマーカ探索, 分子細胞生物学会, Nov. 2016.
992.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 小児内視鏡外科手術における術前3Dシミュレーション・術中ナビゲーションの有用性に関する検討, 第25回日本コンピュータ外科学会大会, Nov. 2016.
993.	Masato Yoshikawa, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第25回日本コンピュータ外科学会大会, Nov. 2016.
994.	Toshiaki Yoshimoto, Kouzou Yoshikawa, 松本規子, 馮睿, Atsushi Takata, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Jun Higashijima and Mitsuo Shimada : LED光の癌細胞および正常細胞に対する効果, 第25回日本コンピュータ外科学会大会, Nov. 2016.
995.	Toshiaki Yoshimoto, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除限界予測の可能性, 第78回日本臨床外科学会総会, Nov. 2016.
996.	Masato Yoshikawa, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 再発膵癌に対する再切除の有用性の検討, 第78回日本臨床外科学会総会, Nov. 2016.
997.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 当科における若手医師の腹腔鏡手術トレーニングの現状と効果, 第78回日本臨床外科学会総会, Nov. 2016.
998.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 若手外科医でも安全・確実に施行できる肝葉切除術, 第78回日本臨床外科学会総会, Nov. 2016.
999.	Yu Saitou, Yuji Morine, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 膵頭十二指腸切除術に対するModified de-rotation法を用いた`` Complete artery-f irst approach'', 第78回日本臨床外科学会総会, Nov. 2016.
1000.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 膵全摘における人工膵臓の有用性における検討, 第78回日本臨床外科学会総会, Nov. 2016.
1001.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Chie Takasu, Yusuke Arakawa and Jun Higashijima : 大腸癌切除不能多発肝転移に対する治療戦略, 第78回日本臨床外科学会総会, Nov. 2016.
1002.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : グリソン一括による肝門処理のコツとピットフォール, 第78回日本臨床外科学会総会, Nov. 2016.
1003.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi and Chie Takasu : 胃癌術後Roux en Y再建による早期耐糖能異常改善効果, 第78回日本臨床外科学会総会, Nov. 2016.
1004.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下胃全摘の再建におけるトラブルシューティング-Overlap法とOrVil法を経験して-, 第78回日本臨床外科学会総会, Nov. 2016.
1005.	Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝臓外科からみた経皮的RFA不適となる肝癌の特徴∼切除例における組織学的門脈侵襲の解析から∼, JDDW2016, Nov. 2016.
1006.	Kouzou Yoshikawa, Mitsuo Shimada and Daichi Ishikawa : LTGにおけるOrVil法の有用性と視野展開の工夫, JDDW2016, Nov. 2016.
1007.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada and Mitsuo Shimada : 多発狭窄を伴った先天性十二指腸狭窄症の1例, 第32回日本小児外科学会秋季シンポジウム(PSJM), Oct. 2016.
1008.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 腹腔鏡下鼠径ヘルニア手術(LPEC法)時に発見された性分化疾患の1例, 第32回日本小児外科学会秋季シンポジウム(PSJM), Oct. 2016.
1009.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi and Chie Takasu : 胃癌術後Roux en Y再建は早期より耐糖能異常を改善する, 第46回胃外科・術後障害研究会, Oct. 2016.
1010.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Atsushi Takata, Toshiaki Yoshimoto, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Mitsuo Shimada : 当科における切除不能・再発進行膵癌に対する治療成績, 第54回日本癌治療学会学術集会, Oct. 2016.
1011.	Daichi Ishikawa, 川下陽一郎, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : FBXW7発現は転移性肝癌における切除後再発予測因子となる, 第54回日本癌治療学会学術集会, Oct. 2016.
1012.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 末梢血Tr1細胞とFoxp3調節性T細胞は担癌状態におけるバイオメーカーとして有用である, 第54回日本癌治療学会学術集会, Oct. 2016.
1013.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi and Chie Takasu : Roux en Y再建は術後早期より耐糖能異常を改善する, 第54回日本癌治療学会学術集会, Oct. 2016.
1014.	Jun Higashijima, Mitsuo Shimada, Masanori Hotsuchi, 八木淑之, Hiroshi Okitsu, 三浦連人, 坂東儀昭, Hidenori Miyake, Takuya Tokunaga, 石川正志, 福山充俊 and 和田大助 : 大腸癌患者において化学療法がQOL，夜間睡眠へ及ぼす影響についての検討, 第54回日本癌治療学会学術集会, Oct. 2016.
1015.	梶浦大資, Hisami Okumura, 平山明由, Takafumi Katayama, Mitsuo Shimada, 冨田勝 and 曽我朋義 : 肝細胞癌切除患者における周術期の血清及び尿のメタボローム解析, 第10回メタボロームシンポジウム, Oct. 2016.
1016.	掛田貴章, 井村涼太, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 造影CT画像(動脈相・門脈相・平衡相)を用いた腹部血管画像解析, 第39回日本生体医工学会中国四国支部大会, III-3, Oct. 2016.
1017.	井村涼太, 掛田貴章, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 多時相造影CTにおける転移性リンパ節の解析, 第39回日本生体医工学会中国四国支部大会, III-4, Oct. 2016.
1018.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa and Masato Yoshikawa : 消化器癌におけるヒストンアセチル化の抗腫瘍効果, 第75回日本癌学会学術集会, Oct. 2016.
1019.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1とFoxp3陽性調節性T細胞は担癌患者の腫瘍免疫に関する検討, 第75回日本癌学会学術集会, Oct. 2016.
1020.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa and Daichi Ishikawa : 胃癌根治切除症例におけるPD1発現の意義, 第75回日本癌学会学術集会, Oct. 2016.
1021.	Toshiaki Yoshimoto, Yu Saitou, Atsushi Takata, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について, 第52回日本移植学会総会, Sep. 2016.
1022.	Yu Saitou, Satoru Imura, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 徳島におけるABO不適合生体肝移植の成績, 第52回日本移植学会総会, Sep. 2016.
1023.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 脂肪由来幹細胞によるInsulin-producing cell作成における新規分化誘導方法に関する検討, 第52回日本移植学会総会, Sep. 2016.
1024.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 術前診断が困難であった肝偽リンパ腫の1例, 第65回日本消化器画像診断研究会, Sep. 2016.
1025.	Matsubara Atsumi, Sonoko Yasui, Yu Saitou, Mayu Tanimura, Sayaka Matsura, Yu Ohiwa, Yoshiko Tani, Akiko Matsumura, Mitsuo Shimada and Yasuhiro Hamada : 胃癌・膵癌患者における術前栄養評価と予後との関連, 第8回日本静脈経腸栄養学会四国支部会学術集会, Vol.8, 45, Sep. 2016.
1026.	Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第11回肝癌治療シミュレーション研究会, Sep. 2016.
1027.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する, 第35回Microwave Surgery研究会, Sep. 2016.
1028.	Satoru Imura, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 担癌グリソン枝マイクロ波凝固による肝小範囲切除の工夫, 第35回Microwave Surgery研究会, Sep. 2016.
1029.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada and Mitsuo Shimada : 慢性炎症下にある小児先天性胆道拡張症の胆道上皮における発癌関連遺伝子発現の検討, 第27回日本消化器癌発生学会総会, Sep. 2016.
1030.	馮睿, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Atsushi Takata and Toshiaki Yoshimoto : Cancer-associated fibroblastsに着目した膵癌細胞におけるnab-paclitaxcelの効果, 第27回日本消化器癌発生学会総会, Sep. 2016.
1031.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第27回日本消化器癌発生学会総会, Sep. 2016.
1032.	Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 転移性肝癌における腫瘍悪性度制御因子としてのTHBS-1の役割, 第27回日本消化器癌発生学会総会, Sep. 2016.
1033.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 消化器癌における末梢血Tr1細胞とFoxp3調節性T細胞の有用性の検討, 第27回日本消化器癌発生学会総会, Sep. 2016.
1034.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌の腫瘍悪性度評価と制御の可能性, 第27回日本消化器癌発生学会総会, Sep. 2016.
1035.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Atsushi Takata, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Jun Higashijima and Mitsuo Shimada : 青色LED光のヒト癌細胞株に対する効果, 第27回日本消化器癌発生学会総会, Sep. 2016.
1036.	Hideya Kashihara, Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : IDOによる免疫能と大腸癌転移機構, 第27回日本消化器癌発生学会総会, Sep. 2016.
1037.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 術前3DCT simulationを行った小児先天性胆道拡張症の1例, 第39回日本膵・胆管合流異常研究会, Sep. 2016.
1038.	Yuji Morine, Mitsuo Shimada, 窪田正幸, Hiroki Ishibashi and 安藤久實 : 膵・胆管合流異常症に対する術式選択の特徴―全国集計解析から―, 第39回日本膵・胆管合流異常研究会, Sep. 2016.
1039.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第91回中国四国外科学会総会/第21回中国四国内視鏡外科研究会, Sep. 2016.
1040.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 小児精索・陰嚢水瘤の診断と治療―特任腹腔鏡下根治術の有用性―, 第5回日本小児診療多種研究会, Jul. 2016.
1041.	A.S. Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and Gen Iinuma : Automatic blood vessel-based liver segmentation through the portal phase CT, IEICE Technical Report, Vol.116, No.160, 29-34, Jul. 2016.
1042.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, 市井啓仁 and Mitsuo Shimada : 転写因子制御による肝虚血再灌流障害の新たな治療法の開発., 第253回徳島医学会学術集会, Jul. 2016.
1043.	平島孝樹, 井村涼太, 掛田貴章, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 造影CT画像(門脈相)を用いた大腸の結腸分類, 日本医用画像工学会大会, PP-31, Jul. 2016.
1044.	Mitsuo Shimada : 「外科の矜恃」‐Orthodox & Serendipity -, 第71回日本消化器外科学会総会, Jul. 2016.
1045.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Boot Camp in Tokushima University., 第71回日本消化器外科学会総会, Jul. 2016.
1046.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The analysis in non-tumor liver tissue to prevent the recurrence after curative treatment of hepatocellular carcinoma., 第71回日本消化器外科学会総会, Jul. 2016.
1047.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : A new strategy forachieving effective islet transplantation with adipose tissue derved stem cells., 第71回日本消化器外科学会総会, Jul. 2016.
1048.	Yuji Morine, Mitsuo Shimada, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa and Masato Yoshikawa : 全国集計からみた膵・胆管合流異常症の臨床摘特徴と術式選択の現状., 第71回日本消化器外科学会総会, Jul. 2016.
1049.	Satoru Imura, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Yuji Morine, Mitsuo Shimada and 住友正幸 : へき地病院から専門医を輩出するための地域外科診療部の役割, 第71回日本消化器外科学会総会, Jul. 2016.
1050.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Masashi Akaike : 若手外科医育成のための卒然教育からの工夫∼移植シンポの早期体験と反転授業を応用した実習の試み∼., 第71回日本消化器外科学会総会, Jul. 2016.
1051.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi and Chie Takasu : A possible effect of metabolic surgery on diabetes and NASH., 第71回日本消化器外科学会総会, Jul. 2016.
1052.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Yuji Morine, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Hiroki Teraoku : 青色LED光は癌細胞増殖を抑制する., 第71回日本消化器外科学会総会, Jul. 2016.
1053.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Toshiaki Yoshimoto, Yuji Morine and Mitsuo Shimada : 大建中湯(TU-100)はTLR4/TNFαを介して総胆管結紮ラットモデルにおける肝障害を抑制する., 第23回外科侵襲とサイトカイン研究会, Jul. 2016.
1054.	Toshiaki Yoshimoto, Kouzou Yoshikawa, 松本規子, Atsushi Takata, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Jun Higashijima and Mitsuo Shimada : 青色LED光のヒト癌細胞株に対する効果, 第23回外科侵襲とサイトカイン研究会, Jul. 2016.
1055.	Masato Yoshikawa, Yu Saitou, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ABO不適合生体肝移植後にCMV感染治療に難渋した一例., 第34回日本肝移植研究会, Jul. 2016.
1056.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : NO阻害と転写活性制御からの虚血再灌流障害., 第34回日本肝移植研究会, Jul. 2016.
1057.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について., 第34回日本肝移植研究会, Jul. 2016.
1058.	Yu Saitou, Sonoko Yasui, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝硬変合併肝切除症例における栄養・免疫状態の特徴, 第52回日本肝癌研究会, Jul. 2016.
1059.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Atsushi Takata : 症例, 第52回日本肝癌研究会, Jul. 2016.
1060.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Intermediate stageの肝癌に対する肝切除は有効か?, 第52回日本肝癌研究会, Jul. 2016.
1061.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌における発生部位別悪性度., 第52回日本肝癌研究会, Jul. 2016.
1062.	Mitsuo Shimada : Improvement of BCLC staging for HCC., 第52回日本肝癌研究会, Jul. 2016.
1063.	Jun Higashijima, Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : Stage2,3直腸癌に対する腹腔鏡下手術の妥当性についての検討., 第85回大腸癌研究会, Jul. 2016.
1064.	Naoki Muguruma, Koichi Okamoto, Shota Fujimoto, Yasuteru Fujino, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Mitsuo Shimada, Hiroshi Miyamoto and Tetsuji Takayama : 分子解析に基づいたAberrant crypt fociの新規イメージング技術開発, がん予防学術大会2016, Jul. 2016.
1065.	Toshiaki Yoshimoto, Kouzou Yoshikawa, 松本規子, Atsushi Takata, Yu Saitou, Masato Yoshikawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Daichi Ishikawa, Shuichi Iwahashi and Mitsuo Shimada : 青色LED光のヒト癌細胞株に対する効果., 第105回日本消化器病学会四国支部例会, Jun. 2016.
1066.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Atsushi Takata, Toshiaki Yoshimoto, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Mitsuo Shimada : 切除不能・再発進行膵癌に対する治療成績., 第105回日本消化器病学会四国支部例会, Jun. 2016.
1067.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : ノンテクニカルスキルを含めた総合手術技能評価法の開発., 第105回日本消化器病学会四国支部例会, Jun. 2016.
1068.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yusuke Arakawa, Shuichi Iwahashi, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : HCCに対して初回RFA治療早期にリンパ節再発をきたし外科的切除を施行した症例., 第41回日本外科系連合学会学術集会, Jun. 2016.
1069.	Yu Saitou, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : PDに対するModified de-rotationを用いた``Complate artery-firstn approach''., 第41回日本外科系連合学会学術集会, Jun. 2016.
1070.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡下胃全摘の再建におけるトラブルシューティング-Overlap法とOrVil法を経験して-., 第41回日本外科系連合学会学術集会, Jun. 2016.
1071.	Toshiaki Yoshimoto, C Enkbold, Atsushi Takata, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝内胆管癌における細胞周期調節因子Fbxw7発現低下の臨床病理学的意義., 第14回日本肝がん分子標的治療研究会, Jun. 2016.
1072.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する., 第14回日本肝がん分子標的治療研究会, Jun. 2016.
1073.	Kouzou Yoshikawa, Mitsuo Shimada and Yuji Morine : 肝切除周術期における大建中湯の有用性., 第67回日本東洋医学会学術総会, Jun. 2016.
1074.	Kouzou Yoshikawa, Mitsuo Shimada, Yuji Morine and Chie Takasu : 外科の立場から見た癌治療における漢方の役割-From bench to bedside-., 第67回日本東洋医学会学術総会, Jun. 2016.
1075.	寺前智史, Koichi Okamoto, Naoki Muguruma, Kumiko Tanaka, Yasuteru Fujino, 香川美和子, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Mitsuo Shimada and Tetsuji Takayama : 若年で原発性十二指腸癌を合併したSTK11全欠失型Peutz–Jeghers症候群の1例, 第22回日本家族性腫瘍学会学術集会, Jun. 2016.
1076.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : EOB-MRIを用いた機能的肝容積による新たな肝切除基準., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
1077.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : Tr1細胞とFoxp3調節性T細胞による膵嚢胞性疾患に関する正確な免疫学的指標探索に関する研究., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
1078.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 胆道癌術後肝内再発に対する肝切除導入効果の検証., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
1079.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 当科における胆道再建における肝管空腸吻合法の工夫., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
1080.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Chie Takasu, Jun Higashijima, 川下陽一郎, Atsushi Takata, Toshiaki Yoshimoto, Satoru Imura and Mitsuo Shimada : 大腸癌肝転移肝切除症例におけるThrombospondin1(THBS)発現の意義とその分子メカニズムの検討., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
1081.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : 大腸癌多発肝転移に対する長期生存を目指した治療戦略., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
1082.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 門脈・肝静脈解剖に基づく合理的な系統的肝切除∼副右肝静脈灌流領域切除を伴う拡大前区域切除., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
1083.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 若手小児外科医のUSMLE step1,2,3取得への挑戦∼グローバルに活躍できる小児外科医を目指して∼., 第53回日本小児外科学会学術集会, May 2016.
1084.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 新生児喉頭蓋谷嚢胞に対する鏡視下開窓術., 第53回日本小児外科学会学術集会, May 2016.
1085.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 小児abdominoscrotal hydrocele (ASH) に対するLPEC法の応用., 第53回日本小児外科学会学術集会, May 2016.
1086.	Masato Yoshikawa, Yuji Morine and Mitsuo Shimada : 肝細胞癌におけるNEK2発現による腫瘍悪性度評価., 第52回日本肝臓学会総会, May 2016.
1087.	Shin-ichiro Yamada, Mitsuo Shimada and Satoru Imura : EOB-MRIを用いた新たな肝切除基準の可能性., 第52回日本肝臓学会総会, May 2016.
1088.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 徳島におけるABO不適合生体肝移植症例の成績., 第42回日本急性肝不全研究会, May 2016.
1089.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのHIF-1の役割., 第102回日本消化器病学会総会, Apr. 2016.
1090.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除基準の可能性, 第102回日本消化器病学会総会, Apr. 2016.
1091.	Hideya Kashihara, Mitsuo Shimada and Toshiaki Yoshimoto : NAFLD/NASHに対する治療オプションとしてのBariatric Surgeryの可能性-基礎から臨床へ-., 第102回日本消化器病学会総会, Apr. 2016.
1092.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : 直腸癌術前CRT症例におけるKi-67, Survivin発現の意義, 第102回日本消化器病学会総会, Apr. 2016.
1093.	Mitsuo Shimada : 外科漢方のOrthodox & Serendipity -DKTフォーラムの成果から見えてきたもの-, 第116回日本外科学会定期学術集会, Apr. 2016.
1094.	Keigo Yada, Hiroki Ishibashi and Mitsuo Shimada : 小児肝外性門脈体循環シャント(2型)に対する腹腔鏡下手術の有用性に関する検討., 第116回日本外科学会定期学術集会, Apr. 2016.
1095.	Shogo Oota, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Kouzou Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第116回日本外科学会定期学術集会, Apr. 2016.
1096.	Shoko Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 急速な進展を来したラブドイド様退形成性癌の一例., 第116回日本外科学会定期学術集会, Apr. 2016.
1097.	関勇輔, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-., 第116回日本外科学会定期学術集会, Apr. 2016.
1098.	Atsushi Takata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Chie Takasu : 腸管修復および癌幹細胞におけるSonic hedgehogの役割., 第116回日本外科学会定期学術集会, Apr. 2016.
1099.	川下陽一郎, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto and Hirohisa Ogawa : 転移性肝癌におけるFbxw7低発現は再発予測因子である., 第116回日本外科学会定期学術集会, Apr. 2016.
1100.	Tetsuya Ikemoto, 鈴木伸明, 硲彰一, 井口東郎, 田中浩明, 有賀淳, 石崎秀信, 楳田祐三, 藤原俊義, 吉松和彦, 清水良一, 林弘人, 坂田晃一郎, 武田茂, 上野富雄, 山本滋, 吉野茂文, Mitsuo Shimada, 永野浩昭 and 岡正朗 : 日本発の新規ペプチド療法開発に向けた進行・再発膵癌に対する標準+ペプチド療法第Ⅰ/Ⅱ相医師主導治験., 第116回日本外科学会定期学術集会, Apr. 2016.
1101.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata and Mitsuo Shimada : 直腸癌術前CRT症例におけるKi-67，Survivin発現の意義, 第116回日本外科学会定期学術集会, Apr. 2016.
1102.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第116回日本外科学会定期学術集会, Apr. 2016.
1103.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのThrombospondin-1(THBS-1)の役割- 第2報 THBS-1制御メカニズムについて -, 第116回日本外科学会定期学術集会, Apr. 2016.
1104.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : HDAC阻害剤は脂肪由来幹細胞からインスリン分泌細胞への分化誘導を促進する., 第116回日本外科学会定期学術集会, Apr. 2016.
1105.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌に対する至適術式と集学的治療., 第116回日本外科学会定期学術集会, Apr. 2016.
1106.	小山啓介, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : スリーブ状胃切除におけるGlucagon-like peptide-1の増加は耐糖能異常・脂肪肝の改善に寄与する., 第116回日本外科学会定期学術集会, Apr. 2016.
1107.	布村俊幸, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Hiroki Teraoku, Masato Yoshikawa and Toshiaki Yoshimoto : 切除不能転移性肝癌を有する透析患者にFOLFOXIRI+Bevを施行しconversionが得られる1例., 第116回日本外科学会定期学術集会, Apr. 2016.
1108.	Chie Takasu, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi and Hideya Kashihara : IDOによる免疫能と大腸癌肝転移機構., 第116回日本外科学会定期学術集会, Apr. 2016.
1109.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : Roux en Y再建は術後早期より耐糖能異常を改善する., 第116回日本外科学会定期学術集会, Apr. 2016.
1110.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Masato Yoshikawa and Toshiaki Yoshimoto : 膵癌細胞におけるResveratrolのShh pathwayを介した細胞増殖抑制効果, 第116回日本外科学会定期学術集会, Apr. 2016.
1111.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : 進行大腸癌に対する新たな予後予測因子の検討., 第116回日本外科学会定期学術集会, Apr. 2016.
1112.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Masato Yoshikawa : 青色LED光は癌細胞増殖を抑制する., 第116回日本外科学会定期学術集会, Apr. 2016.
1113.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Hideya Kashihara, Chie Takasu and Takuya Tokunaga : 胃癌におけるPD-1/PD-L1発現の意義., 第49回制癌剤適応研究会, Mar. 2016.
1114.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kouzou Yoshikawa, 寺奥大貴, 高田厚史 and 良元俊昭 : 肝細胞癌症例におけるNEK2発現による腫瘍悪性度評価, 第49回制癌剤適応研究会, Mar. 2016.
1115.	Tetsuya Ikemoto, 鈴木伸明, 硲彰一, 井口東邦, 田中浩明, 有賀淳, Mitsuo Shimada and 岡正朗 : 進行・再発膵癌に対する標準+ペプチド療法第I/II相医師主導治験から見た癌免疫療法の展望, 第49回制癌剤適応研究会, Mar. 2016.
1116.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Toshihiro Nakao and Chie Takasu : 胃癌における免疫，栄養パラメーターからみた予後予測, 第88回日本胃癌学会総会, Mar. 2016.
1117.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : 高齢者胃癌症例に対するリンパ節郭清範囲縮小の予後に及ぼす影響, 第88回日本胃癌学会総会, Mar. 2016.
1118.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : 脂肪由来幹細胞による膵島移植・膵島再生に関する新たな戦略, 第43回日本膵・膵島移植研究会, Mar. 2016.
1119.	Mayu Tanimura, Sonoko Yasui, Yu Saitou, Matsubara Atsumi, 山田静恵, Yoshiko Tani, Akiko Matsumura, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者における術前栄養評価におけるSGAとODAとの検討, 第31回日本静脈経腸栄養学会, Feb. 2016.
1120.	Hisami Okumura, 平山明由, 梶浦大資, Satoru Imura, Mitsuo Shimada and 曽我朋義 : メタボローム解析による肝切除周術期の生体内代謝物の網羅的な評価, 第31回日本静脈経腸栄養学会学術集会, Feb. 2016.
1121.	Hisami Okumura, 和田宵湖, Takafumi Katayama, Satoru Imura and Mitsuo Shimada : 間接熱量計を用いない就寝前夜食の適応と適正量の評価の検討, 第31回日本静脈経腸栄養学会学術集会, Feb. 2016.
1122.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Hideya Kashihara and Chie Takasu : 腹腔鏡下腹壁瘢痕ヘルニア根治術におけるHybrid法の安全性と有用性, 第30回四国内視鏡外科研究会, Feb. 2016.
1123.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 縫合不全回避のための大腸癌手術における術中血流評価の有用性, 第30回四国内視鏡外科研究会, Feb. 2016.
1124.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡補助下胃全摘術の食道空腸吻合法におけるOrvil法の有用性と再建の工夫, 第30回四国内視鏡外科研究会, Feb. 2016.
1125.	Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 36.3mm細径鉗子を用いたreduced port Lap-Cに関する検討, 第30回四国内視鏡外科研究会, Feb. 2016.
1126.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara and Chie Takasu : 胃癌におけるPD1/PDL1発現の意義, 第252回徳島医学会学術集会, Feb. 2016.
1127.	寺奥大貴, Mitsuo Shimada, 石川大地, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 吉川雅登, 高田厚史 and 良元俊昭 : 消化器担癌状態のバイオマーカーとしての末梢血Tr1細胞とFoxp3調節性T細胞の有用性に関する検討, 第252回徳島医学会学術集会, Feb. 2016.
1128.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 吉川雅登, 寺奥大貴 and 高田厚史 : 肝細胞癌症例におけるNEK2発現による腫瘍悪性度評価, 第252回徳島医学会学術集会, Feb. 2016.
1129.	良元俊昭, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : 腹腔鏡下直腸切断術後に麻痺性イレウス・ARDS・AKIを来たし集学的治療により救命しえた一例, 第24回徳島外科術後管理研究会, Feb. 2016.
1130.	掛田貴章, 井村涼太, 尾澤公亮, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 造影CT画像(動脈相・門脈相・平衡相)を用いた腹部血管画像解析, 電子情報通信学会技術研究報告医用画像, Vol.115, No.401, 237-240, Jan. 2016.
1131.	井村涼太, 掛田貴章, 尾澤公亮, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 多時相造影CTにおける転移性リンパ節の解析, 電子情報通信学会技術研究報告医用画像, Vol.115, No.401, 233-235, Jan. 2016.
1132.	良元俊昭, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada and 高田厚史 : Sorafenib+poly surgeryによるHCC長期生存例∼orafenib投与長期生存条件の検討∼, 第13回日本肝がん分子標的治療研究会, Jan. 2016.
1133.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Hideya Kashihara : 進行大腸癌におけるFbxw7発現は再発予後規定因子となりうる, 第84回大腸癌研究会, Jan. 2016.
1134.	Mayu Tanimura, Sonoko Yasui, Yu Saitou, Matsubara Atsumi, 山田静恵, Yoshiko Tani, Akiko Matsumura, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者におけるSGAを用いた術前栄養スクリーニングとODAの検討, 第19回日本病態栄養学会, Jan. 2016.
1135.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : 臨床実習での技能トレーニングにおける反転授業の効果, 大学教育カンファレンスin徳島, Jan. 2016.
1136.	Naoki Muguruma, Koichi Okamoto, Shota Fujimoto, Yasuteru Fujino, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Mitsuo Shimada and Tetsuji Takayama : GST 活性型新規蛍光プローブによる大腸前癌病変 ACF の in vivo 分子イメージング, 第1回G-PLUS, Dec. 2015.
1137.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara and Chie Takasu : 胃癌におけるPD-1/PD-L1発現の意義, 第22回外科侵襲とサイトカイン研究会, Dec. 2015.
1138.	寺奥大貴, 朱呈瞻, 髙田厚史, 良元俊昭, 吉川雅登, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 加齢肝再生における肝星細胞の役割, 第22回外科侵襲とサイトカイン研究会, Dec. 2015.
1139.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 手技の定型化により腹腔鏡下鼠径ヘルニア手術の標準化は可能である, 第28回日本内視鏡外科学会総会, Dec. 2015.
1140.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 進行大腸癌に対する腹腔鏡手術vs開腹手術のpropensity scoreによる検討, 第28回日本内視鏡外科学会総会, Dec. 2015.
1141.	Jun Higashijima, Hideya Kashihara, Masaaki Nishi, Toshihiro Nakao, Chie Takasu, Kouzou Yoshikawa, Takashi Iwata and Mitsuo Shimada : 縫合不全回避のための大腸癌手術における術中血流評価の有用性, 第28回日本内視鏡外科学会総会, Dec. 2015.
1142.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Takuya Tokunaga : 腹腔鏡補助下胃全摘術の食道空腸吻合法におけるOrVil法の有用性と再建の工夫, 第28回日本内視鏡外科学会総会, Dec. 2015.
1143.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Chie Takasu and Hideya Kashihara : 手術シミュレーションを利用した鏡視下手技が苦手な学生の同定とトレーニングの工夫, 第28回日本内視鏡外科学会総会, Dec. 2015.
1144.	Hiroki Ishibashi, Keigo Yada and Mitsuo Shimada : 重症心身障害児(者)における腹腔鏡下噴門形成術後のwrap herniation(再発)に関する検討, 第28回日本内視鏡外科学会総会, Dec. 2015.
1145.	Hiroki Ishibashi, Keigo Yada and Mitsuo Shimada : 新生児・乳児CCAMに対する胸腔鏡補助下肺切除術の定型化および工夫, 第28回日本内視鏡外科学会総会, Dec. 2015.
1146.	髙田厚史, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 吉川雅登 and 寺奥大貴 : HCCに対して初回RFA治療後早期にリンパ節再発をきたし外科的切除を施行した症例, 第41回日本肝臓学会西部会, Dec. 2015.
1147.	吉川雅登, Shin-ichiro Yamada, 髙田厚史, 良元俊昭, 寺奥大貴, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝内胆管癌との鑑別が困難であった原発性放線菌症の一例, 第41回日本肝臓学会西部会, Dec. 2015.
1148.	Satoru Imura, Yuji Morine and Mitsuo Shimada : 非癌部における肝発癌分子機構の検討 ∼癌幹細胞関連DNA・miRNA発現に着目して∼, 第41回日本肝臓学会西部会, Dec. 2015.
1149.	吉川雅登, Wubetu Gizachew Yismaw, 髙田厚史, 良元俊昭, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脂肪由来幹細胞からインスリン分泌細胞への分化誘導におけるバルプロ酸の分化促進, 第45回日本創傷治癒学会, Nov. 2015.
1150.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下腹壁瘢痕ヘルニア根治術におけるHybrid法の安全性と有用性, 第77回日本臨床外科学会総会, Nov. 2015.
1151.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : Glasgow prognostic score(GPS)を用いた腹腔鏡下進行大腸癌手術における予後予測の検討, 第77回日本臨床外科学会総会, Nov. 2015.
1152.	Jun Higashijima, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Toshihiro Nakao, Kouzou Yoshikawa, Takashi Iwata and Mitsuo Shimada : 下部直腸癌に対する術前化学放射線療法による合併症の予後への影響, 第77回日本臨床外科学会総会, Nov. 2015.
1153.	吉川雅登, Shin-ichiro Yamada, 髙田厚史, 良元俊昭, 寺奥大貴, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Hiroshi Shibata, Hidenori Miyake and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検討∼切除を含む集学的治療の重要性∼, 第77回日本臨床外科学会総会, Nov. 2015.
1154.	寺奥大貴, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 吉川雅登, 髙田厚史 and 良元俊昭 : 若手外科医教育のための膵頭十二指腸切除における3D simulationの有用性, 第77回日本臨床外科学会総会, Nov. 2015.
1155.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術における免疫指標を加味した新たな周術期栄養評価, 第77回日本臨床外科学会総会, Nov. 2015.
1156.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登, Chie Takasu and Jun Higashijima : 大腸癌多発肝転移に対する治療戦略, 第77回日本臨床外科学会総会, Nov. 2015.
1157.	Satoru Imura, 髙田厚史, 良元俊昭, 寺奥大貴, 吉川雅登, Shin-ichiro Yamada, Chie Takasu, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝臓外科における画像シミュレーション, 第77回日本臨床外科学会総会, Nov. 2015.
1158.	Satoru Imura, 髙田厚史, 良元俊昭, 寺奥大貴, 吉川雅登, Shin-ichiro Yamada, Chie Takasu, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝切除における高齢者の特徴と戦略, 第77回日本臨床外科学会総会, Nov. 2015.
1159.	Mitsuo Shimada : 次世代外科医へ伝える手術の理論と技術 -熟練外科医に学ぶ- 1.肝臓 1 開腹下肝切除:グリソン一括処理の完全マスターと一期一会, 第77回日本臨床外科学会総会, Nov. 2015.
1160.	Shin-ichiro Yamada, 良元俊昭, 髙田厚史, 寺奥大貴, 吉川雅登, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 腹腔鏡下肝切除術の適応拡大と標準化への工夫安全な腹腔鏡下肝切除の標準化に向けて ∼適応拡大に先立つ着実な手技の定型化∼, 第9回肝臓内視鏡外科研究会, Nov. 2015.
1161.	Masaaki Nishi, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara and Chie Takasu : 直腸癌手術における縫合不全回避のための術中血流評価の有用性, 第24回日本コンピュータ外科学会大会, Nov. 2015.
1162.	吉川雅登, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 寺奥大貴, 髙田厚史 and 良元俊昭 : 分肝機能に着目したEOB-MRIによる肝予備能評価の有用性, 第24回日本コンピュータ外科学会大会, Nov. 2015.
1163.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 非癌部Thrombospondin-1(THBS1)発現は胃発癌に関連する, 第26回日本消化器癌発生学会総会, Nov. 2015.
1164.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : LED光照射による癌幹細胞制御に関する研究, 第26回日本消化器癌発生学会総会, Nov. 2015.
1165.	寺奥大貴, 髙田厚史, 良元俊昭, 吉川雅登, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝内胆管癌におけるFbxw7発現低下と臨床病理学的意義 - 細胞増殖・EMT誘導との関連に着目して -, 第26回日本消化器癌発生学会総会, Nov. 2015.
1166.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 肝細胞癌におけるEpigenetic遺伝子制御の可能性, 第26回日本消化器癌発生学会総会, Nov. 2015.
1167.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Takuya Tokunaga, Hideya Kashihara and Chie Takasu : 局所進行下部直腸癌に対する多剤併用術前化学放射線療法, 第70回日本大腸肛門病学会学術集会, Nov. 2015.
1168.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 肥満患者に対するスリーブ状胃切除術の有用性に関する検討, 日本消化器病学会四国支部第104回例会, Nov. 2015.
1169.	寺奥大貴, Shin-ichiro Yamada, 良元俊昭, 高田厚史, 吉川雅登, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Mitsuo Shimada and Hidenori Miyake : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-, 日本消化器病学会四国支部第104回例会, Nov. 2015.
1170.	Hisami Okumura, 和田宵湖, 新井田裕樹, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa, 森本佳奈, 倉橋清衛, Takeshi Kondo, Sumiko Yoshida, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Mitsuo Shimada and Munehide Matsuhisa : 本院の腹腔鏡下袖状胃切除術後1年で異なった経過を示した2症例の報告, 第53回糖尿病学会中四国大会, Oct. 2015.
1171.	Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, 良元俊昭, 髙田厚史 and Mitsuo Shimada : 直腸癌術前CRT症例におけるKi-67発現の意義, 第53回日本癌治療学会学術集会, Oct. 2015.
1172.	Hideya Kashihara, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : TGFβを介した腫瘍免疫機構は治癒切除した胃癌再発に関与する, 第53回日本癌治療学会学術集会, Oct. 2015.
1173.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Chie Takasu : StageII/III大腸癌における腹腔鏡手術vs開腹手術のpropensity scoreによる検討, 第53回日本癌治療学会学術集会, Oct. 2015.
1174.	Jun Higashijima, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : 大腸癌肝転移症例における肝転移巣のKISS1発現に関する検討, 第53回日本癌治療学会学術集会, Oct. 2015.
1175.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 吉川雅登 and 寺奥大貴 : 肝細胞癌症例におけるNEK2発現の意義に関する検討, 第53回日本癌治療学会学術集会, Oct. 2015.
1176.	髙田厚史, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 大腸癌肝転移症例における肝転移巣のKISS1発現に関する検討, 第53回日本癌治療学会学術集会, Oct. 2015.
1177.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and 江藤祥平 : 胃癌におけるPD-1発現の意義, 第74回日本癌学会学術総会, Oct. 2015.
1178.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and 江藤祥平 : StageII/III大腸癌腹腔鏡手術と開腹手術のpropensity scoreによる検討, JDDW 2015, Oct. 2015.
1179.	寺奥大貴, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Higashijima, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 石川大地 and 吉川雅登 : 大腸癌肝転移肝切除症例におけるThrombospondin-1(THBS1)発現の意義, 第74回日本癌学会学術総会, Oct. 2015.
1180.	Tetsuya Ikemoto, Mitsuo Shimada, 石川大地, 寺奥大貴, 吉川雅登, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Satoru Imura and Yuji Morine : Tr1細胞と調節性T細胞の坦癌患者における臨床的意義に関する研究, 第74回日本癌学会学術総会, Oct. 2015.
1181.	Tetsuya Ikemoto, Chie Takasu and Mitsuo Shimada : 女性外科医を大いに活躍させる教室の医局運営, JDDW 2015, Oct. 2015.
1182.	Tetsuya Ikemoto, Mitsuo Shimada, 石川大地, Yuji Morine, Satoru Imura, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登 and 良元俊昭 : Tr1細胞とFoxp3調節性T細胞による消化器担癌状態の正確な診断バイオマーカー探索に関する研究, JDDW 2015, Oct. 2015.
1183.	西尾進, 鳥居裕太, 平田有紀奈, 山尾雅美, Shin-ichiro Yamada, Seiji Iwamoto, Hirotsugu Yamada, Naoki Muguruma, Mitsuo Shimada and Masataka Sata : 正常肝に発症した巨大肝細胞癌の1例, 日本超音波医学会第25回四国地方会学術集会, Oct. 2015.
1184.	吉川雅登, Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 市井啓仁 and Mitsuo Shimada : NO阻害と転写活性制御に着目した虚血再灌流傷害治療に向けた基礎的検討, 第51回日本移植学会総会, Oct. 2015.
1185.	Shin-ichiro Yamada, Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Chie Takasu, 吉川雅登, 寺奥大貴, 髙田厚史 and 良元俊昭 : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について, 第51回日本移植学会総会, Oct. 2015.
1186.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 脂肪由来幹細胞が拓く膵島細胞移植成績向上に関する展望と課題, 第51回日本移植学会総会, Oct. 2015.
1187.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : 鏡視下手技が苦手な学生に対するoff-the-jobトレーニングの工夫, 第251回徳島医学会学術集会, Aug. 2015.
1188.	山田亮, 原知也, Shusuke Yagi, Jun Higashijima, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Mitsuo Shimada and Masataka Sata : 下肢静脈血栓症を伴わない下大静脈限局型血栓症の1例, 第251回徳島医学会学術集会(平成27年度夏期), Aug. 2015.
1189.	梶浦大資, Hisami Okumura, Yutaka Taketani, Takafumi Katayama, Akiko Matsumura, Mitsuo Shimada, 平山明由, 冨田勝 and 曽我朋義 : 肝癌患者における肝切除前・後の血清及び尿中メタボローム解析, 第251回徳島医学会, Aug. 2015.
1190.	掛田貴章, 井村涼太, 尾澤公亮, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 造影CT画像(動脈相・門脈相・平衡相)を用いた腹部血管画像解析, 日本医用画像工学会大会, OP8-5, Jul. 2015.
1191.	尾澤公亮, 平島孝樹, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 腹部造影CT画像における血管抽出と分類, 日本医用画像工学会大会, PP35, Jul. 2015.
1192.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : クリニカルクラークシップ学生対象の反転授業応用縫合実習の試み, 第47回日本医学教育学会大会, Jul. 2015.
1193.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第51回日本肝癌研究会, Jul. 2015.
1194.	Satoru Imura, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脾機能亢進症を合併した肝癌に対する脾摘+肝切除の有用性, 第51回日本肝癌研究会, Jul. 2015.
1195.	江藤祥平, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi and Chie Takasu : 進行胃癌におけるPD-1/PD-L1発現は相関し，予後と関連する, 第70回日本消化器外科学会総会, Jul. 2015.
1196.	Toshihiro Nakao, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu and 江藤祥平 : Stage Ⅱ/Ⅲ大腸癌に対する腹腔鏡と開腹手術のプロペンシティスコアによる検, 第70回日本消化器外科学会総会, Jul. 2015.
1197.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu and 江藤祥平 : 腹腔鏡下胃切除における3Dシミュレーションとナビゲーション, 第70回日本消化器外科学会総会, Jul. 2015.
1198.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and 江藤祥平 : 局所進行下部直腸癌に対する術前化学放射線療法の奏効率向上を目指して, 第70回日本消化器外科学会総会, Jul. 2015.
1199.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara and 江藤祥平 : 合併症から学ぶ腹腔鏡下胃全摘出術R-Y再建の工夫-視野展開と吻合の工夫-, 第70回日本消化器外科学会総会, Jul. 2015.
1200.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Chie Takasu, 江藤祥平 and Masashi Akaike : 内視鏡手術時代における卒前教育からのoff-the-jobと反転授業を応用した実習の試み, 第70回日本消化器外科学会総会, Jul. 2015.
1201.	吉川雅登, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu and Shin-ichiro Yamada : 肝細胞癌における腫瘍マーカー発現とEpithelial-mesenchymal transitionに関する検討, 第70回日本消化器外科学会総会, Jul. 2015.
1202.	寺奥大貴, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 吉川雅登 : 大腸癌肝転移における腫瘍内Ki67発現の意義, 第70回日本消化器外科学会総会, Jul. 2015.
1203.	Shin-ichiro Yamada, 吉川雅登, 寺奥大貴, Satoru Imura, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 安全な腹腔鏡下切除の標準化に向けて∼適応拡大に先立つ着実な手技の定型化∼, 第70回日本消化器外科学会総会, Jul. 2015.
1204.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 吉川雅登 and 寺奥大貴 : 肝予備能評価におけるEOB-MRI肝細胞相の有用性の検討, 第70回日本消化器外科学会総会, Jul. 2015.
1205.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Kouzou Yoshikawa, Yusuke Arakawa, Shuichi Iwahashi, Keigo Yada, Yu Saitou and Shin-ichiro Yamada : 肝切除周術期におけるTU-100に関するトランスレーショナルリサーチ, 第70回日本消化器外科学会総会, Jul. 2015.
1206.	Yusuke Arakawa, Mitsuo Shimada, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 小胞体ストレス応対に着目した加齢肝再生不全における肝星細胞の役割についての検討, 第70回日本消化器外科学会総会, Jul. 2015.
1207.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第70回日本消化器外科学会総会, Jul. 2015.
1208.	Satoru Imura, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Yuji Morine, 住友正幸 and Mitsuo Shimada : へき地病院から専門医を輩出するための地域外科診療部の活用, 第70回日本消化器外科学会総会, Jul. 2015.
1209.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, Masaaki Nishi and Chie Takasu : 切除可能大腸癌肝転移に対する原発・転移巣同時切除の妥当性, 第83回大腸癌研究会, Jul. 2015.
1210.	Yu Saitou, Sonoko Yasui, 寺奥大貴, 吉川雅登, Shin-ichiro Yamada, Chie Takasu, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究-体成分分析装置と主観的包括的アセスメントSGA -, 日本外科代謝栄養学会第52回学術集会, Jul. 2015.
1211.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and 江藤祥平 : LED光照射による癌幹細胞制御に関する研究, 第24 回日本癌病態治療研究会, Jun. 2015.
1212.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登 and Gizachew Yismaw : Epigallocatechin gallateはABCトランスポーターを介してstemnessを解除する, 第24 回日本癌病態治療研究会, Jun. 2015.
1213.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and 江藤祥平 : 大腸癌手術における縫合不全回避のための工夫:ICG蛍光システムを用いた腸管血流評価の有用性について, 第103回例会日本消化器病学会総会四国支部, Jun. 2015.
1214.	吉川雅登, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, 石川大地, 寺奥大貴, 良元俊昭, 髙田厚史 and Hidenori Miyake : 肝細胞癌切除症例に対するRFA後肝細胞癌再発例はEMT誘導を介して予後不良となる, 第103回例会日本消化器病学会総会四国支部, Jun. 2015.
1215.	Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Hiroshi Shibata, Hidenori Miyake and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検証-切除を含む集学的治療の重要性-, 第103回例会日本消化器病学会総会四国支部, Jun. 2015.
1216.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術におけるNST介入による周術期栄養評価, 第40回日本外科系連合学会学術集会, Jun. 2015.
1217.	良元俊昭, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, 寺奥大貴 and 吉川雅登 : 若手外科医にも安全な3mm細径鉗子を用いたreduced port Lap-C, 第40回日本外科系連合学会学術集会, Jun. 2015.
1218.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究‐体成分分析装置と主観的包括的アセスメント‐, 第27回日本肝胆膵外科学会, Jun. 2015.
1219.	吉川雅登, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地 and 寺奥大貴 : 肝細胞癌における腫瘍マーカー発現とEMTに関する検討, 第27回日本肝胆膵外科学会, Jun. 2015.
1220.	寺奥大貴, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 石川大地 and 吉川雅登 : 大腸癌肝転移肝切除症例におけるThrombospondin-1(THBS1)発現の意義, 第27回日本肝胆膵外科学会, Jun. 2015.
1221.	Shin-ichiro Yamada, 吉川雅登, 寺奥大貴, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脾機能亢進症を合併した肝癌に対する脾摘+肝切除の有用性, 第27回日本肝胆膵外科学会, Jun. 2015.
1222.	Yu Saitou, エンヘボルトチンボルト, 吉川雅登, 寺奥大貴, 石川大地, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝内胆管癌におけるFbxw7発現低下と臨床病理的意義-細胞増殖・EMT誘導との関連-, 第27回日本肝胆膵外科学会, Jun. 2015.
1223.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 吉川雅登 and 寺奥大貴 : 3mm細径鉗子を用いたreduced port Lap-C, 第27回日本肝胆膵外科学会, Jun. 2015.
1224.	Yusuke Arakawa, Mitsuo Shimada, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 下右肝静脈温存，上中右肝静脈ドレナージ領域を含む合理的拡大肝前区域切除術, 第27回日本肝胆膵外科学会, Jun. 2015.
1225.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登 and 良元俊昭 : Borderline resectable膵癌に対する治療成績の検討, 第27回日本肝胆膵外科学会, Jun. 2015.
1226.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登 and 良元俊昭 : 指導医の立場から見た若手外科医教育のための膵頭十二指腸切除における3Dsimulationの有用性, 第27回日本肝胆膵外科学会, Jun. 2015.
1227.	Satoru Imura, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝予備能評価におけるEOB-MRI肝細胞相の有用性, 第27回日本肝胆膵外科学会, Jun. 2015.
1228.	Shin-ichiro Yamada, 吉川雅登, 寺奥大貴, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 安全な腹腔鏡下肝切除の標準化に向けて-左葉系肝切除における着実な手技の定型化-, 第27回日本肝胆膵外科学会, Jun. 2015.
1229.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第27回日本肝胆膵外科学会, Jun. 2015.
1230.	Mayu Tanimura, Sayaka Matsura, Sonoko Yasui, Yu Saitou, 山田静恵, 谷佳子, Akiko Matsumura, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者の術前栄養評価におけるSGAとODAとの相関, 第7回日本静脈経腸栄養学会四国支部会学術集会, Jun. 2015.
1231.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 重傷心身障害児(者)のGERDに対する腹腔鏡下噴門形成術の予後と術式変遷に関する検討, 第52回日本小児外科学会学術集会, May 2015.
1232.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori, Akira Nii and Mitsuo Shimada : 術中ナビゲーションが有用で胸腔鏡下に摘出し得た中縦隔原発気管原性嚢胞, 第52回日本小児外科学会学術集会, May 2015.
1233.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 大建中湯(TU-100)は胆道閉鎖症ラットモデルにおける肝線維化を抑制する, 第52回日本小児外科学会学術集会, May 2015.
1234.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori, Akira Nii and Mitsuo Shimada : 小児鼠径ヘルニアに対するLPEC法の適応と限界, 第52回日本小児外科学会学術集会, May 2015.
1235.	Satoru Imura, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 吻合部狭窄のない胆管-胆管吻合手技の工夫-, 第33回日本肝移植研究会, May 2015.
1236.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shuichi Iwahashi, Yu Saitou, 吉川雅登 and 寺奥大貴 : 分肝機能に着目したEOB-MRIによる肝予備能評価の有用性, 第51回日本肝臓学会総会, May 2015.
1237.	Shuichi Iwahashi, Mitsuo Shimada, Tatsuya Taniguchi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and 楠本彩子 : 当県肝疾患診療における円滑な地域連携推進のための活動について, 第51回日本肝臓学会総会, May 2015.
1238.	Yusuke Arakawa, Satoru Imura and Mitsuo Shimada : 非B非C型肝細胞癌切除症例の検討, 第51回日本肝臓学会総会, May 2015.
1239.	Satoru Imura, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脾機能亢進症を合併した肝癌に対する非的+肝切除の有用性, 第51回日本肝臓学会総会, May 2015.
1240.	Toshihiro Nakao, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and 江藤祥平 : 腹腔鏡下大腸癌手術におけるICG蛍光法の有用性, 第69回手術手技研究会, May 2015.
1241.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下胃全摘出術R-Y再建の工夫―視野展開と吻合の工夫―, 第69回手術手技研究会, May 2015.
1242.	Shin-ichiro Yamada, 吉川雅登, 寺奥大貴, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 若手外科医教育のための膵頭十二指腸切除における3D simulationの有用性, 第69回手術手技研究会, May 2015.
1243.	Yu Saitou, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 術前3Dシミュレーションを使用した膵頭十二指腸切除におけるmodified de-rotation, 第69回手術手技研究会, May 2015.
1244.	Mitsuo Shimada : 切除不能大腸癌肝転移に対する''Early Conversion'' を目指した治療戦略, 第69回手術手技研究会, May 2015.
1245.	Ahmed S.Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Satake, Noriyuki Moriyama, Toru Utsunomiya and Mitsuo Shimada : Automatic blood vessel-based liver segmentation through the portal phase abdominal CT dataset, IEICE Technical Report, Vol.115, No.25, 127-132, May 2015.
1246.	和田宵湖, Hisami Okumura, Eiji Takeda, Yutaka Taketani, Takafumi Katayama, Yusuke Arakawa, Satoru Imura and Mitsuo Shimada : 肝癌患者における肝切除前後のエネルギー代謝変化の検討, 第2回日本栄養改善学会四国支部学術総会, Apr. 2015.
1247.	Tetsuo Kimura, 武原正典, 岡崎潤, 高岡慶史, 岡田泰行, 宮本佳彦, 松本早代, 三井康裕, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, 髙岡遠, Shinji Kitamura, Masako Kimura, Hiroshi Miyamoto, Naoki Muguruma, Tetsuya Ikemoto, Mitsuo Shimada and Tetsuji Takayama : 非典型的な画像所見を呈する膵神経内分泌腫瘍(膵NET)の治療方針, 第101回日本消化器病学会総会, Apr. 2015.
1248.	Toshihiro Nakao, Mitsuo Shimada and Kouzou Yoshikawa : がん幹細胞制御におけるSonic Hedgehog signalingの役割, 第101回日本消化器病学会総会, Apr. 2015.
1249.	Shuichi Iwahashi, Mitsuo Shimada, 寺奥大貴, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Jun Higashijima, Chie Takasu and 吉川雅登 : Epigallocatechin gallateの消化器癌における抗腫瘍効果の検討, 第101回日本消化器病学会総会, Apr. 2015.
1250.	Yuji Morine, Mitsuo Shimada and Jun Higashijima : 大腸癌多発肝転移に対する治療戦略, 第101回日本消化器病学会総会, Apr. 2015.
1251.	Satoru Imura, Mitsuo Shimada and Jun Higashijima : 進行肝癌に対するソラフェニブ+外科切除併用の効果の検討∼Conversion症例および長期生存例の検証と併せて∼, 第101回日本消化器病学会総会, Apr. 2015.
1252.	良元俊昭, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and 江藤祥平 : 直腸癌に対する腹腔鏡下直腸切断術後骨盤死腔炎に関する検討, 第115回日本外科学会定期学術集会, Apr. 2015.
1253.	江藤祥平, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi and Chie Takasu : 胃癌におけるPD-1,THBS1発現は再発と関係する, 第115回日本外科学会定期学術集会, Apr. 2015.
1254.	Chie Takasu, Yuji Morine, Satoru Imura, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地 and Mitsuo Shimada : 肝虚血再灌流障害の発生・進展機序の解明と統合的治療法開発の取り組み, 第115回日本外科学会定期学術集会, Apr. 2015.
1255.	Toshihiro Nakao, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu and 江藤祥平 : 非癌部組織におけるThrombospondin-1(THBS1)と胃発癌との関連, 第115回日本外科学会定期学術集会, Apr. 2015.
1256.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, 江藤祥平 and 寺奥大貴 : 膵癌細胞におけるResveratrolの autophagyを介した細胞増殖抑制効果, 第115回日本外科学会定期学術集会, Apr. 2015.
1257.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Chie Takasu and Masashi Akaike : 鏡視下手技が苦手な学生をどうトレーニングするか?―off-the-job トレーニングの工夫―, 第115回日本外科学会定期学術集会, Apr. 2015.
1258.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and 江藤祥平 : 局所進行直腸癌に対する集学的治療戦略/下部直腸癌に対する術前化学放射線療法の合併症が予後に与える影響に関する検討, 第115回日本外科学会定期学術集会, Apr. 2015.
1259.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada, Shin-ichiro Yamada and Mitsuo Shimada : 腹腔鏡下Palomo法術後の陰嚢水瘤予防に対する少数リンパ管温存の妥当性, 第115回日本外科学会定期学術集会, Apr. 2015.
1260.	Keigo Yada, Hiroki Mori, Hiroki Ishibashi, Chie Takasu, 寺奥大貴, 吉川雅登, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 大建中湯(TU-100)は胆道閉鎖症ラットモデル由来の肝星細胞活性化を抑制する, 第115回日本外科学会定期学術集会, Apr. 2015.
1261.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 腹腔鏡下に内鼠径輪縫縮と鼠径管後壁補強を可能とするAdvanced LPEC法, 第115回日本外科学会定期学術集会, Apr. 2015.
1262.	太田昇吾, Yu Saitou, 吉川雅登, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : ソラフェニブ投与後切除可能となり長期生存が得られたFGF4強発現進行肝細胞癌の症例, 第115回日本外科学会定期学術集会, Apr. 2015.
1263.	髙田厚史, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 吉川雅登 and 寺奥大貴 : 大腸癌肝転移症例における肝転移巣のKiss1発現は独立予後規定因子となる, 第115回日本外科学会定期学術集会, Apr. 2015.
1264.	石川大地, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 大腸癌におけるmicroRNA-449a発現の意義, 第115回日本外科学会定期学術集会, Apr. 2015.
1265.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, 石川大地, 寺奥大貴 and 吉川雅登 : 肝内胆管癌における細胞周期調節因子Fbxw7の発現低下は独立予後規定因子である, 第115回日本外科学会定期学術集会, Apr. 2015.
1266.	吉川雅登, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝細胞癌における腫瘍マーカー発現は無再発予後因子となる, 第115回日本外科学会定期学術集会, Apr. 2015.
1267.	寺奥大貴, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 石川大地 and 吉川雅登 : 大腸癌肝転移におけるThrombospondin-1(THBS1)発現の意義, 第115回日本外科学会定期学術集会, Apr. 2015.
1268.	Yusuke Arakawa, Mitsuo Shimada, 寺奥大貴, 吉川雅登, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Jun Higashijima : 加齢肝再生不全における肝星細胞の役割についての検討, 第115回日本外科学会定期学術集会, Apr. 2015.
1269.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : Epigallocatechin gallateはABCトランスポーター関連因子を介して抗腫瘍効果を発揮する, 第115回日本外科学会定期学術集会, Apr. 2015.
1270.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 術前3DシミュレーションおよびVSSを使用した膵頭十二指腸切除における modified de-rotation method, 第115回日本外科学会定期学術集会, Apr. 2015.
1271.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地, 寺奥大貴, Chie Takasu, Jun Higashijima and Hidenori Miyake : 大腸癌多発肝転移に対する長期生存を目指した治療戦略, 第115回日本外科学会定期学術集会, Apr. 2015.
1272.	Satoru Imura, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Yuji Morine, Hidenori Miyake, Mitsuo Shimada, 吉川雅登, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Yu Saitou and Chie Takasu : 手技定型化が可能にした門脈·肝静脈解剖に基づく合理的な系統的肝切除-副右肝静脈灌流領域切除を伴う拡大前区域切除術-, 第115回日本外科学会定期学術集会, Apr. 2015.
1273.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究-体成分分析装置と主観的包括アセスメントSGA-, 第115日本外科学会定期学術集会, Apr. 2015.
1274.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Chie Takasu, 江藤祥平, 寺奥大貴, Takashi Iwata, 和田大助, 坂東儀昭, 尾形信也, Hideya Kashihara, Nobuhiro Kurita and Takuya Tokunaga : 術前3Dシュミュレーションを用いた腹腔鏡下胃切除, 第87回日本胃癌学会総会, Mar. 2015.
1275.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, 坂東儀昭, 尾形信也 and 和田大助 : 腹腔鏡下胃全摘出術後の再建における当科での工夫ーOverlapとOrvilとの比較ー, 第87回日本胃癌学会総会, Mar. 2015.
1276.	吉川雅登, 良元俊昭, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝門部胆管癌に対する拡大肝右葉切除後，門脈血栓・大量腹水により管理に難渋した1例, 第23回徳島外科術後管理研究会, Feb. 2015.
1277.	良元俊昭, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and 江藤祥平 : 化学放射線療後に骨盤内臓全摘術を施行し，骨盤死腔炎から小腸会陰瘻を合併した1例, 第23回徳島外科術後管理研究会, Feb. 2015. (Keyword) 国内学会
1278.	Toshihiro Nakao, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu and 江藤祥平 : 腹腔鏡下直腸手術におけるICG蛍光法の検討, 第29回四国内視鏡外科研究会, Feb. 2015. (Keyword) 国内学会
1279.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu, 江藤祥平 and 寺奥大貴 : 腹腔鏡下胃切除における術前3Dシミュレーションの有用性, 第29回四国内視鏡外科研究会, Feb. 2015. (Keyword) 国内学会
1280.	河野洋平, 尾澤公亮, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Shimada and 飯沼元 : 大腸がん切除計画のための腹部細血管の詳細抽出と分類, 第22回日本CT検診学会学術集会, 6-3, Feb. 2015.
1281.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : 反転授業を応用したクリニカルクラークシップ学生対象の縫合実習の試み, 第250回徳島医学会学術集会, Feb. 2015.
1282.	吉川雅登, Mitsuo Shimada, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Satoru Imura and Yuji Morine : 肝細胞癌における腫瘍マーカー発現は無再発予後因子となる, 第250回徳島医学会学術集会, Feb. 2015.
1283.	Keigo Yada, Hiroki Ishibashi, Yuji Morine and Mitsuo Shimada : 大建中湯(TU-100)は胆道閉鎖症ラットモデルにおける肝線維化を抑制する, 第250回徳島医学会学術集会, Feb. 2015. (Keyword) 国内学会
1284.	Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検証 ∼切除を含む集学的治療の重要性∼, 第11回日本肝がん分子標的治療研究会, Jan. 2015.
1285.	Jun Higashijima, 江藤祥平, Chie Takasu, Masaaki Nishi, Toshihiro Nakao, Kouzou Yoshikawa, Takashi Iwata and Mitsuo Shimada : StageⅡ,Ⅲ結腸癌に対する腹腔鏡下手術の妥当性の検討:開腹手術との比較検討, 第82回大腸癌研究会, Jan. 2015. (Keyword) 国内学会
1286.	和田宵湖, Hisami Okumura, 杉原康平, 山本モモ, Yutaka Taketani, Mitsuo Shimada and Eiji Takeda : 肝癌患者における切除量が切除前後のエネルギー代謝に及ぼす影響, 第18回日本病態栄養学会年次学術集会平成27年1月10-11日国立京都国際会館, Jan. 2015.
1287.	杉原康平, Hisami Okumura, 和田宵湖, 山本モモ, Yutaka Taketani, Shin-ichiro Yamada, Satoru Imura, Mitsuo Shimada and Eiji Takeda : 肝細胞癌患者における肝切除術後予後因子としての非蛋白質呼吸商, 第18回日本病態栄養学会年次学術集会平成27年1月10-11日国立京都国際会館, Jan. 2015.
1288.	良元俊昭, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地, 吉川雅登 and 寺奥大貴 : ソラフェニブ投与後切除可能となり長期生存が得られたFGF4強発現進行肝細胞癌の症例, 第102回日本消化器病学会四国支部例会, Nov. 2014. (Keyword) 国内学会
1289.	Eiji Takeda, Hisami Okumura, 和田宵湖, 山本もも, 杉原康平, Yuji Morine, Satoru Imura and Mitsuo Shimada : 中遊離脂肪酸(NEFA)濃度を指標とした就寝前夜食(LES)療法の適応, 第45回日本消化吸収学会総会, Nov. 2014.
1290.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 小児腸重積症に対する超音波装置を用いた診断および非観血的整復術, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1291.	江藤祥平, Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi and Chie Takasu : 腹腔鏡下胃全摘術における肝圧排法による視野展開の有用性, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1292.	Toshihiro Nakao, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, 江藤祥平, 寺奥大貴 and 吉川雅登 : 腹腔鏡下胃切除術ERASプロトコルにおける大建中湯(DKT:TJ-100)の有用性に関する検討, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1293.	Chie Takasu, Masaaki Nishi, Takashi Iwata, Jun Higashijima, Kouzou Yoshikawa, Toshihiro Nakao, Takuya Tokunaga, 江藤祥平 and Mitsuo Shimada : 肥満患者に対するスリーブ状胃切除術の成績, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1294.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu and 江藤祥平 : 若手外科医のための腹腔鏡下胃切除における術前3Dシミュレーションの有用性, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1295.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and 江藤祥平 : 腹腔鏡下胃全摘出術における視野展開と吻合の工夫, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1296.	吉川雅登, Mitsuo Shimada, 寺奥大貴, Wubetu Gizchew Yismaw, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝細胞癌におけるSTAT4発現は腫瘍免疫を反映し予後因子となる, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1297.	寺奥大貴, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地 and 吉川雅登 : 肝細胞癌におけるLine1メチル化レベルは肝切除後予後因子となる, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1298.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Shin-ichiro Yamada, 石川大地, 吉川雅登 and 寺奥大貴 : 立体臓器モデルによる3D virtual hepatectomyと術中navigation systemを駆使した肝切除, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1299.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 膵頭十二指腸切除術に対する取り組みと在院期間短縮についての検討, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1300.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地, Jun Higashijima, Chie Takasu and Hidenori Miyake : 切除不能大腸癌肝転移に対する治療戦略, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1301.	Satoru Imura, 吉川雅登, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 若手肝臓外科医を育成するための取り組み∼3Dプリンターによる術中ナビゲーションと評価シートによるフィードバック∼, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
1302.	江藤祥平, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi and Chie Takasu : 胃癌におけるStathmin1発現とH.pylori 感染の関連, 第25回日本消化器癌発生学会総会, Nov. 2014. (Keyword) 国内学会
1303.	Toshihiro Nakao, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, 江藤祥平, 寺奥大貴 and 吉川雅登 : Sonic Hedgehog signalingの癌幹細胞における意義, 第25回日本消化器癌発生学会総会, Nov. 2014. (Keyword) 国内学会
1304.	Shin-ichiro Yamada, Mitsuo Shimada, 石川大地, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi and Yu Saitou : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第25回日本消化器癌発生学会総会, Nov. 2014. (Keyword) 国内学会
1305.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, 吉川雅登 and 寺奥大貴 : Epigallocatechin gallateは安全性の高い新規抗腫瘍剤として有用である, 第25回日消化器癌発生学会総会, Nov. 2014. (Keyword) 国内学会
1306.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Chie Takasu and 江藤祥平 : 腹腔鏡下胃切除における術前3Dシミュレーション∼若手教育のために∼, 第23回日本コンピュータ外科学会, Nov. 2014. (Keyword) 国内学会
1307.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Shin-ichiro Yamada, 石川大地, 吉川雅登 and 寺奥大貴 : 立体臓器モデルによる3D-virtual hepatectomyと術中navigation systemを用いた肝切除, 第23回日本コンピュータ外科学会, Nov. 2014. (Keyword) 国内学会
1308.	Jun Higashijima, Chie Takasu, Kouzou Yoshikawa, Takashi Iwata and Mitsuo Shimada : 早期下部直腸癌に対する術前化学放射線療法併用局所切除術の成績について, 第69回日本大腸肛門病学会学術集会, Nov. 2014. (Keyword) 国内学会
1309.	江藤祥平, Kouzou Yoshikawa, Takashi Iwata, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Mitsuo Shimada : 大腸癌細胞におけるCD47抑制と放射線増感効果の検討, 第102回日本消化器病学会四国支部例会, Nov. 2014. (Keyword) 国内学会
1310.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 巨大肛門ポリープを伴った女児低位鎖肛の1例, 第30回日本小児外科学会秋季シンポジウム, Oct. 2014. (Keyword) 国内学会
1311.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 鼠径ヘルニアを合併した小児精索静脈瘤に対する腹腔鏡下手術, 第30回日本小児外科学会秋季シンポジウム, Oct. 2014. (Keyword) 国内学会
1312.	Toshihiro Nakao, 江藤祥平 and Mitsuo Shimada : 胃癌術前栄養評価としてのSarcopenia測定の意義, 第22回日本消化器関連学会週間(JDDW), Oct. 2014. (Keyword) 国内学会
1313.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Chie Takasu and 江藤祥平 : 胃GISTに対する腹腔鏡・内視鏡合同手術(LECS)の検討, 第22回日本消化器関連学会週間(JDDW), Oct. 2014. (Keyword) 国内学会
1314.	Kouzou Yoshikawa, Chie Takasu and Mitsuo Shimada : 大建中湯のmicrobiomeを介した腸粘膜防御作用, 第22回日本消化器関連学会週間(JDDW), Oct. 2014. (Keyword) 国内学会
1315.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 高齢者における肝再生不全の肝星細胞からのアプローチ, 第22回日本消化器関連学会週間(JDDW), Oct. 2014. (Keyword) 国内学会
1316.	Satoru Imura, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Chie Takasu, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 根治性からみた進行肝癌初回治療法の選択, 第22回日本消化器関連学会週間(JDDW), Oct. 2014. (Keyword) 国内学会
1317.	山尾雅美, 西尾進, 鳥居裕太, 平田有紀奈, 笹田倫子, Shoichiro Takao, Naoki Muguruma, Hirotsugu Yamada, Mitsuo Shimada and Masataka Sata : 内部に嚢胞性変化を伴った肝過形成結節の1例, 第24回日本超音波医学会四国地方会学術集会, Oct. 2014.
1318.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 胎児診断され腹腔鏡下手術を行った腹腔鏡内精巣奇形腫の1例, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1319.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 成人外科に学ぶ術前3Dシミュレーション・術中ナビゲーション-小児鏡視下肝切除・肺切除への応用-, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1320.	Hiroki Ishibashi, Keigo Yada, Hiroki Mori and Mitsuo Shimada : 成人腹腔鏡下鼠径ヘルニア手術における鼠径部膜構造から学ぶ小児LPEC法, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1321.	Jun Higashijima, 江藤祥平, Chie Takasu, Masaaki Nishi, Toshihiro Nakao, Kouzou Yoshikawa, Takashi Iwata and Mitsuo Shimada : StageⅡ,Ⅲ結腸癌に対する腹腔鏡下手術の妥当性についての検討, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1322.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Chie Takasu and 江藤祥平 : 腹腔鏡下胃切除における術前3Dシュミュレーションの有用性, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1323.	Chie Takasu, Jun Higashijima, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, 江藤祥平, 寺奥大貴, 吉川雅登 and Mitsuo Shimada : 直腸切除術における縫合不全回避のための工夫:ICG蛍光法を用いた腸管血流評価, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1324.	Kouzou Yoshikawa, Mitsuo Shimada, Takashi Iwata, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and 江藤祥平 : 腹腔鏡補助下胃切除術の定型化は技術認定医取得に有用である, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1325.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga, Chie Takasu, 江藤祥平, Toshihiro Nakao and Masashi Akaike : 内視鏡外科手術におけるOff-the-jobトレーニングを科学する, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1326.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, 石川大地, 吉川雅登, 寺奥大貴 and Chie Takasu : 3mm細径鉗子を用いたReduced Port Lap-Cに関する検討, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
1327.	Shin-ichiro Yamada, Gizachew Yismaw, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, 石川大地, 吉川雅登, 寺奥大貴 and Mitsuo Shimada : 分枝鎖アミノ酸はオートファジーを介してインスリン存在下の癌細胞増殖を抑制する, 第73回日本癌学会学術総会, Sep. 2014. (Keyword) 国内学会
1328.	石川大地, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and Gizachew Yismaw : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第73回日本癌学会学術総会, Sep. 2014. (Keyword) 国内学会
1329.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Chie Takasu, 石川大地, 吉川雅登, 寺奥大貴 and Yismaw Gizachew : 安全な新規抗腫瘍剤としてのエピガロカテキンガレート, 第73回日本癌学会学術総会, Sep. 2014. (Keyword) 国内学会
1330.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 紫令湯による膵島破壊抑制機序の解明に関する免疫学的検討, 第50回日本移植学会総会, Sep. 2014. (Keyword) 国内学会
1331.	Yu Saitou, 寺奥大貴, 吉川雅登, 石川大地, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝星細胞からみた加齢肝再生不全の検討, 第50回日本移植学会総会, Sep. 2014. (Keyword) 国内学会
1332.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Chie Takasu and 江藤祥平 : LTGにおける食道空腸吻合のPitfallと工夫, 第89回中国四国外科学会総会・(第19回中国四国内視鏡外科研究会), Sep. 2014. (Keyword) 国内学会
1333.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Chie Takasu and 江藤祥平 : 肥満患者に対するスリーブ状胃切除術の成績, 第89回中国四国外科学会総会・(第19回中国四国内視鏡外科研究会), Sep. 2014. (Keyword) 国内学会
1334.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada and 石川大地 : RFA後肝細胞癌再発例においてEMT誘導を介し腫瘍悪性度が増強する, 第89回中国四国外科学会総会(第19回中国四国内視鏡外科研究会), Sep. 2014. (Keyword) 国内学会
1335.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, 石川大地, 寺奥大貴 and 吉川雅登 : 下右肝静脈温存，上右肝静脈とドレナージ領域を含む合理的拡大肝S8切除術, 第89回中国四国外科学会総会(第19回中国四国内視鏡外科研究会), Sep. 2014. (Keyword) 国内学会
1336.	Ahmed S.Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki and Mitsuo Shimada : Automatic blood vessel-based liver segmentation through the portal phase abdominal CT dataset, IEICE Technical Report, Vol.114, No.200, 27-31, Sep. 2014.
1337.	江藤祥平, Kouzou Yoshikawa, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : CD47抑制による大腸癌細胞の放射線増感効果の検討, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1338.	Jun Higashijima, Mitsuo Shimada, Takashi Iwata, Kouzou Yoshikawa, Masaaki Nishi, Toshihiro Nakao, Chie Takasu and 江藤祥平 : 下部直腸癌に対する新たな術前化学放射線療法(SOX+Bev)について, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1339.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, 松本規子 and 江藤祥平 : 腹腔鏡補助下胃切除術後の再発危険因子, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1340.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Takuya Tokunaga, Hideya Kashihara, 松本規子, 江藤祥平 and Chie Takasu : 胃癌発癌におけるThrombospondin-1(THBS1)発現の意義, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1341.	寺奥大貴, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 石川大地 and Chie Takasu : Epigallocatechin gallateは安全性の高い新規抗腫瘍剤として有用である, 第52回日本癌治療学会学術集会, Aug. 2014.
1342.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 石川大地 and Jun Higashijima : 肝内胆管癌におけるFBXW7発現低下と臨床病理学的意義, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1343.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu and Jun Higashijima : 肝内胆管癌に対するGFP術後補助療法の有用性, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1344.	Satoru Imura, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検証:切除を含む集学的治療の重要性, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1345.	吉川雅登, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Jun Higashijima : 肝細胞癌におけるサルコペニアと臨床病理学的意義, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1346.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and Shin-ichiro Yamada : MicroRNA-449a発現低下は大腸癌の腫瘍進展に関与し予後不良因子となる, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1347.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : RFA後肝細胞癌再発例においてはEMT誘導を介し腫瘍悪性度が増強する, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1348.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地, Jun Higashijima and Chie Takasu : 切除不能大腸癌肝転移に対する肝切除を基軸とした治療戦略, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
1349.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 大腸癌におけるCD47抑制による放射線増感作用に関する検討, 第69回日本消化器外科学会総会, Jul. 2014. (Keyword) 国内学会
1350.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi and Hideya Kashihara : LED照射による癌幹細胞制御に関する研究, 第69回日本消化器外科学会総会, Jul. 2014. (Keyword) 国内学会
1351.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Chie Takasu, Hideya Kashihara and 松本規子 : ハイリスク症例に対する腹腔鏡下胃切除の検討, 第69回日本消化器外科学会総会, Jul. 2014. (Keyword) 国内学会
1352.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu and 江藤祥平 : 腹腔鏡下直腸切除術での縫合不全リスク因子の検討と縫合不全減少のための工夫:ICG蛍光法での腸管血流評価, 第69回日本消化器外科学会総会, Jul. 2014. (Keyword) 国内学会
1353.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Jun Higashijima, Motoya Chikakiyo, Hideya Kashihara, Chie Takasu and 江藤祥平 : 高齢者胃癌症例に対するリンパ節郭清範囲縮小の妥当性, 第69回日本消化器外科学会総会, Jul. 2014. (Keyword) 国内学会
1354.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Motoya Chikakiyo, Takuya Tokunaga and Hideya Kashihara : 内視鏡外科手術のさらなる発展に向けたoff-the-jobとon-the-jobトレーニングの検討, 第69回日本消化器外科学会総会, Jul. 2014. (Keyword) 国内学会
1355.	寺奥大貴, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : 肝細胞癌における顕微鏡的門脈浸潤(vp)予測因子の検討, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1356.	Shin-ichiro Yamada, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : RFA後肝細胞癌再発例においてEMT誘導を介し腫瘍悪性度が増強する-microRNA発現に着目して-, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1357.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : 肝細胞癌におけるSTAT4発現は腫瘍免疫を反映し予後因子となる, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1358.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Chie Takasu and Yu Saitou : 肝胆膵外科手術における周術期栄養評価方法としてのInBodyを用いた体組成分析の有用性に関する検討, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1359.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Chie Takasu : 肝細胞癌におけるLine1 methylation statusは予後因子となる, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1360.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : 安全性の高い新規抗腫瘍剤としてのEpigallocatechin gallate-癌幹細胞治療抵抗性解除をめざして-, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1361.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 80歳以上超高齢者における肝切除の妥当性に関する検討-肝星細胞に着目した加齢再生不全機序の解明-, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1362.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou and 石川大地 : 3D virtual imageと術中navigation systemがもたらした革新的画像技術を用いた安全な肝切除, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1363.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu and Hidenori Miyake : 切除不能転移性肝癌に対する"Early Conversion"を目指したFOLFOXILI療法の可能性, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1364.	Satoru Imura, 石川大地, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 肝切除を基軸とした進行肝癌にたいする集学的治療戦略, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
1365.	吉川雅登, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 予後不良因子を有する進行胆嚢癌における術後補助GFP療法の効果, 第39回日本外科系連合学会学術集会, Jul. 2014. (Keyword) 校内学会
1366.	Jun Higashijima, 江藤祥平, Chie Takasu, Masaaki Nishi, Toshihiro Nakao, Kouzou Yoshikawa, Takashi Iwata and Mitsuo Shimada : 高齢者結腸癌に対する腹腔鏡下手術の妥当性についての検討, 第81回大腸癌研究会, Jul. 2014. (Keyword) 国内学会
1367.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada and 石川大地 : RFA後肝細胞癌再発例はEMT誘導を介して腫瘍悪性度が増強する-RFA後肝細胞癌における肝移植適応に関して-, 第32回日本肝移植研究会, Jul. 2014. (Keyword) 国内学会
1368.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝星細胞からみた加齢肝再生不全の検討, 第32回日本肝移植研究会, Jul. 2014. (Keyword) 国内学会
1369.	Kouzou Yoshikawa, Mitsuo Shimada and Nobuhiro Kurita : 腸管ストレスに対する大建中湯の効果発現機序の解明, 第65回日本東洋医学会学術総会, Jun. 2014. (Keyword) 国内学会
1370.	Chie Takasu, Satoru Imura, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検証, 第10回日本肝がん分子標的治療研究会, Jun. 2014. (Keyword) 国内学会
1371.	寺奥大貴, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and 江藤祥平 : H.pylori陽性胃癌におけるStathmin1発現と予後との関連, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1372.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Chie Takasu and Mitsuo Shimada : 小児先天性胆道拡張症の胆道上皮における発癌関連遺伝子発現の検討, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1373.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu, 松本規子 and 江藤祥平 : 直腸切除術における縫合不全回避のための工夫:ICG蛍光法を用いた腸管血流評価, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1374.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Motoya Chikakiyo, Takuya Tokunaga and Toshihiro Nakao : 卒前・卒後の内視鏡外科手術教育におけるトレーニングの検討, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1375.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and 江藤祥平 : 胃癌におけるda Vinci Surgical System(DVSS)導入期における現状, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1376.	良元俊昭, Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, 荒川悠介 and Shuichi Iwahashi : 術後14年を経過して腹膜藩種再発をきたしたSolid-pseudopap, 第39日本外科系連合学会, Jun. 2014. (Keyword) 国内学会
1377.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 石川大地 : 3D virtual hepatectomyと術中navigation systemを用いた肝切除, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1378.	石川大地, Mitsuo Shimada, Shin-ichiro Yamada, Yu Saitou, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1379.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 脂肪由来幹細胞(ADSCs)の膵島細胞保護作用にはIL-6ではなくVEGFシグナルが関与する, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1380.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : RFA後肝細胞癌再発例におけるEMT関連遺伝子発現の意義, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1381.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Yu Saitou, Shuichi Iwahashi, Shin-ichiro Yamada and 石川大地 : Celiac axis compression syndromeにより術後管理に難渋して膵頭十二指腸切除術, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
1382.	Toshihiro Nakao, Mitsuo Shimada, Takashi Iwata, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Chie Takasu and 江藤祥平 : 局所進行下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術は標準治療になりうるか?, 第101回日本消化器病学会四国支部例会, Jun. 2014. (Keyword) 国内学会
1383.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi and 江藤祥平 : Duodenal-jejunal bypassはmicrobiotaの変化・GLP-1分泌の亢進を介して糖尿病・NASHを改善する, 第101回日本消化器病学会四国支部例会, Jun. 2014. (Keyword) 国内学会
1384.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : 肝細胞癌切除症例におけるRFAの影響-EMTマーカー発現に着目して-, 第26回日本肝胆膵外科学会学術集会, Jun. 2014. (Keyword) 国内学会
1385.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, Chie Takasu and Yu Saitou : InBodyを用いた体組成分析の肝胆膵外科手術における周術期栄養評価の有用性に関する検討, 第26回日本肝胆膵外科学会学術集会, Jun. 2014. (Keyword) 国内学会
1386.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : pT2胆嚢癌術後における予後不良因子陽性例に対する術後GFP療法の有用性, 第26回日本肝胆膵外科学会学術集会, Jun. 2014. (Keyword) 国内学会
1387.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 切除不能転移性肝癌に対する"Early Conversion"を目指したFOLFOKILI療法の可能性, 第26回日本肝胆膵外科学会学術集会, Jun. 2014. (Keyword) 国内学会
1388.	Satoru Imura, 石川大地, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 3D virtual image とNavigation systemがもたらした革新的画像技術を駆使した肝切除, 第26回日本肝胆膵外科学会学術集会, Jun. 2014. (Keyword) 国内学会
1389.	Toru Utsunomiya, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 肝内胆管癌に対する系統系リンパ節郭清の意義と術後補助療法の効果, 第26回日本肝胆膵外科学会学術集会, Jun. 2014. (Keyword) 国内学会
1390.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Shin-ichiro Yamada and 石川大地 : 80歳以上超高齢者における肝切除の妥当性に関する検討-術前栄養評価から見た高齢者の特徴-, 第26回日本肝胆膵外科学科学術集会, Jun. 2014. (Keyword) 国内学会
1391.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 石川大地 : RFA後肝細胞癌再発例においてEMT誘導wp介し腫瘍悪性度が増強する-microRNA発現に着目して-, 第50回日本肝癌研究会, Jun. 2014. (Keyword) 国内学会
1392.	Yusuke Arakawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi and 石川大地 : 肝内胆管癌に対する系統的リンパ節郭清の意義と術後補助療法の効果, 第50回日本肝癌研究会, Jun. 2014. (Keyword) 国内学会
1393.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 切除不能転移性肝癌に対する"Early Conversion"を目指したFOLFOXILI療法の可能性, 第50回日本肝癌研究会, Jun. 2014. (Keyword) 国内学会
1394.	Satoru Imura, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検証:切除を含む集学的治療の重要性, 第50回日本肝癌研究会, Jun. 2014. (Keyword) 国内学会
1395.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : 徳島県におけるより円滑な地域連携・病診連携推進のための活動について, 第50回日本肝臓学会総会, May 2014. (Keyword) 国内学会
1396.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 肝星細胞による加齢肝再生不全機序の検討, 第50回日本肝臓学会総会, May 2014. (Keyword) 国内学会
1397.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第50回日本肝臓学会総会, May 2014. (Keyword) 国内学会
1398.	Satoru Imura, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 局所再発させない適確な症例選択がRFA成績向上につながる∼組織学的門脈浸潤(vp)陽性肝癌を予測し，RFA適応外へ∼, 第50回日本肝臓学会総会, May 2014. (Keyword) 国内学会
1399.	Yu Saitou, 寺奥大貴, 吉川雅登, 石川大地, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 高齢者の肝再生不全の機序解明と治療への応用, 第40回日本急性肝不全研究会, May 2014. (Keyword) 国内学会
1400.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara and 江藤祥平 : 腹腔鏡下腹壁瘢痕ヘルニア根治術における安全性と有用性, 第68回手術手技研究会, May 2014. (Keyword) 国内学会
1401.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Akira Nii and Mitsuo Shimada : 若手小児外科医が考える理想の卒後教育キャリアデザイン∼初期研修と成人外科後期研修の意味と意義∼, 第51回日本小児外科学会学術集会, May 2014. (Keyword) 国内学会
1402.	Keigo Yada, Hiroki Ishibashi, Hiroki Mori, Akira Nii and Mitsuo Shimada : 小児胸腔鏡下肺切除における術前3DシミュレーションおよびiPadを用いた術中ナビゲーション画像の有用性, 第51回日本小児外科学会学術集会, May 2014. (Keyword) 国内学会
1403.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada, Horohiko Sato and Mitsuo Shimada : 小児先天性胆道拡張症の胆道上皮における発癌関連遺伝子発現の検討, 第51回日本小児外科学会学術集会, May 2014. (Keyword) 国内学会
1404.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada, Horohiko Sato and Mitsuo Shimada : 手術手袋が原因のラテックスアレルギーにより術中アナフィラキシーを来した小児例, 第51回日本小児外科学会学術集会, May 2014. (Keyword) 国内学会
1405.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 乳児横隔膜弛緩症に対してラパヘルクロージャーを用い2ポートで行う胸腔鏡下横隔膜縫縮術, 第51回日本小児外科学会学術集会, May 2014. (Keyword) 国内学会
1406.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 小児鼠径部ヘルニア疾患に対するLPEC法の基本手技と応用, 第51回日本小児外科学会学術集会, May 2014. (Keyword) 国内学会
1407.	Hiroki Ishibashi, Hiroki Mori, Mitsuo Shimada and Yuji Morine : 小児膵・胆管合流異常における共通管拡張・非拡張別の臨床像について―合流異常研究会登録症例の解析―, 第51回日本小児外科学会学術集会, May 2014. (Keyword) 国内学会
1408.	Hideya Kashihara, 江藤祥平 and Mitsuo Shimada : Duodenal-jejunal bypassはmicrobiotaの変化・GLP-1分泌の亢進を介して糖尿病・NASHを改善する, 第100回日本消化器病学会総会, Apr. 2014. (Keyword) 国内学会
1409.	Masaaki Nishi, Mitsuo Shimada and Nobuhiro Kurita : 胃癌に対する治療方針決定におけるthrombospondin1(THBS1)発現の意義, 第100回日本消化器病学会総会, Apr. 2014. (Keyword) 国内学会
1410.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara and 松本規子 : 癌幹細胞制御におけるSonic Hedgehog signalingの役割, 第100回日本消化器病学会総会, Apr. 2014. (Keyword) 国内学会
1411.	Kouzou Yoshikawa, 江藤祥平, Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Motoya Chikakiyo, Hideya Kashihara and 松本規子 : 大建中湯のMicrobiomeを介した抗炎症作用発現メカニズムの解明, 第100回日本消化器病学会総会, Apr. 2014. (Keyword) 国内学会
1412.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Chie Takasu and 石川大地 : HCCRFA治療後にリンパ節転移再発を繰り返す症例, 第100回日本消化器病学会総会, Apr. 2014. (Keyword) 国内学会
1413.	良元俊昭, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, 松本規子, 江藤祥平 and Chie Takasu : 原発・肝転移巣ともに腹腔鏡下に切除し得た骨形成性直腸癌の一例, 第114回日本外科学会定期学術集会, Apr. 2014.
1414.	Takuya Tokunaga, Tsutomu Ando, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi and Hideya Kashihara : 地域外科医療を支えるための工夫∼Telementoring systemの導入・有用性∼, 第114回日本外科学会定期学術集会, Apr. 2014.
1415.	Akira Nii, Hiroki Ishibashi, Hiroki Mori, Keigo Yada and Mitsuo Shimada : 先天性胆道拡張症・小児例の胆道上皮における発癌関連遺伝子発現の検討, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1416.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada, Horohiko Sato and Mitsuo Shimada : 小児難治性リンパ管腫に対する治療戦略, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1417.	Hiroki Ishibashi, Hiroki Mori, Keigo Yada, Akira Nii and Mitsuo Shimada : 小児鼠径部ヘルニア疾患に対するLPEC法の功罪, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1418.	宮崎克己, Mitsuo Shimada, 江藤祥平, 松本規子, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Motoya Chikakiyo, Jun Higashijima, Kouzou Yoshikawa, Horohiko Sato, Takashi Iwata and Nobuhiro Kurita : 胃癌術後の経過中に直腸への転移を来した1例, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1419.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu and 松本規子 : H.pyroli陽性胃癌におけるStathminl発現の意義, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1420.	Hideya Kashihara, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 松本規子, 江藤祥平 and Chie Takasu : 胃癌発癌・進展におけるThrombospondin-1(THBS1)発現の意義, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1421.	Jun Higashijima, Mitsuo Shimada, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu, 松本規子 and 江藤祥平 : 下部直腸癌に対する新たな術前化学放射線療法(SOX+Bev)について, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1422.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu and 江藤祥平 : LED光照射による癌細胞制御に関する研究, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1423.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu, 松本規子 and 江藤祥平 : 下部直腸癌に対する術前化学放射線療法の新たな位置付け, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1424.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Hideya Kashihara and 松本規子 : リニアステープラーを用いた食道空腸吻合(Overlap法)のPitfallと工夫, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1425.	Motoya Chikakiyo, Mitsuo Shimada, 江藤祥平, 松本規子, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Jun Higashijima, Kouzou Yoshikawa, Horohiko Sato, Takashi Iwata and Nobuhiro Kurita : 大腸癌株由来cancer sphereにおけるSonic Hedgehog シグナル抑制によるcancer stemness制御に関する研究, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1426.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, Hideya Kashihara, Chie Takasu, 松本規子 and 江藤祥平 : 進行胃癌に対する腹腔鏡下胃切除における再発危険因子と長期予後, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1427.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Masaaki Nishi, Motoya Chikakiyo, Chie Takasu, Hideya Kashihara, 松本規子 and Masashi Akaike : 大学と関連病院が連携した若手医師の研修プログラム構築―地方からの提言―, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1428.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi and Hideya Kashihara : 胃癌におけるda Vinci Surgical System(DVSS)導入期における現状, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1429.	吉川雅登, Mitsuo Shimada, 石川大地, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 若手外科医のための膵頭十二指腸切除における術前3Dsimulationの有用性, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1430.	寺奥大貴, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 進行胆嚢癌の予後因子と術後補助GFP療法の効果, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1431.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 肝星細胞からみた加齢肝再生不全の検討, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1432.	Shin-ichiro Yamada, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 肝細胞癌切除症例に対するRFAの影響(第2報)-RFA後肝細胞癌再発例はEMT誘導を介して予後不良となる-, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1433.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, 石川大地, Shin-ichiro Yamada, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 脂肪由来幹細胞の細胞保護効果には臓器特異性がある, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1434.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : 癌肝細胞治療抵抗性にEpigenetic修飾が関与する(第2報)-Methylation statusと遺伝子発現の変化に着目して-, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1435.	石川大地, Mitsuo Shimada, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1436.	Mami Kanamoto, Yasuhiro Hamada, Yutaka Nakaya, Eiji Takeda, Hisami Okumura, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori and Mitsuo Shimada : NST介入による周術期栄養管理の有用性に関する検討, 第114回日本外科学会定期学術集会, Apr. 2014.
1437.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 大腸癌肝転移のconversion surgeryを目指した治療戦略, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
1438.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 石川大地 : 柴令湯による膵島破壊抑制機序の解明に関する研究, 第114回日本外科学会定期学術集会, Apr. 2014.
1439.	Toru Utsunomiya, Mitsuo Shimada, 石川大地, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Chie Takasu : Role of epigenetic modulation in both tumor and non-tumor liver tissues on risk of recurrence after hepatectomy for hepatocellular carcinoma: A possible implication for personalized medicine, 第114回日本外科学会定期学術集会, Apr. 2014.
1440.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 松本規子 : 進行胃癌に対する腹腔鏡下胃切除手術の長期成績, 第86回日本胃癌学会総会, Mar. 2014.
1441.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也 and 松本規子 : 胃発癌・予後予測因子としてのAID(activation-induced cytidine deaminase)発現の意義, 第86回日本胃癌学会総会, Mar. 2014.
1442.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Kouzou Yoshikawa, 柏原秀也, Horohiko Sato, Jun Higashijima, Motoya Chikakiyo, Takuya Tokunaga, 松本規子 and 江藤祥平 : リスクファクターを有する腹腔鏡下胃切除は安全に施工可能か?, 第86回日本胃癌学会総会, Mar. 2014.
1443.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 地方大学における手術支援ロボット導入期の胃癌手術の問題点, 第86回日本胃癌学会総会, Mar. 2014.
1444.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 松本規子 and 江藤祥平 : 腹腔鏡下胃切除後ERAS(enhanced recovery after surgery)における大建中湯, 第86回日本胃癌学会総会, Mar. 2014.
1445.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : 癌幹細胞治療抵抗性におけるEpigenetic修飾の関与-Methylation statusの変化に着目して-, 第47回制癌剤適応研究会, Mar. 2014. (Keyword) 国内学会
1446.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 紫令湯による糖尿病発症マウスの膵島破壊抑制機序の免疫学的検討, 第41回日本膵・膵島移植研究会, Mar. 2014. (Keyword) 国内学会
1447.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : 癌肝細胞治療抵抗性におけるEpigenetic修飾の関与―Methylation statusの変化に着目して―, 第47回制癌剤適応研究会, Mar. 2014.
1448.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎 and 石川大地 : 紫令湯による糖尿病発症マウスの膵島破壊抑制機序の免疫学的検討, 第41回日本膵・膵島移植研究会, Mar. 2014.
1449.	Masaaki Nishi, Mitsuo Shimada, Horohiko Sato, Nobuhiro Kurita, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Takuya Tokunaga, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 局所進行下部直腸癌に対するS-1/Oxaliplatin/Bevacizumab併用術前CRTと，S-1，UFT併用術前CRTと比較検討, 第47回制癌剤適応研究会, Mar. 2014.
1450.	宮崎克己, Mitsuo Shimada, Tetsuya Ikemoto, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地 and Hidenori Miyake : 経皮的ラジオ波焼灼療法による遅発生横隔膜ヘルニア篏頓(横行結腸)の1例, 第50回日本腹部救急医学会, Mar. 2014. (Keyword) 国内学会
1451.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 膵切除後腹腔内出血に対するIVRに関する検討, 第50回日本腹部救急医学会, Mar. 2014. (Keyword) 国内学会
1452.	宮崎克己, Mitsuo Shimada, Tetsuya Ikemoto, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地 and Hidenori Miyake : 経皮的ラジオ波焼灼療法による遅発生横隔膜ヘルニア篏頓(横行結腸)の1例, 第50回日本腹部救急医学会, Mar. 2014.
1453.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 膵切除後腹腔内出血に対するIVRに関する検討, 第50回日本腹部救急医学会, Mar. 2014.
1454.	花畑佑介, Mitsuo Shimada, 江藤祥平, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 松本規子 : 術前診断が困難だった副腎出血の1例, 第50回日本腹部救急医学会, Mar. 2014.
1455.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 胃癌術後における絞扼性イレウスの診断と治療, 第50回日本腹部救急医学会, Mar. 2014.
1456.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Chie Takasu, 江藤祥平, 寺奥大貴, Takashi Iwata, 和田大助, 坂東儀昭, 尾方信也, Hideya Kashihara, Nobuhiro Kurita and Takuya Tokunaga : 術前3Dシュミュレーションを用いた腹腔鏡下胃切除, 第87回日本胃癌学会総会, Mar. 2014. (Keyword) 国内学会
1457.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, 坂東儀昭, 尾方信也 and 和田大助 : 腹腔鏡下胃全摘出術後の再建における当科での工夫ーOverlapとOrvilとの比較ー, 第87回日本胃癌学会総会, Mar. 2014. (Keyword) 国内学会
1458.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, 柏原秀也, Chie Takasu and 江藤祥平 : 腹腔鏡下腹壁瘢痕ヘルニア根治術における安全性と有用性, 第22回徳島外科術後管理研究会, Mar. 2014.
1459.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 胃癌におけるda Vinci Surgical System(DVSS)導入期における現状, 第6回日本ロボット外科学会, Feb. 2014.
1460.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 胃癌に対する手術支援ロボットda Vinci Surgical System(DVSS)導入期における現状, 第28回四国内視鏡外科研究会, Feb. 2014.
1461.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 直腸切除術における縫合不全回避のための工夫:ICG蛍光法を用いた腸管血流評価, 第28回四国内視鏡外科研究会, Feb. 2014.
1462.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 高齢者に対する肝切除後の肝再生不全の機序解明とその対策:ベッドサイからベンチへのアプローチ, 第248回徳島医学会学術集会(平成25年度冬期), Feb. 2014. (Keyword) 国内学会
1463.	石川大地, Mitsuo Shimada, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第248回徳島医学会学術集会(平成25年度冬期), Feb. 2014. (Keyword) 国内学会
1464.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 高齢者に対する肝切除後の肝再生不全の機序解明とその対策:ベッドサイドからベンチへのアプローチ, 第248回徳島医学会学術集会, Feb. 2014.
1465.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 直腸切除術における縫合不全回避のための工夫:ICG蛍光法を用いた腸管血流評価, 第248回徳島医学会学術集会(平成25年度冬期), Feb. 2014.
1466.	Takashi Iwata, Masashi Akaike, Masami Nagamune, 福富美紀 and Mitsuo Shimada : 海外交流体験実習を利用したスキルスラボでのグローバルスキルトレーニング, 第248回徳島医学会学術集会(平成25年度冬期), Feb. 2014.
1467.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : 反転授業を応用したクリニカルクラークシップ学生対象の縫合実習の試み, 第250回徳島医学会学術集会, Feb. 2014. (Keyword) 国内学会
1468.	山内佑介, 河野洋平, Ahmed Shawky Mohamed, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya and Mitsuo Shimada : 造影CT画像を用いた腹部血管抽出アルゴリズム, 電子情報通信学会技術研究報告医用画像, Vol.113, No.410, 83-84, Jan. 2014.
1469.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 進行肝細胞癌に対するソラフェニブと外科治療を組み合わせた治療成績, 第9回日本肝がん分子標的治療研究会, Jan. 2014. (Keyword) 国内学会
1470.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 進行肝細胞癌に対するソラフェニブと外科治療を組み合わせた治療成績, 第9回日本肝がん分子標的治療研究会, Jan. 2014.
1471.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子, 江藤祥平 and Mitsuo Shimada : 進行下部直腸癌に対する新たな術前化学放射線療法の長期成績と新たな治療の試み, 第80回大腸癌研究会, Jan. 2014.
1472.	杉原康平, Hisami Okumura, Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : エネルギー代謝による生体肝移植後早期における栄養評価, 第17回日本病態栄養学会, Jan. 2014.
1473.	山本モモ, Hisami Okumura, 杉原康平, 寺本有沙, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : 肝硬変患者における窒素出納評価の問題点についての検討, 第17回日本病態栄養学会, Jan. 2014.
1474.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : Toll like receptorを介したtight junction維持による大建中湯のBacterial translocation予防効果, 第20回外科侵襲とサイトカイン研究会, Dec. 2013.
1475.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, 石川大地, 山田眞一郎, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Chie Takasu and Hidenori Miyake : 脂肪由来幹細胞の細胞保護効果には臓器特異性がある, 第20回外科侵襲とサイトカイン研究会, Dec. 2013.
1476.	Hiroki Mori, Hiroki Ishibashi, Horohiko Sato, 矢田圭吾 and Mitsuo Shimada : Finger assistを併用した腹腔鏡補助下高位鎖肛根治術, 第26回日本内視鏡外科学会総会, Nov. 2013.
1477.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾, Horohiko Sato and Mitsuo Shimada : 極低出生体重児発症の鼠径ヘルニアに対するLPEC法, 第26回日本内視鏡外科学会総会, Nov. 2013.
1478.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 食道空腸吻合におけるoverlap法の有用性, 第26回日本内視鏡外科学会総会, Nov. 2013.
1479.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 腹腔鏡下腹壁瘢痕ヘルニア根治術における安全性と有用性, 第26回日本内視鏡外科学会総会, Nov. 2013.
1480.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : 腹腔鏡下直腸切除術における適切なステープリングデバイス使用に基づいた直腸切離・吻合, 第26回日本内視鏡外科学会総会, Nov. 2013.
1481.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Motoya Chikakiyo, 柏原秀也, 松本規子, Takuya Tokunaga and Masashi Akaike : 腹腔鏡下手術トレーニングボックスを用いた鏡視下手術手技理解促進のための基礎的検討, 第26回日本内視鏡外科学会総会, Nov. 2013.
1482.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 胃癌に対するロボット支援手術導入期における現状と問題点, 第26回日本内視鏡外科学会総会, Nov. 2013.
1483.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, Yu Saitou and 石川大地 : Vessel sealing systemを用いた肝嚢胞に対する単孔式腹腔鏡下嚢胞開窓術の有用性, 第26回日本内視鏡外科学会総会, Nov. 2013.
1484.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 石川大地 and Hidenori Miyake : 肝細胞癌における短期・長期予後から見た鏡視下手術の妥当性, 第26回日本内視鏡外科学会総会, Nov. 2013.
1485.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 石川大地 and Chie Takasu : 3D virtual hepatectomyと術中navigation systemを用いた肝切除, 第26回日本内視鏡外科学会総会, Nov. 2013.
1486.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Kouzou Yoshikawa, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 肝胆膵外科領域における漢方製剤使用が周術期管理に与える影響に関する検討, 第23回外科漢方研究会学術集会, Nov. 2013.
1487.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Kouzou Yoshikawa, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 肝癌切除術施行後における臨床的な役割, 第23回外科漢方研究会学術集会, Nov. 2013.
1488.	Hiroki Mori, Hiroki Ishibashi, Horohiko Sato, 矢田圭吾 and Mitsuo Shimada : 重症心身障害児(者)のGERDに対する腹腔鏡下Nissen噴門形成術の検討, 第75回日本臨床外科学会総会, Nov. 2013.
1489.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾, Horohiko Sato and Mitsuo Shimada : 小児鼠径部ヘルニア疾患に対するLPEC法の現況と適応拡大, 第75回日本臨床外科学会総会, Nov. 2013.
1490.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori, Horohiko Sato and Mitsuo Shimada : 若手外科医のECFMG取得への挑戦:初期・外科後期研修中に効率よくECFMGを取得するためのコツとピットフォール, 第75回日本臨床外科学会総会, Nov. 2013.
1491.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 松本規子 : 胃癌Roux-en-Y再建後内ヘルニア予防への取り組み, 第75回日本臨床外科学会総会, Nov. 2013.
1492.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 胃癌におけるda Vinci Surgical System(DVSS)導入期における現状, 第75回日本臨床外科学会総会, Nov. 2013.
1493.	松本規子, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 江藤祥平 and Mitsuo Shimada : 腹腔鏡補助下胃全摘術におけるoverlap法の有用性, 第75回日本臨床外科学会総会, Nov. 2013.
1494.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : 腹腔鏡下直腸切除術におけるICG蛍光法を用いた腸管血流評価と確実な手術手技, 第75回日本臨床外科学会総会, Nov. 2013.
1495.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 腹部高リスク手術症例に対するVTE予防における抗凝固療法の実際, 第75回日本臨床外科学会総会, Nov. 2013.
1496.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi and 松本規子 : 腹腔鏡補助下胃切除術後の再発に関する検討, 第75回日本臨床外科学会総会, Nov. 2013.
1497.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : 局所進行下部直腸癌に対する術前化学放射線療法の成績と側方リンパ郭清の意義, 第75回日本臨床外科学会総会, Nov. 2013.
1498.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Motoya Chikakiyo, Takuya Tokunaga, 松本規子 and Masashi Akaike : 開腹手術は内視鏡下手術トレーニングに必要である∼鏡視下手術理解促進のための基礎的検討∼, 第75回日本臨床外科学会総会, Nov. 2013.
1499.	石川大地, Mitsuo Shimada, 山田眞一郎, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : IPMNにおける梢血調節性T細胞比率による術前悪性度予測と上皮間葉転換, 第75回日本臨床外科学会総会, Nov. 2013.
1500.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 石川大地, Chie Takasu and Hidenori Miyake : 予後不良因子を有する進行胆嚢癌における術後補助GFP療法の効果, 第75回日本臨床外科学会総会, Nov. 2013.
1501.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地 and Hidenori Miyake : Borderline resectable膵癌に対する治療成績の検討, 第75回日本臨床外科学会総会, Nov. 2013.
1502.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 石川大地 and Hidenori Miyake : 肝癌切除例からみた日本に適したステージ分類∼取り扱い規約とUICCの比較から∼, 第75回日本臨床外科学会総会, Nov. 2013.
1503.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, 石川大地, 楠本彩子 and Hidenori Miyake : 徳島県における肝疾患診療連携ネットワークについて, 第75回日本臨床外科学会総会, Nov. 2013.
1504.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Horohiko Sato and Hidenori Miyake : 胆道癌切除例における術後補助GFP療法及び，再発症例に対する再肝切除の有用性, 第75回日本臨床外科学会総会, Nov. 2013.
1505.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 石川大地 and Hidenori Miyake : 大腸癌肝転移のconversion surgeryを目指した治療戦略, 第75回日本臨床外科学会総会, Nov. 2013.
1506.	Toru Utsunomiya, Mitsuo Shimada, 石川大地, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 高度進行肝癌に対する治療戦略―術後補助IFP療法およびソラフェニブ・手術併用の有用性―, 第75回日本臨床外科学会総会, Nov. 2013.
1507.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, 山田眞一郎, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 石川大地 : 80歳以上超高齢者における肝切・PDの妥当性に関する検討, 第75回日本臨床外科学会総会, Nov. 2013.
1508.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 術中ヒヤリハットから得た教訓に基づくStep by stepでの手技工夫, 第7回肝臓内視鏡外科研究会, Nov. 2013.
1509.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾 and Mitsuo Shimada : 胎児診断され先天性胆道拡張症との鑑別を要した胆道閉鎖症の1例, 第40回日本胆道閉鎖症研究会, Nov. 2013.
1510.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Kouzou Yoshikawa and Jun Higashijima : 進行下部直腸癌に対する術前化学放射線療法の長期成績について, 第68回日本大腸肛門病学会学術集会, Nov. 2013.
1511.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 松本規子 : LED光照射による細胞制御に関する検討, 第43回日本創傷治癒学会, Nov. 2013.
1512.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 高齢者の肝再生不全の機序解明と治療への応用, 第43回日本創傷治癒学会, Nov. 2013.
1513.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也 and 松本規子 : 心肺腎合併症患者の胃切除は安全に行えるか, 第51回日本癌治療学会学術集会, Oct. 2013.
1514.	Motoya Chikakiyo, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也, Chie Takasu, 松本規子 and Tomohiko Miyatani : 腹腔鏡下結腸切除術におけるリンパ節廓清の工夫, 第51回日本癌治療学会学術集会, Oct. 2013.
1515.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : 胃癌におけるthrombospondin-1発現の意義, 第51回日本癌治療学会学術集会, Oct. 2013.
1516.	Masaaki Nishi, Mitsuo Shimada, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Takuya Tokunaga, Chie Takasu, 柏原秀也, 松本規子 and 江藤祥平 : 進行下部直腸癌に対するS-1，UFT併用術前化学放射線療法の予後, 第51回日本癌治療学会学術集会, Oct. 2013.
1517.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : ICG蛍光Navigation systemを用いた大腸癌手術における腸管血流評価, 第51回日本癌治療学会学術集会, Oct. 2013.
1518.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 松本規子 : 分子標的薬使用中の緊急手術における問題点と対策, 第51回日本癌治療学会学術集会, Oct. 2013.
1519.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : 下部直腸癌に対する新たな術前化学放射線療法の可能性について, 第51回日本癌治療学会学術集会, Oct. 2013.
1520.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, 山田眞一郎, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 石川大地 and Chie Takasu : 超高齢者における肝胆膵手術の妥当性に関する検討―癌根治によるQOL向上を目指して―, 第51回日本癌治療学会学術集会, Oct. 2013.
1521.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Yu Saitou, Chie Takasu, 石川大地 and Hidenori Miyake : 徳島県における肝癌診療連携ネットワークについて, 第51回日本癌治療学会学術集会, Oct. 2013.
1522.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 石川大地 and Hidenori Miyake : IPMNにおける悪性度予想に関するバイオマーカーとしてのEMT関連因子, 第51回日本癌治療学会学術集会, Oct. 2013.
1523.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, 山田眞一郎 and Hidenori Miyake : 進行肝癌に対するソラフェニブの治療成績―Conversionできた著効例の検討とあわせて―, 第51回日本癌治療学会学術集会, Oct. 2013.
1524.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 石川大地, Chie Takasu and Hidenori Miyake : 大腸癌肝転移に対する治療戦略―外科切除の適応とconversion surgery―, 第51回日本癌治療学会学術集会, Oct. 2013.
1525.	Ahmed Shawky Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Mitsuo Satake, Noriyuki Moriyama, Toru Utsunomiya and Mitsuo Shimada : Liver segmentation based on blood vessel information using the portal phase of a CT dataset, The 36th Japan Society of Medical and Biological Engineering, 37, Oct. 2013.
1526.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : LED光照射による細胞制御に関する検討, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1527.	Motoya Chikakiyo, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 腹部骨盤高リスク手術症例における術後静脈血栓塞栓症予防のためのEnoxaparinの有用性, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1528.	Jun Higashijima, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and Mitsuo Shimada : 局所進行下部直腸癌に対する術前化学放射線療法併用内肛門括約筋切除術(ISR)の成績, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1529.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 根治度・非治癒因子別にみた進行胃癌に対する治療方針決定におけるthrombospondin 1(THBS1)発現の意義, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1530.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masaaki Nishi, 柏原秀也, Chie Takasu and 松本規子 : 胃癌癌部・非癌部におけるAID発現の意義, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1531.	Masaaki Nishi, Mitsuo Shimada and Nobuhiro Kurita : 手術支援ロボットda Vinci Surgical System(DVSS)導入期における現状と問題点―腹腔鏡下手術との比較から―, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1532.	Horohiko Sato, Mitsuo Shimada and Nobuhiro Kurita : 早期下部直腸癌に対する術前化学放射線局所切除術の短期・長期成績について, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1533.	柏原秀也, Masaaki Nishi and Mitsuo Shimada : GLP-1分泌メカニズムに着目した糖尿病・NASHに対するDuodenal-jejunal bypassの有効性, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1534.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, Yu Saitou, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi and Toru Utsunomiya : 進行肝細胞癌に対するソラフェニブと外科治療を組み合わせた治療成績, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1535.	Shuichi Iwahashi, Mitsuo Shimada and 石川大地 : 肝細胞癌切除症例におけるRFAの影響―遺伝子発現に着目した腫瘍悪性度の検討―, JDDW 2013 第21回日本消化器関連学会週間, Oct. 2013.
1536.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 江藤祥平 : LED光照射による大腸癌細胞制御の検討, 第72回日本癌学会学術総会, Oct. 2013.
1537.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : 癌幹細胞制御におけるソニックヘッジホッグシグナルの意義, 第72回日本癌学会学術総会, Oct. 2013.
1538.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Hiroki Mori, 矢田圭吾 and Hidenori Miyake : IPMNにおけるTwist1，Bmi1発現に関する検討, 第72回日本癌学会学術総会, Oct. 2013.
1539.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and 石川大地 : 癌幹細胞の治療抵抗性獲得におけるepigenetic修飾の意義, 第72回日本癌学会学術総会, Oct. 2013.
1540.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, 山田眞一郎, Yuji Morine, Satoru Imura, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Chie Takasu and 浅野間理仁 : 脂肪由来幹細胞の傷害肝へのホーミング効果―癌幹細胞転移メカニズムへの応用―, 第72回日本癌学会学術総会, Oct. 2013.
1541.	矢田圭吾, Hiroki Ishibashi, Horohiko Sato, Hiroki Mori and Mitsuo Shimada : 胎児診断され胆道拡張症との鑑別を要した胆道閉鎖症の1例, 第52回日本小児外科学会中国四国地方会, Sep. 2013.
1542.	Hiroki Mori, Hiroki Ishibashi, 矢田圭吾, Horohiko Sato and Mitsuo Shimada : 緊急気管切開術を要した頚部リンパ管腫の1例, 第52回日本小児外科学会中国四国地方会, Sep. 2013.
1543.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 石川大地 : 3D virtual hepatectomyと術中navigation systemを用いた肝切除, 第8回肝癌治療シミュレーション研究会, Sep. 2013.
1544.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi, 矢田圭吾, 山田眞一郎, 石川大地, Chie Takasu and Hidenori Miyake : 膵・胆管合流異常症例における胆道癌発癌機構に関する研究, 第49回日本胆道学会学術集会, Sep. 2013.
1545.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and Hidenori Miyake : Stem cell markerに着目した細胆管癌の悪性度に関する検討(肝内胆管癌との比較より), 第49回日本胆道学会学術集会, Sep. 2013.
1546.	杉原康平, Hisami Okumura, 山本モモ, 柏原秀也, Kouzou Yoshikawa, Toru Utsunomiya, Nobuhiro Kurita, Mitsuo Shimada and Eiji Takeda : スリーブ状胃切除術前後のエネルギー代謝評価, 第5会日本静脈経腸栄養学会四国支部会学術集会, Sep. 2013.
1547.	Motoya Chikakiyo, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子, 江藤祥平 and Mitsuo Shimada : 腹腔鏡下直腸切除術におけるICG蛍光法を用いた腸管血流評価, 第22回日本コンピュータ外科学会, Sep. 2013.
1548.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : 3Dvirtual hepatectomyと術中navigation systemを用いた肝切除, 第22回日本コンピュータ外科学会, Sep. 2013.
1549.	矢田圭吾, Hiroki Ishibashi, Horohiko Sato, Hiroki Mori and Mitsuo Shimada : 腹腔鏡補助下高位鎖肛根治術におけるFinger assistの有用性について, 第88回中国四国外科学会総会/第18回中国四国内視鏡外科研究会, Sep. 2013.
1550.	Hiroki Mori, Hiroki Ishibashi, Horohiko Sato, 矢田圭吾 and Mitsuo Shimada : 重症心身障害児(者)のGERDに対する腹腔鏡下Nissen噴門形成術の術後成績に関する検討, 第88回中国四国外科学会総会/第18回中国四国内視鏡外科研究会, Sep. 2013.
1551.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 松本規子 : 重篤な心肺腎合併胃癌症例に対するリンパ節郭清範囲縮小の妥当性, 第88回中国四国外科学会総会/第18回中国四国内視鏡外科研究会, Sep. 2013.
1552.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : 局所進行下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術は標準治療になりうるか?, 第88回中国四国外科学会総会/第18回中国四国内視鏡外科研究会, Sep. 2013.
1553.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 手術支援ロボット導入期における胃癌手術の現状と問題点, 第88回中国四国外科学会総会/第18回中国四国内視鏡外科研究会, Sep. 2013.
1554.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu and 江藤祥平 : LED光照射による大腸癌細胞制御に関する検討, 第24回日本消化器癌発生学会総会, Sep. 2013.
1555.	Masaaki Nishi, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Takuya Tokunaga, 柏原秀也, 松本規子 and 江藤祥平 : 進行胃癌に対する治療方針決定におけるthrombospondin1(THBS1)発現の意義, 第24回日本消化器癌発生学会総会, Sep. 2013.
1556.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : ラットsmall-for-size graft modelにおける脾臓内遺伝子発現の変化Ingenuity Pathway Analysisを用いた検討, 第49回日本移植学会総会, Sep. 2013.
1557.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎 and Chie Takasu : 脂肪由来幹細胞を用いた膵島移植成績向上に関する展望と課題, 第49回日本移植学会総会, Sep. 2013.
1558.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎 and Hidenori Miyake : C型肝硬変に対するABO不適合肝移植後の低用量Peg-IFN/RBV療法の有用性, 第49回日本移植学会総会, Sep. 2013.
1559.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, 山田眞一郎, 石川大地, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Hiroki Mori, Yuji Morine and Satoru Imura : ヒト脂肪由来幹細胞による肝傷害軽減効果に関する基礎的検討, 第49回日本移植学会総会, Sep. 2013.
1560.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Hidenori Miyake : IPMNにおけるTwist1，Bmi1発現の意義, 第24回日本消化器癌発生学会総会, Sep. 2013.
1561.	Toru Utsunomiya, Mitsuo Shimada, 石川大地, 山田眞一郎, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝細胞癌の癌部と非癌部の両方におけるFbxw7高発現は術後再発の独立危険因子である, 第24回日本消化器癌発生学会総会, Sep. 2013.
1562.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : 集学的治療により長期生存がえられた生体肝移植後肝細胞再発症例, 第31回中国四国臓器移植研究会, Aug. 2013.
1563.	杉原康平, Hisami Okumura, 寺本有沙, Eiji Takeda, Hiroki Mori, Toru Utsunomiya and Mitsuo Shimada : エネルギー代謝と血液生化学検査からみた肝切除術前後の栄養評価, 第247回徳島医学会, Aug. 2013.
1564.	Takashi Iwata, Masashi Akaike, Masami Nagamune, 福富美紀 and Mitsuo Shimada : 腹腔鏡下手術トレーニングボックスを用いた鏡視下手術手技理解促進のための基礎的検討, 第247回徳島医学会学術集会(平成25年度夏期), Aug. 2013.
1565.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, Chie Takasu, 松本規子 and 江藤祥平 : 肥満症に対する外科療法―基礎的検討と臨床経験―, 第247回徳島医学会学術集会(平成25年度夏期), Aug. 2013.
1566.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto and Shuichi Iwahashi : Vessel sealing systemを用いた肝嚢胞に対する単孔式内視鏡手術, 2nd Reduced Port Surgery Forum 第9回 Needlescopic Surgery meeting/第7回単孔式内視鏡手術研究会, Aug. 2013.
1567.	Takashi Iwata, Mitsuo Shimada, Masami Nagamune, 福富美紀 and Masashi Akaike : システム，支援，フィードバックに着眼した腹腔鏡下手術トレーニング, 第45回日本医学教育学会大会, Jul. 2013.
1568.	藤野泰輝, Naoki Muguruma, Koichi Okamoto, Shinji Kitamura, Hiromi Yano, 高岡遠, 岡崎潤, Takahiro Goji, Hiroshi Miyamoto, Toshiya Okahisa, Mitsuo Shimada and Tetsuji Takayama : 多発性小腸重積を生じたPeutz-Jeghers syndromeの1例, 第19回日本家族性腫瘍学会学術集会, Jul. 2013.
1569.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 松本規子 : Liraglutideとの比較からみたDuodenal-Jejunal Bypassの有用性, 第68回日本消化器外科学会総会, Jul. 2013.
1570.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 腹腔鏡下胃切除後ERAS(enhanced recovery after surgery)における大建中湯の有用性, 第68回日本消化器外科学会総会, Jul. 2013.
1571.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 局所進行下部直腸癌に対する術前化学放射線療法の短期・長期成績について, 第68回日本消化器外科学会総会, Jul. 2013.
1572.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, 柏原秀也, Chie Takasu and 松本規子 : 大腸癌手術での縫合不全予防のためのICG蛍光法を用いた腸管血流評価, 第68回日本消化器外科学会総会, Jul. 2013.
1573.	Hiroki Mori, Mitsuo Shimada, Hiroki Ishibashi, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Shuichi Iwahashi : 膵・胆管合流異常症に対する長期経過中に胆道癌を合併した3症例の検討, 第68回日本消化器外科学会総会, Jul. 2013.
1574.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Chie Takasu : 徳島県の施設アンケートから見た膵島移植候補患者の現状と問題点, 第68回日本消化器外科学会総会, Jul. 2013.
1575.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and Chie Takasu : IPMNにおける抹消血調節性T細胞比率とEMT誘導に関する検討, 第68回日本消化器外科学会総会, Jul. 2013.
1576.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎 and 石川大地 : 肝細胞癌切除症例に対するRFAの影響―遺伝子発現に着目した機序解明へのアプローチ―, 第68回日本消化器外科学会総会, Jul. 2013.
1577.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, 佐々木一, 青沼広光 and 川島昭浩 : 肝癌に対する肝切除周術期生体侵襲におけるWhey protein含有高機能, 第68回日本消化器外科学会総会, Jul. 2013.
1578.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Chie Takasu and Hidenori Miyake : 部分肝機能を考慮した新たな肝切除シミュレーションの展開, 第68回日本消化器外科学会総会, Jul. 2013.
1579.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : 安全・確実な肝葉切除のポイント―術前・術中ナビゲーションと出血制御テクニック―, 第68回日本消化器外科学会総会, Jul. 2013.
1580.	Toru Utsunomiya, Mitsuo Shimada, Chie Takasu, 山田眞一郎, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝細胞癌の術後再発リスク予測には癌部と非癌部のバイオマーカー(Fbxw7)評価が必要である, 第68回日本消化器外科学会総会, Jul. 2013.
1581.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, 山田眞一郎, 矢田圭吾 and 石川大地 : 症例, 第49回日本肝癌研究会, Jul. 2013.
1582.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou, 山田眞一郎, 石川大地 and Hidenori Miyake : 右側肝円策をと伴う肝門部胆管癌切除例からみた肝区域分類の把握, 第49回日本肝癌研究会, Jul. 2013.
1583.	石川大地, Mitsuo Shimada, 山田眞一郎, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 肝細胞癌の癌部・非癌部における細胞周期調節因子Fbxw7の発現低下は独立予後規定因子である, 第49回日本肝癌研究会, Jul. 2013.
1584.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : 肝内胆管癌に対する系統的リンパ節郭清の意義と術後補助療法の効果, 第49回日本肝癌研究会, Jul. 2013.
1585.	Satoru Imura, 石川大地, 浅野間理仁, 山田眞一郎, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 肝細胞癌における顕微鏡的門脈浸潤(vp)予測因子の検討∼RFAが好ましくない肝癌の特徴∼, 第49回日本肝癌研究会, Jul. 2013.
1586.	Toru Utsunomiya, Mitsuo Shimada, 工藤正俊, 市田隆文, 松井修, 泉並木, 松山裕, 坂本亨宇, 中島収, 具英成, 國土典宏 and 幕内雅敏 : 非B非C肝癌4741例における治療成績の比較検討:日本肝癌研究会全国原発性肝癌の追跡調査報告の解析より, 第49回日本肝癌研究会, Jul. 2013.
1587.	Hiroki Mori, Hiroki Ishibashi, 矢田圭吾, Horohiko Sato and Mitsuo Shimada : 胎生期発生の腹腔内停留精巣奇形腫の1例, 第22回日本小児泌尿器科学会総会, Jul. 2013.
1588.	Takashi Iwata, Masashi Akaike, Masami Nagamune, 福富美紀 and Mitsuo Shimada : 腹腔鏡下手術トレーニングボックスを用いた鏡視下手術手技理解促進のための基礎的検討, 第1回日本シミュレーション医療教育学会大会, Jul. 2013.
1589.	Jun Higashijima, Mitsuo Shimada, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : Conversionを目指した大腸癌肝転移に対する新たな治療戦略, 第79回大腸がん研究会, Jul. 2013.
1590.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi and 山田眞一郎 : ABO不適合およびドナー特異的抗HLA抗体陽性のレシピエントに対する生体肝移植の成功例, 第31回日本肝移植研究会, Jul. 2013.
1591.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, 浅野間理仁, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 高齢ドナー肝再生不全と加齢指標マーカーについての検討, 第31回日本肝移植研究会, Jul. 2013.
1592.	Satoru Imura, 石川大地, 浅野間理仁, 山田眞一郎, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Takashi Iwata, Toru Utsunomiya and Mitsuo Shimada : 脳死肝移植推進のための医学生への啓蒙活動の必要性∼ドナーアクションの一環としての取り組み∼, 第31回日本肝移植研究会, Jul. 2013.
1593.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也 and 松本規子 : 胃発癌・予後予測因子としてのAID(activation-induced cytidine deaminase)発現の意義, 第99回日本消化器病学会四国支部例会/第110回日本消化器内視鏡学会四国支部例会, Jun. 2013.
1594.	Motoya Chikakiyo, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 腹腔鏡下横行結腸癌手術におけるVolume Rendering Simulationによる安全・確実なリンパ節郭清の工夫, 第99回日本消化器病学会四国支部例会/第110回日本消化器内視鏡学会四国支部例会, Jun. 2013.
1595.	Jun Higashijima, Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Motoya Chikakiyo, Masaaki Nishi, 柏原秀也, 松本規子 and 江藤祥平 : 局所進行下部直腸癌に対する術前化学放射線療法併用内肛門括約筋切除術(ISR)の成績, 第99回日本消化器病学会四国支部例会/第110回日本消化器内視鏡学会四国支部例会, Jun. 2013.
1596.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Hidenori Miyake : IPMNにおけるEMT関連因子(Twist1, Bmi1)発現の意義についての検討, 第99回日本消化器病学会四国支部例会/第110回日本消化器内視鏡学会四国支部例会, Jun. 2013.
1597.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 高齢ドナー肝再生不全と加齢指標マーカーについての検討, 第99回日本消化器病学会四国支部例会/第110回日本消化器内視鏡学会四国支部例会, Jun. 2013.
1598.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, Horohiko Sato and Hidenori Miyake : IPMNにおけるEMT関連因子(Twist1,Bmi1)発現の意義についての検討, 第22回日本癌病態治療研究会, Jun. 2013.
1599.	吉川雅登, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : ミラノ基準内の肝細胞癌に対する肝切除治療成績に関する検討∼亜区域切除と部分切除の比較∼, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1600.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 山田眞一郎 : 大腸癌肝転移症例に対する腹腔鏡下同時切除の有用性に関する検討, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1601.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎, 浅野間理仁, Chie Takasu and Hidenori Miyake : 癌幹細胞の治療抵抗性獲得と解除におけるEpigenetic修飾の関与, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1602.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : Inbodyを用いた体成分分析と膵臓手術周術期における栄養評価に関する検討, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1603.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, 浅野間理仁, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Toru Utsunomiya, Hidenori Miyake and Chie Takasu : 当科における非B非C型初発肝細胞癌切除症例の検討, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1604.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 山田眞一郎 : 膵IPMNにおけるNotch signallは調節性T細胞expansionおよび腫瘍EMTを増強する, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1605.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 石川大地 and Hidenori Miyake : 大腸癌肝転移に対する治療戦略―外科切除の適応とconversion surgery―, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1606.	Toru Utsunomiya, Mitsuo Shimada, 石川大地, 山田眞一郎, 浅野間理仁, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝門部脈管fusion画像と部分肝機能評価を取り入れた新たな肝切除術前シミュレーションの有用性, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1607.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 石川大地 and Hidenori Miyake : 安全・確実な肝葉切除のポイント―肝離断における出血制御テクニック―, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1608.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 手技定型化による安全確実な肝葉切除術, 第25回日本肝胆膵外科学会・学術集会, Jun. 2013.
1609.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Jun Higashijima, Motoya Chikakiyo, 柏原秀也, Chie Takasu and 松本規子 : PET-CT，DiffusionMRIを組み合わせた新たなGISTの悪性度診断の可能性, 第38回日本外科系連合学会学術集会, Jun. 2013.
1610.	Mami Kanamoto, Mitsuo Shimada, Yutaka Nakaya, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Shuichi Iwahashi, 山田眞一郎, 石川大地 and Hidenori Miyake : Inbodyを用いた体成分分析と膵臓手術周術期における栄養評価に関する検討, 第38回日本外科系連合学会学術集会, Jun. 2013.
1611.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎, 浅野間理仁, 石川大地 and Hidenori Miyake : 肝細胞癌切除例に対するRFAの影響, 第49回日本肝臓学会総会, Jun. 2013.
1612.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 浅野間理仁, 石川大地 and Hidenori Miyake : 分子標薬的Bevacizumabの小胞体ストレス応答を介した肝切除後肝機能障害改善・肝再生促進効果, 第49回日本肝臓学会総会, Jun. 2013.
1613.	矢田圭吾, Mitsuo Shimada, Hiroki Ishibashi, Horohiko Sato and Hiroki Mori : 胆道閉鎖症ラットモデルにおけるバクテリアルトランスロケーションと大建中湯による予防効果についての検討, 第50回日本小児外科学会学術集会, May 2013.
1614.	Hiroki Mori, Hiroki Ishibashi, Horohiko Sato, 矢田圭吾 and Mitsuo Shimada : ラットの膵・胆管合流異常症モデルの意義と課題, 第50回日本小児外科学会学術集会, May 2013.
1615.	Keigo Yada, Mitsuo Shimada, Hiroki Ishibashi, Horohiko Sato, Hiroki Mori and Toru Utsunomiya : Clinical features and outcomes of Hepatoblastoma., 第50回日本小児外科学会学術集会, May 2013.
1616.	Hiroki Ishibashi, 矢田圭吾, Hiroki Mori, Horohiko Sato and Mitsuo Shimada : 小児abdominoscrotal hydroceole(ASH)に対する腹腔鏡下手術, 第50回日本小児外科学会学術集会, May 2013.
1617.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori, Horohiko Sato and Mitsuo Shimada : 小児精巣卵黄嚢癌の1例, 第54回中国四国小児がん研究会, May 2013.
1618.	Hiroki Mori, Hiroki Ishibashi, 矢田圭吾, Horohiko Sato and Mitsuo Shimada : 胎児診断され腹腔鏡下手術を行った腹腔内精巣腫瘍の1例, 第54回中国四国小児がん研究会, May 2013.
1619.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾, Horohiko Sato and Mitsuo Shimada : 腹腔鏡下手術を行った卵巣奇形腫茎捻転の1例, 第54回中国四国小児がん研究会, May 2013.
1620.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾 and Mitsuo Shimada : 小児鼠径ヘルニアに対する腹腔鏡下修復術(LPEC法), 第11回日本ヘルニア学会学術集会, May 2013.
1621.	Akira Nii, Hiroki Ishibashi, Hiroki Mori, 矢田圭吾, 浅野間理仁 and Mitsuo Shimada : 重症心身障害児(者)のGERDに対する腹腔鏡下噴門形成術の術後成績と予後について, 第113回日本外科学会定期学術集会, Apr. 2013.
1622.	矢田圭吾, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 浅野間理仁, 石川大地 and Hidenori Miyake : Bevacizumabの小胞体ストレス応答を介した肝切除後肝機能障害改善・肝再生促進効果, 第113回日本外科学会定期学術集会, Apr. 2013.
1623.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : Light Emitting Diode光を用いた細胞制御に関する研究, 第113回日本外科学会定期学術集会, Apr. 2013.
1624.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu, 松本規子 and Hidenori Miyake : Duodenal-Jejunal Bypassの糖尿病・NASH改善効果に関する研究, 第113回日本外科学会定期学術集会, Apr. 2013.
1625.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and 松本規子 : CPT-11腹腔内投与によるBacterical Translocation発症, 第113回日本外科学会定期学術集会, Apr. 2013.
1626.	Takashi Iwata, Mitsuo Shimada, 松本規子, 柏原秀也, Chie Takasu, Tomohiko Miyatani, Kouzou Yoshikawa, Horohiko Sato and Nobuhiro Kurita : 大腸癌株由来cancer sphereにおけるTight junction発現とSonic Hedgehogシグナルの検討, 第113回日本外科学会定期学術集会, Apr. 2013.
1627.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也, Chie Takasu and 松本規子 : 腹腔鏡下横行結腸癌手術におけるVolume Rendering Simulationによる安全・確実なリンパ節郭清の工夫, 第113回日本外科学会定期学術集会, Apr. 2013.
1628.	Hidenori Miyamoto, 淺野間理仁, 宮本英之, Chie Takasu, Tomohiko Miyatani, Kouzou Yoshikawa, Horohiko Sato and Mitsuo Shimada : 肛門外科領域における画像診断の進歩―3D-power Doppler angiographyの有用性―, 第113回日本外科学会定期学術集会, Apr. 2013.
1629.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 局所進行下部直腸癌に対する術前化学放射線療法併用肛門温存術(ISR)の成績, 第113回日本外科学会定期学術集会, Apr. 2013.
1630.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Tomohiko Miyatani, Chie Takasu, 柏原秀也 and 松本規子 : 腸管ストレスに対する大建中湯の効果発現機序の解明, 第113回日本外科学会定期学術集会, Apr. 2013.
1631.	高田厚史, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 浅野間理仁, Toru Utsunomiya and Hidenori Miyake : 右側肝円索を伴う肝門部胆管癌からみた肝区域分類の把握, 第113回日本外科学会定期学術集会, Apr. 2013.
1632.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu, 松本規子 and Hidenori Miyake : 腹部骨盤外科高リスク症例における術後深部静脈血栓塞栓症予防のための抗凝固法, 第113回日本外科学会定期学術集会, Apr. 2013.
1633.	寺奥大貴, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 浅野間理仁, Toru Utsunomiya and Hidenori Miyake : 肝内胆管癌におけるEMT関連遺伝子発現, 第113回日本外科学会定期学術集会, Apr. 2013.
1634.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 浅野間理仁, 山田眞一郎, Horohiko Sato and Hidenori Miyake : IPMNにおけるEMT関連因子(Twist1, Bmi1)発現の意義についての検討, 第113回日本外科学会定期学術集会, Apr. 2013.
1635.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 浅野間理仁 and 石川大地 : 肝硬変における脾臓の役割と脾摘の有用性, 第113回日本外科学会定期学術集会, Apr. 2013.
1636.	浅野間理仁, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 山田眞一郎 : 脾臓内サイトカイン発現が肝硬変合併肝癌に関与する, 第113回日本外科学会定期学術集会, Apr. 2013.
1637.	Yu Saitou, Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 浅野間理仁, 石川大地 and Hidenori Miyake : 肝発癌母地に着目した肝細胞癌の治療戦略―DNA, miRNA, Methylationアレイを用いた非癌部肝組織の解析より―, 第113回日本外科学会定期学術集会, Apr. 2013.
1638.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎, 浅野間理仁, 石川大地 and Hidenori Miyake : 癌幹細胞の治療抵抗性獲得と喪失にepigenetic修飾が関与している, 第113回日本外科学会定期学術集会, Apr. 2013.
1639.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Horohiko Sato, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : Whey protein含有高機能流動食を用いた周術期栄養療法の有用性, 第113回日本外科学会定期学術集会, Apr. 2013.
1640.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 矢田圭吾 : 胆道癌発がんモデルの膵・胆管合流異常症での発がん特性の解析, 第113回日本外科学会定期学術集会, Apr. 2013.
1641.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, 浅野間理仁, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 高齢者の肝再生不全の機序解明と治療への応用, 第113回日本外科学会定期学術集会, Apr. 2013.
1642.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Yu Saitou, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 脂肪由来幹細胞を用いた肝胆膵領域の再生医療に関するimpactと課題, 第113回日本外科学会定期学術集会, Apr. 2013.
1643.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 浅野間理仁, 山田眞一郎, 石川大地 and Hidenori Miyake : 上右肝静脈ドレナージ領域切除を伴う拡大前区域切除術∼虚血域と鬱血域を残さない合理的な肝切除∼, 第113回日本外科学会定期学術集会, Apr. 2013.
1644.	Yuji Morine and Mitsuo Shimada : 肝内胆管癌のリンパ節郭清の意義〈意義あり vs. 意義なし〉 <意義なし>, 第113回日本外科学会定期学術集会, Apr. 2013.
1645.	Toru Utsunomiya and Mitsuo Shimada : 「肝切除術における肝門部処理の使い分け〈一括処理 vs. 個別処理〉 <一括処理>肝切除術における肝門部処理の使い分け「一括処理の立場より」, 第113回日本外科学会定期学術集会, Apr. 2013.
1646.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : NSTによる栄養管理によってQOLと臨床症状の改善を図った糖尿病合併肝硬変の一例, 第15回四国肝不全研究会, Apr. 2013.
1647.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori, Horohiko Sato, Akira Nii and Mitsuo Shimada : 手術手袋が原因のラテックスアレルギーにより術中アナフィラキシーを来した小児例, 第22回徳島外科術後管理研究会, Mar. 2013.
1648.	柏原秀也, 松本規子 and Mitsuo Shimada : Liraglutideとの比較からみたDuodenal-Jejunal Bypassの糖尿病/NASH改善効果に関する実験的研究, 第99回日本消化器病学会総会, Mar. 2013. (Keyword) 国内学会
1649.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁, 山田眞一郎, Horohiko Sato and Hidenori Miyake : EMT関連因子はIPMNの悪性度，予後に関与する, 第99回日本消化器病学会総会, Mar. 2013. (Keyword) 国内学会
1650.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 高齢者および心肺腎合併胃癌症例に対するリンパ節郭清範囲縮小の妥当性, 第85回日本胃癌学会総会, Feb. 2013. (Keyword) 国内学会
1651.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 腹腔鏡下幽門側胃切除術Roux-en Y再建後の残胃排出遅延および内ヘルニアへの対策, 第85回日本胃癌学会総会, Feb. 2013. (Keyword) 国内学会
1652.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 松本規子 : 胃癌術前腹膜播種診断における腫瘍マーカーの意義, 第85回日本胃癌学会総会, Feb. 2013. (Keyword) 国内学会
1653.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 腹腔鏡下前方切除術における視野展開の手技と工夫, 第27回四国内視鏡外科研究会, Feb. 2013. (Keyword) 国内学会
1654.	寺本有沙, Hisami Okumura, 杉原康平, Takafumi Katayama, Satoru Imura, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : 肝癌および肝移植ドナーの肝切除術前後におけるエネルギー代謝の評価, 第16回日本病態栄養学会, Jan. 2013.
1655.	杉原康平, Hisami Okumura, 寺本有沙, Hiroki Mori, Toru Utsunomiya, Mitsuo Shimada and Eiji Takeda : 肝癌および肝移植ドナーの肝切除術前後におけるエネルギー代謝の評価, 第16回日本病態栄養学会, Jan. 2013.
1656.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁 and 石川大地 : 原発性肝癌における短期・長期予後から見た鏡視下手術の妥当性, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1657.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 腹腔鏡下胃全摘出後再建における合併症予防の工夫とトラブルシューティング, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1658.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 腹腔鏡下鼠径ヘルニア修復術の合併症例から学ぶコツとトラブルシューティング, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1659.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu, 松本規子 and Masashi Akaike : システム，支援，フィードバックに注目した内視鏡下手術トレーニング, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1660.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 進行胃癌に対する腹腔鏡下胃切除手術の長期成績―開腹手術との比較―, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1661.	Toru Utsunomiya, 山田眞一郎 and Mitsuo Shimada : 高齢者に対する肝切除術後の肝再生不全の機序解明とその対策, 第99回日本消化器病学会総会, Dec. 2012. (Keyword) 国内学会
1662.	Tetsuya Ikemoto, 山田眞一郎 and Mitsuo Shimada : 膵腫瘍におけるNotch signalを通じたIndolamine 2,3-deoxygenase(IDO)陽性樹状細胞から誘導される抹消血中調節性T細胞モニタリングに関する検討, 第99回日本消化器病学会総会, Dec. 2012. (Keyword) 国内学会
1663.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 淺野間理仁 : 癌幹細胞の治療抵抗性獲得と解除におけるEpigenetic修飾の関与, 第246回徳島医学会学術集会, Dec. 2012. (Keyword) 国内学会
1664.	寺奥大貴, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎, 淺野間理仁 and 石川大地 : 腹腔内出血に苦しんだ膵体尾部癌の1切除例, 第21回徳島外科術後管理研究会, Dec. 2012. (Keyword) 国内学会
1665.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎, 淺野間理仁 and 石川大地 : 脂肪由来幹細胞(ADSC)の膵島細胞保護作用には，VEGFシグナルが関与する, 第19回外科侵襲とサイトカイン研究会, Dec. 2012. (Keyword) 国内学会
1666.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁, 石川大地 and Hidenori Miyake : Bevacizumabの小胞体ストレス応答を介した大量切除後肝機能障害改善・肝再生促進効果, 第19回外科侵襲とサイトカイン研究会, Dec. 2012. (Keyword) 国内学会
1667.	Mitsuo Shimada : 究極の肝細胞癌は肝移植である, 平成24年度日本肝臓学会後期教育講演会, Dec. 2012. (Keyword) 国内学会
1668.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁 and 石川大地 : 原発性肝癌における短期・長期予後から見た鏡視下手術の妥当性, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1669.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 2mm細径鉗子を用いたHybrid SILS-Cに関する検討, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1670.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁 and 石川大地 : 部分肝機能解析を取り入れた肝切除シミュレーション, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1671.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori, 淺野間理仁, Mitsuo Shimada and Akira Nii : 重症心身障害児(者)のGERDに対する腹腔鏡下噴門形成術の検討, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1672.	Hiroki Ishibashi, 矢田圭吾, Hiroki Mori, 淺野間理仁, Mitsuo Shimada and Akira Nii : 肥厚性幽門狭窄賞に対する腹腔鏡下幽門筋切開術の標準化の工夫, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
1673.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 松本規子 : 開腹胃切除におけるLigasureTM Small Jawの特徴と有効性, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1674.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 残胃排出能，ホルモン分泌能検査からみた胃切除術後再建方法の比較, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1675.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and 松本規子 : 併存疾患を有する高齢大腸癌患者に対する手術成績の検討, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1676.	Chie Takasu, 八木恵子, 角瀬裕子, 開野友佳理, Mami Kanamoto, 久山寿子, 四方祐子, 松本規子 and Mitsuo Shimada : ワークバランス維持実現に向けて, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1677.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也, Chie Takasu and 松本規子 : 化学放射線療法併用した腹腔鏡下直腸切除術の肛門機能と対策, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1678.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 局所進行下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術は標準治療になりうるか?, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1679.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌に対する腹腔鏡下胃全摘術におけるoverlap法を用いた食道空腸再建法の有用性とpit fall, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1680.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 胃癌Roux-en-Y再建後内ヘルニアの病態・診断と予防, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1681.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and Masashi Akaike : 最良の外科医の教育とは何か∼システム，支援，フィードバックに着眼した教育∼, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1682.	松本規子, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 局所進行下部直腸癌に対する術前化学放射線療法の無作為比較試験の測定研究によるテーラーメイド治療の提案, 第23回日本消化器癌発生学会, Nov. 2012. (Keyword) 国内学会
1683.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 松本規子 : 胃癌腹膜播種に関する新たな知見と治療への応用, 第23回日本消化器癌発生学会, Nov. 2012. (Keyword) 国内学会
1684.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, 柏原秀也, Chie Takasu and 松本規子 : ICG蛍光法を用いた大腸癌手術での血流を意識したステープリングデバイスの選択と使用方法, 第21回日本コンピュータ外科学会, Nov. 2012. (Keyword) 国内学会
1685.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Horohiko Sato, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : DSA-HLA抗体陽性のレシピエントに対する生体肝移植の治療戦略, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1686.	石川大地, チンボルトエンヘボルト, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁 and 山田眞一郎 : 肝切除前3Dシミュレーション画像による肝動脈，門脈，胆管の同時評価に関する検討, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1687.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, 淺野間理仁, 山田眞一郎, 矢田圭吾 and 石川大地 : 慢性性血液透析患者の肝癌に対する肝切除術の検討, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1688.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁 and 石川大地 : 80歳以上超高齢者における肝切除，膵頭十二指腸切除の妥当性に関する検討, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1689.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 淺野間理仁, 山田眞一郎, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : 高度門脈侵襲陽性の進行肝細胞癌に対する集学的治療戦略, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1690.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 淺野間理仁 : 2㎜細径鉗子を用いたHybrid SILS-Cに関する検討, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1691.	Toru Utsunomiya, Mitsuo Shimada, 石川大地, 淺野間理仁, 山田眞一郎, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 膵頭十二指腸切除術における輸血率ゼロのための工夫―郭清操作へのエネルギーデバイス導入による出血量軽減効果―, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1692.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, 山田眞一郎, 淺野間理仁, 石川大地 and Hidenori Miyake : IPMN手術適応判定における分子マーカーの検討―NotchシグナルはIPMN手術適応判定に有用である―, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1693.	Hiroki Mori, Hiroki Ishibashi, 矢田圭吾, 淺野間理仁, Mitsuo Shimada and Akira Nii : 小児腸重積症に対する診断および整復術における超音波装置の有用性, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1694.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, 淺野間理仁, 山田眞一郎, 矢田圭吾 and 石川大地 : 日本における女性外科医の抱える問題点と対策∼スウェーデン留学の経験から, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1695.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi and 山田眞一郎 : Vessel sealing systemを用いた肝嚢胞に対する外科的治療, 第6回肝臓内視鏡外科研究会, Nov. 2012. (Keyword) 国内学会
1696.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 淺野間理仁 : 肝細胞癌における短期・長期予後から見た鏡視下手術の妥当性, 第6回肝臓内視鏡外科研究会, Nov. 2012. (Keyword) 国内学会
1697.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 幹細胞マーカーに着目した細胆管癌の悪性度に関する検討―肝内胆管癌との比較より―, 第23回日本消化器癌発生学会, Nov. 2012. (Keyword) 国内学会
1698.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, 淺野間理仁, 齋藤裕, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 非癌部肝組織における小胞体ストレスマーカーの肝癌再発への関与, 第23回日本消化器癌発生学会, Nov. 2012. (Keyword) 国内学会
1699.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 癌幹細胞の治療抵抗性獲得と解除におけるepigenetic修飾の関与, 第23回日本消化器癌発生学会, Nov. 2012. (Keyword) 国内学会
1700.	Mitsuo Shimada : セレンディピティーを求めて, 第23回日本消化器癌発生学会, Nov. 2012. (Keyword) 国内学会
1701.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 淺野間理仁 : 肝切除支援ソフトによる術前シミュレーション，術中ナビゲーション，部分肝臓機能解析, 第21回日本コンピュータ外科学会大会, Nov. 2012. (Keyword) 国内学会
1702.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori, 淺野間理仁, Mitsuo Shimada and Akira Nii : 過去15年間に経験した小児肝芽腫10例の臨床的検討, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1703.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾, 淺野間理仁, Mitsuo Shimada and Akira Nii : 小児鼠径ヘルニアに対する腹腔鏡下修復術(LPEC法)の有用性, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
1704.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori, 淺野間理仁 and Mitsuo Shimada : 横隔膜ヘルニア術後の縦隔膿瘍に対して胸腔鏡膿瘍ドレナージが有用であった1例, 第32回日本小児内視鏡外科・手術手技研究会, Nov. 2012. (Keyword) 国内学会
1705.	松本規子, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu, 柏原秀也 and Mitsuo Shimada : 長寿遺伝子Sirtuinは胃癌の進展に関与する, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1706.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : PET-CT，DiffusionMRI併用でGISTの悪性度診断が可能となる, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1707.	Takashi Iwata, Mitsuo Shimada, Chie Takasu, 柏原秀也, 松本規子, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Horohiko Sato and Nobuhiro Kurita : 心肺腎合併症を有する患者に安全な胃癌手術は施行可能か?, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1708.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 松本規子 : 胃癌術前腹膜播種予測因子としてのHDAC1発現の意義, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1709.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 長寿遺伝子Sirtuin familyのSIRT3は大腸癌の発癌・進展に関与する, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1710.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 胃癌に対する腹腔鏡補助下幽門側胃切除術(LAG)の術後合併症とその対策, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1711.	寺奥大貴, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌術後内ヘルニア症例の検討と予防策, 第10回日本消化器外科学会, Oct. 2012. (Keyword) 国内学会
1712.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌におけるPKCiota発現の意義, 第10回日本消化器外科学会, Oct. 2012. (Keyword) 国内学会
1713.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : 分化型胃癌発癌・進展におけるAID発現の意義, 第10回日本消化器外科学会, Oct. 2012. (Keyword) 国内学会
1714.	Horohiko Sato, Tomohiko Miyatani, Shinya Morimoto, 柏原秀也, Chie Takasu, Kouzou Yoshikawa, Masanori Nishioka, Takashi Iwata, Nobuhiro Kurita and Mitsuo Shimada : 下部直腸癌側方リンパ節移転に対する術前化学放射線療法の無作為比較試験の測定研究によるテーラーメイド治療と新たな治療法の提案, 第10回日本消化器外科学会, Oct. 2012. (Keyword) 国内学会
1715.	Nobuhiro Kurita, Mitsuo Shimada and Horohiko Sato : 術前・術後進行度別に検討した胃癌に対する腹腔鏡下胃切除手術の長期成績, 第10回日本消化器外科学会, Oct. 2012. (Keyword) 国内学会
1716.	Tomohiko Miyatani, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 分子標的薬Bevacizumabの小胞体ストレス応答を介した肝切除後肝機能障害改善効果, 第54回日本消化器病学会大会, Oct. 2012. (Keyword) 国内学会
1717.	Takashi Iwata, Mitsuo Shimada and Toru Utsunomiya : 医学生へのドナーアクション啓発活動の重要性, 第54回日本消化器病学会大会, Oct. 2012. (Keyword) 国内学会
1718.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁, 山田眞一郎 and Horohiko Sato : IPMNにおけるProtein Kinase Ciota発現の意義, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1719.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Horohiko Sato, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 肝内胆管癌と比較した細胆管細胞癌の悪性度に関する検討, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1720.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁 and Horohiko Sato : 高度進行膵癌に対する治療戦略∼Sytemic GFP療法, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1721.	Toru Utsunomiya, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁, 石川大地 and Horohiko Sato : 非癌部肝組織におけるmiR-494およびPTEN発現の臨床病理学的意義, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1722.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Horohiko Sato, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎 and 石川大地 : 肝硬変合併肝癌における脾臓の役割, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1723.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, 淺野間理仁, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Horohiko Sato, Toru Utsunomiya and Hidenori Miyake : 非癌部肝組織における小胞体ストレスマーカーの肝癌再発への関与, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1724.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁, 石川大地 and Hidenori Miyake : 膵胆管合流異常症におけるepigenetic/genetic修飾を介した胆道癌発癌機構に関する検討, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1725.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁 and 石川大地 : 大腸癌肝転移におけるSDF-1/CXCR4 axisの影響に関する研究, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1726.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Horohiko Sato, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Shuichi Iwahashi, 齋藤裕, 山田眞一郎 and 淺野間理仁 : 肝癌に対する肝切除周術期生体侵襲におけるWhey protein含有高機能流動食投与の検討, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1727.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁, 石川大地, Horohiko Sato and Hidenori Miyake : 胆道癌切除例に対するGFP補助療法と再発肝切除導入効果の検証, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1728.	Toru Utsunomiya, Mitsuo Shimada, Tetsuya Ikemoto, Satoru Imura, 山田眞一郎, 淺野間理仁, Yuji Morine, 齋藤裕, Hiroki Mori and Mami Kanamoto : 若手への``完全相伝式''肝葉切除伝承への工夫:無輸血・胆汁瘻ゼロを目指して, JDDW, Oct. 2012. (Keyword) 国内学会
1729.	Mami Kanamoto, Mitsuo Shimada and 佐々木一 : Whey protein含有高機能流動食投与による肝切除周術期の生体侵襲に対する有用性の検討―基礎的実験と臨床的評価―, JDDW, Oct. 2012. (Keyword) 国内学会
1730.	Yuji Morine, Mitsuo Shimada and Mami Kanamoto : 肝癌における幹細胞マーカーの意義の再認識治療抵抗性克服への戦略, JDDW, Oct. 2012. (Keyword) 国内学会
1731.	淺野間理仁, Mitsuo Shimada and Toru Utsunomiya : 肝硬変に対する脾摘後における血小板の肝容積への影響, JDDW, Oct. 2012. (Keyword) 国内学会
1732.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, 山田眞一郎, 淺野間理仁, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 下右肝静脈温存，上右肝静脈及びドレナージ領域を含む合理的拡大肝前区域切除術, 第7回肝癌治療シミュレーション研究会, Oct. 2012. (Keyword) 国内学会
1733.	矢田圭吾, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁, 石川大地 and Hiroki Ishibashi : 膵・胆管合流異常症に胆道癌を合併した3症例についての検討, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1734.	Hiroki Ishibashi, Mitsuo Shimada, Horohiko Sato, Hiroki Mori, 矢田圭吾 and 淺野間理仁 : 小児肝芽腫の臨床的特徴と治療成績に関する検討, 第50回日本癌治療学会学術集会, Oct. 2012. (Keyword) 国内学会
1735.	Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, Miyoshi Yasuo, Mitsuo Shimada, Nakamura Yusuke, Sasa Mitsunori and Toyomasa Katagiri : Involvement of preteasome-associated gene 1(PAG1) in proliferation of triple negative breast cancer, The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
1736.	Hiroki Mori, Hiroki Ishibashi, 矢田圭吾 and Mitsuo Shimada : 原因不明の腸腰筋膿瘍および胸壁皮下膿瘍を来した乳児例, 第51回日本小児外科学会中国四国地方会, Sep. 2012.
1737.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu, 松本規子 and Masashi Akaike : 腹腔鏡下胃切除術のトレーニングにおける開腹術からのフィードバックの有用性について, 第17回中国四国内視鏡外科研究会, Sep. 2012.
1738.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌術後Roux-en-Y再建における内ヘルニア症例の検討, 第87回中国四国外科学会, Sep. 2012.
1739.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 大腸癌における内臓肥満は長寿遺伝子Sirt1を抑制し，癌進展に関与する, 第87回中国四国外科学会, Sep. 2012.
1740.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa and Tomohiko Miyatani : Protein Kinase Ciota is a new prognostic factor in gastric cancer. (Protein Kinase Ciota (PKCiota) ), 第71回日本癌学会学術総会, Sep. 2012. (Keyword) 国内学会
1741.	Tomohiko Miyatani, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Chie Takasu, 柏原秀也 and 松本規子 : Predictive factors in chemoradiotherapy for rectal cancer. ( ), 第71回日本癌学会学術総会, Sep. 2012. (Keyword) 国内学会
1742.	Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, 三好康雄, Mitsuo Shimada, 中村祐輔, 笹三徳 and Toyomasa Katagiri : Involvement of proteasome-associated gene 1 (PAG1) in proliferation of triple negative breast cancer. (トリプルネガティブ乳癌におけるプロテアソーム関連遺伝子PAG1を介した発癌・増殖機構の関与), 第71回日本癌学会学術総会, Sep. 2012. (Keyword) 国内学会
1743.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : Role of Sonic Hedgehog signaling and expression of tight junction in regulation of cancer stem cells. (癌幹細胞制御におけるソニックヘッジホッグシグナルの意義とタイトジャンクション発現に関する検討), 第71回日本癌学会学術総会, Sep. 2012. (Keyword) 国内学会
1744.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, 山田眞一郎 and 淺野間理仁 : 生体肝移植レシピエント術後肝障害に対するWhey protein含有高機能流動食を用いた周術期栄養療法の有用性, 第48回日本移植学会総会, Sep. 2012. (Keyword) 国内学会
1745.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁, Horohiko Sato and Hidenori Miyake : ドナー特異的抗HLA抗体陽性のレシピエントに対する生体肝移植, 第48回日本移植学会総会, Sep. 2012. (Keyword) 国内学会
1746.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁 and 石川大地 : 脂肪由来幹細胞(ADSC)の膵島細胞保護作用には，IL-6シグナルは関与しない, 第48回日本移植学会総会, Sep. 2012. (Keyword) 国内学会
1747.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, 松本慎一, B Naziruddin and M.F. Levy : 自家膵島移植におけるInstant blood-mediated inflammatory reaction発現の検討, 第48回日本移植学会総会, Sep. 2012. (Keyword) 国内学会
1748.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto and Munehide Matsuhisa : 四国地区モデルとしての徳島県の膵島移植待機患者の現状と問題点, 第48回日本移植学会総会, Sep. 2012. (Keyword) 国内学会
1749.	山田眞一郎, Mitsuo Shimada, Yuji Morine, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto and Shuichi Iwahashi : 胆嚢摘出術後に胆管癌を発症した胆管非拡張型膵・胆管合流異常の2症例についての検討, 第48回日本胆道学会学術集会, Sep. 2012. (Keyword) 国内学会
1750.	Hiroki Mori, Hiroki Ishibashi, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁, 山田眞一郎, Hidenori Miyake and Mitsuo Shimada : Risk of carcinogenesis in patients with pancreaticobiliary maljunction through both epigenetic and genetic regulation., 第71回日本癌学会学術総会, Sep. 2012.
1751.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Mami Kanamoto, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : Tumor microenvironment is regulated by tumor Jagged 1 through Indoleamine 2, 3-dioxygenase(IDO) positive dendtric cell., 第71回日本癌学会学術総会, Sep. 2012. (Keyword) 国内学会
1752.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, 山田眞一郎, 淺野間理仁, 石川大地 and Hidenori Miyake : 分枝型IPMNの手術適応判定―分子生物学的マーカーによる評価―, 第87回中国四国外科学会総会, Sep. 2012. (Keyword) 国内学会
1753.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁 and 石川大地 : 胆嚢摘出後に胆管癌を発症した胆管非拡張型膵・胆管合流異常の2症例についての検討, 第35回日本膵・胆管合流異常研究会, Sep. 2012. (Keyword) 国内学会
1754.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 腱中心に発生した遅発性先天性横隔膜ヘルニア嵌頓の1例, 第51回日本小児外科学会中国四国地方会, Sep. 2012. (Keyword) 国内学会
1755.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 小児外科研修を始めるにあたって∼一研修医が考える卒後臨床研修と一般外科研修の意味と意義∼, 第51回日本小児外科学会中国四国地方会, Sep. 2012. (Keyword) 国内学会
1756.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾 and Mitsuo Shimada : 小児鼠径ヘルニアに対する腹腔鏡下手術(LPEC法)の術後成績および有用性, 第51回日本小児外科学会中国四国地方会, Sep. 2012. (Keyword) 国内学会
1757.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾 and Mitsuo Shimada : 幽門腫瘤の固定に血管鉗子を用いた腹腔鏡下幽門筋切開術, 第51回日本小児外科学会中国四国地方会, Sep. 2012. (Keyword) 国内学会
1758.	矢田圭吾, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁, 石川大地 and Hidenori Miyake : 非拡張型膵・胆管合流異常症の胆道上皮は発癌ポテンシャルを有する, 第35回日本膵・胆管合流異常研究会, Sep. 2012. (Keyword) 国内学会
1759.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : ドナー特異的抗HLA抗体陽性のレシピエントに対する生体肝移植の1例, 第30回中国四国臨床臓器移植研究会, Aug. 2012. (Keyword) 国内学会
1760.	寺奥大貴, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa and 柏原秀也 : 胃癌術後内ヘルニア症例の検討と予防策, 第245回徳島医学会学術集会, Jul. 2012.
1761.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 進行下部直腸癌に対する術前化学放射線療法の多施設無作為比較試験の臨床効果と硬化予測遺伝子を応用したテーラーメイド治療への展開, 第245回徳島医学会学術集会, Jul. 2012.
1762.	Takashi Iwata, Mitsuo Shimada, Masami Nagamune and Masashi Akaike : 腹腔鏡下胃切除術の術者研修中における開腹術からのフィードバックの有用性について, 第44回日本医学教育学会大会, Jul. 2012.
1763.	寺奥大貴, Mitsuo Shimada and Chie Takasu : 原発・肝転移巣ともに腹腔鏡下に切除し得た骨形成性直腸癌の一例, 第67回日本消化器外科学会総会, Jul. 2012.
1764.	江藤祥平, Kouzou Yoshikawa and Mitsuo Shimada : 胃癌術後Roux-en-Y再建における内ヘルニア症例の検討, 第67回日本消化器外科学会総会, Jul. 2012.
1765.	Hidenori Miyamoto, 浅野間理仁, 宮本英之 and Mitsuo Shimada : 内痔核硬化療法(ALTA療法)の治療成績向上のための工夫, 第67回日本消化器外科学会総会, Jul. 2012.
1766.	尾方信也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and 柏原秀也 : 下部進行直腸癌に対する化学放射線療法耐性予測における癌幹細胞CD133およびmiRNA-223の有用性について, 第67回日本消化器外科学会総会, Jul. 2012.
1767.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and 柏原秀也 : 超高齢消化管癌に対する手術成績の検討, 第67回日本消化器外科学会総会, Jul. 2012.
1768.	Jun Higashijima, Mitsuo Shimada, 柏原秀也, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa and Tomohiko Miyatani : Duodenal-jejunal bypassによる耐糖能異常改善効果に関する研究, 第67回日本消化器外科学会総会, Jul. 2012.
1769.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 柏原秀也 : 化学療法の効果を含めたStage IV大腸癌細胞分類の提案, 第67回日本消化器外科学会総会, Jul. 2012.
1770.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Nobuhiro Kurita, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 地方大学病院におけるNCD消化器外科領域入力の工夫と課題, 第67回日本消化器外科学会総会, Jul. 2012.
1771.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, Kouzou Yoshikawa and Chie Takasu : 重篤な心肺腎合併胃癌症例に対するリンパ節郭清範囲の縮小の妥当性, 第67回日本消化器外科学会総会, Jul. 2012.
1772.	Tomohiko Miyatani, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto and Hidenori Miyake : Conversionと化療の肝障害軽減を目指した治療戦略, 第67回日本消化器外科学会総会, Jul. 2012.
1773.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : Volume Rendering Simulationを用いた腹腔鏡下横行結腸癌手術, 第67回日本消化器外科学会総会, Jul. 2012.
1774.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 進行胃癌に対する術前補助化学療法の適応決定・個別化治療展開におけるthrombospondin 1(THBS1)発現の意義, 第67回日本消化器外科学会総会, Jul. 2012.
1775.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, Kouzou Yoshikawa, 柏原秀也 and Chie Takasu : 腸管ストレスにおける大建中湯の抗炎症効果―From Bench to Bedside―, 第67回日本消化器外科学会総会, Jul. 2012.
1776.	Horohiko Sato, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and 柏原秀也 : 局所進行下部直腸癌に対する術前化学放射線療法の無作為比較試験の測定研究によるテーラーメイド治療の提案, 第67回日本消化器外科学会総会, Jul. 2012.
1777.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 松本規子 : AID発現とHDAC1-MTA1張る現の相関から見たShort segment Barrett上皮の悪性度の検討, 第21回日本癌病態治療研究会, Jul. 2012.
1778.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, 柏原秀也 and 松本規子 : Conversion chemotherapyに向けてのStage IV大腸癌細分類の提案, 第77回大腸癌研究会, Jul. 2012.
1779.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : 76歳以上の高齢者大腸癌の化学療法の安全性について, 第77回大腸癌研究会, Jul. 2012.
1780.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 松本規子 : CPT-11投与による腸間ストレスに対する大健中湯の効果に関する検討, 第49回日本外科代謝栄養学会学術集会, Jul. 2012.
1781.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto and 山田眞一郎 : Protein Kinase Cι発現はIPMNの新たな予後予測因子となる, 第245回徳島医学会学術集会, Jul. 2012. (Keyword) 国内学会
1782.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎 and 淺野間理仁 : 術前3D-volumetryを用いた下右肝静脈温存，右上肝静脈とドレナージ領域切除を含む合理的拡大肝前区域切除術, 第48回日本肝癌研究会, Jul. 2012. (Keyword) 国内学会
1783.	Yusuke Arakawa, Mitsuo Shimada, 山田眞一郎, 淺野間理仁, 齋藤裕, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 非癌部肝組織における小胞体ストレスマーカー発現, 第48回日本肝癌研究会, Jul. 2012. (Keyword) 国内学会
1784.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 齋藤裕, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 初回肝細胞癌切除後の肝移植適応を考慮した再発予測におけるUp-to-seven基準の検討, 第48回日本肝癌研究会, Jul. 2012. (Keyword) 国内学会
1785.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 鏡視下肝切除定型化と肝細胞癌における短期・長期成績―基本手技とアドバンス手技―, 第48回日本肝癌研究会, Jul. 2012. (Keyword) 国内学会
1786.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, 山田眞一郎, 淺野間理仁, 齋藤裕, Hiroki Mori, Jun Hanaoka, Tetsuya Ikemoto and Yuji Morine : 門脈灌流領域と肝静脈ドレナージ領域の詳細な解析に基づく系統的切除の妥当性, 第48回日本肝癌研究会, Jul. 2012. (Keyword) 国内学会
1787.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕 and 山田眞一郎 : 症例, 第48回日本肝癌研究会, Jul. 2012. (Keyword) 国内学会
1788.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 淺野間理仁 : 進行肝細胞癌に対するSorafenibの使用経験及び著効例の検討, 第48回日本肝癌研究会, Jul. 2012. (Keyword) 国内学会
1789.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 細胆管細胞癌における肝幹細胞由来原発性肝腫瘍の特徴発現とその予後, 第48回日本肝癌研究会, Jul. 2012. (Keyword) 国内学会
1790.	吉川雅登, Mitsuo Shimada and Yuji Morine : 右側肝円索を伴う肝門部胆管癌の切除経験, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1791.	石川大地, Tetsuya Ikemoto and Mitsuo Shimada : 診断に苦慮した高度脂肪化を伴うHCCの1例, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1792.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Hiroki Mori : 肝胆膵外科領域におけるNCD登録システムの確立と術後合併症リスク評価への応用の試み, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1793.	Hiroki Mori, Hiroki Ishibashi, Toru Utsunomiya, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, 淺野間理仁, Hidenori Miyake and Mitsuo Shimada : 膵・胆管合流異常症の胆道上皮における遺伝子異常からみた治療方針, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1794.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 杉本光司 and Hidenori Miyake : 肝臓外科における菌チン蒿湯の有用性, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1795.	Yusuke Arakawa, Mitsuo Shimada, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 非癌部肝組織における小胞体ストレスマーカーの肝癌再発への関与, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1796.	淺野間理仁, Hidenori Miyake, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori and 杉本光司 : 80歳以上超高齢者における肝胆膵手術の是非, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1797.	齋藤裕, Mitsuo Shimada, 淺野間理仁, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto and Hidenori Miyake : 肝硬変における脾摘の効果と脾臓の役割, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1798.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司 and Hidenori Miyake : 術式定型化による適応拡大と原発性肝癌の治療成績 ∼短期・長期予後からみた鏡視下手術の妥当性∼, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1799.	Toru Utsunomiya, Mitsuo Shimada, 淺野間理仁, 山田眞一郎, 齋藤裕, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mami Kanamoto : EOB-MRIによる術前シミュレーションとICG蛍光法による術中ナビゲーション∼肝切除の安全性と根治性の向上∼, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1800.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 齋藤裕 and 山田眞一郎 : 上右肝静脈とそのドレナージ領域合併切除を伴う鬱血領域を加味した系統的前区域切除術, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1801.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎 and Hidenori Miyake : 肝内胆管癌の長期生存獲得の条件とGFP補助療法の有用性, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1802.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎 and 淺野間理仁 : Jagged発現とIndolamine2,3-deoxygenase陽性細胞により誘導される調節性T細胞のIPMN悪性度反映に関する検討, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1803.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 佐々木一, 青沼広光 and 川島昭浩 : 高機能流動食による肝切除周術期管理―基礎的検討からRCTによる有効性評価―, 第67回日本消化器外科学会総会, Jul. 2012. (Keyword) 国内学会
1804.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and 山田眞一郎 : 分子標的薬Bevacizumabは小胞体ストレス応答を介し肝切除後の肝機能障害を改善する, 第21回日本癌病態治療研究会, Jul. 2012. (Keyword) 国内学会
1805.	矢田圭吾, Hiroki Ishibashi, Hiroki Mori and Mitsuo Shimada : 小児肝芽腫の臨床的特徴と治療成績に関する検討, 第245回徳島医学会学術集会, Jul. 2012. (Keyword) 国内学会
1806.	Hiroki Ishibashi, Hiroki Mori, 矢田圭吾 and Mitsuo Shimada : 膵・胆管合流異常の胆道上皮における分子生物学的検討, 第245回徳島医学会学術集会, Jul. 2012. (Keyword) 国内学会
1807.	松本規子, Chie Takasu, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Mitsuo Shimada : メタボ関連大腸癌においてSIRT1発現の低下は癌進展と予後に関係する, 第97回日本消化器病学会四国支部例会, Jun. 2012.
1808.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : Duodenal-jejunal bypassによる耐糖能以上改善効果に関する研究, 第97回日本消化器病学会四国支部例会, Jun. 2012.
1809.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 腫瘍マーカーにHDAC1発現を用いた新規肝細胞癌マーカーの開発, 第97回日本消化器病学会四国支部例会, Jun. 2012.
1810.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : 13C空腸吸収能検査・RI法による排出能検査からみた空腸嚢付加Roux-en-Y再建の意義, 第37回日本外科系連合学会学術集会, Jun. 2012.
1811.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 柏原秀也 : 術前化学放射線療法併用腹腔鏡下直腸切除後の肛門機能について, 第37回日本外科系連合学会学術集会, Jun. 2012.
1812.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 腹腔鏡下胃全摘出術の食道空腸吻合におけるoverlap法のピットホールと再建の工夫, 第37回日本外科系連合学会学術集会, Jun. 2012.
1813.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 高リスク腹部手術後深部静脈血栓塞栓症予防のための抗凝固療法randomized study, 第37回日本外科系連合学会学術集会, Jun. 2012.
1814.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Tomohiko Miyatani, 杉本光司, Shuichi Iwahashi and Hidenori Miyake : ABO不適合肝移植での抗免疫療法の工夫―特に低用量ペグリバHCV療法の有用性について―, Jun. 2012. (Keyword) 国内学会
1815.	吉川雅登, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁 and 山田眞一郎 : 大腸癌肝転移におけるSDF-1/CXCR4 axisの影響に関する研究, 第97回日本消化器病学会四国支部例会, Jun. 2012. (Keyword) 国内学会
1816.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 淺野間理仁, 石川大地 and Hidenori Miyake : 膵・胆管合流異常症における胆道癌発癌機構の解明, 第97回日本消化器病学会四国支部例会, Jun. 2012. (Keyword) 国内学会
1817.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Tomohiko Miyatani, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎 and 淺野間理仁 : 大腸癌肝転移に関する諸問題と新たな治療戦略, 第37回日本外科系連合学会学術集会, Jun. 2012.
1818.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎, 淺野間理仁, Horohiko Sato and Hidenori Miyake : 安全確実な肝葉切除術―出血量軽減のための工夫―, 第37回日本外科系連合学会学術集会, Jun. 2012.
1819.	Mitsuo Shimada : 移植医療における免疫抑制剤の使用法, 第37回日本外科系連合学会学術集会, Jun. 2012.
1820.	Mitsuo Shimada : 安全確実な肝切除術の工夫, 第37回日本外科系連合学会学術集会, Jun. 2012.
1821.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 齋藤裕 and 淺野間理仁 : 進行肝癌術後の肺・肺門リンパ節転移に対してソラフェニブが著効したが，肝内再発を来し肝切除を行った症例, 第6回日本肝がん分子標的治療研究会, Jun. 2012.
1822.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 齋藤裕, 山田眞一郎 and 淺野間理仁 : 進行肝癌に対する集学的治療∼ソラフェニブ・IFP療法の比較∼, 第6回日本肝がん分子標的治療研究会, Jun. 2012.
1823.	Mitsuo Shimada : 臨床研究(Ⅰ), 第6回日本肝がん分子標的治療研究会, Jun. 2012.
1824.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Hiroki Mori, Shuichi Iwahashi, 齋藤裕 and 淺野間理仁 : ヒト脂肪由来幹細胞はVEGFシグナルとは異なる経路で肝細胞傷害を軽減する, 第30回日本肝移植研究会, Jun. 2012.
1825.	Shuichi Iwahashi, Mitsuo Shimada, Toru Utsunomiya, 淺野間理仁, 山田眞一郎, 齋藤裕, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and エンヘボルトチンボルト : 高齢者ドナー肝に関する基礎的検討:肝再生及び肝障害に関して, 第30回日本肝移植研究会, Jun. 2012.
1826.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Tomohiko Miyatani, Shuichi Iwahashi and Hidenori Miyake : C型肝硬変に対する肝移植後の抗ウイルス療法の工夫特に血液型不適合移植後の低用量ペグリバ療法の有用性について, 第30回日本肝移植研究会, Jun. 2012.
1827.	Yusuke Arakawa, Mitsuo Shimada, Satoru Imura, Shuichi Iwahashi, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 肝細胞癌切除後の肝移植適応を考慮した再発予測におけるUp-to-seven基準の妥当性の検討, 第30回日本肝移植研究会, Jun. 2012.
1828.	Mitsuo Shimada : 肝癌移植症例の相互評価Best Criteria in Japanの確立, 第30回日本肝移植研究会, Jun. 2012.
1829.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, 齋藤裕 and 淺野間理仁 : 大腸癌肝転移におけるSDF-1/CXCR4 axisの影響に関する検討, 第48回日本肝臓学会総会, Jun. 2012.
1830.	Yusuke Arakawa, Mitsuo Shimada, Satoru Imura, 山田眞一郎, 淺野間理仁, 齋藤裕, Hiroki Mori, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 非癌部肝組織におけるSTMN1・miR-223発現の肝癌多中心性再発への関与, 第48回日本肝臓学会総会, Jun. 2012.
1831.	Toru Utsunomiya, Tetsuya Ikemoto, Jun Hanaoka, Mitsuo Shimada, Satoru Imura, Yuji Morine, 齋藤裕, 淺野間理仁 and 山田眞一郎 : 肝発癌分子機構におけるがん幹細胞関連DNA・miRNA発現の関与, 第48回日本肝臓学会総会, Jun. 2012.
1832.	Jun Hanaoka, Mitsuo Shimada and Toru Utsunomiya : EOB-MRIによる術前シミュレーションとHyperEye medical systemを用いた術中ナビゲーション, 第48回日本肝臓学会総会, Jun. 2012.
1833.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 肝内胆管癌における癌幹細胞の意義と治療抵抗性克服の可能性, 第48回日本肝臓学会総会, Jun. 2012.
1834.	Yuji Morine, Mitsuo Shimada and Tetsuya Ikemoto : 癌幹細胞のepigenetic修飾と癌根治療法への可能性., 第97回日本消化器病学会総会, May 2012.
1835.	山田眞一郎, Mitsuo Shimada and Hiroshi Shibata : 進行肝癌に対する補助療法としてのIFP療法の有用性およびソラフェニブの適応提案., 第97回日本消化器病学会総会, May 2012.
1836.	矢田圭吾, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁 and 石川大地 : ドナー特異的抗HLA抗体陽性のレシピエントに対して生体肝移植を施行した1症例, 第14回四国肝不全研究会, May 2012.
1837.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 杉本光司, 齋藤裕, 山田眞一郎 and 淺野間理仁 : 下右肝静脈温存，上右肝静脈とそのドレナージ領域を含む合理的拡大肝S8切除術の1例, 第24回日本肝胆膵外科学会・学術集会, May 2012.
1838.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 尾側膵切除における膵断端処理の工夫と膵液瘻低減に関する検討, 第24回日本肝胆膵外科学会・学術集会, May 2012.
1839.	Toru Utsunomiya, Mitsuo Shimada, 齋藤裕, 山田眞一郎, 淺野間理仁, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 門脈灌流領域および肝静脈ドレナージ領域の詳細な解析に基づく合理的な拡大肝前区域切除術, 第24回日本肝胆膵外科学会・学術集会, May 2012.
1840.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 齋藤裕, 淺野間理仁 and Hidenori Miyake : 胆嚢癌に対する腹腔鏡補助下肝S4a+S5切除術の有用性についての検討, 第24回日本肝胆膵外科学会・学術集会, May 2012.
1841.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕 and 山田眞一郎 : 異時性三重複胆道癌に対する外科治療, 第24回日本肝胆膵外科学会・学術集会, May 2012.
1842.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 分枝型IPMNの手術適応``分子生物学的指標による評価'', 第24回日本肝胆膵外科学会・学術集会, May 2012.
1843.	Yusuke Arakawa, Mitsuo Shimada, Satoru Imura, 山田眞一郎, 淺野間理仁, 齋藤裕, Hiroki Mori, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 転移性肝癌と鑑別困難であった限局性類洞拡張障害の一例, 第24回日本肝胆膵外科学会・学術集会, May 2012.
1844.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : EOB-MRIによるOne stop shopping肝予備能検査, 第24回日本肝胆膵外科学会・学術集会, May 2012. (Keyword) 国内学会
1845.	Mitsuo Shimada : 「高難度肝胆膵外科手術の実際∼肝∼」英語版「肝胆膵高難度外科手術」執筆者によるビデオ解説∼, 第24回日本肝胆膵外科学会・学術集会, May 2012.
1846.	チンボルトエンヘボルト, Mitsuo Shimada, Toru Utsunomiya, 山田眞一郎, 齋藤裕, 淺野間理仁, 杉本光司, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝切除前3Dシミュレーション画像による肝動脈，門脈，胆管の同時評価, 第66回手術手技研究会, May 2012. (Keyword) 国内学会
1847.	Yusuke Arakawa, Mitsuo Shimada, Satoru Imura, 山田眞一郎, 淺野間理仁, 齋藤裕, Jun Hanaoka, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Toru Utsunomiya : 下右肝静脈温存，上右肝静脈とドレナージ領域を含む合理的拡大肝S8切除術, 第66回手術手技研究会, May 2012. (Keyword) 国内学会
1848.	Mitsuo Shimada : 手術手技の創意・工夫, 第66回手術手技研究会, May 2012. (Keyword) 国内学会
1849.	矢田圭吾, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, 山田眞一郎, 淺野間理仁 and 石川大地 : ドナー特異的抗HLA抗体陽性のレシピエントに対して生体肝移植術を施行した1症例, 第14回四国肝不全研究会, May 2012. (Keyword) 国内学会
1850.	矢田圭吾, Mitsuo Shimada, Hiroki Ishibashi and Horohiko Sato : 縦隔腫瘍と鑑別を要した左肺葉外肺分画症の1例, 第49回日本小児外科学会学術集会, May 2012. (Keyword) 国内学会
1851.	Hiroki Mori, Mitsuo Shimada, Hiroki Ishibashi and Horohiko Sato : 鼠径ヘルニアに対するLPEC施行後に対側発症を来した3例, 第49回日本小児外科学会学術集会, May 2012. (Keyword) 国内学会
1852.	Hiroki Mori, Hiroki Ishibashi, Horohiko Sato, 矢田圭吾 and Mitsuo Shimada : 腸管蠕動不全が疑われた先天性小腸閉鎖の1例, 第101回徳島周産期研究会, May 2012. (Keyword) 国内学会
1853.	Ahmed Shawky Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya, Mitsuo Shimada and Noriyuki Moriyama : Analysis of hepatic blood vessels for liver surgery planning based on multislice CT datasets, IEICE Technical Report, Vol.112, No.36, May 2012.
1854.	Tomohiko Miyatani, Mitsuo Shimada, Horohiko Sato, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也 and Chie Takasu : CD133はmicroRNAの制御により直腸癌の化学放射線療法耐性に関与する, 第98回日本消化器病学会総会, Apr. 2012.
1855.	Takashi Iwata, Mitsuo Shimada, 柏原秀也, Chie Takasu, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato and Nobuhiro Kurita : Barrett食道に対する治療戦略―胃癌とのmalignant potentialの相違の検討―, 第98回日本消化器病学会総会, Apr. 2012.
1856.	Nobuhiro Kurita, Mitsuo Shimada and Horohiko Sato : The utility of standardization of procedures and tele-surgical system for laparoscopy assisted gastrectomy for gastric cancer in the provincial area., 第98回日本消化器病学会総会, Apr. 2012.
1857.	Chie Takasu, Mitsuo Shimada and Mami Kanamoto : 外科の立場からのキャリヤアップ支援, 第98回日本消化器病学会総会, Apr. 2012.
1858.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : The effect of Dai-kenchu-to in maintenance of microbiomal diversity on intestinal inflammation., 第98回日本消化器病学会総会, Apr. 2012.
1859.	仁木亮介, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 術前によるMDCTによる右胃動脈, 中結腸静脈把握により安全・確実な腹腔鏡下手術が可能になる, 第112回日本外科学会学術集会, Apr. 2012.
1860.	Yoshiyasu Terashima, Mitsuo Shimada, 柏原秀也, Chie Takasu, Masakazu Goto, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato, Takashi Iwata and Nobuhiro Kurita : Short segment Barrett上皮のmalignant potentialの検討∼Activation-induced deaminase(AID)発現とHDAC1-MTA1発現の相関について∼, 第112回日本外科学会学術集会, Apr. 2012.
1861.	四方祐子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 腫瘍マーカーにHDAC1発現を加味した胃癌術後腹膜播種予測式の有用性, 第112回日本外科学会学術集会, Apr. 2012.
1862.	Motoya Chikakiyo, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也, Chie Takasu and Mitsuo Shimada : 胃癌におけるAID発現は分化型癌の進展に関与する, 第112回日本外科学会学術集会, Apr. 2012.
1863.	松本規子, Yusuke Arakawa, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎, 浅野間理仁, Hidenori Miyake and Mitsuo Shimada : ラット大量肝切除における脾臓内遺伝子発現の変化(第二報)Ingenuity Pathway Analysisを用いた検討, 第112回日本外科学会学術集会, Apr. 2012.
1864.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 術前化学放射線療法を併用した腹腔鏡下直腸切除術の肛門機能とQOL, 第112回日本外科学会学術集会, Apr. 2012.
1865.	中尾寿宏, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : KRAS遺伝子変異からみたTight Junctionを標的とした大腸がんの浸潤転移機構の解明, 第112回日本外科学会学術集会, Apr. 2012.
1866.	Masakazu Goto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 大腸癌におけるSirt1発現の低下は内臓肥満と癌進展に関係する, 第112回日本外科学会学術集会, Apr. 2012.
1867.	黒田武志, Chie Takasu, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Mitsuo Shimada : 長寿遺伝子Sirtuin familyのSIRT3は胃癌の進展に関与する可能性がある, 第112回日本外科学会学術集会, Apr. 2012.
1868.	寺奥大貴, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : Protein Kinase Ciota発現は胃癌の新たな予後予測因子となる, 第112回日本外科学会学術集会, Apr. 2012.
1869.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto and Chie Takasu : Metabolic surgeryとしてのDuodenal-Jejunal Bypassの有用性に関する研究, 第112回日本外科学会学術集会, Apr. 2012.
1870.	Chie Takasu, Keisuke Izumi, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto and 柏原秀也 : カロリー制限は大腸発がんを抑制する可能性がある, 第112回日本外科学会学術集会, Apr. 2012.
1871.	Masato Komatsu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : microRNA233はCell cycleを活性化することで直腸癌化学放射線治療感受性を高める可能性がある, 第112回日本外科学会学術集会, Apr. 2012.
1872.	Kouzou Yoshikawa, Chie Takasu, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Mitsuo Shimada : CPT-11はTight Junction障害とTNFα・NF-ҡB経路を介しBacterial Translocationを発症させる, 第112回日本外科学会学術集会, Apr. 2012.
1873.	Jun Higashijima, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, Masato Komatsu, Chie Takasu and 柏原秀也 : 大腸癌におけるmicroRNA223発現の意義についての研究(第二報), 第112回日本外科学会学術集会, Apr. 2012.
1874.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : ヒストンアセチル化により制御されるCD133とTHBS1発現に基づく胃癌の悪性度評価, 第112回日本外科学会学術集会, Apr. 2012.
1875.	Takashi Iwata, Mitsuo Shimada, Chie Takasu, 柏原秀也, Tomohiko Miyatani, Masakazu Goto, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka and Nobuhiro Kurita : 腹腔鏡下幽門側胃切除術Roux-en Y再建の胃閉鎖部に平行な胃空腸吻合は胃排出遅延を克服する, 第112回日本外科学会学術集会, Apr. 2012.
1876.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 腹腔鏡補助下胃切除術の定型化と地方におけるTelesurgery mentoring system導入の意義 ―地方における効率的な普及を目指して―, 第112回日本外科学会学術集会, Apr. 2012.
1877.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 局所進行下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術の妥当性, 第112回日本外科学会学術集会, Apr. 2012.
1878.	Tomohiko Miyatani, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Masakazu Goto, 柏原秀也, Chie Takasu and Mitsuo Shimada : 直腸癌に対するDPD阻害フッ化ピリミジンを用いた術前化学放射線療法のrandomized clinical trial ∼個別化治療を目指して∼, 第112回日本外科学会学術集会, Apr. 2012.
1879.	Mitsuo Shimada : 『発展しつづける中国の小児腫瘍の診療と研究』, 第53回中国四国小児がん研究会, Apr. 2012. (Keyword) 国内学会
1880.	淺野間理仁, Hiroki Mori, 齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Mami Kanamoto, Jun Hanaoka, 杉本光司 and 山田眞一郎 : 脾臓中TGF-β,IL-6発現が肝線維化,，肝再生に関与する, 第98回日本消化器病学会総会, Apr. 2012.
1881.	Toru Utsunomiya, 齋藤裕 and Mitsuo Shimada : 肝細胞癌の多中心性再発リスクに基づく治療法選択の可能性, 第98回日本消化器病学会総会, Apr. 2012. (Keyword) 国内学会
1882.	Mitsuo Shimada, Chie Takasu and Mami Kanamoto : 女性消化器医師が輝き続けるために:外科の立場からのキャリアアップ支援, 第98回日本消化器病学会総会, Apr. 2012. (Keyword) 国内学会
1883.	Takuya Tokunaga, Mitsuo Shimada, Hiroki Mori, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 齋藤裕, 淺野間理仁, 山田眞一郎 and Hidenori Miyake : Bevacizumab(Bev)が小胞体ストレス応答を介して肝切除後肝機能障害を改善する, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1884.	小笠原卓, 齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 淺野間理仁, 山田眞一郎, 杉本光司, Mami Kanamoto, Jun Hanaoka, Yusuke Arakawa, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : ヒト脂肪由来幹細胞はVEGFシグナルとは異なる経路で肝細胞傷害を軽減する, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1885.	西正暁, Mitsuo Shimada, Hiroki Mori, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 齋藤裕, 山田眞一郎, 淺野間理仁, Hidenori Miyake, Eiji Takeda, Hisami Okumura, 佐々木一, 青沼広光 and 川島昭浩 : 肝切除周術期の生体侵襲に対するMEIN(R)投与の有用性の検討―基礎的実験と臨床的評価―, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1886.	篠原永光, 山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, 齋藤裕 and 淺野間理仁 : 大腸癌肝転移におけるSDF-1/CXCR4 axisの影響に関する研究, 第112回日本外科学会定期学術集会, Apr. 2012.
1887.	金村普史, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕 and 山田眞一郎 : 肝転移を有する十二指腸乳頭部癌の外科的切除を中心とした集学的治療, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1888.	Hidenori Miyake, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎 and 淺野間理仁 : 幹細胞マーカーに着目した細胆管癌の悪性度に関する検討―肝内胆管癌との比較より―, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1889.	石川大地, 山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 淺野間理仁 and Hidenori Miyake : 肝硬変症例に対する脾摘後の肝再生に関する研究, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1890.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto and 齋藤裕 : 脂肪由来幹細胞の傷害膵島保護作用に関する研究, 第112回日本外科学会定期学術集会, Apr. 2012.
1891.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 淺野間理仁, 山田眞一郎, 杉本光司, Mami Kanamoto, Jun Hanaoka, Yusuke Arakawa, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : ヒト脂肪由来幹細胞の傷害肝へのhoming効果に関する研究, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1892.	Hiroki Mori, Hiroki Ishibashi, Horohiko Sato, 矢田圭吾 and Mitsuo Shimada : 最近経験した新生児卵巣嚢胞の3例, 第53回中国四国小児がん研究会, Apr. 2012. (Keyword) 国内学会
1893.	Shuichi Iwahashi, 杉本光司, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎, 淺野間理仁, Hidenori Miyake and Mitsuo Shimada : バルプロ酸は膵癌細胞株においてインターフェロンレセプター発現を高め,抗腫瘍効果を増強する, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1894.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 齋藤裕, Chie Takasu, 山田眞一郎 and 淺野間理仁 : 膵・胆管合流異常症の胆道上皮は発癌ポテンシャルを有する, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1895.	Yusuke Arakawa, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, 杉本光司, 齋藤裕, 淺野間理仁, 山田眞一郎, Hidenori Miyake and Mitsuo Shimada : Small-for-size graftにおける脾摘術は肝内のEGR1およびHO-1関連のpathwayを制御する, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1896.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 齋藤裕, 山田眞一郎 and 淺野間理仁 : ドレナージ領域切除を含む合理的拡大肝前区域切除術, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1897.	吉川雅登, 齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 淺野間理仁, 山田眞一郎, 杉本光司, Mami Kanamoto, Jun Hanaoka, Yusuke Arakawa, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 右肝切除後の尾状葉再生に関する研究―尾状葉付き拡大左葉グラフトとの比較―, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1898.	Hiroki Ishibashi, Hiroki Mori, Horohiko Sato, 矢田圭吾 and Mitsuo Shimada : 腹腔鏡補助下手術を施行した肝芽腫の1例, 第53回中国四国小児がん研究会, Apr. 2012. (Keyword) 国内学会
1899.	Akira Nii, Hiroki Ishibashi, 淺野間理仁, Hiroki Mori, Horohiko Sato and Mitsuo Shimada : キャリーオーバーした小児期発症胆道拡張症例の検討, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1900.	Hiroki Ishibashi, Hiroki Mori, Asanoma Michihito, Horohiko Sato and Mitsuo Shimada : 小児内鼠径部疾患におけるadvanced LPEC法の有用性, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1901.	川下陽一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 淺野間理仁 and 山田眞一郎 : より正確な系統的切除のための3D-volumetryを用いた右肝静脈周囲の門脈灌流領域に関する研究, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1902.	淺野間理仁, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, 杉本光司, 齋藤裕 and 山田眞一郎 : 脾臓中マクロファージによるTGF-β発現が肝硬変に関与する, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1903.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 山田眞一郎 and 淺野間理仁 : 紫苓湯(TJ-114)のislet xenotransolantationにおける異種移植免疫応答の減弱効果に関する研究, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1904.	杉本光司, 松本慎一, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎, 淺野間理仁, Hidenori Miyake and Mitsuo Shimada : ドナー特異的輸血とHistone deacetylase阻害剤の併用は膵島移植において免疫寛容を誘導する, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1905.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎 and 淺野間理仁 : ヒト脂肪由来幹細胞を用いた傷害臓器修復に関する研究, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1906.	開野友佳理, Mitsuo Shimada, Yuji Morine, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 予後不良因子を有する進行胆道癌切除例に対するGFP補助療法の有用性, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1907.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, 杉本光司, Shuichi Iwahashi, 齋藤裕, 淺野間理仁, 山田眞一郎 and Hidenori Miyake : 過小グラフトの病態における熱ショック蛋白(HSP)低下とその対策, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1908.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : ヒストンアセチル化制御による癌幹細胞を標的とした治療抵抗性克服の可能性, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1909.	Toru Utsunomiya, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 齋藤裕, 山田眞一郎, 淺野間理仁 and Hidenori Miyake : 肝発癌母地に着目した肝細胞癌の治療戦略―多中心性再発リスクに基づく治療法選択の可能性―, 第112回日本外科学会定期学術集会, Apr. 2012. (Keyword) 国内学会
1910.	Yuji Morine, Shuichi Iwahashi and Mitsuo Shimada : 高齢者消化器疾患の現状と対策:肝胆膵, 第99回日本消化器病学会総会, Mar. 2012.
1911.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and 柏原秀也 : Bevacizumab併用化学療法中に大腸穿孔・穿通をきたした症例の検討., 第48回日本腹部救急医学会, Mar. 2012.
1912.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌術後Roux-en-Y再建における内ヘルニア症例の検討., 第48回日本腹部救急医学会, Mar. 2012.
1913.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, 齋藤裕 and 浅野間理仁 : 脂肪由来幹細胞(ADSC)の傷害膵島保護作用に関する研究., 第39回日本膵・膵島移植研究会, Mar. 2012.
1914.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎 and 浅野間理仁 : TJ-114のporcine islet xenotransplantationにおける異種移植免疫応答の減弱効果に関する研究., 第39回日本膵・膵島移植研究会, Mar. 2012.
1915.	Tomohiko Miyatani, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 浅野間理仁 and 山田眞一郎 : 大腸癌肝転移に対する治療戦略—Conversionと化療の肝障害軽減を目指してー., 第45回制癌剤適応研究会, Mar. 2012.
1916.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 進行再発胃癌におけるthrombospondin 1発現からみた個別化治療への展開., 第45回制癌剤適応研究会, Mar. 2012.
1917.	Hiroki Mori, Hiroki Ishibashi, Horohiko Sato, 浅野間理仁, Mitsuo Shimada, Shuji Kondo, Maki Urushihara and Yukiko Kinoshita : 膀胱尿管逆流症術後に急性薬剤性腎不全を来した1小児例., 第20回徳島外科術後管理研究会, Feb. 2012.
1918.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌術後Roux-en-Y再建における内ヘルニア症例の検討., 第20回徳島外科術後管理研究会, Feb. 2012.
1919.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 大腸癌における細径鉗子を併用した腹腔鏡下単孔式回盲部切除., 第26回四国内視鏡外科研究会, Feb. 2012.
1920.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Masakazu Goto, Kashihara Hideya and Chie Takasu : Delay of Gastric emptying after Roux-en-Y Reconstruction in Laparoscopy Assisted Distal Gastrectomy., 第84回日本胃癌学会総会, Feb. 2012.
1921.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 化学療法著効例に対する外科切除の意義(手術は必要か・いつ手術するか・どこまで切除するか) 高度進行胃癌の集学的治療における外科手術の位置づけ, 日本胃癌学会総会記事, 154, Feb. 2012.
1922.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるoverlap法のピットホールと再建の工夫, 日本胃癌学会総会記事, 243, Feb. 2012.
1923.	Masakazu Goto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌に対する腹腔鏡下胃切除術の手術成績開腹手術の比較, 日本胃癌学会総会記事, 304, Feb. 2012.
1924.	Hiroki Mori, Hiroki Ishibashi, Horohiko Sato, 淺野間理仁, Mitsuo Shimada, Shuji Kondo, Maki Urushihara and Yukiko Kinoshita : 膀胱尿管逆流症術後に急性薬剤性腎不全を来した1小児例, 第20回徳島外科術後管理研究会, Feb. 2012. (Keyword) 国内学会
1925.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也 and Chie Takasu : 大腸癌治療ガイドラインでの肝転移に関する問題点と新たな治療戦略., 第76回大腸癌研究会, Jan. 2012.
1926.	Ahmed S. Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya and Mitsuo Shimada : Classification of liver segments based on blood vessel information using the portal phase of a CT dataset, IEICE Technical Report, Vol.111, No.389, 377-382, Jan. 2012.
1927.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto and Chie Takasu : 重篤な心肺腎合併症を有する胃癌手術は安全に施行可能か?, 日本胃癌学会総会記事, 216, 2012.
1928.	高島啓, Koji Yamaguchi, 原知也, 山崎宙, 小笠原梢, 坂東左知子, 發知淳子, 冨田紀子, 竹内秀和, Toshiyuki Niki, Takayuki Ise, Yuka Ueda, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Jun Hanaoka, Mitsuo Shimada and Masataka Sata : 真性多血症患者に発症した心原生脾梗塞の1例, 第99回日本循環器学会四国地方会, Dec. 2011.
1929.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 杉本光司, Mami Kanamoto, Jun Hanaoka, Yusuke Arakawa, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Hidenori Miyake : ヒト脂肪由来幹細胞はVEGFシグナルとは異なる経路で肝細胞傷害を軽減する., 第18回外科侵襲とサイトカイン研究会, Dec. 2011.
1930.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 進行肝癌術後の補助療法としてのIFP療法の有用性とソラフェニブの適応提案., 第39回日本肝臓学会西部会, Dec. 2011.
1931.	Toru Utsunomiya, Mitsuo Shimada and Satoru Imura : 非癌部肝組織の網羅的DNA・miRNA解析結果からみたNBNC肝癌の分子遺伝学的特徴., 第39回日本肝臓学会西部会, Dec. 2011.
1932.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 胆嚢摘出術における2mm細径鉗子を用いたreduced port surgery., 第24回日本内視鏡外科学会総会, Dec. 2011.
1933.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕 and Hidenori Miyake : 腹腔鏡下肝切除における術式定型化は可能である., 第24回日本内視鏡外科学会総会, Dec. 2011.
1934.	Toru Utsunomiya, Mitsuo Shimada, 山田眞一郎, 浅野間理仁, 齋藤裕, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 消化器外科領域における単孔式腹腔鏡手術の功罪., 第24回日本内視鏡外科学会総会, Dec. 2011.
1935.	Hiroki Mori, Mitsuo Shimada, Hiroki Ishibashi, Horohiko Sato and 浅野間理仁 : foregut duplication cystに対する鏡視下手術., 第24回日本内視鏡外科学会総会, Dec. 2011.
1936.	Hiroki Ishibashi, Hiroki Mori, Horohiko Sato, 浅野間理仁, Mitsuo Shimada, Akira Nii and 曽我美朋子 : 小児先天性門脈体循環シャント(Type2)に対する腹腔鏡下手術., 第24回日本内視鏡外科学会総会, Dec. 2011.
1937.	Chie Takasu, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Toru Utsunomiya and Hidenori Miyake : 肝転移を伴う大腸癌に対する腹腔鏡下の肝と大腸同時切除術の妥当性., 第24回日本内視鏡外科学会総会, Dec. 2011.
1938.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 柏原秀也 : 3D-MDCTによる中結腸静脈を意識した腹腔鏡下横行結腸癌手術., 第24回日本内視鏡外科学会総会, Dec. 2011.
1939.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and Masakazu Goto : 大腸癌における細径鉗子を併用した単孔式回盲部切除., 第24回日本内視鏡外科学会総会, Dec. 2011.
1940.	柏原秀也, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : 腹腔鏡下鼠径ヘルニア修復術の標準術式としての可能性., 第24回日本内視鏡外科学会総会, Dec. 2011.
1941.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : LATGの食道空腸吻合法にのけるステープリングディバイスを用いたoverlap法のピットホールと再建の工夫., 第24回日本内視鏡外科学会総会, Dec. 2011.
1942.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 腹腔鏡補助下胃切除術の定型化による技術認定医取得への加速化., 第24回日本内視鏡外科学会総会, Dec. 2011.
1943.	Takashi Iwata, Mitsuo Shimada, 柏原秀也, Chie Takasu, Masakazu Goto, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato and Nobuhiro Kurita : 腹腔鏡下胃切除術のトレーニングにおける開腹術からのフィードバックの有用性について., 第24回日本内視鏡外科学会総会, Dec. 2011.
1944.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 進行度別に検討した胃癌に対する腹腔鏡下胃切除手術の適応拡大., 第24回日本内視鏡外科学会総会, Dec. 2011.
1945.	Horohiko Sato, Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌における悪性度指標としてAID(activation-induced cytidine deaminase)発現の意義., 第24回日本バイオセラピィ学会学術集会総会, Dec. 2011.
1946.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Toru Utsunomiya : 下部直腸癌に対する化学放射線療法の効果予測因子としてのsurvivin発現 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 516, Nov. 2011. (Keyword) 直腸腫瘍 / 微小管結合蛋白質 / TS-1 / 放射線化学療法 / Survivin / Homo sapiens
1947.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Tetsuya Ikemoto, 山田眞一郎, 浅野間理仁, 杉本光司, Jun Hanaoka, Hiroki Mori, Yuji Morine and Satoru Imura : ヒト脂肪由来幹細胞の傷害肝へのhoming効果に関する研究., 第96回日本消化器病学会四国支部例会/第107回日本消化器内視鏡学会四国地方会, Nov. 2011.
1948.	Takashi Iwata, Mitsuo Shimada, 柏原秀也, Chie Takasu, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato and Nobuhiro Kurita : ラット小腸虚血再灌流傷害に対するGeranylgeranylacetone (GGA)誘導heat shock protein (HSP)の軽減効果の検討., 第96回日本消化器病学会四国支部例会/第107回日本消化器内視鏡学会四国地方会, Nov. 2011.
1949.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 浅野間理仁 : IPMNおよび早期膵癌における末梢血中Foxp3測定の意義., 第22回日本消化器癌発生学会総会, Nov. 2011.
1950.	Toru Utsunomiya, Mitsuo Shimada, Tetsuya Ikemoto, Satoru Imura, 山田眞一郎, 浅野間理仁, 齋藤裕, Hiroki Mori, Jun Hanaoka, Yuji Morine and Mami Kanamoto : 非癌部肝組織におけるmiRNA発現プロファイルに基づく肝発癌リスク予測の試み., 第22回日本消化器癌発生学会総会, Nov. 2011.
1951.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Hiroki Mori, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎, Hiroki Ishibashi and 浅野間理仁 : 膵・胆管合流異常における胆道上皮の分子生物学的検討—胆道上皮は発癌ポテンシャルを有するー., 第22回日本消化器癌発生学会総会, Nov. 2011.
1952.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto and Chie Takasu : Protein Kinase Ciota発現は胃癌の新たな予後予測因子となる., 第96回日本消化器病学会四国支部例会/第107回日本消化器内視鏡学会四国地方会, Nov. 2011.
1953.	Chie Takasu, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Jun Higashijima and 柏原秀也 : miRNA-223による直腸癌の化学放射線療法効果予測は可能か?, 第22回日本消化器癌発生学会総会, Nov. 2011.
1954.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : THBS1発現からみた胃癌腹膜橎種症例に対する個別化治療戦略., 第22回日本消化器癌発生学会総会, Nov. 2011.
1955.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也 and Chie Takasu : 局所高度進行直腸癌に対する術前化学放射線療法併用腹腔鏡下手術 (第66回日本大腸肛門病学会学術集会), Journal of the Japan Society of Coloproctology, Vol.64, No.9, 666, Nov. 2011. (Keyword) 直腸腫瘍(薬物療法,放射線療法,外科的療法); 腹腔鏡法; ネオアジュバント療法; 直腸切断術; *放射線化学療法 / ヒト; 中年(45∼64); 高齢者(65∼79); 高齢者(80∼); 男; 女
1956.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and Masakazu Goto : Volume Rendering Simulationによる中結腸静脈を意識した腹腔鏡下横行結腸癌手術 (第66回日本大腸肛門病学会学術集会), Journal of the Japan Society of Coloproctology, Vol.64, No.9, 653, Nov. 2011. (Keyword) 結腸腫瘍(外科的療法); 腸間膜静脈; 腹腔鏡法; 横行結腸(外科的療法) / *結腸静脈; 容積表現法 / ヒト; 中年(45∼64); 高齢者(65∼79); 高齢者(80∼); 男; 女
1957.	Shinya Morimoto, Nobuhiro Kurita, Kouzou Yoshikawa, Takashi Iwata, Masanori Nishioka, Tomohiko Miyatani, Horohiko Sato, 柏原秀也, Chie Takasu and Mitsuo Shimada : 腹腔鏡下横行結腸癌手術を安全に行うための3D-MDCTによるvolume rendering simulation, Journal of Japan Society of Computer Aided Surgery, Vol.13, No.3, 418-419, Nov. 2011.
1958.	Takashi Iwata, Chie Takasu, 柏原秀也, Masakazu Goto, Tomohiko Miyatani, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato, Nobuhiro Kurita and Mitsuo Shimada : PET-CT，Diffusion MRIを用いたGISTの悪性度診断, Journal of Japan Society of Computer Aided Surgery, Vol.13, No.3, 342-343, Nov. 2011.
1959.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 政清史晃, 原田雅文, Junji Ueno and Noboru Niki : 消化器癌におけるCADSによるリンパ節転移自動診断, Journal of Japan Society of Computer Aided Surgery, Vol.13, No.3, 174-175, Nov. 2011.
1960.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 術前3Dシミュレーションが可能にした右肝静脈合併切除とドレナージ領域を含む拡大肝前区域切除術 (第20回日本コンピュータ外科学会), Journal of Japan Society of Computer Aided Surgery, Vol.13, No.3, 352-353, Nov. 2011.
1961.	Hiroki Mori, Mitsuo Shimada, Hiroki Ishibashi, Horohiko Sato and 浅野間理仁 : 腹腔鏡下小児鼠径ヘルニア手術(LPEC法)術後に対側発症した1例., 第73回日本臨床外科学会総会, Nov. 2011.
1962.	Hiroki Ishibashi, Hiroki Mori, Horohiko Sato, 浅野間理仁, Mitsuo Shimada and Akira Nii : 小児鼠径部疾患に対する内視鏡下手術の現状., 第73回日本臨床外科学会総会, Nov. 2011.
1963.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 淺野間理仁, 山田眞一郎 and Hidenori Miyake : 癌取扱い規約のあり方 UICCとの歩み寄りは必要か? 肝癌切除例からみた癌取り扱い規約の問題点 UICCとの比較から見えたもの, Journal of Japan Surgical Association, Vol.72, 330, Nov. 2011. (Keyword) 肝細胞癌(診断); 腫瘍進行度; 保健医療水準保証 / TNM分類; *癌取扱い規約 / ヒト
1964.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 齋藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : 経験から学ぶ内視鏡下手術のトラブルシューティング(肝臓・胆道・膵臓) 腹腔鏡下肝切除術の短期治療成績の評価術中合併症対策を含めて, Journal of Japan Surgical Association, Vol.72, 343, Nov. 2011. (Keyword) 肝細胞癌(外科的療法); 肝切除(有害作用); 術中合併症; *腹腔鏡法(有害作用); 治療成績 / ヒト
1965.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 分枝型IPMNの治療方針手術適応，縮小手術の是非 IPMNにおける末梢血中Treg比率と局所IDO陽性細胞発現の関連性の検討, Journal of Japan Surgical Association, Vol.72, 360, Nov. 2011. (Keyword) 膵臓腫瘍(病理学); 免疫組織化学; 調節T細胞; Indoleamine 2,3-Dioxygenase / 膵管内乳頭腫瘍(病理学) / ヒト
1966.	Toru Utsunomiya, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 齋藤裕, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 大腸癌肝転移における新たな治療戦略切除不能大腸癌肝転移に対する肝切除へのconversionを目指した治療戦略, Journal of Japan Surgical Association, Vol.72, 372, Nov. 2011. (Keyword) Fluorouracil(治療的利用); Leucovorin(治療的利用); 肝切除; 肝臓腫瘍(転移性,薬物療法,外科的療法); 腫瘍多剤併用療法; 大腸腫瘍; ネオアジュバント療法; Irinotecan(治療的利用); Bevacizumab(治療的利用) / IFL Protocol / ヒト
1967.	Yuji Morine, Mitsuo Shimada, Hiroki Mori, 高松英夫 and 嶋田紘 : 膵胆管合流異常症における手術適応および術式の再検討膵・胆管合流異常の臨床的特徴と術式選択の現状日本膵・胆管合流異常研究会報告, Journal of Japan Surgical Association, Vol.72, 376, Nov. 2011. (Keyword) *膵胆管合流異常(外科的療法) / ヒト
1968.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, 齋藤裕 and 山田眞一郎 : 肝胆膵腫瘍病変における内視鏡下手術の適応拡大腹腔鏡下肝切除の定型化と肝内胆管癌への適応拡大, Journal of Japan Surgical Association, Vol.72, 420, Nov. 2011. (Keyword) 肝切除; 肝内胆管(外科的療法); 胆管癌(外科的療法); 胆管腫瘍(外科的療法); 腹腔鏡法 / ヒト
1969.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 安全確実なエネルギーデバイスを駆使した無結紮肝葉切除術, Journal of Japan Surgical Association, Vol.72, 434, Nov. 2011. (Keyword) 肝切除; 外科用機器; 電気凝固 / ヒト
1970.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, 荒川悠祐, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 膵頭十二指腸切除におけるVessel Sealing Systemによる安全・迅速な膵神経叢郭清, Journal of Japan Surgical Association, Vol.72, 488, Nov. 2011. (Keyword) 腫瘍侵入性; 膵頭十二指腸切除; 膵管癌(外科的療法) / ヒト
1971.	Satoru Imura, Mitsuo Shimada, 山田眞一郎, 淺野間理仁, 齋藤裕, Jun Hanaoka, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 高度肉眼的門脈侵襲陽性の進行肝癌に対する治療戦略, Journal of Japan Surgical Association, Vol.72, 510, Nov. 2011. (Keyword) 肝細胞癌(実験的); 門脈; *流血中腫瘍細胞 / マウス; 動物
1972.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 肝葉切除における中肝静脈右側切除領域に関するピットフォール, Journal of Japan Surgical Association, Vol.72, 511, Nov. 2011. (Keyword) 肝静脈(外科的療法); *肝切除 / ヒト
1973.	Hiroki Mori, Mitsuo Shimada, Yuji Morine, Horohiko Sato, Hiroki Ishibashi and Toru Utsunomiya : 膵胆管合流異常症の胆道上皮の分子生物学的検討胆道上皮は発癌ポテンシャルを有する, Journal of Japan Surgical Association, Vol.72, 623, Nov. 2011. (Keyword) Histone Deacetylases; 上皮(病理学); 胆道(病理学); 腫瘍過程; *膵胆管合流異常(病理学) / ヒト
1974.	江藤祥平, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 右肋骨弓下に挿入する細径鉗子はSILS胆摘導入を容易にする, Journal of Japan Surgical Association, Vol.72, 625, Nov. 2011. (Keyword) 鉗子; 肋骨; *腹腔鏡下胆嚢摘出術 / トロカール / ヒト
1975.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 山田眞一郎 and 浅野間理仁 : 肝右葉切除術後の残肝再生率の検討尾状葉・外側区域・内側区域の再生率の比較, Journal of Japan Surgical Association, Vol.72, 817, Nov. 2011. (Keyword) 肝再生; 肝細胞癌(外科的療法); 肝切除; 肝臓腫瘍(外科的療法,転移性) / 尾状葉 / ヒト
1976.	Takashi Iwata, Mitsuo Shimada, 柏原秀也, Chie Takasu, Masakazu Goto, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato and Nobuhiro Kurita : 食道胃接合部に存在するshort segment Barrett上皮のmalignant potentialからみた治療戦略について, Journal of Japan Surgical Association, Vol.72, 501, Nov. 2011. (Keyword) Barrett食道; 食道胃接合部; *食道腫瘍 / ヒト
1977.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕 and 浅野間理仁 : 脾摘後の肝再生に関する検討, Journal of Japan Surgical Association, Vol.72, 849, Nov. 2011. (Keyword) 肝硬変(外科的療法); 肝再生; *脾臓摘出術 / ヒト
1978.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 進行再発胃癌におけるthrombospondin 1(THBS 1)発現の意義個別化治療への展開, Journal of Japan Surgical Association, Vol.72, 483, Nov. 2011. (Keyword) 胃腫瘍(遺伝学,予後,治療); 腫瘍再発; Thrombospondin 1; オーダーメイド医療 / ヒト
1979.	柏原秀也, Mitsuo Shimada, Masanori Nishioka, Tomohiko Miyatani, Jun Higashijima, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Chie Takasu and Masakazu Goto : 下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術とmicroRNAを用いた効果予測, Journal of Japan Surgical Association, Vol.72, 457, Nov. 2011. (Keyword) 直腸腫瘍(薬物療法,放射線療法,外科的療法); 腹腔鏡法; 治療成績; ネオアジュバント療法; MicroRNAs; *放射線化学療法 / ヒト
1980.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 腹腔鏡下鼠径ヘルニア修復術(TAPP法)の合併症・再発ポイントとその対策, Journal of Japan Surgical Association, Vol.72, 451, Nov. 2011. (Keyword) 再発; 術後合併症; 鼠径ヘルニア(外科的療法); 腹腔鏡法 / ヒト; 成人(19∼44); 中年(45∼64); 高齢者(65∼79); 高齢者(80∼); 男; 女
1981.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるoverlap法のピットホールと再建の工夫, Journal of Japan Surgical Association, Vol.72, 448, Nov. 2011. (Keyword) 胃切除; 腹腔鏡法; 胃形成術; 食道空腸吻合術 / ヒト
1982.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and Masakazu Goto : 血管分岐バリエーションに対応した腹腔鏡下横行結腸癌手術 (第73回日本臨床外科学会総会), Journal of Japan Surgical Association, Vol.72, 418, Nov. 2011. (Keyword) 結腸腫瘍(外科的療法); 結腸切除; 術前診断; *腹腔鏡法; コンピュータシミュレーション; 横行結腸 / 結腸静脈 / ヒト
1983.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 大腸癌化学療法地域連携パス作成への試み (第73回日本臨床外科学会総会), Journal of Japan Surgical Association, Vol.72, 389, Nov. 2011. (Keyword) 術後管理; 大腸腫瘍(薬物療法,外科的療法); 多機関医療協力システム; 地域社会ネットワーク; クリティカルパス / ヒト
1984.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Masakazu Goto, 柏原秀也 and Chie Takasu : 術後深部静脈血栓症予防のための血液抗凝固療法における(第73回日本臨床外科学会総会), Journal of Japan Surgical Association, Vol.72, 364, Nov. 2011. (Keyword) Heparin(治療的利用); Enoxaparin(治療的利用); ランダム化比較試験; 静脈血栓症(予防); Fondaparinux Sodium(治療的利用) / ヒト
1985.	Chie Takasu, 八木恵子, 角瀬裕子, 開野友佳理, Mami Kanamoto, 片岡涼子, 久山寿子, 四方祐子, 松本規子 and Mitsuo Shimada : 女性外科医が外科医として活躍し続けるためのシステム構築に向けて女性外科医の実情と今後のシステム構築に向けて (第73回日本臨床外科学会総会), Journal of Japan Surgical Association, Vol.72, 361, Nov. 2011. (Keyword) 質問紙法; 女性医師; 病院外科部門; 職歴の移動 / ヒト; 女
1986.	山田眞一郎, 浅野間理仁, 齋藤裕, 杉本光司, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Mitsuo Shimada : 胆嚢癌に対する腹腔鏡補助下肝S4a+S5切除術., 第5回肝臓内視鏡外科研究会, Nov. 2011.
1987.	Satoru Imura, 山田眞一郎, 浅野間理仁, 齋藤裕, 杉本光司, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 原発性肝癌に対する鏡視下肝切除の短期・長期成績の検討., 第5回肝臓内視鏡外科研究会, Nov. 2011.
1988.	Mitsuo Shimada : 医と工のバッティング打率3割(マッティング)を目指して消化器外科領域における医工連携の現状と未来国民の負託に応えるべく日本発の機器製品化を早めるために (第20回日本コンピュータ外科学会), Journal of Japan Society of Computer Aided Surgery, Vol.13, No.3, 166-167, Nov. 2011.
1989.	Hiroki Ishibashi, Hiroki Mori, Horohiko Sato, 浅野間理仁, Mitsuo Shimada, Akira Nii and 曽我美朋子 : 小児鼠径部疾患に対する内視鏡下手術の現状(VW)., 第31回日本小児内視鏡外科・手術手技研究会, Oct. 2011.
1990.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Toru Utsunomiya : 下部直腸癌に対する化学放射線療法の効果予測因子としてのsurvivin発現., 第49回日本癌治療学会学術集会, Oct. 2011.
1991.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 浅野間理仁 and Hidenori Miyake : 高齢者に対する膵頭十二指腸切除術の妥当性に関する検討., 第49回日本癌治療学会学術集会, Oct. 2011.
1992.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, 杉本光司, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 切除不能大腸癌肝転移に対する化療後肝切除のベストタイミングと肝脾腫に与える影響., 第49回日本癌治療学会学術集会, Oct. 2011.
1993.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 齋藤裕, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Yuji Morine and Satoru Imura : TJ-48，TJ-137併用がStageIVb膵癌化学療法に与える影響に関する研究., 第49回日本癌治療学会学術集会, Oct. 2011.
1994.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 非癌部肝組織における分子遺伝学的特徴と肝発癌リスクに関する検討., 第49回日本癌治療学会学術集会, Oct. 2011.
1995.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 斎藤裕, 浅野間理仁 and Hidenori Miyake : 高齢者に対する膵頭十二指腸切除術の妥当性に関する検討, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 554, Oct. 2011. (Keyword) 十二指腸腫瘍(外科的療法) / 膵管内乳頭腫瘍(外科的療法) / Homo sapiens / 膵臓腫瘍(外科的療法) / 膵頭十二指腸切除 / 胆道腫瘍(外科的療法) / 高齢者(65∼79)
1996.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, 杉本光司, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 切除不能大腸癌肝転移に対する化療後肝切除のベストタイミングと肝脾腫に与える影響, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 606, Oct. 2011. (Keyword) Fluorouracil(毒性・副作用,治療的利用) / 肝脾腫大(予防,化学的誘発) / ヒト / Leucovorin(毒性・副作用,治療的利用) / 肝腫脹(予防,化学的誘発) / 肝切除 / 肝臓腫瘍(転移性,薬物療法,外科的療法) / 巨脾症(予防,化学的誘発) / 腫瘍多剤併用療法 / 大腸腫瘍 / Irinotecan(毒性・副作用,治療的利用) / Oxaliplatin(毒性・副作用,治療的利用) / Bevacizumab(治療的利用) / FOLFOXIRI Protocol(毒性・副作用)
1997.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 斉藤裕, 山田眞一郎 and 浅野間理仁 : 非癌部肝組織における分子遺伝学的特徴と肝発癌リスクに関する検討, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 612, Oct. 2011. (Keyword) 肝臓腫瘍(遺伝学) / Homo sapiens / 腫瘍過程 / 遺伝子発現プロファイリング / MicroRNAs
1998.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 胆道癌術後再発に対する肝切除導入効果の検証, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 673, Oct. 2011. (Keyword) 肝切除; 腫瘍再発; 胆道腫瘍(外科的療法,予後) / ヒト
1999.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 淺野間理仁, 山田眞一郎 and Hidenori Miyake : Aurora AおよびCD44発現からみた肝癌の臨床病理学的検討, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 686, Oct. 2011. (Keyword) 肝臓腫瘍(病理学,予後); CD44抗原; Protein-Serine-Threonine Kinases / Aurora Kinase / ヒト
2000.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 杉本光司, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 脂肪由来幹細胞はcell contactを介して肝癌細胞の増殖を増強する, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 777, Oct. 2011. (Keyword) 幹細胞; 肝臓腫瘍(実験的); 脂肪組織; 共培養技術; 細胞増殖; 腫瘍細胞系
2001.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 斎藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : 膵胆管合流異常症例における胆道癌発癌機構に関する検討, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 778, Oct. 2011. (Keyword) 胆道腫瘍(病因,病理学); 腫瘍過程; 免疫組織化学; 膵胆管合流異常(合併症,病理学) / ヒト
2002.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕 and 山田眞一郎 : 胆道癌に対し3度の根治的切除が可能であった1例, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 920, Oct. 2011. (Keyword) 肝切除; 空腸(外科的療法); 膵頭十二指腸切除; 腺癌(外科的療法); 総肝管(外科的療法); 胆道腫瘍(外科的療法) / 肝管空腸吻合術; 胆道再建術 / ヒト; 中年(45∼64); 男
2003.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Hiroki Ishibashi, Horohiko Sato, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 杉本光司, 斎藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : Bevacizumabの大量肝切除後における肝障害・肝再生改善効果の基礎研究, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 912, Oct. 2011. (Keyword) 肝再生; 肝切除; 肝臓疾患(病因,予防,実験的); 術後合併症; Wistarラット; Bevacizumab(薬理学,治療的利用) / ラット; 動物; オス
2004.	Masakazu Goto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu, Toru Utsunomiya, Hidenori Miyake, 和田大助 and 惣中康秀 : 胃癌術前進行度診断における腫瘍マーカーの有用性 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 794, Oct. 2011. (Keyword) Carcinoembryonic Antigen / 胃腫瘍 / 腫瘍関連糖質抗原 / 腫瘍進行度 / 腫瘍マーカー / 術前診断 / CA-125抗原 / CA-19-9抗原 / CA-72-4抗原 / Homo sapiens
2005.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and Masashi Akaike : スキルスラボのシミュレーターを駆使した医療トレーニングの有用性 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 727, Oct. 2011. (Keyword) 質問紙法 / 外科手術 / 腫瘍 / 医学生涯教育 / Homo sapiens
2006.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 徳島県における地域がん対策について (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 717, Oct. 2011. (Keyword) 腫瘍 / 多機関医療協力システム / 地域社会ネットワーク / クリティカルパス / Homo sapiens
2007.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : 胃癌におけるProtein Kinase Cι発現の意義 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 657, Oct. 2011. (Keyword) Protein Kinase C / 胃腫瘍 / Protein Kinase C Lambda / Homo sapiens
2008.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也 and Chie Takasu : 胃・大腸癌におけるPrognostic factorとしてのHDAC1・MTA1発現の意義, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 656, Oct. 2011. (Keyword) Histone Deacetylases / Repressor Proteins / 胃腫瘍 / 腺腫 / 大腸腫瘍 / ポリープ / Histone Deacetylase 1 / MTA1 Protein / Homo sapiens
2009.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Jun Higashijima, 柏原秀也 and Chie Takasu : 直腸癌の化学放射線療法耐性における癌幹細胞およびmiRNAの検討 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 645, Oct. 2011. (Keyword) 腫瘍幹細胞 / 腺癌 / 直腸腫瘍 / 放射線抵抗性 / 抗腫瘍剤耐性 / MicroRNAs / 放射線化学療法 / Homo sapiens
2010.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Masakazu Goto, 柏原秀也 and Chie Takasu : 下部直腸癌に対する術前化学放射線療法の適応と腹腔鏡下手術との併用 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 570, Oct. 2011. (Keyword) 直腸腫瘍 / 腹腔鏡法 / ネオアジュバント療法 / TS-1 / 放射線化学療法 / Homo sapiens
2011.	Masanori Nishioka, Hiroshi Okitsu, 三浦連人, 濱田円, 惣中康秀, 福田洋, Tsutomu Ando, 倉立真志, Shinya Morimoto, Tomohiko Miyatani and Mitsuo Shimada : 直腸癌に対するDPD阻害フッ化ピリミジンを用いた術前化学放射線療法の比較 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 569, Oct. 2011. (Keyword) Pyrimidines / 直腸腫瘍 / ネオアジュバント療法 / Tegafur-Uracil / TS-1 / 放射線化学療法 / Pyrimidine Fluoride
2012.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : PET-CT，DiffusionMRIからみたGISTの悪性度診断の可能性 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 486, Oct. 2011. (Keyword) MRI / X線CT / Gastrointestinal Stromal Tumor / 陽電子放射型断層撮影 / Standardized Uptake Value / 腫瘍悪性度 / PET-CT / Homo sapiens
2013.	後藤正和, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu, Toru Utsunomiya, Hidenori Miyake, 和田大助 and 惣中康秀 : 胃癌術前進行度診断における腫瘍マーカーの有用性, 第49回日本癌治療学会学術集会, Oct. 2011.
2014.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕 and 山田眞一郎 : IPMNにおいてJagged1は調節性T細胞を介し腫瘍悪性度を増強する., JDDW(日本消化器関連学会集会) 【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2015.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕, 浅野間理仁 and 山田眞一郎 : 後期高齢者の膵・胆道癌に対する膵頭十二指腸切除術の妥当性の検討., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2016.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 杉本光司, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 切除不能大腸癌肝転移症例に対する化療後肝切除のベストタイミングと化療の影響., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2017.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 非切除胆管癌に対する集学的治療—``Conversion''を目指してー., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2018.	Toru Utsunomiya, Mami Kanamoto, Jun Hanaoka, 山田眞一郎, 齋藤裕, 岩橋衆一, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Mitsuo Shimada, 浅野間理仁 and Hidenori Miyake : 非癌部肝組織の遺伝子発現・miRNA発現パターンに基づく肝発癌のリスクの分子診断., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2019.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : Dダイマーを加味した消化器癌における新たな合併症予測の可能性., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2020.	石川大地, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and 板東儀昭 : 大腸非上皮性腫瘍に対する鏡視下手術の有用性., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2021.	Masakazu Goto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami, Toru Utsunomiya and Hidenori Miyake : 胃癌における悪性度指標としてAID(activation-induced cytidine deaminase)発現の意義., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2022.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Toru Utsunomiya : 超高齢者における消化器疾患の診断と治療., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2023.	尾方信也, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : PET-CT，DiffusionMRIを組み合わせた新たなGISTの悪性度診断の可能性., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2024.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Masakazu Goto, 柏原秀也, Chie Mikami and Toru Utsunomiya : 肥満指標と胃・大腸癌進展との相関に関する検討., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2025.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 腹腔鏡下S状結腸切除，D3の標準化—外科医不足の地方からの提言—., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2026.	Takashi Iwata, Mitsuo Shimada, 柏原秀也, Chie Mikami, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato and Nobuhiro Kurita : ヒストン化学修飾に注目した大腸癌，胃癌，Barrett食道癌の悪性度に関する検討., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2027.	Shinya Morimoto and Mitsuo Shimada : 徳島大学肝疾患相談室について., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2028.	Nobuhiro Kurita, Mitsuo Shimada and Horohiko Sato : 胃癌腹膜橎腫に対するthrombospondin1(THBS1)発現を指標とした個別化治療への展開., JDDW(日本消化器関連学会集会)【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011.
2029.	齋藤裕, Mitsuo Shimada and Toru Utsunomiya : 肝疾患と幹細胞炎症，再生，発癌まで肝虚血再灌流傷害におけるヒト脂肪由来幹細胞homing effectの機序解明, JDDW(日本消化器関連学会集会) 【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Oct. 2011. (Keyword) 幹細胞; 肝臓疾患(合併症); 虚血(合併症,実験的); 再灌流損傷(合併症,実験的); ヌードマウス; BALB Cマウス / マウス; 動物
2030.	山田眞一郎, Mitsuo Shimada and Toru Utsunomiya : エピジェネティクスと消化器癌消化器癌における癌幹細胞マーカー発現の意義とエピジェネティック修飾による制御の可能性 (JDDW(日本消化器関連学会集会) 【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】), Acta Hepatologica Japonica, Vol.52, No.Suppl.2, A572, Oct. 2011. (Keyword) 腫瘍幹細胞; 消化器腫瘍(遺伝学); エピジェネティックプロセス / ヒト
2031.	山田眞一郎, Mitsuo Shimada and Toru Utsunomiya : エピジェネティクスと消化器癌消化器癌における癌幹細胞マーカー発現の意義とエピジェネティック修飾による制御の可能性, JDDW(日本消化器関連学会集会) 【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Vol.52, No.Suppl.2, A572, Oct. 2011. (Keyword) 腫瘍幹細胞; 消化器腫瘍(遺伝学); エピジェネティックプロセス / ヒト
2032.	淺野間理仁, Mitsuo Shimada and Toru Utsunomiya : 消化器疾患におけるprobioticsと機能性食品の有用性 Catechinの大量肝切除後における肝傷害抑制と肝再生促進効果, JDDW(日本消化器関連学会集会) 【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Vol.52, No.Suppl.2, A578, Oct. 2011. (Keyword) Catechin; 肝再生; 肝切除; Wistarラット; 肝線維症(実験的,予防,外科的療法) / ラット; 動物; オス
2033.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 膵癌における血中調節性T細胞を指標とした早期診断の可能性と理論的根拠, JDDW(日本消化器関連学会集会) 【第53回日本消化器病学会，第82回日本消化器内視鏡学会総会，第15回日本肝臓学会大会，第9回日本消化器外科学会】, Vol.108, A907, Oct. 2011. (Keyword) 膵臓腫瘍(診断); 膵管癌(診断); 早期診断; 調節T細胞 / 膵管内乳頭腫瘍(診断) / ヒト
2034.	後藤正和, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami, Toru Utsunomiya, Hidenori Miyake and Akira Tangoku : 胃癌における悪性度指標としてAID (activation-induced cytidine deaminase)発現の意義, JDDW2011(2011年度日本消化器関連学会週間), Oct. 2011.
2035.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 斎藤裕 and Hidenori Miyake : ヒト脂肪由来幹細胞(ADRCs)の傷害膵島保護作用に関する検討, 第47回日本移植学会総会, Vol.46, 203, Oct. 2011. (Keyword) Langerhans島; 脂肪組織; 組織培養技術; *間葉系幹細胞 / ブタ; 動物
2036.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 斉藤裕 and 松本慎一 : 膵島移植におけるdonor specific transfusionとhistone deacetylase inhibitorによる免疫寛容誘導の検討, 第47回日本移植学会総会, Vol.46, 206, Oct. 2011. (Keyword) Langerhans島移植(実験的); ドナー; 免疫寛容; 輸血(実験的); Histone Deacetylase Inhibitors / *ドナー特異的輸血(実験的) / マウス; 動物
2037.	Tetsuya Ikemoto, Mitsuo Shimada, 松本慎一, 岩橋衆一, Yuji Morine, Satoru Imura, Toru Utsunomiya and Jacque Banchereau : 各臓器移植における免疫寛容 IFN inducible IDO+形質細胞様樹状細胞による免疫寛容誘導, 第47回日本移植学会総会, Vol.46, 129, Oct. 2011. (Keyword) Interferons; 樹状細胞; 免疫寛容; Indoleamine 2,3-Dioxygenase / *形質細胞様樹状細胞
2038.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 山田眞一郎, 浅野間理仁, 杉本光司, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : ヒト脂肪由来幹細胞による肝虚血再灌流障害軽減効果に関する基礎的検討, 第47回日本移植学会総会, Vol.46, 254, Oct. 2011. (Keyword) 肝臓疾患(実験的,治療); 虚血(実験的,治療); 再灌流損傷(予防); BALB Cマウス; 間葉系幹細胞移植(実験的) / ヒト; マウス; 動物
2039.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Kouzou Yoshikawa, Jun Higashijima, Hideya Kashihara and Chie Mikami : Preoperative microRNA-223 predicts pathological response to the chemoradiotherapy in rectal cancer, Proceedings of the Japanese Cancer Association, 268, Oct. 2011.
2040.	Komatsu Masato, Tetsuro Yoshimaru, Taisuke Matsuo, Miyoshi Yasuo, Mitsuo Shimada, Nakamura Yusuke, Sasa Mitsunori, Miyano Satoru and Toyomasa Katagiri : Novel therapeutic strategy for Triple Negative Breast Cancer, Proceedings of the Japanese Cancer Association, 237, Oct. 2011.
2041.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Jun Higashijima, Kashihara Hideya and Chie Takasu : Investigation of relationship between Histone acetylation and Sonic Hedgehog pathway in colorectal cancer, Proceedings of the Japanese Cancer Association, 140, Oct. 2011.
2042.	Takashi Iwata, Mitsuo Shimada, Chie Mikami, Kashihara Hideya, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato and Nobuhiro Kurita : THBS1 can be both prognostic and predictive factor of stage IV gastric cancer, Proceedings of the Japanese Cancer Association, 58, Oct. 2011.
2043.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕 and 浅野間理仁 : Indoleamine 2, 3-dioxygenase (IDO) induced active regulatory Tcells play an important role in pancreatic neoplasms, Proceedings of the Japanese Cancer Association, 80, Oct. 2011.
2044.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎, 浅野間理仁, 岩橋衆一 and Hidenori Miyake : Role of CD 151 expression in gallbladde carcinoma, Proceedings of the Japanese Cancer Association, 122, Oct. 2011.
2045.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 山田眞一郎 and 浅野間理仁 : Valproic acid enhances the anti-tumor effect of pegylated interferon-alpha toward pancreatic cancer cell lines, Proceedings of the Japanese Cancer Association, 140, Oct. 2011.
2046.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 花岡潤, 杉本光司, 浅野間理仁 and 山田眞一郎 : 肝虚血再灌流傷害におけるヒト脂肪由来幹細胞ホーミング効果の機序解明 (第70回日本癌学会学術総会), Proceedings of the Japanese Cancer Association, 403-404, Oct. 2011.
2047.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕, 山田眞一郎 and 浅野間理仁 : miRNA expression profiles of non-tumor liver tissues in patients with hepatocellular carcinoma ( 70 ), Proceedings of the Japanese Cancer Association, 448, Oct. 2011.
2048.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 肝葉切除における中肝静脈右側切除領域に関する検討., 第6回肝癌治療シミュレーション研究会, Sep. 2011.
2049.	Hiroki Ishibashi, Hiroki Mori, Horohiko Sato and Mitsuo Shimada : 血流障害，遊走脾を伴った急性胃軸捻転症の1例., 第50回日本小児外科学会中国四国地方会, Sep. 2011.
2050.	Jun Hanaoka, Mitsuo Shimada and Toru Utsunomiya : 単孔式手術導入期におけるHybrid SILS-cholecystectomyの有用性, Journal of Japan Biliary Association, Vol.25, No.3, 393, Sep. 2011. (Keyword) 鉗子; *腹腔鏡下胆嚢摘出術 / ヒト; 男; 女
2051.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 非切除胆管癌に対する集学的治療 GFP療法から切除へ, Journal of Japan Biliary Association, Vol.25, No.3, 407, Sep. 2011. (Keyword) Cisplatin(治療的利用); Fluorouracil(治療的利用); 腫瘍多剤併用療法; 胆管癌(薬物療法,外科的療法); 胆管腫瘍(薬物療法,外科的療法); 胆道外科; 治療成績; ネオアジュバント療法; Gemcitabine(治療的利用) / *胆管切除術 / ヒト
2052.	Hiroki Mori, Mitsuo Shimada, 久山寿子, Hiroki Ishibashi, Horohiko Sato, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕, 浅野間理仁 and 山田眞一郎 : ラット胆管拡張症モデルを用いた膵・胆管合流異常症に関する実験的検討, Journal of Japan Biliary Association, Vol.25, No.3, 499, Sep. 2011. (Keyword) 疾患モデル(動物); 胆道腫瘍(化学的誘発,実験的); 有機スズ化合物(毒性・副作用); Ki-67抗原; Lewラット; 膵胆管合流異常(化学的誘発,実験的); 胆道拡張症(化学的誘発,実験的) / Dibutyldichlorotin(毒性・副作用) / ラット; 動物; オス
2053.	淺野間理仁, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, 齋藤裕 and 山田眞一郎 : 門脈圧亢進症における臓器相関肝・肺・腎・脾肝硬変症の脾臓では肝・脾連関によりTGF-βが高発現する, Japanese Journal of Portal Hypertension, Vol.17, No.3, 45, Sep. 2011. (Keyword) Transforming Growth Factor Beta; 肝硬変; *脾臓(病理学,外科的療法); 脾臓摘出術; 病理解剖 / ヒト
2054.	Hiroki Mori, Mitsuo Shimada, Satoru Imura, 浅野間理仁, 山田眞一郎, 斎藤裕, 杉本光司, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 肝硬変に対する外科的治療としての脾摘術の意義, Japanese Journal of Portal Hypertension, Vol.17, No.3, 50, Sep. 2011. (Keyword) 肝硬変(合併症,外科的療法); 肝切除(実験的); 肝臓腫瘍(合併症); 脾臓摘出術; Wistarラット; マイクロアレイ解析 / ヒト; ラット; 動物; 男; 女; オス
2055.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 斎藤裕, 山田眞一郎, 浅野間理仁, Hiroki Mori and Hidenori Miyake : Major shuntの有無に着目した肝硬変に対する脾摘術の効果, Japanese Journal of Portal Hypertension, Vol.17, No.3, 121, Sep. 2011. (Keyword) 肝硬変(外科的療法); 肝循環; 脾臓摘出術 / ヒト
2056.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 浅野間理仁 and Hiroki Ishibashi : 胆嚢摘出術を施行後，20年経過して胆管癌を発症した胆管非拡張型膵・胆管合流異常の1例, 日本膵・胆管合流異常研究会プロシーディングス, Vol.34, 46-47, Sep. 2011. (Keyword) 腫瘍マーカー; 胆管癌(X線診断,外科的療法,合併症); 胆管腫瘍(X線診断,外科的療法,合併症); 内視鏡的逆行性胆道膵管造影; X線CT; 胆嚢摘出術; 致死的転帰; 膵胆管合流異常(X線診断,外科的療法,合併症); 病理解剖 / 内視鏡的胆管ドレナージ / ヒト; 高齢者(65∼79); 男
2057.	Hiroki Mori, Mitsuo Shimada, Yuji Morine, Horohiko Sato, Hiroki Ishibashi, Toru Utsunomiya and 浅野間理仁 : 膵・胆管合流異常症の胆道上皮における分子生物学的検討, 日本膵・胆管合流異常研究会, Vol.34, 52, Sep. 2011. (Keyword) Histone Deacetylases; 遺伝子発現; 腫瘍マーカー; 上皮; 胆道; Ki-67抗原; *膵胆管合流異常(外科的療法,遺伝学) / ヒト
2058.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, 岩橋衆一, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 膵頭十二指腸切除術におけるVessel sealing systemを用いた安全かつ迅速な膵背側離断., 第65回手術手技研究会, Sep. 2011.
2059.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Toru Utsunomiya : 腹腔鏡補助下胃全摘術の食道空腸吻合法におけるoverlap法の有用性に関する検討., 第65回手術手技研究会, Sep. 2011.
2060.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka and Mami Kanamoto : 画像上極めて特異な像を示した高度脂肪化を伴うHCCの1症例., 第55回日本消化器画像診断研究会, Sep. 2011.
2061.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 杉本光司, 齋藤裕 and 山田眞一郎 : 腹腔鏡下肝切除における術式定型化とその工夫., 第86回中国四国外科学会総会/第16回中国四国内視鏡外科研究会, Sep. 2011.
2062.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるステープリングディバイスを用いたOverlap法のピットホールと再建の工夫., 第86回中国四国外科学会総会/第16回中国四国内視鏡外科研究会, Sep. 2011.
2063.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 柏原秀也 : 腹腔鏡下S状結腸切除における左結腸動脈温存No253郭清., 第86回中国四国外科学会総会/第16回中国四国内視鏡外科研究会, Sep. 2011.
2064.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 単孔式腹腔鏡ヘルニア修復術の検討., 第9回日本ヘルニア学会学術集会, Sep. 2011.
2065.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎 and 浅野間理仁 : C型肝硬変に対するABO不適合肝移植後の低用量Peg-IFN/RBV療法の有用性., 第29回中国四国臨床臓器移植研究会, Aug. 2011.
2066.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 杉本光司, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : ヒト脂肪由来幹細胞による肝傷害軽減効果に関する基礎的検討., 第29回日本ヒト細胞学会学術集会, Aug. 2011.
2067.	Takashi Iwata, Mitsuo Shimada, 小松正人, 柏原秀也, Chie Takasu, Masakazu Goto, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Horohiko Sato and Nobuhiro Kurita : ヒト脂肪由来幹細胞は膵癌，大腸癌細胞の増殖を抑制する., 第29回日本ヒト細胞学会学術集会, Aug. 2011.
2068.	Toru Utsunomiya, Mitsuo Shimada and Mami Kanamoto : 原発性肝がんに対する腹腔鏡下肝切除術の役割., 第81回日本消化器内視鏡学会総会, Aug. 2011.
2069.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 浅野間理仁 : 脂肪組織由来幹細胞は膵β細胞障害を軽減する., 第243回徳島医学会学術集会, Jul. 2011.
2070.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 山田眞一郎, 浅野間理仁, Hiroki Mori and Hidenori Miyake : 膵癌における調節性T細胞を指標とした早期診断の可能性と理論的根拠., 第243回徳島医学会学術集会, Jul. 2011.
2071.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 小松正人, 柏原秀也, Chie Mikami and Tomomi Kuwahara : 腸管ストレスに対する大建中湯の効果, Shikoku Acta Medica, Vol.67, No.5-6, 283, Jul. 2011. (Keyword) 絶食; 腸; 非ステロイド系抗炎症剤(薬理学); 大建中湯(薬理学); ミクロフローラ / 腸内細菌叢 / ラット; 動物
2072.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and 柏原秀也 : 術前imatinib投与と鏡視下手術により肛門温存が可能であった直腸GISTの1例, Shikoku Acta Medica, Vol.67, No.5-6, 292, Jul. 2011. (Keyword) 肛門部; 直腸腫瘍(薬物療法,外科的療法); 腹腔鏡法; ネオアジュバント療法; Gastrointestinal Stromal Tumor(薬物療法,外科的療法); *Imatinib(治療的利用) / ヒト; 中年(45∼64); 男
2073.	Tovuu Lkhagva-Ochir, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, Syuichi Iwahashi, Yu Saito, Nobuhiro Kurita and Hidenori Miyake : CD44 expression in the non-tumor tissues is correlated to the prognosis of the patients with hepatocellular carcinoma., 第47回日本肝癌研究会, Jul. 2011.
2074.	齋藤裕, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : Case report multiple cancer of liver, stomach and lung which is difficult to make differential diagnosis and to decide on courses of treatment., 第47回日本肝癌研究会, Jul. 2011.
2075.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : Clinicopathological features on long-term survival after hepatic resection for hepatocellular carcinoma., 第47回日本肝癌研究会, Jul. 2011.
2076.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 齋藤裕, 山田眞一郎 and 浅野間理仁 : Hepatoprotective effect and reductive effect of splenomegaly by using bevacizumab in L-OHP regimen., 第47回日本肝癌研究会, Jul. 2011.
2077.	山田眞一郎, Mitsuo Shimada, 浅野間理仁, 齋藤裕, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 症例., 第47回日本肝癌研究会, Jul. 2011.
2078.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : Cholangiolocellular ccarcinoma has a feature of a progenitor cell origin., 第47回日本肝癌研究会, Jul. 2011.
2079.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕, Mami Kanamoto and Hidenori Miyake : Standardization for laparoscopic hepatectomy of hepatocellular carcinoma., 第47回日本肝癌研究会, Jul. 2011.
2080.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori and Jun Hanaoka : Treatment strategy for avoiding small -for-size graft in LDLT using left lobe graft., 第47回日本肝癌研究会, Jul. 2011.
2081.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 浅野間理仁 and 山田眞一郎 : Treatment strategy by molecular and genetics approach for non-B non-C hepatocellular caracinoma., 第47回日本肝癌研究会, Jul. 2011.
2082.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, 山田眞一郎, 浅野間理仁, 齋藤裕, 岩橋衆一, Hiroki Mori, Jun Hanaoka, Tetsuya Ikemoto and Yuji Morine : Prediction and treatment strategy for recurrent hepatocellular carcinoma based on the profiles of both gene and miRNA expressions., 第47回日本肝癌研究会, Jul. 2011.
2083.	Takashi Iwata, Masashi Akaike, Masami Nagamune, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka and Hiroshi Okitsu : 地域で研修する若手医師に対する大腸癌鏡下手術の教育における問題点と対策:地方からの提言, 第43回日本医学教育学会大会, Jul. 2011.
2084.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, 浅野間理仁, 山田眞一郎, 齋藤裕, 岩橋衆一, Hiroki Mori, Jun Hanaoka, Tetsuya Ikemoto and Yuji Morine : 尾状葉付き拡大左葉グラフトの術後尾状葉再生率に関する検討., 第29回日本移植研究会, Jul. 2011.
2085.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 山田眞一郎 and 浅野間理仁 : ヒト脂肪由来幹細胞による肝細胞障害軽減効果に関する基礎的検討., 第29回日本移植研究会, Jul. 2011.
2086.	Hiroki Mori, Hiroo Takehara, 久山寿子, Horohiko Sato, Hiroki Ishibashi and Mitsuo Shimada : 食道重複症に対し腹腔鏡下摘出術を施行した1例., 第48回日本小児外科学会学術集会, Jul. 2011.
2087.	Mitsuo Shimada : 転移性肝癌における新たな治療戦略-Conversionと肝障害軽減を目指して, 第66回日本消化器外科学会総会, Jul. 2011.
2088.	Mitsuo Shimada : 新しいエネルギーデバイスの可能性., 第66回日本消化器外科学会総会, Jul. 2011.
2089.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, 岩橋衆一, Hiroki Mori, Mami Kanamoto and Hidenori Miyake : EOB-MRIを用いた肝切除術前検査のone stop shopping, 日本消化器外科学会総会, 207, Jul. 2011. (Keyword) 肝切除; 肝機能検査; MRI; 術前診断; Gadoxetic Acid(診断的利用) / ヒト
2090.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕 and Hidenori Miyake : 胆管非拡張型膵・胆管合流異常に対する診断と治療全国集計からみた膵・胆管合流異常の特徴と当科における症例の発癌関連遺伝子発現の評価, 日本消化器外科学会総会, 260, Jul. 2011. (Keyword) 遺伝子発現; 胆管癌(病因); 胆管腫瘍(病因); 胆嚢腫瘍(病因); 腫瘍過程; 膵胆管合流異常(合併症,遺伝学,外科的療法) / ヒト
2091.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto and Hidenori Miyake : 消化器癌に対する分子生物学の臨床応用(肝胆膵・上部消化管) 肝発癌における非癌部肝組織miRNA発現の意義, 日本消化器外科学会総会, 268, Jul. 2011. (Keyword) 肝細胞癌(遺伝学); 腫瘍過程; MicroRNAs / ヒト
2092.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto and Hidenori Miyake : 最新デバイスを駆使した無結紮肝葉切除術の定型化若手外科医の習熟のための工夫, 日本消化器外科学会総会, 441, Jul. 2011. (Keyword) *肝切除; 医学生涯教育; 外科的ステープリング / ヒト
2093.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一 and Hidenori Miyake : 高度脈管侵襲陽性肝癌術後のSystemic IFN+low-dose FPの有用性理論的根拠と臨床成績, 日本消化器外科学会総会, 442, Jul. 2011. (Keyword) Cisplatin(治療的利用); Interferons(治療的利用); Polyethylene Glycols(治療的利用); 肝細胞癌(実験的,外科的療法,薬物療法); 腫瘍多剤併用療法(実験的); 腫瘍侵入性; 流血中腫瘍細胞; アジュバント化学療法(実験的); 治療成績; Tegafur-Uracil(治療的利用) / Polyethylene Glycol-Interferons(治療的利用); *FP Protocol / マウス; 動物
2094.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka and Mami Kanamoto : 宿主免疫学反応から見たIPMNの手術適応, 日本消化器外科学会総会, 444, Jul. 2011. (Keyword) 膵臓腫瘍(外科的療法,病理学); 調節T細胞 / 膵管内乳頭腫瘍(外科的療法,病理学) / ヒト
2095.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, Mami Kanamoto and Hidenori Miyake : 腹腔鏡下肝切除術の低侵襲性の検証開腹vs.補助下vs.完全鏡視下, 日本消化器外科学会総会, 467, Jul. 2011. (Keyword) 開腹術; 肝切除; 腹腔鏡法; *最小侵襲手術 / ヒト
2096.	Toru Utsunomiya, Mitsuo Shimada, Mami Kanamoto, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 進行大腸癌肝転移例に対する治療のコンセプト肉眼的根治を目指した化療導入による肝切除へのconversion, 日本消化器外科学会総会, 504, Jul. 2011. (Keyword) 肝切除; 肝臓腫瘍(転移性,外科的療法,薬物療法); *大腸腫瘍 / ヒト
2097.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, 斎藤裕 and Hidenori Miyake : 障害肝に対する肝予備能評価アシアロシンチグラフィーとEOB-MRIの応用, 日本消化器外科学会総会, 516, Jul. 2011. (Keyword) 肝機能検査; MRI; *放射性核種イメージング; Gadoxetic Acid(診断的利用); 黄疸-閉塞性 / ヒト
2098.	Masakazu Goto, 三浦連人, 木下貴史, 松山和男, Tadaoki Morimoto, Masanori Nishioka, Mitsuo Shimada and Seiki Tashiro : 下部直腸癌に対する術前化学放射線療法の効果 (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 841, Jul. 2011. (Keyword) 直腸腫瘍 / 治療成績 / ネオアジュバント療法 / 放射線化学療法 / Homo sapiens
2099.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 超高齢胃癌・大腸癌患者に対する縮小手術は標準となるか? (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 566, Jul. 2011. (Keyword) 胃腫瘍 / 胃切除 / 大腸腫瘍 / 80歳以上高齢者 / 大腸切除 / Homo sapiens
2100.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也 and Chie Mikami : 心肺腎合併症を有する胃・大腸癌手術は安全に施行可能か? (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 547, Jul. 2011. (Keyword) 胃腫瘍 / 心臓疾患 / 腎臓疾患 / 大腸腫瘍 / interstitial lung disease / Homo sapiens
2101.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 根治切除不能胃癌に対する術前化学療法の意義と個別化への試み (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 496, Jul. 2011. (Keyword) 胃腫瘍 / 胃切除 / ネオアジュバント療法 / Homo sapiens
2102.	Takashi Iwata, Mitsuo Shimada, Chie Mikami, 柏原秀也, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka and Nobuhiro Kurita : 腹腔鏡下幽門側胃切除術後Roux-en Y再建のピットフォールとしての胃排出遅延について (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 413, Jul. 2011. (Keyword) 胃切除 / 胃内容排出 / 消化不良 / 腹腔鏡法 / Roux-en-Y吻合術 / 幽門 / Homo sapiens
2103.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 単孔式腹腔鏡下鼠径ヘルニア修復術の有用性 (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 390, Jul. 2011. (Keyword) 鼠径ヘルニア / 腹腔鏡法 / 治療成績 / Homo sapiens
2104.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Toru Utsunomiya : 下部直腸癌に対する化学放射線療法併用腹腔鏡下ISR (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 379, Jul. 2011. (Keyword) 直腸腫瘍 / 腹腔鏡法 / 直腸切除 / 放射線化学療法 / 吻合術 / 肛門括約筋温存術 / Homo sapiens
2105.	中尾寿宏, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 大腸癌化学療法の副作用対策としての漢方治療 (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 340, Jul. 2011. (Keyword) 食欲不振 / 末梢神経系疾患 / Cetuximab / Oxaliplatin / 牛車腎気丸 / 十全大補湯 / Homo sapiens
2106.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Mikami : Rubino手術による糖尿病改善効果のメカニズムに関する研究 (第66回日本消化器外科学会総会), 日本消化器外科学会総会, 302, Jul. 2011. (Keyword) 消化器外科 / 耐糖能障害 / 十二指腸空腸吻合術 / rat
2107.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 術前化学放射線療法を併用した腹腔鏡下直腸切除術の工夫と肛門機能 (第66回日本消化器外科学会総会), 日本消化器外科学会総会, Jul. 2011. (Keyword) 肛門部; 直腸腫瘍(薬物療法,外科的療法,放射線療法); 腹腔鏡法; ネオアジュバント療法; 直腸切除; *放射線化学療法 / Homo sapiens
2108.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Masakazu Goto, 柏原秀也 and Chie Takasu : 大腸癌肝転移症例における新たな細分類に関する検討., 第75回大腸癌研究会, Jul. 2011.
2109.	Ahmed Shawky Maklad, Mikio Matsuhiro, Hidenobu Suzuki, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya and Mitsuo Shimada : Extraction of liver volumetry based on blood vessel anatomy from portal phase CT dataset, IEICE Technical Report, Vol.111, No.127, 55-59, Jul. 2011.
2110.	石川大地, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 齋藤裕, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 初発および再発細胆管細胞癌に対して外科的切除を施行した1例., 第95回日本消化器病学会四国支部例会, Jun. 2011.
2111.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 浅野間理仁 : 脂肪由来幹細胞(ADRCs)は液性因子による障害膵島保護作用を有する., 第95回日本消化器病学会四国支部例会, Jun. 2011.
2112.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 細径鉗子を用いたHybrid SILS-cholecystectomyの有用性に関する検討., 95回日本消化器病学会四国支部例会, Jun. 2011.
2113.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 山田眞一郎 and 浅野間理仁 : IPMN悪性度判定においてJagged1発現は有用である., 95回日本消化器病学会四国支部例会, Jun. 2011.
2114.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 浅野間理仁 : Bevacizumabの大量肝切除後における肝障害・肝再生改善効果の基礎検討., 第95回日本消化器病学会四国支部例会, Jun. 2011.
2115.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 齋藤裕, 山田眞一郎 and 浅野間理仁 : One stop shoppingに施行可能なEOB-MRIを用いた肝切除術前検査., 第95回日本消化器病学会四国支部例会, Jun. 2011.
2116.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : Rubino手術による糖尿病改善効果に関する研究., 第95回日本消化器病学会四国支部例会, Jun. 2011.
2117.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Horohiko Sato, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and 柏原秀也 : 四国における進行・再発結腸・直腸癌患者に対するUGT1A1遺伝子多型別塩酸イリノテカンの用量に関する探索的試験., 第95回日本消化器病学会四国支部例会, Jun. 2011.
2118.	Horohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Jun Higashijima, 柏原秀也 and Chie Takasu : ヒストンアセチル化はMTA1とSonic Hedgehog pathwayを介し，大腸癌の発癌・進展に関与する., 第95回日本消化器病学会四国支部例会, Jun. 2011.
2119.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Hidenori Miyake : 再生医療の現状と将来展望ヒト脂肪由来幹細胞の肝再生における役割, Journal of Japanese College of Surgeons, Vol.36, No.3, 345, Jun. 2011. (Keyword) Heparin(薬理学); 肝再生; 幹細胞; 細胞生存; 脂肪組織; 共培養技術; BALB Cマウス; 肝細胞; 再生医学; *幹細胞移植(実験的) / ヒト; マウス; 動物
2120.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 肝胆膵悪性腫瘍手術における血行再建肝細胞癌に対する左葉グラフト肝移植における肝静脈再建吻合口拡大のための工夫, Journal of Japanese College of Surgeons, Vol.36, No.3, 370, Jun. 2011. (Keyword) 肝細胞癌(外科的療法); 肝静脈(外科的療法); 肝臓移植; 血管外科; *吻合術 / ヒト
2121.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 進行肝細胞癌に対するSorafenibの使用経験及び著効例の検討, Journal of Japanese College of Surgeons, Vol.36, No.3, 391, Jun. 2011. (Keyword) 肝細胞癌(薬物療法); 治療成績; Sorafenib(治療的利用,毒性・副作用) / ヒト
2122.	Satoru Imura, Mitsuo Shimada, 山田眞一郎, 淺野間理仁, 齋藤裕, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 超高齢者肝細胞癌に対する肝切除術の妥当性の検討, Journal of Japanese College of Surgeons, Vol.36, No.3, 529, Jun. 2011. (Keyword) 肝細胞癌(外科的療法,病理学,予後); 肝切除; *高齢者保健医療サービス; 治療成績 / ヒト; 高齢者(80∼); 歯学
2123.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Toru Utsunomiya : 胃癌手術に対するMDCTを用いた術前シミュレーションの意義 (第36回日本外科系連合学会学術集会), Journal of Japanese College of Surgeons, Vol.36, No.3, 564, Jun. 2011. (Keyword) 胃腫瘍(外科的療法,X線診断); 胃切除; 腹腔鏡法; コンピュータシミュレーション; *マルチスライスCT / ヒト
2124.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也 and Chie Mikami : 機能温存手術の適応と治療成績(2) 化学放射線療法を併用した腹腔鏡下直腸切除術の肛門機能 (第36回日本外科系連合学会学術集会), Journal of Japanese College of Surgeons, Vol.36, No.3, 406, Jun. 2011. (Keyword) 直腸腫瘍(外科的療法,薬物療法,放射線療法); 排便; 腹腔鏡法; 直腸切除; 放射線化学療法 / ヒト
2125.	Yuji Morine, Mitsuo Shimada, 高松英夫 and 嶋田紘 : 膵・胆管合流異常と癌発生率膵・胆管合流異常研究会全国集計から, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 129, Jun. 2011. (Keyword) *膵胆管合流異常(疫学) / ヒト
2126.	Toru Utsunomiya, Mitsuo Shimada, 斉藤裕, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 肝胆膵外科手術の安全性，根治性を高める画像解析と術前シミュレーション肝切除術前シミュレーションとしてのEOB-MRIの応用 3D-volumetryの融合による肝機能と肝容積の同時評価, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 157, Jun. 2011. (Keyword) 肝切除; 肝臓(画像診断); MRI; 術前診断; 臓器サイズ; コンピュータシミュレーション; 三次元イメージング; Gadoxetic Acid(診断的利用) / ヒト
2127.	淺野間理仁, Mitsuo Shimada, 山田眞一郎, 齋藤裕, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 転移性肝癌における手術適応とタイミング切除不能大腸癌肝転移例に対する化療後肝切除のタイミングと化療の影響, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 178, Jun. 2011. (Keyword) 肝切除; 肝臓腫瘍(転移性,外科的療法,薬物療法); *大腸腫瘍 / ヒト
2128.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 単孔式腹腔鏡下胆嚢摘出術従来法との比較(2) 細径鉗子を用いたHybrid SILSの有用性に関する検討, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 206, Jun. 2011. (Keyword) 鉗子; *腹腔鏡下胆嚢摘出術; 治療成績 / トロカール / ヒト; 男; 女
2129.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 次世代の肝胆膵外科を目指してヒト脂肪由来幹細胞による肝再生療法に関する基礎的検討, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 222, Jun. 2011. (Keyword) 肝再生; 細胞分化; 脂肪組織(移植); 肝細胞; 幹細胞移植(実験的) / ヒト; マウス; 動物
2130.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : 高度肉眼的門脈侵襲陽性の進行肝癌に対する治療戦略, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 243, Jun. 2011. (Keyword) Cisplatin(治療的利用); Interferons(治療的利用); Polyethylene Glycols(治療的利用); 肝細胞癌(実験的,薬物療法); 腫瘍多剤併用療法; 門脈; *流血中腫瘍細胞; Tegafur-Uracil(治療的利用) / Polyethylene Glycol-Interferons(治療的利用); FP Protocol / マウス; 動物
2131.	Mami Kanamoto, Mitsuo Shimada, Yuji Morine, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 胆膵領域癌における有用な術前，術後補助療法進行胆道癌に対するGFP療法の有用性, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 248, Jun. 2011. (Keyword) Cisplatin(治療的利用); 腫瘍多剤併用療法; 胆道腫瘍(薬物療法); 治療成績; Gemcitabine(治療的利用); Tegafur-Uracil(治療的利用) / *FP Protocol / ヒト
2132.	Toru Utsunomiya, Mitsuo Shimada, 斉藤裕, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 安全かつ確実な腹腔鏡下肝切除術を目指して(1) 腹腔鏡下肝切除術の短期治療成績の評価および術中合併症対策, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 256, Jun. 2011. (Keyword) 肝細胞癌(外科的療法); 肝切除(有害作用); 空気塞栓症(病因,予防); 術中合併症; 腹腔鏡法(有害作用); 失血-外科(病因,予防); 治療成績 / ヒト
2133.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 肝切除術の新たな工夫(2) 若手にも導入容易なエネルギーデバイスを駆使した無結紮肝葉切除術, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 265, Jun. 2011. (Keyword) 肝切除(有害作用); 電気凝固; 失血-外科(病因,予防); 超音波メス / ヒト
2134.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Mami Kanamoto, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : Vessel sealing systemによる神経叢郭清, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 282, Jun. 2011. (Keyword) 腫瘍侵入性; リンパ節郭清; 上腸間膜動脈; 膵管癌(外科的療法) / ヒト
2135.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 齋藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : CACS(celiac axis compression syndrome)により術後管理に難渋した膵頭十二指腸切除の1例, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 344, Jun. 2011. (Keyword) 病的狭窄(合併症,外科的療法); 十二指腸疾患(合併症,外科的療法); 術後管理; 膵頭十二指腸切除 / 腹腔動脈起始部圧迫症候群(合併症) / ヒト; 男
2136.	Toru Utsunomiya, Mitsuo Shimada and Hidenori Miyake : 非癌部肝組織の分子遺伝学的特徴に基づくテーラーメード医療への展開, Acta Hepatologica Japonica, Vol.52, No.Suppl.1, A31, Jun. 2011. (Keyword) Alpha-Fetoproteins; Creatine Kinase; 肝炎-B型(合併症); 肝炎-C型(合併症); 肝硬変(合併症,病因,治療); 肝細胞癌(合併症,治療,診断); MRI; X線CT; Acarboxyprothrombin; オーダーメイド医療; Mitochondrial Form Creatine Kinase / ラジオ波焼灼術 / ヒト
2137.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Mami Kanamoto, 岩橋衆一, 齋藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 非B非C型肝癌再発に対する分子遺伝学的治療戦略遺伝子およびmiRNA発現のハイブリッド解析から, Acta Hepatologica Japonica, Vol.52, No.Suppl.1, A62, Jun. 2011. (Keyword) 肝細胞癌(遺伝学,外科的療法); 肝切除; 腫瘍再発; 遺伝子チップ; MicroRNAs / ヒト
2138.	Toru Utsunomiya, Mitsuo Shimada, 浅野間理仁, 齋藤裕, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 切除不能大腸癌肝転移例に対する肉眼的根治を目指した外科的治療戦略, Acta Hepatologica Japonica, Vol.52, No.Suppl.1, A131, Jun. 2011. (Keyword) Fluorouracil(治療的利用); Leucovorin(治療的利用); 肝切除(実験的); 肝臓腫瘍(転移性,外科的療法,薬物療法); 腫瘍多剤併用療法; 疾患モデル(動物); 大腸腫瘍; Irinotecan(治療的利用); Oxaliplatin(治療的利用); Bevacizumab(治療的利用) / IFL Protocol; FOLFOX Protocol / ラット; 動物
2139.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, 岩橋衆一, 斎藤裕, Mami Kanamoto and Hidenori Miyake : EOB-MRIは肝切除術前検査をone stop shoppingに施行可能である, Acta Hepatologica Japonica, Vol.52, No.Suppl.1, A441, Jun. 2011. (Keyword) 肝細胞癌(画像診断,外科的療法); 肝切除; MRI; 術前診断; Gadoxetic Acid(診断的利用) / ヒト
2140.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, 岩橋衆一, 齋藤裕, Mami Kanamoto and Hidenori Miyake : EOB‐MRIは肝切除術前検査をone stop shoppingに施行可能である, 第47回日本肝臓学会総会, Jun. 2011.
2141.	Toru Utsunomiya, Mitsuo Shimada, 浅野間理仁, 齋藤裕, 岩橋衆一, Mami Kanamoto, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 切除不能大腸癌肝転移例に対する肉眼的根治を目指した外科的治療戦略, 第47回日本肝臓学会総会, Jun. 2011.
2142.	久山寿子, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroo Takehara and Akira Nii : 膵・胆管合流異常症に関する実験的検討:ラット胆管拡張モデル., 第111回日本外科学会定期学術集会, May 2011.
2143.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Hidenori Miyake : 直腸・肛門管癌に対する化学放射線療法の効果を予測する., 第111回日本外科学会定期学術集会, May 2011.
2144.	Mitsuo Shimada : 女性外科医が輝き続けるために : 地方からの挑戦(SP-3 特別企画(3)女性外科医の現在と未来,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 160, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543026899809152 (CiNii: 1572543026899809152)
2145.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁, Hidenori Miyake and Yoshimi Bando : SY-2-6 IPMNにおけるJagged1発現の意義に関する研究 : 調節性T細胞上昇の機序解明の観点から(SY-2 シンポジウム(2)IPMNをめぐる諸問題-診断から治療まで-,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 231, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573387451828484736 (CiNii: 1573387451828484736)
2146.	Toru Utsunomiya, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Hidenori Miyake : 切除不能大腸癌肝転移に対する治癒を目指した治療戦略と肝臓外科医の役割(PD3 パネルディスカッション(3)大腸癌肝転移に対する肝切除と非外科的治療の役割分担,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 267, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570291227084133248 (CiNii: 1570291227084133248)
2147.	Yuji Morine, Mitsuo Shimada, 高松英夫 and Seiki Tashiro : PD-8-1 全国集計からみた非拡張型膵・胆管合流異常の特徴と胆道癌発生頻度(PD8 パネルディスカッション(8)胆道拡張のない膵・胆管合流異常症,膵管形成異常症の治療:成人領域と小児領域,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 277, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571135652014252288 (CiNii: 1571135652014252288)
2148.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 浅野間理人 : 脂肪由来幹細胞(ADRCs)の傷害膵島保護作用に関する検討(SF-011 サージカルフォーラム(11)膵臓:基礎-4,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 349, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570009752108919680 (CiNii: 1570009752108919680)
2149.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 山田眞一郎 and Hidenori Miyake : 胆管癌細胞においてHDAC阻害剤はGemcitabineの抗腫瘍効果を増強する : Ingenuity Pathways AnalysisによるGene networkに着目して(SF-014 サージカルフォーラム(14)胆管:基礎,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 352, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571417126992470656 (CiNii: 1571417126992470656)
2150.	Hidenori Miyake, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 胆嚢癌におけるCD151発現の意義(SF-014 サージカルフォーラム(14)胆管:基礎,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 353, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570572702062358016 (CiNii: 1570572702062358016)
2151.	篠原永光, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 川下陽一郎, 岩橋衆一, 齋藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : 大量肝切除前後での脾臓の役割に関する研究(第2報) : Ingenuity Pathway Analysisによる系統的解析(SF-021 サージカルフォーラム(21)門脈,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 361, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571980076945895040 (CiNii: 1571980076945895040)
2152.	Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 遺伝子とmiRNA発現のハイブリッド解析による非B非C肝癌再発に対する分子遺伝学的治療戦略(SF-059 サージカルフォーラム(59)肝臓:基礎-2,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 409, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570572702061427456 (CiNii: 1570572702061427456)
2153.	鷹村和人, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 3D volumetryとICGR15を用いた肝切除限界量の検討(サージカルフォーラム(96)肝臓:診断-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 456, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573950401782239104 (CiNii: 1573950401782239104)
2154.	四方祐子, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 山田眞一郎 and Hidenori Miyake : 抗EGFR抗体は大量肝切除後の肝傷害,肝再生に影響を及ぼすか?(サージカルフォーラム(98)肝臓:基礎-4,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 458, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573668926805539328 (CiNii: 1573668926805539328)
2155.	徳永卓哉, Mitsuo Shimada, 齋藤裕, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 脂肪由来幹細胞は肝細胞傷害を軽減する(サージカルフォーラム(99)肝臓:基礎-5,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 459, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570854177038413312 (CiNii: 1570854177038413312)
2156.	黒田武志, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 山田眞一郎 and Hidenori Miyake : 脂肪由来幹細胞はcell contactを介して肝癌細胞の増殖を増強する(サージカルフォーラム(99)肝臓:基礎-5,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 459, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573387451828820608 (CiNii: 1573387451828820608)
2157.	寺澤敏秀, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 山田眞一郎 and Hidenori Miyake : 細胆管細胞癌は肝幹細胞由来の原発性肝腫瘍の特徴を有する : 幹細胞マーカーの発現パターンに着目して(サージカルフォーラム(100)肝臓:基礎-6,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 460, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573950401782233984 (CiNii: 1573950401782233984)
2158.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : ヒストンアセチル化に基づく消化器癌幹細胞制御の可能性(サージカルフォーラム(100)肝臓:基礎-6,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 461, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573950401782228352 (CiNii: 1573950401782228352)
2159.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : EOB-MRIと3D-volumetryの融合により肝機能と肝容積の同時評価が可能である(PS-022 ポスターセッション(22)肝臓:診断-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 544, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571698601967593216 (CiNii: 1571698601967593216)
2160.	小笠原卓, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : ソラフェニブは肝切除後の肝障害や肝再生に影響を及ぼすか?(PS-025 ポスターセッション(25)肝臓:集学的治療-2,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 549, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573668926804558848 (CiNii: 1573668926804558848)
2161.	淺野間理仁, Mitsuo Shimada, Hiroki Mori, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : 肝硬変症の脾臓におけるTGF-β発現の意義(PS-067 ポスターセッション(67)脾臓-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 620, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571417126992920704 (CiNii: 1571417126992920704)
2162.	松本規子, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 黄疸肝における遺伝子発現の変化(第2報) : Ingenuity Pathways Analysisによる遺伝子ネットワーク解析(PS-102 ポスターセッション(102)肝臓:基礎-3,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 681, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570572702061026816 (CiNii: 1570572702061026816)
2163.	Mami Kanamoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : Bevacizumab投与は大量肝切除後の肝障害・肝再生を改善する(PS-102 ポスターセッション(102)肝臓:基礎-3,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 682, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571980076944575744 (CiNii: 1571980076944575744)
2164.	西正暁, Toru Utsunomiya, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and Hidenori Miyake : 非癌部肝組織におけるmiRNA発現の多中心性肝発癌への関与 : miRNAマイクロアレイを用いた網羅的解析(PS-130 ポスターセッション(130)肝臓:基礎-5,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 730, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573668926804984320 (CiNii: 1573668926804984320)
2165.	開野友佳理, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 高圧酸素療法(HBO)の肝preconditioning効果(Microarray) : Ingenuity Pathways Analysisによる系統的解析(PS-130 ポスターセッション(130)肝臓:基礎-5,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 730, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543026898127360 (CiNii: 1572543026898127360)
2166.	金村普史, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 胆嚢摘出術における細径鉗子を用いたHybrid SILSの有用性(PS-135 ポスターセッション(135)胆管:良性-2,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 738, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543026898121600 (CiNii: 1572543026898121600)
2167.	川下陽一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and Hidenori Miyake : 胆嚢癌におけるSki発現の意義(PS-140 ポスターセッション(140)胆管:悪性-5,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 748, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573668926804992768 (CiNii: 1573668926804992768)
2168.	杉本光司, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto and 松本慎一 : TJ-48が1型糖尿病マウス(NOD mouse)糖尿発症に及ぼす影響に関する研究(PS-142 ポスターセッション(142)膵臓:移植,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 752, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570854177039097856 (CiNii: 1570854177039097856)
2169.	Yusuke Arakawa, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 川下陽一郎, 岩橋衆一, 齋藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : PS-204-5 最新デバイスを駆使し定型化した肝葉切除術 : 若手外科医の習熟のための工夫(PS-204 ポスターセッション(204)肝臓:手術-7,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 860, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573387451829191936 (CiNii: 1573387451829191936)
2170.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 川下陽一郎, 岩橋衆一, 齋藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : 術後肝不全を回避するための黄疸肝に対する3つの工夫(PS-206 ポスターセッション(206)肝臓:周術期管理-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 862, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570572702062078848 (CiNii: 1570572702062078848)
2171.	Akira Nii, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁, Hidenori Miyake, Eiji Takeda, Hisami Okumura, 佐々木一, 青沼広光 and 川島昭浩 : 肝切除周術期MEINR投与の有用性についての検討 : 基礎的実験とRCT(PS-206 ポスターセッション(206)肝臓:周術期管理-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 863, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573668926805901568 (CiNii: 1573668926805901568)
2172.	Yoshiyasu Terashima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Hidenori Miyake : 消化器癌におけるリンパ節転移自動診断システムの開発(SF-029 サージカルフォーラム(29)大腸:診断-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 372, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571417126991072512 (CiNii: 1571417126991072512)
2173.	Motoya Chikakiyo, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 胃癌の悪性度指標としてのProtein Kinase Ciota発現の意義(SF-039 サージカルフォーラム(39)胃:基礎-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 383, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543026897912704 (CiNii: 1572543026897912704)
2174.	大塚敏広, Mitsuo Shimada, 柏原秀也, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Takashi Iwata and Nobuhiro Kurita : Barrett上皮のmalignant potentialに関する検討 : 第2報(SF-069 サージカルフォーラム(69)食道:基礎-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 421, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571698601968282752 (CiNii: 1571698601968282752)
2175.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, Chie Mikami, 柏原秀也 and Tomomi Kuwahara : 大建中湯の新たな抗炎症効果機序の解明 : 腸管マイクロバイオームのDiversity維持に注目して(SF-077 サージカルフォーラム(77)クローン・その他,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 431, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573387451829593984 (CiNii: 1573387451829593984)
2176.	豊田剛, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami, Toru Utsunomiya and Hidenori Miyake : 早期胃癌におけるsafety marginの検討(SF-078 サージカルフォーラム(78)胃:手術-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 433, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571698601969310464 (CiNii: 1571698601969310464)
2177.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Hidenori Miyake : Taxaneを用いて治療を行った胃癌腹膜播種症例におけるthrombospondin 1(THBS1)発現の意義(サージカルフォーラム(83)胃:化学療法,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 440, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571980076946018304 (CiNii: 1571980076946018304)
2178.	山崎誠司, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami, Toru Utsunomiya and Hidenori Miyake : 単孔式腹腔鏡下鼠径ヘルニア修復術の有用性について : TEPP, TAPPと比較検討(VF-007 ビデオフォーラム(7)ヘルニア,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 491, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570854177039284864 (CiNii: 1570854177039284864)
2179.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Hidenori Miyake : Tailor-made preoperative chemoradiotherapy followed by laparoscopic surgery for advanced rectal cancer, Journal of Japan Surgical Society, Vol.112, No.1, 505, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571135652015323392 (CiNii: 1571135652015323392)
2180.	中尾寿宏, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 胃癌におけるThrombospondin 1 (THBS1)発現の意義 : R0手術症例と再発進行症例の比較から(PS-013 ポスターセッション(13)胃:基礎-1,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 529, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1574231876757996928 (CiNii: 1574231876757996928)
2181.	井川浩一, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 術前深達度診断別に検討した胃癌に対する腹腔鏡補助下胃切除手術(LAG)の長期成績(PS-053 ポスターセッション(53)胃:手術-4,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 597, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571698601968026240 (CiNii: 1571698601968026240)
2182.	Takashi Iwata, Mitsuo Shimada, 柏原秀也, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka and Nobuhiro Kurita : 直腸癌に対する腹腔鏡下手術における縫合不全危険因子とその対策(PS-124 ポスターセッション(124)大腸:手術-2,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 719, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543026898617984 (CiNii: 1572543026898617984)
2183.	江藤祥平, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Hidenori Miyake : 直腸癌の化学放射線療法耐性における癌幹細胞およびmiRNAの検討(PS-137 ポスターセッション(137)大腸:化学療法-6,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 741, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572824501874834432 (CiNii: 1572824501874834432)
2184.	Jun Higashijima, Mitsuo Shimada, Chie Mikami, Masanori Nishioka, Takashi Iwata, Nobuhiro Kurita, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Toru Utsunomiya and Hidenori Miyake : 直腸癌の化学放射線療法耐性におけるmicroRNA223と癌修復遺伝子RAD51の関係に関する研究(PS-137 ポスターセッション(137)大腸:化学療法-6,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 742, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571135652014573312 (CiNii: 1571135652014573312)
2185.	江藤昌平, Mitsuo Shimada, Chie Mikami, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Toru Utsunomiya and Hidenori Miyake : 大腸癌におけるmicroRNA223発現の意義に関する研究(PS-167 ポスターセッション(167)大腸:基礎-5,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 795, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573105976851358720 (CiNii: 1573105976851358720)
2186.	尾形頼彦, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Shinya Morimoto : Cetuximabの副作用に対する十全大補湯の効果の検討(PS-170 ポスターセッション(170)大腸:周術期管理-3,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 800, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572261551921246080 (CiNii: 1572261551921246080)
2187.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami, Toru Utsunomiya and Hidenori Miyake : Rubino手術による糖尿病改善効果に関する研究(PS-193 ポスターセッション(193)胃:良性,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 842, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571980076944377984 (CiNii: 1571980076944377984)
2188.	尾方信也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : GISTの悪性度診断におけるPET-CT, DiffusionMRIの有用性の検討(PS-194 ポスターセッション(194)胃:悪性・画像診断,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 843, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570572702060817536 (CiNii: 1570572702060817536)
2189.	片岡涼子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 胃癌術前進行度診断における腫瘍マーカーの有用性(PS-195 ポスターセッション(195)胃:腫瘍マーカー・他,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 844, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572824501874504064 (CiNii: 1572824501874504064)
2190.	中川建夫, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 柏原秀也, Chie Mikami, Toru Utsunomiya and Hidenori Miyake : 同時性遠隔転移を有する大腸癌治療における予後予測因子の検討(PS-197 ポスターセッション(197)大腸:手術-6,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 849, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571135652014220672 (CiNii: 1571135652014220672)
2191.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也, Chie Mikami and Hidenori Miyake : T3, T4下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術(PS-200 ポスターセッション(200)大腸:手術-9,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 853, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572261551922333568 (CiNii: 1572261551922333568)
2192.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : PS-207-6 Catechinは大量肝切除後の肝傷害を軽減し肝再生を促進する(PS-207 ポスターセッション(207)肝臓:周術期管理-2,第111回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.112, No.1, 865, May 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571980076945628032 (CiNii: 1571980076945628032)
2193.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Toru Utsunomiya : THBS1発現からみた胃癌腹膜橎種症例に対するTHBS1発現からみた個別化治療の可能性., 第97回日本消化器病学会総会, May 2011.
2194.	Tomohiko Miyatani, Mitsuo Shimada and Jun Higashijima : 大腸癌化学療法の副作用に対する漢方薬の役割., 第97回日本消化器病学会総会, May 2011.
2195.	Masanori Nishioka, Mitsuo Shimada and Chie Mikami : 個別化治療を目指した直腸・肛門管癌に対する化学放射線療法., 第97回日本消化器病学会総会, May 2011.
2196.	Nobuhiro Kurita, Mitsuo Shimada and 柏原秀也 : NASHに対するRubino手術の予防効果に関する実験的検討., 第97回日本消化器病学会総会, May 2011.
2197.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 浅野間理仁, 山田眞一郎, Nobuhiro Kurita, Hidenori Miyake and Hiroshi Shibata : 非代償性肝硬変に対する外科的治療としての脾摘術の意義., 第97回日本消化器病学会総会, May 2011.
2198.	Toru Utsunomiya, Mitsuo Shimada and Hiroshi Shibata : DNA・miRNAハイブリッド解析によるNBNC肝癌の分子遺伝学的特徴., 第97回日本消化器病学会総会, May 2011.
2199.	岩橋衆一, Mitsuo Shimada and Hiroshi Shibata : 肝硬変に対する脾摘術の効果-major shuntの有無に着目して-., 第97回日本消化器病学会総会, May 2011.
2200.	Jun Hanaoka, Mitsuo Shimada and Hiroki Mori : 黄疸肝切除におけるインチンコウトウ(ICKT)の効果., 第97回日本消化器病学会総会, May 2011.
2201.	Yuji Morine, Mitsuo Shimada and Tetsuya Ikemoto : 癌幹細胞のepigenetic修飾と癌根治療法への可能性, 第97回日本消化器病学会総会, May 2011.
2202.	Takashi Iwata, Mitsuo Shimada and 柏原秀也 : HIF-1, HDAC1発現に注目したBarrett上皮のmalignant potentialに関するepigeneticな検討., 第97回日本消化器病学会総会, Apr. 2011.
2203.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 浅野間理仁 and Hidenori Miyake : ABO不適合肝移植により救命した急性肝不全症例の1例., 第13回四国肝不全研究会, Apr. 2011.
2204.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Kouzou Yoshikawa, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : 腸管ストレスに対する大建中湯(DKT)の可能性-バクテリアルトランスローケーションからマイクロビオーム, 第47回日本腹部救急医学会総会, Mar. 2011.
2205.	柏原秀也, Mitsuo Shimada, Chie Takasu, Tomohiko Miyatani, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Takashi Iwata, Nobuhiro Kurita and Toru Utsunomiya : 直腸癌に対する化学放射線療法での個別化治療∼MicroRNAによる効果予測∼, 第44回制癌剤適応研究会, Mar. 2011.
2206.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 消化器がん地域連携パス運用について∼抗癌剤適応に向けて∼, 第44回制癌剤適応研究会, Mar. 2011.
2207.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 斎藤裕, 山田眞一郎 and 浅野間理仁 : ヒストン脱アセチル化酵素阻害剤による胆管癌細胞株に対する化学療法増強効果の検討, 第44回制癌剤適応研究会, Mar. 2011.
2208.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : Bevacizumab 投与の大量肝切除後における肝障害・肝再生改善効果, 第44回制癌剤適応研究会, Mar. 2011.
2209.	Takashi Iwata, Mitsuo Shimada, 柏原秀也, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka and Nobuhiro Kurita : 腹腔鏡下胃切除術の技術伝承における3D-Ct術前評価の有用性-特に右胃動脈の変位に注目して-, 第83回日本胃癌学会総会, Mar. 2011.
2210.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and Toru Utsunomiya : 80歳以上の超高齢者に対する胃癌手術の安全性，有効性についての検討, 第83回日本胃癌学会総会, Mar. 2011.
2211.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, Chie Takasu and 柏原秀也 : 胃GISTでの悪性度診断決定におけるPET-CTの有用性, 第83回日本胃癌学会総会, Mar. 2011.
2212.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌におけるThrombospondin 1 (THBS1)発現の意義と個別化治療への展開, 第83回日本胃癌学会総会, Mar. 2011.
2213.	Yuji Morine, Mitsuo Shimada and Tetsuya Ikemoto : 癌幹細胞のepigenetic修飾と癌根治療法への可能性, 第97回日本消化器病学会総会, Mar. 2011.
2214.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 化学放射線療法を併用した腹腔鏡下直腸切除術の肛門機能, 第25回四国内視鏡外科研究会, Feb. 2011.
2215.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and Toru Utsunomiya : 腹腔鏡下胃切除術における主要血管処理のヒヤリハット回避のためのMDCT術前血管シミュレーションの意義について, 第25回四国内視鏡外科研究会, Feb. 2011.
2216.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu and Toru Utsunomiya : Rubino手術による糖尿病改善効果のメカニズムに関する研究, 第242回徳島医学会学術集会, Feb. 2011.
2217.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : 胃癌腹膜橎種症例に対する新たな治療戦略—Thrombospondin 1に注目してー., 第242回徳島医学会学術集会, Feb. 2011.
2218.	浅野間理仁, Mitsuo Shimada, Hiroki Mori, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : 肝硬変の脾臓におけるTGF-β発現の意義, 第242回徳島医学会学術集会, Feb. 2011.
2219.	Satoru Imura, Mitsuo Shimada, 山田眞一郎, 浅野間理仁, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 高度肉眼的門脈侵襲陽性の進行肝癌に対する治療戦略—理論的根拠と臨床成績—., 第242回徳島医学会学術集会, Feb. 2011.
2220.	浅野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 金本真美, 岩橋衆一, 斎藤裕 and 山田眞一郎 : 薬剤性肝炎，汎発性腹膜炎，肺アスペルギルス症による肺出血，創傷治癒遷延など様々な合併症を来したHCCの1例, 第19回徳島外科術後管理研究会, Feb. 2011.
2221.	柏原秀也, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Takasu : 局所再発例を含む直腸GISTの検討., 第74回大腸癌研究会, Jan. 2011.
2222.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 柏原秀也 and Chie Takasu : 大腸癌の発生・進行におけるSonic Hedgehog pathway，HDAC1，MTA1発現の意義., 第74回大腸癌研究会, Jan. 2011.
2223.	斎藤裕, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 岩橋衆一, 川下陽一郎, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : 進行肝細胞癌に対するソラフェニブの成績, 第3回日本肝がん分子標的治療研究会, Jan. 2011.
2224.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Toru Utsunomiya : 炎症性サイトカインからみた消化管に対する大建中湯の効果, 第17回外科侵襲とサイトカイン研究会, Dec. 2010.
2225.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 浅野間理仁 : 脂肪由来幹細胞(ADRCs)の傷害膵島保護作用に関する検討, 第17回外科侵襲とサイトカイン研究会, Dec. 2010.
2226.	斎藤裕, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : ヒト脂肪由来幹細胞は肝細胞傷害を軽減する, 第17回外科侵襲とサイトカイン研究会, Dec. 2010.
2227.	斎藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : Catechinは抗酸化作用及び抗炎症左様により大量肝切除後の肝傷害を軽減し肝再生を促進する, 第23回日本バイオセラピィ学会学術集会, Dec. 2010.
2228.	Chie Mikami, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Toru Utsunomiya and Hidenori Miyake : 下部直腸癌に対する化学放射線療法の効果予測因子の検討, 第94回日本消化器病学会四国支部例会, Dec. 2010.
2229.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Hiroki Mori, Jun Hanaoka, 柏原秀也, Chie Mikami and Toru Utsunomiya : 切除不能大腸癌肝転移に対する新規化学療法についての検討, 第94回日本消化器病学会四国支部例会, Dec. 2010.
2230.	山田眞一郎, Mitsuo Shimada, 斎藤裕, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 浅野間理仁 : 脂肪由来幹細胞は液性因子にて肝細胞傷害を軽減する, 第94回日本消化器病学会四国支部例会, Dec. 2010.
2231.	浅野間理仁, Mitsuo Shimada, Hiroki Mori, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : 肝硬変症における脾臓の役割, 第94回日本消化器病学会四国支部例会, Dec. 2010.
2232.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : ヒストンアセチル化に基づく消化器癌肝細胞制御の可能性, 第94回日本消化器病学会四国支部例会, Dec. 2010.
2233.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 浅野間理仁 and 山田眞一郎 : Bevacizumabの肝切除術後肝再生に与える影響, 第40回日本創傷治癒学会, Dec. 2010.
2234.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 小松正人, 柏原秀也 and Chie Mikami : 直腸癌に対する術前化学放射線療法併用腹腔鏡下手術での我々の工夫, 第65回日本大腸肛門病学会学術集会, Nov. 2010.
2235.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : Cetuximabによる皮膚症状に対する十全大補湯の効果に関する検討, 第65回日本大腸肛門病学会学術集会, Nov. 2010.
2236.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani and Hidenori Miyamoto : 腹腔鏡下直腸癌手術における適応拡大と課題, 第65回日本大腸肛門病学会学術集会, Nov. 2010.
2237.	有田正典, Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, 柏原秀也 and Chie Mikami : 腹腔鏡下に切除した大腸平滑筋肉腫の1例, 第72回日本臨床外科学会総会, Nov. 2010.
2238.	Chie Mikami, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Toru Utsunomiya, Hisanori Uehara and Yoshimi Bando : 進行下部直腸癌に対する化学放射線療法の効果予測に関する検討, 第72回日本臨床外科学会総会, Nov. 2010.
2239.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Mikami : Rubino手術による糖・脂質代謝異常改善効果に関する検討, 第72回日本臨床外科学会総会, Nov. 2010.
2240.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 腹膜播種症例のおける治療の限界と可能性-Thrombospondin 1に注目して-, 第72回日本臨床外科学会総会, Nov. 2010.
2241.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 消化器がん，肝炎における診療連携パス運用について, 第72回日本臨床外科学会総会, Nov. 2010.
2242.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 腹腔鏡下及び開腹胃切除術の長期予後・栄養状態の比較検討, 第72回日本臨床外科学会総会, Nov. 2010.
2243.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 進行下部直腸癌に対する化学放射線療法後の腹腔鏡下手術, 第72回日本臨床外科学会総会, Nov. 2010.
2244.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Toru Utsunomiya : 胃癌内視鏡手術におけるMDCT術前血管シミュレーションの意義について, 第72回日本臨床外科学会総会, Nov. 2010.
2245.	Tomohiko Miyatani, Masanori Nishioka, 柏原秀也, Chie Mikami, 小松正人, 中尾寿宏, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Takashi Iwata, Nobuhiro Kurita and Mitsuo Shimada : 腹腔鏡下S状結腸切除,D3郭清の標準化を目指して, 第72回日本臨床外科学会総会, Nov. 2010.
2246.	Tetsuya Ikemoto, Mitsuo Shimada, Kouzou Yoshikawa, Nobuhiro Kurita, Toru Utsunomiya, Takashi Iwata, Masanori Nishioka, Yuji Morine, Jun Higashijima, Hiroki Mori, Tomohiko Miyatani, Jun Hanaoka and Tomomi Kuwahara : 消化器外科領域における漢方の役割腸管ストレスに対する大建中湯の効果—バクテリアルトランスロケーションからマイクロビオームへ, 第20回外科漢方研究会 (第72回日本臨床外科学会関連会合), Nov. 2010.
2247.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : Stage 4膵癌に対するTJ-48の効果についての検討, 第72回日本臨床外科学会総会, Nov. 2010.
2248.	浅野間理仁, Mitsuo Shimada, Hiroki Mori, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : 肝硬変症の脾臓の役割, 第72回日本臨床外科学会総会, Nov. 2010.
2249.	斎藤裕, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 肝細胞癌の術後再発予測における術前AFP-L3分画の役割, 第72回日本臨床外科学会総会, Nov. 2010.
2250.	Satoru Imura, Mitsuo Shimada, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 成人生体肝移植施行例の短期成績:特に左葉グラフト肝移植とC型肝硬変に対する血液型不適合肝移植の成績, 第72回日本臨床外科学会総会, Nov. 2010.
2251.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 斎藤裕, 山田眞一郎, 浅野間理仁 and Yoshimi Bando : IPMN悪性度評価におけるJagged 1発現の有用性, 第72回日本臨床外科学会総会, Nov. 2010.
2252.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 肝離断時無血紮手技を用いた肝後区域切除における我々の工夫, 第72回日本臨床外科学会総会, Nov. 2010.
2253.	川下陽一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : 3D volumetryを用いた下右肝静脈径と環流領域容量計測の有用性∼3Dソフト間の比較から∼, 第72回日本臨床外科学会総会, Nov. 2010.
2254.	Hiroki Mori, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Toru Utsunomiya, Hisami Okumura and Eiji Takeda : 肝切除周術期管理としての呼吸商の意義, 第72回日本臨床外科学会総会, Nov. 2010.
2255.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 安全かつ確実な肝葉切除標準化の工夫, 第72回日本臨床外科学会総会, Nov. 2010.
2256.	Toru Utsunomiya, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 切除不能大腸癌肝転移に対する強力な新規抗癌剤・分子標的剤の試み:根治切除を目指して, 第72回日本臨床外科学会総会, Nov. 2010.
2257.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Hidenori Miyake : 鏡視下左肝切除の定型化と肝癌に対する妥当性, 第72回日本臨床外科学会総会, Nov. 2010.
2258.	Mitsuo Shimada : 女性医師が輝き続けるために∼地方外科教室の挑戦, 第72回日本臨床外科学会総会, Nov. 2010.
2259.	Satoru Imura, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 腹腔鏡下肝葉切除における低侵襲性の検証∼SIRS項目を用いた開腹との比較∼, 第4回肝臓内視鏡外科研究会, Nov. 2010.
2260.	Tomohiko Miyatani, Masanori Nishioka, 柏原秀也, Chie Mikami, 小松正人, 中尾寿宏, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Takashi Iwata, Nobuhiro Kurita and Mitsuo Shimada : 直腸癌に対する化学放射線療法での個別化治療∼MicroRNAによる効果予測∼, 第21回日本消化器癌発生学会総会, Nov. 2010.
2261.	Kouzou Yoshikawa, Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 小松正人, 柏原秀也, Chie Mikami and Toru Utsunomiya : 大腸癌癌細胞に対するHDAC阻害剤を用いた分化誘導に関する研究, 第21回日本消化器癌発生学会総会, Nov. 2010.
2262.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 胃癌の悪性度の指標としてのヒストン修飾の意義, 第21回日本消化器癌発生学会総会, Nov. 2010.
2263.	斎藤裕, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 岩橋衆一, 川下陽一郎, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Toru Utsunomiya : 癌幹細胞マーカーからみた細胆管細胞癌及び胆管細胞癌の発生, 第21回日本消化器癌発生学会総会, Nov. 2010.
2264.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 山田眞一郎 : 免疫学的側面から見たIPMN悪性度上昇に関する検討, 第21回日本消化器癌発生学会総会, Nov. 2010.
2265.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 肝内胆管癌における癌幹細胞を中心とした分子治療の可能性, 第21回日本消化器癌発生学会総会, Nov. 2010.
2266.	Satoru Imura, Mitsuo Shimada, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 肝癌再発形式からみたサルベージ肝移植の可能性, 第21回日本消化器癌発生学会総会, Nov. 2010.
2267.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, 斎藤裕, 岩橋衆一, Hiroki Mori, Jun Hanaoka, Tetsuya Ikemoto and Yuji Morine : 臨床病理学的および分子遺伝学的特徴からみた非B非C型肝癌発生のメカニズム, 第21回日本消化器癌発生学会総会, Nov. 2010.
2268.	Mitsuo Shimada : 感染症は発癌に直接関与しているか?, 第21回日本消化器癌発生学会総会, Nov. 2010.
2269.	Masanori Nishioka, Nobuhiro Kurita, Kouzou Yoshikawa, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, 政清史晃, 原田雅文, Junji Ueno, Hiromu Nishitani, Noboru Niki and Mitsuo Shimada : CADSによるリンパ節転移自動診断(モダリティー比較), 第19回日本コンピューター外科学会, Nov. 2010.
2270.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka and 金本真美 : Gd-EOB-DTPA造影MRIの肝予備能評価の検討, 第19回日本コンピューター外科学会, Nov. 2010.
2271.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 川下陽一郎, 岩橋衆一 and 斎藤裕 : 3D volumetryを用いた下右肝静脈径と灌流領域容量計測の有用性∼異なる3D画像処理ソフトの比較検討∼, 第19回日本コンピューター外科学会, Nov. 2010.
2272.	Chie Mikami, Takashi Iwata, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 小松正人, 柏原秀也, Toru Utsunomiya, Mitsuo Shimada and Hidenori Miyake : 術前化学放射線療法の効果予測因子としてのDNA修復遺伝子RAD51の可能性の検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2273.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami, Toru Utsunomiya and Hidenori Miyake : 消化器癌患者におけるUGT1A1遺伝子多型の検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2274.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 片岡涼子, 小松正人, 柏原秀也 and Chie Mikami : 非治癒因子別に検討した進行再発胃癌に対する集学的治療, 第48回日本癌治療学会学術集会, Oct. 2010.
2275.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 片岡涼子, 柏原秀也 and Chie Mikami : 胃癌RO手術症例に対する腹腔鏡下胃切除術と開腹手術の比較検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2276.	Tomohiko Miyatani, Masanori Nishioka, 柏原秀也, Chie Mikami, 小松正人, 中尾寿宏, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Takashi Iwata and Mitsuo Shimada : L-OHP関連末梢神経障害に対する牛車腎気丸の予防効果, 第48回日本癌治療学会学術集会, Oct. 2010.
2277.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 十全大補湯によるCetuximabの皮膚状態に対する効果の関する検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2278.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and 阿部斗与 : 胃，大腸，肝癌における診療連携パス運用について, 第48回日本癌治療学会学術集会, Oct. 2010.
2279.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 小松正人, 柏原秀也 and Chie Mikami : 下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術と肛門機能, 第48回日本癌治療学会学術集会, Oct. 2010.
2280.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 適応拡大を目指した鏡視下直腸癌手術の工夫, 第48回日本癌治療学会学術集会, Oct. 2010.
2281.	Kouzou Yoshikawa, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人, 柏原秀也 and Chie Mikami : GISTに対する術前分子標的治療導入決定におけるPET-CTの有用性の検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2282.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Akira Tangoku, Hiroshi Okitsu, 藤野良三, 安藤道夫 and 惣中康秀 : 大腸がんに対する鏡視下手術の標準化と普及における問題点と対策:地方からの提言, 第48回日本癌治療学会学術集会, Oct. 2010.
2283.	川下陽一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 川田祐子 and Hidenori Miyake : 肝転移を伴う大腸癌に対する同時切除の検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2284.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 肝内胆管癌に対する鏡視下肝切除の有用性, 第48回日本癌治療学会学術集会, Oct. 2010.
2285.	Toru Utsunomiya, Mitsuo Shimada, Nobuhiro Kurita and Shinya Morimoto : 全体Cancer Board活性化への当院がん診療連携センターの取り組み, 第48回日本癌治療学会学術集会, Oct. 2010.
2286.	山田眞一郎, Mitsuo Shimada, 斎藤裕, 川田祐子, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Shinya Morimoto, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Toru Utsunomiya, Nobuhiro Kurita and Hidenori Miyake : 非B非C型肝癌の臨床的特徴と肝基盤病変の検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2287.	斎藤裕, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 岩橋衆一, 川下陽一郎, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : ヒト脂肪組織由来幹細胞の癌細胞増殖抑制効果の検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2288.	岩橋衆一, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 斎藤裕, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 再発肝癌に対する肝移植の可能性∼Up-to-seven基準での検討∼, 第48回日本癌治療学会学術集会, Oct. 2010.
2289.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 浅野間理仁, 山田眞一郎 and Hidenori Miyake : 肝癌切除術後長期(10年以上)生存例の臨床病理学的特徴, 第48回日本癌治療学会学術集会, Oct. 2010.
2290.	浅野間理仁, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 山田眞一郎 : 肝内胆管癌における癌幹細胞の意義, 第48回日本癌治療学会学術集会, Oct. 2010.
2291.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 切除不能胆管がんに対するGFP療法の有用性., 第48回日本癌治療学会学術集会, Oct. 2010.
2292.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : 進行肝癌に対する補助療法としてのIFP療法の有用性およびソラフェニブの適応提案, 第48回日本癌治療学会学術集会, Oct. 2010.
2293.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Kouzou Yoshikawa, Yuji Morine, Satoru Imura and Hidenori Miyake : TJ48がStageⅣb膵癌に与える臨床病理学的影響に関する研究, 第48回日本癌治療学会学術集会, Oct. 2010.
2294.	Satoru Imura, Mitsuo Shimada, 山田眞一郎, 浅野間理仁, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 肝切除後，長期生存のための条件およびサルベージ肝移植施行のタイミングの検討, 第48回日本癌治療学会学術集会, Oct. 2010.
2295.	Toru Utsunomiya, Mitsuo Shimada, Yuji Morine, 小松正人, 斎藤裕, Hiroki Mori, Jun Hanaoka, 岩橋衆一, Tetsuya Ikemoto and Satoru Imura : がん幹細胞のepigenetic修飾とがん根治療法への可能性, 第48回日本癌治療学会学術集会, Oct. 2010.
2296.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : EOB造影MRIは肝移植適応判断に有用である, 第46回日本移植学会総会, Oct. 2010.
2297.	川下陽一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and Hidenori Miyake : 生体肝移植ドナー手術術前評価における3D-volumetry systemの比較, 第46回日本移植学会総会, Oct. 2010.
2298.	Hiroki Mori, Mitsuo Shimada, 山田眞一郎, 浅野間理仁, 斎藤裕, 岩橋衆一, 杉本光司, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 細胞移植としての脂肪由来幹細胞によるβ細胞置換療法に関する検討, 第46回日本移植学会総会, Oct. 2010.
2299.	Satoru Imura, Mitsuo Shimada, 山田眞一郎, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 再発肝癌に対するサルベージ肝移植の可能性 ∼新旧ミラノ基準での検討∼, 第46回日本移植学会総会, Oct. 2010.
2300.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : C型肝硬変例に対するABO不適合肝移植後のCyAを用いた抗ウイルス療法, 第46回日本移植学会総会, Oct. 2010.
2301.	Tetsuya Ikemoto, Mitsuo Shimada, 松本慎一, 山田眞一郎, 斎藤裕, 岩橋衆一, 杉本光司, Jun Hanaoka, Hiroki Mori, Yuji Morine, Satoru Imura and Toru Utsunomiya : IDO+形質細胞様樹状細胞が誘導する免疫寛容誘導の検討, 第46回日本移植学会総会, Oct. 2010.
2302.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 浅野間理仁 : 過小グラフト回避のための完全左葉グラフト採取手技, 第46回日本移植学会総会, Oct. 2010.
2303.	Tomohiko Miyatani, Nobuhiro Kurita, 柏原秀也, Chie Mikami, 小松正人, 中尾寿宏, Jun Higashijima, Kouzou Yoshikawa, Masanori Nishioka, Takashi Iwata and Mitsuo Shimada : 腹膜転移陽性胃癌に対するTS-1+PTX腹腔内投与と予後予測因子としてのTHBS1発現の意義, 第48回日本癌治療学会学術集会, Oct. 2010.
2304.	Chie Mikami, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 小松正人, 柏原秀也 and Toru Utsunomiya : 単孔式腹腔鏡下虫垂切除術SLISの有用性, 第23回日本内視鏡外科学会総会, Oct. 2010.
2305.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 腹腔鏡補助下胃全摘術の食道空腸吻合法におけるoverlap法の有用性に関する検討, 第23回日本内視鏡外科学会総会, Oct. 2010.
2306.	Jun Higashijima, Nobuhiro Kurita, Yukikiyo Kawakami, Takashi Iwata and Mitsuo Shimada : 地域医療における手術配信システム構築による内視鏡外科の効率的な技術伝承を目指して, 第23回日本内視鏡外科学会総会, Oct. 2010.
2307.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Tomohiko Miyatani, Kouzou Yoshikawa, Chie Mikami, 柏原秀也 and Toru Utsunomiya : 臨床試験適応除外となる心肺合併症を有する大腸癌に対する腹腔鏡下大腸切除, 第23回日本内視鏡外科学会総会, Oct. 2010.
2308.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Hiroshi Okitsu, 藤野良三, 安藤道夫 and 惣中康秀 : 地方における腹腔鏡下胃切除術普及のためのポイント, 第23回日本内視鏡外科学会総会, Oct. 2010.
2309.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Toru Utsunomiya : 鼠径ヘルニアに対する単孔式内視鏡下手術についての検討, 第23回日本内視鏡外科学会総会, Oct. 2010.
2310.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 消化管癌に対するリンパ節転移自動診断システムの開発, 第23回日本内視鏡外科学会総会, Oct. 2010.
2311.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 適応拡大を目指した腹腔鏡下直腸癌手術の工夫, 第23回日本内視鏡外科学会総会, Oct. 2010.
2312.	斎藤裕, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 岩橋衆一, 川下陽一郎, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : E-PASSを用いた急性胆嚢炎術後合併症のリスク評価に関する検討, 第23回日本内視鏡外科学会総会, Oct. 2010.
2313.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 山田眞一郎 : 当科における単孔式腹腔鏡下胆嚢摘出術の経験, 第23回日本内視鏡外科学会総会, Oct. 2010.
2314.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yuji Morine, 調憲, 武冨紹信 and 前原喜彦 : 腹腔鏡下管切除術の肝内胆管癌症例への展開, 第23回日本内視鏡外科学会総会, Oct. 2010.
2315.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 浅野間理仁, 山田眞一郎, Nobuhiro Kurita and Hidenori Miyake : 腹腔鏡下肝葉切除における低侵襲性の検証—SIRS項目を用いた開腹との比較, 第23回日本内視鏡外科学会総会, Oct. 2010.
2316.	徳永卓哉, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 小松正人 and 柏原秀也 : 13C呼気試験法を用いた胃切除術後再建術後の機能評価, 第52回日本消化器病学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2317.	川下陽一郎, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Mikami and Toru Utsunomiya : 消化器癌患者におけるUGT1A1遺伝子多型の検討, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2318.	Chie Mikami, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : 胃癌における術前MDCTのリンパ節転移診断基準の検討, 第8回日本消化器外科学会( JDDW日本消化器関連学会集会), Oct. 2010.
2319.	Kouzou Yoshikawa, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : GISTに対する術前メシル酸イマチニブ療法導入決定にPET-CTは有用か?, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2320.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 片岡涼子, 小松正人 and 柏原秀也 : 未分化型早期胃癌に対する腹腔鏡補助下胃切除術施行例の成績とESD拡大適応の可能性, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2321.	柏原秀也, Mitsuo Shimada and Nobuhiro Kurita : 胃癌手術に対するMDCTを用いた術前シミュレーションの意義, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2322.	Shinya Morimoto, Mitsuo Shimada and Nobuhiro Kurita : 消化器癌におけるリンパ節転移自動診断システムの開発, 第8回日本消化器外科学会 ( JDDW日本消化器関連学会集会), Oct. 2010.
2323.	Masanori Nishioka, Mitsuo Shimada and Nobuhiro Kurita : MicroRNAで直腸・肛門管癌に対する化学放射線療法の効果を予測する, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2324.	西正暁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, Nobuhiro Kurita and Hidenori Miyake : 肝硬変に対する外科的治療, 第14回日本肝臓学会大会 (JDDW日本消化器関連学会集会), Oct. 2010.
2325.	山田眞一郎, Hidenori Miyake, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura and 岩橋衆一 : 超高齢者肝細胞癌に対する肝切除術の妥当性の検討, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2326.	斎藤裕, Mitsuo Shimada, Toru Utsunomiya, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝細胞癌に対する新規分子マーカー探索のための非癌部肝組織を用いた網羅的遺伝子発現解析, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2327.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 川田祐子 and Hidenori Miyake : IPMNにおける末梢血中Foxp3と局所IDO陽性細胞の関連に関する検討, 第8回日本消化器外科学会(JDDW日本消化器関連学会集会), Oct. 2010.
2328.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 岩橋衆一, 斎藤裕 and 山田眞一郎 : 大腸癌肝転移に対する治療戦略, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2329.	Satoru Imura, Mitsuo Shimada, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 再発肝癌に対するサルベージ肝移植の可能性∼新旧ミラノ基準での検討∼, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2330.	久山寿子, Mitsuo Shimada and Toru Utsunomiya : 膵・胆管合流異常症に関する実験的検討:ラット胆管拡張症モデル, 第52回日本消化器病学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2331.	Toru Utsunomiya, Mitsuo Shimada and Satoru Imura : 非癌部肝組織の遺伝子発現からみた肝発癌分子機構に関する検討, 第52回日本消化器病学会(JDDW日本消化器関連学会集会), Oct. 2010.
2332.	Toru Utsunomiya, Mitsuo Shimada and Satoru Imura : 非B非C型肝癌の臨床的及び分子遺伝学的特徴—ウイルス性肝癌との比較, 第14回日本肝臓学会大会, Oct. 2010.
2333.	岩橋衆一, Mitsuo Shimada and Toru Utsunomiya : 胆管癌におけるHDAC阻害剤の有用性の検討, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2334.	Tetsuya Ikemoto, Mitsuo Shimada and Toru Utsunomiya : 1型糖尿病治療に向けた脂肪由来幹細胞のnude mouse導入の基礎的検討, 第8回日本消化器外科学会 (JDDW日本消化器関連学会集会), Oct. 2010.
2335.	Mitsuo Shimada : 非B非C型肝癌の基盤病変の特徴と課題, JDDW(日本消化器関連学会集会) 【第52回日本消化器病学会，第14回日本肝臓学会大会，第8回日本消化器外科学会】, Oct. 2010.
2336.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, 岩橋衆一, 斎藤裕, 山田眞一郎, 浅野間理仁 and Masafumi Harada : Gd-EOB-DTPA造影MRIを用いた新しい肝予備能評価法の検討, 第5回肝癌治療シミュレーション研究会, Sep. 2010.
2337.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 小松正人, 柏原秀也 and Toru Utsunomiya : Rediosensitizing effects of oridonin for human colon cancer. (オリドニンの放射線増感作用に関する検討.), 第69回日本癌学術総会, Sep. 2010.
2338.	柏原秀也, Mitsuo Shimada, 小松正人, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 中尾寿宏, 片岡涼子 and Chie Mikami : A possible effect of HDAC inhibitor on differentiating colon cancer sphere. (大腸癌幹細胞におけるHDAC阻害剤の分化誘導効果についての検討.), 第69回日本癌学術総会, Sep. 2010.
2339.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Tomohiko Miyatani, 小松正人, Chie Mikami and 柏原秀也 : The usefulness of PET-CT for predicting malignant potential of gastrointestinal stromal tumor. (GIST診断におけるPET-CTの役割.), 第69回日本癌学術総会, Sep. 2010.
2340.	Takashi Iwata, Mitsuo Shimada, Hiroki Mori, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : The growth inhibitory effect of human adipose tissue derived stem cell on pancreas and colon cancer cells. (ヒト脂肪由来肝幹細胞の膵癌，大腸癌細胞増殖抑制効果の検討.), 第69回日本癌学術総会, Sep. 2010.
2341.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 小松正人, 柏原秀也 and Chie Mikami : Micro RNA expression predicts pathological response to the chemoradiotherapy in rectal cancer. (MicroRNAによる直腸癌での化学放射線療法の効果予測.), 第69回日本癌学術総会, Sep. 2010.
2342.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 浅野間理仁 and 山田眞一郎 : The impact of bevacizumab on liver regeneration following hepatectomy in rats. (ベバシズマブのラット肝切除後の肝再生に与える影響.), 第69回日本癌学会学術総会, Sep. 2010.
2343.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 浅野間理仁 : Indolamine2,3-deoxygenase (ICO) has influences for the aggressiveness of IPMN through Foxp3+Treg in peripheral blood. (IPMN悪性度上昇における末梢血液Treg上昇のindolamine2,3-deoxygenase(IDO)関与に関する検討.), 第69回日本癌学会学術総会, Sep. 2010.
2344.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : Correlation between CD133 and HDAC in cholangiocarcinoma :A possible epigenetic regulation of cancer stem cell. (肝内胆管癌におけるCD133とHDAC発現との関連に関する検討.), 第69回日本癌学会学術総会, Sep. 2010.
2345.	斎藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 山田眞一郎 and 浅野間理仁 : Adipose-derived stem cells differentiate into hepatocytes in regenerating liver after hepatectomy in mice. (マウス切除肝における脂肪由来幹細胞の肝細胞へ分化(予備研究).), 第69回日本癌学会学術総会, Sep. 2010.
2346.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and 斎藤裕 : Histone deacetylase inhibitor enhances anti-tumor effect of gemcitabine through up-regulating of p21 signaling. (ヒストン脱アセチル化学酵素阻害剤によるp21増強を介したGemicitabine抗腫瘍効果増強.), 第69回日本癌学会学術総会, Sep. 2010.
2347.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : Clinicopathological feaures and gene-expression profiles in hepatocellular carcinoma without B or C viral infection. (非B非C肝癌の臨床病理学的および分子遺伝学的特徴に関する検討.), 第69回日本癌学会学術総会, Sep. 2010.
2348.	久山寿子, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroo Takehara and Akira Nii : 膵・胆管合流異常症に関する実験的検討:ラット胆管拡張症モデル, 第33回日本膵・胆管合流異常研究会, Sep. 2010.
2349.	山田眞一郎, Mitsuo Shimada, Yuji Morine, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 久山寿子, 岩橋衆一, 斎藤裕, 浅野間理仁 and Hidenori Miyake : 胆道癌におけるHMGB1発現の意義, 第33回日本膵・胆管合流異常研究会, Sep. 2010.
2350.	久山寿子, Yuji Morine and Mitsuo Shimada : 全国集計からみた非拡張型膵・胆管合流異常の特徴と胆道癌発生頻度, 第33回日本膵・胆管合流異常研究会, Sep. 2010.
2351.	Satoru Imura, Mitsuo Shimada, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 門亢症併存肝癌に対する脾摘+肝癌局所治療の成績∼肝切除前後の脾臓の役割とあわせて∼, 第17回日本門脈圧亢進症学会総会, Sep. 2010.
2352.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Mikami and Toru Utsunomiya : 鼠径ヘルニアに対する単孔式内視鏡手術についての検討, 第85回中国四国外科学会総会/第15回中国四国内視鏡外科研究会, Sep. 2010.
2353.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, 柏原秀也, Chie Mikami and Toru Utsunomiya : 13C残胃排出能検査によるB-1法vs Roux-en Y再建の比較からみた幽門側胃切除術後再建法の術式選択, 第85回中国四国外科学会総会/第15回中国四国内視鏡外科研究会, Sep. 2010.
2354.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 浅野間理仁 and 山田眞一郎 : 膵頭十二指腸切除術における逆行性肝胆道ドレナージ(RTBD)の必要性に関する検討, 第85回中国四国外科学会総会/第15回中国四国内視鏡外科研究会, Sep. 2010.
2355.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 当科における単孔式腹腔鏡下胆嚢摘出術の導入, 第85回中国四国外科学会総会/第15回中国四国内視鏡外科研究会, Sep. 2010.
2356.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, 斎藤裕, 山田眞一郎 and 浅野間理仁 : 左葉グラフト肝移植における肝静脈再建の工夫∼吻合口拡大のための手技の工夫∼., 第85回中国四国外科学会総会/第15回中国四国内視鏡外科研究会, Sep. 2010.
2357.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕, 浅野間理仁 and Hidenori Miyake : ABO不適合肝移植により救命した亜急性型劇症肝炎症例の経験, 第28回中国四国臨床臓器移植研究会, Aug. 2010.
2358.	Tomohiko Miyatani, Masanori Nishioka, Mitsuo Shimada and Nobuhiro Kurita : 下部直腸癌に対する化学放射線療法と展望, 第241回徳島医学会学術集会, Aug. 2010.
2359.	有田正典, Tomohiko Miyatani and Mitsuo Shimada : 良性腫瘍との鑑別が極めて困難であった肝細胞癌の一例, 第241回徳島医学会学術集会, Aug. 2010.
2360.	斎藤裕, Mitsuo Shimada, Toru Utsunomiya, 浅野間理仁, 山田眞一郎, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : ヒト脂肪由来幹細胞による肝再生促進効果に関する基礎的検討, 第241回徳島医学会学術集会, Aug. 2010.
2361.	松本規子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏 and Toru Utsunomiya : 超音波内視鏡(EUS)を用いた腹腔鏡下胃切除症例における術前深達度診断の有用性と限界, 第65回日本消化器外科学会総会, Jul. 2010.
2362.	小松正人, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏 and Toru Utsunomiya : 大腸癌sphereに対するHDAC阻害剤の効果, 第65回日本消化器外科学会総会, Jul. 2010.
2363.	大浦涼子, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏 and 小松正人 : 胃癌術前進行度診断における腫瘍マーカーの有用性についての検討, 第65回日本消化器外科学会総会, Jul. 2010.
2364.	中尾寿宏, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani and Hidenori Miyake : 進行胃癌に対するS-1併用paclitaxel腹腔内投与療法の臨床第Ⅰ相試験, 第65回日本消化器外科学会総会, Jul. 2010.
2365.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 中尾寿宏 and 小松正人 : 切除不能進行胃癌に対する集学的治療における外科治療の意義についての検討, 第65回日本消化器外科学会総会, Jul. 2010.
2366.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 小松正人 and 柏原秀也 : 下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術, 第65回日本消化器外科学会総会, Jul. 2010.
2367.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, 中尾寿宏, 小松正人 and 柏原秀也 : 腸管ストレスに対する大建中湯の効果-Bacterial translocationからマイクロビオームへ, 第65回日本消化器外科学会総会, Jul. 2010.
2368.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏 and 小松正人 : MicroRNAで直腸・肛門管癌に対する化学放射線療法の効果を予測する, 第65回日本消化器外科学会総会, Jul. 2010.
2369.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, Toru Utsunomiya and Hidenori Miyake : 幽門側胃切除術後再建法の検討:13C残胃排出能検査によるB-I法 vs Roux-en Y再建の比較, 第65回日本消化器外科学会総会, Jul. 2010.
2370.	柏原秀也, Mitsuo Shimada, 桑原知己, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani and Chie Mikami : 大建中湯投与による腸管マイクロビオームの変化の検討, 第47回日本外科代謝栄養学会学術集会, Jul. 2010.
2371.	Erdenebulgan Batmunkh, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Hiroki Mori, Jun Hanaoka and Shuichi Iwahashi : The correlation between cancer stem like cells and epigenetic alteration in intrahepatic cholangiocarcinoma, 第65回日本消化器外科学会総会, Jul. 2010.
2372.	斎藤裕, Mitsuo Shimada, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 高圧酸素療法(HBO)の肝preconditioning効果(Microarray解析), 第65回日本消化器外科学会総会, Jul. 2010.
2373.	松本早代, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : 切除不能膵癌に対する多剤併用化学療法の有用性の検討, 第65回日本消化器外科学会総会, Jul. 2010.
2374.	浅野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and Hidenori Miyake : 大腸癌肝転移治癒切除症例における短期予後の検討∼同時性転移vs異時性転移∼, 第65回日本消化器外科学会総会, Jul. 2010.
2375.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, 岩橋衆一, 斎藤裕 and 川田祐子 : 肝葉切除適応基準の再検討∼Japan criteria(幕内基準)は拡大可能か∼, 第65回日本消化器外科学会総会, Jul. 2010.
2376.	山田眞一郎, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 川田祐子 : 生体肝移植レシピエント術後肝障害に対するMEINの有用性, 第65回日本消化器外科学会総会, Jul. 2010.
2377.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 斎藤裕 and Hidenori Miyake : Gd-EOB-DTPA造影MRIを用いた新しい肝予備能評価法の検討, 第65回日本消化器外科学会総会, Jul. 2010.
2378.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕 and Hidenori Miyake : ミラノ外肝癌切除後の再発様式からみた肝移植適応と補助化学療法としてのIFP療法の有用性, 第65回日本消化器外科学会総会, Jul. 2010.
2379.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 小松正人 and 川田祐子 : 耐糖能傷害に対する脂肪由来幹細胞導入の基礎的検討, 第65回日本消化器外科学会総会, Jul. 2010.
2380.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 川田祐子 : 肝内胆管癌に対する治療戦略-至適術式と非切除例における治療方針, 第65回日本消化器外科学会総会, Jul. 2010.
2381.	Satoru Imura, Mitsuo Shimada, 斎藤裕, 川田祐子, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine and Toru Utsunomiya : 安全な肝葉切除術を目指した術式標準化への工夫, 第65回日本消化器外科学会総会, Jul. 2010.
2382.	Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 川田祐子 and Hidenori Miyake : 切除不能大腸癌転移に対する化学療法後肝切除のタイミングと術式に関する検討, 第65回日本消化器外科学会総会, Jul. 2010.
2383.	Mitsuo Shimada and 高田忠敬 : 肝胆膵外科学会データベース, 第65回日本消化器外科学会総会, Jul. 2010.
2384.	Ahmed S. Maklad, Mikio Matsuhiro, Yoshiki Kawata, Noboru Niki, Toru Utsunomiya, Mitsuo Shimada and Hiromu Nishitani : Liver extraction based on blood vessel using multislice CT datasets, IEICE Technical Report Medical Imaging, Vol.110, No.121, 21-26, Jul. 2010.
2385.	斎藤裕, Mitsuo Shimada, 浅野間理仁, 山田眞一郎, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya, Hisami Okumura and Eiji Takeda : 肝傷害患者における術前栄養指標としての呼吸商の意義, 第47回日本外科代謝栄養学会学術集会, Jul. 2010.
2386.	浅野間理仁, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 斎藤裕 : 細胆管癌における癌幹細胞マーカー発現の検討, 第46回日本肝癌研究会, Jul. 2010.
2387.	Tetsuya Ikemoto, Mitsuo Shimada, 斎藤裕, 山田眞一郎, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Satoru Imura, Yuji Morine and Toru Utsunomiya : 進行肝細胞癌に対するソラフェニブの位置づけ, 第46回日本肝癌研究会, Jul. 2010.
2388.	Satoru Imura, Mitsuo Shimada, 斎藤裕, Shuichi Iwahashi, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya, Hidenori Miyake, Katsuyoshi Tamaki and Tetsuji Takayama : HCV関連肝癌治療後の再発予防を目的としたPEG/Rib併用療法の有効性の検討, 第46回日本肝癌研究会, Jul. 2010.
2389.	斎藤裕, Mitsuo Shimada, 川田祐子, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : (症例), 第46回日本肝癌研究会, Jul. 2010.
2390.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 岩橋衆一, 斎藤裕 and 山田眞一郎 : 切除不能大腸癌肝転移に対する化学療法後肝切除に関する検討, 第46回日本肝癌研究会, Jul. 2010.
2391.	山田眞一郎, Mitsuo Shimada, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya, Nobuhiro Kurita and Hidenori Miyake : 術式定型化による完全鏡視下肝外側区域切除術, 第46回日本肝癌研究会, Jul. 2010.
2392.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 斎藤裕, 川田祐子 and Hidenori Miyake : 肝後区域切除術の標準化を目指した基本と工夫, 第46回日本肝癌研究会, Jul. 2010.
2393.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 斎藤裕, 川田祐子 and Masafumi Harada : Gd-EOB-DTPA造影MRIを用いた新しい肝予備能評価法の検討, 第46回日本肝癌研究会, Jul. 2010.
2394.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, 斎藤裕, 柏原秀也, 岩橋衆一, Hiroki Mori, Jun Hanaoka, Tetsuya Ikemoto and Yuji Morine : 非B非C型肝癌の臨床病理的および分子遺伝学的特徴, 第46回日本肝癌研究会, Jul. 2010.
2395.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也 and Chie Mikami : 鼠径ヘルニアに対する単孔式内視鏡下手術についての検討, 第7回中国四国ヘルニア手術研究会, Jul. 2010.
2396.	Chie Mikami, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 小松正人, 柏原秀也 and Toru Utsunomiya : 緊急虫垂炎手術における腹腔鏡手術SILSの有用性, 第73回大腸癌研究会, Jul. 2010.
2397.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Hiroki Mori, Jun Hanaoka, 柏原秀也, Chie Mikami and Toru Utsunomiya : 切除不能大腸癌肝転移に対する新規化学療法著効後肝切除症例の検討, 第73回大腸癌研究会, Jul. 2010.
2398.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 斎藤裕, 佐々木一, 青沼広光 and 川島昭浩 : 生体肝移植レシピエント術後肝障害に対する高機能流動食MHN02の臨床的効果, 第28回日本肝移植研究会, Jul. 2010.
2399.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 川田祐子, 斎藤裕 and Masafumi Harada : Gd-EOB-DTPA造影MRIを用いた肝不全時の肝予備能の検討, 第28回日本肝移植研究会, Jul. 2010.
2400.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, 斎藤裕 and 山田眞一郎 : 生体肝移植後のB型肝炎再発予防の取り組みと課題, 第28回日本肝移植研究会, Jul. 2010.
2401.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 斎藤裕 and 山田眞一郎 : 過小グラフト回避のための完全左葉グラフト採取手技, 第28回日本肝移植研究会, Jul. 2010.
2402.	Satoru Imura, Mitsuo Shimada, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : Up-to-seven基準内外でみた肝癌切除症例の術後成績の検討, 第28回日本肝移植研究会, Jul. 2010.
2403.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, 斎藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto and Yuji Morine : C型肝硬変に対するABO不適合肝移植後のlow dose PEG-IFN/RBV療法の有用性, 第28回日本肝移植研究会, Jul. 2010.
2404.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 齋藤裕, 山田眞一郎 and 浅野間理仁 : 進行再発肝癌に対するソラフェニブの使用経験及び著効例の検討., 第2回日本肝がん分子標的治療研究会, Jun. 2010.
2405.	Chie Mikami, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 小松正人, 柏原秀也 and Toru Utsunomiya : 大腸癌癌幹細胞に対するHDAC阻害剤の効果, 第93回日本消化器病学会四国支部例会/第104回日本消化器内視鏡学会四国地方会, Jun. 2010.
2406.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 片岡涼子, 小松正人 and Chie Mikami : CPT11によるBacterial Translocationの発症とTight Junction傷害, 第93回日本消化器病学会四国支部例会/第104回日本消化器内視鏡学会四国地方会, Jun. 2010.
2407.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 大浦涼子, 小松正人, 柏原秀也 and Chie Mikami : Crohn病に対する外科治療の適応とタイミング, 第93回日本消化器病学会四国支部例会/第104回日本消化器内視鏡学会四国地方会, Jun. 2010.
2408.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani and 柏原秀也 : 外科的切除を施行した小腸腫瘍の診断と治療, 第93回日本消化器病学会四国支部例会/第104回日本消化器内視鏡学会四国地方会, Jun. 2010.
2409.	齋藤裕, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka and 岩橋衆一 : IDOを介したIPMN悪性化における末梢血中調節性T細胞上昇の機序解明に関する検討., 第93回日本消化器病学会四国支部例会 / 第104回日本消化器内視鏡学会四国地方会, Jun. 2010.
2410.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一 and 齋藤裕 : 定型化による安全確実な腹腔鏡下左肝切除術., 第93回日本消化器病学会四国支部例会 / 第104回日本消化器内視鏡学会四国地方会, Jun. 2010.
2411.	Toru Utsunomiya, Mitsuo Shimada, 齋藤裕, 岩橋衆一, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 切除不能大腸癌肝転移に対する外科の進歩:化学療法後肝切除例の検討., 第93回日本消化器病学会四国支部例会 / 第104回日本消化器内視鏡学会四国地方会, Jun. 2010.
2412.	Jun Higashijima, Masanori Nishioka, 柏原秀也, 小松正人, 中尾寿宏, Tomohiko Miyatani, Kouzou Yoshikawa, Shinya Morimoto, Takashi Iwata, Nobuhiro Kurita, Toru Utsunomiya and Mitsuo Shimada : 腹腔鏡下大腸癌手術におけるLiga Sure AdvanceTMを用いた安全なNo.253リンパ節郭清, 第35回日本外科系連合学会学術集会, Jun. 2010.
2413.	Takashi Iwata, Mitsuo Shimada, 斎藤裕, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka and Nobuhiro Kurita : 安全な鏡視下手術を行うための工夫:内臓脂肪が鏡視下胃切除術に与える影響の検討, 第35回日本外科系連合学会学術集会, Jun. 2010.
2414.	Tetsuya Ikemoto, Mitsuo Shimada, 小松正人, 齋藤裕, Jun Hanaoka, Hiroki Mori, Yuji Morine, Satoru Imura and Toru Utsunomiya : 耐糖能傷害に対する脂肪由来幹細胞導入の基礎的検討., 第93回日本消化器病学会四国支部例会 / 第104回日本消化器内視鏡学会四国地方会, Jun. 2010.
2415.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕, 川田祐子, 佐々木一, 青沼広光 and 川島昭浩 : 生体肝移植レシピエント術後肝障害に対する新規高機能流動食MHN-02の効果., 第35回日本外科系連合学会学術集会, Jun. 2010.
2416.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 川田祐子 : 肝内胆管癌に対する治療戦略∼至適術式と非切除例における治療方針∼., 第35回日本外科系連合学会学術集会, Jun. 2010.
2417.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕 and Hidenori Miyake : 鏡視下肝切除を安全に定型化するための工夫, 第35回日本外科系連合学会学術集会, Jun. 2010.
2418.	Kenji Matsuzaki, Mayumi Takeuchi, Yoshimi Bando, Eiji Kudo, Toru Utsunomiya and Mitsuo Shimada : 細胆管癌の2例:CTおよびMRI所見を中心に, 第24回腹部放射線研究会, Jun. 2010.
2419.	Kouzou Yoshikawa, Mitsuo Shimada and Nobuhiro Kurita : 牛車腎気丸によるL-OHP関連末梢神経障害の予防効果, 第61回日本東洋医学学術総会, Jun. 2010.
2420.	Yuji Morine and Mitsuo Shimada : Bacterial translocation (DKT) ., 第61回日本東洋医学学術総会, Jun. 2010.
2421.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 川田祐子 : 進行肝硬変症例に対する脾摘術の功罪., 第46回日本肝臓学会総会, May 2010.
2422.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Akira Nii, Hiroki Mori, 岩橋衆一, 齋藤裕, 川田祐子, 佐々木一, 青沼広光 and 川島昭浩 : 肝温虚血再灌流傷害に対する高機能流動食MEIN®の有用性., 第46回日本肝臓学会総会, May 2010.
2423.	Tetsuya Ikemoto, Mitsuo Shimada and Toru Utsunomiya : C型肝硬変に対する血液型不適合肝移植後のCyAを用いた抗ウイルス療法., 第46回日本肝臓学会総会, May 2010.
2424.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 川田祐子 and Hidenori Miyake : 新規肝予備能評価におけるGd-EOB-DTPA造影MRIの有用性に関する検討., 第46回日本肝臓学会総会, May 2010.
2425.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, Jun Hanaoka and Yuji Morine : 非癌部肝組織の遺伝子発現解析に着目した肝細胞癌分子マーカーの探索., 第46回日本肝臓学会総会, May 2010.
2426.	齋藤裕, Mitsuo Shimada, 川田祐子, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 診断・治療法の選択に苦慮したインスリノーマの一例., 第22回日本肝胆膵外科学会学術集会, May 2010.
2427.	浅野間理仁, Mitsuo Shimada, 川田祐子, 齋藤裕, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 進行性肝細胞癌に対するソラフェニブの位置付け., 第22回日本肝胆膵外科学会学術集会, May 2010.
2428.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 齋藤裕, 川田祐子, 山田眞一郎 and Hidenori Miyake : 肝内胆管癌におけるHDAC阻害剤の効果の検討., 第22回日本肝胆膵外科学会学術集会, May 2010.
2429.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 齋藤裕, 川田祐子 and Hidenori Miyake : 大腸癌肝転移治癒切除症例に対する術後補助化学療法としてのIRISの有効性及び化療著効後肝切除症例の予後に関する検討., 第22回日本肝胆膵外科学会学術集会, May 2010.
2430.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 川田祐子 and Hidenori Miyake : 肝胆膵高度技能医を目指す若手外科医の膵頭十二指腸切除術., 第22回日本肝胆膵外科学会学術集会, May 2010.
2431.	Satoru Imura, Mitsuo Shimada, 齋藤裕, 川田祐子, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya, Nobuhiro Kurita and Hidenori Miyake : 腹腔鏡下肝切除の術式定型化に必要なもの∼合併症対策と開腹手術手技の応用∼., 第22回日本肝胆膵外科学会学術集会, May 2010.
2432.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 川田祐子 : 新規化学療法により切除可能となった両葉多発性肝転移症例の経験., 第22回日本肝胆膵外科学会学術集会, May 2010.
2433.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 川田祐子 and Hidenori Miyake : 安全確実な拡大肝左葉切除標準化の工夫., 第22回日本肝胆膵外科学会学術集会, May 2010.
2434.	Satoru Imura, Mitsuo Shimada, 齋藤裕, 川田祐子, 岩橋衆一, Jun Hanaoka, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya, Nobuhiro Kurita and Hidenori Miyake : 肝胆膵外科高度技能医を目指す若手外科医の肝臓手術∼グリソン一括処理による肝右葉切除術∼., 第22回日本肝胆膵外科学会学術集会, May 2010.
2435.	Toru Utsunomiya, Mitsuo Shimada, Jun Hanaoka, Satoru Imura, 齋藤裕, 川田祐子, 岩橋衆一, Hiroki Mori, Tetsuya Ikemoto and Yuji Morine : Gd-EOB-DTPA造影MRIを用いた新規肝予備能評価法に関する検討., 第22回日本肝胆膵外科学会学術集会, May 2010.
2436.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : 進行下部直腸癌に対する術前化学放射線療法を併用した腹腔鏡下手術手技, 第64回手術手技研究会, May 2010.
2437.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 川田祐子 : エコーガイド下グリソン先行遮断による系統的縮小肝切除術., 第64回手術手技研究会, May 2010.
2438.	Hisami Okumura, 山内利香, 浦野恵利, Satoru Imura, Toru Utsunomiya and Mitsuo Shimada : 肝疾患患者に対するテーラーメイド栄養管理の血液生化学指標についての検討, 第33回日本栄養アセスメント研究会, May 2010.
2439.	川田祐子, Hiromitsu Takizawa, Hiroaki Toba, Yasushi Nakagawa, Koichiro Kenzaki, Shoji Sakiyama, Kazuya Kondo, Mitsuo Shimada and Akira Tangoku : 先天性心膜欠損を合併した肺嚢胞症の一切除例, 第27回日本呼吸器外科学会総会, May 2010.
2440.	Zhi-Rong Qian, 王路, 中園雅彦, Toshihito Tanahashi, Katsuhiko Yoshimoto, Yoshimi Bando, Eiji Kudo, Mitsuo Shimada and Toshiaki Sano : High Expression of TLR4/MyD88 Signals Correlates with Poor Prognosis in Colorectal Cancer., 第99回日本病理学会総会, Apr. 2010.
2441.	Kouzou Yoshikawa, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, 柏原秀也, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子 and 小松正人 : PET-CTによる悪性度診断に基づいたGISTに対する術前メシル酸イマチニブ療法導入の検討, 第96回日本消化器病学会総会, Apr. 2010.
2442.	Masanori Nishioka, Mitsuo Shimada and Nobuhiro Kurita : 医療費削減および副作用軽減を目指したmodified OPTIMOX療法, 第96回日本消化器病学会総会, Apr. 2010.
2443.	Takashi Iwata, Mitsuo Shimada and Nobuhiro Kurita : 根治切除不能進行胃癌に対するTS-1+paclitaxel腹腔内投与-phase 1 studyと予後予測因子としてのTHBS1発現の意義, 第96回日本消化器病学会総会, Apr. 2010.
2444.	Nobuhiro Kurita, Mitsuo Shimada and Takashi Iwata : 進行再発胃癌におけるTHBS1・HDAC1発現の意義血管新生の観点から, 第96回日本消化器病学会総会, Apr. 2010.
2445.	Hiroki Mori, Mitsuo Shimada, Satoru Imura, 齋藤裕, 川田祐子, 岩橋衆一, Jun Hanaoka, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 肝移植後の再発肝癌に対する治療戦略と肝移植後Follow upの問題点., 第96回日本消化器病学会総会, Apr. 2010.
2446.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, 岩橋衆一, 齋藤裕, 川田祐子 and Masafumi Harada : Gd-EOB-DTPA造影MRI肝細胞造影相における造影効果と99mTc-GSAの相関に関する検討., 第96回日本消化器病学会総会, Apr. 2010.
2447.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕, 川田祐子, Nobuhiro Kurita and Hidenori Miyake : 肉眼的脈管侵襲陽性肝癌に対するIFP療法の効果および切除不能肝癌に対するソラフェニブの使用経験., 第96回日本消化器病学会総会, Apr. 2010.
2448.	岩橋衆一, Mitsuo Shimada, Yuji Morine, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 川田祐子, Nobuhiro Kurita and Hidenori Miyake : StageIVb進行胆嚢癌に対する集学的治療戦略., 第96回日本消化器病学会総会, Apr. 2010.
2449.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Jun Hanaoka, 岩橋衆一, 齋藤裕 and 川田祐子 : IPMNに対するFoxp3+CD4+CD25+細胞による手術適応と予後に関する研究., 第96回日本消化器病学会総会, Apr. 2010.
2450.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, 小松正人, 岩橋衆一, 齋藤裕 and 川田祐子 : 肝内胆管癌の治療戦略における癌幹細胞の意義., 第96回日本消化器病学会総会, Apr. 2010.
2451.	Toru Utsunomiya, Mitsuo Shimada and Satoru Imura : 非癌部肝組織における遺伝子発現解析に基づく新規分子マーカーの探索., 第96回日本消化器病学会総会, Apr. 2010.
2452.	Akira Nii, Mitsuo Shimada, Hiroo Takehara, 久山寿子, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 川田佑子, 齋藤裕, Nobuhiro Kurita and Hidenori Miyake : MHN-02を介してUCP-2Severe NAFL model rat における虚血再灌流を改善する(第2報), 第110回日本外科学会定期学術集会, Apr. 2010.
2453.	久山寿子, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Nobuhiro Kurita, Hidenori Miyake, Akira Nii and Hiroo Takehara : 膵・胆管合流異常症に関する実験的検討:ラット胆管拡張モデル, 第110回日本外科学会定期学術集会, Apr. 2010.
2454.	福岡かおる, Mitsuo Shimada, 桑原知己, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : 大腸中湯投与による抗炎症作用と腸管マイクロビオームの変化の検討, 第110回日本外科学会定期学術集会, Apr. 2010.
2455.	仁木亮介, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人, 柏原秀也 and Toru Utsunomiya : 直腸癌腹腔鏡下手術における縫合不全危険因子の検討, 第110回日本外科学会定期学術集会, Apr. 2010.
2456.	黒田武志, Mitsuo Shimada, 柏原秀也, 小松正人, 大浦涼子, 中尾寿宏, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Takashi Iwata, Nobuhiro Kurita and Toru Utsunomiya : 術後癒着形成のリスクからみた腹腔鏡手術の有用性:ドレーン中分子マーカーの測定から, 第110回日本外科学会定期学術集会, Apr. 2010.
2457.	尾形信也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人, 柏原秀也 and Toru Utsunomiya : 大腸癌におけるThorombospondin1の発現とその意義, 第110回日本外科学会定期学術集会, Apr. 2010.
2458.	柏原秀也, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子 and 小松正人 : 進行再発胃癌化学療法におけるThrombospondin1と予後との関係と機序およびSkiによるTGFβ阻害に関する検討, 第110回日本外科学会定期学術集会, Apr. 2010.
2459.	小松正人, Mitsuo Shimada, Masanori Nishioka, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 柏原秀也 and Toru Utsunomiya : オリドニンの放射線増感作用に関する検討, 第110回日本外科学会定期学術集会, Apr. 2010.
2460.	大浦涼子, 柏原秀也, 小松正人, 中尾寿宏, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Takashi Iwata, Nobuhiro Kurita and Mitsuo Shimada : ラット小腸虚血再灌流傷害に対するGeranylgeranylacetone(GGA)誘導heat shock protein(HSP)の軽減効果の検討—第2報—, 第110回日本外科学会定期学術集会, Apr. 2010.
2461.	Motoya Chikakiyo, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 小松正人, 大浦涼子 and 柏原秀也 : MCD+HF (High fat) rat modelにおけるRubino手術のNASH予防効果(第2報), 第110回日本外科学会定期学術集会, Apr. 2010.
2462.	Tomohiko Miyatani, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : 非治癒因子別に検討したStage IV胃癌に対する外科治療の意義, 第110回日本外科学会定期学術集会, Apr. 2010.
2463.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 小松正人, 大浦涼子 and 柏原秀也 : 胃癌腹膜播種に対するTS-1併用paclitaxel腹腔内投与の臨床第I相試験, 第110回日本外科学会定期学術集会, Apr. 2010.
2464.	Masanori Nishioka, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏 and 小松正人 : 進行再発大腸癌に対するベバシズマブ併用化学療法の検討:地方からの均てん化への提言, 第110回日本外科学会定期学術集会, Apr. 2010.
2465.	Takashi Iwata, Mitsuo Shimada, 柏原秀也, 小松正人, 中尾寿宏, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka and Nobuhiro Kurita : 内視鏡手術時代における教育のノウハウと工夫:内視鏡外科技術認定医とStep by step のトレーニングの有用性, 第110回日本外科学会定期学術集会, Apr. 2010.
2466.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : 消化管癌におけるepigenetics異常の意義:HDAC1・MTA1発現の観点から, 第110回日本外科学会定期学術集会, Apr. 2010.
2467.	Chie Mikami, Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, 斎藤裕, 岩橋衆一, Jun Hanaoka, 金本真美, Tetsuya Ikemoto, Yuji Morine, Hidenori Miyake and Nobuhiro Kurita : 非癌部肝組織におけるstathmin1遺伝子発現解析による肝切除後多中心性再発の予測, 第110回日本外科学会定期学術集会, Apr. 2010.
2468.	冨澤和馬, Mitsuo Shimada, 小松正人, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, 中尾寿宏, 柏原秀也, 岩橋衆一 and Toru Utsunomiya : 癌幹細胞をtargetとした大腸癌治療の実験的検討, 第110回日本外科学会定期学術集会, Apr. 2010.
2469.	後藤正和, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : CD-DST法による胃癌に対する5-FU感受性と臨床病理学的因子との相関に関する研究, 第110回日本外科学会定期学術集会, Apr. 2010.
2470.	中尾寿宏, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人, 柏原秀也 and Toru Utsunomiya : CPT11によるBacterial Translocationの発症とTight Junction傷害, 第110回日本外科学会定期学術集会, Apr. 2010.
2471.	Jun Higashijima, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : C13を用いた空腸吸収能検査・Radioisotope(RI)法による排出能検査からみた胃全摘術後空腸嚢付加Roux-en-Y再建の意義, 第110回日本外科学会定期学術集会, Apr. 2010.
2472.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : micro RNA発現による進行下部直腸癌に対するCRTの効果予測, 第110回日本外科学会定期学術集会, Apr. 2010.
2473.	和田佑馬, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, 川田祐子, Nobuhiro Kurita and Hidenori Miyake : 非B非C肝癌におけるメタボリック症候群., 第110回日本外科学会定期学術集会, Apr. 2010.
2474.	片山智博, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, 川田祐子, Hidenori Miyake and Nobuhiro Kurita : 細胆管癌・混合型肝癌における癌幹細胞マーカー発現の検討., 第110回日本外科学会定期学術集会, Apr. 2010.
2475.	甲斐田剛圭, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, 川田祐子, Nobuhiro Kurita and Hidenori Miyake : 生体肝移植ドナーにおける肝鬱血領域の与える影響., 第110回日本外科学会定期学術集会, Apr. 2010.
2476.	浅野間理仁, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, 川田祐子, Nobuhiro Kurita and Hidenori Miyake : 肝内胆管癌における癌幹細胞の存在と発現意義., 第110回日本外科学会定期学術集会, Apr. 2010.
2477.	山田眞一郎, 柏原秀也, 小松正人, 中尾寿宏, Tomohiko Miyatani, Jun Higashijima, Kouzou Yoshikawa, Shinya Morimoto, Masanori Nishioka, Takashi Iwata, Nobuhiro Kurita and Mitsuo Shimada : ヒト脂肪由来幹細胞は膵癌細胞の増殖を抑制する., 第110回日本外科学会定期学術集会, Apr. 2010.
2478.	齋藤裕, Mitsuo Shimada, Tetsuya Ikemoto, 杉本光司, 岩橋衆一, 川田祐子, Jun Hanaoka, 金本真美, Yuji Morine, Satoru Imura, Toru Utsunomiya, Nobuhiro Kurita, Hidenori Miyake and 松本慎一 : IDO+樹状細胞が誘導する調節生T細胞を用いた免疫寛容誘導の機序解明., 第110回日本外科学会定期学術集会, Apr. 2010.
2479.	川田祐子, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, Nobuhiro Kurita and Hidenori Miyake : CTを用いた内臓脂肪量測定値が肝切除術に対して与える影響の検討., 第110回日本外科学会定期学術集会, Apr. 2010.
2480.	岩橋衆一, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 齋藤裕, 川田祐子, Hidenori Miyake and Nobuhiro Kurita : ヒストン脱アセチル化酵素阻害剤による胆管癌細胞株に対するGemcitabine併用化学療法増強効果の検討., 第110回日本外科学会定期学術集会, Apr. 2010.
2481.	徳永卓哉, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, 川田祐子, Hidenori Miyake and Nobuhiro Kurita : ヒストン脱アセチル化酵素阻害剤による膵癌細胞株に対するGemcitabine及びinterferon-α併用化学療法増強効果の検討., 第110回日本外科学会定期学術集会, Apr. 2010.
2482.	杉本光司, Mitsuo Shimada, Tetsuya Ikemoto, 川田祐子, 齋藤裕, 岩橋衆一, Jun Hanaoka, Yuji Morine, Satoru Imura, Toru Utsunomiya and 花本慎一 : アメリカ・日本間の国際膵島輸送に関する検討., 第110回日本外科学会定期学術集会, Apr. 2010.
2483.	金本真美, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 岩橋衆一, 齋藤裕, Hidenori Miyake and Nobuhiro Kurita : 閉塞性黄疸患者における因蔯嵩湯の効果., 第110回日本外科学会定期学術集会, Apr. 2010.
2484.	Jun Hanaoka, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, 岩橋衆一, 齋藤裕, Hidenori Miyake, Nobuhiro Kurita and 原田雅文 : Gd-EOB-DTPA造影MRI肝細胞造影相における造影効果と肝アシアロシンチグラフィーの相関に関する検討., 第110回日本外科学会定期学術集会, Apr. 2010.
2485.	荒川悠佑, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, 金本真美, Jun Hanaoka, 杉本光司, 岩橋衆一, 齋藤裕, Nobuhiro Kurita and Hidenori Miyake : 膵頭十二指腸切除術におけるExternal stent (RTBD)の必要性に関する検討(RCT)., 第110回日本外科学会定期学術集会, Apr. 2010.
2486.	篠原永光, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Hiroki Mori, 岩橋衆一, 齋藤裕, 川田祐子, Hidenori Miyake and Nobuhiro Kurita : 大腸癌肝転移に対する新規化学療法著効後肝切除例の検討., 第110回日本外科学会定期学術集会, Apr. 2010.
2487.	Tetsuya Ikemoto, Mitsuo Shimada, 川田祐子, 岩畔英樹, 齋藤裕, 小松正人, 金本真美, Jun Hanaoka, Yuji Morine, Satoru Imura and Toru Utsunomiya : 糖能傷害に対する脂肪由来幹細胞導入の基礎的検討., 第110回日本外科学会定期学術集会, Apr. 2010.
2488.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 小松正人, 岩橋衆一, 齋藤裕, 川田祐子, Nobuhiro Kurita and Hidenori Miyake : 肝内胆管癌における癌幹細胞の発現意義と治療戦略としての可能性., 第110回日本外科学会定期学術集会, Apr. 2010.
2489.	Satoru Imura, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, 川田祐子, Nobuhiro Kurita and Hidenori Miyake : 定型化による安全確実な腹腔鏡下左肝切除術., 第110回日本外科学会定期学術集会, Apr. 2010.
2490.	寺澤敏秀, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, 川田祐子, Hidenori Miyake and Nobuhiro Kurita : 胆嚢癌におけるThrombospondin1発現の意義., 第110回日本外科学会定期学術集会, Apr. 2010.
2491.	Hidenori Miyake, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 斎藤裕, 川田祐子 and Nobuhiro Kurita : 胆道癌におけるHMGB1発現の意義., 第110回日本外科学会定期学術集会, Apr. 2010.
2492.	Hiroki Mori, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, 川田祐子, Nobuhiro Kurita and Hidenori Miyake : 生体肝移植ドナーにおける門脈血流支配領域を考慮した完全左葉グラフト採取手技., 第110回日本外科学会定期学術集会, Apr. 2010.
2493.	Toru Utsunomiya, Mitsuo Shimada, Satoru Imura, 齋藤裕, 川田祐子, 岩橋衆一, Jun Hanaoka, 金本真美, Tetsuya Ikemoto and Yuji Morine : エコーガイド下グリソン先行遮断による合理的な肝細胞癌に対する系統的縮小肝切除術., 第110回日本外科学会定期学術集会, Apr. 2010.
2494.	松本規子, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, 金本真美, 岩橋衆一, 齋藤裕, Nobuhiro Kurita and Hidenori Miyake : 黄疸肝における肝・脾臓内遺伝子発現の変化., 第110回日本外科学会定期学術集会, Apr. 2010.
2495.	西正暁, Toru Utsunomiya, Mitsuo Shimada, 齋藤裕, 岩橋衆一, Jun Hanaoka, 金本真美, Tetsuya Ikemoto, Yuji Morine, Hidenori Miyake and Nobuhiro Kurita : 肝細胞癌におけるIFI27遺伝子発現の臨床病理学的特徴., 第110回日本外科学会定期学術集会, Apr. 2010.
2496.	山井礼道, Yota Yamamoto, 湯浅康弘, Takahiro Yoshida, Jun-ichi Seike, Mitsuo Shimada and Akira Tangoku : 食道癌腹膜転移モデルを用いた植物化学サプリメント併用化学療法の検討, 第110回日本外科学会定期学術集会, Apr. 2010.
2497.	Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto and Shinya Morimoto : 肝細胞癌の長期生存を得るためのベストチョイスは何か?, 第110回日本外科学会定期学術集会, Apr. 2010. (Keyword) 学会
2498.	Kouzou Yoshikawa, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, Tomohiko Miyatani, 大浦涼子, 中尾寿宏, 小松正人 and 柏原秀也 : Bevacizumab併用化学療法中の緊急手術における問題点の検討, 第46回日本腹部救急医学会, Mar. 2010.
2499.	中尾寿宏, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 大浦涼子, 小松正人 and 柏原秀也 : 進行・再発大腸癌に対するベバシズマブ併用化学療法の検討 -特に術前化学療法の有用性について, 第43回制癌剤適応研究会, Mar. 2010.
2500.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 大浦涼子, 中尾寿宏, 小松正人 and 柏原秀也 : 切除不能進行胃癌に対するTS-1併用paclitaxel腹腔内投与臨床I相試験, 第43回制癌剤適応研究会, Mar. 2010.
2501.	小松正人, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, Kouzou Yoshikawa and 柏原秀也 : 胃癌術前におけるMDCTを用いたナビゲーションの工夫, 第82回日本胃癌学会総会, Mar. 2010.
2502.	中尾寿宏, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 大浦涼子, 小松正人, 柏原秀也 and Toru Utsunomiya : 進行再発胃癌化学療法におけるThrombospondin1の発現と意義, 第82回日本胃癌学会総会, Mar. 2010.
2503.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 小松正人 and 柏原秀也 : 腹膜播種を伴う胃癌に対するTS-1併用paclitaxel腹腔内投与における薬物動態及び予後予測因子に関する検討, 第82回日本胃癌学会総会, Mar. 2010.
2504.	Nobuhiro Kurita, Mitsuo Shimada, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, 中尾寿宏, 大浦涼子, 小松正人 and 柏原秀也 : 深達度診断から検討した胃癌に対する腹腔鏡補助下胃切除手術の適応拡大, 第82回日本胃癌学会総会, Mar. 2010.
2505.	Kouzou Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, 柏原秀也 and Chie Takasu : StageⅣ胃癌における転移部位別の外科的治療意義と抗癌剤治療における予後予測因子, 第83回日本胃癌学会総会, Mar. 2010.
2506.	Masanori Nishioka, Mitsuo Shimada, Toru Utsunomiya, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 大浦涼子, 小松正人, 柏原秀也 and Hidenori Miyamoto : 進行下部直腸癌に対する術前化学放射線療法併用腹腔鏡下手術の短期成績, 第24回四国内視鏡外科研究会, Feb. 2010.
2507.	松本早代, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 大浦涼子, 柏原秀也 and Mitsuo Shimada : 胃癌術後の内ヘルニアによる大量腸切除を施行し救命し得た1例, 第18回徳島外科術後管理研究会, Feb. 2010.
2508.	岸佳史, マクレッドアハマッド, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Mitsuo Shimada and Hiromu Nishitani : 腹部マルチスライスCT画像からの肝臓領域の抽出, 電子情報通信学会技術報告医用画像, Vol.109, No.407, 453-455, Jan. 2010.
2509.	Maklad Ahmed, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Mitsuo Shimada and Hiromu Nishitani : Computer aided surgery system for liver transplantation using contrast enhanced CT images, IEICE Technical Report Medical Imaging, Vol.109, No.407, 41-44, Jan. 2010.
2510.	浦野恵利, Hisami Okumura, 松本大, 山内利香, Mitsuo Shimada and Eiji Takeda : 肝疾患患者に対するテーラーメイド栄養管理の血液生化学指標についての検討, 第13回日本病態栄養学会年次学術集会, Jan. 2010.
2511.	Shinya Morimoto, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Masanori Nishioka, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 大浦涼子, 柏原秀也 and Toru Utsunomiya : 当科における小腸癌の診断と治療, 第72回大腸癌研究会, Jan. 2010.
2512.	Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kouzou Yoshikawa, Jun Higashijima, 中尾寿宏, 大浦涼子, 小松正人, 柏原秀也 and Hidenori Miyamoto : StageIII大腸癌に対する腹腔鏡下手術のリンパ節郭清と予後, 第72回大腸癌研究会, Jan. 2010.
2513.	政清史晃, Shinsuke Saita, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Kouzou Yoshikawa, Mitsuo Shimada and Hiromu Nishitani : PET/CTとDWI-MRを用いた腹部転移陽性リンパ節のROC解析, 第79回パターン計測部会研究会, Jul. 2009.
2514.	Maklad S. Ahmed, Yoshihumi Kishi, Yoshiki Kawata, Noboru Niki, Masanori Nishioka and Mitsuo Shimada : Liver segmentation algorithm based on extraction of main portal and hepatic veins from multislice CT images, IEICE Technical Report Medical Imaging, Vol.109, No.127, 63-68, Jul. 2009.
2515.	A.S.Mohamed Maklad, Yoshifumi Kishi, Mitsuru Kubo, Yoshiki Kawata, Noboru Niki, Masanori Nishioka and Mitsuo Shimada : Liver segmentation based on extraction of portal and hepatic veins from CT images, 電子情報通信学会技術研究報告医用画像, Vol.108, No.271, 11-16, Oct. 2008.
2516.	A.S.Mohamed Maklad, Yoshihumi Kishi, Mitsuru Kubo, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Mitsuo Shimada and Hiromu Nishitani : Hepatic blood vessels detection from multi slice CT images, Medical Imaging Technology, P37, Aug. 2008.
2517.	岸佳史, A.S.Mohamed Maklad, Mitsuru Kubo, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Mitsuo Shimada and Hiromu Nishitani : 多時相マルチスライスCT画像の肝臓の画像解析, Medical Imaging Technology, P35, Aug. 2008.
2518.	政清史晃, Mitsuru Kubo, Yoshiki Kawata, Noboru Niki, 西岡将規, 宮本英典, 吉川幸造, Mitsuo Shimada and Hiromu Nishitani : 腹部CT画像を用いた肥大リンパ節の抽出アルゴリズム, 電子情報通信学会技術研究報告, Vol.108, No.47, 55-58, May 2008.
2519.	政清史晃, Mitsuru Kubo, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Hidenori Miyamoto, Mitsuo Shimada and Hiromu Nishitani : マルチモダリティ画像を用いた腹部リンパ節の特定アルゴリズム, 電子情報通信学会技術研究報告医用画像, Vol.107, No.326, 43-48, Nov. 2007.
2520.	三宅講太朗, Masanori Nishioka, 杉本光司, 宮谷知彦, Yoshihiro Uto, Hideko Nagasawa, Hitoshi Hori and Mitsuo Shimada : 直腸癌に対する低酸素細胞放射線増感剤TX-1877の放射線増感作用と抗腫瘍効果に関する基礎的研究, 第66回日本癌学会学術総会, Oct. 2007.
2521.	政清史晃, Mitsuru Kubo, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Hidenori Miyamoto, Mitsuo Shimada and Hiromu Nishitani : マルチモダリティ画像を用いた腹部リンパ腫特定に関する基礎的検討, 日本医用画像工学大会, C6-4, Jul. 2007.
2522.	政清史晃, Mitsuru Kubo, Yoshiki Kawata, Noboru Niki, Masanori Nishioka, Hidenori Miyamoto, Mitsuo Shimada and Hiromu Nishitani : CT画像を用いた腹部センチネルリンパ節の自動抽出に関する研究, 電子情報通信学会技術研究報告医用画像, Vol.106, No.510, 69-72, Jan. 2007.
2523.	三宅講太朗, 西岡将規, Hideko Nagasawa, Yoshihiro Uto, Hitoshi Hori and Mitsuo Shimada : 膵臓癌に対する低酸素細胞放射線増感剤TX-1877誘導体の放射線増感作用と抗腫瘍効果に関する基礎的研究, 第65回日本癌学会学術総会, Sep. 2006.
2524.	Seisuke Okamura, 木村哲夫, 板垣達三, 井本佳孝, 梶雅子, Hiroshi Miyamoto, Naoki Muguruma, Susumu Ito, 西岡将規 and Mitsuo Shimada : 輪状潰瘍瘢痕によるイレウス症状を呈した小腸結核の一例, 第85回日本消化器病学会四国支部例会, Jun. 2006.
2525.	Masahiko Fujii, Satoru Imura and Mitsuo Shimada : 進行肝癌に対する術後IFN併用化学療法と肝移植の適応, DDW-Japan2005(第9回日本肝臓学会大会), Oct. 2005.
2526.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, Mitsuo Shimada and 前原喜彦 : 九州大学における肝移植:生体肝移植の役割と位置づけ, DDW2005 シンポジウム, Oct. 2005.
2527.	Yuji Soejima, Mitsuo Shimada, Akinobu Taketomi, Tomoharu Sumiyoshi, Hideaki Uchiyama, Tomonobu Gion, Noboru Harada, Yusuke Yonemura, Hideki Ijichi and Yoshihiko Maehara : Role of cyclosporine in living donor liver transplantation:Kyushu university experience, 学術国際シンポジウム「免疫の進化」, Aug. 2005.
2528.	Masahiko Fujii, Satoru Imura, Yuji Morine, 池本哲也, Yuji Soejima and Mitsuo Shimada : 肝右葉切除における機会吻器を用いた安全なGlisson 鞘一括処理, 第60回日本消化器外科学会総会, Jul. 2005.
2529.	Nobuhiro Kurita, Takashi Iwata, 西岡将規, 本田純子, Tsutomu Ando, Atsushi Umemoto and Mitsuo Shimada : 胃全摘後空腸嚢を用いたRoux-en Y再建症例の検討, 第60回日本消化器外科学会定期学術総会, Jul. 2005.
2530.	Masahiko Fujii, Satoru Imura, Yuji Morine, 池本哲也, Yuji Soejima and Mitsuo Shimada : B型肝炎合併肝細胞癌に対する生体肝移植, 第83回日本消化器病学会四国支部例会, Jun. 2005.
2531.	Masahiko Fujii, Satoru Imura, Yuji Morine, 池本哲也 and Mitsuo Shimada : Small-for-size graft における肝不全の病態と対策, 第17回日本肝胆膵外科学会, Jun. 2005.
2532.	Masahiko Fujii, 安藤勤, Satoru Imura, Yuji Morine, 西岡将規, 池本哲也 and Mitsuo Shimada : 大腸癌肝転移に対する外科的治療の意義, 第41回日本肝癌研究会, Jun. 2005.
2533.	Masahiko Fujii, Yuji Morine, Satoru Imura, 池本哲也, Seiki Tashiro, 寺澤敏秀, 三宅秀則 and Mitsuo Shimada : ss胆嚢癌に対する至適術式としてのS4a+S5区域切除術, 第105回日本外科学会総会, May 2005.
2534.	Nobuhiro Kurita, Takashi Iwata, 西岡将規, Tsutomu Ando and Mitsuo Shimada : 新たなbacterial translocationの臨床的評価法の開発, 第105回日本外科学会定期学術集会, May 2005.
2535.	Nobuhiro Kurita, Takashi Iwata, 西岡将規, Tsutomu Ando and Mitsuo Shimada : 進行胃癌症例に対する術前科学療法の意義, 第77回日本胃癌学会総会, May 2005.
2536.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, 原田昇, 伊地知秀樹, 米村祐輔, Mitsuo Shimada and 前原喜彦 : 移植医からみたHCV陽性レシピエントの対応, 伊豆肝臓カンファレンス2004, Dec. 2004.
2537.	Nobuhiro Kurita, Takashi Iwata, 新居章, 池本哲也, 西岡将規, Tsutomu Ando and Mitsuo Shimada : 胃癌に対する鏡視下手術の経験, 第17回日本内視鏡外科学会総会, Nov. 2004.
2538.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, 原田昇, 伊地知秀樹, 米村祐輔, Mitsuo Shimada and 前原喜彦 : 生体肝移植におけるドナー選択の問題点と対策, 第8回日本肝臓学会DDW2004パネルディスカッション, Oct. 2004.
2539.	Nobuhiro Kurita, Takashi Iwata, 小笠原卓, 池本哲也, 西岡将規 and Mitsuo Shimada : D2郭清を行ったfStageⅢ胃癌症例の検討, 第66回日本臨床外科学会総会, Oct. 2004.
2540.	Masahiko Fujii, Yuji Morine, Satoru Imura, 篠原永光 and Mitsuo Shimada : 高度血管侵襲陽性肝細胞癌に対する治療戦略, 第66回日本臨床外科学会総会, Oct. 2004.
2541.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, 原田昇, 伊地知秀樹, 米村祐輔, Mitsuo Shimada and 前原喜彦 : 生体肝移植におけるC型肝炎再発に対する戦略, 第40回日本移植学会パネルディスカッション, Sep. 2004.
2542.	Masahiko Fujii, Yuji Morine, Satoru Imura, 篠原永光 and Mitsuo Shimada : 肝細胞癌に対する生体肝移植の現状と展望, 第22回中四国臨床臓器移植研究会, Aug. 2004.
2543.	Yuji Soejima, 武冨紹信, Mitsuo Shimada, 吉住朋晴, 内山秀昭, 原田昇, 伊地知秀樹, 米村祐輔 and 前原喜彦 : 生体肝移植における術前・術後の門脈血栓・閉塞に対する血行再建, 第59回日本消化器外科学会ビデオシンポジウム, Jul. 2004.
2544.	Yuji Soejima, 武冨紹信, Mitsuo Shimada, 吉住朋晴, 内山秀昭, 原田昇, 伊地知秀樹, 米村祐輔 and 前原喜彦 : 生体肝移植における術前・術後の門脈血栓・閉塞に対する血行再建, 第22回日本肝移植研究会ビデオフォーラム, Jul. 2004.
2545.	Masahiko Fujii, Yuji Morine, Satoru Imura, 篠原永光 and Mitsuo Shimada : 肝細胞癌に対する生体肝移植の現状と展望, 第81回日本消化器病学会四国支部例会, Jun. 2004.
2546.	Yuji Soejima, 武冨紹信, 吉住朋晴, 内山秀昭, 原田昇, 伊地知秀樹, 米村祐輔, 調憲, Mitsuo Shimada and 前原喜彦 : 進行肝細胞癌に対する根治的治療法としての生体肝移植と将来展望, 第40回日本肝癌研究会ワークショップ, Jun. 2004.
2547.	Yuji Soejima, Mitsuo Shimada, 調憲, 田中真二, 末廣剛敏, 武冨紹信, 吉住朋晴 and 前原喜彦 : 進行肝細胞癌に対する根治的治療法としての生体肝移植, 第104回日本外科学会定期学術集会パネルディスカッション, Apr. 2004.
2548.	Yuji Soejima, Mitsuo Shimada, 吉住朋晴 and 前原喜彦 : 生体肝移植後のB型肝炎の再発と予防戦略, 第6回日本肝臓学会大会ワークショップ, Oct. 2003.
2549.	Yuji Soejima, Mitsuo Shimada, 末廣剛敏, 吉住朋晴 and 前原喜彦 : 肝細胞癌に対する生体肝移植の適応と問題点, 第15回日本肝胆膵外科学会シンポジウム, May 2003.
2550.	Yuji Soejima, Mitsuo Shimada, 末廣剛敏, 吉住朋晴 and 前原喜彦 : 生体肝移植後のB型肝炎再発に対する戦略, 第21回日本肝移植研究会シンポジウム, Apr. 2003.
2551.	Mitsuo Shimada : 肝不全治療の選択肢としての生体肝移植, 三区連合内科医学術講演会, Nov. 2002.
2552.	Yuji Soejima, Mitsuo Shimada, 末廣剛敏, 廣重彰二, 寺師貴啓, 二宮瑞樹, 塩谷聡子, 原田昇, 伊地知秀樹, 米村祐輔 and 前原喜彦 : 肝癌に対する生体肝移植パネルディスカッション, 第20回日本肝移植研究会, Jul. 2002.
2553.	Mitsuo Shimada : 手術支援ロボットの進歩∼患者さんにより優しい治療をめざして∼, 話題の医学(テレビ放映), Jun. 2002.
2554.	Mitsuo Shimada : 九州大学における生体肝移植の現状と展望, 第40回肝臓クリニカルセミナー, May 2002.
2555.	Mitsuo Shimada : 九州大学における生体肝移植の現状, 第10回大分肝疾患研究会, Feb. 2002.
2556.	Mitsuo Shimada, 吉野一郎, 富川盛雅, 北村薫, 橋爪誠 and 杉町圭蔵 : Master-slave型手術支援ロボット``da Vinci''を用いた内視鏡下手術, ビデオシンポジウム, Nov. 2001.
2557.	Mitsuo Shimada : 九州大学における生体肝移植の現状, 中津医師会学術講演会, Oct. 2001.
2558.	Mitsuo Shimada, 富川盛雅, 橋爪誠 and 杉町圭蔵 : 手術支援ロボットの現状と課題∼Master-slave manipulatoe ``da Vinci''の使用経験から∼, シンポジウム, Oct. 2001.
2559.	Mitsuo Shimada, 播本憲史, 辻田英司, 前原伸一郎, 力丸竜也, 山下洋市, 田中真二, 調憲 and 杉町圭蔵 : 原発性肝癌に対する腹腔鏡下肝切除術, シンポジウム, Sep. 2001.
2560.	Mitsuo Shimada, 調憲, 田中真二, 山下洋市, 力丸竜也, 前原伸一郎, 辻田英司, 播本憲史 and 杉町圭蔵 : 肝癌に対するRFによる治療:ラジオ波の適応と効果肝癌に対する鏡視下radiofrequency ablationの治療成績, シンポジウム, Sep. 2001.
2561.	Mitsuo Shimada, 調憲, 足立英輔, 田中真二, 山下洋市, 力丸竜也, 前原伸一郎, 辻田英司, 播本憲史 and 杉町圭蔵 : 肝癌に対する腹腔鏡下肝切除術の妥当性, シンポジウム, Jul. 2001.
2562.	Mitsuo Shimada, 山下洋市 and 杉町圭蔵 : 臨床応用を前提とした肝癌の遺伝子治療:Electroporation法を用いたInterleukin-12の腫瘍内導入, シンポジウム, Apr. 2001.
2563.	Mitsuo Shimada, 辻田英司, 前原伸一郎, 力丸竜也, 山下洋市, 田中真二, 足立英輔 and 杉町圭蔵 : 肝切除における術式の工夫と低侵襲手術実現への挑戦, シンポジウム, Apr. 2001.
2564.	Mitsuo Shimada : 外科手術支援ロボットの進歩と課題, 日本コンピューター外科学会学術講演会特別講演, Mar. 2001.
2565.	Mitsuo Shimada and 杉町圭蔵 : Lipiodolization:歴史的変遷と臨床成績, 特別講演, Nov. 2000.
2566.	Mitsuo Shimada : 先端技術とカスタムメイド·ケア ∼医療の近未来像∼, 福岡県保険医協会支部総会, Sep. 2000.
2567.	Mitsuo Shimada, 調憲, 山下洋市, 中澤浩二, 井嶋博之, 船津和守 and 杉町圭蔵 : ハイブリッド型人工肝を用いた急性肝不全治療の可能性, シンポジウム, Mar. 2000.
2568.	Mitsuo Shimada, 宇都宮徹, 祇園智信, 長谷川博文, 濱津隆之, 山下洋市, 調憲 and 杉町圭蔵 : 手術侵襲に対する生体反応のmodulationによるLess Invasive Surgeryへの挑戦, シンポジウム, Jul. 1999.
2569.	Mitsuo Shimada, 宇都宮徹, 祇園智信, 田口健一, 長谷川博文, 山下洋市, 濱津隆之, 相島慎一, 竹中賢治 and 杉町圭蔵 : 再発肝細胞癌に対する戦略ー再切除における予後因子の検討からー, シンポジウム, Feb. 1999.
2570.	Mitsuo Shimada, 宇都宮徹, 祇園智信, 長谷川博文 and 杉町圭蔵 : 進行癌の予後因子と治療戦略, シンポジウム, Nov. 1998.
2571.	Mitsuo Shimada, 長谷川博文, 祇園智信, 調憲, 金田安史 and 杉町圭蔵 : 肝細胞癌における遺伝子診断と治療の可能性, シンポジウム, Oct. 1998.
2572.	Mitsuo Shimada, 調憲, 池田泰治, 梶山潔, 祇園智信, 長谷川博文, 矢永勝彦, 竹中賢治 and 杉町圭蔵 : 肝細胞癌切除後遺残再発のリスクファクターの解析ならびに対策, シンポジウム, Feb. 1998.
2573.	Mitsuo Shimada, 竹中賢治, 調憲, 前田貴司, 梶山潔, 藤原雄, 祇園智信 and 杉町圭蔵 : 小肝細胞癌に対する肝切除10年の成績:予後·再発因子からみた肝切除の意義と今後の課題, シンポジウム, Oct. 1996.
2574.	Mitsuo Shimada, 竹中賢治, 調憲, 前田貴司, 梶山潔, 藤原隆, 祇園智信 and 杉町圭蔵 : 進行肝癌に対する肝切除の適応と限界ー肝切除適応におけるVIscoreの意義, 第32回日本肝癌研究会シンポジウム, Jun. 1996.
2575.	Mitsuo Shimada, 竹中賢治, 矢永勝彦, 西崎隆, 調憲, 藤原雄, 祇園智信 and 杉町圭蔵 : 肝機能評価からみた肝細胞癌の術式の選択:過去10年間の肝切除術式術後重大合併症危険因子の検討, 第96回日本外科学会総会パネルディスカッション, Apr. 1996.
2576.	Mitsuo Shimada, 竹中賢治, 矢永勝彦, 西崎隆, 調憲 and 杉町圭蔵 : 肝切除における血液凝固異常と対策, ワークショップ, Nov. 1995.
2577.	Mitsuo Shimada, Kenji Takenaka, Takashi Matsumata, Akinobu Taketomi, Kazuharu Yamamoto and Keizo Sugimachi : Cytokine in surgical stress: change and regulation of cytokines in hepatectomy, International Symposium, Jul. 1994.
2578.	Mitsuo Shimada, 松股孝, 矢永勝彦, 西崎隆, 調憲, 武富紹信 and 杉町圭蔵 : 手術侵襲時の生体反応に関する最近の知見ー肝切除術におけるcytkine, prostaglandinおよび凝固線溶系の変動ー, 第30回日本外科代謝栄養学会シンポジウム, Jul. 1993.
2579.	Mitsuo Shimada : 医療情報システムの臓器移植へ寄与, ワークショップ, May 1990.
2580.	Mitsuo Shimada, 岡留健一郎, 東秀史, 池田哲夫, 竹中賢治 and 杉町圭蔵 : 肝保存における潅流液の流速波形の意義, パネルディスカッション, Apr. 1990.

Et cetera, Workshop:

1.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : 経肛門的内視鏡下直腸間膜切除術TaTME併用ロボット支援下直腸切除術の有用性, 日本消化器病学会四国支部第114回例会, Dec. 2020.
2.	Takuya Tokunaga, Mitsuo Shimada, Yu Saitou, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto, Toshiaki Yoshimoto and 杉本真樹 : Trans-perineal APRにおける術前VR・MRシミュレーション, 第29回日本コンピュータ外科学会大会, Nov. 2020.
3.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Mitsuo Shimada : 血液透析患者に対する胃癌手術症例の検討, 第58回日本癌治療学会学術集会, Oct. 2020.
4.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shohei Eto and Toshiaki Yoshimoto : ロボット支援下胃切除術における左側LCSの有用性, 第58回日本癌治療学会学術集会, Oct. 2020.
5.	Kouzou Yoshikawa, Mitsuo Shimada, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Yukako Takehara : 進行胃癌に対するロボット支援下胃切除術の有用性-地方からの提言-, 第74回手術手技研究会, Oct. 2020.
6.	高橋叡, Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Tetsuya Ikemoto : MRIが郭清範囲決定の一助となった早期胃癌の1例, 第120回日本外科学会定期学術集会, Aug. 2020.
7.	Yukako Takehara, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Mitsuo Shimada : 大腸癌におけるFrailの意義とメカニズムの検討, 第120回日本外科学会定期学術集会, Aug. 2020.
8.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yukako Takehara and Mitsuo Shimada : 血液透析患者に対する胃癌手術症例の検討, 第120回日本外科学会定期学術集会, Aug. 2020.
9.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Yu Saitou, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and 杉本真樹 : 直腸切断術TpTMEにおける術前VR・MRシミュレーションと術中尿道造影ナビゲーションの有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
10.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Toshiaki Yoshimoto : 腹腔鏡下胃・大腸癌手術における術前減量プログラムは短期成績改善に寄与する, 第120回日本外科学会定期学術集会, Aug. 2020.
11.	Masaaki Nishi, Mitsuo Shimada, Takuya Tokunaga, Kouzou Yoshikawa, Tomohiko Miyatani, Chie Takasu, Hideya Kashihara, Toshiaki Yoshimoto and Yukako Takehara : 下部直腸癌CRT後リンパ球CRP比(LCR)は予後不良因子になる, 第120回日本外科学会定期学術集会, Aug. 2020.
12.	Kouzou Yoshikawa, Mitsuo Shimada, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Toshiaki Yoshimoto : 胃癌術前T1N0症例における正診率向上の取り組み-的確なリンパ節郭清を目指して-, 第120回日本外科学会定期学術集会, Aug. 2020.
13.	Chie Takasu, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara and Yukako Takehara : 地方外科から発信するダイバーシティ・インクルージョンを目指した取り組み, 第120回日本外科学会定期学術集会, Aug. 2020.
14.	Toshiaki Yoshimoto, Yukako Takehara, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga, Tomohiko Miyatani, Kouzou Yoshikawa, Yuji Morine and Mitsuo Shimada : LED 光による新たな癌制御法の開発, 第261 回徳島医学会学術集会(令和 2 年度夏期), Aug. 2020.
15.	Toshiaki Yoshimoto, Yuji Morine, Kouzou Yoshikawa, Masatake Akutagawa, Takahiro Emoto, Mitsuo Shimada and Yohsuke Kinouchi : Blue light emitting diodeによる大腸癌増殖制御効果, LED総合フォーラム2020 in 徳島, 129-130, Feb. 2020.
16.	Sonoko Yasui-Yamada, Yu Ohiwa, Nozomi Aotani, Natsumi Kagiya, Mami Takimoto, 野村聡子, Yoshiko Suzuki, Hideya Kashihara, Yu Saitou, Masaaki Nishi, Mitsuo Shimada and Yasuhiro Hamada : 消化器癌患者における術前栄養・予後指標としてのPhase angleの臨床的実用性の検討, 第260回徳島医学会学術集会, Feb. 2020.
17.	Yuji Morine, Kouzou Yoshikawa, Masatake Akutagawa, Takahiro Emoto, Mitsuo Shimada and Yohsuke Kinouchi : Cliical impact of light emittng diode on digestive diseases, IEICE Technical Report (MBE), Vol.117, No.165, 1-6, Jul. 2017. (Keyword) LED / digestive cancer / regenerative medicine / photoreceptor
18.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, 山田眞一郎, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : InBodyを用いた体組成分析の肝胆膵外科手術における周術期栄養評価の有用性に関する検討, 第249回徳島医学会学術集会, Jul. 2014.
19.	Mami Kanamoto, Yasuhiro Hamada, Yutaka Nakaya, Eiji Takeda, Hisami Okumura, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori and Mitsuo Shimada : NST介入による周術期栄養管理の有用性に関する検討, Journal of Japan Surgical Society, Vol.115, No.2, 782, Mar. 2014. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573105977706375936 (CiNii: 1573105977706375936)
20.	N Kinjo, Mitsuo Shimada, Takashi Maeda, Shinji Tanaka, Ken Shirabe and Yoshihiko Maehara : Preoperatively undiagnosable intrahepatic bile duct dilatation contains early-stage intrahepatic cholangiocarcinoma, Hepato-Gastroenterology, Vol.52, No.65, 1368-1371, Sep. 2005. (Summary) Intrahepatic bile duct dilatation is a clue to indicating the presence of IHCC. Moreover it is still often difficult to find IHCC at an early stage in spite of recent progress in the area of molecular biological markers and imaging modalities. We had three interesting cases in which we were suspicious of the presence of IHCC. Preoperative imaging studies of these three cases showed the dilatation and stenosis of the intrahepatic bile duct without any apparent mass. As IHCC could not be ruled out, a hepatectomy was done for the purpose of both diagnosis and treatment of the patients. Postoperative diagnoses were IHCC in one, hepatolithiasis in another and chronic cholangitis in the third patient. A histological analysis revealed that the tumor of IHCC was not infiltrating the parenchyma of the liver with neither vascular nor lymphatic invasion, which suggested that it was an initial nature of the IHCC. In the case of intrahepatic bile duct dilatation and stenosis, which makes it hard to identify IHCC, surgical resection is crucial to make a definite diagnosis and prescribe the most effective course of treatment. (Keyword) Abdominal Pain / Adenocarcinoma / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Cholangiopancreatography, Endoscopic Retrograde / Dilatation, Pathologic / Humans / Liver Neoplasms / Male / Middle Aged (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16201076 ● Search Scopus @ Elsevier (PMID): 16201076 (PubMed: 16201076)
21.	Kazuhito Takamura, Hidenori Miyake, Hiroki Mori, Yoshiyasu Terashima, Tsutomu Ando, Masahiko Fujii, Seiki Tashiro and Mitsuo Shimada : Balloon occluded retrograde transvenous obliteration and percutaneous transhepatic obliteration for ruptured duodenal varices after operation for rectal cancer with multiple liver metastasis: report of a case, The Journal of Medical Investigation : JMI, Vol.52, No.3,4, 212-217, Aug. 2005. (Summary) We report a patient with duodenal varices oozing blood who had undergone low anterior resection of the rectum and resection of the liver tumor because of multiple liver metastasis from rectal cancer 80 months previously. Although endoscopic variceal ligation (EVL) was carried out for the ruptured duodenal varices, their bleeding persisted and hepatic encephalopathy also appeared. Finally, balloon occluded retrograde transvenous obliteration (BRTO) with percutaneous transhepatic obliteration (PTO) was carried out for the duodenal varices. Percutaneous transhepatic portography revealed detailed hemodynamics. Following PTO, the duodenal varices were stagnated by BRTO, and no complications were recognized. No re-bleeding episode has been observed since the treatment. In addition, the hepatic encephalopathy was also improved. (Keyword) Adult / Balloon Occlusion / Duodenum / Embolization, Therapeutic / Female / Humans / Liver Neoplasms / Postoperative Complications / Rectal Neoplasms / Rupture, Spontaneous / Varicose Veins (Tokushima University Institutional Repository) ● Metadata: 110780 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.52.212 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16167541 ● Search Scopus @ Elsevier (PMID): 16167541 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.52.212 (Tokushima University Institutional Repository: 110780, DOI: 10.2152/jmi.52.212, PubMed: 16167541)
22.	Kazuhito Takamura, Hidenori Miyake, Masahiko Fujii, Masaharu Nishi, Seiki Tashiro and Mitsuo Shimada : Multiple hepatic angiomyolipomas with a solitary omental angiomyolipoma, The Journal of Medical Investigation : JMI, Vol.52, No.3,4, 218-222, Aug. 2005. (Summary) Angiomyolipoma (AML) is a rare benign tumor that occurs most commonly in the kidney. Lesions in the liver are usually solitary and multiple AMLs of the liver are extremelyrare. Furthermore, extra renal or hepatic AML are rarely found. We report an unusual case of a 34-year-old man with a solitary omental AML and multiple hepatic AMLs. At the age of 23, the patient underwent right nephrectomy and enucleation of a left renal tumor because of bilateral AMLs. At the age of 34, more than 6 lesions in the liver and an enlarged solitary omental AML were discovered. The omental tumor, 50 x 40mm, 49g, was extirpated; it was well-defined and encapsulated a soft elastic mass. Histologically it was an epithelioid AML and positive for the melanogenesis-related marker HMB-45, the same as the earlier right renal tumor. We describe the first case of a solitary omental AML, which had metastasized, and with more than 6 hepatic AMLs. (Keyword) Adult / Angiomyolipoma / Humans / Liver Neoplasms / Male / Omentum / Peritoneal Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110781 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.52.218 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16167542 ● Search Scopus @ Elsevier (PMID): 16167542 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.52.218 (Tokushima University Institutional Repository: 110781, DOI: 10.2152/jmi.52.218, PubMed: 16167542)
23.	池本哲也, 西岡将規, 安藤勤, 八和田裕子, Yoshiyasu Terashima, Hitoshi Ikushima and Mitsuo Shimada : 術前放射線化学療法が著効した下部進行直腸癌の1例, Japanese Journal of Cancer and Chemotherapy, Vol.32, No.1, 95-97, 2005.
24.	Norifumi Harimoto, Mitsuo Shimada, Ken Shirabe, Shinji Tanaka, Akinobu Taketomi, Eiji Tsujita, Shin-ichiro Maehara, Shinji Itoh, Dai Kitagawa, Hiroshi Honda and Yoshihiko Maehara : Images of interest. Hepatobiliary and pancreatic: peritoneal dissemination mimicking liver metastases, Journal of Gastroenterology and Hepatology, Vol.19, No.8, 938, Aug. 2004. (Keyword) Angiography / Diagnosis, Differential / Diaphragm / Female / Gallbladder Neoplasms / Hepatic Artery / Humans / Liver Neoplasms / Ovarian Neoplasms / Peritoneal Neoplasms / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1440-1746.2004.03569.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15242502 ● Search Scopus @ Elsevier (PMID): 15242502 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1440-1746.2004.03569.x (DOI: 10.1111/j.1440-1746.2004.03569.x, PubMed: 15242502)
25.	米村祐輔, Mitsuo Shimada, 吉住朋晴, 武冨紹信 and 前原喜彦 : C型肝硬変に対する生体肝移植後に急速な経過をたどり死亡したfibrosing cholestatic hepatitis の一例, The Journal of the Japan Surgical Association, Vol.65, 3257-3262, 2004.
26.	三宅講太朗, 安藤道夫, 喜多良孝, 橋本崇代, 三宮建治, 櫛田明俊, 佐木川光 and Mitsuo Shimada : 上腸間膜静脈血栓症の一例, Shikoku Acta Medica, Vol.60, 106-109, 2004. (Tokushima University Institutional Repository) ● Metadata: 40066 (Tokushima University Institutional Repository: 40066)
27.	三宅講太朗, 安藤道夫, 喜多良孝, 橋本崇代, 三宮建治, 櫛田俊明, 佐木川光 and Mitsuo Shimada : 大腸癌に対する5-FU・アイソボリン療法で効果が認められた2例, Shikoku Acta Medica, Vol.60, 101-105, 2004. (Tokushima University Institutional Repository) ● Metadata: 40065 (Tokushima University Institutional Repository: 40065)
28.	Norifumi Harimoto, Mitsuo Shimada, Eiji Tsujita, Shinichiro Maehara, Tatsuya Rikimaru, Yo-ichi Yamashita, Takashi Maeda, Shinji Tanaka, Ken Shirabe and Keizo Sugimachi : Laparoscopic hepatectomy and dissection of lymph nodes for intrahepatic cholangiocarcinoma. Case report, Surgical Endoscopy, Vol.16, No.12, 1806, Dec. 2002.
29.	Shin-ichiro Maehara, Norifumi Harimoto, Eiji Tsujita, Tatsuya Rikimaru, Yo-ichi Yamashita, Shinji Tanaka, Eisuke Adachi, Ken Shirabe, Mitsuo Shimada and Keizo Sugimachi : Laparoscopy-assisted hepatectomy using the Endoclose: a case report, Surgical Endoscopy, Vol.16, No.9, 1363-1364, Sep. 2002. (Summary) Hemostasis of a resected stump of liver is extremely difficult in laparoscopic hepatectomy. Although Pringle's maneuver, which is a total clamping of the hepatoduodenal ligament, is a useful technique, it is often difficult in laparoscopic circumstances. Moreover, total inflow occlusion leads to postoperative liver damage. Therefore, the local bleeding method is ideal. The Endoclose, a device for port site closure, is formed from an outer sheath and an inner needle with a notch to load the suture. The Endoclose is loaded with a suture and passed through the liver. The suture is left under the liver, and the device is removed. Next, the suture carrier is passed through the liver at an appropriate distance, and the suture is regrasped by this suture carrier and brought out of the liver. Herein we report a case in which a new bleeding control method using Endoclose was introduced for laparoscopy-assisted hepatectomy. (Keyword) Aged / Hemostasis, Endoscopic / Hepatectomy / Humans / Laparoscopy / Liver / Liver Neoplasms / Male / Suture Techniques / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-001-4145-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12235509 ● Search Scopus @ Elsevier (PMID): 12235509 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-001-4145-6 (DOI: 10.1007/s00464-001-4145-6, PubMed: 12235509)
30.	Toshiro Kuroiwa, Kengo Yoshimitsu, Hiroshi Honda, Hiroyuki Irie, Hitoshi Aibe, Kenji Shinozaki, Kouji Masuda, Mitsuo Shimada and Kazuhiro Hayashida : Re: Two-stage transcatheter arterial embolization of a large hepatic artery pseudoaneurysm causing obstructive jaundice, CardioVascular and Interventional Radiology, Vol.25, No.1, 76-77, Jan. 2002.
31.	Ryu Matsuo, Hisanobu Ogata, Hiroshi Tsuji, Takanari Kitazono, Mitsuo Shimada, Kenichi Taguchi and Masatoshi Fujishima : Spontaneous regression of hepatocellular carcinoma--a case report, Hepato-Gastroenterology, Vol.48, No.42, 1740-1742, Nov. 2001.
32.	Yo-ichi Yamashita, Mitsuo Shimada, Ken-ichi Taguchi, Tomonobu Gion, Hirofumi Hasegawa, Tohru Utsunomiya, Takayuki Hamatsu, Takashi Matsumata and Keizo Sugimachi : Hepatic sclerosing hemangioma mimicking a metastatic liver tumor: report of a case, Surgery Today, Vol.30, No.9, 849-852, Sep. 2000. (Summary) We present herein the case of a sclerosing hemangioma of the liver which was extremely difficult to differentiate from liver metastasis of rectal cancer, in a 67-year-old woman. All the radiological findings were compatible with liver metastasis; however, marginal pooling of the tumor revealed by computed tomographic angiography and magnetic resonance imaging scans was inconsistent with a diagnosis of liver metastasis. At laparotomy, the tumor was macroscopically unusual in that it was yellowish elastic-hard with a very clear margin, and thus, it did not have the appearance of a metastatic tumor. Mile's operation and a partial hepatectomy were performed, followed by an uneventful postoperative course and no signs of recurrence. The carcinoembryonic antigen (CEA) level in the peripheral blood was not elevated at any time. The postoperative pathological diagnosis was a rare hepatic tumor, namely, a "sclerosing hemangioma," based on the findings of cellular fibrous stroma containing vascular channels with flattened endothelial cells. Preoperatively differentiating between sclerosing hemangioma and a metastatic liver tumor from colorectal cancer may be very difficult; however, this case demonstrated some interesting characteristics, namely, the serum CEA level was not elevated, marginal pooling of the tumor was found in the enhanced radiological findings, and the tumor was macroscopically unusual. Therefore, the possibility of sclerosing hemangioma should be borne in mind when considering the differential diagnosis of patients suspected of having colorectal liver metastasis. A preoperative biopsy should be carried out and when a laparotomy is performed under the misdiagnosis of colorectal liver metastasis, it is advisable that either an intraoperative needle biopsy or a frozen histological analysis be undertaken to avoid unnecessary extended hepatic resection of this rare benign hepatic tumor. (Keyword) Aged / Angiography / Carcinoembryonic Antigen / Colorectal Neoplasms / Diagnosis, Differential / Female / Histiocytoma, Benign Fibrous / Humans / Liver Neoplasms / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1080/00397910008087096 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11039718 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033790716 (DOI: 10.1080/00397910008087096, PubMed: 11039718, Elsevier: Scopus)
33.	Kensuke Takeuchi, Kimihiro Komori, Shinji Ohta, Mitsuo Shimada, Yoshikazu Yonemitsu and Keizo Sugimachi : A simultaneous resection of a concomitant abdominal aortic aneurysm and hepatocellular carcinoma: two cases, International Surgery, Vol.85, No.2, 152-157, Apr. 2000.
34.	Shigeki Wakiyama, K Yoshimura, Mitsuo Shimada, Kiyoshi Kajiyama and Keizo Sugimachi : Heterotopic gastric mucosa in a gallbladder with an anomalous union of the pancreatobiliary duct: a case report, Hepato-Gastroenterology, Vol.45, No.23, 1488-1491, Sep. 1998. (Summary) A 25 year-old woman experienced a sudden onset of epigastralgia with nausea, and consulted our hospital. Because the abdominal pain did not subside with medication, she was hospitalized. On physical examination she had a slight tenderness of the right upper abdominal quadrant. Laboratory studies disclosed increases in the serum alkaline phosphatase, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, and serum amylase levels. Abdominal ultrasonography, computed tomography, and endoscopic retrograde cholangiopancreatography revealed choledocholithiasis and a pancreatic duct which originated from the common bile duct. A common bile duct stone was removed with a basket catheter after an endoscopic sphincterotomy was performed. Since an anomalous union of a pancreatobiliary duct is a high risk factor of gallbladder cancer, laparoscopic cholecystectomy was perfomed. The post-operative course was uneventful and she was discharged on the twentieth post-operative day. In a microscopical examination of the resected specimen, a pyloric type gastric mucosa was clearly evident in the submucosa, while the remaining gallbladder demonstrated chronic cholecystitis. Some cases of heterotopic gastric mucosa in the gallbladder come from metaplasia, and metaplasia is also one of the most important factors in the carcinogenesis of gallbladder cancer. In conclusion, the present case is the first report of gastric mucosa with an anomalous union of the pancreatobiliary duct. Heterotopic gastric mucosa in the gallbladder may be one of the causes of gallbladder cancer, and close attention should, therefore, be paid to any occurrence of heterotopic gastric mucosa in this region. (Keyword) Adult / Cholangiopancreatography, Endoscopic Retrograde / Choristoma / Common Bile Duct / Female / Gallbladder Diseases / Gallstones / Gastric Mucosa / Humans / Pancreatic Ducts (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9840091 ● Search Scopus @ Elsevier (PMID): 9840091 (PubMed: 9840091)
35.	Hirofumi Hasegawa, Kenji Takenaka, Kiyoshi Kajiyama, Ken Shirabe, Mitsuo Shimada, H Gondo and Keizo Sugimachi : Virus-associated hemophagocytic syndrome after hepatic resection: a case report, Hepato-Gastroenterology, Vol.45, No.19, 216-219, Jan. 1998. (Summary) Virus-associated hemophagocytic syndrome (VAHS) is associated with a systemic viral infection and is mainly observed in immunosuppressed adult patients. This rare disease is characterized by symptoms which include a high fever, pancytopenia, and splenomegaly and sometimes results in a fatal outcome. However, thus far, little has been reported on VAHS in general surgical patients. We herein report this rare complication which occurred in a patient with hepatocellular carcinoma, as well as chronic hepatitis C, after a hepatic resection. A 66-year-old man with chronic hepatitis C and recurrent hepatocellular carcinoma underwent a repeat hepatic resection without any blood transfusions. In the early postoperative period, he recovered uneventfully. However, he suddenly began to suffer from a high fever (38.4 degrees C) and severe pancytopenia 8 days after surgery. Activated macrophages, which phagocytosed erythrocytes, were identified by a cytological study of the bone marrow. The patient was therefore treated with methylprednisolone pulse therapy 13 days after surgery. On the day following the initial administration of methylprednisolone, his clinical condition drastically improved. Fortunately, with methylprednisolone therapy, our patient recovered from acute, severe pancytopenia. In general surgery, it is often difficult for surgeons to use steroids due to their negative side effects. However, when symptoms such as fever, general fatigue and pancytopenia are observed, even in posthepatectomy patients with hepatocellular carcinoma and hepatitis, a bone marrow aspiration should be performed as soon as possible, and when VAHS is suspected, steroid pulse therapy should be the first treatment of choice. This rare but sometimes fatal complication should thus be taken into consideration in the postoperative management of hepatectomized patients with chronic hepatitis C. (Keyword) Aged / Carcinoma, Hepatocellular / Hepatectomy / Hepatitis C, Chronic / Histiocytosis, Non-Langerhans-Cell / Humans / Liver Neoplasms / Male (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9496516 ● Search Scopus @ Elsevier (PMID): 9496516 (PubMed: 9496516)
36.	Yuh Fujiwara, Kenji Takenaka, Kiyoshi Kajiyama, Takashi Maeda, Tomonobu Gion, Ken Shirabe, Mitsuo Shimada and Keizo Sugimachi : The characteristics of hepatocellular carcinoma with a high level of serum lactic dehydrogenase: a case report, Hepato-Gastroenterology, Vol.44, No.15, 820-823, May 1997.
37.	Shigeki Wakiyama, Kousei Yoshimura, Mitsuo Shimada and Keizo Sugimachi : Lupus peritonitis mimicking acute surgical abdomen in a patient with systemic lupus erythematosus: report of a case, Surgery Today, Vol.26, No.9, 715-718, Sep. 1996. (Keyword) lupus peritonitis / SLE / acute surgical abdomen
38.	Kazuharu Yamamoto, Kenji Takenaka, Kiyoshi Kajiyama, Takashi Maeda, Ken Shirabe, Mitsuo Shimada and Keizo Sugimachi : A primary adenosquamous carcinoma of the liver with an elevated level of serum squamous cell carcinoma related antigen, Hepato-Gastroenterology, Vol.43, No.9, 658-662, May 1996. (Summary) A case of primary adenosquamous carcinoma of the liver with an elevated level of serum squamous cell carcinoma related antigen is herein reported. Various hypotheses on the pathogenesis of adenosquamous carcinoma of the liver have been set forth previously, however there is still no widely accepted theory because of the absence of any sufficient evidence. The postoperative transition of serum squamous cell carcinoma related antigen and the immunohistochemical findings using anti-involucrin antigen in this case support the hypothesis that the squamous cell carcinoma component arises as a result of the metaplastic transformation of adenocarcinoma cells. (Keyword) Aged / Antigens, Neoplasm / Carcinoma, Adenosquamous / Humans / Immunoenzyme Techniques / Liver / Liver Neoplasms / Male / Serpins (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8799411 ● Search Scopus @ Elsevier (PMID): 8799411 (PubMed: 8799411)
39.	Akinobu Taketomi, Kenji Takenaka, Ken Shirabe, Takashi Matsumata, Takashi Maeda, Mitsuo Shimada, H Ishibashi and Keizo Sugimachi : Surgically resected primary malignant lymphoma of the liver, Hepato-Gastroenterology, Vol.43, No.9, 651-657, May 1996.
40.	Mitsuo Shimada, Kiyoshi Kajiyama, A Saitoh and T Kano : Cystic neoplasms of the liver: a report of two cases with special reference to cystadenocarcinoma, Hepato-Gastroenterology, Vol.43, No.7, 249-254, Jan. 1996. (Summary) We herein present two cases with cystic neoplasms of the liver, both successfully treated by a surgical resection. One patient underwent a tumor enucleation, while the other had a left hepatic lobectomy and left caudate lobectomy. Although the follow-up period is still relatively short, both patients are doing well without any sign of recurrence. The specimens were histopathologically examined including immunohistochemical staining. Both tumors were unilocular-cystic and contained mucus. One tumor was considered to have originated from a cystadenoma with a mesenchymal stroma, which has been espoused by Wheeler and Edmondson, while the other tumor was considered to have originated from the bile duct. Therefore, the diagnosis of one patient was cystadenocarcinoma, while the other was considered to be a mucin-producing papillary adenocarcinoma of the intrahepatic bile duct. No invasive growth to the liver parenchyma or the surrounding tissues was observed in either case. Thus, a surgical resection should be the first choice of treatment for cystic neoplasms of the liver. Furthermore, a malignant transformation of cystadenoma with a mesenchymal stroma should be given a special entity in cystadenocarcinoma. (Keyword) Adenocarcinoma, Mucinous / Adenocarcinoma, Papillary / Aged / Cystadenocarcinoma / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8682473 ● Search Scopus @ Elsevier (PMID): 8682473 (PubMed: 8682473)
41.	脇山茂樹, 吉村行生, Mitsuo Shimada and 杉町圭蔵 : 上行結腸癌との鑑別に難渋した狭窄型虚血性陽炎の1例, 外科診療, Vol.38, No.10, 1225-1229, 1996.
42.	脇山茂樹, 吉村行生, Mitsuo Shimada, 梶山潔 and 杉町圭蔵 : 頚部リンパ節腫大を主訴としたトキソプラズマ症の1例, 外科診療, Vol.38, No.1, 87-90, 1996.
43.	Takashi Maeda, Mitsuo Shimada, Ken Shirabe, Akinobu Taketomi, Takashi Matsumata and Keizo Sugimachi : Strategies for intractable ascites after hepatic resection: analysis of two cases, The British Journal of Clinical Practice, Vol.49, No.3, 149-151, May 1995. (Summary) Intractable ascites after hepatic resection is one of the gravest complications pertaining to deterioration in a patient's quality of life. Two cases are presented with intractable ascites that did not respond to ordinary conservative treatment after hepatic resection but were eventually successfully treated. The authors propose the following strategies: the conducting of aggressive and extensive examinations including angiography; and a peritoneovenous shunt for patients demonstrating no definite cause, to improve their quality of life. (Keyword) Ascites / Embolization, Therapeutic / Humans / Liver Cirrhosis / Male / Middle Aged / Peritoneovenous Shunt / Postoperative Complications (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7779667 ● Search Scopus @ Elsevier (PMID): 7779667 (PubMed: 7779667)
44.	Mitsuo Shimada, T Maeda, A Saitoh, I Morotomi and T Kano : Needle track seeding after percutaneous ethanol injection therapy for small hepatocellular carcinoma, Journal of Surgical Oncology, Vol.58, No.4, 278-281, Apr. 1995.
45.	Takashi Maeda, Mitsuo Shimada, Takashi Matsumata, Eisuke Adachi, Akinobu Taketomi, Y Tashiro, Masazumi Tsuneyoshi, K Sueishi and Keizo Sugimachi : Xanthogranulomatous cholecystitis masquerading as gallbladder carcinoma, The American Journal of Gastroenterology, Vol.89, No.4, 628-630, Apr. 1994. (Summary) We herein present a case of xanthogranulomatous cholecystitis which involved both the liver and transverse colon, clinically mimicking gallbladder carcinoma. Such cases may sometimes be judged inoperable due to extensive extra-gallbladder invasion, and thus it is necessary for physicians to take this lesion into consideration when making a diagnosis. An intraoperative biopsy is necessary, therefore, even when the features seem to clearly indicate inoperable carcinoma. (Keyword) Aged / Biopsy / Cholecystitis / Colonic Diseases / Diagnosis, Differential / Diagnostic Imaging / Female / Gallbladder / Gallbladder Neoplasms / Granuloma / Humans / Liver Diseases / Xanthomatosis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8147372 ● Search Scopus @ Elsevier (PMID): 8147372 (PubMed: 8147372)
46.	Mitsuo Shimada, Takashi Matsumata, Yasuharu Ikeda, Keiko Urata, Hiroshi Hayashi, M Shimizu and Keizo Sugimachi : Multiple hepatic hemangiomas with significant arterioportal venous shunting, Cancer, Vol.73, No.2, 304-307, Jan. 1994. (Summary) A patient with multiple hepatic hemangiomas and significant arterioportal shunting who was successfully treated by a left-hepatic lobectomy is presented herein. In hemangiomas with significant arterioportal venous shunting, it is essential to differentiate between hepatocellular carcinoma and hypervascular metastatic tumors because few typical findings of hemangioma can be recognized. Moreover, an increased hepatic arterial flow can increase the risk of spontaneous rupture as well as portal hypertension due to the increased inflow to the portal vein. Therefore, a definitive diagnosis should be made by liver biopsy when imaging alone is not sufficient to rule out malignancy. Furthermore, hepatic resection for hemangiomas with significant arterioportal venous shunting may be indicated due to the higher risk of rupture and the possibility of progressive portal hypertension. (Keyword) Angiography / Carcinoma, Hepatocellular / Diagnosis, Differential / Hemangioma, Cavernous / Humans / Liver Neoplasms / Magnetic Resonance Imaging / Male / Middle Aged / Neoplasms, Multiple Primary / Portal System (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8293392 ● Search Scopus @ Elsevier (PMID): 8293392 (PubMed: 8293392)
47.	Mitsuo Shimada, Kenichiro Okadome, Kimihiro Komori, H Takeuchi and Keizo Sugimachi : A new application of centrifugal pump to axillo-iliac temporary bypass during surgery of thoracic aortic aneurysm - a case report, Vascular Surgery, Vol.27, No.2, 140-146, 1993.
48.	杉町圭蔵, 矢永勝彦, Mitsuo Shimada, 東秀史, 板阪英俊, 池田哲夫, 松股孝, 柿添三郎, 池部正彦, 岡留健一郎, 兼松隆之 and 朔元則 : 体外肝切除術-本邦第一例目の経験-, Surgery, Vol.52, 717-720, 1990.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Gut-brain axisからみたMetabolic surgeryの血糖抑制効果 (Project/Area Number: 24K11741 )
脂肪由来幹細胞ADSCから誘導した肝細胞様細胞HLCの免疫原性獲得に関する研究 (Project/Area Number: 23K08028 )
オルガノイドを用いた脂肪由来幹細胞からの超高機能肝細胞様細胞の確立 (Project/Area Number: 23K24395 )
AIを用いた対話型医療面接トレーニングシステムの開発 (Project/Area Number: 22K10363 )
Development of integrated treatment for impaired liver regeneration on non-alcoholic steatohepatitis (Project/Area Number: 18H02871 )
A study of an educational program using unidentified fresh cadaver and simulators to improve medical safety skills. (Project/Area Number: 17K08918 )
Immune response mediated by hepatic stellate cells with endoplasmic reticulum stress in liver transplantation. (Project/Area Number: 15K10027 )
Cancer Diagnosis and Prognosis Assistance Based on Multidisciplinary Computational Anatomy (Project/Area Number: 26108007 )
Computer-aided detection of metastatic diseases in lympha node, liver, and lung from colorectal cancer (Project/Area Number: 26560260 )
Study on international sense upbringing of overseas interchange program in Clinical Skills Laboratory. (Project/Area Number: 26460603 )
Development of multidisciplinary therapy for aged liver insufficiency based on the mechanism of hepatic stellate cell dysfunction. (Project/Area Number: 26293288 )
The role of unfolded protein response on hepatic stellate cell in old liver ischemia reperfusion injury and liver regeneration (Project/Area Number: 25861194 )
The basic research for establishment of a new strategy for IBMIR control in islet transplantation by ADSC (Project/Area Number: 25462114 )
Mechanism of host organs and tumor microenvironment that related tumor recurrence after liver transplantation (Project/Area Number: 25462092 )
Regulation of aged liver regenerative disorder focused of epigenetic changes (Project/Area Number: 25462091 )
バクテリアルトランスロケーション下の腸管免疫機構の解明と治療法への展開 (Project/Area Number: 25461950 )
Development of treatment for bacterial translocation in rat's biliary atresia model. (Project/Area Number: 24890151 )
The possible mechanism on homing effect of adipose-derived stem cells to the injured liver (Project/Area Number: 24659611 )
肝発癌分子機構におけるがん幹細胞関連ｍｉＲＮＡ発現の関与 (Project/Area Number: 24592003 )
The role of sonic hedgehog signaling in intestinal injury (Project/Area Number: 23791536 )
Investigation of immune tolerance in the islet transplantation using adipose tissue derived stem cell. (Project/Area Number: 23592010 )
Development of multidisciplinary therapy based on mechanism of liver insufficiency in a use of Aged partial graft after liver transplantation. (Project/Area Number: 23390324 )
The study to clarify a mechanism of replacing growth of the hepatocellular carcinoma using the adipose tissue derived stem cells (Project/Area Number: 22659243 )
Comprehensive analysis for epigenetic modulation of the effects of anticancer agents on cancer stem cells (Project/Area Number: 22659233 )
The possibility of hepatic regenerative medicine usingadipose tissue-derived mesenchymal stem cell (ADRC) (Project/Area Number: 22591506 )
Computer-Aided Diagnosis Based on Computational Anatomical Models (Project/Area Number: 21103005 )
The role of the transcelluIar route and paracelluIar route in bacterial translocation (Project/Area Number: 21791293 )
Mechanism of recurrence in hepatocel lular carcinoma after livertransplantation (Project/Area Number: 21791292 )
Prevention of bacterial translocation in small bowel transplantation and study for immune syetem of small intestine. (Project/Area Number: 20790959 )
Expression of sonic hedgehog signaling for regulation of liver regeneration after massive hepatectomy of the rat liver (Project/Area Number: 20790958 )
脂肪肝グラフト部分肝移植における機能不全の解明と統合的治療法の開発 (Project/Area Number: 20390359 )
Research on image evaluation of pre and post operationfor living donor liver transplantation (Project/Area Number: 19700383 )
細胞の冬眠タンパク誘導を利用した新たな肝保存装置の開発 (Project/Area Number: 19659342 )
低酸素環境を標的とした膵臓癌に対する新たな治療法の開発 (Project/Area Number: 19591590 )
Development of new methods to assess bacterial translocation evaluating paraoellularroute (Project/Area Number: 19591485 )
Prevention of hepatocellular carcinoma recurrence after livertransplantation by managing regulatory T cells (Project/Area Number: 19591484 )
Development of measurement for hepatic isc hemia-repetfusion in jiry accoidirg to are gulation of activin-follistin system (Project/Area Number: 18591516 )
Development of the new immunological tolerance induction which uses Notch ligands in islet transplantation (Project/Area Number: 18591414 )
光触媒作用を応用した新たな人工肝補助装置の開発 (Project/Area Number: 17659390 )
The investigation of regulatory mechanism on liver regeneration after massive hepatectomy (Project/Area Number: 17591408 )
A New Methods to Assess Bacterial Translocation (Project/Area Number: 17591338 )
Analysis of novel angiogenesis-related genes and development of tumor dormancy therapy (Project/Area Number: 17390371 )
The strategies for overcoming the graft dysfunction after liver transplantation using small-for-size graft (Project/Area Number: 17390370 )
Identification of differentiation regulated gene and application to differentiation inducing gene therapy (Project/Area Number: 14571210 )
Analysis of newly identified anglogenic genes and the signal inhibition for tumor dormancy therapy (Project/Area Number: 14571141 )
Promotion of liver regeneration and intrahepatic metastasis of hepatocellular carcinoma by Histone acetylation (Project/Area Number: 14370392 )
Development of a Hybrid Artificial Liver for Treatment of Chronic Liver Failure Patients (Project/Area Number: 14205119 )
低侵襲腹腔鏡下手術支援のための近赤外線による組織内血管同定 (Project/Area Number: 13878179 )
Development of a super liver graft resistant to various kinds of injuries by a gene-transfer technique (Project/Area Number: 13357011 )
Regulation of multiple angiogenic signaling and development of cancer-specific gene therapy (Project/Area Number: 12671164 )
Studies on the development of telemedicine network system in the disaster emergency medical treatment (Project/Area Number: 12307055 )
Development of a Hybrid Artificial Liver for Treatment of Acute and Chronic Liver Failure Patients (Project/Area Number: 12305053 )
エレクトロポレーション法を用いた新たな肝細胞癌に対する遺伝子治療の開発 (Project/Area Number: 12217108 )
癌化シグナル伝達Wnt/Fzを制御する新しいがん関連遺伝子の同定とその機能解析 (Project/Area Number: 12213100 )
Study of new metastatic mechanism in hepatocellular carcinoma (Project/Area Number: 11671247 )
Development of Hybrid Artificial Liver for Clinical Treatment of Fulminant Hepatic Failure Patient (Project/Area Number: 10305062 )
肝細胞癌の再発メカニズムの解明ならびに制御に関する研究 (Project/Area Number: 09770942 )
肝切除における肝障害メカニズムの解明:類洞内皮細胞への接着分子発現の意義と制御 (Project/Area Number: 08770975 )
アポトーシス導入による肝細胞癌の特異的増殖制御 (Project/Area Number: 06454370 )
移植肝Viabilityの総合的判定指標に関する研究 (Project/Area Number: 04454319 )
Graft preservation for liver transplantation. (Project/Area Number: 62440051 )
Search by Researcher Number (10216070)

Professor : Shimada, Mitsuo

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)